BEST AVAILABLE COPY

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 15:03:58 ; Search time 3 Seconds
(without alignments)
8.730 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 87 seqs, 1705 residues

Total number of hits satisfying chosen parameters: 174

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Published_Applications_NA_New

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 89 summaries

Database : pubnewdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	40	0.5	40	1	US-11-254-920-23	Sequence 23, Appl
	2	40	0.5	40	1	US-11-254-920-26	Sequence 26, Appl
	3	24	0.3	24	1	US-11-301-360-1068	Sequence 1068, Ap
	4	21	0.3	21	1	US-11-301-360-907	Sequence 907, App
	5	20.8	0.3	25	1	US-11-348-413-272631	Sequence 272631,
	6	20.8	0.3	25	1	US-11-348-413-887327	Sequence 887327,
	7	20.2	0.3	25	1	US-11-217-529-38533	Sequence 38533, A
c	8	20.2	0.3	25	1	US-11-348-413-1181218	Sequence 1181218,
	9	20.2	0.3	25	1	US-11-348-413-1233632	Sequence 1233632,
	10	20	0.3	20	1	US-10-204-067A-13	Sequence 13, Appl
c	11	20	0.3	20	1	US-11-254-920-15	Sequence 15, Appl
	12	20	0.3	20	1	US-11-254-920-18	Sequence 18, Appl
	13	20	0.3	20	1	US-11-081-309-1	Sequence 1, Appli
c	14	20	0.3	20	1	US-11-081-309-2	Sequence 2, Appli
	15	20	0.3	20	1	US-11-320-440-326	Sequence 326, App
c	16	19.8	0.3	23	1	US-11-287-152-2	Sequence 2, Appli
c	17	19	0.2	19	1	US-11-320-440-150	Sequence 150, App
	18	19	0.2	21	1	US-11-370-301-22	Sequence 22, Appl
c	19	17.8	0.2	22	1	US-11-247-659-11	Sequence 11, Appl
	20	17	0.2	19	1	US-10-881-580-117	Sequence 117, App
c	21	17	0.2	19	1	US-10-881-580-245	Sequence 245, App
c	22	17	0.2	19	1	US-11-217-936-452	Sequence 452, App
	23	17	0.2	19	1	US-11-217-936-562	Sequence 562, App
c	24	17	0.2	20	1	US-11-294-621-318	Sequence 318, App
c	25	16.8	0.2	20	1	US-11-043-842-219	Sequence 219, App
c	26	16.8	0.2	20	1	US-11-198-885-157	Sequence 157, App
	27	16.8	0.2	21	1	US-10-548-681-103	Sequence 103, App
	28	16.2	0.2	19	1	US-11-241-596-259	Sequence 259, App
	29	16.2	0.2	19	1	US-11-269-347A-29	Sequence 29, Appl
	30	16	0.2	16	1	US-10-514-349-6	Sequence 6, Appli
	31	16	0.2	17	1	US-10-514-349-7	Sequence 7, Appli
	32	16	0.2	18	1	US-10-514-349-8	Sequence 8, Appli
	33	16	0.2	18	1	US-10-753-718-4272	Sequence 4272, Ap
	34	16	0.2	18	1	US-11-211-917-144	Sequence 144, App
	35	16	0.2	18	1	US-11-301-360-913	Sequence 913, App
	36	16	0.2	18	1	US-11-301-360-939	Sequence 939, App
	37	16	0.2	18	1	US-11-102-097-111	Sequence 111, App
c	38	16	0.2	19	1	US-10-424-339-163	Sequence 163, App
	39	16	0.2	19	1	US-10-424-339-326	Sequence 326, App
c	40	16	0.2	19	1	US-10-533-166-29	Sequence 29, Appl
c	41	16	0.2	19	1	US-11-224-573-153	Sequence 153, App
c	42	16	0.2	19	1	US-11-217-936-3874	Sequence 3874, Ap
	43	16	0.2	19	1	US-11-217-936-3970	Sequence 3970, Ap
c	44	16	0.2	19	1	US-11-217-936-4807	Sequence 4807, Ap
	45	16	0.2	19	1	US-11-217-936-4904	Sequence 4904, Ap
c	46	16	0.2	19	1	US-11-334-885-1	Sequence 1, Appli
c	47	16	0.2	20	1	US-10-514-349-11	Sequence 11, Appl
	48	16	0.2	20	1	US-11-053-733A-2	Sequence 2, Appli
c	49	16	0.2	20	1	US-11-248-241-1	Sequence 1, Appli
	50	16	0.2	20	1	US-11-248-241-2	Sequence 2, Appli
c	51	16	0.2	20	1	US-11-224-573-158	Sequence 158, App
c	52	16	0.2	20	1	US-11-224-573-163	Sequence 163, App
c	53	16	0.2	20	1	US-11-254-920-11	Sequence 11, Appl
	54	16	0.2	20	1	US-11-254-920-14	Sequence 14, Appl
	55	16	0.2	20	1	US-11-301-360-226	Sequence 226, App
	56	16	0.2	20	1	US-11-301-360-556	Sequence 556, App
c	57	16	0.2	20	1	US-11-301-360-560	Sequence 560, App
c	58	15.8	0.2	19	1	US-10-501-834-70	Sequence 70, Appl
	59	15.8	0.2	19	1	US-11-217-936-27	Sequence 27, Appl
c	60	15.8	0.2	19	1	US-11-217-936-142	Sequence 142, App
	61	15.4	0.2	17	1	US-11-255-139A-521	Sequence 521, App
	62	15.4	0.2	19	1	US-10-753-718-4087	Sequence 4087, Ap
	63	15.4	0.2	19	1	US-10-753-718-4088	Sequence 4088, Ap
	64	15.4	0.2	19	1	US-10-753-718-4089	Sequence 4089, Ap
c	65	15.4	0.2	19	1	US-11-344-702-596	Sequence 596, App
c	66	15.4	0.2	19	1	US-11-345-361-596	Sequence 596, App
	67	15	0.2	15	1	US-10-514-349-5	Sequence 5, Appli
	68	15	0.2	15	1	US-10-250-492-13	Sequence 13, Appl
	69	15	0.2	15	1	US-10-691-012-17	Sequence 17, Appl
c	70	15	0.2	15	1	US-10-691-012-18	Sequence 18, Appl
c	71	15	0.2	15	1	US-11-242-139-239	Sequence 239, App
	72	15	0.2	17	1	US-11-255-139A-522	Sequence 522, App
	73	15	0.2	17	1	US-11-255-139A-523	Sequence 523, App
	74	15	0.2	18	1	US-10-753-718-4271	Sequence 4271, Ap
c	75	15	0.2	18	1	US-11-340-574-44	Sequence 44, Appl
	76	15	0.2	18	1	US-11-257-851A-23	Sequence 23, Appl
	77	15	0.2	18	1	US-11-257-851A-29	Sequence 29, Appl
	78	15	0.2	40	1	US-11-254-920-23	Sequence 23, Appl
c	79	15	0.2	40	1	US-11-254-920-26	Sequence 26, Appl
c	80	14.4	0.2	17	1	US-10-524-432-365	Sequence 365, App
	81	14.4	0.2	17	1	US-11-255-139A-520	Sequence 520, App
c	82	14.4	0.2	18	1	US-10-858-013-990	Sequence 990, App
	83	14.4	0.2	18	1	US-11-370-584-4233	Sequence 4233, Ap
c	84	14.4	0.2	18	1	US-11-370-584-7435	Sequence 7435, Ap
	85	14	0.2	17	1	US-11-255-139A-524	Sequence 524, App
	86	13.8	0.2	17	1	US-10-524-432-480	Sequence 480, App
	87	13.8	0.2	17	1	US-11-255-139A-519	Sequence 519, App
	88	13.8	0.2	17	1	US-11-255-139A-1646	Sequence 1646, Ap
c	89	13.8	0.2	17	1	US-11-255-139A-4373	Sequence 4373, Ap

ALIGNMENTS

RESULT 1
US-11-254-920-23/c
; Sequence 23, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, Andrew
; APPLICANT: JUTEAU, Jean-Marc
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
; FILE REFERENCE: 0999266-0000
; CURRENT APPLICATION NUMBER: US/11/254,920
; CURRENT FILING DATE: 2005-10-20
; PRIOR APPLICATION NUMBER: US 10/969,812

```
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: REP 2055 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(40)
;   OTHER INFORMATION: Phosphorothioate linkages
US-11-254-920-23

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 0.0038;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 2
US-11-254-920-26
; Sequence 26, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Rep 2033 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(40)
;   OTHER INFORMATION: Phosphorothioate linkages
US-11-254-920-26

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 0.0038;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 40


RESULT 3
US-11-301-360-1068
; Sequence 1068, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.7;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 4
US-11-301-360-907
; Sequence 907, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 907
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-907

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 4.9;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 5
US-11-348-413-272631
; Sequence 272631, Application US/11348413
; Publication No. US20060160121A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  APPLICANT:  Murphy, Ellen
;  APPLICANT:  Olmsted, Stephen
;  TITLE OF INVENTION: PROBE ARRAYS FOR DETECTING MULTIPLE STRAINS OF DIFFERENT SPECIES
```

```
;  FILE REFERENCE: 031896-084100 (AM 101724)
;  CURRENT APPLICATION NUMBER: US/11/348,413
;  CURRENT FILING DATE:  2006-02-07
;  PRIOR APPLICATION NUMBER: PCT/US05/035471
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 11/243,445
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 60/615,573
;  PRIOR FILING DATE: 2004-10-05
;  NUMBER OF SEQ ID NOS: 1276209
; SEQ ID NO 272631
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(25)
;   OTHER INFORMATION: SEQ ID NO: 7898; WAN01UMST; Start 198; Stop 222;
;   OTHER INFORMATION: 000000010000000
US-11-348-413-272631

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   58.3%;  Pred. No. 6.6;
  Matches   14;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5434 CAUUUAAUGGGGAUUCCACUAUCU 5457
              || ::||: ||||::||||:|:|:
Db          2 CAATTAATAGGGATTCCACTATCT 25


RESULT 6
US-11-348-413-887327
; Sequence 887327, Application US/11348413
; Publication No. US20060160121A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  APPLICANT:  Murphy, Ellen
;  APPLICANT:  Olmsted, Stephen
;  TITLE OF INVENTION: PROBE ARRAYS FOR DETECTING MULTIPLE STRAINS OF DIFFERENT SPECIES
;  FILE REFERENCE: 031896-084100 (AM 101724)
;  CURRENT APPLICATION NUMBER: US/11/348,413
;  CURRENT FILING DATE:  2006-02-07
;  PRIOR APPLICATION NUMBER: PCT/US05/035471
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 11/243,445
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 60/615,573
;  PRIOR FILING DATE: 2004-10-05
;  NUMBER OF SEQ ID NOS: 1276209
; SEQ ID NO 887327
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(25)
;   OTHER INFORMATION: SEQ ID NO: 7898; WAN01UMST_at; Start 199; Stop 223;
;   OTHER INFORMATION: 000000010000000
US-11-348-413-887327

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   58.3%;  Pred. No. 6.6;
  Matches   14;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5434 CAUUUAAUGGGGAUUCCACUAUCU 5457
              || ::||: ||||::||||:|:|:
Db          1 CAATTAATAGGGATTCCACTATCT 24


RESULT 7
US-11-217-529-38533
; Sequence 38533, Application US/11217529
; Publication No. US20060099612A1
; GENERAL INFORMATION:
;  APPLICANT: SUNTORY LIMITED
;  APPLICANT:  NAKAO, YOSHIHIRO
;  APPLICANT:  NAKAMURA, NORIHISA
;  APPLICANT:  KODAMA, YUKIKO
;  APPLICANT:  FUJIMURA, TOMOKO
;  APPLICANT:  ASHIKARI, TOSHIHIKO
;  TITLE OF INVENTION: METHODS FOR ANALYZING GENES OF INDUSTRIAL YEASTS
;  FILE REFERENCE: S-38-285
;  CURRENT APPLICATION NUMBER: US/11/217,529
;  CURRENT FILING DATE:  2005-09-02
;  PRIOR APPLICATION NUMBER: US 10/932,182
;  PRIOR FILING DATE: 2004-09-02
;  NUMBER OF SEQ ID NOS: 197023
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 38533
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Saccharomyces pastorianus
US-11-217-529-38533

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 8.4;
  Matches   13;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3509 UAUUGCUGUGGGGAAAUCUUCUCCUU 3533
              :| :|| |:|||||| :|::|:||::
Db          1 TAATGCCGTGGGAATTCTTCTCCTT 25


RESULT 8
US-11-348-413-1181218/c
; Sequence 1181218, Application US/11348413
; Publication No. US20060160121A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  APPLICANT:  Murphy, Ellen
;  APPLICANT:  Olmsted, Stephen
;  TITLE OF INVENTION: PROBE ARRAYS FOR DETECTING MULTIPLE STRAINS OF DIFFERENT SPECIES
;  FILE REFERENCE: 031896-084100 (AM 101724)
;  CURRENT APPLICATION NUMBER: US/11/348,413
;  CURRENT FILING DATE:  2006-02-07
;  PRIOR APPLICATION NUMBER: PCT/US05/035471
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 11/243,445
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 60/615,573
;  PRIOR FILING DATE: 2004-10-05
;  NUMBER OF SEQ ID NOS: 1276209
; SEQ ID NO 1181218
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(25)
;   OTHER INFORMATION: SEQ ID NO: 15979; WAN01OW62_at; Start 43; Stop 67;
;   OTHER INFORMATION: 000000000011101
US-11-348-413-1181218

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   40.0%;  Pred. No. 8.4;
  Matches   10;  Conservative   12;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       5172 CAUUCUAUUUUGGGUAUUAAUAUAU 5196
```

```
              ||::|:|::::||  |:: |:|:|:
Db         25 CATTCTATTTTGGCAATTTATATAT 1


RESULT 9
US-11-348-413-1233632
; Sequence 1233632, Application US/11348413
; Publication No. US20060160121A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  APPLICANT:  Murphy, Ellen
;  APPLICANT:  Olmsted, Stephen
;  TITLE OF INVENTION: PROBE ARRAYS FOR DETECTING MULTIPLE STRAINS OF DIFFERENT SPECIES
;  FILE REFERENCE: 031896-084100 (AM 101724)
;  CURRENT APPLICATION NUMBER: US/11/348,413
;  CURRENT FILING DATE:  2006-02-07
;  PRIOR APPLICATION NUMBER: PCT/US05/035471
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 11/243,445
;  PRIOR FILING DATE: 2005-10-05
;  PRIOR APPLICATION NUMBER: US 60/615,573
;  PRIOR FILING DATE: 2004-10-05
;  NUMBER OF SEQ ID NOS: 1276209
; SEQ ID NO 1233632
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(25)
;   OTHER INFORMATION: SEQ ID NO: 17441; WAN01UQT9_at; Start 447; Stop 471;
;   OTHER INFORMATION: 000000000000000
US-11-348-413-1233632

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   60.0%;  Pred. No. 8.4;
  Matches   15;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       4971 UGGAACUAAAGCAAAUUUUAGACCU 4995
              :|||| :|||| | |::::|||||:
Db          1 TGGAATTAAAGAAGATTTTAGACCT 25


RESULT 10
US-10-204-067A-13
; Sequence 13, Application US/10204067A
; Publication No. US20060142218A1
; GENERAL INFORMATION:
;  APPLICANT: Ohta, Kunihiro
;  APPLICANT:  Shibata, Takehiko
;  TITLE OF INVENTION: METHOD OF CONTROLLING TELOMERE LENGTH
;  FILE REFERENCE: 11283-032US1
;  CURRENT APPLICATION NUMBER: US/10/204,067A
;  CURRENT FILING DATE:  2002-08-16
;  PRIOR APPLICATION NUMBER: PCT/JP01/01024
;  PRIOR FILING DATE: 2001-02-14
;  PRIOR APPLICATION NUMBER: JP 2000-41929
;  PRIOR FILING DATE: 2000-02-18
;  NUMBER OF SEQ ID NOS: 13
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:synthetic DNA
US-10-204-067A-13

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 11
US-11-254-920-15/c
; Sequence 15, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: AC10 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(20)
;   OTHER INFORMATION: Phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)...(0)
;   OTHER INFORMATION: FITC label
US-11-254-920-15

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 12
US-11-254-920-18
; Sequence 18, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: TG10 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
```

```
;   LOCATION: (1)...(20)
;   OTHER INFORMATION: Phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)...(0)
;   OTHER INFORMATION: FITC label
US-11-254-920-18

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 13
US-11-081-309-1
; Sequence 1, Application US/11081309
; Publication No. US20060142229A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  McNeeley, Patricia A.
;  TITLE OF INVENTION: METHODS OF TREATING LUPUS BASED ON ANTIBODY
;  TITLE OF INVENTION:  AFFINITY AND SCREENING METHODS AND COMPOSITIONS FOR USE
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 252312007401
;  CURRENT APPLICATION NUMBER: US/11/081,309
;  CURRENT FILING DATE:  2005-03-15
;  PRIOR APPLICATION NUMBER: US 09/724,822
;  PRIOR FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 60/167,716
;  PRIOR FILING DATE: 1999-11-28
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
US-11-081-309-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 14
US-11-081-309-2/c
; Sequence 2, Application US/11081309
; Publication No. US20060142229A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  McNeeley, Patricia A.
;  TITLE OF INVENTION: METHODS OF TREATING LUPUS BASED ON ANTIBODY
;  TITLE OF INVENTION:  AFFINITY AND SCREENING METHODS AND COMPOSITIONS FOR USE
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 252312007401
;  CURRENT APPLICATION NUMBER: US/11/081,309
;  CURRENT FILING DATE:  2005-03-15
;  PRIOR APPLICATION NUMBER: US 09/724,822
;  PRIOR FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 60/167,716
;  PRIOR FILING DATE: 1999-11-28
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
US-11-081-309-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 15
US-11-320-440-326
; Sequence 326, Application US/11320440
; Publication No. US20060141518A1
; GENERAL INFORMATION:
;  APPLICANT: Applera Corporation
;  TITLE OF INVENTION: Detection of Gene Expression
;  FILE REFERENCE: 9692-000052
;  CURRENT APPLICATION NUMBER: US/11/320,440
;  CURRENT FILING DATE:  2005-12-28
;  NUMBER OF SEQ ID NOS: 330
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 326
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: synthetically derived target sequence
US-11-320-440-326

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 7;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2711 AGUUUGCCCGGGAGAGACUU 2730
              ||:::|||||||||||||::
Db          1 AGTTTGCCCGGGAGAGACTT 20


RESULT 16
US-11-287-152-2/c
; Sequence 2, Application US/11287152
; Publication No. US20060122117A1
; GENERAL INFORMATION:
;  APPLICANT: CHILDREN'S MEDICAL CENTER CORPORATION
;  TITLE OF INVENTION: METHOD OF TREATING RETINOPATHIES AND DISORDERS
;  TITLE OF INVENTION:  ASSOCIATED WITH BLOOD VESSEL LOSS
;  FILE REFERENCE: 701039-53711-PCT
;  CURRENT APPLICATION NUMBER: US/11/287,152
;  CURRENT FILING DATE:  2005-11-25
;  PRIOR APPLICATION NUMBER: PRIOR  APPLICATION NUMBER: PCT/US04/17472
;  PRIOR FILING DATE: 2004-06-03
;  PRIOR APPLICATION NUMBER: 60/475,684
;  PRIOR FILING DATE: 2003-04-06
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: primer
US-11-287-152-2

  Query Match             0.3%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   73.9%;  Pred. No. 9;
```

```
  Matches   17;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2509 AAGUCUAAUCUGGAGCUGAUCAC 2531
              |||:| || |:|||||:||:|||
Db         23 AAGTCAAACCTGGAGCTGATCAC 1


RESULT 17
US-11-320-440-150/c
; Sequence 150, Application US/11320440
; Publication No. US20060141518A1
; GENERAL INFORMATION:
;  APPLICANT: Applera Corporation
;  TITLE OF INVENTION: Detection of Gene Expression
;  FILE REFERENCE: 9692-000052
;  CURRENT APPLICATION NUMBER: US/11/320,440
;  CURRENT FILING DATE:  2005-12-28
;  NUMBER OF SEQ ID NOS: 330
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 150
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: synthetically derived complement of the target sequence
US-11-320-440-150

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 10;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2747 UUGGAAGAGGGGCUUUUGG 2765
              ::|||||||||||::::||
Db         19 TTGGAAGAGGGGCTTTTGG 1


RESULT 18
US-11-370-301-22
; Sequence 22, Application US/11370301
; Publication No. US20060182783A1
; GENERAL INFORMATION:
;  APPLICANT: Hughes, Patrick M.
;  APPLICANT:  Malone, Tom
;  APPLICANT:  DeVries, Gerald W.
;  APPLICANT:  Edelman, Jeffrey L.
;  APPLICANT:  Blanda, Wendy L.
;  APPLICANT:  Spada, Lon T.
;  APPLICANT:  Baciu, Peter T.
;  APPLICANT:  Whitcup, Scott M.
;  TITLE OF INVENTION: Anti-Angiogenic Sustained Release Intraocular Implants and
;  TITLE OF INVENTION:  Related Methods
;  FILE REFERENCE: D-3157 CIP2 P
;  CURRENT APPLICATION NUMBER: US/11/370,301
;  CURRENT FILING DATE:  2006-03-08
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: siRNA
US-11-370-301-22

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 19
US-11-247-659-11/c
; Sequence 11, Application US/11247659
; Publication No. US20060141568A1
; GENERAL INFORMATION:
;  APPLICANT: Bank, Rudolf A.
;  APPLICANT:  Van der Slot, Annemarie J.
;  APPLICANT:  Zuurmond, Anne-Marie
;  APPLICANT:  Te Koppele, Johannes M.
;  TITLE OF INVENTION: Modification of collagenous materials and medical
;  TITLE OF INVENTION:  treatment, diagnosis and monitoring of fibrotic conditions
;  FILE REFERENCE: P60187US00
;  CURRENT APPLICATION NUMBER: US/11/247,659
;  CURRENT FILING DATE:  2005-10-11
;  PRIOR APPLICATION NUMBER: US 09/450,209
;  PRIOR FILING DATE: 1999-11-29
;  NUMBER OF SEQ ID NOS: 59
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
US-11-247-659-11

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   42.9%;  Pred. No. 19;
  Matches    9;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6994
              |:|:|: :|:|:|:|: :|:|
Db         21 GTGTGTCTGTGTGTGTATGTG 1


RESULT 20
US-10-881-580-117
; Sequence 117, Application US/10881580
; Publication No. US20060142225A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Cyclin Dependent Kinase-2
;  TITLE OF INVENTION:  (CDK2) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 400/194 (MBHB04-525)
;  CURRENT APPLICATION NUMBER: US/10/881,580
;  CURRENT FILING DATE:  2004-06-30
;  PRIOR APPLICATION NUMBER: PCT/US03/03662
;  PRIOR FILING DATE: 2003-02-06
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2003-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 382
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 117
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-881-580-117

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |||||||||||||||||
Db          1 CUUUUUUUUUUUUUUUU 17


RESULT 21
US-10-881-580-245/c
; Sequence 245, Application US/10881580
; Publication No. US20060142225A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Cyclin Dependent Kinase-2
;  TITLE OF INVENTION:  (CDK2) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 400/194 (MBHB04-525)
;  CURRENT APPLICATION NUMBER: US/10/881,580
;  CURRENT FILING DATE:  2004-06-30
;  PRIOR APPLICATION NUMBER: PCT/US03/03662
;  PRIOR FILING DATE: 2003-02-06
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2003-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 382
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-881-580-245

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 22;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db         19 CTTTTTTTTTTTTTTTT 3


RESULT 22
US-11-217-936-452/c
; Sequence 452, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 452
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-452

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 22;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db         19 TTTTTTTTTTTTTTTTC 3


RESULT 23
US-11-217-936-562
; Sequence 562, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-562

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              |||||||||||||||||
Db          1 UUUUUUUUUUUUUUUUC 17


RESULT 24
US-11-294-621-318/c
; Sequence 318, Application US/11294621
; Publication No. US20060147959A1
; GENERAL INFORMATION:
;  APPLICANT: BELL, DAPHNE WINIFRED
;  APPLICANT:  HABER, DANIEL A.
;  APPLICANT:  JANNE, PASI ANTERO
;  APPLICANT:  JOHNSON, BRUCE E.
;  APPLICANT:  LYNCH, THOMAS J.
;  APPLICANT:  MEYERSON, MATTHEW
;  APPLICANT:  PAEZ, JUAN GUILLERMO
```

```
;  APPLICANT:  SELLERS, WILLIAM R.
;  APPLICANT:  SETTLEMAN, JEFFREY E.
;  APPLICANT:  SORDELLA, RAFFAELLA
;  TITLE OF INVENTION: METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO
;  TITLE OF INVENTION:  EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING
;  TITLE OF INVENTION:  TREATMENTS
;  FILE REFERENCE: 030258-055147
;  CURRENT APPLICATION NUMBER: US/11/294,621
;  CURRENT FILING DATE:  2005-12-05
;  PRIOR APPLICATION NUMBER: PCT/US05/010645
;  PRIOR FILING DATE: 2005-03-31
;  PRIOR APPLICATION NUMBER: 60/558,218
;  PRIOR FILING DATE: 2004-03-31
;  PRIOR APPLICATION NUMBER: 60/561,095
;  PRIOR FILING DATE: 2004-04-09
;  PRIOR APPLICATION NUMBER: 60/565,753
;  PRIOR FILING DATE: 2004-04-27
;  PRIOR APPLICATION NUMBER: 60/565,985
;  PRIOR FILING DATE: 2004-04-27
;  PRIOR APPLICATION NUMBER: 60/574,035
;  PRIOR FILING DATE: 2004-05-25
;  PRIOR APPLICATION NUMBER: 60/577,916
;  PRIOR FILING DATE: 2004-06-07
;  PRIOR APPLICATION NUMBER: 60/592,287
;  PRIOR FILING DATE: 2004-07-29
;  NUMBER OF SEQ ID NOS: 762
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 318
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-11-294-621-318

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   70.6%;  Pred. No. 23;
  Matches   12;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3644 UCAUGCUGGACUGCUGG 3660
              :||:||:||||:||:||
Db         19 TCATGCTGGACTGCTGG 3


RESULT 25
US-11-043-842-219/c
; Sequence 219, Application US/11043842
; Publication No. US20060183131A1
; GENERAL INFORMATION:
;  APPLICANT: Compugen Ltd
;  TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
;  TITLE OF INVENTION:  THEREOF FOR DIAGNOSIS OF BREAST CANCER
;  FILE REFERENCE: 1847.1004
;  CURRENT APPLICATION NUMBER: US/11/043,842
;  CURRENT FILING DATE:  2005-01-27
;  NUMBER OF SEQ ID NOS: 1028
; SEQ ID NO 219
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-043-842-219

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 25;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 26
US-11-198-885-157/c
; Sequence 157, Application US/11198885
; Publication No. US20060128020A1
; GENERAL INFORMATION:
;  APPLICANT: Calos, Michele
;  TITLE OF INVENTION: METHODS OF UNIDIRECTIONAL, SITE-SPECIFIC
;  TITLE OF INVENTION:  INTEGRATION INTO A GENOME, COMPOSITIONS AND KITS FOR
;  TITLE OF INVENTION:  PRACTICING THE SAME
;  FILE REFERENCE: POET-001CIP
;  CURRENT APPLICATION NUMBER: US/11/198,885
;  CURRENT FILING DATE:  2005-08-04
;  PRIOR APPLICATION NUMBER: 11/003,941
;  PRIOR FILING DATE: 2004-12-03
;  PRIOR APPLICATION NUMBER: PCT/US03/17702
;  PRIOR FILING DATE: 2003-06-03
;  PRIOR APPLICATION NUMBER: 60/385,933
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/386,325
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/385,934
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/385,929
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/386,597
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/385,944
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/416,989
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 216
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Bacteriophage Phi-C31
US-11-198-885-157

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 25;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4247 ACUCCACCCCACCCAUCUAG 4266
              ||:||||| ||||||:|: |
Db         20 ACTCCACCTCACCCATCTGG 1


RESULT 27
US-10-548-681-103
; Sequence 103, Application US/10548681
; Publication No. US20060166214A1
; GENERAL INFORMATION:
;  APPLICANT: Yukio KATO
;  APPLICANT:  Koichiro TSUJI
;  APPLICANT:  Chika KOIKE
;  TITLE OF INVENTION: Marker for detecting mesenchymal stem cell and method of distingu
;  TITLE OF INVENTION:  mesenchymal stem cell using the marker
;  FILE REFERENCE: 4439-4035
;  CURRENT APPLICATION NUMBER: US/10/548,681
;  CURRENT FILING DATE:  2005-09-08
;  PRIOR APPLICATION NUMBER: JP2003-63077
;  PRIOR FILING DATE: 2000-03-10
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 103
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: CELL DIVISION CYCLE 2, G1 TO S AND G2 TO M (CDC2), MRNA
US-10-548-681-103

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   55.0%;  Pred. No. 27;
  Matches   11;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       3366 UGAUUUUGGCCUUGCCCGGG 3385
              :||::::||||::||| | |
Db          2 TGATTTTGGCCTTGCCAGAG 21


RESULT 28
US-11-241-596-259
; Sequence 259, Application US/11241596
; Publication No. US20060134786A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Kenneth A.
;  TITLE OF INVENTION: NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL
;  TITLE OF INVENTION:  FOR MODIFYING PLANT CHARACTERISTICS
;  FILE REFERENCE: 2750-2191PUS2
;  CURRENT APPLICATION NUMBER: US/11/241,596
;  CURRENT FILING DATE:  2005-09-30
;  PRIOR APPLICATION NUMBER: 60/615,081
;  PRIOR FILING DATE: 2004-09-30
;  NUMBER OF SEQ ID NOS: 259
; SEQ ID NO 259
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligo(dtV)18 primer
US-11-241-596-259

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 30;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTV 19


RESULT 29
US-11-269-347A-29
; Sequence 29, Application US/11269347A
; Publication No. US20060142233A1
; GENERAL INFORMATION:
;  APPLICANT: Li, Ting-Kai
;  APPLICANT:  Carr, Lucinda G.
;  APPLICANT:  Ellison, Julie A.
;  APPLICANT:  Chang, Hwai Wen
;  APPLICANT:  Lo, David D.
;  TITLE OF INVENTION: Gene Expression and Genetic Changes Implicated in Alcoholism
;  FILE REFERENCE: NEU-109.P.1.1
;  CURRENT APPLICATION NUMBER: US/11/269,347A
;  CURRENT FILING DATE:  2005-11-08
;  PRIOR APPLICATION NUMBER: 60/626,362
;  PRIOR FILING DATE: 2004-11-09
;  NUMBER OF SEQ ID NOS: 50
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 29
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-11-269-347A-29

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 30;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTV 19


RESULT 30
US-10-514-349-6
; Sequence 6, Application US/10514349
; Publication No. US20060105331A1
; GENERAL INFORMATION:
;  APPLICANT: Kamme, Fredrik Carl
;  APPLICANT:  Zhu, Jessica Y.
;  TITLE OF INVENTION: METHODS FOR IMPROVING RNA TRANSCRIPTION REACTIONS
;  FILE REFERENCE: ORT1637-US
;  CURRENT APPLICATION NUMBER: US/10/514,349
;  CURRENT FILING DATE:  2004-11-12
;  PRIOR APPLICATION NUMBER: US 60/384,454
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: PCT/US03/17103
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Transcription reagent
US-10-514-349-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 27;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 31
US-10-514-349-7
; Sequence 7, Application US/10514349
; Publication No. US20060105331A1
; GENERAL INFORMATION:
;  APPLICANT: Kamme, Fredrik Carl
;  APPLICANT:  Zhu, Jessica Y.
;  TITLE OF INVENTION: METHODS FOR IMPROVING RNA TRANSCRIPTION REACTIONS
;  FILE REFERENCE: ORT1637-US
;  CURRENT APPLICATION NUMBER: US/10/514,349
;  CURRENT FILING DATE:  2004-11-12
;  PRIOR APPLICATION NUMBER: US 60/384,454
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: PCT/US03/17103
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Transcription reagent
US-10-514-349-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 29;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 32
US-10-514-349-8
; Sequence 8, Application US/10514349
; Publication No. US20060105331A1
; GENERAL INFORMATION:
;  APPLICANT: Kamme, Fredrik Carl
```

```
;  APPLICANT:  Zhu, Jessica Y.
;  TITLE OF INVENTION: METHODS FOR IMPROVING RNA TRANSCRIPTION REACTIONS
;  FILE REFERENCE: ORT1637-US
;  CURRENT APPLICATION NUMBER: US/10/514,349
;  CURRENT FILING DATE:  2004-11-12
;  PRIOR APPLICATION NUMBER: US 60/384,454
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: PCT/US03/17103
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Transcription reagent
US-10-514-349-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 31;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 33
US-10-753-718-4272
; Sequence 4272, Application US/10753718
; Publication No. US20060178326A1
; GENERAL INFORMATION:
;  APPLICANT: Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE: 480124.407
;  CURRENT APPLICATION NUMBER: US/10/753,718
;  CURRENT FILING DATE:  2004-01-08
;  PRIOR APPLICATION NUMBER: US/09/696,791
;  PRIOR FILING DATE: 2000-10-25
;  NUMBER OF SEQ ID NOS: 4523
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4272
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-10-753-718-4272

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   56.2%;  Pred. No. 31;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGCC 3381
              :|||::::||||::|||
Db          3 TGATTTTGGCCTTGCC 18


RESULT 34
US-11-211-917-144
; Sequence 144, Application US/11211917
; Publication No. US20060093600A1
; GENERAL INFORMATION:
;  APPLICANT: BEDIAN, VAHE
;  APPLICANT:  GLADUE, RONALD P.
;  APPLICANT:  CORVALAN, JOSE
;  APPLICANT:  JIA, XIAO-CHI
;  APPLICANT:  FENG, XIAO
;  TITLE OF INVENTION: ANTIBODIES TO CD40
;  FILE REFERENCE: ABX-PF/3 US
;  CURRENT APPLICATION NUMBER: US/11/211,917
;  CURRENT FILING DATE:  2005-08-25
;  PRIOR APPLICATION NUMBER: US/10/292,088
;  PRIOR FILING DATE: 2002-11-08
;  PRIOR APPLICATION NUMBER: 60/348,980
;  PRIOR FILING DATE: 2001-11-09
;  NUMBER OF SEQ ID NOS: 147
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 144
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-11-211-917-144

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 31;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 35
US-11-301-360-913
; Sequence 913, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 31;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 36
US-11-301-360-939
; Sequence 939, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
```

```
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 31;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 37
US-11-102-097-111
; Sequence 111, Application US/11102097
; Publication No. US20060160759A1
; GENERAL INFORMATION:
;  APPLICANT: Chen, et al.
;  TITLE OF INVENTION: Influenza Therapeutic
;  FILE REFERENCE: 0492611-0621
;  CURRENT APPLICATION NUMBER: US/11/102,097
;  CURRENT FILING DATE:  2005-04-08
;  NUMBER OF SEQ ID NOS: 2926
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 111
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: mRNA
US-11-102-097-111

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 31;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 38
US-10-424-339-163/c
; Sequence 163, Application US/10424339
; Publication No. US20060127891A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Polisky, Barry
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of MAP Kinase Gene
;  TITLE OF INVENTION:  Expression or Expression of Genes Involved in MAP Kinase Pathway
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/113 (MBHB03-388)
;  CURRENT APPLICATION NUMBER: US/10/424,339
;  CURRENT FILING DATE:  2003-04-25
;  PRIOR APPLICATION NUMBER: PCT/US 03/02510
;  PRIOR FILING DATE: 2003-01-28
;  PRIOR APPLICATION NUMBER: PCT/US 03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  NUMBER OF SEQ ID NOS: 1714
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense
US-10-424-339-163

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 33;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 39
US-10-424-339-326
; Sequence 326, Application US/10424339
; Publication No. US20060127891A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Polisky, Barry
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of MAP Kinase Gene
;  TITLE OF INVENTION:  Expression or Expression of Genes Involved in MAP Kinase Pathwa
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/113 (MBHB03-388)
;  CURRENT APPLICATION NUMBER: US/10/424,339
;  CURRENT FILING DATE:  2003-04-25
;  PRIOR APPLICATION NUMBER: PCT/US 03/02510
;  PRIOR FILING DATE: 2003-01-28
;  PRIOR APPLICATION NUMBER: PCT/US 03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
```

```
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  NUMBER OF SEQ ID NOS: 1714
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-424-339-326

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 40
US-10-533-166-29/c
; Sequence 29, Application US/10533166
; Publication No. US20060172302A1
; GENERAL INFORMATION:
;  APPLICANT: HERMANSEN, Arne
;  APPLICANT:  KLEMSDAL, Sonja
;  APPLICANT:  NAERSTAD, Ragnhild
;  APPLICANT:  WANNER, Leslie
;  APPLICANT:  LUND, Grete
;  TITLE OF INVENTION: ASSAY METHOD
;  FILE REFERENCE: Q87648
;  CURRENT APPLICATION NUMBER: US/10/533,166
;  CURRENT FILING DATE:  2005-04-29
;  PRIOR APPLICATION NUMBER: GB 0225550.3
;  PRIOR FILING DATE: 2002-11-01
;  PRIOR APPLICATION NUMBER: GB 0225551.1
;  PRIOR FILING DATE: 2002-11-01
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 29
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Chemically-synthesized oligonucleotide primer
US-10-533-166-29

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 33;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 41
US-11-224-573-153/c
; Sequence 153, Application US/11224573
; Publication No. US20060134660A1
; GENERAL INFORMATION:
;  APPLICANT: Quinlan, et al.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0046
;  CURRENT APPLICATION NUMBER: US/11/224,573
;  CURRENT FILING DATE:  2005-09-12
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 153
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Anti-alien in spike control concept.  Sequences of alien genes
;   OTHER INFORMATION: designed by linking four 70mer alien sequences together.
US-11-224-573-153

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 33;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 42
US-11-217-936-3874/c
; Sequence 3874, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3874
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-3874

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 33;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 43
US-11-217-936-3970
; Sequence 3970, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3970
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-3970
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 44
US-11-217-936-4807/c
; Sequence 4807, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4807
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-4807

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 33;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 45
US-11-217-936-4904
; Sequence 4904, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4904
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-4904

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 46
US-11-334-885-1/c
; Sequence 1, Application US/11334885
; Publication No. US20060166246A1
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Biotechnology Inc.
;  APPLICANT:  Barnett, Charles Jason
;  APPLICANT:  Beck, Jim
;  TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase
;  TITLE OF INVENTION:  Chain Reaction
;  FILE REFERENCE: 60063P1
;  CURRENT APPLICATION NUMBER: US/11/334,885
;  CURRENT FILING DATE:  2006-01-19
;  PRIOR APPLICATION NUMBER: US/10/623,880
;  PRIOR FILING DATE: 2003-07-21
;  PRIOR APPLICATION NUMBER: US/09/939,379B
;  PRIOR FILING DATE: 2001-08-24
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1) . .(19)
;   OTHER INFORMATION: Primer ITS1
US-11-334-885-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 33;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 47
US-10-514-349-11/c
; Sequence 11, Application US/10514349
; Publication No. US20060105331A1
; GENERAL INFORMATION:
;  APPLICANT: Kamme, Fredrik Carl
;  APPLICANT:  Zhu, Jessica Y.
;  TITLE OF INVENTION: METHODS FOR IMPROVING RNA TRANSCRIPTION REACTIONS
;  FILE REFERENCE: ORT1637-US
;  CURRENT APPLICATION NUMBER: US/10/514,349
;  CURRENT FILING DATE:  2004-11-12
;  PRIOR APPLICATION NUMBER: US 60/384,454
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: PCT/US03/17103
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Transcription reagent
US-10-514-349-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5
```

```
RESULT 48
US-11-053-733A-2
; Sequence 2, Application US/11053733A
; Publication No. US20060178509A1
; GENERAL INFORMATION:
;  APPLICANT: Kalakota, Reddy S
;  TITLE OF INVENTION: Phosphoramidite Activator for Oligonucleotide Synthesis
;  FILE REFERENCE: H0008499-4734
;  CURRENT APPLICATION NUMBER: US/11/053,733A
;  CURRENT FILING DATE:  2005-02-08
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: RNA 20-mer
US-11-053-733A-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 49
US-11-248-241-1/c
; Sequence 1, Application US/11248241
; Publication No. US20060105366A1
; GENERAL INFORMATION:
;  APPLICANT: Shinichi HIROSHIMA
;  APPLICANT:  Hiroshi TAKIGUCHI
;  APPLICANT:  Hitoshi FUKUSHIMA
;  APPLICANT:  Shinobu YOKOKAWA
;  TITLE OF INVENTION: Specific Base Sequence Detection Method and Primer
;  TITLE OF INVENTION:  Extension Reaction Detection Method
;  FILE REFERENCE: 125119
;  CURRENT APPLICATION NUMBER: US/11/248,241
;  CURRENT FILING DATE:  2005-10-13
;  PRIOR APPLICATION NUMBER: JP 2004-331367
;  PRIOR FILING DATE: 2004-11-16
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: a probe immobilized on an electrode
US-11-248-241-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 50
US-11-248-241-2
; Sequence 2, Application US/11248241
; Publication No. US20060105366A1
; GENERAL INFORMATION:
;  APPLICANT: Shinichi HIROSHIMA
;  APPLICANT:  Hiroshi TAKIGUCHI
;  APPLICANT:  Hitoshi FUKUSHIMA
;  APPLICANT:  Shinobu YOKOKAWA
;  TITLE OF INVENTION: Specific Base Sequence Detection Method and Primer
;  TITLE OF INVENTION:  Extension Reaction Detection Method
;  FILE REFERENCE: 125119
;  CURRENT APPLICATION NUMBER: US/11/248,241
;  CURRENT FILING DATE:  2005-10-13
;  PRIOR APPLICATION NUMBER: JP 2004-331367
;  PRIOR FILING DATE: 2004-11-16
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: a probe immobilized on an electrode
US-11-248-241-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 51
US-11-224-573-158/c
; Sequence 158, Application US/11224573
; Publication No. US20060134660A1
; GENERAL INFORMATION:
;  APPLICANT: Quinlan, et al.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0046
;  CURRENT APPLICATION NUMBER: US/11/224,573
;  CURRENT FILING DATE:  2005-09-12
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Anti-alien in spike control concept.  Sequences of alien genes
;   OTHER INFORMATION: designed by linking four 70mer alien sequences together.
US-11-224-573-158

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 52
US-11-224-573-163/c
; Sequence 163, Application US/11224573
; Publication No. US20060134660A1
; GENERAL INFORMATION:
;  APPLICANT: Quinlan, et al.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0046
;  CURRENT APPLICATION NUMBER: US/11/224,573
;  CURRENT FILING DATE:  2005-09-12
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
```

```
;   FEATURE:
;   OTHER INFORMATION: Anti-alien in spike control concept.  Sequences of alien genes
;   OTHER INFORMATION: designed by linking four 70mer alien sequences together.
US-11-224-573-163

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 53
US-11-254-920-11/c
; Sequence 11, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: A20 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(20)
;   OTHER INFORMATION: Phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)...(0)
;   OTHER INFORMATION: FITC label
US-11-254-920-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 54
US-11-254-920-14
; Sequence 14, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: T20 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(20)
;   OTHER INFORMATION: Phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)...(0)
;   OTHER INFORMATION: FITC label
US-11-254-920-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 55
US-11-301-360-226
; Sequence 226, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-226

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 56
US-11-301-360-556
; Sequence 556, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
```

```
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 57
US-11-301-360-560/c
; Sequence 560, Application US/11301360
; Publication No. US20060154890A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE
;  TITLE OF INVENTION:  TREATMENT OF ASTHMA AND ALLERGY
;  FILE REFERENCE: C1037.70013US02
;  CURRENT APPLICATION NUMBER: US/11/301,360
;  CURRENT FILING DATE:  2005-12-09
;  PRIOR APPLICATION NUMBER: US 09/776,479
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-11-301-360-560

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 34;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 58
US-10-501-834-70/c
; Sequence 70, Application US/10501834
; Publication No. US20060088828A1
; GENERAL INFORMATION:
;  APPLICANT: Harris, Peter C., Ward, Christopher J., Rossetti, Sandro, and Torres,
;  APPLICANT:  Vicente E.
;  TITLE OF INVENTION: Polycystic Kidney Disease Nucleic Acids
;  TITLE OF INVENTION:  and Proteins
;  FILE REFERENCE: 07039/386US1
;  CURRENT APPLICATION NUMBER: US/10/501,834
;  CURRENT FILING DATE:  2004-07-19
;  PRIOR APPLICATION NUMBER: PCT/US03/02038
;  PRIOR FILING DATE: 2003-01-23
;  PRIOR APPLICATION NUMBER: 60/351,110
;  PRIOR FILING DATE: 2002-01-23
;  NUMBER OF SEQ ID NOS: 221
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 70
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-501-834-70

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 35;
  Matches    9;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6998 GUGUGUGUGUGUGUGUGGG 7016
              |: :|:|:|:|:|:|:|: ||
Db         19 GTATGTGTGTGTGTGTAGG 1


RESULT 59
US-11-217-936-27
; Sequence 27, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 27
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-27

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 35;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2933 UGGGAGCCUGCACCAAGCA 2951
              |||| |||||||||| |||
Db          1 UGGGGGCCUGCACCAUGCA 19


RESULT 60
US-11-217-936-142/c
; Sequence 142, Application US/11217936
; Publication No. US20060148743A1
; GENERAL INFORMATION:
;  APPLICANT: Jadhab, Vasant
;  APPLICANT:  Carroll, Joseph
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Histone Deacetylase
;  TITLE OF INVENTION:  (HDAC) Gene Expression Using Short Interfering Nucleic Acid
;  TITLE OF INVENTION:  (siNA)
;  FILE REFERENCE: 05-727 (400/271)
;  CURRENT APPLICATION NUMBER: US/11/217,936
;  CURRENT FILING DATE:  2005-09-01
;  NUMBER OF SEQ ID NOS: 5036
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 142
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-11-217-936-142

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 35;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2933 UGGGAGCCUGCACCAAGCA 2951
              :||| |||:|||||| |||
Db         19 TGGGGGCCTGCACCATGCA 1


RESULT 61
US-11-255-139A-521
; Sequence 521, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 521
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-521

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUU 6359
              | ||||||||||||||||
Db          1 UUCUUUUUUUUUUUUU 17


RESULT 62
US-10-753-718-4087
; Sequence 4087, Application US/10753718
; Publication No. US20060178326A1
; GENERAL INFORMATION:
;  APPLICANT: Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE: 480124.407
;  CURRENT APPLICATION NUMBER: US/10/753,718
;  CURRENT FILING DATE:  2004-01-08
;  PRIOR APPLICATION NUMBER: US/09/696,791
;  PRIOR FILING DATE: 2000-10-25
;  NUMBER OF SEQ ID NOS: 4523
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4087
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-10-753-718-4087

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 41;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          3 TTGTGATTTTTATAATA 19


RESULT 63
US-10-753-718-4088
; Sequence 4088, Application US/10753718
; Publication No. US20060178326A1
; GENERAL INFORMATION:
;  APPLICANT: Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE: 480124.407
;  CURRENT APPLICATION NUMBER: US/10/753,718
;  CURRENT FILING DATE:  2004-01-08
;  PRIOR APPLICATION NUMBER: US/09/696,791
;  PRIOR FILING DATE: 2000-10-25
;  NUMBER OF SEQ ID NOS: 4523
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4088
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-10-753-718-4088

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 41;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          2 TTGTGATTTTTATAATA 18


RESULT 64
US-10-753-718-4089
; Sequence 4089, Application US/10753718
; Publication No. US20060178326A1
; GENERAL INFORMATION:
;  APPLICANT: Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE: 480124.407
;  CURRENT APPLICATION NUMBER: US/10/753,718
;  CURRENT FILING DATE:  2004-01-08
;  PRIOR APPLICATION NUMBER: US/09/696,791
;  PRIOR FILING DATE: 2000-10-25
;  NUMBER OF SEQ ID NOS: 4523
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4089
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-10-753-718-4089

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 41;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          1 TTGTGATTTTTATAATA 17


RESULT 65
US-11-344-702-596/c
; Sequence 596, Application US/11344702
```

```
; Publication No. US20060172963A1
; GENERAL INFORMATION:
;  APPLICANT: Shepard, Allan R.
;  APPLICANT:  Chatterton, Jon E.
;  APPLICANT:  Clark, Abbot F.
;  TITLE OF INVENTION: RNAi-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS
;  FILE REFERENCE: 45263-P008US1
;  CURRENT APPLICATION NUMBER: US/11/344,702
;  CURRENT FILING DATE:  2006-02-01
;  PRIOR APPLICATION NUMBER: US 60/648,926
;  PRIOR FILING DATE: 2005-02-01
;  PRIOR APPLICATION NUMBER: US 60/753,364
;  PRIOR FILING DATE: 2005-12-22
;  NUMBER OF SEQ ID NOS: 724
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 596
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: TARGETING SEQUENCE
US-11-344-702-596

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   47.1%;  Pred. No. 41;
  Matches    8;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              : :|:|:|:|:|:|:||
Db         19 TTTGTGTGTGTGTGTGG 3


RESULT 66
US-11-345-361-596/c
; Sequence 596, Application US/11345361
; Publication No. US20060172965A1
; GENERAL INFORMATION:
;  APPLICANT: Shepard, Allan R.
;  APPLICANT:  Chatterton, Jon E.
;  APPLICANT:  Clark, Abbot F.
;  APPLICANT:  Wax, Martin B.
;  TITLE OF INVENTION: RNAi-MEDIATED INHIBITION OF OCULAR TARGETS
;  FILE REFERENCE: 45263-P008US2
;  CURRENT APPLICATION NUMBER: US/11/345,361
;  CURRENT FILING DATE:  2006-02-01
;  PRIOR APPLICATION NUMBER: US 60/648,926
;  PRIOR FILING DATE: 2005-02-01
;  PRIOR APPLICATION NUMBER: US 60/753,364
;  PRIOR FILING DATE: 2005-12-22
;  NUMBER OF SEQ ID NOS: 724
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 596
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: TARGETING SEQUENCE
US-11-345-361-596

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   47.1%;  Pred. No. 41;
  Matches    8;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              : :|:|:|:|:|:|:||
Db         19 TTTGTGTGTGTGTGTGG 3


RESULT 67
US-10-514-349-5
; Sequence 5, Application US/10514349
; Publication No. US20060105331A1
; GENERAL INFORMATION:
;  APPLICANT: Kamme, Fredrik Carl
;  APPLICANT:  Zhu, Jessica Y.
;  TITLE OF INVENTION: METHODS FOR IMPROVING RNA TRANSCRIPTION REACTIONS
;  FILE REFERENCE: ORT1637-US
;  CURRENT APPLICATION NUMBER: US/10/514,349
;  CURRENT FILING DATE:  2004-11-12
;  PRIOR APPLICATION NUMBER: US 60/384,454
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: PCT/US03/17103
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Transcription reagent
US-10-514-349-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 38;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 68
US-10-250-492-13
; Sequence 13, Application US/10250492
; Publication No. US20060149046A1
; GENERAL INFORMATION:
;  APPLICANT: Proligo, LLC
;  APPLICANT:  ARAR, Khalil
;  TITLE OF INVENTION: Methods and compositions for the serial synthesis of two or more
;  TITLE OF INVENTION:  oligonucleotides on the same solid support
;  FILE REFERENCE: PRO.10
;  CURRENT APPLICATION NUMBER: US/10/250,492
;  CURRENT FILING DATE:  2003-07-01
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Ligand
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(15)
US-10-250-492-13

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 38;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 69
US-10-691-012-17
; Sequence 17, Application US/10691012
; Publication No. US20060160731A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
```

```
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/10/691,012
;  CURRENT FILING DATE:  2003-10-22
;  PRIOR APPLICATION NUMBER: US/08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Novel Sequence
US-10-691-012-17

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 38;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 70
US-10-691-012-18/c
; Sequence 18, Application US/10691012
; Publication No. US20060160731A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/10/691,012
;  CURRENT FILING DATE:  2003-10-22
;  PRIOR APPLICATION NUMBER: US/08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Novel Sequence
US-10-691-012-18

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 38;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 71
US-11-242-139-239/c
; Sequence 239, Application US/11242139
; Publication No. US20060099619A1
; GENERAL INFORMATION:
;  APPLICANT: REMACLE, JOSE
;  APPLICANT:  DU LONGUEVILLE, FRANCOISE
;  APPLICANT:  HAMELS, SANDRINE
;  TITLE OF INVENTION: DETECTION AND QUANTIFICATION OF MIRNA ON MICRO-ARRAYS
;  FILE REFERENCE: 035642-0107
;  CURRENT APPLICATION NUMBER: US/11/242,139
;  CURRENT FILING DATE:  2005-10-04
;  PRIOR APPLICATION NUMBER: 10/637,656
;  PRIOR FILING DATE: 2003-08-11
;  NUMBER OF SEQ ID NOS: 239
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: poly A sequence
US-11-242-139-239

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 38;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 72
US-11-255-139A-522
; Sequence 522, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 522
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-522

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
              |||||||||||||||
Db          2 CUUUUUUUUUUUUUU 16


RESULT 73
US-11-255-139A-523
; Sequence 523, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-523

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
```

```
              ||||||||||||||||
Db          1 CUUUUUUUUUUUUUU 15


RESULT 74
US-10-753-718-4271
; Sequence 4271, Application US/10753718
; Publication No. US20060178326A1
; GENERAL INFORMATION:
;  APPLICANT: Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE: 480124.407
;  CURRENT APPLICATION NUMBER: US/10/753,718
;  CURRENT FILING DATE:  2004-01-08
;  PRIOR APPLICATION NUMBER: US/09/696,791
;  PRIOR FILING DATE: 2000-10-25
;  NUMBER OF SEQ ID NOS: 4523
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4271
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-10-753-718-4271

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   53.3%;  Pred. No. 45;
  Matches    8;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGC 3380
              :||::::||||::||
Db          4 TGATTTTGGCCTTGC 18


RESULT 75
US-11-340-574-44/c
; Sequence 44, Application US/11340574
; Publication No. US20060177856A1
; GENERAL INFORMATION:
;  APPLICANT: KURANE, RYUICHIRO
;  APPLICANT:  KANAGAWA, TAKAHIRO
;  APPLICANT:  KAMAGATA, YOICHI
;  APPLICANT:  YAMADA, KAZUTAKA
;  APPLICANT:  YOKOMAKU, TOYOKAZU
;  APPLICANT:  KOYAMA, OSAMU
;  APPLICANT:  FURUSHO, KENTA
;  TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
;  TITLE OF INVENTION:  NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
;  TITLE OF INVENTION:  THE METHOD
;  FILE REFERENCE: 199953US0XDIV
;  CURRENT APPLICATION NUMBER: US/11/340,574
;  CURRENT FILING DATE:  2006-01-27
;  PRIOR APPLICATION NUMBER: US/09/725,265
;  PRIOR FILING DATE: 2000-11-29
;  PRIOR APPLICATION NUMBER: US 09/556,127
;  PRIOR FILING DATE: 2000-04-20
;  PRIOR APPLICATION NUMBER: JP 1999-111601
;  PRIOR FILING DATE: 1999-04-20
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
US-11-340-574-44

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   13.3%;  Pred. No. 45;
  Matches    2;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCC 6363
              :::::::::::::||
Db         18 TTTTTTTTTTTTCC 4


RESULT 76
US-11-257-851A-23
; Sequence 23, Application US/11257851A
; Publication No. US20060105951A1
; GENERAL INFORMATION:
;  APPLICANT: Cunningham, Mark
;  APPLICANT:  Stojanovic-Susulic, Vedrana
;  APPLICANT:  O'Neil, Karyn
;  APPLICANT:  Huang, Chichi
;  APPLICANT:  Luo, Jeffrey
;  TITLE OF INVENTION: Melanocortin Receptor Binding Mimetibodies, Compositions, Methods
;  TITLE OF INVENTION:  Uses
;  FILE REFERENCE: CEN5080 USA NP
;  CURRENT APPLICATION NUMBER: US/11/257,851A
;  CURRENT FILING DATE:  2005-10-25
;  PRIOR APPLICATION NUMBER: 60/621,960
;  PRIOR FILING DATE: 2004-10-25
;  NUMBER OF SEQ ID NOS: 85
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: In Vitro synthesized DNA encoding a flexible peptide sequence
US-11-257-851A-23

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         27 GGCAGCGGCGGCGGC 41
              |||||||||||||||
Db          1 GGCAGCGGCGGCGGC 15


RESULT 77
US-11-257-851A-29
; Sequence 29, Application US/11257851A
; Publication No. US20060105951A1
; GENERAL INFORMATION:
;  APPLICANT: Cunningham, Mark
;  APPLICANT:  Stojanovic-Susulic, Vedrana
;  APPLICANT:  O'Neil, Karyn
;  APPLICANT:  Huang, Chichi
;  APPLICANT:  Luo, Jeffrey
;  TITLE OF INVENTION: Melanocortin Receptor Binding Mimetibodies, Compositions, Methods
;  TITLE OF INVENTION:  Uses
;  FILE REFERENCE: CEN5080 USA NP
;  CURRENT APPLICATION NUMBER: US/11/257,851A
;  CURRENT FILING DATE:  2005-10-25
;  PRIOR APPLICATION NUMBER: 60/621,960
;  PRIOR FILING DATE: 2004-10-25
;  NUMBER OF SEQ ID NOS: 85
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: In Vitro synthesized DNA encoding a flexible peptide sequence
US-11-257-851A-29

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          27 GGCAGCGGCGGCGGC 41
               ||||||||||||||||
Db           1 GGCAGCGGCGGCGGC 15


RESULT 78
US-11-254-920-23
; Sequence 23, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: REP 2055 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(40)
;   OTHER INFORMATION: Phosphorothioate linkages
US-11-254-920-23

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 67;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy         899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
               | ||| ||   | ||||||   ||| ||  | |||  ||
Db           1 ACACACACACACACACACACACACACACACACACACACA 39


RESULT 79
US-11-254-920-26/c
; Sequence 26, Application US/11254920
; Publication No. US20060135458A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 0999266-0000
;  CURRENT APPLICATION NUMBER: US/11/254,920
;  CURRENT FILING DATE:  2005-10-20
;  PRIOR APPLICATION NUMBER: US 10/969,812
;  PRIOR FILING DATE: 2004-10-19
;  PRIOR APPLICATION NUMBER: US 60/668,983
;  PRIOR FILING DATE: 2005-04-07
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Rep 2033 oligomer
;   FEATURE:
;   NAME/KEY: misc_structure
;   LOCATION: (1)...(40)
;   OTHER INFORMATION: Phosphorothioate linkages
US-11-254-920-26

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 67;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy         899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
               | ||| ||   | ||||||   ||| ||  | |||  ||
Db          39 ACACACACACACACACACACACACACACACACACACACA 1


RESULT 80
US-10-524-432-365/c
; Sequence 365, Application US/10524432
; Publication No. US20060127902A1
; GENERAL INFORMATION:
;  APPLICANT: Genzyme Corporation
;  APPLICANT:  The Johns Hopkins University
;  TITLE OF INVENTION: BRAIN ENDOTHELIAL EXPRESSION PATTERNS
;  FILE REFERENCE: 003482.00010
;  CURRENT APPLICATION NUMBER: US/10/524,432
;  CURRENT FILING DATE:  2005-02-15
;  PRIOR APPLICATION NUMBER: US 60/403,390
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: US 60/458,978
;  PRIOR FILING DATE: 2003-04-01
;  NUMBER OF SEQ ID NOS: 869
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 365
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-524-432-365

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 53;
  Matches    9;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        7003 UGUGUGUGUGUGGGUG 7018
               :|:|:|:|:| |||:|
Db          17 TGTGTGTGTGAGGGTG 2


RESULT 81
US-11-255-139A-520
; Sequence 520, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 520
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-520

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 53;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        6343 UACUUUUUUUUUUUUU 6358
               | ||||||||||||||
Db           2 UUCUUUUUUUUUUUUU 17


RESULT 82
US-10-858-013-990/c
; Sequence 990, Application US/10858013
```

```
; Publication No. US20060135455A1
; GENERAL INFORMATION:
;  APPLICANT: Sheikhnejad, Reza
;  APPLICANT:  Sooch, Mina P.
;  APPLICANT:  Goodwin, Neal
;  APPLICANT:  Olson, David
;  TITLE OF INVENTION: Methods and Compositions for the Inhibition of Gene Expression
;  FILE REFERENCE: PRONAI-09056
;  CURRENT APPLICATION NUMBER: US/10/858,013
;  CURRENT FILING DATE:  2004-06-01
;  NUMBER OF SEQ ID NOS: 1439
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 990
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (5)..(5)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (8)..(8)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (11)..(11)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: methylated C nucleotide
US-10-858-013-990

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              |||| ||||||||||
Db         18 CGGCGGCGGCGGCGGC 3


RESULT 83
US-11-370-584-4233
; Sequence 4233, Application US/11370584
; Publication No. US20060177863A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high
;  TITLE OF INVENTION:  density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/11/370,584
;  CURRENT FILING DATE:  2006-03-08
;  PRIOR APPLICATION NUMBER: US/10/349,143
;  PRIOR FILING DATE: 2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4233
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-14090 for SEQ 299,
US-11-370-584-4233

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 56;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2416 GAAGAGGAUGAAGGUG 2431
              |||||||:|||| :|
Db          2 GAAGAGGATGAAGCTG 17


RESULT 84
US-11-370-584-7435/c
; Sequence 7435, Application US/11370584
; Publication No. US20060177863A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high
;  TITLE OF INVENTION:  density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/11/370,584
;  CURRENT FILING DATE:  2006-03-08
;  PRIOR APPLICATION NUMBER: US/10/349,143
;  PRIOR FILING DATE: 2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7435
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-4649 for SEQ 3501,
US-11-370-584-7435

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 56;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1734 CAGCAACAUGGGAAAC 1749
              | ||||||:|||||||
Db         18 CTGCAACATGGGAAAC 3


RESULT 85
US-11-255-139A-524
; Sequence 524, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
```

```
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 524
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-524

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6359
              ||||||||||||||
Db          1 UUUUUUUUUUUUUU 14


RESULT 86
US-10-524-432-480
; Sequence 480, Application US/10524432
; Publication No. US20060127902A1
; GENERAL INFORMATION:
;  APPLICANT: Genzyme Corporation
;  APPLICANT:  The Johns Hopkins University
;  TITLE OF INVENTION: BRAIN ENDOTHELIAL EXPRESSION PATTERNS
;  FILE REFERENCE: 003482.00010
;  CURRENT APPLICATION NUMBER: US/10/524,432
;  CURRENT FILING DATE:  2005-02-15
;  PRIOR APPLICATION NUMBER: US 60/403,390
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: US 60/458,978
;  PRIOR FILING DATE: 2003-04-01
;  NUMBER OF SEQ ID NOS: 869
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 480
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-524-432-480

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 65;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7637 CUUUGUAUUCUCCUUUG 7653
              |:::| | :|:||:::|
Db          1 CTTTGCACTCTCCTTTG 17


RESULT 87
US-11-255-139A-519
; Sequence 519, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 519
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-519

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 65;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6341 UCUACUUUUUUUUUUUU 6357
              | | ||||||||||||||
Db          1 UAUUCUUUUUUUUUUUU 17


RESULT 88
US-11-255-139A-1646
; Sequence 1646, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1646
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-1646

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 65;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |||| || |||||||||
Db          1 CUUUAUUCUUUUUUUUU 17


RESULT 89
US-11-255-139A-4373/c
; Sequence 4373, Application US/11255139A
; Publication No. US20060154271A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/11/255,139A
;  CURRENT FILING DATE:  2005-10-20
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4373
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-255-139A-4373

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 65;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4009 AUGCUGAAGCGCUUCAC 4025
              |:||:| || ||::|||
Db         17 ATGCTGGAGAGCTTCAC 1


Search completed: August 31, 2006, 15:04:02
Job time : 4 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 15:02:24 ; Search time 47 Seconds
(without alignments)
7.312 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 962 seqs, 22375 residues

Total number of hits satisfying chosen parameters: 1924

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 922 summaries

Published_Applications_NA_Main

Database : pubmaindb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	40	0.5	40	1	US-09-852-903C-25	Sequence 25, Appl
c	2	40	0.5	40	1	US-10-661-088-24	Sequence 24, Appl
c	3	40	0.5	40	1	US-10-661-097-24	Sequence 24, Appl
c	4	40	0.5	40	1	US-10-661-099-24	Sequence 24, Appl
c	5	40	0.5	40	1	US-10-661-355-24	Sequence 24, Appl
c	6	40	0.5	40	1	US-10-661-402-24	Sequence 24, Appl
c	7	40	0.5	40	1	US-10-661-403-24	Sequence 24, Appl
c	8	40	0.5	40	1	US-10-661-415-24	Sequence 24, Appl
c	9	40	0.5	40	1	US-10-969-812A-23	Sequence 23, Appl
	10	39	0.5	39	1	US-09-263-959-678	Sequence 678, App
c	11	38	0.5	38	1	US-09-852-903C-24	Sequence 24, Appl
	12	36.4	0.5	38	1	US-10-105-901-18	Sequence 18, Appl
	13	36.4	0.5	38	1	US-11-043-693-18	Sequence 18, Appl
c	14	36	0.5	36	1	US-09-852-903C-23	Sequence 23, Appl
c	15	36	0.5	36	1	US-09-909-317-7	Sequence 7, Appli
c	16	34	0.4	34	1	US-09-852-903C-22	Sequence 22, Appl
	17	33.4	0.4	36	1	US-10-105-901-6	Sequence 6, Appli
	18	33.4	0.4	36	1	US-11-043-693-6	Sequence 6, Appli
	19	32.4	0.4	34	1	US-09-263-959-711	Sequence 711, App
c	20	32	0.4	32	1	US-09-852-903C-21	Sequence 21, Appl
c	21	32	0.4	32	1	US-10-723-940-10	Sequence 10, Appl
	22	31.4	0.4	33	1	US-10-105-901-22	Sequence 22, Appl
	23	31.4	0.4	33	1	US-10-105-901-30	Sequence 30, Appl
	24	31.4	0.4	33	1	US-11-043-693-22	Sequence 22, Appl
	25	31.4	0.4	33	1	US-11-043-693-30	Sequence 30, Appl
	26	31	0.4	31	1	US-10-085-906-27	Sequence 27, Appl
	27	30.8	0.4	34	1	US-09-778-900A-15	Sequence 15, Appl
	28	30.8	0.4	34	1	US-10-621-116-15	Sequence 15, Appl
	29	30.6	0.4	31	1	US-09-778-900A-6	Sequence 6, Appli
	30	30.6	0.4	31	1	US-09-778-900A-7	Sequence 7, Appli
	31	30.6	0.4	31	1	US-09-778-900A-8	Sequence 8, Appli
	32	30.6	0.4	31	1	US-10-621-116-6	Sequence 6, Appli
	33	30.6	0.4	31	1	US-10-621-116-7	Sequence 7, Appli
	34	30.6	0.4	31	1	US-10-621-116-8	Sequence 8, Appli
	35	30.6	0.4	37	1	US-10-105-901-14	Sequence 14, Appl
	36	30.6	0.4	37	1	US-11-043-693-14	Sequence 14, Appl
	37	30	0.4	30	1	US-10-085-906-93	Sequence 93, Appl
c	38	28	0.4	28	1	US-09-778-900A-16	Sequence 16, Appl
c	39	28	0.4	28	1	US-10-621-116-16	Sequence 16, Appl
	40	28	0.4	28	1	US-11-085-982-21	Sequence 21, Appl
	41	28	0.4	31	1	US-09-778-900A-11	Sequence 11, Appl
	42	28	0.4	31	1	US-10-621-116-11	Sequence 11, Appl
	43	27.6	0.4	34	1	US-10-105-901-8	Sequence 8, Appli
	44	27.6	0.4	34	1	US-11-043-693-8	Sequence 8, Appli
	45	27.4	0.4	29	1	US-09-263-959-665	Sequence 665, App
	46	27	0.4	27	1	US-09-263-959-770	Sequence 770, App
	47	27	0.4	27	1	US-09-735-363A-1	Sequence 1, Appli
	48	27	0.4	27	1	US-09-735-363A-5	Sequence 5, Appli
	49	27	0.4	27	1	US-09-735-363A-66	Sequence 66, Appl
	50	27	0.4	27	1	US-10-168-327-2	Sequence 2, Appli
c	51	27	0.4	27	1	US-10-310-914A-167077	Sequence 167077,
	52	26.8	0.3	30	1	US-09-263-959-600	Sequence 600, App
	53	26.8	0.3	30	1	US-10-105-901-26	Sequence 26, Appl
	54	26.8	0.3	30	1	US-11-043-693-26	Sequence 26, Appl
	55	26.2	0.3	31	1	US-10-105-901-20	Sequence 20, Appl
	56	26.2	0.3	31	1	US-11-043-693-20	Sequence 20, Appl
c	57	26	0.3	26	1	US-09-953-318-5	Sequence 5, Appli
c	58	26	0.3	26	1	US-10-446-373-5	Sequence 5, Appli
c	59	25	0.3	25	1	US-10-105-901-36	Sequence 36, Appl
	60	25	0.3	25	1	US-10-105-901-37	Sequence 37, Appl
	61	25	0.3	25	1	US-10-246-091-21	Sequence 21, Appl
	62	25	0.3	25	1	US-10-246-091-23	Sequence 23, Appl
c	63	25	0.3	25	1	US-10-246-091-24	Sequence 24, Appl
	64	25	0.3	25	1	US-10-719-956-380113	Sequence 380113,
	65	25	0.3	25	1	US-10-809-189-43420	Sequence 43420, A
	66	25	0.3	25	1	US-10-809-189-43421	Sequence 43421, A
	67	25	0.3	25	1	US-10-809-189-43422	Sequence 43422, A
	68	25	0.3	25	1	US-10-809-189-43423	Sequence 43423, A
	69	25	0.3	25	1	US-10-809-189-43424	Sequence 43424, A
	70	25	0.3	25	1	US-10-809-189-43425	Sequence 43425, A
	71	25	0.3	25	1	US-10-809-189-43426	Sequence 43426, A
	72	25	0.3	25	1	US-10-809-189-43427	Sequence 43427, A
	73	25	0.3	25	1	US-10-809-189-43428	Sequence 43428, A
	74	25	0.3	25	1	US-10-809-189-43429	Sequence 43429, A
	75	25	0.3	25	1	US-10-809-189-43430	Sequence 43430, A
	76	25	0.3	25	1	US-10-809-189-43431	Sequence 43431, A
	77	25	0.3	25	1	US-10-809-189-43432	Sequence 43432, A
	78	25	0.3	25	1	US-10-809-189-43433	Sequence 43433, A
	79	25	0.3	25	1	US-10-809-189-43434	Sequence 43434, A
	80	25	0.3	25	1	US-10-809-189-43435	Sequence 43435, A
	81	25	0.3	25	1	US-10-809-189-43436	Sequence 43436, A
	82	25	0.3	25	1	US-10-809-189-43437	Sequence 43437, A
	83	25	0.3	25	1	US-10-809-189-43438	Sequence 43438, A
	84	25	0.3	25	1	US-10-809-189-43439	Sequence 43439, A
c	85	25	0.3	25	1	US-11-036-317-172411	Sequence 172411,
c	86	25	0.3	25	1	US-11-036-317-221149	Sequence 221149,
c	87	25	0.3	25	1	US-11-043-693-36	Sequence 36, Appl
	88	25	0.3	25	1	US-11-043-693-37	Sequence 37, Appl
	89	25	0.3	25	1	US-11-060-756-61058	Sequence 61058, A
	90	25	0.3	25	1	US-11-121-849-126900	Sequence 126900,
	91	25	0.3	25	1	US-11-121-849-126901	Sequence 126901,
	92	25	0.3	25	1	US-11-121-849-126902	Sequence 126902,
	93	25	0.3	25	1	US-11-121-849-126903	Sequence 126903,
	94	25	0.3	25	1	US-11-121-849-126904	Sequence 126904,
	95	25	0.3	25	1	US-11-121-849-126905	Sequence 126905,
	96	25	0.3	25	1	US-11-121-849-126906	Sequence 126906,
	97	25	0.3	25	1	US-11-121-849-126907	Sequence 126907,
	98	25	0.3	25	1	US-11-121-849-126908	Sequence 126908,
	99	25	0.3	25	1	US-11-121-849-126909	Sequence 126909,
	100	25	0.3	25	1	US-11-121-849-126910	Sequence 126910,
	101	25	0.3	25	1	US-11-121-849-280598	Sequence 280598,
	102	25	0.3	25	1	US-11-121-849-280599	Sequence 280599,
	103	25	0.3	25	1	US-11-121-849-280600	Sequence 280600,
	104	25	0.3	25	1	US-11-121-849-280601	Sequence 280601,
	105	25	0.3	25	1	US-11-121-849-280602	Sequence 280602,
	106	25	0.3	25	1	US-11-121-849-280603	Sequence 280603,

107	25	0.3	25	1	US-11-121-849-280604	Sequence 280604,
108	25	0.3	25	1	US-11-121-849-280605	Sequence 280605,
109	25	0.3	25	1	US-11-121-849-280606	Sequence 280606,
110	25	0.3	25	1	US-11-121-849-280607	Sequence 280607,
111	25	0.3	25	1	US-11-121-849-280608	Sequence 280608,
112	25	0.3	31	1	US-09-778-900A-12	Sequence 12, Appl
113	25	0.3	31	1	US-10-621-116-12	Sequence 12, Appl
114	24.6	0.3	25	1	US-10-750-185-22523	Sequence 22523, A
115	24.6	0.3	25	1	US-10-750-623-22523	Sequence 22523, A
116	24	0.3	24	1	US-09-735-363A-21	Sequence 21, Appl
117	24	0.3	24	1	US-09-735-363A-22	Sequence 22, Appl
118	24	0.3	24	1	US-09-776-479-1068	Sequence 1068, Ap
119	24	0.3	24	1	US-09-776-479-1068	Sequence 1068, Ap
c 120	24	0.3	24	1	US-09-805-761-44	Sequence 44, Appl
121	24	0.3	24	1	US-09-815-153-20	Sequence 20, Appl
c 122	24	0.3	24	1	US-09-909-317-6	Sequence 6, Appli
123	24	0.3	24	1	US-10-017-995-1068	Sequence 1068, Ap
124	24	0.3	24	1	US-10-112-653-1012	Sequence 1012, Ap
125	24	0.3	24	1	US-10-314-578-1068	Sequence 1068, Ap
126	24	0.3	24	1	US-10-374-307-12	Sequence 12, Appl
c 127	24	0.3	24	1	US-10-374-307-7	Sequence 7, Appli
128	24	0.3	24	1	US-10-428-487-78	Sequence 78, Appl
129	24	0.3	24	1	US-10-665-951-2254	Sequence 2254, Ap
130	24	0.3	24	1	US-10-758-155-2254	Sequence 2254, Ap
131	24	0.3	24	1	US-10-831-620-2254	Sequence 2254, Ap
132	24	0.3	24	1	US-10-831-778-1068	Sequence 1068, Ap
133	24	0.3	24	1	US-10-844-076-2254	Sequence 2254, Ap
134	24	0.3	24	1	US-10-857-715-112	Sequence 112, App
135	24	0.3	24	1	US-10-944-611-2707	Sequence 2707, Ap
136	24	0.3	24	1	US-10-962-898-2707	Sequence 2707, Ap
137	24	0.3	24	1	US-11-127-654-1012	Sequence 1012, Ap
c 138	23.4	0.3	25	1	US-10-455-470-30	Sequence 30, Appl
139	23.4	0.3	25	1	US-10-719-956-380112	Sequence 380112,
140	23.4	0.3	25	1	US-10-956-157-70209	Sequence 70209, A
141	23.4	0.3	25	1	US-11-036-317-435129	Sequence 435129,
142	23.4	0.3	25	1	US-11-136-527-109884	Sequence 109884,
143	23	0.3	23	1	US-09-805-761-42	Sequence 42, Appl
144	23	0.3	23	1	US-09-805-761-43	Sequence 43, Appl
c 145	23	0.3	23	1	US-09-815-153-32	Sequence 32, Appl
c 146	23	0.3	23	1	US-09-815-153-46	Sequence 46, Appl
147	23	0.3	23	1	US-10-101-018-10	Sequence 10, Appl
c 148	23	0.3	23	1	US-10-246-091-22	Sequence 22, Appl
c 149	23	0.3	23	1	US-10-428-487-76	Sequence 76, Appl
c 150	23	0.3	23	1	US-10-428-487-80	Sequence 80, Appl
151	23	0.3	23	1	US-10-915-896-605	Sequence 605, App
c 152	23	0.3	23	1	US-10-922-154-14	Sequence 14, Appl
153	22.2	0.3	27	1	US-10-105-901-16	Sequence 16, Appl
154	22.2	0.3	27	1	US-11-043-693-16	Sequence 16, Appl
155	22	0.3	22	1	US-09-815-153-33	Sequence 33, Appl
156	22	0.3	22	1	US-10-007-574-3	Sequence 3, Appli
c 157	22	0.3	22	1	US-10-007-574-4	Sequence 4, Appli
158	22	0.3	22	1	US-10-428-487-79	Sequence 79, Appl
159	22	0.3	22	1	US-11-085-982-19	Sequence 19, Appl
c 160	22	0.3	23	1	US-09-866-316B-1	Sequence 1, Appli
c 161	22	0.3	23	1	US-10-715-285-1	Sequence 1, Appli
c 162	22	0.3	25	1	US-09-866-316B-3	Sequence 3, Appli
c 163	22	0.3	25	1	US-10-715-285-3	Sequence 3, Appli
164	21.8	0.3	25	1	US-10-105-901-4	Sequence 4, Appli
165	21.8	0.3	25	1	US-10-716-029-50	Sequence 50, Appl
166	21.8	0.3	25	1	US-10-719-956-106703	Sequence 106703,
167	21.8	0.3	25	1	US-10-888-435-185	Sequence 185, App
168	21.8	0.3	25	1	US-11-036-317-433154	Sequence 433154,
169	21.8	0.3	25	1	US-11-036-317-518975	Sequence 518975,
170	21.8	0.3	25	1	US-11-036-317-813720	Sequence 813720,
171	21.8	0.3	25	1	US-11-036-317-813721	Sequence 813721,
172	21.8	0.3	25	1	US-11-036-317-822861	Sequence 822861,
173	21.8	0.3	25	1	US-11-043-693-4	Sequence 4, Appli
174	21.8	0.3	25	1	US-11-121-634-89	Sequence 89, Appl
c 175	21.4	0.3	23	1	US-09-263-959-774	Sequence 774, App
c 176	21.4	0.3	23	1	US-09-805-761-45	Sequence 45, Appl
177	21.4	0.3	25	1	US-10-719-900-140318	Sequence 140318,
178	21	0.3	21	1	US-09-735-363A-19	Sequence 19, Appl
179	21	0.3	21	1	US-09-735-363A-20	Sequence 20, Appl
180	21	0.3	21	1	US-09-776-479-907	Sequence 907, App
181	21	0.3	21	1	US-10-017-995-907	Sequence 907, App
182	21	0.3	21	1	US-10-112-653-876	Sequence 876, App
183	21	0.3	21	1	US-10-160-232-3	Sequence 3, Appli
184	21	0.3	21	1	US-10-314-578-907	Sequence 907, App
185	21	0.3	21	1	US-10-425-668-7	Sequence 7, Appli
c 186	21	0.3	21	1	US-10-506-997-89	Sequence 89, Appl
c 187	21	0.3	21	1	US-10-727-780A-24	Sequence 24, Appl
188	21	0.3	21	1	US-10-831-778-907	Sequence 907, App
189	21	0.3	21	1	US-11-127-654-876	Sequence 876, App
190	21	0.3	21	1	US-11-250-411-3	Sequence 3, Appli
191	20.8	0.3	24	1	US-10-655-727-3	Sequence 3, Appli
c 192	20.8	0.3	24	1	US-10-845-667-1307	Sequence 1307, Ap
c 193	20.8	0.3	24	1	US-10-845-667-557	Sequence 557, App
c 194	20.8	0.3	24	1	US-10-973-783-936	Sequence 936, App
195	20.8	0.3	25	1	US-10-719-900-468567	Sequence 468567,
196	20.8	0.3	25	1	US-10-719-900-572884	Sequence 572884,
197	20.8	0.3	25	1	US-10-719-900-695000	Sequence 695000,
c 198	20.8	0.3	25	1	US-11-036-317-13707	Sequence 13707, A
199	20.8	0.3	25	1	US-11-036-317-410272	Sequence 410272,
200	20.4	0.3	23	1	US-10-357-488-5	Sequence 5, Appli
c 201	20.4	0.3	24	1	US-11-216-660-131	Sequence 131, App
202	20.2	0.3	25	1	US-10-469-313A-2	Sequence 2, Appli
203	20.2	0.3	25	1	US-10-719-900-800686	Sequence 800686,
204	20.2	0.3	25	1	US-10-719-956-106704	Sequence 106704,
205	20.2	0.3	25	1	US-10-719-956-229476	Sequence 229476,
206	20.2	0.3	25	1	US-10-888-435-187	Sequence 187, App
207	20.2	0.3	25	1	US-10-932-182A-38533	Sequence 38533, A
208	20.2	0.3	25	1	US-11-036-317-189348	Sequence 189348,
209	20.2	0.3	25	1	US-11-036-317-418561	Sequence 418561,
210	20.2	0.3	25	1	US-11-036-317-431134	Sequence 431134,
211	20.2	0.3	25	1	US-11-036-317-436168	Sequence 436168,
212	20.2	0.3	25	1	US-11-036-317-518974	Sequence 518974,
213	20.2	0.3	25	1	US-11-036-317-822860	Sequence 822860,
214	20.2	0.3	25	1	US-11-036-317-870867	Sequence 870867,
c 215	20.2	0.3	25	1	US-11-121-849-343059	Sequence 343059,
216	20.2	0.3	70	1	US/10/763	Sequence 132, App
217	20	0.3	20	1	US-09-845-742B-1	Sequence 1, Appli
c 218	20	0.3	20	1	US-09-845-742B-2	Sequence 2, Appli
219	20	0.3	20	1	US-09-916-369A-4	Sequence 4, Appli
220	20	0.3	20	1	US-10-085-906-33	Sequence 33, Appl
221	20	0.3	20	1	US-10-101-018-1	Sequence 1, Appli
c 222	20	0.3	20	1	US-10-165-854-1	Sequence 1, Appli
223	20	0.3	20	1	US-10-165-854-2	Sequence 2, Appli
224	20	0.3	20	1	US-10-219-238-1	Sequence 1, Appli
c 225	20	0.3	20	1	US-10-219-238-2	Sequence 2, Appli
226	20	0.3	20	1	US-10-407-818-13	Sequence 13, Appl
c 227	20	0.3	20	1	US-10-407-818-14	Sequence 14, Appl
228	20	0.3	20	1	US-10-407-818-16	Sequence 16, Appl
229	20	0.3	20	1	US-10-425-668-3	Sequence 3, Appli
c 230	20	0.3	20	1	US-10-425-668-4	Sequence 4, Appli
c 231	20	0.3	20	1	US-10-661-088-16	Sequence 16, Appl
232	20	0.3	20	1	US-10-661-088-19	Sequence 19, Appl
c 233	20	0.3	20	1	US-10-661-097-16	Sequence 16, Appl
234	20	0.3	20	1	US-10-661-097-19	Sequence 19, Appl
c 235	20	0.3	20	1	US-10-661-099-16	Sequence 16, Appl
236	20	0.3	20	1	US-10-661-099-19	Sequence 19, Appl
c 237	20	0.3	20	1	US-10-661-355-16	Sequence 16, Appl
238	20	0.3	20	1	US-10-661-355-19	Sequence 19, Appl
c 239	20	0.3	20	1	US-10-661-402-16	Sequence 16, Appl
240	20	0.3	20	1	US-10-661-402-19	Sequence 19, Appl
c 241	20	0.3	20	1	US-10-661-403-16	Sequence 16, Appl
242	20	0.3	20	1	US-10-661-403-19	Sequence 19, Appl
c 243	20	0.3	20	1	US-10-661-415-16	Sequence 16, Appl
244	20	0.3	20	1	US-10-661-415-19	Sequence 19, Appl
c 245	20	0.3	20	1	US-10-671-395-138	Sequence 138, App
246	20	0.3	20	1	US-10-748-541-1	Sequence 1, Appli
c 247	20	0.3	20	1	US-10-748-541-2	Sequence 2, Appli
248	20	0.3	20	1	US-10-814-555-1	Sequence 1, Appli
c 249	20	0.3	20	1	US-10-814-555-2	Sequence 2, Appli
250	20	0.3	20	1	US-10-846-113A-43	Sequence 43, Appl
c 251	20	0.3	20	1	US-10-846-113A-44	Sequence 44, Appl
252	20	0.3	20	1	US-10-846-113A-45	Sequence 45, Appl

	253	20	0.3	20	1	US-10-857-715-110	Sequence 110, App
c	254	20	0.3	20	1	US-10-857-715-111	Sequence 111, App
c	255	20	0.3	20	1	US-10-969-812A-15	Sequence 15, Appl
	256	20	0.3	20	1	US-10-969-812A-18	Sequence 18, Appl
c	257	20	0.3	21	1	US-10-121-235-13	Sequence 13, Appl
c	258	20	0.3	21	1	US-10-121-235-9	Sequence 9, Appli
c	259	20	0.3	21	1	US-10-385-193-1	Sequence 1, Appli
	260	20	0.3	21	1	US-10-385-193-2	Sequence 2, Appli
	261	20	0.3	21	1	US-10-947-637-897	Sequence 897, App
c	262	20	0.3	23	1	US-10-466-894-1869	Sequence 1869, Ap
	263	20	0.3	25	1	US-10-719-900-731924	Sequence 731924,
c	264	20	0.3	25	1	US-10-934-048A-12114	Sequence 12114, A
	265	19.4	0.3	21	1	US-10-857-780-4391	Sequence 4391, Ap
c	266	19.4	0.3	21	1	US-10-857-780-4393	Sequence 4393, Ap
	267	19.4	0.3	21	1	US-10-922-154-13	Sequence 13, Appl
	268	19.4	0.3	21	1	US-10-947-637-895	Sequence 895, App
	269	19.2	0.2	24	1	US-10-469-313A-3	Sequence 3, Appli
c	270	19.2	0.3	24	1	US-10-845-667-1483	Sequence 1483, Ap
c	271	19	0.2	19	1	US-09-557-423-7	Sequence 7, Appli
	272	19	0.2	19	1	US-09-557-423-8	Sequence 8, Appli
c	273	19	0.2	19	1	US-09-969-373-3086	Sequence 3086, Ap
	274	19	0.2	19	1	US-10-506-997-88	Sequence 88, Appl
	275	19	0.2	19	1	US-10-871-222-390	Sequence 390, App
c	276	19	0.2	19	1	US-10-871-222-494	Sequence 494, App
c	277	19	0.2	19	1	US-10-893-010-145	Sequence 145, App
	278	19	0.2	19	1	US-10-893-010-384	Sequence 384, App
	279	19	0.2	19	1	US-11-083-784-733	Sequence 733, App
	280	19	0.2	19	1	US-11-101-244-733	Sequence 733, App
	281	19	0.2	21	1	US-10-444-853A-297	Sequence 297, App
	282	19	0.2	21	1	US-10-444-853A-298	Sequence 298, App
	283	19	0.2	21	1	US-10-444-853A-299	Sequence 299, App
	284	19	0.2	21	1	US-10-444-853A-300	Sequence 300, App
c	285	19	0.2	21	1	US-10-444-853A-301	Sequence 301, App
c	286	19	0.2	21	1	US-10-444-853A-302	Sequence 302, App
c	287	19	0.2	21	1	US-10-444-853A-303	Sequence 303, App
c	288	19	0.2	21	1	US-10-444-853A-304	Sequence 304, App
c	289	19	0.2	21	1	US-10-444-853A-305	Sequence 305, App
c	290	19	0.2	21	1	US-10-444-853A-306	Sequence 306, App
c	291	19	0.2	21	1	US-10-444-853A-307	Sequence 307, App
c	292	19	0.2	21	1	US-10-444-853A-308	Sequence 308, App
	293	19	0.2	21	1	US-10-444-853A-345	Sequence 345, App
	294	19	0.2	21	1	US-10-444-853A-346	Sequence 346, App
	295	19	0.2	21	1	US-10-444-853A-347	Sequence 347, App
	296	19	0.2	21	1	US-10-444-853A-348	Sequence 348, App
	297	19	0.2	21	1	US-10-444-853A-396	Sequence 396, App
c	298	19	0.2	21	1	US-10-444-853A-397	Sequence 397, App
c	299	19	0.2	21	1	US-10-444-853A-398	Sequence 398, App
c	300	19	0.2	21	1	US-10-444-853A-399	Sequence 399, App
c	301	19	0.2	21	1	US-10-444-853A-400	Sequence 400, App
c	302	19	0.2	21	1	US-10-444-853A-401	Sequence 401, App
c	303	19	0.2	21	1	US-10-444-853A-414	Sequence 414, App
c	304	19	0.2	21	1	US-10-444-853A-415	Sequence 415, App
c	305	19	0.2	21	1	US-10-444-853A-416	Sequence 416, App
c	306	19	0.2	21	1	US-10-444-853A-417	Sequence 417, App
c	307	19	0.2	21	1	US-10-444-853A-418	Sequence 418, App
	308	19	0.2	21	1	US-10-444-853A-419	Sequence 419, App
c	309	19	0.2	21	1	US-10-444-853A-420	Sequence 420, App
	310	19	0.2	21	1	US-10-444-853A-621	Sequence 621, App
c	311	19	0.2	21	1	US-10-444-853A-622	Sequence 622, App
	312	19	0.2	21	1	US-10-757-803-297	Sequence 297, App
	313	19	0.2	21	1	US-10-757-803-298	Sequence 298, App
	314	19	0.2	21	1	US-10-757-803-299	Sequence 299, App
	315	19	0.2	21	1	US-10-757-803-300	Sequence 300, App
c	316	19	0.2	21	1	US-10-757-803-301	Sequence 301, App
c	317	19	0.2	21	1	US-10-757-803-302	Sequence 302, App
c	318	19	0.2	21	1	US-10-757-803-303	Sequence 303, App
c	319	19	0.2	21	1	US-10-757-803-304	Sequence 304, App
c	320	19	0.2	21	1	US-10-757-803-305	Sequence 305, App
c	321	19	0.2	21	1	US-10-757-803-306	Sequence 306, App
c	322	19	0.2	21	1	US-10-757-803-307	Sequence 307, App
c	323	19	0.2	21	1	US-10-757-803-308	Sequence 308, App
	324	19	0.2	21	1	US-10-757-803-345	Sequence 345, App
	325	19	0.2	21	1	US-10-757-803-346	Sequence 346, App
	326	19	0.2	21	1	US-10-757-803-347	Sequence 347, App
	327	19	0.2	21	1	US-10-757-803-348	Sequence 348, App
	328	19	0.2	21	1	US-10-757-803-396	Sequence 396, App
c	329	19	0.2	21	1	US-10-757-803-397	Sequence 397, App
c	330	19	0.2	21	1	US-10-757-803-398	Sequence 398, App
c	331	19	0.2	21	1	US-10-757-803-399	Sequence 399, App
c	332	19	0.2	21	1	US-10-757-803-400	Sequence 400, App
c	333	19	0.2	21	1	US-10-757-803-401	Sequence 401, App
c	334	19	0.2	21	1	US-10-757-803-414	Sequence 414, App
c	335	19	0.2	21	1	US-10-757-803-415	Sequence 415, App
c	336	19	0.2	21	1	US-10-757-803-416	Sequence 416, App
c	337	19	0.2	21	1	US-10-757-803-417	Sequence 417, App
c	338	19	0.2	21	1	US-10-757-803-418	Sequence 418, App
	339	19	0.2	21	1	US-10-757-803-419	Sequence 419, App
c	340	19	0.2	21	1	US-10-757-803-420	Sequence 420, App
	341	19	0.2	21	1	US-10-757-803-621	Sequence 621, App
c	342	19	0.2	21	1	US-10-757-803-622	Sequence 622, App
	343	19	0.2	21	1	US-10-820-622-64	Sequence 64, Appl
c	344	19	0.2	21	1	US-10-820-622-65	Sequence 65, Appl
	345	19	0.2	21	1	US-10-820-622-66	Sequence 66, Appl
c	346	19	0.2	21	1	US-10-820-622-67	Sequence 67, Appl
	347	19	0.2	21	1	US-10-820-622-68	Sequence 68, Appl
c	348	19	0.2	21	1	US-10-820-622-69	Sequence 69, Appl
	349	19	0.2	21	1	US-10-820-622-70	Sequence 70, Appl
	350	19	0.2	21	1	US-10-820-622-71	Sequence 71, Appl
c	351	19	0.2	21	1	US-10-820-622-72	Sequence 72, Appl
	352	19	0.2	21	1	US-10-826-966-297	Sequence 297, App
	353	19	0.2	21	1	US-10-826-966-298	Sequence 298, App
	354	19	0.2	21	1	US-10-826-966-299	Sequence 299, App
	355	19	0.2	21	1	US-10-826-966-300	Sequence 300, App
c	356	19	0.2	21	1	US-10-826-966-301	Sequence 301, App
c	357	19	0.2	21	1	US-10-826-966-302	Sequence 302, App
c	358	19	0.2	21	1	US-10-826-966-303	Sequence 303, App
c	359	19	0.2	21	1	US-10-826-966-304	Sequence 304, App
c	360	19	0.2	21	1	US-10-826-966-305	Sequence 305, App
c	361	19	0.2	21	1	US-10-826-966-306	Sequence 306, App
c	362	19	0.2	21	1	US-10-826-966-307	Sequence 307, App
c	363	19	0.2	21	1	US-10-826-966-308	Sequence 308, App
	364	19	0.2	21	1	US-10-826-966-345	Sequence 345, App
	365	19	0.2	21	1	US-10-826-966-346	Sequence 346, App
	366	19	0.2	21	1	US-10-826-966-347	Sequence 347, App
	367	19	0.2	21	1	US-10-826-966-348	Sequence 348, App
	368	19	0.2	21	1	US-10-826-966-396	Sequence 396, App
c	369	19	0.2	21	1	US-10-826-966-397	Sequence 397, App
c	370	19	0.2	21	1	US-10-826-966-398	Sequence 398, App
c	371	19	0.2	21	1	US-10-826-966-399	Sequence 399, App
c	372	19	0.2	21	1	US-10-826-966-400	Sequence 400, App
c	373	19	0.2	21	1	US-10-826-966-401	Sequence 401, App
c	374	19	0.2	21	1	US-10-826-966-414	Sequence 414, App
c	375	19	0.2	21	1	US-10-826-966-415	Sequence 415, App
c	376	19	0.2	21	1	US-10-826-966-416	Sequence 416, App
c	377	19	0.2	21	1	US-10-826-966-417	Sequence 417, App
c	378	19	0.2	21	1	US-10-826-966-418	Sequence 418, App
	379	19	0.2	21	1	US-10-826-966-419	Sequence 419, App
c	380	19	0.2	21	1	US-10-826-966-420	Sequence 420, App
	381	19	0.2	21	1	US-10-826-966-621	Sequence 621, App
c	382	19	0.2	21	1	US-10-826-966-622	Sequence 622, App
	383	19	0.2	21	1	US-10-947-637-896	Sequence 896, App
c	384	19	0.2	22	1	US-10-764-957-411	Sequence 411, App
	385	18.8	0.2	23	1	US-10-048-866D-10	Sequence 10, Appl
	386	18.4	0.2	20	1	US-10-517-544-40	Sequence 40, Appl
c	387	18.4	0.2	20	1	US-10-769-744-394	Sequence 394, App
c	388	18.4	0.2	20	1	US-10-857-780-4135	Sequence 4135, Ap
	389	18.4	0.2	20	1	US-10-857-780-4392	Sequence 4392, Ap
c	390	18.4	0.2	20	1	US-11-069-908-6019	Sequence 6019, Ap
	391	18.4	0.2	21	1	US-10-751-736-38782	Sequence 38782, A
	392	18.4	0.2	21	1	US-10-751-736-38783	Sequence 38783, A
	393	18.4	0.2	21	1	US-10-751-736-52502	Sequence 52502, A
	394	18	0.2	18	1	US-09-735-363A-17	Sequence 17, Appl
	395	18	0.2	18	1	US-09-735-363A-18	Sequence 18, Appl
	396	18	0.2	18	1	US-09-896-650A-28	Sequence 28, Appl
c	397	18	0.2	18	1	US-10-011-204-1	Sequence 1, Appli
	398	18	0.2	18	1	US-10-011-204-2	Sequence 2, Appli

	399	18	0.2	18	1	US-10-138-674-1411	Sequence 1411, Ap
	400	18	0.2	18	1	US-10-287-949A-1411	Sequence 1411, Ap
c	401	18	0.2	18	1	US-10-399-019-10	Sequence 10, Appl
c	402	18	0.2	18	1	US-10-399-019-11	Sequence 11, Appl
c	403	18	0.2	18	1	US-10-399-019-12	Sequence 12, Appl
c	404	18	0.2	18	1	US-10-399-019-13	Sequence 13, Appl
c	405	18	0.2	18	1	US-10-399-019-9	Sequence 9, Appli
c	406	18	0.2	18	1	US-10-751-235-59	Sequence 59, Appl
	407	18	0.2	18	1	US-10-951-303-1411	Sequence 1411, Ap
c	408	18	0.2	19	1	US-10-923-470-123	Sequence 123, App
	409	18	0.2	19	1	US-10-923-470-246	Sequence 246, App
c	410	18	0.2	21	1	US-10-786-720-11539	Sequence 11539, A
c	411	17.8	0.2	21	1	US-09-768-917-10	Sequence 10, Appl
	412	17.8	0.2	21	1	US-10-085-906-412	Sequence 412, App
	413	17.8	0.2	21	1	US-10-751-736-12824	Sequence 12824, A
	414	17.8	0.2	21	1	US-10-751-736-50830	Sequence 50830, A
	415	17.8	0.2	21	1	US-10-751-736-52501	Sequence 52501, A
c	416	17.8	0.2	21	1	US-10-786-720-11524	Sequence 11524, A
c	417	17.8	0.2	21	1	US-10-786-720-11527	Sequence 11527, A
c	418	17.8	0.2	21	1	US-10-786-720-11530	Sequence 11530, A
c	419	17.8	0.2	21	1	US-10-786-720-11542	Sequence 11542, A
	420	17.8	0.2	22	1	US-10-094-466-105	Sequence 105, App
c	421	17.8	0.2	22	1	US-10-184-372-11	Sequence 11, Appl
c	422	17.8	0.2	22	1	US-10-508-932-16	Sequence 16, Appl
c	423	17.8	0.2	22	1	US-11-061-140-289	Sequence 289, App
	424	17.4	0.2	19	1	US-09-909-544-5	Sequence 5, Appli
	425	17.4	0.2	19	1	US-10-155-785-5	Sequence 5, Appli
c	426	17.4	0.2	19	1	US-10-497-101-2	Sequence 2, Appli
c	427	17.4	0.2	19	1	US-10-871-222-150	Sequence 150, App
	428	17.4	0.2	19	1	US-10-871-222-300	Sequence 300, App
	429	17.4	0.2	19	1	US-10-923-522-618	Sequence 618, App
c	430	17.4	0.2	19	1	US-10-923-522-937	Sequence 937, App
c	431	17.4	0.2	19	1	US-10-923-580-152	Sequence 152, App
	432	17.4	0.2	19	1	US-10-923-580-4	Sequence 4, Appli
	433	17.4	0.2	19	1	US-11-040-947-5	Sequence 5, Appli
	434	17.4	0.2	20	1	US-09-969-373-2420	Sequence 2420, Ap
	435	17.4	0.2	20	1	US-09-969-373-2422	Sequence 2422, Ap
	436	17.4	0.2	20	1	US-10-476-961-80	Sequence 80, Appl
c	437	17.4	0.2	20	1	US-10-664-639A-36	Sequence 36, Appl
c	438	17.4	0.2	21	1	US-10-751-736-38784	Sequence 38784, A
c	439	17.4	0.2	21	1	US-10-751-736-52503	Sequence 52503, A
c	440	17.4	0.2	21	1	US-10-770-726-8905	Sequence 8905, Ap
	441	17	0.2	17	1	US-09-263-959-557	Sequence 557, App
	442	17	0.2	17	1	US-09-263-959-705	Sequence 705, App
	443	17	0.2	17	1	US-09-263-959-970	Sequence 970, App
	444	17	0.2	17	1	US-09-958-221A-18	Sequence 18, Appl
c	445	17	0.2	17	1	US-09-958-221A-19	Sequence 19, Appl
	446	17	0.2	17	1	US-10-333-461-24	Sequence 24, Appl
	447	17	0.2	17	1	US-10-352-253A-24	Sequence 24, Appl
	448	17	0.2	17	1	US-10-352-255A-24	Sequence 24, Appl
	449	17	0.2	17	1	US-10-676-849-18	Sequence 18, Appl
	450	17	0.2	17	1	US-10-676-849-18	Sequence 18, Appl
c	451	17	0.2	17	1	US-10-676-849-19	Sequence 19, Appl
c	452	17	0.2	17	1	US-10-676-849-19	Sequence 19, Appl
	453	17	0.2	17	1	US-10-712-633-1	Sequence 1, Appli
c	454	17	0.2	18	1	US-09-904-744-1	Sequence 1, Appli
	455	17	0.2	18	1	US-09-994-311-7	Sequence 7, Appli
	456	17	0.2	18	1	US-10-333-461-18	Sequence 18, Appl
	457	17	0.2	18	1	US-10-352-253A-18	Sequence 18, Appl
	458	17	0.2	18	1	US-10-352-255A-18	Sequence 18, Appl
	459	17	0.2	18	1	US-10-669-962-28	Sequence 28, Appl
	460	17	0.2	18	1	US-10-872-984-7	Sequence 7, Appli
	461	17	0.2	18	1	US-10-941-717A-22	Sequence 22, Appl
	462	17	0.2	18	1	US-10-941-717A-25	Sequence 25, Appl
	463	17	0.2	18	1	US-10-941-717A-36	Sequence 36, Appl
	464	17	0.2	19	1	US-10-800-487-162	Sequence 162, App
c	465	17	0.2	19	1	US-10-800-487-328	Sequence 328, App
	466	17	0.2	19	1	US-10-923-181-162	Sequence 162, App
c	467	17	0.2	19	1	US-10-923-181-328	Sequence 328, App
	468	17	0.2	20	1	US-09-005-243-34	Sequence 34, Appl
	469	17	0.2	20	1	US-09-224-683-34	Sequence 34, Appl
	470	17	0.2	20	1	US-10-175-608-34	Sequence 34, Appl
	471	17	0.2	20	1	US-10-353-783-34	Sequence 34, Appl
	472	17	0.2	20	1	US-10-620-642-34	Sequence 34, Appl
	473	17	0.2	21	1	US-09-775-479-14	Sequence 14, Appl
	474	17	0.2	21	1	US-10-410-031-188	Sequence 188, App
	475	17	0.2	21	1	US-10-786-720-11541	Sequence 11541, A
c	476	17	0.2	21	1	US-10-845-667-868	Sequence 868, App
	477	17	0.2	21	1	US-10-866-388A-6	Sequence 6, Appli
c	478	17	0.2	21	1	US-10-973-783-1249	Sequence 1249, Ap
c	479	16.8	0.2	20	1	US-10-301-832-122	Sequence 122, App
	480	16.8	0.2	20	1	US-10-301-832-46	Sequence 46, Appl
c	481	16.8	0.2	20	1	US-10-667-236-41	Sequence 41, Appl
	482	16.8	0.2	20	1	US-10-831-286A-35908	Sequence 35908, A
	483	16.8	0.2	20	1	US-10-840-590-1187	Sequence 1187, Ap
c	484	16.8	0.2	20	1	US-10-944-274-41	Sequence 41, Appl
c	485	16.8	0.2	20	1	US-11-003-941A-157	Sequence 157, App
c	486	16.8	0.2	20	1	US-11-051-720-1244	Sequence 1244, Ap
c	487	16.8	0.2	20	1	US-11-051-720-450	Sequence 450, App
	488	16.8	0.2	20	1	US-11-069-908-6716	Sequence 6716, Ap
	489	16.8	0.2	20	1	US-11-184-065A-25	Sequence 25, Appl
c	490	16.8	0.2	21	1	US-10-252-155-373	Sequence 373, App
c	491	16.8	0.2	21	1	US-10-252-155-374	Sequence 374, App
c	492	16.8	0.2	21	1	US-10-734-372A-23	Sequence 23, Appl
	493	16.8	0.2	21	1	US-10-751-736-22059	Sequence 22059, A
	494	16.8	0.2	21	1	US-10-751-736-22320	Sequence 22320, A
	495	16.8	0.2	21	1	US-10-751-736-22434	Sequence 22434, A
c	496	16.8	0.2	21	1	US-10-751-736-23745	Sequence 23745, A
	497	16.8	0.2	21	1	US-10-751-736-38570	Sequence 38570, A
	498	16.8	0.2	21	1	US-10-751-736-50831	Sequence 50831, A
	499	16.8	0.2	21	1	US-10-751-736-52499	Sequence 52499, A
c	500	16.8	0.2	21	1	US-10-758-636A-29	Sequence 29, Appl
c	501	16.8	0.2	21	1	US-10-758-672A-29	Sequence 29, Appl
	502	16.8	0.2	21	1	US-10-770-726-17546	Sequence 17546, A
	503	16.8	0.2	21	1	US-10-770-726-28434	Sequence 28434, A
	504	16.8	0.2	21	1	US-10-770-726-37634	Sequence 37634, A
	505	16.8	0.2	21	1	US-10-770-726-38651	Sequence 38651, A
	506	16.8	0.2	21	1	US-10-770-726-38652	Sequence 38652, A
	507	16.8	0.2	21	1	US-10-786-720-11526	Sequence 11526, A
	508	16.8	0.2	21	1	US-10-786-720-11529	Sequence 11529, A
	509	16.8	0.2	21	1	US-10-786-720-11532	Sequence 11532, A
	510	16.8	0.2	21	1	US-10-786-720-11544	Sequence 11544, A
c	511	16.8	0.2	21	1	US-10-847-918-5942	Sequence 5942, Ap
	512	16.8	0.2	21	1	US-10-847-918-5943	Sequence 5943, Ap
c	513	16.6	0.2	70	1	US/10/763	Sequence 112, App
c	514	16.4	0.2	18	1	US-09-263-959-983	Sequence 983, App
	515	16.4	0.2	18	1	US-09-994-311-5	Sequence 5, Appli
	516	16.4	0.2	18	1	US-10-085-906-135	Sequence 135, App
c	517	16.4	0.2	18	1	US-10-399-019-2	Sequence 2, Appli
	518	16.4	0.2	18	1	US-10-872-984-5	Sequence 5, Appli
c	519	16.4	0.2	19	1	US-09-917-138-2	Sequence 2, Appli
c	520	16.4	0.2	19	1	US-10-517-544-62	Sequence 62, Appl
	521	16.4	0.2	19	1	US-10-683-990-194	Sequence 194, App
c	522	16.4	0.2	19	1	US-10-683-990-97	Sequence 97, Appl
	523	16.4	0.2	19	1	US-10-922-761-194	Sequence 194, App
c	524	16.4	0.2	19	1	US-10-922-761-97	Sequence 97, Appl
	525	16.4	0.2	20	1	US-10-189-266-119	Sequence 119, App
c	526	16.4	0.2	20	1	US-10-189-266-52	Sequence 52, Appl
	527	16.4	0.2	20	1	US-10-289-762-4759	Sequence 4759, Ap
c	528	16.4	0.2	20	1	US-10-297-056-18	Sequence 18, Appl
	529	16.4	0.2	20	1	US-10-357-488-26	Sequence 26, Appl
	530	16.4	0.2	20	1	US-10-831-286A-33197	Sequence 33197, A
	531	16.4	0.2	20	1	US-10-831-286A-34234	Sequence 34234, A
	532	16.4	0.2	20	1	US-10-831-286A-40853	Sequence 40853, A
	533	16.4	0.2	70	1	US/10/763	Sequence 126, App
	534	16.2	0.2	18	1	US-09-981-397A-1	Sequence 1, Appli
	535	16.2	0.2	19	1	US-09-371-307-85	Sequence 85, Appl
c	536	16.2	0.2	19	1	US-10-103-614A-4	Sequence 4, Appli
	537	16.2	0.2	19	1	US-10-176-884-44	Sequence 44, Appl
	538	16.2	0.2	19	1	US-10-177-478-1	Sequence 1, Appli
	539	16.2	0.2	19	1	US-10-182-230-196	Sequence 196, App
	540	16.2	0.2	19	1	US-10-401-321-85	Sequence 85, Appl
	541	16.2	0.2	19	1	US-10-950-095-73	Sequence 73, Appl
	542	16.2	0.2	19	1	US-10-950-321-1	Sequence 1, Appli
	543	16.2	0.2	19	1	US-10-957-569-1	Sequence 1, Appli
	544	16.2	0.2	19	1	US-10-965-470-1	Sequence 1, Appli

	545	16.2	0.2	19	1	US-10-981-334-67	Sequence 67, Appl
	546	16.2	0.2	19	1	US-11-010-239-132	Sequence 132, App
	547	16.2	0.2	19	1	US-11-051-456-44	Sequence 44, Appl
	548	16.2	0.2	19	1	US-11-114-406-1	Sequence 1, Appli
	549	16	0.2	16	1	US-09-152-059-70	Sequence 70, Appl
c	550	16	0.2	16	1	US-09-438-486-131	Sequence 131, App
	551	16	0.2	16	1	US-09-739-928-2	Sequence 2, Appli
c	552	16	0.2	16	1	US-09-766-253-131	Sequence 131, App
	553	16	0.2	16	1	US-09-805-296D-9	Sequence 9, Appli
c	554	16	0.2	16	1	US-09-843-676-131	Sequence 131, App
	555	16	0.2	16	1	US-09-895-585-9	Sequence 9, Appli
	556	16	0.2	16	1	US-10-008-029-70	Sequence 70, Appl
c	557	16	0.2	16	1	US-10-053-758-131	Sequence 131, App
c	558	16	0.2	16	1	US-10-054-295-131	Sequence 131, App
c	559	16	0.2	16	1	US-10-054-611-131	Sequence 131, App
	560	16	0.2	16	1	US-10-072-975-9	Sequence 9, Appli
	561	16	0.2	16	1	US-10-092-885-27	Sequence 27, Appl
c	562	16	0.2	16	1	US-10-121-641D-1	Sequence 1, Appli
c	563	16	0.2	16	1	US-10-164-915-2	Sequence 2, Appli
	564	16	0.2	16	1	US-10-203-780-9	Sequence 9, Appli
c	565	16	0.2	16	1	US-10-208-357-22	Sequence 22, Appl
	566	16	0.2	16	1	US-10-208-650-70	Sequence 70, Appl
	567	16	0.2	16	1	US-10-227-001-21	Sequence 21, Appl
	568	16	0.2	16	1	US-10-360-275-9	Sequence 9, Appli
c	569	16	0.2	16	1	US-10-398-483-10	Sequence 10, Appl
	570	16	0.2	16	1	US-10-755-118-94	Sequence 94, Appl
	571	16	0.2	16	1	US-10-776-099-9	Sequence 9, Appli
	572	16	0.2	16	1	US-11-132-650-70	Sequence 70, Appl
c	573	16	0.2	16	1	US-11-145-005A-130	Sequence 130, App
	574	16	0.2	17	1	US-09-090-672B-107	Sequence 107, App
	575	16	0.2	17	1	US-09-438-486-132	Sequence 132, App
	576	16	0.2	17	1	US-09-726-096A-5	Sequence 5, Appli
	577	16	0.2	17	1	US-09-730-559B-109	Sequence 109, App
	578	16	0.2	17	1	US-09-766-253-132	Sequence 132, App
	579	16	0.2	17	1	US-09-843-676-132	Sequence 132, App
	580	16	0.2	17	1	US-09-958-221A-16	Sequence 16, Appl
	581	16	0.2	17	1	US-09-958-221A-17	Sequence 17, Appl
c	582	16	0.2	17	1	US-09-958-221A-20	Sequence 20, Appl
c	583	16	0.2	17	1	US-09-958-221A-21	Sequence 21, Appl
	584	16	0.2	17	1	US-10-053-758-132	Sequence 132, App
	585	16	0.2	17	1	US-10-054-295-132	Sequence 132, App
	586	16	0.2	17	1	US-10-054-611-132	Sequence 132, App
	587	16	0.2	17	1	US-10-117-267-5	Sequence 5, Appli
c	588	16	0.2	17	1	US-10-208-357-23	Sequence 23, Appl
	589	16	0.2	17	1	US-10-220-373-8	Sequence 8, Appli
	590	16	0.2	17	1	US-10-238-700-2794	Sequence 2794, Ap
	591	16	0.2	17	1	US-10-239-734-4	Sequence 4, Appli
c	592	16	0.2	17	1	US-10-324-409B-16	Sequence 16, Appl
	593	16	0.2	17	1	US-10-380-254-4	Sequence 4, Appli
	594	16	0.2	17	1	US-10-380-255-7	Sequence 7, Appli
	595	16	0.2	17	1	US-10-398-877-19	Sequence 19, Appl
	596	16	0.2	17	1	US-10-398-885A-3	Sequence 3, Appli
	597	16	0.2	17	1	US-10-408-025-5	Sequence 5, Appli
c	598	16	0.2	17	1	US-10-519-122-81	Sequence 81, Appl
	599	16	0.2	17	1	US-10-608-863-4	Sequence 4, Appli
	600	16	0.2	17	1	US-10-676-849-16	Sequence 16, Appl
	601	16	0.2	17	1	US-10-676-849-16	Sequence 16, Appl
	602	16	0.2	17	1	US-10-676-849-17	Sequence 17, Appl
	603	16	0.2	17	1	US-10-676-849-17	Sequence 17, Appl
c	604	16	0.2	17	1	US-10-676-849-20	Sequence 20, Appl
c	605	16	0.2	17	1	US-10-676-849-20	Sequence 20, Appl
c	606	16	0.2	17	1	US-10-676-849-21	Sequence 21, Appl
c	607	16	0.2	17	1	US-10-676-849-21	Sequence 21, Appl
	608	16	0.2	17	1	US-10-724-270-1473	Sequence 1473, Ap
	609	16	0.2	17	1	US-10-735-592-11	Sequence 11, Appl
	610	16	0.2	17	1	US-10-735-592-49	Sequence 49, Appl
	611	16	0.2	17	1	US-10-735-592-55	Sequence 55, Appl
	612	16	0.2	17	1	US-10-735-592-8	Sequence 8, Appli
	613	16	0.2	17	1	US-10-951-549-3	Sequence 3, Appli
	614	16	0.2	17	1	US-11-099-683-1	Sequence 1, Appli
	615	16	0.2	17	1	US-11-099-683-31	Sequence 31, Appl
	616	16	0.2	17	1	US-11-099-683-32	Sequence 32, Appl
	617	16	0.2	17	1	US-11-099-683-43	Sequence 43, Appl
	618	16	0.2	17	1	US-11-099-683-44	Sequence 44, Appl
	619	16	0.2	18	1	US-09-370-541-14	Sequence 14, Appl
	620	16	0.2	18	1	US-09-776-479-913	Sequence 913, App
	621	16	0.2	18	1	US-09-776-479-913	Sequence 913, App
	622	16	0.2	18	1	US-09-776-479-939	Sequence 939, App
	623	16	0.2	18	1	US-09-776-479-939	Sequence 939, App
	624	16	0.2	18	1	US-09-809-545A-84	Sequence 84, Appl
	625	16	0.2	18	1	US-09-888-326-837	Sequence 837, App
	626	16	0.2	18	1	US-09-979-275A-7	Sequence 7, Appli
	627	16	0.2	18	1	US-09-994-311-6	Sequence 6, Appli
	628	16	0.2	18	1	US-10-017-995-913	Sequence 913, App
	629	16	0.2	18	1	US-10-017-995-939	Sequence 939, App
	630	16	0.2	18	1	US-10-056-479A-15	Sequence 15, Appl
	631	16	0.2	18	1	US-10-075-335-9	Sequence 9, Appli
	632	16	0.2	18	1	US-10-112-653-882	Sequence 882, App
	633	16	0.2	18	1	US-10-125-295-9	Sequence 9, Appli
	634	16	0.2	18	1	US-10-206-613-4	Sequence 4, Appli
c	635	16	0.2	18	1	US-10-208-357-24	Sequence 24, Appl
c	636	16	0.2	18	1	US-10-271-602B-84	Sequence 84, Appl
	637	16	0.2	18	1	US-10-292-088-144	Sequence 144, App
	638	16	0.2	18	1	US-10-314-578-913	Sequence 913, App
	639	16	0.2	18	1	US-10-314-578-939	Sequence 939, App
	640	16	0.2	18	1	US-10-334-143-204	Sequence 204, App
	641	16	0.2	18	1	US-10-352-704-12	Sequence 12, Appl
c	642	16	0.2	18	1	US-10-352-704-18	Sequence 18, Appl
	643	16	0.2	18	1	US-10-389-155-97	Sequence 97, Appl
	644	16	0.2	18	1	US-10-389-417-97	Sequence 97, Appl
c	645	16	0.2	18	1	US-10-407-089-22	Sequence 22, Appl
	646	16	0.2	18	1	US-10-494-141A-1	Sequence 1, Appli
	647	16	0.2	18	1	US-10-494-141A-11	Sequence 11, Appl
	648	16	0.2	18	1	US-10-494-141A-12	Sequence 12, Appl
c	649	16	0.2	18	1	US-10-494-141A-27	Sequence 27, Appl
	650	16	0.2	18	1	US-10-494-141A-7	Sequence 7, Appli
	651	16	0.2	18	1	US-10-497-091-284	Sequence 284, App
c	652	16	0.2	18	1	US-10-497-091-300	Sequence 300, App
	653	16	0.2	18	1	US-10-503-120-1	Sequence 1, Appli
	654	16	0.2	18	1	US-10-503-120-10	Sequence 10, Appl
c	655	16	0.2	18	1	US-10-503-120-21	Sequence 21, Appl
	656	16	0.2	18	1	US-10-503-120-8	Sequence 8, Appli
	657	16	0.2	18	1	US-10-503-120-9	Sequence 9, Appli
	658	16	0.2	18	1	US-10-543-683-4	Sequence 4, Appli
	659	16	0.2	18	1	US-10-601-140A-24	Sequence 24, Appl
c	660	16	0.2	18	1	US-10-628-525-30	Sequence 30, Appl
	661	16	0.2	18	1	US-10-638-141-10	Sequence 10, Appl
	662	16	0.2	18	1	US-10-653-416-26	Sequence 26, Appl
	663	16	0.2	18	1	US-10-669-962-27	Sequence 27, Appl
	664	16	0.2	18	1	US-10-669-962-29	Sequence 29, Appl
	665	16	0.2	18	1	US-10-674-159A-112	Sequence 112, App
	666	16	0.2	18	1	US-10-735-592-1	Sequence 1, Appli
	667	16	0.2	18	1	US-10-766-096-9	Sequence 9, Appli
	668	16	0.2	18	1	US-10-775-973-10	Sequence 10, Appl
	669	16	0.2	18	1	US-10-776-917-141	Sequence 141, App
	670	16	0.2	18	1	US-10-776-933-150	Sequence 150, App
	671	16	0.2	18	1	US-10-776-934-741	Sequence 741, App
	672	16	0.2	18	1	US-10-785-744-15	Sequence 15, Appl
	673	16	0.2	18	1	US-10-831-778-913	Sequence 913, App
	674	16	0.2	18	1	US-10-831-778-939	Sequence 939, App
c	675	16	0.2	18	1	US-10-849-072-21	Sequence 21, Appl
	676	16	0.2	18	1	US-10-849-072-23	Sequence 23, Appl
	677	16	0.2	18	1	US-10-872-984-6	Sequence 6, Appli
	678	16	0.2	18	1	US-10-884-617-2	Sequence 2, Appli
	679	16	0.2	18	1	US-10-959-440-84	Sequence 84, Appl
	680	16	0.2	18	1	US-11-024-428-7	Sequence 7, Appli
c	681	16	0.2	18	1	US-11-041-103-69	Sequence 69, Appl
	682	16	0.2	18	1	US-11-127-654-882	Sequence 882, App
	683	16	0.2	18	1	US-11-237-922-26	Sequence 26, Appl
c	684	16	0.2	19	1	US-09-802-110B-111	Sequence 111, App
	685	16	0.2	19	1	US-09-853-526-515	Sequence 515, App
	686	16	0.2	19	1	US-09-901-484A-515	Sequence 515, App
	687	16	0.2	19	1	US-09-917-138-1	Sequence 1, Appli
c	688	16	0.2	19	1	US-09-939-379B-1	Sequence 1, Appli
c	689	16	0.2	19	1	US-09-961-663-1	Sequence 1, Appli
c	690	16	0.2	19	1	US-09-961-755A-9	Sequence 9, Appli

691	16	0.2	19	1	US-09-970-971A-15	Sequence 15, Appl
692	16	0.2	19	1	US-09-970-971A-16	Sequence 16, Appl
693	16	0.2	19	1	US-09-970-971A-26	Sequence 26, Appl
694	16	0.2	19	1	US-09-996-292A-54	Sequence 54, Appl
695	16	0.2	19	1	US-09-996-292A-55	Sequence 55, Appl
696	16	0.2	19	1	US-10-013-295-54	Sequence 54, Appl
697	16	0.2	19	1	US-10-013-295-55	Sequence 55, Appl
c 698	16	0.2	19	1	US-10-096-221-3	Sequence 3, Appli
699	16	0.2	19	1	US-10-098-816-15	Sequence 15, Appl
700	16	0.2	19	1	US-10-098-816-16	Sequence 16, Appl
701	16	0.2	19	1	US-10-098-816-17	Sequence 17, Appl
702	16	0.2	19	1	US-10-098-816-18	Sequence 18, Appl
703	16	0.2	19	1	US-10-098-816-26	Sequence 26, Appl
c 704	16	0.2	19	1	US-10-100-321-22	Sequence 22, Appl
c 705	16	0.2	19	1	US-10-100-321-24	Sequence 24, Appl
706	16	0.2	19	1	US-10-123-597-1	Sequence 1, Appli
707	16	0.2	19	1	US-10-123-597-12	Sequence 12, Appl
708	16	0.2	19	1	US-10-123-597-14	Sequence 14, Appl
709	16	0.2	19	1	US-10-123-597-15	Sequence 15, Appl
710	16	0.2	19	1	US-10-123-597-2	Sequence 2, Appli
711	16	0.2	19	1	US-10-123-597-25	Sequence 25, Appl
712	16	0.2	19	1	US-10-123-597-3	Sequence 3, Appli
713	16	0.2	19	1	US-10-123-597-4	Sequence 4, Appli
714	16	0.2	19	1	US-10-123-597-5	Sequence 5, Appli
715	16	0.2	19	1	US-10-123-597-6	Sequence 6, Appli
716	16	0.2	19	1	US-10-123-597-7	Sequence 7, Appli
717	16	0.2	19	1	US-10-123-597-8	Sequence 8, Appli
718	16	0.2	19	1	US-10-170-172-16	Sequence 16, Appl
c 719	16	0.2	19	1	US-10-199-559-1	Sequence 1, Appli
c 720	16	0.2	19	1	US-10-205-309-325	Sequence 325, App
721	16	0.2	19	1	US-10-205-309-650	Sequence 650, App
c 722	16	0.2	19	1	US-10-206-693-551	Sequence 551, App
723	16	0.2	19	1	US-10-206-693-650	Sequence 650, App
c 724	16	0.2	19	1	US-10-208-357-25	Sequence 25, Appl
c 725	16	0.2	19	1	US-10-210-130-354	Sequence 354, App
726	16	0.2	19	1	US-10-232-881-1	Sequence 1, Appli
727	16	0.2	19	1	US-10-247-893-13	Sequence 13, Appl
728	16	0.2	19	1	US-10-247-893-3	Sequence 3, Appli
729	16	0.2	19	1	US-10-247-893-7	Sequence 7, Appli
730	16	0.2	19	1	US-10-322-242-1	Sequence 1, Appli
731	16	0.2	19	1	US-10-331-109-33	Sequence 33, Appl
732	16	0.2	19	1	US-10-359-328-26	Sequence 26, Appl
733	16	0.2	19	1	US-10-359-328-5	Sequence 5, Appli
c 734	16	0.2	19	1	US-10-371-600-14	Sequence 14, Appl
735	16	0.2	19	1	US-10-387-346B-154	Sequence 154, App
c 736	16	0.2	19	1	US-10-453-372-1392	Sequence 1392, Ap
c 737	16	0.2	19	1	US-10-468-250A-145	Sequence 145, App
c 738	16	0.2	19	1	US-10-490-726-1	Sequence 1, Appli
c 739	16	0.2	19	1	US-10-514-861-31	Sequence 31, Appl
c 740	16	0.2	19	1	US-10-623-880-1	Sequence 1, Appli
741	16	0.2	19	1	US-10-700-884-23	Sequence 23, Appl
742	16	0.2	19	1	US-10-700-884-23	Sequence 23, Appl
c 743	16	0.2	19	1	US-10-757-093-24	Sequence 24, Appl
744	16	0.2	19	1	US-10-760-940-1	Sequence 1, Appli
c 745	16	0.2	19	1	US-10-773-904-9	Sequence 9, Appli
c 746	16	0.2	19	1	US-10-773-905-9	Sequence 9, Appli
c 747	16	0.2	19	1	US-10-913-246-22	Sequence 22, Appl
c 748	16	0.2	19	1	US-10-913-246-24	Sequence 24, Appl
c 749	16	0.2	19	1	US-10-923-379-163	Sequence 163, App
750	16	0.2	19	1	US-10-923-379-326	Sequence 326, App
c 751	16	0.2	19	1	US-10-923-522-270	Sequence 270, App
752	16	0.2	19	1	US-10-923-522-7	Sequence 7, Appli
c 753	16	0.2	19	1	US-10-934-890-22	Sequence 22, Appl
c 754	16	0.2	19	1	US-10-934-890-24	Sequence 24, Appl
755	16	0.2	19	1	US-10-934-944-363	Sequence 363, App
756	16	0.2	19	1	US-10-940-360-1	Sequence 1, Appli
757	16	0.2	19	1	US-10-950-095-74	Sequence 74, Appl
758	16	0.2	19	1	US-10-950-321-2	Sequence 2, Appli
759	16	0.2	19	1	US-10-957-569-2	Sequence 2, Appli
760	16	0.2	19	1	US-10-981-334-68	Sequence 68, Appl
761	16	0.2	19	1	US-11-010-239-133	Sequence 133, App
762	16	0.2	19	1	US-11-014-373-274	Sequence 274, App
c 763	16	0.2	19	1	US-11-014-373-551	Sequence 551, App
764	16	0.2	19	1	US-11-116-881A-2260	Sequence 2260, Ap
c 765	16	0.2	19	1	US-11-148-593-3	Sequence 3, Appli
c 766	16	0.2	20	1	US/10/763	Sequence 161, App
c 767	16	0.2	20	1	US/10/763	Sequence 166, App
768	16	0.2	20	1	US-09-005-243-32	Sequence 32, Appl
769	16	0.2	20	1	US-09-005-243-33	Sequence 33, Appl
770	16	0.2	20	1	US-09-224-683-32	Sequence 32, Appl
771	16	0.2	20	1	US-09-224-683-33	Sequence 33, Appl
772	16	0.2	20	1	US-09-726-096A-1	Sequence 1, Appli
c 773	16	0.2	20	1	US-09-760-500A-55	Sequence 55, Appl
774	16	0.2	20	1	US-09-771-554-5	Sequence 5, Appli
775	16	0.2	20	1	US-09-776-479-226	Sequence 226, App
776	16	0.2	20	1	US-09-776-479-556	Sequence 556, App
777	16	0.2	20	1	US-09-776-479-556	Sequence 556, App
c 778	16	0.2	20	1	US-09-776-479-560	Sequence 560, App
c 779	16	0.2	20	1	US-09-820-279B-55	Sequence 55, Appl
c 780	16	0.2	20	1	US-09-880-505-83	Sequence 83, Appl
781	16	0.2	20	1	US-09-881-535-2	Sequence 2, Appli
c 782	16	0.2	20	1	US-09-888-326-2	Sequence 2, Appli
783	16	0.2	20	1	US-09-888-326-838	Sequence 838, App
784	16	0.2	20	1	US-09-888-326-839	Sequence 839, App
785	16	0.2	20	1	US-09-912-014-16	Sequence 16, Appl
786	16	0.2	20	1	US-09-916-369A-1	Sequence 1, Appli
c 787	16	0.2	20	1	US-09-916-369A-3	Sequence 3, Appli
c 788	16	0.2	20	1	US-09-927-777A-55	Sequence 55, Appl
c 789	16	0.2	20	1	US-09-927-777A-70	Sequence 70, Appl
c 790	16	0.2	20	1	US-09-957-313A-55	Sequence 55, Appl
c 791	16	0.2	20	1	US-09-957-318A-55	Sequence 55, Appl
c 792	16	0.2	20	1	US-09-961-949A-55	Sequence 55, Appl
c 793	16	0.2	20	1	US-09-966-312-55	Sequence 55, Appl
c 794	16	0.2	20	1	US-09-966-491A-55	Sequence 55, Appl
c 795	16	0.2	20	1	US-09-967-409A-55	Sequence 55, Appl
c 796	16	0.2	20	1	US-09-973-638A-55	Sequence 55, Appl
c 797	16	0.2	20	1	US-09-973-788A-55	Sequence 55, Appl
c 798	16	0.2	20	1	US-09-974-007-55	Sequence 55, Appl
c 799	16	0.2	20	1	US-09-974-500A-55	Sequence 55, Appl
c 800	16	0.2	20	1	US-09-975-059A-55	Sequence 55, Appl
c 801	16	0.2	20	1	US-09-975-062A-55	Sequence 55, Appl
c 802	16	0.2	20	1	US-09-975-376A-55	Sequence 55, Appl
c 803	16	0.2	20	1	US-09-975-498-55	Sequence 55, Appl
c 804	16	0.2	20	1	US-09-976-378A-55	Sequence 55, Appl
c 805	16	0.2	20	1	US-09-976-577-55	Sequence 55, Appl
c 806	16	0.2	20	1	US-09-976-601A-55	Sequence 55, Appl
c 807	16	0.2	20	1	US-09-976-617A-55	Sequence 55, Appl
c 808	16	0.2	20	1	US-09-976-863A-55	Sequence 55, Appl
c 809	16	0.2	20	1	US-09-976-900A-55	Sequence 55, Appl
c 810	16	0.2	20	1	US-09-976-968A-55	Sequence 55, Appl
c 811	16	0.2	20	1	US-09-976-971A-55	Sequence 55, Appl
c 812	16	0.2	20	1	US-09-981-344-55	Sequence 55, Appl
c 813	16	0.2	20	1	US-09-994-701B-5	Sequence 5, Appli
814	16	0.2	20	1	US-09-994-701B-6	Sequence 6, Appli
815	16	0.2	20	1	US-09-997-672-40	Sequence 40, Appl
c 816	16	0.2	20	1	US-10-008-978-55	Sequence 55, Appl
c 817	16	0.2	20	1	US-10-008-978-70	Sequence 70, Appl
818	16	0.2	20	1	US-10-017-995-226	Sequence 226, App
819	16	0.2	20	1	US-10-017-995-556	Sequence 556, App
c 820	16	0.2	20	1	US-10-017-995-560	Sequence 560, App
c 821	16	0.2	20	1	US-10-051-643-83	Sequence 83, Appl
c 822	16	0.2	20	1	US-10-077-383-5	Sequence 5, Appli
823	16	0.2	20	1	US-10-077-383-6	Sequence 6, Appli
824	16	0.2	20	1	US-10-112-653-218	Sequence 218, App
825	16	0.2	20	1	US-10-112-653-533	Sequence 533, App
c 826	16	0.2	20	1	US-10-112-653-537	Sequence 537, App
827	16	0.2	20	1	US-10-117-267-1	Sequence 1, Appli
828	16	0.2	20	1	US-10-175-608-32	Sequence 32, Appl
829	16	0.2	20	1	US-10-175-608-33	Sequence 33, Appl
c 830	16	0.2	20	1	US-10-176-055-11	Sequence 11, Appl
831	16	0.2	20	1	US-10-181-200-10	Sequence 10, Appl
832	16	0.2	20	1	US-10-181-200-15	Sequence 15, Appl
833	16	0.2	20	1	US-10-188-404-66	Sequence 66, Appl
c 834	16	0.2	20	1	US-10-194-138-32	Sequence 32, Appl
c 835	16	0.2	20	1	US-10-208-357-26	Sequence 26, Appl
836	16	0.2	20	1	US-10-234-764-10	Sequence 10, Appl

	837	16	0.2	20	1	US-10-252-093-2 Sequence 2, Appli
	838	16	0.2	20	1	US-10-255-434-14 Sequence 14, Appl
c	839	16	0.2	20	1	US-10-255-434-26 Sequence 26, Appl
c	840	16	0.2	20	1	US-10-266-983-55 Sequence 55, Appl
c	841	16	0.2	20	1	US-10-266-983-70 Sequence 70, Appl
	842	16	0.2	20	1	US-10-278-047-1 Sequence 1, Appli
	843	16	0.2	20	1	US-10-314-578-226 Sequence 226, App
	844	16	0.2	20	1	US-10-314-578-556 Sequence 556, App
c	845	16	0.2	20	1	US-10-314-578-560 Sequence 560, App
	846	16	0.2	20	1	US-10-353-783-32 Sequence 32, Appl
	847	16	0.2	20	1	US-10-353-783-33 Sequence 33, Appl
	848	16	0.2	20	1	US-10-371-066-16 Sequence 16, Appl
c	849	16	0.2	20	1	US-10-410-324-55 Sequence 55, Appl
c	850	16	0.2	20	1	US-10-431-341-31 Sequence 31, Appl
	851	16	0.2	20	1	US-10-601-140A-1 Sequence 1, Appli
	852	16	0.2	20	1	US-10-601-140A-10 Sequence 10, Appl
	853	16	0.2	20	1	US-10-601-140A-2 Sequence 2, Appli
	854	16	0.2	20	1	US-10-601-140A-23 Sequence 23, Appl
	855	16	0.2	20	1	US-10-601-140A-3 Sequence 3, Appli
c	856	16	0.2	20	1	US-10-601-140A-34 Sequence 34, Appl
	857	16	0.2	20	1	US-10-601-140A-4 Sequence 4, Appli
	858	16	0.2	20	1	US-10-601-140A-40 Sequence 40, Appl
c	859	16	0.2	20	1	US-10-601-140A-44 Sequence 44, Appl
	860	16	0.2	20	1	US-10-601-140A-6 Sequence 6, Appli
	861	16	0.2	20	1	US-10-601-140A-7 Sequence 7, Appli
	862	16	0.2	20	1	US-10-601-140A-8 Sequence 8, Appli
	863	16	0.2	20	1	US-10-601-140A-9 Sequence 9, Appli
	864	16	0.2	20	1	US-10-620-642-32 Sequence 32, Appl
	865	16	0.2	20	1	US-10-620-642-33 Sequence 33, Appl
c	866	16	0.2	20	1	US-10-640-618-55 Sequence 55, Appl
	867	16	0.2	20	1	US-10-653-416-25 Sequence 25, Appl
c	868	16	0.2	20	1	US-10-661-088-12 Sequence 12, Appl
	869	16	0.2	20	1	US-10-661-088-15 Sequence 15, Appl
c	870	16	0.2	20	1	US-10-661-097-12 Sequence 12, Appl
	871	16	0.2	20	1	US-10-661-097-15 Sequence 15, Appl
c	872	16	0.2	20	1	US-10-661-099-12 Sequence 12, Appl
	873	16	0.2	20	1	US-10-661-099-15 Sequence 15, Appl
c	874	16	0.2	20	1	US-10-661-355-12 Sequence 12, Appl
	875	16	0.2	20	1	US-10-661-355-15 Sequence 15, Appl
c	876	16	0.2	20	1	US-10-661-402-12 Sequence 12, Appl
	877	16	0.2	20	1	US-10-661-402-15 Sequence 15, Appl
c	878	16	0.2	20	1	US-10-661-403-12 Sequence 12, Appl
	879	16	0.2	20	1	US-10-661-403-15 Sequence 15, Appl
c	880	16	0.2	20	1	US-10-661-415-12 Sequence 12, Appl
	881	16	0.2	20	1	US-10-661-415-15 Sequence 15, Appl
c	882	16	0.2	20	1	US-10-716-829-55 Sequence 55, Appl
c	883	16	0.2	20	1	US-10-728-078-14 Sequence 14, Appl
	884	16	0.2	20	1	US-10-728-078-23 Sequence 23, Appl
	885	16	0.2	20	1	US-10-728-399-87 Sequence 87, Appl
c	886	16	0.2	20	1	US-10-789-831-22 Sequence 22, Appl
	887	16	0.2	20	1	US-10-789-831-23 Sequence 23, Appl
c	888	16	0.2	20	1	US-10-789-831-24 Sequence 24, Appl
	889	16	0.2	20	1	US-10-831-778-226 Sequence 226, App
	890	16	0.2	20	1	US-10-831-778-556 Sequence 556, App
c	891	16	0.2	20	1	US-10-831-778-560 Sequence 560, App
	892	16	0.2	20	1	US-10-831-901A-29728 Sequence 29728, A
	893	16	0.2	20	1	US-10-831-901A-29729 Sequence 29729, A
	894	16	0.2	20	1	US-10-831-901A-29730 Sequence 29730, A
	895	16	0.2	20	1	US-10-831-901A-29731 Sequence 29731, A
	896	16	0.2	20	1	US-10-831-901A-29732 Sequence 29732, A
	897	16	0.2	20	1	US-10-831-901A-29733 Sequence 29733, A
	898	16	0.2	20	1	US-10-831-901A-29734 Sequence 29734, A
	899	16	0.2	20	1	US-10-831-901A-29735 Sequence 29735, A
	900	16	0.2	20	1	US-10-831-901A-29736 Sequence 29736, A
c	901	16	0.2	20	1	US-10-845-667-118 Sequence 118, App
	902	16	0.2	20	1	US-10-847-502-10 Sequence 10, Appl
	903	16	0.2	20	1	US-10-847-502-15 Sequence 15, Appl
	904	16	0.2	20	1	US-10-876-086-49 Sequence 49, Appl
c	905	16	0.2	20	1	US-10-969-812A-11 Sequence 11, Appl
	906	16	0.2	20	1	US-10-969-812A-14 Sequence 14, Appl
c	907	16	0.2	20	1	US-10-973-783-495 Sequence 495, App
	908	16	0.2	20	1	US-10-989-723-23 Sequence 23, Appl
	909	16	0.2	20	1	US-10-995-051-23 Sequence 23, Appl
	910	16	0.2	20	1	US-10-995-051-26 Sequence 26, Appl
c	911	16	0.2	20	1	US-10-995-051-31 Sequence 31, Appl
c	912	16	0.2	20	1	US-11-050-983-55 Sequence 55, Appl
c	913	16	0.2	20	1	US-11-050-983-70 Sequence 70, Appl
	914	16	0.2	20	1	US-11-066-434-7 Sequence 7, Appli
	915	16	0.2	20	1	US-11-081-880A-1 Sequence 1, Appli
	916	16	0.2	20	1	US-11-083-210-1 Sequence 1, Appli
	917	16	0.2	20	1	US-11-121-165A-10 Sequence 10, Appl
c	918	16	0.2	20	1	US-11-121-165A-7 Sequence 7, Appli
	919	16	0.2	20	1	US-11-127-654-218 Sequence 218, App
	920	16	0.2	20	1	US-11-127-654-533 Sequence 533, App
c	921	16	0.2	20	1	US-11-127-654-537 Sequence 537, App
	922	16	0.2	20	1	US-11-237-922-25 Sequence 25, Appl

ALIGNMENTS

```
RESULT 1
US-09-852-903C-25/c
; Sequence 25, Application US/09852903C
; Publication No. US20030104376A1
; GENERAL INFORMATION:
;  APPLICANT: Diatech Pty. Ltd.
;  TITLE OF INVENTION: An assay
;  FILE REFERENCE: 2414918/EJH
;  CURRENT APPLICATION NUMBER: US/09/852,903C
;  CURRENT FILING DATE:  2001-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,771
;  PRIOR FILING DATE: 2000-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,559
;  PRIOR FILING DATE: 2000-05-10
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: CA-21
US-09-852-903C-25

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
                :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 2
US-10-661-088-24/c
; Sequence 24, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0206
;  CURRENT APPLICATION NUMBER: US/10/661,088
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
```

```
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-088-24

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 3
US-10-661-097-24/c
; Sequence 24, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0204
;  CURRENT APPLICATION NUMBER: US/10/661,097
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-097-24

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 4
US-10-661-099-24/c
; Sequence 24, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
;  FILE REFERENCE: 029849/0203
;  CURRENT APPLICATION NUMBER: US/10/661,099
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-099-24

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 5
US-10-661-355-24/c
; Sequence 24, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0208
;  CURRENT APPLICATION NUMBER: US/10/661,355
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-355-24

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 6
US-10-661-402-24/c
; Sequence 24, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 029849/0207
;  CURRENT APPLICATION NUMBER: US/10/661,402
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
```

```
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-402-24

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.6;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|
```

```
;       COUNTRY:  US
;       ZIP:  98104-7092
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/263,959
;       FILING DATE:  05-MAR-1999
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  McMasters, David D.
;       REGISTRATION NUMBER:  33,963
;       REFERENCE/DOCKET NUMBER:  920010.426C2
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (206) 622-4900
;       TELEFAX:  (206) 682-6031
;   INFORMATION FOR SEQ ID NO:  678:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  39 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-263-959-678

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   51.3%;  Pred. No. 3.3;
  Matches   20;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 11
US-09-852-903C-24/c
; Sequence 24, Application US/09852903C
; Publication No. US20030104376A1
; GENERAL INFORMATION:
;  APPLICANT: Diatech Pty. Ltd.
;  TITLE OF INVENTION: An assay
;  FILE REFERENCE: 2414918/EJH
;  CURRENT APPLICATION NUMBER: US/09/852,903C
;  CURRENT FILING DATE:  2001-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,771
;  PRIOR FILING DATE: 2000-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,559
;  PRIOR FILING DATE: 2000-05-10
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
;   LENGTH: 38
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: CA-20
US-09-852-903C-24

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 4.2;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 12
US-10-105-901-18
; Sequence 18, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 48
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dolly A. Vance
;            REGISTRATION NUMBER: 39,054
;            REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 18:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 38 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..36
;       SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-105-901-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 6;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 13
US-11-043-693-18
; Sequence 18, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
```

```
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-11-043-693-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 6;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||| :|||||||||||:|:|
Db             1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 14
US-09-852-903C-23/c
; Sequence 23, Application US/09852903C
; Publication No. US20030104376A1
; GENERAL INFORMATION:
;  APPLICANT: Diatech Pty. Ltd.
;  TITLE OF INVENTION: An assay
;  FILE REFERENCE: 2414918/EJH
;  CURRENT APPLICATION NUMBER: US/09/852,903C
;  CURRENT FILING DATE:  2001-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,771
;  PRIOR FILING DATE: 2000-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,559
;  PRIOR FILING DATE: 2000-05-10
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 23
;   LENGTH: 36
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..7)
;   OTHER INFORMATION: CA-19
US-09-852-903C-23

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 6.8;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 15
US-09-909-317-7/c
; Sequence 7, Application US/09909317
; Publication No. US20040152075A1
; GENERAL INFORMATION:
;  APPLICANT: Betty P. Tsao (Inventor)
;  APPLICANT:  Rita M. Cantor (Inventor)
;  APPLICANT:  Jerome I. Rotter (Inventor)
;  TITLE OF INVENTION: Genetic Marker Test for Lupus
;  FILE REFERENCE: 18810-82152
;  CURRENT APPLICATION NUMBER: US/09/909,317
;  CURRENT FILING DATE:  2001-07-18
;  PRIOR APPLICATION NUMBER: 09/280,181
;  PRIOR FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 36
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-909-317-7

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 6.8;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 16
US-09-852-903C-22/c
; Sequence 22, Application US/09852903C
; Publication No. US20030104376A1
; GENERAL INFORMATION:
;  APPLICANT: Diatech Pty. Ltd.
;  TITLE OF INVENTION: An assay
;  FILE REFERENCE: 2414918/EJH
;  CURRENT APPLICATION NUMBER: US/09/852,903C
;  CURRENT FILING DATE:  2001-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,771
;  PRIOR FILING DATE: 2000-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,559
;  PRIOR FILING DATE: 2000-05-10
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
;   LENGTH: 34
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..7)
;   OTHER INFORMATION: CA-18
US-09-852-903C-22

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
```

```
  Best Local Similarity   50.0%;  Pred. No. 11;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 17
US-10-105-901-6
; Sequence 6, Application US/10105901
; Publication No. US20030092604A1
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 48
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dolly A. Vance
;            REGISTRATION NUMBER: 39,054
;            REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 6:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 36 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..36
;       SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-105-901-6

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 12;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 18
US-11-043-693-6
; Sequence 6, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-11-043-693-6

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 12;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 19
US-09-263-959-711
; Sequence 711, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
```

```
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  711:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-711

  Query Match             0.4%;  Score 32.4;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 16;
  Matches   17;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|  |:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGCGTGTGTGTGTGTGTGTGTG 34


RESULT 20
US-09-852-903C-21/c
; Sequence 21, Application US/09852903C
; Publication No. US20030104376A1
; GENERAL INFORMATION:
;  APPLICANT: Diatech Pty. Ltd.
;  TITLE OF INVENTION: An assay
;  FILE REFERENCE: 2414918/EJH
;  CURRENT APPLICATION NUMBER: US/09/852,903C
;  CURRENT FILING DATE:  2001-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,771
;  PRIOR FILING DATE: 2000-05-09
;  PRIOR APPLICATION NUMBER: US 60/202,559
;  PRIOR FILING DATE: 2000-05-10
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
;   LENGTH: 32
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: CA-17
US-09-852-903C-21

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 18;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 21
US-10-723-940-10/c
; Sequence 10, Application US/10723940
; Publication No. US20040185468A1
; GENERAL INFORMATION:
;  APPLICANT: Leonard, Sherry
;  APPLICANT:  Freeman, Robert
;  TITLE OF INVENTION: Promoter Variants in the Alpha-7 Nicotinic Acetylcholine Recepto
;  TITLE OF INVENTION:  Gene
;  FILE REFERENCE: VARD-07989
;  CURRENT APPLICATION NUMBER: US/10/723,940
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: 08/956,518
;  PRIOR FILING DATE: 1997-10-23
;  NUMBER OF SEQ ID NOS: 180
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 32
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-723-940-10

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 18;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 22
US-10-105-901-22
; Sequence 22, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
```

```
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;          TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;    INFORMATION FOR SEQ ID NO: 22:
;          SEQUENCE CHARACTERISTICS:
;             LENGTH: 33 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;          MOLECULE TYPE: DNA
;          FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..33
;          SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-105-901-22

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 20;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 23
US-10-105-901-30
; Sequence 30, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;    INFORMATION FOR SEQ ID NO: 30:
;          SEQUENCE CHARACTERISTICS:
;             LENGTH: 33 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;          MOLECULE TYPE: DNA
;          FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..33
;          SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-10-105-901-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 20;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::|||| |||:|||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 24
US-11-043-693-22
; Sequence 22, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-11-043-693-22
```

```
  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 20;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :|||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 25
US-11-043-693-30
; Sequence 30, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-11-043-693-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 20;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 26
US-10-085-906-27
; Sequence 27, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
;  APPLICANT: Ying, Vincent
;  APPLICANT:  Wu, Paul
;  APPLICANT:  Gray, Gary S.
;  TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
;  TITLE OF INVENTION:  COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
;  FILE REFERENCE: GNN-5343CP2
;  CURRENT APPLICATION NUMBER: US/10/085,906
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: US 60/126,215
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 09/534,061
;  PRIOR FILING DATE: 2000-03-24
;  PRIOR APPLICATION NUMBER: PCT/US00/07938
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 545
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-085-906-27

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 23;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 31


RESULT 27
US-09-778-900A-15
; Sequence 15, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 34
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-778-900A-15

  Query Match             0.4%;  Score 30.8;  DB 1;  Length 34;
  Best Local Similarity   64.7%;  Pred. No. 23;
  Matches   22;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1919 AUGGGUUUCAUGUUAACUUGGAAAAAAUGCCGAC 1952
              |:|||:::||:|::|||::|||||||||:||  ||
Db          1 ATGGGTTTCATGTTAACTTGGAAAAAATGCGTAC 34


RESULT 28
US-10-621-116-15
; Sequence 15, Application US/10621116
; Publication No. US20040091912A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 34
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-15

  Query Match             0.4%;  Score 30.8;  DB 1;  Length 34;
  Best Local Similarity   64.7%;  Pred. No. 23;
  Matches   22;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1919 AUGGGUUUCAUGUUAACUUGGAAAAAAUGCCGAC 1952
              |:|||:::||:|::|||::|||||||||:||  ||
Db          1 ATGGGTTTCATGTTAACTTGGAAAAAATGCGTAC 34


RESULT 29
US-09-778-900A-6
; Sequence 6, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-778-900A-6

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   90.3%;  Pred. No. 25;
  Matches   28;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 GGAAAAAAAUGCCGACGGAAGGAGAGGACCUG 1968
              ||||||||:||||||:|||||||||||||:|
Db          1 GGAAAAAATGCCGACRGAAGGAGAGGACCTG 31


RESULT 30
US-09-778-900A-7
; Sequence 7, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-778-900A-7

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 25;
  Matches   21;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3438 GAAAUGGAUGGCUCCCGAAUCUAUCUUUGAC 3468
              ||||:|||:|||:||:|||:|:|:|:::|||
Db          1 GAAATGGATGGCTCCYGAATCTATCTTTGAC 31


RESULT 31
US-09-778-900A-8
; Sequence 8, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-778-900A-8

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   64.5%;  Pred. No. 25;
  Matches   20;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3873 UGAUGAUGUCAGAUAUGUAAAUGCUUUCAAG 3903
              :||:||:|:||||:|:|:|||:||:::||||
Db          1 TGATGATGTCAGATAYGTAAATGCTTTCAAG 31


RESULT 32
US-10-621-116-6
; Sequence 6, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-6

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   90.3%;  Pred. No. 25;
  Matches   28;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 GGAAAAAAAUGCCGACGGAAGGAGAGGACCUG 1968
              ||||||||:||||||:|||||||||||||:|
Db          1 GGAAAAAATGCCGACRGAAGGAGAGGACCTG 31


RESULT 33
```

```
US-10-621-116-7
; Sequence 7, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-7

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 25;
  Matches   21;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3438 GAAAUGGAUGGCUCCCGAAUCUAUCUUUGAC 3468
             ||||:|||:|||:||:|||:|:|:|:::|||
Db          1 GAAATGGATGGCTCCYGAATCTATCTTTGAC 31


RESULT 34
US-10-621-116-8
; Sequence 8, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-8

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   64.5%;  Pred. No. 25;
  Matches   20;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3873 UGAUGAUGUCAGAUAUGUAAAUGCUUUCAAG 3903
             :||:||:|:||||:|:|:|||:||:::||||
Db          1 TGATGATGTCAGATAYGTAAATGCTTTCAAG 31


RESULT 35
US-10-105-901-14
; Sequence 14, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 14:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 37 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..36
;        SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-10-105-901-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 23;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
             |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 36
US-11-043-693-14
; Sequence 14, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/11/043,693
;       FILING DATE:  26-Jan-2005
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/10/105,901
;       FILING DATE:  20-Mar-2002
;       APPLICATION NUMBER:  09/348,886
;       FILING DATE:  01-JUL-1999
;       APPLICATION NUMBER:  US 08/643,839
;       FILING DATE:  07-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Richard F. Trecartin
;       REGISTRATION NUMBER:  31,801
;       REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  14:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  37 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..36
US-11-043-693-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 23;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 37
US-10-085-906-93
; Sequence 93, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
;  APPLICANT: Ying, Vincent
;  APPLICANT:  Wu, Paul
;  APPLICANT:  Gray, Gary S.
;  TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
;  TITLE OF INVENTION:  COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
;  FILE REFERENCE: GNN-5343CP2
;  CURRENT APPLICATION NUMBER: US/10/085,906
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: US 60/126,215
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 09/534,061
;  PRIOR FILING DATE: 2000-03-24
;  PRIOR APPLICATION NUMBER: PCT/US00/07938
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 545
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 93
;   LENGTH: 30
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-085-906-93

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 30;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 38
US-09-778-900A-16/c
; Sequence 16, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 28
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-778-900A-16

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   64.3%;  Pred. No. 49;
  Matches   18;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2098 AUCACUCUUAAUCUUACCAUCAUGAAUG 2125
              |:|||:|::||:|::||||:||:|||:|
Db         28 ATCACTCTTAATCTTACCATCATGAATG 1


RESULT 39
US-10-621-116-16/c
; Sequence 16, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
;   LENGTH: 28
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-16

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   64.3%;  Pred. No. 49;
  Matches   18;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2098 AUCACUCUUAAUCUUACCAUCAUGAAUG 2125
              |:|||:|::||:|::||||:||:|||:|
Db         28 ATCACTCTTAATCTTACCATCATGAATG 1


RESULT 40
US-11-085-982-21
; Sequence 21, Application US/11085982
; Publication No. US20060030597A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: GERRITSEN, MARY E.
;  APPLICANT:  XIN, XIAOHUA
;  TITLE OF INVENTION: METHOD OF INHIBITING ANGIOGENESIS
;  FILE REFERENCE: GEN01-006-CON2-US
;  CURRENT APPLICATION NUMBER: US/11/085,982
;  CURRENT FILING DATE:  2005-03-22
;  PRIOR APPLICATION NUMBER: 09/865,859
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 09/443,010
;  PRIOR FILING DATE: 1999-11-17
;  PRIOR APPLICATION NUMBER: 60/116,530
;  PRIOR FILING DATE: 1999-01-20
;  PRIOR APPLICATION NUMBER: 60/109,328
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 21
;   LENGTH: 28
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-11-085-982-21

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   71.4%;  Pred. No. 49;
  Matches   20;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGAGUUUG 2716
                ||::|:||:||||||||:|||||:::|
Db          1 CCTTATGATGCCAGCAAGTGGGAGTTTG 28


RESULT 41
US-09-778-900A-11
; Sequence 11, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-778-900A-11

  Query Match             0.4%;  Score 28;  DB 1;  Length 31;
  Best Local Similarity   76.7%;  Pred. No. 46;
  Matches   23;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        177 GACGGACUCUGGCGGCCGGGUCGUUGGCCG 206
              |||||||:|:|||||:||||:| ::|||||
Db          1 GACGGACTCTGGCGGYCGGGTCTTTGGCCG 30


RESULT 42
US-10-621-116-11
; Sequence 11, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-621-116-11

  Query Match             0.4%;  Score 28;  DB 1;  Length 31;
  Best Local Similarity   76.7%;  Pred. No. 46;
  Matches   23;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        177 GACGGACUCUGGCGGCCGGGUCGUUGGCCG 206
              |||||||:|:|||||:||||:| ::|||||
Db          1 GACGGACTCTGGCGGYCGGGTCTTTGGCCG 30


RESULT 43
US-10-105-901-8
; Sequence 8, Application US/10105901
; Publication No. US20030092604A1
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 48
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dolly A. Vance
;            REGISTRATION NUMBER: 39,054
;            REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 8:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 34 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  2..34
;       SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-105-901-8
```

```
  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 47;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||    || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 44
US-11-043-693-8
; Sequence 8, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..34
US-11-043-693-8

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 47;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||    || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 45
US-09-263-959-665
; Sequence 665, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  665:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-665

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 55;
  Matches   14;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|: :|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTTTGTGTGTGTGTGTG 29


RESULT 46
US-09-263-959-770
; Sequence 770, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  770:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-770

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 63;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 47
US-09-735-363A-1
; Sequence 1, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-1

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 63;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 48
US-09-735-363A-5
; Sequence 5, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-5

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 63;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 49
US-09-735-363A-66
; Sequence 66, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 66
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-66

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 63;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 50
US-10-168-327-2
; Sequence 2, Application US/10168327
; Publication No. US20030176381A1
; GENERAL INFORMATION:
;  APPLICANT: Phillips, Nigel C.
;  APPLICANT:  Filion, Mario C.
;  TITLE OF INVENTION: Hyaluronic Acid in the Treatment of Cancer
;  FILE REFERENCE: 02811-0211  (42368-274915)
;  CURRENT APPLICATION NUMBER: US/10/168,327
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: PCT/CA00/01562
;  PRIOR FILING DATE: 2000-12-28
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 2
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-168-327-2

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 63;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 51
US-10-310-914A-167077/c
; Sequence 167077, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 167077
;   LENGTH: 27
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-167077

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 63;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7013 UGGGUGUGGGUGUAUGUGUGUUUUGUG 7039
              :|||:|:|||:|:|:|:|:|::::|:|
Db         27 TGGGTGTGGGTGTATGTGTGTTTTGTG 1


RESULT 52
US-09-263-959-600
; Sequence 600, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  600:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-600

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   43.3%;  Pred. No. 61;
  Matches   13;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|: :|: :|:|:|:|:|:|:|:|
Db          1 TGTGTGTCTGTATGTGTGTGTGTGTGTG 30


RESULT 53
US-10-105-901-26
; Sequence 26, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 26:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 30 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        FEATURE:
```

```
;             NAME/KEY:  CDS
;             LOCATION:  1..30
;        SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-10-105-901-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 61;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 54
US-11-043-693-26
; Sequence 26, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..30
US-11-043-693-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 61;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 55
US-10-105-901-20
; Sequence 20, Application US/10105901
; Publication No. US20030092604A1
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 48
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dolly A. Vance
;            REGISTRATION NUMBER: 39,054
;            REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 20:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 31 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  2..31
;       SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-105-901-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 68;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 56
US-11-043-693-20
; Sequence 20, Application US/11043693
```

```
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..31
US-11-043-693-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 68;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
             |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 57
US-09-953-318-5/c
; Sequence 5, Application US/09953318
; Publication No. US20030105036A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0232
;  CURRENT APPLICATION NUMBER: US/09/953,318
;  CURRENT FILING DATE:  2001-09-13
;  NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 5
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-09-953-318-5

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   57.7%;  Pred. No. 80;
  Matches   15;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1399 UUGACUCGUGGCUACUCGUUAAUUAU 1424
              ::|||:||:|||:||:||::||::|:
Db         26 TTGACTCGTGGCTACTCGTTAATTAT 1


RESULT 58
US-10-446-373-5/c
; Sequence 5, Application US/10446373
; Publication No. US20030204076A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPT
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0232
;  CURRENT APPLICATION NUMBER: US/10/446,373
;  CURRENT FILING DATE:  2003-05-28
;  PRIOR APPLICATION NUMBER: US/09/953,318
;  PRIOR FILING DATE: 2001-09-13
;  NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 5
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-446-373-5

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   57.7%;  Pred. No. 80;
  Matches   15;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1399 UUGACUCGUGGCUACUCGUUAAUUAU 1424
              ::|||:||:|||:||:||::||::|:
Db         26 TTGACTCGTGGCTACTCGTTAATTAT 1


RESULT 59
US-10-105-901-36/c
; Sequence 36, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
```

```
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 36:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 25 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-10-105-901-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
             ||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 60
US-10-105-901-37
; Sequence 37, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 37:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 25 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-10-105-901-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::|||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 61
US-10-246-091-21
; Sequence 21, Application US/10246091
; Publication No. US20030203844A1
; GENERAL INFORMATION:
;  APPLICANT: Delfani, Kioumars
;  APPLICANT:  Janson, Ann Marie
;  APPLICANT:  Kuhn, Georg
;  APPLICANT:  Plate, Karlheinz
;  APPLICANT:  Schnazer, Anne
;  APPLICANT:  Wachs, Frank-Peter
;  APPLICANT:  Zhao, Ming
;  TITLE OF INVENTION: Treatment of Central Nervous System Disorders
;  FILE REFERENCE: 21882-504 (PDGF/VEGF)
;  CURRENT APPLICATION NUMBER: US/10/246,091
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: 60/323,381
;  PRIOR FILING DATE: 2001-09-19
;  PRIOR APPLICATION NUMBER: 60/326,044
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-246-091-21

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        939 AGAUGUCCAAAUAAGCACACCACGC 963
              |||:|:|||||:|||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 62
US-10-246-091-23
; Sequence 23, Application US/10246091
; Publication No. US20030203844A1
; GENERAL INFORMATION:
;  APPLICANT: Delfani, Kioumars
;  APPLICANT:  Janson, Ann Marie
```

```
;  APPLICANT:  Kuhn, Georg
;  APPLICANT:  Plate, Karlheinz
;  APPLICANT:  Schnazer, Anne
;  APPLICANT:  Wachs, Frank-Peter
;  APPLICANT:  Zhao, Ming
;  TITLE OF INVENTION: Treatment of Central Nervous System Disorders
;  FILE REFERENCE: 21882-504 (PDGF/VEGF)
;  CURRENT APPLICATION NUMBER: US/10/246,091
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: 60/323,381
;  PRIOR FILING DATE: 2001-09-19
;  PRIOR APPLICATION NUMBER: 60/326,044
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-246-091-23

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        939 AGAUGUCCAAAUAAGCACACCACGC 963
              |||:|:|||||:|||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 63
US-10-246-091-24/c
; Sequence 24, Application US/10246091
; Publication No. US20030203844A1
; GENERAL INFORMATION:
;  APPLICANT: Delfani, Kioumars
;  APPLICANT:  Janson, Ann Marie
;  APPLICANT:  Kuhn, Georg
;  APPLICANT:  Plate, Karlheinz
;  APPLICANT:  Schnazer, Anne
;  APPLICANT:  Wachs, Frank-Peter
;  APPLICANT:  Zhao, Ming
;  TITLE OF INVENTION: Treatment of Central Nervous System Disorders
;  FILE REFERENCE: 21882-504 (PDGF/VEGF)
;  CURRENT APPLICATION NUMBER: US/10/246,091
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: 60/323,381
;  PRIOR FILING DATE: 2001-09-19
;  PRIOR APPLICATION NUMBER: 60/326,044
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-246-091-24

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1385 AAUCUGCUCGCUAUUUGACUCGUGG 1409
              ||:|:|||:|||:|:::|||:||:||
Db         25 AATCTGCTCGCTATTTGACTCGTGG 1


RESULT 64
US-10-719-956-380113
; Sequence 380113, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 380113
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-380113

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2144 GCACCUAUGCCUGCAGAGCCAGGAA 2168
              |||||:|:|||:|||||||||||||
Db          1 GCACCTATGCCTGCAGAGCCAGGAA 25


RESULT 65
US-10-809-189-43420
; Sequence 43420, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43420
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43420

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4020 CUUCACCUGGACUGACAGCAAACCC 4044
              |::||||:||||:||||||||||||
Db          1 CTTCACCTGGACTGACAGCAAACCC 25


RESULT 66
US-10-809-189-43421
; Sequence 43421, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
```

```
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43421
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43421

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 1e+02;
  Matches   23;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4029 GACUGACAGCAAACCCAAGGCCUCG 4053
              |||:||||||||||||||||||:||
Db          1 GACTGACAGCAAACCCAAGGCCTCG 25


RESULT 67
US-10-809-189-43422
; Sequence 43422, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43422
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43422

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4119 CAGUUUCUGCCAUUCCAGCUGUGGG 4143
              |||:::|:||||::|||||:|:|||
Db          1 CAGTTTCTGCCATTCCAGCTGTGGG 25


RESULT 68
US-10-809-189-43423
; Sequence 43423, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43423
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43423

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4122 UUUCUGCCAUUCCAGCUGUGGGCAC 4146
              :::|:||||::|||||:|:||||||
Db          1 TTTCTGCCATTCCAGCTGTGGGCAC 25


RESULT 69
US-10-809-189-43424
; Sequence 43424, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43424
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43424

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4125 CUGCCAUUCCAGCUGUGGGCACGUC 4149
              |:||||::|||||:|:|||||||:|
Db          1 CTGCCATTCCAGCTGTGGGCACGTC 25


RESULT 70
US-10-809-189-43425
; Sequence 43425, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43425
;   LENGTH: 25
;   TYPE: DNA
```

```
;   ORGANISM: mus musculus
US-10-809-189-43425

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4128 CCAUUCCAGCUGUGGGCACGUCAGC 4152
              |||::|||||:|:|||||||:||||
Db          1 CCATTCCAGCTGTGGGCACGTCAGC 25


RESULT 71
US-10-809-189-43426
; Sequence 43426, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43426
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43426

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4137 CUGUGGGCACGUCAGCGAAGGCAAG 4161
              |:|:|||||||:|||||||||||||
Db          1 CTGTGGGCACGTCAGCGAAGGCAAG 25


RESULT 72
US-10-809-189-43427
; Sequence 43427, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43427
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43427

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4158 CAAGCGCAGGUUCACCUACGACCAC 4182
              ||||||||||::||||:||||||||
Db          1 CAAGCGCAGGTTCACCTACGACCAC 25


RESULT 73
US-10-809-189-43428
; Sequence 43428, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43428
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43428

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4164 CAGGUUCACCUACGACCACGCUGAG 4188
              ||||::||||:||||||||||:|||
Db          1 CAGGTTCACCTACGACCACGCTGAG 25


RESULT 74
US-10-809-189-43429
; Sequence 43429, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43429
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43429

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4167 GUUCACCUACGACCACGCUGAGCUG 4191
              |::||||:||||||||||:||||:|
Db          1 GTTCACCTACGACCACGCTGAGCTG 25
```

```
RESULT 75
US-10-809-189-43430
; Sequence 43430, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43430
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43430

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4170 CACCUACGACCACGCUGAGCUGGAA 4194
              ||||:|||||||||:||||:||||
Db          1 CACCTACGACCACGCTGAGCTGGAA 25


RESULT 76
US-10-809-189-43431
; Sequence 43431, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43431
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43431

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4179 CCACGCUGAGCUGGAAAGGAAAAUC 4203
              ||||||:||||:||||||||||:|
Db          1 CCACGCTGAGCTGGAAAGGAAAATC 25


RESULT 77
US-10-809-189-43432
; Sequence 43432, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43432
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43432

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4032 UGACAGCAAACCCAAGGCCUCGCUC 4056
              :||||||||||||||||||:|||:|
Db          1 TGACAGCAAACCCAAGGCCTCGCTC 25


RESULT 78
US-10-809-189-43433
; Sequence 43433, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43433
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43433

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4038 CAAACCCAAGGCCUCGCUCAAGAUU 4062
              |||||||||||||:|||:|||||::
Db          1 CAAACCCAAGGCCTCGCTCAAGATT 25


RESULT 79
US-10-809-189-43434
; Sequence 43434, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
```

```
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43434
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43434

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4041 ACCCAAGGCCUCGCUCAAGAUUGAC 4065
              ||||||||||:|||:|||||::|||
Db          1 ACCCAAGGCCTCGCTCAAGATTGAC 25


RESULT 80
US-10-809-189-43435
; Sequence 43435, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43435
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43435

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4047 GGCCUCGCUCAAGAUUGACUUGAGA 4071
              ||||:|||:|||||::|||::||||
Db          1 GGCCTCGCTCAAGATTGACTTGAGA 25


RESULT 81
US-10-809-189-43436
; Sequence 43436, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43436
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43436

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4086 UAAGGAGUCGGGGCUGUCUGAUGUC 4110
              :||||||:||||||:|:|:||:|:|
Db          1 TAAGGAGTCGGGGCTGTCTGATGTC 25


RESULT 82
US-10-809-189-43437
; Sequence 43437, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43437
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43437

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4110 CAGCAGGCCCAGUUUCUGCCAUUCC 4134
              ||||||||||||:::|:||||::||
Db          1 CAGCAGGCCCAGTTTCTGCCATTCC 25


RESULT 83
US-10-809-189-43438
; Sequence 43438, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43438
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43438

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4113 CAGGCCCAGUUUCUGCCAUUCCAGC 4137
              |||||||||:::|:||||::|||||
Db          1 CAGGCCCAGTTTCTGCCATTCCAGC 25


RESULT 84
US-10-809-189-43439
; Sequence 43439, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43439
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-43439

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4116 GCCCAGUUUCUGCCAUUCCAGCUGU 4140
              ||||||:::|:||||::||||||:|:
Db          1 GCCCAGTTTCTGCCATTCCAGCTGT 25


RESULT 85
US-11-036-317-172411/c
; Sequence 172411, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 172411
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-172411

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1e+02;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         25 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 86
US-11-036-317-221149/c
; Sequence 221149, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 221149
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-221149

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db         25 GTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 87
US-11-043-693-36/c
; Sequence 36, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
US-11-043-693-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
                ||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 88
US-11-043-693-37
; Sequence 37, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
US-11-043-693-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::|||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 89
US-11-060-756-61058
; Sequence 61058, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61058
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-61058

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5997 UAAGUAACCGAAGAAUGUAUGCCUC 6021
              :|||:||||||||||:|:|:|||:|
Db          1 TAAGTAACCGAAGAATGTATGCCTC 25


RESULT 90
US-11-121-849-126900
; Sequence 126900, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126900
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126900

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   56.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7419 AAUGUUAGUUUAGCUGAUUGUAUGG 7443
              ||:|::||:::|||:||::|:|:||
Db          1 AATGTTAGTTTAGCTGATTGTATGG 25
```

```
RESULT 91
US-11-121-849-126901
; Sequence 126901, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126901
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126901

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7467 GUUUGUUUUACCUAUUUCACAACUG 7491
              |:::|::::|||:|:::|||||||:|
Db          1 GTTTGTTTTACCTATTTCACAACTG 25


RESULT 92
US-11-121-849-126902
; Sequence 126902, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126902
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126902

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   56.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7471 GUUUUACCUAUUUCACAACUGUGUA 7495
              |::::|||:|:::||||||:|:|:|
Db          1 GTTTTACCTATTTCACAACTGTGTA 25


RESULT 93
US-11-121-849-126903
; Sequence 126903, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126903
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126903

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7497 AUUGCCAAUAAUUCCUGUCCAUGAA 7521
              |::|||||:||::||:|:|||:|||
Db          1 ATTGCCAATAATTCCTGTCCATGAA 25


RESULT 94
US-11-121-849-126904
; Sequence 126904, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126904
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126904

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7503 AAUAAUUCCUGUCCAUGAAAAUGCA 7527
              ||:||::||:|:|||:|||||:|||
Db          1 AATAATTCCTGTCCATGAAAATGCA 25


RESULT 95
US-11-121-849-126905
; Sequence 126905, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126905
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126905

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1e+02;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       7519 GAAAAUGCAAAUUAUCCAGUGUAGA 7543
             |||||:|||||::|:||||:|:|||
Db          1 GAAAATGCAAATTATCCAGTGTAGA 25


RESULT 96
US-11-121-849-126906
; Sequence 126906, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126906
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126906

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7539 GUAGAUAUAUUUGACCAUCACCCUA 7563
             |:|||:|:|:::|||||:|||||:|
Db          1 GTAGATATATTTGACCATCACCCTA 25


RESULT 97
US-11-121-849-126907
; Sequence 126907, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126907
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126907

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7550 UGACCAUCACCCUAUGGAUAUUGGC 7574
             :|||||:|||||:|:|||:|::|||
Db          1 TGACCATCACCCTATGGATATTGGC 25


RESULT 98
US-11-121-849-126908
; Sequence 126908, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126908
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126908

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7600 CAUUUCAGCCUGAAUGUCUGCCUAU 7624
             ||:::|||||:|||:|:|:|||:|:
Db          1 CATTTCAGCCTGAATGTCTGCCTAT 25


RESULT 99
US-11-121-849-126909
; Sequence 126909, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126909
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126909

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   56.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7612 AAUGUCUGCCUAUAUAUUCUCUGCU 7636
             ||:|:|:|||:|:|:|::|:|:||:
Db          1 AATGTCTGCCTATATATTCTCTGCT 25


RESULT 100
US-11-121-849-126910
; Sequence 126910, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 126910
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-126910
```

```
  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7619 GCCUAUAUAUUCUCUGCUCUUUGUA 7643
              |||:|:|:|::|:|:||:|:::|:|
Db          1 GCCTATATATTCTCTGCTCTTTGTA 25


RESULT 101
US-11-121-849-280598
; Sequence 280598, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280598
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280598

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6816 GUGUCUUGUCAGUCCAAGAAGUGAC 6840
              |:|:|::|:|||:|||||||:|||
Db          1 GTGTCTTGTCAGTCCAAGAAGTGAC 25


RESULT 102
US-11-121-849-280599
; Sequence 280599, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280599
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280599

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6833 GAAGUGACACCGAGAUGUUAAUUUU 6857
              ||||:||||||||||:|::||::::
Db          1 GAAGTGACACCGAGATGTTAATTTT 25


RESULT 103
US-11-121-849-280600
; Sequence 280600, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280600
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280600

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6866 GUGCCUUGUUUCCUAGCCCACAAGA 6890
              |:|||::|:::||:||||||||||
Db          1 GTGCCTTGTTTCCTAGCCCACAAGA 25


RESULT 104
US-11-121-849-280601
; Sequence 280601, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280601
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280601

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6873 GUUUCCUAGCCCACAAGAAUGCAAA 6897
              |:::||:||||||||||||:|||||
Db          1 GTTTCCTAGCCCACAAGAATGCAAA 25


RESULT 105
US-11-121-849-280602
; Sequence 280602, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280602
;   LENGTH: 25
```

```
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280602

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6723 ACUAACAAAGAACGAGCACUUCCUU 6747
              ||:||||||||||||||::||::
Db          1 ACTAACAAAGAACGAGCACTTCCTT 25


RESULT 106
US-11-121-849-280603
; Sequence 280603, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280603
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280603

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6899 AUCAAACAGAUACUCGCUAGCCUCA 6923
              |:|||||||:||:|||:||||:||
Db          1 ATCAAACAGATACTCGCTAGCCTCA 25


RESULT 107
US-11-121-849-280604
; Sequence 280604, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280604
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280604

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6906 AGAUACUCGCUAGCCUCAUUUAAAU 6930
              |||:||:|||:||||:||:::|||:
Db          1 AGATACTCGCTAGCCTCATTTAAAT 25


RESULT 108
US-11-121-849-280605
; Sequence 280605, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280605
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280605

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches   20;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6938 AGGAGGAGUGCAUCUUUGGCCGACA 6962
              ||||||||:|||:|:::||||||||
Db          1 AGGAGGAGTGCATCTTTGGCCGACA 25


RESULT 109
US-11-121-849-280606
; Sequence 280606, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280606
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-280606

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1e+02;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6949 AUCUUUGGCCGACAGUGGUGUAACU 6973
              |:|:::||||||||:||:|:|||:
Db          1 ATCTTTGGCCGACAGTGGTGTAACT 25


RESULT 110
US-11-121-849-280607
; Sequence 280607, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
```

```
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280607
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: Homo sapien
US-11-121-849-280607

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUUUCUGAGA 6762
              ||||::||:::|||||:::|:||||
Db          1 GCACTTCCTTTCAGAGTTTCTGAGA 25


RESULT 111
US-11-121-849-280608
; Sequence 280608, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 280608
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: Homo sapien
US-11-121-849-280608

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1e+02;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6762 AUAAUGUACGUGGAACAGUCUGGGU 6786
              |:||:|:|||:|||||||:|:|||:
Db          1 ATAATGTACGTGGAACAGTCTGGGT 25


RESULT 112
US-09-778-900A-12
; Sequence 12, Application US/09778900A
; Publication No. US20020192647A1
; GENERAL INFORMATION:
;  APPLICANT: SMITH, JOHN C.
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: PLS/009901/0277123
;  CURRENT APPLICATION NUMBER: US/09/778,900A
;  CURRENT FILING DATE:  2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
;    LENGTH: 31
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-778-900A-12

  Query Match             0.3%;  Score 25;  DB 1;  Length 31;
  Best Local Similarity   74.1%;  Pred. No. 89;
  Matches   20;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 UCUGGCGGCCGGGUCGUUGGCCGGGGG 210
              :|:||||||||||:|:::||||| |||
Db          1 TCTGGCGGCCGGGTCKTTGGCCGCGGG 27


RESULT 113
US-10-621-116-12
; Sequence 12, Application US/10621116
; Publication No. US20040091912A1
; GENERAL INFORMATION:
;  APPLICANT: Smith, John Craig
;  TITLE OF INVENTION: DIAGNOSTIC METHOD
;  FILE REFERENCE: 06275-276002
;  CURRENT APPLICATION NUMBER: US/10/621,116
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 09/778,900
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: GB 0004232.5
;  PRIOR FILING DATE: 2000-02-24
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
;    LENGTH: 31
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-621-116-12

  Query Match             0.3%;  Score 25;  DB 1;  Length 31;
  Best Local Similarity   74.1%;  Pred. No. 89;
  Matches   20;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 UCUGGCGGCCGGGUCGUUGGCCGGGGG 210
              :|:||||||||||:|:::||||| |||
Db          1 TCTGGCGGCCGGGTCKTTGGCCGCGGG 27


RESULT 114
US-10-750-185-22523
; Sequence 22523, Application US/10750185
; Publication No. US20050260603A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-2
;  CURRENT APPLICATION NUMBER: US/10/750,185
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 22523
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: Artificial sequence
;    FEATURE:
;    OTHER INFORMATION: Extension Primer
US-10-750-185-22523

  Query Match             0.3%;  Score 24.6;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGYG 25


RESULT 115
US-10-750-623-22523
```

```
; Sequence 22523, Application US/10750623
; Publication No. US20050287531A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-1
;  CURRENT APPLICATION NUMBER: US/10/750,623
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 22523
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Extension Primer
US-10-750-623-22523

  Query Match             0.3%;  Score 24.6;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
             |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGYG 25


RESULT 116
US-09-735-363A-21
; Sequence 21, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-21

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGG 6996
             :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 117
US-09-735-363A-22
; Sequence 22, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-22

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6997
             |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGT 24


RESULT 118
US-09-776-479-1068
; Sequence 1068, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGG 6996
             :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 119
US-09-776-479-1068
; Sequence 1068, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
```

```
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 120
US-09-805-761-44/c
; Sequence 44, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
;  APPLICANT: Gill, Parkesh
;  APPLICANT:  Masood, Rizwan
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
;  TITLE OF INVENTION:  VEGF OLIGONUCLEOTIDES
;  FILE REFERENCE: 21327-701CON2
;  CURRENT APPLICATION NUMBER: US/09/805,761
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/00019
;  PRIOR FILING DATE: 2001-01-19
;  PRIOR APPLICATION NUMBER: US 09/487,023
;  PRIOR FILING DATE: 2000-01-19
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 2000-11-24
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: US 60/037,004
;  PRIOR FILING DATE: 1997-01-31
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 44
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-2 gene specific primers for RT-PCT
US-09-805-761-44

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   83.3%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3736 CAACAGGAUGGUAAAGACUACAUC 3759
              ||||||||:||:||||||:|||:|
Db         24 CAACAGGATGGTAAAGACTACATC 1


RESULT 121
US-09-815-153-20
; Sequence 20, Application US/09815153
; Patent No. US20020132978A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 10716/34
;  CURRENT APPLICATION NUMBER: US/09/815,153
;  CURRENT FILING DATE:  2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-815-153-20

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   21;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2449 ACCAACCAGAAGGGCUCUGUGGAA 2472
              ||||||||||||||:|:|:||||
Db          1 ACCAACCAGAAGGGCTCTGTGGAA 24


RESULT 122
US-09-909-317-6/c
; Sequence 6, Application US/09909317
; Publication No. US20040152075A1
; GENERAL INFORMATION:
;  APPLICANT: Betty P. Tsao (Inventor)
;  APPLICANT:  Rita M. Cantor (Inventor)
;  APPLICANT:  Jerome I. Rotter (Inventor)
;  TITLE OF INVENTION: Genetic Marker Test for Lupus
;  FILE REFERENCE: 18810-82152
;  CURRENT APPLICATION NUMBER: US/09/909,317
;  CURRENT FILING DATE:  2001-07-18
;  PRIOR APPLICATION NUMBER: 09/280,181
;  PRIOR FILING DATE: 1999-03-29
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-909-317-6

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 123
US-10-017-995-1068
; Sequence 1068, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 124
US-10-112-653-1012
; Sequence 1012, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1012
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-1012

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 125
US-10-314-578-1068
; Sequence 1068, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 126
US-10-374-307-12
; Sequence 12, Application US/10374307
; Publication No. US20040170984A1
; GENERAL INFORMATION:
;  APPLICANT: Leproust, Eric M.
;  APPLICANT:  Amorese, Douglas A.
;  APPLICANT:  Kronick, Mel N.
;  TITLE OF INVENTION: METHODS AND DEVICES FOR DETECTING
;  TITLE OF INVENTION:  PRINTHEAD MISALIGNMENT OF AN IN SITU POLYMERIC ARRAY
;  TITLE OF INVENTION:  SYNTHESIS DEVICE
;  FILE REFERENCE: AGIL-078
;  CURRENT APPLICATION NUMBER: US/10/374,307
;  CURRENT FILING DATE:  2003-02-25
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-374-307-12

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24


RESULT 127
US-10-374-307-7/c
; Sequence 7, Application US/10374307
; Publication No. US20040170984A1
; GENERAL INFORMATION:
;  APPLICANT: Leproust, Eric M.
;  APPLICANT:  Amorese, Douglas A.
;  APPLICANT:  Kronick, Mel N.
;  TITLE OF INVENTION: METHODS AND DEVICES FOR DETECTING
;  TITLE OF INVENTION:  PRINTHEAD MISALIGNMENT OF AN IN SITU POLYMERIC ARRAY
;  TITLE OF INVENTION:  SYNTHESIS DEVICE
;  FILE REFERENCE: AGIL-078
;  CURRENT APPLICATION NUMBER: US/10/374,307
;  CURRENT FILING DATE:  2003-02-25
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-374-307-7

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db         24 GTGTGTGTGTGTGTGTGTGTGTGT 1
```

```
RESULT 128
US-10-428-487-78
; Sequence 78, Application US/10428487
; Publication No. US20040006780A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 09800080-0103
;  CURRENT APPLICATION NUMBER: US/10/428,487
;  CURRENT FILING DATE:  2003-05-02
;  PRIOR APPLICATION NUMBER: 09/815,153
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-22
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 78
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: primer
US-10-428-487-78

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   21;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2449 ACCAACCAGAAGGGCUCUGUGGAA 2472
                ||||||||||||||:|:|:||||
Db          1 ACCAACCAGAAGGGCTCTGTGGAA 24


RESULT 129
US-10-665-951-2254
; Sequence 2254, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2254
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-665-951-2254

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 130
US-10-758-155-2254
; Sequence 2254, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2254
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-758-155-2254

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 131
```

```
US-10-831-620-2254
; Sequence 2254, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2254
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-831-620-2254

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 132
US-10-831-778-1068
; Sequence 1068, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-1068

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 133
US-10-844-076-2254
; Sequence 2254, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2254
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-844-076-2254

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 134
US-10-857-715-112
; Sequence 112, Application US/10857715
```

```
; Publication No. US20050164218A1
; GENERAL INFORMATION:
;  APPLICANT: Agus David
;  APPLICANT:  Baker Joffre
;  APPLICANT:  Natale Ron
;  APPLICANT:  Shak Steven
;  TITLE OF INVENTION: Gene Expression Markers for Response to
;  TITLE OF INVENTION:  EGFR Inhibitors Drugs
;  FILE REFERENCE: 39740/0011
;  CURRENT APPLICATION NUMBER: US/10/857,715
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: 60/474,908
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 232
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 112
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: probe
US-10-857-715-112

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   21;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3474 CUACAGCACCAAGAGCGACGUGUG 3497
              |:||||||||||||||||||:|:|
Db          1 CTACAGCACCAAGAGCGACGTGTG 24


RESULT 135
US-10-944-611-2707
; Sequence 2707, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2707
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-944-611-2707

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 136
US-10-962-898-2707
; Sequence 2707, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2707
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-962-898-2707

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 137
US-11-127-654-1012
; Sequence 1012, Application US/11127654
```

```
; Publication No. US20050250726A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1012
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-1012

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 138
US-10-455-470-30/c
; Sequence 30, Application US/10455470
; Publication No. US20040170613A1
; GENERAL INFORMATION:
;  APPLICANT: Ferrara, Napoleone
;  APPLICANT:  Hillan, Kenneth J.
;  APPLICANT:  Le Couter, Jennifer
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR LIVER GROWTH AND LIVER PROTECTION
;  FILE REFERENCE: P1849R1US
;  CURRENT APPLICATION NUMBER: US/10/455,470
;  CURRENT FILING DATE:  2003-06-05
;  PRIOR APPLICATION NUMBER: US 60/386,637
;  PRIOR FILING DATE: 2002-06-05
;  NUMBER OF SEQ ID NOS: 36
; SEQ ID NO 30
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: sequence is synthesized
;   FEATURE:
;   NAME/KEY: PCR probe
;   LOCATION: Full
;   OTHER INFORMATION: Flt-1 probe
US-10-455-470-30

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1.5e+02;
  Matches   20;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2703 CAAGUGGGAGUUUGCCCGGGAGAGA 2727
              ||||:|||||:::|| |||||||||
Db         25 CAAGTGGGAGTTTGCACGGGAGAGA 1


RESULT 139
US-10-719-956-380112
; Sequence 380112, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 380112
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-380112

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1.5e+02;
  Matches   21;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2144 GCACCUAUGCCUGCAGAGCCAGGAA 2168
              |||||:|:|||: ||||||||||||
Db          1 GCACCTATGCCTCCAGAGCCAGGAA 25


RESULT 140
US-10-956-157-70209
; Sequence 70209, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William
;  TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
;  TITLE OF INVENTION:  HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
;  FILE REFERENCE: 031896-043000 (AM 101081)
;  CURRENT APPLICATION NUMBER: US/10/956,157
;  CURRENT FILING DATE:  2004-10-04
;  NUMBER OF SEQ ID NOS: 319805
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70209
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-70209

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|: :|:|:|:|:|:|:|:|:|:|
Db          1 GTGTATGTGTGTGTGTGTGTGTG 25


RESULT 141
US-11-036-317-435129
; Sequence 435129, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 435129
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-435129
```

```
  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3313 GACCUGGCAGCGAGAAACAUUCUUU 3337
              ||||:|||||||||||||: |:::
Db          1 GACCTGGCAGCGAGAAACATCCTTT 25


RESULT 142
US-11-136-527-109884
; Sequence 109884, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 109884
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-109884

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 1.5e+02;
  Matches   17;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4419 UUUUGACUAACAAGAAUGUAACUCC 4443
              ::::|||:|||||||||:|:||| ||
Db          1 TTTTGACTAACAAGAATGTAACCCC 25


RESULT 143
US-09-805-761-42
; Sequence 42, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
;  APPLICANT: Gill, Parkesh
;  APPLICANT:  Masood, Rizwan
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
;  TITLE OF INVENTION:  VEGF OLIGONUCLEOTIDES
;  FILE REFERENCE: 21327-701CON2
;  CURRENT APPLICATION NUMBER: US/09/805,761
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/00019
;  PRIOR FILING DATE: 2001-01-19
;  PRIOR APPLICATION NUMBER: US 09/487,023
;  PRIOR FILING DATE: 2000-01-19
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 2000-11-24
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: US 60/037,004
;  PRIOR FILING DATE: 1997-01-31
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-1 gene specific primers for RT-PCR
US-09-805-761-42

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 144
US-09-805-761-43
; Sequence 43, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
;  APPLICANT: Gill, Parkesh
;  APPLICANT:  Masood, Rizwan
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
;  TITLE OF INVENTION:  VEGF OLIGONUCLEOTIDES
;  FILE REFERENCE: 21327-701CON2
;  CURRENT APPLICATION NUMBER: US/09/805,761
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/00019
;  PRIOR FILING DATE: 2001-01-19
;  PRIOR APPLICATION NUMBER: US 09/487,023
;  PRIOR FILING DATE: 2000-01-19
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 2000-11-24
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: US 60/037,004
;  PRIOR FILING DATE: 1997-01-31
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-1 gene specific primers for RT-PCR
US-09-805-761-43

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 145
US-09-815-153-32/c
; Sequence 32, Application US/09815153
; Patent No. US20020132978A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 10716/34
;  CURRENT APPLICATION NUMBER: US/09/815,153
;  CURRENT FILING DATE:  2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-815-153-32
```

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2473 AGUUCAGCAUACCUCACUGUUCA 2495
              ||::|||||:|||:|||:|::||
Db         23 AGTTCAGCATACCTCACTGTTCA 1


RESULT 146
US-09-815-153-46/c
; Sequence 46, Application US/09815153
; Patent No. US20020132978A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 10716/34
;  CURRENT APPLICATION NUMBER: US/09/815,153
;  CURRENT FILING DATE:  2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-815-153-46

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2473 AGUUCAGCAUACCUCACUGUUCA 2495
              ||::|||||:|||:|||:|::||
Db         23 AGTTCAGCATACCTCACTGTTCA 1


RESULT 147
US-10-101-018-10
; Sequence 10, Application US/10101018
; Publication No. US20030120038A1
; GENERAL INFORMATION:
;  APPLICANT: Kendall, Richard L.
;  APPLICANT:  Thomas, Kenneth A., Jr.
;  TITLE OF INVENTION: INHIBITOR OF VASCULAR ENDOTHELIAL CELL
;  TITLE OF INVENTION:  GROWTH FACTOR
;  FILE REFERENCE: 18888DC
;  CURRENT APPLICATION NUMBER: US/10/101,018
;  CURRENT FILING DATE:  2002-03-19
;  PRIOR APPLICATION NUMBER: 09/232,777
;  PRIOR FILING DATE: 1999-01-15
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-101-018-10

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 148
US-10-246-091-22/c
; Sequence 22, Application US/10246091
; Publication No. US20030203844A1
; GENERAL INFORMATION:
;  APPLICANT: Delfani, Kioumars
;  APPLICANT:  Janson, Ann Marie
;  APPLICANT:  Kuhn, Georg
;  APPLICANT:  Plate, Karlheinz
;  APPLICANT:  Schnazer, Anne
;  APPLICANT:  Wachs, Frank-Peter
;  APPLICANT:  Zhao, Ming
;  TITLE OF INVENTION: Treatment of Central Nervous System Disorders
;  FILE REFERENCE: 21882-504 (PDGF/VEGF)
;  CURRENT APPLICATION NUMBER: US/10/246,091
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: 60/323,381
;  PRIOR FILING DATE: 2001-09-19
;  PRIOR APPLICATION NUMBER: 60/326,044
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-246-091-22

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1263 UCGAAAACAGCAGGUGCUUGAAA 1285
              :|||||||||||||:||::||||
Db         23 TCGAAAACAGCAGGTGCTTGAAA 1


RESULT 149
US-10-428-487-76/c
; Sequence 76, Application US/10428487
; Publication No. US20040006780A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 09800080-0103
;  CURRENT APPLICATION NUMBER: US/10/428,487
;  CURRENT FILING DATE:  2003-05-02
;  PRIOR APPLICATION NUMBER: 09/815,153
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-22
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 76
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: primer
US-10-428-487-76

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2473 AGUUCAGCAUACCUCACUGUUCA 2495
              ||::|||||:|||:|||:|::||
```

```
Db         23 AGTTCAGCATACCTCACTGTTCA 1


RESULT 150
US-10-428-487-80/c
; Sequence 80, Application US/10428487
; Publication No. US20040006780A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 09800080-0103
;  CURRENT APPLICATION NUMBER: US/10/428,487
;  CURRENT FILING DATE:  2003-05-02
;  PRIOR APPLICATION NUMBER: 09/815,153
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-22
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 80
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: primer
US-10-428-487-80

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2473 AGUUCAGCAUACCUCACUGUUCA 2495
              ||::|||||:|||:|||:|::||
Db         23 AGTTCAGCATACCTCACTGTTCA 1


RESULT 151
US-10-915-896-605
; Sequence 605, Application US/10915896
; Publication No. US20050159378A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapuetics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of MYC and/or MYB Gene
;  TITLE OF INVENTION:  Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/167 (MBHB 02-1105-C)
;  CURRENT APPLICATION NUMBER: US/10/915,896
;  CURRENT FILING DATE:  2004-08-11
;  PRIOR APPLICATION NUMBER: PCT/US03/05326
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/418,655
;  PRIOR FILING DATE: 2002-10-15
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 686
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 605
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-915-896-605

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 152
US-10-922-154-14/c
; Sequence 14, Application US/10922154
; Publication No. US20050069528A1
; GENERAL INFORMATION:
;  APPLICANT: Teicher, Beverly
;  TITLE OF INVENTION: MAMMALIAN ENDOTHELIAL CELL MODEL SYSTEMS
;  FILE REFERENCE: 003482.00009
;  CURRENT APPLICATION NUMBER: US/10/922,154
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: 60/453,828
;  PRIOR FILING DATE: 2000-03-12
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-922-154-14

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 1.7e+02;
  Matches   20;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3005 ACUACCUCAAGAGCAAACGUGAC 3027
              ||:|||:|||||||||||||:|||
Db         23 ACTACCTCAAGAGCAAACGTGAC 1


RESULT 153
US-10-105-901-16
; Sequence 16, Application US/10105901
; Publication No. US20030092604A1
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 48
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
```

```
;             APPLICATION NUMBER: US/10/105,901
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dolly A. Vance
;             REGISTRATION NUMBER: 39,054
;             REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 16:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 27 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..27
;        SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-105-901-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 154
US-11-043-693-16
; Sequence 16, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Richard F. Trecartin
;      REGISTRATION NUMBER:  31,801
;      REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..27
US-11-043-693-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 155
US-09-815-153-33
; Sequence 33, Application US/09815153
; Patent No. US20020132978A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 10716/34
;  CURRENT APPLICATION NUMBER: US/09/815,153
;  CURRENT FILING DATE:  2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-815-153-33

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   77.3%;  Pred. No. 2.2e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2426 AAGGUGUCUAUCACUGCAAAGC 2447
              ||||:|:|:|:|||:|||||||
Db          1 AAGGTGTCTATCACTGCAAAGC 22


RESULT 156
US-10-007-574-3
; Sequence 3, Application US/10007574
; Publication No. US20030100107A1
; GENERAL INFORMATION:
;  APPLICANT: PESCHLE, Cesare
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENERATING DIFFERENTIATED
;  TITLE OF INVENTION:  HUMAN CELLS
;  FILE REFERENCE: 9855-26U3
;  CURRENT APPLICATION NUMBER: US/10/007,574
;  CURRENT FILING DATE:  2001-11-09
```

```
;  PRIOR APPLICATION NUMBER: US 60/087,153
;  PRIOR FILING DATE: 1998-05-29
;  PRIOR APPLICATION NUMBER: US 09/322,352
;  PRIOR FILING DATE: 1999-05-28
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-10-007-574-3

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   86.4%;  Pred. No. 2.2e+02;
  Matches   19;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3109 AAACCAAGACUAGAUAGCGUCA 3130
              ||||||||||:|||:||||:||
Db             1 AAACCAAGACTAGATAGCGTCA 22


RESULT 157
US-10-007-574-4/c
; Sequence 4, Application US/10007574
; Publication No. US20030100107A1
; GENERAL INFORMATION:
;  APPLICANT: PESCHLE, Cesare
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENERATING DIFFERENTIATED
;  TITLE OF INVENTION:  HUMAN CELLS
;  FILE REFERENCE: 9855-26U3
;  CURRENT APPLICATION NUMBER: US/10/007,574
;  CURRENT FILING DATE:  2001-11-09
;  PRIOR APPLICATION NUMBER: US 60/087,153
;  PRIOR FILING DATE: 1998-05-29
;  PRIOR APPLICATION NUMBER: US 09/322,352
;  PRIOR FILING DATE: 1999-05-28
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-10-007-574-4

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 2.2e+02;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 AAGAACCCCGAUUAUGUGAGAA 3415
              ||||||||||::|:|:|||||
Db            22 AAGAACCCCGATTATGTGAGAA 1


RESULT 158
US-10-428-487-79
; Sequence 79, Application US/10428487
; Publication No. US20040006780A1
; GENERAL INFORMATION:
;  APPLICANT: RASTELLI, LUCA K.
;  APPLICANT:  GERBER, HANS-PETER
;  TITLE OF INVENTION: VEGF-MODULATED GENES AND METHODS EMPLOYING THEM
;  FILE REFERENCE: 09800080-0103
;  CURRENT APPLICATION NUMBER: US/10/428,487
;  CURRENT FILING DATE:  2003-05-02
;  PRIOR APPLICATION NUMBER: 09/815,153
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/191,201
;  PRIOR FILING DATE: 2000-03-22
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 79
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: primer
US-10-428-487-79

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   77.3%;  Pred. No. 2.2e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2426 AAGGUGUCUAUCACUGCAAAGC 2447
              ||||:|:|:|:|||:|||||||
Db             1 AAGGTGTCTATCACTGCAAAGC 22


RESULT 159
US-11-085-982-19
; Sequence 19, Application US/11085982
; Publication No. US20060030597A1
; GENERAL INFORMATION:
;  APPLICANT: GERRITSEN, MARY E.
;  APPLICANT:  XIN, XIAOHUA
;  TITLE OF INVENTION: METHOD OF INHIBITING ANGIOGENESIS
;  FILE REFERENCE: GEN01-006-CON2-US
;  CURRENT APPLICATION NUMBER: US/11/085,982
;  CURRENT FILING DATE:  2005-03-22
;  PRIOR APPLICATION NUMBER: 09/865,859
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 09/443,010
;  PRIOR FILING DATE: 1999-11-17
;  PRIOR APPLICATION NUMBER: 60/116,530
;  PRIOR FILING DATE: 1999-01-20
;  PRIOR APPLICATION NUMBER: 60/109,328
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 19
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-11-085-982-19

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   72.7%;  Pred. No. 2.2e+02;
  Matches   16;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2648 ACCCAGAUGAAGUUCCUUUGGA 2669
              |||||||:||||::||:::|||
Db             1 ACCCAGATGAAGTTCCTTTGGA 22


RESULT 160
US-09-866-316B-1/c
; Sequence 1, Application US/09866316B
; Patent No. US20020142980A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with No. US20020142980A1el Chemical Compo
```

```
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/09/866,316B
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(7)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(22)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   NAME/KEY: misc_feature
;   LOCATION: (8)..(16)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(22)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-09-866-316B-1

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   77.3%;  Pred. No. 2.1e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
             ::||:|||||:||||||||:||
Db         22 TTCATGAGCCTGGAAAGAATCA 1


RESULT 161
US-10-715-285-1/c
; Sequence 1, Application US/10715285
; Publication No. US20050176018A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with Novel Chemical Compositions Capable c
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/10/715,285
;  CURRENT FILING DATE:  2003-11-17
;  PRIOR APPLICATION NUMBER: US/09/866,316B
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(7)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(22)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (8)..(16)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(22)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-715-285-1

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   77.3%;  Pred. No. 2.1e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
             ::||:|||||:||||||||:||
Db         22 TTCATGAGCCTGGAAAGAATCA 1


RESULT 162
US-09-866-316B-3/c
; Sequence 3, Application US/09866316B
; Patent No. US20020142980A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with No. US20020142980A1el Chemical Compos
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/09/866,316B
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (25)..(25)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(8)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(24)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(17)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-09-866-316B-3

  Query Match             0.3%;  Score 22;  DB 1;  Length 25;
  Best Local Similarity   77.3%;  Pred. No. 2e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         23 TTCATGAGCCTGGAAAGAATCA 2


RESULT 163
US-10-715-285-3/c
; Sequence 3, Application US/10715285
; Publication No. US20050176018A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with Novel Chemical Compositions Capable o
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/10/715,285
;  CURRENT FILING DATE:  2003-11-17
;  PRIOR APPLICATION NUMBER: US/09/866,316B
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (25)..(25)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(8)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(24)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(17)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-715-285-3

  Query Match             0.3%;  Score 22;  DB 1;  Length 25;
  Best Local Similarity   77.3%;  Pred. No. 2e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         23 TTCATGAGCCTGGAAAGAATCA 2


RESULT 164
US-10-105-901-4
; Sequence 4, Application US/10105901
; Publication No. US20030092604A1
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 48
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Flehr Hohbach Test Albritton & Herbert LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dolly A. Vance
;            REGISTRATION NUMBER: 39,054
;            REFERENCE/DOCKET NUMBER: A-63291-2/RMS/DAV
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 4:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 25 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  2..25
;       SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-105-901-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
```

```
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 165
US-10-716-029-50
; Sequence 50, Application US/10716029
; Publication No. US20040171038A1
; GENERAL INFORMATION:
;  APPLICANT: Nicklin, Martin
;  APPLICANT:  Duff, Gordon
;  APPLICANT:  Kornman, Kenneth
;  APPLICANT:  Kolpin, Maryam R
;  APPLICANT:  Hsieh, Chung-Ming
;  APPLICANT:  Govindaraju, Raju
;  APPLICANT:  Aziz, Nazneen
;  TITLE OF INVENTION: The IL-1 Gene Cluster and Associated Inflammatory Polymorphisms
;  TITLE OF INVENTION:  and Haplotypes
;  FILE REFERENCE: 24299-524 CON
;  CURRENT APPLICATION NUMBER: US/10/716,029
;  CURRENT FILING DATE:  2003-11-17
;  PRIOR APPLICATION NUMBER: 10/351,702
;  PRIOR FILING DATE: 2003-01-25
;  PRIOR APPLICATION NUMBER: 60/351,951
;  PRIOR FILING DATE: 2002-01-25
;  NUMBER OF SEQ ID NOS: 277
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-716-029-50

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGG 6998
              |:|:|:|:|: :|:|: :|:|:|:|
Db          1 GTGTGTGTGTCTGTGTTTGTGTGTG 25


RESULT 166
US-10-719-956-106703
; Sequence 106703, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 106703
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-106703

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 2.1e+02;
  Matches   20;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1750 AGAAUUGAGAGCAUCACUCAGCGCA 1774
              ||||: ||| |||:|||:|||||||
Db          1 AGAATCGAGGGCATCACTCAGCGCA 25


RESULT 167
US-10-888-435-185
; Sequence 185, Application US/10888435
; Publication No. US20050048544A1
; GENERAL INFORMATION:
;  APPLICANT: GARDNER, PHYLLIS
;  APPLICANT:  SCHRIJVER, IRIS
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETERMINING
;  TITLE OF INVENTION:  WHETHER A SUBJECT CARRIES A CYSTIC FIBROSIS TRANSMEMBRANE
;  TITLE OF INVENTION:  CONDUCTANCE REGULATOR (CFTR) GENE MUTATION
;  FILE REFERENCE: STAN-295
;  CURRENT APPLICATION NUMBER: US/10/888,435
;  CURRENT FILING DATE:  2004-07-09
;  PRIOR APPLICATION NUMBER: 60/486,763
;  PRIOR FILING DATE: 2003-07-10
;  NUMBER OF SEQ ID NOS: 437
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-10-888-435-185

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   40.0%;  Pred. No. 2.1e+02;
  Matches   10;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|: : :
Db          1 TGTGTGTGTGTGTGTGTGTTTTT 25


RESULT 168
US-11-036-317-433154
; Sequence 433154, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 433154
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-433154

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2916 GAACGUGGUUAACCUGCUGGGAGCC 2940
              ||| |:||::||||: |:|||||||
Db          1 GAATGTGGTTAACCTCCTGGGAGCC 25


RESULT 169
US-11-036-317-518975
; Sequence 518975, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
```

```
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 518975
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-518975

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2912 AUCUGAACGUGGUUAACCUGCUGGG 2936
              | |:|||||:||: ||||:||:|||
Db          1 ACCTGAACGTGGTCAACCTGCTGGG 25


RESULT 170
US-11-036-317-813720
; Sequence 813720, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 813720
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-813720

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        789 UGGAAAACGCAUAAUCUGGGACAGU 813
              :|||||| ||: |:|:|||||||:
Db          1 TGGAAAACTCATCATCTGGGACAGT 25


RESULT 171
US-11-036-317-813721
; Sequence 813721, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 813721
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-813721

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        789 UGGAAAACGCAUAAUCUGGGACAGU 813
              :|||||| ||: |:|:|||||||:
Db          1 TGGAAAACTCATGATCTGGGACAGT 25


RESULT 172
US-11-036-317-822861
; Sequence 822861, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 822861
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-822861

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2921 UGGUUAACCUGCUGGGAGCCUGCAC 2945
              :||: ||||:||:||| |||:||||
Db          1 TGGTCAACCTGCTGGGGGCCTGCAC 25


RESULT 173
US-11-043-693-4
; Sequence 4, Application US/11043693
; Publication No. US20050281831A1
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  52
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dorsey & Whitney LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/11/043,693
;      FILING DATE:  26-Jan-2005
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/10/105,901
;      FILING DATE:  20-Mar-2002
;      APPLICATION NUMBER:  09/348,886
;      FILING DATE:  01-JUL-1999
;      APPLICATION NUMBER:  US 08/643,839
```

```
;       FILING DATE:  07-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Richard F. Trecartin
;       REGISTRATION NUMBER:  31,801
;       REFERENCE/DOCKET NUMBER:  A-63291-3/RFT/NBC
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  25 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  2..25
US-11-043-693-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 174
US-11-121-634-89
; Sequence 89, Application US/11121634
; Publication No. US20050282198A1
; GENERAL INFORMATION:
;  APPLICANT: Duff, Gordon
;  TITLE OF INVENTION: Diagnostics and Therapeutics for Diseases Associated with an IL-1
;  TITLE OF INVENTION:  Inflammatory Haplotype
;  FILE REFERENCE: 24299-508CON3 CIP1
;  CURRENT APPLICATION NUMBER: US/11/121,634
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: US 10/802,061
;  PRIOR FILING DATE: 2004-03-15
;  PRIOR APPLICATION NUMBER: US 09/845,129
;  PRIOR FILING DATE: 2001-04-27
;  PRIOR APPLICATION NUMBER: US 09/345,217
;  PRIOR FILING DATE: 1999-06-30
;  PRIOR APPLICATION NUMBER: PCT/GB98/01481
;  PRIOR FILING DATE: 1998-05-21
;  PRIOR APPLICATION NUMBER: GB9711040.7
;  PRIOR FILING DATE: 1997-05-29
;  PRIOR APPLICATION NUMBER: US 10/300,011
;  PRIOR FILING DATE: 2002-11-19
;  PRIOR APPLICATION NUMBER: US 60/386,020
;  PRIOR FILING DATE: 2002-06-05
;  PRIOR APPLICATION NUMBER: US 60/331,681
;  PRIOR FILING DATE: 2001-11-19
;  PRIOR APPLICATION NUMBER: US 60/567,727
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 202
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 89
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-11-121-634-89

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|: :|:|: :|:|:|:|
Db          1 GTGTGTGTGTYTGTGTTTGTGTGTG 25


RESULT 175
US-09-263-959-774/c
; Sequence 774, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  774:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-774

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   43.5%;  Pred. No. 2.4e+02;
  Matches   10;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|: :|:|:|:|:|:
Db         23 TGTGTGTGTGTATGTGTGTGTGT 1


RESULT 176
US-09-805-761-45/c
; Sequence 45, Application US/09805761
; Patent No. US20020165174A1
; GENERAL INFORMATION:
;  APPLICANT: Gill, Parkesh
;  APPLICANT:  Masood, Rizwan
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ANTISENSE
;  TITLE OF INVENTION:  VEGF OLIGONUCLEOTIDES
;  FILE REFERENCE: 21327-701CON2
;  CURRENT APPLICATION NUMBER: US/09/805,761
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/00019
;  PRIOR FILING DATE: 2001-01-19
;  PRIOR APPLICATION NUMBER: US 09/487,023
;  PRIOR FILING DATE: 2000-01-19
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 2000-11-24
;  PRIOR APPLICATION NUMBER: US 09/016,541
;  PRIOR FILING DATE: 1998-01-30
```

```
;  PRIOR APPLICATION NUMBER: US 60/037,004
;  PRIOR FILING DATE: 1997-01-31
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-2 gene specific primers for RT-PCT
US-09-805-761-45

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+02;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||| ||:||:||||:||:||||
Db         23 CAGACCATGCTGGACTGCTGGCA 1


RESULT 177
US-10-719-900-140318
; Sequence 140318, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 140318
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-140318

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 25;
  Best Local Similarity   65.2%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6521 AACUCAGGUUUGUAGCAUACAUG 6543
              |||:||||:::|:||||:|| :|
Db          3 AACTCAGGTTTGTAGCATACTTG 25


RESULT 178
US-09-735-363A-19
; Sequence 19, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-19

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 179
US-09-735-363A-20
; Sequence 20, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-20

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21


RESULT 180
US-09-776-479-907
; Sequence 907, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 907
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-907

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 21


RESULT 181
US-10-017-995-907
; Sequence 907, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 907
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-907

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 21


RESULT 182
US-10-112-653-876
; Sequence 876, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 876
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-876

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 21


RESULT 183
US-10-160-232-3
; Sequence 3, Application US/10160232
; Publication No. US20030088075A1
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  ITO, MIKITO
;  APPLICANT:  HANAI, NOBUO
;  APPLICANT:  KAWADA, YOKO
;  APPLICANT:  NAKAMURA, KAZUYASU
;  APPLICANT:  SHIBUYA, MASABUMI
;  TITLE OF INVENTION: ANTI-HUMAN VEGF RECEPTOR FLT-1 MONOCLONAL ANTIBODY
;  FILE REFERENCE: 249-107
;  CURRENT APPLICATION NUMBER: US/10/160,232
;  CURRENT FILING DATE:  2002-06-04
;  PRIOR APPLICATION NUMBER: US/09/453,718
;  PRIOR FILING DATE: 1999-12-03
;  PRIOR APPLICATION NUMBER: 09/315,051
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/119,014
;  PRIOR FILING DATE: 1998-07-20
;  PRIOR APPLICATION NUMBER: PCT/JP97/04259
;  PRIOR FILING DATE: 1997-11-21
;  NUMBER OF SEQ ID NOS: 96
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-10-160-232-3

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 184
US-10-314-578-907
; Sequence 907, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 907
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-907

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:|:
```

```
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 185
US-10-425-668-7
; Sequence 7, Application US/10425668
; Publication No. US20030175271A1
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  SATO, YASUFUMI
;  TITLE OF INVENTION: VEGF ACTIVITY INHIBITOR
;  FILE REFERENCE: 249-151
;  CURRENT APPLICATION NUMBER: US/10/425,668
;  CURRENT FILING DATE:  2003-04-30
;  PRIOR APPLICATION NUMBER: US/09/700,865
;  PRIOR FILING DATE: 2000-11-20
;  PRIOR APPLICATION NUMBER: PCT/JP99/02660
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: P. HEI. 10-138999
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-10-425-668-7

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 186
US-10-506-997-89/c
; Sequence 89, Application US/10506997
; Publication No. US20050234225A1
; GENERAL INFORMATION:
;  APPLICANT: ImClone Systems Incorporated
;  TITLE OF INVENTION: Human Antibodies Specific To KDR And Uses Thereof
;  FILE REFERENCE: 11245/47802
;  CURRENT APPLICATION NUMBER: US/10/506,997
;  CURRENT FILING DATE:  2004-09-04
;  PRIOR APPLICATION NUMBER: PCT/US03/06459
;  PRIOR FILING DATE: 2003-03-04
;  PRIOR APPLICATION NUMBER: 60/361,783
;  PRIOR FILING DATE: 2002-03-04
;  NUMBER OF SEQ ID NOS: 93
;  SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 89
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: amplification primer for Flt-1
US-10-506-997-89

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3895 GCUUUCAAGUUCAUGAGCCUG 3915
              ||:::||||::||:|||||:|
Db         21 GCTTTCAAGTTCATGAGCCTG 1


RESULT 187
US-10-727-780A-24/c
; Sequence 24, Application US/10727780A
; Publication No. US20050233329A1
; GENERAL INFORMATION:
;  APPLICANT: Vaish, Narendra
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Sirna Therapeutics, Inc.
;  TITLE OF INVENTION: Inhibition of Gene Expression Using Duplex Forming
;  TITLE OF INVENTION:  Oligonucleotides
;  FILE REFERENCE: 03-1070 (400.139)
;  CURRENT APPLICATION NUMBER: US/10/727,780A
;  CURRENT FILING DATE:  2003-12-03
;  NUMBER OF SEQ ID NOS: 772
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: RNA
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: internucleotide phosphorothioate linkage
US-10-727-780A-24

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.8e+02;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 188
US-10-831-778-907
; Sequence 907, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 907
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-907

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21
```

```
RESULT 189
US-11-127-654-876
; Sequence 876, Application US/11127654
; Publication No. US20050250726A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 876
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-876

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 190
US-11-250-411-3
; Sequence 3, Application US/11250411
; Publication No. US20060034838A1
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  ITO, MIKITO
;  APPLICANT:  HANAI, NOBUO
;  APPLICANT:  KAWADA, YOKO
;  APPLICANT:  NAKAMURA, KAZUYASU
;  APPLICANT:  SHIBUYA, MASABUMI
;  TITLE OF INVENTION: ANTI-HUMAN VEGF RECEPTOR FLT-1 MONOCLONAL ANTIBODY
;  FILE REFERENCE: 249-107
;  CURRENT APPLICATION NUMBER: US/11/250,411
;  CURRENT FILING DATE:  2005-10-17
;  PRIOR APPLICATION NUMBER: US/09/453,718
;  PRIOR FILING DATE: 1999-12-03
;  PRIOR APPLICATION NUMBER: 09/315,051
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/119,014
;  PRIOR FILING DATE: 1998-07-20
;  PRIOR APPLICATION NUMBER: PCT/JP97/04259
;  PRIOR FILING DATE: 1997-11-21
;  NUMBER OF SEQ ID NOS: 111
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-11-250-411-3

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 191
US-10-655-727-3
; Sequence 3, Application US/10655727
; Publication No. US20050054089A1
; GENERAL INFORMATION:
;  APPLICANT: Helfand, Stuart C.
;  APPLICANT:  Akhtar, Nasim
;  APPLICANT:  Dickerson, Erin B.
;  APPLICANT:  Padilla, Marcia
;  TITLE OF INVENTION: A Malignant Endothelial Cell Line and Uses Thereof in Models for
;  TITLE OF INVENTION:  Angiogenesis
;  FILE REFERENCE: WARP-0014
;  CURRENT APPLICATION NUMBER: US/10/655,727
;  CURRENT FILING DATE:  2003-09-05
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-655-727-3

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   66.7%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        416 AAGCAGCCCAUAAAUGGUCUUUGC 439
              ||||||||||:  |:||:|:::||
Db          1 AAGCAGCCCATTCATGGTCTTTGC 24


RESULT 192
US-10-845-667-1307/c
; Sequence 1307, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Conditions Associated With Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-091
;  CURRENT APPLICATION NUMBER: US/10/845,667
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1506
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1307
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-845-667-1307

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   41.7%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|: :|:|:|:|: :|
Db         24 TGTGTGTGTGTATGTGTGTGTTTG 1


RESULT 193
US-10-845-667-557/c
; Sequence 557, Application US/10845667
; Publication No. US20050026183A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Conditions Associated With Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-091
;  CURRENT APPLICATION NUMBER: US/10/845,667
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1506
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 557
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-845-667-557

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   41.7%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|: :|:|:|:|: :|
Db         24 TGTGTGTGTGTATGTGTGTGTTTG 1


RESULT 194
US-10-973-783-936/c
; Sequence 936, Application US/10973783
; Publication No. US20050164246A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Lung Cancer with Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-100
;  CURRENT APPLICATION NUMBER: US/10/973,783
;  CURRENT FILING DATE:  2004-10-25
;  PRIOR APPLICATION NUMBER: US 10/845,667
;  PRIOR FILING DATE: 2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1513
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 936
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe sequence (LSO1)
US-10-973-783-936

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   41.7%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|: :|:|:|:|: :|
Db         24 TGTGTGTGTGTATGTGTGTGTTTG 1


RESULT 195
US-10-719-900-468567
; Sequence 468567, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 468567
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-468567

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   62.5%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1703 AUAAUGAAGAGUCCUUUAUCCUGG 1726
              | ||:||||| :||:::|:||:||
Db          2 AGAATGAAGAATCCTTTATCCTGG 25


RESULT 196
US-10-719-900-572884
; Sequence 572884, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 572884
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-572884

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   75.0%;  Pred. No. 2.6e+02;
  Matches   18;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1585 CUGGGCAGCAGACAAAUCCUGACU 1608
              |:||||||||||||| :||: ||:
Db          2 CTGGGCAGCAGACAAGTCCTCACT 25


RESULT 197
US-10-719-900-695000
; Sequence 695000, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 695000
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-695000

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   79.2%;  Pred. No. 2.6e+02;
  Matches   19;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAAG 1548
              |:|||||| |||| :||||||||
```

```
Db          1 GTGAAACCTCAGATCTACGAAAAG 24


RESULT 198
US-11-036-317-13707/c
; Sequence 13707, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 13707
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-13707

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   79.2%;  Pred. No. 2.6e+02;
  Matches   19;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5903 UCAGAAGCUGGAGAGGCAACAGUG 5926
                :||||| |:| ||||||||||:|
Db         24 TCAGAATCTGAAGAGGCAACAGTG 1


RESULT 199
US-11-036-317-410272
; Sequence 410272, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 410272
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-410272

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   20;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3468 CAAAAUCUACAGCACCAAGAGCGA 3491
                |||  :|:||||||||||||||||
Db          1 CAAGGTCTACAGCACCAAGAGCGA 24


RESULT 200
US-10-357-488-5
; Sequence 5, Application US/10357488
; Publication No. US20030194730A1
; GENERAL INFORMATION:
;  APPLICANT: Centre For DNA Fingerprinting and Diagnostics
;  TITLE OF INVENTION: No. US20030194730A1el FISSR-PCR primers and markers and a method
;  TITLE OF INVENTION:  primers and markers for identifying genetic constitution and bre
;  TITLE OF INVENTION:  varities.
;  FILE REFERENCE: 782-indian
;  CURRENT APPLICATION NUMBER: US/10/357,488
;  CURRENT FILING DATE:  2003-02-04
;  PRIOR APPLICATION NUMBER: 260/MAS/2002
;  PRIOR FILING DATE: 2002-04-08
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-5

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 23;
  Best Local Similarity   45.5%;  Pred. No. 2.9e+02;
  Matches   10;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6995
                |: :|:|:|:|:|:|:|:|:|:|:
Db          2 GTATGTGTGTGTGTGTGTGT 23


RESULT 201
US-11-216-660-131/c
; Sequence 131, Application US/11216660
; Publication No. US20060068428A1
; GENERAL INFORMATION:
;  APPLICANT: Vance, Jeffery M.
;  APPLICANT:  Li, Yi-Ju
;  APPLICANT:  Pericak-Vance, Margaret A.
;  APPLICANT:  Martin, Eden R.
;  APPLICANT:  Scott, William K.
;  APPLICANT:  Hauser, Michael A.
;  APPLICANT:  Stajich, Jeffrey M.
;  APPLICANT:  Oliveira, Sofia
;  APPLICANT:  van der Walt, Joelle
;  TITLE OF INVENTION: IDENTIFICATION OF GENTIC MARKERS ASSOCIATED WITH PARKINSON
;  TITLE OF INVENTION:  DISEASE
;  FILE REFERENCE: 5405-314IP
;  CURRENT APPLICATION NUMBER: US/11/216,660
;  CURRENT FILING DATE:  2005-08-31
;  PRIOR APPLICATION NUMBER: US 10/979,297
;  PRIOR FILING DATE: 2004-11-02
;  PRIOR APPLICATION NUMBER: US 60/516,861
;  PRIOR FILING DATE: 2003-11-03
;  NUMBER OF SEQ ID NOS: 250
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 131
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-11-216-660-131

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 2.9e+02;
  Matches   11;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUG 6992
                | :|:|:|:|:|:|:|:|:|:|:|
Db         22 AATGTGTGTGTGTGTGTGTGTG 1


RESULT 202
US-10-469-313A-2
; Sequence 2, Application US/10469313A
; Publication No. US20050084854A1
; GENERAL INFORMATION:
;  APPLICANT: Lloyd, Robert M.
;  APPLICANT:  Uzgiris, Arejas
;  APPLICANT:  Huong, Hoe Tzong-Jyh
```

```
;  TITLE OF INVENTION: Methods and Primers for Evaluating HIV-1 Mutations
;  FILE REFERENCE: 49493.830036.US1
;  CURRENT APPLICATION NUMBER: US/10/469,313A
;  CURRENT FILING DATE:  2003-08-29
;  PRIOR APPLICATION NUMBER: PCT/US02/06632
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: US 60/273,683
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-469-313A-2

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   60.0%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2749 GGAAGAGGGGCUUUUGGAAAAGUGG 2773
              |:|::|:||||: ::||||| |:||
Db          1 GRARRARGGGCTGTTGGAAATGTGG 25


RESULT 203
US-10-719-900-800686
; Sequence 800686, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 800686
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-800686

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   56.0%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1502 UCACUGCCACUCUAAUUGUCAAUGU 1526
              :|||:|||||:|: |::|: || |:
Db          1 TCACTGCCACTCTCATTGTAAACGT 25


RESULT 204
US-10-719-956-106704
; Sequence 106704, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 106704
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-106704

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 2.9e+02;
  Matches   19;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1750 AGAAUUGAGAGCAUCACUCAGCGCA 1774
              ||||: ||| || :|||:|||||||
Db          1 AGAATCGAGGGCTTCACTCAGCGCA 25


RESULT 205
US-10-719-956-229476
; Sequence 229476, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 229476
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-229476

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1907 CAGAUGUGCCAAAUGGGUUUCAUGU 1931
              ||||:|:|||||| || :::|| |:
Db          1 CAGATGTGCCAAACGGCTTTCACGT 25


RESULT 206
US-10-888-435-187
; Sequence 187, Application US/10888435
; Publication No. US20050048544A1
; GENERAL INFORMATION:
;  APPLICANT: GARDNER, PHYLLIS
;  APPLICANT:  SCHRIJVER, IRIS
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETERMINING
;  TITLE OF INVENTION:  WHETHER A SUBJECT CARRIES A CYSTIC FIBROSIS TRANSMEMBRANE
;  TITLE OF INVENTION:  CONDUCTANCE REGULATOR (CFTR) GENE MUTATION
;  FILE REFERENCE: STAN-295
;  CURRENT APPLICATION NUMBER: US/10/888,435
;  CURRENT FILING DATE:  2004-07-09
;  PRIOR APPLICATION NUMBER: 60/486,763
;  PRIOR FILING DATE: 2003-07-10
;  NUMBER OF SEQ ID NOS: 437
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 187
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-10-888-435-187

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   36.0%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative   13;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|: : : :
Db          1 TGTGTGTGTGTGTGTGTGTTTTTT 25


RESULT 207
US-10-932-182A-38533
```

```
; Sequence 38533, Application US/10932182A
; Publication No. US20060046253A1
; GENERAL INFORMATION:
;  APPLICANT: NAKAO, YOSHIHIRO
;  APPLICANT:  NAKAMURA, NORIHISA
;  APPLICANT:  KODAMA, YUKIKO
;  APPLICANT:  FUJIMURA, TOMOKO
;  APPLICANT:  ASHIKARI, TOSHIHIKO
;  TITLE OF INVENTION: METHODS FOR ANALYZING GENES OF INDUSTRIAL YEASTS
;  FILE REFERENCE: 030685-043
;  CURRENT APPLICATION NUMBER: US/10/932,182A
;  CURRENT FILING DATE:  2004-09-02
;  NUMBER OF SEQ ID NOS: 197023
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 38533
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Saccharomyces pastorianus
US-10-932-182A-38533

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3509 UAUUGCUGUGGGAAAUCUUCUCCUU 3533
              :| :|| |:||||| :|::|:||::
Db          1 TAATGCCGTGGGAATTCTTCTCCTT 25


RESULT 208
US-11-036-317-189348
; Sequence 189348, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 189348
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-189348

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3485 AGAGCGACGUGUGGUCUUACGGAGU 3509
              ||||||| |:|:||:|::  ||||:
Db          1 AGAGCGATGTGTGGTCTTTTGGAGT 25


RESULT 209
US-11-036-317-418561
; Sequence 418561, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 418561
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-418561

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6111 CCUGGCAGCGGCUUUUGUGGAAGAC 6135
              | :||||| | |::::|:|||||||
Db          1 CATGGCAGTGCCTTTTGTGGAAGAC 25


RESULT 210
US-11-036-317-431134
; Sequence 431134, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 431134
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-431134

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   60.0%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3357 GAAGAUUUGUGAUUUUGGCCUUGCC 3381
              |||||:::| || :::|||||: |||
Db          1 GAAGATTTGCGACTTTGGCCTGGCC 25


RESULT 211
US-11-036-317-436168
; Sequence 436168, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 436168
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-436168

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2290 GACUGUCAUGCUAAUGGUGUCCCCG 2314
              |||:|:|| ||:|  ||:|:|||||
```

```
Db          1 GACTGTCAAGCTAGAGGTGTCCCCG 25


RESULT 212
US-11-036-317-518974
; Sequence 518974, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 518974
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-518974

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2912 AUCUGAACGUGGUUAACCUGCUGGG 2936
              | |:|||||:||  ||||:||:|||
Db          1 ACCTGAACGTGGACAACCTGCTGGG 25


RESULT 213
US-11-036-317-822860
; Sequence 822860, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 822860
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-822860

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2921 UGGUUAACCUGCUGGGAGCCUGCAC 2945
              :||: ||||:|| ||| |||:||||
Db          1 TGGTCAACCTGCAGGGGGCCTGCAC 25


RESULT 214
US-11-036-317-870867
; Sequence 870867, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 870867
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-870867

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3485 AGAGCGACGUGUGGUCUUACGGAGU 3509
              ||||||| |:|:||:|::  ||||:
Db          1 AGAGCGATGTGTGGTCTTTTGGAGT 25


RESULT 215
US-11-121-849-343059/c
; Sequence 343059, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 343059
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-343059

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       5995 UCUAAGUAACCGAAGAAUGUAUGCC 6019
              :|:||| ||||||||||: :|: ||
Db         25 TCTAAGAAACCGAAGAATCTATACC 1


RESULT 216
US/10/763
; Sequence 132, Application US/10763039A
; Publication No. US20050239082A1
; GENERAL INFORMATION:
;  APPLICANT: Jarrell, Kevin A.
;  APPLICANT:  Vishwanath, Prashanth
;  APPLICANT:  Smith, Temple
;  APPLICANT:  Short, Glenn F.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0036
;  CURRENT APPLICATION NUMBER: US/10/763,039A
;  CURRENT FILING DATE:  2004-01-22
;  NUMBER OF SEQ ID NOS: 166
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 132
;   LENGTH: 70
;   TYPE: DNA
;   ORGANISM: Oligonucleotides identified according to the present invention as alien t
US/10/763,039A-132

  Query Match             0.3%;  Score 20.2;  DB 1;  Length 70;
  Best Local Similarity   38.6%;  Pred. No. 1.4e+02;
```

```
  Matches   22;  Conservative   12;  Mismatches   23;  Indels    0;  Gaps    0;

Qy       4926 CAUUUUCUGGAUUCUGGGAGGCAAGAAAAGGACAAAUAUCUUUUUUGGAACUAAAGC 4982
              || ::  :   :: :  | | |||||  | |||||     : ::::|| ||:| | |
Db         10 CAATTAGTCTTTTGTCCGGGCCAAGAGTACGACAACGGGGTATTTTGGTACTATATC 66


RESULT 217
US-09-845-742B-1
; Sequence 1, Application US/09845742B
; Publication No. US20030215801A1
; GENERAL INFORMATION:
;  APPLICANT: Pieken, Wolfgang
;  APPLICANT:  Wolter, Andreas
;  APPLICANT:  Sebesta P, David
;  APPLICANT:  Leuck, Michael
;  APPLICANT:  Latham-Timmons A, Hallie
;  APPLICANT:  Pilon, John
;  APPLICANT:  Husar M, Gregory
;  TITLE OF INVENTION: METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE
;  TITLE OF INVENTION:  CYCLOADDITION BIOCONJUGATION METHOD
;  FILE REFERENCE: PRO.03
;  CURRENT APPLICATION NUMBER: US/09/845,742B
;  CURRENT FILING DATE:  2001-05-01
;  PRIOR APPLICATION NUMBER: 60/201,561
;  PRIOR FILING DATE: 2000-05-01
;  PRIOR APPLICATION NUMBER: 60/265,020
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: 09/341,337
;  PRIOR FILING DATE: 1999-07-08
;  PRIOR APPLICATION NUMBER: PCT/US98/00649
;  PRIOR FILING DATE: 1998-01-08
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Nucleic Acid Ligand
US-09-845-742B-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 218
US-09-845-742B-2/c
; Sequence 2, Application US/09845742B
; Publication No. US20030215801A1
; GENERAL INFORMATION:
;  APPLICANT: Pieken, Wolfgang
;  APPLICANT:  Wolter, Andreas
;  APPLICANT:  Sebesta P, David
;  APPLICANT:  Leuck, Michael
;  APPLICANT:  Latham-Timmons A, Hallie
;  APPLICANT:  Pilon, John
;  APPLICANT:  Husar M, Gregory
;  TITLE OF INVENTION: METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE
;  TITLE OF INVENTION:  CYCLOADDITION BIOCONJUGATION METHOD
;  FILE REFERENCE: PRO.03
;  CURRENT APPLICATION NUMBER: US/09/845,742B
;  CURRENT FILING DATE:  2001-05-01
;  PRIOR APPLICATION NUMBER: 60/201,561
;  PRIOR FILING DATE: 2000-05-01
;  PRIOR APPLICATION NUMBER: 60/265,020
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: 09/341,337
;  PRIOR FILING DATE: 1999-07-08
;  PRIOR APPLICATION NUMBER: PCT/US98/00649
;  PRIOR FILING DATE: 1998-01-08
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Nucleic Acid Ligand
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: C at position 1 is substituted at the 5' position
;   OTHER INFORMATION: with a fluorescein.
US-09-845-742B-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 219
US-09-916-369A-4
; Sequence 4, Application US/09916369A
; Publication No. US20020058802A1
; GENERAL INFORMATION:
;  APPLICANT: Dellinger, Douglas J
;  APPLICANT:  Perbost, Michael GM
;  APPLICANT:  Caruthers, Marvin H
;  APPLICANT:  Betley, Jason R
;  TITLE OF INVENTION: Synthesis of Polynucleotides Using Combined Oxidation/Deprotectio
;  TITLE OF INVENTION:  Chemistry
;  FILE REFERENCE: 10003869-1
;  CURRENT APPLICATION NUMBER: US/09/916,369A
;  CURRENT FILING DATE:  2001-07-21
;  PRIOR APPLICATION NUMBER: US 09/627,249
;  PRIOR FILING DATE: 2000-07-28
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic sequence
US-09-916-369A-4

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 220
US-10-085-906-33
; Sequence 33, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
;  APPLICANT: Ying, Vincent
;  APPLICANT:  Wu, Paul
;  APPLICANT:  Gray, Gary S.
;  TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
```

```
;  TITLE OF INVENTION:  COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
;  FILE REFERENCE: GNN-5343CP2
;  CURRENT APPLICATION NUMBER: US/10/085,906
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: US 60/126,215
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 09/534,061
;  PRIOR FILING DATE: 2000-03-24
;  PRIOR APPLICATION NUMBER: PCT/US00/07938
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 545
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-085-906-33

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 221
US-10-101-018-1
; Sequence 1, Application US/10101018
; Publication No. US20030120038A1
; GENERAL INFORMATION:
;  APPLICANT: Kendall, Richard L.
;  APPLICANT:  Thomas, Kenneth A., Jr.
;  TITLE OF INVENTION: INHIBITOR OF VASCULAR ENDOTHELIAL CELL
;  TITLE OF INVENTION:  GROWTH FACTOR
;  FILE REFERENCE: 18888DC
;  CURRENT APPLICATION NUMBER: US/10/101,018
;  CURRENT FILING DATE:  2002-03-19
;  PRIOR APPLICATION NUMBER: 09/232,777
;  PRIOR FILING DATE: 1999-01-15
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-101-018-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1808 GCACCUUGGUUGUGGCUGAC 1827
              |||||::||::|:|||:|||
Db          1 GCACCTTGGTTGTGGCTGAC 20


RESULT 222
US-10-165-854-1/c
; Sequence 1, Application US/10165854
; Publication No. US20030059807A1
; GENERAL INFORMATION:
;  APPLICANT: Roach , Jeffrey  Shawn
;  APPLICANT:  Wolter, Andreas
;  TITLE OF INVENTION: MICROCALORIMETRIC DETECTION OF ANALYTES AND BINDING EVENTS
;  FILE REFERENCE: PRO06
;  CURRENT APPLICATION NUMBER: US/10/165,854
;  CURRENT FILING DATE:  2002-06-07
;  PRIOR APPLICATION NUMBER: 60/296,685
;  PRIOR FILING DATE: 2001-06-07
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-165-854-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 223
US-10-165-854-2
; Sequence 2, Application US/10165854
; Publication No. US20030059807A1
; GENERAL INFORMATION:
;  APPLICANT: Roach , Jeffrey  Shawn
;  APPLICANT:  Wolter, Andreas
;  TITLE OF INVENTION: MICROCALORIMETRIC DETECTION OF ANALYTES AND BINDING EVENTS
;  FILE REFERENCE: PRO06
;  CURRENT APPLICATION NUMBER: US/10/165,854
;  CURRENT FILING DATE:  2002-06-07
;  PRIOR APPLICATION NUMBER: 60/296,685
;  PRIOR FILING DATE: 2001-06-07
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-165-854-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 224
US-10-219-238-1
; Sequence 1, Application US/10219238
; Publication No. US20030114405A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  Hepburn, Bonnie
;  TITLE OF INVENTION: METHODS OF TREATING SYSTEMIC LUPUS
;  TITLE OF INVENTION:  ERYTHEMATOSUS IN INDIVIDUALS HAVING
;  TITLE OF INVENTION:  SIGNIFICANTLY IMPAIRED RENAL FUNCTION
;  FILE REFERENCE: 252312007800
;  CURRENT APPLICATION NUMBER: US/10/219,238
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: US 60/314,281
;  PRIOR FILING DATE: 2001-08-22
;  PRIOR APPLICATION NUMBER: US 60/311,858
;  PRIOR FILING DATE: 2001-08-13
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-219-238-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 225
US-10-219-238-2/c
; Sequence 2, Application US/10219238
; Publication No. US20030114405A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  Hepburn, Bonnie
;  TITLE OF INVENTION: METHODS OF TREATING SYSTEMIC LUPUS
;  TITLE OF INVENTION:  ERYTHEMATOSUS IN INDIVIDUALS HAVING
;  TITLE OF INVENTION:  SIGNIFICANTLY IMPAIRED RENAL FUNCTION
;  FILE REFERENCE: 252312007800
;  CURRENT APPLICATION NUMBER: US/10/219,238
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: US 60/314,281
;  PRIOR FILING DATE: 2001-08-22
;  PRIOR APPLICATION NUMBER: US 60/311,858
;  PRIOR FILING DATE: 2001-08-13
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-219-238-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 226
US-10-407-818-13
; Sequence 13, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
;  APPLICANT: RABBANI, ELAZAR
;  APPLICANT:  STAVRIANOPOULOS, JANNIS G.
;  APPLICANT:  DONEGAN, JAMES J.
;  TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
;  TITLE OF INVENTION:  THEREFOR
;  FILE REFERENCE: ENZ-65
;  CURRENT APPLICATION NUMBER: US/10/407,818
;  CURRENT FILING DATE:  2003-04-03
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-407-818-13

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 227
US-10-407-818-14/c
; Sequence 14, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
;  APPLICANT: RABBANI, ELAZAR
;  APPLICANT:  STAVRIANOPOULOS, JANNIS G.
;  APPLICANT:  DONEGAN, JAMES J.
;  TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
;  TITLE OF INVENTION:  THEREFOR
;  FILE REFERENCE: ENZ-65
;  CURRENT APPLICATION NUMBER: US/10/407,818
;  CURRENT FILING DATE:  2003-04-03
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-407-818-14

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 228
US-10-407-818-16
; Sequence 16, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
;  APPLICANT: RABBANI, ELAZAR
;  APPLICANT:  STAVRIANOPOULOS, JANNIS G.
;  APPLICANT:  DONEGAN, JAMES J.
;  TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
;  TITLE OF INVENTION:  THEREFOR
;  FILE REFERENCE: ENZ-65
;  CURRENT APPLICATION NUMBER: US/10/407,818
;  CURRENT FILING DATE:  2003-04-03
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

```
;  OTHER INFORMATION: oligonucleotide
US-10-407-818-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   60.0%;  Pred. No. 3.5e+02;
  Matches   12;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|||:|:|:|:|||:|:|
Db          1 TGTGUGTGTGTGTGUGTGTG 20


RESULT 229
US-10-425-668-3
; Sequence 3, Application US/10425668
; Publication No. US20030175271A1
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  SATO, YASUFUMI
;  TITLE OF INVENTION: VEGF ACTIVITY INHIBITOR
;  FILE REFERENCE: 249-151
;  CURRENT APPLICATION NUMBER: US/10/425,668
;  CURRENT FILING DATE:  2003-04-30
;  PRIOR APPLICATION NUMBER: US/09/700,865
;  PRIOR FILING DATE: 2000-11-20
;  PRIOR APPLICATION NUMBER: PCT/JP99/02660
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: P. HEI. 10-138999
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-10-425-668-3

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3438 GAAAUGGAUGGCUCCCGAAU 3457
              ||||:|||:|||:||||||:
Db          1 GAAATGGATGGCTCCCGAAT 20


RESULT 230
US-10-425-668-4/c
; Sequence 4, Application US/10425668
; Publication No. US20030175271A1
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  SATO, YASUFUMI
;  TITLE OF INVENTION: VEGF ACTIVITY INHIBITOR
;  FILE REFERENCE: 249-151
;  CURRENT APPLICATION NUMBER: US/10/425,668
;  CURRENT FILING DATE:  2003-04-30
;  PRIOR APPLICATION NUMBER: US/09/700,865
;  PRIOR FILING DATE: 2000-11-20
;  PRIOR APPLICATION NUMBER: PCT/JP99/02660
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: P. HEI. 10-138999
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-10-425-668-4

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 3.5e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4009 AUGCUGAAGCGCUUCACCUG 4028
              |:||:|||||||::||||:|
Db         20 ATGCTGAAGCGCTTCACCTG 1


RESULT 231
US-10-661-088-16/c
; Sequence 16, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0206
;  CURRENT APPLICATION NUMBER: US/10/661,088
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-088-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 232
US-10-661-088-19
; Sequence 19, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0206
;  CURRENT APPLICATION NUMBER: US/10/661,088
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

```
;   OTHER INFORMATION: oligonucleotide
US-10-661-088-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 233
US-10-661-097-16/c
; Sequence 16, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0204
;  CURRENT APPLICATION NUMBER: US/10/661,097
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-097-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 234
US-10-661-097-19
; Sequence 19, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0204
;  CURRENT APPLICATION NUMBER: US/10/661,097
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-097-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 235
US-10-661-099-16/c
; Sequence 16, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
;  FILE REFERENCE: 029849/0203
;  CURRENT APPLICATION NUMBER: US/10/661,099
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-099-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 236
US-10-661-099-19
; Sequence 19, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
;  FILE REFERENCE: 029849/0203
;  CURRENT APPLICATION NUMBER: US/10/661,099
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-099-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 237
US-10-661-355-16/c
; Sequence 16, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0208
;  CURRENT APPLICATION NUMBER: US/10/661,355
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-355-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 238
US-10-661-355-19
; Sequence 19, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0208
;  CURRENT APPLICATION NUMBER: US/10/661,355
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-355-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 239
US-10-661-402-16/c
; Sequence 16, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 029849/0207
;  CURRENT APPLICATION NUMBER: US/10/661,402
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-402-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 240
US-10-661-402-19
; Sequence 19, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 029849/0207
;  CURRENT APPLICATION NUMBER: US/10/661,402
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-402-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 241
US-10-661-403-16/c
; Sequence 16, Application US/10661403
; Publication No. US20050176661A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0202
;  CURRENT APPLICATION NUMBER: US/10/661,403
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-403-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 242
US-10-661-403-19
; Sequence 19, Application US/10661403
; Publication No. US20050176661A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0202
;  CURRENT APPLICATION NUMBER: US/10/661,403
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-403-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 243
US-10-661-415-16/c
; Sequence 16, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
;  FILE REFERENCE: 029849/0205
;  CURRENT APPLICATION NUMBER: US/10/661,415
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-415-16

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 244
US-10-661-415-19
; Sequence 19, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
;  FILE REFERENCE: 029849/0205
;  CURRENT APPLICATION NUMBER: US/10/661,415
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
```

```
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-415-19

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 245
US-10-671-395-138/c
; Sequence 138, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 138
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-138

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 246
US-10-748-541-1
; Sequence 1, Application US/10748541
; Publication No. US20040208864A1
; GENERAL INFORMATION:
;  APPLICANT: Strand, Vibeke
;  APPLICANT:  Linnik, Matthew D.
;  APPLICANT:  Joh, Tenshang
;  TITLE OF INVENTION: METHODS OF IMPROVING HEALTH-RELATED
;  TITLE OF INVENTION:  QUALITY OF LIFE IN INDIVIDUALS WITH SYSTEMIC LUPUS
;  TITLE OF INVENTION:  ERYTHEMATOSUS
;  FILE REFERENCE: 252312007900
;  CURRENT APPLICATION NUMBER: US/10/748,541
;  CURRENT FILING DATE:  2003-12-29
;  PRIOR APPLICATION NUMBER: US 60/436,906
;  PRIOR FILING DATE: 2002-12-27
;  PRIOR APPLICATION NUMBER: US 60/478,128
;  PRIOR FILING DATE: 2003-06-11
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-748-541-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 247
US-10-748-541-2/c
; Sequence 2, Application US/10748541
; Publication No. US20040208864A1
; GENERAL INFORMATION:
;  APPLICANT: Strand, Vibeke
;  APPLICANT:  Linnik, Matthew D.
;  APPLICANT:  Joh, Tenshang
;  TITLE OF INVENTION: METHODS OF IMPROVING HEALTH-RELATED
;  TITLE OF INVENTION:  QUALITY OF LIFE IN INDIVIDUALS WITH SYSTEMIC LUPUS
;  TITLE OF INVENTION:  ERYTHEMATOSUS
;  FILE REFERENCE: 252312007900
;  CURRENT APPLICATION NUMBER: US/10/748,541
;  CURRENT FILING DATE:  2003-12-29
;  PRIOR APPLICATION NUMBER: US 60/436,906
;  PRIOR FILING DATE: 2002-12-27
;  PRIOR APPLICATION NUMBER: US 60/478,128
;  PRIOR FILING DATE: 2003-06-11
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-748-541-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 248
US-10-814-555-1
; Sequence 1, Application US/10814555
; Publication No. US20040258683A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  Joh, Tenshang
;  TITLE OF INVENTION: METHODS OF TREATING AND MONITORING
;  TITLE OF INVENTION:  SYSTEMIC LUPUS ERYTHEMATOSUS IN INDIVIDUALS
;  FILE REFERENCE: 252312008000
;  CURRENT APPLICATION NUMBER: US/10/814,555
;  CURRENT FILING DATE:  2004-03-30
;  PRIOR APPLICATION NUMBER: US 60/459,470
;  PRIOR FILING DATE: 2003-03-30
;  PRIOR APPLICATION NUMBER: US 60/478,127
;  PRIOR FILING DATE: 2003-06-11
;  NUMBER OF SEQ ID NOS: 3
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-814-555-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 249
US-10-814-555-2/c
; Sequence 2, Application US/10814555
; Publication No. US20040258683A1
; GENERAL INFORMATION:
;  APPLICANT: Linnik, Matthew D.
;  APPLICANT:  Joh, Tenshang
;  TITLE OF INVENTION: METHODS OF TREATING AND MONITORING
;  TITLE OF INVENTION:  SYSTEMIC LUPUS ERYTHEMATOSUS IN INDIVIDUALS
;  FILE REFERENCE: 252312008000
;  CURRENT APPLICATION NUMBER: US/10/814,555
;  CURRENT FILING DATE:  2004-03-30
;  PRIOR APPLICATION NUMBER: US 60/459,470
;  PRIOR FILING DATE: 2003-03-30
;  PRIOR APPLICATION NUMBER: US 60/478,127
;  PRIOR FILING DATE: 2003-06-11
;  NUMBER OF SEQ ID NOS: 3
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-814-555-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 250
US-10-846-113A-43
; Sequence 43, Application US/10846113A
; Publication No. US20050239088A1
; GENERAL INFORMATION:
;  APPLICANT: Shepard, H. Michael
;  APPLICANT:  Clinton, Gail M.
;  APPLICANT:  Lackey, David B.
;  APPLICANT:  Jin, Pei
;  TITLE OF INVENTION: INTRON FUSION PROTEINS, AND
;  TITLE OF INVENTION:  METHODS OF IDENTIFYING AND USING SAME
;  FILE REFERENCE: 17118-006001
;  CURRENT APPLICATION NUMBER: US/10/846,113A
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,141
;  PRIOR FILING DATE: 2003-05-16
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer -
US-10-846-113A-43

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        102 GGGGAAGUGGUUGUCUCCUG 121
              |||||||:||::|:|:||:|
Db          1 GGGGAAGTGGTTGTCTCCTG 20


RESULT 251
US-10-846-113A-44/c
; Sequence 44, Application US/10846113A
; Publication No. US20050239088A1
; GENERAL INFORMATION:
;  APPLICANT: Shepard, H. Michael
;  APPLICANT:  Clinton, Gail M.
;  APPLICANT:  Lackey, David B.
;  APPLICANT:  Jin, Pei
;  TITLE OF INVENTION: INTRON FUSION PROTEINS, AND
;  TITLE OF INVENTION:  METHODS OF IDENTIFYING AND USING SAME
;  FILE REFERENCE: 17118-006001
;  CURRENT APPLICATION NUMBER: US/10/846,113A
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,141
;  PRIOR FILING DATE: 2003-05-16
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 44
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer -
US-10-846-113A-44

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 AGAUGUGCCAAAUGGGUUUC 1927
              |||:|:||||||:|||:::|
Db         20 AGATGTGCCAAATGGGTTTC 1


RESULT 252
US-10-846-113A-45
; Sequence 45, Application US/10846113A
; Publication No. US20050239088A1
; GENERAL INFORMATION:
;  APPLICANT: Shepard, H. Michael
;  APPLICANT:  Clinton, Gail M.
;  APPLICANT:  Lackey, David B.
;  APPLICANT:  Jin, Pei
;  TITLE OF INVENTION: INTRON FUSION PROTEINS, AND
;  TITLE OF INVENTION:  METHODS OF IDENTIFYING AND USING SAME
;  FILE REFERENCE: 17118-006001
;  CURRENT APPLICATION NUMBER: US/10/846,113A
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,141
;  PRIOR FILING DATE: 2003-05-16
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer -
US-10-846-113A-45

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
```

Best Local Similarity 75.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy        858 GCUUCUGACCUGUGAAGCAA 877
              ||::|:||||:|:|||||||
Db          1 GCTTCTGACCTGTGAAGCAA 20
```

RESULT 253
US-10-857-715-110
; Sequence 110, Application US/10857715
; Publication No. US20050164218A1
; GENERAL INFORMATION:
; APPLICANT: Agus David
; APPLICANT: Baker Joffre
; APPLICANT: Natale Ron
; APPLICANT: Shak Steven
; TITLE OF INVENTION: Gene Expression Markers for Response to
; TITLE OF INVENTION: EGFR Inhibitors Drugs
; FILE REFERENCE: 39740/0011
; CURRENT APPLICATION NUMBER: US/10/857,715
; CURRENT FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/474,908
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: forward primer
US-10-857-715-110

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 65.0%; Pred. No. 3.5e+02;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3447 GGCUCCCGAAUCUAUCUUUG 3466
              |||:||||||:|:|:|:::|
Db          1 GGCTCCCGAATCTATCTTTG 20
```

RESULT 254
US-10-857-715-111/c
; Sequence 111, Application US/10857715
; Publication No. US20050164218A1
; GENERAL INFORMATION:
; APPLICANT: Agus David
; APPLICANT: Baker Joffre
; APPLICANT: Natale Ron
; APPLICANT: Shak Steven
; TITLE OF INVENTION: Gene Expression Markers for Response to
; TITLE OF INVENTION: EGFR Inhibitors Drugs
; FILE REFERENCE: 39740/0011
; CURRENT APPLICATION NUMBER: US/10/857,715
; CURRENT FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/474,908
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: reverse primer
US-10-857-715-111

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 3.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3502 UACGGAGUAUUGCUGUGGGA 3521
              :||||||:|::||:|:||||
Db         20 TACGGAGTATTGCTGTGGGA 1
```

RESULT 255
US-10-969-812A-15/c
; Sequence 15, Application US/10969812A
; Publication No. US20050196382A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, Andrew
; APPLICANT: JUTEAU, Jean-Marc
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 16051-11us
; CURRENT APPLICATION NUMBER: US/10/969,812A
; CURRENT FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: US10/661,402
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: US 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: US 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-969-812A-15

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 50.0%; Pred. No. 3.5e+02;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1
```

RESULT 256
US-10-969-812A-18
; Sequence 18, Application US/10969812A
; Publication No. US20050196382A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, Andrew
; APPLICANT: JUTEAU, Jean-Marc
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
; FILE REFERENCE: 16051-11us
; CURRENT APPLICATION NUMBER: US/10/969,812A
; CURRENT FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: US10/661,402
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: US 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: US 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-969-812A-18

Query Match 0.3%; Score 20; DB 1; Length 20;

```
  Best Local Similarity   50.0%;  Pred. No. 3.5e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 257
US-10-121-235-13/c
; Sequence 13, Application US/10121235
; Publication No. US20030032609A1
; GENERAL INFORMATION:
;  APPLICANT: Lee, Mu-En
;  APPLICANT:  Maemura, Koji
;  APPLICANT:  Hsieh, Chung-Ming
;  TITLE OF INVENTION: METHODS OF MODULATING OF ANGIOGENESIS
;  FILE REFERENCE: 05433/037001
;  CURRENT APPLICATION NUMBER: US/10/121,235
;  CURRENT FILING DATE:  2002-04-12
;  PRIOR APPLICATION NUMBER: US 09/374,454
;  PRIOR FILING DATE: 1999-08-13
;  PRIOR APPLICATION NUMBER: US 60/096,515
;  PRIOR FILING DATE: 1998-08-14
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 13
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-10-121-235-13

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 258
US-10-121-235-9/c
; Sequence 9, Application US/10121235
; Publication No. US20030032609A1
; GENERAL INFORMATION:
;  APPLICANT: Lee, Mu-En
;  APPLICANT:  Maemura, Koji
;  APPLICANT:  Hsieh, Chung-Ming
;  TITLE OF INVENTION: METHODS OF MODULATING OF ANGIOGENESIS
;  FILE REFERENCE: 05433/037001
;  CURRENT APPLICATION NUMBER: US/10/121,235
;  CURRENT FILING DATE:  2002-04-12
;  PRIOR APPLICATION NUMBER: US 09/374,454
;  PRIOR FILING DATE: 1999-08-13
;  PRIOR APPLICATION NUMBER: US 60/096,515
;  PRIOR FILING DATE: 1998-08-14
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-10-121-235-9

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 259
US-10-385-193-1/c
; Sequence 1, Application US/10385193
; Publication No. US20030229218A1
; GENERAL INFORMATION:
;  APPLICANT: Nanda D. Sinha
;  TITLE OF INVENTION: Synthons for Oligonucleotide Synthesis
;  FILE REFERENCE: 2733.1001-001
;  CURRENT APPLICATION NUMBER: US/10/385,193
;  CURRENT FILING DATE:  2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/230,685
;  PRIOR FILING DATE: 2000-09-07
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-10-385-193-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 260
US-10-385-193-2
; Sequence 2, Application US/10385193
; Publication No. US20030229218A1
; GENERAL INFORMATION:
;  APPLICANT: Nanda D. Sinha
;  TITLE OF INVENTION: Synthons for Oligonucleotide Synthesis
;  FILE REFERENCE: 2733.1001-001
;  CURRENT APPLICATION NUMBER: US/10/385,193
;  CURRENT FILING DATE:  2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/230,685
;  PRIOR FILING DATE: 2000-09-07
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-10-385-193-2

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 261
US-10-947-637-897
; Sequence 897, Application US/10947637
; Publication No. US20050181385A1
; GENERAL INFORMATION:
;  APPLICANT: Linsley, Peter
```

```
;  APPLICANT:  Mao, Mao
;  APPLICANT:  Kim, Annette
;  APPLICANT:  Friend, Stephen
;  APPLICANT:  Bartz, Steven
;  APPLICANT:  Cleary, Michele
;  TITLE OF INVENTION: Synthetic Lethal Screen Using RNA
;  TITLE OF INVENTION:  Interference
;  FILE REFERENCE: 9301-243-999
;  CURRENT APPLICATION NUMBER: US/10/947,637
;  CURRENT FILING DATE:  2004-09-22
;  PRIOR APPLICATION NUMBER: 60/554,284
;  PRIOR FILING DATE: 2004-03-17
;  PRIOR APPLICATION NUMBER: 60/548,568
;  PRIOR FILING DATE: 2004-02-27
;  PRIOR APPLICATION NUMBER: 60/505,229
;  PRIOR FILING DATE: 2003-09-22
;  NUMBER OF SEQ ID NOS: 1239
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 897
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: siRNA with 19 paired ribonucleotides and two
;   OTHER INFORMATION: unpaired nucleotides("t") on the 3' end of each
;   OTHER INFORMATION: strand  used in screens of DNA damaging agents:
;   OTHER INFORMATION: camptothecin screen
US-10-947-637-897

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 3.4e+02;
  Matches   19;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3563 UGGAUGAGGACUUUUGCAGU 3582
              ||||||||||||||||||:
Db          1 UGGAUGAGGACUUUUGCAGT 20


RESULT 262
US-10-466-894-1869/c
; Sequence 1869, Application US/10466894
; Publication No. US20040241671A1
; GENERAL INFORMATION:
;  APPLICANT: Telerman, Adam
;  APPLICANT:  Amson, Robert
;  APPLICANT:  Tuijnder, Marius
;  APPLICANT:  Susini, Laurent
;  TITLE OF INVENTION: SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPRESSION,
;  TITLE OF INVENTION:  TUMOUR REVERSION, APOPTOSIS AND/OR VIRUS RESISTANCE
;  TITLE OF INVENTION:  AND THEIR USE AS MEDICINES
;  FILE REFERENCE: 10918-014-999
;  CURRENT APPLICATION NUMBER: US/10/466,894
;  CURRENT FILING DATE:  2003-07-23
;  PRIOR APPLICATION NUMBER: PCT/FR02/00273
;  PRIOR FILING DATE: 2002-01-23
;  PRIOR APPLICATION NUMBER: FR01/00899
;  PRIOR FILING DATE: 2001-01-23
;  NUMBER OF SEQ ID NOS: 2270
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1869
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 4, 6
;   OTHER INFORMATION: n = A,T,C or G
US-10-466-894-1869

  Query Match             0.3%;  Score 20;  DB 1;  Length 23;
  Best Local Similarity   22.7%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUCCAAA 6366
              |:::::::::::::::: | |||
Db         22 CTTTTTTTTTTTTTTNCNAAA 1


RESULT 263
US-10-719-900-731924
; Sequence 731924, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 731924
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-731924

  Query Match             0.3%;  Score 20;  DB 1;  Length 25;
  Best Local Similarity   75.0%;  Pred. No. 3e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        579 AGCUGUACCUACUUCAAAGA 598
              |||:|:|||:||::||||||
Db          5 AGCTGTACCTACTTCAAAGA 24


RESULT 264
US-10-934-048A-12114/c
; Sequence 12114, Application US/10934048A
; Publication No. US20060051770A1
; GENERAL INFORMATION:
;  APPLICANT: Tanya Makeev
;  TITLE OF INVENTION: Methods of Genetic Analysis of Yeast
;  FILE REFERENCE: 3699
;  CURRENT APPLICATION NUMBER: US/10/934,048A
;  CURRENT FILING DATE:  2004-09-03
;  NUMBER OF SEQ ID NOS: 120855
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 12114
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: S. cerevisiae
US-10-934-048A-12114

  Query Match             0.3%;  Score 20;  DB 1;  Length 25;
  Best Local Similarity   60.0%;  Pred. No. 3e+02;
  Matches   12;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7006 GUGUGUGUGGGUGUGGGUGU 7025
              |:|:|:|:|||:|:|||:|:
Db         20 GTGTGTGTGGGTGTGGGTGT 1


RESULT 265
US-10-857-780-4391
; Sequence 4391, Application US/10857780
; Publication No. US20050272043A1
; GENERAL INFORMATION:
;  APPLICANT: ROTH, RICHARD B.
;  APPLICANT:  BRAUN, ANDREAS
;  APPLICANT:  KAMMERER, STEFAN M.
;  APPLICANT:  NELSON, MATTHEW ROBERTS
;  APPLICANT:  RENELAND, RIKARD HENRY
;  APPLICANT:  HOYAL-WRIGHTSON, CAROLYN R.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS
```

```
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: SEQ-4069-CP
;  CURRENT APPLICATION NUMBER: US/10/857,780
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: 10/723,681
;  PRIOR FILING DATE: 2003-11-25
;  PRIOR APPLICATION NUMBER: 60/490,234
;  PRIOR FILING DATE: 2003-07-24
;  PRIOR APPLICATION NUMBER: 60/525,239
;  PRIOR FILING DATE: 2003-11-25
;  NUMBER OF SEQ ID NOS: 4962
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4391
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-857-780-4391

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|: :|:|:|:|:|:|:|:|:
Db          1 TGTTTGTGTGTGTGTGTGTGT 21


RESULT 266
US-10-857-780-4393/c
; Sequence 4393, Application US/10857780
; Publication No. US20050272043A1
; GENERAL INFORMATION:
;  APPLICANT: ROTH, RICHARD B.
;  APPLICANT:  BRAUN, ANDREAS
;  APPLICANT:  KAMMERER, STEFAN M.
;  APPLICANT:  NELSON, MATTHEW ROBERTS
;  APPLICANT:  RENELAND, RIKARD HENRY
;  APPLICANT:  HOYAL-WRIGHTSON, CAROLYN R.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: SEQ-4069-CP
;  CURRENT APPLICATION NUMBER: US/10/857,780
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: 10/723,681
;  PRIOR FILING DATE: 2003-11-25
;  PRIOR APPLICATION NUMBER: 60/490,234
;  PRIOR FILING DATE: 2003-07-24
;  PRIOR APPLICATION NUMBER: 60/525,239
;  PRIOR FILING DATE: 2003-11-25
;  NUMBER OF SEQ ID NOS: 4962
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4393
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-857-780-4393

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|: :|:|:|:|:|:|:
Db         21 TGTGTGTTTGTGTGTGTGTGT 1


RESULT 267
US-10-922-154-13
; Sequence 13, Application US/10922154
; Publication No. US20050069528A1
; GENERAL INFORMATION:
;  APPLICANT: Teicher, Beverly
;  TITLE OF INVENTION: MAMMALIAN ENDOTHELIAL CELL MODEL SYSTEMS
;  FILE REFERENCE: 003482.00009
;  CURRENT APPLICATION NUMBER: US/10/922,154
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: 60/453,828
;  PRIOR FILING DATE: 2000-03-12
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 13
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-922-154-13

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 3.9e+02;
  Matches   18;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 CUGGGAGCCUGCACCAAGCAA 2952
              |:||||||:|||| ||||||
Db          1 CTGGGAGCCTGCACGAAGCAA 21


RESULT 268
US-10-947-637-895
; Sequence 895, Application US/10947637
; Publication No. US20050181385A1
; GENERAL INFORMATION:
;  APPLICANT: Linsley, Peter
;  APPLICANT:  Mao, Mao
;  APPLICANT:  Kim, Annette
;  APPLICANT:  Friend, Stephen
;  APPLICANT:  Bartz, Steven
;  APPLICANT:  Cleary, Michele
;  TITLE OF INVENTION: Synthetic Lethal Screen Using RNA
;  TITLE OF INVENTION:  Interference
;  FILE REFERENCE: 9301-243-999
;  CURRENT APPLICATION NUMBER: US/10/947,637
;  CURRENT FILING DATE:  2004-09-22
;  PRIOR APPLICATION NUMBER: 60/554,284
;  PRIOR FILING DATE: 2004-03-17
;  PRIOR APPLICATION NUMBER: 60/548,568
;  PRIOR FILING DATE: 2004-02-27
;  PRIOR APPLICATION NUMBER: 60/505,229
;  PRIOR FILING DATE: 2003-09-22
;  NUMBER OF SEQ ID NOS: 1239
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 895
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: siRNA with 19 paired ribonucleotides and two
;   OTHER INFORMATION: unpaired nucleotides("t") on the 3' end of each
;   OTHER INFORMATION: strand  used in screens of DNA damaging agents:
;   OTHER INFORMATION: camptothecin screen
US-10-947-637-895

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 3.9e+02;
  Matches   19;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1260 ACAUCGAAAACAGCAGGUGCU 1280
              |||||||||||||||||||| :
Db          1 ACAUCGAAAACAGCAGGUGTT 21


RESULT 269
US-10-469-313A-3
; Sequence 3, Application US/10469313A
```

```
; Publication No. US20050084854A1
; GENERAL INFORMATION:
;  APPLICANT: Lloyd, Robert M.
;  APPLICANT:  Uzgiris, Arejas
;  APPLICANT:  Huong, Hoe Tzong-Jyh
;  TITLE OF INVENTION: Methods and Primers for Evaluating HIV-1 Mutations
;  FILE REFERENCE: 49493.830036.US1
;  CURRENT APPLICATION NUMBER: US/10/469,313A
;  CURRENT FILING DATE:  2003-08-29
;  PRIOR APPLICATION NUMBER: PCT/US02/06632
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: US 60/273,683
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-469-313A-3

  Query Match             0.2%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   58.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2749 GGAAGAGGGGCUUUUGGAAAAGUG 2772
              |:|::|:||||: ::||||| |:|
Db          1 GRARRARGGGCTGTTGGAAATGTG 24


RESULT 270
US-10-845-667-1483/c
; Sequence 1483, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Conditions Associated With Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-091
;  CURRENT APPLICATION NUMBER: US/10/845,667
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1506
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1483
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-845-667-1483

  Query Match             0.3%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   45.8%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       7006 GUGUGUGUGGGUGUGGGUGUAUGU 7029
              |:|:|: :| |:|:| |:|:|:|:
Db         24 GTGTGTTTGAGTGTGTGTGTATGT 1


RESULT 271
US-09-557-423-7/c
; Sequence 7, Application US/09557423
; Patent No. US20020094555A1
; GENERAL INFORMATION:
;  APPLICANT: Belotserkovskii, Boris
;  APPLICANT:  Reddy, Gurucharan
;  APPLICANT:  Zarling, David A.
;  TITLE OF INVENTION: Locked Nucleic Acid Hybrids and Methods of Use
;  FILE REFERENCE: A-68112-1/RFT/RMS/BTC
;  CURRENT APPLICATION NUMBER: US/09/557,423
;  CURRENT FILING DATE:  2000-04-21
;  PRIOR APPLICATION NUMBER: USSN 60/130,345
;  PRIOR FILING DATE: 1999-04-21
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Z-DNA
US-09-557-423-7

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 272
US-09-557-423-8
; Sequence 8, Application US/09557423
; Patent No. US20020094555A1
; GENERAL INFORMATION:
;  APPLICANT: Belotserkovskii, Boris
;  APPLICANT:  Reddy, Gurucharan
;  APPLICANT:  Zarling, David A.
;  TITLE OF INVENTION: Locked Nucleic Acid Hybrids and Methods of Use
;  FILE REFERENCE: A-68112-1/RFT/RMS/BTC
;  CURRENT APPLICATION NUMBER: US/09/557,423
;  CURRENT FILING DATE:  2000-04-21
;  PRIOR APPLICATION NUMBER: USSN 60/130,345
;  PRIOR FILING DATE: 1999-04-21
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Z-DNA
US-09-557-423-8

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 19


RESULT 273
US-09-969-373-3086/c
; Sequence 3086, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3086
```

```
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-3086

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 274
US-10-506-997-88
; Sequence 88, Application US/10506997
; Publication No. US20050234225A1
; GENERAL INFORMATION:
;  APPLICANT: ImClone Systems Incorporated
;  TITLE OF INVENTION: Human Antibodies Specific To KDR And Uses Thereof
;  FILE REFERENCE: 11245/47802
;  CURRENT APPLICATION NUMBER: US/10/506,997
;  CURRENT FILING DATE:  2004-09-04
;  PRIOR APPLICATION NUMBER: PCT/US03/06459
;  PRIOR FILING DATE: 2003-03-04
;  PRIOR APPLICATION NUMBER: 60/361,783
;  PRIOR FILING DATE: 2002-03-04
;  NUMBER OF SEQ ID NOS: 93
;  SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 88
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: amplification primer for Flt-1
US-10-506-997-88

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3362 UUUGUGAUUUUGGCCUUGC 3380
              :::|:||::::||||::||
Db          1 TTTGTGATTTTGGCCTTGC 19


RESULT 275
US-10-871-222-390
; Sequence 390, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
;  TITLE OF INVENTION:  Synthase Ligand (FASL) Gene Expression Using Short Interfering
;  TITLE OF INVENTION:  Nucleic Acid (SINA)
;  FILE REFERENCE: 400/164  (MBHB04-487)
;  CURRENT APPLICATION NUMBER: US/10/871,222
;  CURRENT FILING DATE:  2004-06-18
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US10/826966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US10/757803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US10/720448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US10/693059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US10/444853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 706
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 390
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-871-222-390

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              ||||||||||||||||||||
Db          1 UGUGUGUGUGUGUGUGUGU 19


RESULT 276
US-10-871-222-494/c
; Sequence 494, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
;  TITLE OF INVENTION:  Synthase Ligand (FASL) Gene Expression Using Short Interfering
;  TITLE OF INVENTION:  Nucleic Acid (SINA)
;  FILE REFERENCE: 400/164  (MBHB04-487)
;  CURRENT APPLICATION NUMBER: US/10/871,222
;  CURRENT FILING DATE:  2004-06-18
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US10/826966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US10/757803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US10/720448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US10/693059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US10/444853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 706
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-871-222-494
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 277
US-10-893-010-145/c
; Sequence 145, Application US/10893010
; Publication No. US20050164224A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Thompson, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Cyclin D1 Gene Expressior
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/170 (MBHB02-1005-C)
;  CURRENT APPLICATION NUMBER: US/10/893,010
;  CURRENT FILING DATE:  2004-07-16
;  PRIOR APPLICATION NUMBER: PCT/US 03/03662
;  PRIOR FILING DATE: 2003-02-06
;  PRIOR APPLICATION NUMBER: US 60/411,275
;  PRIOR FILING DATE: 2002-09-17
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-03
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 526
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 145
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-893-010-145

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 278
US-10-893-010-384
; Sequence 384, Application US/10893010
; Publication No. US20050164224A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Thompson, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Cyclin D1 Gene Expressior
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/170 (MBHB02-1005-C)
;  CURRENT APPLICATION NUMBER: US/10/893,010
;  CURRENT FILING DATE:  2004-07-16
;  PRIOR APPLICATION NUMBER: PCT/US 03/03662
;  PRIOR FILING DATE: 2003-02-06
;  PRIOR APPLICATION NUMBER: US 60/411,275
;  PRIOR FILING DATE: 2002-09-17
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-03
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 526
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 384
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-893-010-384

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              |||||||||||||||||||
Db          1 UGUGUGUGUGUGUGUGUGU 19


RESULT 279
US-11-083-784-733
; Sequence 733, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 733
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-733
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3015 GAGCAAACGUGACUUAUUU 3033
              |||||||||||||||||||
Db          1 GAGCAAACGUGACUUAUUU 19


RESULT 280
US-11-101-244-733
; Sequence 733, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 733
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-733

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3015 GAGCAAACGUGACUUAUUU 3033
              |||||||||||||||||||
Db          1 GAGCAAACGUGACUUAUUU 19


RESULT 281
US-10-444-853A-297
; Sequence 297, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-297

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 282
US-10-444-853A-298
; Sequence 298, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 298
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-298

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
             |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 283
US-10-444-853A-299
; Sequence 299, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 299
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-299

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
             |||||||||||||||||||
Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 284
US-10-444-853A-300
; Sequence 300, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 300
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-300

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 285
US-10-444-853A-301/c
; Sequence 301, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-301

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 286
US-10-444-853A-302/c
; Sequence 302, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
```

```
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-302

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 287
US-10-444-853A-303/c
; Sequence 303, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 303
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-303

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              ||:|||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 288
US-10-444-853A-304/c
; Sequence 304, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
```

```
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 304
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-304

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 289
US-10-444-853A-305/c
; Sequence 305, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 305
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-305

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 290
US-10-444-853A-306/c
; Sequence 306, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
```

```
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 306
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(20)
;    OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(21)
;    OTHER INFORMATION: n stands for thymidine
US-10-444-853A-306

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 291
US-10-444-853A-307/c
; Sequence 307, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 307
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(20)
;    OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(21)
;    OTHER INFORMATION: n stands for thymidine
US-10-444-853A-307

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
                ||:|||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 292
US-10-444-853A-308/c
; Sequence 308, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
```

```
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 308
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-308

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 293
US-10-444-853A-345
; Sequence 345, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 345
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(8)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-345

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 294
US-10-444-853A-346
; Sequence 346, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
```

```
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 346
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-346
```

```
  Query Match              0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 295
US-10-444-853A-347
; Sequence 347, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 347
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-methyl
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-347

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              |||||||||||||||||||
Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 296
US-10-444-853A-348
; Sequence 348, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 348
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-348

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 297
US-10-444-853A-396
; Sequence 396, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
```

```
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 396
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-444-853A-396

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 298
US-10-444-853A-397/c
; Sequence 397, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 397
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-397
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 299
US-10-444-853A-398/c
; Sequence 398, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 398
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: inverted thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-398

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 300
US-10-444-853A-399/c
; Sequence 399, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 399
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-399

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 301
US-10-444-853A-400/c
; Sequence 400, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 400
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: glyceryl moiety
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-400

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 302
```

```
US-10-444-853A-401/c
; Sequence 401, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 401
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(2)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(5)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (7)..(7)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (9)..(12)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (14)..(14)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (17)..(18)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(21)
;    OTHER INFORMATION: L-thymidine
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(20)
;    OTHER INFORMATION: n stands for thymidine
US-10-444-853A-401

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 303
US-10-444-853A-414/c
; Sequence 414, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 414
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
```

```
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-414

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 304
US-10-444-853A-415/c
; Sequence 415, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 415
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for inverted thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-444-853A-415

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 305
US-10-444-853A-416/c
; Sequence 416, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
```

```
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 416
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
US-10-444-853A-416

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 306
US-10-444-853A-417/c
; Sequence 417, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 417
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for glyceryl moiety
US-10-444-853A-417

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 307
US-10-444-853A-418/c
; Sequence 418, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 418
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for L-thymidine
US-10-444-853A-418

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 308
US-10-444-853A-419
; Sequence 419, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
```

```
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 419
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(1)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(1)
;    OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(5)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (7)..(7)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (12)..(12)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (14)..(14)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (17)..(17)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(21)
;    OTHER INFORMATION: n stands for thymidine
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(21)
;    OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-444-853A-419

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 309
US-10-444-853A-420/c
; Sequence 420, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 420
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(2)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(5)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (7)..(7)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (9)..(12)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
```

```
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-420

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 310
US-10-444-853A-621
; Sequence 621, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 621
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-444-853A-621

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       349 CUGAGUUUAAAAGGCACCC 367
             |||||||||||||||||||
Db         1 CUGAGUUUAAAAGGCACCC 19


RESULT 311
US-10-444-853A-622/c
; Sequence 622, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Mokler, Victor
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/114 (MBHB03-465)
;  CURRENT APPLICATION NUMBER: US/10/444,853A
;  CURRENT FILING DATE:  2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 626
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 622
;   LENGTH: 21
```

```
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-444-853A-622

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 312
US-10-757-803-297
; Sequence 297, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 297
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-297

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 313
US-10-757-803-298
; Sequence 298, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 298
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-298

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 314
US-10-757-803-299
; Sequence 299, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 299
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-299

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              |||||||||||||||||||
Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 315
US-10-757-803-300
; Sequence 300, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
```

```
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-300

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 316
US-10-757-803-301/c
; Sequence 301, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 301
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-301

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 317
US-10-757-803-302/c
; Sequence 302, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
```

```
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-302

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 318
US-10-757-803-303/c
; Sequence 303, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 303
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-303

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
                ||:|||||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 319
US-10-757-803-304/c
; Sequence 304, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
```

```
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 304
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-304

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 320
US-10-757-803-305/c
```

```
; Sequence 305, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 305
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-305

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1
```

```
RESULT 321
US-10-757-803-306/c
; Sequence 306, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 306
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-306

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
             ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1
```

```
RESULT 322
US-10-757-803-307/c
; Sequence 307, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 307
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-307

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
```

```
              ||:||||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 323
US-10-757-803-308/c
; Sequence 308, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 308
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-308

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 324
US-10-757-803-345
; Sequence 345, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 345
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(8)
```

```
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-345

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 325
US-10-757-803-346
; Sequence 346, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 346
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-346

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 326
US-10-757-803-347
; Sequence 347, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
```

```
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 347
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-347

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              |||||||||||||||||||

Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 327
US-10-757-803-348
; Sequence 348, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 348
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
```

```
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-348

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 328
US-10-757-803-396
; Sequence 396, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 396
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-757-803-396

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 329
US-10-757-803-397/c
; Sequence 397, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
```

```
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 397
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-397

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 330
US-10-757-803-398/c
; Sequence 398, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 398
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: inverted thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-398

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 331
US-10-757-803-399/c
; Sequence 399, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tonggian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 399
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-399

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 332
US-10-757-803-400/c
; Sequence 400, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
```

```
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 400
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: glyceryl moiety
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-400

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 333
US-10-757-803-401/c
; Sequence 401, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 401
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: L-thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-401

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 334
US-10-757-803-414/c
; Sequence 414, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tonggian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 414
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-757-803-414

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 335
US-10-757-803-415/c
; Sequence 415, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
```

```
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 415
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(2)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(5)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (7)..(7)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (9)..(12)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (14)..(14)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (17)..(18)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(20)
;    OTHER INFORMATION: n stands for inverted thymidine
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(21)
;    OTHER INFORMATION: n stands for thymidine
US-10-757-803-415

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 336
US-10-757-803-416/c
; Sequence 416, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 416
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(2)
```

```
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
US-10-757-803-416

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 337
US-10-757-803-417/c
; Sequence 417, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 417
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for glyceryl moiety
US-10-757-803-417

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 338
US-10-757-803-418/c
; Sequence 418, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
```

```
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 418
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(2)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(5)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (7)..(7)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (9)..(12)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (14)..(14)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (17)..(18)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(20)
;    OTHER INFORMATION: n stands for thymidine
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(21)
;    OTHER INFORMATION: n stands for L-thymidine
US-10-757-803-418

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 339
US-10-757-803-419
; Sequence 419, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 419
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-757-803-419

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
             ||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 340
US-10-757-803-420/c
; Sequence 420, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 420
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-420

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
             ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1
```

```
RESULT 341
US-10-757-803-621
; Sequence 621, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-757-803-621

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              ||||||||||||||||||| 
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 342
US-10-757-803-622/c
; Sequence 622, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Morrissey, David
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  Jamison, Sharon
;  APPLICANT:  Vaish, Nerendra
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  James, Thompson
;  APPLICANT:  Vargeese, Chandra
;  APPLICANT:  Wang, Weimen
;  APPLICANT:  Tongqian, Chen
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/142 (03-465-C)
;  CURRENT APPLICATION NUMBER: US/10/757,803
;  CURRENT FILING DATE:  2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 622
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-757-803-622
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 343
US-10-820-622-64
; Sequence 64, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 64
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-820-622-64

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              |||||||||||||||||||
Db          1 UCUGAUGAUGUCAGAUAUG 19


RESULT 344
US-10-820-622-65/c
; Sequence 65, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal glyceryl moeity
US-10-820-622-65

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   63.2%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              :|:||:||:|:||||:|:|
Db         19 TCTGATGATGTCAGATATG 1


RESULT 345
US-10-820-622-66
; Sequence 66, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 66
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(8)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(9)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (10)..(10)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (13)..(15)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-820-622-66

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              ||||||||||||||||||||
Db          1 UCUGAUGAUGUCAGAUAUG 19


RESULT 346
US-10-820-622-67/c
; Sequence 67, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 67
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (3)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(4)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (5)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (8)..(9)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (10)..(10)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(11)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: 2'-O-Methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal glyceryl moeity
US-10-820-622-67

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   63.2%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              :|:||:||:|:||||:|:|
Db         19 TCTGATGATGTCAGATATG 1


RESULT 347
US-10-820-622-68
; Sequence 68, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
```

```
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 68
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(9)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(12)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-820-622-68

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
             ||||||||||||||||||||
Db          1 UCUGAUGAUGUCAGAUAUG 19


RESULT 348
US-10-820-622-69/c
; Sequence 69, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (3)..(3)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (5)..(7)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (10)..(10)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkag
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal glyceryl moeity
US-10-820-622-69

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   63.2%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
             :|:||:||:|:||||:|:|
Db         19 TCTGATGATGTCAGATATG 1


RESULT 349
US-10-820-622-70
; Sequence 70, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
```

```
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(9)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-820-622-70

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              |||||||||||||||||||
Db          1 UCUGAUGAUGUCAGAUAUG 19


RESULT 350
US-10-820-622-71
; Sequence 71, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 71
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(9)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-820-622-71

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              |||||||||||||||||||
Db          1 UCUGAUGAUGUCAGAUAUG 19


RESULT 351
US-10-820-622-72/c
; Sequence 72, Application US/10820622
; Publication No. US20050042632A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Susan, Radka
;  TITLE OF INVENTION: Antibodies Having Specificity for Nucleic Acids
;  FILE REFERENCE: 900/051 (MBHB02-030-B)
;  CURRENT APPLICATION NUMBER: US/10/820,622
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: US 10/366,191
;  PRIOR FILING DATE: 2003-02-12
;  PRIOR APPLICATION NUMBER: US 60/356,298
;  PRIOR FILING DATE: 2002-02-13
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 72
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (3)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(4)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (5)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (8)..(9)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (10)..(10)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(11)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: 2'-deoxy
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal glyceryl moeity
US-10-820-622-72

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   63.2%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              :|:||:||:|:||||:|:|
Db         19 TCTGATGATGTCAGATATG 1


RESULT 352
US-10-826-966-297
; Sequence 297, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 297
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-297

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 353
US-10-826-966-298
; Sequence 298, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
```

```
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 298
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-298

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
             |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 354
US-10-826-966-299
; Sequence 299, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 299
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-299

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
             |||||||||||||||||||
Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 355
US-10-826-966-300
; Sequence 300, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
```

```
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-300

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 356
US-10-826-966-301/c
; Sequence 301, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 301
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-301

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       349 CUGAGUUUAAAAGGCACCC 367
             |:|||:::||||||||||
Db        19 CTGAGTTTAAAAGGCACCC 1


RESULT 357
US-10-826-966-302/c
; Sequence 302, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-302

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 358
US-10-826-966-303/c
; Sequence 303, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 303
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-303

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              ||:||||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 359
US-10-826-966-304/c
; Sequence 304, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 304
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(5)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
```

```
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-304

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 360
US-10-826-966-305/c
; Sequence 305, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 305
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-305

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       349 CUGAGUUUAAAAGGCACCC 367
             |:|||:::|||||||||||
Db        19 CTGAGTTTAAAAGGCACCC 1


RESULT 361
US-10-826-966-306/c
; Sequence 306, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 306
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-306

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 362
US-10-826-966-307/c
; Sequence 307, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
```

```
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 307
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(20)
;    OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(21)
;    OTHER INFORMATION: n stands for thymidine
US-10-826-966-307

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 4.2e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
              ||:||||||||:|||||||
Db         19 CCTGGAAAGAATCAAAACC 1


RESULT 363
US-10-826-966-308/c
; Sequence 308, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 308
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(20)
;    OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (20)..(21)
;    OTHER INFORMATION: n stands for thymidine
US-10-826-966-308

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 4.2e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||:|:||:|
Db         19 GCAAGGAGGGCCTCTGATG 1


RESULT 364
US-10-826-966-345
; Sequence 345, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
```

```
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 345
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(8)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-345

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 365
US-10-826-966-346
; Sequence 346, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 346
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-346

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              |||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 366
US-10-826-966-347
```

```
; Sequence 347, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 347
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-347

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACC 3930
             ||||||||||||||||||||
Db          1 CCUGGAAAGAAUCAAAACC 19


RESULT 367
US-10-826-966-348
; Sequence 348, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 348
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(2)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (11)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-348

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2949 GCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||||||
Db          1 GCAAGGAGGGCCUCUGAUG 19


RESULT 368
US-10-826-966-396
; Sequence 396, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 396
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-826-966-396

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 369
US-10-826-966-397/c
; Sequence 397, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 397
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-397

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 370
US-10-826-966-398/c
; Sequence 398, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 398
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: inverted thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-398

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 371
US-10-826-966-399/c
; Sequence 399, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
```

```
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 399
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-399

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 372
US-10-826-966-400/c
; Sequence 400, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 400
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: glyceryl moiety
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-400

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
```

```
                     ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 373
US-10-826-966-401/c
; Sequence 401, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 401
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: L-thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-401

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 374
US-10-826-966-414/c
; Sequence 414, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 414
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-414

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 375
US-10-826-966-415/c
; Sequence 415, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 415
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for inverted thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for thymidine
US-10-826-966-415

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
                ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 376
US-10-826-966-416/c
; Sequence 416, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 416
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for 3'-deoxy thymidine
US-10-826-966-416

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 377
US-10-826-966-417/c
; Sequence 417, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 417
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for glyceryl moiety
US-10-826-966-417

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 378
US-10-826-966-418/c
; Sequence 418, Application US/10826966
; Publication No. US20050032733A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 418
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: n stands for L-thymidine
US-10-826-966-418

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 379
US-10-826-966-419
; Sequence 419, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 419
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-826-966-419

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||||||||||
Db          1 CAACCACAAAAUACAACAA 19


RESULT 380
US-10-826-966-420/c
; Sequence 420, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 420
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(12)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-420

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAA 2358
              ||||||||||:|||||||
Db         19 CAACCACAAAATACAACAA 1


RESULT 381
US-10-826-966-621
; Sequence 621, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
```

```
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moeity
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (21)..(21)
;   OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moeity
US-10-826-966-621

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCC 19


RESULT 382
US-10-826-966-622/c
; Sequence 622, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Macejak, Dennis
;  APPLICANT:  Morrissey, David
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
;  TITLE OF INVENTION:  Chemically Modified Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/151 (03-465-D)
;  CURRENT APPLICATION NUMBER: US/10/826,966
;  CURRENT FILING DATE:  2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/652,791
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/422,704
;  PRIOR FILING DATE: 2003-04-24
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 669
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 622
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(21)
;   OTHER INFORMATION: n stands for thymidine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(20)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-826-966-622

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 383
US-10-947-637-896
; Sequence 896, Application US/10947637
; Publication No. US20050181385A1
; GENERAL INFORMATION:
;  APPLICANT: Linsley, Peter
;  APPLICANT:  Mao, Mao
;  APPLICANT:  Kim, Annette
;  APPLICANT:  Friend, Stephen
;  APPLICANT:  Bartz, Steven
;  APPLICANT:  Cleary, Michele
;  TITLE OF INVENTION: Synthetic Lethal Screen Using RNA
;  TITLE OF INVENTION:  Interference
;  FILE REFERENCE: 9301-243-999
;  CURRENT APPLICATION NUMBER: US/10/947,637
;  CURRENT FILING DATE:  2004-09-22
;  PRIOR APPLICATION NUMBER: 60/554,284
;  PRIOR FILING DATE: 2004-03-17
;  PRIOR APPLICATION NUMBER: 60/548,568
;  PRIOR FILING DATE: 2004-02-27
;  PRIOR APPLICATION NUMBER: 60/505,229
;  PRIOR FILING DATE: 2003-09-22
;  NUMBER OF SEQ ID NOS: 1239
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 896
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: siRNA with 19 paired ribonucleotides and two
;   OTHER INFORMATION: unpaired nucleotides("t") on the 3' end of each
;   OTHER INFORMATION: strand  used in screens of DNA damaging agents:
;   OTHER INFORMATION: camptothecin screen
US-10-947-637-896

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6938 AGGAGGAGUGCAUCUUUGG 6956
              |||||||||||||||||||
Db          1 AGGAGGAGUGCAUCUUUGG 19


RESULT 384
US-10-764-957-411/c
; Sequence 411, Application US/10764957
; Publication No. US20050054596A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Pavco, Pamela
```

```
;  APPLICANT:  Beigelman, Leo
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/144 (MBHB02-742-O)
;  CURRENT APPLICATION NUMBER: US/10/764,957
;  CURRENT FILING DATE:  2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 473
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 411
;    LENGTH: 22
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(3)
;    OTHER INFORMATION: 2'-O-methyl
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(1)
;    OTHER INFORMATION: 5'Amino Mod C3-TFA attached moeity
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (4)..(4)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (5)..(5)
;    OTHER INFORMATION: 2'-O-methyl
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (6)..(11)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (12)..(14)
;    OTHER INFORMATION: 2'-O-methyl
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (15)..(17)
;    OTHER INFORMATION: 2'-deoxy-2'-fluoro
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (18)..(19)
;    OTHER INFORMATION: 2'-O-methyl
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(22)
;    OTHER INFORMATION: n stands for thymidine
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (21)..(21)
;    OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-764-957-411

  Query Match             0.2%;  Score 19;  DB 1;  Length 22;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::|||||||||||
Db         20 CTGAGTTTAAAAGGCACCC 2


RESULT 385
US-10-048-866D-10
; Sequence 10, Application US/10048866D
; Publication No. US20050003476A1
; GENERAL INFORMATION:
;  APPLICANT: SUNTORY LIMITED
;  TITLE OF INVENTION: Novel gene encoding glycosyltransferase
;  FILE REFERENCE: 1003552
;  CURRENT APPLICATION NUMBER: US/10/048,866D
;  CURRENT FILING DATE:  2002-02-04
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;    LENGTH: 23
;    TYPE: DNA
;    ORGANISM: Artificial sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:Primer
US-10-048-866D-10

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 4.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUU 6361
              |:| | ::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 386
US-10-517-544-40
; Sequence 40, Application US/10517544
; Publication No. US20050250100A1
; GENERAL INFORMATION:
;  APPLICANT: RIKEN
;  APPLICANT:  KABUSHIKI KAISHA DNAFORM
;  TITLE OF INVENTION: Method for utilizing the 5'end of mRNA for cloning and analysis
;  FILE REFERENCE: 1336(PCT)
;  CURRENT APPLICATION NUMBER: US/10/517,544
;  CURRENT FILING DATE:  2004-12-10
;  PRIOR APPLICATION NUMBER: JP 2002-171851
;  PRIOR FILING DATE: 2002-06-12
;  PRIOR APPLICATION NUMBER: JP 2002-235294
;  PRIOR FILING DATE: 2002-08-12
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial
;    FEATURE:
;    OTHER INFORMATION: tag8
US-10-517-544-40

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 4.9e+02;
  Matches   10;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
```

```
              |:|:|:|:|:|:|:| |:|:
Db          1 GTGTGTGTGTGTGTGCGTGT 20


RESULT 387
US-10-769-744-394/c
; Sequence 394, Application US/10769744
; Publication No. US20050282855A1
; GENERAL INFORMATION:
;  APPLICANT: Helgadottir et al.
;  TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION
;  FILE REFERENCE: 30847/2051-004
;  CURRENT APPLICATION NUMBER: US/10/769,744
;  CURRENT FILING DATE:  2004-01-30
;  PRIOR APPLICATION NUMBER: PCT/US03/32556
;  PRIOR FILING DATE: 2003-10-16
;  PRIOR APPLICATION NUMBER: US 60/419,433
;  PRIOR FILING DATE: 2002-10-17
;  PRIOR APPLICATION NUMBER: US 60/449,331
;  PRIOR FILING DATE: 2003-02-21
;  NUMBER OF SEQ ID NOS: 609
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 394
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-769-744-394

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 4.9e+02;
  Matches   10;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:| |:
Db         20 GTGTGTGTGTGTGTGTGCGT 1


RESULT 388
US-10-857-780-4135/c
; Sequence 4135, Application US/10857780
; Publication No. US20050272043A1
; GENERAL INFORMATION:
;  APPLICANT: ROTH, RICHARD B.
;  APPLICANT:  BRAUN, ANDREAS
;  APPLICANT:  KAMMERER, STEFAN M.
;  APPLICANT:  NELSON, MATTHEW ROBERTS
;  APPLICANT:  RENELAND, RIKARD HENRY
;  APPLICANT:  HOYAL-WRIGHTSON, CAROLYN R.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: SEQ-4069-CP
;  CURRENT APPLICATION NUMBER: US/10/857,780
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: 10/723,681
;  PRIOR FILING DATE: 2003-11-25
;  PRIOR APPLICATION NUMBER: 60/490,234
;  PRIOR FILING DATE: 2003-07-24
;  PRIOR APPLICATION NUMBER: 60/525,239
;  PRIOR FILING DATE: 2003-11-25
;  NUMBER OF SEQ ID NOS: 4962
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4135
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-857-780-4135

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 4.9e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6992
              :|:|: :|:|:|:|:|:|:|
Db         20 TGTGTCTGTGTGTGTGTG 1


RESULT 389
US-10-857-780-4392
; Sequence 4392, Application US/10857780
; Publication No. US20050272043A1
; GENERAL INFORMATION:
;  APPLICANT: ROTH, RICHARD B.
;  APPLICANT:  BRAUN, ANDREAS
;  APPLICANT:  KAMMERER, STEFAN M.
;  APPLICANT:  NELSON, MATTHEW ROBERTS
;  APPLICANT:  RENELAND, RIKARD HENRY
;  APPLICANT:  HOYAL-WRIGHTSON, CAROLYN R.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: SEQ-4069-CP
;  CURRENT APPLICATION NUMBER: US/10/857,780
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: 10/723,681
;  PRIOR FILING DATE: 2003-11-25
;  PRIOR APPLICATION NUMBER: 60/490,234
;  PRIOR FILING DATE: 2003-07-24
;  PRIOR APPLICATION NUMBER: 60/525,239
;  PRIOR FILING DATE: 2003-11-25
;  NUMBER OF SEQ ID NOS: 4962
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4392
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-857-780-4392

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 4.9e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|: :|:|:|:
Db          1 GTGTGTGTGTGTCTGTGTGT 20


RESULT 390
US-11-069-908-6019/c
; Sequence 6019, Application US/11069908
; Publication No. US20050266432A1
; GENERAL INFORMATION:
;  APPLICANT: OLIPHANT, ARNOLD
;  APPLICANT:  MURRAY, SARAH
;  TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
;  TITLE OF INVENTION:  CONDITIONS
;  FILE REFERENCE: 029011-0402
;  CURRENT APPLICATION NUMBER: US/11/069,908
;  CURRENT FILING DATE:  2005-02-28
;  PRIOR APPLICATION NUMBER: 60/547,823
;  PRIOR FILING DATE: 2004-02-26
;  NUMBER OF SEQ ID NOS: 7098
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6019
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-6019

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 4.9e+02;
  Matches   10;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:| |:|:|
Db         20 TGTGTGTGTGTGTGAGTGTG 1


RESULT 391
US-10-751-736-38782
; Sequence 38782, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38782
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-10-751-736-38782

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 4.7e+02;
  Matches   10;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6970 AACUGUGUGUGUGUGUGUGU 6989
              | |:|:|:|:|:|:|:|:|:
Db          2 ATCTGTGTGTGTGTGTGTGT 21


RESULT 392
US-10-751-736-38783
; Sequence 38783, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38783
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-38783

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 4.7e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGU 6991
              |||||||||||||||||| |
Db          2 CUGUGUGUGUGUGUGUGUUU 21


RESULT 393
US-10-751-736-52502
; Sequence 52502, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52502
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-52502

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 4.7e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |||||||| ||||||||||
Db          1 GUGUGUGUUUGUGUGUGUGU 20


RESULT 394
US-09-735-363A-17
; Sequence 17, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-17

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTG 18


RESULT 395
US-09-735-363A-18
; Sequence 18, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
;  APPLICANT: Filion, Mario
;  APPLICANT:  Phillip, Nigel
```

```
;  TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
;  FILE REFERENCE: 02811-0181
;  CURRENT APPLICATION NUMBER: US/09/735,363A
;  CURRENT FILING DATE:  2000-12-12
;  PRIOR APPLICATION NUMBER: 60/170,325
;  PRIOR FILING DATE: 1999-12-13
;  PRIOR APPLICATION NUMBER: 60/228,925
;  PRIOR FILING DATE: 2000-08-29
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-18

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
              |:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGT 18


RESULT 396
US-09-896-650A-28
; Sequence 28, Application US/09896650A
; Patent No. US20020146704A1
; GENERAL INFORMATION:
;  APPLICANT: Head, Steven
;  APPLICANT:  Boyce-Jacino, Michael
;  APPLICANT:  Karn, Jonathan
;  APPLICANT:  Goelet, Philip
;  TITLE OF INVENTION: De No. US20020146704A1o or "Universal" Sequencing Array
;  FILE REFERENCE: 13019-2
;  CURRENT APPLICATION NUMBER: US/09/896,650A
;  CURRENT FILING DATE:  2001-06-29
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Reagent Sequence
US-09-896-650A-28

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTG 18


RESULT 397
US-10-011-204-1/c
; Sequence 1, Application US/10011204
; Publication No. US20020182617A1
; GENERAL INFORMATION:
;  APPLICANT: EKINS, Roger P
;  TITLE OF INVENTION: Binding assay using binding agents with tail groups
;  FILE REFERENCE: 0380-P01180US0
;  CURRENT APPLICATION NUMBER: US/10/011,204
;  CURRENT FILING DATE:  2001-11-08
;  PRIOR APPLICATION NUMBER: US/08/700,530
;  PRIOR FILING DATE: 1996-10-23
;  PRIOR APPLICATION NUMBER: PCT/GB95/00521
;  PRIOR FILING DATE: 1995-03-10
;  PRIOR APPLICATION NUMBER: GB 9404709.9
;  PRIOR FILING DATE: 1994-03-11
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-011-204-1

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db         18 TGTGTGTGTGTGTGTGTG 1


RESULT 398
US-10-011-204-2
; Sequence 2, Application US/10011204
; Publication No. US20020182617A1
; GENERAL INFORMATION:
;  APPLICANT: EKINS, Roger P
;  TITLE OF INVENTION: Binding assay using binding agents with tail groups
;  FILE REFERENCE: 0380-P01180US0
;  CURRENT APPLICATION NUMBER: US/10/011,204
;  CURRENT FILING DATE:  2001-11-08
;  PRIOR APPLICATION NUMBER: US/08/700,530
;  PRIOR FILING DATE: 1996-10-23
;  PRIOR APPLICATION NUMBER: PCT/GB95/00521
;  PRIOR FILING DATE: 1995-03-10
;  PRIOR APPLICATION NUMBER: GB 9404709.9
;  PRIOR FILING DATE: 1994-03-11
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-011-204-2

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
              |:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGT 18


RESULT 399
US-10-138-674-1411
; Sequence 1411, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
```

```
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 400
US-10-287-949A-1411
; Sequence 1411, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 401
US-10-399-019-10/c
; Sequence 10, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-10

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 5.7e+02;
  Matches   14;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 UGAAAUGGUGAGUAAGGA 458
              :||||:||:|||:|||||
Db         18 TGAAATGGTGAGTAAGGA 1


RESULT 402
US-10-399-019-11/c
; Sequence 11, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-11

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 5.7e+02;
  Matches   17;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        592 UCAAAGAAGAAGGAAACA 609
              :||||||||||||||||||
Db         18 TCAAAGAAGAAGGAAACA 1


RESULT 403
US-10-399-019-12/c
; Sequence 12, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-12

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        437 UGCCUGAAAUGGUGAGUA 454
              :|||:||||:||:|||:|
Db         18 TGCCTGAAATGGTGAGTA 1
```

```
RESULT 404
US-10-399-019-13/c
; Sequence 13, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-13

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 5.7e+02;
  Matches   12;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        436 UUGCCUGAAAUGGUGAGU 453
              ::|||:||||:||:|||:
Db         18 TTGCCTGAAATGGTGAGT 1


RESULT 405
US-10-399-019-9/c
; Sequence 9, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-9

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 CAAAGAAGAAGGAAACAG 610
              ||||||||||||||||||
Db         18 CAAAGAAGAAGGAAACAG 1


RESULT 406
US-10-751-235-59/c
; Sequence 59, Application US/10751235
; Publication No. US20050150002A1
; GENERAL INFORMATION:
;  APPLICANT: DellaPenna, Dean
;  APPLICANT:  Tian, Li
;  APPLICANT:  Kim, Joonyul
;  TITLE OF INVENTION: Novel Carotenoid Hydroxylases for Use in Engineering Carotenoid
;  TITLE OF INVENTION:  Metabolism in Plants
;  FILE REFERENCE: MSU-08604
;  CURRENT APPLICATION NUMBER: US/10/751,235
;  CURRENT FILING DATE:  2004-01-02
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 59
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-751-235-59

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db         18 TGTGTGTGTGTGTGTGTG 1


RESULT 407
US-10-951-303-1411
; Sequence 1411, Application US/10951303
; Publication No. US20050227937A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/10/951,303
;  CURRENT FILING DATE:  2004-09-27
;  PRIOR APPLICATION NUMBER: US/09/685,664
;  PRIOR FILING DATE: 2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-951-303-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 408
US-10-923-470-123/c
; Sequence 123, Application US/10923470
; Publication No. US20050227935A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
```

```
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of TNF and TNF Receptor Gene
;  TITLE OF INVENTION:  Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/215 (MBHB02-1236-F)
;  CURRENT APPLICATION NUMBER: US/10/923,470
;  CURRENT FILING DATE:  2004-08-20
;  NUMBER OF SEQ ID NOS: 372
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-10-923-470-123

  Query Match             0.2%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   22.2%;  Pred. No. 5.5e+02;
  Matches    4;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::||||
Db         19 TTTTTTTTTTTTTTCCAA 2


RESULT 409
US-10-923-470-246
; Sequence 246, Application US/10923470
; Publication No. US20050227935A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of TNF and TNF Receptor Gene
;  TITLE OF INVENTION:  Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/215 (MBHB02-1236-F)
;  CURRENT APPLICATION NUMBER: US/10/923,470
;  CURRENT FILING DATE:  2004-08-20
;  NUMBER OF SEQ ID NOS: 372
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 246
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-10-923-470-246

  Query Match             0.2%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 5.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCCAA 6365
              ||||||||||||||||||
Db          1 UUUUUUUUUUUUUUCCAA 18


RESULT 410
US-10-786-720-11539/c
; Sequence 11539, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11539
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11539

  Query Match             0.2%;  Score 18;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db         18 TGTGTGTGTGTGTGTGTG 1


RESULT 411
US-09-768-917-10/c
; Sequence 10, Application US/09768917
; Patent No. US20020034494A1
; GENERAL INFORMATION:
;  APPLICANT: Vicari, Alain P.
;  APPLICANT:  Caux, Christophe
;  APPLICANT:  LaFace, Drake
;  TITLE OF INVENTION: Chemokines as Adjuvants of Immune Response
;  FILE REFERENCE: SF0896K US
;  CURRENT APPLICATION NUMBER: US/09/768,917
;  CURRENT FILING DATE:  2001-01-24
;  PRIOR APPLICATION NUMBER: EP 0 974 357
;  PRIOR FILING DATE: 1998-07-16
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-768-917-10

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:| |:|:| |:|:|
Db         21 GTGTGTGTGAGTGTGAGTGTG 1


RESULT 412
US-10-085-906-412
; Sequence 412, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
;  APPLICANT: Ying, Vincent
;  APPLICANT:  Wu, Paul
;  APPLICANT:  Gray, Gary S.
;  TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
;  TITLE OF INVENTION:  COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
;  FILE REFERENCE: GNN-5343CP2
;  CURRENT APPLICATION NUMBER: US/10/085,906
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: US 60/126,215
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 09/534,061
;  PRIOR FILING DATE: 2000-03-24
;  PRIOR APPLICATION NUMBER: PCT/US00/07938
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 545
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 412
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
```

```
US-10-085-906-412

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 5.3e+02;
  Matches    9;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|: :|:|:|: :|
Db          1 GTGTGTGTGTCTGTGTGTCTG 21


RESULT 413
US-10-751-736-12824
; Sequence 12824, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12824
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-12824

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 5.3e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3810 UGCCUUCUCUGAGGACUUCUU 3830
              ||| || ||||||||||||||
Db          1 UGCUUUGUCUGAGGACUUCUU 21


RESULT 414
US-10-751-736-50830
; Sequence 50830, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50830
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-10-751-736-50830

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 5.3e+02;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3184 GAUGUUGAGGAAGAGGAGGAU 3204
              ||:| :|||||||||||| ||:
Db          1 GATGATGAGGAAGAGGAAGAT 21


RESULT 415
US-10-751-736-52501
; Sequence 52501, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52501
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-10-751-736-52501

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 5.3e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              | |:|:|:|: :|:|:|:|:|
Db          1 GAGTGTGTGTTTGTGTGTGTG 21


RESULT 416
US-10-786-720-11524/c
; Sequence 11524, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11524
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11524

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 5.3e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|  :|:|:|:|:|:|:|
Db         21 GTGTGCATGTGTGTGTGTGTG 1


RESULT 417
US-10-786-720-11527/c
; Sequence 11527, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
```

```
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11527
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11527

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 5.3e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|  :|:|:|:|:|:|
Db         21 GTGTGTGCATGTGTGTGTGTG 1


RESULT 418
US-10-786-720-11530/c
; Sequence 11530, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11530
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11530

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 5.3e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|  :|:|:|:|:|
Db         21 GTGTGTGTGCATGTGTGTGTG 1


RESULT 419
US-10-786-720-11542/c
; Sequence 11542, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11542
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11542

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 5.3e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|  :|:|:|:|:|:|:|:|
Db         21 GTGGATGTGTGTGTGTGTGTG 1


RESULT 420
US-10-094-466-105
; Sequence 105, Application US/10094466
; Publication No. US20030203363A1
; GENERAL INFORMATION:
;  APPLICANT: Spytek et al.
;  TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM
;  TITLE OF INVENTION:  AND METHODS OF USING
;  TITLE OF INVENTION:  THE SAME
;  FILE REFERENCE: 21402-290D
;  CURRENT APPLICATION NUMBER: US/10/094,466
;  CURRENT FILING DATE:  2002-03-07
;  PRIOR APPLICATION NUMBER: 60/274,281
;  PRIOR FILING DATE: 2001-03-08
;  PRIOR APPLICATION NUMBER: 60/288,148
;  PRIOR FILING DATE: 2001-05-02
;  PRIOR APPLICATION NUMBER: 60/274,849
;  PRIOR FILING DATE: 2001-03-09
;  PRIOR APPLICATION NUMBER: 60/275,235
;  PRIOR FILING DATE: 2001-03-12
;  PRIOR APPLICATION NUMBER: 60/338,375
;  PRIOR FILING DATE: 2001-12-04
;  PRIOR APPLICATION NUMBER: 60/275,579
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: 60/335,302
;  PRIOR FILING DATE: 2001-10-31
;  PRIOR APPLICATION NUMBER: 60/275,601
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: 60/276,000
;  PRIOR FILING DATE: 2001-03-14
;  PRIOR APPLICATION NUMBER: 60/277,338
;  PRIOR FILING DATE: 2001-03-20
;  Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 114
;  SOFTWARE: PatIn 2.1
; SEQ ID NO 105
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-094-466-105

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   52.4%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              | |:|:|:|:|:| |:|:|:|
Db          1 GAGTGTGTGTGTGAGTGTGTG 21


RESULT 421
US-10-184-372-11/c
; Sequence 11, Application US/10184372
; Publication No. US20030219852A1
; GENERAL INFORMATION:
;  APPLICANT: Bank, Rudolf A.
;  APPLICANT:  Van der Slot, Annemarie J.
;  APPLICANT:  Zuurmond, Anne-Marie
;  APPLICANT:  Te Koppele, Johannes M.
;  TITLE OF INVENTION: Modification of collagenous materials and medical treatment, dia
```

```
;  TITLE OF INVENTION:  and monitoring of fibrotic conditions
;  FILE REFERENCE: P60187US00
;  CURRENT APPLICATION NUMBER: US/10/184,372
;  CURRENT FILING DATE:  2003-06-19
;  PRIOR APPLICATION NUMBER: US 09/450,209
;  PRIOR FILING DATE: 1999-11-29
;  NUMBER OF SEQ ID NOS: 59
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
US-10-184-372-11

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   42.9%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6994
              |:|:|: :|:|:|:|: :|:|
Db         21 GTGTGTCTGTGTGTGTATGTG 1


RESULT 422
US-10-508-932-16/c
; Sequence 16, Application US/10508932
; Publication No. US20050260586A1
; GENERAL INFORMATION:
;  APPLICANT: Medical College of Ohio
;  APPLICANT:  Willey, James C.
;  APPLICANT:  Weaver, David A.
;  APPLICANT:  Warner, Kristy A.
;  APPLICANT:  Graves, Timothy G.
;  APPLICANT:  DeMuth, Jeffrey P.
;  APPLICANT:  Crawford, Erin L.
;  TITLE OF INVENTION: Method and Compositions for the Diagnosis and Treatment of Non-Sm
;  TITLE OF INVENTION:  Lung Cancer Using Gene Expression Profiles
;  FILE REFERENCE: 9050
;  CURRENT APPLICATION NUMBER: US/10/508,932
;  CURRENT FILING DATE:  2004-09-24
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-508-932-16

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   47.6%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3352 GUGGUGAAGAUUUGUGAUUUU 3372
              |:||:|||||::: :||:: :
Db         21 GTGGTGAAGATTTTTGATTCT 1


RESULT 423
US-11-061-140-289/c
; Sequence 289, Application US/11061140
; Publication No. US20050256073A1
; GENERAL INFORMATION:
;  APPLICANT: Grayson B. Lipford
;  APPLICANT:  Alexandra Forsbach
;  TITLE OF INVENTION: IMMUNOSTIMULATORY VIRAL RNA OLIGONUCLEOTIDES
;  FILE REFERENCE: C1037.70053US01
;  CURRENT APPLICATION NUMBER: US/11/061,140
;  CURRENT FILING DATE:  2005-02-18
;  PRIOR APPLICATION NUMBER: US 60/545,988
;  PRIOR FILING DATE: 2004-02-19
;  NUMBER OF SEQ ID NOS: 344
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 289
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-061-140-289

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 5.1e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              |||||||||  ||| |||||||
Db         21 AACAACCACCAAAAACAACAA 1


RESULT 424
US-09-909-544-5
; Sequence 5, Application US/09909544
; Patent No. US20020160951A1
; GENERAL INFORMATION:
;  APPLICANT: Lue, Tom F.
;  APPLICANT:  Lin, Ching-Shwun
;  APPLICANT:  Kan, Yuet W.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PREVENTING
;  TITLE OF INVENTION:  AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE SEXUAL
;  TITLE OF INVENTION:  AROUSAL DISORDER
;  FILE REFERENCE: 220022001600
;  CURRENT APPLICATION NUMBER: US/09/909,544
;  CURRENT FILING DATE:  2001-07-19
;  PRIOR APPLICATION NUMBER: 60/220,031
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-1s Primer
US-09-909-544-5

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||| :||:||||||
Db          1 ATGCTGGATTGCTGGCACA 19


RESULT 425
US-10-155-785-5
; Sequence 5, Application US/10155785
; Publication No. US20030096747A1
; GENERAL INFORMATION:
;  APPLICANT: LUE, Tom
;  APPLICANT:  LIN, Ching-Sgwun
;  APPLICANT:  CAROLL, Peter
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PREVENTING
;  TITLE OF INVENTION:  AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE SEXUAL
;  TITLE OF INVENTION:  AROUSAL DISORDER
;  FILE REFERENCE: 22002-20016.20
;  CURRENT APPLICATION NUMBER: US/10/155,785
;  CURRENT FILING DATE:  2002-05-23
;  PRIOR APPLICATION NUMBER: US 09/909,544
;  PRIOR FILING DATE: 2001-07-19
;  PRIOR APPLICATION NUMBER: US 60/220,031
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: FastSEQ for Windows Version 4.0
```

```
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer VEGFR-1s
US-10-155-785-5

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||| :||:||||||
Db             1 ATGCTGGATTGCTGGCACA 19


RESULT 426
US-10-497-101-2/c
; Sequence 2, Application US/10497101
; Publication No. US20060051330A1
; GENERAL INFORMATION:
;  APPLICANT: Universitaetsklinikum Hamburg-Eppendorf
;  APPLICANT:  Hossfeld, Dieter Kurt
;  APPLICANT:  Fiedler, Walter
;  APPLICANT:  Gehling, Ursula
;  APPLICANT:  Loges, Sonja
;  TITLE OF INVENTION: Method for carrying out the ex vivo expansion and ex vivo differe
;  TITLE OF INVENTION:  of multipotent stem cells
;  FILE REFERENCE: 66741-036
;  CURRENT APPLICATION NUMBER: US/10/497,101
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: PCT/EP02/13142
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Description of the artificial sequence: outer KDR sense primer
US-10-497-101-2

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCU 3658
              |||| ||:||:||||:||:
Db            19 CAGACCATGCTGGACTGCT 1


RESULT 427
US-10-871-222-150/c
; Sequence 150, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
;  TITLE OF INVENTION:  Synthase Ligand (FASL) Gene Expression Using Short Interfering
;  TITLE OF INVENTION:  Nucleic Acid (SINA)
;  FILE REFERENCE: 400/164  (MBHB04-487)
;  CURRENT APPLICATION NUMBER: US/10/871,222
;  CURRENT FILING DATE:  2004-06-18
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US10/826966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US10/757803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US10/720448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US10/693059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US10/444853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 706
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 150
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-871-222-150

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   15.8%;  Pred. No. 6.2e+02;
  Matches    3;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::::: |||
Db            19 TTTTTTTTTTTTTTTACCA 1


RESULT 428
US-10-871-222-300
; Sequence 300, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
;  TITLE OF INVENTION:  Synthase Ligand (FASL) Gene Expression Using Short Interfering
;  TITLE OF INVENTION:  Nucleic Acid (SINA)
;  FILE REFERENCE: 400/164  (MBHB04-487)
;  CURRENT APPLICATION NUMBER: US/10/871,222
;  CURRENT FILING DATE:  2004-06-18
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US10/826966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US10/757803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US10/720448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US10/693059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US10/444853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 706
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-871-222-300

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 6.2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ||||||||||||||||| |||
Db          1 UUUUUUUUUUUUUUUUACCA 19


RESULT 429
US-10-923-522-618
; Sequence 618, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 618
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-923-522-618

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 6.2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3506 GAGUAUUGCUGUGGGAAAU 3524
              |||||||||| ||||||||
Db          1 GAGUAUUGCUUUGGGAAAU 19


RESULT 430
US-10-923-522-937/c
; Sequence 937, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 937
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-522-937

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 6.2e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3506 GAGUAUUGCUGUGGGAAAU 3524
              |||:|::||: :|||||||:
Db         19 GAGTATTGCTTTGGGAAAT 1


RESULT 431
US-10-923-580-152/c
; Sequence 152, Application US/10923580
; Publication No. US20050159382A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Usman, Nassim
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Polycomb Group Protein
;  TITLE OF INVENTION:  EZH2 Gene Expression Using Short Interfering Nucleic Acid (siNA
;  FILE REFERENCE: 400/211 (MBHB03-074-C)
;  CURRENT APPLICATION NUMBER: US/10/923,580
;  CURRENT FILING DATE:  2004-08-19
;  PRIOR APPLICATION NUMBER: PCT/US03/04402
;  PRIOR FILING DATE: 2003-02-13
;  PRIOR APPLICATION NUMBER: US 60/427,467
;  PRIOR FILING DATE: 2002-11-19
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
```

```
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 424
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-580-152

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 6.2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         23 CCCCGGCAGCGGCGGCGGC 41
              ||||||| ||||||||||||
Db         19 CCCCGGCGGCGGCGGCGGC 1


RESULT 432
US-10-923-580-4
; Sequence 4, Application US/10923580
; Publication No. US20050159382A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Usman, Nassim
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Polycomb Group Protein
;  TITLE OF INVENTION:  EZH2 Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/211 (MBHB03-074-C)
;  CURRENT APPLICATION NUMBER: US/10/923,580
;  CURRENT FILING DATE:  2004-08-19
;  PRIOR APPLICATION NUMBER: PCT/US03/04402
;  PRIOR FILING DATE: 2003-02-13
;  PRIOR APPLICATION NUMBER: US 60/427,467
;  PRIOR FILING DATE: 2002-11-19
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 424
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-923-580-4

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 6.2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         23 CCCCGGCAGCGGCGGCGGC 41
              ||||||| ||||||||||||
Db          1 CCCCGGCGGCGGCGGCGGC 19


RESULT 433
US-11-040-947-5
; Sequence 5, Application US/11040947
; Publication No. US20050233962A1
; GENERAL INFORMATION:
;  APPLICANT: LUE, Tom F.
;  APPLICANT:  LIN, Ching-Shwun
;  APPLICANT:  CARROLL, Peter
;  APPLICANT:  KAN, Yuet W.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PREVENTING
;  TITLE OF INVENTION:  AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE SEXUAL
;  TITLE OF INVENTION:  AROUSAL DISORDER
;  FILE REFERENCE: 220022001611
;  CURRENT APPLICATION NUMBER: US/11/040,947
;  CURRENT FILING DATE:  2005-01-21
;  PRIOR APPLICATION NUMBER: US 10/155,785
;  PRIOR FILING DATE: 2002-05-23
;  PRIOR APPLICATION NUMBER: US 09/909,544
;  PRIOR FILING DATE: 2001-07-19
;  PRIOR APPLICATION NUMBER: US 60/220,031
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer VEGFR-1s
US-11-040-947-5

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||| :||:||||||
Db          1 ATGCTGGATTGCTGGCACA 19


RESULT 434
US-09-969-373-2420
; Sequence 2420, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2420
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-2420

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   47.4%;  Pred. No. 6e+02;
  Matches    9;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUG 6990
              |:|:|:|: :|:|:|:|:|
Db          2 CTGTGTGTTTGTGTGTGTG 20


RESULT 435
US-09-969-373-2422
; Sequence 2422, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2422
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-2422

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   47.4%;  Pred. No. 6e+02;
  Matches    9;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUG 6990
              |:|:|:|: :|:|:|:|:|
Db          2 CTGTGTGTTTGTGTGTGTG 20


RESULT 436
US-10-476-961-80
; Sequence 80, Application US/10476961
; Publication No. US20040241843A1
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Isis Pharmaceuticals, Inc.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
;  FILE REFERENCE: RTSP-0393
;  CURRENT APPLICATION NUMBER: US/10/476,961
;  CURRENT FILING DATE:  2003-11-05
;  PRIOR APPLICATION NUMBER: 2001-05-07
;  PRIOR FILING DATE: 09/851,062
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-961-80

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   63.2%;  Pred. No. 6e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        294 CAGCUGUCUGCUUCUCACA 312
              || |:|:|:||::|:||||
Db          2 CATCTGTCTGCTTCTCACA 20


RESULT 437
US-10-664-639A-36/c
; Sequence 36, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
;  APPLICANT: Vickers, Timothy
;  APPLICANT:  Koo, Seongjoon
;  APPLICANT:  Bennett, C. Frank
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Dean, Nicholas, M.
;  APPLICANT:  Baker, Brenda F.
;  TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
;  TITLE OF INVENTION:  Double-Stranded Oligomeric Compounds
;  FILE REFERENCE: ISIS0001-100 (CORE00027US)
;  CURRENT APPLICATION NUMBER: US/10/664,639A
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 60/411,780
;  PRIOR FILING DATE: 2002-09-18
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(6)
;   OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(20)
;   OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-36

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   42.1%;  Pred. No. 6e+02;
  Matches    8;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|: :|:|:
Db         20 TGTGTGTGTGTGTATGTGT 2


RESULT 438
US-10-751-736-38784/c
; Sequence 38784, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38784
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
```

```
US-10-751-736-38784

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   42.1%;  Pred. No. 5.7e+02;
  Matches    8;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|: :
Db         21 TGTGTGTGTGTGTGTGTCT 3


RESULT 439
US-10-751-736-52503/c
; Sequence 52503, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52503
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-52503

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   47.4%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|: :|:|:|:|
Db         21 GTGTGTGTGTTTGTGTGTG 3


RESULT 440
US-10-770-726-8905/c
; Sequence 8905, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8905
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-8905

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.7e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3694 GAACUUGUGGAAAAACUAG 3712
              ||||::|:|||| |||:||
Db         21 GAACTTGTGGAACAACTAG 3


RESULT 441
US-09-263-959-557
; Sequence 557, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  557:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-557

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 7.2e+02;
  Matches    8;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGT 17


RESULT 442
US-09-263-959-705
; Sequence 705, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  705:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-705

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 7.2e+02;
  Matches    8;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGT 17


RESULT 443
US-09-263-959-970
; Sequence 970, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  970:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-970

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 7.2e+02;
  Matches    8;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGT 17


RESULT 444
US-09-958-221A-18
; Sequence 18, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-18

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTG 17


RESULT 445
US-09-958-221A-19/c
; Sequence 19, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-19

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:||
Db         17 TGTGTGTGTGTGTGTGG 1
```

```
RESULT 446
US-10-333-461-24
; Sequence 24, Application US/10333461
; Publication No. US20030165952A1
; GENERAL INFORMATION:
;  APPLICANT: Global Genomics AB
;  APPLICANT:  Linnarsson, Sten
;  APPLICANT:  Ernfors, Patrik
;  APPLICANT:  Bauren, Goran
;  TITLE OF INVENTION: Methods for analysis and identification of transcribed
;  TITLE OF INVENTION:  genes, and fingerprinting
;  FILE REFERENCE: smwfp5941752
;  CURRENT APPLICATION NUMBER: US/10/333,461
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: GB 0018016.6
;  PRIOR FILING DATE: 2000-07-21
;  PRIOR APPLICATION NUMBER: US 60/219,925
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Double-stranded product DNA
US-10-333-461-24

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 7.2e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17


RESULT 447
US-10-352-253A-24
; Sequence 24, Application US/10352253A
; Publication No. US20030175908A1
; GENERAL INFORMATION:
;  APPLICANT: Linnarsson, Sten
;  APPLICANT:  Ernfors, Patrik
;  APPLICANT:  Bauren, Goran
;  APPLICANT:  Metsis, Ats
;  APPLICANT:  Pihlak, Arno
;  APPLICANT:  Montelius, Andreas
;  TITLE OF INVENTION: Methods And Means For Manipulating Nucleic Acid
;  FILE REFERENCE: 620-234
;  CURRENT APPLICATION NUMBER: US/10/352,253A
;  CURRENT FILING DATE:  2003-01-28
;  PRIOR APPLICATION NUMBER: US 60/352,215
;  PRIOR FILING DATE: 2002-01-29
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Double-stranded product DNA
US-10-352-253A-24

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 7.2e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17


RESULT 448
US-10-352-255A-24
; Sequence 24, Application US/10352255A
; Publication No. US20030215839A1
; GENERAL INFORMATION:
;  APPLICANT: LONNERBERG, Peter
;  APPLICANT:  OLDIN, Mats
;  APPLICANT:  LINNARSSON, Sten
;  APPLICANT:  ERNFORS, Patrik
;  TITLE OF INVENTION: Methods and Means for Identification of Gene Features
;  FILE REFERENCE: 620-235
;  CURRENT APPLICATION NUMBER: US/10/352,255A
;  CURRENT FILING DATE:  2003-01-28
;  PRIOR APPLICATION NUMBER: US 60/352,245
;  PRIOR FILING DATE: 2002-01-29
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Double-stranded product DNA
US-10-352-255A-24

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 7.2e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17


RESULT 449
US-10-676-849-18
; Sequence 18, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-18

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTG 17
```

```
RESULT 450
US-10-676-849-18
; Sequence 18, Application US/10676849
; Publication No. US20050164203A9
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-18

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTG 17


RESULT 451
US-10-676-849-19/c
; Sequence 19, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-19

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:||
Db         17 TGTGTGTGTGTGTGTGG 1


RESULT 452
US-10-676-849-19/c
; Sequence 19, Application US/10676849
; Publication No. US20050164203A9
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-19

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 7.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:||
Db         17 TGTGTGTGTGTGTGTGG 1


RESULT 453
US-10-712-633-1
; Sequence 1, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FAC
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-1
```

Query Match 0.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          9 UCCUCUCGGCUCCUCCC 25
              |||||||||||||||||
Db          1 UCCUCUCGGCUCCUCCC 17
```

RESULT 454
US-09-904-744-1/c
; Sequence 1, Application US/09904744
; Patent No. US20020150905A1
; GENERAL INFORMATION:
; APPLICANT: Barbera-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; TITLE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-1

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 11.8%; Pred. No. 6.9e+02;
Matches 2; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db         18 TTTTTTTTTTTTTTTCC 2
```

RESULT 455
US-09-994-311-7
; Sequence 7, Application US/09994311
; Publication No. US20030082556A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/09/994,311
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-7

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17
```

RESULT 456
US-10-333-461-18
; Sequence 18, Application US/10333461
; Publication No. US20030165952A1
; GENERAL INFORMATION:
; APPLICANT: Global Genomics AB
; APPLICANT: Linnarsson, Sten
; APPLICANT: Ernfors, Patrik
; APPLICANT: Bauren, Goran
; TITLE OF INVENTION: Methods for analysis and identification of transcribed
; TITLE OF INVENTION: genes, and fingerprinting
; FILE REFERENCE: smwfp5941752
; CURRENT APPLICATION NUMBER: US/10/333,461
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: GB 0018016.6
; PRIOR FILING DATE: 2000-07-21
; PRIOR APPLICATION NUMBER: US 60/219,925
; PRIOR FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-333-461-18

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17
```

RESULT 457
US-10-352-253A-18
; Sequence 18, Application US/10352253A
; Publication No. US20030175908A1
; GENERAL INFORMATION:
; APPLICANT: Linnarsson, Sten
; APPLICANT: Ernfors, Patrik
; APPLICANT: Bauren, Goran
; APPLICANT: Metsis, Ats
; APPLICANT: Pihlak, Arno
; APPLICANT: Montelius, Andreas
; TITLE OF INVENTION: Methods And Means For Manipulating Nucleic Acid
; FILE REFERENCE: 620-234
; CURRENT APPLICATION NUMBER: US/10/352,253A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,215
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-253A-18

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUUC 6362
:::::::::::::::::|
Db 1 TTTTTTTTTTTTTTTTC 17

RESULT 458
US-10-352-255A-18
; Sequence 18, Application US/10352255A
; Publication No. US20030215839A1
; GENERAL INFORMATION:
; APPLICANT: LONNERBERG, Peter
; APPLICANT: OLDIN, Mats
; APPLICANT: LINNARSSON, Sten
; APPLICANT: ERNFORS, Patrik
; TITLE OF INVENTION: Methods and Means for Identification of Gene Features
; FILE REFERENCE: 620-235
; CURRENT APPLICATION NUMBER: US/10/352,255A
; CURRENT FILING DATE: 2003-01-28
; PRIOR APPLICATION NUMBER: US 60/352,245
; PRIOR FILING DATE: 2002-01-29
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Double-stranded product DNA
US-10-352-255A-18

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUUC 6362
:::::::::::::::::|
Db 1 TTTTTTTTTTTTTTTTC 17

RESULT 459
US-10-669-962-28
; Sequence 28, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-28

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUUC 6362
:::::::::::::::::|
Db 2 TTTTTTTTTTTTTTTTC 18

RESULT 460
US-10-872-984-7
; Sequence 7, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-7

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 5.9%; Pred. No. 6.9e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUUC 6362
:::::::::::::::::|
Db 1 TTTTTTTTTTTTTTTTC 17

RESULT 461
US-10-941-717A-22
; Sequence 22, Application US/10941717A
; Publication No. US20060057592A1
; GENERAL INFORMATION:
; APPLICANT: Griep, Mark
; APPLICANT: Hinrichs, Steven
; APPLICANT: Koepsell, Scott
; APPLICANT: Sayood, Khalid
; APPLICANT: Takacs, James M.
; TITLE OF INVENTION: Methods for Identifying Primase
; TITLE OF INVENTION: Trinucleotide Initiation Sites and Identification of
; TITLE OF INVENTION: Inhibitors of Primase Activity
; FILE REFERENCE: UNMC 63204
; CURRENT APPLICATION NUMBER: US/10/941,717A
; CURRENT FILING DATE: 2004-09-15
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic sequence
US-10-941-717A-22

Query Match 0.2%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |||||||||||||||||
Db          2 GUGUGUGUGUGUGUGUG 18


RESULT 462
US-10-941-717A-25
; Sequence 25, Application US/10941717A
; Publication No. US20060057592A1
; GENERAL INFORMATION:
;  APPLICANT: Griep, Mark
;  APPLICANT:  Hinrichs, Steven
;  APPLICANT:  Koepsell, Scott
;  APPLICANT:  Sayood, Khalid
;  APPLICANT:  Takacs, James M.
;  TITLE OF INVENTION: Methods for Identifying Primase
;  TITLE OF INVENTION:  Trinucleotide Initiation Sites and Identification of
;  TITLE OF INVENTION:  Inhibitors of Primase Activity
;  FILE REFERENCE: UNMC 63204
;  CURRENT APPLICATION NUMBER: US/10/941,717A
;  CURRENT FILING DATE:  2004-09-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence
US-10-941-717A-25

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 6.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTG 18


RESULT 463
US-10-941-717A-36
; Sequence 36, Application US/10941717A
; Publication No. US20060057592A1
; GENERAL INFORMATION:
;  APPLICANT: Griep, Mark
;  APPLICANT:  Hinrichs, Steven
;  APPLICANT:  Koepsell, Scott
;  APPLICANT:  Sayood, Khalid
;  APPLICANT:  Takacs, James M.
;  TITLE OF INVENTION: Methods for Identifying Primase
;  TITLE OF INVENTION:  Trinucleotide Initiation Sites and Identification of
;  TITLE OF INVENTION:  Inhibitors of Primase Activity
;  FILE REFERENCE: UNMC 63204
;  CURRENT APPLICATION NUMBER: US/10/941,717A
;  CURRENT FILING DATE:  2004-09-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 36
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-941-717A-36

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 6.9e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |||||||||||||||||

Db          2 GUGUGUGUGUGUGUGUG 18


RESULT 464
US-10-800-487-162
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;  TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/148 (MBHB04-218)
;  CURRENT APPLICATION NUMBER: US/10/800,487
;  CURRENT FILING DATE:  2004-03-15
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-15
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 438
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-800-487-162

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 6.7e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              |||||||||||||||||
Db          3 UUUUUUUUUUUUUUUUC 19


RESULT 465
US-10-800-487-328/c
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;  TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/148 (MBHB04-218)
;  CURRENT APPLICATION NUMBER: US/10/800,487
;  CURRENT FILING DATE:  2004-03-15
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-15
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
```

```
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/427,160
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 438
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-800-487-328

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 6.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db         17 TTTTTTTTTTTTTTTTC 1


RESULT 466
US-10-923-181-162
; Sequence 162, Application US/10923181
; Publication No. US20050187174A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;  TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/221 (MBHB04-218-A)
;  CURRENT APPLICATION NUMBER: US/10/923,181
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/800,487
;  PRIOR FILING DATE: 2004-03-15
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: PCT/US04/13456
;  PRIOR FILING DATE: 2004-04-30
;  PRIOR APPLICATION NUMBER: US 10/780,447
;  PRIOR FILING DATE: 2004-02-13
;  PRIOR APPLICATION NUMBER: US 60/292,217
;  PRIOR FILING DATE: 2001-05-18
;  PRIOR APPLICATION NUMBER: US 60/362,016
;  PRIOR FILING DATE: 2002-03-06
;  PRIOR APPLICATION NUMBER: US 60/306,883
;  PRIOR FILING DATE: 2001-07-20
;  PRIOR APPLICATION NUMBER: US 60/311,865
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: US 10/727,780
;  PRIOR FILING DATE: 2003-12-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 458
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-923-181-162

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 6.7e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              |||||||||||||||||
Db          3 UUUUUUUUUUUUUUUUC 19


RESULT 467
US-10-923-181-328/c
; Sequence 328, Application US/10923181
; Publication No. US20050187174A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;  TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;  TITLE OF INVENTION:  Acid (siNA)
;  FILE REFERENCE: 400/221 (MBHB04-218-A)
;  CURRENT APPLICATION NUMBER: US/10/923,181
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/800,487
;  PRIOR FILING DATE: 2004-03-15
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: PCT/US04/13456
;  PRIOR FILING DATE: 2004-04-30
;  PRIOR APPLICATION NUMBER: US 10/780,447
;  PRIOR FILING DATE: 2004-02-13
;  PRIOR APPLICATION NUMBER: US 60/292,217
;  PRIOR FILING DATE: 2001-05-18
;  PRIOR APPLICATION NUMBER: US 60/362,016
;  PRIOR FILING DATE: 2002-03-06
;  PRIOR APPLICATION NUMBER: US 60/306,883
;  PRIOR FILING DATE: 2001-07-20
;  PRIOR APPLICATION NUMBER: US 60/311,865
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: US 10/727,780
;  PRIOR FILING DATE: 2003-12-03
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 458
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-181-328

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 6.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db         17 TTTTTTTTTTTTTTTTC 1


RESULT 468
US-09-005-243-34
```

```
; Sequence 34, Application US/09005243
; Patent No. US20020018763A1
; GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/005,243
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/34465
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-005-243-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 6.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTC 19


RESULT 469
US-09-224-683-34
; Sequence 34, Application US/09224683
; Patent No. US20020031491A1
; GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 6.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTC 19
```

```
RESULT 470
US-10-175-608-34
; Sequence 34, Application US/10175608
; Publication No. US20040181044A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/175,608
;             FILING DATE: 16-Oct-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/635,249
;             FILING DATE: 07-AUG-2000
;             APPLICATION NUMBER: 09/486,546
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 09/589,701
;             FILING DATE: 10-OCT-1991
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/35199
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 34:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-175-608-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 6.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19
```

```
RESULT 471
US-10-353-783-34
; Sequence 34, Application US/10353783
; Publication No. US20050261175A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/353,783
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/448,729
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 34:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-353-783-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 6.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 472
US-10-620-642-34
```

```
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
;  GENERAL INFORMATION:
;       APPLICANT: Zsebo, Krisztina M.
;                  Bosselman, Robert A.
;                  Suggs, Sidney V.
;                  Martin, Francis H.
;       TITLE OF INVENTION: Stem Cell Factor
;       NUMBER OF SEQUENCES: 104
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;            STREET: 6300 Sears Tower, 233 South Wacker Drive
;            CITY: Chicago
;            STATE: Illinois
;            COUNTRY: United States of America
;            ZIP: 60606-6402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/620,642
;            FILING DATE: 16-Jul-2003
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/10/175,608
;            FILING DATE: 16-Oct-2002
;            APPLICATION NUMBER: 09/635,249
;            FILING DATE: 07-AUG-2000
;            APPLICATION NUMBER: 09/486,546
;            FILING DATE: 24-MAY-1995
;            APPLICATION NUMBER: 08/172,329
;            FILING DATE: 21-DEC-1993
;            APPLICATION NUMBER: 07/982,255
;            FILING DATE: 25-NOV-1992
;            APPLICATION NUMBER: 07/684,535
;            FILING DATE: 10-APR-1991
;            APPLICATION NUMBER: 09/589,701
;            FILING DATE: 10-OCT-1991
;            APPLICATION NUMBER: 07/573,616
;            FILING DATE: 24-AUG-1990
;            APPLICATION NUMBER: 07/537,198
;            FILING DATE: 11-JUN-1990
;            APPLICATION NUMBER: 07/422,383
;            FILING DATE: 16-OCT-1989
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Clough, David W.
;            REGISTRATION NUMBER: 36,107
;            REFERENCE/DOCKET NUMBER: 01017/35199
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 312/474-6300
;            TELEFAX: 312/474-0448
;            TELEX: <Unknown>
;  INFORMATION FOR SEQ ID NO: 34:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 6.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 473
US-09-775-479-14
; Sequence 14, Application US/09775479
; Publication No. US20040067197A1
; GENERAL INFORMATION:
;  APPLICANT: LECLERC, Guy
;  APPLICANT:  MARTEL, R,mi
;  TITLE OF INVENTION: RADIOLABELED DNA CARRIER, METHOD OF
;  TITLE OF INVENTION:  RADIOLABELED DNA CARRIER, METHOD OF PREPARATION AND
;  TITLE OF INVENTION:  THERAPEUTIC USES THEREOF
;  FILE REFERENCE: 12168-1US-2
;  CURRENT APPLICATION NUMBER: US/09/775,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: 09/318,106
;  PRIOR FILING DATE: 1999-05-24
;  PRIOR APPLICATION NUMBER: 08/756,728
;  PRIOR FILING DATE: 1996-11-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 14
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-09-775-479-14

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   11.8%;  Pred. No. 6.2e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db          4 TTTTTTTTTTTTTTCC 20


RESULT 474
US-10-410-031-188
; Sequence 188, Application US/10410031
; Publication No. US20040010817A1
; GENERAL INFORMATION:
;  APPLICANT: Shockey, Jay M.
;  APPLICANT:  Schnurr, Judy
;  APPLICANT:  Browse, John A.
;  TITLE OF INVENTION: Plant Acyl-CoA Synthetases
;  FILE REFERENCE: DOW-07654
;  CURRENT APPLICATION NUMBER: US/10/410,031
;  CURRENT FILING DATE:  2003-04-09
;  NUMBER OF SEQ ID NOS: 191
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-410-031-188

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   5.9%;  Pred. No. 6.2e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          5 TTTTTTTTTTTTTTTTC 21


RESULT 475
US-10-786-720-11541
; Sequence 11541, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
```

```
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11541
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11541

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 6.2e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              |||||||||||||||||
Db          4 UGUGUGUGUGUGUGUGU 20


RESULT 476
US-10-845-667-868/c
; Sequence 868, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Conditions Associated With Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-091
;  CURRENT APPLICATION NUMBER: US/10/845,667
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1506
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 868
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-845-667-868

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   52.9%;  Pred. No. 6.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:||
Db         21 TGTGTGTGTGTGTGTGG 5


RESULT 477
US-10-866-388A-6
; Sequence 6, Application US/10866388A
; Publication No. US20050170367A1
; GENERAL INFORMATION:
;  APPLICANT: QUAKE, STEPHEN R.
;  APPLICANT:  BUZBY, PHILIP R.
;  TITLE OF INVENTION: FLORESCENTLY LABLED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS
;  TITLE OF INVENTION:  THEREOF FOR SEQUENCING NUCLEIC ACIDS
;  FILE REFERENCE: HEL-008
;  CURRENT APPLICATION NUMBER: US/10/866,388A
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: 60/477,426
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/477,429
;  PRIOR FILING DATE: 2003-06-10
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Hypothetical
;   OTHER INFORMATION: nucleotide sequence
US-10-866-388A-6

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 6.2e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              |||||||||||||||||
Db          5 UUUUUUUUUUUUUUUUC 21


RESULT 478
US-10-973-783-1249/c
; Sequence 1249, Application US/10973783
; Publication No. US20050164246A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Lung Cancer with Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-100
;  CURRENT APPLICATION NUMBER: US/10/973,783
;  CURRENT FILING DATE:  2004-10-25
;  PRIOR APPLICATION NUMBER: US 10/845,667
;  PRIOR FILING DATE: 2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1513
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1249
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe sequence (ASO2)
US-10-973-783-1249

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   52.9%;  Pred. No. 6.2e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:||
Db         21 TGTGTGTGTGTGTGTGG 5


RESULT 479
US-10-301-832-122/c
; Sequence 122, Application US/10301832
; Publication No. US20040102390A1
; GENERAL INFORMATION:
;  APPLICANT: Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF NOTCH3 EXPRESSION
;  FILE REFERENCE: RTS-0414
;  CURRENT APPLICATION NUMBER: US/10/301,832
;  CURRENT FILING DATE:  2002-11-21
;  NUMBER OF SEQ ID NOS: 155
; SEQ ID NO 122
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-301-832-122

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
```

```
  Best Local Similarity   70.0%;  Pred. No. 6.7e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6115 GCAGCGGCUUUUGUGGAAGA 6134
              ||||||||: ::|: |||||
Db         20 GCAGCGGCTGTTGTTGAAGA 1


RESULT 480
US-10-301-832-46
; Sequence 46, Application US/10301832
; Publication No. US20040102390A1
; GENERAL INFORMATION:
;  APPLICANT: Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF NOTCH3 EXPRESSION
;  FILE REFERENCE: RTS-0414
;  CURRENT APPLICATION NUMBER: US/10/301,832
;  CURRENT FILING DATE:  2002-11-21
;  NUMBER OF SEQ ID NOS: 155
; SEQ ID NO 46
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-301-832-46

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 6.7e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6115 GCAGCGGCUUUUGUGGAAGA 6134
              ||||||||: ::|: |||||
Db          1 GCAGCGGCTGTTGTTGAAGA 20


RESULT 481
US-10-667-236-41/c
; Sequence 41, Application US/10667236
; Publication No. US20050060764A1
; GENERAL INFORMATION:
;  APPLICANT: Susan Gregory
;  TITLE OF INVENTION: MOUSE MODEL FOR BONE METABOLISM
;  FILE REFERENCE: 23546-8149/BIOL0019US
;  CURRENT APPLICATION NUMBER: US/10/667,236
;  CURRENT FILING DATE:  2003-09-17
;  NUMBER OF SEQ ID NOS: 358
; SEQ ID NO 41
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-667-236-41

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7515 CCAUGAAAAUGCAAAUUAUC 7534
              |||:|||||:||| |:: :|
Db         20 CCATGAAAATGCAGATTTTC 1


RESULT 482
US-10-831-286A-35908
; Sequence 35908, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35908
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Bacillus lentus
US-10-831-286A-35908

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 6.7e+02;
  Matches   16;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5346 AAGGGAAGACCCCGUCUCUA 5365
              |||||||||||| |:|:| |
Db          1 AAGGGAAGACCCTGTCTCCA 20


RESULT 483
US-10-840-590-1187
; Sequence 1187, Application US/10840590
; Publication No. US20050233341A1
; GENERAL INFORMATION:
;  APPLICANT: ROTH, RICHARD B.
;  APPLICANT:  NELSON, MATTHEW ROBERTS
;  APPLICANT:  KAMMERER, STEFAN M.
;  APPLICANT:  BRAUN, ANDREAS
;  APPLICANT:  HOYAL-WRIGHTSON, CAROLYN R.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING RISK OF MELANOMA AND TREATMENTS THEREOF
;  FILE REFERENCE: SEQ-4061-CP
;  CURRENT APPLICATION NUMBER: US/10/840,590
;  CURRENT FILING DATE:  2004-05-05
;  PRIOR APPLICATION NUMBER: 60/489,703
;  PRIOR FILING DATE: 2003-07-23
;  NUMBER OF SEQ ID NOS: 1638
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1187
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-840-590-1187

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 6.7e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1844 UCUACAUUUGCAUAGCUUCC 1863
              :|:|| :::|||: ||::||
Db          1 TCTACTTTTGCATTGCTTCC 20


RESULT 484
US-10-944-274-41/c
; Sequence 41, Application US/10944274
; Publication No. US20050148533A1
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  APPLICANT:  Kathleen Myers
;  APPLICANT:  Joshua Finger
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: MODULATION OF RANKL EXPRESSION
;  FILE REFERENCE: 23546-08148/RTS-0618US
```

```
;  CURRENT APPLICATION NUMBER: US/10/944,274
;  CURRENT FILING DATE:  2004-09-17
;  NUMBER OF SEQ ID NOS: 355
; SEQ ID NO 41
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-944-274-41

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7515 CCAUGAAAAUGCAAAUUAUC 7534
              |||:|||||:||| |:: :|
Db         20 CCATGAAAATGCAGATTTTC 1


RESULT 485
US-11-003-941A-157/c
; Sequence 157, Application US/11003941A
; Publication No. US20050208021A1
; GENERAL INFORMATION:
;  APPLICANT: Calos, Michele
;  TITLE OF INVENTION: METHODS OF UNIDIRECTIONAL, SITE-SPECIFIC
;  TITLE OF INVENTION:  INTEGRATION INTO A GENOME, COMPOSITIONS AND KITS FOR
;  TITLE OF INVENTION:  PRACTICING THE SAME
;  FILE REFERENCE: POET-001
;  CURRENT APPLICATION NUMBER: US/11/003,941A
;  CURRENT FILING DATE:  2004-12-03
;  PRIOR APPLICATION NUMBER: PCT/US03/17702
;  PRIOR FILING DATE: 2003-06-03
;  PRIOR APPLICATION NUMBER: 60/385,933
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/386,325
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/385,934
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/385,929
;  PRIOR FILING DATE: 2002-06-04
;  PRIOR APPLICATION NUMBER: 60/386,597
;  PRIOR FILING DATE: 2002-06-04
;  NUMBER OF SEQ ID NOS: 216
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Bacteriophage Phi-C31
US-11-003-941A-157

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 6.7e+02;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4247 ACUCCACCCCACCCAUCUAG 4266
              ||:||||| ||||||:|: |
Db         20 ACTCCACCTCACCCATCTGG 1


RESULT 486
US-11-051-720-1244/c
; Sequence 1244, Application US/11051720
; Publication No. US20060046257A1
; GENERAL INFORMATION:
;  APPLICANT: Compugen Ltd
;  TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS
;  TITLE OF INVENTION:  THEREOF FOR DIAGNOSIS OF LUNG CANCER
;  FILE REFERENCE: 1847.1002
;  CURRENT APPLICATION NUMBER: US/11/051,720
;  CURRENT FILING DATE:  2005-01-27
;  NUMBER OF SEQ ID NOS: 1780
; SEQ ID NO 1244
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-051-720-1244

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 6.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 487
US-11-051-720-450/c
; Sequence 450, Application US/11051720
; Publication No. US20060046257A1
; GENERAL INFORMATION:
;  APPLICANT: Compugen Ltd
;  TITLE OF INVENTION: NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHOD
;  TITLE OF INVENTION:  THEREOF FOR DIAGNOSIS OF LUNG CANCER
;  FILE REFERENCE: 1847.1002
;  CURRENT APPLICATION NUMBER: US/11/051,720
;  CURRENT FILING DATE:  2005-01-27
;  NUMBER OF SEQ ID NOS: 1780
; SEQ ID NO 450
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-051-720-450

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 6.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 488
US-11-069-908-6716
; Sequence 6716, Application US/11069908
; Publication No. US20050266432A1
; GENERAL INFORMATION:
;  APPLICANT: OLIPHANT, ARNOLD
;  APPLICANT:  MURRAY, SARAH
;  TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
;  TITLE OF INVENTION:  CONDITIONS
;  FILE REFERENCE: 029011-0402
;  CURRENT APPLICATION NUMBER: US/11/069,908
;  CURRENT FILING DATE:  2005-02-28
;  PRIOR APPLICATION NUMBER: 60/547,823
;  PRIOR FILING DATE: 2004-02-26
;  NUMBER OF SEQ ID NOS: 7098
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6716
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-6716

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 6.7e+02;
  Matches    9;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       6974 GUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|  :|:|:|:
Db          1 GTGTGTGTGTGCCTGTGTGT 20


RESULT 489
US-11-184-065A-25
; Sequence 25, Application US/11184065A
; Publication No. US20060019923A1
; GENERAL INFORMATION:
;  APPLICANT: Davis, Heather L
;  APPLICANT:  McCluskie, Michael J
;  APPLICANT:  Drane, Debra P
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR INDUCING INNATE IMMUNE RESPONSES
;  FILE REFERENCE: C1037.70056US01
;  CURRENT APPLICATION NUMBER: US/11/184,065A
;  CURRENT FILING DATE:  2005-07-18
;  PRIOR APPLICATION NUMBER: US 60/589,258
;  PRIOR FILING DATE: 2004-07-18
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: where all linkages are phosphorothioate linkages
US-11-184-065A-25

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   5.0%;  Pred. No. 6.7e+02;
  Matches    1;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6341 UCUACUUUUUUUUUUUUUUU 6360
              : : |:::::::::::::::::
Db          1 TGTGCTTTTTTTTTTTTTTT 20


RESULT 490
US-10-252-155-373/c
; Sequence 373, Application US/10252155
; Publication No. US20040068096A1
; GENERAL INFORMATION:
;  APPLICANT: Bristol-Myers Squibb Company
;  TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT
;  TITLE OF INVENTION:  MULTI-DRUG RESISTANT PROTEINS
;  FILE REFERENCE: D0152 NP
;  CURRENT APPLICATION NUMBER: US/10/252,155
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US 60/324,172
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: US 60/333,700
;  PRIOR FILING DATE: 2001-11-27
;  NUMBER OF SEQ ID NOS: 783
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 373
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-252-155-373

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   80.0%;  Pred. No. 6.4e+02;
  Matches   16;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4728 AUGUGAGGAGGAAAAGGAAA 4747
              |:|:| ||||||| ||||||
Db         20 ATGTGTGGAGGAACAGGAAA 1


RESULT 491
US-10-252-155-374/c
; Sequence 374, Application US/10252155
; Publication No. US20040068096A1
; GENERAL INFORMATION:
;  APPLICANT: Bristol-Myers Squibb Company
;  TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT
;  TITLE OF INVENTION:  MULTI-DRUG RESISTANT PROTEINS
;  FILE REFERENCE: D0152 NP
;  CURRENT APPLICATION NUMBER: US/10/252,155
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US 60/324,172
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: US 60/333,700
;  PRIOR FILING DATE: 2001-11-27
;  NUMBER OF SEQ ID NOS: 783
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 374
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-252-155-374

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   80.0%;  Pred. No. 6.4e+02;
  Matches   16;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4728 AUGUGAGGAGGAAAAGGAAA 4747
              |:|:| ||||||| ||||||
Db         20 ATGTGTGGAGGAACAGGAAA 1


RESULT 492
US-10-734-372A-23/c
; Sequence 23, Application US/10734372A
; Publication No. US20040219600A1
; GENERAL INFORMATION:
;  APPLICANT: St. Jude Children's Research Hospital
;  APPLICANT:  University of Tennessee Research Corporation
;  APPLICANT:  Smeyne, Richard J.
;  APPLICANT:  Tharp, Ruby
;  APPLICANT:  Smeyne, Michelle
;  APPLICANT:  Williams, Robert
;  TITLE OF INVENTION: Method for Determining Sensitivity to Environmental Toxins and
;  TITLE OF INVENTION:  Susceptibility to Parkinson's Disease
;  FILE REFERENCE: 023868.43877
;  CURRENT APPLICATION NUMBER: US/10/734,372A
;  CURRENT FILING DATE:  2003-12-12
;  PRIOR APPLICATION NUMBER: 60/433,437
;  PRIOR FILING DATE: 2002-12-13
;  NUMBER OF SEQ ID NOS: 71
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Not a naturally occurring sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(21)
;   OTHER INFORMATION: GSTmu1 (chr3) 3' primer
US-10-734-372A-23

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5662 GGGAGACAGGGUAGGAAAGG 5681
              |||||||||  | ||||||||
Db         21 GGGAGACAGAGGAGGAAAGG 2
```

```
RESULT 493
US-10-751-736-22059
; Sequence 22059, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22059
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-22059

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 UUACGUCACCUAACAUCACU 747
              ||| |||||||||||||| |
Db          1 UUAGGUCACCUAACAUCAAU 20


RESULT 494
US-10-751-736-22320
; Sequence 22320, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22320
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-22320

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 UUACGUCACCUAACAUCACU 747
              ||| |||||||||||||| |
Db          2 UUAGGUCACCUAACAUCAAU 21


RESULT 495
US-10-751-736-22434
; Sequence 22434, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22434
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-22434

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 UUACGUCACCUAACAUCACU 747
              ||| |||||||||||||| |
Db          1 UUAGGUCACCUAACAUCAAU 20


RESULT 496
US-10-751-736-23745/c
; Sequence 23745, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23745
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-23745

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   60.0%;  Pred. No. 6.4e+02;
  Matches   12;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7314 UUUCCUAAAAUAAACUCAAA 7333
              :::||: |||:||||:| ||
Db         20 TTTCCTGAAATAAACTCTAA 1


RESULT 497
US-10-751-736-38570
; Sequence 38570, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
```

```
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38570
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-38570

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6970 AACUGUGUGUGUGUGUGU 6989
              | |||||||||||||||| |
Db          2 AUCUGUGUGUGUGUGUUU 21


RESULT 498
US-10-751-736-50831
; Sequence 50831, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50831
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-50831

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3186 UGUUGAGGAAGAGGAGGAUU 3205
              || |||||||||||| ||||
Db          1 UGAUGAGGAAGAGGAAGAUU 20


RESULT 499
US-10-751-736-52499
; Sequence 52499, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52499
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-52499

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6993
              | |||||||| |||||||||
Db          1 GAGUGUGUGUUUGUGUGUGU 20


RESULT 500
US-10-758-636A-29/c
; Sequence 29, Application US/10758636A
; Publication No. US20050089876A1
; GENERAL INFORMATION:
;  APPLICANT: Han, et al.
;  TITLE OF INVENTION: HUMAN E3 ALPHA UBIQUITIN LIGASE FAMILY
;  FILE REFERENCE: 01017/35966C
;  CURRENT APPLICATION NUMBER: US/10/758,636A
;  CURRENT FILING DATE:  2004-01-15
;  PRIOR APPLICATION NUMBER: US 09/724,126
;  PRIOR FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 60/187,911
;  PRIOR FILING DATE: 2000-03-08
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-758-636A-29

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 6.4e+02;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1436 CUGAAGAGGAUGCAGGGAAU 1455
              |:|||| | |:||||||||:
Db         21 CTGAAGTGCATGCAGGGAAT 2


RESULT 501
US-10-758-672A-29/c
; Sequence 29, Application US/10758672A
; Publication No. US20040185037A1
; GENERAL INFORMATION:
;  APPLICANT: Han, et al.
;  TITLE OF INVENTION: HUMAN E3 ALPHA UBIQUITIN LIGASE FAMILY
;  FILE REFERENCE: 01017/35966B
;  CURRENT APPLICATION NUMBER: US/10/758,672A
;  CURRENT FILING DATE:  2004-01-15
;  PRIOR APPLICATION NUMBER: US 09/724,126
;  PRIOR FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 60/187,911
;  PRIOR FILING DATE: 2000-03-08
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-10-758-672A-29

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 6.4e+02;
```

```
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1436 CUGAAGAGGAUGCAGGGAAU 1455
              |:|||| | |:||||||||:
Db         21 CTGAAGTGCATGCAGGGAAT 2


RESULT 502
US-10-770-726-17546
; Sequence 17546, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17546
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17546

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   70.0%;  Pred. No. 6.4e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3645 CAUGCUGGACUGCUGGCACA 3664
              ||:||:||||:| :|||| |
Db          1 CATGCTGGACTGTTGGCAGA 20


RESULT 503
US-10-770-726-28434
; Sequence 28434, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28434
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-28434

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6993
              |||||  ||||||||||||||
Db          1 GUGUGCAUGUGUGUGUGU 20


RESULT 504
US-10-770-726-37634
; Sequence 37634, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATIN
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37634
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-37634

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   70.0%;  Pred. No. 6.4e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3439 AAAUGGAUGGCUCCCGAAUC 3458
              |||:|||:|||:|| || :|
Db          1 AAATGGATGGCTCCAGAGTC 20


RESULT 505
US-10-770-726-38651
; Sequence 38651, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATIN
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38651
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-38651

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   70.0%;  Pred. No. 6.4e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3439 AAAUGGAUGGCUCCCGAAUC 3458
              |||:|||:|||:|| || :|
Db          2 AAATGGATGGCTCCAGAGTC 21


RESULT 506
US-10-770-726-38652
; Sequence 38652, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATIN
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38652
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
```

```
US-10-770-726-38652

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3440 AAUGGAUGGCUCCCGAAUCU 3459
              |||||||||||| || |||
Db          1 AAUGGAUGGCUCCAGAGUCU 20


RESULT 507
US-10-786-720-11526
; Sequence 11526, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11526
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11526

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |||||  |||||||||||||
Db          1 GUGUGCAUGUGUGUGUGUGU 20


RESULT 508
US-10-786-720-11529
; Sequence 11529, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11529
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11529

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |||||||  ||||||||||
Db          1 GUGUGUGCAUGUGUGUGUGU 20


RESULT 509
US-10-786-720-11532
; Sequence 11532, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11532
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11532

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |||||||||  |||||||||
Db          1 GUGUGUGUGCAUGUGUGUGU 20


RESULT 510
US-10-786-720-11544
; Sequence 11544, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11544
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11544

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |||  ||||||||||||||||
Db          1 GUGGAUGUGUGUGUGUGUGU 20


RESULT 511
US-10-847-918-5942/c
; Sequence 5942, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Be, Xiaobing
;  APPLICANT:  Liu, Wei
;  APPLICANT:  Slonim, Donna
;  APPLICANT:  Howes, Steve
;  TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
;  FILE REFERENCE: 031896-026000 (AM101264)
;  CURRENT APPLICATION NUMBER: US/10/847,918
;  CURRENT FILING DATE:  2004-05-19
;  PRIOR APPLICATION NUMBER: US 60/471,729
```

```
;  PRIOR FILING DATE: 2003-05-20
;  NUMBER OF SEQ ID NOS: 14937
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5942
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-847-918-5942

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   80.0%;  Pred. No. 6.4e+02;
  Matches   16;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2186 AAAUCCUCCAGAAGAAAGAA 2205
              || :||:|||| ||||||||
Db         21 AATTCCTCCAGGAGAAAGAA 2


RESULT 512
US-10-847-918-5943
; Sequence 5943, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Be, Xiaobing
;  APPLICANT:  Liu, Wei
;  APPLICANT:  Slonim, Donna
;  APPLICANT:  Howes, Steve
;  TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
;  FILE REFERENCE: 031896-026000 (AM101264)
;  CURRENT APPLICATION NUMBER: US/10/847,918
;  CURRENT FILING DATE:  2004-05-19
;  PRIOR APPLICATION NUMBER: US 60/471,729
;  PRIOR FILING DATE: 2003-05-20
;  NUMBER OF SEQ ID NOS: 14937
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5943
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-847-918-5943

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 6.4e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2189 UCCUCCAGAAGAAAGAAAUU 2208
              |||||||| |||||||| ||
Db          2 UCCUCCAGGAGAAAGAACUU 21


RESULT 513
US/10/763/c
; Sequence 112, Application US/10763039A
; Publication No. US20050239082A1
; GENERAL INFORMATION:
;  APPLICANT: Jarrell, Kevin A.
;  APPLICANT:  Vishwanath, Prashanth
;  APPLICANT:  Smith, Temple
;  APPLICANT:  Short, Glenn F.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0036
;  CURRENT APPLICATION NUMBER: US/10/763,039A
;  CURRENT FILING DATE:  2004-01-22
;  NUMBER OF SEQ ID NOS: 166
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
;   LENGTH: 70
;   TYPE: DNA
;   ORGANISM: Oligonucleotides identified according to the present invention as alien to
US/10/763,039A-112

  Query Match             0.2%;  Score 16.6;  DB 1;  Length 70;
  Best Local Similarity   48.7%;  Pred. No. 2.7e+02;
  Matches   19;  Conservative    6;  Mismatches   14;  Indels    0;  Gaps    0;

Qy       3760 CCAAUCAAUGCCAUACUGACAGGAAAUAGUGGGUUUACA 3798
              || |: | :|| |:||: | ||| | :   | | : |||
Db         48 CCGATAAGTGCGATACTCAAAGGTACTTCCGCGGTGACA 10


RESULT 514
US-09-263-959-983/c
; Sequence 983, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  983:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-983

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   44.4%;  Pred. No. 7.8e+02;
  Matches    8;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|: :|:|:|:|:|
Db         18 TGTGTGTATGTGTGTGTG 1


RESULT 515
US-09-994-311-5
; Sequence 5, Application US/09994311
; Publication No. US20030082556A1
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/09/994,311
;  CURRENT FILING DATE:  2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
```

```
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-5

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   5.6%;  Pred. No. 7.8e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              :::::::::::::::::  |
Db          1 TTTTTTTTTTTTTTTTGC 18


RESULT 516
US-10-085-906-135
; Sequence 135, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
;  APPLICANT: Ying, Vincent
;  APPLICANT:  Wu, Paul
;  APPLICANT:  Gray, Gary S.
;  TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
;  TITLE OF INVENTION:  COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
;  FILE REFERENCE: GNN-5343CP2
;  CURRENT APPLICATION NUMBER: US/10/085,906
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: US 60/126,215
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 09/534,061
;  PRIOR FILING DATE: 2000-03-24
;  PRIOR APPLICATION NUMBER: PCT/US00/07938
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 545
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 135
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-085-906-135

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 7.8e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
              |:|:| |:|:|:|:|:|:
Db          1 GTGTGCGTGTGTGTGTGT 18


RESULT 517
US-10-399-019-2/c
; Sequence 2, Application US/10399019
; Publication No. US20030186920A1
; GENERAL INFORMATION:
;  APPLICANT: Institute de Cardiologie de Montreal
;  APPLICANT:  Sirois, Martin G
;  TITLE OF INVENTION: Antisense Oligonucleotides Directed
;  TITLE OF INVENTION:  Toward Mammalian VEGF Receptor Genes and Uses Thereof
;  FILE REFERENCE: 817-103PCTa
;  CURRENT APPLICATION NUMBER: US/10/399,019
;  CURRENT FILING DATE:  2003-04-10
;  PRIOR APPLICATION NUMBER: 09/687,239
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-399-019-2

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 7.8e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3475 UACAGCACCAAGAGCGAC 3492
              :| ||||||||||||||||
Db         18 TATAGCACCAAGAGCGAC 1


RESULT 518
US-10-872-984-5
; Sequence 5, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/10/872,984
;  CURRENT FILING DATE:  2004-06-21
;  PRIOR APPLICATION NUMBER: US/09/994,311
;  PRIOR FILING DATE: 2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   5.6%;  Pred. No. 7.8e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              :::::::::::::::::  |
Db          1 TTTTTTTTTTTTTTTTGC 18


RESULT 519
US-09-917-138-2/c
; Sequence 2, Application US/09917138
; Patent No. US20020031776A1
; GENERAL INFORMATION:
;  APPLICANT: TULLIS, Richard
;  APPLICANT:  STEIFFEL, Jerome
;  TITLE OF INVENTION: ENZYMATIC LABELIING AND DETECTION OF DNA
;  TITLE OF INVENTION:  HYBRIDIZATION PROBES
;  FILE REFERENCE: 24730-2207B
;  CURRENT APPLICATION NUMBER: US/09/917,138
;  CURRENT FILING DATE:  2001-07-26
;  PRIOR APPLICATION NUMBER: 09/580,358
;  PRIOR FILING DATE: 2000-05-25
;  PRIOR APPLICATION NUMBER: 60/136,545
;  PRIOR FILING DATE: 1999-05-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 19
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: Combined DNA/RNA
US-09-917-138-2

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   5.6%;  Pred. No. 7.5e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
              | ::::::::::::::::
Db         19 ATTTTTTTTTTTTTTTTT 2


RESULT 520
US-10-517-544-62/c
; Sequence 62, Application US/10517544
; Publication No. US20050250100A1
; GENERAL INFORMATION:
;  APPLICANT: RIKEN
;  APPLICANT:  KABUSHIKI KAISHA DNAFORM
;  TITLE OF INVENTION: Method for utilizing the 5'end of mRNA for cloning and analysis
;  FILE REFERENCE: 1336(PCT)
;  CURRENT APPLICATION NUMBER: US/10/517,544
;  CURRENT FILING DATE:  2004-12-10
;  PRIOR APPLICATION NUMBER: JP 2002-171851
;  PRIOR FILING DATE: 2002-06-12
;  PRIOR APPLICATION NUMBER: JP 2002-235294
;  PRIOR FILING DATE: 2002-08-12
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: tag3
US-10-517-544-62

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   5.6%;  Pred. No. 7.5e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
              | ::::::::::::::::
Db         19 AGTTTTTTTTTTTTTTTT 2


RESULT 521
US-10-683-990-194
; Sequence 194, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-683-990-194

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 7.5e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUUCCAAA 6366
              |||||||||||||||| |
Db          1 UUUUUUUUUUUUUUCCACA 18


RESULT 522
US-10-683-990-97/c
; Sequence 97, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97
;   LENGTH: 19
;   TYPE: RNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-683-990-97

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   22.2%;  Pred. No. 7.5e+02;
  Matches    4;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCCAAA 6366
              :::::::::::::|||  |
Db         19 TTTTTTTTTTTTTCCACA 2


RESULT 523
US-10-922-761-194
; Sequence 194, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/223  (MBHB 04-736-A)
;  CURRENT APPLICATION NUMBER: US/10/922,761
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/683,990
;  PRIOR FILING DATE: 2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2004-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 320
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-922-761-194

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 7.5e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCCAAA 6366
              |||||||||||||||||  |
Db          1 UUUUUUUUUUUUUCCACA 18


RESULT 524
US-10-922-761-97/c
; Sequence 97, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/223  (MBHB 04-736-A)
;  CURRENT APPLICATION NUMBER: US/10/922,761
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/683,990
;  PRIOR FILING DATE: 2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2004-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 320
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 97
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-922-761-97

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   22.2%;  Pred. No. 7.5e+02;
  Matches    4;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCCAAA 6366
              :::::::::::::|||  |
Db         19 TTTTTTTTTTTTTCCACA 2


RESULT 525
US-10-189-266-119
; Sequence 119, Application US/10189266
; Publication No. US20040006029A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CELL DIVISION CYCLE 2 EXPRESSION
;  FILE REFERENCE: RTS-0384
;  CURRENT APPLICATION NUMBER: US/10/189,266
;  CURRENT FILING DATE:  2002-07-02
;  NUMBER OF SEQ ID NOS: 150
; SEQ ID NO 119
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-189-266-119

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   55.6%;  Pred. No. 7.2e+02;
  Matches   10;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGCCCG 3383
```

```
                :||::::||||::||| |
Db          2 TGATTTTGGCCTTGCCAG 19


RESULT 526
US-10-189-266-52/c
; Sequence 52, Application US/10189266
; Publication No. US20040006029A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CELL DIVISION CYCLE 2 EXPRESSION
;  FILE REFERENCE: RTS-0384
;  CURRENT APPLICATION NUMBER: US/10/189,266
;  CURRENT FILING DATE:  2002-07-02
;  NUMBER OF SEQ ID NOS: 150
; SEQ ID NO 52
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-189-266-52

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   55.6%;  Pred. No. 7.2e+02;
  Matches   10;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGCCCG 3383
                :||::::||||::||| |
Db         19 TGATTTTGGCCTTGCCAG 2


RESULT 527
US-10-289-762-4759
; Sequence 4759, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4759
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-4759

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   77.8%;  Pred. No. 7.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3156 CGGCUUUCAGGAAGAUAA 3173
                ||||: :||||||||:||
Db          1 CGGCTATCAGGAAGATAA 18


RESULT 528
US-10-297-056-18/c
; Sequence 18, Application US/10297056
; Publication No. US20060030045A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Isis Pharmaceuticals, Inc.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
;  FILE REFERENCE: RTSP-0150
;  CURRENT APPLICATION NUMBER: US/10/297,056
;  CURRENT FILING DATE:  2002-12-02
;  PRIOR APPLICATION NUMBER: 09/593,711
;  PRIOR FILING DATE: 2000-06-13
;  NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 18
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-297-056-18

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 7.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         24 CCCGGCAGCGGCGGCGGC 41
              |||||||||||||||| ||
Db         20 CCCGGCAGCGGCGGCAGC 3


RESULT 529
US-10-357-488-26
; Sequence 26, Application US/10357488
; Publication No. US20030194730A1
; GENERAL INFORMATION:
;  APPLICANT: Centre For DNA Fingerprinting and Diagnostics
;  TITLE OF INVENTION: No. US20030194730A1el FISSR-PCR primers and markers and a method
;  TITLE OF INVENTION:  primers and markers for identifying genetic constitution and br
;  TITLE OF INVENTION:  varities.
;  FILE REFERENCE: 782-indian
;  CURRENT APPLICATION NUMBER: US/10/357,488
;  CURRENT FILING DATE:  2003-02-04
;  PRIOR APPLICATION NUMBER: 260/MAS/2002
;  PRIOR FILING DATE: 2002-04-08
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-26

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   44.4%;  Pred. No. 7.2e+02;
  Matches    8;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
                |:|:|:|:|:|:|:|: :
Db          1 GTGTGTGTGTGTGTGTAT 18


RESULT 530
US-10-831-286A-33197
; Sequence 33197, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33197
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Yersinia ruckeri
US-10-831-286A-33197

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 7.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6647 AAUAGCACUGAAAAUUGA 6664
              ||:|||||:||| |::||
Db          2 AATAGCACTGAACATTGA 19


RESULT 531
US-10-831-286A-34234
; Sequence 34234, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34234
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Yersinia ruckeri
US-10-831-286A-34234

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 7.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6647 AAUAGCACUGAAAAUUGA 6664
              ||:|||||:||| |::||
Db          3 AATAGCACTGAACATTGA 20


RESULT 532
US-10-831-286A-40853
; Sequence 40853, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40853
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Yersinia ruckeri
US-10-831-286A-40853

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   72.2%;  Pred. No. 7.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6647 AAUAGCACUGAAAAUUGA 6664
              ||:|||||:||| |::||
Db          1 AATAGCACTGAACATTGA 18


RESULT 533
US/10/763
; Sequence 126, Application US/10763039A
; Publication No. US20050239082A1
; GENERAL INFORMATION:
;  APPLICANT: Jarrell, Kevin A.
;  APPLICANT:  Vishwanath, Prashanth
;  APPLICANT:  Smith, Temple
;  APPLICANT:  Short, Glenn F.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0036
;  CURRENT APPLICATION NUMBER: US/10/763,039A
;  CURRENT FILING DATE:  2004-01-22
;  NUMBER OF SEQ ID NOS: 166
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 126
;   LENGTH: 70
;   TYPE: DNA
;   ORGANISM: Oligonucleotides identified according to the present invention as alien tc
US/10/763,039A-126

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 70;
  Best Local Similarity   35.3%;  Pred. No. 2.8e+02;
  Matches   12;  Conservative   11;  Mismatches   11;  Indels    0;  Gaps    0;

Qy       1390 GCUCGCUAUUUGACUCGUGGCUACUCGUUAAUUA 1423
              ||: | : :::|| :|| | :| : |:: |: |
Db         35 GCTTGATGTTTGAGTCGCAGATATTAGTTTATAA 68


RESULT 534
US-09-981-397A-1
; Sequence 1, Application US/09981397A
; Publication No. US20030082519A1
; GENERAL INFORMATION:
;  APPLICANT: Axxima Pharmaceuticals AG
;  APPLICANT:  Schubart, Daniel
;  APPLICANT:  Habenberger, Peter
;  APPLICANT:  Stein-Gerlach, Matthias
;  APPLICANT:  Bevec, Dorian
;  TITLE OF INVENTION: Cellular Kinases Involved in Cytomegalovirus Infection and their
;  TITLE OF INVENTION:  Inhibition
;  FILE REFERENCE: AXM-004.1 US
;  CURRENT APPLICATION NUMBER: US/09/981,397A
;  CURRENT FILING DATE:  2002-06-28
;  PRIOR APPLICATION NUMBER: 60/240,750
;  PRIOR FILING DATE: 2000-10-16
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic polyT primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: n = a,c,g or t
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: v = a,g or c
US-09-981-397A-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 18;
```

```
  Best Local Similarity   0.0%;  Pred. No. 8.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          1 TTTTTTTTTTTTTTTV 17


RESULT 535
US-09-371-307-85
; Sequence 85, Application US/09371307A
; Patent No. US20020053095A1
; GENERAL INFORMATION:
;  APPLICANT: Brown, Sherri M.
;  APPLICANT: Heck, Gregory R.
;  APPLICANT: Piller, Kenneth J.
;  APPLICANT: Kishore, Ganesh M.
;  APPLICANT: Elich, Tedd D.
;  APPLICANT: Logusch, Eugene W.
;  APPLICANT: Rao, Sudabathula
;  APPLICANT: Ream, Joel E.
;  APPLICANT: Logusch, Sherry J.
;  TITLE OF INVENTION: Methods for controlling gibberellin levels
;  FILE REFERENCE: MOBT:216
;  CURRENT APPLICATION NUMBER: US/09/371,307A
;  CURRENT FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 89
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 85
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Primer
US-09-371-307-85

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTV 19


RESULT 536
US-10-103-614A-4/c
; Sequence 4, Application US/10103614A
; Publication No. US20030059796A1
; GENERAL INFORMATION:
;  APPLICANT: SALMAN AL-MAHMOOD
;  TITLE OF INVENTION: METHOD FOR IDENTIFYING NOVEL GENES INVOLVED IN THE
;  TITLE OF INVENTION:  REGULATION OF ANGIOGENESIS, STUDY OF SAID GENES AND USE
;  TITLE OF INVENTION:  THEREOF FOR THERAPEUTIC PURPOSES
;  FILE REFERENCE: 1071-02
;  CURRENT APPLICATION NUMBER: US/10/103,614A
;  CURRENT FILING DATE:  2002-08-22
;  PRIOR APPLICATION NUMBER: PCT/FR00/02607
;  PRIOR FILING DATE: 2000-09-20
;  PRIOR APPLICATION NUMBER: FR 99/11790
;  PRIOR FILING DATE: 1999-09-21
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: a, t, c or g
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: a, t, c or g
US-10-103-614A-4

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db         18 TTTTTTTTTTTTTTTB 2


RESULT 537
US-10-176-884-44
; Sequence 44, Application US/10176884
; Publication No. US20030126642A1
; GENERAL INFORMATION:
;  APPLICANT: Fischer, Robert
;  APPLICANT:  Kinoshita, Tetsu
;  APPLICANT:  Yadegari, Ramin
;  APPLICANT:  Gehring, Mary
;  APPLICANT:  Okamuro, Jack
;  APPLICANT:  Dang, Van-Dinh
;  APPLICANT:  The Regents of the University of California
;  APPLICANT:  Ceres, Inc.
;  TITLE OF INVENTION: Compositions and Methods for Modulating Plant
;  TITLE OF INVENTION:  Development
;  FILE REFERENCE: 02307O-116710US
;  CURRENT APPLICATION NUMBER: US/10/176,884
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: US 60/300,506
;  PRIOR FILING DATE: 2001-06-22
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo(dT)-18
;   OTHER INFORMATION: primer, oligo dTV
US-10-176-884-44

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTV 19


RESULT 538
US-10-177-478-1
; Sequence 1, Application US/10177478
; Publication No. US20030165903A1
; GENERAL INFORMATION:
;  APPLICANT: Dang, Van-Dinh
;  APPLICANT:  Okamuro, Jack
;  TITLE OF INVENTION: Chimeric Histone Acetyltransferase
;  TITLE OF INVENTION:  Polypeptides
;  FILE REFERENCE: 11696-037001
;  CURRENT APPLICATION NUMBER: US/10/177,478
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: U.S. 60/300,135
;  PRIOR FILING DATE: 2001-06-22
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-177-478-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 539
US-10-182-230-196
; Sequence 196, Application US/10182230
; Publication No. US20030215817A1
; GENERAL INFORMATION:
;  APPLICANT: Leonardi, Amedeo
;  APPLICANT:  Sartani, Abraham
;  APPLICANT:  Glass, James R.
;  APPLICANT:  Sutcliffe, J. Gregor
;  APPLICANT:  Hasel, Karl W.
;  TITLE OF INVENTION: Modulation of Gene Expression in Formation of Fatty Atherosclerot
;  TITLE OF INVENTION:  Lesions
;  FILE REFERENCE: 216019-143
;  CURRENT APPLICATION NUMBER: US/10/182,230
;  CURRENT FILING DATE:  2003-02-03
;  PRIOR APPLICATION NUMBER: 60/177,963
;  PRIOR FILING DATE: 2000-01-25
;  NUMBER OF SEQ ID NOS: 197
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 196
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: 3' sequencing primer for dire
;   OTHER INFORMATION: ct sequencing
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: v stands for a, c, or g
US-10-182-230-196

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 540
US-10-401-321-85
; Sequence 85, Application US/10401321
; Publication No. US20030233679A1
; GENERAL INFORMATION:
;  APPLICANT: Brown, Sherri M.
;  APPLICANT:  Heck, Gregory R.
;  APPLICANT:  Piller, Kenneth J.
;  APPLICANT:  Kilshore, Ganesh M.
;  APPLICANT:  Elich, Tedd D.
;  APPLICANT:  Logusch, Eugene W.
;  APPLICANT:  Rao, Sudabathula
;  APPLICANT:  Ream, Joel E.
;  APPLICANT:  Logusch, Sherry J.
;  APPLICANT:  Baerson, Scott R.
;  TITLE OF INVENTION: Methods for Controlling Gibberellin Levels
;  FILE REFERENCE: 11899.0216.DVUS01 (MOBT:216--1)
;  CURRENT APPLICATION NUMBER: US/10/401,321
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 89
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-401-321-85

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 541
US-10-950-095-73
; Sequence 73, Application US/10950095
; Publication No. US20050223434A1
; GENERAL INFORMATION:
;  APPLICANT: ALEXANDROV, Nickolai, et. al.
;  TITLE OF INVENTION: NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR
;  TITLE OF INVENTION:  MODIFYING PLANT CHARACTERISTICS
;  FILE REFERENCE: 2750-1578PUS2
;  CURRENT APPLICATION NUMBER: US/10/950,095
;  CURRENT FILING DATE:  2004-09-23
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo(dT)18 primer
US-10-950-095-73

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 542
US-10-950-321-1
; Sequence 1, Application US/10950321
; Publication No. US20050223422A1
; GENERAL INFORMATION:
;  APPLICANT: COOK, Zhihong et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1577PUS2
;  CURRENT APPLICATION NUMBER: US/10/950,321
;  CURRENT FILING DATE:  2004-09-23
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligo(dT)18 primer
US-10-950-321-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 543
US-10-957-569-1
; Sequence 1, Application US/10957569
; Publication No. US20050246785A1
; GENERAL INFORMATION:
;  APPLICANT: COOK, Zhihong et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1577PUS3
;  CURRENT APPLICATION NUMBER: US/10/957,569
;  CURRENT FILING DATE:  2004-09-30
;  PRIOR APPLICATION NUMBER: US 10/950,321
;  PRIOR FILING DATE: 2004-09-23
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligo(dT)18 primer
US-10-957-569-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 544
US-10-965-470-1
; Sequence 1, Application US/10965470
; Publication No. US20050204429A1
; GENERAL INFORMATION:
;  APPLICANT: PENNELL, Roger
;  APPLICANT:  APUYA, Nestor
;  APPLICANT:  MEDRANO, Leonard
;  APPLICANT:  FELDMANN, Kenneth
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1580PUS2
;  CURRENT APPLICATION NUMBER: US/10/965,470
;  CURRENT FILING DATE:  2004-10-13
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide primer
US-10-965-470-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 545
US-10-981-334-67
; Sequence 67, Application US/10981334
; Publication No. US20060008816A1
; GENERAL INFORMATION:
;  APPLICANT: LU, Yu-Ping et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1581PUS2
;  CURRENT APPLICATION NUMBER: US/10/981,334
;  CURRENT FILING DATE:  2004-11-04
;  NUMBER OF SEQ ID NOS: 68
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo(dT)18 primer
US-10-981-334-67

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 546
US-11-010-239-132
; Sequence 132, Application US/11010239
; Publication No. US20060015970A1
; GENERAL INFORMATION:
;  APPLICANT: Roger PENNELL
;  APPLICANT:  Jack OKAMURO
;  APPLICANT:  Richard SCHNEEBERGER
;  APPLICANT:  Yiwen FANG
;  APPLICANT:  Shing KWOK
;  APPLICANT:  Diane JOFUKU
;  APPLICANT:  Edward A. KIEGLE
;  APPLICANT:  Jonathan DONSON
;  APPLICANT:  Nestor APUYA
;  TITLE OF INVENTION: NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR
;  TITLE OF INVENTION:  MODIFYING PLANT CHARACTERISTICS
;  FILE REFERENCE: 2750-1585PUS2
;  CURRENT APPLICATION NUMBER: US/11/010,239
;  CURRENT FILING DATE:  2004-12-09
;  PRIOR APPLICATION NUMBER: US 60/529,352
;  PRIOR FILING DATE: 2003-12-12
;  NUMBER OF SEQ ID NOS: 133
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo(dT)18 primer
US-11-010-239-132

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 547
US-11-051-456-44
; Sequence 44, Application US/11051456
; Publication No. US20050229270A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Fischer, Robert
;  APPLICANT:  Kinoshita, Tetsu
;  APPLICANT:  Yadegari, Ramin
;  APPLICANT:  Gehring, Mary
;  APPLICANT:  Okamuro, Jack
;  APPLICANT:  Dang, Van-Dinh
;  APPLICANT:  The Regents of the University of California
;  APPLICANT:  Ceres, Inc.
;  TITLE OF INVENTION: Compositions and Methods for Modulating Plant
;  TITLE OF INVENTION:  Development
;  FILE REFERENCE: 02307O-116710US
;  CURRENT APPLICATION NUMBER: US/11/051,456
;  CURRENT FILING DATE:  2005-02-04
;  PRIOR APPLICATION NUMBER: US/10/176,884
;  PRIOR FILING DATE: 2002-06-21
;  PRIOR APPLICATION NUMBER: US 60/300,506
;  PRIOR FILING DATE: 2001-06-22
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo(dT)-18
;   OTHER INFORMATION: primer, oligo dTV
US-11-051-456-44

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 548
US-11-114-406-1
; Sequence 1, Application US/11114406
; Publication No. US20050266559A1
; GENERAL INFORMATION:
;  APPLICANT: KWOK, Shing et al.
;  TITLE OF INVENTION: SHADE RESPONSIVE PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINA
;  TITLE OF INVENTION:  AND USES THEREOF
;  FILE REFERENCE: 2750-2140PUS2
;  CURRENT APPLICATION NUMBER: US/11/114,406
;  CURRENT FILING DATE:  2005-04-25
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide primer
US-11-114-406-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 549
US-09-152-059-70
; Sequence 70, Application US/09152059
; Patent No. US20020068708A1
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165 (71994)
;  CURRENT APPLICATION NUMBER: US/09/152,059
;  CURRENT FILING DATE:  1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-152-059-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 550
US-09-438-486-131/c
; Sequence 131, Application US/09438486
; Publication No. US20030009019A1
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. US20030009019A1el Telomerase
;    NUMBER OF SEQUENCES:  223
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/438,486
;      FILING DATE:  12-NOV-1999
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/851,843
;      FILING DATE:  06-MAY-1997
;      CLASSIFICATION:  536
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/846,017
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/844,419
;      FILING DATE:  18-APR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/724,643
;      FILING DATE:  01-OCT-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Apple,  Randolph T.
;      REGISTRATION NUMBER:  36,429
;      REFERENCE/DOCKET NUMBER:  015389-002931US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  131:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-438-486-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 551
US-09-739-928-2
; Sequence 2, Application US/09739928
; Patent No. US20020052482A1
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/739,928
;             FILING DATE: 11-May-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;             APPLICATION NUMBER: US 09/507,345
;             FILING DATE: 18-FEB-2000
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003510US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 2:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-739-928-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 552
US-09-766-253-131/c
; Sequence 131, Application US/09766253
; Publication No. US20020187471A1
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. US20020187471A1el Telomerase
;        NUMBER OF SEQUENCES: 171
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/766,253
;             FILING DATE: 19-Jan-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/846,017
;             FILING DATE: 1997-04-25
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002920US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 131:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 131:
```

```
US-09-766-253-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 553
US-09-805-296D-9
; Sequence 9, Application US/09805296D
; Patent No. US20020155989A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1US
;  CURRENT APPLICATION NUMBER: US/09/805,296D
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Construct
US-09-805-296D-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 554
US-09-843-676-131/c
; Sequence 131, Application US/09843676
; Patent No. US20020164786A1
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. US20020164786A1el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/843,676
;             FILING DATE: 26-Apr-2001
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/854,050
;             FILING DATE: 09-MAY-1997
;             APPLICATION NUMBER: US 08/846,017
;             FILING DATE: 25-APR-1997
;             APPLICATION NUMBER: US 08/844,419
;             FILING DATE: 18-APR-1997
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002930US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 131:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-09-843-676-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 555
US-09-895-585-9
; Sequence 9, Application US/09895585
; Publication No. US20020081725A1
; GENERAL INFORMATION:
;  APPLICANT: Tsang, Wen-Ghih
;  APPLICANT:  Zheng, Tianli
;  APPLICANT:  Huang, Chang Jiang
;  APPLICANT:  AmCyte, Inc.
;  TITLE OF INVENTION: Culturing Pancreatic Stem Cells Having a Specified,
;  TITLE OF INVENTION:  Intermediate Stage of Development
;  FILE REFERENCE: 021164-000100US
;  CURRENT APPLICATION NUMBER: US/09/895,585
;  CURRENT FILING DATE:  2002-12-10
;  PRIOR APPLICATION NUMBER: US 60/215,634
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 60/246,306
;  PRIOR FILING DATE: 2000-11-06
;  PRIOR APPLICATION NUMBER: US 60/291,787
;  PRIOR FILING DATE: 2001-05-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo-(dT)-16
```

```
US-09-895-585-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 556
US-10-008-029-70
; Sequence 70, Application US/10008029
; Publication No. US20030134808A1
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165-C2(71994)
;  CURRENT APPLICATION NUMBER: US/10/008,029
;  CURRENT FILING DATE:  2001-11-05
;  PRIOR APPLICATION NUMBER: 09/152,059
;  PRIOR FILING DATE: 1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-008-029-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 557
US-10-053-758-131/c
; Sequence 131, Application US/10053758
; Publication No. US20030032075A1
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. US20030032075A1el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/053,758
;             FILING DATE: 18-Jan-2002
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/854,050
;             FILING DATE: 09-MAY-1997
;             APPLICATION NUMBER: US 08/851,843
;             FILING DATE: 06-MAY-1997
;             APPLICATION NUMBER: US 08/846,017
;             FILING DATE: 25-APR-1997
;             APPLICATION NUMBER: US 08/844,419
;             FILING DATE: 18-APR-1997
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002930US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 131:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-10-053-758-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 558
US-10-054-295-131/c
; Sequence 131, Application US/10054295
; Publication No. US20030044953A1
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. US20030044953A1el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
```

```
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,295
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 131:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 16 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-10-054-295-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 559
US-10-054-611-131/c
; Sequence 131, Application US/10054611
; Publication No. US20030059787A1
;   GENERAL INFORMATION:
;         APPLICANT: Cech, Thomas R.
;                    Lingner, Joachim
;                    Nakamura, Toru
;                    Chapman, Karen B.
;                    Morin, Gregg B.
;                    Harley, Calvin
;                    Andrews, William H.
;         TITLE OF INVENTION: No. US20030059787A1el Telomerase
;         NUMBER OF SEQUENCES: 225
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Townsend and Townsend and Crew LLP
;              STREET: Two Embarcadero Center, 8th Floor
;              CITY: San Francisco
;              STATE: California
;              COUNTRY: United States of America
;              ZIP: 94111
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,611
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 131:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 16 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-10-054-611-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 560
US-10-072-975-9
; Sequence 9, Application US/10072975
; Publication No. US20030059789A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1.1US
;  CURRENT APPLICATION NUMBER: US/10/072,975
;  CURRENT FILING DATE:  2002-02-09
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  PRIOR APPLICATION NUMBER: 09/805,296
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/0811
;  PRIOR FILING DATE: 2001-03-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Construct
US-10-072-975-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
```

```
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 561
US-10-092-885-27
; Sequence 27, Application US/10092885
; Publication No. US20030190618A1
; GENERAL INFORMATION:
;  APPLICANT: SAMAL, BABRU
;  APPLICANT:  LI, YUAN
;  APPLICANT:  HERMIDA, LEANDRO C.
;  APPLICANT:  HOPPA, NANCY L.
;  APPLICANT:  JOHE, KARL K.
;  TITLE OF INVENTION: METHOD FOR GENERATING FIVE PRIME BIASED TANDEM TAG
;  TITLE OF INVENTION:  LIBRARIES OF CDNAS
;  FILE REFERENCE: 0109015/026
;  CURRENT APPLICATION NUMBER: US/10/092,885
;  CURRENT FILING DATE:  2002-03-06
;  NUMBER OF SEQ ID NOS: 60
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-092-885-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 9.1e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGU 6989
              |:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGT 16


RESULT 562
US-10-121-641D-1/c
; Sequence 1, Application US/10121641D
; Publication No. US20050175993A1
; GENERAL INFORMATION:
;  APPLICANT: LARGE SCALE BIOLOGY CORPORATION
;  APPLICANT:  WEI, CHIA-LIN
;  TITLE OF INVENTION: METHOD FOR MAKING FULL-LENGTH CODING SEQUENCE CDNA LIBRARIES
;  FILE REFERENCE: LSB.206.NPUS00
;  CURRENT APPLICATION NUMBER: US/10/121,641D
;  CURRENT FILING DATE:  2002-04-12
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Tail Sequence
US-10-121-641D-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 563
US-10-164-915-2/c
; Sequence 2, Application US/10164915
; Publication No. US20030148391A1
; GENERAL INFORMATION:
;  APPLICANT: Salafsky, Joshua S.
;  TITLE OF INVENTION: Method Using a Surface-Selective No. US20030148391A1linear Optic
;  TITLE OF INVENTION:  for Detection of Interactions Involving a Conformational Change
;  FILE REFERENCE: 11100-035-999
;  CURRENT APPLICATION NUMBER: US/10/164,915
;  CURRENT FILING DATE:  2002-06-06
;  PRIOR APPLICATION NUMBER: 60/253,862
;  PRIOR FILING DATE: 2000-11-29
;  PRIOR APPLICATION NUMBER: 60/260,249
;  PRIOR FILING DATE: 2001-01-08
;  PRIOR APPLICATION NUMBER: 60/265,775
;  PRIOR FILING DATE: 2001-02-01
;  PRIOR APPLICATION NUMBER: 60/278,941
;  PRIOR FILING DATE: 2001-01-27
;  NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 2
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Aritificial Sequence: Oligonucleotide structure f
;   OTHER INFORMATION: molecular beacon
US-10-164-915-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   6.2%;  Pred. No. 9.1e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db         16 TTTTTTTTTTTTTTTC 1


RESULT 564
US-10-203-780-9
; Sequence 9, Application US/10203780
; Publication No. US20030165914A1
; GENERAL INFORMATION:
;  APPLICANT: CUZIN, MARC
;  APPLICANT:  PELTIE, PHILIPPE
;  APPLICANT:  FONTECAVE, MARC
;  APPLICANT:  DECOUT, JEAN-LUC
;  APPLICANT:  DUEYMES, CECILE
;  TITLE OF INVENTION: ANALYSIS OF BIOLOGICAL TARGETS USING A BIOCHIP COMPRISING A FLUO
;  TITLE OF INVENTION:  MARKER
;  FILE REFERENCE: 226286US0XPCT
;  CURRENT APPLICATION NUMBER: US/10/203,780
;  CURRENT FILING DATE:  2002-11-25
;  PRIOR APPLICATION NUMBER: PCT/FR01/00516
;  PRIOR FILING DATE: 2001-02-22
;  PRIOR APPLICATION NUMBER: FR 00 02236
;  PRIOR FILING DATE: 2000-02-23
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: t is modified with a covalent linkage to flavin
US-10-203-780-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db          1 TTTTTTTTTTTTTTT 16


RESULT 565
US-10-208-357-22/c
; Sequence 22, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
;  APPLICANT: Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION: Peptide Acceptor Ligation Methods
;  FILE REFERENCE: 50036/031002
;  CURRENT APPLICATION NUMBER: US/10/208,357
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US/09/619,103
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: 60/145,834
;  PRIOR FILING DATE: 1999-07-27
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 566
US-10-208-650-70
; Sequence 70, Application US/10208650
; Publication No. US20030144231A1
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165-C2(71994)
;  CURRENT APPLICATION NUMBER: US/10/208,650
;  CURRENT FILING DATE:  2002-07-29
;  PRIOR APPLICATION NUMBER: US/10/008,029
;  PRIOR FILING DATE: 2001-11-05
;  PRIOR APPLICATION NUMBER: 09/152,059
;  PRIOR FILING DATE: 1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-208-650-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 567
US-10-227-001-21
; Sequence 21, Application US/10227001
; Publication No. US20030113765A1
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Afonina, Irina Aleksandrovna
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: Hybridization-Triggered Fluorescent
;  TITLE OF INVENTION:  Detection of Nucleic Acids
;  FILE REFERENCE: 17682A-004210US
;  CURRENT APPLICATION NUMBER: US/10/227,001
;  CURRENT FILING DATE:  2002-08-21
;  PRIOR APPLICATION NUMBER: US 09/428,236
;  PRIOR FILING DATE: 1999-10-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 21
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: R2 (ODN) of fluorophore-MGB-ODN
;   OTHER INFORMATION: conjugate
US-10-227-001-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 568
US-10-360-275-9
; Sequence 9, Application US/10360275
; Publication No. US20040014644A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Choob, Mikhail
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: AM102.P.1.1.1US
;  CURRENT APPLICATION NUMBER: US/10/360,275
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US 10/072,975
;  PRIOR FILING DATE: 2002-02-09
;  PRIOR APPLICATION NUMBER: US 09/805,296
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  NUMBER OF SEQ ID NOS: 37
```

```
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Construct
US-10-360-275-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 569
US-10-398-483-10/c
; Sequence 10, Application US/10398483
; Publication No. US20040166499A1
; GENERAL INFORMATION:
;  APPLICANT: Hayashizaki, Yoshihide
;  TITLE OF INVENTION: Oligonucleotide linkers comprising a variable cohesive portion an
;  TITLE OF INVENTION:  for the preparation of polynucleotide libraries by using said li
;  FILE REFERENCE: 2870-0247P
;  CURRENT APPLICATION NUMBER: US/10/398,483
;  CURRENT FILING DATE:  2003-04-04
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence used in the preparation of a full-length cDNA library
US-10-398-483-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 570
US-10-755-118-94
; Sequence 94, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
;  FILE REFERENCE: ISIS-5427
;  CURRENT APPLICATION NUMBER: US/10/755,118
;  CURRENT FILING DATE:  2004-01-09
;  PRIOR APPLICATION NUMBER: US 08/462,977
;  PRIOR FILING DATE: 1995-06-05
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  PRIOR APPLICATION NUMBER: PCT/EP92/01219
;  PRIOR FILING DATE: 1992-05-22
;  PRIOR APPLICATION NUMBER: DN 510/92
;  PRIOR FILING DATE: 1992-04-15
;  PRIOR APPLICATION NUMBER: DN 987/91
;  PRIOR FILING DATE: 1991-05-24
;  PRIOR APPLICATION NUMBER: DN 986/91
;  PRIOR FILING DATE: 1991-05-24
;  NUMBER OF SEQ ID NOS: 157
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-755-118-94

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 571
US-10-776-099-9
; Sequence 9, Application US/10776099
; Publication No. US20040141957A1
; GENERAL INFORMATION:
;  APPLICANT: Tsang, Wen-Ghih
;  APPLICANT:  Zheng, Tianli
;  APPLICANT:  Huang, Chang Jiang
;  APPLICANT:  AmCyte, Inc.
;  TITLE OF INVENTION: Culturing Pancreatic Stem Cells Having a Specified,
;  TITLE OF INVENTION:  Intermediate Stage of Development
;  FILE REFERENCE: 021164-000100US
;  CURRENT APPLICATION NUMBER: US/10/776,099
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: US/09/895,585
;  PRIOR FILING DATE: 2002-12-10
;  PRIOR APPLICATION NUMBER: US 60/215,634
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 60/246,306
;  PRIOR FILING DATE: 2000-11-06
;  PRIOR APPLICATION NUMBER: US 60/291,787
;  PRIOR FILING DATE: 2001-05-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo-(dT)-16
US-10-776-099-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 572
US-11-132-650-70
; Sequence 70, Application US/11132650
; Publication No. US20050287566A1
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165-C2(71994)
;  CURRENT APPLICATION NUMBER: US/11/132,650
```

```
;  CURRENT FILING DATE:  2005-05-18
;  PRIOR APPLICATION NUMBER: 09/152,059
;  PRIOR FILING DATE: 1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-11-132-650-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 573
US-11-145-005A-130/c
; Sequence 130, Application US/11145005A
; Publication No. US20060084083A1
; GENERAL INFORMATION:
;  APPLICANT: RUAN, YIJUN
;  APPLICANT:  WEI, CHIALIN
;  TITLE OF INVENTION: METHOD TO GENERATE OR DETERMINE NUCLEIC ACID TAGS
;  TITLE OF INVENTION:  CORRESPONDING TO THE TERMINAL ENDS OF DNA MOLECULES
;  TITLE OF INVENTION:  USING SEQUENCES ANALYSIS OF GENE EXPRESSION (TERMINAL
;  TITLE OF INVENTION:  SAGE)
;  FILE REFERENCE: 674175-2001
;  CURRENT APPLICATION NUMBER: US/11/145,005A
;  CURRENT FILING DATE:  2005-06-03
;  PRIOR APPLICATION NUMBER: PCT/SG03/00255
;  PRIOR FILING DATE: 2003-12-04
;  PRIOR APPLICATION NUMBER: GB 0228289.5
;  PRIOR FILING DATE: 2002-12-04
;  NUMBER OF SEQ ID NOS: 165
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 130
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-11-145-005A-130

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 9.1e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 574
US-09-090-672B-107
; Sequence 107, Application US/09090672B
; Patent No. US20020068707A1
;  GENERAL INFORMATION:
;    APPLICANT:  Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
;    APPLICANT:  Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
;    APPLICANT:  Shigemasa; Takei, Masami
;    TITLE OF INVENTION:  IgA Nephropathy-Related Genes
;    NUMBER OF SEQUENCES:  111
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fitzpatrick, Cella, Harper & Scinto
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      ZIP:  10112-3801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  Compaq PC
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WordPerfect 8.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/090,672B
;      FILING DATE:  04-JUNE-1998
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP97/04468
;      FILING DATE:  05-DEC-1997
;      APPLICATION NUMBER:  JP-8-325763
;      FILING DATE:  05-DEC-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Perry, Lawrence S.
;      REGISTRATION NUMBER:  31865
;      REFERENCE/DOCKET NUMBER:  766.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 218-2100
;      TELEFAX:  (212) 218-2200
;  INFORMATION FOR SEQ ID NO:  107:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid, synthetic DNA
US-09-090-672B-107

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 575
US-09-438-486-132
; Sequence 132, Application US/09438486
; Publication No. US20030009019A1
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. US20030009019A1el Telomerase
;    NUMBER OF SEQUENCES:  223
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
```

```
;       STREET:  Two Embarcadero Center, 8th Floor
;       CITY:  San Francisco
;       STATE:  California
;       COUNTRY:  United States of America
;       ZIP:  94111-3834
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/438,486
;       FILING DATE:  12-NOV-1999
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/851,843
;       FILING DATE:  06-MAY-1997
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/846,017
;       FILING DATE:  25-APR-1997
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/844,419
;       FILING DATE:  18-APR-1997
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/724,643
;       FILING DATE:  01-OCT-1996
;       CLASSIFICATION:  536
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Apple,  Randolph T.
;       REGISTRATION NUMBER:  36,429
;       REFERENCE/DOCKET NUMBER:  015389-002931US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 576-0200
;       TELEFAX:  (415) 576-0300
;   INFORMATION FOR SEQ ID NO:  132:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-438-486-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 576
US-09-726-096A-5
; Sequence 5, Application US/09726096A
; Publication No. US20010016652A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Back
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS4528
;  CURRENT APPLICATION NUMBER: US/09/726,096A
;  CURRENT FILING DATE:  2000-11-29
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE); phosphorothioate
;   OTHER INFORMATION: internucleoside linkage
US-09-726-096A-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 577
US-09-730-559B-109
; Sequence 109, Application US/09730559B
; Publication No. US20030207828A1
; GENERAL INFORMATION:
;  APPLICANT: ISHIWATA, TETSUYOSHI
;  APPLICANT:  SAKURADA, MIKIKO
;  APPLICANT:  KAWABATA, AYAKO
;  APPLICANT:  NAKAGAWA, SATOSHI
;  APPLICANT:  NISHI, TATSUNARI
;  APPLICANT:  KUGA, TETSURO
;  APPLICANT:  SAWADA, SHIGEMASA
;  APPLICANT:  TAKEI, MASAMI
;  APPLICANT:  SHIBATA, KENJI
;  APPLICANT:  FURUYA, AKIKO
;  TITLE OF INVENTION: IgA NEPHROPATHY-ASSOCIATED GENE
;  FILE REFERENCE: 766.21 CIP
;  CURRENT APPLICATION NUMBER: US/09/730,559B
;  CURRENT FILING DATE:  2000-12-07
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 109
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-730-559B-109

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 578
US-09-766-253-132
; Sequence 132, Application US/09766253
; Publication No. US20020187471A1
;   GENERAL INFORMATION:
;       APPLICANT: Cech, Thomas R.
;                  Lingner, Joachim
;                  Nakamura, Toru
;                  Chapman, Karen B.
;                  Morin, Gregg B.
;                  Harley, Calvin
;                  Andrews, William H.
;       TITLE OF INVENTION: No. US20020187471A1el Telomerase
;       NUMBER OF SEQUENCES: 171
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, 8th Floor
;            CITY: San Francisco
```

```
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/766,253
;             FILING DATE: 19-Jan-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/846,017
;             FILING DATE: 1997-04-25
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002920US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-766-253-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 579
US-09-843-676-132
; Sequence 132, Application US/09843676
; Patent No. US20020164786A1
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. US20020164786A1el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/843,676
;             FILING DATE: 26-Apr-2001
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/854,050
;             FILING DATE: 09-MAY-1997
;             APPLICATION NUMBER: US 08/846,017
;             FILING DATE: 25-APR-1997
;             APPLICATION NUMBER: US 08/844,419
;             FILING DATE: 18-APR-1997
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002930US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-843-676-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 580
US-09-958-221A-16
; Sequence 16, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 581
US-09-958-221A-17
; Sequence 17, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
```

```
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 582
US-09-958-221A-20/c
; Sequence 20, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 583
US-09-958-221A-21/c
; Sequence 21, Application US/09958221A
; Publication No. US20030017471A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 584
US-10-053-758-132
; Sequence 132, Application US/10053758
; Publication No. US20030032075A1
;  GENERAL INFORMATION:
;       APPLICANT: Cech, Thomas R.
;                  Lingner, Joachim
;                  Nakamura, Toru
;                  Chapman, Karen B.
;                  Morin, Gregg B.
;                  Harley, Calvin
;                  Andrews, William H.
;       TITLE OF INVENTION: No. US20030032075A1el Telomerase
;       NUMBER OF SEQUENCES: 225
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, 8th Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States of America
;            ZIP: 94111
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/053,758
;            FILING DATE: 18-Jan-2002
;            CLASSIFICATION: 536
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/854,050
;            FILING DATE: 09-MAY-1997
;            APPLICATION NUMBER: US 08/851,843
;            FILING DATE: 06-MAY-1997
;            APPLICATION NUMBER: US 08/846,017
;            FILING DATE: 25-APR-1997
;            APPLICATION NUMBER: US 08/844,419
;            FILING DATE: 18-APR-1997
;            APPLICATION NUMBER: US 08/724,643
;            FILING DATE: 01-OCT-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Apple,  Randolph T.
;            REGISTRATION NUMBER: 36,429
;            REFERENCE/DOCKET NUMBER: 015389-002930US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;  INFORMATION FOR SEQ ID NO: 132:
;       SEQUENCE CHARACTERISTICS:
```

```
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-10-053-758-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 585
US-10-054-295-132
; Sequence 132, Application US/10054295
; Publication No. US20030044953A1
;   GENERAL INFORMATION:
;         APPLICANT: Cech, Thomas R.
;                    Lingner, Joachim
;                    Nakamura, Toru
;                    Chapman, Karen B.
;                    Morin, Gregg B.
;                    Harley, Calvin
;                    Andrews, William H.
;         TITLE OF INVENTION: No. US20030044953A1el Telomerase
;         NUMBER OF SEQUENCES: 225
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Townsend and Townsend and Crew LLP
;              STREET: Two Embarcadero Center, 8th Floor
;              CITY: San Francisco
;              STATE: California
;              COUNTRY: United States of America
;              ZIP: 94111
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,295
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 132:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 17 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-10-054-295-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 586
US-10-054-611-132
; Sequence 132, Application US/10054611
; Publication No. US20030059787A1
;   GENERAL INFORMATION:
;         APPLICANT: Cech, Thomas R.
;                    Lingner, Joachim
;                    Nakamura, Toru
;                    Chapman, Karen B.
;                    Morin, Gregg B.
;                    Harley, Calvin
;                    Andrews, William H.
;         TITLE OF INVENTION: No. US20030059787A1el Telomerase
;         NUMBER OF SEQUENCES: 225
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Townsend and Townsend and Crew LLP
;              STREET: Two Embarcadero Center, 8th Floor
;              CITY: San Francisco
;              STATE: California
;              COUNTRY: United States of America
;              ZIP: 94111
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,611
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 132:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 17 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-10-054-611-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 587
US-10-117-267-5
```

```
; Sequence 5, Application US/10117267
; Publication No. US20030045698A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Ph.D., Martin A.
;  TITLE OF INVENTION: Compounds,Processes And Intermediates For Synthesis Of Mixed Back
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS-5039
;  CURRENT APPLICATION NUMBER: US/10/117,267
;  CURRENT FILING DATE:  2002-04-05
;  PRIOR APPLICATION NUMBER: 09/726,096
;  PRIOR FILING DATE: 2000-11-29
;  PRIOR APPLICATION NUMBER: 09/250,075
;  PRIOR FILING DATE: 1999-02-12
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE); phosphorothioate
;   OTHER INFORMATION: internucleoside linkage
US-10-117-267-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 588
US-10-208-357-23/c
; Sequence 23, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
;  APPLICANT: Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION: Peptide Acceptor Ligation Methods
;  FILE REFERENCE: 50036/031002
;  CURRENT APPLICATION NUMBER: US/10/208,357
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US/09/619,103
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: 60/145,834
;  PRIOR FILING DATE: 1999-07-27
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 589
US-10-220-373-8
; Sequence 8, Application US/10220373
; Publication No. US20030180743A1
; GENERAL INFORMATION:
;  APPLICANT: NAGASU, Takeshi
;  APPLICANT:  OSHIDA, Tadahiro
;  APPLICANT:  OBAYASHI, Izumi
;  APPLICANT:  MATSUI, Keiko
;  APPLICANT:  SAITO, Hirohisa
;  TITLE OF INVENTION: METHOD OF TESTING FOR ALLERGIC DISEASE
;  FILE REFERENCE: SHZ-010US
;  CURRENT APPLICATION NUMBER: US/10/220,373
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: JP 2000-61832
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Artificially
;   OTHER INFORMATION: Synthesized Primer Sequence
US-10-220-373-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 590
US-10-238-700-2794
; Sequence 2794, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Leve
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2794
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-2794

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        148 GGCGCGGGGCCGGCGG 163
              ||||||||||||||||
Db          1 GGCGCGGGGCCGGCGG 16


RESULT 591
US-10-239-734-4
; Sequence 4, Application US/10239734
; Publication No. US20040161746A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: GENOX RESEARCH, INC.
;  APPLICANT:  JAPAN AS REPRESENTED BY GENERAL DIRECTOR OF AGENCY OF NATIONAL CENTER FOR
;  APPLICANT:  CHILD HEALTH AND DEVELOPMENT
;  APPLICANT:  Matsumoto, Yoshiko
;  APPLICANT:  Tsujimoto, Gozoh
;  APPLICANT:  Nagasu, Takeshi
;  APPLICANT:  Sugita, Yuji
;  APPLICANT:  Oshida, Tadahiro
;  APPLICANT:  Imai, Yukiho
;  TITLE OF INVENTION: Method of Testing For Allergic Disease
;  FILE REFERENCE: SHIMIZU-07379
;  CURRENT APPLICATION NUMBER: US/10/239,734
;  CURRENT FILING DATE:  2002-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP01/11286
;  PRIOR FILING DATE: 2001-12-21
;  PRIOR APPLICATION NUMBER: 2000-389476 JP
;  PRIOR FILING DATE: 2000-12-21
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: "GT15C", an artificially synthesized primer sequence
US-10-239-734-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 592
US-10-324-409B-16/c
; Sequence 16, Application US/10324409B
; Publication No. US20040086880A1
; GENERAL INFORMATION:
;  APPLICANT: Sampson, et al.
;  TITLE OF INVENTION: Method of Producing Nucleic Acid Molecules with Reduced
;  TITLE OF INVENTION:  Secondary Structure
;  FILE REFERENCE: 2003309-0028
;  CURRENT APPLICATION NUMBER: US/10/324,409B
;  CURRENT FILING DATE:  2002-12-18
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Anneal Primer
US-10-324-409B-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 593
US-10-380-254-4
; Sequence 4, Application US/10380254
; Publication No. US20040038252A1
; GENERAL INFORMATION:
;  APPLICANT: Sugita et al.
;  TITLE OF INVENTION: METHOD OF TESTING FOR ALLERGIC DISEASES
;  FILE REFERENCE: 6235-64773
;  CURRENT APPLICATION NUMBER: US/10/380,254
;  CURRENT FILING DATE:  2003-03-11
;  PRIOR APPLICATION NUMBER: PCT/JP01/08246
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: JP 2000-291318
;  PRIOR FILING DATE: 2000-09-25
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:an artificially
;   OTHER INFORMATION: synthesized primer sequence
US-10-380-254-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 594
US-10-380-255-7
; Sequence 7, Application US/10380255
; Publication No. US20040023263A1
; GENERAL INFORMATION:
;  APPLICANT: Sugita et al.
;  TITLE OF INVENTION: METHOD OF TESTING FOR ALLERGIC DISEASES
;  FILE REFERENCE: 6235-64935
;  CURRENT APPLICATION NUMBER: US/10/380,255
;  CURRENT FILING DATE:  2003-03-11
;  PRIOR APPLICATION NUMBER: PCT/JP01/08247
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: JP 2000-293021
;  PRIOR FILING DATE: 2000-09-26
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:an artificially
;   OTHER INFORMATION: synthesized primer sequence
US-10-380-255-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 595
US-10-398-877-19
; Sequence 19, Application US/10398877
; Publication No. US20040058351A1
; GENERAL INFORMATION:
;  APPLICANT: Sugita, Yuji
;  APPLICANT:  Hashida, Ryoichi
;  APPLICANT:  Ogawa, Kaoru
;  APPLICANT:  Nagasu, Takeshi
;  APPLICANT:  Obayashi, Masaya
;  APPLICANT:  Saito, Hirohisa
;  TITLE OF INVENTION: Method of Testing for Allergic Diseases
```

```
;  FILE REFERENCE: SHIMIZU-07906
;  CURRENT APPLICATION NUMBER: US/10/398,877
;  CURRENT FILING DATE:  2003-04-11
;  PRIOR APPLICATION NUMBER: PCT/JP01/08574
;  PRIOR FILING DATE: 2001-09-28
;  PRIOR APPLICATION NUMBER: JP 2000-314093
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 105
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-398-877-19

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              :::::::::::::::|
Db          2 TTTTTTTTTTTTTTC 17


RESULT 596
US-10-398-885A-3
; Sequence 3, Application US/10398885A
; Publication No. US20040053282A1
; GENERAL INFORMATION:
;  APPLICANT: Sugita, Yuji
;  APPLICANT:  Hashida, Ryoichi
;  APPLICANT:  Ogawa, Kaoru
;  APPLICANT:  Nagasu, Takeshi
;  APPLICANT:  Obayashi, Masaya
;  APPLICANT:  Saito, Hirohisa
;  APPLICANT:  Takahasi, Eiki
;  TITLE OF INVENTION: Method of Testing For Allergic Diseases
;  FILE REFERENCE: SHIMIZU-07907
;  CURRENT APPLICATION NUMBER: US/10/398,885A
;  CURRENT FILING DATE:  2003-08-11
;  PRIOR APPLICATION NUMBER: PCT/JP01/08937
;  PRIOR FILING DATE: 2001-10-11
;  PRIOR APPLICATION NUMBER: JP 2000-314093
;  PRIOR FILING DATE: 2000-10-13
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-398-885A-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              :::::::::::::::|
Db          2 TTTTTTTTTTTTTTC 17


RESULT 597
US-10-408-025-5
; Sequence 5, Application US/10408025
; Publication No. US20030224423A1
; GENERAL INFORMATION:
;  APPLICANT: Matsumoto, Yoshiko
;  APPLICANT:  Imai, Yukiho
;  APPLICANT:  Yoshida, Nei
;  APPLICANT:  Oshida, Tadahiro
;  APPLICANT:  Sugita, Yuji
;  APPLICANT:  Saito, Hirohisa
;  TITLE OF INVENTION: Method of Testing for Allergic Diseases
;  FILE REFERENCE: SHIMIZU-07914
;  CURRENT APPLICATION NUMBER: US/10/408,025
;  CURRENT FILING DATE:  2003-04-03
;  PRIOR APPLICATION NUMBER: 2002-100908
;  PRIOR FILING DATE: 2002-04-03
;  PRIOR APPLICATION NUMBER: PCT/JP03/02047
;  PRIOR FILING DATE: 2003-02-25
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-408-025-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              :::::::::::::::|
Db          2 TTTTTTTTTTTTTTC 17


RESULT 598
US-10-519-122-81/c
; Sequence 81, Application US/10519122
; Publication No. US20060058252A1
; GENERAL INFORMATION:
;  APPLICANT: Clawson, Gary A.
;  APPLICANT:  Pan, Wei-Hua
;  APPLICANT:  Thiboutot, Diane
;  APPLICANT:  Christensen, Neil
;  TITLE OF INVENTION: METHODS AND MATERIALS FOR TREATING HUMAN
;  TITLE OF INVENTION:  PAPILLOMAVIRUS INFECTIONS
;  FILE REFERENCE: 14017-008US1
;  CURRENT APPLICATION NUMBER: US/10/519,122
;  CURRENT FILING DATE:  2004-12-22
;  PRIOR APPLICATION NUMBER: PCT/US03/20340
;  PRIOR FILING DATE: 2003-06-26
;  PRIOR APPLICATION NUMBER: US 60/449,066
;  PRIOR FILING DATE: 2003-02-21
;  PRIOR APPLICATION NUMBER: US 60/417,997
;  PRIOR FILING DATE: 2002-10-14
;  PRIOR APPLICATION NUMBER: US 60/391,795
;  PRIOR FILING DATE: 2002-06-26
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 81
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: exemplary sequence (5' end)
US-10-519-122-81

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 599
US-10-608-863-4
```

```
; Sequence 4, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
;  APPLICANT: Hashida, Ryoichi
;  APPLICANT:  Kagaya, Shinji
;  APPLICANT:  Yayoi, Yoshihiro
;  APPLICANT:  Sugita, Yuji
;  APPLICANT:  Saito, Hirohisa
;  TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
;  TITLE OF INVENTION:  ALLERGIC DISEASES
;  FILE REFERENCE: 3462.1003-000
;  CURRENT APPLICATION NUMBER: US/10/608,863
;  CURRENT FILING DATE:  2003-06-27
;  PRIOR APPLICATION NUMBER: JP 2002-188490
;  PRIOR FILING DATE: 2002-06-27
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Artificially
;   OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 600
US-10-676-849-16
; Sequence 16, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 601
US-10-676-849-16
; Sequence 16, Application US/10676849
; Publication No. US20050164203A9
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 602
US-10-676-849-17
; Sequence 17, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 603
US-10-676-849-17
; Sequence 17, Application US/10676849
```

```
; Publication No. US20050164203A9
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 604
US-10-676-849-20/c
; Sequence 20, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 605
US-10-676-849-20/c
; Sequence 20, Application US/10676849
; Publication No. US20050164203A9
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 606
US-10-676-849-21/c
; Sequence 21, Application US/10676849
; Publication No. US20050009038A1
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 607
US-10-676-849-21/c
; Sequence 21, Application US/10676849
; Publication No. US20050164203A9
; GENERAL INFORMATION:
```

```
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/10/676,849
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US/09/958,221
;  PRIOR FILING DATE: 2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-676-849-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 8.7e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 608
US-10-724-270-1473
; Sequence 1473, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1473
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-1473

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        148 GGCGCGGGGCCGGCGG 163
              ||||||||||||||||
Db          1 GGCGCGGGGCCGGCGG 16


RESULT 609
US-10-735-592-11
; Sequence 11, Application US/10735592
; Publication No. US20040171571A1
; GENERAL INFORMATION:
;  APPLICANT: Art, Krieg
;  APPLICANT:  Joerg, Vollmer
;  TITLE OF INVENTION: 5' CPG Nucleic Acids and Methods of Use
;  FILE REFERENCE: C1037.70038US01
;  CURRENT APPLICATION NUMBER: US/10/735,592
;  CURRENT FILING DATE:  2003-12-11
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-735-592-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 610
US-10-735-592-49
; Sequence 49, Application US/10735592
; Publication No. US20040171571A1
; GENERAL INFORMATION:
;  APPLICANT: Art, Krieg
;  APPLICANT:  Joerg, Vollmer
;  TITLE OF INVENTION: 5' CPG Nucleic Acids and Methods of Use
;  FILE REFERENCE: C1037.70038US01
;  CURRENT APPLICATION NUMBER: US/10/735,592
;  CURRENT FILING DATE:  2003-12-11
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-735-592-49

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 611
US-10-735-592-55
; Sequence 55, Application US/10735592
; Publication No. US20040171571A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Art, Krieg
;  APPLICANT:  Joerg, Vollmer
;  TITLE OF INVENTION: 5' CPG Nucleic Acids and Methods of Use
;  FILE REFERENCE: C1037.70038US01
;  CURRENT APPLICATION NUMBER: US/10/735,592
;  CURRENT FILING DATE:  2003-12-11
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 55
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-735-592-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   12.5%;  Pred. No. 8.7e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6360
              ||:::::::::::::::
Db          2 CUTTTTTTTTTTTTTT 17


RESULT 612
US-10-735-592-8
; Sequence 8, Application US/10735592
; Publication No. US20040171571A1
; GENERAL INFORMATION:
;  APPLICANT: Art, Krieg
;  APPLICANT:  Joerg, Vollmer
;  TITLE OF INVENTION: 5' CPG Nucleic Acids and Methods of Use
;  FILE REFERENCE: C1037.70038US01
;  CURRENT APPLICATION NUMBER: US/10/735,592
;  CURRENT FILING DATE:  2003-12-11
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-735-592-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 613
US-10-951-549-3
; Sequence 3, Application US/10951549
; Publication No. US20050202461A1
; GENERAL INFORMATION:
;  APPLICANT: Datascope Investment Corp.
;  APPLICANT:  Getts, Robert C.
;  APPLICANT:  Kadushin, James
;  APPLICANT:  Schwalm, Jaime
;  APPLICANT:  Howerton, Kevin
;  TITLE OF INVENTION: Method for Converting Generic Nucleic Acid Priming Sequences
;  FILE REFERENCE: 4081.024.400
;  CURRENT APPLICATION NUMBER: US/10/951,549
;  CURRENT FILING DATE:  2004-09-27
;  PRIOR APPLICATION NUMBER: PCT/US03/09232
;  PRIOR FILING DATE: 2003-03-25
;  PRIOR APPLICATION NUMBER: US 10/825,776
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 60/261,231
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 10/730,823
;  PRIOR FILING DATE: 2003-12-08
;  PRIOR APPLICATION NUMBER: PCT/US01/29589
;  PRIOR FILING DATE: 2001-09-20
;  PRIOR APPLICATION NUMBER: US 60/234,060
;  PRIOR FILING DATE: 2000-09-20
;  PRIOR APPLICATION NUMBER: US 09/908,950
;  PRIOR FILING DATE: 2001-07-19
;  PRIOR APPLICATION NUMBER: US 60/219,397
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: US 60/187,681
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: US 09/802,162
;  PRIOR FILING DATE: 2001-03-08
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: poly dT primer
;   FEATURE:
;   NAME/KEY: polydT
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: Phosphorylated poly dT, which binds to a bridging oligonucleotid
US-10-951-549-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 614
US-11-099-683-1
; Sequence 1, Application US/11099683
; Publication No. US20060019916A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES
;  FILE REFERENCE: C1037.70047US01
;  CURRENT APPLICATION NUMBER: US/11/099,683
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: US 60/558,951
;  PRIOR FILING DATE: 2004-04-02
;  NUMBER OF SEQ ID NOS: 143
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: where all linkages between bases are phosphorothioate linkages
US-11-099-683-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6360
              |:::::::::::::::
```

```
Db          2 CTTTTTTTTTTTTTT 17


RESULT 615
US-11-099-683-31
; Sequence 31, Application US/11099683
; Publication No. US20060019916A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES
;  FILE REFERENCE: C1037.70047US01
;  CURRENT APPLICATION NUMBER: US/11/099,683
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: US 60/558,951
;  PRIOR FILING DATE: 2004-04-02
;  NUMBER OF SEQ ID NOS: 143
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: where the linkages between bases are phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: where in is uracil
US-11-099-683-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6360
              |:::::::::::::::
Db          2 CTTTTTTTTTTTTTTT 17


RESULT 616
US-11-099-683-32
; Sequence 32, Application US/11099683
; Publication No. US20060019916A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES
;  FILE REFERENCE: C1037.70047US01
;  CURRENT APPLICATION NUMBER: US/11/099,683
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: US 60/558,951
;  PRIOR FILING DATE: 2004-04-02
;  NUMBER OF SEQ ID NOS: 143
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: where the linkages between bases are phosphorothioate linkages
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: wherein n is 5-methoxythymidine
US-11-099-683-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6360
              |:::::::::::::::
Db          2 CTTTTTTTTTTTTTTT 17


RESULT 617
US-11-099-683-43
; Sequence 43, Application US/11099683
; Publication No. US20060019916A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES
;  FILE REFERENCE: C1037.70047US01
;  CURRENT APPLICATION NUMBER: US/11/099,683
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: US 60/558,951
;  PRIOR FILING DATE: 2004-04-02
;  NUMBER OF SEQ ID NOS: 143
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 43
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: where the linkages between bases are phosphorothioate linkages
US-11-099-683-43

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 8.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 618
US-11-099-683-44
; Sequence 44, Application US/11099683
; Publication No. US20060019916A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES
;  FILE REFERENCE: C1037.70047US01
;  CURRENT APPLICATION NUMBER: US/11/099,683
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: US 60/558,951
;  PRIOR FILING DATE: 2004-04-02
;  NUMBER OF SEQ ID NOS: 143
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: where the linkages between bases are phosphorothioate linkages
US-11-099-683-44
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 8.7e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 619
US-09-370-541-14
; Sequence 14, Application US/09370541
; Publication No. US20030088079A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT: Prakash, Thazha P
;  APPLICANT: Kawasaki, Andrew M
;  TITLE OF INVENTION: Aminoxxy-Modified Nucleosidic Compounds And Oligomeric
;  TITLE OF INVENTION: Compounds Prepared Therefrom
;  FILE REFERENCE: ISIS3993
;  CURRENT APPLICATION NUMBER: US/09/370,541
;  CURRENT FILING DATE: 1999-08-09
;  EARLIER APPLICATION NUMBER: 09/130,973
;  EARLIER FILING DATE: 1998-08-07
;  EARLIER APPLICATION NUMBER: 09/016,520
;  EARLIER FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  EARLIER APPLICATION NUMBER: 09/344,260
;  EARLIER FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: sequence
US-09-370-541-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 620
US-09-776-479-913
; Sequence 913, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 621
US-09-776-479-913
; Sequence 913, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 622
US-09-776-479-939
; Sequence 939, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
```

```
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 623
US-09-776-479-939
; Sequence 939, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 624
US-09-809-545A-84
; Sequence 84, Application US/09809545A
; Patent No. US20020110804A1
; GENERAL INFORMATION:
;  APPLICANT: Stanton, Lawrence W.
;  APPLICANT:  White, R. Tyler
;  TITLE OF INVENTION: SECRETED FACTORS
;  FILE REFERENCE: SCIOS.017A
;  CURRENT APPLICATION NUMBER: US/09/809,545A
;  CURRENT FILING DATE:  2001-03-14
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 625
US-09-888-326-837
; Sequence 837, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 837
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-837

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 626
US-09-979-275A-7
; Sequence 7, Application US/09979275A
; Publication No. US20040110919A1
; GENERAL INFORMATION:
;  APPLICANT: NAGAI, HIROSHI
;  APPLICANT:  KURODA, KYOKO
;  APPLICANT:  NAKAJIMA, TERUMI
;  TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
;  TITLE OF INVENTION:  ENCODING THE PROTEIN
;  FILE REFERENCE: 037181.50611US
;  CURRENT APPLICATION NUMBER: US/09/979,275A
;  CURRENT FILING DATE:  2003-05-27
;  PRIOR APPLICATION NUMBER: PCT/JP01/02209
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: JP 2000-78967
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-09-979-275A-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 627
US-09-994-311-6
; Sequence 6, Application US/09994311
; Publication No. US20030082556A1
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/09/994,311
;  CURRENT FILING DATE:  2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 628
US-10-017-995-913
; Sequence 913, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 629
US-10-017-995-939
; Sequence 939, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 630
US-10-056-479A-15
; Sequence 15, Application US/10056479A
; Publication No. US20030175678A1
; GENERAL INFORMATION:
;  APPLICANT: Bowen, Banjamin A.
;  APPLICANT:  Deakin, Edward
;  APPLICANT:  Goldsmith, Neil
;  APPLICANT:  Haudenschild, Christian
;  APPLICANT:  Houck, David
;  APPLICANT:  McAlpine, James B.
;  APPLICANT:  Neilsen, Soren
;  APPLICANT:  Pazoles, Christopher
;  APPLICANT:  Spencer, Marget E.
;  APPLICANT:  Stafford, Angela
;  TITLE OF INVENTION: Methods for Identifying Genes Regulating
;  TITLE OF INVENTION:  Desired Cell Phenotypes
;  FILE REFERENCE: 50273/005002
;  CURRENT APPLICATION NUMBER: US/10/056,479A
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US 60/263,807
;  PRIOR FILING DATE: 2001-01-24
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-056-479A-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 631
US-10-075-335-9
; Sequence 9, Application US/10075335
; Publication No. US20030186237A1
; GENERAL INFORMATION:
;  APPLICANT: Ginsberg, Stephen
;  APPLICANT:  Che, Shaoli
;  TITLE OF INVENTION: Methods and Compositions of Amplifying RNA
```

```
;  FILE REFERENCE: HO-P02202US2
;  CURRENT APPLICATION NUMBER: US/10/075,335
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/268,664
;  PRIOR FILING DATE: 2001-02-14
;  PRIOR APPLICATION NUMBER: 60/348,242
;  PRIOR FILING DATE: 2001-11-07
;  PRIOR APPLICATION NUMBER: 60/268,645
;  PRIOR FILING DATE: 2001-02-14
;  PRIOR APPLICATION NUMBER: 60/344,557
;  PRIOR FILING DATE: 2001-11-07
;  PRIOR APPLICATION NUMBER: 60/306,216
;  PRIOR FILING DATE: 2001-07-18
;  PRIOR APPLICATION NUMBER: 60/350,176
;  PRIOR FILING DATE: 2001-11-09
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-075-335-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 632
US-10-112-653-882
; Sequence 882, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 882
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-882

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 633
US-10-125-295-9
; Sequence 9, Application US/10125295
; Publication No. US20020164572A1
;   GENERAL INFORMATION:
;        APPLICANT: Lin, Ching-I Patsy
;                   Wallace, Robert Bruce
;                   Cossman, Jeffrey
;                   French, Cynthia
;        TITLE OF INVENTION: Lyophilization of Cultured Human Cells
;                            to Preserve RNA and DNA
;        NUMBER OF SEQUENCES: 9
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/125,295
;             FILING DATE: 17-Apr-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/545,225
;             FILING DATE: 07-Apr-2000
;             APPLICATION NUMBER: US 08/884,029
;             FILING DATE: 27-JUN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Parent, Annette S.
;             REGISTRATION NUMBER: 42,058
;             REFERENCE/DOCKET NUMBER: 02558B-059100US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 9:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  13..18
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "t at positions 13-18 may be
;             present or absent"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-125-295-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 634
US-10-206-613-4
; Sequence 4, Application US/10206613
; Publication No. US20030104432A1
; GENERAL INFORMATION:
;  APPLICANT: Xu, Zhidong
;  APPLICANT:  Jablons, David
;  APPLICANT:  You, Liang
;  APPLICANT:  He, Biao
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Methods of Amplifying Long Sense Strand RNA
;  FILE REFERENCE: 02307O-119510US
;  CURRENT APPLICATION NUMBER: US/10/206,613
;  CURRENT FILING DATE:  2002-11-04
```

```
;  PRIOR APPLICATION NUMBER: US 60/308,190
;  PRIOR FILING DATE: 2001-07-27
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo dT-18
;   OTHER INFORMATION: linker primer
US-10-206-613-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 635
US-10-208-357-24/c
; Sequence 24, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
;  APPLICANT: Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION: Peptide Acceptor Ligation Methods
;  FILE REFERENCE: 50036/031002
;  CURRENT APPLICATION NUMBER: US/10/208,357
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US/09/619,103
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: 60/145,834
;  PRIOR FILING DATE: 1999-07-27
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 636
US-10-271-602B-84/c
; Sequence 84, Application US/10271602B
; Publication No. US20040002073A1
; GENERAL INFORMATION:
;  APPLICANT: Alice Xiang Li
;  APPLICANT:  Ghazala Hashmi
;  APPLICANT:  Michael Seul
;  TITLE OF INVENTION: MULTIPLEXED ANALYSIS OF POLYMORPHIC LOCI
;  TITLE OF INVENTION:  BY CONCURRENT INTERROGATION AND ENZYME-MEDIATED DETECTION
;  FILE REFERENCE: eMAP-US
;  CURRENT APPLICATION NUMBER: US/10/271,602B
;  CURRENT FILING DATE:  2002-10-15
;  PRIOR APPLICATION NUMBER: 60/329,427
;  PRIOR FILING DATE: 2001-10-14
;  PRIOR APPLICATION NUMBER: 60/329,620
;  PRIOR FILING DATE: 2001-10-15
;  PRIOR APPLICATION NUMBER: 60/329,428
;  PRIOR FILING DATE: 2001-10-14
;  PRIOR APPLICATION NUMBER: 60/329,619
;  PRIOR FILING DATE: 2001-10-15
;  PRIOR APPLICATION NUMBER: 60/364,416
;  PRIOR FILING DATE: 2002-03-14
;  NUMBER OF SEQ ID NOS: 212
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe sequence derived from human genomic sequence
US-10-271-602B-84

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 637
US-10-292-088-144
; Sequence 144, Application US/10292088
; Publication No. US20030211100A1
; GENERAL INFORMATION:
;  APPLICANT: BEDIAN, VAHE
;  APPLICANT:  GLADUE, RONALD P.
;  APPLICANT:  CORVALAN, JOSE
;  APPLICANT:  JIA, XIAO-CHI
;  APPLICANT:  FENG, XIAO
;  TITLE OF INVENTION: ANTIBODIES TO CD40
;  FILE REFERENCE: ABX-PF/3 US
;  CURRENT APPLICATION NUMBER: US/10/292,088
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/348,980
;  PRIOR FILING DATE: 2001-11-09
;  NUMBER OF SEQ ID NOS: 147
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 144
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-292-088-144

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 638
US-10-314-578-913
; Sequence 913, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
```

```
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 639
US-10-314-578-939
; Sequence 939, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 640
US-10-334-143-204
; Sequence 204, Application US/10334143
; Publication No. US20040009549A1
; GENERAL INFORMATION:
;  APPLICANT: GRIGORIEV, IGOR VYACHESLAVOVICH
;  APPLICANT:  SUDARSANAM, SUCHA
;  TITLE OF INVENTION: METHOD FOR DETECTING REMOTE HOMOLOGUES AND NOVEL
;  TITLE OF INVENTION:  KINASES IDENTIFIED WITH THE METHOD
;  FILE REFERENCE: 038602/1543
;  CURRENT APPLICATION NUMBER: US/10/334,143
;  CURRENT FILING DATE:  2002-12-31
;  PRIOR APPLICATION NUMBER: 60/343,169
;  PRIOR FILING DATE: 2001-12-31
;  NUMBER OF SEQ ID NOS: 207
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 204
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides in length
US-10-334-143-204

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 641
US-10-352-704-12
; Sequence 12, Application US/10352704
; Publication No. US20030176690A1
;   GENERAL INFORMATION:
;        APPLICANT: Chatelain, Francois
;                   Kumarev, Viktor
;        TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                            a Solid Support and Apparatus Permitting its
;                            Implementation
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Jacobson, Price, Holman & Stern
;             STREET: 400 Seventh St. N.W.
;             CITY: Washington D.C
;             STATE: D.C
;             COUNTRY: U.S.A.
;             ZIP: 20004
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/352,704
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/358,556A
;             FILING DATE: 14-DEC-1994
;             APPLICATION NUMBER: FR 9315164
;             FILING DATE: 16-DEC-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Player, William E.
;             REGISTRATION NUMBER: 31,409
;             REFERENCE/DOCKET NUMBER: 10577/P58418
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (202)638-6666
;             TELEFAX: (202) 393-5350
;             TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 12:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
```

```
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       FRAGMENT TYPE: N-terminal
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..18
;       SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 642
US-10-352-704-18/c
; Sequence 18, Application US/10352704
; Publication No. US20030176690A1
;   GENERAL INFORMATION:
;       APPLICANT: Chatelain, Francois
;                  Kumarev, Viktor
;       TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                           a Solid Support and Apparatus Permitting its
;                           Implementation
;       NUMBER OF SEQUENCES: 31
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Jacobson, Price, Holman & Stern
;            STREET: 400 Seventh St. N.W.
;            CITY: Washington D.C
;            STATE: D.C
;            COUNTRY: U.S.A.
;            ZIP: 20004
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/352,704
;            FILING DATE: 28-Jan-2003
;            CLASSIFICATION: 536
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/358,556A
;            FILING DATE: 14-DEC-1994
;            APPLICATION NUMBER: FR 9315164
;            FILING DATE: 16-DEC-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Player, William E.
;            REGISTRATION NUMBER: 31,409
;            REFERENCE/DOCKET NUMBER: 10577/P58418
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (202)638-6666
;            TELEFAX: (202) 393-5350
;            TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 18:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       FRAGMENT TYPE: N-terminal
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..18
;       SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 643
US-10-389-155-97
; Sequence 97, Application US/10389155
; Publication No. US20030229208A1
;   GENERAL INFORMATION:
;       APPLICANT: Queen, Cary L.
;                  Co, Man Sung
;                  Schneider, William P.
;                  Landolfi, Nicholas F.
;                  Coelingh, Kathleen L.
;                  Selick, Harold E.
;       TITLE OF INVENTION: Improved Humanized Immunoglobulins
;       NUMBER OF SEQUENCES: 100
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/389,155
;            FILING DATE: 13-Mar-2003
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/325,000
;            FILING DATE: 01-JUN-1999
;            APPLICATION NUMBER: US 07/290,975
;            FILING DATE: 28-DEC-1988
;            APPLICATION NUMBER: US 07/310,252
;            FILING DATE: 13-FEB-1989
;            APPLICATION NUMBER: US 07/590,274
;            FILING DATE: 28-SEP-1990
;            APPLICATION NUMBER: US 07/634,278
;            FILING DATE: 19-DEC-1990
;            APPLICATION NUMBER: US 08/484,537
;            FILING DATE: 07-JUN-1995
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Smith, William M.
;            REGISTRATION NUMBER: 30,223
;            REFERENCE/DOCKET NUMBER: 011823-002650US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 97:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  13..18
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "T at positions 13-18 may be
;            present or absent"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-10-389-155-97
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 644
US-10-389-417-97
; Sequence 97, Application US/10389417
; Publication No. US20040049014A1
;   GENERAL INFORMATION:
;        APPLICANT: Queen, Cary L.
;                   Co, Man Sung
;                   Schneider, William P.
;                   Landolfi, Nicholas F.
;                   Coelingh, Kathleen L.
;                   Selick, Harold E.
;        TITLE OF INVENTION: Improved Humanized Immunoglobulins
;        NUMBER OF SEQUENCES: 100
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/389,417
;             FILING DATE: 13-Mar-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/325,000
;             FILING DATE: 01-JUN-1999
;             APPLICATION NUMBER: US 07/290,975
;             FILING DATE: 28-DEC-1988
;             APPLICATION NUMBER: US 07/310,252
;             FILING DATE: 13-FEB-1989
;             APPLICATION NUMBER: US 07/590,274
;             FILING DATE: 28-SEP-1990
;             APPLICATION NUMBER: US 07/634,278
;             FILING DATE: 19-DEC-1990
;             APPLICATION NUMBER: US 08/484,537
;             FILING DATE: 07-JUN-1995
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Smith, William M.
;             REGISTRATION NUMBER: 30,223
;             REFERENCE/DOCKET NUMBER: 011823-002650US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 97:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  13..18
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "T at positions 13-18 may be
;             present or absent"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-10-389-417-97

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 645
US-10-407-089-22/c
; Sequence 22, Application US/10407089
; Publication No. US20030224419A1
; GENERAL INFORMATION:
;  APPLICANT: Corcoran, Kevin C.
;  APPLICANT:  Eletr, Sam
;  TITLE OF INVENTION: System for Determining a Signature of a
;  TITLE OF INVENTION:  Nucleotide Sequence
;  FILE REFERENCE: 55525-8040.US00
;  CURRENT APPLICATION NUMBER: US/10/407,089
;  CURRENT FILING DATE:  2003-04-02
;  PRIOR APPLICATION NUMBER: US/09/654,187
;  PRIOR FILING DATE: 2000-09-01
;  PRIOR APPLICATION NUMBER: US 60/182,454
;  PRIOR FILING DATE: 2000-02-15
;  PRIOR APPLICATION NUMBER: PCT/US98/11224
;  PRIOR FILING DATE: 1998-05-22
;  PRIOR APPLICATION NUMBER: US 08/862,610
;  PRIOR FILING DATE: 1997-05-23
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: adaptor
US-10-407-089-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   12.5%;  Pred. No. 8.4e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCC 6363
              ::::::::::::::||
Db         18 TTTTTTTTTTTTTTCC 3


RESULT 646
US-10-494-141A-1
; Sequence 1, Application US/10494141A
; Publication No. US20050233455A1
; GENERAL INFORMATION:
;  APPLICANT: DAMHA, MASAD J.
;  APPLICANT:  VIAZOVKINA, EKATERINA
;  APPLICANT:  MANGOS, MARIA M.
;  APPLICANT:  PARNIAK, MICHAEL A.
;  APPLICANT:  MIN, KYUNG-LYUM
;  TITLE OF INVENTION: ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 701826-055310
;  CURRENT APPLICATION NUMBER: US/10/494,141A
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: PCT/CA02/01628
;  PRIOR FILING DATE: 2002-10-29
;  PRIOR APPLICATION NUMBER: 60/330,719
;  PRIOR FILING DATE: 2001-10-29
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polynucleotide sequence
US-10-494-141A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 647
US-10-494-141A-11
; Sequence 11, Application US/10494141A
; Publication No. US20050233455A1
; GENERAL INFORMATION:
;  APPLICANT: DAMHA, MASAD J.
;  APPLICANT:  VIAZOVKINA, EKATERINA
;  APPLICANT:  MANGOS, MARIA M.
;  APPLICANT:  PARNIAK, MICHAEL A.
;  APPLICANT:  MIN, KYUNG-LYUM
;  TITLE OF INVENTION: ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 701826-055310
;  CURRENT APPLICATION NUMBER: US/10/494,141A
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: PCT/CA02/01628
;  PRIOR FILING DATE: 2002-10-29
;  PRIOR APPLICATION NUMBER: 60/330,719
;  PRIOR FILING DATE: 2001-10-29
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 11
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polynucleotide sequence
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(9)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoroarabinothymidine
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (10)
;   OTHER INFORMATION: secouridine
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (11)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoroarabinothymidine
US-10-494-141A-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   6.2%;  Pred. No. 8.4e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              :::::::::|::::::
Db          1 TTTTTTTTTUTTTTTT 16


RESULT 648
US-10-494-141A-12
; Sequence 12, Application US/10494141A
; Publication No. US20050233455A1
; GENERAL INFORMATION:
;  APPLICANT: DAMHA, MASAD J.
;  APPLICANT:  VIAZOVKINA, EKATERINA
;  APPLICANT:  MANGOS, MARIA M.
;  APPLICANT:  PARNIAK, MICHAEL A.
;  APPLICANT:  MIN, KYUNG-LYUM
;  TITLE OF INVENTION: ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 701826-055310
;  CURRENT APPLICATION NUMBER: US/10/494,141A
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: PCT/CA02/01628
;  PRIOR FILING DATE: 2002-10-29
;  PRIOR APPLICATION NUMBER: 60/330,719
;  PRIOR FILING DATE: 2001-10-29
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 12
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polynucleotide sequence
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(8)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoroarabinothymidine
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (9)..(10)
;   OTHER INFORMATION: secouridine
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (11)..(18)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoroarabinothymidine
US-10-494-141A-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   12.5%;  Pred. No. 8.4e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              :::::::::||::::::
Db          1 TTTTTTTTUUTTTTTT 16


RESULT 649
US-10-494-141A-27/c
; Sequence 27, Application US/10494141A
; Publication No. US20050233455A1
; GENERAL INFORMATION:
;  APPLICANT: DAMHA, MASAD J.
;  APPLICANT:  VIAZOVKINA, EKATERINA
;  APPLICANT:  MANGOS, MARIA M.
;  APPLICANT:  PARNIAK, MICHAEL A.
;  APPLICANT:  MIN, KYUNG-LYUM
;  TITLE OF INVENTION: ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 701826-055310
;  CURRENT APPLICATION NUMBER: US/10/494,141A
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: PCT/CA02/01628
;  PRIOR FILING DATE: 2002-10-29
;  PRIOR APPLICATION NUMBER: 60/330,719
;  PRIOR FILING DATE: 2001-10-29
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 27
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polynucleotide sequence
US-10-494-141A-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
```

```
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 650
US-10-494-141A-7
; Sequence 7, Application US/10494141A
; Publication No. US20050233455A1
; GENERAL INFORMATION:
;  APPLICANT: DAMHA, MASAD J.
;  APPLICANT:  VIAZOVKINA, EKATERINA
;  APPLICANT:  MANGOS, MARIA M.
;  APPLICANT:  PARNIAK, MICHAEL A.
;  APPLICANT:  MIN, KYUNG-LYUM
;  TITLE OF INVENTION: ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 701826-055310
;  CURRENT APPLICATION NUMBER: US/10/494,141A
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: PCT/CA02/01628
;  PRIOR FILING DATE: 2002-10-29
;  PRIOR APPLICATION NUMBER: 60/330,719
;  PRIOR FILING DATE: 2001-10-29
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polynucleotide sequence
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: fluoroarabinothymidine
US-10-494-141A-7

  Query Match              0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity    0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 651
US-10-497-091-284
; Sequence 284, Application US/10497091
; Publication No. US20050074863A1
; GENERAL INFORMATION:
;  APPLICANT: HELLENDOORN, Koen
;  APPLICANT:  BAKER, Matthew
;  APPLICANT:  WILLIAMS, Steven
;  APPLICANT:  CARR, Francis  J.
;  TITLE OF INVENTION: T-CELL EPITOPES IN CARBOXYPEPTIDASE G2
;  FILE REFERENCE: MER-130
;  CURRENT APPLICATION NUMBER: US/10/497,091
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: PCT/EP02/13351
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: EP02020634.8
;  PRIOR FILING DATE: 2002-09-13
;  PRIOR APPLICATION NUMBER: EP02001778.6
;  PRIOR FILING DATE: 2002-01-25
;  PRIOR APPLICATION NUMBER: EP01128519.4
;  PRIOR FILING DATE: 2001-11-29
;  NUMBER OF SEQ ID NOS: 312
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 284
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-497-091-284

  Query Match              0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 8.4e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2828 UGAAAAUGCUGAAAGA 2843
              :|||||:||:||||||
Db          2 TGAAAATGCTGAAAGA 17


RESULT 652
US-10-497-091-300/c
; Sequence 300, Application US/10497091
; Publication No. US20050074863A1
; GENERAL INFORMATION:
;  APPLICANT: HELLENDOORN, Koen
;  APPLICANT:  BAKER, Matthew
;  APPLICANT:  WILLIAMS, Steven
;  APPLICANT:  CARR, Francis  J.
;  TITLE OF INVENTION: T-CELL EPITOPES IN CARBOXYPEPTIDASE G2
;  FILE REFERENCE: MER-130
;  CURRENT APPLICATION NUMBER: US/10/497,091
;  CURRENT FILING DATE:  2004-05-28
;  PRIOR APPLICATION NUMBER: PCT/EP02/13351
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: EP02020634.8
;  PRIOR FILING DATE: 2002-09-13
;  PRIOR APPLICATION NUMBER: EP02001778.6
;  PRIOR FILING DATE: 2002-01-25
;  PRIOR APPLICATION NUMBER: EP01128519.4
;  PRIOR FILING DATE: 2001-11-29
;  NUMBER OF SEQ ID NOS: 312
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 300
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-497-091-300

  Query Match              0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 8.4e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2828 UGAAAAUGCUGAAAGA 2843
              :|||||:||:||||||
Db         17 TGAAAATGCTGAAAGA 2


RESULT 653
US-10-503-120-1
; Sequence 1, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
;  APPLICANT: MCGILL UNIVERSITY ET AL.
;  TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
;  FILE REFERENCE: 85827-63
;  CURRENT APPLICATION NUMBER: US/10/503,120
;  CURRENT FILING DATE:  2004-07-30
;  PRIOR APPLICATION NUMBER: US 60/352,873
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
```

```
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-503-120-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 654
US-10-503-120-10
; Sequence 10, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
;  APPLICANT: MCGILL UNIVERSITY ET AL.
;  TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
;  FILE REFERENCE: 85827-63
;  CURRENT APPLICATION NUMBER: US/10/503,120
;  CURRENT FILING DATE:  2004-07-30
;  PRIOR APPLICATION NUMBER: US 60/352,873
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: Residues 1-6 and 13-18 are 2'-O-methyl-D-uridine
US-10-503-120-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   62.5%;  Pred. No. 8.4e+02;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||::::::||||
Db          1 UUUUUUTTTTTTUUUU 16


RESULT 655
US-10-503-120-21/c
; Sequence 21, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
;  APPLICANT: MCGILL UNIVERSITY ET AL.
;  TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
;  FILE REFERENCE: 85827-63
;  CURRENT APPLICATION NUMBER: US/10/503,120
;  CURRENT FILING DATE:  2004-07-30
;  PRIOR APPLICATION NUMBER: US 60/352,873
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Target RNA oligonucleotide
US-10-503-120-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 656
US-10-503-120-8
; Sequence 8, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
;  APPLICANT: MCGILL UNIVERSITY ET AL.
;  TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREO
;  FILE REFERENCE: 85827-63
;  CURRENT APPLICATION NUMBER: US/10/503,120
;  CURRENT FILING DATE:  2004-07-30
;  PRIOR APPLICATION NUMBER: US 60/352,873
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: Residues 1, 3, 5, 7, 9, 11, 13, 15 and 17 are 2'-O-methyl-D-urid
;   OTHER INFORMATION: ne
US-10-503-120-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 8.4e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              |:|:|:|:|:|:|:|:
Db          1 UTUTUTUTUTUTUTUT 16


RESULT 657
US-10-503-120-9
; Sequence 9, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
;  APPLICANT: MCGILL UNIVERSITY ET AL.
;  TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREO
;  FILE REFERENCE: 85827-63
;  CURRENT APPLICATION NUMBER: US/10/503,120
;  CURRENT FILING DATE:  2004-07-30
;  PRIOR APPLICATION NUMBER: US 60/352,873
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(15)
;   OTHER INFORMATION: Residues 1-3, 7-9, and 13-15 are 2'-O-methyl-D-uridine
US-10-503-120-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   56.2%;  Pred. No. 8.4e+02;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              |||:::|||:::|||:
Db          1 UUUTTTUUUTTTUUUT 16


RESULT 658
US-10-543-683-4
; Sequence 4, Application US/10543683
; Publication No. US20060035235A1
; GENERAL INFORMATION:
;  APPLICANT: Mitsugu USUI
;  APPLICANT:  Toshihiko FUJIKAWA
;  TITLE OF INVENTION: Signal Amplification Method for Detecting Expressed Gene
;  FILE REFERENCE: 2005-1209A/WMC/01531
;  CURRENT APPLICATION NUMBER: US/10/543,683
;  CURRENT FILING DATE:  2005-07-28
;  PRIOR APPLICATION NUMBER: JP 2003-037212
;  PRIOR FILING DATE: 2003-02-14
;  NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 4
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: poly dT primer
US-10-543-683-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 659
US-10-601-140A-24
; Sequence 24, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 660
US-10-628-525-30/c
; Sequence 30, Application US/10628525
; Publication No. US20040185114A1
;   GENERAL INFORMATION:
;        APPLICANT: Keeling, Peter
;                   Guan, Hanping
;        TITLE OF INVENTION: Starch Encapsulation
;        NUMBER OF SEQUENCES: 37
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Greenlee, Winner and Sullivan, P.C.
;             STREET: 5370 Manhattan Circle
;             CITY: Boulder
;             STATE: CO
;             COUNTRY: US
;             ZIP: 80303
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/628,525
;             FILING DATE: 28-Jul-2003
;             CLASSIFICATION: 800
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/941,445
;             FILING DATE: 30-SEP-1997
;             APPLICATION NUMBER: US 60/026,855
;             FILING DATE: 30-SEP-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Winner, Ellen P
;             REGISTRATION NUMBER: 28,547
;             REFERENCE/DOCKET NUMBER: 89-97
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (303) 499-8080
;             TELEFAX: (303) 499-8089
;   INFORMATION FOR SEQ ID NO: 30:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: double
;             TOPOLOGY: Not Relevant
;        MOLECULE TYPE: cDNA to mRNA
;        HYPOTHETICAL: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-10-628-525-30

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 661
US-10-638-141-10
; Sequence 10, Application US/10638141
; Publication No. US20050003364A1
; GENERAL INFORMATION:
;  APPLICANT: Stanton, Lawrence W.
;  APPLICANT:  Kapoun, Ann Marie
;  TITLE OF INVENTION: SECRETED FACTORS
;  FILE REFERENCE: SCIOS.013A
;  CURRENT APPLICATION NUMBER: US/10/638,141
;  CURRENT FILING DATE:  2003-08-07
;  PRIOR APPLICATION NUMBER: US/09/665,728
;  PRIOR FILING DATE: 2000-09-20
;  PRIOR APPLICATION NUMBER: 60/156,277
;  PRIOR FILING DATE: 1999-09-27
;  NUMBER OF SEQ ID NOS: 19
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-10-638-141-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 662
US-10-653-416-26
; Sequence 26, Application US/10653416
; Publication No. US20040110201A1
; GENERAL INFORMATION:
;  APPLICANT: RASHTCHIAN, AYOUB
;  APPLICANT:  SCHUSTER, DAVID M.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR CDNA SYNTHESIS
;  FILE REFERENCE: 38266-0011
;  CURRENT APPLICATION NUMBER: US/10/653,416
;  CURRENT FILING DATE:  2003-09-03
;  PRIOR APPLICATION NUMBER: 60/407,248
;  PRIOR FILING DATE: 2002-09-03
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 26
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according
;   OTHER INFORMATION: to the specification as filed
US-10-653-416-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 663
US-10-669-962-27
; Sequence 27, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
;  APPLICANT: Brugliera, Filippa
;  APPLICANT:  Holton, Timothy A.
;  APPLICANT:  Michael, Michael Z.
;  TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 11658
;  CURRENT APPLICATION NUMBER: US/10/669,962
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: US/09/142,108C
;  PRIOR FILING DATE: 1998-09-01
;  PRIOR APPLICATION NUMBER: PN8386
;  PRIOR FILING DATE: 1996-03-01
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 664
US-10-669-962-29
; Sequence 29, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
;  APPLICANT: Brugliera, Filippa
;  APPLICANT:  Holton, Timothy A.
;  APPLICANT:  Michael, Michael Z.
;  TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 11658
;  CURRENT APPLICATION NUMBER: US/10/669,962
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: US/09/142,108C
;  PRIOR FILING DATE: 1998-09-01
;  PRIOR APPLICATION NUMBER: PN8386
;  PRIOR FILING DATE: 1996-03-01
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 665
US-10-674-159A-112
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
;  APPLICANT: Chen, Jianzhu
;  APPLICANT:  Ge, Qing
;  APPLICANT:  Eisen, Herman
;  TITLE OF INVENTION: Influenza Therapeutic
;  FILE REFERENCE: 0492611-0506
;  CURRENT APPLICATION NUMBER: US/10/674,159A
;  CURRENT FILING DATE:  2003-09-29
;  NUMBER OF SEQ ID NOS: 271
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: mRNA
```

```
US-10-674-159A-112

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 666
US-10-735-592-1
; Sequence 1, Application US/10735592
; Publication No. US20040171571A1
; GENERAL INFORMATION:
;  APPLICANT: Art, Krieg
;  APPLICANT:  Joerg, Vollmer
;  TITLE OF INVENTION: 5' CPG Nucleic Acids and Methods of Use
;  FILE REFERENCE: C1037.70038US01
;  CURRENT APPLICATION NUMBER: US/10/735,592
;  CURRENT FILING DATE:  2003-12-11
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-735-592-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 667
US-10-766-096-9
; Sequence 9, Application US/10766096
; Publication No. US20040265786A1
;   GENERAL INFORMATION:
;        APPLICANT: Lin, Ching-I Patsy
;                   Wallace, Robert Bruce
;                   Cossman, Jeffrey
;                   French, Cynthia
;        TITLE OF INVENTION: Lyophilization of Cultured Human Cells
;                            to Preserve RNA and DNA
;        NUMBER OF SEQUENCES: 9
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/766,096
;             FILING DATE: 27-Jan-2004
;             CLASSIFICATION: 435
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/884,029
;             FILING DATE: 27-JUN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Parent, Annette S.
;             REGISTRATION NUMBER: 42,058
;             REFERENCE/DOCKET NUMBER: 02558B-059100US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 9:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  13..18
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "t at positions 13-18 may be
;             present or absent"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-766-096-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 668
US-10-775-973-10
; Sequence 10, Application US/10775973
; Publication No. US20050158729A1
; GENERAL INFORMATION:
;  APPLICANT: Stanton, Lawrence W.
;  APPLICANT:  Kapoun, Ann Marie
;  TITLE OF INVENTION: SECRETED FACTORS
;  FILE REFERENCE: SCIOS.014A
;  CURRENT APPLICATION NUMBER: US/10/775,973
;  CURRENT FILING DATE:  2004-02-09
;  PRIOR APPLICATION NUMBER: US/09/665,976
;  PRIOR FILING DATE: 2000-09-20
;  PRIOR APPLICATION NUMBER: 60/156,280
;  PRIOR FILING DATE: 1999-09-27
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-10-775-973-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 669
US-10-776-917-141
; Sequence 141, Application US/10776917
; Publication No. US20040248840A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
```

```
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION
;  FILE REFERENCE: 58609(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,917
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,363
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: DK 2003-01539
;  PRIOR FILING DATE: 2003-10-20
;  NUMBER OF SEQ ID NOS: 201
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 141
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: poly-T oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
;   OTHER INFORMATION: specification as filed
US-10-776-917-141

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 670
US-10-776-933-150
; Sequence 150, Application US/10776933
; Publication No. US20040241717A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 58614(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,933
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,374
;  PRIOR FILING DATE: 2003-02-10
;  NUMBER OF SEQ ID NOS: 150
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 150
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: poly-T oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: This sequence may emcompass 12-18 nucleotides
;   OTHER INFORMATION: according to the specification as filed
US-10-776-933-150

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 671
US-10-776-934-741
; Sequence 741, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
;  APPLICANT: HANSEN, BO
;  APPLICANT:  THRUE, CHARLOTTE ALBAEK
;  APPLICANT:  WESTERGAARD, MAJKEN
;  APPLICANT:  PETERSEN, KAMILLE DUMONG
;  APPLICANT:  WISSENBACH, MARGIT
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: 58610(71432)
;  CURRENT APPLICATION NUMBER: US/10/776,934
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: 60/446,372
;  PRIOR FILING DATE: 2003-02-10
;  PRIOR APPLICATION NUMBER: 60/523,591
;  PRIOR FILING DATE: 2003-11-19
;  NUMBER OF SEQ ID NOS: 741
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 741
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: poly-T oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
;   OTHER INFORMATION: specification as filed
US-10-776-934-741

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 672
US-10-785-744-15
; Sequence 15, Application US/10785744
; Publication No. US20040133941A1
; GENERAL INFORMATION:
;  APPLICANT: Bowen, Banjamin A.
;  APPLICANT:  Deakin, Edward
;  APPLICANT:  Goldsmith, Neil
;  APPLICANT:  Haudenschild, Christian
;  APPLICANT:  Houck, David
;  APPLICANT:  McAlpine, James B.
;  APPLICANT:  Neilsen, Soren
;  APPLICANT:  Pazoles, Christopher
;  APPLICANT:  Spencer, Marget E.
;  APPLICANT:  Stafford, Angela
;  TITLE OF INVENTION: Methods for Identifying Genes Regulating
;  TITLE OF INVENTION:  Desired Cell Phenotypes
;  FILE REFERENCE: 50273/005002
;  CURRENT APPLICATION NUMBER: US/10/785,744
;  CURRENT FILING DATE:  2004-02-23
;  PRIOR APPLICATION NUMBER: US/10/056,479
;  PRIOR FILING DATE: 2003-02-07
;  PRIOR APPLICATION NUMBER: US 60/263,807
;  PRIOR FILING DATE: 2001-01-24
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-785-744-15
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 673
US-10-831-778-913
; Sequence 913, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 913
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 674
US-10-831-778-939
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 939
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-939

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 675
US-10-849-072-21/c
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
;  APPLICANT: Roche Diagnostics GmbH
;  TITLE OF INVENTION: High density labeling of DNA with modified or
;  TITLE OF INVENTION:  "chromophore" carrying nucleotides and DNA polymerases
;  TITLE OF INVENTION:  used
;  FILE REFERENCE: 4780/00/WO
;  CURRENT APPLICATION NUMBER: US/10/849,072
;  CURRENT FILING DATE:  2004-05-19
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: second
;   OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 676
US-10-849-072-23
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
;  APPLICANT: Roche Diagnostics GmbH
;  TITLE OF INVENTION: High density labeling of DNA with modified or
;  TITLE OF INVENTION:  "chromophore" carrying nucleotides and DNA polymerases
;  TITLE OF INVENTION:  used
;  FILE REFERENCE: 4780/00/WO
;  CURRENT APPLICATION NUMBER: US/10/849,072
;  CURRENT FILING DATE:  2004-05-19
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: second
;   OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 677
US-10-872-984-6
; Sequence 6, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/10/872,984
;  CURRENT FILING DATE:  2004-06-21
;  PRIOR APPLICATION NUMBER: US/09/994,311
;  PRIOR FILING DATE: 2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 678
US-10-884-617-2
; Sequence 2, Application US/10884617
; Publication No. US20050054730A1
; GENERAL INFORMATION:
;  APPLICANT: Fu, Jin
;  APPLICANT:  Gaetani, Silvana
;  APPLICANT:  Piomelli, Daniele
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Compounds, Compositions and Treatments of
;  TITLE OF INVENTION:  Oleoylethanolamide-Like Modulators of PPARalpha
;  FILE REFERENCE: 02307E-133310US
;  CURRENT APPLICATION NUMBER: US/10/884,617
;  CURRENT FILING DATE:  2004-07-01
;  PRIOR APPLICATION NUMBER: US 60/279,542
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/336,289
;  PRIOR FILING DATE: 2001-10-31
;  PRIOR APPLICATION NUMBER: US 10/112,509
;  PRIOR FILING DATE: 2002-03-27
;  PRIOR APPLICATION NUMBER: US 60/485,062
;  PRIOR FILING DATE: 2003-07-02
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Oligo(dT)-12-18
;   OTHER INFORMATION: primer for reverse transcription of total RNA
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(18)
;   OTHER INFORMATION: t at positions 13-18 may be present or absent
US-10-884-617-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 679
US-10-959-440-84
; Sequence 84, Application US/10959440
; Publication No. US20050208605A1
; GENERAL INFORMATION:
;  APPLICANT: Stanton, Lawrence W.
;  APPLICANT:  White, R. Tyler
;  TITLE OF INVENTION: SECRETED FACTORS
;  FILE REFERENCE: SCIOS.017A
;  CURRENT APPLICATION NUMBER: US/10/959,440
;  CURRENT FILING DATE:  2004-10-05
;  PRIOR APPLICATION NUMBER: US/09/809,545
;  PRIOR FILING DATE: 2001-03-14
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-10-959-440-84

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 680
US-11-024-428-7
; Sequence 7, Application US/11024428
; Publication No. US20050106676A1
; GENERAL INFORMATION:
;  APPLICANT: NAGAI, HIROSHI
;  APPLICANT:  KURODA, KYOKO
;  APPLICANT:  NAKAJIMA, TERUMI
;  TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
;  TITLE OF INVENTION:  ENCODING THE PROTEIN
;  FILE REFERENCE: 037181.50611US
;  CURRENT APPLICATION NUMBER: US/11/024,428
;  CURRENT FILING DATE:  2004-12-30
;  PRIOR APPLICATION NUMBER: US/09/979,275
;  PRIOR FILING DATE: 2003-05-27
;  PRIOR APPLICATION NUMBER: PCT/JP01/02209
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: JP 2000-78967
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-11-024-428-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 681
US-11-041-103-69/c
; Sequence 69, Application US/11041103
; Publication No. US20050287548A1
; GENERAL INFORMATION:
;  APPLICANT: Georgia Tech Research Corporation
;  APPLICANT:  Bao, Gang
;  APPLICANT:  Nitin, Nitin
;  TITLE OF INVENTION: Activatable Probes and Methods For In Vivo Gene Detection
;  FILE REFERENCE: 820701-1195
;  CURRENT APPLICATION NUMBER: US/11/041,103
;  CURRENT FILING DATE:  2005-01-21
;  PRIOR APPLICATION NUMBER: 10/179,730
;  PRIOR FILING DATE: 2002-06-25
;  PRIOR APPLICATION NUMBER: 60/300,672
;  PRIOR FILING DATE: 2001-06-25
;  PRIOR APPLICATION NUMBER: 60/303,258
;  PRIOR FILING DATE: 2001-07-03
;  PRIOR APPLICATION NUMBER: 60/538,381
;  PRIOR FILING DATE: 2004-01-21
;  PRIOR APPLICATION NUMBER: 60/538,382
;  PRIOR FILING DATE: 2004-01-21
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 69
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Control
US-11-041-103-69

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 682
US-11-127-654-882
; Sequence 882, Application US/11127654
; Publication No. US20050250726A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 882
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-882

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 683
US-11-237-922-26
; Sequence 26, Application US/11237922
; Publication No. US20060068436A1
; GENERAL INFORMATION:
;  APPLICANT: RASHTCHIAN, AYOUB
;  APPLICANT:  SCHUSTER, DAVID M.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR CDNA SYNTHESIS
;  FILE REFERENCE: 38266-0011
;  CURRENT APPLICATION NUMBER: US/11/237,922
;  CURRENT FILING DATE:  2005-09-29
;  PRIOR APPLICATION NUMBER: US/10/653,416
;  PRIOR FILING DATE: 2003-09-03
;  PRIOR APPLICATION NUMBER: 60/407,248
;  PRIOR FILING DATE: 2002-09-03
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 26
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according
;   OTHER INFORMATION: to the specification as filed
US-11-237-922-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 8.4e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 684
US-09-802-110B-111/c
; Sequence 111, Application US/09802110B
; Publication No. US20030082535A1
;   GENERAL INFORMATION:
;        APPLICANT: Leushner, James
;                   Hui, May
;                   Dunn, James M.
;                   LaCroix, Jean-Michel
;        TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR
;                            DETECTION AND IDENTIFICATION OF MICROORGANISMS
;        NUMBER OF SEQUENCES: 189
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Oppedahl & Larson LLP
;             STREET: PO Box 5068
;             CITY: Dillon
;             STATE: CO
;             COUNTRY: US
;             ZIP: 80435
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;             COMPUTER: IBM compatible
;             OPERATING SYSTEM: MS DOS
;             SOFTWARE: Word Perfect
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/802,110B
;             FILING DATE: 07-Mar-2001
```

```
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: <Unknown>
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Larson, Marina T.
;             REGISTRATION NUMBER: 32,038
;             REFERENCE/DOCKET NUMBER: VGEN.P-058-2
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (970) 468-6600
;             TELEFAX: (970) 468-0104
;             TELEX: <Unknown>
;    INFORMATION FOR SEQ ID NO: 111:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 19
;             TYPE: nucleic acid
;             STRANDEDNESS: double
;             TOPOLOGY: linear
;        MOLECULE TYPE: other nucleic acid
;        HYPOTHETICAL: no
;        ANTI-SENSE: yes
;        FRAGMENT TYPE: internal
;        SEQUENCE DESCRIPTION: SEQ ID NO: 111:
US-09-802-110B-111

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 685
US-09-853-526-515
; Sequence 515, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Ilya, Chumakov
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/853,526
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 515
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: potential microsequencing oligo for 4-4-187.mis2
US-09-853-526-515

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 686
US-09-901-484A-515
; Sequence 515, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate Cancer Gene
;  FILE REFERENCE: GEN-T111XC3D2
;  CURRENT APPLICATION NUMBER: US/09/901,484A
;  CURRENT FILING DATE:  2001-07-09
;  PRIOR APPLICATION NUMBER: US 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: US 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: US 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  PRIOR APPLICATION NUMBER: US 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: US 09/853,526
;  PRIOR FILING DATE: 2001-05-11
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 515
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: potential microsequencing oligo for 4-4-187.mis2
US-09-901-484A-515

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 687
US-09-917-138-1
; Sequence 1, Application US/09917138
; Patent No. US20020031776A1
; GENERAL INFORMATION:
;  APPLICANT: TULLIS, Richard
;  APPLICANT:  STEIFFEL, Jerome
;  TITLE OF INVENTION: ENZYMATIC LABELIING AND DETECTION OF DNA
;  TITLE OF INVENTION:  HYBRIDIZATION PROBES
;  FILE REFERENCE: 24730-2207B
;  CURRENT APPLICATION NUMBER: US/09/917,138
;  CURRENT FILING DATE:  2001-07-26
;  PRIOR APPLICATION NUMBER: 09/580,358
;  PRIOR FILING DATE: 2000-05-25
;  PRIOR APPLICATION NUMBER: 60/136,545
;  PRIOR FILING DATE: 1999-05-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
;   NAME/KEY: modified_base
;   LOCATION: (1)
```

```
;   OTHER INFORMATION: Biotinylation at the 5' end
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: Combined DNA/RNA
US-09-917-138-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 688
US-09-939-379B-1/c
; Sequence 1, Application US/09939379B
; Publication No. US20030099946A1
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Biotechnology Inc.
;  APPLICANT:  Barnett, Charles Jason
;  APPLICANT:  Beck, Jim
;  TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase Chain Reaction
;  FILE REFERENCE: 60063P1
;  CURRENT APPLICATION NUMBER: US/09/939,379B
;  CURRENT FILING DATE:  2002-04-08
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1) . .(19)
;   OTHER INFORMATION: Primer ITS1
US-09-939-379B-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 689
US-09-961-663-1/c
; Sequence 1, Application US/09961663
; Patent No. US20020115084A1
; GENERAL INFORMATION:
;  APPLICANT: Barnett, Jason
;  APPLICANT:  Beck, James
;  TITLE OF INVENTION: Detection of Mycosphaerella Using the Polymerase Chain
;  TITLE OF INVENTION:  Reaction
;  FILE REFERENCE: PB/5-31382A
;  CURRENT APPLICATION NUMBER: US/09/961,663
;  CURRENT FILING DATE:  2001-09-24
;  PRIOR APPLICATION NUMBER: US 60/211902
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer ITS1
US-09-961-663-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 690
US-09-961-755A-9/c
; Sequence 9, Application US/09961755A
; Publication No. US20030113722A1
; GENERAL INFORMATION:
;  APPLICANT: Beck, Jim
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION: Detection of Fusarium Species infecting Corn Using the
;  TITLE OF INVENTION:  Polymerase Chain Reaction
;  FILE REFERENCE: 60055
;  CURRENT APPLICATION NUMBER: US/09/961,755A
;  CURRENT FILING DATE:  2001-09-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Primer ITS1
US-09-961-755A-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 691
US-09-970-971A-15
; Sequence 15, Application US/09970971A
; Publication No. US20030096979A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Kawasaki, Andrew M.
;  TITLE OF INVENTION: Oligonucleotides Having  DNA Form and B-DNA Form Conformational G
;  FILE REFERENCE: ISIS4789
;  CURRENT APPLICATION NUMBER: US/09/970,971A
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030096979A1el Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 3'-O-MOE
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: P=O
US-09-970-971A-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
```

```
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 692
US-09-970-971A-16
; Sequence 16, Application US/09970971A
; Publication No. US20030096979A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Kawasaki, Andrew M.
;  TITLE OF INVENTION: Oligonucleotides Having  DNA Form and B-DNA Form Conformational C
;  FILE REFERENCE: ISIS4789
;  CURRENT APPLICATION NUMBER: US/09/970,971A
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030096979A1el Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 3'-O-MOE
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: P=O
US-09-970-971A-16

  Query Match              0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 693
US-09-970-971A-26
; Sequence 26, Application US/09970971A
; Publication No. US20030096979A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Kawasaki, Andrew M.
;  TITLE OF INVENTION: Oligonucleotides Having  DNA Form and B-DNA Form Conformational C
;  FILE REFERENCE: ISIS4789
;  CURRENT APPLICATION NUMBER: US/09/970,971A
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030096979A1el Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-modified T
US-09-970-971A-26

  Query Match              0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 694
US-09-996-292A-54
; Sequence 54, Application US/09996292A
; Publication No. US20030158403A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Rajeev, Kallanthottathil Gopalan
;  TITLE OF INVENTION: Nuclease Resistant Chimeric Oligonucleotides
;  FILE REFERENCE: ISIS-4804
;  CURRENT APPLICATION NUMBER: US/09/996,292A
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 54
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Completely synthetic sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: N= phenoxazine
US-09-996-292A-54

  Query Match              0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 695
US-09-996-292A-55
; Sequence 55, Application US/09996292A
; Publication No. US20030158403A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Rajeev, Kallanthottathil Gopalan
;  TITLE OF INVENTION: Nuclease Resistant Chimeric Oligonucleotides
;  FILE REFERENCE: ISIS-4804
;  CURRENT APPLICATION NUMBER: US/09/996,292A
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Completely synthetic sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: N= G-clamp modification
US-09-996-292A-55
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 696
US-10-013-295-54
; Sequence 54, Application US/10013295
; Publication No. US20030175906A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  TITLE OF INVENTION: Nuclease Resistant Chimeric Oligonucleotides
;  FILE REFERENCE: ISIS4948
;  CURRENT APPLICATION NUMBER: US/10/013,295
;  CURRENT FILING DATE:  2001-12-10
;  PRIOR APPLICATION NUMBER: 60/302,682
;  PRIOR FILING DATE: 2001-07-03
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 54
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030175906A1el Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: N= phenoxazine
US-10-013-295-54

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 697
US-10-013-295-55
; Sequence 55, Application US/10013295
; Publication No. US20030175906A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  TITLE OF INVENTION: Nuclease Resistant Chimeric Oligonucleotides
;  FILE REFERENCE: ISIS4948
;  CURRENT APPLICATION NUMBER: US/10/013,295
;  CURRENT FILING DATE:  2001-12-10
;  PRIOR APPLICATION NUMBER: 60/302,682
;  PRIOR FILING DATE: 2001-07-03
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030175906A1el Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: N= G-clamp modification
US-10-013-295-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 698
US-10-096-221-3/c
; Sequence 3, Application US/10096221
; Publication No. US20020164628A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000700
;  CURRENT APPLICATION NUMBER: US/10/096,221
;  CURRENT FILING DATE:  2002-06-27
;  PRIOR APPLICATION NUMBER: US 60/274,236
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-10-096-221-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 699
US-10-098-816-15
; Sequence 15, Application US/10098816
; Publication No. US20030105311A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-10-098-816-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 700
US-10-098-816-16
; Sequence 16, Application US/10098816
; Publication No. US20030105311A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE linkage
US-10-098-816-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 701
US-10-098-816-17
; Sequence 17, Application US/10098816
; Publication No. US20030105311A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-10-098-816-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 702
US-10-098-816-18
; Sequence 18, Application US/10098816
; Publication No. US20030105311A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2' - O-MOE
US-10-098-816-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 703
US-10-098-816-26
; Sequence 26, Application US/10098816
; Publication No. US20030105311A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
US-10-098-816-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 704
US-10-100-321-22/c
; Sequence 22, Application US/10100321
; Publication No. US20030087251A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/100,321
;  CURRENT FILING DATE:  2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-10-100-321-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 705
US-10-100-321-24/c
; Sequence 24, Application US/10100321
; Publication No. US20030087251A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/100,321
;  CURRENT FILING DATE:  2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-100-321-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 706
US-10-123-597-1
; Sequence 1, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
```

```
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-aminooxyethoxy
US-10-123-597-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 707
US-10-123-597-12
; Sequence 12, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 708
US-10-123-597-14
; Sequence 14, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 709
US-10-123-597-15
; Sequence 15, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 710
US-10-123-597-2
; Sequence 2, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'dimethylaminooxyethoxy
US-10-123-597-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 711
US-10-123-597-25
; Sequence 25, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methyleneiminooxyethoxy
US-10-123-597-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 712
US-10-123-597-3
; Sequence 3, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methoxyethoxy
US-10-123-597-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 713
US-10-123-597-4
; Sequence 4, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 714
US-10-123-597-5
; Sequence 5, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
US-10-123-597-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 715
US-10-123-597-6
; Sequence 6, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-O-propyl
US-10-123-597-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 716
US-10-123-597-7
; Sequence 7, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 5-methyl-2'dimethylaminooxyethoxy
US-10-123-597-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 717
US-10-123-597-8
; Sequence 8, Application US/10123597
; Publication No. US20030078415A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
```

```
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
US-10-123-597-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 718
US-10-170-172-16
; Sequence 16, Application US/10170172
; Publication No. US20030190632A1
; GENERAL INFORMATION:
;  APPLICANT: SOSNOWSKI, RONALD G
;  APPLICANT:  BUTLER, WILLIAM F
;  APPLICANT:  TU, EUGENE
;  APPLICANT:  NERENBERG, MICHAEL I
;  APPLICANT:  HELLER, MICHAEL J
;  APPLICANT:  EDMAN, CARL F
;  TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING MICROELECTRONIC
;  TITLE OF INVENTION:  INTEGRATED SYSTEMS, COMPONENT DEVICES, MECHANISMS,
;  TITLE OF INVENTION:  METHODS, AND PROCEDURES FOR MOLECULAR BIOLOGICAL
;  TITLE OF INVENTION:  ANALYSIS AND DIAGNOSTICS
;  FILE REFERENCE: DAVID B. MURPHY:  Nanogen 227/194
;  CURRENT APPLICATION NUMBER: US/10/170,172
;  CURRENT FILING DATE:  2002-06-11
;  PRIOR APPLICATION NUMBER: US/08/986,065
;  PRIOR FILING DATE: 1997-12-05
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Amine
;   OTHER INFORMATION: conjugate to provide reactivity with dyes
US-10-170-172-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 719
US-10-199-559-1/c
; Sequence 1, Application US/10199559
; Publication No. US20030099975A1
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Biotechnology Inc.
;  APPLICANT:  Barnett, Charles Jason
;  APPLICANT:  Beck, Jim
;  TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase
;  TITLE OF INVENTION:  Chain Reaction
;  FILE REFERENCE: 60063P1
;  CURRENT APPLICATION NUMBER: US/10/199,559
;  CURRENT FILING DATE:  2002-07-19
;  PRIOR APPLICATION NUMBER: US/09/939,379B
;  PRIOR FILING DATE: 2002-04-08
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1) . .(19)
;   OTHER INFORMATION: Primer ITS1
US-10-199-559-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 720
US-10-205-309-325/c
; Sequence 325, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 325
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-205-309-325

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 721
US-10-205-309-650
; Sequence 650, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 650
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-205-309-650

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
```

```
                    ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 722
US-10-206-693-551/c
; Sequence 551, Application US/10206693
; Publication No. US20050261212A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Nogo and Nogo Receptor Ge
;  TITLE OF INVENTION:  Expression using Short Interfering RNA
;  FILE REFERENCE: 900/034 (MBHB02-732)
;  CURRENT APPLICATION NUMBER: US/10/206,693
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 551
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-206-693-551

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 723
US-10-206-693-650
; Sequence 650, Application US/10206693
; Publication No. US20050261212A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Nogo and Nogo Receptor Ge
;  TITLE OF INVENTION:  Expression using Short Interfering RNA
;  FILE REFERENCE: 900/034 (MBHB02-732)
;  CURRENT APPLICATION NUMBER: US/10/206,693
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 650
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-206-693-650

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 724
US-10-208-357-25/c
; Sequence 25, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
;  APPLICANT: Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION: Peptide Acceptor Ligation Methods
;  FILE REFERENCE: 50036/031002
;  CURRENT APPLICATION NUMBER: US/10/208,357
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US/09/619,103
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: 60/145,834
;  PRIOR FILING DATE: 1999-07-27
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 725
US-10-210-130-354/c
; Sequence 354, Application US/10210130
; Publication No. US20040014053A1
; GENERAL INFORMATION:
;  APPLICANT: Zerhusen, Bryan D.
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Kekuda, Ramesh
;  APPLICANT:  Miller, Charles E.
;  APPLICANT:  Rieger, Daniel K.
;  APPLICANT:  Pena, Carol E.A.
;  APPLICANT:  Shimkets, Richard A.
;  APPLICANT:  Li, Li
;  APPLICANT:  Berghs, Constance
;  APPLICANT:  Zhong, Mei
;  APPLICANT:  Casman, Stacie J.
;  APPLICANT:  Voss, Edward Z.
;  APPLICANT:  Boldog, Ferenc L.
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Ji, Weizhen
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Vernet, Corine A.M.
;  APPLICANT:  Leite, Mario W.
;  APPLICANT:  Guo, Xiaojia Sasha
;  APPLICANT:  Anderson, David W.
;  APPLICANT:  Spytek, Kimberly A.
;  APPLICANT:  Gerlach, Valerie
;  APPLICANT:  Burgess, Catherine E.
;  APPLICANT:  Khramtsov, Nikolai V.
;  APPLICANT:  Ort, Tatiana
;  APPLICANT:  Ellerman, Karen
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Agee, Michele L.
;  APPLICANT:  Chaudhuri, Amitabha
;  APPLICANT:  Chant, John S.
;  APPLICANT:  DiPippo, Vincent A.
;  APPLICANT:  Edinger, Shlomit R.
;  APPLICANT:  Eisen, Andrew J.
;  APPLICANT:  Gangolli, Esha A.
;  APPLICANT:  Giot, Loic
;  APPLICANT:  Ooi, Chean Eng
;  APPLICANT:  Rothenberg, Mark E.
;  APPLICANT:  Spaderna, Steven K.
;  APPLICANT:  Hjalt, Tord
```

```
;  APPLICANT:  Liu, Xiaohong
;  APPLICANT:  Taupier, Raymond J., Jr.
;  APPLICANT:  Catterton, Elina
;  APPLICANT:  Shenoy, Suresh G.
;  TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
;  FILE REFERENCE: 21402-416C (Cura-716 SMT)
;  CURRENT APPLICATION NUMBER: US/10/210,130
;  CURRENT FILING DATE:  2002-08-01
;  PRIOR APPLICATION NUMBER: 60/309,501
;  PRIOR FILING DATE: 2001-08-02
;  PRIOR APPLICATION NUMBER: 60/316,508
;  PRIOR FILING DATE: 2001-08-31
;  PRIOR APPLICATION NUMBER: 60/354,655
;  PRIOR FILING DATE: 2002-02-05
;  PRIOR APPLICATION NUMBER: 60/310,291
;  PRIOR FILING DATE: 2001-08-03
;  PRIOR APPLICATION NUMBER: 60/383,887
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: 60/310,951
;  PRIOR FILING DATE: 2001-08-08
;  PRIOR APPLICATION NUMBER: 60/323,936
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: 60/381,039
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/311,292
;  PRIOR FILING DATE: 2001-08-09
;  PRIOR APPLICATION NUMBER: 60/311,979
;  PRIOR FILING DATE: 2001-08-13
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 369
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 354
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artifical Sequence:  Primer/Probe
US-10-210-130-354

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 8e+02;
  Matches   11;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3803 CAACUCCUGCCUUCUC 3818
              ||||:||:|||::|:|
Db         19 CAACTCCTGCCTTCTC 4


RESULT 726
US-10-232-881-1
; Sequence 1, Application US/10232881
; Publication No. US20030088088A1
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga
;  APPLICANT:  Manoharan, Muthia
;  APPLICANT:  Capaldi, Daniel
;  APPLICANT:  Krotz, Achim
;  APPLICANT:  Cole, Douglas
;  APPLICANT:  Guzaev, Andrei
;  TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric
;  TITLE OF INVENTION:  Compounds
;  FILE REFERENCE: ISIS3380
;  CURRENT APPLICATION NUMBER: US/10/232,881
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: US/09/288,679
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/118,564
;  PRIOR FILING DATE: 1999-02-04
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: No. US20030088088A1el Sequence
US-10-232-881-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 727
US-10-247-893-13
; Sequence 13, Application US/10247893
; Publication No. US20030092046A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-10-247-893-13

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 728
US-10-247-893-3
; Sequence 3, Application US/10247893
; Publication No. US20030092046A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
```

```
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-10-247-893-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 729
US-10-247-893-7
; Sequence 7, Application US/10247893
; Publication No. US20030092046A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-10-247-893-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 730
US-10-322-242-1
; Sequence 1, Application US/10322242
; Publication No. US20030139586A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Maier, Martin
;  APPLICANT:  An, Haoyun
;  TITLE OF INVENTION: C3'-Methylene Hydrogen Phosphonate Oligomers and Related Compoun
;  FILE REFERENCE: ISIS-3312
;  CURRENT APPLICATION NUMBER: US/10/322,242
;  CURRENT FILING DATE:  2002-12-18
;  PRIOR APPLICATION NUMBER: US/09/349,033
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-10-322-242-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 731
US-10-331-109-33
; Sequence 33, Application US/10331109
; Publication No. US20030215891A1
; GENERAL INFORMATION:
;  APPLICANT: Bickel, et al.
;  TITLE OF INVENTION: Method for the qualitative and/or quantitative detection of mole
;  TITLE OF INVENTION:  interactions on probe arrays
;  FILE REFERENCE: 12671/1
;  CURRENT APPLICATION NUMBER: US/10/331,109
;  CURRENT FILING DATE:  2002-12-27
;  PRIOR APPLICATION NUMBER: PCT/EP01/07575
;  PRIOR FILING DATE: 2001-07-02
;  PRIOR APPLICATION NUMBER: DE 100 33 334.6
;  PRIOR FILING DATE: 2000-07-01
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Description of the artificial sequence:
;   OTHER INFORMATION: Oligonucleotide probe
US-10-331-109-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 732
US-10-359-328-26
; Sequence 26, Application US/10359328
; Publication No. US20040009938A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  TITLE OF INVENTION: METHODS OF ENHANCING RENAL UPTAKE OF OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-5140
;  CURRENT APPLICATION NUMBER: US/10/359,328
;  CURRENT FILING DATE:  2003-02-06
;  PRIOR APPLICATION NUMBER: US 09/370,625
```

```
;  PRIOR FILING DATE: 1999-08-06
;  PRIOR APPLICATION NUMBER: US 09/130,566
;  PRIOR FILING DATE: 1998-08-07
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-       5-methyl uridi
;   OTHER INFORMATION: sub-T)
US-10-359-328-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 733
US-10-359-328-5
; Sequence 5, Application US/10359328
; Publication No. US20040009938A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  TITLE OF INVENTION: METHODS OF ENHANCING RENAL UPTAKE OF OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-5140
;  CURRENT APPLICATION NUMBER: US/10/359,328
;  CURRENT FILING DATE:  2003-02-06
;  PRIOR APPLICATION NUMBER: US 09/370,625
;  PRIOR FILING DATE: 1999-08-06
;  PRIOR APPLICATION NUMBER: US 09/130,566
;  PRIOR FILING DATE: 1998-08-07
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-modified T
US-10-359-328-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 734
US-10-371-600-14/c
; Sequence 14, Application US/10371600
; Publication No. US20030180776A1
; GENERAL INFORMATION:
;  APPLICANT: WU, MING
;  APPLICANT:  ULLMAN, EDWIN F.
;  TITLE OF INVENTION: DETECTION BY SLIDING TEMPLATE AMPLIFICATION
;  FILE REFERENCE: 3817.10-2
;  CURRENT APPLICATION NUMBER: US/10/371,600
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: 60/359,223
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: 60/379,360
;  PRIOR FILING DATE: 2002-05-08
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-371-600-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 735
US-10-387-346B-154
; Sequence 154, Application US/10387346B
; Publication No. US20040117869A1
; GENERAL INFORMATION:
;  APPLICANT: Xu, Dongmei
;  TITLE OF INVENTION: Cloning of Cytochrome P450 Genes from
;  TITLE OF INVENTION:  Nicotiana
;  FILE REFERENCE: 78623
;  CURRENT APPLICATION NUMBER: US/10/387,346B
;  CURRENT FILING DATE:  2003-03-12
;  PRIOR APPLICATION NUMBER: 10/293,252
;  PRIOR FILING DATE: 2002-11-13
;  PRIOR APPLICATION NUMBER: 10/340,861
;  PRIOR FILING DATE: 2003-01-10
;  PRIOR APPLICATION NUMBER: 60/363,684
;  PRIOR FILING DATE: 2002-03-12
;  PRIOR APPLICATION NUMBER: 60/347,444
;  PRIOR FILING DATE: 2002-01-11
;  PRIOR APPLICATION NUMBER: 60/337,684
;  PRIOR FILING DATE: 2001-11-13
;  NUMBER OF SEQ ID NOS: 156
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 154
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Nicotiana
US-10-387-346B-154

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 736
US-10-453-372-1392/c
; Sequence 1392, Application US/10453372
; Publication No. US20060003323A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, et al.
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-589 A
```

```
;  CURRENT APPLICATION NUMBER: US/10/453,372
;  CURRENT FILING DATE:  2003-06-03
;  PRIOR APPLICATION NUMBER: 09/789390
;  PRIOR FILING DATE: 2001-02-23
;  PRIOR APPLICATION NUMBER: 60/185967
;  PRIOR FILING DATE: 2000-03-01
;  PRIOR APPLICATION NUMBER: 09/823187
;  PRIOR FILING DATE: 2001-03-29
;  PRIOR APPLICATION NUMBER: 60/195792
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: 09/839446
;  PRIOR FILING DATE: 2001-03-19
;  PRIOR APPLICATION NUMBER: 60/199476
;  PRIOR FILING DATE: 2000-03-25
;  PRIOR APPLICATION NUMBER: 09/863776
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: 60/208263
;  PRIOR FILING DATE: 2000-05-31
;  PRIOR APPLICATION NUMBER: 09/939398
;  PRIOR FILING DATE: 2001-08-24
;  PRIOR APPLICATION NUMBER: 60/227800
;  PRIOR FILING DATE: 2000-08-25
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1609
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 1392
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artifical Sequence:  Primer/Probe
US-10-453-372-1392

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 8e+02;
  Matches   14;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2452 AACCAGAAGGGCUCUG 2467
              ||||||||||||:|:|
Db         17 AACCAGAAGGGCTCTG 2


RESULT 737
US-10-468-250A-145/c
; Sequence 145, Application US/10468250A
; Publication No. US20040157287A1
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Limited
;  APPLICANT:  Greenland, Andrew James
;  APPLICANT:  Jepson, Ian
;  APPLICANT:  Martinez, Alberto
;  APPLICANT:  Roxbee Cox, Lynne Marie
;  TITLE OF INVENTION: REGULATORY ELEMENTS SUITABLE FOR USE IN GENE EXPRESSION
;  FILE REFERENCE: 50597/PPDUSPCT
;  CURRENT APPLICATION NUMBER: US/10/468,250A
;  CURRENT FILING DATE:  2003-08-11
;  PRIOR APPLICATION NUMBER: PCT/GB02/00633
;  PRIOR FILING DATE: 2002-02-13
;  PRIOR APPLICATION NUMBER: GB0103520.3
;  PRIOR FILING DATE: 2001-02-13
;  NUMBER OF SEQ ID NOS: 147
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 145
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide ITS
US-10-468-250A-145

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 738
US-10-490-726-1/c
; Sequence 1, Application US/10490726
; Publication No. US20050260584A1
; GENERAL INFORMATION:
;  APPLICANT: Lindsley et al.
;  TITLE OF INVENTION: NUCLEIC ACIDS FOR THE IDENTIFICATION OF FUNGI AND
;  TITLE OF INVENTION:  METHODS FOR USING THE SAME
;  FILE REFERENCE: 68177
;  CURRENT APPLICATION NUMBER: US/10/490,726
;  CURRENT FILING DATE:  2004-03-24
;  PRIOR APPLICATION NUMBER: PCT/US02/30605
;  PRIOR FILING DATE: 2002-09-25
;  PRIOR APPLICATION NUMBER: US 60/325,241
;  PRIOR FILING DATE: 2001-09-26
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Universal forward primer
US-10-490-726-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 739
US-10-514-861-31/c
; Sequence 31, Application US/10514861
; Publication No. US20050170358A1
; GENERAL INFORMATION:
;  APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS
;  APPLICANT:  REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND
;  APPLICANT:  HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
;  APPLICANT:  Morrison, Christine J.
;  APPLICANT:  Hinrikson, Hans Peter
;  TITLE OF INVENTION: MOLECULAR IDENTIFICATION OF ASPERGILLUS SPECIES
;  FILE REFERENCE: 6395-64951-06
;  CURRENT APPLICATION NUMBER: US/10/514,861
;  CURRENT FILING DATE:  2004-11-16
;  PRIOR APPLICATION NUMBER: PCT/US03/16076
;  PRIOR FILING DATE: 2003-05-16
;  PRIOR APPLICATION NUMBER: US 60/381,463
;  PRIOR FILING DATE: 2002-05-17
;  NUMBER OF SEQ ID NOS: 67
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer.
US-10-514-861-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
```

```
                  ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 740
US-10-623-880-1/c
; Sequence 1, Application US/10623880
; Publication No. US20040029255A1
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Biotechnology Inc.
;  APPLICANT:  Barnett, Charles Jason
;  APPLICANT:  Beck, Jim
;  TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase
;  TITLE OF INVENTION:  Chain Reaction
;  FILE REFERENCE: 60063P1
;  CURRENT APPLICATION NUMBER: US/10/623,880
;  CURRENT FILING DATE:  2003-07-21
;  PRIOR APPLICATION NUMBER: US/09/939,379B
;  PRIOR FILING DATE: 2001-08-24
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Primer ITS1
US-10-623-880-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                  ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 741
US-10-700-884-23
; Sequence 23, Application US/10700884
; Publication No. US20050037370A1
; GENERAL INFORMATION:
;  APPLICANT: Baker, Brenda F.
;  APPLICANT:  Eldrup, Anne B.
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Bhat, Balkrishen
;  APPLICANT:  Griffey, Richard
;  APPLICANT:  Swayze, Eric E.
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Rajeev, Kallanthottathil G.
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
;  TITLE OF INVENTION:  AND GUANINE AND THEIR USE IN GENE MODULATION
;  FILE REFERENCE: ISIS-5317
;  CURRENT APPLICATION NUMBER: US/10/700,884
;  CURRENT FILING DATE:  2003-11-04
;  PRIOR APPLICATION NUMBER: US 10/635,380
;  PRIOR FILING DATE: 2003-08-06
;  PRIOR APPLICATION NUMBER: US 60/423,760
;  PRIOR FILING DATE: 2002-11-05
;  PRIOR APPLICATION NUMBER: US 10/078,949
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/479,783
;  PRIOR FILING DATE: 2000-01-07
;  PRIOR APPLICATION NUMBER: US 08/870,608
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: US 08/659,440
;  PRIOR FILING DATE: 1996-06-06
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 742
US-10-700-884-23
; Sequence 23, Application US/10700884
; Publication No. US20050118605A9
; GENERAL INFORMATION:
;  APPLICANT: Baker, Brenda F.
;  APPLICANT:  Eldrup, Anne B.
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Bhat, Balkrishen
;  APPLICANT:  Griffey, Richard
;  APPLICANT:  Swayze, Eric E.
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Rajeev, Kallanthottathil G.
;  TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
;  TITLE OF INVENTION:  AND GUANINE AND THEIR USE IN GENE MODULATION
;  FILE REFERENCE: ISIS-5317
;  CURRENT APPLICATION NUMBER: US/10/700,884
;  CURRENT FILING DATE:  2003-11-04
;  PRIOR APPLICATION NUMBER: US 10/635,380
;  PRIOR FILING DATE: 2003-08-06
;  PRIOR APPLICATION NUMBER: US 60/423,760
;  PRIOR FILING DATE: 2002-11-05
;  PRIOR APPLICATION NUMBER: US 10/078,949
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/479,783
;  PRIOR FILING DATE: 2000-01-07
;  PRIOR APPLICATION NUMBER: US 08/870,608
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: US 08/659,440
;  PRIOR FILING DATE: 1996-06-06
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 743
US-10-757-093-24/c
; Sequence 24, Application US/10757093
; Publication No. US20050153448A1
; GENERAL INFORMATION:
;  APPLICANT: CAMBIA
;  TITLE OF INVENTION: Fungal beta-glucuronidase genes and gene products
;  FILE REFERENCE: 415
;  CURRENT APPLICATION NUMBER: US/10/757,093
;  CURRENT FILING DATE:  2004-01-14
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: primer ITS-fwd1
US-10-757-093-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 744
US-10-760-940-1
; Sequence 1, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Capaldi, Daniel C.
;  APPLICANT:  Krotz, Achim
;  APPLICANT:  Cole, Douglas L.
;  APPLICANT:  Guzaev, Andrei
;  TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
;  FILE REFERENCE: ISIS-5422
;  CURRENT APPLICATION NUMBER: US/10/760,940
;  CURRENT FILING DATE:  2004-01-20
;  PRIOR APPLICATION NUMBER: US 10/232,881
;  PRIOR FILING DATE: 2002-08-30
;  PRIOR APPLICATION NUMBER: US 09/288,679
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: US 60/118,564
;  PRIOR FILING DATE: 1999-02-04
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-760-940-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 745
US-10-773-904-9/c
; Sequence 9, Application US/10773904
; Publication No. US20040259120A1
; GENERAL INFORMATION:
;  APPLICANT: Beck, Jim
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION: Detection of Fusarium Species infecting Corn Using the
;  TITLE OF INVENTION:  Polymerase Chain Reaction
;  FILE REFERENCE: 60055
;  CURRENT APPLICATION NUMBER: US/10/773,904
;  CURRENT FILING DATE:  2004-02-06
;  PRIOR APPLICATION NUMBER: US/09/961,755
;  PRIOR FILING DATE: 2001-09-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Primer ITS1
US-10-773-904-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 746
US-10-773-905-9/c
; Sequence 9, Application US/10773905
; Publication No. US20040259121A1
; GENERAL INFORMATION:
;  APPLICANT: Beck, Jim
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION: Detection of Fusarium Species infecting Corn Using the
;  TITLE OF INVENTION:  Polymerase Chain Reaction
;  FILE REFERENCE: 60055
;  CURRENT APPLICATION NUMBER: US/10/773,905
;  CURRENT FILING DATE:  2004-02-06
;  PRIOR APPLICATION NUMBER: US/09/961,755
;  PRIOR FILING DATE: 2001-09-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Primer ITS1
US-10-773-905-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 747
US-10-913-246-22/c
; Sequence 22, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/913,246
;  CURRENT FILING DATE:  2004-08-05
;  PRIOR APPLICATION NUMBER: US/10/100,321
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 748
US-10-913-246-24/c
; Sequence 24, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/913,246
;  CURRENT FILING DATE:  2004-08-05
;  PRIOR APPLICATION NUMBER: US/10/100,321
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-913-246-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 749
US-10-923-379-163/c
; Sequence 163, Application US/10923379
; Publication No. US20050239731A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  Chowrira, Bharat
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of MAP Kinase Gene
;  TITLE OF INVENTION:  Expression or Expression of Genes Involved in MAP Kinase Pathway
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 03-040-D; (400.233)
;  CURRENT APPLICATION NUMBER: US/10/923,379
;  CURRENT FILING DATE:  2004-08-20
;  NUMBER OF SEQ ID NOS: 2360
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 163
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-923-379-163

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 750
US-10-923-379-326
; Sequence 326, Application US/10923379
; Publication No. US20050239731A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Haeberli, Peter
;  APPLICANT:  Chowrira, Bharat
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of MAP Kinase Gene
;  TITLE OF INVENTION:  Expression or Expression of Genes Involved in MAP Kinase Pathway
;  TITLE OF INVENTION:  Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 03-040-D; (400.233)
;  CURRENT APPLICATION NUMBER: US/10/923,379
;  CURRENT FILING DATE:  2004-08-20
;  NUMBER OF SEQ ID NOS: 2360
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-379-326

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 751
US-10-923-522-270/c
; Sequence 270, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
```

```
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 270
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-522-270

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              ||||||||||||||||
Db         18 CGGCAGCGGCGGCGGC 3


RESULT 752
US-10-923-522-7
; Sequence 7, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense
US-10-923-522-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              ||||||||||||||||
Db          2 CGGCAGCGGCGGCGGC 17


RESULT 753
US-10-934-890-22/c
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/934,890
;  CURRENT FILING DATE:  2004-09-03
;  PRIOR APPLICATION NUMBER: US/10/100,321
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 754
US-10-934-890-24/c
; Sequence 24, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
```

```
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/934,890
;  CURRENT FILING DATE:  2004-09-03
;  PRIOR APPLICATION NUMBER: US/10/100,321
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-934-890-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 755
US-10-934-944-363
; Sequence 363, Application US/10934944
; Publication No. US20060037096A1
; GENERAL INFORMATION:
;  APPLICANT: Xu, Dongmei
;  TITLE OF INVENTION: Cloning of Cytochrome P450 Genes From Nicotiana
;  FILE REFERENCE: 07678/141008
;  CURRENT APPLICATION NUMBER: US/10/934,944
;  CURRENT FILING DATE:  2004-09-03
;  PRIOR APPLICATION NUMBER: 10/686,947
;  PRIOR FILING DATE: 2003-10-16
;  PRIOR APPLICATION NUMBER: 60/503,989
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: 60/485,368
;  PRIOR FILING DATE: 2003-07-08
;  PRIOR APPLICATION NUMBER: 10/387,346
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: 10/340,861
;  PRIOR FILING DATE: 2003-01-10
;  PRIOR APPLICATION NUMBER: 10/293,252
;  PRIOR FILING DATE: 2002-11-13
;  PRIOR APPLICATION NUMBER: 60/418,933
;  PRIOR FILING DATE: 2002-10-16
;  PRIOR APPLICATION NUMBER: 60/363,684
;  PRIOR FILING DATE: 2002-03-12
;  PRIOR APPLICATION NUMBER: 60/347,444
;  PRIOR FILING DATE: 2002-01-11
;  PRIOR APPLICATION NUMBER: 60/337,684
;  PRIOR FILING DATE: 2001-11-13
;  NUMBER OF SEQ ID NOS: 387
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 363
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Nicotiana tabacum
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n = a, t, c, or g
US-10-934-944-363

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 756
US-10-940-360-1
; Sequence 1, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga
;  APPLICANT:  Manoharan, Muthia
;  APPLICANT:  Capaldi, Daniel
;  APPLICANT:  Krotz, Achim
;  APPLICANT:  Cole, Douglas
;  APPLICANT:  Guzaev, Andrei
;  TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
;  FILE REFERENCE: ISIS3380
;  CURRENT APPLICATION NUMBER: US/10/940,360
;  CURRENT FILING DATE:  2004-09-14
;  PRIOR APPLICATION NUMBER: US/09/288,679
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/118,564
;  PRIOR FILING DATE: 1999-02-04
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Novel Sequence
US-10-940-360-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 757
US-10-950-095-74
; Sequence 74, Application US/10950095
; Publication No. US20050223434A1
; GENERAL INFORMATION:
;  APPLICANT: ALEXANDROV, Nickolai, et. al.
;  TITLE OF INVENTION: NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR
;  TITLE OF INVENTION:  MODIFYING PLANT CHARACTERISTICS
;  FILE REFERENCE: 2750-1578PUS2
;  CURRENT APPLICATION NUMBER: US/10/950,095
;  CURRENT FILING DATE:  2004-09-23
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo dTV primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n is a, c, or g
US-10-950-095-74

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
```

```
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 758
US-10-950-321-2
; Sequence 2, Application US/10950321
; Publication No. US20050223422A1
; GENERAL INFORMATION:
;  APPLICANT: COOK, Zhihong et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1577PUS2
;  CURRENT APPLICATION NUMBER: US/10/950,321
;  CURRENT FILING DATE:  2004-09-23
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligo dTV primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n is a, c, or g
US-10-950-321-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 759
US-10-957-569-2
; Sequence 2, Application US/10957569
; Publication No. US20050246785A1
; GENERAL INFORMATION:
;  APPLICANT: COOK, Zhihong et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1577PUS3
;  CURRENT APPLICATION NUMBER: US/10/957,569
;  CURRENT FILING DATE:  2004-09-30
;  PRIOR APPLICATION NUMBER: US 10/950,321
;  PRIOR FILING DATE: 2004-09-23
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligo dTV primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n is a, c, or g
US-10-957-569-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 760
US-10-981-334-68
; Sequence 68, Application US/10981334
; Publication No. US20060008816A1
; GENERAL INFORMATION:
;  APPLICANT: LU, Yu-Ping et al.
;  TITLE OF INVENTION: PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: 2750-1581PUS2
;  CURRENT APPLICATION NUMBER: US/10/981,334
;  CURRENT FILING DATE:  2004-11-04
;  NUMBER OF SEQ ID NOS: 68
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 68
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo dTV primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n is a, c, or g
US-10-981-334-68

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 761
US-11-010-239-133
; Sequence 133, Application US/11010239
; Publication No. US20060015970A1
; GENERAL INFORMATION:
;  APPLICANT: Roger PENNELL
;  APPLICANT:  Jack OKAMURO
;  APPLICANT:  Richard SCHNEEBERGER
;  APPLICANT:  Yiwen FANG
;  APPLICANT:  Shing KWOK
;  APPLICANT:  Diane JOFUKU
;  APPLICANT:  Edward A. KIEGLE
;  APPLICANT:  Jonathan DONSON
;  APPLICANT:  Nestor APUYA
;  TITLE OF INVENTION: NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR
;  TITLE OF INVENTION:  MODIFYING PLANT CHARACTERISTICS
;  FILE REFERENCE: 2750-1585PUS2
;  CURRENT APPLICATION NUMBER: US/11/010,239
;  CURRENT FILING DATE:  2004-12-09
;  PRIOR APPLICATION NUMBER: US 60/529,352
;  PRIOR FILING DATE: 2003-12-12
;  NUMBER OF SEQ ID NOS: 133
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligo dTV primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n is a, c, or g
US-11-010-239-133

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 762
US-11-014-373-274
; Sequence 274, Application US/11014373
; Publication No. US20050196781A1
; GENERAL INFORMATION:
;  APPLICANT: Robin, Howard
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA INTERFERENCE MEDIATED INHIBITION OF STAT3 GENE EXPRESSION
;  TITLE OF INVENTION:  USING SHORT INTERFERING NUCLEIC ACID (siNA)
;  FILE REFERENCE: 400/241 MBHB04-1067
;  CURRENT APPLICATION NUMBER: US/11/014,373
;  CURRENT FILING DATE:  2004-12-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 678
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 274
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Target Sequence/siNA sense region
US-11-014-373-274

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 763
US-11-014-373-551/c
; Sequence 551, Application US/11014373
; Publication No. US20050196781A1
; GENERAL INFORMATION:
;  APPLICANT: Robin, Howard
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA INTERFERENCE MEDIATED INHIBITION OF STAT3 GENE EXPRESSION
;  TITLE OF INVENTION:  USING SHORT INTERFERING NUCLEIC ACID (siNA)
;  FILE REFERENCE: 400/241 MBHB04-1067
;  CURRENT APPLICATION NUMBER: US/11/014,373
;  CURRENT FILING DATE:  2004-12-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 678
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 551
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Target Sequence/siNA sense region
US-11-014-373-551

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 764
US-11-116-881A-2260
; Sequence 2260, Application US/11116881A
; Publication No. US20060041949A1
; GENERAL INFORMATION:
;  APPLICANT: Xu, Dongmei
;  APPLICANT:  Nielsen, Mark  T.
;  TITLE OF INVENTION: Nicotiana Nucleic Acid Molecules and Uses Thereof
;  FILE REFERENCE: 07678/141014
;  CURRENT APPLICATION NUMBER: US/11/116,881A
;  CURRENT FILING DATE:  2005-04-27
;  PRIOR APPLICATION NUMBER: 60/665,451
;  PRIOR FILING DATE: 2005-03-24
;  PRIOR APPLICATION NUMBER: 60/665,097
;  PRIOR FILING DATE: 2005-03-24
;  PRIOR APPLICATION NUMBER: 60/646,764
;  PRIOR FILING DATE: 2005-01-25
;  PRIOR APPLICATION NUMBER: 60/607,357
;  PRIOR FILING DATE: 2004-09-03
;  PRIOR APPLICATION NUMBER: 60/566,235
;  PRIOR FILING DATE: 2004-04-29
;  PRIOR APPLICATION NUMBER: 10/934,944
;  PRIOR FILING DATE: 2004-09-03
;  PRIOR APPLICATION NUMBER: 10/943,507
;  PRIOR FILING DATE: 2004-09-17
;  PRIOR APPLICATION NUMBER: 60/503,989
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: 60/485,368
;  PRIOR FILING DATE: 2003-07-08
;  PRIOR APPLICATION NUMBER: 60/418,933
;  PRIOR FILING DATE: 2002-10-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2300
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2260
;   LENGTH: 19
```

```
;   TYPE: DNA
;   ORGANISM: Nicotiana tabacum
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n = a, t, c, or g
US-11-116-881A-2260

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 765
US-11-148-593-3/c
; Sequence 3, Application US/11148593
; Publication No. US20060014182A1
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQEUNCES
;  FILE REFERENCE: 492692000701
;  CURRENT APPLICATION NUMBER: US/11/148,593
;  CURRENT FILING DATE:  2005-06-08
;  PRIOR APPLICATION NUMBER: 10/096,221
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: 60/274,236
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-11-148-593-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 766
US/10/763/c
; Sequence 161, Application US/10763039A
; Publication No. US20050239082A1
; GENERAL INFORMATION:
;  APPLICANT: Jarrell, Kevin A.
;  APPLICANT:  Vishwanath, Prashanth
;  APPLICANT:  Smith, Temple
;  APPLICANT:  Short, Glenn F.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0036
;  CURRENT APPLICATION NUMBER: US/10/763,039A
;  CURRENT FILING DATE:  2004-01-22
;  NUMBER OF SEQ ID NOS: 166
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Anti-alien in spike control concept. Sequences of alien genes designed by
US/10/763,039A-161

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 767
US/10/763/c
; Sequence 166, Application US/10763039A
; Publication No. US20050239082A1
; GENERAL INFORMATION:
;  APPLICANT: Jarrell, Kevin A.
;  APPLICANT:  Vishwanath, Prashanth
;  APPLICANT:  Smith, Temple
;  APPLICANT:  Short, Glenn F.
;  TITLE OF INVENTION: Alien Sequences
;  FILE REFERENCE: 2003320-0036
;  CURRENT APPLICATION NUMBER: US/10/763,039A
;  CURRENT FILING DATE:  2004-01-22
;  NUMBER OF SEQ ID NOS: 166
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Anti-alien in spike control concept. Sequences of alien genes designed by
US/10/763,039A-166

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 768
US-09-005-243-32
; Sequence 32, Application US/09005243
; Patent No. US20020018763A1
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/005,243
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/34465
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-005-243-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 769
US-09-005-243-33
; Sequence 33, Application US/09005243
; Patent No. US20020018763A1
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/005,243
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/34465
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-005-243-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 770
US-09-224-683-32
; Sequence 32, Application US/09224683
; Patent No. US20020031491A1
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
```

```
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 771
US-09-224-683-33
; Sequence 33, Application US/09224683
; Patent No. US20020031491A1
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 772
US-09-726-096A-1
; Sequence 1, Application US/09726096A
; Publication No. US20010016652A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Bac'
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS4528
;  CURRENT APPLICATION NUMBER: US/09/726,096A
;  CURRENT FILING DATE:  2000-11-29
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-09-726-096A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
```

```
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 773
US-09-760-500A-55/c
; Sequence 55, Application US/09760500A
; Patent No. US20020155442A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-715-A
;  CURRENT APPLICATION NUMBER: US/09/760,500A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-760-500A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 774
US-09-771-554-5
; Sequence 5, Application US/09771554
; Patent No. US20020155496A1
; GENERAL INFORMATION:
;  APPLICANT: CHARLES, Marie Helene
;  APPLICANT:  PIGA, Nadia
;  APPLICANT:  BATTAIL-POIROT, Nicole
;  APPLICANT:  VERON, Laurent
;  APPLICANT:  DELAIR, Thierry
;  APPLICANT:  MANDRAND, Bernard
;  TITLE OF INVENTION: SATURATED AND UNSATURATED ABIETANE DERIVATIVES, DERIVED CONJUGATE
;  TITLE OF INVENTION:  USES IN A DIAGNOSTIC COMPOSITION, A REAGENT AND A DEVICE
;  FILE REFERENCE: 108473
;  CURRENT APPLICATION NUMBER: US/09/771,554
;  CURRENT FILING DATE:  2001-01-31
;  PRIOR APPLICATION NUMBER: PCT/FR99/01846
;  PRIOR FILING DATE: 1999-07-27
;  PRIOR APPLICATION NUMBER: FR 98/10084
;  PRIOR FILING DATE: 1998-07-31
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-771-554-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 775
US-09-776-479-226
; Sequence 226, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-226

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 776
US-09-776-479-556
; Sequence 556, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
```

```
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 777
US-09-776-479-556
; Sequence 556, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 778
US-09-776-479-560/c
; Sequence 560, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-560

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 779
US-09-820-279B-55/c
; Sequence 55, Application US/09820279B
; Publication No. US20030022169A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1085-A
;  CURRENT APPLICATION NUMBER: US/09/820,279B
;  CURRENT FILING DATE:  2001-03-28
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-820-279B-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 780
US-09-880-505-83/c
; Sequence 83, Application US/09880505
; Publication No. US20030007976A1
; GENERAL INFORMATION:
;  APPLICANT: Watson, James D.
;  APPLICANT:  Tan, Paul L.J.
;  APPLICANT:  Prestidge, Ross
;  TITLE OF INVENTION: Methods and Compounds for the Treatment
;  TITLE OF INVENTION:  of Immunologically-Mediated Skin Disorders
;  FILE REFERENCE: 11000.1007c2
;  CURRENT APPLICATION NUMBER: US/09/880,505
;  CURRENT FILING DATE:  2001-06-13
```

```
;  PRIOR APPLICATION NUMBER: US 09/324,542
;  PRIOR FILING DATE: 1999-06-02
;  PRIOR APPLICATION NUMBER: US 08/997,080
;  PRIOR FILING DATE: 1997-12-23
;  NUMBER OF SEQ ID NOS: 194
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Made in a lab
US-09-880-505-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 781
US-09-881-535-2
; Sequence 2, Application US/09881535
; Publication No. US20030069410A1
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga T.
;  TITLE OF INVENTION: Methods For Preparing Oligonucleotides Having Chiral Phosphorothi
;  TITLE OF INVENTION:  Linkages
;  FILE REFERENCE: ISIS4785
;  CURRENT APPLICATION NUMBER: US/09/881,535
;  CURRENT FILING DATE:  2001-06-14
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030069410A1el Sequence
US-09-881-535-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 782
US-09-888-326-2/c
; Sequence 2, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphodiester backbone
US-09-888-326-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 783
US-09-888-326-838
; Sequence 838, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 838
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-838

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 784
US-09-888-326-839
; Sequence 839, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 839
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphodiester backbone
US-09-888-326-839

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 785
US-09-912-014-16
; Sequence 16, Application US/09912014
; Publication No. US20030059929A1
;   GENERAL INFORMATION:
;        APPLICANT: Heller, Michael J.; and Tu, Eugene
;        TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
;                            MICROELECTRONIC SYSTEMS AND DEVICES FOR
;                            MOLECULAR BIOLOGICAL ANALYSIS AND
;                            DIAGNOSTICS
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 611 West Sixth Street
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: USA
;             ZIP: 90017
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;             COMPUTER: IBM compatible
;             OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
;             SOFTWARE: WordPerfect (Version 5.1)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/912,014
;             FILING DATE: 24-Jul-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/146,504
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Warburg, Richard J.
;             REGISTRATION NUMBER: 32,327
;             REFERENCE/DOCKET NUMBER: 203/218
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (213) 489-1600
;             TELEFAX: (213) 955-0440
;             TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 16:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-912-014-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 786
US-09-916-369A-1
; Sequence 1, Application US/09916369A
; Publication No. US20020058802A1
; GENERAL INFORMATION:
;  APPLICANT: Dellinger, Douglas J
;  APPLICANT:  Perbost, Michael GM
;  APPLICANT:  Caruthers, Marvin H
;  APPLICANT:  Betley, Jason R
;  TITLE OF INVENTION: Synthesis of Polynucleotides Using Combined Oxidation/Deprotecti
;  TITLE OF INVENTION:  Chemistry
;  FILE REFERENCE: 10003869-1
;  CURRENT APPLICATION NUMBER: US/09/916,369A
;  CURRENT FILING DATE:  2001-07-21
;  PRIOR APPLICATION NUMBER: US 09/627,249
;  PRIOR FILING DATE: 2000-07-28
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic sequence
US-09-916-369A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 787
US-09-916-369A-3/c
; Sequence 3, Application US/09916369A
; Publication No. US20020058802A1
; GENERAL INFORMATION:
;  APPLICANT: Dellinger, Douglas J
;  APPLICANT:  Perbost, Michael GM
;  APPLICANT:  Caruthers, Marvin H
;  APPLICANT:  Betley, Jason R
;  TITLE OF INVENTION: Synthesis of Polynucleotides Using Combined Oxidation/Deprotecti
;  TITLE OF INVENTION:  Chemistry
;  FILE REFERENCE: 10003869-1
;  CURRENT APPLICATION NUMBER: US/09/916,369A
;  CURRENT FILING DATE:  2001-07-21
;  PRIOR APPLICATION NUMBER: US 09/627,249
;  PRIOR FILING DATE: 2000-07-28
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic sequence
US-09-916-369A-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 788
US-09-927-777A-55/c
; Sequence 55, Application US/09927777A
; Patent No. US20020172953A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-653-A
;  CURRENT APPLICATION NUMBER: US/09/927,777A
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 60/224,631
;  PRIOR FILING DATE: 2000-08-11
;  PRIOR APPLICATION NUMBER: 60/254,392
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/255,235
;  PRIOR FILING DATE: 2000-12-11
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-927-777A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 789
US-09-927-777A-70/c
; Sequence 70, Application US/09927777A
; Patent No. US20020172953A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-653-A
;  CURRENT APPLICATION NUMBER: US/09/927,777A
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 60/224,631
;  PRIOR FILING DATE: 2000-08-11
;  PRIOR APPLICATION NUMBER: 60/254,392
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/255,235
;  PRIOR FILING DATE: 2000-12-11
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-927-777A-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 790
US-09-957-313A-55/c
; Sequence 55, Application US/09957313A
; Publication No. US20030059777A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i3
;  CURRENT APPLICATION NUMBER: US/09/957,313A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
```

```
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-957-313A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 791
US-09-957-318A-55/c
; Sequence 55, Application US/09957318A
; Publication No. US20030049630A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i2
;  CURRENT APPLICATION NUMBER: US/09/957,318A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-957-318A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 792
US-09-961-949A-55/c
; Sequence 55, Application US/09961949A
; Patent No. US20020146720A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i1
;  CURRENT APPLICATION NUMBER: US/09/961,949A
;  CURRENT FILING DATE:  2001-09-20
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-961-949A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 793
US-09-966-312-55/c
; Sequence 55, Application US/09966312
; Patent No. US20020164605A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i5
;  CURRENT APPLICATION NUMBER: US/09/966,312
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
```

```
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-966-312-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 794
US-09-966-491A-55/c
; Sequence 55, Application US/09966491A
; Publication No. US20020182611A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i4
;  CURRENT APPLICATION NUMBER: US/09/966,491A
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-966-491A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 795
US-09-967-409A-55/c
; Sequence 55, Application US/09967409A
; Patent No. US20020155458A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i6
;  CURRENT APPLICATION NUMBER: US/09/967,409A
;  CURRENT FILING DATE:  2001-09-28
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-967-409A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 796
US-09-973-638A-55/c
; Sequence 55, Application US/09973638A
; Patent No. US20020137070A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i9
;  CURRENT APPLICATION NUMBER: US/09/973,638A
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
```

```
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-973-638A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 797
US-09-973-788A-55/c
; Sequence 55, Application US/09973788A
; Patent No. US20020127574A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i10
;  CURRENT APPLICATION NUMBER: US/09/973,788A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-973-788A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 798
US-09-974-007-55/c
; Sequence 55, Application US/09974007
; Patent No. US20020137071A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i8
;  CURRENT APPLICATION NUMBER: US/09/974,007
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-974-007-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 799
US-09-974-500A-55/c
; Sequence 55, Application US/09974500A
; Publication No. US20030049631A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i7
;  CURRENT APPLICATION NUMBER: US/09/974,500A
;  CURRENT FILING DATE:  2002-04-01
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
```

```
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-974-500A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 800
US-09-975-059A-55/c
; Sequence 55, Application US/09975059A
; Publication No. US20030143538A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i15
;  CURRENT APPLICATION NUMBER: US/09/975,059A
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 801
US-09-975-062A-55/c
; Sequence 55, Application US/09975062A
; Patent No. US20020155459A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i11
;  CURRENT APPLICATION NUMBER: US/09/975,062A
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-062A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 802
US-09-975-376A-55/c
; Sequence 55, Application US/09975376A
; Publication No. US20030054358A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i12
;  CURRENT APPLICATION NUMBER: US/09/975,376A
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
```

```
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-376A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 803
US-09-975-498-55/c
; Sequence 55, Application US/09975498
; Publication No. US20020160381A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i14
;  CURRENT APPLICATION NUMBER: US/09/975,498
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-498-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 804
US-09-976-378A-55/c
; Sequence 55, Application US/09976378A
; Patent No. US20020155461A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i25
;  CURRENT APPLICATION NUMBER: US/09/976,378A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-378A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 805
US-09-976-577-55/c
; Sequence 55, Application US/09976577
; Patent No. US20020155462A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i20
;  CURRENT APPLICATION NUMBER: US/09/976,577
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
```

```
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-577-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 806
US-09-976-601A-55/c
; Sequence 55, Application US/09976601A
; Publication No. US20030124528A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i16
;  CURRENT APPLICATION NUMBER: US/09/976,601A
;  CURRENT FILING DATE:  2001-10-15
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-601A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 807
US-09-976-617A-55/c
; Sequence 55, Application US/09976617A
; Patent No. US20020137072A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i24
;  CURRENT APPLICATION NUMBER: US/09/976,617A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-617A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 808
US-09-976-863A-55/c
; Sequence 55, Application US/09976863A
; Publication No. US20030068622A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i19
;  CURRENT APPLICATION NUMBER: US/09/976,863A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
```

```
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-863A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 809
US-09-976-900A-55/c
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i23
;  CURRENT APPLICATION NUMBER: US/09/976,900A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-900A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 810
US-09-976-968A-55/c
; Sequence 55, Application US/09976968A
; Publication No. US20030148282A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i17
;  CURRENT APPLICATION NUMBER: US/09/976,968A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-968A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 811
US-09-976-971A-55/c
; Sequence 55, Application US/09976971A
; Publication No. US20020182613A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i18
;  CURRENT APPLICATION NUMBER: US/09/976,971A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-971A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 812
US-09-981-344-55/c
; Sequence 55, Application US/09981344
; Publication No. US20030044805A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i22
;  CURRENT APPLICATION NUMBER: US/09/981,344
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-981-344-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 813
US-09-994-701B-5/c
; Sequence 5, Application US/09994701B
; Publication No. US20040152076A1
; GENERAL INFORMATION:
;  APPLICANT: Richard C. Willson and Jason C. Murphy
;  TITLE OF INVENTION: NUCLEIC ACID SEPARATION USING IMMOBILIZED METAL AFFINITY CHROMATC
;  FILE REFERENCE: 96605/13UTL
;  CURRENT APPLICATION NUMBER: US/09/994,701B
;  CURRENT FILING DATE:  2001-11-06
;  PRIOR APPLICATION NUMBER: 60/246292
;  PRIOR FILING DATE: 2000-11-06
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-09-994-701B-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 814
US-09-994-701B-6
; Sequence 6, Application US/09994701B
; Publication No. US20040152076A1
; GENERAL INFORMATION:
;  APPLICANT: Richard C. Willson and Jason C. Murphy
;  TITLE OF INVENTION: NUCLEIC ACID SEPARATION USING IMMOBILIZED METAL AFFINITY CHROMATC
;  FILE REFERENCE: 96605/13UTL
;  CURRENT APPLICATION NUMBER: US/09/994,701B
;  CURRENT FILING DATE:  2001-11-06
;  PRIOR APPLICATION NUMBER: 60/246292
;  PRIOR FILING DATE: 2000-11-06
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-09-994-701B-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 815
US-09-997-672-40
; Sequence 40, Application US/09997672
; Publication No. US20030061632A1
; GENERAL INFORMATION:
;  APPLICANT: Weterings, Koen
;  APPLICANT:  Apuya, Nestor R.
;  APPLICANT:  Tatarinova, Tatiana
;  APPLICANT:  Goldberg, Robert B.
;  APPLICANT:  The Regents of the University of California
;  APPLICANT:  Ceres, Inc.
;  TITLE OF INVENTION: Polynucleotides Useful for Modulationg Transcription
;  FILE REFERENCE: 02307O-115810US
;  CURRENT APPLICATION NUMBER: US/09/997,672
;  CURRENT FILING DATE:  2001-11-28
;  PRIOR APPLICATION NUMBER: US 60/253,672
;  PRIOR FILING DATE: 2000-11-28
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn Ver. 2.1
```

; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligo(dT-20)
; OTHER INFORMATION: primer
US-09-997-672-40

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 7.8e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 816
US-10-008-978-55/c
; Sequence 55, Application US/10008978
; Publication No. US20030087242A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: Park, So-Jung
; APPLICANT: Lu, Gang
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-1272-C
; CURRENT APPLICATION NUMBER: US/10/008,978
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: 09/927,777
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/224,631
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,418
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/255,236
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: 60/282,640
; PRIOR FILING DATE: 2000-04-01
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-10-008-978-55

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 7.8e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 817
US-10-008-978-70/c
; Sequence 70, Application US/10008978
; Publication No. US20030087242A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; APPLICANT: Garimella, Viswanadham
; APPLICANT: Li, Zhi
; APPLICANT: Park, So-Jung
; APPLICANT: Lu, Gang
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-1272-C
; CURRENT APPLICATION NUMBER: US/10/008,978
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: 09/927,777
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/820,279
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 09/760,500
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/176,409
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/192,699
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; PRIOR APPLICATION NUMBER: 60/213,906
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 60/224,631
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/254,392
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,418
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/255,235
; PRIOR FILING DATE: 2000-12-11

```
;  PRIOR APPLICATION NUMBER: 60/255,236
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 60/282,640
;  PRIOR FILING DATE: 2000-04-01
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-008-978-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 818
US-10-017-995-226
; Sequence 226, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-226

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 819
US-10-017-995-556
; Sequence 556, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 820
US-10-017-995-560/c
; Sequence 560, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-560

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 821
US-10-051-643-83/c
; Sequence 83, Application US/10051643
; Publication No. US20020197265A1
; GENERAL INFORMATION:
;  APPLICANT: Watson, James D.
;  APPLICANT:  Tan, Paul L. J.
;  TITLE OF INVENTION: Methods and Compounds for the Treatment
;  TITLE OF INVENTION:  of Immunologically-Mediated Diseases of the Respiratory
;  TITLE OF INVENTION:  System using Mycobacterium Vaccae
;  FILE REFERENCE: 11000.1008c2
;  CURRENT APPLICATION NUMBER: US/10/051,643
;  CURRENT FILING DATE:  2002-01-18
;  PRIOR APPLICATION NUMBER: US09/156,181
;  PRIOR FILING DATE: 1998-09-17
;  PRIOR APPLICATION NUMBER: US 08/996,624
;  PRIOR FILING DATE: 1997-12-23
;  NUMBER OF SEQ ID NOS: 208
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Made in a lab
US-10-051-643-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
```

```
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 822
US-10-077-383-5/c
; Sequence 5, Application US/10077383
; Publication No. US20030050444A1
; GENERAL INFORMATION:
;  APPLICANT: Haydock, Paul V.
;  APPLICANT:  U'Ren, Jack
;  APPLICANT:  Saigene Corporation
;  TITLE OF INVENTION: Nucleic Acid Amplification Using an RNA Polymerase and
;  TITLE OF INVENTION:  DNA/RNA Mixed Polymer Intermediate Products
;  FILE REFERENCE: 018048-001710US
;  CURRENT APPLICATION NUMBER: US/10/077,383
;  CURRENT FILING DATE:  2002-02-15
;  PRIOR APPLICATION NUMBER: US 60/296,812
;  PRIOR FILING DATE: 2001-06-07
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:(A)-12-20
;   OTHER INFORMATION: homopolymer spacer sequence
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(20)
;   OTHER INFORMATION: a at positions 13-20 may be present or absent
US-10-077-383-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 823
US-10-077-383-6
; Sequence 6, Application US/10077383
; Publication No. US20030050444A1
; GENERAL INFORMATION:
;  APPLICANT: Haydock, Paul V.
;  APPLICANT:  U'Ren, Jack
;  APPLICANT:  Saigene Corporation
;  TITLE OF INVENTION: Nucleic Acid Amplification Using an RNA Polymerase and
;  TITLE OF INVENTION:  DNA/RNA Mixed Polymer Intermediate Products
;  FILE REFERENCE: 018048-001710US
;  CURRENT APPLICATION NUMBER: US/10/077,383
;  CURRENT FILING DATE:  2002-02-15
;  PRIOR APPLICATION NUMBER: US 60/296,812
;  PRIOR FILING DATE: 2001-06-07
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:(T)-12-20
;   OTHER INFORMATION: homopolymer spacer sequence
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(20)
;   OTHER INFORMATION: t at positions 13-20 may be present or absent
US-10-077-383-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 824
US-10-112-653-218
; Sequence 218, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-218

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 825
US-10-112-653-533
; Sequence 533, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 533
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-533

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 826
US-10-112-653-537/c
; Sequence 537, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 537
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-537

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 827
US-10-117-267-1
; Sequence 1, Application US/10117267
; Publication No. US20030045698A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Ph.D., Martin A.
;  TITLE OF INVENTION: Compounds,Processes And Intermediates For Synthesis Of Mixed Back
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS-5039
;  CURRENT APPLICATION NUMBER: US/10/117,267
;  CURRENT FILING DATE:  2002-04-05
;  PRIOR APPLICATION NUMBER: 09/726,096
;  PRIOR FILING DATE: 2000-11-29
;  PRIOR APPLICATION NUMBER: 09/250,075
;  PRIOR FILING DATE: 1999-02-12
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-10-117-267-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 828
US-10-175-608-32
; Sequence 32, Application US/10175608
; Publication No. US20040181044A1
;  GENERAL INFORMATION:
;       APPLICANT: Zsebo, Krisztina M.
;                  Bosselman, Robert A.
;                  Suggs, Sidney V.
;                  Martin, Francis H.
;       TITLE OF INVENTION: Stem Cell Factor
;       NUMBER OF SEQUENCES: 104
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;            STREET: 6300 Sears Tower, 233 South Wacker Drive
;            CITY: Chicago
;            STATE: Illinois
;            COUNTRY: United States of America
;            ZIP: 60606-6402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/175,608
;            FILING DATE: 16-Oct-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/635,249
;            FILING DATE: 07-AUG-2000
;            APPLICATION NUMBER: 09/486,546
;            FILING DATE: 24-MAY-1995
;            APPLICATION NUMBER: 08/172,329
;            FILING DATE: 21-DEC-1993
;            APPLICATION NUMBER: 07/982,255
;            FILING DATE: 25-NOV-1992
;            APPLICATION NUMBER: 07/684,535
;            FILING DATE: 10-APR-1991
;            APPLICATION NUMBER: 09/589,701
;            FILING DATE: 10-OCT-1991
;            APPLICATION NUMBER: 07/573,616
;            FILING DATE: 24-AUG-1990
;            APPLICATION NUMBER: 07/537,198
;            FILING DATE: 11-JUN-1990
;            APPLICATION NUMBER: 07/422,383
;            FILING DATE: 16-OCT-1989
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Clough, David W.
;            REGISTRATION NUMBER: 36,107
;            REFERENCE/DOCKET NUMBER: 01017/35199
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 312/474-6300
;            TELEFAX: 312/474-0448
;            TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 32:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-175-608-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
```

```
                :::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 829
US-10-175-608-33
; Sequence 33, Application US/10175608
; Publication No. US20040181044A1
;  GENERAL INFORMATION:
;       APPLICANT: Zsebo, Krisztina M.
;                  Bosselman, Robert A.
;                  Suggs, Sidney V.
;                  Martin, Francis H.
;       TITLE OF INVENTION: Stem Cell Factor
;       NUMBER OF SEQUENCES: 104
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;            STREET: 6300 Sears Tower, 233 South Wacker Drive
;            CITY: Chicago
;            STATE: Illinois
;            COUNTRY: United States of America
;            ZIP: 60606-6402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/175,608
;            FILING DATE: 16-Oct-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/635,249
;            FILING DATE: 07-AUG-2000
;            APPLICATION NUMBER: 09/486,546
;            FILING DATE: 24-MAY-1995
;            APPLICATION NUMBER: 08/172,329
;            FILING DATE: 21-DEC-1993
;            APPLICATION NUMBER: 07/982,255
;            FILING DATE: 25-NOV-1992
;            APPLICATION NUMBER: 07/684,535
;            FILING DATE: 10-APR-1991
;            APPLICATION NUMBER: 09/589,701
;            FILING DATE: 10-OCT-1991
;            APPLICATION NUMBER: 07/573,616
;            FILING DATE: 24-AUG-1990
;            APPLICATION NUMBER: 07/537,198
;            FILING DATE: 11-JUN-1990
;            APPLICATION NUMBER: 07/422,383
;            FILING DATE: 16-OCT-1989
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Clough, David W.
;            REGISTRATION NUMBER: 36,107
;            REFERENCE/DOCKET NUMBER: 01017/35199
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 312/474-6300
;            TELEFAX: 312/474-0448
;            TELEX: <Unknown>
;  INFORMATION FOR SEQ ID NO: 33:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-175-608-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                :::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 830
US-10-176-055-11/c
; Sequence 11, Application US/10176055
; Publication No. US20030013109A1
; GENERAL INFORMATION:
;  APPLICANT: Evident Technologies
;  TITLE OF INVENTION: Haiprin Sensors Using Quenchable Fluorescing Agents
;  FILE REFERENCE: 11739/26
;  CURRENT APPLICATION NUMBER: US/10/176,055
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: 60/299,460
;  PRIOR FILING DATE: 2001-06-21
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown Organism
;   FEATURE:
;   OTHER INFORMATION: Description of Unknown Organism: Target sequence
;   FEATURE:
;   OTHER INFORMATION: Target sequence that is desired to be detected and
;   OTHER INFORMATION: that has a nucleotide sequence that is
;   OTHER INFORMATION: complementary to the sequence of complementary
;   OTHER INFORMATION: probe of hairpin loop assembly
US-10-176-055-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                :::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 831
US-10-181-200-10
; Sequence 10, Application US/10181200
; Publication No. US20030212267A1
; GENERAL INFORMATION:
;  APPLICANT: Cole, Douglas L.
;  APPLICANT:  Ravikumar, Vasulinga T.
;  APPLICANT:  Cheruvallath, Zacharia S.
;  TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4709
;  CURRENT APPLICATION NUMBER: US/10/181,200
;  CURRENT FILING DATE:  2002-12-12
;  PRIOR APPLICATION NUMBER: PCT/US01/00715
;  PRIOR FILING DATE: 2001-01-10
;  PRIOR APPLICATION NUMBER: US 09/481,486
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methoyxethyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: phosphorothioate 20-mer
US-10-181-200-10
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 832
US-10-181-200-15
; Sequence 15, Application US/10181200
; Publication No. US20030212267A1
; GENERAL INFORMATION:
;  APPLICANT: Cole, Douglas L.
;  APPLICANT:  Ravikumar, Vasulinga T.
;  APPLICANT:  Cheruvallath, Zacharia S.
;  TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4709
;  CURRENT APPLICATION NUMBER: US/10/181,200
;  CURRENT FILING DATE:  2002-12-12
;  PRIOR APPLICATION NUMBER: PCT/US01/00715
;  PRIOR FILING DATE: 2001-01-10
;  PRIOR APPLICATION NUMBER: US 09/481,486
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: phosphorothioate 20-mer
US-10-181-200-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 833
US-10-188-404-66
; Sequence 66, Application US/10188404
; Publication No. US20030105286A1
; GENERAL INFORMATION:
;  APPLICANT: Egholm, Michael
;  APPLICANT:  Neilsen, Peter
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Dueholm, Kim L.
;  APPLICANT:  Christensen, Leif
;  APPLICANT:  Coull, James M.
;  APPLICANT:  Kiely, John
;  APPLICANT:  Griffith, Michael
;  TITLE OF INVENTION: Linked Peptide Nucleic Acids
;  FILE REFERENCE: ISIS5042
;  CURRENT APPLICATION NUMBER: US/10/188,404
;  CURRENT FILING DATE:  2002-07-01
;  PRIOR APPLICATION NUMBER: 08/275,951
;  PRIOR FILING DATE: 1994-07-15
;  PRIOR APPLICATION NUMBER: 08/765,798
;  PRIOR FILING DATE: 1997-04-23
;  NUMBER OF SEQ ID NOS: 69
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (10)..(11)
;   OTHER INFORMATION: Amino Hexanoic Acid, Amino Ethyl Glycine,
;   OTHER INFORMATION: Acetyl, Amino Hexanoic Acid Linkage
US-10-188-404-66

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 834
US-10-194-138-32/c
; Sequence 32, Application US/10194138
; Publication No. US20030082588A1
; GENERAL INFORMATION:
;  APPLICANT: Nanosphere, Inc.
;  APPLICANT:  Garimella, Viswanadham
;  TITLE OF INVENTION: Method for Immobilizing Molecules onto Surfaces
;  FILE REFERENCE: 01-897-B
;  CURRENT APPLICATION NUMBER: US/10/194,138
;  CURRENT FILING DATE:  2002-07-12
;  PRIOR APPLICATION NUMBER: 60/363472
;  PRIOR FILING DATE: 2002-03-12
;  PRIOR APPLICATION NUMBER: 60/305369
;  PRIOR FILING DATE: 2001-07-13
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: "a20" oligonucleotide probe
US-10-194-138-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 835
US-10-208-357-26/c
; Sequence 26, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
;  APPLICANT: Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION: Peptide Acceptor Ligation Methods
;  FILE REFERENCE: 50036/031002
;  CURRENT APPLICATION NUMBER: US/10/208,357
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US/09/619,103
;  PRIOR FILING DATE: 2000-07-19
```

```
;  PRIOR APPLICATION NUMBER: 60/145,834
;  PRIOR FILING DATE: 1999-07-27
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-10-208-357-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 836
US-10-234-764-10
; Sequence 10, Application US/10234764
; Publication No. US20030113769A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Lonnberg, Harri
;  APPLICANT:  Salo, Harri
;  APPLICANT:  Virta, Pasi
;  TITLE OF INVENTION: Aminooxy Functionalized Oligomers
;  FILE REFERENCE: ISIS5089
;  CURRENT APPLICATION NUMBER: US/10/234,764
;  CURRENT FILING DATE:  2002-09-03
;  PRIOR APPLICATION NUMBER: 09/016,520
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 09/344,260
;  PRIOR FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
US-10-234-764-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 837
US-10-252-093-2
; Sequence 2, Application US/10252093
; Publication No. US20030129734A1
; GENERAL INFORMATION:
;  APPLICANT: ABE, FUMIYOSHI
;  APPLICANT:  HORIKOSHI, KOKI
;  TITLE OF INVENTION: Copper tolerant yeast and its pectinase
;  FILE REFERENCE: 228375US0XCONT
;  CURRENT APPLICATION NUMBER: US/10/252,093
;  CURRENT FILING DATE:  2002-09-23
;  PRIOR APPLICATION NUMBER: PCT/JP01/02255
;  PRIOR FILING DATE: 2001-03-22
;  PRIOR APPLICATION NUMBER: JP 2000-83571
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
US-10-252-093-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   81.2%;  Pred. No. 7.8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db          3 CGCAGGTTCACCTACG 18


RESULT 838
US-10-255-434-14
; Sequence 14, Application US/10255434
; Publication No. US20030129626A1
; GENERAL INFORMATION:
;  APPLICANT: Nielsen, Kirsten V.
;  APPLICANT:  Hyldig-Nielsen, Jens J.
;  APPLICANT:  Williams, Brett F.
;  TITLE OF INVENTION: Methods, Kits And Compositions Pertaining To The
;  TITLE OF INVENTION:  Suppression Of Detectable Probe Binding To Randomly
;  TITLE OF INVENTION:  Distributed Repeat Sequences In Genomic Nucleic Acid
;  FILE REFERENCE: BP0101-US
;  CURRENT APPLICATION NUMBER: US/10/255,434
;  CURRENT FILING DATE:  2002-09-24
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:Synthetic
;   OTHER INFORMATION: Oligomer Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic Probe
;   OTHER INFORMATION: Sequence
US-10-255-434-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 839
US-10-255-434-26/c
; Sequence 26, Application US/10255434
; Publication No. US20030129626A1
; GENERAL INFORMATION:
;  APPLICANT: Nielsen, Kirsten V.
;  APPLICANT:  Hyldig-Nielsen, Jens J.
;  APPLICANT:  Williams, Brett F.
;  TITLE OF INVENTION: Methods, Kits And Compositions Pertaining To The
;  TITLE OF INVENTION:  Suppression Of Detectable Probe Binding To Randomly
;  TITLE OF INVENTION:  Distributed Repeat Sequences In Genomic Nucleic Acid
;  FILE REFERENCE: BP0101-US
;  CURRENT APPLICATION NUMBER: US/10/255,434
;  CURRENT FILING DATE:  2002-09-24
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:Synthetic
;   OTHER INFORMATION: Oligomer Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic Probe
;   OTHER INFORMATION: Sequence
US-10-255-434-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 840
US-10-266-983-55/c
; Sequence 55, Application US/10266983
; Publication No. US20030207296A1
; GENERAL INFORMATION:
;  APPLICANT: Park, So-Jung
;  APPLICANT:  Taton, Thomas Andrew
;  APPLICANT:  Mirkin, Chad A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 01-1565-A
;  CURRENT APPLICATION NUMBER: US/10/266,983
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 82
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-266-983-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 841
US-10-266-983-70/c
; Sequence 70, Application US/10266983
; Publication No. US20030207296A1
; GENERAL INFORMATION:
;  APPLICANT: Park, So-Jung
;  APPLICANT:  Taton, Thomas Andrew
;  APPLICANT:  Mirkin, Chad A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 01-1565-A
;  CURRENT APPLICATION NUMBER: US/10/266,983
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 82
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-266-983-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 842
US-10-278-047-1
; Sequence 1, Application US/10278047
; Publication No. US20030143591A1
; GENERAL INFORMATION:
;  APPLICANT: Davies, Martin
;  APPLICANT:  Bruce, Ian
;  APPLICANT:  Wolter, Andreas
;  TITLE OF INVENTION: NUCLEIC ACID PROBES AND METHODS TO DETECT AND/OR QUANTIFY NUCLEIC
;  TITLE OF INVENTION:  ACID ANALYTES
;  FILE REFERENCE: PRO.07
;  CURRENT APPLICATION NUMBER: US/10/278,047
;  CURRENT FILING DATE:  2002-10-21
;  PRIOR APPLICATION NUMBER: 60/336,432
;  PRIOR FILING DATE: 2001-10-19
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
US-10-278-047-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 843
US-10-314-578-226
; Sequence 226, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-226

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 844
US-10-314-578-556
; Sequence 556, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 845
US-10-314-578-560/c
; Sequence 560, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-560

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 846
US-10-353-783-32
; Sequence 32, Application US/10353783
; Publication No. US20050261175A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
```

```
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/353,783
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/448,729
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;    INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-353-783-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 847
US-10-353-783-33
; Sequence 33, Application US/10353783
; Publication No. US20050261175A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/353,783
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/448,729
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;    INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-353-783-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 848
US-10-371-066-16
; Sequence 16, Application US/10371066
; Publication No. US20030162214A1
;   GENERAL INFORMATION:
;        APPLICANT: Heller, Michael J.; and Tu, Eugene
;        TITLE OF INVENTION: SELF-ADDRESSABLE SELF-ASSEMBLING
;                            MICROELECTRONIC SYSTEMS AND DEVICES FOR
;                            MOLECULAR BIOLOGICAL ANALYSIS AND
;                            DIAGNOSTICS
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 611 West Sixth Street
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: USA
;             ZIP: 90017
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;             COMPUTER: IBM compatible
```

```
;             OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
;             SOFTWARE: WordPerfect (Version 5.1)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/371,066
;             FILING DATE: 21-Feb-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/146,504
;             FILING DATE: No. US20030162214Alember 1, 1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Warburg, Richard J.
;             REGISTRATION NUMBER: 32,327
;             REFERENCE/DOCKET NUMBER: 203/218
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (213) 489-1600
;             TELEFAX: (213) 955-0440
;             TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 16:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-371-066-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 849
US-10-410-324-55/c
; Sequence 55, Application US/10410324
; Publication No. US20030180783A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-I26
;  CURRENT APPLICATION NUMBER: US/10/410,324
;  CURRENT FILING DATE:  2003-04-09
;  PRIOR APPLICATION NUMBER: 09/961,949
;  PRIOR FILING DATE: 2001-09-20
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-410-324-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 850
US-10-431-341-31/c
; Sequence 31, Application US/10431341
; Publication No. US20040086897A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad
;  APPLICANT:  Cao , Yun-Wei
;  APPLICANT:  Jin, Rongchao
;  TITLE OF INVENTION: Nanoparticle Probes with Raman Spectroscopic Fingerprints for An
;  TITLE OF INVENTION:  Detection
;  FILE REFERENCE: 02-338-C
;  CURRENT APPLICATION NUMBER: US/10/431,341
;  CURRENT FILING DATE:  2003-05-07
;  PRIOR APPLICATION NUMBER: US 60/378,538
;  PRIOR FILING DATE: 2002-05-07
;  PRIOR APPLICATION NUMBER: US 60/383,630
;  PRIOR FILING DATE: 2002-05-28
;  PRIOR APPLICATION NUMBER: US 10/172,428
;  PRIOR FILING DATE: 2002-06-14
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 31
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: Synthetic target sequence
US-10-431-341-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 851
US-10-601-140A-1
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-601-140A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 852
US-10-601-140A-10
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (3)..(5)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (10)..(12)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (17)..(19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 853
US-10-601-140A-2
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (3)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (5)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (7)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (9)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (11)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (15)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (17)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 854
US-10-601-140A-23
; Sequence 23, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
```

```
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: oligonucleotide capture probe
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (1)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (3)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (5)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (7)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (9)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (11)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (15)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (17)
;    OTHER INFORMATION: LNA monomer
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (19)
;    OTHER INFORMATION: LNA monomer
US-10-601-140A-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 855
US-10-601-140A-3
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: oligonucleotide
US-10-601-140A-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 856
US-10-601-140A-34/c
; Sequence 34, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: oligonucleotide linker
US-10-601-140A-34

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 857
US-10-601-140A-4
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
```

```
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (4)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (7)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (10)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (16)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 858
US-10-601-140A-40
; Sequence 40, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 40
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-601-140A-40

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 859
US-10-601-140A-44/c
; Sequence 44, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-601-140A-44

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 860
US-10-601-140A-6
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (3)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (7)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (11)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
```

```
;   LOCATION: (15)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 861
US-10-601-140A-7
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (4)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (9)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (14)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 862
US-10-601-140A-8
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 863
US-10-601-140A-9
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
;  APPLICANT: KAUPPINEN, SAKARI
;  APPLICANT:  JACOBSEN, NANA
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;  TITLE OF INVENTION:  NUCLEOTIDE SEQUENCE
;  FILE REFERENCE: 57764(71994)
;  CURRENT APPLICATION NUMBER: US/10/601,140A
;  CURRENT FILING DATE:  2003-06-20
;  PRIOR APPLICATION NUMBER: US 60/390,928
;  PRIOR FILING DATE: 2002-06-24
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (3)..(4)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (8)..(9)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (13)..(14)
;   OTHER INFORMATION: LNA monomer
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: LNA monomer
US-10-601-140A-9
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 864
US-10-620-642-32
; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/620,642
;             FILING DATE: 16-Jul-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/10/175,608
;             FILING DATE: 16-Oct-2002
;             APPLICATION NUMBER: 09/635,249
;             FILING DATE: 07-AUG-2000
;             APPLICATION NUMBER: 09/486,546
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 09/589,701
;             FILING DATE: 10-OCT-1991
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/35199
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:

US-10-620-642-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 865
US-10-620-642-33
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/620,642
;             FILING DATE: 16-Jul-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/10/175,608
;             FILING DATE: 16-Oct-2002
;             APPLICATION NUMBER: 09/635,249
;             FILING DATE: 07-AUG-2000
;             APPLICATION NUMBER: 09/486,546
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 09/589,701
;             FILING DATE: 10-OCT-1991
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/35199
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
```

```
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 866
US-10-640-618-55/c
; Sequence 55, Application US/10640618
; Publication No. US20040072231A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  So-Jung Park
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1085-G
;  CURRENT APPLICATION NUMBER: US/10/640,618
;  CURRENT FILING DATE:  2003-08-21
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/254,392
;  PRIOR FILING DATE: 2001-12-08
;  PRIOR APPLICATION NUMBER: 60/255,235
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-640-618-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 867
US-10-653-416-25
; Sequence 25, Application US/10653416
; Publication No. US20040110201A1
; GENERAL INFORMATION:
;  APPLICANT: RASHTCHIAN, AYOUB
;  APPLICANT:  SCHUSTER, DAVID M.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR CDNA SYNTHESIS
;  FILE REFERENCE: 38266-0011
;  CURRENT APPLICATION NUMBER: US/10/653,416
;  CURRENT FILING DATE:  2003-09-03
;  PRIOR APPLICATION NUMBER: 60/407,248
;  PRIOR FILING DATE: 2002-09-03
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-653-416-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 868
US-10-661-088-12/c
; Sequence 12, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0206
;  CURRENT APPLICATION NUMBER: US/10/661,088
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-088-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 869
US-10-661-088-15
; Sequence 15, Application US/10661088
```

```
; Publication No. US20040162253A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0206
;  CURRENT APPLICATION NUMBER: US/10/661,088
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-088-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 870
US-10-661-097-12/c
; Sequence 12, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0204
;  CURRENT APPLICATION NUMBER: US/10/661,097
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-097-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 871
US-10-661-097-15
; Sequence 15, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
;  FILE REFERENCE: 029849/0204
;  CURRENT APPLICATION NUMBER: US/10/661,097
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-097-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 872
US-10-661-099-12/c
; Sequence 12, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
;  FILE REFERENCE: 029849/0203
;  CURRENT APPLICATION NUMBER: US/10/661,099
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-099-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 873
```

```
US-10-661-099-15
; Sequence 15, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
;  FILE REFERENCE: 029849/0203
;  CURRENT APPLICATION NUMBER: US/10/661,099
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-099-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 874
US-10-661-355-12/c
; Sequence 12, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0208
;  CURRENT APPLICATION NUMBER: US/10/661,355
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-355-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 875
US-10-661-355-15
; Sequence 15, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0208
;  CURRENT APPLICATION NUMBER: US/10/661,355
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-355-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 876
US-10-661-402-12/c
; Sequence 12, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 029849/0207
;  CURRENT APPLICATION NUMBER: US/10/661,402
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-402-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5
```

```
RESULT 877
US-10-661-402-15
; Sequence 15, Application US/10661402
; Publication No. US20050153912A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 029849/0207
;  CURRENT APPLICATION NUMBER: US/10/661,402
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-402-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 878
US-10-661-403-12/c
; Sequence 12, Application US/10661403
; Publication No. US20050176661A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0202
;  CURRENT APPLICATION NUMBER: US/10/661,403
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-403-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 879
US-10-661-403-15
; Sequence 15, Application US/10661403
; Publication No. US20050176661A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
;  FILE REFERENCE: 029849/0202
;  CURRENT APPLICATION NUMBER: US/10/661,403
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-403-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 880
US-10-661-415-12/c
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
;  FILE REFERENCE: 029849/0205
;  CURRENT APPLICATION NUMBER: US/10/661,415
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-415-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db         20 TTTTTTTTTTTTTTT 5


RESULT 881
US-10-661-415-15
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, ANDREW
;  APPLICANT:  JUTEAU, JEAN-MARC
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
;  FILE REFERENCE: 029849/0205
;  CURRENT APPLICATION NUMBER: US/10/661,415
;  CURRENT FILING DATE:  2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-661-415-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 882
US-10-716-829-55/c
; Sequence 55, Application US/10716829
; Publication No. US20040110220A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-715-A
;  CURRENT APPLICATION NUMBER: US/10/716,829
;  CURRENT FILING DATE:  2003-11-18
;  PRIOR APPLICATION NUMBER: US/09/760,500A
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-716-829-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 883
US-10-728-078-14/c
; Sequence 14, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
;  APPLICANT: Lipovsek, Dasa
;  APPLICANT:  Wagner, Richard W
;  APPLICANT:  Kuimelis, Robert G
;  TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
;  TITLE OF INVENTION:  AND OTHER BINDING PROTEINS
;  FILE REFERENCE: 50036/021004
;  CURRENT APPLICATION NUMBER: US/10/728,078
;  CURRENT FILING DATE:  2003-12-03
;  PRIOR APPLICATION NUMBER: US/09/688,566
;  PRIOR FILING DATE: 2000-10-16
;  PRIOR APPLICATION NUMBER: US 60/111,737
;  PRIOR FILING DATE: 1998-12-10
;  PRIOR APPLICATION NUMBER: US 09/456,693
;  PRIOR FILING DATE: 1999-12-09
;  PRIOR APPLICATION NUMBER: US 09/515,260
;  PRIOR FILING DATE: 2000-02-29
;  NUMBER OF SEQ ID NOS: 202
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 884
US-10-728-078-23
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
;  APPLICANT: Lipovsek, Dasa
;  APPLICANT:  Wagner, Richard W
;  APPLICANT:  Kuimelis, Robert G
;  TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
;  TITLE OF INVENTION:  AND OTHER BINDING PROTEINS
;  FILE REFERENCE: 50036/021004
;  CURRENT APPLICATION NUMBER: US/10/728,078
;  CURRENT FILING DATE:  2003-12-03
;  PRIOR APPLICATION NUMBER: US/09/688,566
;  PRIOR FILING DATE: 2000-10-16
;  PRIOR APPLICATION NUMBER: US 60/111,737
```

```
;  PRIOR FILING DATE: 1998-12-10
;  PRIOR APPLICATION NUMBER: US 09/456,693
;  PRIOR FILING DATE: 1999-12-09
;  PRIOR APPLICATION NUMBER: US 09/515,260
;  PRIOR FILING DATE: 2000-02-29
;  NUMBER OF SEQ ID NOS: 202
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-728-078-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 885
US-10-728-399-87
; Sequence 87, Application US/10728399
; Publication No. US20040132078A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Colca, Jerry
;  TITLE OF INVENTION: ANTISENSE MODULATION OF mitoNEET EXPRESSION
;  FILE REFERENCE: 01455_1
;  CURRENT APPLICATION NUMBER: US/10/728,399
;  CURRENT FILING DATE:  2003-12-05
;  NUMBER OF SEQ ID NOS: 627
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 87
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human mitoNEET antisense
US-10-728-399-87

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 886
US-10-789-831-22/c
; Sequence 22, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
;  APPLICANT: Bao, Yijia P.
;  APPLICANT:  Muller, Uwe R.
;  TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH  UNIVERSAL NANOPARTICLE
;  TITLE OF INVENTION:  PROBES IN MICROARRAY ASSAY FORMAT
;  FILE REFERENCE: 03-214-A
;  CURRENT APPLICATION NUMBER: US/10/789,831
;  CURRENT FILING DATE:  2004-02-27
;  PRIOR APPLICATION NUMBER: US 60/450,268
;  PRIOR FILING DATE: 2003-02-27
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: detection probe
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: a comprises an epiandrosterone disulfide group
US-10-789-831-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 887
US-10-789-831-23
; Sequence 23, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
;  APPLICANT: Bao, Yijia P.
;  APPLICANT:  Muller, Uwe R.
;  TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH  UNIVERSAL NANOPARTICLE
;  TITLE OF INVENTION:  PROBES IN MICROARRAY ASSAY FORMAT
;  FILE REFERENCE: 03-214-A
;  CURRENT APPLICATION NUMBER: US/10/789,831
;  CURRENT FILING DATE:  2004-02-27
;  PRIOR APPLICATION NUMBER: US 60/450,268
;  PRIOR FILING DATE: 2003-02-27
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: detection probe
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: t comprises an epiandrosterone disulfide group
US-10-789-831-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 888
US-10-789-831-24/c
; Sequence 24, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
;  APPLICANT: Bao, Yijia P.
;  APPLICANT:  Muller, Uwe R.
;  TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH  UNIVERSAL NANOPARTICLE
;  TITLE OF INVENTION:  PROBES IN MICROARRAY ASSAY FORMAT
;  FILE REFERENCE: 03-214-A
;  CURRENT APPLICATION NUMBER: US/10/789,831
;  CURRENT FILING DATE:  2004-02-27
;  PRIOR APPLICATION NUMBER: US 60/450,268
;  PRIOR FILING DATE: 2003-02-27
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
```

```
;   FEATURE:
;   OTHER INFORMATION: detection probe
US-10-789-831-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 889
US-10-831-778-226
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-226

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 890
US-10-831-778-556
; Sequence 556, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-556

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 891
US-10-831-778-560/c
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/831,778
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 892
US-10-831-901A-29728
; Sequence 29728, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
```

```
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29728
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29728

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 893
US-10-831-901A-29729
; Sequence 29729, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29729
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29729

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 894
US-10-831-901A-29730
; Sequence 29730, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29730
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29730

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 895
US-10-831-901A-29731
; Sequence 29731, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
```

```
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29731
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29731

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 896
US-10-831-901A-29732
; Sequence 29732, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29732
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29732

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 897
US-10-831-901A-29733
; Sequence 29733, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
;  FILE REFERENCE: ISIS0083-100 (BIOL0008US)
;  CURRENT APPLICATION NUMBER: US/10/831,901A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/466,426
;  PRIOR FILING DATE: 2003-04-28
;  PRIOR APPLICATION NUMBER: 60/468,562
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/467,770
;  PRIOR FILING DATE: 2003-04-30
;  PRIOR APPLICATION NUMBER: 60/468,627
;  PRIOR FILING DATE: 2003-05-06
;  PRIOR APPLICATION NUMBER: 60/477,637
;  PRIOR FILING DATE: 2003-06-10
;  PRIOR APPLICATION NUMBER: 60/483,579
;  PRIOR FILING DATE: 2003-06-27
;  NUMBER OF SEQ ID NOS: 30063
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29733
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense compound
US-10-831-901A-29733

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 898
US-10-831-901A-29734
; Sequence 29734, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
;  APPLICANT: Crooke, Stanley T.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Massire, Christian
;  APPLICANT:  Hofstadler, Steven A.
;  APPLICANT:  Lowery, Kristin Sannes
;  APPLICANT:  Swayze, Eric
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  Bennett, C. Frank
;  TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;  TITLE OF INVENTION:  Acute Respiratory Syndrome (SARS)
```

; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29734
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29734

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 7.8e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 899
US-10-831-901A-29735
; Sequence 29735, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29735
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29735

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 7.8e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 900
US-10-831-901A-29736
; Sequence 29736, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29736
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29736

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 7.8e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 901
US-10-845-667-118/c
; Sequence 118, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Bibikova, Marina
; TITLE OF INVENTION: Methods and Compositions For Diagnosing
; TITLE OF INVENTION: Conditions Associated With Specific DNA Methylation Patterns
; FILE REFERENCE: 67234-091

```
;  CURRENT APPLICATION NUMBER: US/10/845,667
;  CURRENT FILING DATE:  2004-05-14
;  PRIOR APPLICATION NUMBER: 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1506
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapeins
US-10-845-667-118

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   56.2%;  Pred. No. 7.8e+02;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7000 GUGUGUGUGUGUGUGG 7015
              |:|:|:|:|:|:|:||
Db         19 GTGTGTGTGTGTGTGG 4


RESULT 902
US-10-847-502-10
; Sequence 10, Application US/10847502
; Publication No. US20050165226A1
; GENERAL INFORMATION:
;  APPLICANT: Cole, Douglas L.
;  APPLICANT:  Ravikumar, Vasulinga T.
;  APPLICANT:  Cheruvallath, Zacharia S.
;  TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4709
;  CURRENT APPLICATION NUMBER: US/10/847,502
;  CURRENT FILING DATE:  2004-05-17
;  PRIOR APPLICATION NUMBER: US/10/181,200
;  PRIOR FILING DATE: 2002-12-12
;  PRIOR APPLICATION NUMBER: PCT/US01/00715
;  PRIOR FILING DATE: 2001-01-10
;  PRIOR APPLICATION NUMBER: US 09/481,486
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methoyxethyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: phosphorothioate 20-mer
US-10-847-502-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 903
US-10-847-502-15
; Sequence 15, Application US/10847502
; Publication No. US20050165226A1
; GENERAL INFORMATION:
;  APPLICANT: Cole, Douglas L.
;  APPLICANT:  Ravikumar, Vasulinga T.
;  APPLICANT:  Cheruvallath, Zacharia S.
;  TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4709
;  CURRENT APPLICATION NUMBER: US/10/847,502
;  CURRENT FILING DATE:  2004-05-17
;  PRIOR APPLICATION NUMBER: US/10/181,200
;  PRIOR FILING DATE: 2002-12-12
;  PRIOR APPLICATION NUMBER: PCT/US01/00715
;  PRIOR FILING DATE: 2001-01-10
;  PRIOR APPLICATION NUMBER: US 09/481,486
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: phosphorothioate 20-mer
US-10-847-502-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 904
US-10-876-086-49
; Sequence 49, Application US/10876086
; Publication No. US20050066389A1
; GENERAL INFORMATION:
;  APPLICANT: Gallie, Daniel R.
;  APPLICANT:  Young, Todd E.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Genes Which Produce Staygreen Characteristics in Maize
;  TITLE OF INVENTION:  and Their Uses
;  FILE REFERENCE: 02307O-137010US
;  CURRENT APPLICATION NUMBER: US/10/876,086
;  CURRENT FILING DATE:  2004-06-23
;  NUMBER OF SEQ ID NOS: 50
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo-dT(20)
;   OTHER INFORMATION: primer
US-10-876-086-49

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 905
US-10-969-812A-11/c
```

```
; Sequence 11, Application US/10969812A
; Publication No. US20050196382A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 16051-11us
;  CURRENT APPLICATION NUMBER: US/10/969,812A
;  CURRENT FILING DATE:  2004-10-19
;  PRIOR APPLICATION NUMBER: US10/661,402
;  PRIOR FILING DATE: 2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: US 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: US 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-969-812A-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 906
US-10-969-812A-14
; Sequence 14, Application US/10969812A
; Publication No. US20050196382A1
; GENERAL INFORMATION:
;  APPLICANT: VAILLANT, Andrew
;  APPLICANT:  JUTEAU, Jean-Marc
;  TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
;  FILE REFERENCE: 16051-11us
;  CURRENT APPLICATION NUMBER: US/10/969,812A
;  CURRENT FILING DATE:  2004-10-19
;  PRIOR APPLICATION NUMBER: US10/661,402
;  PRIOR FILING DATE: 2003-09-12
;  PRIOR APPLICATION NUMBER: PCT/IB03/04573
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: US 60/430,934
;  PRIOR FILING DATE: 2002-12-05
;  PRIOR APPLICATION NUMBER: US 60/410,264
;  PRIOR FILING DATE: 2002-09-13
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-969-812A-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 907
US-10-973-783-495/c
; Sequence 495, Application US/10973783
; Publication No. US20050164246A1
; GENERAL INFORMATION:
;  APPLICANT: Fan, Jian-Bing
;  APPLICANT:  Bibikova, Marina
;  TITLE OF INVENTION: Methods and Compositions For Diagnosing
;  TITLE OF INVENTION:  Lung Cancer with Specific DNA Methylation Patterns
;  FILE REFERENCE: 67234-100
;  CURRENT APPLICATION NUMBER: US/10/973,783
;  CURRENT FILING DATE:  2004-10-25
;  PRIOR APPLICATION NUMBER: US 10/845,667
;  PRIOR FILING DATE: 2004-05-14
;  PRIOR APPLICATION NUMBER: US 60/471,488
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 1513
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 495
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe sequence (ASO1)
US-10-973-783-495

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   56.2%;  Pred. No. 7.8e+02;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7000 GUGUGUGUGUGUGUGG 7015
              |:|:|:|:|:|:|:||
Db         19 GTGTGTGTGTGTGTGG 4


RESULT 908
US-10-989-723-23
; Sequence 23, Application US/10989723
; Publication No. US20050255548A1
; GENERAL INFORMATION:
;  APPLICANT: Lipovsek, Dasa
;  APPLICANT:  Wagner, Richard W.
;  APPLICANT:  Kuimelis, Robert G.
;  TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
;  TITLE OF INVENTION:  AND OTHER BINDING PROTEINS
;  FILE REFERENCE: COTH-P05-507
;  CURRENT APPLICATION NUMBER: US/10/989,723
;  CURRENT FILING DATE:  2004-11-15
;  PRIOR APPLICATION NUMBER: US 09/515,260
;  PRIOR FILING DATE: 2000-02-29
;  PRIOR APPLICATION NUMBER: US 09/456,693
;  PRIOR FILING DATE: 1999-12-09
;  PRIOR APPLICATION NUMBER: US 60/111,737
;  PRIOR FILING DATE: 1998-12-10
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide primer
US-10-989-723-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 909
US-10-995-051-23
; Sequence 23, Application US/10995051
; Publication No. US20050250094A1
; GENERAL INFORMATION:
;  APPLICANT: Storhoff, James
;  APPLICANT:  Lucas, Adam
;  APPLICANT:  Muller, Uwe
;  APPLICANT:  Bao, Yijia P
;  TITLE OF INVENTION: Method for Detecting Analytes Based on Evanescent Illumination
;  TITLE OF INVENTION:  and Scatter-Based Detection of Nanoparticle Probe Complexes
;  FILE REFERENCE: MBHB-03-466-E
;  CURRENT APPLICATION NUMBER: US/10/995,051
;  CURRENT FILING DATE:  2004-11-22
;  PRIOR APPLICATION NUMBER: 10/854,848
;  PRIOR FILING DATE: 2004-05-27
;  PRIOR APPLICATION NUMBER: 60/474,569
;  PRIOR FILING DATE: 2003-05-30
;  PRIOR APPLICATION NUMBER: 60/499,034
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: 60/517,450
;  PRIOR FILING DATE: 2003-11-04
;  PRIOR APPLICATION NUMBER: 60/567,874
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: T20 oligonucleotide
US-10-995-051-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 910
US-10-995-051-26
; Sequence 26, Application US/10995051
; Publication No. US20050250094A1
; GENERAL INFORMATION:
;  APPLICANT: Storhoff, James
;  APPLICANT:  Lucas, Adam
;  APPLICANT:  Muller, Uwe
;  APPLICANT:  Bao, Yijia P
;  TITLE OF INVENTION: Method for Detecting Analytes Based on Evanescent Illumination
;  TITLE OF INVENTION:  and Scatter-Based Detection of Nanoparticle Probe Complexes
;  FILE REFERENCE: MBHB-03-466-E
;  CURRENT APPLICATION NUMBER: US/10/995,051
;  CURRENT FILING DATE:  2004-11-22
;  PRIOR APPLICATION NUMBER: 10/854,848
;  PRIOR FILING DATE: 2004-05-27
;  PRIOR APPLICATION NUMBER: 60/474,569
;  PRIOR FILING DATE: 2003-05-30
;  PRIOR APPLICATION NUMBER: 60/499,034
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: 60/517,450
;  PRIOR FILING DATE: 2003-11-04
;  PRIOR APPLICATION NUMBER: 60/567,874
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: T20 diluent
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: t is linked to a steroid
US-10-995-051-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 911
US-10-995-051-31/c
; Sequence 31, Application US/10995051
; Publication No. US20050250094A1
; GENERAL INFORMATION:
;  APPLICANT: Storhoff, James
;  APPLICANT:  Lucas, Adam
;  APPLICANT:  Muller, Uwe
;  APPLICANT:  Bao, Yijia P
;  TITLE OF INVENTION: Method for Detecting Analytes Based on Evanescent Illumination
;  TITLE OF INVENTION:  and Scatter-Based Detection of Nanoparticle Probe Complexes
;  FILE REFERENCE: MBHB-03-466-E
;  CURRENT APPLICATION NUMBER: US/10/995,051
;  CURRENT FILING DATE:  2004-11-22
;  PRIOR APPLICATION NUMBER: 10/854,848
;  PRIOR FILING DATE: 2004-05-27
;  PRIOR APPLICATION NUMBER: 60/474,569
;  PRIOR FILING DATE: 2003-05-30
;  PRIOR APPLICATION NUMBER: 60/499,034
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: 60/517,450
;  PRIOR FILING DATE: 2003-11-04
;  PRIOR APPLICATION NUMBER: 60/567,874
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Deoxyadenosine Spacer
US-10-995-051-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 912
US-11-050-983-55/c
; Sequence 55, Application US/11050983
; Publication No. US20060068378A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
```

```
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  APPLICANT:  Lu, Gang
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1272-C
;  CURRENT APPLICATION NUMBER: US/11/050,983
;  CURRENT FILING DATE:  2005-02-04
;  PRIOR APPLICATION NUMBER: US/10/008,978
;  PRIOR FILING DATE: 2001-12-07
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-11-050-983-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 913
US-11-050-983-70/c
; Sequence 70, Application US/11050983
; Publication No. US20060068378A1
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  APPLICANT:  Lu, Gang
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1272-C
;  CURRENT APPLICATION NUMBER: US/11/050,983
;  CURRENT FILING DATE:  2005-02-04
;  PRIOR APPLICATION NUMBER: US/10/008,978
;  PRIOR FILING DATE: 2001-12-07
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-11-050-983-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 914
US-11-066-434-7
; Sequence 7, Application US/11066434
; Publication No. US20050254998A1
; GENERAL INFORMATION:
;  APPLICANT: Ebara Corporation
;  TITLE OF INVENTION: REACTIVE DETECTION CHIP AND SPOTTER SUITABLE FOR MANUFACTURING TH
;  FILE REFERENCE: FP/E-6-883US
;  CURRENT APPLICATION NUMBER: US/11/066,434
;  CURRENT FILING DATE:  2005-02-28
;  NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 7
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe for microchip
US-11-066-434-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 915
US-11-081-880A-1
; Sequence 1, Application US/11081880A
; Publication No. US20060041115A1
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga
;  TITLE OF INVENTION: METHODS FOR PREPARING OLIGONUCLEOTIDES
;  TITLE OF INVENTION:  HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES
```

```
;  FILE REFERENCE: ISIS-5588
;  CURRENT APPLICATION NUMBER: US/11/081,880A
;  CURRENT FILING DATE:  2005-03-15
;  PRIOR APPLICATION NUMBER: 10/932,630
;  PRIOR FILING DATE: 2004-09-02
;  PRIOR APPLICATION NUMBER: 09/881,535
;  PRIOR FILING DATE: 2001-06-14
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Compound
US-11-081-880A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 916
US-11-083-210-1
; Sequence 1, Application US/11083210
; Publication No. US20050233360A1
; GENERAL INFORMATION:
;  APPLICANT: Davies, Martin
;  APPLICANT:  Bruce, Ian
;  APPLICANT:  Wolter, Andreas
;  TITLE OF INVENTION: NUCLEIC ACID PROBES AND METHODS TO DETECT AND/OR QUANTIFY NUCLEIC
;  TITLE OF INVENTION:  ACID ANALYTES
;  FILE REFERENCE: PRO.07
;  CURRENT APPLICATION NUMBER: US/11/083,210
;  CURRENT FILING DATE:  2005-03-16
;  PRIOR APPLICATION NUMBER: US/10/278,047
;  PRIOR FILING DATE: 2002-10-21
;  PRIOR APPLICATION NUMBER: 60/336,432
;  PRIOR FILING DATE: 2001-10-19
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
US-11-083-210-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 917
US-11-121-165A-10
; Sequence 10, Application US/11121165A
; Publication No. US20060014172A1
; GENERAL INFORMATION:
;  APPLICANT: Nanosphere, Inc
;  APPLICANT:  Muller, Uwe
;  APPLICANT:  Storhoff, James J
;  APPLICANT:  Senical, Michael J
;  APPLICANT:  Garimella, Viswanadham
;  TITLE OF INVENTION: Aptamer-Nanoparticle Conjugates and Method of Use For Target
;  TITLE OF INVENTION:  Analyte Detection
;  FILE REFERENCE: 04-060-A
;  CURRENT APPLICATION NUMBER: US/11/121,165A
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 10/995,051
;  PRIOR FILING DATE: 2004-11-22
;  PRIOR APPLICATION NUMBER: 60/567,874
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic sequence that is a poly-T oligonucleotide.
US-11-121-165A-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 918
US-11-121-165A-7/c
; Sequence 7, Application US/11121165A
; Publication No. US20060014172A1
; GENERAL INFORMATION:
;  APPLICANT: Nanosphere, Inc
;  APPLICANT:  Muller, Uwe
;  APPLICANT:  Storhoff, James J
;  APPLICANT:  Senical, Michael J
;  APPLICANT:  Garimella, Viswanadham
;  TITLE OF INVENTION: Aptamer-Nanoparticle Conjugates and Method of Use For Target
;  TITLE OF INVENTION:  Analyte Detection
;  FILE REFERENCE: 04-060-A
;  CURRENT APPLICATION NUMBER: US/11/121,165A
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 10/995,051
;  PRIOR FILING DATE: 2004-11-22
;  PRIOR APPLICATION NUMBER: 60/567,874
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic poly-A oligonucleotide
US-11-121-165A-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 919
US-11-127-654-218
; Sequence 218, Application US/11127654
; Publication No. US20050250726A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-218

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 920
US-11-127-654-533
; Sequence 533, Application US/11127654
; Publication No. US20050250726A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 533
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-533

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 921
US-11-127-654-537/c
; Sequence 537, Application US/11127654
; Publication No. US20050250726A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR TREATMENT OF NON-ALLERGIC
;  TITLE OF INVENTION:  INFLAMMATORY DISEASES
;  FILE REFERENCE: C1039.70060US01
;  CURRENT APPLICATION NUMBER: US/11/127,654
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 10/112,653
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 537
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-11-127-654-537

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 922
US-11-237-922-25
; Sequence 25, Application US/11237922
; Publication No. US20060068436A1
; GENERAL INFORMATION:
;  APPLICANT: RASHTCHIAN, AYOUB
;  APPLICANT:  SCHUSTER, DAVID M.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR CDNA SYNTHESIS
;  FILE REFERENCE: 38266-0011
;  CURRENT APPLICATION NUMBER: US/11/237,922
;  CURRENT FILING DATE:  2005-09-29
;  PRIOR APPLICATION NUMBER: US/10/653,416
;  PRIOR FILING DATE: 2003-09-03
;  PRIOR APPLICATION NUMBER: 60/407,248
;  PRIOR FILING DATE: 2002-09-03
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-11-237-922-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 7.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


Search completed: August 31, 2006, 15:03:13
Job time : 49 secs
```

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 14:59:20 ; Search time 424 Seconds
(without alignments)
7.190 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 10442 seqs, 198472 residues

Total number of hits satisfying chosen parameters: 20884

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

N_Geneseq

Database : ngsdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		40	0.5	40	1	AAQ34091	Sequence of a micr
c 2		40	0.5	40	1	AAT66054	(dC-dA)n.(dG-dT)n
c 3		40	0.5	40	1	AAT65725	Repeat sequence fr
c 4		40	0.5	40	1	AAT66051	(dC-dA)n.(dG-dT)n
c 5		40	0.5	40	1	AAS13773	Simple sequence re
c 6		40	0.5	40	1	ABK24300	Human microsatelli
7		39	0.5	39	1	AAQ33648	Microsatellite seq
8		39	0.5	39	1	AAQ33825	Microsatellite seq
9		39	0.5	39	1	AAQ33807	Microsatellite seq
c 10		39	0.5	39	1	AAT65731	Repeat sequence fr
11		39	0.5	39	1	ADH70484	Human Vbeta gene r
c 12		38.4	0.5	40	1	AAT65736	Repeat sequence fr
c 13		38.4	0.5	40	1	AAT65743	Repeat sequence fr
c 14		38	0.5	38	1	AAT65750	Repeat sequence fr
c 15		38	0.5	38	1	AAT66048	(dC-dA)n.(dG-dT)n
c 16		38	0.5	38	1	AAA65562	Porcine microsatel
c 17		38	0.5	38	1	ABK24299	Human microsatelli
c 18		37.4	0.5	39	1	AAT65714	Repeat sequence fr
19		37	0.5	37	1	AAQ34041	Microsatellite seq
20		37	0.5	37	1	AAQ34178	Microsatellite seq
21		37	0.5	37	1	AAQ33900	Microsatellite seq
c 22		37	0.5	37	1	AAT65732	Repeat sequence fr
c 23		36.8	0.5	40	1	AAZ98493	H. discus derived
c 24		36.4	0.5	38	1	AAT65708	Repeat sequence fr
25		36	0.5	36	1	AAQ33974	Microsatellite seq
26		36	0.5	36	1	AAQ33953	Microsatellite seq
27		36	0.5	36	1	AAQ34068	Microsatellite seq
28		36	0.5	36	1	AAQ33828	Microsatellite seq
29		36	0.5	36	1	AAQ33906	Microsatellite seq
30		36	0.5	36	1	AAQ33819	Microsatellite seq
31		36	0.5	36	1	AAQ33882	Microsatellite seq
c 32		36	0.5	36	1	AAT65784	Repeat sequence fr
c 33		36	0.5	36	1	AAT65720	Repeat sequence fr
34		36	0.5	36	1	AAS13713	Simple sequence re
c 35		36	0.5	36	1	ABK24298	Human microsatelli
c 36		36	0.5	36	1	ADO81134	Prion protein poly
c 37		36	0.5	36	1	ADO80224	Wheat SSR containi
c 38		36	0.5	36	1	ADR16078	Human PARP DNA 97-
39		35.8	0.5	39	1	AAQ33737	Microsatellite seq
c 40		35	0.5	35	1	AAT65711	Repeat sequence fr
c 41		35	0.5	35	1	AAT65747	Repeat sequence fr
c 42		35	0.5	38	1	AAQ68850	Human chromosomal
43		34	0.4	34	1	AAQ33692	Microsatellite seq
44		34	0.4	34	1	AAQ33776	Microsatellite seq
45		34	0.4	34	1	AAQ33921	Microsatellite seq
46		34	0.4	34	1	AAQ33873	Microsatellite seq
c 47		34	0.4	34	1	AAT65722	Repeat sequence fr
c 48		34	0.4	34	1	AAT65744	Repeat sequence fr
c 49		34	0.4	34	1	AAT65748	Repeat sequence fr
c 50		34	0.4	34	1	AAT65742	Repeat sequence fr
c 51		34	0.4	34	1	AAT65772	Repeat sequence fr
c 52		34	0.4	34	1	ABK24297	Human microsatelli
53		33.8	0.4	37	1	AAQ33669	Microsatellite seq
54		33.4	0.4	35	1	AAQ33713	Microsatellite seq
55		33	0.4	33	1	AAQ34097	Sequence of a micr
56		33	0.4	33	1	AAQ34009	Microsatellite seq
c 57		33	0.4	33	1	AAT65754	Repeat sequence fr
c 58		33	0.4	33	1	AAT65705	Repeat sequence fr
59		32.8	0.4	38	1	AAQ33894	Microsatellite seq
60		32.4	0.4	34	1	ADH70517	Human Vbeta gene r
61		32.2	0.4	37	1	AAQ33698	Microsatellite seq
62		32	0.4	32	1	AAQ33666	Microsatellite seq
c 63		32	0.4	32	1	AAT65790	Repeat sequence fr
c 64		32	0.4	32	1	AAT65752	Repeat sequence fr
c 65		32	0.4	32	1	AAX56155	Human alpha-7 nico
c 66		32	0.4	32	1	AAZ98487	H. discus derived
c 67		32	0.4	32	1	ABK24296	Human microsatelli
c 68		32	0.4	32	1	ADR88479	Alpha 7 nicotinic
69		31.6	0.4	38	1	AAQ33767	Microsatellite seq
70		31	0.4	31	1	AAQ34047	Microsatellite seq
71		31	0.4	31	1	AAQ33867	Microsatellite seq
72		31	0.4	31	1	AAQ34032	Microsatellite seq
73		31	0.4	31	1	AAQ33822	Microsatellite seq
74		31	0.4	31	1	AAQ33657	Microsatellite seq
c 75		31	0.4	31	1	AAT65765	Repeat sequence fr
c 76		31	0.4	31	1	AAT65759	Repeat sequence fr
c 77		31	0.4	31	1	AAT65753	Repeat sequence fr
78		30.8	0.4	34	1	AAD19466	Human flt-1 gene p
79		30.6	0.4	31	1	AAD19457	Human flt-1 gene p
80		30.6	0.4	31	1	AAD19459	Human flt-1 gene p
81		30.6	0.4	31	1	AAD19458	Human flt-1 gene p
82		30.6	0.4	37	1	AAQ33710	Microsatellite seq
83		30.4	0.4	32	1	AAQ34119	Sequence of a micr
c 84		30.4	0.4	32	1	AAT66057	(dC-dA)n.(dG-dT)n
85		30	0.4	30	1	AAQ33965	Microsatellite seq
c 86		30	0.4	30	1	AAT65789	Repeat sequence fr
c 87		30	0.4	30	1	AAS13788	Simple sequence re
88		30	0.4	30	1	AAS13787	Simple sequence re
89		30	0.4	30	1	AAL42354	Novel sand pear mi
90		29.8	0.4	33	1	AAQ33944	Microsatellite seq
91		29.2	0.4	35	1	AAQ33695	Microsatellite seq
92		29	0.4	29	1	AAQ33687	Microsatellite seq
93		29	0.4	29	1	AAQ33846	Microsatellite seq
94		29	0.4	29	1	AAQ33956	Microsatellite seq
95		29	0.4	29	1	AAQ33977	Microsatellite seq
c 96		29	0.4	29	1	AAQ83953	Oligonucleotide cl
c 97		29	0.4	29	1	AAT65760	Repeat sequence fr
c 98		29	0.4	29	1	AAT65712	Repeat sequence fr
c 99		29	0.4	29	1	AAF60474	Oligonucleotide cl
c 100		29	0.4	29	1	ABK66322	Human gene specifi
101		28.2	0.4	33	1	AAQ33731	Microsatellite seq
102		28	0.4	28	1	AAQ34027	Microsatellite seq
103		28	0.4	28	1	AAQ33645	Microsatellite seq
104		28	0.4	28	1	AAQ34161	Sequence of a micr
105		28	0.4	28	1	AAQ34035	Microsatellite seq
c 106		28	0.4	28	1	AAT66102	Repeat sequence fo

	107	28	0.4	28	1	AAA60165	Human Flt-1 gene p
c	108	28	0.4	28	1	AAS13711	Simple sequence re
c	109	28	0.4	28	1	AAD19467	Human flt-1 gene a
	110	28	0.4	31	1	AAD19462	Human flt-1 gene p
	111	27.4	0.4	29	1	ADH70471	Human Vbeta gene r
c	112	27.4	0.4	30	1	AAZ98502	H. discus derived
	113	27	0.4	27	1	AAQ34044	Microsatellite seq
	114	27	0.4	27	1	AAQ33678	Microsatellite seq
	115	27	0.4	27	1	AAQ33804	Microsatellite seq
	116	27	0.4	27	1	AAQ34181	Microsatellite seq
	117	27	0.4	27	1	AAQ34012	Microsatellite seq
	118	27	0.4	27	1	AAQ34143	Sequence of a micr
c	119	27	0.4	27	1	AAQ83951	Oligonucleotide cl
c	120	27	0.4	27	1	AAT65733	Repeat sequence fr
	121	27	0.4	27	1	AAH24300	Synthetic antineop
	122	27	0.4	27	1	AAH46017	Synthetic oligonuc
	123	27	0.4	27	1	AAH46001	Synthetic oligonuc
	124	27	0.4	27	1	AAH46005	Synthetic oligonuc
c	125	27	0.4	27	1	AAF60473	Oligonucleotide cl
	126	27	0.4	27	1	ABK66321	Human gene specifi
	127	27	0.4	27	1	ADH70576	Human Vbeta gene r
c	128	26.8	0.3	30	1	AAT66066	(dC-dA)n.(dG-dT)n
	129	26.8	0.3	30	1	ADH70406	Human Vbeta gene r
	130	26.4	0.3	28	1	AAQ34074	Microsatellite seq
	131	26.4	0.3	28	1	AAQ33843	Microsatellite seq
c	132	26.2	0.3	32	1	AAZ98509	H. discus derived
	133	26	0.3	26	1	AAQ34083	Microsatellite seq
	134	26	0.3	26	1	AAQ33684	Microsatellite seq
	135	26	0.3	26	1	AAQ33704	Microsatellite seq
	136	26	0.3	26	1	AAQ33831	Microsatellite seq
	137	26	0.3	26	1	AAQ33837	Microsatellite seq
c	138	26	0.3	26	1	ACC86710	Human VEGFR-1 reve
	139	26	0.3	26	1	ACC86711	Human VEGFR-1 prob
c	140	26	0.3	26	1	ADO81053	Cow prion protein
	141	25.8	0.3	29	1	AAQ33630	Microsatellite seq
	142	25.4	0.3	27	1	AAQ34077	Microsatellite seq
	143	25	0.3	25	1	AAQ33918	Microsatellite seq
	144	25	0.3	25	1	AAQ33642	Microsatellite seq
	145	25	0.3	25	1	AAQ33962	Microsatellite seq
	146	25	0.3	25	1	AAQ33861	Microsatellite seq
c	147	25	0.3	25	1	AAT65734	Repeat sequence fr
c	148	25	0.3	25	1	AAV17238	Primer #2 set #1 f
	149	25	0.3	25	1	AAV17239	Primer #1 set #2 f
	150	25	0.3	25	1	AAH38303	SNP specific SNPE
	151	25	0.3	25	1	ABQ80262	FLT-1 primer #3.
c	152	25	0.3	25	1	ABQ80263	FLT-1 primer #4.
	153	25	0.3	25	1	ABQ80260	FLT-1 primer #1.
	154	25	0.3	26	1	AAQ47179	MHC DR A intron bi
	155	25	0.3	31	1	AAD19463	Human flt-1 gene p
	156	24.2	0.3	30	1	AAA91139	PCR primer for chi
	157	24	0.3	24	1	AAQ33986	Microsatellite seq
	158	24	0.3	24	1	AAQ34158	Sequence of a micr
	159	24	0.3	24	1	AAQ33909	Microsatellite seq
	160	24	0.3	24	1	AAQ34065	Microsatellite seq
	161	24	0.3	24	1	AAQ34024	Microsatellite seq
	162	24	0.3	24	1	AAQ33707	Microsatellite seq
c	163	24	0.3	24	1	AAT66096	Repeat sequence fo
	164	24	0.3	24	1	AAH46015	Synthetic oligonuc
	165	24	0.3	24	1	AAH46016	Synthetic oligonuc
	166	24	0.3	24	1	AAF99862	Immunostimulatory
	167	24	0.3	24	1	AAI67482	Probe sequence use
c	168	24	0.3	24	1	AAH23019	VEGFR-1 gene speci
	169	24	0.3	24	1	ABS78584	Angiogenesis inhib
	170	24	0.3	24	1	ACH03377	Immunostimulatory
	171	24	0.3	24	1	ADB37364	Immunostimulatory
c	172	24	0.3	24	1	ABX90510	Human VEGFR-1 RT-P
c	173	24	0.3	24	1	ADO81094	Sheep prion protei
c	174	24	0.3	24	1	ADO81099	Sheep prion protei
c	175	24	0.3	24	1	ADO81051	Cow prion protein
c	176	24	0.3	24	1	ADR16077	Human PARP DNA 85-
c	177	24	0.3	24	1	ADR48240	Microarray synthes
	178	24	0.3	24	1	ADR48245	Microarray synthes
	179	24	0.3	24	1	ADU90384	Allergic response
	180	24	0.3	24	1	ADW26360	EGFR inhibitor can
	181	24	0.3	24	1	ADY89670	VEGF/VEGFR siRNA t
c	182	24	0.3	24	1	ADZ79699	Human FLT-1 cDNA,
	183	24	0.3	24	1	AED38906	VEGFR target regio
	184	24	0.3	24	1	AED75802	Immunostimulatory
c	185	24	0.3	25	1	AAH40163	SNP specific SNPE
	186	24	0.3	28	1	AAQ33933	Microsatellite seq
	187	23.8	0.3	27	1	AAQ33740	Microsatellite seq
c	188	23.4	0.3	25	1	AAH40155	SNP specific SNPE
c	189	23.4	0.3	25	1	AAH40159	SNP specific SNPE
c	190	23.4	0.3	25	1	ADG82647	Flt-1 gene probe.
	191	23	0.3	23	1	AAQ33663	Microsatellite seq
	192	23	0.3	23	1	AAQ33773	Microsatellite seq
	193	23	0.3	23	1	AAQ33885	Microsatellite seq
	194	23	0.3	23	1	AAQ74272	sVEGF-RTMI PCR pri
c	195	23	0.3	23	1	AAT66105	Repeat sequence fo
	196	23	0.3	23	1	AAV09341	Soluble truncated
	197	23	0.3	23	1	AAX04439	Primer #4 for gene
c	198	23	0.3	23	1	AAI67480	Forward primer use
c	199	23	0.3	23	1	AAI67484	Reverse primer use
	200	23	0.3	23	1	AAH23018	VEGFR-1 gene speci
c	201	23	0.3	23	1	AAF60472	Oligonucleotide cl
c	202	23	0.3	23	1	ABQ80261	FLT-1 primer #2.
	203	23	0.3	23	1	ADF37815	Human VEGFR1 short
	204	23	0.3	23	1	ADF37711	Human VEGFR1 short
	205	23	0.3	23	1	ADF37813	Human VEGFR1 short
	206	23	0.3	23	1	ADF37817	Human VEGFR1 short
	207	23	0.3	23	1	ADF37819	Human VEGFR1 short
	208	23	0.3	23	1	ADF37812	Human VEGFR1 short
	209	23	0.3	23	1	ADF37818	Human VEGFR1 short
	210	23	0.3	23	1	ADF37708	Human VEGFR1 short
	211	23	0.3	23	1	ADF37710	Human VEGFR1 short
	212	23	0.3	23	1	ADF37709	Human VEGFR1 short
	213	23	0.3	23	1	ADF37814	Human VEGFR1 short
	214	23	0.3	23	1	ADF37816	Human VEGFR1 short
	215	23	0.3	23	1	ADF48468	Human Myb mRNA tra
	216	23	0.3	23	1	ADF23241	Human ftl receptor
c	217	23	0.3	23	1	ADF88105	Single nucleotide
	218	23	0.3	23	1	ADG29494	FLT1 siNA-target R
	219	23	0.3	23	1	ADG29490	FLT1 siNA-target R
	220	23	0.3	23	1	ADG29495	FLT1 siNA-target R
	221	23	0.3	23	1	ADG29496	FLT1 siNA-target R
	222	23	0.3	23	1	ADG29497	FLT1 siNA-target R
	223	23	0.3	23	1	ADG29493	FLT1 siNA-target R
	224	23	0.3	23	1	ADG29492	FLT1 siNA-target R
	225	23	0.3	23	1	ADG29491	FLT1/MYB/PKR siNA-
	226	23	0.3	23	1	ABX90509	Human VEGFR-1 RT-P
	227	23	0.3	23	1	ADY89153	VEGF/VEGFR siRNA S
	228	23	0.3	23	1	ADY89265	VEGFR siRNA target
	229	23	0.3	23	1	ADY89291	VEGFR siRNA target
	230	23	0.3	23	1	ADY89315	VEGFR siRNA target
	231	23	0.3	23	1	ADY89324	VEGFR siRNA target
	232	23	0.3	23	1	ADY89340	VEGFR siRNA target
	233	23	0.3	23	1	ADY89341	VEGFR siRNA target
	234	23	0.3	23	1	ADY89348	VEGFR siRNA target
	235	23	0.3	23	1	ADY89353	VEGFR siRNA target
	236	23	0.3	23	1	ADY89355	VEGFR siRNA target
	237	23	0.3	23	1	ADY89362	VEGFR siRNA target
	238	23	0.3	23	1	ADY89201	VEGF/VEGFR siRNA S
	239	23	0.3	23	1	ADY89254	VEGFR siRNA target
	240	23	0.3	23	1	ADY89261	VEGFR siRNA target
	241	23	0.3	23	1	ADY89270	VEGFR siRNA target
	242	23	0.3	23	1	ADY89301	VEGFR siRNA target
	243	23	0.3	23	1	ADY89308	VEGFR siRNA target
	244	23	0.3	23	1	ADY89310	VEGFR siRNA target
	245	23	0.3	23	1	ADY89325	VEGFR siRNA target
	246	23	0.3	23	1	ADY89326	VEGFR siRNA target
	247	23	0.3	23	1	ADY89336	VEGFR siRNA target
	248	23	0.3	23	1	ADY89359	VEGFR siRNA target
	249	23	0.3	23	1	ADY89183	VEGF/VEGFR siRNA S
	250	23	0.3	23	1	ADY89191	VEGF/VEGFR siRNA S
	251	23	0.3	23	1	ADY89296	VEGFR siRNA target
	252	23	0.3	23	1	ADY89306	VEGFR siRNA target

253	23	0.3	23	1	ADY89320	VEGFR siRNA target
254	23	0.3	23	1	ADY89329	VEGFR siRNA target
255	23	0.3	23	1	ADY89332	VEGFR siRNA target
256	23	0.3	23	1	ADY89345	VEGFR siRNA target
257	23	0.3	23	1	ADY89354	VEGFR siRNA target
258	23	0.3	23	1	ADY89363	VEGFR siRNA target
259	23	0.3	23	1	ADY89249	VEGFR siRNA target
260	23	0.3	23	1	ADY89250	VEGFR siRNA target
261	23	0.3	23	1	ADY89264	VEGFR siRNA target
262	23	0.3	23	1	ADY89368	VEGFR siRNA target
263	23	0.3	23	1	ADY89671	VEGF/VEGFR DFO siR
264	23	0.3	23	1	ADY89187	VEGF/VEGFR siRNA S
265	23	0.3	23	1	ADY89252	VEGFR siRNA target
266	23	0.3	23	1	ADY89274	VEGFR siRNA target
267	23	0.3	23	1	ADY89295	VEGFR siRNA target
268	23	0.3	23	1	ADY89300	VEGFR siRNA target
269	23	0.3	23	1	ADY89358	VEGFR siRNA target
270	23	0.3	23	1	ADY89271	VEGFR siRNA target
271	23	0.3	23	1	ADY89286	VEGFR siRNA target
272	23	0.3	23	1	ADY89289	VEGFR siRNA target
273	23	0.3	23	1	ADY89293	VEGFR siRNA target
274	23	0.3	23	1	ADY89303	VEGFR siRNA target
275	23	0.3	23	1	ADY89307	VEGFR siRNA target
276	23	0.3	23	1	ADY89312	VEGFR siRNA target
277	23	0.3	23	1	ADY89356	VEGFR siRNA target
278	23	0.3	23	1	ADY89172	VEGF/VEGFR siRNA S
279	23	0.3	23	1	ADY89180	VEGF/VEGFR siRNA S
280	23	0.3	23	1	ADY89304	VEGFR siRNA target
281	23	0.3	23	1	ADY89338	VEGFR siRNA target
282	23	0.3	23	1	ADY89344	VEGFR siRNA target
283	23	0.3	23	1	ADY89357	VEGFR siRNA target
284	23	0.3	23	1	ADY89361	VEGFR siRNA target
285	23	0.3	23	1	ADY89262	VEGFR siRNA target
286	23	0.3	23	1	ADY89267	VEGFR siRNA target
287	23	0.3	23	1	ADY89279	VEGFR siRNA target
288	23	0.3	23	1	ADY89333	VEGFR siRNA target
289	23	0.3	23	1	ADY89339	VEGFR siRNA target
290	23	0.3	23	1	ADY89253	VEGFR siRNA target
291	23	0.3	23	1	ADY89256	VEGFR siRNA target
292	23	0.3	23	1	ADY89260	VEGFR siRNA target
293	23	0.3	23	1	ADY89269	VEGFR siRNA target
294	23	0.3	23	1	ADY89272	VEGFR siRNA target
295	23	0.3	23	1	ADY89273	VEGFR siRNA target
296	23	0.3	23	1	ADY89292	VEGFR siRNA target
297	23	0.3	23	1	ADY89305	VEGFR siRNA target
298	23	0.3	23	1	ADY89365	VEGFR siRNA target
299	23	0.3	23	1	ADY89218	VEGF/VEGFR siRNA S
300	23	0.3	23	1	ADY89278	VEGFR siRNA target
301	23	0.3	23	1	ADY89302	VEGFR siRNA target
302	23	0.3	23	1	ADY89309	VEGFR siRNA target
303	23	0.3	23	1	ADY89314	VEGFR siRNA target
304	23	0.3	23	1	ADY89337	VEGFR siRNA target
305	23	0.3	23	1	ADY89343	VEGFR siRNA target
306	23	0.3	23	1	ADY89364	VEGFR siRNA target
307	23	0.3	23	1	ADY89277	VEGFR siRNA target
308	23	0.3	23	1	ADY89285	VEGFR siRNA target
309	23	0.3	23	1	ADY89335	VEGFR siRNA target
310	23	0.3	23	1	ADY89342	VEGFR siRNA target
311	23	0.3	23	1	ADY89349	VEGFR siRNA target
312	23	0.3	23	1	ADY89350	VEGFR siRNA target
313	23	0.3	23	1	ADY89366	VEGFR siRNA target
314	23	0.3	23	1	ADY89165	VEGF/VEGFR siRNA S
315	23	0.3	23	1	ADY89212	VEGF/VEGFR siRNA S
316	23	0.3	23	1	ADY89251	VEGFR siRNA target
317	23	0.3	23	1	ADY89288	VEGFR siRNA target
318	23	0.3	23	1	ADY89298	VEGFR siRNA target
319	23	0.3	23	1	ADY89318	VEGFR siRNA target
320	23	0.3	23	1	ADY89323	VEGFR siRNA target
321	23	0.3	23	1	ADY89334	VEGFR siRNA target
322	23	0.3	23	1	ADY89347	VEGFR siRNA target
323	23	0.3	23	1	ADY89206	VEGF/VEGFR siRNA S
324	23	0.3	23	1	ADY89283	VEGFR siRNA target
325	23	0.3	23	1	ADY89284	VEGFR siRNA target
326	23	0.3	23	1	ADY89299	VEGFR siRNA target
327	23	0.3	23	1	ADY89313	VEGFR siRNA target
328	23	0.3	23	1	ADY89322	VEGFR siRNA target
329	23	0.3	23	1	ADY89328	VEGFR siRNA target
330	23	0.3	23	1	ADY89159	VEGF/VEGFR siRNA S
331	23	0.3	23	1	ADY89255	VEGFR siRNA target
332	23	0.3	23	1	ADY89294	VEGFR siRNA target
333	23	0.3	23	1	ADY89330	VEGFR siRNA target
334	23	0.3	23	1	ADY89331	VEGFR siRNA target
335	23	0.3	23	1	ADY89346	VEGFR siRNA target
336	23	0.3	23	1	ADY89352	VEGFR siRNA target
337	23	0.3	23	1	ADY89367	VEGFR siRNA target
338	23	0.3	23	1	ADY89176	VEGF/VEGFR siRNA S
339	23	0.3	23	1	ADY89266	VEGFR siRNA target
340	23	0.3	23	1	ADY89275	VEGFR siRNA target
341	23	0.3	23	1	ADY89280	VEGFR siRNA target
342	23	0.3	23	1	ADY89281	VEGFR siRNA target
343	23	0.3	23	1	ADY89282	VEGFR siRNA target
344	23	0.3	23	1	ADY89311	VEGFR siRNA target
345	23	0.3	23	1	ADY89316	VEGFR siRNA target
346	23	0.3	23	1	ADY89317	VEGFR siRNA target
347	23	0.3	23	1	ADY89196	VEGF/VEGFR siRNA S
348	23	0.3	23	1	ADY89222	VEGF/VEGFR siRNA S
349	23	0.3	23	1	ADY89263	VEGFR siRNA target
350	23	0.3	23	1	ADY89268	VEGFR siRNA target
351	23	0.3	23	1	ADY89276	VEGFR siRNA target
352	23	0.3	23	1	ADY89287	VEGFR siRNA target
353	23	0.3	23	1	ADY89290	VEGFR siRNA target
354	23	0.3	23	1	ADY89297	VEGFR siRNA target
355	23	0.3	23	1	ADY89319	VEGFR siRNA target
356	23	0.3	23	1	ADY89321	VEGFR siRNA target
357	23	0.3	23	1	ADY89327	VEGFR siRNA target
358	23	0.3	23	1	ADY89351	VEGFR siRNA target
359	23	0.3	23	1	ADY89360	VEGFR siRNA target
c 360	23	0.3	23	1	ADY80935	Human VEGFR1 rever
361	23	0.3	23	1	AED38441	VEGF or VEGFR-spec
362	23	0.3	23	1	AED38485	VEGFR target regio
363	23	0.3	23	1	AED38526	VEGFR target regio
364	23	0.3	23	1	AED38553	VEGFR target regio
365	23	0.3	23	1	AED38575	VEGFR target regio
366	23	0.3	23	1	AED38577	VEGFR target regio
367	23	0.3	23	1	AED38394	VEGF or VEGFR-spec
368	23	0.3	23	1	AED38411	VEGF or VEGFR-spec
369	23	0.3	23	1	AED38517	VEGFR target regio
370	23	0.3	23	1	AED38539	VEGFR target regio
371	23	0.3	23	1	AED38564	VEGFR target regio
372	23	0.3	23	1	AED38586	VEGFR target regio
373	23	0.3	23	1	AED38599	VEGFR target regio
374	23	0.3	23	1	AED38600	VEGFR target regio
375	23	0.3	23	1	AED38601	VEGFR target regio
376	23	0.3	23	1	AED38486	VEGFR target regio
377	23	0.3	23	1	AED38520	VEGFR target regio
378	23	0.3	23	1	AED38530	VEGFR target regio
379	23	0.3	23	1	AED38546	VEGFR target regio
380	23	0.3	23	1	AED38552	VEGFR target regio
381	23	0.3	23	1	AED38559	VEGFR target regio
382	23	0.3	23	1	AED38570	VEGFR target regio
383	23	0.3	23	1	AED38582	VEGFR target regio
384	23	0.3	23	1	AED38588	VEGFR target regio
385	23	0.3	23	1	AED38591	VEGFR target regio
386	23	0.3	23	1	AED38602	VEGFR target regio
387	23	0.3	23	1	AED38907	VEGFR target regio
388	23	0.3	23	1	AED38436	VEGF or VEGFR-spec
389	23	0.3	23	1	AED38496	VEGFR target regio
390	23	0.3	23	1	AED38504	VEGFR target regio
391	23	0.3	23	1	AED38521	VEGFR target regio
392	23	0.3	23	1	AED38535	VEGFR target regio
393	23	0.3	23	1	AED38537	VEGFR target regio
394	23	0.3	23	1	AED38550	VEGFR target regio
395	23	0.3	23	1	AED38572	VEGFR target regio
396	23	0.3	23	1	AED38580	VEGFR target regio
397	23	0.3	23	1	AED38595	VEGFR target regio
398	23	0.3	23	1	AED38498	VEGFR target regio

399	23	0.3	23	1	AED38502	VEGFR target regio
400	23	0.3	23	1	AED38519	VEGFR target regio
401	23	0.3	23	1	AED38529	VEGFR target regio
402	23	0.3	23	1	AED38531	VEGFR target regio
403	23	0.3	23	1	AED38579	VEGFR target regio
404	23	0.3	23	1	AED38589	VEGFR target regio
405	23	0.3	23	1	AED38501	VEGFR target regio
406	23	0.3	23	1	AED38510	VEGFR target regio
407	23	0.3	23	1	AED38515	VEGFR target regio
408	23	0.3	23	1	AED38528	VEGFR target regio
409	23	0.3	23	1	AED38558	VEGFR target regio
410	23	0.3	23	1	AED38592	VEGFR target regio
411	23	0.3	23	1	AED38418	VEGF or VEGFR-spec
412	23	0.3	23	1	AED38490	VEGFR target regio
413	23	0.3	23	1	AED38516	VEGFR target regio
414	23	0.3	23	1	AED38576	VEGFR target regio
415	23	0.3	23	1	AED38584	VEGFR target regio
416	23	0.3	23	1	AED38457	VEGF or VEGFR-spec
417	23	0.3	23	1	AED38484	VEGFR target regio
418	23	0.3	23	1	AED38487	VEGFR target regio
419	23	0.3	23	1	AED38488	VEGFR target regio
420	23	0.3	23	1	AED38503	VEGFR target regio
421	23	0.3	23	1	AED38512	VEGFR target regio
422	23	0.3	23	1	AED38513	VEGFR target regio
423	23	0.3	23	1	AED38525	VEGFR target regio
424	23	0.3	23	1	AED38532	VEGFR target regio
425	23	0.3	23	1	AED38538	VEGFR target regio
426	23	0.3	23	1	AED38556	VEGFR target regio
427	23	0.3	23	1	AED38566	VEGFR target regio
428	23	0.3	23	1	AED38567	VEGFR target regio
429	23	0.3	23	1	AED38569	VEGFR target regio
430	23	0.3	23	1	AED38573	VEGFR target regio
431	23	0.3	23	1	AED38574	VEGFR target regio
432	23	0.3	23	1	AED38453	VEGF or VEGFR-spec
433	23	0.3	23	1	AED38491	VEGFR target regio
434	23	0.3	23	1	AED38497	VEGFR target regio
435	23	0.3	23	1	AED38506	VEGFR target regio
436	23	0.3	23	1	AED38544	VEGFR target regio
437	23	0.3	23	1	AED38548	VEGFR target regio
438	23	0.3	23	1	AED38563	VEGFR target regio
439	23	0.3	23	1	AED38571	VEGFR target regio
440	23	0.3	23	1	AED38499	VEGFR target regio
441	23	0.3	23	1	AED38514	VEGFR target regio
442	23	0.3	23	1	AED38541	VEGFR target regio
443	23	0.3	23	1	AED38557	VEGFR target regio
444	23	0.3	23	1	AED38560	VEGFR target regio
445	23	0.3	23	1	AED38603	VEGFR target regio
446	23	0.3	23	1	AED38415	VEGF or VEGFR-spec
447	23	0.3	23	1	AED38447	VEGF or VEGFR-spec
448	23	0.3	23	1	AED38509	VEGFR target regio
449	23	0.3	23	1	AED38511	VEGFR target regio
450	23	0.3	23	1	AED38523	VEGFR target regio
451	23	0.3	23	1	AED38524	VEGFR target regio
452	23	0.3	23	1	AED38542	VEGFR target regio
453	23	0.3	23	1	AED38555	VEGFR target regio
454	23	0.3	23	1	AED38568	VEGFR target regio
455	23	0.3	23	1	AED38388	VEGF or VEGFR-spec
456	23	0.3	23	1	AED38407	VEGF or VEGFR-spec
457	23	0.3	23	1	AED38422	VEGF or VEGFR-spec
458	23	0.3	23	1	AED38426	VEGF or VEGFR-spec
459	23	0.3	23	1	AED38489	VEGFR target regio
460	23	0.3	23	1	AED38522	VEGFR target regio
461	23	0.3	23	1	AED38527	VEGFR target regio
462	23	0.3	23	1	AED38540	VEGFR target regio
463	23	0.3	23	1	AED38545	VEGFR target regio
464	23	0.3	23	1	AED38561	VEGFR target regio
465	23	0.3	23	1	AED38581	VEGFR target regio
466	23	0.3	23	1	AED38593	VEGFR target regio
467	23	0.3	23	1	AED38596	VEGFR target regio
468	23	0.3	23	1	AED38400	VEGF or VEGFR-spec
469	23	0.3	23	1	AED38495	VEGFR target regio
470	23	0.3	23	1	AED38518	VEGFR target regio
471	23	0.3	23	1	AED38533	VEGFR target regio
472	23	0.3	23	1	AED38534	VEGFR target regio
473	23	0.3	23	1	AED38543	VEGFR target regio
474	23	0.3	23	1	AED38549	VEGFR target regio
475	23	0.3	23	1	AED38583	VEGFR target regio
476	23	0.3	23	1	AED38507	VEGFR target regio
477	23	0.3	23	1	AED38554	VEGFR target regio
478	23	0.3	23	1	AED38565	VEGFR target regio
479	23	0.3	23	1	AED38578	VEGFR target regio
480	23	0.3	23	1	AED38587	VEGFR target regio
481	23	0.3	23	1	AED38598	VEGFR target regio
482	23	0.3	23	1	AED38508	VEGFR target regio
483	23	0.3	23	1	AED38536	VEGFR target regio
484	23	0.3	23	1	AED38547	VEGFR target regio
485	23	0.3	23	1	AED38562	VEGFR target regio
486	23	0.3	23	1	AED38585	VEGFR target regio
487	23	0.3	23	1	AED38590	VEGFR target regio
488	23	0.3	23	1	AED38597	VEGFR target regio
489	23	0.3	23	1	AED38431	VEGF or VEGFR-spec
490	23	0.3	23	1	AED38500	VEGFR target regio
491	23	0.3	23	1	AED38505	VEGFR target regio
492	23	0.3	23	1	AED38551	VEGFR target regio
493	23	0.3	23	1	AED38594	VEGFR target regio
494	23	0.3	23	1	AEF05631	Human FLT-1 d2 PCR
c 495	22.8	0.3	26	1	AAI64469	SSR motif #19. Un
496	22.4	0.3	24	1	ABZ57678	Human zinc finger
c 497	22.2	0.3	27	1	AAQ95132	Spinocerebellar at
498	22.2	0.3	27	1	AAA80358	Human ASTH1I 5' re
499	22	0.3	22	1	AAQ33810	Microsatellite seq
500	22	0.3	22	1	AAQ33675	Microsatellite seq
501	22	0.3	22	1	AAQ34038	Microsatellite seq
502	22	0.3	22	1	AAQ34080	Microsatellite seq
503	22	0.3	22	1	AAQ33991	Microsatellite seq
c 504	22	0.3	22	1	AAQ83952	Oligonucleotide cl
c 505	22	0.3	22	1	AAT65727	Repeat sequence fr
c 506	22	0.3	22	1	AAX90491	Vascular endotheli
507	22	0.3	22	1	AAX90490	Vascular endotheli
508	22	0.3	22	1	AAA60163	Human Flt-1 gene f
509	22	0.3	22	1	AAZ65606	Immunosuppressant
c 510	22	0.3	22	1	AAZ56473	Vascular endotheli
511	22	0.3	22	1	AAZ56472	Vascular endotheli
512	22	0.3	22	1	AAI67483	Forward primer use
513	22	0.3	22	1	AAI64448	SSR motif #8. Uni
c 514	22	0.3	22	1	ADO81143	Prion protein poly
c 515	22	0.3	22	1	ADO81098	Sheep prion protei
516	22	0.3	22	1	AEE49146	Cell surface recep
c 517	22	0.3	22	1	AEE49157	Cell surface recep
518	22	0.3	23	1	ADY89188	VEGF/VEGFR siRNA S
519	22	0.3	23	1	ADY89178	VEGF/VEGFR siRNA S
520	22	0.3	23	1	ADY89185	VEGF/VEGFR siRNA S
521	22	0.3	23	1	AED38423	VEGF or VEGFR-spec
522	22	0.3	23	1	AED38413	VEGF or VEGFR-spec
523	22	0.3	23	1	AED38420	VEGF or VEGFR-spec
524	21.8	0.3	25	1	ADB38952	Human interleukin
c 525	21.8	0.3	25	1	ADU79977	Flt-1 PCR primer S
526	21.8	0.3	25	1	ADU79976	Flt-1 PCR primer S
527	21.8	0.3	25	1	ADW15365	Human CFTR probe S
528	21.8	0.3	25	1	AEE01146	Human interleukin
c 529	21.4	0.3	23	1	AAH23021	VEGFR-2 gene speci
530	21.4	0.3	23	1	ADF17593	Flt-1 PCR primer S
c 531	21.4	0.3	23	1	ABX90512	Human VEGFR-2 RT-P
c 532	21.4	0.3	23	1	ADH70580	Human Vbeta gene r
533	21.4	0.3	23	1	ADY89174	VEGF/VEGFR siRNA S
534	21.4	0.3	23	1	ADY89179	VEGF/VEGFR siRNA S
535	21.4	0.3	23	1	ADY89189	VEGF/VEGFR siRNA S
536	21.4	0.3	23	1	ADY89200	VEGF/VEGFR siRNA S
537	21.4	0.3	23	1	ADY89181	VEGF/VEGFR siRNA S
538	21.4	0.3	23	1	ADY89184	VEGF/VEGFR siRNA S
539	21.4	0.3	23	1	ADY89205	VEGF/VEGFR siRNA S
540	21.4	0.3	23	1	AED38414	VEGF or VEGFR-spec
541	21.4	0.3	23	1	AED38435	VEGF or VEGFR-spec
542	21.4	0.3	23	1	AED38409	VEGF or VEGFR-spec
543	21.4	0.3	23	1	AED38424	VEGF or VEGFR-spec
544	21.4	0.3	23	1	AED38416	VEGF or VEGFR-spec

	545	21.4	0.3	23	1	AED38440	VEGF or VEGFR-spec
	546	21.4	0.3	23	1	AED38419	VEGF or VEGFR-spec
c	547	21.4	0.3	23	1	AEF05632	Human FLT-1 d2 PCR
c	548	21.4	0.3	24	1	AAT62084	Primer used in FLT
c	549	21.4	0.3	24	1	AAV01459	Human VEGF recepto
c	550	21.4	0.3	24	1	AAH39074	SNP specific lower
c	551	21.4	0.3	24	1	ABZ70239	Murine tricarboxyl
	552	21.4	0.3	25	1	ADS85996	PCAV-derived 25mer
	553	21.2	0.3	23	1	ADD69512	5' anchored (ISSR)
	554	21.2	0.3	26	1	AAQ44016	Target sequence #8
	555	21	0.3	21	1	AAQ33891	Microsatellite seq
	556	21	0.3	21	1	AAQ34015	Microsatellite seq
	557	21	0.3	21	1	AAQ33879	Microsatellite seq
	558	21	0.3	21	1	AAX90296	Oligonucleotide RT
c	559	21	0.3	21	1	AAT65738	Repeat sequence fr
	560	21	0.3	21	1	AAT62083	Primer used in FLT
	561	21	0.3	21	1	AAV01458	Human VEGF recepto
	562	21	0.3	21	1	AAV35480	Anti-human VEGF re
c	563	21	0.3	21	1	AAV21522	L-oncogene primer
	564	21	0.3	21	1	AAV21523	L-oncogene primer
c	565	21	0.3	21	1	AAV21521	L-oncogene primer
	566	21	0.3	21	1	AAZ40392	PCR primer for hum
	567	21	0.3	21	1	AAZ87755	Anti-human VEGF re
	568	21	0.3	21	1	AAH46013	Synthetic oligonuc
	569	21	0.3	21	1	AAH46014	Synthetic oligonuc
	570	21	0.3	21	1	AAF99702	Immunostimulatory
c	571	21	0.3	21	1	AAD21676	VEGFR-1 DNA amplif
	572	21	0.3	21	1	ABS78423	Angiogenesis inhib
c	573	21	0.3	21	1	ABZ76711	Human vascular end
c	574	21	0.3	21	1	ADA13965	Short interfering
c	575	21	0.3	21	1	ADA13968	Short interfering
c	576	21	0.3	21	1	ADA13971	Short interfering
c	577	21	0.3	21	1	ADA13964	Short interfering
c	578	21	0.3	21	1	ADA13969	Short interfering
	579	21	0.3	21	1	ADA13615	Short interfering
	580	21	0.3	21	1	ADA13962	Short interfering
c	581	21	0.3	21	1	ADA13988	Short interfering
c	582	21	0.3	21	1	ADA13662	Short interfering
c	583	21	0.3	21	1	ADA13967	Short interfering
	584	21	0.3	21	1	ACH03241	Immunostimulatory
	585	21	0.3	21	1	ADB37204	Immunostimulatory
c	586	21	0.3	21	1	ADD80859	Human Flt-1 revers
c	587	21	0.3	21	1	ADF37752	Human VEGFR1 short
c	588	21	0.3	21	1	ADF37900	Human VEGFR1 short
c	589	21	0.3	21	1	ADF37908	Human VEGFR1 short
	590	21	0.3	21	1	ADF37738	Human VEGFR1 short
c	591	21	0.3	21	1	ADF37751	Human VEGFR1 short
c	592	21	0.3	21	1	ADF37929	Human VEGFR1 short
c	593	21	0.3	21	1	ADF37740	Human VEGFR1 short
c	594	21	0.3	21	1	ADF37923	Human VEGFR1 short
c	595	21	0.3	21	1	ADF37931	Human VEGFR1 short
c	596	21	0.3	21	1	ADF37719	Human VEGFR1 short
c	597	21	0.3	21	1	ADF37745	Human VEGFR1 short
c	598	21	0.3	21	1	ADF37715	Human VEGFR1 short
c	599	21	0.3	21	1	ADF37845	Human VEGFR1 short
c	600	21	0.3	21	1	ADF37920	Human VEGFR1 short
c	601	21	0.3	21	1	ADF37716	Human VEGFR1 short
c	602	21	0.3	21	1	ADF37775	Human VEGFR1 short
	603	21	0.3	21	1	ADF37911	Human VEGFR1 short
c	604	21	0.3	21	1	ADF37933	Human VEGFR1 short
c	605	21	0.3	21	1	ADF37729	Human VEGFR1 short
c	606	21	0.3	21	1	ADF37902	Human VEGFR1 short
c	607	21	0.3	21	1	ADF37746	Human VEGFR1 short
c	608	21	0.3	21	1	ADF37837	Human VEGFR1 short
c	609	21	0.3	21	1	ADF37899	Human VEGFR1 short
	610	21	0.3	21	1	ADF37905	Human VEGFR1 short
c	611	21	0.3	21	1	ADF37714	Human VEGFR1 short
	612	21	0.3	21	1	ADF37897	Human VEGFR1 short
c	613	21	0.3	21	1	ADF37907	Human VEGFR1 short
c	614	21	0.3	21	1	ADF37739	Human VEGFR1 short
c	615	21	0.3	21	1	ADF37790	Human VEGFR1 short
c	616	21	0.3	21	1	ADF37937	Human VEGFR1 short
c	617	21	0.3	21	1	ADF37829	Human VEGFR1 short
c	618	21	0.3	21	1	ADF37910	Human VEGFR1 short
c	619	21	0.3	21	1	ADF37912	Human VEGFR1 short
c	620	21	0.3	21	1	ADF37935	Human VEGFR1 short
c	621	21	0.3	21	1	ADF37938	Human VEGFR1 short
c	622	21	0.3	21	1	ADF37776	Human VEGFR1 short
c	623	21	0.3	21	1	ADG29831	FLT1-targeted siNA
c	624	21	0.3	21	1	ADG29860	FLT1-targeted siNA
c	625	21	0.3	21	1	ADG29836	FLT1-targeted siNA
c	626	21	0.3	21	1	ADG29859	FLT1-targeted siNA
c	627	21	0.3	21	1	ADG29885	FLT1-targeted siNA
c	628	21	0.3	21	1	ADG29829	FLT1-targeted siNA
	629	21	0.3	21	1	ADG29883	FLT1-targeted siNA
c	630	21	0.3	21	1	ADG29884	FLT1-targeted siNA
	631	21	0.3	21	1	ADG29826	FLT1-targeted siNA
c	632	21	0.3	21	1	ADG29890	FLT1-targeted siNA
c	633	21	0.3	21	1	ADG29896	FLT1-targeted siNA
c	634	21	0.3	21	1	ADG29828	FLT1-targeted siNA
c	635	21	0.3	21	1	ADG29864	FLT1-targeted siNA
c	636	21	0.3	21	1	ADG29935	FLT1-targeted siNA
c	637	21	0.3	21	1	ADG29861	FLT1-targeted siNA
c	638	21	0.3	21	1	ADG29921	FLT1-targeted siNA
c	639	21	0.3	21	1	ADG29874	FLT1-targeted siNA
	640	21	0.3	21	1	ADG29840	FLT1-targeted siNA
c	641	21	0.3	21	1	ADG29897	FLT1-targeted siNA
c	642	21	0.3	21	1	ADG29920	FLT1-targeted siNA
c	643	21	0.3	21	1	ADG29839	FLT1-targeted siNA
c	644	21	0.3	21	1	ADG30354	Small interfering
c	645	21	0.3	21	1	ADG29837	FLT1-targeted siNA
c	646	21	0.3	21	1	ADG29891	FLT1-targeted siNA
c	647	21	0.3	21	1	ADG29841	FLT1-targeted siNA
c	648	21	0.3	21	1	ADG29849	FLT1-targeted siNA
	649	21	0.3	21	1	ADG29834	FLT1-targeted siNA
c	650	21	0.3	21	1	ADG29852	FLT1-targeted siNA
	651	21	0.3	21	1	ADJ97337	Human Flt-1 DNA se
	652	21	0.3	21	1	ADJ97349	Human Flt-1 DNA se
	653	21	0.3	21	1	ADJ97365	Human Flt-1 DNA se
	654	21	0.3	21	1	ADJ97381	Human Flt-1 DNA se
	655	21	0.3	21	1	ADJ97395	Human Flt-1 DNA se
	656	21	0.3	21	1	ADJ97400	Human Flt-1 DNA se
	657	21	0.3	21	1	ADJ97401	Human Flt-1 DNA se
	658	21	0.3	21	1	ADJ97420	Human Flt-1 DNA se
	659	21	0.3	21	1	ADJ97434	Human Flt-1 DNA se
	660	21	0.3	21	1	ADJ97439	Human Flt-1 DNA se
	661	21	0.3	21	1	ADJ97444	Human Flt-1 DNA se
	662	21	0.3	21	1	ADJ97454	Human Flt-1 DNA se
	663	21	0.3	21	1	ADJ97466	Human Flt-1 DNA se
	664	21	0.3	21	1	ADJ97467	Human Flt-1 DNA se
	665	21	0.3	21	1	ADJ97474	Human Flt-1 DNA se
	666	21	0.3	21	1	ADJ97502	Human Flt-1 DNA se
	667	21	0.3	21	1	ADJ97514	Human Flt-1 DNA se
	668	21	0.3	21	1	ADJ97518	Human Flt-1 DNA se
	669	21	0.3	21	1	ADJ97524	Human Flt-1 DNA se
	670	21	0.3	21	1	ADJ97553	Human Flt-1 DNA se
	671	21	0.3	21	1	ADJ97612	Human Flt-1 DNA se
	672	21	0.3	21	1	ADJ97631	Human Flt-1 DNA se
	673	21	0.3	21	1	ADJ97655	Human Flt-1 DNA se
	674	21	0.3	21	1	ADJ97657	Human Flt-1 DNA se
	675	21	0.3	21	1	ADJ97658	Human Flt-1 DNA se
	676	21	0.3	21	1	ADJ97662	Human Flt-1 DNA se
	677	21	0.3	21	1	ADJ97675	Human Flt-1 DNA se
	678	21	0.3	21	1	ADJ97682	Human Flt-1 DNA se
	679	21	0.3	21	1	ADJ97699	Human Flt-1 DNA se
	680	21	0.3	21	1	ADJ97373	Human Flt-1 DNA se
	681	21	0.3	21	1	ADJ97383	Human Flt-1 DNA se
	682	21	0.3	21	1	ADJ97393	Human Flt-1 DNA se
	683	21	0.3	21	1	ADJ97412	Human Flt-1 DNA se
	684	21	0.3	21	1	ADJ97419	Human Flt-1 DNA se
	685	21	0.3	21	1	ADJ97422	Human Flt-1 DNA se
	686	21	0.3	21	1	ADJ97425	Human Flt-1 DNA se
	687	21	0.3	21	1	ADJ97441	Human Flt-1 DNA se
	688	21	0.3	21	1	ADJ97494	Human Flt-1 DNA se
	689	21	0.3	21	1	ADJ97495	Human Flt-1 DNA se
	690	21	0.3	21	1	ADJ97499	Human Flt-1 DNA se

691	21	0.3	21	1	ADJ97505	Human Flt-1 DNA se
692	21	0.3	21	1	ADJ97506	Human Flt-1 DNA se
693	21	0.3	21	1	ADJ97508	Human Flt-1 DNA se
694	21	0.3	21	1	ADJ97515	Human Flt-1 DNA se
695	21	0.3	21	1	ADJ97538	Human Flt-1 DNA se
696	21	0.3	21	1	ADJ97548	Human Flt-1 DNA se
697	21	0.3	21	1	ADJ97573	Human Flt-1 DNA se
698	21	0.3	21	1	ADJ97580	Human Flt-1 DNA se
699	21	0.3	21	1	ADJ97585	Human Flt-1 DNA se
700	21	0.3	21	1	ADJ97608	Human Flt-1 DNA se
701	21	0.3	21	1	ADJ97665	Human Flt-1 DNA se
702	21	0.3	21	1	ADJ97667	Human Flt-1 DNA se
703	21	0.3	21	1	ADJ97670	Human Flt-1 DNA se
704	21	0.3	21	1	ADJ97681	Human Flt-1 DNA se
705	21	0.3	21	1	ADJ97695	Human Flt-1 DNA se
706	21	0.3	21	1	ADJ97327	Human Flt-1 DNA se
707	21	0.3	21	1	ADJ97333	Human Flt-1 DNA se
708	21	0.3	21	1	ADJ97370	Human Flt-1 DNA se
709	21	0.3	21	1	ADJ97380	Human Flt-1 DNA se
710	21	0.3	21	1	ADJ97385	Human Flt-1 DNA se
711	21	0.3	21	1	ADJ97399	Human Flt-1 DNA se
712	21	0.3	21	1	ADJ97408	Human Flt-1 DNA se
713	21	0.3	21	1	ADJ97437	Human Flt-1 DNA se
714	21	0.3	21	1	ADJ97469	Human Flt-1 DNA se
715	21	0.3	21	1	ADJ97490	Human Flt-1 DNA se
716	21	0.3	21	1	ADJ97533	Human Flt-1 DNA se
717	21	0.3	21	1	ADJ97552	Human Flt-1 DNA se
718	21	0.3	21	1	ADJ97556	Human Flt-1 DNA se
719	21	0.3	21	1	ADJ97564	Human Flt-1 DNA se
720	21	0.3	21	1	ADJ97565	Human Flt-1 DNA se
721	21	0.3	21	1	ADJ97581	Human Flt-1 DNA se
722	21	0.3	21	1	ADJ97623	Human Flt-1 DNA se
723	21	0.3	21	1	ADJ97626	Human Flt-1 DNA se
724	21	0.3	21	1	ADJ97635	Human Flt-1 DNA se
725	21	0.3	21	1	ADJ97661	Human Flt-1 DNA se
726	21	0.3	21	1	ADJ97663	Human Flt-1 DNA se
727	21	0.3	21	1	ADJ97678	Human Flt-1 DNA se
728	21	0.3	21	1	ADJ97679	Human Flt-1 DNA se
729	21	0.3	21	1	ADJ97683	Human Flt-1 DNA se
730	21	0.3	21	1	ADJ97689	Human Flt-1 DNA se
731	21	0.3	21	1	ADJ97701	Human Flt-1 DNA se
732	21	0.3	21	1	ADJ97704	Human Flt-1 DNA se
733	21	0.3	21	1	ADJ97716	Human Flt-1 DNA se
734	21	0.3	21	1	ADJ97731	Human Flt-1 DNA se
735	21	0.3	21	1	ADJ97325	Human Flt-1 DNA se
736	21	0.3	21	1	ADJ97331	Human Flt-1 DNA se
737	21	0.3	21	1	ADJ97359	Human Flt-1 DNA se
738	21	0.3	21	1	ADJ97363	Human Flt-1 DNA se
739	21	0.3	21	1	ADJ97377	Human Flt-1 DNA se
740	21	0.3	21	1	ADJ97378	Human Flt-1 DNA se
741	21	0.3	21	1	ADJ97402	Human Flt-1 DNA se
742	21	0.3	21	1	ADJ97418	Human Flt-1 DNA se
743	21	0.3	21	1	ADJ97445	Human Flt-1 DNA se
744	21	0.3	21	1	ADJ97453	Human Flt-1 DNA se
745	21	0.3	21	1	ADJ97457	Human Flt-1 DNA se
746	21	0.3	21	1	ADJ97461	Human Flt-1 DNA se
747	21	0.3	21	1	ADJ97476	Human Flt-1 DNA se
748	21	0.3	21	1	ADJ97497	Human Flt-1 DNA se
749	21	0.3	21	1	ADJ97519	Human Flt-1 DNA se
750	21	0.3	21	1	ADJ97522	Human Flt-1 DNA se
751	21	0.3	21	1	ADJ97540	Human Flt-1 DNA se
752	21	0.3	21	1	ADJ97543	Human Flt-1 DNA se
753	21	0.3	21	1	ADJ97597	Human Flt-1 DNA se
754	21	0.3	21	1	ADJ97642	Human Flt-1 DNA se
755	21	0.3	21	1	ADJ97647	Human Flt-1 DNA se
756	21	0.3	21	1	ADJ97650	Human Flt-1 DNA se
757	21	0.3	21	1	ADJ97698	Human Flt-1 DNA se
758	21	0.3	21	1	ADJ97703	Human Flt-1 DNA se
759	21	0.3	21	1	ADJ97721	Human Flt-1 DNA se
760	21	0.3	21	1	ADJ97318	Human Flt-1 DNA se
761	21	0.3	21	1	ADJ97332	Human Flt-1 DNA se
762	21	0.3	21	1	ADJ97335	Human Flt-1 DNA se
763	21	0.3	21	1	ADJ97348	Human Flt-1 DNA se
764	21	0.3	21	1	ADJ97362	Human Flt-1 DNA se
765	21	0.3	21	1	ADJ97384	Human Flt-1 DNA se
766	21	0.3	21	1	ADJ97396	Human Flt-1 DNA se
767	21	0.3	21	1	ADJ97397	Human Flt-1 DNA se
768	21	0.3	21	1	ADJ97411	Human Flt-1 DNA se
769	21	0.3	21	1	ADJ97462	Human Flt-1 DNA se
770	21	0.3	21	1	ADJ97464	Human Flt-1 DNA se
771	21	0.3	21	1	ADJ97475	Human Flt-1 DNA se
772	21	0.3	21	1	ADJ97489	Human Flt-1 DNA se
773	21	0.3	21	1	ADJ97491	Human Flt-1 DNA se
774	21	0.3	21	1	ADJ97500	Human Flt-1 DNA se
775	21	0.3	21	1	ADJ97507	Human Flt-1 DNA se
776	21	0.3	21	1	ADJ97509	Human Flt-1 DNA se
777	21	0.3	21	1	ADJ97525	Human Flt-1 DNA se
778	21	0.3	21	1	ADJ97559	Human Flt-1 DNA se
779	21	0.3	21	1	ADJ97574	Human Flt-1 DNA se
780	21	0.3	21	1	ADJ97576	Human Flt-1 DNA se
781	21	0.3	21	1	ADJ97591	Human Flt-1 DNA se
782	21	0.3	21	1	ADJ97601	Human Flt-1 DNA se
783	21	0.3	21	1	ADJ97605	Human Flt-1 DNA se
784	21	0.3	21	1	ADJ97656	Human Flt-1 DNA se
785	21	0.3	21	1	ADJ97671	Human Flt-1 DNA se
786	21	0.3	21	1	ADJ97676	Human Flt-1 DNA se
787	21	0.3	21	1	ADJ97677	Human Flt-1 DNA se
788	21	0.3	21	1	ADJ97688	Human Flt-1 DNA se
789	21	0.3	21	1	ADJ97727	Human Flt-1 DNA se
790	21	0.3	21	1	ADJ97343	Human Flt-1 DNA se
791	21	0.3	21	1	ADJ97344	Human Flt-1 DNA se
792	21	0.3	21	1	ADJ97346	Human Flt-1 DNA se
793	21	0.3	21	1	ADJ97382	Human Flt-1 DNA se
794	21	0.3	21	1	ADJ97409	Human Flt-1 DNA se
795	21	0.3	21	1	ADJ97413	Human Flt-1 DNA se
796	21	0.3	21	1	ADJ97415	Human Flt-1 DNA se
797	21	0.3	21	1	ADJ97423	Human Flt-1 DNA se
798	21	0.3	21	1	ADJ97452	Human Flt-1 DNA se
799	21	0.3	21	1	ADJ97488	Human Flt-1 DNA se
800	21	0.3	21	1	ADJ97492	Human Flt-1 DNA se
801	21	0.3	21	1	ADJ97513	Human Flt-1 DNA se
802	21	0.3	21	1	ADJ97516	Human Flt-1 DNA se
803	21	0.3	21	1	ADJ97521	Human Flt-1 DNA se
804	21	0.3	21	1	ADJ97590	Human Flt-1 DNA se
805	21	0.3	21	1	ADJ97593	Human Flt-1 DNA se
806	21	0.3	21	1	ADJ97603	Human Flt-1 DNA se
807	21	0.3	21	1	ADJ97628	Human Flt-1 DNA se
808	21	0.3	21	1	ADJ97633	Human Flt-1 DNA se
809	21	0.3	21	1	ADJ97638	Human Flt-1 DNA se
810	21	0.3	21	1	ADJ97640	Human Flt-1 DNA se
811	21	0.3	21	1	ADJ97651	Human Flt-1 DNA se
812	21	0.3	21	1	ADJ97680	Human Flt-1 DNA se
813	21	0.3	21	1	ADJ97685	Human Flt-1 DNA se
814	21	0.3	21	1	ADJ97692	Human Flt-1 DNA se
815	21	0.3	21	1	ADJ97694	Human Flt-1 DNA se
816	21	0.3	21	1	ADJ97707	Human Flt-1 DNA se
817	21	0.3	21	1	ADJ97352	Human Flt-1 DNA se
818	21	0.3	21	1	ADJ97354	Human Flt-1 DNA se
819	21	0.3	21	1	ADJ97355	Human Flt-1 DNA se
820	21	0.3	21	1	ADJ97416	Human Flt-1 DNA se
821	21	0.3	21	1	ADJ97450	Human Flt-1 DNA se
822	21	0.3	21	1	ADJ97465	Human Flt-1 DNA se
823	21	0.3	21	1	ADJ97470	Human Flt-1 DNA se
824	21	0.3	21	1	ADJ97484	Human Flt-1 DNA se
825	21	0.3	21	1	ADJ97561	Human Flt-1 DNA se
826	21	0.3	21	1	ADJ97566	Human Flt-1 DNA se
827	21	0.3	21	1	ADJ97572	Human Flt-1 DNA se
828	21	0.3	21	1	ADJ97587	Human Flt-1 DNA se
829	21	0.3	21	1	ADJ97595	Human Flt-1 DNA se
830	21	0.3	21	1	ADJ97602	Human Flt-1 DNA se
831	21	0.3	21	1	ADJ97617	Human Flt-1 DNA se
832	21	0.3	21	1	ADJ97659	Human Flt-1 DNA se
833	21	0.3	21	1	ADJ97664	Human Flt-1 DNA se
834	21	0.3	21	1	ADJ97674	Human Flt-1 DNA se
835	21	0.3	21	1	ADJ97713	Human Flt-1 DNA se
836	21	0.3	21	1	ADJ97728	Human Flt-1 DNA se

837	21	0.3	21	1	ADJ97328	Human Flt-1 DNA se
838	21	0.3	21	1	ADJ97341	Human Flt-1 DNA se
839	21	0.3	21	1	ADJ97345	Human Flt-1 DNA se
840	21	0.3	21	1	ADJ97386	Human Flt-1 DNA se
841	21	0.3	21	1	ADJ97398	Human Flt-1 DNA se
842	21	0.3	21	1	ADJ97426	Human Flt-1 DNA se
843	21	0.3	21	1	ADJ97463	Human Flt-1 DNA se
844	21	0.3	21	1	ADJ97481	Human Flt-1 DNA se
845	21	0.3	21	1	ADJ97487	Human Flt-1 DNA se
846	21	0.3	21	1	ADJ97496	Human Flt-1 DNA se
847	21	0.3	21	1	ADJ97531	Human Flt-1 DNA se
848	21	0.3	21	1	ADJ97532	Human Flt-1 DNA se
849	21	0.3	21	1	ADJ97549	Human Flt-1 DNA se
850	21	0.3	21	1	ADJ97550	Human Flt-1 DNA se
851	21	0.3	21	1	ADJ97557	Human Flt-1 DNA se
852	21	0.3	21	1	ADJ97594	Human Flt-1 DNA se
853	21	0.3	21	1	ADJ97615	Human Flt-1 DNA se
854	21	0.3	21	1	ADJ97634	Human Flt-1 DNA se
855	21	0.3	21	1	ADJ97684	Human Flt-1 DNA se
856	21	0.3	21	1	ADJ97696	Human Flt-1 DNA se
857	21	0.3	21	1	ADJ97711	Human Flt-1 DNA se
858	21	0.3	21	1	ADJ97715	Human Flt-1 DNA se
859	21	0.3	21	1	ADJ97321	Human Flt-1 DNA se
860	21	0.3	21	1	ADJ97336	Human Flt-1 DNA se
861	21	0.3	21	1	ADJ97361	Human Flt-1 DNA se
862	21	0.3	21	1	ADJ97374	Human Flt-1 DNA se
863	21	0.3	21	1	ADJ97392	Human Flt-1 DNA se
864	21	0.3	21	1	ADJ97421	Human Flt-1 DNA se
865	21	0.3	21	1	ADJ97471	Human Flt-1 DNA se
866	21	0.3	21	1	ADJ97498	Human Flt-1 DNA se
867	21	0.3	21	1	ADJ97503	Human Flt-1 DNA se
868	21	0.3	21	1	ADJ97511	Human Flt-1 DNA se
869	21	0.3	21	1	ADJ97555	Human Flt-1 DNA se
870	21	0.3	21	1	ADJ97571	Human Flt-1 DNA se
871	21	0.3	21	1	ADJ97583	Human Flt-1 DNA se
872	21	0.3	21	1	ADJ97609	Human Flt-1 DNA se
873	21	0.3	21	1	ADJ97619	Human Flt-1 DNA se
874	21	0.3	21	1	ADJ97627	Human Flt-1 DNA se
875	21	0.3	21	1	ADJ97643	Human Flt-1 DNA se
876	21	0.3	21	1	ADJ97648	Human Flt-1 DNA se
877	21	0.3	21	1	ADJ97668	Human Flt-1 DNA se
878	21	0.3	21	1	ADJ97669	Human Flt-1 DNA se
879	21	0.3	21	1	ADJ97691	Human Flt-1 DNA se
880	21	0.3	21	1	ADJ97705	Human Flt-1 DNA se
881	21	0.3	21	1	ADJ97729	Human Flt-1 DNA se
882	21	0.3	21	1	ADJ97326	Human Flt-1 DNA se
883	21	0.3	21	1	ADJ97330	Human Flt-1 DNA se
884	21	0.3	21	1	ADJ97340	Human Flt-1 DNA se
885	21	0.3	21	1	ADJ97353	Human Flt-1 DNA se
886	21	0.3	21	1	ADJ97357	Human Flt-1 DNA se
887	21	0.3	21	1	ADJ97358	Human Flt-1 DNA se
888	21	0.3	21	1	ADJ97424	Human Flt-1 DNA se
889	21	0.3	21	1	ADJ97449	Human Flt-1 DNA se
890	21	0.3	21	1	ADJ97456	Human Flt-1 DNA se
891	21	0.3	21	1	ADJ97458	Human Flt-1 DNA se
892	21	0.3	21	1	ADJ97459	Human Flt-1 DNA se
893	21	0.3	21	1	ADJ97512	Human Flt-1 DNA se
894	21	0.3	21	1	ADJ97527	Human Flt-1 DNA se
895	21	0.3	21	1	ADJ97554	Human Flt-1 DNA se
896	21	0.3	21	1	ADJ97596	Human Flt-1 DNA se
897	21	0.3	21	1	ADJ97600	Human Flt-1 DNA se
898	21	0.3	21	1	ADJ97613	Human Flt-1 DNA se
899	21	0.3	21	1	ADJ97614	Human Flt-1 DNA se
900	21	0.3	21	1	ADJ97625	Human Flt-1 DNA se
901	21	0.3	21	1	ADJ97636	Human Flt-1 DNA se
902	21	0.3	21	1	ADJ97649	Human Flt-1 DNA se
903	21	0.3	21	1	ADJ97712	Human Flt-1 DNA se
904	21	0.3	21	1	ADJ97730	Human Flt-1 DNA se
905	21	0.3	21	1	ADJ97322	Human Flt-1 DNA se
906	21	0.3	21	1	ADJ97324	Human Flt-1 DNA se
907	21	0.3	21	1	ADJ97334	Human Flt-1 DNA se
908	21	0.3	21	1	ADJ97350	Human Flt-1 DNA se
909	21	0.3	21	1	ADJ97369	Human Flt-1 DNA se
910	21	0.3	21	1	ADJ97388	Human Flt-1 DNA se
911	21	0.3	21	1	ADJ97389	Human Flt-1 DNA se
912	21	0.3	21	1	ADJ97391	Human Flt-1 DNA se
913	21	0.3	21	1	ADJ97394	Human Flt-1 DNA se
914	21	0.3	21	1	ADJ97405	Human Flt-1 DNA se
915	21	0.3	21	1	ADJ97480	Human Flt-1 DNA se
916	21	0.3	21	1	ADJ97520	Human Flt-1 DNA se
917	21	0.3	21	1	ADJ97523	Human Flt-1 DNA se
918	21	0.3	21	1	ADJ97535	Human Flt-1 DNA se
919	21	0.3	21	1	ADJ97545	Human Flt-1 DNA se
920	21	0.3	21	1	ADJ97551	Human Flt-1 DNA se
921	21	0.3	21	1	ADJ97568	Human Flt-1 DNA se
922	21	0.3	21	1	ADJ97570	Human Flt-1 DNA se
923	21	0.3	21	1	ADJ97577	Human Flt-1 DNA se
924	21	0.3	21	1	ADJ97578	Human Flt-1 DNA se
925	21	0.3	21	1	ADJ97599	Human Flt-1 DNA se
926	21	0.3	21	1	ADJ97618	Human Flt-1 DNA se
927	21	0.3	21	1	ADJ97620	Human Flt-1 DNA se
928	21	0.3	21	1	ADJ97624	Human Flt-1 DNA se
929	21	0.3	21	1	ADJ97639	Human Flt-1 DNA se
930	21	0.3	21	1	ADJ97641	Human Flt-1 DNA se
931	21	0.3	21	1	ADJ97646	Human Flt-1 DNA se
932	21	0.3	21	1	ADJ97672	Human Flt-1 DNA se
933	21	0.3	21	1	ADJ97693	Human Flt-1 DNA se
934	21	0.3	21	1	ADJ97717	Human Flt-1 DNA se
935	21	0.3	21	1	ADJ97720	Human Flt-1 DNA se
936	21	0.3	21	1	ADJ97722	Human Flt-1 DNA se
937	21	0.3	21	1	ADJ97726	Human Flt-1 DNA se
938	21	0.3	21	1	ADJ97320	Human Flt-1 DNA se
939	21	0.3	21	1	ADJ97323	Human Flt-1 DNA se
940	21	0.3	21	1	ADJ97339	Human Flt-1 DNA se
941	21	0.3	21	1	ADJ97351	Human Flt-1 DNA se
942	21	0.3	21	1	ADJ97356	Human Flt-1 DNA se
943	21	0.3	21	1	ADJ97372	Human Flt-1 DNA se
944	21	0.3	21	1	ADJ97375	Human Flt-1 DNA se
945	21	0.3	21	1	ADJ97379	Human Flt-1 DNA se
946	21	0.3	21	1	ADJ97387	Human Flt-1 DNA se
947	21	0.3	21	1	ADJ97414	Human Flt-1 DNA se
948	21	0.3	21	1	ADJ97417	Human Flt-1 DNA se
949	21	0.3	21	1	ADJ97427	Human Flt-1 DNA se
950	21	0.3	21	1	ADJ97430	Human Flt-1 DNA se
951	21	0.3	21	1	ADJ97438	Human Flt-1 DNA se
952	21	0.3	21	1	ADJ97440	Human Flt-1 DNA se
953	21	0.3	21	1	ADJ97442	Human Flt-1 DNA se
954	21	0.3	21	1	ADJ97451	Human Flt-1 DNA se
955	21	0.3	21	1	ADJ97455	Human Flt-1 DNA se
956	21	0.3	21	1	ADJ97478	Human Flt-1 DNA se
957	21	0.3	21	1	ADJ97537	Human Flt-1 DNA se
958	21	0.3	21	1	ADJ97542	Human Flt-1 DNA se
959	21	0.3	21	1	ADJ97546	Human Flt-1 DNA se
960	21	0.3	21	1	ADJ97584	Human Flt-1 DNA se
961	21	0.3	21	1	ADJ97588	Human Flt-1 DNA se
962	21	0.3	21	1	ADJ97598	Human Flt-1 DNA se
963	21	0.3	21	1	ADJ97606	Human Flt-1 DNA se
964	21	0.3	21	1	ADJ97645	Human Flt-1 DNA se
965	21	0.3	21	1	ADJ97686	Human Flt-1 DNA se
966	21	0.3	21	1	ADJ97697	Human Flt-1 DNA se
967	21	0.3	21	1	ADJ97709	Human Flt-1 DNA se
968	21	0.3	21	1	ADJ97723	Human Flt-1 DNA se
969	21	0.3	21	1	ADJ97364	Human Flt-1 DNA se
970	21	0.3	21	1	ADJ97403	Human Flt-1 DNA se
971	21	0.3	21	1	ADJ97410	Human Flt-1 DNA se
972	21	0.3	21	1	ADJ97428	Human Flt-1 DNA se
973	21	0.3	21	1	ADJ97436	Human Flt-1 DNA se
974	21	0.3	21	1	ADJ97472	Human Flt-1 DNA se
975	21	0.3	21	1	ADJ97477	Human Flt-1 DNA se
976	21	0.3	21	1	ADJ97486	Human Flt-1 DNA se
977	21	0.3	21	1	ADJ97501	Human Flt-1 DNA se
978	21	0.3	21	1	ADJ97517	Human Flt-1 DNA se
979	21	0.3	21	1	ADJ97526	Human Flt-1 DNA se
980	21	0.3	21	1	ADJ97558	Human Flt-1 DNA se
981	21	0.3	21	1	ADJ97560	Human Flt-1 DNA se
982	21	0.3	21	1	ADJ97562	Human Flt-1 DNA se

983	21	0.3	21	1	ADJ97567	Human Flt-1 DNA se
984	21	0.3	21	1	ADJ97575	Human Flt-1 DNA se
985	21	0.3	21	1	ADJ97607	Human Flt-1 DNA se
986	21	0.3	21	1	ADJ97616	Human Flt-1 DNA se
987	21	0.3	21	1	ADJ97710	Human Flt-1 DNA se
988	21	0.3	21	1	ADJ97714	Human Flt-1 DNA se
989	21	0.3	21	1	ADJ97719	Human Flt-1 DNA se
990	21	0.3	21	1	ADJ97338	Human Flt-1 DNA se
991	21	0.3	21	1	ADJ97347	Human Flt-1 DNA se
992	21	0.3	21	1	ADJ97406	Human Flt-1 DNA se
993	21	0.3	21	1	ADJ97407	Human Flt-1 DNA se
994	21	0.3	21	1	ADJ97460	Human Flt-1 DNA se
995	21	0.3	21	1	ADJ97468	Human Flt-1 DNA se
996	21	0.3	21	1	ADJ97510	Human Flt-1 DNA se
997	21	0.3	21	1	ADJ97528	Human Flt-1 DNA se
998	21	0.3	21	1	ADJ97529	Human Flt-1 DNA se
999	21	0.3	21	1	ADJ97544	Human Flt-1 DNA se
1000	21	0.3	21	1	ADJ97547	Human Flt-1 DNA se

ALIGNMENTS

```
RESULT 1
AAQ34091
ID   AAQ34091 standard; DNA; 40 BP.
XX
AC   AAQ34091;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA52.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 368; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 40 BP; 0 A; 0 C; 20 G; 20 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 40


RESULT 2
AAT66054/c
ID   AAT66054 standard; DNA; 40 BP.
XX
AC   AAT66054;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   (dC-dA)n.(dG-dT)n polymorphic repeat sequence #3.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 8; Col 57-58; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The repeats, when
CC   analysed, fall into 4 categories: 1) perfect repeats which are
CC   alternating tandem CA repeats with no interruptions and without adjacent
CC   repeats of another sequence; 2) imperfect repeats which are defined as 2
CC   or more runs of uninterrupted CA repeats separated by no more than 3
CC   consecutive non-repeat bases; 3) compound perfect repeats which are
CC   uninterrupted runs of CA separated by no more than 3 consecutive non-
CC   repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC   longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC   least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC   which are defined as for the perfect compound repeats except that the
CC   runs of CA are interrupted. The sequence presented here is an example of
CC   a perfect repeat sequence of structure: (CA)20. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 40 BP; 20 A; 20 C; 0 G; 0 T; 0 U; 0 Other;
```

```
  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 3
AAT65725/c
ID   AAT65725 standard; DNA; 40 BP.
XX
AC   AAT65725;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd23.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf23 which contains the repeat sequence having the
CC   formula: (AC)20. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 40 BP; 20 A; 20 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 4
AAT66051/c
ID   AAT66051 standard; DNA; 40 BP.
XX
AC   AAT66051;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   (dC-dA)n.(dG-dT)n polymorphic repeat sequence #2.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 8; Col 57-58; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The repeats, when
CC   analysed, fall into 4 categories: 1) perfect repeats which are
CC   alternating tandem CA repeats with no interruptions and without adjacent
CC   repeats of another sequence; 2) imperfect repeats which are defined as 2
CC   or more runs of uninterrupted CA repeats separated by no more than 3
CC   consecutive non-repeat bases; 3) compound perfect repeats which are
CC   uninterrupted runs of CA separated by no more than 3 consecutive non-
CC   repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC   longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC   least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC   which are defined as for the perfect compound repeats except that the
CC   runs of CA are interrupted. The sequence presented here is an example of
CC   a perfect repeat sequence of structure; (AC)20. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 40 BP; 20 A; 20 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 5
AAS13773/c
ID   AAS13773 standard; DNA; 40 BP.
XX
AC   AAS13773;
```

```
XX
DT   08-MAY-2002  (first entry)
XX
DE   Simple sequence repeat, SSR, #44.
XX
KW   Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW   cereal profiling; grass profiling; seed batch purity testing.
XX
OS   Synthetic.
XX
PN   NZ509193-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509193.
XX
PR   24-DEC-1999;   99AU-00004906.
PR   04-MAY-2000; 2000AU-00007310.
XX
PA   (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA   (UYSC-) UNIV SOUTHERN CROSS.
PA   (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA   (UYAD-) UNIV ADELAIDE.
PA   (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX
PI   Forster JW,  Jones ES;
XX
DR   WPI; 2001-512563/56.
XX
PT   New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT   core elements isolated from ryegrass and fescue, useful for selecting of
PT   genes in grass or cereal breeding or profiling grass or cereal species
PT   varieties.
XX
PS   Claim 13; Page 53; 72pp; English.
XX
CC   The invention relates to a substantially purified or isolated nucleic
CC   acid (I) from ryegrass or fescue species including a simple sequence
CC   repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC   2-6 nucleotides in length. Also included are a nucleic acid primer
CC   suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC   library of ryegrass or fescue genomic DNA enriched for SSRs and
CC   identifying clones in the library containing SSRs, a library of ryegrass
CC   or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC   a gene in grass or cereal breeding by identifying an SSR that is closely
CC   associated with the gene such that the SSR and the gene are
CC   preferentially co-inherited, and selecting for the SSR in the breeding, a
CC   method for DNA profiling grass or cereal species varieties by assessing
CC   variation between SSR varieties and testing the purity of grass or cereal
CC   seed batches by assessing variation within seed batch of an SSR. The SSRs
CC   may be used in the selection of genes in grass or cereal breeding, for
CC   profiling grass or cereal species varieties, for testing the purity of
CC   grass or cereal seed batches, and for DNA profiling to establish the
CC   distinct identity, uniformity and/or stability of a cultivar. The present
CC   sequence is a ryegrass or fescue SSR
XX
SQ   Sequence 40 BP; 20 A; 20 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 6
ABK24300/c
ID   ABK24300 standard; DNA; 40 BP.
XX
AC   ABK24300;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human microsatellite D1S191 detection PCR primer #8.
XX
KW   Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
KW   nucleotide length polymorphism detection; neurodegenerative disease;
KW   fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
KW   gene mapping; population study; human; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200185987-A1.
XX
PD   15-NOV-2001.
XX
PF   09-MAY-2001; 2001WO-AU000526.
XX
PR   09-MAY-2000; 2000US-0202771P.
PR   10-MAY-2000; 2000US-0202559P.
XX
PA   (DIAT-) DIATECH PTY LTD.
XX
PI   Brockhurst V,  Timms P,  Wolter L,  Barnard R,  Giffard PM;
XX
DR   WPI; 2002-121948/16.
XX
PT   Detecting a nucleotide repeat region in a nucleic acid having a
PT   particular length, useful for identifying nucleotide length polymorphism
PT   associated with a neurodegenerative disease, comprises using a ligase-
PT   assisted spacer addition assay.
XX
PS   Example 10; Page 55; 89pp; English.
XX
CC   The invention relates to a method of identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length, comprising employing ligase-assisted spacer addition
CC   (LASA) assay. The method is useful in the identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length. In particular, the method is useful for identification
CC   of a nucleotide length polymorphism in animals or humans, which is
CC   associated with a neurodegenerative disease including fragile X syndrome,
CC   Huntington's disease, or muscular dystrophy. Furthermore, the method may
CC   be used for identifying and/or typing microorganisms including yeasts and
CC   lower uni- and multi-cellular organisms, as well as prokaryotic
CC   microorganisms; and for genotyping subjects including humans. The method
CC   is also useful for detecting certain cancers and other malignancies.
CC   Moreover, the method can be used to provide markers for use in
CC   identification of human and non-human individuals, plants and
CC   microorganisms, to ascertain parentage of human or non-human individual,
CC   and to monitor responses to therapies including the possibility of
CC   nucleic acid damage. The nucleotide polymorphisms may be used in forensic
CC   science to identify a particular victim or an alleged perpetrator of a
CC   crime, in gene mapping and population studies. LASA may also be used in
CC   the manufacture of a kit for detecting and/or identifying nucleotide
CC   repeat regions such as a nucleotide length polymorphism in a eukaryotic
CC   genome. The LASA method avoids the time and cost required by prior art
CC   methods using gel electrophoresis and Southern transfer analysis. In
CC   particular, current diagnosis of Huntington's disease relies heavily upon
CC   the use of gel electrophoresis, a process that has proved difficult to
CC   automate or miniaturise. The LASA method allows total avoidance of this
CC   limiting step, making it a strong candidate for future use in clinical
CC   and laboratory procedures. ABK24276-ABK24313 represent primers used to
CC   detect polymorphisms or microsatellites as described in the method of the
CC   invention
XX
SQ   Sequence 40 BP; 20 A; 20 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 80;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
```

```
Db         40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 7
AAQ33648
ID   AAQ33648 standard; DNA; 39 BP.
XX
AC   AAQ33648;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone MTGT4B.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 189; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 39 BP; 0 A; 0 C; 19 G; 20 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   48.7%;  Pred. No. 97;
  Matches   19;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39


RESULT 8
AAQ33825
ID   AAQ33825 standard; DNA; 39 BP.
XX
AC   AAQ33825;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA227.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 259; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 39 BP; 0 A; 0 C; 19 G; 20 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   48.7%;  Pred. No. 97;
  Matches   19;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39


RESULT 9
AAQ33807
ID   AAQ33807 standard; DNA; 39 BP.
XX
AC   AAQ33807;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA213.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
```

```
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 252; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 39 BP; 0 A; 0 C; 20 G; 19 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   51.3%;  Pred. No. 97;
  Matches   20;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 10
AAT65731/c
ID   AAT65731 standard; DNA; 39 BP.
XX
AC   AAT65731;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd29.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf29 which contains the repeat sequence having the
CC   formula: (AC)19.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 39 BP; 20 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   48.7%;  Pred. No. 97;
  Matches   19;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         39 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 11
ADH70484
ID   ADH70484 standard; DNA; 39 BP.
XX
AC   ADH70484;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #274.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
```

```
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 678; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 39 BP; 0 A; 0 C; 20 G; 19 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   51.3%;  Pred. No. 97;
  Matches   20;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 12
AAT65736/c
ID   AAT65736 standard; DNA; 40 BP.
XX
AC   AAT65736;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd34.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf34 which contains the repeat sequence having the
CC   formula: (AC)4AT(AC)15. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 40 BP; 20 A; 19 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGT 1


RESULT 13
AAT65743/c
ID   AAT65743 standard; DNA; 40 BP.
XX
AC   AAT65743;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd42.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
```

```
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf42 which contains the repeat sequence having the
CC   formula: (CA)16T(AC)3.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 40 BP; 20 A; 19 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 14
AAT65750/c
ID   AAT65750 standard; DNA; 38 BP.
XX
AC   AAT65750;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd50.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf50 which contains the repeat sequence having the
CC   formula: (CA)19. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 15
AAT66048/c
ID   AAT66048 standard; DNA; 38 BP.
XX
AC   AAT66048;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   (dC-dA)n.(dG-dT)n polymorphic repeat sequence #1.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 8; Col 57-58; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The repeats, when
CC   analysed, fall into 4 categories: 1) perfect repeats which are
CC   alternating tandem CA repeats with no interruptions and without adjacent
CC   repeats of another sequence; 2) imperfect repeats which are defined as 2
CC   or more runs of uninterrupted CA repeats separated by no more than 3
CC   consecutive non-repeat bases; 3) compound perfect repeats which are
CC   uninterrupted runs of CA separated by no more than 3 consecutive non-
CC   repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC   longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC   least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC   which are defined as for the perfect compound repeats except that the
CC   runs of CA are interrupted. The sequence presented here is an example of
CC   a perfect repeat sequence of structure: (AC)19. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;
```

```
  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         38 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 16
AAA65562/c
ID   AAA65562 standard; DNA; 38 BP.
XX
AC   AAA65562;
XX
DT   10-NOV-2000  (first entry)
XX
DE   Porcine microsatellite PIGQTL3 oligonucleotide #31.
XX
KW   Porcine; pig; wild boar; quantitative trait locus; QTL; chromosome 2;
KW   mapping; 2p1.7; select breeding; genotype; phenotype; muscle mass;
KW   fat deposition; IGF2; insulin-like growth factor 2; microsatellite; ds.
XX
OS   Sus scrofa.
XX
PN   WO200036143-A2.
XX
PD   22-JUN-2000.
XX
PF   16-DEC-1999;   99WO-EP010209.
XX
PR   16-DEC-1998;   98EP-00204291.
XX
PA   (UYLI-) UNIV LIEGE.
PA   (MELI-) MELICA HB.
PA   (SEGH-) SEGHERSGENTEC NV.
XX
PI   Andersson L,  Georges M,  Spincemaille G;
XX
DR   WPI; 2000-431612/37.
XX
PT   Selecting a domestic animal for having desired genotypic properties
PT   comprises testing the animal for the presence of a parentally imprinted
PT   quantitative trait locus which is related to muscle mass and/or fat
PT   deposition.
XX
PS   Example 4; Fig 10; 107pp; English.
XX
CC   The present invention describes a method (M1) for selecting a domestic
CC   animal for having desired genotypic properties. The method comprises
CC   testing the animal for the presence of a parentally imprinted
CC   quantitative trait locus (QTL). The pig QTL is located at chromosome 2,
CC   mapping at around position 2p1.7. Also described are: (1) an isolated
CC   and/or recombinant nucleic acid (N1) comprising a parentally imprinted
CC   QTL or its functional fragment; (2) an isolated and/or recombinant
CC   nucleic acid (N2) comprising a synthetic parentally imprinted QTL derived
CC   from at least one chromosome or its functional fragment; (3) an animal
CC   such as pig selected for having desired genotypic or potential phenotypic
CC   properties; (4) a transgenic animal comprising N1 or N2; and (5) sperm or
CC   an embryo derived from the animal of (3) or (4). N1 or its fragment is
CC   useful for selecting an animal destined for slaughter or a breeding
CC   animal having desired genotypic or potential phenotypic properties. The
CC   properties are related to muscle mass and/or fat deposition. The sperm or
CC   an embryo are useful in breeding animals destined for slaughter. The
CC   present sequence represents a microsatellite oligonucleotide, which is
CC   given in an example from the present invention for the identification of
CC   DNA sequence polymorphisms in the IGF2 (insulin-like growth factor 2) and
CC   flanking loci
XX
SQ   Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 17
ABK24299/c
ID   ABK24299 standard; DNA; 38 BP.
XX
AC   ABK24299;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human microsatellite D1S191 detection PCR primer #7.
XX
KW   Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
KW   nucleotide length polymorphism detection; neurodegenerative disease;
KW   fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
KW   gene mapping; population study; human; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200185987-A1.
XX
PD   15-NOV-2001.
XX
PF   09-MAY-2001; 2001WO-AU000526.
XX
PR   09-MAY-2000; 2000US-0202771P.
PR   10-MAY-2000; 2000US-0202559P.
XX
PA   (DIAT-) DIATECH PTY LTD.
XX
PI   Brockhurst V,  Timms P,  Wolter L,  Barnard R,  Giffard PM;
XX
DR   WPI; 2002-121948/16.
XX
PT   Detecting a nucleotide repeat region in a nucleic acid having a
PT   particular length, useful for identifying nucleotide length polymorphism
PT   associated with a neurodegenerative disease, comprises using a ligase-
PT   assisted spacer addition assay.
XX
PS   Example 10; Page 55; 89pp; English.
XX
CC   The invention relates to a method of identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length, comprising employing ligase-assisted spacer addition
CC   (LASA) assay. The method is useful in the identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length. In particular, the method is useful for identification
CC   of a nucleotide length polymorphism in animals or humans, which is
CC   associated with a neurodegenerative disease including fragile X syndrome,
CC   Huntington's disease, or muscular dystrophy. Furthermore, the method may
CC   be used for identifying and/or typing microorganisms including yeasts and
CC   lower uni- and multi-cellular organisms, as well as prokaryotic
CC   microorganisms; and for genotyping subjects including humans. The method
CC   is also useful for detecting certain cancers and other malignancies.
CC   Moreover, the method can be used to provide markers for use in
CC   identification of human and non-human individuals, plants and
CC   microorganisms, to ascertain parentage of human or non-human individual,
CC   and to monitor responses to therapies including the possibility of
CC   nucleic acid damage. The nucleotide polymorphisms may be used in forensic
CC   science to identify a particular victim or an alleged perpetrator of a
CC   crime, in gene mapping and population studies. LASA may also be used in
CC   the manufacture of a kit for detecting and/or identifying nucleotide
CC   repeat regions such as a nucleotide length polymorphism in a eukaryotic
CC   genome. The LASA method avoids the time and cost required by prior art
CC   methods using gel electrophoresis and Southern transfer analysis. In
CC   particular, current diagnosis of Huntington's disease relies heavily upon
CC   the use of gel electrophoresis, a process that has proved difficult to
CC   automate or miniaturise. The LASA method allows total avoidance of this
```

```
CC   limiting step, making it a strong candidate for future use in clinical
CC   and laboratory procedures. ABK24276-ABK24313 represent primers used to
CC   detect polymorphisms or microsatellites as described in the method of the
CC   invention
XX
SQ   Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 18
AAT65714/c
ID   AAT65714 standard; DNA; 39 BP.
XX
AC   AAT65714;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd12.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf12 which contains the repeat sequence having the
CC   formula: (AC)11AT(AC)8A. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 39 BP; 20 A; 18 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 37.4;  DB 1;  Length 39;
  Best Local Similarity   46.2%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|: :|:|:|:|:|:|:|:|:|:|:
Db         39 TGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGT 1


RESULT 19
AAQ34041
ID   AAQ34041 standard; DNA; 37 BP.
XX
AC   AAQ34041;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA433.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 347; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 37 BP; 0 A; 0 C; 18 G; 19 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37


RESULT 20
AAQ34178
ID   AAQ34178 standard; DNA; 37 BP.
XX
```

```
AC   AAQ34178;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA94.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 402; 517pp; English.
XX
CC   The sequence is a bovine microsatellite sequence obtd. by screening a
CC   library of bovine MboI DNA fragments of between 250 and 500 bp with an
CC   (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-
CC   hybridised. Assuming independent distribution of microsatellites and MboI
CC   sites, the frequency of (T6)n >9 microsatellites in the bovine genome is
CC   estimated at >100, 000. The sequence information for ca. 230 such bovine
CC   microsatellites is summarised in the specification and indexed herein
CC   (see below). The sequences upstream and downstream of the microsatellite
CC   sequence were used to generate the required PCR primers for in vitro
CC   amplification of the corresp. microsatellite (using the program
CC   OPTIPRIM). The microsatellites may be used to identify individuals, for
CC   parentage testing, and in the genetic mapping of economic trait loci, or
CC   genes involved the determinism of economically important traits esp. in
CC   cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 37 BP; 0 A; 0 C; 19 G; 18 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   51.4%;  Pred. No. 1.4e+02;
  Matches   19;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 37


RESULT 21
AAQ33900
ID   AAQ33900 standard; DNA; 37 BP.
XX
AC   AAQ33900;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA310.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 289; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 37 BP; 0 A; 0 C; 18 G; 19 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37


RESULT 22
AAT65732/c
ID   AAT65732 standard; DNA; 37 BP.
XX
AC   AAT65732;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd30.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
```

```
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf30 which contains the repeat sequence having the
CC   formula: (AC)18.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 37 BP; 19 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         37 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 23
AAZ98493/c
ID   AAZ98493 standard; DNA; 40 BP.
XX
AC   AAZ98493;
XX
DT   19-JUN-2000  (first entry)
XX
DE   H. discus derived sequence #11.
XX
KW   Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
KW   Haliotis discus; ss.
XX
OS   Haliotis discus.
XX
PN   WO200011156-A1.
XX
PD   02-MAR-2000.
XX
PF   01-JUL-1999;   99WO-JP003551.
XX
PR   18-AUG-1998;   98JP-00232153.
XX
PA   (NORQ ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX
PI   Takahashi H,  Sekino M;
XX
DR   WPI; 2000-224692/19.
XX
PT   Isolation of satellite sequences from genomic DNA for use as DNA markers
PT   comprises isolating a library with high homogeneity by DNA fragmentation.
XX
PS   Example 5; Page 14; 35pp; Japanese.
XX
CC   The invention provides a novel method for isolation of satellite
CC   sequences from genomic DNA that comprises fragmentation of the DNA by a
CC   method which is not dependent on base sequences, then selection of the
CC   satellite sequences from the obtained genomic library of high
CC   homogeneity. The method is useful for the isolation of microsatellite DNA
CC   sequences which can be used as DNA markers. The new method markedly
CC   improves the efficiency of isolation of satellite sequences in comparison
CC   to prior art methods which are reliant on base sequences. Sequences
CC   AAZ98483-514 represent sequences from Haliotis discus, used in the method
CC   of the invention
XX
SQ   Sequence 40 BP; 19 A; 19 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36.8;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:| |:|
Db         40 TGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGTG 1


RESULT 24
AAT65708/c
ID   AAT65708 standard; DNA; 38 BP.
XX
AC   AAT65708;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd6.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf6 which contains the repeat sequence having the
CC   formula: (CA)5AA(CA)13. (Updated on 25-MAR-2003 to correct PF field.)
XX
```

```
SQ   Sequence 38 BP; 20 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   47.4%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   19;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTTTGTGTGTGTG 1


RESULT 25
AAQ33974
ID   AAQ33974 standard; DNA; 36 BP.
XX
AC   AAQ33974;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA377.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 319; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 26
AAQ33953
ID   AAQ33953 standard; DNA; 36 BP.
XX
AC   AAQ33953;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA35.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 311; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 27
AAQ34068
ID   AAQ34068 standard; DNA; 36 BP.
XX
AC   AAQ34068;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
```

```
DE   Microsatellite sequence from clone TGLA445.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 358; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 28
AAQ33828
ID   AAQ33828 standard; DNA; 36 BP.
XX
AC   AAQ33828;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA23.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 261; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 29
AAQ33906
ID   AAQ33906 standard; DNA; 36 BP.
XX
AC   AAQ33906;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA318.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
```

```
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 292; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 30
AAQ33819
ID   AAQ33819 standard; DNA; 36 BP.
XX
AC   AAQ33819;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA222.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 257; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 31
AAQ33882
ID   AAQ33882 standard; DNA; 36 BP.
XX
AC   AAQ33882;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA303.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM; '
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 282; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
```

```
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 32
AAT65784/c
ID   AAT65784 standard; DNA; 36 BP.
XX
AC   AAT65784;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd113.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 13-14; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf113 which contains the repeat sequence having the
CC   formula: (AC)18. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 33
AAT65720/c
ID   AAT65720 standard; DNA; 36 BP.
XX
AC   AAT65720;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd18.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf18 which contains the repeat sequence having the
CC   formula: (AC)18. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 34
AAS13713
ID   AAS13713 standard; DNA; 36 BP.
XX
AC   AAS13713;
XX
```

```
DT   08-MAY-2002  (first entry)
XX
DE   Simple sequence repeat, SSR, #10.
XX
KW   Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW   cereal profiling; grass profiling; seed batch purity testing.
XX
OS   Poeae.
XX
PN   NZ509193-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509193.
XX
PR   24-DEC-1999;   99AU-00004906.
PR   04-MAY-2000; 2000AU-00007310.
XX
PA   (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA   (UYSC-) UNIV SOUTHERN CROSS.
PA   (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA   (UYAD-) UNIV ADELAIDE.
PA   (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX
PI   Forster JW,  Jones ES;
XX
DR   WPI; 2001-512563/56.
XX
PT   New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT   core elements isolated from ryegrass and fescue, useful for selecting of
PT   genes in grass or cereal breeding or profiling grass or cereal species
PT   varieties.
XX
PS   Claim 6; Page 51; 72pp; English.
XX
CC   The invention relates to a substantially purified or isolated nucleic
CC   acid (I) from ryegrass or fescue species including a simple sequence
CC   repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC   2-6 nucleotides in length. Also included are a nucleic acid primer
CC   suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC   library of ryegrass or fescue genomic DNA enriched for SSRs and
CC   identifying clones in the library containing SSRs, a library of ryegrass
CC   or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC   a gene in grass or cereal breeding by identifying an SSR that is closely
CC   associated with the gene such that the SSR and the gene are
CC   preferentially co-inherited, and selecting for the SSR in the breeding, a
CC   method for DNA profiling grass or cereal species varieties by assessing
CC   variation between SSR varieties and testing the purity of grass or cereal
CC   seed batches by assessing variation within seed batch of an SSR. The SSRs
CC   may be used in the selection of genes in grass or cereal breeding, for
CC   profiling grass or cereal species varieties, for testing the purity of
CC   grass or cereal seed batches, and for DNA profiling to establish the
CC   distinct identity, uniformity and/or stability of a cultivar. The present
CC   sequence is a ryegrass or fescue SSR
XX
SQ   Sequence 36 BP; 0 A; 0 C; 18 G; 18 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 35
ABK24298/c
ID   ABK24298 standard; DNA; 36 BP.
XX
AC   ABK24298;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human microsatellite D1S191 detection PCR primer #6.
XX
KW   Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
KW   nucleotide length polymorphism detection; neurodegenerative disease;
KW   fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
KW   gene mapping; population study; human; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200185987-A1.
XX
PD   15-NOV-2001.
XX
PF   09-MAY-2001; 2001WO-AU000526.
XX
PR   09-MAY-2000; 2000US-0202771P.
PR   10-MAY-2000; 2000US-0202559P.
XX
PA   (DIAT-) DIATECH PTY LTD.
XX
PI   Brockhurst V,  Timms P,  Wolter L,  Barnard R,  Giffard PM;
XX
DR   WPI; 2002-121948/16.
XX
PT   Detecting a nucleotide repeat region in a nucleic acid having a
PT   particular length, useful for identifying nucleotide length polymorphism
PT   associated with a neurodegenerative disease, comprises using a ligase-
PT   assisted spacer addition assay.
XX
PS   Example 10; Page 55; 89pp; English.
XX
CC   The invention relates to a method of identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length, comprising employing ligase-assisted spacer addition
CC   (LASA) assay. The method is useful in the identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length. In particular, the method is useful for identification
CC   of a nucleotide length polymorphism in animals or humans, which is
CC   associated with a neurodegenerative disease including fragile X syndrome,
CC   Huntington's disease, or muscular dystrophy. Furthermore, the method may
CC   be used for identifying and/or typing microorganisms including yeasts and
CC   lower uni- and multi-cellular organisms, as well as prokaryotic
CC   microorganisms; and for genotyping subjects including humans. The method
CC   is also useful for detecting certain cancers and other malignancies.
CC   Moreover, the method can be used to provide markers for use in
CC   identification of human and non-human individuals, plants and
CC   microorganisms, to ascertain parentage of human or non-human individual,
CC   and to monitor responses to therapies including the possibility of
CC   nucleic acid damage. The nucleotide polymorphisms may be used in forensic
CC   science to identify a particular victim or an alleged perpetrator of a
CC   crime, in gene mapping and population studies. LASA may also be used in
CC   the manufacture of a kit for detecting and/or identifying nucleotide
CC   repeat regions such as a nucleotide length polymorphism in a eukaryotic
CC   genome. The LASA method avoids the time and cost required by prior art
CC   methods using gel electrophoresis and Southern transfer analysis. In
CC   particular, current diagnosis of Huntington's disease relies heavily upon
CC   the use of gel electrophoresis, a process that has proved difficult to
CC   automate or miniaturise. The LASA method allows total avoidance of this
CC   limiting step, making it a strong candidate for future use in clinical
CC   and laboratory procedures. ABK24276-ABK24313 represent primers used to
CC   detect polymorphisms or microsatellites as described in the method of the
CC   invention
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

```
RESULT 36
ADO81134/c
ID   ADO81134 standard; DNA; 36 BP.
XX
AC   ADO81134;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Prion protein polymorphic microsatellite marker consensus sequence #12.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; ds.
XX
OS   Synthetic.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Claim 9; Page 50; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a prion protein polymorphic microsatellite marker
CC   consensus sequence.
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 37
ADO80224/c
ID   ADO80224 standard; DNA; 36 BP.
XX
AC   ADO80224;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Wheat SSR containing amplification genetic marker, Xgwm637.
XX
KW   highly-dormant wheat; genetic marker; high dormancy; seed; chromosome 4A;
KW   ss.
XX
OS   Triticum.
XX
PN   JP2004113007-A.
XX
PD   15-APR-2004.
XX
PF   24-SEP-2002; 2002JP-00276822.
XX
PR   24-SEP-2002; 2002JP-00276822.
XX
PA   (HOKK-) HOKKAIDO GREEN BIO KENKYUSHO KK.
XX
DR   WPI; 2004-310662/29.
XX
PT   Selecting highly-dormant wheat using genetic marker associated with gene
PT   that provides high dormancy to seeds.
XX
PS   Claim 9; SEQ ID NO 7; 13pp; Japanese.
XX
CC   The invention relates to a novel method for selecting highly-dormant
CC   wheat using a genetic marker associated with a gene that provides high
CC   dormancy to the seeds. In the method of the invention, the genetic marker
CC   exists specifically in the genetic region within 44 cM from the gene
CC   associated with high dormancy in chromosome 4A. The method is useful for
CC   selecting highly-dormant wheat. This polynucleotide sequence represents a
CC   wheat genetic marker of the invention.
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 38
ADR16078/c
ID   ADR16078 standard; DNA; 36 BP.
XX
AC   ADR16078;
XX
DT   21-OCT-2004  (first entry)
XX
DE   Human PARP DNA 97-bp allelic fragment.
XX
KW   Genetic testing; systemic lupus erythematosus; SLE;
KW   poly(ADP-ribosyl)polymerase; PARP; genetic counselling; human; ds.
XX
OS   Homo sapiens.
XX
PN   US2004152075-A1.
XX
PD   05-AUG-2004.
XX
PF   18-JUL-2001; 2001US-00909317.
XX
PR   29-MAR-1999;   99US-00280181.
XX
PA   (TSAO/) TSAO B P.
PA   (CANT/) CANTOR R M.
PA   (ROTT/) ROTTER J I.
```

```
XX
PI   Tsao BP,  Cantor RM,  Rotter JI;
XX
DR   WPI; 2004-561490/54.
XX
PT   Genetic testing for systemic lupus erythematosus in human, by amplifying
PT   nucleic acids from tissue sample to obtain amplification products, and
PT   detecting presence or absence of dinucleotide repeat sequence in
PT   amplification products.
XX
PS   Claim 2; SEQ ID NO 7; 17pp; English.
XX
CC   The invention relates to a genetic testing method for diagnosing systemic
CC   lupus erythematosus (SLE) in human. The method involves amplifying
CC   nucleic acids from human tissue samples and detecting the presence or
CC   absence of variant alleles of a gene encoding poly(ADP-ribosyl)polymerase
CC   (PARP), which is a diagnostic of SLE or indication of a genetic
CC   predisposition for developing SLE. The method is useful for genetic
CC   testing for SLE in a human subject. It is useful in genetic counselling
CC   to provide useful information to persons considering their reproductive
CC   options. The present sequence is human PARP DNA 97-bp allelic fragment.
CC   This sequence is used to illustrate the method of the invention.
XX
SQ   Sequence 36 BP; 18 A; 18 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 39
AAQ33737
ID   AAQ33737 standard; DNA; 39 BP.
XX
AC   AAQ33737;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA153.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 225; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 39 BP; 2 A; 0 C; 17 G; 20 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 35.8;  DB 1;  Length 39;
  Best Local Similarity   46.2%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6969 UAACUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|  :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39


RESULT 40
AAT65711/c
ID   AAT65711 standard; DNA; 35 BP.
XX
AC   AAT65711;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd9.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
```

```
CC   the marker clone Mdf9 which contains the repeat sequence having the
CC   formula: (CA)17G. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 35 BP; 17 A; 17 C; 1 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         35 CTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 41
AAT65747/c
ID   AAT65747 standard; DNA; 35 BP.
XX
AC   AAT65747;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd47.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf47 which contains the repeat sequence having the
CC   formula: (AC)17.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 35 BP; 18 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 2.1e+02;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         35 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 42
AAQ68850/c
ID   AAQ68850 standard; DNA; 38 BP.
XX
AC   AAQ68850;
XX
DT   25-MAR-2003  (revised)
DT   28-OCT-1994  (first entry)
XX
DE   Human chromosomal repeat element.
XX
KW   Yeast Artificial Chromosome; YAC; polymerase chain reaction; PCR;
KW   sequence tagged site; genetic disorder; diagnosis; abnormality;
KW   Prader-Willi; Angelman; Beckwith-Wiedermann; syndrome; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   repeat_region    5. .38
FT                    /*tag=  a
FT                    /rpt_type= tandem
FT   repeat_unit      5. .6
FT                    /*tag=  b
XX
PN   WO9406936-A1.
XX
PD   31-MAR-1994.
XX
PF   10-SEP-1993;   93WO-US008501.
XX
PR   11-SEP-1992;   92US-00943639.
XX
PA   (BAYU ) BAYLOR COLLEGE MEDICINE.
XX
PI   Airhart SD,  Mutirangura A,  Ledbetter DH;
XX
DR   WPI; 1994-118484/14.
XX
PT   Diagnosis of genetic disorders associated with chromosomal abnormalities
PT   and uniparental disomy, e.g. Prader-Willi:Angelman syndrome - using in
PT   situ hybridisation using probes spanning the IR4-3R or GABRB3 regions.
XX
PS   Example 8; Page 64; 91pp; English.
XX
CC   Sequences flanking a ACAC(CA)17 (AAQ68850) repeat element were used to
CC   design PCR primers AAQ45259 and AAQ45260. The chromosomal localisation
CC   was assigned to the Angelman Syndrome/Prader-Willi Syndrome region at
CC   15q11-13. The dinucleotide repeat was confirmed to be on chromosome 15 by
CC   PCR of somatic cell hybrids. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 35;  DB 1;  Length 38;
  Best Local Similarity   51.4%;  Pred. No. 2.5e+02;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6981 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:||
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGG 4


RESULT 43
AAQ33692
ID   AAQ33692 standard; DNA; 34 BP.
XX
AC   AAQ33692;
XX
DT   25-MAR-2003  (revised)
```

```
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA126.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 207; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 34 BP; 0 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 34


RESULT 44
AAQ33776
ID   AAQ33776 standard; DNA; 34 BP.
XX
AC   AAQ33776;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA179.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 240; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 34 BP; 0 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 34


RESULT 45
AAQ33921
ID   AAQ33921 standard; DNA; 34 BP.
XX
AC   AAQ33921;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA328.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
```

```
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 298; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 34 BP; 0 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 34


RESULT 46
AAQ33873
ID   AAQ33873 standard; DNA; 34 BP.
XX
AC   AAQ33873;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA28.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 279; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 34 BP; 0 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 34


RESULT 47
AAT65722/c
ID   AAT65722 standard; DNA; 34 BP.
XX
AC   AAT65722;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd20.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
```

```
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf20 which contains the repeat sequence having the
CC   formula: (AC)17. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 48
AAT65744/c
ID   AAT65744 standard; DNA; 34 BP.
XX
AC   AAT65744;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd44.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf44 which contains the repeat sequence having the
CC   formula: (CA)17. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 49
AAT65748/c
ID   AAT65748 standard; DNA; 34 BP.
XX
AC   AAT65748;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd48.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf48 which contains the repeat sequence having the
CC   formula: (AC)17. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 50
AAT65742/c
ID   AAT65742 standard; DNA; 34 BP.
XX
```

```
AC   AAT65742;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd41.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf14 which contains the repeat sequence having the
CC   formula: (AC)17. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 51
AAT65772/c
ID   AAT65772 standard; DNA; 34 BP.
XX
AC   AAT65772;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd101.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 13-14; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf101 which contains the repeat sequence having the
CC   formula: (AC)17. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 52
ABK24297/c
ID   ABK24297 standard; DNA; 34 BP.
XX
AC   ABK24297;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human microsatellite D1S191 detection PCR primer #5.
XX
KW   Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
KW   nucleotide length polymorphism detection; neurodegenerative disease;
KW   fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
KW   gene mapping; population study; human; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200185987-A1.
XX
PD   15-NOV-2001.
XX
PF   09-MAY-2001; 2001WO-AU000526.
XX
PR   09-MAY-2000; 2000US-0202771P.
```

```
PR   10-MAY-2000; 2000US-0202559P.
XX
PA   (DIAT-) DIATECH PTY LTD.
XX
PI   Brockhurst V,  Timms P,  Wolter L,  Barnard R,  Giffard PM;
XX
DR   WPI; 2002-121948/16.
XX
PT   Detecting a nucleotide repeat region in a nucleic acid having a
PT   particular length, useful for identifying nucleotide length polymorphism
PT   associated with a neurodegenerative disease, comprises using a ligase-
PT   assisted spacer addition assay.
XX
PS   Example 10; Page 55; 89pp; English.
XX
CC   The invention relates to a method of identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length, comprising employing ligase-assisted spacer addition
CC   (LASA) assay. The method is useful in the identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length. In particular, the method is useful for identification
CC   of a nucleotide length polymorphism in animals or humans, which is
CC   associated with a neurodegenerative disease including fragile X syndrome,
CC   Huntington's disease, or muscular dystrophy. Furthermore, the method may
CC   be used for identifying and/or typing microorganisms including yeasts and
CC   lower uni- and multi-cellular organisms, as well as prokaryotic
CC   microorganisms; and for genotyping subjects including humans. The method
CC   is also useful for detecting certain cancers and other malignancies.
CC   Moreover, the method can be used to provide markers for use in
CC   identification of human and non-human individuals, plants and
CC   microorganisms, to ascertain parentage of human or non-human individual,
CC   and to monitor responses to therapies including the possibility of
CC   nucleic acid damage. The nucleotide polymorphisms may be used in forensic
CC   science to identify a particular victim or an alleged perpetrator of a
CC   crime, in gene mapping and population studies. LASA may also be used in
CC   the manufacture of a kit for detecting and/or identifying nucleotide
CC   repeat regions such as a nucleotide length polymorphism in a eukaryotic
CC   genome. The LASA method avoids the time and cost required by prior art
CC   methods using gel electrophoresis and Southern transfer analysis. In
CC   particular, current diagnosis of Huntington's disease relies heavily upon
CC   the use of gel electrophoresis, a process that has proved difficult to
CC   automate or miniaturise. The LASA method allows total avoidance of this
CC   limiting step, making it a strong candidate for future use in clinical
CC   and laboratory procedures. ABK24276-ABK24313 represent primers used to
CC   detect polymorphisms or microsatellites as described in the method of the
CC   invention
XX
SQ   Sequence 34 BP; 17 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 2.5e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 53
AAQ33669
ID   AAQ33669 standard; DNA; 37 BP.
XX
AC   AAQ33669;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA112.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 197; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 37 BP; 1 A; 1 C; 18 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33.8;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 3.1e+02;
  Matches   18;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:| |:|:|: :|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGCGTGTGTATGTGTGTGTGTG 37


RESULT 54
AAQ33713
ID   AAQ33713 standard; DNA; 35 BP.
XX
AC   AAQ33713;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA134.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
```

```
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 215; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 35 BP; 1 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTG 35


RESULT 55
AAQ34097
ID   AAQ34097 standard; DNA; 33 BP.
XX
AC   AAQ34097;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA54.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 370; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 33 BP; 0 A; 0 C; 16 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 3e+02;
  Matches   16;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 56
AAQ34009
ID   AAQ34009 standard; DNA; 33 BP.
XX
AC   AAQ34009;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA415.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 334; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
```

```
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 33 BP; 0 A; 0 C; 16 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 3e+02;
  Matches   16;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 57
AAT65754/c
ID   AAT65754 standard; DNA; 33 BP.
XX
AC   AAT65754;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd58.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf58 which contains the repeat sequence having the
CC   formula: (CA)16.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 33 BP; 16 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 3e+02;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 58
AAT65705/c
ID   AAT65705 standard; DNA; 33 BP.
XX
AC   AAT65705;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd3.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf3 which contains the repeat sequence having the
CC   formula: (CA)16C. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 33 BP; 16 A; 17 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 3e+02;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 59
AAQ33894
```

```
ID   AAQ33894 standard; DNA; 38 BP.
XX
AC   AAQ33894;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA309.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 287; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 38 BP; 1 A; 0 C; 19 G; 18 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32.8;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6980 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGG 7015
              |:|:|:|:| |:|:|:|:|:|:|:|:|:|:|: |
Db          1 GTGTGTGTGAGTGTGTGTGTGTGTGTGTGTGTTG 36


RESULT 60
ADH70517
ID   ADH70517 standard; DNA; 34 BP.
XX
AC   ADH70517;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #307.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises.
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 711; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 34 BP; 0 A; 1 C; 17 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32.4;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 3.7e+02;
  Matches   17;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:| |:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGCGTGTGTGTGTGTGTGTGTGTG 34


RESULT 61
AAQ33698
ID   AAQ33698 standard; DNA; 37 BP.
XX
AC   AAQ33698;
```

```
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA128.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 209; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 37 BP; 2 A; 1 C; 15 G; 19 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32.2;  DB 1;  Length 37;
  Best Local Similarity   40.5%;  Pred. No. 4.6e+02;
  Matches   15;  Conservative   19;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|: : :|:|:|:|:|:|:|:|:|: :|:
Db          1 TGTGTGTGTGTCTATGTGTGTGTGTGTGTGTGTATGT 37


RESULT 62
AAQ33666
ID   AAQ33666 standard; DNA; 32 BP.
XX
AC   AAQ33666;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA111.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 196; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 32 BP; 0 A; 0 C; 16 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 32


RESULT 63
AAT65790/c
ID   AAT65790 standard; DNA; 32 BP.
XX
AC   AAT65790;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd119.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
```

```
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 13-14; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf119 which contains the repeat sequence having the
CC   formula: (AC)16. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 64
AAT65752/c
ID   AAT65752 standard; DNA; 32 BP.
XX
AC   AAT65752;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd55.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf55 which contains the repeat sequence having the
CC   formula: (AC)16. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 65
AAX56155/c
ID   AAX56155 standard; DNA; 32 BP.
XX
AC   AAX56155;
XX
DT   15-JUL-1999  (first entry)
XX
DE   Human alpha-7 nicotinic receptor probe SEQ ID NO:10.
XX
KW   Human; alpha-7 nicotinic receptor; neuronal; hybridisation; probe;
KW   alpha-7 neuronal nicotinic acetylcholine receptor; schizophrenia;
KW   small cell lung carcinoma; breast cancer; nicotine-dependent illness;
KW   epilepsy; juvenile myoclonic epilepsy; Prader-Willi syndrome;
KW   Angelman's syndrome; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9920757-A2.
XX
PD   29-APR-1999.
XX
PF   15-OCT-1998;   98WO-US021762.
XX
PR   23-OCT-1997;   97US-00956518.
XX
PA   (LEON/) LEONARD S.
PA   (FREE/) FREEDMAN R.
XX
PI   Leonard S,  Freedman R;
XX
DR   WPI; 1999-288306/24.
XX
PT   Human alpha-7 neuronal nicotinic acetylcholine receptor and related
PT   polynucleotides.
XX
PS   Claim 9; Page 63; 104pp; English.
XX
CC   The present invention describes an isolated nucleotide sequence (I)
CC   encoding at least a portion of the human alpha-7 neuronal nicotinic
CC   acetylcholine receptor (alpha7-hnAChR). Also described are: (1) a peptide
CC   encoded by (I); (2) a vector comprising (I); (3) a host cell transformed
CC   with a vector of (2); (4) a polynucleotide comprising at least 15
CC   nucleotides which hybridises under stringent conditions to at least a
```

```
CC   portion of (I); (5) a method for detection of a polynucleotide encoding
CC   alpha 7-hnAChR in a biological sample; and (6) a method for amplification
CC   of nucleic acid from a sample suspected of containing nucleic acid
CC   encoding alpha 7-hnAChR. The primers and probes from the present
CC   invention can be used on brain tissue and blood samples of humans
CC   suspected of suffering from schizophrenia, small cell lung carcinoma,
CC   breast cancer and nicotine-dependent illness. This is particularly useful
CC   for diagnosis of schizophrenia. Other illnesses that can be
CC   studied/diagnosed are epilepsy (e.g. juvenile myoclonic epilepsy) and
CC   Prader-Willi and Angelman's syndromes
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 66
AAZ98487/c
ID   AAZ98487 standard; DNA; 32 BP.
XX
AC   AAZ98487;
XX
DT   19-JUN-2000  (first entry)
XX
DE   H. discus derived sequence #5.
XX
KW   Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
KW   Haliotis discus; ss.
XX
OS   Haliotis discus.
XX
PN   WO200011156-A1.
XX
PD   02-MAR-2000.
XX
PF   01-JUL-1999;   99WO-JP003551.
XX
PR   18-AUG-1998;   98JP-00232153.
XX
PA   (NORQ ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX
PI   Takahashi H,  Sekino M;
XX
DR   WPI; 2000-224692/19.
XX
PT   Isolation of satellite sequences from genomic DNA for use as DNA markers
PT   comprises isolating a library with high homogeneity by DNA fragmentation.
XX
PS   Example 5; Page 14; 35pp; Japanese.
XX
CC   The invention provides a novel method for isolation of satellite
CC   sequences from genomic DNA that comprises fragmentation of the DNA by a
CC   method which is not dependent on base sequences, then selection of the
CC   satellite sequences from the obtained genomic library of high
CC   homogeneity. The method is useful for the isolation of microsatellite DNA
CC   sequences which can be used as DNA markers. The new method markedly
CC   improves the efficiency of isolation of satellite sequences in comparison
CC   to prior art methods which are reliant on base sequences. Sequences
CC   AAZ98483-514 represent sequences from Haliotis discus, used in the method
CC   of the invention
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 67
ABK24296/c
ID   ABK24296 standard; DNA; 32 BP.
XX
AC   ABK24296;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human microsatellite D1S191 detection PCR primer #4.
XX
KW   Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
KW   nucleotide length polymorphism detection; neurodegenerative disease;
KW   fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
KW   gene mapping; population study; human; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200185987-A1.
XX
PD   15-NOV-2001.
XX
PF   09-MAY-2001; 2001WO-AU000526.
XX
PR   09-MAY-2000; 2000US-0202771P.
PR   10-MAY-2000; 2000US-0202559P.
XX
PA   (DIAT-) DIATECH PTY LTD.
XX
PI   Brockhurst V,  Timms P,  Wolter L,  Barnard R,  Giffard PM;
XX
DR   WPI; 2002-121948/16.
XX
PT   Detecting a nucleotide repeat region in a nucleic acid having a
PT   particular length, useful for identifying nucleotide length polymorphism
PT   associated with a neurodegenerative disease, comprises using a ligase-
PT   assisted spacer addition assay.
XX
PS   Example 10; Page 55; 89pp; English.
XX
CC   The invention relates to a method of identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length, comprising employing ligase-assisted spacer addition
CC   (LASA) assay. The method is useful in the identifying or detecting a
CC   nucleotide repeat region in a nucleic acid molecule characterised by a
CC   particular length. In particular, the method is useful for identification
CC   of a nucleotide length polymorphism in animals or humans, which is
CC   associated with a neurodegenerative disease including fragile X syndrome,
CC   Huntington's disease, or muscular dystrophy. Furthermore, the method may
CC   be used for identifying and/or typing microorganisms including yeasts and
CC   lower uni- and multi-cellular organisms, as well as prokaryotic
CC   microorganisms; and for genotyping subjects including humans. The method
CC   is also useful for detecting certain cancers and other malignancies.
CC   Moreover, the method can be used to provide markers for use in
CC   identification of human and non-human individuals, plants and
CC   microorganisms, to ascertain parentage of human or non-human individual,
CC   and to monitor responses to therapies including the possibility of
CC   nucleic acid damage. The nucleotide polymorphisms may be used in forensic
CC   science to identify a particular victim or an alleged perpetrator of a
CC   crime, in gene mapping and population studies. LASA may also be used in
CC   the manufacture of a kit for detecting and/or identifying nucleotide
CC   repeat regions such as a nucleotide length polymorphism in a eukaryotic
CC   genome. The LASA method avoids the time and cost required by prior art
CC   methods using gel electrophoresis and Southern transfer analysis. In
CC   particular, current diagnosis of Huntington's disease relies heavily upon
CC   the use of gel electrophoresis, a process that has proved difficult to
CC   automate or miniaturise. The LASA method allows total avoidance of this
CC   limiting step, making it a strong candidate for future use in clinical
CC   and laboratory procedures. ABK24276-ABK24313 represent primers used to
```

```
CC   detect polymorphisms or microsatellites as described in the method of the
CC   invention
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 68
ADR88479/c
ID   ADR88479 standard; DNA; 32 BP.
XX
AC   ADR88479;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Alpha 7 nicotinic ACh receptor associated oligonucleotide.
XX
KW   schizophrenia; alpha7 allele; polymorphism; ss;
KW   alpha 7 nicotinic ACh receptor; human.
XX
OS   Synthetic.
XX
PN   US2004185468-A1.
XX
PD   23-SEP-2004.
XX
PF   26-NOV-2003; 2003US-00723940.
XX
PR   23-OCT-1997;   97US-00956518.
XX
PA   (USGO ) USA DEPT VETERANS AFFAIRS.
XX
PI   Leonard S,  Freedman R;
XX
DR   WPI; 2004-689185/67.
XX
PT   Identifying individuals predisposed to schizophrenia, by providing
PT   nucleic acid comprising alpha7 allele from subject, detecting
PT   polymorphism within alpha7 allele, and correlating polymorphism with
PT   predisposition to schizophrenia.
XX
PS   Example 2; SEQ ID NO 10; 105pp; English.
XX
CC   The invention describes a method of identifying (M1) individuals
CC   predisposed to schizophrenia, involving providing a nucleic acid from a
CC   human subject, where the nucleic acid comprises an alpha7 allele,
CC   detecting the presence of a polymorphism within the alpha7 allele, and
CC   correlating the presence of the polymorphism with a predisposition to
CC   schizophrenia. Also described are: a kit for determining if a subject is
CC   predisposed to schizophrenia, comprising a reagent suitable for use in
CC   specifically detecting a polymorphism in an alpha7 allele, and
CC   instructions for determining whether a subject is predisposed to
CC   schizophrenia; and screening (M2) compounds, involving providing a cell
CC   comprising an alpha7 allele with the polymorphism, and one or more test
CC   compounds, contacting the cell with the test compound, and detecting a
CC   change in alpha7 expression in the cell in the presence of the test
CC   compound relative to the absence of the test compound. (M1) is useful for
CC   identifying individuals predisposed to schizophrenia. This sequence
CC   represents an oligonucleotide associated with the screening of human
CC   alpha 7 nicotinic ACh receptor polynucleotides.
XX
SQ   Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 69
AAQ33767
ID   AAQ33767 standard; DNA; 38 BP.
XX
AC   AAQ33767;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA172.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 236; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 38 BP; 4 A; 0 C; 19 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31.6;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 5.6e+02;
  Matches   19;  Conservative   15;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :| |:|:| |:|:|:|:|:|:|:|:| |:|:| |:|:|
Db          1 TGAGTGTGAGTGTGTGTGTGTGTGAGTGTGAGTGTG 38


RESULT 70
AAQ34047
ID   AAQ34047 standard; DNA; 31 BP.
XX
```

```
AC   AAQ34047;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA436.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 349; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 31 BP; 0 A; 0 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31


RESULT 71
AAQ33867
ID   AAQ33867 standard; DNA; 31 BP.
XX
AC   AAQ33867;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA27.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 276; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 31 BP; 0 A; 0 C; 16 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 4.4e+02;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 31


RESULT 72
AAQ34032
ID   AAQ34032 standard; DNA; 31 BP.
XX
AC   AAQ34032;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA429.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
```

```
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 343; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 31 BP; 0 A; 0 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31


RESULT 73
AAQ33822
ID   AAQ33822 standard; DNA; 31 BP.
XX
AC   AAQ33822;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA226.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 258; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 31 BP; 0 A; 0 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31


RESULT 74
AAQ33657
ID   AAQ33657 standard; DNA; 31 BP.
XX
AC   AAQ33657;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA102.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 192; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
```

```
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 31 BP; 0 A; 0 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31


RESULT 75
AAT65765/c
ID   AAT65765 standard; DNA; 31 BP.
XX
AC   AAT65765;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd79.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf79 which contains the repeat sequence having the
CC   formula: (AC)15.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 31 BP; 16 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 76
AAT65759/c
ID   AAT65759 standard; DNA; 31 BP.
XX
AC   AAT65759;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd64.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf64 which contains the repeat sequence having the
CC   formula: (AC)15.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 31 BP; 16 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 77
```

```
AAT65753/c
ID   AAT65753 standard; DNA; 31 BP.
XX
AC   AAT65753;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd57.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf57 which contains the repeat sequence having the
CC   formula: (CA)15.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 31 BP; 15 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 4.4e+02;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 78
AAD19466
ID   AAD19466 standard; DNA; 34 BP.
XX
AC   AAD19466;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human flt-1 gene polymorphism identifying diagnostic PCR primer #1.
XX
KW   Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW   opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW   diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW   vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW   cancer; medicament; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1130123-A2.
XX
PD   05-SEP-2001.
XX
PF   20-FEB-2001; 2001EP-00301489.
XX
PR   24-FEB-2000; 2000GB-00004232.
XX
PA   (ASTR ) ASTRAZENECA AB.
XX
PI   Smith JC;
XX
DR   WPI; 2001-608199/70.
XX
PT   Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT   assessing predisposition or susceptibility to diseases mediated by an flt
PT   -1 ligand, comprises determining the nucleic acid sequence at one or more
PT   point positions.
XX
PS   Example 1; Page 15; 30pp; English.
XX
CC   The invention relates to novel sequence and polymorphisms in the human
CC   flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC   growth factor (VEGFR-1). The invention also relates to a method for
CC   diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC   1 gene. The method is useful for assessing the predisposition and/or
CC   susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC   to recognise individuals who are particularly at risk from developing
CC   these conditions, and in the development of new drug therapies that
CC   selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC   polymorphisms are used in the diagnosis and treatment of cancer and
CC   angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC   arthritis and endometriosis. Polymorphisms are also used in mapping the
CC   human genome and to elucidate the genetic component of the diseases, as
CC   genetic markers for this region in linkage studies. The nucleic acids are
CC   useful as components in databases useful in sequence identity, genome
CC   mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC   is useful in the preparation of a medicament for treating VEGF-mediated
CC   diseases in a human diagnosed as having a single nucleotide polymorphism
CC   at one or more of the defined positions. The present DNA sequence is a
CC   PCR primer which is used for identifying human flt-1 gene polymorphism
XX
SQ   Sequence 34 BP; 11 A; 4 C; 8 G; 11 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30.8;  DB 1;  Length 34;
  Best Local Similarity   64.7%;  Pred. No. 5.5e+02;
  Matches   22;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1919 AUGGGUUUCAUGUUAACUUGGAAAAAAUGCCGAC 1952
              |:|||:::||:|::|||::|||||||:||  ||
Db          1 ATGGGTTTCATGTTAACTTGGAAAAAATGCGTAC 34


RESULT 79
AAD19457
ID   AAD19457 standard; DNA; 31 BP.
XX
AC   AAD19457;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human flt-1 gene polymorphism detecting allele specific probe #1.
XX
KW   Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW   opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW   diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
```

KW vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW cancer; medicament; probe; ss.
XX
OS Homo sapiens.
XX
PN EP1130123-A2.
XX
PD 05-SEP-2001.
XX
PF 20-FEB-2001; 2001EP-00301489.
XX
PR 24-FEB-2000; 2000GB-00004232.
XX
PA (ASTR) ASTRAZENECA AB.
XX
PI Smith JC;
XX
DR WPI; 2001-608199/70.
XX
PT Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT assessing predisposition or susceptibility to diseases mediated by an flt
PT -1 ligand, comprises determining the nucleic acid sequence at one or more
PT point positions.
XX
PS Claim 11; Page 3; 30pp; English.
XX
CC The invention relates to novel sequence and polymorphisms in the human
CC flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC growth factor (VEGFR-1). The invention also relates to a method for
CC diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC 1 gene. The method is useful for assessing the predisposition and/or
CC susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC to recognise individuals who are particularly at risk from developing
CC these conditions, and in the development of new drug therapies that
CC selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC polymorphisms are used in the diagnosis and treatment of cancer and
CC angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC arthritis and endometriosis. Polymorphisms are also used in mapping the
CC human genome and to elucidate the genetic component of the diseases, as
CC genetic markers for this region in linkage studies. The nucleic acids are
CC useful as components in databases useful in sequence identity, genome
CC mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC is useful in the preparation of a medicament for treating VEGF-mediated
CC diseases in a human diagnosed as having a single nucleotide polymorphism
CC at one or more of the defined positions. The present DNA sequence is a
CC allele specific nucleotide probe which is used for detecting human flt-1
CC gene polymorphism
XX
SQ Sequence 31 BP; 12 A; 5 C; 11 G; 2 T; 0 U; 1 Other;

```
  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   90.3%;  Pred. No. 4.8e+02;
  Matches   28;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 GGAAAAAAUGCCGACGGAAGGAGAGGACCUG 1968
              ||||||||:||||||:|||||||||||||:|
Db          1 GGAAAAAATGCCGACRGAAGGAGAGGACCTG 31
```

RESULT 80
AAD19459
ID AAD19459 standard; DNA; 31 BP.
XX
AC AAD19459;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human flt-1 gene polymorphism detecting allele specific probe #3.
XX
KW Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW cancer; medicament; probe; ss.
XX
OS Homo sapiens.
XX
PN EP1130123-A2.
XX
PD 05-SEP-2001.
XX
PF 20-FEB-2001; 2001EP-00301489.
XX
PR 24-FEB-2000; 2000GB-00004232.
XX
PA (ASTR) ASTRAZENECA AB.
XX
PI Smith JC;
XX
DR WPI; 2001-608199/70.
XX
PT Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT assessing predisposition or susceptibility to diseases mediated by an flt
PT -1 ligand, comprises determining the nucleic acid sequence at one or more
PT point positions.
XX
PS Claim 11; Page 4; 30pp; English.
XX
CC The invention relates to novel sequence and polymorphisms in the human
CC flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC growth factor (VEGFR-1). The invention also relates to a method for
CC diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC 1 gene. The method is useful for assessing the predisposition and/or
CC susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC to recognise individuals who are particularly at risk from developing
CC these conditions, and in the development of new drug therapies that
CC selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC polymorphisms are used in the diagnosis and treatment of cancer and
CC angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC arthritis and endometriosis. Polymorphisms are also used in mapping the
CC human genome and to elucidate the genetic component of the diseases, as
CC genetic markers for this region in linkage studies. The nucleic acids are
CC useful as components in databases useful in sequence identity, genome
CC mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC is useful in the preparation of a medicament for treating VEGF-mediated
CC diseases in a human diagnosed as having a single nucleotide polymorphism
CC at one or more of the defined positions. The present DNA sequence is a
CC allele specific nucleotide probe which is used for detecting human flt-1
CC gene polymorphism
XX
SQ Sequence 31 BP; 10 A; 3 C; 7 G; 10 T; 0 U; 1 Other;

```
  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   64.5%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3873 UGAUGAUGUCAGAUAUGUAAAUGCUUUCAAG 3903
              :||:||:|:||||:|:|:|||:||:::||||
Db          1 TGATGATGTCAGATAYGTAAATGCTTTCAAG 31
```

RESULT 81
AAD19458
ID AAD19458 standard; DNA; 31 BP.
XX
AC AAD19458;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human flt-1 gene polymorphism detecting allele specific probe #2.
XX
KW Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW cancer; medicament; probe; ss.

```
XX
OS   Homo sapiens.
XX
PN   EP1130123-A2.
XX
PD   05-SEP-2001.
XX
PF   20-FEB-2001; 2001EP-00301489.
XX
PR   24-FEB-2000; 2000GB-00004232.
XX
PA   (ASTR ) ASTRAZENECA AB.
XX
PI   Smith JC;
XX
DR   WPI; 2001-608199/70.
XX
PT   Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT   assessing predisposition or susceptibility to diseases mediated by an flt
PT   -1 ligand, comprises determining the nucleic acid sequence at one or more
PT   point positions.
XX
PS   Claim 11; Page 4; 30pp; English.
XX
CC   The invention relates to novel sequence and polymorphisms in the human
CC   flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC   growth factor (VEGFR-1). The invention also relates to a method for
CC   diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC   1 gene. The method is useful for assessing the predisposition and/or
CC   susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC   to recognise individuals who are particularly at risk from developing
CC   these conditions, and in the development of new drug therapies that
CC   selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC   polymorphisms are used in the diagnosis and treatment of cancer and
CC   angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC   arthritis and endometriosis. Polymorphisms are also used in mapping the
CC   human genome and to elucidate the genetic component of the diseases, as
CC   genetic markers for this region in linkage studies. The nucleic acids are
CC   useful as components in databases useful in sequence identity, genome
CC   mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC   is useful in the preparation of a medicament for treating VEGF-mediated
CC   diseases in a human diagnosed as having a single nucleotide polymorphism
CC   at one or more of the defined positions. The present DNA sequence is a
CC   allele specific nucleotide probe which is used for detecting human flt-1
CC   gene polymorphism
XX
SQ   Sequence 31 BP; 8 A; 6 C; 7 G; 9 T; 0 U; 1 Other;

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 4.8e+02;
  Matches   21;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3438 GAAAUGGAUGGCUCCCGAAUCUAUCUUUGAC 3468
              ||||:|||:|||:||:|||:|:|:|:::|||
Db          1 GAAATGGATGGCTCCYGAATCTATCTTTGAC 31


RESULT 82
AAQ33710
ID   AAQ33710 standard; DNA; 37 BP.
XX
AC   AAQ33710;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA132.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 214; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 37 BP; 4 A; 0 C; 14 G; 19 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   37.8%;  Pred. No. 6.8e+02;
  Matches   14;  Conservative   19;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|: : :|: : :
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTATATGTATAT 37


RESULT 83
AAQ34119
ID   AAQ34119 standard; DNA; 32 BP.
XX
AC   AAQ34119;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA67.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
```

```
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 378; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 32 BP; 0 A; 1 C; 16 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30.4;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 5.4e+02;
  Matches   16;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:| |:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGCGTGTGTGTGTGTG 32


RESULT 84
AAT66057/c
ID   AAT66057 standard; DNA; 32 BP.
XX
AC   AAT66057;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   (dC-dA)n.(dG-dT)n polymorphic repeat sequence #4.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 8; Col 57-58; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The repeats, when
CC   analysed, fall into 4 categories: 1) perfect repeats which are
CC   alternating tandem CA repeats with no interruptions and without adjacent
CC   repeats of another sequence; 2) imperfect repeats which are defined as 2
CC   or more runs of uninterrupted CA repeats separated by no more than 3
CC   consecutive non-repeat bases; 3) compound perfect repeats which are
CC   uninterrupted runs of CA separated by no more than 3 consecutive non-
CC   repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC   longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC   least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC   which are defined as for the perfect compound repeats except that the
CC   runs of CA are interrupted. This sequence is an example of an imperfect
CC   repeat sequence of structure: (CA)11CT(CA)4. (Updated on 25-MAR-2003 to
CC   correct PF field.)
XX
SQ   Sequence 32 BP; 15 A; 16 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30.4;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 5.4e+02;
  Matches   16;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:| |:|:|:|:|:|:|:|:|:|:|
Db          32 TGTGTGTGAGTGTGTGTGTGTGTGTGTGTG 1


RESULT 85
AAQ33965
ID   AAQ33965 standard; DNA; 30 BP.
XX
AC   AAQ33965;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA357.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 316; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
```

```
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 30 BP; 0 A; 0 C; 15 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.2e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 86
AAT65789/c
ID   AAT65789 standard; DNA; 30 BP.
XX
AC   AAT65789;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd118.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 13-14; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf118 which contains the repeat sequence having the
CC   formula: (AC)15. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 30 BP; 15 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.2e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         30 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 87
AAS13788/c
ID   AAS13788 standard; DNA; 30 BP.
XX
AC   AAS13788;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Simple sequence repeat, SSR, #59.
XX
KW   Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW   cereal profiling; grass profiling; seed batch purity testing.
XX
OS   Synthetic.
XX
PN   NZ509193-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509193.
XX
PR   24-DEC-1999;   99AU-00004906.
PR   04-MAY-2000; 2000AU-00007310.
XX
PA   (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA   (UYSC-) UNIV SOUTHERN CROSS.
PA   (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA   (UYAD-) UNIV ADELAIDE.
PA   (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX
PI   Forster JW,  Jones ES;
XX
DR   WPI; 2001-512563/56.
XX
PT   New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT   core elements isolated from ryegrass and fescue, useful for selecting of
PT   genes in grass or cereal breeding or profiling grass or cereal species
PT   varieties.
XX
PS   Claim 13; Page 53; 72pp; English.
XX
CC   The invention relates to a substantially purified or isolated nucleic
CC   acid (I) from ryegrass or fescue species including a simple sequence
CC   repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC   2-6 nucleotides in length. Also included are a nucleic acid primer
CC   suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC   library of ryegrass or fescue genomic DNA enriched for SSRs and
CC   identifying clones in the library containing SSRs, a library of ryegrass
CC   or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC   a gene in grass or cereal breeding by identifying an SSR that is closely
CC   associated with the gene such that the SSR and the gene are
CC   preferentially co-inherited, and selecting for the SSR in the breeding, a
CC   method for DNA profiling grass or cereal species varieties by assessing
CC   variation between SSR varieties and testing the purity of grass or cereal
CC   seed batches by assessing variation within seed batch of an SSR. The SSRs
CC   may be used in the selection of genes in grass or cereal breeding, for
CC   profiling grass or cereal species varieties, for testing the purity of
CC   grass or cereal seed batches, and for DNA profiling to establish the
CC   distinct identity, uniformity and/or stability of a cultivar. The present
CC   sequence is a ryegrass or fescue SSR
```

```
XX
SQ   Sequence 30 BP; 15 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.2e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         30 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 88
AAS13787
ID   AAS13787 standard; DNA; 30 BP.
XX
AC   AAS13787;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Simple sequence repeat, SSR, #58.
XX
KW   Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW   cereal profiling; grass profiling; seed batch purity testing.
XX
OS   Synthetic.
XX
PN   NZ509193-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509193.
XX
PR   24-DEC-1999;   99AU-00004906.
PR   04-MAY-2000; 2000AU-00007310.
XX
PA   (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA   (UYSC-) UNIV SOUTHERN CROSS.
PA   (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA   (UYAD-) UNIV ADELAIDE.
PA   (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX
PI   Forster JW,  Jones ES;
XX
DR   WPI; 2001-512563/56.
XX
PT   New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT   core elements isolated from ryegrass and fescue, useful for selecting of
PT   genes in grass or cereal breeding or profiling grass or cereal species
PT   varieties.
XX
PS   Claim 13; Page 53; 72pp; English.
XX
CC   The invention relates to a substantially purified or isolated nucleic
CC   acid (I) from ryegrass or fescue species including a simple sequence
CC   repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC   2-6 nucleotides in length. Also included are a nucleic acid primer
CC   suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC   library of ryegrass or fescue genomic DNA enriched for SSRs and
CC   identifying clones in the library containing SSRs, a library of ryegrass
CC   or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC   a gene in grass or cereal breeding by identifying an SSR that is closely
CC   associated with the gene such that the SSR and the gene are
CC   preferentially co-inherited, and selecting for the SSR in the breeding, a
CC   method for DNA profiling grass or cereal species varieties by assessing
CC   variation between SSR varieties and testing the purity of grass or cereal
CC   seed batches by assessing variation within seed batch of an SSR. The SSRs
CC   may be used in the selection of genes in grass or cereal breeding, for
CC   profiling grass or cereal species varieties, for testing the purity of
CC   grass or cereal seed batches, and for DNA profiling to establish the
CC   distinct identity, uniformity and/or stability of a cultivar. The present
CC   sequence is a ryegrass or fescue SSR
XX
SQ   Sequence 30 BP; 0 A; 0 C; 15 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.2e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 89
AAL42354
ID   AAL42354 standard; DNA; 30 BP.
XX
AC   AAL42354;
XX
DT   28-JUN-2002  (first entry)
XX
DE   Novel sand pear microsatellite DNA probe 3.
XX
KW   Sand pear; ss; probe; novel microsatellite DNA sequence;
KW   Pyrus plant discrimination.
XX
OS   Pyrus pyrifolia.
XX
PN   JP2002034597-A.
XX
PD   05-FEB-2002.
XX
PF   21-JUL-2000; 2000JP-00220339.
XX
PR   21-JUL-2000; 2000JP-00220339.
XX
PA   (DOKU-) DOKURITSU GYOSEI HOJIN NOGYO SEIBUTSU SH.
XX
DR   WPI; 2002-298819/34.
XX
PT   A new microsatellite DNA derived from a Pyrus plant and discrimination of
PT   Pyrus plants by using it.
XX
PS   Example 1; Page 22; 22pp; Japanese.
XX
CC   The invention comprises a novel microsatellite DNA sequence derived from
CC   Pyrus plants. The invention also comprises a method for discriminating
CC   Pyrus plants - utilising the novel Pyrus microsatellite DNA. The novel
CC   microsatellite DNA sequence can be used in discriminating Pyrus plants.
CC   The present DNA sequence represents a probe specific for a novel Pyrus
CC   pyrifolia (sand pear) microsatellite DNA sequence
XX
SQ   Sequence 30 BP; 0 A; 0 C; 15 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.2e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 90
AAQ33944
ID   AAQ33944 standard; DNA; 33 BP.
XX
AC   AAQ33944;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA342.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
```

```
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 307; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 33 BP; 1 A; 1 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29.8;  DB 1;  Length 33;
  Best Local Similarity   45.5%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|  :|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGCATGTGTGT 33


RESULT 91
AAQ33695
ID   AAQ33695 standard; DNA; 35 BP.
XX
AC   AAQ33695;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA127.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 208; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 35 BP; 3 A; 1 C; 15 G; 16 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29.2;  DB 1;  Length 35;
  Best Local Similarity   47.1%;  Pred. No. 8.5e+02;
  Matches   16;  Conservative   15;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6969 UAACUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|  :|:|:| |:|:|:|:|:|:|:|:|:|:|
Db          2 TATATGTGTGCGTGTGTGTGTGTGTGTGTGTG 35


RESULT 92
AAQ33687
ID   AAQ33687 standard; DNA; 29 BP.
XX
AC   AAQ33687;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA124.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
```

```
XX
PS   Table 7; Page 204; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 29 BP; 0 A; 0 C; 14 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 93
AAQ33846
ID   AAQ33846 standard; DNA; 29 BP.
XX
AC   AAQ33846;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA257.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 268; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 29 BP; 0 A; 0 C; 14 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 94
AAQ33956
ID   AAQ33956 standard; DNA; 29 BP.
XX
AC   AAQ33956;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA351.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 312; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
```

```
SQ   Sequence 29 BP; 0 A; 0 C; 14 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 95
AAQ33977
ID   AAQ33977 standard; DNA; 29 BP.
XX
AC   AAQ33977;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA378.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 320; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 29 BP; 0 A; 0 C; 14 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 96
AAQ83953/c
ID   AAQ83953 standard; DNA; 29 BP.
XX
AC   AAQ83953;
XX
DT   25-MAR-2003  (revised)
DT   04-OCT-1995  (first entry)
XX
DE   Oligonucleotide clamp q, for producing comb-type brached polymer.
XX
KW   HIV; pol; nef; oligonucleotide clamp; branched; macromolecule; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   2. .3
FT                   /*tag=  a
FT                   /note= "A(pnp)C, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
FT   modified_base   8. .9
FT                   /*tag=  b
FT                   /note= "A(pnp)C, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
FT   modified_base   14. .15
FT                   /*tag=  c
FT                   /note= "A(pnp)C, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
FT   modified_base   29
FT                   /*tag=  d
FT                   /note= "Modified with -NH-C(=O)CH2Br"
XX
PN   WO9501365-A1.
XX
PD   12-JAN-1995.
XX
PF   05-JUL-1994;   94WO-US007557.
XX
PR   02-JUL-1993;   93US-00087386.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Gryaznov SM;
XX
DR   WPI; 1995-060944/08.
XX
PT   Synthesis of branched polymers and novel branched polymeric structures -
PT   used as molecular probes esp. for detecting poly-nucleotide(s).
XX
PS   Example 9; Page 34; 52pp; English.
XX
CC   The sequences given in AAQ83939, AAQ83953 and AAQ83940 are used in the
CC   construction of an oligonucleotide clamp. The clamp is a comb-type
CC   branched polymer which has 5' termini and was used to bind a target
CC   sequence comprising a segment of the HIV pol and nef genes in single
CC   stranded or double stranded forms. An oligonucleotide clamp is a compound
CC   capable of forming a covalently closed macromolecule or a stable circular
CC   complex after specifically binding to the target polynucleotide.
CC   Oligonucleotide clamps generally comprise one or more oligonucleotide
CC   moieties capable of specific binding to the target molecule and one or
CC   more pairs of binding moieties covalently linked to the oligonucleotide
CC   moieties. Upon annealing of the oligonucleotides moieties to the target
CC   polynucleotide, the binding moieties of a pair are bought into
CC   juxtaposition so that they form a stable covalent or non-covalent linkage
CC   or complex. The interaction of the binding moieties effectively clamps
CC   the specifically annealed oligonucleotide moieties to the target
CC   polynucleotide. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 29 BP; 14 A; 15 C; 0 G; 0 T; 0 U; 0 Other;
```

```
  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 6.2e+02;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 97
AAT65760/c
ID   AAT65760 standard; DNA; 29 BP.
XX
AC   AAT65760;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd65.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf65 which contains the repeat sequence having the
CC   formula: (CA)14.5. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 29 BP; 14 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 6.2e+02;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 98
AAT65712/c
ID   AAT65712 standard; DNA; 29 BP.
XX
AC   AAT65712;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd10.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf10 which contains the repeat sequence having the
CC   formula: (AC)14A. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 29 BP; 15 A; 14 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 6.2e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         29 TGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 99
AAF60474/c
ID   AAF60474 standard; DNA; 29 BP.
XX
AC   AAF60474;
XX
DT   27-APR-2001  (first entry)
XX
DE   Oligonucleotide clamp #23.
XX
```

KW Oligonucleotide clamp; ds.
XX
OS Unidentified.
XX
PN US6180777-B1.
XX
PD 30-JAN-2001.
XX
PF 03-JAN-1997; 97US-00787321.
XX
PR 12-JAN-1996; 96US-0009918P.
XX
PA (FARB) BAYER CORP.
XX
PI Horn T;
XX
DR WPI; 2001-201911/20.
XX
PT Synthesizing branched nucleic acids useful as diagnostic and molecular
PT probes, involves combining first units having haloalkylamino groups and
PT second units having thiol or phosphorothioate groups.
XX
PS Example 9; Col 19-20; 20pp; English.
XX
CC The present invention relates to a method for synthesising a branched or
CC multiply connected macromolecular structure, comprising oligonucleotide
CC clamps (OC). The macromolecular structure is capable of specifically
CC binding to a target molecule, and can therefore be used as probes. At
CC least one OC comprises a target binding sequence that binds specifically
CC and stably with the target molecule, and at least two OCs comprise signal
CC generation moieties capable of generating a detectable signal in the
CC presence of the target molecule. In addition the OCs are connected to one
CC another by thioalkylamino, or thiophosphorylalkylamino bridges. The
CC present sequence is an OC used in the present invention
XX
SQ Sequence 29 BP; 14 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 29; DB 1; Length 29;
Best Local Similarity 51.7%; Pred. No. 6.2e+02;
Matches 15; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 100
ABK66322/c
ID ABK66322 standard; DNA; 29 BP.
XX
AC ABK66322;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human gene specific PCR primer #410.
XX
KW Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS Homo sapiens.
XX
PN US6352829-B1.
XX
PD 05-MAR-2002.
XX
PF 05-JAN-1999; 99US-00225928.
XX
PR 21-MAY-1997; 97US-00859998.
XX
PA (CLON-) CLONTECH LAB INC.
XX
PI Chenchik A, Jokhadze G, Bibilashvilli R;
XX
DR WPI; 2002-314699/35.
XX
PT Producing sub-population of labeled nucleic acids, useful for analyzing
PT differences in RNA profiles between several different physiological
PT sources, using set of distinct gene specific primers.
XX
PS Example 3; SEQ ID NO 410; 11pp; English.
XX
CC The invention relates to producing a sub-population of labeled nucleic
CC acids (NAs) comprising contacting a NA sample from a physiological
CC source, with a pool of 50 distinct gene specific primers under suitable
CC conditions to enzymatically generate sub-population of NAs, where each
CC gene specific primer has a sequence complementary to a distinct mRNA, and
CC each labeled NA is generated using a single gene specific primer. The
CC method is useful for producing a sub-population of labeled NAs which is
CC useful for analysing the differences in the RNA profiles between several
CC different physiological sources, where the method comprises producing
CC subpopulation of labeled NAs for the different physiological sources,
CC comprising the populations for each physiological source to identify
CC differences in the population, where the comparison is preferably
CC performed by hybridising the labeled NAs for each of the distinct
CC physiological sources to an array of probe NAs stably associated with the
CC surface of a substrate to produce a hybridisation pattern for each of the
CC sources, and comparing the patterns for each of the sources, where
CC differential gene expression assays are utilised in differential
CC expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC tissue, or different tissue or subtissue types. The present sequence is a
CC human gene specific PCR primer used in the method of the invention. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from USPTO
CC at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ Sequence 29 BP; 5 A; 5 C; 11 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 29; DB 1; Length 29;
Best Local Similarity 82.8%; Pred. No. 6.2e+02;
Matches 24; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
:|:|:||||||:||||||||||||||:||
Db 29 TCTCTACCCACTGGGCAGCAGACAAATCC 1

RESULT 101
AAQ33731
ID AAQ33731 standard; DNA; 33 BP.
XX
AC AAQ33731;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA149.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
PI Georges M, Massey JM;
XX
DR WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene

```
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 222; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 33 BP; 3 A; 0 C; 13 G; 17 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28.2;  DB 1;  Length 33;
  Best Local Similarity   42.4%;  Pred. No. 9.7e+02;
  Matches   14;  Conservative   16;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6967 UGUAACUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              : :|  :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TATATATGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 102
AAQ34027
ID   AAQ34027 standard; DNA; 28 BP.
XX
AC   AAQ34027;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA424.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 341; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 0 A; 0 C; 14 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28


RESULT 103
AAQ33645
ID   AAQ33645 standard; DNA; 28 BP.
XX
AC   AAQ33645;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone MTGT3.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 187; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
```

```
XX
SQ   Sequence 28 BP; 0 A; 0 C; 14 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 104
AAQ34161
ID   AAQ34161 standard; DNA; 28 BP.
XX
AC   AAQ34161;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA82.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 395; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 0 A; 0 C; 14 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 105
AAQ34035
ID   AAQ34035 standard; DNA; 28 BP.
XX
AC   AAQ34035;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA431.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 345; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 0 A; 0 C; 14 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 106
AAT66102/c
ID   AAT66102 standard; DNA; 28 BP.
XX
AC   AAT66102;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
```

```
XX
DE   Repeat sequence found in the human chromosomal clone SW10.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 9; Col 61-62; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The sequences AAT66084-
CC   T66107 represent repeat sequences of low informativeness found in
CC   specific human genes. This repeat sequence is found in the human
CC   chromosomal clone SW10. The sequence is amplified by primers AAT66103-4.
CC   (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 28 BP; 14 A; 14 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         28 GTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 107
AAA60165
ID   AAA60165 standard; DNA; 28 BP.
XX
AC   AAA60165;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Human Flt-1 gene probe.
XX
KW   Peroxisome proliferator activated receptor; angiogenesis inhibition;
KW   neovascularisation; tumour growth; metastasis; rheumatoid arthritis;
KW   psoriasis; atherosclerosis; diabetes; retinopathy; PPAR; Flt-1;
KW   retrolental fibroplasia; age-related macular degeneration; human;
KW   neovascular glaucoma; hemangioma; thyroid hyperplasia; Grave's disease;
KW   inflammatiobesity; transplantation; transcription factor; probe; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   misc_difference 1
FT                   /*tag=  a
FT                   /note= "5' end labelled with reporter fluorescent dye"
FT   misc_difference 28
FT                   /*tag=  b
FT                   /note= "3' end labelled with quencher fluorescent dye"
XX
PN   WO200030628-A2.
XX
PD   02-JUN-2000.
XX
PF   18-NOV-1999;   99WO-US027612.
XX
PR   20-NOV-1998;   98US-0109328P.
PR   20-JAN-1999;   99US-0116530P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Gerritsen ME,  Xin XE;
XX
DR   WPI; 2000-411807/35.
XX
PT   Inhibiting angiogenesis comprises administration of PPAR gamma ligands
PT   for treating tumors, neovascularization and rheumatoid arthritis.
XX
PS   Example 5; Page 31; 52pp; English.
XX
CC   Peroxisome proliferators are agents that induce peroxisomal
CC   proliferation. Peroxisome proliferator-activated receptors (PPARs) are
CC   members of the steroid receptor superfamily, and are ligand-activated
CC   transcription factors. There are three mammalian subtypes of PPAR, alpha,
CC   beta (also known as delta) and gamma. The present invention relates to
CC   inhibiting angiogenesis by contacting PPAR gamma with a PPAR gamma
CC   ligand. This method may be used to treat tumours, and diseases
CC   characterised by excessive neovascularisation e.g. rheumatoid arthritis,
CC   psoriasis, atherosclerosis, diabetes, retinopathy, retrolental
CC   fibroplasia, neovascular glaucoma, age-related macular degeneration,
CC   hemangiomas, thyroid hyperplasias, Grave's disease, tissue
CC   transplantation, chronic inflammation, lung inflammation, endometriosis
CC   and obesity. The present sequence is a probe for human Flt-1 gene. Flt-1
CC   is an endothelial cell tyrosine kinase receptor for vascular endothelial
CC   growth factor (VEGF) and has an important role in angiogenesis. The
CC   present sequence was used to determine whether PPARgamma activation leads
CC   to an alteration in Flt-1 gene expression and hence angiogenesis. An
CC   increase in Flt-1 levels was found after PPARgamma activation
XX
SQ   Sequence 28 BP; 6 A; 5 C; 9 G; 8 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   71.4%;  Pred. No. 7.4e+02;
  Matches   20;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGAGUUUG 2716
              ||::|:||:|||||||||:|||||:::|
Db          1 CCTTATGATGCCAGCAAGTGGGAGTTTG 28


RESULT 108
AAS13711/c
ID   AAS13711 standard; DNA; 28 BP.
XX
AC   AAS13711;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Simple sequence repeat, SSR, #8.
XX
KW   Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
KW   cereal profiling; grass profiling; seed batch purity testing.
XX
OS   Poeae.
XX
PN   NZ509193-A.
XX
```

```
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509193.
XX
PR   24-DEC-1999;   99AU-00004906.
PR   04-MAY-2000; 2000AU-00007310.
XX
PA   (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
PA   (UYSC-) UNIV SOUTHERN CROSS.
PA   (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
PA   (UYAD-) UNIV ADELAIDE.
PA   (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX
PI   Forster JW,  Jones ES;
XX
DR   WPI; 2001-512563/56.
XX
PT   New simple sequence repeats having 2 or more tandemly repeated nucleotide
PT   core elements isolated from ryegrass and fescue, useful for selecting of
PT   genes in grass or cereal breeding or profiling grass or cereal species
PT   varieties.
XX
PS   Claim 6; Page 51; 72pp; English.
XX
CC   The invention relates to a substantially purified or isolated nucleic
CC   acid (I) from ryegrass or fescue species including a simple sequence
CC   repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
CC   2-6 nucleotides in length. Also included are a nucleic acid primer
CC   suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
CC   library of ryegrass or fescue genomic DNA enriched for SSRs and
CC   identifying clones in the library containing SSRs, a library of ryegrass
CC   or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
CC   a gene in grass or cereal breeding by identifying an SSR that is closely
CC   associated with the gene such that the SSR and the gene are
CC   preferentially co-inherited, and selecting for the SSR in the breeding, a
CC   method for DNA profiling grass or cereal species varieties by assessing
CC   variation between SSR varieties and testing the purity of grass or cereal
CC   seed batches by assessing variation within seed batch of an SSR. The SSRs
CC   may be used in the selection of genes in grass or cereal breeding, for
CC   profiling grass or cereal species varieties, for testing the purity of
CC   grass or cereal seed batches, and for DNA profiling to establish the
CC   distinct identity, uniformity and/or stability of a cultivar. The present
CC   sequence is a ryegrass or fescue SSR
XX
SQ   Sequence 28 BP; 14 A; 14 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         28 TGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 109
AAD19467/c
ID   AAD19467 standard; DNA; 28 BP.
XX
AC   AAD19467;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human flt-1 gene amplifying reverse PCR primer #1.
XX
KW   Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW   opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW   diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW   vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW   cancer; medicament; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1130123-A2.
XX
PD   05-SEP-2001.
XX
PF   20-FEB-2001; 2001EP-00301489.
XX
PR   24-FEB-2000; 2000GB-00004232.
XX
PA   (ASTR ) ASTRAZENECA AB.
XX
PI   Smith JC;
XX
DR   WPI; 2001-608199/70.
XX
PT   Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT   assessing predisposition or susceptibility to diseases mediated by an flt
PT   -1 ligand, comprises determining the nucleic acid sequence at one or more
PT   point positions.
XX
PS   Example 1; Page 16; 30pp; English.
XX
CC   The invention relates to novel sequence and polymorphisms in the human
CC   flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC   growth factor (VEGFR-1). The invention also relates to a method for
CC   diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC   1 gene. The method is useful for assessing the predisposition and/or
CC   susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC   to recognise individuals who are particularly at risk from developing
CC   these conditions, and in the development of new drug therapies that
CC   selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC   polymorphisms are used in the diagnosis and treatment of cancer and
CC   angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC   arthritis and endometriosis. Polymorphisms are also used in mapping the
CC   human genome and to elucidate the genetic component of the diseases, as
CC   genetic markers for this region in linkage studies. The nucleic acids are
CC   useful as components in databases useful in sequence identity, genome
CC   mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC   is useful in the preparation of a medicament for treating VEGF-mediated
CC   diseases in a human diagnosed as having a single nucleotide polymorphism
CC   at one or more of the defined positions. The present DNA sequence is a
CC   PCR primer which is used for amplifying human flt-1 gene
XX
SQ   Sequence 28 BP; 10 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   64.3%;  Pred. No. 7.4e+02;
  Matches   18;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2098 AUCACUCUUAAUCUUACCAUCAUGAAUG 2125
              |:|||:|::||:|::||||:||:|||:|
Db         28 ATCACTCTTAATCTTACCATCATGAATG 1


RESULT 110
AAD19462
ID   AAD19462 standard; DNA; 31 BP.
XX
AC   AAD19462;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human flt-1 gene polymorphism detecting allele specific probe #6.
XX
KW   Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW   opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW   diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW   vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW   cancer; medicament; probe; ss.
XX
OS   Homo sapiens.
XX
PN   EP1130123-A2.
XX
```

```
PD   05-SEP-2001.
XX
PF   20-FEB-2001; 2001EP-00301489.
XX
PR   24-FEB-2000; 2000GB-00004232.
XX
PA   (ASTR ) ASTRAZENECA AB.
XX
PI   Smith JC;
XX
DR   WPI; 2001-608199/70.
XX
PT   Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT   assessing predisposition or susceptibility to diseases mediated by an flt
PT   -1 ligand, comprises determining the nucleic acid sequence at one or more
PT   point positions.
XX
PS   Claim 11; Page 4; 30pp; English.
XX
CC   The invention relates to novel sequence and polymorphisms in the human
CC   flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC   growth factor (VEGFR-1). The invention also relates to a method for
CC   diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC   1 gene. The method is useful for assessing the predisposition and/or
CC   susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC   to recognise individuals who are particularly at risk from developing
CC   these conditions, and in the development of new drug therapies that
CC   selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC   polymorphisms are used in the diagnosis and treatment of cancer and
CC   angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC   arthritis and endometriosis. Polymorphisms are also used in mapping the
CC   human genome and to elucidate the genetic component of the diseases, as
CC   genetic markers for this region in linkage studies. The nucleic acids are
CC   useful as components in databases useful in sequence identity, genome
CC   mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC   is useful in the preparation of a medicament for treating VEGF-mediated
CC   diseases in a human diagnosed as having a single nucleotide polymorphism
CC   at one or more of the defined positions. The present DNA sequence is a
CC   allele specific nucleotide probe which is used for detecting human flt-1
CC   gene polymorphism
XX
SQ   Sequence 31 BP; 2 A; 9 C; 13 G; 6 T; 0 U; 1 Other;

  Query Match             0.4%;  Score 28;  DB 1;  Length 31;
  Best Local Similarity   76.7%;  Pred. No. 9e+02;
  Matches   23;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        177 GACGGACUCUGGCGGCCGGGUCGUUGGCCG 206
              |||||||:|:|||||:||||:| ::|||||
Db          1 GACGGACTCTGGCGGYCGGGTCTTTGGCCG 30


RESULT 111
ADH70471
ID   ADH70471 standard; DNA; 29 BP.
XX
AC   ADH70471;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #261.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 665; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 29 BP; 0 A; 0 C; 14 G; 15 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 9.1e+02;
  Matches   14;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|: :|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTTTGTGTGTGTGTGTGTG 29


RESULT 112
AAZ98502/c
ID   AAZ98502 standard; DNA; 30 BP.
XX
AC   AAZ98502;
XX
DT   19-JUN-2000  (first entry)
XX
DE   H. discus derived sequence #20.
XX
KW   Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
KW   Haliotis discus; ss.
XX
OS   Haliotis discus.
```

```
XX
PN   WO200011156-A1.
XX
PD   02-MAR-2000.
XX
PF   01-JUL-1999;   99WO-JP003551.
XX
PR   18-AUG-1998;   98JP-00232153.
XX
PA   (NORQ ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX
PI   Takahashi H,  Sekino M;
XX
DR   WPI; 2000-224692/19.
XX
PT   Isolation of satellite sequences from genomic DNA for use as DNA markers
PT   comprises isolating a library with high homogeneity by DNA fragmentation.
XX
PS   Example 5; Page 14; 35pp; Japanese.
XX
CC   The invention provides a novel method for isolation of satellite
CC   sequences from genomic DNA that comprises fragmentation of the DNA by a
CC   method which is not dependent on base sequences, then selection of the
CC   satellite sequences from the obtained genomic library of high
CC   homogeneity. The method is useful for the isolation of microsatellite DNA
CC   sequences which can be used as DNA markers. The new method markedly
CC   improves the efficiency of isolation of satellite sequences in comparison
CC   to prior art methods which are reliant on base sequences. Sequences
CC   AAZ98483-514 represent sequences from Haliotis discus, used in the method
CC   of the invention
XX
SQ   Sequence 30 BP; 15 A; 13 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 30;
  Best Local Similarity   44.8%;  Pred. No. 9.8e+02;
  Matches   13;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|: :|:
Db         30 TGTGTGTGTGTGTGTGTGTGTGTATGT 2


RESULT 113
AAQ34044
ID   AAQ34044 standard; DNA; 27 BP.
XX
AC   AAQ34044;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA435.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 348; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 114
AAQ33678
ID   AAQ33678 standard; DNA; 27 BP.
XX
AC   AAQ33678;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA12.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 201; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
```

```
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
             :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 115
AAQ33804
ID   AAQ33804 standard; DNA; 27 BP.
XX
AC   AAQ33804;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA210.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 251; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
             :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 116
AAQ34181
ID   AAQ34181 standard; DNA; 27 BP.
XX
AC   AAQ34181;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA98.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 403; 517pp; English.
XX
CC   The sequence is a bovine microsatellite sequence obtd. by screening a
CC   library of bovine MboI DNA fragments of between 250 and 500 bp with an
CC   (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-
CC   hybridised. Assuming independent distribution of microsatellites and MboI
CC   sites, the frequency of (T6)n >9 microsatellites in the bovine genome is
CC   estimated at >100, 000. The sequence information for ca. 230 such bovine
CC   microsatellites is summarised in the specification and indexed herein
CC   (see below). The sequences upstream and downstream of the microsatellite
CC   sequence were used to generate the required PCR primers for in vitro
CC   amplification of the corresp. microsatellite (using the program
CC   OPTIPRIM). The microsatellites may be used to identify individuals, for
CC   parentage testing, and in the genetic mapping of economic trait loci, or
CC   genes involved the determinism of economically important traits esp. in
CC   cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
             :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27
```

```
RESULT 117
AAQ34012
ID   AAQ34012 standard; DNA; 27 BP.
XX
AC   AAQ34012;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA417.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 335; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 118
AAQ34143
ID   AAQ34143 standard; DNA; 27 BP.
XX
AC   AAQ34143;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA76.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 388; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 119
AAQ83951/c
ID   AAQ83951 standard; DNA; 27 BP.
XX
AC   AAQ83951;
XX
DT   25-MAR-2003  (revised)
DT   04-OCT-1995  (first entry)
XX
DE   Oligonucleotide clamp 1, containing loop-and-branch forming region.
XX
KW   HIV; pol; nef; oligonucleotide clamp; branched; macromolecule; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /note= "Modified with SP(O-)(=O)-"
```

```
FT   modified_base   27
FT                   /*tag=  b
FT                   /note= "Modified with -OP(O-)(=O)S"
XX
PN   WO9501365-A1.
XX
PD   12-JAN-1995.
XX
PF   05-JUL-1994;   94WO-US007557.
XX
PR   02-JUL-1993;   93US-00087386.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Gryaznov SM;
XX
DR   WPI; 1995-060944/08.
XX
PT   Synthesis of branched polymers and novel branched polymeric structures -
PT   used as molecular probes esp. for detecting poly-nucleotide(s).
XX
PS   Example 7; Page 33; 52pp; English.
XX
CC   This sequence represents an oligonucleotide clamp which was used to bind
CC   a target sequence comprising a segment of the HIV pol and nef genes in
CC   single stranded or double stranded forms. This molecule forms a loop-and-
CC   branch comfigurartion. An oligonucleotide clamp is a compound capable of
CC   forming a covalently closed macromolecule or a stable circular complex
CC   after specifically binding to the target polynucleotide. Oligonucleotide
CC   clamps generally comprise one or more oligonucleotide moieties capable of
CC   specific binding to the target molecule and one or more pairs of binding
CC   moieties covalently linked to the oligonucleotide moieties. Upon
CC   annealing of the oligonucleotides moieties to the target polynucleotide,
CC   the binding moieties of a pair are bought into juxtaposition so that they
CC   form a stable covalent or non-covalent linkage or complex. The
CC   interaction of the binding moieties effectively clamps the specifically
CC   annealed oligonucleotide moieties to the target polynucleotide. (Updated
CC   on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 27 BP; 13 A; 14 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 120
AAT65733/c
ID   AAT65733 standard; DNA; 27 BP.
XX
AC   AAT65733;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd31.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 1; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf31 which contains the repeat sequence having the
CC   formula: (AC)13A. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 27 BP; 14 A; 13 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         27 TGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 121
AAH24300
ID   AAH24300 standard; DNA; 27 BP.
XX
AC   AAH24300;
XX
DT   21-SEP-2001  (first entry)
XX
DE   Synthetic antineoplastic oligonucleotide, SEQ ID NO:2.
XX
KW   Antineoplastic oligonucleotide; hyaluronic acid; HA; cytokine production;
KW   interleukin; IL-6; IL-12; synergistic action; standard dose reduction;
KW   side-effect reduction; drug resistance reduction;
KW   immunosensitisation reduction; cancer; tumour; cytostatic; ss.
XX
OS   Synthetic.
XX
PN   WO200147561-A1.
XX
PD   05-JUL-2001.
XX
PF   28-DEC-2000; 2000WO-CA001562.
XX
PR   28-DEC-1999;   99US-0173375P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-408766/43.
XX
PT   Synergistic compositions comprising hyaluronic acid and Mycobacterium
PT   phlei DNA and cell walls, useful for treating cancers.
```

```
XX
PS   Example 7; Page 23; 27pp; English.
XX
CC   The invention relates to compositions for the treatment of cancers,
CC   comprising purified hyaluronic acid (HA) and a second antineoplastic
CC   agent such as Mycobacterium phlei DNA, a Mycobacterium phlei DNA/cell
CC   wall complex, a cytotoxic chemotherapeutic drug or a synthetic
CC   antineoplastic oligonucleotide. On its own, HA stimulates the production
CC   of the cytokines interleukin-6 (IL-6) and IL-12 by immune system cells.
CC   In combination, HA and the second antineoplastic agent of the composition
CC   act synergistically to potentiate each other's ability to inhibit
CC   proliferation and induce apoptosis in cancer cells. Due to the synergy
CC   between the HA and the second antineoplastic agent, a reduced standard
CC   dose of the second antineoplastic agent can be used without compromising
CC   the therapeutic effectiveness of the cancer treatment. The reduction in
CC   dose helps to reduce adverse side-effects and the development of drug
CC   resistance or immunosensitisation, thereby improving the quality of life
CC   for the patient. In addition, as HA is inexpensive and as most
CC   chemotherapeutic drugs are expensive, the combined use of HA and a
CC   chemotherapeutic drug can significantly reduce the cost of cancer
CC   treatment. The increase in dose effectiveness, decrease in toxicity and
CC   decrease in cost address provide important benefits for mammals,
CC   including humans. The present sequence represents a synthetic
CC   antineoplastic oligonucleotide which was used in a composition with HA in
CC   an exemplification of the invention
XX
SQ   Sequence 27 BP; 0 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 122
AAH46017
ID   AAH46017 standard; DNA; 27 BP.
XX
AC   AAH46017;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 17.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Disclosure; Page 74; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 27 BP; 0 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 123
AAH46001
ID   AAH46001 standard; DNA; 27 BP.
XX
AC   AAH46001;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 1.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Example 4; Page 16; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
```

```
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 27 BP; 0 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 124
AAH46005
ID   AAH46005 standard; DNA; 27 BP.
XX
AC   AAH46005;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 5.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Example 4; Page 16; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 125
AAF60473/c
ID   AAF60473 standard; DNA; 27 BP.
XX
AC   AAF60473;
XX
DT   27-APR-2001  (first entry)
XX
DE   Oligonucleotide clamp #19.
XX
KW   Oligonucleotide clamp; ds.
XX
OS   Unidentified.
XX
PN   US6180777-B1.
XX
PD   30-JAN-2001.
XX
PF   03-JAN-1997;   97US-00787321.
XX
PR   12-JAN-1996;   96US-0009918P.
XX
PA   (FARB ) BAYER CORP.
XX
PI   Horn T;
XX
DR   WPI; 2001-201911/20.
XX
PT   Synthesizing branched nucleic acids useful as diagnostic and molecular
PT   probes, involves combining first units having haloalkylamino groups and
PT   second units having thiol or phosphorothioate groups.
XX
PS   Disclosure; Col 29-30; 20pp; English.
XX
CC   The present invention relates to a method for synthesising a branched or
CC   multiply connected macromolecular structure, comprising oligonucleotide
CC   clamps (OC). The macromolecular structure is capable of specifically
CC   binding to a target molecule, and can therefore be used as probes. At
CC   least one OC comprises a target binding sequence that binds specifically
CC   and stably with the target molecule, and at least two OCs comprise signal
CC   generation moieties capable of generating a detectable signal in the
CC   presence of the target molecule. In addition the OCs are connected to one
CC   another by thioalkylamino, or thiophosphorylalkylamino bridges. The
CC   present sequence is an OC used in the present invention
XX
SQ   Sequence 27 BP; 13 A; 14 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 126
```

```
ABK66321
ID   ABK66321 standard; DNA; 27 BP.
XX
AC   ABK66321;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human gene specific PCR primer #409.
XX
KW   Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS   Homo sapiens.
XX
PN   US6352829-B1.
XX
PD   05-MAR-2002.
XX
PF   05-JAN-1999;   99US-00225928.
XX
PR   21-MAY-1997;   97US-00859998.
XX
PA   (CLON-) CLONTECH LAB INC.
XX
PI   Chenchik A,  Jokhadze G,  Bibilashvilli R;
XX
DR   WPI; 2002-314699/35.
XX
PT   Producing sub-population of labeled nucleic acids, useful for analyzing
PT   differences in RNA profiles between several different physiological
PT   sources, using set of distinct gene specific primers.
XX
PS   Example 3; SEQ ID NO 409; 11pp; English.
XX
CC   The invention relates to producing a sub-population of labeled nucleic
CC   acids (NAs) comprising contacting a NA sample from a physiological
CC   source, with a pool of 50 distinct gene specific primers under suitable
CC   conditions to enzymatically generate sub-population of NAs, where each
CC   gene specific primer has a sequence complementary to a distinct mRNA, and
CC   each labeled NA is generated using a single gene specific primer. The
CC   method is useful for producing a sub-population of labeled NAs which is
CC   useful for analysing the differences in the RNA profiles between several
CC   different physiological sources, where the method comprises producing
CC   subpopulation of labeled NAs for the different physiological sources,
CC   comprising the populations for each physiological source to identify
CC   differences in the population, where the comparison is preferably
CC   performed by hybridising the labeled NAs for each of the distinct
CC   physiological sources to an array of probe NAs stably associated with the
CC   surface of a substrate to produce a hybridisation pattern for each of the
CC   sources, and comparing the patterns for each of the sources, where
CC   differential gene expression assays are utilised in differential
CC   expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC   tissue, or different tissue or subtissue types. The present sequence is a
CC   human gene specific PCR primer used in the method of the invention. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from USPTO
CC   at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ   Sequence 27 BP; 4 A; 8 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 8.8e+02;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
              |:|||:||||||||:|::|||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 127
ADH70576
ID   ADH70576 standard; DNA; 27 BP.
XX
AC   ADH70576;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #366.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 770; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 27
```

```
RESULT 128
AAT66066/c
ID   AAT66066 standard; DNA; 30 BP.
XX
AC   AAT66066;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   (dC-dA)n.(dG-dT)n polymorphic repeat sequence #7.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 8; Col 57-58; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The repeats, when
CC   analysed, fall into 4 categories: 1) perfect repeats which are
CC   alternating tandem CA repeats with no interruptions and without adjacent
CC   repeats of another sequence; 2) imperfect repeats which are defined as 2
CC   or more runs of uninterrupted CA repeats separated by no more than 3
CC   consecutive non-repeat bases; 3) compound perfect repeats which are
CC   uninterrupted runs of CA separated by no more than 3 consecutive non-
CC   repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC   longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC   least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC   which are defined as for the perfect compound repeats except that the
CC   runs of CA are interrupted. This sequence is an example of an imperfect
CC   repeat sequence of structure: (CA)5G(ACA)G(AC)7A. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 30 BP; 15 A; 13 C; 2 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   43.3%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|: :|: :|:|:|:|:|
Db         30 TGTGTGTGTGTGTCTGTCTGTGTGTGTG 1


RESULT 129
ADH70406
ID   ADH70406 standard; DNA; 30 BP.
XX
AC   ADH70406;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #196.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 600; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 30 BP; 1 A; 1 C; 13 G; 15 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   43.3%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|: :|: :|:|:|:|:|:|:|:|
Db          1 TGTGTGTCTGTATGTGTGTGTGTGTGTG 30


RESULT 130
AAQ34074
ID   AAQ34074 standard; DNA; 28 BP.
XX
AC   AAQ34074;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA45.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 360; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 1 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26.4;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
              :|:|:|:|:|:| |:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGAGTGTGTGTGTGTGTG 28


RESULT 131
AAQ33843
ID   AAQ33843 standard; DNA; 28 BP.
XX
AC   AAQ33843;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA255.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 267; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 0 A; 1 C; 13 G; 14 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26.4;  DB 1;  Length 28;
  Best Local Similarity   46.4%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|: :|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTCTGTGTGTGT 28


RESULT 132
AAZ98509/c
ID   AAZ98509 standard; DNA; 32 BP.
XX
AC   AAZ98509;
XX
DT   19-JUN-2000  (first entry)
XX
DE   H. discus derived sequence #27.
XX
KW   Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
KW   Haliotis discus; ss.
XX
OS   Haliotis discus.
XX
```

```
PN   WO200011156-A1.
XX
PD   02-MAR-2000.
XX
PF   01-JUL-1999;   99WO-JP003551.
XX
PR   18-AUG-1998;   98JP-00232153.
XX
PA   (NORQ ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX
PI   Takahashi H,  Sekino M;
XX
DR   WPI; 2000-224692/19.
XX
PT   Isolation of satellite sequences from genomic DNA for use as DNA markers
PT   comprises isolating a library with high homogeneity by DNA fragmentation.
XX
PS   Example 5; Page 14; 35pp; Japanese.
XX
CC   The invention provides a novel method for isolation of satellite
CC   sequences from genomic DNA that comprises fragmentation of the DNA by a
CC   method which is not dependent on base sequences, then selection of the
CC   satellite sequences from the obtained genomic library of high
CC   homogeneity. The method is useful for the isolation of microsatellite DNA
CC   sequences which can be used as DNA markers. The new method markedly
CC   improves the efficiency of isolation of satellite sequences in comparison
CC   to prior art methods which are reliant on base sequences. Sequences
CC   AAZ98483-514 represent sequences from Haliotis discus, used in the method
CC   of the invention
XX
SQ   Sequence 32 BP; 10 A; 22 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 32;
  Best Local Similarity   58.1%;  Pred. No. 1.5e+03;
  Matches   18;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6994 GUGUGUGUGUGUGUGUGUGUGGGGUGUGGGUG 7024
                | |:|:|:|:|:|:|:|:|:||| | |||:|
Db         31 GGGTGTGTGTGTGTGTGTGGGGGGGGGTG 1


RESULT 133
AAQ34083
ID   AAQ34083 standard; DNA; 26 BP.
XX
AC   AAQ34083;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA49.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 364; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
                :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 26


RESULT 134
AAQ33684
ID   AAQ33684 standard; DNA; 26 BP.
XX
AC   AAQ33684;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA123.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 203; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
```

```
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26


RESULT 135
AAQ33704
ID   AAQ33704 standard; DNA; 26 BP.
XX
AC   AAQ33704;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA130.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 211; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26


RESULT 136
AAQ33831
ID   AAQ33831 standard; DNA; 26 BP.
XX
AC   AAQ33831;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA231.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 262; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 26
```

c

```
RESULT 137
AAQ33837
ID   AAQ33837 standard; DNA; 26 BP.
XX
AC   AAQ33837;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA25.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 264; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 26


RESULT 138
ACC86710/c
ID   ACC86710 standard; DNA; 26 BP.
XX
AC   ACC86710;
XX
DT   04-AUG-2003  (first entry)
XX
DE   Human VEGFR-1 reverse PCR primer SEQ ID NO:5.
XX
KW   Vascular endothelial growth factor receptor 1; VEGF receptor; VEGFR;
KW   inhibitor; cytostatic; antirheumatic; antiarthritic; antiangiogenic;
KW   antiinflammatory; antisense gene therapy; hyperproliferative disorder;
KW   cancer; rheumatoid arthritis; angiogenesis; infection; inflammation;
KW   tumour formation; chromosome 13q12; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003022227-A2.
XX
PD   20-MAR-2003.
XX
PF   12-SEP-2002; 2002WO-US029148.
XX
PR   13-SEP-2001; 2001US-00953318.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Watt AT;
XX
DR   WPI; 2003-301004/29.
XX
PT   New antisense oligonucleotide targeted to a nucleic acid encoding
PT   vascular endothelial growth factor receptor-1, useful for diagnosing or
PT   treating cancer, rheumatoid arthritis, or diseases or conditions
PT   involving angiogenesis.
XX
PS   Example 13; Page 79; 150pp; English.
XX
CC   The present invention describes a compound (C) 8-50 nucleobases in length
CC   targeted to a nucleic acid molecule encoding vascular endothelial growth
CC   factor receptor-1 (VEGFR-1), where the compound inhibits the expression
CC   of VEGFR-1 and specifically hybridises with the nucleic acid encoding
CC   VEGFR-1 or with an 8-nucleobase portion of an active site on the nucleic
CC   acid molecule encoding VEGFR-1. Also described: (1) a composition
CC   comprising (C) and a carrier or diluent; (2) inhibiting the expression of
CC   VEGFR-1 in cells or tissues by contacting the cells or tissues with (C)
CC   so that the expression of VEGFR-1 is inhibited; and (3) treating an
CC   animal having a disease or condition associated with VEGFR-1 by
CC   administering (C) to the animal so that the expression of VEGFR-1 is
CC   inhibited. (C) has antiangiogenic, antirheumatic, antiarthritic,
CC   cytostatic and antiinflammatory activities, and can be used in antisense
CC   gene therapy. The antisense compounds are useful for modulating the
CC   expression of VEGFR-1 and for treating diseases or conditions associated
CC   with the expression of VEGFR-1, such as hyperproliferative disorders
CC   (e.g. cancer), rheumatoid arthritis, or diseases or conditions involving
CC   angiogenesis. The antisense compounds are also useful for diagnostics,
CC   therapeutics, prophylaxis, e.g. to prevent or delay infection,
CC   inflammation or tumour formation, as research reagents and kits, and in
CC   distinguishing between functions of various members of a biological
CC   pathway. The present sequence represents a PCR primer for human VEGFR-1,
CC   which is used in an example from the present invention. Human VEGFR-1 is
CC   located from chromosome 13q12
XX
SQ   Sequence 26 BP; 11 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   57.7%;  Pred. No. 1e+03;
  Matches   15;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1399 UUGACUCGUGGCUACUCGUUAAUUAU 1424
              ::|||:||:|||:||:||::||::|:
Db         26 TTGACTCGTGGCTACTCGTTAATTAT 1


RESULT 139
ACC86711
ID   ACC86711 standard; DNA; 26 BP.
XX
AC   ACC86711;
XX
```

```
DT   04-AUG-2003  (first entry)
XX
DE   Human VEGFR-1 probe SEQ ID NO:6.
XX
KW   Vascular endothelial growth factor receptor 1; VEGF receptor; VEGFR;
KW   inhibitor; cytostatic; antirheumatic; antiarthritic; antiangiogenic;
KW   antiinflammatory; antisense gene therapy; hyperproliferative disorder;
KW   cancer; rheumatoid arthritis; angiogenesis; infection; inflammation;
KW   tumour formation; chromosome 13q12; probe; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003022227-A2.
XX
PD   20-MAR-2003.
XX
PF   12-SEP-2002; 2002WO-US029148.
XX
PR   13-SEP-2001; 2001US-00953318.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Watt AT;
XX
DR   WPI; 2003-301004/29.
XX
PT   New antisense oligonucleotide targeted to a nucleic acid encoding
PT   vascular endothelial growth factor receptor-1, useful for diagnosing or
PT   treating cancer, rheumatoid arthritis, or diseases or conditions
PT   involving angiogenesis.
XX
PS   Example 13; Page 79; 150pp; English.
XX
CC   The present invention describes a compound (C) 8-50 nucleobases in length
CC   targeted to a nucleic acid molecule encoding vascular endothelial growth
CC   factor receptor-1 (VEGFR-1), where the compound inhibits the expression
CC   of VEGFR-1 and specifically hybridises with the nucleic acid encoding
CC   VEGFR-1 or with an 8-nucleobase portion of an active site on the nucleic
CC   acid molecule encoding VEGFR-1. Also described: (1) a composition
CC   comprising (C) and a carrier or diluent; (2) inhibiting the expression of
CC   VEGFR-1 in cells or tissues by contacting the cells or tissues with (C)
CC   so that the expression of VEGFR-1 is inhibited; and (3) treating an
CC   animal having a disease or condition associated with VEGFR-1 by
CC   administering (C) to the animal so that the expression of VEGFR-1 is
CC   inhibited. (C) has antiangiogenic, antirheumatic, antiarthritic,
CC   cytostatic and antiinflammatory activities, and can be used in antisense
CC   gene therapy. The antisense compounds are useful for modulating the
CC   expression of VEGFR-1 and for treating diseases or conditions associated
CC   with the expression of VEGFR-1, such as hyperproliferative disorders
CC   (e.g. cancer), rheumatoid arthritis, or diseases or conditions involving
CC   angiogenesis. The antisense compounds are also useful for diagnostics,
CC   therapeutics, prophylaxis, e.g. to prevent or delay infection,
CC   inflammation or tumour formation, as research reagents and kits, and in
CC   distinguishing between functions of various members of a biological
CC   pathway. The present sequence represents a probe for human VEGFR-1, which
CC   is used in an example from the present invention. Human VEGFR-1 is
CC   located from chromosome 13q12
XX
SQ   Sequence 26 BP; 6 A; 8 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   76.9%;  Pred. No. 1e+03;
  Matches   20;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1371 ACCUGCGACUGAGAAAUCUGCUCGCU 1396
              |||:|||||:||||||:|:||:||||:
Db          1 ACCTGCGACTGAGAAATCTGCTCGCT 26


RESULT 140
ADO81053/c
ID   ADO81053 standard; DNA; 26 BP.
XX
AC   ADO81053;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Cow prion protein microsatellite locus primer #65.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; cow;
KW   microsatellite; PCR; primer; ss.
XX
OS   Bos taurus.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Example 3; Page 27; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a primer used to genotype a region of the cow prion
CC   protein (PrP) comprising a polymorphic microsatellite locus.
XX
SQ   Sequence 26 BP; 13 A; 13 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         26 TGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 141
AAQ33630
ID   AAQ33630 standard; DNA; 29 BP.
XX
AC   AAQ33630;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
```

```
DE   Microsatellite sequence from clone GBPRLGR.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 181; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 29 BP; 1 A; 0 C; 13 G; 15 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25.8;  DB 1;  Length 29;
  Best Local Similarity   44.8%;  Pred. No. 1.3e+03;
  Matches   13;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |: :|:|:|:|:|:|: :|:|:|:|:|:|
Db          1 GTTTGTGTGTGTGTATGTGTGTGTGTG 29


RESULT 142
AAQ34077
ID   AAQ34077 standard; DNA; 27 BP.
XX
AC   AAQ34077;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA47.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 362; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 1 A; 0 C; 13 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25.4;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 1.3e+03;
  Matches   13;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|: :|:|:|:|:|:|:|:|
Db          1 GTGTGTGTATGTGTGTGTGTGTGTG 27


RESULT 143
AAQ33918
ID   AAQ33918 standard; DNA; 25 BP.
XX
AC   AAQ33918;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA327.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
```

```
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 297; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 25


RESULT 144
AAQ33642
ID   AAQ33642 standard; DNA; 25 BP.
XX
AC   AAQ33642;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone MTGT13B.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 186; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 25


RESULT 145
AAQ33962
ID   AAQ33962 standard; DNA; 25 BP.
XX
AC   AAQ33962;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA354.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 315; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
```

```
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 25


RESULT 146
AAQ33861
ID   AAQ33861 standard; DNA; 25 BP.
XX
AC   AAQ33861;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA264.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 274; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 25 BP; 0 A; 0 C; 13 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
                :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTG 25


RESULT 147
AAT65734/c
ID   AAT65734 standard; DNA; 25 BP.
XX
AC   AAT65734;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd32.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf32 which contains the repeat sequence having the
CC   formula: (AC)12A. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 25 BP; 13 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         25 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 148
AAV17238/c
ID   AAV17238 standard; DNA; 25 BP.
XX
AC   AAV17238;
XX
```

```
DT   28-MAY-1998  (first entry)
XX
DE   Primer #2 set #1 for flt-1.
XX
KW   PCR primer; flt-1; chimeric factor; vascular endothelial growth factor;
KW   VEGF receptor; KDR receptor; FLT4 receptor; inhibitor; angiogenesis;
KW   endothelial cell proliferation; malignant tumour; retinopathy; therapy;
KW   rheumatoid arthritis; psoriasis; neovascular glaucoma; lung inflammation;
KW   thyroid hypertrophy; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9744453-A1.
XX
PD   27-NOV-1997.
XX
PF   06-MAY-1997;   97WO-US007694.
XX
PR   07-MAY-1996;   96US-00643839.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Davis-Smyth TL,  Chen H,  Presta L,  Ferrara N;
XX
DR   WPI; 1998-018508/02.
XX
PT   Chimeric vascular endothelial growth factor receptor - contains
PT   immunoglobulin like domain from flt-1 or KDR receptor, useful to inhibit
PT   cell proliferation and angiogenesis.
XX
PS   Example 1; Page 40; 62pp; English.
XX
CC   This sequence represents a primer for flt-1 which is used in the chimeric
CC   factor of the invention. The factor is a chimeric vascular endothelial
CC   growth factor (VEGF) receptor capable of binding and inhibiting VEGF,
CC   which comprises: (a) immunoglobulin (Ig) like domains 1, 2 and 3 of the
CC   flt-1 and/or KDR receptor; or (b) extracellular domain of the FLT4
CC   receptor, in which Ig like domain 2 is replaced by Ig like domain 2 of
CC   the flt-1 or KDR receptor, where 1 or more other Ig like domains of the
CC   FLT4 receptor are, or are not replaced by the corresponding Ig like
CC   domain of the flt-1 or KDR receptor. Host cells containing DNA encoding
CC   the chimeric factor can be used for the recombinant production of the
CC   chimeric VEGF receptor, which can be used to inhibit VEGF activity, e.g.
CC   endothelial cell proliferation and angiogenesis, in mammals. The chimeric
CC   VEGF receptor can be used to treat conditions associated with undesired
CC   angiogenesis, specifically a wide range of malignant tumours, but also
CC   retinopathy, rheumatoid arthritis, psoriasis, neovascular glaucoma,
CC   thyroid hypertrophy and lung inflammation
XX
SQ   Sequence 25 BP; 4 A; 7 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 1.2e+03;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 149
AAV17239
ID   AAV17239 standard; DNA; 25 BP.
XX
AC   AAV17239;
XX
DT   28-MAY-1998  (first entry)
XX
DE   Primer #1 set #2 for flt-1.
XX
KW   PCR primer; flt-1; chimeric factor; vascular endothelial growth factor;
KW   VEGF receptor; KDR receptor; FLT4 receptor; inhibitor; angiogenesis;
KW   endothelial cell proliferation; malignant tumour; retinopathy; therapy;
KW   rheumatoid arthritis; psoriasis; neovascular glaucoma; lung inflammation;
KW   thyroid hypertrophy; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9744453-A1.
XX
PD   27-NOV-1997.
XX
PF   06-MAY-1997;   97WO-US007694.
XX
PR   07-MAY-1996;   96US-00643839.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Davis-Smyth TL,  Chen H,  Presta L,  Ferrara N;
XX
DR   WPI; 1998-018508/02.
XX
PT   Chimeric vascular endothelial growth factor receptor - contains
PT   immunoglobulin like domain from flt-1 or KDR receptor, useful to inhibit
PT   cell proliferation and angiogenesis.
XX
PS   Example 1; Page 41; 62pp; English.
XX
CC   This sequence represents a primer for flt-1 which is used in the chimeric
CC   factor of the invention. The factor is a chimeric vascular endothelial
CC   growth factor (VEGF) receptor capable of binding and inhibiting VEGF,
CC   which comprises: (a) immunoglobulin (Ig) like domains 1, 2 and 3 of the
CC   flt-1 and/or KDR receptor; or (b) extracellular domain of the FLT4
CC   receptor, in which Ig like domain 2 is replaced by Ig like domain 2 of
CC   the flt-1 or KDR receptor, where 1 or more other Ig like domains of the
CC   FLT4 receptor are, or are not replaced by the corresponding Ig like
CC   domain of the flt-1 or KDR receptor. Host cells containing DNA encoding
CC   the chimeric factor can be used for the recombinant production of the
CC   chimeric VEGF receptor, which can be used to inhibit VEGF activity, e.g.
CC   endothelial cell proliferation and angiogenesis, in mammals. The chimeric
CC   VEGF receptor can be used to treat conditions associated with undesired
CC   angiogenesis, specifically a wide range of malignant tumours, but also
CC   retinopathy, rheumatoid arthritis, psoriasis, neovascular glaucoma,
CC   thyroid hypertrophy and lung inflammation
XX
SQ   Sequence 25 BP; 5 A; 7 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:|||:|::|:|||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 150
AAH38303
ID   AAH38303 standard; DNA; 25 BP.
XX
AC   AAH38303;
XX
DT   14-AUG-2001  (first entry)
XX
DE   SNP specific SNPE primer SEQ ID 1099.
XX
KW   Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW   SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW   Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW   polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW   acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW   inflammation; forensic investigation; paternity analysis; primer; ss.
XX
OS   Homo sapiens.
```

XX
PN WO200129262-A2.
XX
PD 26-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US028436.
XX
PR 15-OCT-1999; 99US-0160096P.
XX
PA (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI Picoult-Newburg L, Pohl M;
XX
DR WPI; 2001-290930/30.
XX
PT New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX
PS Claim 1; Page 55; 83pp; English.
XX
CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC diseases, including, rheumatoid arthritis, multiple sclerosis,
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a single nucleotide
CC primer extension (SNPE) primer specific for a human SNP containing DNA
CC sequence
XX
SQ Sequence 25 BP; 0 A; 0 C; 13 G; 12 T; 0 U; 0 Other;

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 1.2e+03;
Matches 13; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
|:|:|:|:|:|:|:|:|:|:|:|:|
Db 1 GTGTGTGTGTGTGTGTGTGTGTG 25

RESULT 151
ABQ80262
ID ABQ80262 standard; cDNA; 25 BP.
XX
AC ABQ80262;
XX
DT 27-JUN-2003 (first entry)
XX
DE FLT-1 primer #3.
XX
KW PCR; nervous system; platelet-derived growth factor; PDGF; psychosis;
KW vascular endothelial growth factor; VEGF; neural; stem cell; memory;
KW progenitor cell; neurodegeneration; ischaemia; neurological trauma;
KW neuropsychiatry; learning; Parkinson's disease; Huntington's disease;
KW Amyotrophic Lateral Sclerosis; spinal ischaemia; ischaemic stroke;
KW spinal cord injury; cancer-related; schizophrenia; Alzheimer's disease;
KW depression; anxiety; phobia; stress; cognitive function; aggression;
KW drug; alcohol; abuse; obsessive compulsive behaviour; proliferation;
KW seasonal mood disorder; personality disorder; cerebral palsy; primer;
KW multi-infarct; dementia; Lewy body; age related; geriatric; growth;
KW epilepsy; brain injury; multiple sclerosis; autism; differentiation;
KW attention deficit disorder; narcolepsy; amplify; ss.
XX
OS Homo sapiens.
XX
PN WO2003024478-A1.
XX
PD 27-MAR-2003.
XX
PF 19-SEP-2002; 2002WO-IB003998.
XX
PR 19-SEP-2001; 2001US-0323381P.
PR 28-SEP-2001; 2001US-0326044P.
XX
PA (NEUR-) NEURONOVA AB.
XX
PI Delfani K, Janson AM, Kuhn GH, Plate K, Schanzer A, Wachs F;
PI Zhao M;
XX
DR WPI; 2003-354563/33.
XX
PT Use of platelet-derived growth factor, vascular endothelial growth
PT factor, or their modulators for modulating neural stem cell or neural
PT progenitor cell activity, particularly for treating e.g. Alzheimer's,
PT ischemia or stroke.
XX
PS Example 11; Page 77; 119pp; English.
XX
CC The sequences given in ABQ80256-69 are primers which were used to
CC identify the presence of vascular endothelial growth factor (VEGF), or
CC the VEGF receptors, Flk1, FLT-1 and FLT-4 in human stem cells (HSC). The
CC method of the invention for alleviating or reducing a symptom of a
CC disease or disorder of the nervous system comprises administering
CC platelet-derived growth factor (PDGF), vascular endothelial growth factor
CC (VEGF), a combination of PDGF and VEGF, or a PDGF or VEGF agonist, to a
CC patient in order to modulate neural stem cell or neural progenitor cell
CC activity in vivo. The method is useful for alleviating or reducing the
CC symptoms of a disease or disorder of the nervous system, e.g.
CC neurodegenerative disorders, neural stem cell disorders, neural
CC progenitor disorders, ischaemic disorders, neurological traumas,
CC affective disorders, neuropsychiatric disorders or learning and memory
CC disorders. In particular, the method is useful for alleviating or
CC treating Parkinson's disease and disorders, Huntington's disease,
CC Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischaemia,
CC ischaemic stroke, spinal cord injury or cancer-related brain/ spinal cord
CC injury, schizophrenia and öther psychoses, depression, bipolar
CC depression/disorder, anxiety syndromes/disorders, phobias, stress and
CC related syndromes, cognitive function disorders, aggression, drug and
CC alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood
CC disorder, borderline personality disorder, cerebral palsy, life style
CC drug, multi-infarct dementia, Lewy body dementia, age related/geriatric
CC dementia, epilepsy and injury related to epilepsy, spinal cord injury,
CC brain injury, trauma related brain/spinal cord injury, anti-cancer
CC treatment related brain/spinal cord tissue injury, infection and
CC inflammation related brain/spinal cord injury, environmental toxin
CC related brain/spinal cord injury, multiple sclerosis, autism, attention
CC deficit disorders, narcolepsy or sleep disorders. The PDGF and/or VEGF,
CC is useful in the manufacture of a medicament for alleviating or treating
CC these diseases or disorders, accelerating growth of neural stem cells or
CC neural progenitor cells, or inducing proliferation or differentiation of
CC these cells. This primer gives an estimated band size of 470 bp
XX
SQ Sequence 25 BP; 10 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.2e+03;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 939 AGAUGUCCAAAUAAGCACACCACGC 963

```
                  |||:|:|||||:|||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 152
ABQ80263/c
ID   ABQ80263 standard; cDNA; 25 BP.
XX
AC   ABQ80263;
XX
DT   27-JUN-2003  (first entry)
XX
DE   FLT-1 primer #4.
XX
KW   PCR; nervous system; platelet-derived growth factor; PDGF; psychosis;
KW   vascular endothelial growth factor; VEGF; neural; stem cell; memory;
KW   progenitor cell; neurodegeneration; ischaemia; neurological trauma;
KW   neuropsychiatry; learning; Parkinson's disease; Huntington's disease;
KW   Amyotrophic Lateral Sclerosis; spinal ischaemia; ischaemic stroke;
KW   spinal cord injury; cancer-related; schizophrenia; Alzheimer's disease;
KW   depression; anxiety; phobia; stress; cognitive function; aggression;
KW   drug; alcohol; abuse; obsessive compulsive behaviour; proliferation;
KW   seasonal mood disorder; personality disorder; cerebral palsy; primer;
KW   multi-infarct; dementia; Lewy body; age related; geriatric; growth;
KW   epilepsy; brain injury; multiple sclerosis; autism; differentiation;
KW   attention deficit disorder; narcolepsy; amplify; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003024478-A1.
XX
PD   27-MAR-2003.
XX
PF   19-SEP-2002; 2002WO-IB003998.
XX
PR   19-SEP-2001; 2001US-0323381P.
PR   28-SEP-2001; 2001US-0326044P.
XX
PA   (NEUR-) NEURONOVA AB.
XX
PI   Delfani K,  Janson AM,  Kuhn GH,  Plate K,  Schanzer A,  Wachs F;
PI   Zhao M;
XX
DR   WPI; 2003-354563/33.
XX
PT   Use of platelet-derived growth factor, vascular endothelial growth
PT   factor, or their modulators for modulating neural stem cell or neural
PT   progenitor cell activity, particularly for treating e.g. Alzheimer's,
PT   ischemia or stroke.
XX
PS   Example 11; Page 77; 119pp; English.
XX
CC   The sequences given in ABQ80256-69 are primers which were used to
CC   identify the presence of vascular endothelial growth factor (VEGF), or
CC   the VEGF receptors, Flk1, FLT-1 and FLT-4 in human stem cells (HSC). The
CC   method of the invention for alleviating or reducing a symptom of a
CC   disease or disorder of the nervous system comprises administering
CC   platelet-derived growth factor (PDGF), vascular endothelial growth factor
CC   (VEGF), a combination of PDGF and VEGF, or a PDGF or VEGF agonist, to a
CC   patient in order to modulate neural stem cell or neural progenitor cell
CC   activity in vivo. The method is useful for alleviating or reducing the
CC   symptoms of a disease or disorder of the nervous system, e.g.
CC   neurodegenerative disorders, neural stem cell disorders, neural
CC   progenitor disorders, ischaemic disorders, neurological traumas,
CC   affective disorders, neuropsychiatric disorders or learning and memory
CC   disorders. In particular, the method is useful for alleviating or
CC   treating Parkinson's disease and disorders, Huntington's disease,
CC   Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischaemia,
CC   ischaemic stroke, spinal cord injury or cancer-related brain/ spinal cord
CC   injury, schizophrenia and other psychoses, depression, bipolar
CC   depression/disorder, anxiety syndromes/disorders, phobias, stress and
CC   related syndromes, cognitive function disorders, aggression, drug and
CC   alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood
CC   disorder, borderline personality disorder, cerebral palsy, life style
CC   drug, multi-infarct dementia, Lewy body dementia, age related/geriatric
CC   dementia, epilepsy and injury related to epilepsy, spinal cord injury,
CC   brain injury, trauma related brain/spinal cord injury, anti-cancer
CC   treatment related brain/spinal cord tissue injury, infection and
CC   inflammation related brain/spinal cord injury, environmental toxin
CC   related brain/spinal cord injury, multiple sclerosis, autism, attention
CC   deficit disorders, narcolepsy or sleep disorders. The PDGF and/or VEGF,
CC   is useful in the manufacture of a medicament for alleviating or treating
CC   these diseases or disorders, accelerating growth of neural stem cells or
CC   neural progenitor cells, or inducing proliferation or differentiation of
CC   these cells. This primer gives an estimated band size of 470 bp
XX
SQ   Sequence 25 BP; 9 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1385 AAUCUGCUCGCUAUUUGACUCGUGG 1409
                ||:|:||:|||:|:::|||:||:||
Db         25 AATCTGCTCGCTATTTGACTCGTGG 1


RESULT 153
ABQ80260
ID   ABQ80260 standard; cDNA; 25 BP.
XX
AC   ABQ80260;
XX
DT   27-JUN-2003  (first entry)
XX
DE   FLT-1 primer #1.
XX
KW   PCR; nervous system; platelet-derived growth factor; PDGF; psychosis;
KW   vascular endothelial growth factor; VEGF; neural; stem cell; memory;
KW   progenitor cell; neurodegeneration; ischaemia; neurological trauma;
KW   neuropsychiatry; learning; Parkinson's disease; Huntington's disease;
KW   Amyotrophic Lateral Sclerosis; spinal ischaemia; ischaemic stroke;
KW   spinal cord injury; cancer-related; schizophrenia; Alzheimer's disease;
KW   depression; anxiety; phobia; stress; cognitive function; aggression;
KW   drug; alcohol; abuse; obsessive compulsive behaviour; proliferation;
KW   seasonal mood disorder; personality disorder; cerebral palsy; primer;
KW   multi-infarct; dementia; Lewy body; age related; geriatric; growth;
KW   epilepsy; brain injury; multiple sclerosis; autism; differentiation;
KW   attention deficit disorder; narcolepsy; amplify; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003024478-A1.
XX
PD   27-MAR-2003.
XX
PF   19-SEP-2002; 2002WO-IB003998.
XX
PR   19-SEP-2001; 2001US-0323381P.
PR   28-SEP-2001; 2001US-0326044P.
XX
PA   (NEUR-) NEURONOVA AB.
XX
PI   Delfani K,  Janson AM,  Kuhn GH,  Plate K,  Schanzer A,  Wachs F;
PI   Zhao M;
XX
DR   WPI; 2003-354563/33.
XX
PT   Use of platelet-derived growth factor, vascular endothelial growth
PT   factor, or their modulators for modulating neural stem cell or neural
PT   progenitor cell activity, particularly for treating e.g. Alzheimer's,
PT   ischemia or stroke.
XX
PS   Example 11; Page 77; 119pp; English.
XX
CC   The sequences given in ABQ80256-69 are primers which were used to
```

```
CC   identify the presence of vascular endothelial growth factor (VEGF), or
CC   the VEGF receptors, Flk1, FLT-1 and FLT-4 in human stem cells (HSC). The
CC   method of the invention for alleviating or reducing a symptom of a
CC   disease or disorder of the nervous system comprises administering
CC   platelet-derived growth factor (PDGF), vascular endothelial growth factor
CC   (VEGF), a combination of PDGF and VEGF, or a PDGF or VEGF agonist, to a
CC   patient in order to modulate neural stem cell or neural progenitor cell
CC   activity in vivo. The method is useful for alleviating or reducing the
CC   symptoms of a disease or disorder of the nervous system, e.g.
CC   neurodegenerative disorders, neural stem cell disorders, neural
CC   progenitor disorders, ischaemic disorders, neurological traumas,
CC   affective disorders, neuropsychiatric disorders or learning and memory
CC   disorders. In particular, the method is useful for alleviating or
CC   treating Parkinson's disease and disorders, Huntington's disease,
CC   Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischaemia,
CC   ischaemic stroke, spinal cord injury or cancer-related brain/ spinal cord
CC   injury, schizophrenia and other psychoses, depression, bipolar
CC   depression/disorder, anxiety syndromes/disorders, phobias, stress and
CC   related syndromes, cognitive function disorders, aggression, drug and
CC   alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood
CC   disorder, borderline personality disorder, cerebral palsy, life style
CC   drug, multi-infarct dementia, Lewy body dementia, age related/geriatric
CC   dementia, epilepsy and injury related to epilepsy, spinal cord injury,
CC   brain injury, trauma related brain/spinal cord injury, anti-cancer
CC   treatment related brain/spinal cord tissue injury, infection and
CC   inflammation related brain/spinal cord injury, environmental toxin
CC   related brain/spinal cord injury, multiple sclerosis, autism, attention
CC   deficit disorders, narcolepsy or sleep disorders. The PDGF and/or VEGF,
CC   is useful in the manufacture of a medicament for alleviating or treating
CC   these diseases or disorders, accelerating growth of neural stem cells or
CC   neural progenitor cells, or inducing proliferation or differentiation of
CC   these cells. This primer gives an estimated band size of 347 bp
XX
SQ   Sequence 25 BP; 10 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 1.2e+03;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        939 AGAUGUCCAAAUAAGCACACCACGC 963
              |||:|:|||||:|||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 154
AAQ47179
ID   AAQ47179 standard; DNA; 26 BP.
XX
AC   AAQ47179;
XX
DT   25-MAR-2003  (revised)
DT   25-JAN-1994  (first entry)
XX
DE   MHC DR A intron binding oligomer GTcon.
XX
KW   MHC; major histocompatability complex; class II; control oligomers; DR A;
KW   transplantation; antigen; autoimmune disease; ss.
XX
OS   Synthetic.
XX
PN   WO9314769-A1.
XX
PD   05-AUG-1993.
XX
PF   29-JAN-1993;   93WO-US000797.
XX
PR   31-JAN-1992;   92US-00830427.
PR   14-SEP-1992;   92US-00944868.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Weiss TL,  Garovoy MR,  Hunt A,  Huey B,  Tam S;
XX
DR   WPI; 1993-258367/32.
XX
PT   Depletion of transplantation antigens in donor cells - using anti-sense
PT   or triplex-forming oligonucleotide(s), used for treating auto-immune
PT   disease and in transplants.
XX
PS   Example; Page 22; 71pp; English.
XX
CC   The sequences given in AAQ47176-77 represent triplex forming oligo-
CC   nucleotides which bind to the mRNA sequence of the MHC class II locus DR
CC   A structural gene at positions 851-876. The sequences given in AAQ47178-
CC   80 represent control oligomers which contain base compositions similar to
CC   that around this DR A region but not containing the correct sequences. DR
CC   A is a transplantation antigen. Binding of this sequence to the DR A gene
CC   inhibits antigen production. This method may be used for treating
CC   individuals with autoimmune disease, characterised by dysfunctional
CC   expression of a transplantation antigen. It may also be used to produce
CC   cells which are more easily transplanted into a recipient. (Updated on 25
CC   -MAR-2003 to correct PN field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 14 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 26;
  Best Local Similarity   52.0%;  Pred. No. 1.3e+03;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTG 26


RESULT 155
AAD19463
ID   AAD19463 standard; DNA; 31 BP.
XX
AC   AAD19463;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human flt-1 gene polymorphism detecting allele specific probe #7.
XX
KW   Human; flt-1 gene; cytostatic; haemostatic; gene mapping; gynaecological;
KW   opthalmological; rheumatoid arthritis; endometriosis; angiogenic disease;
KW   diabetic retinopathy; psoriasis; VEGFR-1; drug therapy; pharmacogenetic;
KW   vascular endothelial growth factor; single nucleotide polymorphism; SNP;
KW   cancer; medicament; probe; ss.
XX
OS   Homo sapiens.
XX
PN   EP1130123-A2.
XX
PD   05-SEP-2001.
XX
PF   20-FEB-2001; 2001EP-00301489.
XX
PR   24-FEB-2000; 2000GB-00004232.
XX
PA   (ASTR ) ASTRAZENECA AB.
XX
PI   Smith JC;
XX
DR   WPI; 2001-608199/70.
XX
PT   Diagnosing single nucleotide polymorphism in human flt-1 gene, for
PT   assessing predisposition or susceptibility to diseases mediated by an flt
PT   -1 ligand, comprises determining the nucleic acid sequence at one or more
PT   point positions.
XX
PS   Claim 11; Page 4; 30pp; English.
XX
CC   The invention relates to novel sequence and polymorphisms in the human
CC   flt-1 gene. Flt-1 is one of the two receptors for vascular endothelial
CC   growth factor (VEGFR-1). The invention also relates to a method for
```

```
CC   diagnosing one or more single nucleotide polymorphism (SNP) in human flt-
CC   1 gene. The method is useful for assessing the predisposition and/or
CC   susceptibility of an individual to diseases mediated by an flt-1 ligand,
CC   to recognise individuals who are particularly at risk from developing
CC   these conditions, and in the development of new drug therapies that
CC   selectively target one or more allelic variants of the flt-1 gene. Flt-1
CC   polymorphisms are used in the diagnosis and treatment of cancer and
CC   angiogenic diseases such as diabetic retinopathies, psoriasis, rheumatoid
CC   arthritis and endometriosis. Polymorphisms are also used in mapping the
CC   human genome and to elucidate the genetic component of the diseases, as
CC   genetic markers for this region in linkage studies. The nucleic acids are
CC   useful as components in databases useful in sequence identity, genome
CC   mapping, pharmacogenetics and other search analyses. The flt-1 antagonist
CC   is useful in the preparation of a medicament for treating VEGF-mediated
CC   diseases in a human diagnosed as having a single nucleotide polymorphism
CC   at one or more of the defined positions. The present DNA sequence is a
CC   allele specific nucleotide probe which is used for detecting human flt-1
CC   gene polymorphism
XX
SQ   Sequence 31 BP; 1 A; 9 C; 15 G; 5 T; 0 U; 1 Other;

  Query Match             0.3%;  Score 25;  DB 1;  Length 31;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+03;
  Matches   20;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 UCUGGCGGCCGGGUCGUUGGCCGGGGG 210
              :|:|||||||||||:|:::||||| |||
Db          1 TCTGGCGGCCGGGTCKTTGGCCGCGGG 27


RESULT 156
AAA91139
ID   AAA91139 standard; DNA; 30 BP.
XX
AC   AAA91139;
XX
DT   20-APR-2001  (first entry)
XX
DE   PCR primer for chimeric protein construction.
XX
KW   Apoptosis; chimeric protein; cancer; inflammation; autoimmune disease;
KW   psoriasis; therapy; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200100854-A2.
XX
PD   04-JAN-2001.
XX
PF   26-JUN-2000; 2000WO-GB002449.
XX
PR   24-JUN-1999;   99GB-00014650.
XX
PA   (ANGI-) ANGIOGENE PHARM LTD.
XX
PI   Davis PD;
XX
DR   WPI; 2001-102899/11.
XX
PT   New nucleic acid encoding a chimeric cell surface protein, useful for
PT   treating cancer, inflammation, autoimmune disease or psoriasis.
XX
PS   Example 2; Page 40; 78pp; English.
XX
CC   This sequence represents a PCR primer, used to create the coding sequence
CC   for a chimeric protein of the invention. The chimeric proteins comprise:
CC   (a) an extra-cellular domain which binds multivalent ligand
CC   preferentially at the surface of a target cell relative to a non-target
CC   cell; (b) a membrane spanning domain; and (c) a cytoplasmic domain which
CC   induces cell death in a target cell upon binding of the extra-cellular
CC   domain with the multivalent ligand. The DNA and protein are useful for
CC   inducing apoptosis in a target cell in vitro. The sequences are useful
CC   for treating cancer, inflammation, autoimmune disease or psoriasis
XX
SQ   Sequence 30 BP; 2 A; 12 C; 14 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24.2;  DB 1;  Length 30;
  Best Local Similarity   82.8%;  Pred. No. 2.1e+03;
  Matches   24;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         62 CGGGUGCAGCGGCCAGCGGGCCUGGCGGC 90
              ||||: | |||||||||||||:|||| |
Db          2 CGGGTACCGCGGCCAGCGGGCCTGGCGCC 30


RESULT 157
AAQ33986
ID   AAQ33986 standard; DNA; 24 BP.
XX
AC   AAQ33986;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA382.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 324; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n.>9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24
```

```
RESULT 158
AAQ34158
ID   AAQ34158 standard; DNA; 24 BP.
XX
AC   AAQ34158;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Sequence of a microsatellite from clone TGLA80.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 394; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 159
AAQ33909
ID   AAQ33909 standard; DNA; 24 BP.
XX
AC   AAQ33909;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA322.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 293; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24


RESULT 160
AAQ34065
ID   AAQ34065 standard; DNA; 24 BP.
XX
AC   AAQ34065;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA444.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
```

```
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 357; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGT 24


RESULT 161
AAQ34024
ID   AAQ34024 standard; DNA; 24 BP.
XX
AC   AAQ34024;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA423.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 340; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 162
AAQ33707
ID   AAQ33707 standard; DNA; 24 BP.
XX
AC   AAQ33707;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA131.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 213; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
```

```
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 163
AAT66096/c
ID   AAT66096 standard; DNA; 24 BP.
XX
AC   AAT66096;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   Repeat sequence found in the human chromosomal clone JW42.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 9; Col 61-62; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The sequences AAT66084-
CC   T66107 represent repeat sequences of low informativeness found in
CC   specific human genes. This repeat sequence is found in the human
CC   chromosomal clone JW42. The sequence is amplified by primers AAT66097-8.
CC   (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 164
AAH46015
ID   AAH46015 standard; DNA; 24 BP.
XX
AC   AAH46015;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 15.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Example 4; Page 17; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 165
AAH46016
ID   AAH46016 standard; DNA; 24 BP.
XX
AC   AAH46016;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 16.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Claim 6; Page 17; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGT 24


RESULT 166
AAF99862
ID   AAF99862 standard; DNA; 24 BP.
XX
AC   AAF99862;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #978.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 59; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 167
AAI67482
ID   AAI67482 standard; DNA; 24 BP.
XX
AC   AAI67482;
XX
DT   11-FEB-2002  (first entry)
XX
DE   Probe sequence used for real-time RT-PCR analysis.
XX
```

KW ARP; angiogenesis; vascular endothelial growth factor; VEGF; cytostatic;
KW arginine-rich protein; cardiant; antirheumatic; antiarthritic; human;
KW antiatherosclerotic; vasotropic; gynecological; antidiabetic; vulnerary;
KW antiulcer; dermatological; ophthalmological; antipsoriatic; apoptosis;
KW gene therapy; RT-PCR; primer; ss.
XX
OS Synthetic.
XX
PN WO200170174-A2.
XX
PD 27-SEP-2001.
XX
PF 21-MAR-2001; 2001WO-US009043.
XX
PR 22-MAR-2000; 2000US-0191201P.
XX
PA (CURA-) CURAGEN CORP.
PA (GETH) GENENTECH INC.
XX
PI Rastelli LK, Gerber H;
XX
DR WPI; 2001-639087/73.
XX
PT Modulating angiogenesis and/or apoptosis for preventing or treating
PT cancer, myocardial infarction and promoting healing, by modulating the
PT activity of vascular endothelial growth factor-modulated gene
PT polypeptide.
XX
PS Example 2; Page 103; 155pp; English.
XX
CC The invention relates to modulating angiogenesis and cell survival that
CC involves modulating the activity of at least one vascular endothelial
CC growth factor (VEGF)-modulated gene polypeptide. The method is useful for
CC modulating angiogenesis and cell survival, for treating tumour and cancer
CC by decreasing angiogenesis in cancerous tumours and treating myocardial
CC infarction and promoting healing, by increasing angiogenesis. Transgenic
CC non-human animals, having disrupted arginine-rich protein (ARP), are
CC useful for determining the clinical stage of ovarian tumorous, which is
CC useful for determining if the tumour has potential for metastasis. ARP is
CC useful in gene therapy and in diagnostic applications. VEGFmg proteins
CC are useful in the treatment of tumours, neoplasias, hemangiomas,
CC rheumatoid arthritis, atherosclerosis, idiopathic pulmonary fibrosis,
CC vascular restenosis, arteriovenous malformations, meningioma, neovascular
CC glaucoma, psoriasis, hemophilic joints, hypertrophic scars, Osler-Weber
CC syndrome, scleroderma, vascular adhesion pathologies, synovitis,
CC dermatitis, endometriosis, diabetic retinopathy, neovascularization
CC associated with corneal injury or grafts, wound, sore, and ulcer healing.
CC Sequences AAI67449-487 represent probe primer sets used for real-time RT-
CC PCR analysis of differential gene expression
XX
SQ Sequence 24 BP; 8 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 24; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.4e+03;
Matches 21; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2449 ACCAACCAGAAGGGCUCUGUGGAA 2472
                ||||||||||||||:|:|:||||
Db          1 ACCAACCAGAAGGGCTCTGTGGAA 24
```

RESULT 168
AAH23019/c
ID AAH23019 standard; DNA; 24 BP.
XX
AC AAH23019;
XX
DT 17-SEP-2001 (first entry)
XX
DE VEGFR-1 gene specific reverse primer.
XX
KW Vascular endothelial growth factor; VEGF; antisense; angiogenesis;
KW cell proliferation; Kaposi's sarcoma; cancer; melanoma; cytostatic;
KW antisense therapy; RT-PCR; primer; VEGFR-1; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200152904-A2.
XX
PD 26-JUL-2001.
XX
PF 19-JAN-2001; 2001WO-US000019.
XX
PR 19-JAN-2000; 2000US-00487023.
XX
PA (GILL/) GILL P S.
XX
PI Gill PS, Masood R;
XX
DR WPI; 2001-451898/48.
XX
PT Novel antisense oligonucleotides useful for inhibiting vascular
PT endothelial growth factor expression, angiogenesis and for treating
PT cancer, e.g., Kaposi's sarcoma, ovarian cancer and prostrate cancer.
XX
PS Example 12; Page 56; 105pp; English.
XX
CC The invention provides a composition comprising one or more antisense
CC oligonucleotides directed against vascular endothelial growth factor
CC (VEGF) where the antisense oligonucleotides inhibits proliferation of
CC cells exhibiting autocrine VEGF activity at an IC_5_0 concentration of
CC between 0.5-2.5 micro Ma. The antisense oligonucleotides may be directed
CC against VEGF for inhibiting cancer cell proliferation and angiogenesis.
CC Preferably the oligonucleotide AAH23032 (a modified version of AAH22984)
CC is used and may be utilized to treat Kaposi's sarcoma, ovarian cancer,
CC prostrate cancer, pancreatic cancer or melanoma. Sequences AAH23012-023
CC represent gene-specific primers used in RT-PCR amplification of VEGF
CC receptors
XX
SQ Sequence 24 BP; 4 A; 5 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.3%; Score 24; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 1.4e+03;
Matches 20; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3736 CAACAGGAUGGUAAAGACUACAUC 3759
                ||||||||:||:||||||:|||:|
Db         24 CAACAGGATGGTAAAGACTACATC 1
```

RESULT 169
ABS78584
ID ABS78584 standard; DNA; 24 BP.
XX
AC ABS78584;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #1068.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophiliac joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX

```
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
XX
PS   Claim 2; Page 38; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 170
ACH03377
ID   ACH03377 standard; DNA; 24 BP.
XX
AC   ACH03377;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #1012.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 36; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 171
ADB37364
ID   ADB37364 standard; DNA; 24 BP.
XX
AC   ADB37364;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #978.
XX
KW   ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW   hypo-responsive subject; immunostimulatory.
XX
OS   Synthetic.
XX
PN   US2003087848-A1.
XX
PD   08-MAY-2003.
XX
PF   02-FEB-2001; 2001US-00776479.
XX
PR   03-FEB-2000; 2000US-0179991P.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2003-657977/62.
XX
PT   Treating and/or preventing allergy or asthma using an immunostimulatory
PT   nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS   Disclosure; Page 20; 221pp; English.
XX
CC   The invention relates to a method of treating or preventing allergy or
CC   asthma which comprises administering to a subject a poly-G nucleic acid
CC   in an aerosol formulation. The methods and compositions of the present
CC   invention are useful for diagnosing and/or treating asthma and allergy
CC   especially in a hypo-responsive subject. The present sequence represents
CC   an immunostimulatory nucleic acid of the invention.
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
```

```
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 172
ABX90510/c
ID   ABX90510 standard; DNA; 24 BP.
XX
AC   ABX90510;
XX
DT   01-MAY-2003  (first entry)
XX
DE   Human VEGFR-1 RT-PCR primer #2.
XX
KW   Antisense; ss; PCR; VEGF; vascular endothelial growth factor; human;
KW   cancer; angiogenesis; neoplastic proliferation; cellular proliferation;
KW   primer; RT-PCR; reverse transcriptase PCR.
XX
OS   Homo sapiens.
XX
PN   US2002165174-A1.
XX
PD   07-NOV-2002.
XX
PF   13-MAR-2001; 2001US-00805761.
XX
PR   31-JAN-1997;   97US-0037004P.
PR   30-JAN-1998;   98US-00016541.
PR   19-JAN-2000; 2000US-00487023.
PR   19-JAN-2001; 2001WO-US000019.
XX
PA   (GILL/) GILL P S.
PA   (MASO/) MASOOD R.
XX
PI   Gill PS,  Masood R;
XX
DR   WPI; 2003-255224/25.
XX
PT   New composition comprising an antisense oligonucleotide directed against
PT   vascular endothelial growth factor, useful for preparing a composition
PT   for treating cancer.
XX
PS   Example 12; Page 19; 54pp; English.
XX
CC   The invention relates to a composition comprising an antisense
CC   oligonucleotide directed against vascular endothelial growth factor
CC   (VEGF). The antisense oligonucleotide is useful for preparing a
CC   composition treating cancer, neoplastic proliferation, abnormal cellular
CC   proliferation and preventing angiogenesis. The present sequence is a
CC   reverse transcriptase (RT)-PCR primer for a VEGF or related gene, used to
CC   clone the coding region for expression in tumour cell lines. The cell
CC   lines were used to test prospective antisense oligonucleotides
XX
SQ   Sequence 24 BP; 4 A; 5 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   83.3%;  Pred. No. 1.4e+03;
  Matches   20;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3736 CAACAGGAUGGUAAAGACUACAUC 3759
              ||||||||:||:||||||:|||:|
Db         24 CAACAGGATGGTAAAGACTACATC 1


RESULT 173
ADO81094/c
ID   ADO81094 standard; DNA; 24 BP.
XX
AC   ADO81094;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Sheep prion protein microsatellite locus primer #65.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; PCR; primer; ss.
XX
OS   Ovis aries.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Example 3; Page 30; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a primer used to genotype a region of the sheep prion
CC   protein (PrP) comprising a polymorphic microsatellite locus.
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTG 1


RESULT 174
ADO81099/c
ID   ADO81099 standard; DNA; 24 BP.
XX
AC   ADO81099;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Sheep prion protein microsatellite locus primer #70.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
```

```
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; PCR; primer; ss.
XX
OS   Ovis aries.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Example 3; Page 30; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a primer used to genotype a region of the sheep prion
CC   protein (PrP) comprising a polymorphic microsatellite locus.
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 175
ADO81051/c
ID   ADO81051 standard; DNA; 24 BP.
XX
AC   ADO81051;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Cow prion protein microsatellite locus primer #63.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; cow;
KW   microsatellite; PCR; primer; ss.
XX
OS   Bos taurus.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Example 3; Page 27; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a primer used to genotype a region of the cow prion
CC   protein (PrP) comprising a polymorphic microsatellite locus.
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 176
ADR16077/c
ID   ADR16077 standard; DNA; 24 BP.
XX
AC   ADR16077;
XX
DT   21-OCT-2004  (first entry)
XX
DE   Human PARP DNA 85-bp allelic fragment.
XX
KW   Genetic testing; systemic lupus erythematosus; SLE;
KW   poly(ADP-ribosyl)polymerase; PARP; genetic counselling; human; ds.
XX
OS   Homo sapiens.
XX
PN   US2004152075-A1.
XX
PD   05-AUG-2004.
XX
PF   18-JUL-2001; 2001US-00909317.
XX
PR   29-MAR-1999;   99US-00280181.
XX
PA   (TSAO/) TSAO B P.
```

```
PA   (CANT/) CANTOR R M.
PA   (ROTT/) ROTTER J I.
XX
PI   Tsao BP,  Cantor RM,  Rotter JI;
XX
DR   WPI; 2004-561490/54.
XX
PT   Genetic testing for systemic lupus erythematosus in human, by amplifying
PT   nucleic acids from tissue sample to obtain amplification products, and
PT   detecting presence or absence of dinucleotide repeat sequence in
PT   amplification products.
XX
PS   Claim 1; SEQ ID NO 6; 17pp; English.
XX
CC   The invention relates to a genetic testing method for diagnosing systemic
CC   lupus erythematosus (SLE) in human. The method involves amplifying
CC   nucleic acids from human tissue samples and detecting the presence or
CC   absence of variant alleles of a gene encoding poly(ADP-ribosyl)polymerase
CC   (PARP), which is a diagnostic of SLE or indication of a genetic
CC   predisposition for developing SLE. The method is useful for genetic
CC   testing for SLE in a human subject. It is useful in genetic counselling
CC   to provide useful information to persons considering their reproductive
CC   options. The present sequence is human PARP DNA 85-bp allelic fragment.
CC   This sequence is used to illustrate the method of the invention.
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 177
ADR48240/c
ID   ADR48240 standard; DNA; 24 BP.
XX
AC   ADR48240;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Microarray synthesised oligonucleotide #4.
XX
KW   ss; deposition unit misalignment; polymeric array synthesis;
KW   pulse jet misalignment; printhead misalignment; microarray.
XX
OS   Synthetic.
XX
PN   US2004170984-A1.
XX
PD   02-SEP-2004.
XX
PF   25-FEB-2003; 2003US-00374307.
XX
PR   25-FEB-2003; 2003US-00374307.
XX
PA   (LEPR/) LEPROUST E M.
PA   (AMOR/) AMORESE D A.
PA   (KRON/) KRONICK M N.
XX
PI   Leproust EM,  Amorese DA,  Kronick MN;
XX
DR   WPI; 2004-634540/61.
XX
PT   Detection of deposition unit misalignment of in situ polymeric array
PT   synthesis device, by contacting test probe feature with different
PT   distinguishably labeled targets, and evaluating binding of labeled
PT   targets to test probe feature.
XX
PS   Example 2; Page 16; 36pp; English.
XX
CC   The invention relates to a method of detection of deposition unit
CC   misalignment of an in situ polymeric array synthesis device which
CC   comprises synthesising test probe feature(s) on substrate using in situ
CC   polymeric array synthesis device, contacting test probe feature with at
CC   least two different distinguishably labelled targets and evaluating
CC   binding of labelled targets to test probe feature to detect any pulse jet
CC   misalignment of polymeric array synthesis device. The method is useful
CC   for detecting deposition unit misalignment e.g. printhead misalignment,
CC   of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
CC   method is easy to use, cost effective. effective at detecting printhead
CC   misalignments and may enable immediate detection and/or adjustments of
CC   one or more printheads of an in situ nucleic acid array synthesis fluid
CC   deposition device if misalignment is detected. THe present sequence
CC   represents an oligonucleotide synthesised on a microarray.
XX
SQ   Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db         24 GTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 178
ADR48245
ID   ADR48245 standard; DNA; 24 BP.
XX
AC   ADR48245;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Microarray synthesised oligonucleotide #9.
XX
KW   ss; deposition unit misalignment; polymeric array synthesis;
KW   pulse jet misalignment; printhead misalignment; microarray.
XX
OS   Synthetic.
XX
PN   US2004170984-A1.
XX
PD   02-SEP-2004.
XX
PF   25-FEB-2003; 2003US-00374307.
XX
PR   25-FEB-2003; 2003US-00374307.
XX
PA   (LEPR/) LEPROUST E M.
PA   (AMOR/) AMORESE D A.
PA   (KRON/) KRONICK M N.
XX
PI   Leproust EM,  Amorese DA,  Kronick MN;
XX
DR   WPI; 2004-634540/61.
XX
PT   Detection of deposition unit misalignment of in situ polymeric array
PT   synthesis device, by contacting test probe feature with different
PT   distinguishably labeled targets, and evaluating binding of labeled
PT   targets to test probe feature.
XX
PS   Example 2; Page 16; 36pp; English.
XX
CC   The invention relates to a method of detection of deposition unit
CC   misalignment of an in situ polymeric array synthesis device which
CC   comprises synthesising test probe feature(s) on substrate using in situ
CC   polymeric array synthesis device, contacting test probe feature with at
CC   least two different distinguishably labelled targets and evaluating
CC   binding of labelled targets to test probe feature to detect any pulse jet
CC   misalignment of polymeric array synthesis device. The method is useful
CC   for detecting deposition unit misalignment e.g. printhead misalignment,
```

```
CC   of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
CC   method is easy to use, cost effective. effective at detecting printhead
CC   misalignments and may enable immediate detection and/or adjustments of
CC   one or more printheads of an in situ nucleic acid array synthesis fluid
CC   deposition device if misalignment is detected. THe present sequence
CC   represents an oligonucleotide synthesised on a microarray.
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGT 24


RESULT 179
ADU90384
ID   ADU90384 standard; DNA; 24 BP.
XX
AC   ADU90384;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Allergic response suppressor oligonucleotide #1068.
XX
KW   ss; antiasthmatic; antiallergic; dermatological; antiinflammatory;
KW   antibacterial; virucide; immunoglobulin E antagonist; allergy;
KW   immunostimulator; asthma; rhinitis; urticaria; dermatitis;
KW   bacterial infection; viral infection.
XX
OS   Synthetic.
XX
PN   US2004235774-A1.
XX
PD   25-NOV-2004.
XX
PF   23-APR-2004; 2004US-00831778.
XX
PR   03-FEB-2000; 2000US-0179991P.
PR   02-FEB-2001; 2001US-00776479.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2004-833006/82.
XX
PT   Suppressing allergies, including asthma, rhinitis, urticaria and atopic
PT   dermatitis, in a subject, comprises administering a first and second dose
PT   of an immunostimulatory nucleic acid.
XX
PS   Disclosure; SEQ ID NO 1068; 235pp; English.
XX
CC   The invention relates to a method of suppressing a symptom of an allergic
CC   response in a subject by administering a first and second dose of an
CC   immunostimulatory nucleic acid that comprises a nucleotide sequence
CC   comprising 5'-cg-3', and where the second dose is administered from 1 day
CC   to 8 weeks after the first dose. The methods and compositions of the
CC   present invention are useful for the treatment or prevention of asthma
CC   and allergy, including rhinitis, urticaria and atopic dermatitis, using
CC   an immunostimulatory nucleic acid alone or in combination with other
CC   medicaments. They can also be used in preventing bacterial and viral
CC   infections. This sequence represents an oligonucleotide used in the
CC   method of the invention.
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 180
ADW26360
ID   ADW26360 standard; DNA; 24 BP.
XX
AC   ADW26360;
XX
DT   10-MAR-2005  (first entry)
XX
DE   EGFR inhibitor cancer treatment prognostic marker DNA probe - SEQ ID 112.
XX
KW   prognosis; selectable marker; cancer; cytostatic; ovary tumor;
KW   colon tumor; pancreatic cancer; non-small-cell lung cancer; breast tumor;
KW   head & neck tumor; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004111273-A2.
XX
PD   23-DEC-2004.
XX
PF   28-MAY-2004; 2004WO-US017215.
XX
PR   30-MAY-2003; 2003US-0474908P.
XX
PA   (GENO-) GENOMIC HEALTH INC.
XX
PI   Agus D,  Baker JB,  Natale R,  Shak S;
XX
DR   WPI; 2005-040123/04.
XX
PT   Predicting if a subject responds to epidermal growth factor receptor
PT   (EGFR) inhibitor treatment, useful for cancer patients, by determining
PT   expression level of prognostic RNA transcripts of genes e.g. FUS, or its
PT   expression product.
XX
PS   Claim 41; SEQ ID NO 112; 77pp; English.
XX
CC   The invention comprises a method for predicting the likelihood that a
CC   subject will respond to cancer treatment with an epidermal growth factor
CC   receptor (EGFR) inhibitor. The method involves determining the expression
CC   level of one or more prognostic RNA transcripts or their expression
CC   products in a biological sample comprising cancer cells obtained from the
CC   patient. The method of the invention is useful for predicting whether a
CC   patient is likely to respond well to treatment with an EGFR inhibitor,
CC   especially patients having: ovarian cancer, colon cancer, pancreatic
CC   cancer, non-small cell lung cancer, breast cancer, and head/neck cancer.
CC   The present DNA sequence represents a probe which is specific for a
CC   prognostic marker of the invention.
XX
SQ   Sequence 24 BP; 7 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+03;
  Matches   21;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3474 CUACAGCACCAAGAGCGACGUGUG 3497
              |:||||||||||||||||||:|:|
Db          1 CTACAGCACCAAGAGCGACGTGTG 24


RESULT 181
ADY89670
ID   ADY89670 standard; RNA; 24 BP.
XX
AC   ADY89670;
```

```
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA target sequence SEQ ID NO 2707.
XX
KW   ss; VEGF; pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2707; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA target sequence.
XX
SQ   Sequence 24 BP; 9 A; 7 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+03;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 182
ADZ79699/c
ID   ADZ79699 standard; DNA; 24 BP.
XX
AC   ADZ79699;
XX
DT   14-JUL-2005  (first entry)
XX
DE   Human FLT-1 cDNA, antisense PCR primer.
XX
KW   angiogenic; pharmaceutical; angiogenesis stimulation; endothelium;
KW   arteriosclerosis; retinopathy; brain malformation; diabetes;
KW   hereditary hemorrhagic telangiectasia; antiarteriosclerotic;
KW   ophthalmological; antidiabetic; immunosuppressive;
KW   fms-related tyrosine kinase 1; FLT-1; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2005039616-A1.
XX
PD   06-MAY-2005.
XX
PF   28-OCT-2004; 2004WO-IL000992.
XX
PR   29-OCT-2003; 2003US-0514895P.
PR   02-APR-2004; 2004US-0558558P.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX
PI   Hardy B,  Battler A,  Raiter A,  Kornowski R,  Weiss C;
XX
DR   WPI; 2005-333433/34.
XX
PT   New angiogenic peptides, useful for promoting angiogenesis in a tissue of
PT   a subject suffering from arteriosclerosis, retinopathy, remodeling
PT   disorder, von Hippel-Lindau syndrome, diabetes and/or hereditary
PT   hemorrhagic telangiectasia.
XX
PS   Example 3; SEQ ID NO 22; 114pp; English.
XX
CC   The invention relates to angiogenic peptides given as SEQ ID Nos. 2, 4,
CC   6, 8, 10 or 12 in the specification. Also described are: (i) a
CC   composition-of-matter comprising at least two peptides, each
CC   independently selected from those cited above, (ii) a pharmaceutical
CC   composition comprising a therapeutically effective amount of any of the
CC   peptides cited above, or a peptide having an amino acid sequence of SEQ
CC   ID No. 13 or 32 as given in the specification, the peptide being at least
CC   6 and no more than 50 amino acid residues in length, (iii) a method of
CC   promoting angiogenesis in a tissue of a subject comprising providing to
CC   the subject, a therapeutically effective amount of the peptide cited
CC   above, (iv) a nucleic acid construct comprising a polynucleotide sequence
CC   encoding any of the peptides cited above, (v) a composition for targeting
CC   a drug to endothelial cells, the composition comprising the drug fused to
CC   any of the peptides cited above, and (vi) a method of identifying
CC   putative angiogenic molecules comprising providing endothelial cells
CC   having peptides bound to it, each of the peptides is selected as above,
CC   and identifying a molecule capable of displacing the peptides from the
CC   endothelial cells, to thus identify putative angiogenic molecules. The
CC   peptides of the invention are useful for promoting angiogenesis in a
CC   tissue of a subject suffering from arteriosclerosis, retinopathy,
CC   remodeling disorder, von Hippel-Lindau syndrome, diabetes and/or
CC   hereditary hemorrhagic telangiectasia. This sequence represents a PCR
CC   primer used to amplify human fms-related tyrosine kinase 1 (FLT-1) cDNA
CC   in the examples of the present invention.
XX
SQ   Sequence 24 BP; 6 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   75.0%;  Pred. No. 1.4e+03;
  Matches   18;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1794 GAAUAAGAUGGCUAGCACCUUGGU 1817
              |||:||||:|||:||||||::||:
Db         24 GAATAAGATGGCTAGCACCTTGGT 1


RESULT 183
AED38906
ID   AED38906 standard; RNA; 24 BP.
XX
AC   AED38906;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2707.
```

```
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2707; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 24 BP; 9 A; 7 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+03;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAUC 375
              ||||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAUC 24


RESULT 184
AED75802
ID   AED75802 standard; DNA; 24 BP.
XX
AC   AED75802;
XX
DT   12-JAN-2006  (first entry)
XX
DE   Immunostimulatory oligonucleotide, SEQ ID 1012.
XX
KW   Immunostimulant; Antiinflammatory; Antipsoriatic; Gastrointestinal-Gen.;
KW   Antiulcer; Dermatological; Antiallergic; helper T-lymphocyte;
KW   immune stimulation; inflammation; psoriasis; inflammatory bowel disease;
KW   Crohns disease; ulcerative colitis; eczema; skin allergy;
KW   contact dermatitis; ss; phosphorothioate.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .24
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
XX
PN   US2005250726-A1.
XX
PD   10-NOV-2005.
XX
PF   12-MAY-2005; 2005US-00127654.
XX
PR   29-MAR-2001; 2001US-0279642P.
PR   29-MAR-2002; 2002US-00112653.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2005-768014/78.
XX
PT   Use of an immunostimulatory nucleic acid and a cyclooxygenase inhibitor
PT   to augment T-helper1 cells like immune activation and to treat non-
PT   allergic inflammatory diseases, e.g. psoriasis and Crohn's disease.
XX
PS   Disclosure; SEQ ID NO 1012; 58pp; English.
XX
CC   The present invention relates to a method for augmenting T-helper 1 cells
CC   (Th1)-like immune activation in a subject. The method comprises
CC   administrating an immunostimulatory nucleic acid (I) to induce Th1-like
CC   immune activation; and administrating a cyclooxygenase inhibitor (II) to
CC   inhibit prostaglandin expression, is new. The present sequence is one
CC   such immunostimulatory nucleic acid. (I) is useful for treating non-
CC   allergic inflammatory diseases such as psoriasis, inflammatory bowel
CC   diseases (Crohn's disease and ulcerative colitis), eczema, allergic
CC   contact dermatitis or latex dermatitis.
XX
SQ   Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
```

```
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 185
AAH40163/c
ID   AAH40163 standard; DNA; 25 BP.
XX
AC   AAH40163;
XX
DT   14-AUG-2001  (first entry)
XX
DE   SNP specific SNPE primer SEQ ID 2959.
XX
KW   Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW   SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW   Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW   polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW   acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW   inflammation; forensic investigation; paternity analysis; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200129262-A2.
XX
PD   26-APR-2001.
XX
PF   13-OCT-2000; 2000WO-US028436.
XX
PR   15-OCT-1999;   99US-0160096P.
XX
PA   (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI   Picoult-Newburg L,  Pohl M;
XX
DR   WPI; 2001-290930/30.
XX
PT   New genotyping oligonucleotide, useful for detecting the presence,
PT   absence or identity of single polynucleotide polymorphism in a nucleic
PT   acid sample.
XX
PS   Claim 1; Page 65; 83pp; English.
XX
CC   Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC   primer extension (SNPE) primers, and the sequences of regions flanking
CC   sites of single nucleotide polymorphisms SNPs. The present invention
CC   includes kits for determining the presence or absence of a SNP, using the
CC   oligonucleotides of the invention. The PCR primers are used to amplify a
CC   SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC   The oligonucleotides are useful for genotyping a nucleic acid sample by
CC   performing a single-nucleotide primer extension reaction. The
CC   oligonucleotides are useful for determining the presence, absence or
CC   identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC   assess by association analysis the genotype of an individual or group of
CC   individuals, having a pathological phenotypic trait suspected of being
CC   caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC   agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC   osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC   traits also include symptoms of or susceptibility to multifactorial
CC   disease of which a component is or may be genetic such as autoimmune
CC   diseases, including, rheumatoid arthritis, multiple sclerosis,
CC   inflammation, cancer, nervous system diseases and infection by pathogenic
CC   microorganism. The method is also useful in forensic investigations and
CC   paternity analysis. The present sequence represents a single nucleotide
CC   primer extension (SNPE) primer specific for a human SNP containing DNA
CC   sequence
XX
SQ   Sequence 25 BP; 12 A; 12 C; 1 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 25;
  Best Local Similarity   50.0%;  Pred. No. 1.5e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db         24 GTGTGTGTGTGTGTGTGTGTGT 1


RESULT 186
AAQ33933
ID   AAQ33933 standard; DNA; 28 BP.
XX
AC   AAQ33933;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA339.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 303; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 28 BP; 0 A; 0 C; 14 G; 14 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 24;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 1.9e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          5 GTGTGTGTGTGTGTGTGTGTGT 28


RESULT 187
AAQ33740
ID   AAQ33740 standard; DNA; 27 BP.
XX
AC   AAQ33740;
```

```
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA154.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 226; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 27 BP; 2 A; 0 C; 12 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23.8;  DB 1;  Length 27;
  Best Local Similarity   44.4%;  Pred. No. 1.9e+03;
  Matches   12;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6989 UGUGUGUGUGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:|: : :|:|:||
Db          1 TGTGTGTGTGTGTGTGTATATGTGTGG 27


RESULT 188
AAH40155/c
ID   AAH40155 standard; DNA; 25 BP.
XX
AC   AAH40155;
XX
DT   14-AUG-2001  (first entry)
XX
DE   SNP specific SNPE primer SEQ ID 2951.
XX
KW   Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW   SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW   Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW   polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW   acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW   inflammation; forensic investigation; paternity analysis; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200129262-A2.
XX
PD   26-APR-2001.
XX
PF   13-OCT-2000; 2000WO-US028436.
XX
PR   15-OCT-1999;   99US-0160096P.
XX
PA   (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI   Picoult-Newburg L,  Pohl M;
XX
DR   WPI; 2001-290930/30.
XX
PT   New genotyping oligonucleotide, useful for detecting the presence,
PT   absence or identity of single polynucleotide polymorphism in a nucleic
PT   acid sample.
XX
PS   Claim 1; Page 65; 83pp; English.
XX
CC   Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC   primer extension (SNPE) primers, and the sequences of regions flanking
CC   sites of single nucleotide polymorphisms SNPs. The present invention
CC   includes kits for determining the presence or absence of a SNP, using the
CC   oligonucleotides of the invention. The PCR primers are used to amplify a
CC   SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC   The oligonucleotides are useful for genotyping a nucleic acid sample by
CC   performing a single-nucleotide primer extension reaction. The
CC   oligonucleotides are useful for determining the presence, absence or
CC   identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC   assess by association analysis the genotype of an individual or group of
CC   individuals, having a pathological phenotypic trait suspected of being
CC   caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC   agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC   osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC   traits also include symptoms of or susceptibility to multifactorial
CC   disease of which a component is or may be genetic such as autoimmune
CC   diseases, including, rheumatoid arthritis, multiple sclerosis,
CC   inflammation, cancer, nervous system diseases and infection by pathogenic
CC   microorganism. The method is also useful in forensic investigations and
CC   paternity analysis. The present sequence represents a single nucleotide
CC   primer extension (SNPE) primer specific for a human SNP containing DNA
CC   sequence
XX
SQ   Sequence 25 BP; 11 A; 11 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.8e+03;
  Matches   13;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGU 6995
              || |:|:|:|:|:|:|:|:|:|:|:
Db         25 ACCGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 189
AAH40159/c
ID   AAH40159 standard; DNA; 25 BP.
XX
AC   AAH40159;
XX
DT   14-AUG-2001  (first entry)
XX
DE   SNP specific SNPE primer SEQ ID 2955.
XX
KW   Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW   SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW   Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
```

KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW inflammation; forensic investigation; paternity analysis; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129262-A2.
XX
PD 26-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US028436.
XX
PR 15-OCT-1999; 99US-0160096P.
XX
PA (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI Picoult-Newburg L, Pohl M;
XX
DR WPI; 2001-290930/30.
XX
PT New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX
PS Claim 1; Page 65; 83pp; English.
XX
CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC diseases, including, rheumatoid arthritis, multiple sclerosis,
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a single nucleotide
CC primer extension (SNPE) primer specific for a human SNP containing DNA
CC sequence
XX
SQ Sequence 25 BP; 11 A; 12 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 1.8e+03;
Matches 13; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

Qy 6972 CUGUGUGUGUGUGUGUGUGUGUGUG 6996
| |:|:|:|:|:|:|:|:|:|:|:|:|
Db 25 CCGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 190
ADG82647/c
ID ADG82647 standard; DNA; 25 BP.
XX
AC ADG82647;
XX
DT 11-MAR-2004 (first entry)
XX
DE Flt-1 gene probe.
XX
KW liver growth; hepatocyte proliferation; pathological liver condition;
KW liver damage; vascular endothelial growth factor receptor modulator;
KW VEGFR modulator; hepatotropic; antiinflammatory; liver growth promoter;
KW liver failure; hepatitis; liver cirrhosis; toxic liver damage;
KW medicamentary liver damage; hepatic encephalopathy; hepatic coma;
KW hepatic necrosis; probe; ss.
XX
OS Synthetic.
XX
PN WO2003103581-A2.
XX
PD 18-DEC-2003.
XX
PF 05-JUN-2003; 2003WO-US017591.
XX
PR 05-JUN-2002; 2002US-0386637P.
XX
PA (GETH) GENENTECH INC.
XX
PI Ferrara N, Hillan KJ, Le Couter J;
XX
DR WPI; 2004-071254/07.
XX
PT Promoting liver growth or promoting hepatocyte proliferation in liver of
PT subject, treating pathological liver condition e.g. cirrhosis in subject,
PT by administering vascular endothelial growth factor receptor modulator.
XX
PS Example 4; Page 44; 64pp; English.
XX
CC The present invention describes a method for promoting (M1) liver growth
CC or promoting (M2) hepatocyte proliferation in the liver of a subject,
CC treating (M3) a pathological liver condition in a subject, or protecting
CC (M4) liver from damage in the subject due to exposure to a hepatotoxic
CC agent, which involves administering to the subject a vascular endothelial
CC growth factor receptor (VEGFR) modulating agent (I). Also described: (1)
CC an article of manufacture comprising a container, composition contained
CC within the container and a label on the container instructing uses of the
CC composition for promoting liver growth, where the composition comprises a
CC VEGFR modulating agent in the amount effective to promote liver growth;
CC and (2) a kit comprising a first container, a LABEL on the first
CC container, and a composition contained within the first container, where
CC the composition comprises a VEGFR modulating agent in the amount
CC effective to promote liver growth, a second container comprising a buffer
CC and an instruction for using the kit for promoting liver growth. (I) has
CC hepatotropic and antiinflammatory activities, and can be used as a VEGFR
CC modulator, and a liver growth promoter. (I) can be used for promoting
CC liver growth or hepatocyte proliferation in the liver of a subject,
CC treating a pathological liver condition in a subject such as liver
CC failure, hepatitis, liver cirrhosis, toxic liver damage, medicamentary
CC liver damage, hepatic encephalopathy, hepatic coma or hepatic necrosis,
CC or for protecting liver from damage in a subject due to exposure to
CC hepatotoxic agent. The VEGFR modulator create a local cascade of
CC signaling events originating in sinusoidal endothelial cells following
CC VEGF receptor activation, which is much more potent and beneficial in
CC promoting hepatocyte proliferation and liver growth than systemic
CC delivery of the principal liver mitogen, hepatocyte growth factor (HGF).
CC The present sequence is used in the exemplification of the present
CC invention.
XX
SQ Sequence 25 BP; 4 A; 11 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 1.8e+03;
Matches 20; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2703 CAAGUGGGAGUUUGCCCGGGAGAGA 2727
|||||:|||||:::|| |||||||||
Db 25 CAAGTGGGAGTTTGCACGGGAGAGA 1

RESULT 191
AAQ33663
ID AAQ33663 standard; DNA; 23 BP.
XX

```
AC   AAQ33663;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA110.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 195; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.7e+03;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGT 23


RESULT 192
AAQ33773
ID   AAQ33773 standard; DNA; 23 BP.
XX
AC   AAQ33773;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA176.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 239; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.7e+03;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGT 23


RESULT 193
AAQ33885
ID   AAQ33885 standard; DNA; 23 BP.
XX
AC   AAQ33885;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA304.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
```

```
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 283; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.7e+03;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGT 23


RESULT 194
AAQ74272
ID   AAQ74272 standard; DNA; 23 BP.
XX
AC   AAQ74272;
XX
DT   25-MAR-2003  (revised)
DT   02-OCT-1995  (first entry)
XX
DE   sVEGF-RTMI PCR primer.
XX
KW   Vascular endothelial cell growth factor inhibitor; VEGF; sVEGF-RTMI; FLT;
KW   tyrosine-kinase receptor; HUVEC; primer; PCR; polymerase chain reaction;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO9421679-A1.
XX
PD   29-SEP-1994.
XX
PF   25-FEB-1994;   94WO-US001957.
XX
PR   25-MAR-1993;   93US-00038769.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Kendall RL,  Thomas KA;
XX
DR   WPI; 1994-316941/39.
XX
PT   Vascular endothelial cell growth factor inhibitors - bind growth factor
PT   with high affinity but without signal transduction.
XX
PS   Example 7; Page 41; 128pp; English.
XX
CC   The PCR primers given in AAQ74272-72 were used to construct a C-terminal
CC   truncated form, sVEGF-RTMI (AAR62487), of FLT (a known VEGF receptor),
CC   useful as a VEGF inhibitor. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 23 BP; 3 A; 6 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              |||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 195
AAT66105/c
ID   AAT66105 standard; DNA; 23 BP.
XX
AC   AAT66105;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   Repeat sequence found in the human chromosomal clone SW13.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Example 9; Col 61-62; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. The sequences AAT66084-
CC   T66107 represent repeat sequences of low informativeness found in
CC   specific human genes. This repeat sequence is found in the human
CC   chromosomal clone SW13. The sequence is amplified by primers AAT66106-7.
CC   (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 23 BP; 12 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.7e+03;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
```

```
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 196
AAV09341
ID   AAV09341 standard; DNA; 23 BP.
XX
AC   AAV09341;
XX
DT   13-MAY-1998  (first entry)
XX
DE   Soluble truncated VEGF receptor (VEGF-RTMI) DNA amplifying primer 1.
XX
KW   Vascular endothelial cell growth factor; VEGF; receptor; inhibitor;
KW   soluble; treatment; angiogenesis; psoriasis; tumour; arthritis;
KW   truncated; FLT; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5712380-A.
XX
PD   27-JAN-1998.
XX
PF   21-APR-1994;   94US-00232538.
XX
PR   25-MAR-1993;   93US-00038769.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Thomas KA,  Kendall RL;
XX
DR   WPI; 1998-120032/11.
XX
PT   Nucleic acid encoding soluble form of vascular endothelial cell growth
PT   factor receptor - and related vector and transformed cells, expressing
PT   soluble inhibitor of VEGF useful for inhibiting angiogenesis, e.g. for
PT   treatment of psoriasis, arthritis, tumours etc.
XX
PS   Example 7; Col 15; 47pp; English.
XX
CC   This primer is used for the PCR amplification of FLT, a vascular
CC   endothelial cell growth factor (VEGF). This generates a soluble truncated
CC   form of FLT (sVEGF-RTMI) containing the transmembrane region of FLT. A
CC   related soluble VEGF receptor/inhibitor (sVEGF-RI) molecule represents a
CC   fragment of the VEGF receptor that binds VEGF with high affinity but is
CC   unable to transduce a signal. sVEGF-RI is used to inhibit VEGF activity,
CC   specifically VEGF-induced angiogenesis, particularly for treatment of
CC   psoriasis, rheumatoid arthritis, haemangiomas, angiofibromas, diabetic
CC   retinopathy, neovascular glaucoma or tumour vascularisation. The sVEGF-RI
CC   can be administered topically or intravenously or from slow-release
CC   matrices
XX
SQ   Sequence 23 BP; 3 A; 6 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 197
AAX04439
ID   AAX04439 standard; DNA; 23 BP.
XX
AC   AAX04439;
XX
DT   27-APR-1999  (first entry)
XX
DE   Primer #4 for generating truncated FLT receptor.
XX
KW   Soluble; vascular endothelial cell growth factor; receptor; sVEGF-RI;
KW   inhibitor; angiogenesis; psoriasis; arthritis; angiofibroma; haemangioma;
KW   diabetic retinopathy; neovascular glaucoma; tumour vascularisation;
KW   primer; PCR; amplification; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5861484-A.
XX
PD   19-JAN-1999.
XX
PF   21-JAN-1997;   97US-00786164.
XX
PR   25-MAR-1993;   93US-00038769.
PR   21-APR-1994;   94US-00232538.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Thomas KA,  Kendall RL;
XX
DR   WPI; 1999-130431/11.
XX
PT   Soluble soluble vascular endothelial cell growth factor inhibitor protein
PT   - useful for treating angiogenesis-related diseases or preventing tumour
PT   vascularisation.
XX
PS   Example 7; Col 22; 50pp; English.
XX
CC   Primers AAX04439-X04440 were used to PCR amplify and generate a truncated
CC   FTL receptor (a vascular endothelial cell growth factor (VEGF) receptor).
CC   The resultant protein, designated sVEGF-RTMI (AAW68008), can be used to
CC   inhibit the activity of VEGF, preventing it from activating its receptors
CC   on vascular endothelial cells. An inhibitor of VEGF would be useful for
CC   treating angiogenesis-related diseases, e.g. psoriasis, arthritis,
CC   haemangiomas, angiofibromas, diabetic retinopathy and neovascular
CC   glaucoma, and for preventing tumour vascularisation
XX
SQ   Sequence 23 BP; 3 A; 6 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 198
AAI67480/c
ID   AAI67480 standard; DNA; 23 BP.
XX
AC   AAI67480;
XX
DT   11-FEB-2002  (first entry)
XX
DE   Forward primer used for real-time RT-PCR analysis.
XX
KW   ARP; angiogenesis; vascular endothelial growth factor; VEGF; cytostatic;
KW   arginine-rich protein; cardiant; antirheumatic; antiarthritic; human;
KW   antiatherosclerotic; vasotropic; gynecological; antidiabetic; vulnerary;
KW   antiulcer; dermatological; ophthalmological; antipsoriatic; apoptosis;
KW   gene therapy; RT-PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO200170174-A2.
XX
PD   27-SEP-2001.
XX
```

PF 21-MAR-2001; 2001WO-US009043.
XX
PR 22-MAR-2000; 2000US-0191201P.
XX
PA (CURA-) CURAGEN CORP.
PA (GETH) GENENTECH INC.
XX
PI Rastelli LK, Gerber H;
XX
DR WPI; 2001-639087/73.
XX
PT Modulating angiogenesis and/or apoptosis for preventing or treating
PT cancer, myocardial infarction and promoting healing, by modulating the
PT activity of vascular endothelial growth factor-modulated gene
PT polypeptide.
XX
PS Example 2; Page 103; 155pp; English.
XX
CC The invention relates to modulating angiogenesis and cell survival that
CC involves modulating the activity of at least one vascular endothelial
CC growth factor (VEGF)-modulated gene polypeptide. The method is useful for
CC modulating angiogenesis and cell survival, for treating tumour and cancer
CC by decreasing angiogenesis in cancerous tumours and treating myocardial
CC infarction and promoting healing, by increasing angiogenesis. Transgenic
CC non-human animals, having disrupted arginine-rich protein (ARP), are
CC useful for determining the clinical stage of ovarian tumorous, which is
CC useful for determining if the tumour has potential for metastasis. ARP is
CC useful in gene therapy and in diagnostic applications. VEGFmg proteins
CC are useful in the treatment of tumours, neoplasias, hemangiomas,
CC rheumatoid arthritis, atherosclerosis, idiopathic pulmonary fibrosis,
CC vascular restenosis, arteriovenous malformations, meningioma, neovascular
CC glaucoma, psoriasis, hemophilic joints, hypertrophic scars, Osler-Weber
CC syndrome, scleroderma, vascular adhesion pathologies, synovitis,
CC dermatitis, endometriosis, diabetic retinopathy, neovascularization
CC associated with corneal injury or grafts, wound, sore, and ulcer healing.
CC Sequences AAI67449-487 represent probe primer sets used for real-time RT-
CC PCR analysis of differential gene expression
XX
SQ Sequence 23 BP; 7 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 1.7e+03;
Matches 16; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2473 AGUUCAGCAUACCUCACUGUUCA 2495
||::|||||:|||:|||:|::||
Db 23 AGTTCAGCATACCTCACTGTTCA 1

RESULT 199
AAI67484/c
ID AAI67484 standard; DNA; 23 BP.
XX
AC AAI67484;
XX
DT 11-FEB-2002 (first entry)
XX
DE Reverse primer used for real-time RT-PCR analysis.
XX
KW ARP; angiogenesis; vascular endothelial growth factor; VEGF; cytostatic;
KW arginine-rich protein; cardiant; antirheumatic; antiarthritic; human;
KW antiatherosclerotic; vasotropic; gynecological; antidiabetic; vulnerary;
KW antiulcer; dermatological; ophthalmological; antipsoriatic; apoptosis;
KW gene therapy; RT-PCR; primer; ss.
XX
OS Synthetic.
XX
PN WO200170174-A2.
XX
PD 27-SEP-2001.
XX
PF 21-MAR-2001; 2001WO-US009043.
XX
PR 22-MAR-2000; 2000US-0191201P.
XX
PA (CURA-) CURAGEN CORP.
PA (GETH) GENENTECH INC.
XX
PI Rastelli LK, Gerber H;
XX
DR WPI; 2001-639087/73.
XX
PT Modulating angiogenesis and/or apoptosis for preventing or treating
PT cancer, myocardial infarction and promoting healing, by modulating the
PT activity of vascular endothelial growth factor-modulated gene
PT polypeptide.
XX
PS Example 2; Page 103; 155pp; English.
XX
CC The invention relates to modulating angiogenesis and cell survival that
CC involves modulating the activity of at least one vascular endothelial
CC growth factor (VEGF)-modulated gene polypeptide. The method is useful for
CC modulating angiogenesis and cell survival, for treating tumour and cancer
CC by decreasing angiogenesis in cancerous tumours and treating myocardial
CC infarction and promoting healing, by increasing angiogenesis. Transgenic
CC non-human animals, having disrupted arginine-rich protein (ARP), are
CC useful for determining the clinical stage of ovarian tumorous, which is
CC useful for determining if the tumour has potential for metastasis. ARP is
CC useful in gene therapy and in diagnostic applications. VEGFmg proteins
CC are useful in the treatment of tumours, neoplasias, hemangiomas,
CC rheumatoid arthritis, atherosclerosis, idiopathic pulmonary fibrosis,
CC vascular restenosis, arteriovenous malformations, meningioma, neovascular
CC glaucoma, psoriasis, hemophilic joints, hypertrophic scars, Osler-Weber
CC syndrome, scleroderma, vascular adhesion pathologies, synovitis,
CC dermatitis, endometriosis, diabetic retinopathy, neovascularization
CC associated with corneal injury or grafts, wound, sore, and ulcer healing.
CC Sequences AAI67449-487 represent probe primer sets used for real-time RT-
CC PCR analysis of differential gene expression
XX
SQ Sequence 23 BP; 7 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 1.7e+03;
Matches 16; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2473 AGUUCAGCAUACCUCACUGUUCA 2495
||::|||||:|||:|||:|::||
Db 23 AGTTCAGCATACCTCACTGTTCA 1

RESULT 200
AAH23018
ID AAH23018 standard; DNA; 23 BP.
XX
AC AAH23018;
XX
DT 17-SEP-2001 (first entry)
XX
DE VEGFR-1 gene specific forward primer.
XX
KW Vascular endothelial growth factor; VEGF; antisense; angiogenesis;
KW cell proliferation; Kaposi's sarcoma; cancer; melanoma; cytostatic;
KW antisense therapy; RT-PCR; primer; VEGFR-1; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200152904-A2.
XX
PD 26-JUL-2001.
XX
PF 19-JAN-2001; 2001WO-US000019.
XX
PR 19-JAN-2000; 2000US-00487023.
XX
PA (GILL/) GILL P S.

```
XX
PI   Gill PS,  Masood R;
XX
DR   WPI; 2001-451898/48.
XX
PT   Novel antisense oligonucleotides useful for inhibiting vascular
PT   endothelial growth factor expression, angiogenesis and for treating
PT   cancer, e.g., Kaposi's sarcoma, ovarian cancer and prostrate cancer.
XX
PS   Example 12; Page 56; 105pp; English.
XX
CC   The invention provides a composition comprising one or more antisense
CC   oligonucleotides directed against vascular endothelial growth factor
CC   (VEGF) where the antisense oligonucleotides inhibits proliferation of
CC   cells exhibiting autocrine VEGF activity at an IC_5_0 concentration of
CC   between 0.5-2.5 micro Ma. The antisense oligonucleotides may be directed
CC   against VEGF for inhibiting cancer cell proliferation and angiogenesis.
CC   Preferably the oligonucleotide AAH23032 (a modified version of AAH22984)
CC   is used and may be utilized to treat Kaposi's sarcoma, ovarian cancer,
CC   prostrate cancer, pancreatic cancer or melanoma. Sequences AAH23012-023
CC   represent gene-specific primers used in RT-PCR amplification of VEGF
CC   receptors
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 201
AAF60472/c
ID   AAF60472 standard; DNA; 23 BP.
XX
AC   AAF60472;
XX
DT   27-APR-2001  (first entry)
XX
DE   Oligonucleotide clamp #17.
XX
KW   Oligonucleotide clamp; ds.
XX
OS   Unidentified.
XX
PN   US6180777-B1.
XX
PD   30-JAN-2001.
XX
PF   03-JAN-1997;   97US-00787321.
XX
PR   12-JAN-1996;   96US-0009918P.
XX
PA   (FARB ) BAYER CORP.
XX
PI   Horn T;
XX
DR   WPI; 2001-201911/20.
XX
PT   Synthesizing branched nucleic acids useful as diagnostic and molecular
PT   probes, involves combining first units having haloalkylamino groups and
PT   second units having thiol or phosphorothioate groups.
XX
PS   Example 7; Col 19; 20pp; English.
XX
CC   The present invention relates to a method for synthesising a branched or
CC   multiply connected macromolecular structure, comprising oligonucleotide
CC   clamps (OC). The macromolecular structure is capable of specifically
CC   binding to a target molecule, and can therefore be used as probes. At
CC   least one OC comprises a target binding sequence that binds specifically
CC   and stably with the target molecule, and at least two OCs comprise signal
CC   generation moieties capable of generating a detectable signal in the
CC   presence of the target molecule. In addition the OCs are connected to one
CC   another by thioalkylamino, or thiophosphorylalkylamino bridges. The
CC   present sequence is an OC used in the present invention
XX
SQ   Sequence 23 BP; 11 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 1.7e+03;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|
Db         23 GTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 202
ABQ80261/c
ID   ABQ80261 standard; cDNA; 23 BP.
XX
AC   ABQ80261;
XX
DT   27-JUN-2003  (first entry)
XX
DE   FLT-1 primer #2.
XX
KW   PCR; nervous system; platelet-derived growth factor; PDGF; psychosis;
KW   vascular endothelial growth factor; VEGF; neural; stem cell; memory;
KW   progenitor cell; neurodegeneration; ischaemia; neurological trauma;
KW   neuropsychiatry; learning; Parkinson's disease; Huntington's disease;
KW   Amyotrophic Lateral Sclerosis; spinal ischaemia; ischaemic stroke;
KW   spinal cord injury; cancer-related; schizophrenia; Alzheimer's disease;
KW   depression; anxiety; phobia; stress; cognitive function; aggression;
KW   drug; alcohol; abuse; obsessive compulsive behaviour; proliferation;
KW   seasonal mood disorder; personality disorder; cerebral palsy; primer;
KW   multi-infarct; dementia; Lewy body; age related; geriatric; growth;
KW   epilepsy; brain injury; multiple sclerosis; autism; differentiation;
KW   attention deficit disorder; narcolepsy; amplify; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003024478-A1.
XX
PD   27-MAR-2003.
XX
PF   19-SEP-2002; 2002WO-IB003998.
XX
PR   19-SEP-2001; 2001US-0323381P.
PR   28-SEP-2001; 2001US-0326044P.
XX
PA   (NEUR-) NEURONOVA AB.
XX
PI   Delfani K,  Janson AM,  Kuhn GH,  Plate K,  Schanzer A,  Wachs F;
PI   Zhao M;
XX
DR   WPI; 2003-354563/33.
XX
PT   Use of platelet-derived growth factor, vascular endothelial growth
PT   factor, or their modulators for modulating neural stem cell or neural
PT   progenitor cell activity, particularly for treating e.g. Alzheimer's,
PT   ischemia or stroke.
XX
PS   Example 11; Page 77; 119pp; English.
XX
CC   The sequences given in ABQ80256-69 are primers which were used to
CC   identify the presence of vascular endothelial growth factor (VEGF), or
CC   the VEGF receptors, Flk1, FLT-1 and FLT-4 in human stem cells (HSC). The
CC   method of the invention for alleviating or reducing a symptom of a
CC   disease or disorder of the nervous system comprises administering
CC   platelet-derived growth factor (PDGF), vascular endothelial growth factor
CC   (VEGF), a combination of PDGF and VEGF, or a PDGF or VEGF agonist, to a
CC   patient in order to modulate neural stem cell or neural progenitor cell
```

```
CC   activity in vivo. The method is useful for alleviating or reducing the
CC   symptoms of a disease or disorder of the nervous system, e.g.
CC   neurodegenerative disorders, neural stem cell disorders, neural
CC   progenitor disorders, ischaemic disorders, neurological traumas,
CC   affective disorders, neuropsychiatric disorders or learning and memory
CC   disorders. In particular, the method is useful for alleviating or
CC   treating Parkinson's disease and disorders, Huntington's disease,
CC   Alzheimer's disease, Amyotrophic Lateral Sclerosis, spinal ischaemia,
CC   ischaemic stroke, spinal cord injury or cancer-related brain/ spinal cord
CC   injury, schizophrenia and other psychoses, depression, bipolar
CC   depression/disorder, anxiety syndromes/disorders, phobias, stress and
CC   related syndromes, cognitive function disorders, aggression, drug and
CC   alcohol abuse, obsessive compulsive behaviour syndromes, seasonal mood
CC   disorder, borderline personality disorder, cerebral palsy, life style
CC   drug, multi-infarct dementia, Lewy body dementia, age related/geriatric
CC   dementia, epilepsy and injury related to epilepsy, spinal cord injury,
CC   brain injury, trauma related brain/spinal cord injury, anti-cancer
CC   treatment related brain/spinal cord tissue injury, infection and
CC   inflammation related brain/spinal cord injury, environmental toxin
CC   related brain/spinal cord injury, multiple sclerosis, autism, attention
CC   deficit disorders, narcolepsy or sleep disorders. The PDGF and/or VEGF,
CC   is useful in the manufacture of a medicament for alleviating or treating
CC   these diseases or disorders, accelerating growth of neural stem cells or
CC   neural progenitor cells, or inducing proliferation or differentiation of
CC   these cells. This primer gives an estimated band size of 347 bp
XX
SQ   Sequence 23 BP; 4 A; 6 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1263 UCGAAAACAGCAGGUGCUUGAAA 1285
              :|||||||||||||:||::||||
Db         23 TCGAAAACAGCAGGTGCTTGAAA 1


RESULT 203
ADF37815
ID   ADF37815 standard; RNA; 23 BP.
XX
AC   ADF37815;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2012.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2012; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
              |||||||||||||||||||||||
Db          1 AAGCAAGGAGGGCCUCUGAUGGU 23


RESULT 204
ADF37711
ID   ADF37711 standard; RNA; 23 BP.
XX
AC   ADF37711;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2000.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
```

```
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2000; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2785 GCAUUUGGCAUUAAGAAAUCACC 2807
              |||||||||||||||||||||||
Db          1 GCAUUUGGCAUUAAGAAAUCACC 23


RESULT 205
ADF37813
ID   ADF37813 standard; RNA; 23 BP.
XX
AC   ADF37813;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2010.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2010; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 15 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 206
ADF37817
ID   ADF37817 standard; RNA; 23 BP.
XX
AC   ADF37817;
XX
```

DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2014.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2014; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 23 BP; 6 A; 2 C; 8 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3501 UUACGGAGUAUUGCUGUGGGAAA 3523
|||||||||||||||||||||||
Db 1 UUACGGAGUAUUGCUGUGGGAAA 23

RESULT 207
ADF37819
ID ADF37819 standard; RNA; 23 BP.
XX
AC ADF37819;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2016.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2016; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of

```
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 14 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
              |||||||||||||||||||||||
Db          1 AGCAAAAAGCAAGGGAGAAAAGA 23


RESULT 208
ADF37812
ID   ADF37812 standard; RNA; 23 BP.
XX
AC   ADF37812;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2009.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2009; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCCAG 369
              |||||||||||||||||||||||
Db          1 AACUGAGUUUAAAAGGCACCCAG 23


RESULT 209
ADF37818
ID   ADF37818 standard; RNA; 23 BP.
XX
AC   ADF37818;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2015.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
```

```
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2015; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4713 UAGCAGGCCUAAGACAUGUGAGG 4735
              |||||||||||||||||||||||
Db          1 UAGCAGGCCUAAGACAUGUGAGG 23


RESULT 210
ADF37708
ID   ADF37708 standard; RNA; 23 BP.
XX
AC   ADF37708;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:1997.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1997; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 23 BP; 3 A; 7 C; 5 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        296 GCUGUCUGCUUCUCACAGGAUCU 318
              |||||||||||||||||||||||
Db          1 GCUGUCUGCUUCUCACAGGAUCU 23


RESULT 211
ADF37710
ID   ADF37710 standard; RNA; 23 BP.
XX
AC   ADF37710;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:1999.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
```

PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 1999; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 23 BP; 8 A; 4 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1955 AAGGAGAGGACCUGAAACUGUCU 1977
||||||||||||||||||||||||
Db 1 AAGGAGAGGACCUGAAACUGUCU 23

RESULT 212
ADF37709
ID ADF37709 standard; RNA; 23 BP.
XX
AC ADF37709;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:1998.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 1998; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 23 BP; 8 A; 4 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1954 GAAGGAGAGGACCUGAAACUGUC 1976
|||||||||||||||||||||||
Db 1 GAAGGAGAGGACCUGAAACUGUC 23

RESULT 213
ADF37814
ID ADF37814 standard; RNA; 23 BP.
XX
AC ADF37814;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2011.

XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2011; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 23 BP; 10 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3910 AGCCUGGAAAGAAUCAAAACCUU 3932
||||||||||||||||||||||||
Db 1 AGCCUGGAAAGAAUCAAAACCUU 23

RESULT 214
ADF37816
ID ADF37816 standard; RNA; 23 BP.
XX
AC ADF37816;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2013.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2013; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX

```
SQ   Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 UCGUGUAAGGAGUGGACCAUCAU 1204
              |||||||||||||||||||||||
Db          1 UCGUGUAAGGAGUGGACCAUCAU 23


RESULT 215
ADF48468
ID   ADF48468 standard; mRNA; 23 BP.
XX
AC   ADF48468;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human Myb mRNA transcript target sequence, SEQ ID 605.
XX
KW   Human; Myc; Myb; cancer; proliferative disease; restenosis;
KW   polycystic kidney disease; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; cytostatic; vasotropic;
KW   nephrotropic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070917-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005326.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-OCT-2002; 2002US-0418655P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689784/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of Myc or Myb genes.
XX
PS   Example 7; Page 138; 161pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human Myc or Myb genes by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of the Myc or Myb genes in cells, tissue
CC   explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC   transplants for the treatment of a variety of conditions. They may be
CC   used for treating cancers and other proliferative diseases, such as
CC   restenosis and polycystic kidney disease. The siNAs are also useful for
CC   drug screening, diagnosis, therapeutic target identification and
CC   validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents a human Myb transcript target sequence.
XX
SQ   Sequence 23 BP; 15 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 216
ADF23241
ID   ADF23241 standard; DNA; 23 BP.
XX
AC   ADF23241;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human ftl receptor mutagenesis primer #1.
XX
KW   vascular endothelial growth factor; VEGF inhibitor; VEGF;
KW   cellular VEGF receptor activity; psoriasis; rheumatoid arthritis;
KW   haemangioma; angiofibroma; diabetic retinopathy; neovascular glaucoma;
KW   human; primer; mutagenesis; ss; ftl.
XX
OS   Homo sapiens.
XX
PN   US2003120038-A1.
XX
PD   26-JUN-2003.
XX
PF   19-MAR-2002; 2002US-00101018.
XX
PR   25-MAR-1993;   93US-00038769.
PR   21-APR-1994;   94US-00232538.
PR   21-JAN-1997;   97US-00786164.
PR   15-JAN-1999;   99US-00232773.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Kendall RL,  Thomas KA;
XX
DR   WPI; 2003-863450/80.
XX
PT   New soluble vascular endothelial growth factor (VEGF) inhibitors, sVEGF-
PT   RI, sVEGF-RII, sVEGF-RTMI and sVEGF-RTMII, useful for treating psoriasis,
PT   rheumatoid arthritis, hemangiomas, angiofibromas, or diabetic
PT   retinopathy.
XX
PS   Example 7; SEQ ID NO 10; 59pp; English.
XX
CC   The invention relates to a substantially pure form of soluble vascular
CC   endothelial growth factor (VEGF) inhibitor, which specifically binds VEGF
CC   and inhibits cellular VEGF receptor activity. The VEGF inhibitor is
CC   useful for treating psoriasis, rheumatoid arthritis, haemangiomas,
CC   angiofibromas, diabetic retinopathy, and neovascular glaucoma. The
CC   present sequence is used in the exemplification of the invention.
XX
SQ   Sequence 23 BP; 3 A; 6 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
```

```
                  ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 217
ADF88105/c
ID   ADF88105 standard; DNA; 23 BP.
XX
AC   ADF88105;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Single nucleotide polymorphism detection primer, SEQ ID No 1688.
XX
KW   human; single nucleotide polymorphism; microarray; side effect; ss;
KW   primer; PCR.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   JP2003235571-A.
XX
PD   26-AUG-2003.
XX
PF   12-FEB-2002; 2002JP-00034717.
XX
PR   12-FEB-2002; 2002JP-00034717.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2003-820454/77.
XX
PT   Novel polynucleotide useful for detecting single nucleotide polymorphisms
PT   in human gene.
XX
PS   Claim 2; SEQ ID NO 1688; 704pp; Japanese.
XX
CC   The invention relates to a novel polynucleotide isolated and purified
CC   from a human gene having any one of 935 fully defined sequences as given
CC   in specification, or a sequence having a base substitution. The invention
CC   further relates to: an oligonucleotide containing single nucleotide
CC   polymorphisms; a PCR primer set chosen from the combination of two DNA
CC   fragments from any one of 1220 fully defined sequences as given in
CC   specification; a labelling probe containing the SNP containing oligo; and
CC   a microarray equipped with the SNP containing oligo. The isolated human
CC   gene of the invention is useful for detecting the single nucleotide
CC   polymorphisms in human gene. The isolated human gene is also useful for
CC   diagnosis of disease and determination of side effect to a medical agent.
CC   The isolated human gene is also effective in detecting single nucleotide
CC   polymorphisms in a human gene. This polynucleotide sequence represents
CC   one of the PCR primers used in the single nucleotide polymorphism
CC   detection method of the invention.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.7e+03;
  Matches   18;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3341 CUGAGAACAACGUGGUGAAGAUU 3363
                |:||||||||||:||:|||||::
Db         23 CTGAGAACAACGTGGTGAAGATT 1


RESULT 218
ADG29494
ID   ADG29494 standard; RNA; 23 BP.
XX
AC   ADG29494;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 60.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 60; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 UCGUGUAAGGAGUGGACCAUCAU 1204
                ||||||||||||||||||||||
Db          1 UCGUGUAAGGAGUGGACCAUCAU 23


RESULT 219
ADG29490
ID   ADG29490 standard; RNA; 23 BP.
XX
AC   ADG29490;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 56.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 56; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCCAG 369
              |||||||||||||||||||||||
Db          1 AACUGAGUUUAAAAGGCACCCAG 23


RESULT 220
ADG29495
ID   ADG29495 standard; RNA; 23 BP.
XX
AC   ADG29495;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 61.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 61; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 6 A; 2 C; 8 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3501 UUACGGAGUAUUGCUGUGGGAAA 3523
              |||||||||||||||||||||||
Db          1 UUACGGAGUAUUGCUGUGGGAAA 23


RESULT 221
ADG29496
ID   ADG29496 standard; RNA; 23 BP.
XX
AC   ADG29496;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 62.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 62; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4713 UAGCAGGCCUAAGACAUGUGAGG 4735
             |||||||||||||||||||||||
Db          1 UAGCAGGCCUAAGACAUGUGAGG 23


RESULT 222
ADG29497
ID   ADG29497 standard; RNA; 23 BP.
XX
AC   ADG29497;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 63.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 63; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 14 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
             |||||||||||||||||||||||
Db          1 AGCAAAAAGCAAGGGAGAAAAGA 23


RESULT 223
ADG29493
ID   ADG29493 standard; RNA; 23 BP.
XX
AC   ADG29493;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 59.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 59; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
             |||||||||||||||||||||||
Db          1 AAGCAAGGAGGGCCUCUGAUGGU 23


RESULT 224
ADG29492
ID   ADG29492 standard; RNA; 23 BP.
XX
AC   ADG29492;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1 siNA-target RNA - SEQ ID 58.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 58; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 10 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3910 AGCCUGGAAAGAAUCAAAACCUU 3932
             |||||||||||||||||||||||
Db          1 AGCCUGGAAAGAAUCAAAACCUU 23


RESULT 225
ADG29491
ID   ADG29491 standard; RNA; 23 BP.
XX
AC   ADG29491;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1/MYB/PKR siNA-target RNA - SEQ ID 57.
```

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; target; ss; FLT1; MYB; PKR.
XX
OS   Unidentified.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 57; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA
CC   target DNA of the invention.
XX
SQ   Sequence 23 BP; 15 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
             |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 226
ABX90509
ID   ABX90509 standard; DNA; 23 BP.
XX
AC   ABX90509;
XX
DT   01-MAY-2003  (first entry)
XX
DE   Human VEGFR-1 RT-PCR primer #1.
XX
KW   Antisense; ss; PCR; VEGF; vascular endothelial growth factor; human;
KW   cancer; angiogenesis; neoplastic proliferation; cellular proliferation;
KW   primer; RT-PCR; reverse transcriptase PCR.
XX
OS   Homo sapiens.
XX
PN   US2002165174-A1.
XX
PD   07-NOV-2002.
XX
PF   13-MAR-2001; 2001US-00805761.
XX
PR   31-JAN-1997;   97US-0037004P.
PR   30-JAN-1998;   98US-00016541.
PR   19-JAN-2000; 2000US-00487023.
PR   19-JAN-2001; 2001WO-US000019.
XX
PA   (GILL/) GILL P S.
PA   (MASO/) MASOOD R.
XX
PI   Gill PS,  Masood R;
XX
DR   WPI; 2003-255224/25.
XX
PT   New composition comprising an antisense oligonucleotide directed against
PT   vascular endothelial growth factor, useful for preparing a composition
PT   for treating cancer.
XX
PS   Example 12; Page 19; 54pp; English.
XX
CC   The invention relates to a composition comprising an antisense
CC   oligonucleotide directed against vascular endothelial growth factor
CC   (VEGF). The antisense oligonucleotide is useful for preparing a
CC   composition treating cancer, neoplastic proliferation, abnormal cellular
CC   proliferation and preventing angiogenesis. The present sequence is a
CC   reverse transcriptase (RT)-PCR primer for a VEGF or related gene, used to
CC   clone the coding region for expression in tumour cell lines. The cell
CC   lines were used to test prospective antisense oligonucleotides
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.7e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 227
ADY89153
ID   ADY89153 standard; RNA; 23 BP.
XX
AC   ADY89153;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2189.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
```

```
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2189; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3643 AUCAUGCUGGACUGCUGGCACAG 3665
             |||||||||||||||||||||||
Db          1 AUCAUGCUGGACUGCUGGCACAG 23


RESULT 228
ADY89265
ID   ADY89265 standard; RNA; 23 BP.
XX
AC   ADY89265;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2301.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2301; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        350 UGAGUUUAAAAGGCACCCAGCAC 372
              |||||||||||||||||||||||
Db          1 UGAGUUUAAAAGGCACCCAGCAC 23


RESULT 229
ADY89291
ID   ADY89291 standard; RNA; 23 BP.
XX
AC   ADY89291;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2327.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
```

```
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2327; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        797 GCAUAAUCUGGGACAGUAGAAAG 819
              |||||||||||||||||||||||
Db          1 GCAUAAUCUGGGACAGUAGAAAG 23


RESULT 230
ADY89315
ID   ADY89315 standard; RNA; 23 BP.
XX
AC   ADY89315;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2351.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2351; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 UUUCAAGUGGCCAGAGGCAUGGA 3281
              |||||||||||||||||||||||
Db          1 UUUCAAGUGGCCAGAGGCAUGGA 23


RESULT 231
ADY89324
ID   ADY89324 standard; RNA; 23 BP.
XX
AC   ADY89324;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2360.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2360; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
```

```
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3899 UCAAGUUCAUGAGCCUGGAAAGA 3921
              |||||||||||||||||||||||
Db          1 UCAAGUUCAUGAGCCUGGAAAGA 23


RESULT 232
ADY89340
ID   ADY89340 standard; RNA; 23 BP.
XX
AC   ADY89340;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2376.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2376; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 13 A; 7 C; 2 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAAGAGC 2362
              |||||||||||||||||||||||
Db          1 CAACCACAAAAUACAACAAGAGC 23


RESULT 233
ADY89341
ID   ADY89341 standard; RNA; 23 BP.
XX
AC   ADY89341;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2377.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2377; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2363 CUGGAAUUAUUUUAGGACCAGGA 2385
              |||||||||||||||||||||||
```

```
Db          1 CUGGAAUUAUUUUAGGACCAGGA 23


RESULT 234
ADY89348
ID   ADY89348 standard; RNA; 23 BP.
XX
AC   ADY89348;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2384.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2384; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 3 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2395 CUGUUUAUUGAAAGAGUCACAGA 2417
             |||||||||||||||||||||||
Db          1 CUGUUUAUUGAAAGAGUCACAGA 23


RESULT 235
ADY89353
ID   ADY89353 standard; RNA; 23 BP.
XX
AC   ADY89353;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2389.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2389; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2784 AGCAUUUGGCAUUAAGAAAUCAC 2806
             |||||||||||||||||||||||
Db          1 AGCAUUUGGCAUUAAGAAAUCAC 23


RESULT 236
ADY89355
ID   ADY89355 standard; RNA; 23 BP.
XX
AC   ADY89355;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2391.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
```

```
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2391; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2787 AUUUGGCAUUAAGAAAUCACCUA 2809
              |||||||||||||||||||||||
Db          1 AUUUGGCAUUAAGAAAUCACCUA 23


RESULT 237
ADY89362
ID   ADY89362 standard; RNA; 23 BP.
XX
AC   ADY89362;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2398.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2398; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 3 C; 9 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2951 AAGGAGGGCCUCUGAUGGUGAUU 2973
              |||||||||||||||||||||||
Db          1 AAGGAGGGCCUCUGAUGGUGAUU 23


RESULT 238
ADY89201
ID   ADY89201 standard; RNA; 23 BP.
XX
AC   ADY89201;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2237.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
```

PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2237; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3640 CAGAUCAUGCUGGACUGCUGGCA 3662
||||||||||||||||||||||||
Db 1 CAGAUCAUGCUGGACUGCUGGCA 23

RESULT 239
ADY89254
ID ADY89254 standard; RNA; 23 BP.
XX
AC ADY89254;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2290.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2290; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
||||||||||||||||||||||||
Db 1 AAGCAAGGAGGGCCUCUGAUGGU 23

RESULT 240
ADY89261
ID ADY89261 standard; RNA; 23 BP.
XX
AC ADY89261;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2297.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;

```
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2297; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        345 UGAACUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||||||
Db          1 UGAACUGAGUUUAAAAGGCACCC 23


RESULT 241
ADY89270
ID   ADY89270 standard; RNA; 23 BP.
XX
AC   ADY89270;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2306.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2306; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 14 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
              |||||||||||||||||||||||
Db          1 AGCAAAAAGCAAGGGAGAAAAGA 23


RESULT 242
ADY89301
ID   ADY89301 standard; RNA; 23 BP.
XX
AC   ADY89301;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2337.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2337; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
```

```
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 2 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2413 ACAGAAGAGGAUGAAGGUGUCUA 2435
              |||||||||||||||||||||||
Db          1 ACAGAAGAGGAUGAAGGUGUCUA 23


RESULT 243
ADY89308
ID   ADY89308 standard; RNA; 23 BP.
XX
AC   ADY89308;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2344.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2344; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 13 A; 5 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3098 AACAAGGCAAGAAACCAAGACUA 3120
              |||||||||||||||||||||||
Db          1 AACAAGGCAAGAAACCAAGACUA 23


RESULT 244
ADY89310
ID   ADY89310 standard; RNA; 23 BP.
XX
AC   ADY89310;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2346.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2346; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 0 C; 12 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3180 GAGUGAUGUUGAGGAAGAGGAGG 3202
              |||||||||||||||||||||||
Db          1 GAGUGAUGUUGAGGAAGAGGAGG 23
```

```
RESULT 245
ADY89325
ID   ADY89325 standard; RNA; 23 BP.
XX
AC   ADY89325;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2361.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2361; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3900 CAAGUUCAUGAGCCUGGAAAGAA 3922
             |||||||||||||||||||||||
Db          1 CAAGUUCAUGAGCCUGGAAAGAA 23


RESULT 246
ADY89326
ID   ADY89326 standard; RNA; 23 BP.
XX
AC   ADY89326;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2362.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2362; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 10 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3908 UGAGCCUGGAAAGAAUCAAAACC 3930
             |||||||||||||||||||||||
Db          1 UGAGCCUGGAAAGAAUCAAAACC 23


RESULT 247
ADY89336
ID   ADY89336 standard; RNA; 23 BP.
XX
AC   ADY89336;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2372.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
```

PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2372; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 7 A; 11 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5355 CCCCGUCUCUAUACCAACCAAAC 5377
||||||||||||||||||||||||
Db 1 CCCCGUCUCUAUACCAACCAAAC 23

RESULT 248
ADY89359
ID ADY89359 standard; RNA; 23 BP.
XX
AC ADY89359;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2395.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2395; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 6 A; 6 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2945 CCAAGCAAGGAGGGCCUCUGAUG 2967
||||||||||||||||||||||||
Db 1 CCAAGCAAGGAGGGCCUCUGAUG 23

RESULT 249
ADY89183
ID ADY89183 standard; RNA; 23 BP.
XX
AC ADY89183;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2219.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.

```
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2219; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2690 CUUAUGAUGCCAGCAAGUGGGAG 2712
             |||||||||||||||||||||||
Db          1 CUUAUGAUGCCAGCAAGUGGGAG 23


RESULT 250
ADY89191
ID   ADY89191 standard; RNA; 23 BP.
XX
AC   ADY89191;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2227.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2227; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3638 AUCAGAUCAUGCUGGACUGCUGG 3660
             |||||||||||||||||||||||
Db          1 AUCAGAUCAUGCUGGACUGCUGG 23


RESULT 251
ADY89296
ID   ADY89296 standard; RNA; 23 BP.
XX
AC   ADY89296;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2332.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
```

```
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2332; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1664 ACCAUAAUCAUUCCGAAGCAAGG 1686
             |||||||||||||||||||||||
Db          1 ACCAUAAUCAUUCCGAAGCAAGG 23


RESULT 252
ADY89306
ID   ADY89306 standard; RNA; 23 BP.
XX
AC   ADY89306;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2342.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2342; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 2 C; 7 G; 0 T; 9 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 UGAUGGUGAUUGUUGAAUACUGC 2985
             |||||||||||||||||||||||
Db          1 UGAUGGUGAUUGUUGAAUACUGC 23


RESULT 253
ADY89320
ID   ADY89320 standard; RNA; 23 BP.
XX
AC   ADY89320;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2356.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2356; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
```

```
XX
SQ   Sequence 23 BP; 3 A; 5 C; 5 G; 0 T; 10 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3511 UUGCUGUGGGAAAUCUUCUCCUU 3533
              |||||||||||||||||||||||
Db          1 UUGCUGUGGGAAAUCUUCUCCUU 23


RESULT 254
ADY89329
ID   ADY89329 standard; RNA; 23 BP.
XX
AC   ADY89329;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2365.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2365; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 9 C; 5 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4633 UGCAGCCCAAAACCCAGGGCAAC 4655
              |||||||||||||||||||||||
Db          1 UGCAGCCCAAAACCCAGGGCAAC 23


RESULT 255
ADY89332
ID   ADY89332 standard; RNA; 23 BP.
XX
AC   ADY89332;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2368.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2368; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 4 A; 7 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5135 GUCUCCAGGCCAUGAUGGCCUUA 5157
              |||||||||||||||||||||||
Db          1 GUCUCCAGGCCAUGAUGGCCUUA 23


RESULT 256
ADY89345
```

```
ID   ADY89345 standard; RNA; 23 BP.
XX
AC   ADY89345;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2381.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2381; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2392 ACGCUGUUUAUUGAAAGAGUCAC 2414
              |||||||||||||||||||||||
Db          1 ACGCUGUUUAUUGAAAGAGUCAC 23


RESULT 257
ADY89354
ID   ADY89354 standard; RNA; 23 BP.
XX
AC   ADY89354;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2390.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2390; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2786 CAUUUGGCAUUAAGAAAUCACCU 2808
              |||||||||||||||||||||||
Db          1 CAUUUGGCAUUAAGAAAUCACCU 23


RESULT 258
ADY89363
ID   ADY89363 standard; RNA; 23 BP.
XX
AC   ADY89363;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2399.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
```

```
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2399; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 4 A; 3 C; 10 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2952 AGGAGGGCCUCUGAUGGUGAUUG 2974
             |||||||||||||||||||||||
Db          1 AGGAGGGCCUCUGAUGGUGAUUG 23


RESULT 259
ADY89249
ID   ADY89249 standard; RNA; 23 BP.
XX
AC   ADY89249;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2285.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2285; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 3 A; 7 C; 5 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        296 GCUGUCUGCUUCUCACAGGAUCU 318
              |||||||||||||||||||||||
Db          1 GCUGUCUGCUUCUCACAGGAUCU 23


RESULT 260
ADY89250
ID   ADY89250 standard; RNA; 23 BP.
XX
AC   ADY89250;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2286.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
```

PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2286; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 8 A; 4 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1954 GAAGGAGAGGACCUGAAACUGUC 1976
||||||||||||||||||||||||
Db 1 GAAGGAGAGGACCUGAAACUGUC 23

RESULT 261
ADY89264
ID ADY89264 standard; RNA; 23 BP.
XX
AC ADY89264;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2300.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2300; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 349 CUGAGUUUAAAAGGCACCCAGCA 371
|||||||||||||||||||||||
Db 1 CUGAGUUUAAAAGGCACCCAGCA 23

RESULT 262
ADY89368
ID ADY89368 standard; RNA; 23 BP.
XX
AC ADY89368;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2404.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.

```
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2404; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4417 UUUUUUGACUAACAAGAAUGUAA 4439
              |||||||||||||||||||||||
Db          1 UUUUUUGACUAACAAGAAUGUAA 23


RESULT 263
ADY89671
ID   ADY89671 standard; RNA; 23 BP.
XX
AC   ADY89671;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR DFO siRNA target sequence SEQ ID NO 2708.
XX
KW   ss; VEGF; pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2708; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR DFO siRNA target sequence.
XX
SQ   Sequence 23 BP; 10 A; 3 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1227 GCAUAUAUAUGAUAAAGCAUUCA 1249
              |||||||||||||||||||||||
Db          1 GCAUAUAUAUGAUAAAGCAUUCA 23


RESULT 264
ADY89187
ID   ADY89187 standard; RNA; 23 BP.
XX
AC   ADY89187;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2223.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2223; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 6 A; 3 C; 8 G; 0 T; 6 U; 0 Other;
```

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2691 UUAUGAUGCCAGCAAGUGGGAGU 2713
              |||||||||||||||||||||||
Db          1 UUAUGAUGCCAGCAAGUGGGAGU 23


RESULT 265
ADY89252
ID   ADY89252 standard; RNA; 23 BP.
XX
AC   ADY89252;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2288.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2288; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2785 GCAUUUGGCAUUAAGAAAUCACC 2807
              |||||||||||||||||||||||
Db          1 GCAUUUGGCAUUAAGAAAUCACC 23


RESULT 266
ADY89274
ID   ADY89274 standard; RNA; 23 BP.
XX
AC   ADY89274;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2310.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2310; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5351 AAGACCCCGUCUCUAUACCAACC 5373
              |||||||||||||||||||||||
Db          1 AAGACCCCGUCUCUAUACCAACC 23


RESULT 267
ADY89295
ID   ADY89295 standard; RNA; 23 BP.
XX
AC   ADY89295;
```

```
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2331.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2331; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 AAUCAAGUGGUUCUGGCACCCCU 1660
              |||||||||||||||||||||||
Db          1 AAUCAAGUGGUUCUGGCACCCCU 23


RESULT 268
ADY89300
ID   ADY89300 standard; RNA; 23 BP.
XX
AC   ADY89300;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2336.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2336; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2358 AGAGCCUGGAAUUAUUUUAGGAC 2380
              |||||||||||||||||||||||
Db          1 AGAGCCUGGAAUUAUUUUAGGAC 23


RESULT 269
ADY89358
ID   ADY89358 standard; RNA; 23 BP.
XX
AC   ADY89358;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2394.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
```

```
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2394; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2859 CGAGUACAAAGCUCUGAUGACUG 2881
             |||||||||||||||||||||||
Db          1 CGAGUACAAAGCUCUGAUGACUG 23


RESULT 270
ADY89271
ID   ADY89271 standard; RNA; 23 BP.
XX
AC   ADY89271;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2307.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2307; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 9 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1499 ACCUCACUGCCACUCUAAUUGUC 1521
              |||||||||||||||||||||||
Db          1 ACCUCACUGCCACUCUAAUUGUC 23


RESULT 271
ADY89286
ID   ADY89286 standard; RNA; 23 BP.
XX
AC   ADY89286;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2322.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
```

PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2322; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 9 A; 5 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 756 AAAAAAGUUUCCACUUGACACUU 778
||||||||||||||||||||||||
Db 1 AAAAAAGUUUCCACUUGACACUU 23

RESULT 272
ADY89289
ID ADY89289 standard; RNA; 23 BP.
XX
AC ADY89289;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2325.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2325; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 795 ACGCAUAAUCUGGGACAGUAGAA 817
||||||||||||||||||||||||
Db 1 ACGCAUAAUCUGGGACAGUAGAA 23

RESULT 273
ADY89293
ID ADY89293 standard; RNA; 23 BP.
XX
AC ADY89293;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2329.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2329; 396pp; English.

```
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 2 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1436 CUGAAGAGGAUGCAGGGAAUUAU 1458
              |||||||||||||||||||||||
Db          1 CUGAAGAGGAUGCAGGGAAUUAU 23


RESULT 274
ADY89303
ID   ADY89303 standard; RNA; 23 BP.
XX
AC   ADY89303;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2339.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2339; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 6 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2516 AUCUGGAGCUGAUCACUCUAACA 2538
              |||||||||||||||||||||||
Db          1 AUCUGGAGCUGAUCACUCUAACA 23


RESULT 275
ADY89307
ID   ADY89307 standard; RNA; 23 BP.
XX
AC   ADY89307;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2343.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2343; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 11 A; 4 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3072 GAAAGAAAAAAUGGAGCCAGGCC 3094
              |||||||||||||||||||||||
Db          1 GAAAGAAAAAAUGGAGCCAGGCC 23


RESULT 276
ADY89312
ID   ADY89312 standard; RNA; 23 BP.
XX
AC   ADY89312;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2348.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2348; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3251 CUUACAGUUUUCAAGUGGCCAGA 3273
              |||||||||||||||||||||||
Db          1 CUUACAGUUUUCAAGUGGCCAGA 23


RESULT 277
ADY89356
ID   ADY89356 standard; RNA; 23 BP.
XX
AC   ADY89356;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2392.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2392; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 4 A; 5 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2810 CGUGCCGGACUGUGGCUGUGAAA 2832
              |||||||||||||||||||||||
Db          1 CGUGCCGGACUGUGGCUGUGAAA 23


RESULT 278
ADY89172
ID   ADY89172 standard; RNA; 23 BP.
XX
AC   ADY89172;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2208.
```

```
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2208; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUGG 2709
             |||||||||||||||||||||||
Db          1 UCCCUUAUGAUGCCAGCAAGUGG 23


RESULT 279
ADY89180
ID   ADY89180 standard; RNA; 23 BP.
XX
AC   ADY89180;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2216.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2216; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
             |||||||||||||||||||||||
Db          1 CCUUAUGAUGCCAGCAAGUGGGA 23


RESULT 280
ADY89304
ID   ADY89304 standard; RNA; 23 BP.
XX
AC   ADY89304;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2340.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
```

```
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2340; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 10 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2701 AGCAAGUGGGAGUUUGCCCGGGA 2723
             |||||||||||||||||||||||
Db          1 AGCAAGUGGGAGUUUGCCCGGGA 23


RESULT 281
ADY89338
ID   ADY89338 standard; RNA; 23 BP.
XX
AC   ADY89338;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2374.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2374; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5706 AUCAAGUGGGCCUUGGAUCGCUA 5728
             |||||||||||||||||||||||
Db          1 AUCAAGUGGGCCUUGGAUCGCUA 23


RESULT 282
ADY89344
ID   ADY89344 standard; RNA; 23 BP.
XX
AC   ADY89344;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2380.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
```

```
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2380; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2391 CACGCUGUUUAUUGAAAGAGUCA 2413
              |||||||||||||||||||||||
Db          1 CACGCUGUUUAUUGAAAGAGUCA 23


RESULT 283
ADY89357
ID   ADY89357 standard; RNA; 23 BP.
XX
AC   ADY89357;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2393.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2393; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2858 GCGAGUACAAAGCUCUGAUGACU 2880
              |||||||||||||||||||||||
Db          1 GCGAGUACAAAGCUCUGAUGACU 23


RESULT 284
ADY89361
ID   ADY89361 standard; RNA; 23 BP.
XX
AC   ADY89361;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2397.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2397; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
```

```
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2950 CAAGGAGGGCCUCUGAUGGUGAU 2972
              |||||||||||||||||||||||
Db          1 CAAGGAGGGCCUCUGAUGGUGAU 23


RESULT 285
ADY89262
ID   ADY89262 standard; RNA; 23 BP.
XX
AC   ADY89262;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2298.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2298; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        346 GAACUGAGUUUAAAAGGCACCCA 368
              |||||||||||||||||||||||
Db          1 GAACUGAGUUUAAAAGGCACCCA 23


RESULT 286
ADY89267
ID   ADY89267 standard; RNA; 23 BP.
XX
AC   ADY89267;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2303.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2303; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 UCGUGUAAGGAGUGGACCAUCAU 1204
              |||||||||||||||||||||||
```

```
Db          1 UCGUGUAAGGAGUGGACCAUCAU 23


RESULT 287
ADY89279
ID   ADY89279 standard; RNA; 23 BP.
XX
AC   ADY89279;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2315.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2315; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        250 AUGGUCAGCUACUGGGACACCGG 272
              |||||||||||||||||||||||
Db          1 AUGGUCAGCUACUGGGACACCGG 23


RESULT 288
ADY89333
ID   ADY89333 standard; RNA; 23 BP.
XX
AC   ADY89333;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2369.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2369; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 4 A; 8 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5136 UCUCCAGGCCAUGAUGGCCUUAC 5158
              |||||||||||||||||||||||
Db          1 UCUCCAGGCCAUGAUGGCCUUAC 23


RESULT 289
ADY89339
ID   ADY89339 standard; RNA; 23 BP.
XX
AC   ADY89339;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2375.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
```

XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2375; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 16 A; 6 C; 0 G; 0 T; 1 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2336 AAAACAACCACAAAAUACAACAA 2358
||||||||||||||||||||||||
Db 1 AAAACAACCACAAAAUACAACAA 23

RESULT 290
ADY89253
ID ADY89253 standard; RNA; 23 BP.
XX
AC ADY89253;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2289.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2289; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 347 AACUGAGUUUAAAAGGCACCCAG 369
|||||||||||||||||||||||
Db 1 AACUGAGUUUAAAAGGCACCCAG 23

RESULT 291
ADY89256
ID ADY89256 standard; RNA; 23 BP.
XX
AC ADY89256;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2292.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.

```
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2292; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 15 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
             |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 292
ADY89260
ID   ADY89260 standard; RNA; 23 BP.
XX
AC   ADY89260;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2296.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2296; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        344 CUGAACUGAGUUUAAAAGGCACC 366
              |||||||||||||||||||||||
Db          1 CUGAACUGAGUUUAAAAGGCACC 23


RESULT 293
ADY89269
ID   ADY89269 standard; RNA; 23 BP.
XX
AC   ADY89269;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2305.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
```

DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2305; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 7 A; 4 C; 8 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4713 UAGCAGGCCUAAGACAUGUGAGG 4735
||||||||||||||||||||||||
Db 1 UAGCAGGCCUAAGACAUGUGAGG 23

RESULT 294
ADY89272
ID ADY89272 standard; RNA; 23 BP.
XX
AC ADY89272;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2308.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2308; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 5 A; 9 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1500 CCUCACUGCCACUCUAAUUGUCA 1522
||||||||||||||||||||||||
Db 1 CCUCACUGCCACUCUAAUUGUCA 23

RESULT 295
ADY89273
ID ADY89273 standard; RNA; 23 BP.
XX
AC ADY89273;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2309.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2309; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The

```
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 8 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGUCAA 1523
              |||||||||||||||||||||||
Db          1 CUCACUGCCACUCUAAUUGUCAA 23


RESULT 296
ADY89292
ID   ADY89292 standard; RNA; 23 BP.
XX
AC   ADY89292;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2328.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2328; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1218 CACCUCAGUGCAUAUAUAUGAUA 1240
              |||||||||||||||||||||||
Db          1 CACCUCAGUGCAUAUAUAUGAUA 23


RESULT 297
ADY89305
ID   ADY89305 standard; RNA; 23 BP.
XX
AC   ADY89305;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2341.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2341; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2793 CAUUAAGAAAUCACCUACGUGCC 2815
              |||||||||||||||||||||||
Db          1 CAUUAAGAAAUCACCUACGUGCC 23


RESULT 298
```

```
ADY89365
ID   ADY89365 standard; RNA; 23 BP.
XX
AC   ADY89365;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2401.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2401; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3261 UCAAGUGGCCAGAGGCAUGGAGU 3283
             |||||||||||||||||||||||
Db          1 UCAAGUGGCCAGAGGCAUGGAGU 23


RESULT 299
ADY89218
ID   ADY89218 standard; RNA; 23 BP.
XX
AC   ADY89218;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2254.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2254; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 10 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3737 AACAGGAUGGUAAAGACUACAUC 3759
             |||||||||||||||||||||||
Db          1 AACAGGAUGGUAAAGACUACAUC 23


RESULT 300
ADY89278
ID   ADY89278 standard; RNA; 23 BP.
XX
AC   ADY89278;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2314.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
```

PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2314; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 249 CAUGGUCAGCUACUGGGACACCG 271
||||||||||||||||||||||||
Db 1 CAUGGUCAGCUACUGGGACACCG 23

RESULT 301
ADY89302
ID ADY89302 standard; RNA; 23 BP.
XX
AC ADY89302;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2338.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2338; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 5 A; 6 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2512 UCUAAUCUGGAGCUGAUCACUCU 2534
|||||||||||||||||||||||
Db 1 UCUAAUCUGGAGCUGAUCACUCU 23

RESULT 302
ADY89309
ID ADY89309 standard; RNA; 23 BP.
XX
AC ADY89309;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2345.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.

PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2345; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 12 A; 5 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3099 ACAAGGCAAGAAACCAAGACUAG 3121
||||||||||||||||||||||
Db 1 ACAAGGCAAGAAACCAAGACUAG 23

RESULT 303
ADY89314
ID ADY89314 standard; RNA; 23 BP.
XX
AC ADY89314;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2350.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2350; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 5 A; 4 C; 8 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3258 UUUUCAAGUGGCCAGAGGCAUGG 3280
||||||||||||||||||||||
Db 1 UUUUCAAGUGGCCAGAGGCAUGG 23

RESULT 304
ADY89337
ID ADY89337 standard; RNA; 23 BP.
XX
AC ADY89337;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2373.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and

PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2373; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 4 A; 5 C; 8 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5705 GAUCAAGUGGGCCUUGGAUCGCU 5727
||||||||||||||||||||||||
Db 1 GAUCAAGUGGGCCUUGGAUCGCU 23

RESULT 305
ADY89343
ID ADY89343 standard; RNA; 23 BP.
XX
AC ADY89343;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2379.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2379; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 6 A; 4 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2390 GCACGCUGUUUAUUGAAAGAGUC 2412
||||||||||||||||||||||||
Db 1 GCACGCUGUUUAUUGAAAGAGUC 23

RESULT 306
ADY89364
ID ADY89364 standard; RNA; 23 BP.
XX
AC ADY89364;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2400.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2400; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3260 UUCAAGUGGCCAGAGGCAUGGAG 3282
              |||||||||||||||||||||||
Db          1 UUCAAGUGGCCAGAGGCAUGGAG 23


RESULT 307
ADY89277
ID   ADY89277 standard; RNA; 23 BP.
XX
AC   ADY89277;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2313.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2313; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 3 A; 6 C; 12 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        120 UGGCUGGAGCCGCGAGACGGGCG 142
              |||||||||||||||||||||||
Db          1 UGGCUGGAGCCGCGAGACGGGCG 23


RESULT 308
ADY89285
ID   ADY89285 standard; RNA; 23 BP.
XX
AC   ADY89285;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2321.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2321; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 2 A; 8 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        708 GCUCGUCAUUCCCUGCCGGGUUA 730
              |||||||||||||||||||||||
Db          1 GCUCGUCAUUCCCUGCCGGGUUA 23


RESULT 309
ADY89335
ID   ADY89335 standard; RNA; 23 BP.
XX
```

```
AC   ADY89335;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2371.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2371; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 10 C; 1 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5354 ACCCCGUCUCUAUACCAACCAAA 5376
             |||||||||||||||||||||||
Db          1 ACCCCGUCUCUAUACCAACCAAA 23


RESULT 310
ADY89342
ID   ADY89342 standard; RNA; 23 BP.
XX
AC   ADY89342;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2378.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2378; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2389 AGCACGCUGUUUAUUGAAAGAGU 2411
             |||||||||||||||||||||||
Db          1 AGCACGCUGUUUAUUGAAAGAGU 23


RESULT 311
ADY89349
ID   ADY89349 standard; RNA; 23 BP.
XX
AC   ADY89349;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2385.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
```

```
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2385; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 2 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2396 UGUUUAUUGAAAGAGUCACAGAA 2418
             |||||||||||||||||||||||
Db          1 UGUUUAUUGAAAGAGUCACAGAA 23


RESULT 312
ADY89350
ID   ADY89350 standard; RNA; 23 BP.
XX
AC   ADY89350;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2386.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2386; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2695 GAUGCCAGCAAGUGGGAGUUUGC 2717
             |||||||||||||||||||||||
Db          1 GAUGCCAGCAAGUGGGAGUUUGC 23


RESULT 313
ADY89366
ID   ADY89366 standard; RNA; 23 BP.
XX
AC   ADY89366;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2402.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
```

```
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2402; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3264 AGUGGCCAGAGGCAUGGAGUUCC 3286
             |||||||||||||||||||||||
Db          1 AGUGGCCAGAGGCAUGGAGUUCC 23


RESULT 314
ADY89165
ID   ADY89165 standard; RNA; 23 BP.
XX
AC   ADY89165;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2201.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2201; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3645 CAUGCUGGACUGCUGGCACAGAG 3667
             |||||||||||||||||||||||
Db          1 CAUGCUGGACUGCUGGCACAGAG 23


RESULT 315
ADY89212
ID   ADY89212 standard; RNA; 23 BP.
XX
AC   ADY89212;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2248.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
```

PT cancers.
XX
PS Disclosure; SEQ ID NO 2248; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3642 GAUCAUGCUGGACUGCUGGCACA 3664
||||||||||||||||||||||||
Db 1 GAUCAUGCUGGACUGCUGGCACA 23

RESULT 316
ADY89251
ID ADY89251 standard; RNA; 23 BP.
XX
AC ADY89251;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2287.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2287; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 8 A; 4 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1955 AAGGAGAGGACCUGAAACUGUCU 1977
|||||||||||||||||||||||
Db 1 AAGGAGAGGACCUGAAACUGUCU 23

RESULT 317
ADY89288
ID ADY89288 standard; RNA; 23 BP.
XX
AC ADY89288;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2324.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2324; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;

```
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        794 AACGCAUAAUCUGGGACAGUAGA 816
              |||||||||||||||||||||||
Db          1 AACGCAUAAUCUGGGACAGUAGA 23


RESULT 318
ADY89298
ID   ADY89298 standard; RNA; 23 BP.
XX
AC   ADY89298;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2334.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2334; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2245 AACCUCAGUGAUCACACAGUGGC 2267
              |||||||||||||||||||||||
Db          1 AACCUCAGUGAUCACACAGUGGC 23


RESULT 319
ADY89318
ID   ADY89318 standard; RNA; 23 BP.
XX
AC   ADY89318;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2354.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2354; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3322 GCGAGAAACAUUCUUUUAUCUGA 3344
              |||||||||||||||||||||||
Db          1 GCGAGAAACAUUCUUUUAUCUGA 23


RESULT 320
ADY89323
ID   ADY89323 standard; RNA; 23 BP.
XX
AC   ADY89323;
XX
```

```
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2359.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2359; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3863 CAGGAAGCUCUGAUGAUGUCAGA 3885
             |||||||||||||||||||||||
Db          1 CAGGAAGCUCUGAUGAUGUCAGA 23


RESULT 321
ADY89334
ID   ADY89334 standard; RNA; 23 BP.
XX
AC   ADY89334;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2370.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2370; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5352 AGACCCCGUCUCUAUACCAACCA 5374
             |||||||||||||||||||||||
Db          1 AGACCCCGUCUCUAUACCAACCA 23


RESULT 322
ADY89347
ID   ADY89347 standard; RNA; 23 BP.
XX
AC   ADY89347;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2383.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
```

PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2383; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2394 GCUGUUUAUUGAAAGAGUCACAG 2416
||||||||||||||||||||||||
Db 1 GCUGUUUAUUGAAAGAGUCACAG 23

RESULT 323
ADY89206
ID ADY89206 standard; RNA; 23 BP.
XX
AC ADY89206;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2242.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2242; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3641 AGAUCAUGCUGGACUGCUGGCAC 3663
||||||||||||||||||||||||
Db 1 AGAUCAUGCUGGACUGCUGGCAC 23

RESULT 324
ADY89283
ID ADY89283 standard; RNA; 23 BP.
XX
AC ADY89283;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2319.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.

PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2319; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 13 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 593 CAAAGAAGAAGGAAACAGAAUCU 615
||||||||||||||||||||||
Db 1 CAAAGAAGAAGGAAACAGAAUCU 23

RESULT 325
ADY89284
ID ADY89284 standard; RNA; 23 BP.
XX
AC ADY89284;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2320.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2320; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 2 A; 8 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 707 AGCUCGUCAUUCCCUGCCGGGUU 729
||||||||||||||||||||||
Db 1 AGCUCGUCAUUCCCUGCCGGGUU 23

RESULT 326
ADY89299
ID ADY89299 standard; RNA; 23 BP.
XX
AC ADY89299;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2335.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2335; 396pp; English.

```
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 8 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2246 ACCUCAGUGAUCACACAGUGGCC 2268
              |||||||||||||||||||||||
Db          1 ACCUCAGUGAUCACACAGUGGCC 23


RESULT 327
ADY89313
ID   ADY89313 standard; RNA; 23 BP.
XX
AC   ADY89313;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2349.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2349; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3252 UUACAGUUUUCAAGUGGCCAGAG 3274
              |||||||||||||||||||||||
Db          1 UUACAGUUUUCAAGUGGCCAGAG 23


RESULT 328
ADY89322
ID   ADY89322 standard; RNA; 23 BP.
XX
AC   ADY89322;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2358.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2358; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3862 UCAGGAAGCUCUGAUGAUGUCAG 3884
              |||||||||||||||||||||||
Db          1 UCAGGAAGCUCUGAUGAUGUCAG 23


RESULT 329
ADY89328
ID   ADY89328 standard; RNA; 23 BP.
XX
AC   ADY89328;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2364.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2364; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 7 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4152 CGAAGGCAAGCGCAGGUUCACCU 4174
              |||||||||||||||||||||||
Db          1 CGAAGGCAAGCGCAGGUUCACCU 23


RESULT 330
ADY89159
ID   ADY89159 standard; RNA; 23 BP.
XX
AC   ADY89159;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2195.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2195; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3644 UCAUGCUGGACUGCUGGCACAGA 3666
              |||||||||||||||||||||||
Db          1 UCAUGCUGGACUGCUGGCACAGA 23


RESULT 331
ADY89255
ID   ADY89255 standard; RNA; 23 BP.
XX
AC   ADY89255;
XX
DT   16-JUN-2005  (first entry)
XX
```

DE VEGFR siRNA target sequence SEQ ID NO 2291.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2291; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 10 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3910 AGCCUGGAAAGAAUCAAAACCUU 3932
              |||||||||||||||||||||||
Db          1 AGCCUGGAAAGAAUCAAAACCUU 23
```

RESULT 332
ADY89294
ID ADY89294 standard; RNA; 23 BP.
XX
AC ADY89294;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2330.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2330; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 6 A; 5 C; 6 G; 0 T; 6 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1539 UUACGAAAAGGCCGUGUCAUCGU 1561
              |||||||||||||||||||||||
Db          1 UUACGAAAAGGCCGUGUCAUCGU 23
```

RESULT 333
ADY89330
ID ADY89330 standard; RNA; 23 BP.
XX
AC ADY89330;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2366.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.

```
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2366; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 12 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4943 GAGGCAAGAAAAGGACAAAUAUC 4965
             |||||||||||||||||||||||
Db          1 GAGGCAAGAAAAGGACAAAUAUC 23


RESULT 334
ADY89331
ID   ADY89331 standard; RNA; 23 BP.
XX
AC   ADY89331;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2367.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2367; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5088 UUGGCUCCUCUAGUAAGAUGCAC 5110
              |||||||||||||||||||||||
Db          1 UUGGCUCCUCUAGUAAGAUGCAC 23


RESULT 335
ADY89346
ID   ADY89346 standard; RNA; 23 BP.
XX
AC   ADY89346;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2382.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
```

XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2382; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2393 CGCUGUUUAUUGAAAGAGUCACA 2415
||||||||||||||||||||||||
Db 1 CGCUGUUUAUUGAAAGAGUCACA 23

RESULT 336
ADY89352
ID ADY89352 standard; RNA; 23 BP.
XX
AC ADY89352;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2388.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2388; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 9 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2783 CAGCAUUUGGCAUUAAGAAAUCA 2805
|||||||||||||||||||||||
Db 1 CAGCAUUUGGCAUUAAGAAAUCA 23

RESULT 337
ADY89367
ID ADY89367 standard; RNA; 23 BP.
XX
AC ADY89367;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA target sequence SEQ ID NO 2403.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2403; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first

```
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 10 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3909 GAGCCUGGAAAGAAUCAAAACCU 3931
              |||||||||||||||||||||||
Db          1 GAGCCUGGAAAGAAUCAAAACCU 23


RESULT 338
ADY89176
ID   ADY89176 standard; RNA; 23 BP.
XX
AC   ADY89176;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2212.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2212; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2688 CCCUUAUGAUGCCAGCAAGUGGG 2710
              |||||||||||||||||||||||
Db          1 CCCUUAUGAUGCCAGCAAGUGGG 23


RESULT 339
ADY89266
ID   ADY89266 standard; RNA; 23 BP.
XX
AC   ADY89266;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2302.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2302; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 GAGUUUAAAAGGCACCCAGCACA 373
              |||||||||||||||||||||||
```

```
Db          1 GAGUUUAAAAGGCACCCAGCACA 23


RESULT 340
ADY89275
ID   ADY89275 standard; RNA; 23 BP.
XX
AC   ADY89275;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2311.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2311; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 1 A; 6 C; 13 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         45 GAGCGGGCUCCGGGGCUCGGGUG 67
              |||||||||||||||||||||||
Db          1 GAGCGGGCUCCGGGGCUCGGGUG 23


RESULT 341
ADY89280
ID   ADY89280 standard; RNA; 23 BP.
XX
AC   ADY89280;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2316.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2316; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAU 374
              |||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAU 23


RESULT 342
ADY89281
ID   ADY89281 standard; RNA; 23 BP.
XX
AC   ADY89281;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2317.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
```

```
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2317; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 6 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 AGCAGCCCAUAAAUGGUCUUUGC 439
              |||||||||||||||||||||||
Db          1 AGCAGCCCAUAAAUGGUCUUUGC 23


RESULT 343
ADY89282
ID   ADY89282 standard; RNA; 23 BP.
XX
AC   ADY89282;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2318.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2318; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 13 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        592 UCAAAGAAGAAGGAAACAGAAUC 614
              |||||||||||||||||||||||
Db          1 UCAAAGAAGAAGGAAACAGAAUC 23


RESULT 344
ADY89311
ID   ADY89311 standard; RNA; 23 BP.
XX
AC   ADY89311;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2347.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
```

```
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2347; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 0 C; 11 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3181 AGUGAUGUUGAGGAAGAGGAGGA 3203
             |||||||||||||||||||||||
Db          1 AGUGAUGUUGAGGAAGAGGAGGA 23


RESULT 345
ADY89316
ID   ADY89316 standard; RNA; 23 BP.
XX
AC   ADY89316;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2352.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2352; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3292 UCCAGAAAGUGCAUUCAUCGGGA 3314
             |||||||||||||||||||||||
Db          1 UCCAGAAAGUGCAUUCAUCGGGA 23


RESULT 346
ADY89317
ID   ADY89317 standard; RNA; 23 BP.
XX
AC   ADY89317;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2353.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
```

DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2353; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3321 AGCGAGAAACAUUCUUUUAUCUG 3343
||||||||||||||||||||||||
Db 1 AGCGAGAAACAUUCUUUUAUCUG 23

RESULT 347
ADY89196
ID ADY89196 standard; RNA; 23 BP.
XX
AC ADY89196;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2232.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2232; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 4 A; 6 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3639 UCAGAUCAUGCUGGACUGCUGGC 3661
||||||||||||||||||||||||
Db 1 UCAGAUCAUGCUGGACUGCUGGC 23

RESULT 348
ADY89222
ID ADY89222 standard; RNA; 23 BP.
XX
AC ADY89222;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2258.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2258; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The

```
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3738 ACAGGAUGGUAAAGACUACAUCC 3760
              |||||||||||||||||||||||
Db          1 ACAGGAUGGUAAAGACUACAUCC 23


RESULT 349
ADY89263
ID   ADY89263 standard; RNA; 23 BP.
XX
AC   ADY89263;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2299.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2299; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        348 ACUGAGUUUAAAAGGCACCCAGC 370
              |||||||||||||||||||||||
Db          1 ACUGAGUUUAAAAGGCACCCAGC 23


RESULT 350
ADY89268
ID   ADY89268 standard; RNA; 23 BP.
XX
AC   ADY89268;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2304.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2304; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 6 A; 2 C; 8 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3501 UUACGGAGUAUUGCUGUGGGAAA 3523
              |||||||||||||||||||||||
Db          1 UUACGGAGUAUUGCUGUGGGAAA 23
```

```
RESULT 351
ADY89276
ID   ADY89276 standard; RNA; 23 BP.
XX
AC   ADY89276;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2312.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2312; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 3 A; 7 C; 11 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        119 CUGGCUGGAGCCGCGAGACGGGC 141
              |||||||||||||||||||||||
Db          1 CUGGCUGGAGCCGCGAGACGGGC 23


RESULT 352
ADY89287
ID   ADY89287 standard; RNA; 23 BP.
XX
AC   ADY89287;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2323.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2323; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        757 AAAAAGUUUCCACUUGACACUUU 779
              |||||||||||||||||||||||
Db          1 AAAAAGUUUCCACUUGACACUUU 23


RESULT 353
ADY89290
ID   ADY89290 standard; RNA; 23 BP.
XX
AC   ADY89290;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2326.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
```

```
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2326; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        796 CGCAUAAUCUGGGACAGUAGAAA 818
              |||||||||||||||||||||||
Db          1 CGCAUAAUCUGGGACAGUAGAAA 23


RESULT 354
ADY89297
ID   ADY89297 standard; RNA; 23 BP.
XX
AC   ADY89297;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2333.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2333; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 9 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1875 GACUGUGGGAAGAAACAUAAGCU 1897
              |||||||||||||||||||||||
Db          1 GACUGUGGGAAGAAACAUAAGCU 23


RESULT 355
ADY89319
ID   ADY89319 standard; RNA; 23 BP.
XX
AC   ADY89319;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2355.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
```

```
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2355; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3323 CGAGAAACAUUCUUUUAUCUGAG 3345
              |||||||||||||||||||||||
Db          1 CGAGAAACAUUCUUUUAUCUGAG 23


RESULT 356
ADY89321
ID   ADY89321 standard; RNA; 23 BP.
XX
AC   ADY89321;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2357.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2357; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 3 A; 7 C; 4 G; 0 T; 9 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3810 UGCCUUCUCUGAGGACUUCUUCA 3832
              |||||||||||||||||||||||
Db          1 UGCCUUCUCUGAGGACUUCUUCA 23


RESULT 357
ADY89327
ID   ADY89327 standard; RNA; 23 BP.
XX
AC   ADY89327;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2363.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
```

```
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2363; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 9 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4134 CAGCUGUGGGCACGUCAGCGAAG 4156
              |||||||||||||||||||||||
Db          1 CAGCUGUGGGCACGUCAGCGAAG 23


RESULT 358
ADY89351
ID   ADY89351 standard; RNA; 23 BP.
XX
AC   ADY89351;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2387.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2387; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 23 BP; 4 A; 6 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2697 UGCCAGCAAGUGGGAGUUUGCCC 2719
              |||||||||||||||||||||||
Db          1 UGCCAGCAAGUGGGAGUUUGCCC 23


RESULT 359
ADY89360
ID   ADY89360 standard; RNA; 23 BP.
XX
AC   ADY89360;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2396.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2396; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
```

```
SQ   Sequence 23 BP; 5 A; 4 C; 10 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2948 AGCAAGGAGGGCCUCUGAUGGUG 2970
              |||||||||||||||||||||||
Db          1 AGCAAGGAGGGCCUCUGAUGGUG 23


RESULT 360
ADY80935/c
ID   ADY80935 standard; DNA; 23 BP.
XX
AC   ADY80935;
XX
DT   16-JUN-2005  (first entry)
XX
DE   Human VEGFR1 reverse PCR primer SEQ ID NO:14.
XX
KW   bone marrow; ovary tumor; antiangiogenic; cytostatic; PCR; primer; ss;
KW   vascular endothelial growth factor receptor.
XX
OS   Homo sapiens.
XX
PN   US2005069528-A1.
XX
PD   31-MAR-2005.
XX
PF   20-AUG-2004; 2004US-00922154.
XX
PR   21-AUG-2003; 2003US-0496676P.
XX
PA   (GENZ ) GENZYME CORP.
XX
PI   Teicher B;
XX
DR   WPI; 2005-252938/26.
XX
PT   New isolated population of adherent human endothelial precursor cells
PT   (EPCs) made by stimulating human bone marrow cells expressing endothelial
PT   lineage markers, useful in evaluating anti-angiogenic and pro-angiogenic
PT   agents.
XX
PS   Example 1; SEQ ID NO 14; 33pp; English.
XX
CC   The invention relates to an isolated population of adherent human
CC   endothelial precursor cells (EPCs) made by stimulating human bone marrow
CC   cells expressing endothelial lineage markers AC133 and CD34 with VEGF,
CC   bFGF and heparin, and capable of invading human ovarian cancer cell
CC   clusters in a three dimensional in vitro assay. Also described: (1) a
CC   method of evaluating test agents as pro-angiogenic or anti-angiogenic
CC   factors, comprising contacting an isolated population of adherent human
CC   EPCs as described above with a test agent, evaluating tubule formation,
CC   or invasion by the isolated population contacted with the test agent
CC   relative to an isolated population not contacted with a test agent, and
CC   identifying the test agent as having potential use as a pro-angiogenic
CC   factor if it increases tubule formation, migration or invasion, and
CC   identifying the test agent as having potential use as an anti-angiogenic
CC   factor it decreases tubule formation, migration or invasion; (2) a method
CC   of stimulating AC133+/CD34+ human bone marrow cells, comprising culturing
CC   the cells on a collagen- and/or fibronectin-coated surface in the
CC   presence of FBS, VEGF and heparin; (3) a model system for human
CC   vasculature, comprising a nude mouse which has been co-injected with
CC   reconstituted basement membrane matrix and the isolated population of
CC   adherent human EPCs as cited above, or comprising a sample of Matrigel
CC   and aEPCs which has been removed from the nude mouse; (4) a method of
CC   identifying a mouse cell line useful as a model for tumor endothelial
CC   cells, comprising determining expression of two or more murine tumor
CC   endothelial markers in one or more mouse cell lines, selecting a mouse
CC   cell line which expressed at least two of the markers more than it
CC   expressed 18S RNA; and (5) a method of evaluating test agents as pro-
CC   angiogenic or anti-angiogenic factors, comprising contacting a mouse cell
CC   line selected by the method of (4) with a test agent, evaluating tubule
CC   formation, migration or invasion by the mouse cell line contacted with
CC   the test agent relative to the mouse cell line not contacted with a test
CC   agent, and identifying the test agent as having potential use as a pro-
CC   angiogenic factor if it increases tubule formation, migration or
CC   invasion, and identifying the test agent as having potential use an anti-
CC   angiogenic factor if it decreases tubule formation, migration or
CC   invasion. Antiangiogenic; Cytostatic. The methods and compositions of the
CC   present invention are useful for manufacturing model systems of tumor
CC   endothelial cells to evaluate potential anti-angiogenic and pro-
CC   angiogenic agents. The present sequence represents a PCR primer for human
CC   VEGFR1, which is used in an example from the present invention for murine
CC   cell line evaluation.
XX
SQ   Sequence 23 BP; 3 A; 4 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 1.7e+03;
  Matches   20;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3005 ACUACCUCAAGAGCAAACGUGAC 3027
              ||:|||:|||||||||||||:|||
Db         23 ACTACCTCAAGAGCAAACGTGAC 1


RESULT 361
AED38441
ID   AED38441 standard; RNA; 23 BP.
XX
AC   AED38441;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2242.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
```

PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2242; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3641 AGAUCAUGCUGGACUGCUGGCAC 3663
||||||||||||||||||||||||
Db 1 AGAUCAUGCUGGACUGCUGGCAC 23

RESULT 362
AED38485
ID AED38485 standard; RNA; 23 BP.
XX
AC AED38485;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2286.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2286; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 8 A; 4 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1954 GAAGGAGAGGACCUGAAACUGUC 1976
|||||||||||||||||||||||
Db 1 GAAGGAGAGGACCUGAAACUGUC 23

RESULT 363
AED38526
ID AED38526 standard; RNA; 23 BP.
XX
AC AED38526;
XX
DT 15-DEC-2005 (first entry)

```
XX
DE   VEGFR target region for siRNA - SEQ ID 2327.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2327; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        797 GCAUAAUCUGGGACAGUAGAAAG 819
              |||||||||||||||||||||||
Db          1 GCAUAAUCUGGGACAGUAGAAAG 23


RESULT 364
AED38553
ID   AED38553 standard; RNA; 23 BP.
XX
AC   AED38553;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2354.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
```

```
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2354; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3322 GCGAGAAACAUUCUUUUAUCUGA 3344
              |||||||||||||||||||||||
Db          1 GCGAGAAACAUUCUUUUAUCUGA 23


RESULT 365
AED38575
ID   AED38575 standard; RNA; 23 BP.
XX
AC   AED38575;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2376.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2376; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 13 A; 7 C; 2 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAAGAGC 2362
              |||||||||||||||||||||||
Db          1 CAACCACAAAAUACAACAAGAGC 23


RESULT 366
AED38577
ID   AED38577 standard; RNA; 23 BP.
XX
AC   AED38577;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2378.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
```

```
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2378; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2389 AGCACGCUGUUUAUUGAAAGAGU 2411
              |||||||||||||||||||||||
Db          1 AGCACGCUGUUUAUUGAAAGAGU 23


RESULT 367
AED38394
ID   AED38394 standard; RNA; 23 BP.
XX
AC   AED38394;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2195.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2195; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
```

```
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3644 UCAUGCUGGACUGCUGGCACAGA 3666
              |||||||||||||||||||||||
Db          1 UCAUGCUGGACUGCUGGCACAGA 23


RESULT 368
AED38411
ID   AED38411 standard; RNA; 23 BP.
XX
AC   AED38411;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2212.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2212; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2688 CCCUUAUGAUGCCAGCAAGUGGG 2710
              |||||||||||||||||||||||
Db          1 CCCUUAUGAUGCCAGCAAGUGGG 23


RESULT 369
AED38517
ID   AED38517 standard; RNA; 23 BP.
XX
AC   AED38517;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2318.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
```

```
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2318; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 13 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        592 UCAAAGAAGAAGGAAACAGAAUC 614
              |||||||||||||||||||||||
Db          1 UCAAAGAAGAAGGAAACAGAAUC 23


RESULT 370
AED38539
ID   AED38539 standard; RNA; 23 BP.
XX
AC   AED38539;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2340.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2340; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 10 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2701 AGCAAGUGGGAGUUUGCCCGGGA 2723
              |||||||||||||||||||||||
```

```
Db          1 AGCAAGUGGGAGUUUGCCCGGGA 23

RESULT 371
AED38564
ID   AED38564 standard; RNA; 23 BP.
XX
AC   AED38564;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2365.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2365; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 9 C; 5 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4633 UGCAGCCCAAAACCCAGGGCAAC 4655
              |||||||||||||||||||||||
Db          1 UGCAGCCCAAAACCCAGGGCAAC 23


RESULT 372
AED38586
ID   AED38586 standard; RNA; 23 BP.
XX
AC   AED38586;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2387.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
```

```
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2387; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 4 A; 6 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2697 UGCCAGCAAGUGGGAGUUUGCCC 2719
             |||||||||||||||||||||||
Db          1 UGCCAGCAAGUGGGAGUUUGCCC 23


RESULT 373
AED38599
ID   AED38599 standard; RNA; 23 BP.
XX
AC   AED38599;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2400.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2400; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3260 UUCAAGUGGCCAGAGGCAUGGAG 3282
             |||||||||||||||||||||||
Db          1 UUCAAGUGGCCAGAGGCAUGGAG 23


RESULT 374
AED38600
ID   AED38600 standard; RNA; 23 BP.
XX
AC   AED38600;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2401.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
```

```
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2401; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match           0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3261 UCAAGUGGCCAGAGGCAUGGAGU 3283
             |||||||||||||||||||||||
Db          1 UCAAGUGGCCAGAGGCAUGGAGU 23


RESULT 375
AED38601
ID   AED38601 standard; RNA; 23 BP.
XX
AC   AED38601;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2402.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
```

```
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2402; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3264 AGUGGCCAGAGGCAUGGAGUUCC 3286
             |||||||||||||||||||||||
Db          1 AGUGGCCAGAGGCAUGGAGUUCC 23


RESULT 376
AED38486
ID   AED38486 standard; RNA; 23 BP.
XX
AC   AED38486;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2287.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2287; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 4 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGUCU 1977
             |||||||||||||||||||||||
Db          1 AAGGAGAGGACCUGAAACUGUCU 23


RESULT 377
AED38520
ID   AED38520 standard; RNA; 23 BP.
XX
AC   AED38520;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2321.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
```

PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2321; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 2 A; 8 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 708 GCUCGUCAUUCCCUGCCGGGUUA 730
||||||||||||||||||||||||
Db 1 GCUCGUCAUUCCCUGCCGGGUUA 23

RESULT 378
AED38530
ID AED38530 standard; RNA; 23 BP.
XX
AC AED38530;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2331.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2331; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 7 C; 5 G; 0 T; 6 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 AAUCAAGUGGUUCUGGCACCCCU 1660
              |||||||||||||||||||||||
Db          1 AAUCAAGUGGUUCUGGCACCCCU 23


RESULT 379
AED38546
ID   AED38546 standard; RNA; 23 BP.
XX
AC   AED38546;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2347.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2347; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 0 C; 11 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3181 AGUGAUGUUGAGGAAGAGGAGGA 3203
              |||||||||||||||||||||||
Db          1 AGUGAUGUUGAGGAAGAGGAGGA 23


RESULT 380
AED38552
ID   AED38552 standard; RNA; 23 BP.
XX
AC   AED38552;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2353.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
```

PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2353; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3321 AGCGAGAAACAUUCUUUUAUCUG 3343
||||||||||||||||||||||||
Db 1 AGCGAGAAACAUUCUUUUAUCUG 23

RESULT 381
AED38559
ID AED38559 standard; RNA; 23 BP.
XX
AC AED38559;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2360.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2360; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 8 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3899 UCAAGUUCAUGAGCCUGGAAAGA 3921
||||||||||||||||||||||||
Db 1 UCAAGUUCAUGAGCCUGGAAAGA 23

RESULT 382
AED38570
ID AED38570 standard; RNA; 23 BP.
XX
AC AED38570;
XX
DT 15-DEC-2005 (first entry)

```
XX
DE   VEGFR target region for siRNA - SEQ ID 2371.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2371; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 10 C; 1 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5354 ACCCCGUCUCUAUACCAACCAAA 5376
              |||||||||||||||||||||||
Db          1 ACCCCGUCUCUAUACCAACCAAA 23


RESULT 383
AED38582
ID   AED38582 standard; RNA; 23 BP.
XX
AC   AED38582;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2383.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
```

```
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2383; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2394 GCUGUUUAUUGAAAGAGUCACAG 2416
              |||||||||||||||||||||||
Db          1 GCUGUUUAUUGAAAGAGUCACAG 23


RESULT 384
AED38588
ID   AED38588 standard; RNA; 23 BP.
XX
AC   AED38588;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2389.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2389; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2784 AGCAUUUGGCAUUAAGAAAUCAC 2806
              |||||||||||||||||||||||
Db          1 AGCAUUUGGCAUUAAGAAAUCAC 23


RESULT 385
AED38591
ID   AED38591 standard; RNA; 23 BP.
XX
AC   AED38591;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2392.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
```

```
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2392; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 4 A; 5 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2810 CGUGCCGGACUGUGGCUGUGAAA 2832
                ||||||||||||||||||||||
Db          1 CGUGCCGGACUGUGGCUGUGAAA 23


RESULT 386
AED38602
ID   AED38602 standard; RNA; 23 BP.
XX
AC   AED38602;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2403.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2403; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
```

```
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 10 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3909 GAGCCUGGAAAGAAUCAAAACCU 3931
              |||||||||||||||||||||||
Db          1 GAGCCUGGAAAGAAUCAAAACCU 23


RESULT 387
AED38907
ID   AED38907 standard; RNA; 23 BP.
XX
AC   AED38907;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2708.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2708; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 10 A; 3 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1227 GCAUAUAUAUGAUAAAGCAUUCA 1249
              |||||||||||||||||||||||
Db          1 GCAUAUAUAUGAUAAAGCAUUCA 23


RESULT 388
AED38436
ID   AED38436 standard; RNA; 23 BP.
XX
AC   AED38436;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2237.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
```

```
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2237; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||||||||||||||||||||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 389
AED38496
ID   AED38496 standard; RNA; 23 BP.
XX
AC   AED38496;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2297.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2297; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        345 UGAACUGAGUUUAAAAGGCACCC 367
              |||||||||||||||||||||||
Db          1 UGAACUGAGUUUAAAAGGCACCC 23
```

```
RESULT 390
AED38504
ID   AED38504 standard; RNA; 23 BP.
XX
AC   AED38504;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2305.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2305; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4713 UAGCAGGCCUAAGACAUGUGAGG 4735
             |||||||||||||||||||||||
Db          1 UAGCAGGCCUAAGACAUGUGAGG 23


RESULT 391
AED38521
ID   AED38521 standard; RNA; 23 BP.
XX
AC   AED38521;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2322.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
```

PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2322; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 5 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 756 AAAAAAGUUUCCACUUGACACUU 778
||||||||||||||||||||||||
Db 1 AAAAAAGUUUCCACUUGACACUU 23

RESULT 392
AED38535
ID AED38535 standard; RNA; 23 BP.
XX
AC AED38535;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2336.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2336; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2358 AGAGCCUGGAAUUAUUUUAGGAC 2380
||||||||||||||||||||||||
Db 1 AGAGCCUGGAAUUAUUUUAGGAC 23

RESULT 393
AED38537
ID AED38537 standard; RNA; 23 BP.
XX
AC AED38537;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2338.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX

OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2338; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2512 UCUAAUCUGGAGCUGAUCACUCU 2534
|||||||||||||||||||||||
Db 1 UCUAAUCUGGAGCUGAUCACUCU 23

RESULT 394
AED38550
ID AED38550 standard; RNA; 23 BP.
XX
AC AED38550;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2351.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula

PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2351; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3259 UUUCAAGUGGCCAGAGGCAUGGA 3281
||||||||||||||||||||||||
Db 1 UUUCAAGUGGCCAGAGGCAUGGA 23

RESULT 395
AED38572
ID AED38572 standard; RNA; 23 BP.
XX
AC AED38572;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2373.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2373; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 4 A; 5 C; 8 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5705 GAUCAAGUGGGCCUUGGAUCGCU 5727
||||||||||||||||||||||||
Db 1 GAUCAAGUGGGCCUUGGAUCGCU 23

RESULT 396
AED38580
ID AED38580 standard; RNA; 23 BP.
XX
AC AED38580;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2381.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2381; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2392 ACGCUGUUUAUUGAAAGAGUCAC 2414
||||||||||||||||||||||||
Db 1 ACGCUGUUUAUUGAAAGAGUCAC 23

RESULT 397
AED38595
ID AED38595 standard; RNA; 23 BP.
XX
AC AED38595;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2396.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2396; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 4 C; 10 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;

```
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2948 AGCAAGGAGGGCCUCUGAUGGUG 2970
              |||||||||||||||||||||||
Db          1 AGCAAGGAGGGCCUCUGAUGGUG 23


RESULT 398
AED38498
ID   AED38498 standard; RNA; 23 BP.
XX
AC   AED38498;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2299.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2299; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        348 ACUGAGUUUAAAAGGCACCCAGC 370
              |||||||||||||||||||||||
Db          1 ACUGAGUUUAAAAGGCACCCAGC 23


RESULT 399
AED38502
ID   AED38502 standard; RNA; 23 BP.
XX
AC   AED38502;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2303.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
```

PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2303; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1182 UCGUGUAAGGAGUGGACCAUCAU 1204
||||||||||||||||||||||||
Db 1 UCGUGUAAGGAGUGGACCAUCAU 23

RESULT 400
AED38519
ID AED38519 standard; RNA; 23 BP.
XX
AC AED38519;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2320.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2320; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 2 A; 8 C; 6 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 707 AGCUCGUCAUUCCCUGCCGGGUU 729
||||||||||||||||||||||||
Db 1 AGCUCGUCAUUCCCUGCCGGGUU 23

RESULT 401
AED38529
ID AED38529 standard; RNA; 23 BP.
XX
AC AED38529;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2330.

```
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2330; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1539 UUACGAAAAGGCCGUGUCAUCGU 1561
              |||||||||||||||||||||||
Db          1 UUACGAAAAGGCCGUGUCAUCGU 23


RESULT 402
AED38531
ID   AED38531 standard; RNA; 23 BP.
XX
AC   AED38531;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2332.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
```

```
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2332; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1664 ACCAUAAUCAUUCCGAAGCAAGG 1686
             |||||||||||||||||||||||
Db          1 ACCAUAAUCAUUCCGAAGCAAGG 23


RESULT 403
AED38579
ID   AED38579 standard; RNA; 23 BP.
XX
AC   AED38579;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2380.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2380; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2391 CACGCUGUUUAUUGAAAGAGUCA 2413
             |||||||||||||||||||||||
Db          1 CACGCUGUUUAUUGAAAGAGUCA 23


RESULT 404
AED38589
ID   AED38589 standard; RNA; 23 BP.
XX
AC   AED38589;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2390.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
```

```
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2390; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2786 CAUUUGGCAUUAAGAAAUCACCU 2808
              |||||||||||||||||||||||
Db          1 CAUUUGGCAUUAAGAAAUCACCU 23


RESULT 405
AED38501
ID   AED38501 standard; RNA; 23 BP.
XX
AC   AED38501;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2302.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2302; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
```

CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 351 GAGUUUAAAAGGCACCCAGCACA 373
||||||||||||||||||||||
Db 1 GAGUUUAAAAGGCACCCAGCACA 23

RESULT 406
AED38510
ID AED38510 standard; RNA; 23 BP.
XX
AC AED38510;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2311.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2311; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 1 A; 6 C; 13 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 45 GAGCGGGCUCCGGGGCUCGGGUG 67
|||||||||||||||||||||||
Db 1 GAGCGGGCUCCGGGGCUCGGGUG 23

RESULT 407
AED38515
ID AED38515 standard; RNA; 23 BP.
XX
AC AED38515;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2316.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.

```
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2316; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCACAU 374
              |||||||||||||||||||||||
Db          1 AGUUUAAAAGGCACCCAGCACAU 23


RESULT 408
AED38528
ID   AED38528 standard; RNA; 23 BP.
XX
AC   AED38528;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2329.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2329; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 2 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1436 CUGAAGAGGAUGCAGGGAAUUAU 1458
              |||||||||||||||||||||||
Db          1 CUGAAGAGGAUGCAGGGAAUUAU 23


RESULT 409
AED38558
ID   AED38558 standard; RNA; 23 BP.
```

XX
AC AED38558;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2359.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2359; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 4 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3863 CAGGAAGCUCUGAUGAUGUCAGA 3885
||||||||||||||||||||||
Db 1 CAGGAAGCUCUGAUGAUGUCAGA 23

RESULT 410
AED38592
ID AED38592 standard; RNA; 23 BP.
XX
AC AED38592;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2393.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.

```
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2393; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2858 GCGAGUACAAAGCUCUGAUGACU 2880
              |||||||||||||||||||||||
Db          1 GCGAGUACAAAGCUCUGAUGACU 23


RESULT 411
AED38418
ID   AED38418 standard; RNA; 23 BP.
XX
AC   AED38418;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2219.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2219; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2690 CUUAUGAUGCCAGCAAGUGGGAG 2712
              |||||||||||||||||||||||
Db          1 CUUAUGAUGCCAGCAAGUGGGAG 23


RESULT 412
AED38490
ID   AED38490 standard; RNA; 23 BP.
XX
AC   AED38490;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2291.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
```

PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2291; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 10 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3910 AGCCUGGAAAGAAUCAAAACCUU 3932
||||||||||||||||||||||||
Db 1 AGCCUGGAAAGAAUCAAAACCUU 23

RESULT 413
AED38516
ID AED38516 standard; RNA; 23 BP.
XX
AC AED38516;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2317.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.

```
XX
PS   Example 13; SEQ ID NO 2317; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 6 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        417 AGCAGCCCAUAAAUGGUCUUUGC 439
              |||||||||||||||||||||||
Db          1 AGCAGCCCAUAAAUGGUCUUUGC 23


RESULT 414
AED38576
ID   AED38576 standard; RNA; 23 BP.
XX
AC   AED38576;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2377.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2377; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2363 CUGGAAUUAUUUUAGGACCAGGA 2385
              |||||||||||||||||||||||
Db          1 CUGGAAUUAUUUUAGGACCAGGA 23


RESULT 415
AED38584
ID   AED38584 standard; RNA; 23 BP.
XX
AC   AED38584;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2385.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
```

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2385; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 2 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2396 UGUUUAUUGAAAGAGUCACAGAA 2418
||||||||||||||||||||||||
Db 1 UGUUUAUUGAAAGAGUCACAGAA 23

RESULT 416
AED38457
ID AED38457 standard; RNA; 23 BP.
XX
AC AED38457;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2258.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2258; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3738 ACAGGAUGGUAAAGACUACAUCC 3760
              |||||||||||||||||||||||
Db          1 ACAGGAUGGUAAAGACUACAUCC 23
```

RESULT 417
AED38484
ID AED38484 standard; RNA; 23 BP.
XX
AC AED38484;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2285.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2285; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 3 A; 7 C; 5 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        296 GCUGUCUGCUUCUCACAGGAUCU 318
              |||||||||||||||||||||||
Db          1 GCUGUCUGCUUCUCACAGGAUCU 23
```

RESULT 418
AED38487
ID AED38487 standard; RNA; 23 BP.
XX
AC AED38487;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2288.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.

```
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2288; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2785 GCAUUUGGCAUUAAGAAAUCACC 2807
              |||||||||||||||||||||||
Db          1 GCAUUUGGCAUUAAGAAAUCACC 23


RESULT 419
AED38488
ID   AED38488 standard; RNA; 23 BP.
XX
AC   AED38488;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2289.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2289; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCCAG 369
              |||||||||||||||||||||||
Db          1 AACUGAGUUUAAAAGGCACCCAG 23


RESULT 420
AED38503
ID   AED38503 standard; RNA; 23 BP.
XX
AC   AED38503;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2304.
```

```
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2304; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 2 C; 8 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3501 UUACGGAGUAUUGCUGUGGGAAA 3523
              |||||||||||||||||||||||
Db          1 UUACGGAGUAUUGCUGUGGGAAA 23


RESULT 421
AED38512
ID   AED38512 standard; RNA; 23 BP.
XX
AC   AED38512;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2313.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
```

```
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2313; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 3 A; 6 C; 12 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        120 UGGCUGGAGCCGCGAGACGGGCG 142
              |||||||||||||||||||||||
Db          1 UGGCUGGAGCCGCGAGACGGGCG 23


RESULT 422
AED38513
ID   AED38513 standard; RNA; 23 BP.
XX
AC   AED38513;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2314.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2314; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        249 CAUGGUCAGCUACUGGGACACCG 271
              |||||||||||||||||||||||
Db          1 CAUGGUCAGCUACUGGGACACCG 23


RESULT 423
AED38525
ID   AED38525 standard; RNA; 23 BP.
XX
AC   AED38525;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2326.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
```

PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2326; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 796 CGCAUAAUCUGGGACAGUAGAAA 818
||||||||||||||||||||||||
Db 1 CGCAUAAUCUGGGACAGUAGAAA 23

RESULT 424
AED38532
ID AED38532 standard; RNA; 23 BP.
XX
AC AED38532;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2333.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2333; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a

```
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1875 GACUGUGGGAAGAAACAUAAGCU 1897
              |||||||||||||||||||||||
Db          1 GACUGUGGGAAGAAACAUAAGCU 23


RESULT 425
AED38538
ID   AED38538 standard; RNA; 23 BP.
XX
AC   AED38538;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2339.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2339; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 6 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2516 AUCUGGAGCUGAUCACUCUAACA 2538
              |||||||||||||||||||||||
Db          1 AUCUGGAGCUGAUCACUCUAACA 23


RESULT 426
AED38556
ID   AED38556 standard; RNA; 23 BP.
XX
AC   AED38556;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2357.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
```

PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2357; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 3 A; 7 C; 4 G; 0 T; 9 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3810 UGCCUUCUCUGAGGACUUCUUCA 3832
||||||||||||||||||||||||
Db 1 UGCCUUCUCUGAGGACUUCUUCA 23

RESULT 427
AED38566
ID AED38566 standard; RNA; 23 BP.
XX
AC AED38566;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2367.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2367; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5088 UUGGCUCCUCUAGUAAGAUGCAC 5110
||||||||||||||||||||||||
Db 1 UUGGCUCCUCUAGUAAGAUGCAC 23

RESULT 428
AED38567
ID AED38567 standard; RNA; 23 BP.

XX
AC AED38567;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2368.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2368; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 4 A; 7 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5135 GUCUCCAGGCCAUGAUGGCCUUA 5157
||||||||||||||||||||||||
Db 1 GUCUCCAGGCCAUGAUGGCCUUA 23

RESULT 429
AED38569
ID AED38569 standard; RNA; 23 BP.
XX
AC AED38569;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2370.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.

PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2370; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5352 AGACCCCGUCUCUAUACCAACCA 5374
||||||||||||||||||||||||
Db 1 AGACCCCGUCUCUAUACCAACCA 23

RESULT 430
AED38573
ID AED38573 standard; RNA; 23 BP.
XX
AC AED38573;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2374.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2374; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5706 AUCAAGUGGGCCUUGGAUCGCUA 5728
||||||||||||||||||||||||
Db 1 AUCAAGUGGGCCUUGGAUCGCUA 23

RESULT 431
AED38574
ID AED38574 standard; RNA; 23 BP.
XX
AC AED38574;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2375.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX

```
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2375; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 16 A; 6 C; 0 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2336 AAAACAACCACAAAAUACAACAA 2358
             |||||||||||||||||||||||
Db          1 AAAACAACCACAAAAUACAACAA 23
```

```
RESULT 432
AED38453
ID   AED38453 standard; RNA; 23 BP.
XX
AC   AED38453;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2254.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
```

```
XX
PS   Example 13; SEQ ID NO 2254; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 10 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3737 AACAGGAUGGUAAAGACUACAUC 3759
              |||||||||||||||||||||||
Db          1 AACAGGAUGGUAAAGACUACAUC 23


RESULT 433
AED38491
ID   AED38491 standard; RNA; 23 BP.
XX
AC   AED38491;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2292.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2292; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 15 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              |||||||||||||||||||||||
Db          1 AACAACCACAAAAUACAACAAGA 23


RESULT 434
AED38497
ID   AED38497 standard; RNA; 23 BP.
XX
AC   AED38497;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2298.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
```

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2298; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 346 GAACUGAGUUUAAAAGGCACCCA 368
||||||||||||||||||||||||
Db 1 GAACUGAGUUUAAAAGGCACCCA 23

RESULT 435
AED38506
ID AED38506 standard; RNA; 23 BP.
XX
AC AED38506;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2307.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2307; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 9 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1499 ACCUCACUGCCACUCUAAUUGUC 1521
              |||||||||||||||||||||||
Db          1 ACCUCACUGCCACUCUAAUUGUC 23
```

RESULT 436
AED38544
ID AED38544 standard; RNA; 23 BP.
XX
AC AED38544;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2345.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2345; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 12 A; 5 C; 5 G; 0 T; 1 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3099 ACAAGGCAAGAAACCAAGACUAG 3121
              |||||||||||||||||||||||
Db          1 ACAAGGCAAGAAACCAAGACUAG 23
```

RESULT 437
AED38548
ID AED38548 standard; RNA; 23 BP.
XX
AC AED38548;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2349.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.

```
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2349; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3252 UUACAGUUUUCAAGUGGCCAGAG 3274
             |||||||||||||||||||||||
Db          1 UUACAGUUUUCAAGUGGCCAGAG 23


RESULT 438
AED38563
ID   AED38563 standard; RNA; 23 BP.
XX
AC   AED38563;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2364.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2364; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 7 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4152 CGAAGGCAAGCGCAGGUUCACCU 4174
             |||||||||||||||||||||||
Db          1 CGAAGGCAAGCGCAGGUUCACCU 23


RESULT 439
AED38571
ID   AED38571 standard; RNA; 23 BP.
XX
AC   AED38571;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2372.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
```

KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2372; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 11 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5355 CCCCGUCUCUAUACCAACCAAAC 5377
||||||||||||||||||||||
Db 1 CCCCGUCUCUAUACCAACCAAAC 23

RESULT 440
AED38499
ID AED38499 standard; RNA; 23 BP.
XX
AC AED38499;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2300.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;

```
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2300; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCCAGCA 371
              |||||||||||||||||||||||
Db          1 CUGAGUUUAAAAGGCACCCAGCA 23


RESULT 441
AED38514
ID   AED38514 standard; RNA; 23 BP.
XX
AC   AED38514;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2315.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2315; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        250 AUGGUCAGCUACUGGGACACCGG 272
              |||||||||||||||||||||||
Db          1 AUGGUCAGCUACUGGGACACCGG 23


RESULT 442
AED38541
ID   AED38541 standard; RNA; 23 BP.
XX
AC   AED38541;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2342.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
```

```
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2342; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 2 C; 7 G; 0 T; 9 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 UGAUGGUGAUUGUUGAAUACUGC 2985
             |||||||||||||||||||||||
Db          1 UGAUGGUGAUUGUUGAAUACUGC 23


RESULT 443
AED38557
ID   AED38557 standard; RNA; 23 BP.
XX
AC   AED38557;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2358.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2358; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
```

```
SQ   Sequence 23 BP; 6 A; 4 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3862 UCAGGAAGCUCUGAUGAUGUCAG 3884
              |||||||||||||||||||||||
Db          1 UCAGGAAGCUCUGAUGAUGUCAG 23


RESULT 444
AED38560
ID   AED38560 standard; RNA; 23 BP.
XX
AC   AED38560;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2361.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2361; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3900 CAAGUUCAUGAGCCUGGAAAGAA 3922
              |||||||||||||||||||||||
Db          1 CAAGUUCAUGAGCCUGGAAAGAA 23


RESULT 445
AED38603
ID   AED38603 standard; RNA; 23 BP.
XX
AC   AED38603;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2404.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
```

```
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2404; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4417 UUUUUUGACUAACAAGAAUGUAA 4439
              |||||||||||||||||||||||
Db          1 UUUUUUGACUAACAAGAAUGUAA 23


RESULT 446
AED38415
ID   AED38415 standard; RNA; 23 BP.
XX
AC   AED38415;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2216.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2216; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
              |||||||||||||||||||||||
Db          1 CCUUAUGAUGCCAGCAAGUGGGA 23


RESULT 447
AED38447
ID   AED38447 standard; RNA; 23 BP.
```

XX
AC AED38447;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2248.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2248; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3642 GAUCAUGCUGGACUGCUGGCACA 3664
||||||||||||||||||||||
Db 1 GAUCAUGCUGGACUGCUGGCACA 23

RESULT 448
AED38509
ID AED38509 standard; RNA; 23 BP.
XX
AC AED38509;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2310.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.

```
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2310; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5351 AAGACCCCGUCUCUAUACCAACC 5373
              |||||||||||||||||||||||
Db          1 AAGACCCCGUCUCUAUACCAACC 23


RESULT 449
AED38511
ID   AED38511 standard; RNA; 23 BP.
XX
AC   AED38511;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2312.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2312; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 3 A; 7 C; 11 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        119 CUGGCUGGAGCCGCGAGACGGGC 141
              |||||||||||||||||||||||
Db          1 CUGGCUGGAGCCGCGAGACGGGC 23


RESULT 450
AED38523
ID   AED38523 standard; RNA; 23 BP.
XX
AC   AED38523;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2324.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
```

PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2324; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 794 AACGCAUAAUCUGGGACAGUAGA 816
||||||||||||||||||||||||
Db 1 AACGCAUAAUCUGGGACAGUAGA 23

RESULT 451
AED38524
ID AED38524 standard; RNA; 23 BP.
XX
AC AED38524;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2325.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.

```
XX
PS   Example 13; SEQ ID NO 2325; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        795 ACGCAUAAUCUGGGACAGUAGAA 817
              |||||||||||||||||||||||
Db          1 ACGCAUAAUCUGGGACAGUAGAA 23


RESULT 452
AED38542
ID   AED38542 standard; RNA; 23 BP.
XX
AC   AED38542;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2343.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2343; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 11 A; 4 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3072 GAAAGAAAAAAUGGAGCCAGGCC 3094
              |||||||||||||||||||||||
Db          1 GAAAGAAAAAAUGGAGCCAGGCC 23


RESULT 453
AED38555
ID   AED38555 standard; RNA; 23 BP.
XX
AC   AED38555;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2356.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
```

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2356; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 3 A; 5 C; 5 G; 0 T; 10 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3511 UUGCUGUGGGAAAUCUUCUCCUU 3533
||||||||||||||||||||||||
Db 1 UUGCUGUGGGAAAUCUUCUCCUU 23

RESULT 454
AED38568
ID AED38568 standard; RNA; 23 BP.
XX
AC AED38568;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2369.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2369; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 4 A; 8 C; 5 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       5136 UCUCCAGGCCAUGAUGGCCUUAC 5158
              |||||||||||||||||||||||
Db          1 UCUCCAGGCCAUGAUGGCCUUAC 23


RESULT 455
AED38388
ID   AED38388 standard; RNA; 23 BP.
XX
AC   AED38388;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2189.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2189; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3643 AUCAUGCUGGACUGCUGGCACAG 3665
              |||||||||||||||||||||||
Db          1 AUCAUGCUGGACUGCUGGCACAG 23


RESULT 456
AED38407
ID   AED38407 standard; RNA; 23 BP.
XX
AC   AED38407;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2208.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
```

PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2208; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 5 A; 6 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2687 UCCCUUAUGAUGCCAGCAAGUGG 2709
||||||||||||||||||||||||
Db 1 UCCCUUAUGAUGCCAGCAAGUGG 23

RESULT 457
AED38422
ID AED38422 standard; RNA; 23 BP.
XX
AC AED38422;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2223.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2223; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 6 A; 3 C; 8 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2691 UUAUGAUGCCAGCAAGUGGGAGU 2713
|||||||||||||||||||||||
Db 1 UUAUGAUGCCAGCAAGUGGGAGU 23

RESULT 458
AED38426
ID AED38426 standard; RNA; 23 BP.
XX
AC AED38426;

```
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2227.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2227; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3638 AUCAGAUCAUGCUGGACUGCUGG 3660
              |||||||||||||||||||||||
Db          1 AUCAGAUCAUGCUGGACUGCUGG 23


RESULT 459
AED38489
ID   AED38489 standard; RNA; 23 BP.
XX
AC   AED38489;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2290.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
```

```
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2290; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
             |||||||||||||||||||||||
Db          1 AAGCAAGGAGGGCCUCUGAUGGU 23


RESULT 460
AED38522
ID   AED38522 standard; RNA; 23 BP.
XX
AC   AED38522;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2323.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2323; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        757 AAAAAGUUUCCACUUGACACUUU 779
              |||||||||||||||||||||||
Db          1 AAAAAGUUUCCACUUGACACUUU 23


RESULT 461
AED38527
ID   AED38527 standard; RNA; 23 BP.
XX
AC   AED38527;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2328.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
```

```
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2328; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1218 CACCUCAGUGCAUAUAUAUGAUA 1240
              |||||||||||||||||||||||
Db          1 CACCUCAGUGCAUAUAUAUGAUA 23
```

```
RESULT 462
AED38540
ID   AED38540 standard; RNA; 23 BP.
XX
AC   AED38540;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2341.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2341; 266pp; English.
```

```
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2793 CAUUAAGAAAUCACCUACGUGCC 2815
              |||||||||||||||||||||||
Db          1 CAUUAAGAAAUCACCUACGUGCC 23


RESULT 463
AED38545
ID   AED38545 standard; RNA; 23 BP.
XX
AC   AED38545;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2346.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2346; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 0 C; 12 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3180 GAGUGAUGUUGAGGAAGAGGAGG 3202
              |||||||||||||||||||||||
Db          1 GAGUGAUGUUGAGGAAGAGGAGG 23


RESULT 464
AED38561
ID   AED38561 standard; RNA; 23 BP.
XX
AC   AED38561;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2362.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
```

```
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2362; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 10 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3908 UGAGCCUGGAAAGAAUCAAAACC 3930
              |||||||||||||||||||||||
Db          1 UGAGCCUGGAAAGAAUCAAAACC 23


RESULT 465
AED38581
ID   AED38581 standard; RNA; 23 BP.
XX
AC   AED38581;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2382.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2382; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2393 CGCUGUUUAUUGAAAGAGUCACA 2415
              |||||||||||||||||||||||
```

```
Db          1 CGCUGUUUAUUGAAAGAGUCACA 23


RESULT 466
AED38593
ID   AED38593 standard; RNA; 23 BP.
XX
AC   AED38593;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2394.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2394; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2859 CGAGUACAAAGCUCUGAUGACUG 2881
             |||||||||||||||||||||||
Db          1 CGAGUACAAAGCUCUGAUGACUG 23


RESULT 467
AED38596
ID   AED38596 standard; RNA; 23 BP.
XX
AC   AED38596;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2397.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
```

```
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2397; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2950 CAAGGAGGGCCUCUGAUGGUGAU 2972
             |||||||||||||||||||||||
Db          1 CAAGGAGGGCCUCUGAUGGUGAU 23


RESULT 468
AED38400
ID   AED38400 standard; RNA; 23 BP.
XX
AC   AED38400;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2201.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2201; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3645 CAUGCUGGACUGCUGGCACAGAG 3667
             |||||||||||||||||||||||
Db          1 CAUGCUGGACUGCUGGCACAGAG 23


RESULT 469
AED38495
ID   AED38495 standard; RNA; 23 BP.
XX
AC   AED38495;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2296.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
```

KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2296; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 8 A; 5 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 344 CUGAACUGAGUUUAAAAGGCACC 366
||||||||||||||||||||||||
Db 1 CUGAACUGAGUUUAAAAGGCACC 23

RESULT 470
AED38518
ID AED38518 standard; RNA; 23 BP.
XX
AC AED38518;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2319.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;

```
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2319; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 13 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 CAAAGAAGAAGGAAACAGAAUCU 615
              |||||||||||||||||||||||
Db          1 CAAAGAAGAAGGAAACAGAAUCU 23


RESULT 471
AED38533
ID   AED38533 standard; RNA; 23 BP.
XX
AC   AED38533;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2334.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2334; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2245 AACCUCAGUGAUCACACAGUGGC 2267
              |||||||||||||||||||||||
Db          1 AACCUCAGUGAUCACACAGUGGC 23


RESULT 472
AED38534
ID   AED38534 standard; RNA; 23 BP.
XX
AC   AED38534;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2335.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
```

```
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2335; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 8 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2246 ACCUCAGUGAUCACACAGUGGCC 2268
              |||||||||||||||||||||||
Db          1 ACCUCAGUGAUCACACAGUGGCC 23


RESULT 473
AED38543
ID   AED38543 standard; RNA; 23 BP.
XX
AC   AED38543;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2344.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2344; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
```

```
SQ   Sequence 23 BP; 13 A; 5 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3098 AACAAGGCAAGAAACCAAGACUA 3120
              |||||||||||||||||||||||
Db          1 AACAAGGCAAGAAACCAAGACUA 23


RESULT 474
AED38549
ID   AED38549 standard; RNA; 23 BP.
XX
AC   AED38549;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2350.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2350; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 4 C; 8 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3258 UUUUCAAGUGGCCAGAGGCAUGG 3280
              |||||||||||||||||||||||
Db          1 UUUUCAAGUGGCCAGAGGCAUGG 23


RESULT 475
AED38583
ID   AED38583 standard; RNA; 23 BP.
XX
AC   AED38583;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2384.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
```

PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2384; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 8 A; 3 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2395 CUGUUUAUUGAAAGAGUCACAGA 2417
||||||||||||||||||||||||
Db 1 CUGUUUAUUGAAAGAGUCACAGA 23

RESULT 476
AED38507
ID AED38507 standard; RNA; 23 BP.
XX
AC AED38507;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2308.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2308; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 9 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1500 CCUCACUGCCACUCUAAUUGUCA 1522
||||||||||||||||||||||||
Db 1 CCUCACUGCCACUCUAAUUGUCA 23

RESULT 477
AED38554
ID AED38554 standard; RNA; 23 BP.
XX
AC AED38554;

```
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2355.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2355; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3323 CGAGAAACAUUCUUUUAUCUGAG 3345
             |||||||||||||||||||||||
Db          1 CGAGAAACAUUCUUUUAUCUGAG 23


RESULT 478
AED38565
ID   AED38565 standard; RNA; 23 BP.
XX
AC   AED38565;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2366.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
```

```
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2366; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 12 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4943 GAGGCAAGAAAAGGACAAAUAUC 4965
              |||||||||||||||||||||||
Db          1 GAGGCAAGAAAAGGACAAAUAUC 23


RESULT 479
AED38578
ID   AED38578 standard; RNA; 23 BP.
XX
AC   AED38578;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2379.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2379; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2390 GCACGCUGUUUAUUGAAAGAGUC 2412
              |||||||||||||||||||||||
Db          1 GCACGCUGUUUAUUGAAAGAGUC 23


RESULT 480
AED38587
ID   AED38587 standard; RNA; 23 BP.
XX
AC   AED38587;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2388.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
```

```
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2388; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2783 CAGCAUUUGGCAUUAAGAAAUCA 2805
                ||||||||||||||||||||||
Db          1 CAGCAUUUGGCAUUAAGAAAUCA 23


RESULT 481
AED38598
ID   AED38598 standard; RNA; 23 BP.
XX
AC   AED38598;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2399.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2399; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
```

```
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 4 A; 3 C; 10 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2952 AGGAGGGCCUCUGAUGGUGAUUG 2974
             |||||||||||||||||||||||
Db          1 AGGAGGGCCUCUGAUGGUGAUUG 23


RESULT 482
AED38508
ID   AED38508 standard; RNA; 23 BP.
XX
AC   AED38508;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2309.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2309; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 8 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGUCAA 1523
             |||||||||||||||||||||||
Db          1 CUCACUGCCACUCUAAUUGUCAA 23


RESULT 483
AED38536
ID   AED38536 standard; RNA; 23 BP.
XX
AC   AED38536;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2337.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
```

```
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2337; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 9 A; 2 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2413 ACAGAAGAGGAUGAAGGUGUCUA 2435
              |||||||||||||||||||||||
Db          1 ACAGAAGAGGAUGAAGGUGUCUA 23


RESULT 484
AED38547
ID   AED38547 standard; RNA; 23 BP.
XX
AC   AED38547;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2348.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2348; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3251 CUUACAGUUUUCAAGUGGCCAGA 3273
              |||||||||||||||||||||||
Db          1 CUUACAGUUUUCAAGUGGCCAGA 23
```

```
RESULT 485
AED38562
ID   AED38562 standard; RNA; 23 BP.
XX
AC   AED38562;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2363.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2363; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 9 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4134 CAGCUGUGGGCACGUCAGCGAAG 4156
             |||||||||||||||||||||||
Db          1 CAGCUGUGGGCACGUCAGCGAAG 23


RESULT 486
AED38585
ID   AED38585 standard; RNA; 23 BP.
XX
AC   AED38585;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2386.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
```

PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2386; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 5 A; 4 C; 9 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2695 GAUGCCAGCAAGUGGGAGUUUGC 2717
||||||||||||||||||||||||
Db 1 GAUGCCAGCAAGUGGGAGUUUGC 23

RESULT 487
AED38590
ID AED38590 standard; RNA; 23 BP.
XX
AC AED38590;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2391.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2391; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 9 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2787 AUUUGGCAUUAAGAAAUCACCUA 2809
||||||||||||||||||||||||
Db 1 AUUUGGCAUUAAGAAAUCACCUA 23

RESULT 488
AED38597
ID AED38597 standard; RNA; 23 BP.
XX
AC AED38597;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2398.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX

```
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2398; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 5 A; 3 C; 9 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2951 AAGGAGGGCCUCUGAUGGUGAUU 2973
                ||||||||||||||||||||||
Db          1 AAGGAGGGCCUCUGAUGGUGAUU 23


RESULT 489
AED38431
ID   AED38431 standard; RNA; 23 BP.
XX
AC   AED38431;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2232.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
```

```
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2232; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 4 A; 6 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3639 UCAGAUCAUGCUGGACUGCUGGC 3661
              |||||||||||||||||||||||
Db          1 UCAGAUCAUGCUGGACUGCUGGC 23


RESULT 490
AED38500
ID   AED38500 standard; RNA; 23 BP.
XX
AC   AED38500;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2301.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2301; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 8 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        350 UGAGUUUAAAAGGCACCCAGCAC 372
              |||||||||||||||||||||||
Db          1 UGAGUUUAAAAGGCACCCAGCAC 23


RESULT 491
AED38505
ID   AED38505 standard; RNA; 23 BP.
XX
AC   AED38505;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2306.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
```

PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2306; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 14 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
||||||||||||||||||||||||
Db 1 AGCAAAAAGCAAGGGAGAAAAGA 23

RESULT 492
AED38551
ID AED38551 standard; RNA; 23 BP.
XX
AC AED38551;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGFR target region for siRNA - SEQ ID 2352.
XX
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2352; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present RNA sequence represents a target region for a
CC VEGFR-specific siRNA.
XX
SQ Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3292 UCCAGAAAGUGCAUUCAUCGGGA 3314
              |||||||||||||||||||||||
Db          1 UCCAGAAAGUGCAUUCAUCGGGA 23


RESULT 493
AED38594
ID   AED38594 standard; RNA; 23 BP.
XX
AC   AED38594;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGFR target region for siRNA - SEQ ID 2395.
XX
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2395; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present RNA sequence represents a target region for a
CC   VEGFR-specific siRNA.
XX
SQ   Sequence 23 BP; 6 A; 6 C; 8 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2945 CCAAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||||||||||||
Db          1 CCAAGCAAGGAGGGCCUCUGAUG 23


RESULT 494
AEF05631
ID   AEF05631 standard; DNA; 23 BP.
XX
AC   AEF05631;
XX
DT   23-FEB-2006  (first entry)
XX
DE   Human FLT-1 d2 PCR primer #1.
XX
KW   Cytostatic; Antidiabetic; Ophthalmological; Antiarthritic; Antianemic;
KW   Gynecological; Antiangiogenic; FLT-1; fms-like tyrosine kinase; KDR;
KW   tyrosine kinase receptor; VEGF; vascular endothelial growth factor;
KW   pharmaceutical; angiogenesis; tumor; diabetic retinopathy; arthritis;
KW   anemia; hyperplasia; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   WO2005121176-A1.
XX
PD   22-DEC-2005.
XX
PF   08-JUN-2005; 2005WO-CN000802.
XX
PR   08-JUN-2004; 2004CN-00044965.
XX
PA   (CHEN-) CHENGDU KANGHONG TECHNOLOGY ENTERPRISES.
XX
PI   Liu Z;
XX
DR   WPI; 2006-048154/05.
XX
PT   Angiogenesis-inhibiting chimeric recombinant proteins and their encoded
PT   DNA sequences, useful in producing pharmaceutical compositions for drugs
PT   to inhibit angiogenesis and to treat e.g. tumor.
XX
PS   Example 1; Page 8; 31pp; Chinese.
XX
CC   The invention relates to chimeric proteins constructed from various
CC   fragments of FLT-1 (fms-like tyrosine kinase) and KDR, which are tyrosine
CC   kinase receptors of VEGF (vascular endothelial growth factor). The
CC   proteins and their encoded DNA sequences are useful in producing
CC   pharmaceutical compositions for drugs to inhibit angiogenesis and to
CC   treat e.g. tumor, diabetic retinopathy, arthritis, anemia or endometrial
CC   hyperplasia. The present sequence represents a VEGF tyrosine kinase
```

```
CC   receptor related protein PCR primer.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        649 CCUUUCGUAGAGAUGUACAGUGA 671
              ||:::||:|||||:|:||||:||
Db          1 CCTTTCGTAGAGATGTACAGTGA 23


RESULT 495
AAI64469/c
ID   AAI64469 standard; DNA; 26 BP.
XX
AC   AAI64469;
XX
DT   23-NOV-2001  (first entry)
XX
DE   SSR motif #19.
XX
KW   Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
KW   trait mapping; marker-assisted selection; gene selection; legume;
KW   DNA profiling; breeding; ds.
XX
OS   Unidentified.
XX
PN   NZ509194-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509194.
XX
PR   24-DEC-1999;   99AU-00004907.
PR   28-MAR-2000; 2000AU-00006520.
XX
PA   (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.
XX
PI   Koelliker R,  Forster JW;
XX
DR   WPI; 2001-431058/46.
XX
PT   Novel simple sequence repeats in clover species useful for selection of
PT   genes in legume breeding, for profiling legume species varieties and for
PT   testing the purity of legume seed batches.
XX
PS   Example 1; Page 19; 52pp; English.
XX
CC   The present invention relates to Simple Sequence Repeats (SSRs) from
CC   clover species. SSRs, also called microsatellites, are based on a 1-7
CC   nucleotide core element which is tandemly repeated. The SSR array is
CC   embedded in complex flanking DNA. SSRs are ideal markers for genome
CC   mapping, trait mapping and marker-assisted selection. The SSRs may be
CC   used in methods for selecting genes in clover/ legume breeding. The SSRs
CC   are also useful for DNA profiling of clover varieties and for testing the
CC   purity of legume seed batches. The present sequence is a SSR motif, which
CC   was used in the present invention
XX
SQ   Sequence 26 BP; 12 A; 12 C; 2 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22.8;  DB 1;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 2.2e+03;
  Matches   12;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:  |:|:|:|:|:
Db         26 GTGTGTGTGTGTGTCCGTGTGTGTGT 1


RESULT 496
ABZ57678
ID   ABZ57678 standard; DNA; 24 BP.
XX
AC   ABZ57678;
XX
DT   10-APR-2003  (first entry)
XX
DE   Human zinc finger protein 9.46 RT-PCR primer, SEQ ID NO:3.
XX
KW   Human; zinc finger protein 9.46; recombinant production; gene therapy;
KW   malignant tumour; cancer; blood disease; human immunodeficiency virus;
KW   HIV infection; immune disorder; inflammatory condition; cytostatic;
KW   antiinflammatory; immunomodulator; reverse transcription-PCR; RT-PCR;
KW   primer; ss.
XX
OS   Homo sapiens.
XX
PN   CN1361165-A.
XX
PD   31-JUL-2002.
XX
PF   26-DEC-2000; 2000CN-00136331.
XX
PR   26-DEC-2000; 2000CN-00136331.
XX
PA   (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2003-000239/01.
XX
PT   New polypeptide human zinc finger protein 9.46 and polynucleotides
PT   encoding this polypeptide.
XX
PS   Example 2; Page 16 (Disclosure); 31pp; Chinese.
XX
CC   The invention relates to human zinc finger protein 9.46 (ABP58904) and
CC   nucleic acids encoding it (ABZ57677). The protein has a molecular weight
CC   of 9.46 kD. The invention also relates to a method for the recombinant
CC   production of the protein, an antagonist of the protein, and the use of
CC   the protein, gene and antagonist in therapeutic applications. Zinc finger
CC   protein 9.46 can be used in the treatment of a variety of diseases such
CC   as malignant tumours, blood diseases, HIV (human immunodeficiency virus)
CC   infection, immune disorders and inflammatory conditions. Sequences
CC   ABZ57678-ABZ57679 represent reverse transcription-PCR (RT-PCR) primers
CC   used in an exemplification of the invention to isolate human zinc finger
CC   protein 9.46 cDNA
XX
SQ   Sequence 24 BP; 0 A; 0 C; 13 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22.4;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 2.1e+03;
  Matches   12;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:| |:|:|:|:|:|:|:|:
Db          1 GTGTGTGGGTGTGTGTGTGTGTGT 24


RESULT 497
AAQ95132/c
ID   AAQ95132 standard; DNA; 27 BP.
XX
AC   AAQ95132;
XX
DT   25-MAR-2003  (revised)
DT   28-SEP-1995  (first entry)
XX
DE   Spinocerebellar ataxia type 1 BamCA PCR primer.
XX
KW   Spinocerebellar ataxia type 1; SCA 1; presymptomatic diagnosis;
KW   BamCA PCR primer; ss.
XX
OS   Synthetic.
```

```
XX
PN   WO9501437-A2.
XX
PD   12-JAN-1995.
XX
PF   29-JUN-1994;   94WO-US007336.
XX
PR   29-JUN-1993;   93US-00084365.
PR   28-JUN-1994;   94US-00267803.
XX
PA   (MINU ) UNIV MINNESOTA.
XX
PI   Orr HT,  Chung M,  Zoghbi HY;
XX
DR   WPI; 1995-061001/08.
XX
PT   New autosomal dominant spinocerebellar ataxia type 1 nucleic acid - used
PT   to develop prods. for detection or presymptomatic diagnosis of a SCA1
PT   disorder.
XX
PS   Example I; Page 37; 111pp; English.
XX
CC   AAQ95132 and M13U are a pair of primers for the PCR amplification of
CC   AAQ84793, a new autosomal dominant spinocerebellar ataxia type 1 (SCA 1)
CC   nucleic acid. The nucleic acid and its protein product (AAR71111) can be
CC   used to develop products, for the presymptomatic detection of a SCA 1
CC   disorder. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 27 BP; 10 A; 14 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 2.7e+03;
  Matches   14;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6996 GUGUGUGUGUGUGUGUGGGUGUGGG 7022
              |:|:|:|:|:|:|:|:|| :  |||
Db         27 GTGTGTGTGTGTGTGTGGATCCGGG 1


RESULT 498
AAA80358
ID   AAA80358 standard; DNA; 27 BP.
XX
AC   AAA80358;
XX
DT   22-NOV-2000  (first entry)
XX
DE   Human ASTH1I 5' region polymorphic site, SEQ ID NO:103 (b).
XX
KW   ASTH1 locus; ASTH1I; ASTH1J; human; chromosome 11p; asthma;
KW   bronchial hyperreactivity; ets family; transcription factor;
KW   splice variant; genetic predisposition; polymorphism; antibody;
KW   drug screening; prophylaxis; therapy; diagnosis;
KW   single nucleotide polymorphism; SNP; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(12. .17,TA)
FT                   /*tag=  a
XX
PN   US6087485-A.
XX
PD   11-JUL-2000.
XX
PF   21-JAN-1998;   98US-00009913.
XX
PR   21-JAN-1997;   97US-0035663P.
PR   01-JUL-1997;   97US-0051432P.
XX
PA   (AXYS-) AXYS PHARM INC.
XX
PI   Galvin M,  Miller A,  North M,  Cardon L,  Buckler A;
PI   Brooks-Wilson AR,  Carey AH;
XX
DR   WPI; 2000-505109/45.
XX
PT   New nucleic acids other than naturally occurring chromosomes encoding
PT   ASTH1 protein, for e.g. screening compositions that modulate expression
PT   or function of ASTH1 proteins or as diagnostics for genetic
PT   predisposition to asthma.
XX
PS   Example; Col 41-42; 131pp; English.
XX
CC   The invention relates to the ASTH1 locus on the short arm of human
CC   chromosome (11p). This locus comprises the ASTH1I and ASTH1J genes, which
CC   are associated with a genetic predisposition to asthma and bronchial
CC   hyperreactivity. The ASTH1I and ASTH1J genes are oriented in opposite
CC   directions with the ASTH1 locus, and have similar patterns of expression
CC   and common sequence motifs. They are both expressed in trachea, lung and
CC   several other tissues. ASTH1I and ASTH1J are novel members of the ets
CC   family of transcription factors, which have been implicated in the
CC   activation of a variety of genes including the TCRa gene and cytokine
CC   genes known to be important in the aetiology of asthma. Both ASTH1I and
CC   ASTH1J mRNAs are alternatively spliced. Alternative splicing of
CC   transcripts has no effect on the open reading frame of ASTH1J, as the
CC   exons involved are all 5' to the start codon in exon b. In contrast,
CC   alternative splicing of ASTH1I transcripts results in 3 different ASTH1I
CC   isoforms. The invention also encompasses mouse asth1j protein. The ASTH1
CC   nucleic acids are useful as diagnostics to identify a hereditary
CC   predisposition to asthma, as probes for identifying ASTH1 related genes,
CC   for identifying expression of the gene in a biological specimen, and for
CC   generating genetically modified non-human animals or site specific gene
CC   modifications in cell lines. The encoded ASTH1 proteins are useful as
CC   immunogens to raise specific antibodies; in drug screening for
CC   compositions that mimic or modulate activity or expression of ASTH1I
CC   and/or ASTH1J (including altered forms of these proteins); and as a
CC   therapeutic. The ASTH1 genes or fragments thereof, encoded proteins,
CC   ASTH1 genomic regulatory regions, and anti-ASTH1I and anti-ASTH1J
CC   antibodies are useful in the identification of individuals predisposed to
CC   development of asthma, and for modulation of gene activity in vivo for
CC   prophylactic and therapeutic purposes. The intact ASTH1I or ASTH1J
CC   proteins or active fragments thereof may be used to modulate or reduce
CC   bronchial hyperreactivity. Sequences AAA80260-A80261 and AAA80264-A80416
CC   represent polymorphic sites within the ASTH1J or ASTH1I genes
XX
SQ   Sequence 27 BP; 1 A; 2 C; 13 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 2.7e+03;
  Matches   13;  Conservative   11;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|: :|:| | |:|
Db          1 GTGTGTGTGTGTGTGTATGTGCGCGTG 27


RESULT 499
AAQ33810
ID   AAQ33810 standard; DNA; 22 BP.
XX
AC   AAQ33810;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA214.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
```

```
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 253; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6995
              |:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTG 22


RESULT 500
AAQ33675
ID   AAQ33675 standard; DNA; 22 BP.
XX
AC   AAQ33675;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA117.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 199; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 22


RESULT 501
AAQ34038
ID   AAQ34038 standard; DNA; 22 BP.
XX
AC   AAQ34038;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA432.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 346; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
```

```
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 22


RESULT 502
AAQ34080
ID   AAQ34080 standard; DNA; 22 BP.
XX
AC   AAQ34080;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA48.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 363; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 22


RESULT 503
AAQ33991
ID   AAQ33991 standard; DNA; 22 BP.
XX
AC   AAQ33991;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA39.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 327; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
```

```
                :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 22


RESULT 504
AAQ83952/c
ID   AAQ83952 standard; DNA; 22 BP.
XX
AC   AAQ83952;
XX
DT   25-MAR-2003  (revised)
DT   04-OCT-1995  (first entry)
XX
DE   Oligonucleotide clamp n, for producing comb-type brached polymer.
XX
KW   HIV; pol; nef; oligonucleotide clamp; branched; macromolecule; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /note= "Modified with BrCH2(=O)CNH-"
FT   modified_base   8. .9
FT                   /*tag=  b
FT                   /note= "C(pnp)A, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
FT   modified_base   14. .15
FT                   /*tag=  c
FT                   /note= "C(pnp)A, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
FT   modified_base   21. .22
FT                   /*tag=  d
FT                   /note= "C(pnp)A, pnp = a linkage or monomer containing a
FT                   bromoacetylamino functionality, and p = phosphodiester
FT                   linkage"
XX
PN   WO9501365-A1.
XX
PD   12-JAN-1995.
XX
PF   05-JUL-1994;   94WO-US007557.
XX
PR   02-JUL-1993;   93US-00087386.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Gryaznov SM;
XX
DR   WPI; 1995-060944/08.
XX
PT   Synthesis of branched polymers and novel branched polymeric structures -
PT   used as molecular probes esp. for detecting poly-nucleotide(s).
XX
PS   Example 8; Page 33; 52pp; English.
XX
CC   The sequences given in AAQ83938, AAQ83952 and AAQ83940 are used in the
CC   construction of an oligonucleotide clamp. The clamp is a comb-type
CC   branched polymer which has 3' termini and was used to bind a target
CC   sequence comprising a segment of the HIV pol and nef genes in single
CC   stranded or double stranded forms. An oligonucleotide clamp is a compound
CC   capable of forming a covalently closed macromolecule or a stable circular
CC   complex after specifically binding to the target polynucleotide.
CC   Oligonucleotide clamps generally comprise one or more oligonucleotide
CC   moieties capable of specific binding to the target molecule and one or
CC   more pairs of binding moieties covalently linked to the oligonucleotide
CC   moieties. Upon annealing of the oligonucleotides moieties to the target
CC   polynucleotide, the binding moieties of a pair are bought into
CC   juxtaposition so that they form a stable covalent or non-covalent linkage
CC   or complex. The interaction of the binding moieties effectively clamps
CC   the specifically annealed oligonucleotide moieties to the target
CC   polynucleotide. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6995
                |:|:|:|:|:|:|:|:|:|:|
Db         22 GTGTGTGTGTGTGTGTGTGT 1


RESULT 505
AAT65727/c
ID   AAT65727 standard; DNA; 22 BP.
XX
AC   AAT65727;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd25.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf25 which contains the repeat sequence having the
CC   formula: (AC)11. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6995
                |:|:|:|:|:|:|:|:|:|:|
```

```
Db         22 GTGTGTGTGTGTGTGTGTGT 1


RESULT 506
AAX90491/c
ID   AAX90491 standard; DNA; 22 BP.
XX
AC   AAX90491;
XX
DT   04-OCT-1999  (first entry)
XX
DE   Vascular endothelial growth factor isoform PCR primer flt1-A.
XX
KW   Vascular endothelial growth factor; VEGF; expression; amplification;
KW   hybridisation; tumour; cancer; diagnosis; VEGF189; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9939002-A1.
XX
PD   05-AUG-1999.
XX
PF   27-JAN-1999;   99WO-JP000344.
XX
PR   30-JAN-1998;   98JP-00018534.
XX
PA   (NAKA/) NAKAMURA M.
XX
PI   Nakamura M;
XX
DR   WPI; 1999-469341/39.
XX
PT   Determining expression pattern of vascular endothelial growth factor
PT   isoforms in biological samples by nucleotide amplification.
XX
PS   Example 1; Page 10-11; 47pp; Japanese.
XX
CC   The present invention describes a method for determining the expression
CC   pattern of isoforms of vascular endothelial growth factor (VEGF) in
CC   biological samples by nucleotide amplification using appropriate primers.
CC   Expression of isoforms of VEGF, especially VEGF189, is implicated in the
CC   development and growth of tumours, and determination of the expression
CC   patterns of the isoforms is important for the diagnosis and investigation
CC   of these disorders, including cancer of the colon, liver, breast, lung,
CC   skeletal muscle, kidney and brain. The present sequence represents a PCR
CC   primer for a VEGF isoform which is used in an example from the present
CC   invention
XX
SQ   Sequence 22 BP; 3 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   86.4%;  Pred. No. 2e+03;
  Matches   19;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3125 GCGUCACCAGCAGCGAAAGCUU 3146
              |||:||||||||||||||||::
Db         22 GCGTCACCAGCAGCGAAAGCTT 1


RESULT 507
AAX90490
ID   AAX90490 standard; DNA; 22 BP.
XX
AC   AAX90490;
XX
DT   04-OCT-1999  (first entry)
XX
DE   Vascular endothelial growth factor isoform PCR primer flt1-S.
XX
KW   Vascular endothelial growth factor; VEGF; expression; amplification;
KW   hybridisation; tumour; cancer; diagnosis; VEGF189; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9939002-A1.
XX
PD   05-AUG-1999.
XX
PF   27-JAN-1999;   99WO-JP000344.
XX
PR   30-JAN-1998;   98JP-00018534.
XX
PA   (NAKA/) NAKAMURA M.
XX
PI   Nakamura M;
XX
DR   WPI; 1999-469341/39.
XX
PT   Determining expression pattern of vascular endothelial growth factor
PT   isoforms in biological samples by nucleotide amplification.
XX
PS   Example 1; Page 10; 47pp; Japanese.
XX
CC   The present invention describes a method for determining the expression
CC   pattern of isoforms of vascular endothelial growth factor (VEGF) in
CC   biological samples by nucleotide amplification using appropriate primers.
CC   Expression of isoforms of VEGF, especially VEGF189, is implicated in the
CC   development and growth of tumours, and determination of the expression
CC   patterns of the isoforms is important for the diagnosis and investigation
CC   of these disorders, including cancer of the colon, liver, breast, lung,
CC   skeletal muscle, kidney and brain. The present sequence represents a PCR
CC   primer for a VEGF isoform which is used in an example from the present
CC   invention
XX
SQ   Sequence 22 BP; 4 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2669 AUGAGCAGUGUGAGCGGCUCCC 2690
              |:||||||:|:|||||||:|||
Db          1 ATGAGCAGTGTGAGCGGCTCCC 22


RESULT 508
AAA60163
ID   AAA60163 standard; DNA; 22 BP.
XX
AC   AAA60163;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Human Flt-1 gene forward PCR primer.
XX
KW   Peroxisome proliferator activated receptor; angiogenesis inhibition;
KW   neovascularisation; tumour growth; metastasis; rheumatoid arthritis;
KW   psoriasis; atherosclerosis; diabetes; retinopathy; PPAR; Flt-1;
KW   retrolental fibroplasia; age-related macular degeneration; human;
KW   neovascular glaucoma; hemangioma; thyroid hyperplasia; Grave's disease;
KW   inflammatiobesity; transplantation; transcription factor; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200030628-A2.
XX
PD   02-JUN-2000.
XX
PF   18-NOV-1999;   99WO-US027612.
XX
PR   20-NOV-1998;   98US-0109328P.
PR   20-JAN-1999;   99US-0116530P.
XX
PA   (GETH ) GENENTECH INC.
```

```
XX
PI   Gerritsen ME,  Xin XE;
XX
DR   WPI; 2000-411807/35.
XX
PT   Inhibiting angiogenesis comprises administration of PPAR gamma ligands
PT   for treating tumors, neovascularization and rheumatoid arthritis.
XX
PS   Example 5; Page 31; 52pp; English.
XX
CC   Peroxisome proliferators are agents that induce peroxisomal
CC   proliferation. Peroxisome proliferator-activated receptors (PPARs) are
CC   members of the steroid receptor superfamily, and are ligand-activated
CC   transcription factors. There are three mammalian subtypes of PPAR, alpha,
CC   beta (also known as delta) and gamma. The present invention relates to
CC   inhibiting angiogenesis by contacting PPAR gamma with a PPAR gamma
CC   ligand. This method may be used to treat tumours, and diseases
CC   characterised by excessive neovascularisation e.g. rheumatoid arthritis,
CC   psoriasis, atherosclerosis, diabetes, retinopathy, retrolental
CC   fibroplasia, neovascular glaucoma, age-related macular degeneration,
CC   hemangiomas, thyroid hyperplasias, Grave's disease, tissue
CC   transplantation, chronic inflammation, lung inflammation, endometriosis
CC   and obesity. The present sequence is a PCR primer for human Flt-1 gene.
CC   Flt-1 is an endothelial cell tyrosine kinase receptor for vascular
CC   endothelial growth factor (VEGF) and has an important role in
CC   angiogenesis. The present sequence was used to determine whether
CC   PPARgamma activation leads to an alteration in Flt-1 gene expression and
CC   hence angiogenesis. An increase in Flt-1 levels was found after PPARgamma
CC   activation
XX
SQ   Sequence 22 BP; 6 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   72.7%;  Pred. No. 2e+03;
  Matches   16;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2648 ACCCAGAUGAAGUUCCUUUGGA 2669
              |||||||:||||::||:::|||
Db          1 ACCCAGATGAAGTTCCTTTGGA 22


RESULT 509
AAZ65606
ID   AAZ65606 standard; DNA; 22 BP.
XX
AC   AAZ65606;
XX
DT   30-MAR-2000  (first entry)
XX
DE   Immunosuppressant inhibitor oligonucleotide flt-1567.
XX
KW   Immunosuppressant inhibitor; transforming growth factor beta; TGF beta;
KW   vascular endothelial growth factor; VEGF; interleukin-10; IL-10; cancer;
KW   prostaglandin E2; PGE2; immune response; tumour; asthma; Crohn's disease;
KW   monocyte chemotactic protein-1; MCP-1; ulcerative colitis; diabetes;
KW   glomerulonephritis; acute respiratory distress syndrome; ss;
KW   atherosclerosis.
XX
OS   Unidentified.
XX
PN   WO9963975-A2.
XX
PD   16-DEC-1999.
XX
PF   10-JUN-1999;   99WO-EP004013.
XX
PR   10-JUN-1998;   98EP-00110709.
PR   25-JUL-1998;   98EP-00113974.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Schlingensiepen R,  Brysch W;
XX
DR   WPI; 2000-097470/08.
XX
PT   Composition containing immune stimulant and inhibitor of agent that
PT   adversely affects the immune response, for treating cancers and
PT   infections.
XX
PS   Claim 10; Fig 1; 30pp; English.
XX
CC   This sequence is an immunosuppressant inhibitor oligonucleotide, which is
CC   used in the invention. The invention relates to a composition which
CC   contains at least one inhibitor (less than 100 kD) of a substance (e.g.
CC   transforming growth factor TGF-beta, vascular endothelial growth factor
CC   VEGF, interleukin-10 IL-10, prostaglandin E2 PGE2, or their receptors)
CC   that adversely affects the immune response. The composition also includes
CC   at least one stimulant that positively affects the immune response. This
CC   oligonucleotide is an example of an inhibitor that is used in the
CC   composition. The composition is used as an immunostimulant for the
CC   treatment of neoplasms and infections, particularly hyperproliferation;
CC   leukaemia; (non-)Hodgkin's lymphoma; carcinoma (of oesophagus, bronchi,
CC   colon-rectum, stomach, intestine, gall bladder or duct, pancreas, anus,
CC   breast, ovary, cervix, endometrium, prostate or bladder), liver tumours,
CC   malignant melanoma, brain tumours and sarcomas. The oligonucleotides,
CC   most of which are directed against TGFbeta or VEGF, are inhibitors of
CC   monocyte chemotactic protein-1 (MCP-1) and are useful as anti-
CC   inflammatories for treating e.g. asthma, Crohn's disease, ulcerative
CC   colitis, diabetes, glomerulonephritis, acute respiratory distress
CC   syndrome and the formation of atherosclerotic plaque
XX
SQ   Sequence 22 BP; 5 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   72.7%;  Pred. No. 2e+03;
  Matches   16;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUG 2708
              :|||::|:|||:||||||||:|
Db          1 TCCCTTATGATGCCAGCAAGTG 22


RESULT 510
AAZ56473/c
ID   AAZ56473 standard; DNA; 22 BP.
XX
AC   AAZ56473;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Vascular endothelial growth factor receptor KDR RT-PCR primer #4.
XX
KW   Vascular endothelial growth factor receptor; KDR; VEGFRII; VEGFR;
KW   haematopoietic stem cell population; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9961584-A1.
XX
PD   02-DEC-1999.
XX
PF   28-MAY-1999;   99WO-US012054.
XX
PR   29-MAY-1998;   98US-0087153P.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
PA   (SUPE-) INST SUPERIORE DI SANITA.
PA   (ZIEG/) ZIEGLER B L.
XX
PI   Ziegler BL,  Peschle C;
XX
DR   WPI; 2000-086715/07.
XX
PT   Preparation of a cell population.
XX
PS   Example; Page 45; 83pp; English.
```

```
XX
CC   The present invention describes a method for preparing a cell population
CC   enriched for long-term repopulating human haematopoietic stem cells. The
CC   method comprises obtaining a population of cells from human
CC   haematopoietic tissue and isolating a population of KDR+ cells. KDR is a
CC   human vascular endothelial growth factor receptor (VEGFRII). The novel
CC   cell population can be used to inhibit rejection of a transplanted organ,
CC   by administering the KDR+ cells of the donor to a tissue recipient. The
CC   present sequence represents a reverse transcription PCR primer, which is
CC   used in an example from the present invention
XX
SQ   Sequence 22 BP; 4 A; 5 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 AAGAACCCCGAUUAUGUGAGAA 3415
              ||||||||||::|:|:|||||
Db         22 AAGAACCCCGATTATGTGAGAA 1


RESULT 511
AAZ56472
ID   AAZ56472 standard; DNA; 22 BP.
XX
AC   AAZ56472;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Vascular endothelial growth factor receptor KDR RT-PCR primer #3.
XX
KW   Vascular endothelial growth factor receptor; KDR; VEGFRII; VEGFR;
KW   haematopoietic stem cell population; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9961584-A1.
XX
PD   02-DEC-1999.
XX
PF   28-MAY-1999;   99WO-US012054.
XX
PR   29-MAY-1998;   98US-0087153P.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
PA   (SUPE-) INST SUPERIORE DI SANITA.
PA   (ZIEG/) ZIEGLER B L.
XX
PI   Ziegler BL,  Peschle C;
XX
DR   WPI; 2000-086715/07.
XX
PT   Preparation of a cell population.
XX
PS   Example; Page 45; 83pp; English.
XX
CC   The present invention describes a method for preparing a cell population
CC   enriched for long-term repopulating human haematopoietic stem cells. The
CC   method comprises obtaining a population of cells from human
CC   haematopoietic tissue and isolating a population of KDR+ cells. KDR is a
CC   human vascular endothelial growth factor receptor (VEGFRII). The novel
CC   cell population can be used to inhibit rejection of a transplanted organ,
CC   by administering the KDR+ cells of the donor to a tissue recipient. The
CC   present sequence represents a reverse transcription PCR primer, which is
CC   used in an example from the present invention
XX
SQ   Sequence 22 BP; 10 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   86.4%;  Pred. No. 2e+03;
  Matches   19;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3109 AAACCAAGACUAGAUAGCGUCA 3130
              ||||||||||:|||:||||:||
Db          1 AAACCAAGACTAGATAGCGTCA 22


RESULT 512
AAI67483
ID   AAI67483 standard; DNA; 22 BP.
XX
AC   AAI67483;
XX
DT   11-FEB-2002  (first entry)
XX
DE   Forward primer used for real-time RT-PCR analysis.
XX
KW   ARP; angiogenesis; vascular endothelial growth factor; VEGF; cytostatic;
KW   arginine-rich protein; cardiant; antirheumatic; antiarthritic; human;
KW   antiatherosclerotic; vasotropic; gynecological; antidiabetic; vulnerary;
KW   antiulcer; dermatological; ophthalmological; antipsoriatic; apoptosis;
KW   gene therapy; RT-PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO200170174-A2.
XX
PD   27-SEP-2001.
XX
PF   21-MAR-2001; 2001WO-US009043.
XX
PR   22-MAR-2000; 2000US-0191201P.
XX
PA   (CURA-) CURAGEN CORP.
PA   (GETH ) GENENTECH INC.
XX
PI   Rastelli LK,  Gerber H;
XX
DR   WPI; 2001-639087/73.
XX
PT   Modulating angiogenesis and/or apoptosis for preventing or treating
PT   cancer, myocardial infarction and promoting healing, by modulating the
PT   activity of vascular endothelial growth factor-modulated gene
PT   polypeptide.
XX
PS   Example 2; Page 103; 155pp; English.
XX
CC   The invention relates to modulating angiogenesis and cell survival that
CC   involves modulating the activity of at least one vascular endothelial
CC   growth factor (VEGF)-modulated gene polypeptide. The method is useful for
CC   modulating angiogenesis and cell survival, for treating tumour and cancer
CC   by decreasing angiogenesis in cancerous tumours and treating myocardial
CC   infarction and promoting healing, by increasing angiogenesis. Transgenic
CC   non-human animals, having disrupted arginine-rich protein (ARP), are
CC   useful for determining the clinical stage of ovarian tumorous, which is
CC   useful for determining if the tumour has potential for metastasis. ARP is
CC   useful in gene therapy and in diagnostic applications. VEGFmg proteins
CC   are useful in the treatment of tumours, neoplasias, hemangiomas,
CC   rheumatoid arthritis, atherosclerosis, idiopathic pulmonary fibrosis,
CC   vascular restenosis, arteriovenous malformations, meningioma, neovascular
CC   glaucoma, psoriasis, hemophilic joints, hypertrophic scars, Osler-Weber
CC   syndrome, scleroderma, vascular adhesion pathologies, synovitis,
CC   dermatitis, endometriosis, diabetic retinopathy, neovascularization
CC   associated with corneal injury or grafts, wound, sore, and ulcer healing.
CC   Sequences AAI67449-487 represent probe primer sets used for real-time RT-
CC   PCR analysis of differential gene expression
XX
SQ   Sequence 22 BP; 7 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   77.3%;  Pred. No. 2e+03;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2426 AAGGUGUCUAUCACUGCAAAGC 2447
              ||||:|:|:|:|||:|||||||
```

```
Db          1 AAGGTGTCTATCACTGCAAAGC 22


RESULT 513
AAI64448
ID   AAI64448 standard; DNA; 22 BP.
XX
AC   AAI64448;
XX
DT   23-NOV-2001  (first entry)
XX
DE   SSR motif #8.
XX
KW   Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
KW   trait mapping; marker-assisted selection; gene selection; legume;
KW   DNA profiling; breeding; ds.
XX
OS   Unidentified.
XX
PN   NZ509194-A.
XX
PD   25-MAY-2001.
XX
PF   03-JAN-2001; 2001NZ-00509194.
XX
PR   24-DEC-1999;   99AU-00004907.
PR   28-MAR-2000; 2000AU-00006520.
XX
PA   (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.
XX
PI   Koelliker R,  Forster JW;
XX
DR   WPI; 2001-431058/46.
XX
PT   Novel simple sequence repeats in clover species useful for selection of
PT   genes in legume breeding, for profiling legume species varieties and for
PT   testing the purity of legume seed batches.
XX
PS   Claim 6; Page 35; 52pp; English.
XX
CC   The present invention relates to Simple Sequence Repeats (SSRs) from
CC   clover species. SSRs, also called microsatellites, are based on a 1-7
CC   nucleotide core element which is tandemly repeated. The SSR array is
CC   embedded in complex flanking DNA. SSRs are ideal markers for genome
CC   mapping, trait mapping and marker-assisted selection. The SSRs may be
CC   used in methods for selecting genes in clover/ legume breeding. The SSRs
CC   are also useful for DNA profiling of clover varieties and for testing the
CC   purity of legume seed batches. The present sequence is a SSR motif, which
CC   was used in the present invention
XX
SQ   Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 22


RESULT 514
ADO81143/c
ID   ADO81143 standard; DNA; 22 BP.
XX
AC   ADO81143;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Prion protein polymorphic microsatellite marker consensus sequence #21.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; ds.
XX
OS   Synthetic.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Claim 9; Page 50; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a prion protein polymorphic microsatellite marker
CC   consensus sequence.
XX
SQ   Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 22


RESULT 515
ADO81098/c
ID   ADO81098 standard; DNA; 22 BP.
XX
AC   ADO81098;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Sheep prion protein microsatellite locus primer #69.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; PCR; primer; ss.
XX
OS   Ovis aries.
XX
```

```
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Example 3; Page 30; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a primer used to genotype a region of the sheep prion
CC   protein (PrP) comprising a polymorphic microsatellite locus.
XX
SQ   Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|
Db         22 TGTGTGTGTGTGTGTGTGTG 1


RESULT 516
AEE49146
ID   AEE49146 standard; DNA; 22 BP.
XX
AC   AEE49146;
XX
DT   09-FEB-2006  (first entry)
XX
DE   Cell surface receptor isoform primer SEQ ID NO 65.
XX
KW   immunosuppressive; cytostatic; nootropic; neuroprotective; antiarthritic;
KW   antiinflammatory; antirheumatic; virucide; pharmaceutical; therapeutic;
KW   cell signaling; cell proliferation; angiogenesis; neovascularization;
KW   neurodegenerative disease; neuroprotective; neurological disease;
KW   inflammation; hyperproliferation; cancer; parasitic infection;
KW   antiparasitic; viral infection; virucide; infection;
KW   angiogenesis disorder; antiangiogenic; cardiovascular disease; tumor;
KW   neoplasm; immune disorder; cell surface receptor; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2005113596-A2.
XX
PD   01-DEC-2005.
XX
PF   13-MAY-2005; 2005WO-US017051.
XX
PR   14-MAY-2004; 2004US-0571289P.
PR   18-JUN-2004; 2004US-0580990P.
PR   30-MAR-2005; 2005US-0666825P.
XX
PA   (RECE-) RECEPTOR BIOLOGIX INC.
XX
PI   Jin P,  Shepard MH;
XX
DR   WPI; 2005-812226/82.
XX
PT   New polypeptides, specifically isoforms of cell surface receptors, such
PT   as EphA, VEGF, MET, RON, CSF, etc, useful treating cancer, or
PT   inflammatory, infectious, angiogenesis-related conditions, or immune
PT   disorders.
XX
PS   Example 1; SEQ ID NO 65; 647pp; English.
XX
CC   The invention describes an isolated polypeptide, comprising at least one
CC   domain of an EphA or EphB receptor, where the polypeptide comprises an
CC   ephrin ligand binding domain and the polypeptide lacks one or more amino
CC   acids corresponding to the transmembrane domain of the EphA or EphB
CC   receptor where the membrane localization of the polypeptide is reduced or
CC   abolished compared to the EphA or EphB receptor. The polypeptides,
CC   compositions, molecules and methods are useful for treating cancers,
CC   inflammatory diseases, infectious diseases angiogenesis-related
CC   conditions (conditions involving angiogenesis), cell proliferation-
CC   related conditions, conditions involving hyperproliferation of cells,
CC   immune disorders and neurodegenerative diseases. The disease or condition
CC   is selected from rheumatoid arthritis, multiple sclerosis, posterior
CC   intraocular inflammation, uveitic disorders, ocular surface inflammatory
CC   disorders, neovascular disease, proliferative vitreoretinopathy,
CC   atherosclerosis, rheumatoid arthritis, hemangioma, diabetes mellitus,
CC   inflammatory bowel disease, psoriasis, Alzheimer's disease, lupus,
CC   vascular stenosis, restenosis, inflammatory joint disease,
CC   atherosclerosis, urinary obstructive syndromes, and asthma. The disease
CC   or condition is selected from carcinoma, lymphoma, blastoma, sarcoma,
CC   leukemia, lymphoid malignancies, squamous cell cancer, small-cell lung
CC   cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous
CC   carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer,
CC   gastric cancer, stomach cancer, gastrointestinal cancer, pancreatic
CC   cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer,
CC   bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer,
CC   colorectal cancer, endometrial or uterine carcinoma, salivary gland
CC   carcinoma, kidney/renal cancer, prostate cancer, vulval cancer, thyroid
CC   cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and
CC   neck cancer. The disease or condition includes infection by a virus or a
CC   parasite. The virus is selected from Myxoma virus, Vaccinia virus,
CC   Tanapox virus, Epstein-Barr virus, Herpes simplex virus, Cytomegalovirus,
CC   Herpesvirus saimiri, Hepatitis B virus, African swine fever virus,
CC   Parovirus, Human Immune deficiency virus (HIV), Hepatitis C virus,
CC   Influenza virus, Respiratory syncytial virus, Measles virus, Vesicular
CC   stomatitis virus, Dengue virus and Ebola virus. The combination is useful
CC   for treating angiogenic-related disorder, a tumor and/or an immune
CC   disorder. This sequence represents a primer for isolation of DNA encoding
CC   a cell surface receptor isoform polynucleotide.
XX
SQ   Sequence 22 BP; 5 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        249 CAUGGUCAGCUACUGGGACACC 270
              ||:||:||||:||:||||||||
Db          1 CATGGTCAGCTACTGGGACACC 22


RESULT 517
AEE49157/c
ID   AEE49157 standard; DNA; 22 BP.
```

XX
AC AEE49157;
XX
DT 09-FEB-2006 (first entry)
XX
DE Cell surface receptor isoform primer SEQ ID NO 76.
XX
KW immunosuppressive; cytostatic; nootropic; neuroprotective; antiarthritic;
KW antiinflammatory; antirheumatic; virucide; pharmaceutical; therapeutic;
KW cell signaling; cell proliferation; angiogenesis; neovascularization;
KW neurodegenerative disease; neuroprotective; neurological disease;
KW inflammation; hyperproliferation; cancer; parasitic infection;
KW antiparasitic; viral infection; virucide; infection;
KW angiogenesis disorder; antiangiogenic; cardiovascular disease; tumor;
KW neoplasm; immune disorder; cell surface receptor; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2005113596-A2.
XX
PD 01-DEC-2005.
XX
PF 13-MAY-2005; 2005WO-US017051.
XX
PR 14-MAY-2004; 2004US-0571289P.
PR 18-JUN-2004; 2004US-0580990P.
PR 30-MAR-2005; 2005US-0666825P.
XX
PA (RECE-) RECEPTOR BIOLOGIX INC.
XX
PI Jin P, Shepard MH;
XX
DR WPI; 2005-812226/82.
XX
PT New polypeptides, specifically isoforms of cell surface receptors, such
PT as EphA, VEGF, MET, RON, CSF, etc, useful treating cancer, or
PT inflammatory, infectious, angiogenesis-related conditions, or immune
PT disorders.
XX
PS Example 1; SEQ ID NO 76; 647pp; English.
XX
CC The invention describes an isolated polypeptide, comprising at least one
CC domain of an EphA or EphB receptor, where the polypeptide comprises an
CC ephrin ligand binding domain and the polypeptide lacks one or more amino
CC acids corresponding to the transmembrane domain of the EphA or EphB
CC receptor where the membrane localization of the polypeptide is reduced or
CC abolished compared to the EphA or EphB receptor. The polypeptides,
CC compositions, molecules and methods are useful for treating cancers,
CC inflammatory diseases, infectious diseases angiogenesis-related
CC conditions (conditions involving angiogenesis), cell proliferation-
CC related conditions, conditions involving hyperproliferation of cells,
CC immune disorders and neurodegenerative diseases. The disease or condition
CC is selected from rheumatoid arthritis, multiple sclerosis, posterior
CC intraocular inflammation, uveitic disorders, ocular surface inflammatory
CC disorders, neovascular disease, proliferative vitreoretinopathy,
CC atherosclerosis, rheumatoid arthritis, hemangioma, diabetes mellitus,
CC inflammatory bowel disease, psoriasis, Alzheimer's disease, lupus,
CC vascular stenosis, restenosis, inflammatory joint disease,
CC atherosclerosis, urinary obstructive syndromes, and asthma. The disease
CC or condition is selected from carcinoma, lymphoma, blastoma, sarcoma,
CC leukemia, lymphoid malignancies, squamous cell cancer, small-cell lung
CC cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous
CC carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer,
CC gastric cancer, stomach cancer, gastrointestinal cancer, pancreatic
CC cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer,
CC bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer,
CC colorectal cancer, endometrial or uterine carcinoma, salivary gland
CC carcinoma, kidney/renal cancer, prostate cancer, vulval cancer, thyroid
CC cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and
CC neck cancer. The disease or condition includes infection by a virus or a
CC parasite. The virus is selected from Myxoma virus, Vaccinia virus,
CC Tanapox virus, Epstein-Barr virus, Herpes simplex virus, Cytomegalovirus,
CC Herpesvirus saimiri, Hepatitis B virus, African swine fever virus,
CC Parovirus, Human Immune deficiency virus (HIV), Hepatitis C virus,
CC Influenza virus, Respiratory syncytial virus, Measles virus, Vesicular
CC stomatitis virus, Dengue virus and Ebola virus. The combination is useful
CC for treating angiogenic-related disorder, a tumor and/or an immune
CC disorder. This sequence represents a primer for isolation of DNA encoding
CC a cell surface receptor isoform polynucleotide.
XX
SQ Sequence 22 BP; 5 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 22; DB 1; Length 22;
Best Local Similarity 77.3%; Pred. No. 2e+03;
Matches 17; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1763 UCACUCAGCGCAUGGCAAUAAU 1784
:|||:|||||||:|||||:||:
Db 22 TCACTCAGCGCATGGCAATAAT 1

RESULT 518
ADY89188
ID ADY89188 standard; RNA; 23 BP.
XX
AC ADY89188;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2224.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2224; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.

```
XX
SQ   Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2692 UAUGAUGCCAGCAAGUGGGAGU 2713
              ||||||||||||||||||||||
Db          2 UAUGAUGCCAGCAAGUGGGAGU 23


RESULT 519
ADY89178
ID   ADY89178 standard; RNA; 23 BP.
XX
AC   ADY89178;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2214.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2214; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGG 2710
              ||||||||||||||||||||||
Db          2 CCUUAUGAUGCCAGCAAGUGGG 23


RESULT 520
ADY89185
ID   ADY89185 standard; RNA; 23 BP.
XX
AC   ADY89185;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2221.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2221; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2690 CUUAUGAUGCCAGCAAGUGGGA 2711
              ||||||||||||||||||||||
Db          1 CUUAUGAUGCCAGCAAGUGGGA 22
```

```
RESULT 521
AED38423
ID   AED38423 standard; RNA; 23 BP.
XX
AC   AED38423;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2224.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2224; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 6 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2692 UAUGAUGCCAGCAAGUGGGAGU 2713
              ||||||||||||||||||||||
Db          2 UAUGAUGCCAGCAAGUGGGAGU 23


RESULT 522
AED38413
ID   AED38413 standard; RNA; 23 BP.
XX
AC   AED38413;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2214.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
```

PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2214; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 5 A; 5 C; 8 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 22; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2689 CCUUAUGAUGCCAGCAAGUGGG 2710
||||||||||||||||||||||
Db 2 CCUUAUGAUGCCAGCAAGUGGG 23

RESULT 523
AED38420
ID AED38420 standard; RNA; 23 BP.
XX
AC AED38420;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2221.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2221; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 7 A; 4 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 22; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2690 CUUAUGAUGCCAGCAAGUGGGA 2711
||||||||||||||||||||||
Db 1 CUUAUGAUGCCAGCAAGUGGGA 22

RESULT 524
ADB38952
ID ADB38952 standard; DNA; 25 BP.
XX
AC ADB38952;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human interleukin 1RNic single nucleotide polymorphism (SNP) region 21.
XX

```
KW   interleukin 1 gene cluster; IL-1 gene cluster; IL-1 like gene;
KW   IL-1 locus; single nucleotide polymorphisms; SNP; IL-1 haplotype;
KW   inflammatory disease; IL-1 associated inflammatory phenotype;
KW   primary inflammatory cytokine; IL-1 alpha; IL-1 beta; IL1A; IL1B; IL1RN;
KW   IL-1 receptor antagonist; IL-1RA; anti-inflammatory; chromosome 2q13;
KW   antiinflammatory; antiarthritic; hepatotropic; osteopathic; gene therapy;
KW   arthritis; hepatic inflammation; chronic obstructive pulmonary disease;
KW   osteoporosis; ds; IL-1RNic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(11,T)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO2003064600-A2.
XX
PD   07-AUG-2003.
XX
PF   27-JAN-2003; 2003WO-US002232.
XX
PR   25-JAN-2002; 2002US-0351951P.
XX
PA   (INTE-) INTERLEUKIN GENETICS INC.
XX
PI   Nicklin M,  Duff G,  Kornman K,  Kolpin MR,  Hsieh C,  Govindaraju R;
PI   Aziz N;
XX
DR   WPI; 2003-618359/58.
XX
PT   Determining whether the subject has or is predisposed to developing a
PT   disease or condition that is associated with an IL-1 inflammatory
PT   haplotype, useful for treating inflammation, comprises detecting an IL-1
PT   allele.
XX
PS   Claim 18; Fig 10A; 96pp; English.
XX
CC   This invention relates to the identification and use of genetic
CC   information from the human interleukin 1 (IL-1) gene cluster including
CC   the structure and organisation of novel IL-1 like genes found within the
CC   IL-1 locus as well as polymorphisms (single nucleotide polymorphisms;
CC   SNPs) and associated haplotypes within these genes. The invention also
CC   relates to the use of these polymorphisms and haplotypes for predicting
CC   IL-1 associated phenotypes (for example increased or decreased risk of
CC   inflammatory disease) and for treating IL-1 associated inflammatory
CC   phenotypes. IL-1 is a primary inflammatory cytokine and has been
CC   implicated in mediating both acute and chronic pathological inflammatory
CC   diseases. Two functionally similar molecules, IL-1 alpha and IL-1 beta,
CC   are encoded by genes IL1A and IL1B. A third gene of the family (IL1RN)
CC   encodes IL-1 receptor antagonist (IL-1RA), an anti-inflammatory non-
CC   signalling molecule that competes for receptor binding with IL-1 alpha
CC   and IL-1 beta. The IL-1 gene cluster is on the long arm of chromosome 2
CC   (2q13). Compounds which modulate the activity of IL-1 alpha, IL-1 beta or
CC   IL-1RA may have antiinflammatory, antiarthritic, hepatotropic or
CC   osteopathic activity. In addition, the sequences encoding the IL-1
CC   proteins may be useful for gene therapy. The methods and polynucleotide
CC   sequence may be useful for diagnosing and treating an inflammatory
CC   disease, for example arthritis, hepatic inflammation, chronic obstructive
CC   pulmonary disease and osteoporosis. The present sequence is that of the
CC   region surrounding and including a single nucleotide polymorphism of the
CC   invention in the human IL1RN gene.
XX
SQ   Sequence 25 BP; 0 A; 1 C; 11 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 2.6e+03;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
             |:|:|:|:|: :|:|: :|:|:|:|
Db          1 GTGTGTGTGTCTGTGTTTGTGTGTG 25
```

```
RESULT 525
ADU79977/c
ID   ADU79977 standard; DNA; 25 BP.
XX
AC   ADU79977;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Flt-1 PCR primer SEQ ID NO 7.
XX
KW   tissue disintegration; neuroprotective; antiparkinsonian; antiasthmatic;
KW   hepatotropic; virucide; antidiabetic; antiulcer;
KW   general gastrointestinal; general respiratory; cardiant; nephrotropic;
KW   antiinflammatory; dermatological; neurological disease;
KW   Parkinson's disease; respiratory disease; asthma; circulatory disease;
KW   myocardial infarction; liver disease; hepatitis; pancreatic disease;
KW   diabetes; digestive tract disease; ulcerative colitis; kidney disease;
KW   nephritis; genitourinary disease; dermatological disorder; ss; primer;
KW   PCR; Flt-1.
XX
OS   Unidentified.
XX
PN   WO2004101775-A1.
XX
PD   25-NOV-2004.
XX
PF   14-MAY-2004; 2004WO-JP006912.
XX
PR   16-MAY-2003; 2003JP-00139605.
PR   09-OCT-2003; 2003JP-00351168.
PR   17-DEC-2003; 2003JP-00419400.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
PA   (UYKE-) UNIV KEIO.
XX
PI   Suda T,  Hirao A,  Arai F,  Sakurada K,  Yamada Y,  Ando H,  Sato H;
PI   Yokoyama H,  Ishihara M;
XX
DR   WPI; 2004-834002/82.
XX
PT   Novel CD45 negative and CXCR4 positive stem cells derived from adult
PT   tissue, useful for prophylaxis and/or treatment of diseases involving
PT   tissue disintegration such as neurological and respiratory diseases.
XX
PS   Example 1; SEQ ID NO 7; 57pp; Japanese.
XX
CC   This invention describes a novel pluripotent stem cell derived from an
CC   adult tissue which is CD45 negative and CXCR4 positive. The novel cells
CC   are extracted from human bone marrow, skin, skeletal muscle, fat tissue
CC   or peripheral blood by collagenase treatment and separated using anti-
CC   CD45, anti-CD34 and anti-Ter119 antibodies. The stem cells can be used as
CC   preventative and/or therapeutic agents for diseases involving tissue
CC   disintegration. Proliferating the stem cells involves culturing the cells
CC   in a culture medium containing fibronectin and macrophage colony
CC   stimulating factor (M-CSF) and/or leukemia inhibiting factor (LIF). The
CC   products of the invention have neuroprotective, antiparkinsonian,
CC   antiasthmatic, hepatotropic, virucide, antidiabetic, antiulcer, general
CC   gastrointestinal, general respiratory, cardiant, nephrotropic,
CC   antiinflammatory and dermatological activity. The invention is useful for
CC   prophylaxis and/or treatment of diseases involving tissue disintegration
CC   such as neurological disease e.g. Parkinson's disease, respiratory
CC   disease e.g. asthma, circulatory disease e.g. myocardial infarction,
CC   liver disease e.g. hepatitis, pancreatic disease e.g. diabetes, digestive
CC   tract disease e.g. ulcerative colitis, kidney disease e.g. nephritis and
CC   dermatological disorders e.g. bedsores. This sequence represents a PCT
CC   primer used to amplify the Flt-1 gene, which is associated with the
CC   method of the invention.
XX
SQ   Sequence 25 BP; 7 A; 5 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.6e+03;
```

```
  Matches   16;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3249 UUCUUACAGUUUUCAAGUGGCCAGA 3273
              ::| :||||::: ||||:|||||||
Db         25 TTCCTACAGTTTCCAAGTGGCCAGA 1


RESULT 526
ADU79976
ID   ADU79976 standard; DNA; 25 BP.
XX
AC   ADU79976;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Flt-1 PCR primer SEQ ID NO 6.
XX
KW   tissue disintegration; neuroprotective; antiparkinsonian; antiasthmatic;
KW   hepatotropic; virucide; antidiabetic; antiulcer;
KW   general gastrointestinal; general respiratory; cardiant; nephrotropic;
KW   antiinflammatory; dermatological; neurological disease;
KW   Parkinson's disease; respiratory disease; asthma; circulatory disease;
KW   myocardial infarction; liver disease; hepatitis; pancreatic disease;
KW   diabetes; digestive tract disease; ulcerative colitis; kidney disease;
KW   nephritis; genitourinary disease; dermatological disorder; ss; primer;
KW   PCR; Flt-1.
XX
OS   Unidentified.
XX
PN   WO2004101775-A1.
XX
PD   25-NOV-2004.
XX
PF   14-MAY-2004; 2004WO-JP006912.
XX
PR   16-MAY-2003; 2003JP-00139605.
PR   09-OCT-2003; 2003JP-00351168.
PR   17-DEC-2003; 2003JP-00419400.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
PA   (UYKE-) UNIV KEIO.
XX
PI   Suda T,  Hirao A,  Arai F,  Sakurada K,  Yamada Y,  Ando H,  Sato H;
PI   Yokoyama H,  Ishihara M;
XX
DR   WPI; 2004-834002/82.
XX
PT   Novel CD45 negative and CXCR4 positive stem cells derived from adult
PT   tissue, useful for prophylaxis and/or treatment of diseases involving
PT   tissue disintegration such as neurological and respiratory diseases.
XX
PS   Example 1; SEQ ID NO 6; 57pp; Japanese.
XX
CC   This invention describes a novel pluripotent stem cell derived from an
CC   adult tissue which is CD45 negative and CXCR4 positive. The novel cells
CC   are extracted from human bone marrow, skin, skeletal muscle, fat tissue
CC   or peripheral blood by collagenase treatment and separated using anti-
CC   CD45, anti-CD34 and anti-Ter119 antibodies. The stem cells can be used as
CC   preventative and/or therapeutic agents for diseases involving tissue
CC   disintegration. Proliferating the stem cells involves culturing the cells
CC   in a culture medium containing fibronectin and macrophage colony
CC   stimulating factor (M-CSF) and/or leukemia inhibiting factor (LIF). The
CC   products of the invention have neuroprotective, antiparkinsonian,
CC   antiasthmatic, hepatotropic, virucide, antidiabetic, antiulcer, general
CC   gastrointestinal, general respiratory, cardiant, nephrotropic,
CC   antiinflammatory and dermatological activity. The invention is useful for
CC   prophylaxis and/or treatment of diseases involving tissue disintegration
CC   such as neurological disease e.g. Parkinson's disease, respiratory
CC   disease e.g. asthma, circulatory disease e.g. myocardial infarction,
CC   liver disease e.g. hepatitis, pancreatic disease e.g. diabetes, digestive
CC   tract disease e.g. ulcerative colitis, kidney disease e.g. nephritis and
CC   dermatological disorders e.g. bedsores. This sequence represents a PCT
CC   primer used to amplify the Flt-1 gene, which is associated with the
CC   method of the invention.
XX
SQ   Sequence 25 BP; 5 A; 5 C; 8 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 2.6e+03;
  Matches   16;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2958 GCCUCUGAUGGUGAUUGUUGAAUAC 2982
              |||:|:||:||:||: |: |||:||
Db          1 GCCTCTGATGGTGATCGTGGAATAC 25


RESULT 527
ADW15365
ID   ADW15365 standard; DNA; 25 BP.
XX
AC   ADW15365;
XX
DT   07-APR-2005  (first entry)
XX
DE   Human CFTR probe SEQ ID NO 185.
XX
KW   DNA polymorphism; snp detection; microarray;
KW   Cystic Fibrosis Transmembrane Conductance Regulator; CFTR;
KW   cystic fibrosis; cns-gen.; respiratory-gen.; gastrointestinal disease;
KW   respiratory disease; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO2005006951-A2.
XX
PD   27-JAN-2005.
XX
PF   09-JUL-2004; 2004WO-US021909.
XX
PR   10-JUL-2003; 2003US-0486763P.
XX
PA   (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
PI   Gardner P,  Schrijver I;
XX
DR   WPI; 2005-132248/14.
XX
PT   Determining whether a subject carries a Cystic Fibrosis Transmembrane
PT   Conductance Regulator (CFTR) gene mutation comprises contacting an array
PT   comprising distinct nucleic acid CFTR gene mutation probes with a nucleic
PT   acid sample.
XX
PS   Disclosure; SEQ ID NO 185; 52pp; English.
XX
CC   The invention describes methods for determining whether a subject carries
CC   a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene
CC   mutation comprising use of a nucleic acid array of CFTR gene mutation
CC   probes. Also described are: determining (M1) whether a subject carries a
CC   Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutation,
CC   comprising: contacting an array of distinct nucleic acid CFTR gene
CC   mutation probes with a sample; contacting the sample-contacted array with
CC   a polymerase and at least two distinguishably labeled dideoxynucleotides
CC   under primer extension conditions; and detecting the presence of any
CC   resultant terminally labeled nucleic acids immobilized on the array to
CC   determine whether the subject carries a CFTR mutation; determining (M2)
CC   whether a subject carries a Cystic Fibrosis Transmembrane Conductance
CC   Regulator (CFTR) gene mutation, comprising: contacting an array of at
CC   least 50 distinct nucleic acid CFTR gene mutation probes with a sample;
CC   and detecting the presence of any target nucleic acids immobilized on the
CC   array to determine whether the subject carries a CFTR mutation; an array
CC   comprising at least 50 distinct nucleic acid CFTR gene mutation probes
CC   immobilized on a solid support; and a kit for use in detecting a CFTR
CC   mutation comprising the array and at least two distinguishably labeled
CC   dideoxynucleotides (ddNTPs). The methods are useful in determining
CC   whether a subject carries a Cystic Fibrosis Transmembrane Conductance
CC   Regulator (CFTR) gene mutation. The method allows simultaneous screening
```

```
CC   for large numbers of distinct CFTR mutations and is suitable for routine
CC   CF carrier screening. This sequence represents a probe used to detect
CC   mutations in the CFTR gene.
XX
SQ   Sequence 25 BP; 0 A; 0 C; 10 G; 15 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   40.0%;  Pred. No. 2.6e+03;
  Matches   10;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|: : :
Db          1 TGTGTGTGTGTGTGTGTGTTTTT 25


RESULT 528
AEE01146
ID   AEE01146 standard; DNA; 25 BP.
XX
AC   AEE01146;
XX
DT   26-JAN-2006  (first entry)
XX
DE   Human interleukin (IL)-1RNic SNP fragment DNA #5.
XX
KW   periodontal disease; interleukin; IL-1RNic; ds; SNP;
KW   singlenucleotide polymorphism.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(11,g)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO2005108619-A2.
XX
PD   17-NOV-2005.
XX
PF   03-MAY-2005; 2005WO-US015267.
XX
PR   03-MAY-2004; 2004US-0567727P.
XX
PA   (INTE-) INTERLEUKIN GENETICS INC.
XX
PI   Duff GW,  Kornman K,  Wilkins L,  Chen HM,  Rogus J;
XX
DR   WPI; 2005-811015/82.
XX
PT   Identifying a subject having increased IL-1B transcription, for
PT   identifying if the subject is predisposed to periodontal disease, by
PT   providing a biological sample comprising genomic DNA, and identifying an
PT   IL-1B allele in the sample.
XX
PS   Example 8; Page 70; 126pp; English.
XX
CC   The invention relates to a method of identifying a subject having
CC   increased IL-1B transcription providing a biological sample comprising
CC   genomic DNA from the subject, and identifying an IL-1B allele selected
CC   from IL-1B (-3737) allele 1 and/or IL-1B (-1468) allele 1 in the sample,
CC   where the presence of the allele indicates that the subject has increased
CC   IL-1B transcription. The methods are useful for identifying if the
CC   subject is predisposed to periodontal disease, and as assays for
CC   identifying therapeutics for treating and/or preventing the development
CC   of the disease. The present sequence represents a human interleukin (IL)-
CC   1RNic SNP fragment DNA.
XX
SQ   Sequence 25 BP; 0 A; 1 C; 11 G; 13 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 2.6e+03;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|: :|:|: :|:|:|:|
Db          1 GTGTGTGTGTCTGTGTTTGTGTGTG 25


RESULT 529
AAH23021/c
ID   AAH23021 standard; DNA; 23 BP.
XX
AC   AAH23021;
XX
DT   17-SEP-2001  (first entry)
XX
DE   VEGFR-2 gene specific reverse primer.
XX
KW   Vascular endothelial growth factor; VEGF; antisense; angiogenesis;
KW   cell proliferation; Kaposi's sarcoma; cancer; melanoma; cytostatic;
KW   antisense therapy; RT-PCR; primer; VEGFR-2; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200152904-A2.
XX
PD   26-JUL-2001.
XX
PF   19-JAN-2001; 2001WO-US000019.
XX
PR   19-JAN-2000; 2000US-00487023.
XX
PA   (GILL/) GILL P S.
XX
PI   Gill PS,  Masood R;
XX
DR   WPI; 2001-451898/48.
XX
PT   Novel antisense oligonucleotides useful for inhibiting vascular
PT   endothelial growth factor expression, angiogenesis and for treating
PT   cancer, e.g., Kaposi's sarcoma, ovarian cancer and prostrate cancer.
XX
PS   Example 12; Page 56; 105pp; English.
XX
CC   The invention provides a composition comprising one or more antisense
CC   oligonucleotides directed against vascular endothelial growth factor
CC   (VEGF) where the antisense oligonucleotides inhibits proliferation of
CC   cells exhibiting autocrine VEGF activity at an IC_5_0 concentration of
CC   between 0.5-2.5 micro Ma. The antisense oligonucleotides may be directed
CC   against VEGF for inhibiting cancer cell proliferation and angiogenesis.
CC   Preferably the oligonucleotide AAH23032 (a modified version of AAH22984)
CC   is used and may be utilized to treat Kaposi's sarcoma, ovarian cancer,
CC   prostrate cancer, pancreatic cancer or melanoma. Sequences AAH23012-023
CC   represent gene-specific primers used in RT-PCR amplification of VEGF
CC   receptors
XX
SQ   Sequence 23 BP; 4 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||| ||:||:||||:||:||||
Db         23 CAGACCATGCTGGACTGCTGGCA 1


RESULT 530
ADF17593
ID   ADF17593 standard; DNA; 23 BP.
XX
AC   ADF17593;
XX
DT   12-FEB-2004  (first entry)
XX
```

```
DE   Flt-1 PCR primer SEQ ID NO:5.
XX
KW   neovascularisation agent; activin stimulator;
KW   anti-neovascularisation agent; activin inhibitor;
KW   neovascularisation regulator; ischaemic condition; atherosclerosis;
KW   occlusive arteriosclerosis; lower limb vascular occlusion;
KW   myocardial infarction; angina pectoris; cerebral embolism;
KW   recalcitrant skin ulcer; diabetes; pancreatic islet cell regeneration;
KW   diabetic retinopathy; senile macular degeneration;
KW   chronic rheumatoid arthritis; cancer; psoriasis vulgaris; PCR primer;
KW   Flt-1; ss.
XX
OS   Synthetic.
XX
PN   WO2003094966-A1.
XX
PD   20-NOV-2003.
XX
PF   12-MAY-2003; 2003WO-JP005901.
XX
PR   10-MAY-2002; 2002JP-00135575.
XX
PA   (AJIN ) AJINOMOTO CO INC.
XX
PI   Kojima I,  Maeshima K,  Eto Y;
XX
DR   WPI; 2003-903943/82.
XX
PT   Agents promoting or suppressing neovascularization containing activin
PT   stimulator or activin inhibitor, to treat ischemic conditions, diabetes
PT   and skin ulcers, or rheumatoid arthritis, diabetic retinopathy and
PT   cancer, etc.
XX
PS   Example 2; SEQ ID NO 5; 37pp; Japanese.
XX
CC   The present invention describes a neovascularisation agent (I), which has
CC   an activin stimulator as an active component. Also described: (1) an anti
CC   -neovascularisation agent (II) containing an activin inhibitor as an
CC   active component; and (2) a neovascularisation regulator comprising (I)
CC   and (II). The neovascularisation agent (I) can be used to prevent or
CC   treat ischaemic conditions, atherosclerosis, occlusive arteriosclerosis,
CC   lower limb vascular occlusion, myocardial infarction, angina pectoris,
CC   cerebral embolism, recalcitrant skin ulcers; and diabetes, through
CC   pancreatic islet cell regeneration. The anti-neovascularisation agent
CC   (II) can be used to prevent or treat diabetic retinopathy, senile macular
CC   degeneration, chronic rheumatoid arthritis, cancer, psoriasis vulgaris.
CC   The present sequence represents a PCR primer for Flt-1, which is used in
CC   an example from the present invention.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3475 UACAGCACCAAGAGCGACGUGUG 3497
              :| |||||||||||||||||:|:|
Db          1 TATAGCACCAAGAGCGACGTGTG 23


RESULT 531
ABX90512/c
ID   ABX90512 standard; DNA; 23 BP.
XX
AC   ABX90512;
XX
DT   01-MAY-2003  (first entry)
XX
DE   Human VEGFR-2 RT-PCR primer #2.
XX
KW   Antisense; ss; PCR; VEGF; vascular endothelial growth factor; human;
KW   cancer; angiogenesis; neoplastic proliferation; cellular proliferation;
KW   primer; RT-PCR; reverse transcriptase PCR.
XX
OS   Homo sapiens.
XX
PN   US2002165174-A1.
XX
PD   07-NOV-2002.
XX
PF   13-MAR-2001; 2001US-00805761.
XX
PR   31-JAN-1997;   97US-0037004P.
PR   30-JAN-1998;   98US-00016541.
PR   19-JAN-2000; 2000US-00487023.
PR   19-JAN-2001; 2001WO-US000019.
XX
PA   (GILL/) GILL P S.
PA   (MASO/) MASOOD R.
XX
PI   Gill PS,  Masood R;
XX
DR   WPI; 2003-255224/25.
XX
PT   New composition comprising an antisense oligonucleotide directed against
PT   vascular endothelial growth factor, useful for preparing a composition
PT   for treating cancer.
XX
PS   Example 12; Page 19; 54pp; English.
XX
CC   The invention relates to a composition comprising an antisense
CC   oligonucleotide directed against vascular endothelial growth factor
CC   (VEGF). The antisense oligonucleotide is useful for preparing a
CC   composition treating cancer, neoplastic proliferation, abnormal cellular
CC   proliferation and preventing angiogenesis. The present sequence is a
CC   reverse transcriptase (RT)-PCR primer for a VEGF or related gene, used to
CC   clone the coding region for expression in tumour cell lines. The cell
CC   lines were used to test prospective antisense oligonucleotides
XX
SQ   Sequence 23 BP; 4 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||| ||:||:||||:||:||||
Db         23 CAGACCATGCTGGACTGCTGGCA 1


RESULT 532
ADH70580/c
ID   ADH70580 standard; DNA; 23 BP.
XX
AC   ADH70580;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #370.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
```

```
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 774; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 23 BP; 12 A; 10 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   43.5%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|: :|:|:|:|:|:|:
Db         23 TGTGTGTGTGTATGTGTGTGTGT 1


RESULT 533
ADY89174
ID   ADY89174 standard; RNA; 23 BP.
XX
AC   ADY89174;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2210.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2210; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUGG 2709
              |||||||||||||||||||||||
Db          1 UGCCUUAUGAUGCCAGCAAGUGG 23


RESULT 534
ADY89179
ID   ADY89179 standard; RNA; 23 BP.
XX
AC   ADY89179;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2215.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
```

```
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2215; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
             |||||||||||||||||| |||||
Db          1 CCUUAUGAUGCCAGCAAAUGGGA 23


RESULT 535
ADY89189
ID   ADY89189 standard; RNA; 23 BP.
XX
AC   ADY89189;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2225.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2225; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 7 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2691 UUAUGAUGCCAGCAAGUGGGAGU 2713
             |||||||||||||||||||| |
Db          1 UUAUGAUGCCAGCAAGUGGGAAU 23


RESULT 536
ADY89200
ID   ADY89200 standard; RNA; 23 BP.
XX
AC   ADY89200;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2236.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
```

```
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2236; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
             |||| ||||||||||||||||||||
Db          1 CAGACCAUGCUGGACUGCUGGCA 23


RESULT 537
ADY89181
ID   ADY89181 standard; RNA; 23 BP.
XX
AC   ADY89181;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2217.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2217; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 6 A; 6 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
              || ||||||||||||||||||||
Db          1 CCCUAUGAUGCCAGCAAGUGGGA 23


RESULT 538
ADY89184
ID   ADY89184 standard; RNA; 23 BP.
XX
AC   ADY89184;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2220.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2220; 396pp; English.
XX
```

```
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2690 CUUAUGAUGCCAGCAAGUGGGAG 2712
              | ||||||||||||||||||||||
Db          1 CCUAUGAUGCCAGCAAGUGGGAG 23


RESULT 539
ADY89205
ID   ADY89205 standard; RNA; 23 BP.
XX
AC   ADY89205;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2241.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2241; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3641 AGAUCAUGCUGGACUGCUGGCAC 3663
              ||| ||||||||||||||||||||
Db          1 AGACCAUGCUGGACUGCUGGCAC 23


RESULT 540
AED38414
ID   AED38414 standard; RNA; 23 BP.
XX
AC   AED38414;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2215.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
```

```
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2215; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
                ||||||||||||||||| |||||
Db          1 CCUUAUGAUGCCAGCAAAUGGGA 23


RESULT 541
AED38435
ID   AED38435 standard; RNA; 23 BP.
XX
AC   AED38435;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2236.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2236; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
                ||||  ||||||||||||||||||
Db          1 CAGACCAUGCUGGACUGCUGGCA 23


RESULT 542
AED38409
ID   AED38409 standard; RNA; 23 BP.
XX
AC   AED38409;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2210.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
```

```
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2210; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 5 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUGG 2709
                | ||||||||||||||||||||||
Db          1 UGCCUUAUGAUGCCAGCAAGUGG 23
```

```
RESULT 543
AED38424
ID   AED38424 standard; RNA; 23 BP.
XX
AC   AED38424;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2225.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
```

PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2225; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 7 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.3%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 2.4e+03;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2691 UUAUGAUGCCAGCAAGUGGGAGU 2713
||||||||||||||||||||| |
Db 1 UUAUGAUGCCAGCAAGUGGGAAU 23

RESULT 544
AED38416
ID AED38416 standard; RNA; 23 BP.
XX
AC AED38416;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2217.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409493P.
PR 15-JAN-2003; 2003US-0440129P.
PR 14-FEB-2003; 2003WO-US004566.
PR 20-FEB-2003; 2003WO-US005022.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004WO-US013456.
PR 11-MAY-2004; 2004US-00844076.
PR 24-MAY-2004; 2004WO-US016390.
PR 09-JUN-2004; 2004US-00863973.
PR 20-AUG-2004; 2004US-00922675.
PR 16-SEP-2004; 2004US-00944611.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-664178/68.
XX
PT New multifunctional siNA molecule comprising a structure having Formula
PT MF-III, useful for treating a respiratory disease selected from asthma,
PT COPD, and allergic rhinitis.
XX
PS Example 13; SEQ ID NO 2217; 266pp; English.
XX
CC The invention comprises short interfering nucleic acid (siNA) molecules
CC which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC (VEGFR) gene expression. The siNA molecules of the invention are useful
CC for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC siRNA sequence that was used in an example of the invention.
XX
SQ Sequence 23 BP; 6 A; 6 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 0.3%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 2.4e+03;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2689 CCUUAUGAUGCCAGCAAGUGGGA 2711
|| |||||||||||||||||||
Db 1 CCCUAUGAUGCCAGCAAGUGGGA 23

RESULT 545
AED38440
ID AED38440 standard; RNA; 23 BP.
XX
AC AED38440;
XX
DT 15-DEC-2005 (first entry)
XX
DE VEGF or VEGFR-specific siRNA sequence - SEQ ID 2241.
XX
KW vascular endothelial growth factor;
KW vascular endothelial growth factor receptor; respiratory disease;
KW respiratory-gen.; asthma; antiasthmatic;
KW chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW antiinflammatory; RNA interference; gene silencing; siRNA;
KW short interfering RNA; ss.
XX
OS Unidentified.
XX
PN US2005222066-A1.
XX
PD 06-OCT-2005.
XX
PF 12-OCT-2004; 2004US-00962898.
XX
PR 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.

```
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2241; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 5 A; 7 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3641 AGAUCAUGCUGGACUGCUGGCAC 3663
              ||| ||||||||||||||||||||
Db          1 AGACCAUGCUGGACUGCUGGCAC 23


RESULT 546
AED38419
ID   AED38419 standard; RNA; 23 BP.
XX
AC   AED38419;
XX
DT   15-DEC-2005  (first entry)
XX
DE   VEGF or VEGFR-specific siRNA sequence - SEQ ID 2220.
XX
KW   vascular endothelial growth factor;
KW   vascular endothelial growth factor receptor; respiratory disease;
KW   respiratory-gen.; asthma; antiasthmatic;
KW   chronic obstructive pulmonary disease; allergic rhinitis; antiallergic;
KW   antiinflammatory; RNA interference; gene silencing; siRNA;
KW   short interfering RNA; ss.
XX
OS   Unidentified.
XX
PN   US2005222066-A1.
XX
PD   06-OCT-2005.
XX
PF   12-OCT-2004; 2004US-00962898.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   17-MAY-2002; 2002WO-US015876.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409493P.
PR   15-JAN-2003; 2003US-0440129P.
PR   14-FEB-2003; 2003WO-US004566.
PR   20-FEB-2003; 2003WO-US005022.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004WO-US013456.
PR   11-MAY-2004; 2004US-00844076.
PR   24-MAY-2004; 2004WO-US016390.
PR   09-JUN-2004; 2004US-00863973.
PR   20-AUG-2004; 2004US-00922675.
PR   16-SEP-2004; 2004US-00944611.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Richards I,  Mcswiggen J;
XX
DR   WPI; 2005-664178/68.
XX
PT   New multifunctional siNA molecule comprising a structure having Formula
PT   MF-III, useful for treating a respiratory disease selected from asthma,
PT   COPD, and allergic rhinitis.
XX
PS   Example 13; SEQ ID NO 2220; 266pp; English.
XX
CC   The invention comprises short interfering nucleic acid (siNA) molecules
CC   which modulate vascular endothelial growth factor (VEGF) or VEGF receptor
CC   (VEGFR) gene expression. The siNA molecules of the invention are useful
CC   for treating respiratory diseases (e.g. asthma, COPD, and allergic
CC   rhinitis). The present nucleic acid represents a VEGF/VEGFR-specific
```

```
CC   siRNA sequence that was used in an example of the invention.
XX
SQ   Sequence 23 BP; 6 A; 5 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 2.4e+03;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2690 CUUAUGAUGCCAGCAAGUGGGAG 2712
              | ||||||||||||||||||||||
Db          1 CCUAUGAUGCCAGCAAGUGGGAG 23


RESULT 547
AEF05632/c
ID   AEF05632 standard; DNA; 23 BP.
XX
AC   AEF05632;
XX
DT   23-FEB-2006  (first entry)
XX
DE   Human FLT-1 d2 PCR primer #2.
XX
KW   Cytostatic; Antidiabetic; Ophthalmological; Antiarthritic; Antianemic;
KW   Gynecological; Antiangiogenic; FLT-1; fms-like tyrosine kinase; KDR;
KW   tyrosine kinase receptor; VEGF; vascular endothelial growth factor;
KW   pharmaceutical; angiogenesis; tumor; diabetic retinopathy; arthritis;
KW   anemia; hyperplasia; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   WO2005121176-A1.
XX
PD   22-DEC-2005.
XX
PF   08-JUN-2005; 2005WO-CN000802.
XX
PR   08-JUN-2004; 2004CN-00044965.
XX
PA   (CHEN-) CHENGDU KANGHONG TECHNOLOGY ENTERPRISES.
XX
PI   Liu Z;
XX
DR   WPI; 2006-048154/05.
XX
PT   Angiogenesis-inhibiting chimeric recombinant proteins and their encoded
PT   DNA sequences, useful in producing pharmaceutical compositions for drugs
PT   to inhibit angiogenesis and to treat e.g. tumor.
XX
PS   Example 1; Page 8; 31pp; Chinese.
XX
CC   The invention relates to chimeric proteins constructed from various
CC   fragments of FLT-1 (fms-like tyrosine kinase) and KDR, which are tyrosine
CC   kinase receptors of VEGF (vascular endothelial growth factor). The
CC   proteins and their encoded DNA sequences are useful in producing
CC   pharmaceutical compositions for drugs to inhibit angiogenesis and to
CC   treat e.g. tumor, diabetic retinopathy, arthritis, anemia or endometrial
CC   hyperplasia. The present sequence represents a VEGF tyrosine kinase
CC   receptor related protein PCR primer.
XX
SQ   Sequence 23 BP; 4 A; 2 C; 5 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        917 AUCGACAAACCAAUACAAUCAUA 939
              |: ||||||||||:||||:||:|
Db         23 ATGGACAAACCAATACAATCATA 1


RESULT 548
AAT62084/c
ID   AAT62084 standard; DNA; 24 BP.
XX
AC   AAT62084;
XX
DT   25-MAR-2003  (revised)
DT   16-DEC-1997  (first entry)
XX
DE   Primer used in FLT receptor amino-terminal fragment preparation.
XX
KW   Amino-terminal; fragment; vascular endothelial growth factor; VEGF; FLT;
KW   receptor; immunoglobulin; Ig; domain; extracellular; region; treatment;
KW   disorder; cell proliferation; inhibition; neovascularisation;
KW   solid cancer; diagnosis; antibody; soluble; signal transduction;
KW   polymerase chain reaction; amplification; primer; PCR; ss.
XX
OS   Synthetic.
XX
PN   WO9713787-A1.
XX
PD   17-APR-1997.
XX
PF   07-OCT-1996;   96WO-JP002906.
XX
PR   07-OCT-1995;   95JP-00286476.
PR   23-JUL-1996;   96JP-00211892.
XX
PA   (TOAG ) TOA GOSEI KK.
XX
PI   Shibuya M,  Okamoto M,  Matsumoto T,  Segawa T;
XX
DR   WPI; 1997-235841/21.
XX
PT   FLT receptor derived vascular endothelial growth factor inhibitor -
PT   contains the first and second immunoglobulin like domains of the FLT
PT   extracellular region, but not the sixth and seventh.
XX
PS   Disclosure; Page 7; 83pp; Japanese.
XX
CC   The present sequence is a primer used in the preparation of DNA encoding
CC   an amino-terminal fragment of the vascular endothelial growth factor
CC   (VEGF) FLT receptor, which contains the 1st and 2nd immunoglobulin (Ig)
CC   like domains of the FLT extracellular region, but not the 6th and 7th Ig
CC   like domains. The fragment can be used to treat disorders associated with
CC   excessive endothelial cell proliferation or neovascularisation, e.g.
CC   solid cancers. Diagnostic reagents may contain the fragment, or
CC   antibodies raised against it. The fragment is much more soluble than full
CC   length FLT and binds VEGF effectively, resulting in VEGF inhibition
CC   without signal transduction. (Updated on 25-MAR-2003 to correct PA
CC   field.)
XX
SQ   Sequence 24 BP; 5 A; 4 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2.6e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:||||||||||:::|||||  |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 549
AAV01459/c
ID   AAV01459 standard; DNA; 24 BP.
XX
AC   AAV01459;
XX
DT   25-MAR-1998  (first entry)
XX
DE   Human VEGF receptor extracellular domain primer #2.
XX
KW   Immunoglobulin-like domain; extracellular domain; VEGF; human; primer;
KW   vascular endothelial cell growth factor receptor; amplification; PCR;
```

```
KW   truncation; mutant; tumour; vascularisation; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   JP09255700-A.
XX
PD   30-SEP-1997.
XX
PF   22-MAR-1996;   96JP-00066711.
XX
PR   22-MAR-1996;   96JP-00066711.
XX
PA   (TOAG ) TOA GOSEI CHEM IND LTD.
XX
DR   WPI; 1997-532773/49.
XX
PT   Vascular endothelial growth factor binding polypeptide(s) - used in the
PT   treatment of solid tumours etc.
XX
PS   Disclosure; Page 12; 19pp; Japanese.
XX
CC   Primers AAV01458-V01459 were used to amplify the sequence encoding the
CC   extracellular domain of VEGF (vascular endothelial cell growth factor)
CC   receptor FLT (AAV01457). The VEGF receptor sequence can be used to
CC   generate truncated mutants which comprise the immunoglobulin-like domains
CC   1-3, 1-4, 1-5 or 1-7. The polypeptides can be used in treatment of solid
CC   tumours and other diseases accompanied by pathological vascularisation
CC   since they inhibit vascularisation by stimulation with VEGF
XX
SQ   Sequence 24 BP; 5 A; 4 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2.6e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:||||||||||:::|||||  |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 550
AAH39074/c
ID   AAH39074 standard; DNA; 24 BP.
XX
AC   AAH39074;
XX
DT   14-AUG-2001  (first entry)
XX
DE   SNP specific lower PCR primer SEQ ID 1870.
XX
KW   Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW   SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW   Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW   polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW   acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW   inflammation; forensic investigation; paternity analysis; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200129262-A2.
XX
PD   26-APR-2001.
XX
PF   13-OCT-2000; 2000WO-US028436.
XX
PR   15-OCT-1999;   99US-0160096P.
XX
PA   (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI   Picoult-Newburg L,  Pohl M;
XX
DR   WPI; 2001-290930/30.
XX
PT   New genotyping oligonucleotide, useful for detecting the presence,
PT   absence or identity of single polynucleotide polymorphism in a nucleic
PT   acid sample.
XX
PS   Claim 1; Page 59; 83pp; English.
XX
CC   Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC   primer extension (SNPE) primers, and the sequences of regions flanking
CC   sites of single nucleotide polymorphisms SNPs. The present invention
CC   includes kits for determining the presence or absence of a SNP, using the
CC   oligonucleotides of the invention. The PCR primers are used to amplify a
CC   SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC   The oligonucleotides are useful for genotyping a nucleic acid sample by
CC   performing a single-nucleotide primer extension reaction. The
CC   oligonucleotides are useful for determining the presence, absence or
CC   identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC   assess by association analysis the genotype of an individual or group of
CC   individuals, having a pathological phenotypic trait suspected of being
CC   caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC   agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC   osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC   traits also include symptoms of or susceptibility to multifactorial
CC   disease of which a component is or may be genetic such as autoimmune
CC   diseases, including, rheumatoid arthritis, multiple sclerosis,
CC   inflammation, cancer, nervous system diseases and infection by pathogenic
CC   microorganism. The method is also useful in forensic investigations and
CC   paternity analysis. The present sequence represents a PCR primer specific
CC   for a human SNP containing DNA sequence
XX
SQ   Sequence 24 BP; 12 A; 11 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   47.8%;  Pred. No. 2.6e+03;
  Matches   11;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGU 6993
              | :|:|:|:|:|:|:|:|:|:|:
Db         23 ATTGTGTGTGTGTGTGTGTGT 1


RESULT 551
ABZ70239/c
ID   ABZ70239 standard; DNA; 24 BP.
XX
AC   ABZ70239;
XX
DT   25-APR-2003  (first entry)
XX
DE   Murine tricarboxylic acid carrier 13.53 PCR primer #1.
XX
KW   Murine; tricarboxylic acid carrier 13.53; tumour; cytostatic; haemopathy;
KW   HIV infection; anti-HIV; immunological disease; inflammation; PCR;
KW   primer; ss.
XX
OS   Mus sp.
XX
PN   CN1361126-A.
XX
PD   31-JUL-2002.
XX
PF   26-DEC-2000; 2000CN-00136313.
XX
PR   26-DEC-2000; 2000CN-00136313.
XX
PA   (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-751545/82.
XX
PT   New polypeptide murine tricarboxylic acid carrier 13.53 and
```

```
PT   polynucleotides encoding this polypeptide.
XX
PS   Example 2; Page 17 (Disclosure); 33pp; Chinese.
XX
CC   The present invention relates to murine tricarboxylic acid carrier 13.53
CC   (see ABP59163). The protein is useful for treating various diseases, such
CC   as malignant tumours, haemopathy, HIV infection, immunological diseases
CC   and various inflammations. The present sequence is a PCR primer, which
CC   was used in an example from the invention
XX
SQ   Sequence 24 BP; 10 A; 12 C; 2 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   52.2%;  Pred. No. 2.6e+03;
  Matches   12;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:| |:|:|:|
Db         23 GTGTGTGTGTGTGTGCGTGTGTG 1


RESULT 552
ADS85996
ID   ADS85996 standard; DNA; 25 BP.
XX
AC   ADS85996;
XX
DT   18-NOV-2004  (first entry)
XX
DE   PCAV-derived 25mer probe/primer #400.
XX
KW   HERV-K; PCAV; ss; chromosome 22q11.2; prostate cancer; cytostatic; LTR;
KW   long terminal repeat; Alu sequence; MER11a; primer; probe.
XX
OS   Human endogenous retrovirus.
XX
PN   WO2004037972-A2.
XX
PD   06-MAY-2004.
XX
PF   09-DEC-2002; 2002WO-US039136.
XX
PR   07-DEC-2001; 2001US-00016604.
PR   07-DEC-2001; 2001US-0340640P.
PR   07-DEC-2001; 2001WO-US047824.
PR   12-JUN-2002; 2002US-0388046P.
XX
PA   (CHIR ) CHIRON CORP.
XX
PI   Hardy SF,  Garcia P,  Williams LT,  Escobedo J;
XX
DR   WPI; 2004-365501/34.
XX
PT   Diagnosing prostate cancer comprises detecting in a patient sample the
PT   presence or absence of an expression product of a human endogenous
PT   retrovirus (PCAV) located at megabase 20.428 on chromosome 22.
XX
PS   Claim 13; SEQ ID NO 736; 209pp; English.
XX
CC   The invention relates to diagnosing prostate cancer comprises detecting
CC   in a patient sample the presence or absence of an expression product of a
CC   human endogenous retrovirus (PCAV) located at megabase 20.428 on
CC   chromosome 22. PCAV is a HERV-K family retrovirus and has Alu sequence
CC   interrupting the env gene, a unique gag sequence a MER11a insertion
CC   element , 2 tandem 5' LTRs (long terminal repeat) and a fragmented 3'
CC   LTR. Also included are cDNAs, mRNAs, genes, polypeptides, transcription
CC   units, splice junction sequences and splice acceptor/donor sequences
CC   derived or expressed from PCAV, primer/probes for PCAV, an antibody that
CC   binds to the polypeptide, a pharmaceutical composition comprising the
CC   nucleic acid, polypeptide or antibody and a carrier, raising an immune
CC   response in a patient and screening for compounds with activity against
CC   cancer or prostate cancer. The method is useful for diagnosing or raising
CC   an immune response against prostate cancer. The present sequence is a
CC   PCAV sequence suitable for use as a PCR primer or probe.
XX
SQ   Sequence 25 BP; 1 A; 1 C; 11 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 25;
  Best Local Similarity   47.8%;  Pred. No. 2.8e+03;
  Matches   11;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|: :|:|:|:|:|:|
Db          3 CTGTGTGTGTATGTGTGTGTGTG 25


RESULT 553
ADD69512
ID   ADD69512 standard; DNA; 23 BP.
XX
AC   ADD69512;
XX
DT   15-JAN-2004  (first entry)
XX
DE   5' anchored (ISSR)-PCR primer - SEQ ID 5 alternative.
XX
KW   inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
KW   animal; Basmati rice; ss.
XX
OS   Synthetic.
XX
PN   WO2003085133-A2.
XX
PD   16-OCT-2003.
XX
PF   09-JAN-2003; 2003WO-IB000041.
XX
PR   08-APR-2002; 2002IN-CH000260.
XX
PA   (DNAF-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
XX
PI   Nagaraju JG;
XX
DR   WPI; 2003-804317/75.
XX
PT   New set of inter-simple sequence repeats (ISSR)-PCR primers for
PT   genotyping eukaryotes, useful for genotyping diverse genomes of plant and
PT   animal systems.
XX
PS   Claim 1; Page 17; 60pp; English.
XX
CC   The invention relates to a novel set of inter-simple sequence repeats
CC   (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
CC   invention may be useful for genotyping diverse genomes of plant and
CC   animal systems, in particular for distinguishing Basmati rice varieties
CC   from non-Basmati rice varieties and traditional Basmati rice varieties
CC   from evolved Basmati rice varieties. The current sequence is that of the
CC   5' anchored (ISSR)-PCR primer of the invention.
XX
SQ   Sequence 23 BP; 0 A; 1 C; 9 G; 11 T; 0 U; 2 Other;

  Query Match             0.3%;  Score 21.2;  DB 1;  Length 23;
  Best Local Similarity   40.9%;  Pred. No. 2.5e+03;
  Matches    9;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6995
              ::::|:|:|:|:|:|:|:|:
Db          2 RTRTGTGTGTGTGTGTGTGT 23


RESULT 554
AAQ44016
ID   AAQ44016 standard; DNA; 26 BP.
XX
AC   AAQ44016;
XX
```

```
DT   25-MAR-2003  (revised)
DT   28-OCT-1993  (first entry)
XX
DE   Target sequence #8.
XX
KW   Purine; pyrimidine; tracts; therapeutic; diagnostic; control;
KW   gene expresssion; mRNA synthesis suppression; ds.
XX
OS   Synthetic.
XX
PN   WO9312230-A1.
XX
PD   24-JUN-1993.
XX
PF   11-DEC-1992;   92WO-US010792.
XX
PR   13-DEC-1991;   91US-00808452.
PR   21-JAN-1992;   92US-00826934.
XX
PA   (STRI ) SRI INT.
XX
PI   Jayasena SD,  Johnston BH;
XX
DR   WPI; 1993-214172/26.
XX
PT   New oligo:nucleotide(s) forming triple helix with target nucleic acid -
PT   contain purine and pyrimidine tracts in specific orientations, useful
PT   therapeutically or diagnostically e.g. for inactivating HIV RNA, etc.
XX
PS   Example; Fig 14a; 101pp; English.
XX
CC   The sequence is that of the target sequence #8 which was used in an
CC   experiment to determine the in vitro cleavage of target duplexes to
CC   evaluate the lengths of purine and pyrimidine tracts which are useful in
CC   obtaining oligonucleotides capable of triple helix formation with target
CC   nucleic acids. The complementary strand overhangs the 3' end by the
CC   sequence CTAG and the sense strand overhangs the complementary strand by
CC   the sequence AATT. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 26 BP; 2 A; 1 C; 11 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21.2;  DB 1;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 3.2e+03;
  Matches   12;  Conservative   11;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGUG 6996
                | :  |:|:|:|:|:|:|:|:|:|:|
Db          1 AATTCGTGTGTGTGTGTGTGTGTGTG 26


RESULT 555
AAQ33891
ID   AAQ33891 standard; DNA; 21 BP.
XX
AC   AAQ33891;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA307.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 286; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
                :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 556
AAQ34015
ID   AAQ34015 standard; DNA; 21 BP.
XX
AC   AAQ34015;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA419.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
```

```
PS   Table 7; Page 336; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 21 BP; 0 A; 0 C; 11 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21


RESULT 557
AAQ33879
ID   AAQ33879 standard; DNA; 21 BP.
XX
AC   AAQ33879;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1993  (first entry)
XX
DE   Microsatellite sequence from clone TGLA301.
XX
KW   PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW   genetic mapping; traits; amplification; ss.
XX
OS   Bos taurus.
XX
PN   WO9213102-A1.
XX
PD   06-AUG-1992.
XX
PF   15-JAN-1992;   92WO-US000340.
XX
PR   15-JAN-1991;   91US-00642342.
XX
PA   (GENM-) GENMARK.
XX
PI   Georges M,  Massey JM;
XX
DR   WPI; 1992-284684/34.
XX
PT   Polymorphic bovine DNA markers - used in genetic identification, gene
PT   mapping, and selective breeding.
XX
PS   Table 7; Page 281; 517pp; English.
XX
CC   The sequence is that of a bovine microsatellite sequence obtd. by
CC   screening a library of bovine MboI DNA fragments of between 250 and 500
CC   bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC   clones cross-hybridised. Assuming independent distribution of
CC   microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC   in the bovine genome is estimated at >100, 000. The sequence information
CC   for ca. 230 such bovine microsatellites is summarised in the
CC   specification and indexed herein (see below). The sequences upstream and
CC   downstream of the microsatellite sequence were used to generate the
CC   required PCR primers for in vitro amplification of the corresp.
CC   microsatellite (using the program OPTIPRIM). The microsatellites may be
CC   used to identify individuals, for parentage testing, and in the genetic
CC   mapping of economic trait loci, or genes involved the determinism of
CC   economically important traits esp. in cattle, to allow selective
CC   breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 558
AAX90296
ID   AAX90296 standard; DNA; 21 BP.
XX
AC   AAX90296;
XX
DT   24-SEP-1999  (first entry)
XX
DE   Oligonucleotide RTC05 used in an Example from US5932556.
XX
KW   CD28; inhibition; antisense oligonucleotide; interleukin 2; IL-2;
KW   immune system mediated disease; gamma-interferon; IL-8; ss.
XX
OS   Synthetic.
XX
PN   US5932556-A.
XX
PD   03-AUG-1999.
XX
PF   18-SEP-1995;   95US-00529878.
XX
PR   09-FEB-1995;   95US-00387041.
PR   18-SEP-1995;   95US-00529878.
XX
PA   (TAMR/) TAM R C.
XX
PI   Tam RC;
XX
DR   WPI; 1996-384228/38.
XX
PT   Oligo:nucleotide which reduces CD28 gene expression in T cells - for
PT   treating immune system diseases, e.g. graft vs. host disease, septic
PT   shock, psoriasis, etc.
XX
PS   Example; Col 13; 45pp; English.
XX
CC   The present invention describes a method for inhibiting the expression of
CC   CD28, IL-2, gamma-interferon or IL-8 in a mammal. The method comprises
CC   subcutaneous administration of an oligonucleotide (OGN). AAX90288 to
CC   AAX90291 represent specifically claimed OGNs for use in the method. The
CC   OGNs are used for the treatment of immune system-mediated diseases.
CC   AAX90292 to AAX90323 represent oligonucleotides used in the
CC   exemplification of the present invention
XX
SQ   Sequence 21 BP; 0 A; 0 C; 11 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21
```

```
RESULT 559
AAT65738/c
ID   AAT65738 standard; DNA; 21 BP.
XX
AC   AAT65738;
XX
DT   25-MAR-2003  (revised)
DT   17-JUN-1997  (first entry)
XX
DE   Repeat sequence from polymorphic marker clone Mfd37.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Homo sapiens.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 9-10; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The inserts from the clones were amplified
CC   by primers AAT65798-T66047. Those clones where the repeat sequence has
CC   been determined are shown in AAT65704-797. This repeat sequence is from
CC   the marker clone Mdf37 which contains the repeat sequence having the
CC   formula: (AC)10A. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 21 BP; 11 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db         21 TGTGTGTGTGTGTGTGTGTGT 1


RESULT 560
AAT62083
ID   AAT62083 standard; DNA; 21 BP.
XX
AC   AAT62083;
XX
DT   25-MAR-2003  (revised)
DT   16-DEC-1997  (first entry)
XX
DE   Primer used in FLT receptor amino-terminal fragment preparation.
XX
KW   Amino-terminal; fragment; vascular endothelial growth factor; VEGF; FLT;
KW   receptor; immunoglobulin; Ig; domain; extracellular; region; treatment;
KW   disorder; cell proliferation; inhibition; neovascularisation;
KW   solid cancer; diagnosis; antibody; soluble; signal transduction;
KW   polymerase chain reaction; amplification; primer; PCR; ss.
XX
OS   Synthetic.
XX
PN   WO9713787-A1.
XX
PD   17-APR-1997.
XX
PF   07-OCT-1996;   96WO-JP002906.
XX
PR   07-OCT-1995;   95JP-00286476.
PR   23-JUL-1996;   96JP-00211892.
XX
PA   (TOAG ) TOA GOSEI KK.
XX
PI   Shibuya M,  Okamoto M,  Matsumoto T,  Segawa T;
XX
DR   WPI; 1997-235841/21.
XX
PT   FLT receptor derived vascular endothelial growth factor inhibitor -
PT   contains the first and second immunoglobulin like domains of the FLT
PT   extracellular region, but not the sixth and seventh.
XX
PS   Disclosure; Page 7; 83pp; Japanese.
XX
CC   The present sequence is a primer used in the preparation of DNA encoding
CC   an amino-terminal fragment of the vascular endothelial growth factor
CC   (VEGF) FLT receptor, which contains the 1st and 2nd immunoglobulin (Ig)
CC   like domains of the FLT extracellular region, but not the 6th and 7th Ig
CC   like domains. The fragment can be used to treat disorders associated with
CC   excessive endothelial cell proliferation or neovascularisation, e.g.
CC   solid cancers. Diagnostic reagents may contain the fragment, or
CC   antibodies raised against it. The fragment is much more soluble than full
CC   length FLT and binds VEGF effectively, resulting in VEGF inhibition
CC   without signal transduction. (Updated on 25-MAR-2003 to correct PA
CC   field.)
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 CGUCGCGCUCACCAUGGUCAG 257
              ||:|||||:|||||:||:|||
Db          1 CGTCGCGCTCACCATGGTCAG 21


RESULT 561
AAV01458
ID   AAV01458 standard; DNA; 21 BP.
XX
AC   AAV01458;
XX
DT   25-MAR-1998  (first entry)
XX
DE   Human VEGF receptor extracellular domain primer #1.
XX
KW   Immunoglobulin-like domain; extracellular domain; VEGF; human; primer;
KW   vascular endothelial cell growth factor receptor; amplification; PCR;
KW   truncation; mutant; tumour; vascularisation; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   JP09255700-A.
```

```
XX
PD   30-SEP-1997.
XX
PF   22-MAR-1996;   96JP-00066711.
XX
PR   22-MAR-1996;   96JP-00066711.
XX
PA   (TOAG ) TOA GOSEI CHEM IND LTD.
XX
DR   WPI; 1997-532773/49.
XX
PT   Vascular endothelial growth factor binding polypeptide(s) - used in the
PT   treatment of solid tumours etc.
XX
PS   Disclosure; Page 12; 19pp; Japanese.
XX
CC   Primers AAV01458-V01459 were used to amplify the sequence encoding the
CC   extracellular domain of VEGF (vascular endothelial cell growth factor)
CC   receptor FLT (AAV01457). The VEGF receptor sequence can be used to
CC   generate truncated mutants which comprise the immunoglobulin-like domains
CC   1-3, 1-4, 1-5 or 1-7. The polypeptides can be used in treatment of solid
CC   tumours and other diseases accompanied by pathological vascularisation
CC   since they inhibit vascularisation by stimulation with VEGF
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 CGUCGCGCUCACCAUGGUCAG 257
              ||:|||||:|||||:||:|||
Db          1 CGTCGCGCTCACCATGGTCAG 21


RESULT 562
AAV35480
ID   AAV35480 standard; DNA; 21 BP.
XX
AC   AAV35480;
XX
DT   23-SEP-1998  (first entry)
XX
DE   Anti-human VEGF receptor Flt-1 Mab primer DNA #3.
XX
KW   VEGF receptor; monoclonal antibody; Mab; Flt-1; primer; human;
KW   vascular endothelial growth factor receptor; diagnosis; treatment;
KW   disease; abnormal vascularisation; propagation; metastasis; tumour;
KW   chronic rheumatoid arthritis; retinopathy; psoriasis; diabetes;
KW   prematurity; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9822616-A1.
XX
PD   28-MAY-1998.
XX
PF   21-NOV-1997;   97WO-JP004259.
XX
PR   21-NOV-1996;   96JP-00311109.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI   Shitara K,  Ito M,  Hanai N,  Shibuya M;
XX
DR   WPI; 1998-312500/27.
XX
PT   Monoclonal antibody against human VEGF receptor Flt-1 - inhibits binding
PT   of vascular endothelial growth factor to its receptor and is suitable for
PT   diagnosis and treatment of diseases involving abnormal vascularisation.
XX
PS   Disclosure; Page 36; 57pp; Japanese.
XX
CC   AAV35478-V35481 are primers used in a method resulting in the isolation
CC   of a monoclonal antibody (Mab) which recognise the human vascular
CC   endothelial growth factor (VEGF) receptor Flt-1 or epitopes contained in
CC   the first 750 residues (especially the first 338 residues) from the N-
CC   terminal of the receptor protein, and which bind with the Flt-1 receptor
CC   of immune cells. The antibodies inhibit the binding of human VEGF to the
CC   Flt-1 receptor and are useful in the diagnosis and treatment of diseases
CC   involving abnormal vascularisation, such as the propagation and
CC   metastasis of solid tumours, chronic rheumatoid arthritis, diabetic
CC   retinopathy, retinopathy of prematurity, and psoriasis
XX
SQ   Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 563
AAV21522/c
ID   AAV21522 standard; cDNA; 21 BP.
XX
AC   AAV21522;
XX
DT   14-AUG-1998  (first entry)
XX
DE   L-oncogene primer BCFLT2L (forward).
XX
KW   L-oncogene; diagnosis; treatment; ovarian cancer; antibody; antisense;
KW   ss; PCR; primer; amplification.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9807851-A2.
XX
PD   26-FEB-1998.
XX
PF   22-AUG-1997;   97WO-EP004600.
XX
PR   22-AUG-1996;   96CA-02183900.
XX
PA   (BERG/) BERGMANN J E.
PA   (PRED/) PREDDIE E R.
XX
PI   Bergmann JE,  Preddie ER;
XX
DR   WPI; 1998-169156/15.
XX
PT   Human breast cancer related genes - used for diagnosis, pre-symptomatic
PT   detection and therapy of breast and ovarian cancers.
XX
PS   Disclosure; Fig 10; 96pp; English.
XX
CC   Primers AAV21521-V21539 are used in reverse transcriptase PCR to detect L
CC   -oncogene mRNA in clinical specimens. L-oncogenes and the proteins
CC   encoded can be used in the diagnosis and treatment of breast and ovarian
CC   cancer. Antibodies and multiple antigenic peptide epitopes can be used to
CC   detect the presence of the proteins. The antibodies can also be used to
CC   block the activity of the proteins. Antisense molecules can be used to
CC   prevent expression of the proteins
XX
SQ   Sequence 21 BP; 11 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       7022 GUGUAUGUGUGUUUUGUGCAU 7042
              |:|:|:|:|:|::::|:|||:
Db         21 GTGTATGTGTGTTTTGTGCAT 1


RESULT 564
AAV21523
ID   AAV21523 standard; cDNA; 21 BP.
XX
AC   AAV21523;
XX
DT   14-AUG-1998  (first entry)
XX
DE   L-oncogene primer BCFLT2L (reverse).
XX
KW   L-oncogene; diagnosis; treatment; ovarian cancer; antibody; antisense;
KW   ss; PCR; primer; amplification.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9807851-A2.
XX
PD   26-FEB-1998.
XX
PF   22-AUG-1997;   97WO-EP004600.
XX
PR   22-AUG-1996;   96CA-02183900.
XX
PA   (BERG/) BERGMANN J E.
PA   (PRED/) PREDDIE E R.
XX
PI   Bergmann JE,  Preddie ER;
XX
DR   WPI; 1998-169156/15.
XX
PT   Human breast cancer related genes - used for diagnosis, pre-symptomatic
PT   detection and therapy of breast and ovarian cancers.
XX
PS   Disclosure; Fig 10; 96pp; English.
XX
CC   Primers AAV21521-V21539 are used in reverse transcriptase PCR to detect L
CC   -oncogene mRNA in clinical specimens. L-oncogenes and the proteins
CC   encoded can be used in the diagnosis and treatment of breast and ovarian
CC   cancer. Antibodies and multiple antigenic peptide epitopes can be used to
CC   detect the presence of the proteins. The antibodies can also be used to
CC   block the activity of the proteins. Antisense molecules can be used to
CC   prevent expression of the proteins
XX
SQ   Sequence 21 BP; 6 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6841 ACCGAGAUGUUAAUUUUAGGG 6861
              |||||||:|::||::::|||||
Db          1 ACCGAGATGTTAATTTTAGGG 21


RESULT 565
AAV21521/c
ID   AAV21521 standard; cDNA; 21 BP.
XX
AC   AAV21521;
XX
DT   14-AUG-1998  (first entry)
XX
DE   L-oncogene primer BCFLT1L (forward).
XX
KW   L-oncogene; diagnosis; treatment; ovarian cancer; antibody; antisense;
KW   ss; PCR; primer; amplification.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9807851-A2.
XX
PD   26-FEB-1998.
XX
PF   22-AUG-1997;   97WO-EP004600.
XX
PR   22-AUG-1996;   96CA-02183900.
XX
PA   (BERG/) BERGMANN J E.
PA   (PRED/) PREDDIE E R.
XX
PI   Bergmann JE,  Preddie ER;
XX
DR   WPI; 1998-169156/15.
XX
PT   Human breast cancer related genes - used for diagnosis, pre-symptomatic
PT   detection and therapy of breast and ovarian cancers.
XX
PS   Disclosure; Fig 10; 96pp; English.
XX
CC   Primers AAV21521-V21539 are used in reverse transcriptase PCR to detect L
CC   -oncogene mRNA in clinical specimens. L-oncogenes and the proteins
CC   encoded can be used in the diagnosis and treatment of breast and ovarian
CC   cancer. Antibodies and multiple antigenic peptide epitopes can be used to
CC   detect the presence of the proteins. The antibodies can also be used to
CC   block the activity of the proteins. Antisense molecules can be used to
CC   prevent expression of the proteins
XX
SQ   Sequence 21 BP; 9 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 2.3e+03;
  Matches   12;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7165 CCAUCUUCAUAUAAUAUACUU 7185
              |||:|::||:|:||:|:||::
Db         21 CCATCTTCATATAATATACTT 1


RESULT 566
AAZ40392
ID   AAZ40392 standard; DNA; 21 BP.
XX
AC   AAZ40392;
XX
DT   03-MAR-2000  (first entry)
XX
DE   PCR primer for human flt-#3-7 coding sequence.
XX
KW   PCR primer; VEGF; KDR; signal transduction inhibitor; human; arthritis;
KW   vascular endothelial growth factor; VEGF receptor; rheumatoid arthritis;
KW   fms-like tyrosine kinase-1; Flt-1; abnormal neovascularisation; therapy;
KW   kinase insert domain-containing receptor; solid tumour metastasis; ss;
KW   proliferation; diabetic retinopathy; premature retinopathy; psoriasis.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9959636-A1.
XX
PD   25-NOV-1999.
XX
PF   20-MAY-1999;   99WO-JP002660.
XX
PR   20-MAY-1998;   98JP-00138999.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI   Shitara K,  Sato Y;
XX
```

```
DR   WPI; 2000-053197/04.
XX
PT   Remedies with enhanced efficacy, useful in diagnosis or treating diseases
PT   due to abnormal neovascularization e.g. proliferation or metastasis of
PT   solid tumor, rheumatoid arthritis and psoriasis.
XX
PS   Example 1; Page 95; 111pp; Japanese.
XX
CC   This sequence is a PCR primer for the human flt-#3-7 coding sequence. The
CC   invention relates to a drug that comprises a combination of: (1) a
CC   substance inhibiting signal transduction mediated by the human vascular
CC   endothelial growth factor (VEGF) receptor fms-like tyrosine kinase-1 (Flt
CC   -1); and (2) a substance inhibiting signal transduction mediated by the
CC   human VEGF receptor kinase insert domain-containing receptor (KDR). The
CC   drug compositions are useful in diagnosis or treating diseases due to
CC   abnormal neovascularisation such as proliferation or metastasis of solid
CC   tumours, arthritis in rheumatoid arthritis, diabetic retinopathy,
CC   premature retinopathy and psoriasis. The compositions have enhanced
CC   efficacy
XX
SQ   Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 567
AAZ87755
ID   AAZ87755 standard; DNA; 21 BP.
XX
AC   AAZ87755;
XX
DT   08-MAY-2000  (first entry)
XX
DE   Anti-human VEGF receptor Flt-1 antibody related sequence #55.
XX
KW   Antibody; human; vascular endothelial growth factor; VEGF receptor;
KW   Flt-1; neovascularisation; cell proliferation; metastasis; tumour;
KW   rheumatoid arthritis; retinopathy; psoriasis; ss.
XX
OS   Mus musculus.
XX
PN   WO9960025-A1.
XX
PD   25-NOV-1999.
XX
PF   20-MAY-1999;   99WO-JP002661.
XX
PR   20-MAY-1998;   98JP-00139000.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI   Shitara K,  Ito M,  Kawada Y,  Nakamura K;
XX
DR   WPI; 2000-072431/06.
XX
PT   Gene recombinant antibodies, useful for diagnosis and as remedies for
PT   diseases due to abnormal neovascularization e.g. proliferation or
PT   metastasis of solid tumor, rheumatoid arthritis, diabetic retinopathy and
PT   psoriasis.
XX
PS   Disclosure; Page 181; 210pp; Japanese.
XX
CC   The invention relates to a gene recombinant antibody that has specific
CC   reaction with human vascular endothelial growth factor (VEGF) receptor
CC   Flt-1. The antibodies are useful for diagnosis and as remedies for
CC   diseases due to abnormal neovascularisation such as proliferation or
CC   metastasis of solid tumor, arthritis in rheumatoid arthritis, diabetic
CC   retinopathy, premature retinopathy and psoriasis
XX
SQ   Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 568
AAH46013
ID   AAH46013 standard; DNA; 21 BP.
XX
AC   AAH46013;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 13.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Example 4; Page 17; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 21


RESULT 569
AAH46014
ID   AAH46014 standard; DNA; 21 BP.
XX
AC   AAH46014;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Synthetic oligonucleotide 14.
XX
KW   Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW   cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW   tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW   lymphoma; ss.
XX
OS   Synthetic.
XX
PN   WO200144465-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-CA001467.
XX
PR   13-DEC-1999;   99US-0170325P.
PR   29-AUG-2000; 2000US-0228925P.
XX
PA   (BION-) BIONICHE LIFE SCI INC.
XX
PI   Phillips NC,  Filion MC;
XX
DR   WPI; 2001-398150/42.
XX
PT   Composition comprising synthetic oligonucleotides which comprise multiple
PT   repeats of dinucleotides such as GT, TG useful for treating cancer by
PT   inducing cell cycle arrest, inhibiting proliferation, activating
PT   caspases.
XX
PS   Example 4; Page 17; 77pp; English.
XX
CC   The present sequence is that of a synthetic oligonucleotide useful to the
CC   invention. The invention relates to a composition, comprising a 2 to 20
CC   base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC   repeats of dinucleotides such as GT, TG, etc., according to specific
CC   formula and having cytostatic activity. The oligonucleotide compositions
CC   are useful for inducing cell cycle arrest, inhibition of proliferation,
CC   activation of caspases and induction of apoptosis or production of
CC   cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC   necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC   cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC   and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC   colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC   independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC   resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC   and hormone dependence
XX
SQ   Sequence 21 BP; 0 A; 0 C; 11 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTG 21


RESULT 570
AAF99702
ID   AAF99702 standard; DNA; 21 BP.
XX
AC   AAF99702;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #818.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 56; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21


RESULT 571
AAD21676/c
ID   AAD21676 standard; DNA; 21 BP.
XX
AC   AAD21676;
XX
DT   28-JAN-2002  (first entry)
XX
DE   VEGFR-1 DNA amplifying reverse PCR primer.
```

XX
KW Vascular endothelial growth factor receptor-1 VEGFR-1; antagonist;
KW cytostatic; hypervariable region; myelocytic leukaemia; lymphocytic;
KW erythrocytic; monocytic; multiple myeloma; lymphoid cell; tumour;
KW Hodgkin's disease; PCR primer; ss.
XX
OS Unidentified.
XX
PN WO200174296-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US010504.
XX
PR 31-MAR-2000; 2000US-00540770.
XX
PA (IMCL-) IMCLONE SYSTEMS INC.
PA (CORR) CORNELL RES FOUND INC.
XX
PI Witte L, Rafii S;
XX
DR WPI; 2001-662942/76.
XX
PT Inhibiting growth of non-solid tumor cells useful to treat bone marrow
PT tumors such as leukemias or multiple myeloma comprises treatment with an
PT antagonist of a vascular endothelial growth factor receptor.
XX
PS Example 1; Page 23; 68pp; English.
XX
CC The invention relates to a method for inhibiting the growth of non-solid
CC tumour cells that are stimulated by a ligand of vascular endothelial
CC growth factor receptor (VEGFR) in mammals particularly humans. The method
CC involves treating the mammals with humanised VEGFR monoclonal antibodies
CC (antagonists). Humanised monoclonal antibody comprises humanised mouse
CC variable region joined to human constant region, where the humanised
CC mouse variable region contains mouse complementarity determining region
CC (CDR) grafted into human variable region. The method is useful for
CC treating leukaemias such as acute or chronic myelocytic leukaemia, acute
CC or chronic lymphocytic leukaemia, erythrocytic or monocytic leukaemia,
CC multiple myelomas and lymphoid cells, particularly those related to non-
CC Hodgkin's and Hodgkin's disease. The present DNA sequence is a reverse
CC PCR primer which is used for amplifying vascular endothelial growth
CC factor receptor-1 (VEGFR-1) DNA used in the exemplification of the
CC invention
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3895 GCUUUCAAGUUCAUGAGCCUG 3915
||:::||||::||:|||||:|
Db 21 GCTTTCAAGTTCATGAGCCTG 1

RESULT 572
ABS78423
ID ABS78423 standard; DNA; 21 BP.
XX
AC ABS78423;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #907.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophiliac joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
PF 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-0255534P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Bratzler RL;
XX
DR WPI; 2002-566690/60.
XX
PT Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
PS Claim 2; Page 35; 276pp; English.
XX
CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 2.3e+03;
Matches 10; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

Qy 6973 UGUGUGUGUGUGUGUGUGUGU 6993
:|:|:|:|:|:|:|:|:|:|:
Db 1 TGTGTGTGTGTGTGTGTGTGT 21

RESULT 573
ABZ76711/c
ID ABZ76711 standard; DNA; 21 BP.
XX
AC ABZ76711;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human vascular endothelial growth factor receptor 1 PCR primer #2.
XX
KW Human; vascular endothelial growth factor receptor; VEGFR-1; VEGFR-2;
KW vascular endothelial growth factor; platelet derived growth factor; VEGF;
KW PIGF; beta-actin; VEGFR-1 antagonist; cytostatic; tumour; cancer;
KW autocrine stimulation inhibitor; adenocarcinoma; malignant glioma;
KW leukaemia; angiogenesis inhibitor; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003006059-A1.
XX
PD 23-JAN-2003.
XX
PF 15-JUL-2002; 2002WO-US022540.
XX

```
PR   13-JUL-2001; 2001US-0304751P.
XX
PA   (IMCL-) IMCLONE SYSTEMS INC.
XX
PI   Wu Y,  Rafii S,  Witte L;
XX
DR   WPI; 2003-221662/21.
XX
PT   Prevention or reduction of the growth of tumor cells expressing
PT   functional vascular endothelial growth factor-1 receptors, comprises use
PT   of a vascular endothelial growth factor-1 receptor antagonist.
XX
PS   Example 1; Page 15; 31pp; English.
XX
CC   The present invention describes a method for the prevention or reduction
CC   of the growth of tumour cells expressing functional vascular endothelial
CC   growth factor (VEGF)-1 receptors (VEGFR-1) comprising administration of a
CC   VEGFR-1 antagonist to a mammal. VEGFR-1 antagonists have cytostatic
CC   activity, and can be used as autocrine stimulation inhibitors. VEGFR-1
CC   antagonists can be used for preventing or reducing the growth of tumour
CC   cells from substantially non-vascularised cancer such as breast cancer,
CC   ovarian cancer, brain cancer, kidney cancer, bladder cancer,
CC   adenocarcinoma, malignant gliomas and leukaemias in mammal e.g. human.
CC   The VEGFR-1 antagonist binds specifically to the extracellular domain of
CC   a VEGFR expressed on the tumour cell. The VEGFR-1 antagonist inhibits
CC   angiogenesis, hence inhibits tumour growth at low concentration. The
CC   present sequence represents a PCR primer for VEGFR-1, which is used in an
CC   example from the present invention
XX
SQ   Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3895 GCUUUCAAGUUCAUGAGCCUG 3915
              ||:::||||::||:|||||:|
Db         21 GCTTTCAAGTTCATGAGCCTG 1


RESULT 574
ADA13965/c
ID   ADA13965 standard; RNA; 21 BP.
XX
AC   ADA13965;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:302.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
OS   Synthetic.
XX
PN   WO2003070918-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005346.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D,  Zinnen S,  Pavco P;
PI   Morrissey D,  Fosnaugh K,  Mokler V,  Jamison S;
XX
DR   WPI; 2003-689785/65.
XX
PT   New short interfering nucleic acid containing no ribonucleotides, useful
PT   e.g. for treating viral infection, downregulates expression of target
PT   gene or RNA.
XX
PS   Example 4; Page 142; 204pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of a target gene, where
CC   the siNA molecule comprises no ribonucleotides and each strand of the
CC   double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC   a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC   molecule that inhibits replication of a virus and optionally does not
CC   require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC   that inhibits expression of a target gene and does not require presence
CC   of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC   expression of a target gene by mediating RNA interference; and (5) a
CC   method for modulating expression of a gene in a cell using siNA
CC   molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC   antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC   cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC   and endocrine activities. The siNA's are useful for downregulating
CC   expression of target genes, inhibiting expression of target RNA, and
CC   inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC   therapy of any disorder that responds to modulation of gene expression,
CC   especially animal and plant viral infections, specifically hepatitis B or
CC   C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC   syncytial or influenza viruses, and also many other diseases such as
CC   restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC   prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC   endocrine or reproductive diseases; and (b) for diagnosis, target
CC   validation, genomic discovery, genetic engineering, pharmacogenomics and
CC   analysis of gene function. Chemical modification of siNA molecules
CC   improves interfering activity; stability; cellular uptake; binding
CC   affinity and/or mediates increased polymerase activity. siNA may be
CC   designed to target many related genes containing a conserved sequence.
CC   The present sequence represents a siNA oligonucleotide sequence, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 575
ADA13968/c
ID   ADA13968 standard; RNA; 21 BP.
XX
AC   ADA13968;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:305.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
```

```
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
OS   Synthetic.
XX
PN   WO2003070918-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005346.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D,  Zinnen S,  Pavco P;
PI   Morrissey D,  Fosnaugh K,  Mokler V,  Jamison S;
XX
DR   WPI; 2003-689785/65.
XX
PT   New short interfering nucleic acid containing no ribonucleotides, useful
PT   e.g. for treating viral infection, downregulates expression of target
PT   gene or RNA.
XX
PS   Example 4; Page 142; 204pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of a target gene, where
CC   the siNA molecule comprises no ribonucleotides and each strand of the
CC   double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC   a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC   molecule that inhibits replication of a virus and optionally does not
CC   require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC   that inhibits expression of a target gene and does not require presence
CC   of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC   expression of a target gene by mediating RNA interference; and (5) a
CC   method for modulating expression of a gene in a cell using siNA
CC   molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC   antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC   cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC   and endocrine activities. The siNA's are useful for downregulating
CC   expression of target genes, inhibiting expression of target RNA, and
CC   inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC   therapy of any disorder that responds to modulation of gene expression,
CC   especially animal and plant viral infections, specifically hepatitis B or
CC   C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC   syncytial or influenza viruses, and also many other diseases such as
CC   restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC   prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC   endocrine or reproductive diseases; and (b) for diagnosis, target
CC   validation, genomic discovery, genetic engineering, pharmacogenomics and
CC   analysis of gene function. Chemical modification of siNA molecules
CC   improves interfering activity; stability; cellular uptake; binding
CC   affinity and/or mediates increased polymerase activity. siNA may be
CC   designed to target many related genes containing a conserved sequence.
CC   The present sequence represents a siNA oligonucleotide sequence, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 576
ADA13971/c
ID   ADA13971 standard; RNA; 21 BP.
XX
AC   ADA13971;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:308.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
OS   Synthetic.
XX
PN   WO2003070918-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005346.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D,  Zinnen S,  Pavco P;
PI   Morrissey D,  Fosnaugh K,  Mokler V,  Jamison S;
XX
DR   WPI; 2003-689785/65.
XX
PT   New short interfering nucleic acid containing no ribonucleotides, useful
PT   e.g. for treating viral infection, downregulates expression of target
PT   gene or RNA.
XX
PS   Example 4; Page 142; 204pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of a target gene, where
CC   the siNA molecule comprises no ribonucleotides and each strand of the
CC   double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC   a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC   molecule that inhibits replication of a virus and optionally does not
CC   require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC   that inhibits expression of a target gene and does not require presence
CC   of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC   expression of a target gene by mediating RNA interference; and (5) a
CC   method for modulating expression of a gene in a cell using siNA
CC   molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC   antiinflammatory, plant antiviral, vasotropic, neuroprotective,
```

```
CC   cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC   and endocrine activities. The siNA's are useful for downregulating
CC   expression of target genes, inhibiting expression of target RNA, and
CC   inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC   therapy of any disorder that responds to modulation of gene expression,
CC   especially animal and plant viral infections, specifically hepatitis B or
CC   C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC   syncytial or influenza viruses, and also many other diseases such as
CC   restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC   prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC   endocrine or reproductive diseases; and (b) for diagnosis, target
CC   validation, genomic discovery, genetic engineering, pharmacogenomics and
CC   analysis of gene function. Chemical modification of siNA molecules
CC   improves interfering activity; stability; cellular uptake; binding
CC   affinity and/or mediates increased polymerase activity. siNA may be
CC   designed to target many related genes containing a conserved sequence.
CC   The present sequence represents a siNA oligonucleotide sequence, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 577
ADA13964/c
ID   ADA13964 standard; RNA; 21 BP.
XX
AC   ADA13964;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:301.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
OS   Synthetic.
XX
PN   WO2003070918-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005346.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D,  Zinnen S,  Pavco P;
PI   Morrissey D,  Fosnaugh K,  Mokler V,  Jamison S;
XX
DR   WPI; 2003-689785/65.
XX
PT   New short interfering nucleic acid containing no ribonucleotides, useful
PT   e.g. for treating viral infection, downregulates expression of target
PT   gene or RNA.
XX
PS   Example 4; Page 142; 204pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of a target gene, where
CC   the siNA molecule comprises no ribonucleotides and each strand of the
CC   double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC   a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC   molecule that inhibits replication of a virus and optionally does not
CC   require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC   that inhibits expression of a target gene and does not require presence
CC   of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC   expression of a target gene by mediating RNA interference; and (5) a
CC   method for modulating expression of a gene in a cell using siNA
CC   molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC   antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC   cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC   and endocrine activities. The siNA's are useful for downregulating
CC   expression of target genes, inhibiting expression of target RNA, and
CC   inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC   therapy of any disorder that responds to modulation of gene expression,
CC   especially animal and plant viral infections, specifically hepatitis B or
CC   C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC   syncytial or influenza viruses, and also many other diseases such as
CC   restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC   prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC   endocrine or reproductive diseases; and (b) for diagnosis, target
CC   validation, genomic discovery, genetic engineering, pharmacogenomics and
CC   analysis of gene function. Chemical modification of siNA molecules
CC   improves interfering activity; stability; cellular uptake; binding
CC   affinity and/or mediates increased polymerase activity. siNA may be
CC   designed to target many related genes containing a conserved sequence.
CC   The present sequence represents a siNA oligonucleotide sequence, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 578
ADA13969/c
ID   ADA13969 standard; RNA; 21 BP.
XX
AC   ADA13969;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:306.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
```

OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
DR WPI; 2003-689785/65.
XX
PT New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
PS Example 4; Page 142; 204pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 579

ADA13615
ID ADA13615 standard; RNA; 21 BP.
XX
AC ADA13615;
XX
DT 20-NOV-2003 (first entry)
XX
DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:347.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
DR WPI; 2003-689785/65.
XX
PT New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
PS Example 4; Page 144; 204pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,

CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3912 CCUGGAAAGAAUCAAAACCUU 3932
||||||||||||||||||::
Db 1 CCUGGAAAGAAUCAAAACCTT 21

RESULT 580
ADA13962
ID ADA13962 standard; RNA; 21 BP.
XX
AC ADA13962;
XX
DT 20-NOV-2003 (first entry)
XX
DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:299.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
DR WPI; 2003-689785/65.
XX
PT New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
PS Example 4; Page 142; 204pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3912 CCUGGAAAGAAUCAAAACCUU 3932
||||||||||||||||||::
Db 1 CCUGGAAAGAAUCAAAACCTT 21

RESULT 581
ADA13988/c
ID ADA13988 standard; RNA; 21 BP.
XX
AC ADA13988;
XX
DT 20-NOV-2003 (first entry)
XX
DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:420.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
DR WPI; 2003-689785/65.
XX
PT New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
PS Example 4; Page 146; 204pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 582
ADA13662/c
ID ADA13662 standard; RNA; 21 BP.
XX
AC ADA13662;
XX
DT 20-NOV-2003 (first entry)
XX
DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:499.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
DR WPI; 2003-689785/65.
XX
PT New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
PS Example 2; Fig 3; 204pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. SiNA molécules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 583
ADA13967/c
ID   ADA13967 standard; RNA; 21 BP.
XX
AC   ADA13967;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:304.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; expression; replication;
KW   inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW   antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW   cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW   endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW   herpes simplex; cytomegalovirus; human papillomavirus;
KW   respiratory syncytial virus; influenza virus; restenosis;
KW   neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW   pulmonary; renal; liver; mitochondrial; reproductive disease;
KW   chemical modification; ss.
XX
OS   Synthetic.
XX
PN   WO2003070918-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005346.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D,  Zinnen S,  Pavco P;
PI   Morrissey D,  Fosnaugh K,  Mokler V,  Jamison S;
XX
DR   WPI; 2003-689785/65.
XX
PT   New short interfering nucleic acid containing no ribonucleotides, useful
PT   e.g. for treating viral infection, downregulates expression of target
PT   gene or RNA.
XX
PS   Example 4; Page 142; 204pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of a target gene, where
CC   the siNA molecule comprises no ribonucleotides and each strand of the
CC   double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC   a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC   molecule that inhibits replication of a virus and optionally does not
CC   require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC   that inhibits expression of a target gene and does not require presence
CC   of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC   expression of a target gene by mediating RNA interference; and (5) a
CC   method for modulating expression of a gene in a cell using siNA
CC   molecules. SiNA's can have virucide, anti-HIV, hepatotropic,
CC   antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC   cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC   and endocrine activities. The siNA's are useful for downregulating
CC   expression of target genes, inhibiting expression of target RNA, and
CC   inhibiting replication of a virus. SiNA molecules can be used: (a) for
CC   therapy of any disorder that responds to modulation of gene expression,
CC   especially animal and plant viral infections, specifically hepatitis B or
CC   C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC   syncytial or influenza viruses, and also many other diseases such as
CC   restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC   prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC   endocrine or reproductive diseases; and (b) for diagnosis, target
CC   validation, genomic discovery, genetic engineering, pharmacogenomics and
CC   analysis of gene function. Chemical modification of siNA molecules
CC   improves interfering activity; stability; cellular uptake; binding
CC   affinity and/or mediates increased polymerase activity. siNA may be
CC   designed to target many related genes containing a conserved sequence.
CC   The present sequence represents a siNA oligonucleotide sequence, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 584
ACH03241
ID   ACH03241 standard; DNA; 21 BP.
XX
AC   ACH03241;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #876.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 32; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
```

```
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 585
ADB37204
ID   ADB37204 standard; DNA; 21 BP.
XX
AC   ADB37204;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #818.
XX
KW   ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW   hypo-responsive subject; immunostimulatory.
XX
OS   Synthetic.
XX
PN   US2003087848-A1.
XX
PD   08-MAY-2003.
XX
PF   02-FEB-2001; 2001US-00776479.
XX
PR   03-FEB-2000; 2000US-0179991P.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2003-657977/62.
XX
PT   Treating and/or preventing allergy or asthma using an immunostimulatory
PT   nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS   Disclosure; Page 17; 221pp; English.
XX
CC   The invention relates to a method of treating or preventing allergy or
CC   asthma which comprises administering to a subject a poly-G nucleic acid
CC   in an aerosol formulation. The methods and compositions of the present
CC   invention are useful for diagnosing and/or treating asthma and allergy
CC   especially in a hypo-responsive subject. The present sequence represents
CC   an immunostimulatory nucleic acid of the invention.
XX
SQ   Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.3e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 586
ADD80859/c
ID   ADD80859 standard; DNA; 21 BP.
XX
AC   ADD80859;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human Flt-1 reverse PCR primer SEQ ID NO:89.
XX
KW   human; antibody; KDR; cytostatic; gene therapy; anti-KDR antibody;
KW   tumour; angiogenesis; Flt-1; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003075840-A2.
XX
PD   18-SEP-2003.
XX
PF   04-MAR-2003; 2003WO-US006459.
XX
PR   04-MAR-2002; 2002US-0361783P.
XX
PA   (IMCL-) IMCLONE SYSTEMS INC.
XX
PI   Zhu Z;
XX
DR   WPI; 2003-779032/73.
XX
PT   New human anti-KDR antibody, useful for preparing a composition for
PT   reducing tumor growth and inhibiting angiogenesis.
XX
PS   Example 4; SEQ ID NO 89; 49pp; English.
XX
CC   The invention relates to a novel isolated human antibody or its fragment
CC   binds selectively to KDR. An antibody of the invention has cytostatic
CC   activity, and may have a use in gene therapy. The antibody is anti-KDR
CC   antibody. The antibody is useful for preparing a composition for reducing
CC   tumour growth and inhibiting angiogenesis. The present sequence is used
CC   in the exemplification of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3895 GCUUUCAAGUUCAUGAGCCUG 3915
              ||:::||||::||:|||||:|
Db         21 GCTTTCAAGTTCATGAGCCTG 1


RESULT 587
ADF37752/c
ID   ADF37752 standard; RNA; 21 BP.
XX
AC   ADF37752;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2165.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
```

```
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2165; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 588
ADF37900/c
ID   ADF37900 standard; RNA; 21 BP.
XX
AC   ADF37900;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2097.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2097; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 589
ADF37908/c
ID   ADF37908 standard; RNA; 21 BP.
XX
```

```
AC   ADF37908;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2105.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2105; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
             ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 590
ADF37738
ID   ADF37738 standard; RNA; 21 BP.
XX
AC   ADF37738;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2151.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2151; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
```

```
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              ||||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 591
ADF37751/c
ID   ADF37751 standard; RNA; 21 BP.
XX
AC   ADF37751;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2164.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2164; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 592
ADF37929/c
ID   ADF37929 standard; RNA; 21 BP.
XX
AC   ADF37929;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2218.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
```

PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Disclosure; SEQ ID NO 2229; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 593
ADF37740/c
ID ADF37740 standard; RNA; 21 BP.
XX
AC ADF37740;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2153.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2153; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2947 AAGCAAGGAGGGCCUCUGAUG 2967
||||||||||||||:|:||:|
Db 21 AAGCAAGGAGGGCCTCTGATG 1

RESULT 594
ADF37923/c
ID ADF37923 standard; RNA; 21 BP.
XX
AC ADF37923;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2120.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.

```
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2120; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
             ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 595
ADF37931/c
ID   ADF37931 standard; RNA; 21 BP.
XX
AC   ADF37931;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2220.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Disclosure; SEQ ID NO 2231; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
             ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 596
ADF37719/c
ID   ADF37719 standard; RNA; 21 BP.
XX
AC   ADF37719;
XX
DT   12-FEB-2004  (first entry)
```

XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2132.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2132; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 597
ADF37745/c
ID ADF37745 standard; RNA; 21 BP.
XX
AC ADF37745;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2158.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2158; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the

```
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 598
ADF37715/c
ID   ADF37715 standard; RNA; 21 BP.
XX
AC   ADF37715;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2128.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2128; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 599
ADF37845/c
ID   ADF37845 standard; RNA; 21 BP.
XX
AC   ADF37845;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2042.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
```

```
XX
PS   Example 3; SEQ ID NO 2042; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 3 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGU 1975
              ||||||||||||:|||||:|:
Db         21 AAGGAGAGGACCTGAAACTGT 1


RESULT 600
ADF37920/c
ID   ADF37920 standard; RNA; 21 BP.
XX
AC   ADF37920;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2117.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2117; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 601
ADF37716/c
ID   ADF37716 standard; RNA; 21 BP.
XX
AC   ADF37716;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2129.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
```

PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2129; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 1 T; 13 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 602
ADF37775/c
ID ADF37775 standard; RNA; 21 BP.
XX
AC ADF37775;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2188.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2188; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 347 AACUGAGUUUAAAAGGCACCC 367
|||:|||:::||||||||||
Db 21 AACTGAGTTTAAAAGGCACCC 1

RESULT 603
ADF37911
ID ADF37911 standard; RNA; 21 BP.
XX
AC ADF37911;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2108.
XX

KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2108; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 13 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2340 CAACCACAAAAUACAACAAGA 2360
||||||||||||||||||||
Db 1 CAACCACAAAAUACAACAAGA 21

RESULT 604
ADF37933/c
ID ADF37933 standard; RNA; 21 BP.
XX
AC ADF37933;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2222.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Disclosure; SEQ ID NO 2233; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 605
ADF37729/c
ID   ADF37729 standard; RNA; 21 BP.
XX
AC   ADF37729;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2142.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2142; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 606
ADF37902/c
ID   ADF37902 standard; RNA; 21 BP.
XX
AC   ADF37902;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2099.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2099; 207pp; English.
XX
```

```
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 607
ADF37746/c
ID   ADF37746 standard; RNA; 21 BP.
XX
AC   ADF37746;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2159.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2159; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 608
ADF37837/c
ID   ADF37837 standard; RNA; 21 BP.
XX
AC   ADF37837;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2034.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
```

```
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2034; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 3 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGU 1975
              ||||||||||||:|||||:|:
Db         21 AAGGAGAGGACCTGAAACTGT 1


RESULT 609
ADF37899/c
ID   ADF37899 standard; RNA; 21 BP.
XX
AC   ADF37899;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2096.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2096; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 610
ADF37905
ID   ADF37905 standard; RNA; 21 BP.
XX
AC   ADF37905;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2102.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
```

```
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2102; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              |||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 611
ADF37714/c
ID   ADF37714 standard; RNA; 21 BP.
XX
AC   ADF37714;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2127.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2127; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 1 T; 13 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
```

```
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 612
ADF37897
ID   ADF37897 standard; RNA; 21 BP.
XX
AC   ADF37897;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2094.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2094; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              ||||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 613
ADF37907/c
ID   ADF37907 standard; RNA; 21 BP.
XX
AC   ADF37907;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2104.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2104; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
```

CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 347 AACUGAGUUUAAAAGGCACCC 367
||||:|||:::||||||||||
Db 21 AACTGAGTTTAAAAGGCACCC 1

RESULT 614
ADF37739/c
ID ADF37739 standard; RNA; 21 BP.
XX
AC ADF37739;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2152.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2152; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 347 AACUGAGUUUAAAAGGCACCC 367
||||:|||:::||||||||||
Db 21 AACTGAGTTTAAAAGGCACCC 1

RESULT 615
ADF37790/c
ID ADF37790 standard; RNA; 21 BP.
XX
AC ADF37790;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2203.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2203; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 616
ADF37937/c
ID ADF37937 standard; RNA; 21 BP.
XX
AC ADF37937;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2226.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Disclosure; SEQ ID NO 2237; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 617
ADF37829/c
ID ADF37829 standard; RNA; 21 BP.
XX
AC ADF37829;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2026.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;

```
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2026; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 3 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGU 1975
              ||||||||||||:|||||:|:
Db         21 AAGGAGAGGACCTGAAACTGT 1


RESULT 618
ADF37910/c
ID   ADF37910 standard; RNA; 21 BP.
XX
AC   ADF37910;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2107.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2107; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
```

```
                ||||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 619
ADF37912/c
ID   ADF37912 standard; RNA; 21 BP.
XX
AC   ADF37912;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2109.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 2109; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 0 T; 14 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
                ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 620
ADF37935/c
ID   ADF37935 standard; RNA; 21 BP.
XX
AC   ADF37935;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2224.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Disclosure; SEQ ID NO 2235; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
```

```
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 621
ADF37938/c
ID   ADF37938 standard; RNA; 21 BP.
XX
AC   ADF37938;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2227.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Disclosure; SEQ ID NO 2238; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 622
ADF37776/c
ID   ADF37776 standard; RNA; 21 BP.
XX
AC   ADF37776;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2189.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
```

PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 2189; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2947 AAGCAAGGAGGGCCUCUGAUG 2967
||||||||||||||:|:||:|
Db 21 AAGCAAGGAGGGCCTCTGATG 1

RESULT 623
ADG29831/c
ID ADG29831 standard; RNA; 21 BP.
XX
AC ADG29831;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 397.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 397; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2947 AAGCAAGGAGGGCCUCUGAUG 2967
||||||||||||||:|:||:|
Db 21 AAGCAAGGAGGGCCTCTGATG 1

RESULT 624
ADG29860/c
ID ADG29860 standard; RNA; 21 BP.
XX
AC ADG29860;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 426.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 426; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 625
ADG29836/c
ID ADG29836 standard; RNA; 21 BP.
XX
AC ADG29836;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 402.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 402; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 347 AACUGAGUUUAAAAGGCACCC 367
|||:|||:::|||||||||||
Db 21 AACTGAGTTTAAAAGGCACCC 1

RESULT 626
ADG29859/c
ID ADG29859 standard; RNA; 21 BP.
XX
AC ADG29859;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 425.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 425; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 1 T; 13 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 627
ADG29885/c
ID ADG29885 standard; RNA; 21 BP.
XX
AC ADG29885;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 451.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 451; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2947 AAGCAAGGAGGGCCUCUGAUG 2967
||||||||||||||:|:||:|
Db 21 AAGCAAGGAGGGCCTCTGATG 1

RESULT 628
ADG29829/c
ID ADG29829 standard; RNA; 21 BP.
XX
AC ADG29829;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 395.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.

```
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 395; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 629
ADG29883
ID   ADG29883 standard; RNA; 21 BP.
XX
AC   ADG29883;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 449.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 449; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              ||||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 630
ADG29884/c
ID   ADG29884 standard; RNA; 21 BP.
XX
AC   ADG29884;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 450.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
```

```
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 450; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 631
ADG29826
ID   ADG29826 standard; RNA; 21 BP.
XX
AC   ADG29826;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 392.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 392; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              ||||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 632
ADG29890/c
ID   ADG29890 standard; RNA; 21 BP.
XX
AC   ADG29890;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 456.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
```

```
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 456; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 633
ADG29896/c
ID   ADG29896 standard; RNA; 21 BP.
XX
AC   ADG29896;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 462.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 462; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1


RESULT 634
ADG29828/c
ID   ADG29828 standard; RNA; 21 BP.
XX
AC   ADG29828;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 394.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
```

XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 394; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1
```

RESULT 635
ADG29864/c
ID ADG29864 standard; RNA; 21 BP.
XX
AC ADG29864;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 430.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 430; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1
```

RESULT 636
ADG29935/c
ID ADG29935 standard; RNA; 21 BP.
XX
AC ADG29935;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 501.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX

OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 501; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 637
ADG29861/c
ID ADG29861 standard; RNA; 21 BP.
XX
AC ADG29861;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 427.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 427; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 1 T; 13 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 AACAACCACAAAAUACAACAA 2358
||||||||||||:|||||||
Db 21 AACAACCACAAAATACAACAA 1

RESULT 638
ADG29921/c
ID ADG29921 standard; RNA; 21 BP.
XX
AC ADG29921;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 487.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;

```
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 487; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1


RESULT 639
ADG29874/c
ID   ADG29874 standard; RNA; 21 BP.
XX
AC   ADG29874;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 440.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 440; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              |||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 640
ADG29840
ID   ADG29840 standard; RNA; 21 BP.
XX
AC   ADG29840;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA RNA - SEQ ID 406.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
```

KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; FLT1.
XX
OS Unidentified.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 406; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA RNA
CC of the invention.
XX
SQ Sequence 21 BP; 13 A; 6 C; 1 G; 0 T; 1 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAAGA 2360
              |||||||||||||||||||||
Db          1 CAACCACAAAAUACAACAAGA 21
```

RESULT 641
ADG29897/c
ID ADG29897 standard; RNA; 21 BP.
XX
AC ADG29897;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 463.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 463; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1
```

RESULT 642
ADG29920/c
ID ADG29920 standard; RNA; 21 BP.
XX
AC ADG29920;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 486.
XX
KW double-stranded short interfering nucleic acid; siNA;

KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 486; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCC 367
              |||:|||:::|||||||||||
Db         21 AACTGAGTTTAAAAGGCACCC 1
```

RESULT 643
ADG29839/c
ID ADG29839 standard; RNA; 21 BP.
XX
AC ADG29839;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 405.
XX

KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 405; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              |||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1
```

RESULT 644
ADG30354/c
ID ADG30354 standard; RNA; 21 BP.
XX
AC ADG30354;
XX
DT 26-FEB-2004 (first entry)
XX
DE Small interfering nucleic acid DNA-RNA hybrid - SEQ ID 931.

```
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 2; SEQ ID NO 931; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 645
ADG29837/c
ID   ADG29837 standard; RNA; 21 BP.
XX
AC   ADG29837;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 403.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 403; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 646
ADG29891/c
ID   ADG29891 standard; RNA; 21 BP.
XX
AC   ADG29891;
XX
DT   26-FEB-2004  (first entry)
```

XX
DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 457.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS Unidentified.
OS Synthetic.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 457; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 4 G; 2 T; 4 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUG 2967
              ||||||||||||||:|:||:|
Db         21 AAGCAAGGAGGGCCTCTGATG 1
```

RESULT 647
ADG29841/c
ID ADG29841 standard; RNA; 21 BP.
XX
AC ADG29841;
XX
DT 26-FEB-2004 (first entry)
XX
DE FLT1-targeted siNA RNA - SEQ ID 407.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; FLT1.
XX
OS Unidentified.
XX
PN WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005028.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX
DR WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
PS Example 24; SEQ ID NO 407; 593pp; English.
XX
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA RNA
CC of the invention.
XX
SQ Sequence 21 BP; 1 A; 0 C; 6 G; 0 T; 14 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1
```

RESULT 648
ADG29849/c
ID ADG29849 standard; RNA; 21 BP.
XX
AC ADG29849;
XX

```
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 415.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 415; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 649
ADG29834
ID   ADG29834 standard; RNA; 21 BP.
XX
AC   ADG29834;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 400.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 400; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 3 G; 2 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 CCUGGAAAGAAUCAAAACCUU 3932
              ||||||||||||||||||::
Db          1 CCUGGAAAGAAUCAAAACCTT 21


RESULT 650
ADG29852/c
ID   ADG29852 standard; RNA; 21 BP.
XX
```

```
AC   ADG29852;
XX
DT   26-FEB-2004  (first entry)
XX
DE   FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 418.
XX
KW   double-stranded short interfering nucleic acid; siNA;
KW   antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW   anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW   Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW   amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLT1.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2003074654-A2.
XX
PD   12-SEP-2003.
XX
PF   20-FEB-2003; 2003WO-US005028.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B,  Pavco P,  Fosnaugh K;
PI   Jamison S,  Usman N,  Thompson J;
XX
DR   WPI; 2003-731676/69.
XX
PT   New double-stranded short interfering nucleic acid molecule, useful for
PT   down-regulating the expression of an endogenous mammalian target gene or
PT   for treating diseases that respond to modulation of gene expression or
PT   activity.
XX
PS   Example 24; SEQ ID NO 418; 593pp; English.
XX
CC   The invention relates to a double-stranded short interfering nucleic acid
CC   (siNA) molecule that down-regulates expression of an endogenous mammalian
CC   target gene comprising one or more chemical modifications and each strand
CC   of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC   the invention demonstrates antiarteriosclerotic, neuroprotective,
CC   nootropic, antiparkinsonian and anticonvulsant activities and may be
CC   useful for down-regulating the expression of an endogenous mammalian
CC   target gene and therefore in the treatment of any disease or condition
CC   that responds to modulation of gene expression or activity in a cell,
CC   tissue or organism. The disease or condition may include pulmonary
CC   diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC   Parkinson's disease, epilepsy, dementia, huntington's disease or
CC   amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC   gene therapy applications. The current sequence is that of the siNA DNA-
CC   RNA hybrid of the invention.
XX
SQ   Sequence 21 BP; 1 A; 0 C; 6 G; 2 T; 12 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 651
ADJ97337
ID   ADJ97337 standard; DNA; 21 BP.
XX
AC   ADJ97337;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 110.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 110; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        506 AACAAUUCUGCAGUACUUUAA 526
              |||||::|:||||:||:::||
Db          1 AACAATTCTGCAGTACTTTAA 21


RESULT 652
ADJ97349
ID   ADJ97349 standard; DNA; 21 BP.
XX
```

```
AC   ADJ97349;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 122.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 122; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 AAGGAAACAGAAUCUGCAAUC 621
              ||||||||||||:|:||||:|
Db          1 AAGGAAACAGAATCTGCAATC 21


RESULT 653
ADJ97365
ID   ADJ97365 standard; DNA; 21 BP.
XX
AC   ADJ97365;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 138.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 138; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        760 AAGUUUCCACUUGACACUUUG 780
              |||:::||||::|||||:::|
Db          1 AAGTTTCCACTTGACACTTTG 21


RESULT 654
ADJ97381
ID   ADJ97381 standard; DNA; 21 BP.
XX
AC   ADJ97381;
XX
```

```
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 154.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 154; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        883 AAUGGGCAUUUGUAUAAGACA 903
              ||:|||||:::|:|:||||||
Db          1 AATGGGCATTTGTATAAGACA 21


RESULT 655
ADJ97395
ID   ADJ97395 standard; DNA; 21 BP.
XX
AC   ADJ97395;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 168.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 168; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1024 AACACGAGAGUUCAAAUGACC 1044
              ||||||||||::||||:||||
Db          1 AACACGAGAGTTCAAATGACC 21


RESULT 656
ADJ97400
ID   ADJ97400 standard; DNA; 21 BP.
XX
AC   ADJ97400;
XX
DT   06-MAY-2004  (first entry)
XX
```

```
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 173.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 173; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1063 AAAAAUAAGAGAGCUUCCGUA 1083
             |||||:||||||||::|||:|
Db          1 AAAAATAAGAGAGCTTCCGTA 21


RESULT 657
ADJ97401
ID   ADJ97401 standard; DNA; 21 BP.
XX
AC   ADJ97401;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 174.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 174; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1064 AAAAUAAGAGAGCUUCCGUAA 1084
             ||||:||||||||::|||:||
Db          1 AAAATAAGAGAGCTTCCGTAA 21


RESULT 658
ADJ97420
ID   ADJ97420 standard; DNA; 21 BP.
XX
AC   ADJ97420;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 193.
XX
```

```
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 193; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1208 AAUCUGUUAACACCUCAGUGC 1228
              ||:|:|::||||||:|||:||
Db          1 AATCTGTTAACACCTCAGTGC 21


RESULT 659
ADJ97434
ID   ADJ97434 standard; DNA; 21 BP.
XX
AC   ADJ97434;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 207.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 207; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1327 AAGGCAUUUCCCUCGCCGGAA 1347
              ||||||:::|||:||||||||
Db          1 AAGGCATTTCCCTCGCCGGAA 21


RESULT 660
ADJ97439
ID   ADJ97439 standard; DNA; 21 BP.
XX
AC   ADJ97439;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 212.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
```

```
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 212; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1384 AAAUCUGCUCGCUAUUUGACU 1404
              |||:|:||:|||:|:::|||:
Db          1 AAATCTGCTCGCTATTTGACT 21


RESULT 661
ADJ97444
ID   ADJ97444 standard; DNA; 21 BP.
XX
AC   ADJ97444;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 217.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 217; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1439 AAGAGGAUGCAGGGAAUUAUA 1459
              |||||||:||||||||::|:|
Db          1 AAGAGGATGCAGGGAATTATA 21


RESULT 662
ADJ97454
ID   ADJ97454 standard; DNA; 21 BP.
XX
AC   ADJ97454;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 227.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
```

KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 227; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 8 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1497 AAACCUCACUGCCACUCUAAU 1517
              |||||:|||:|||||:|:||:
Db          1 AAACCTCACTGCCACTCTAAT 21
```

RESULT 663
ADJ97466
ID ADJ97466 standard; DNA; 21 BP.
XX
AC ADJ97466;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 239.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 239; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1638 AAUCAAGUGGUUCUGGCACCC 1658
              ||:||||:||::|:|||||||
Db          1 AATCAAGTGGTTCTGGCACCC 21
```

RESULT 664
ADJ97467
ID ADJ97467 standard; DNA; 21 BP.
XX
AC ADJ97467;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 240.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;

KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 240; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 3 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1642 AAGUGGUUCUGGCACCCCUGU 1662
||||:||::|:||||||||:|:
Db 1 AAGTGGTTCTGGCACCCCTGT 21

RESULT 665
ADJ97474
ID ADJ97474 standard; DNA; 21 BP.
XX
AC ADJ97474;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 247.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 247; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1709 AAGAGUCCUUUAUCCUGGAUG 1729
|||||:||:::|:||:|||:|
Db 1 AAGAGTCCTTTATCCTGGATG 21

RESULT 666
ADJ97502
ID ADJ97502 standard; DNA; 21 BP.
XX
AC ADJ97502;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 275.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX

```
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 275; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1944 AAUGCCGACGGAAGGAGAGGA 1964
              ||:||||||||||||||||||
Db          1 AATGCCGACGGAAGGAGAGGA 21


RESULT 667
ADJ97514
ID   ADJ97514 standard; DNA; 21 BP.
XX
AC   ADJ97514;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 287.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 287; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2070 AAAAAUGGCCAUCACUAAGGA 2090
              |||||:|||||:|||:|||||
Db          1 AAAAATGGCCATCACTAAGGA 21


RESULT 668
ADJ97518
ID   ADJ97518 standard; DNA; 21 BP.
XX
AC   ADJ97518;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 291.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
```

```
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 291; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2086 AAGGAGCACUCCAUCACUCUU 2106
             |||||||||:|||:|||:|::
Db          1 AAGGAGCACTCCATCACTCTT 21


RESULT 669
ADJ97524
ID   ADJ97524 standard; DNA; 21 BP.
XX
AC   ADJ97524;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 297.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 297; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 12 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2186 AAAUCCUCCAGAAGAAAGAAA 2206
              |||:||:|||||||||||||||
Db          1 AAATCCTCCAGAAGAAAGAAA 21


RESULT 670
ADJ97553
ID   ADJ97553 standard; DNA; 21 BP.
XX
AC   ADJ97553;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 326.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
```

PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 326; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2444 AAGCCACCAACCAGAAGGGCU 2464
              ||||||||||||||||||||:
Db          1 AAGCCACCAACCAGAAGGGCT 21
```

RESULT 671
ADJ97612
ID ADJ97612 standard; DNA; 21 BP.
XX
AC ADJ97612;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 385.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 385; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3013 AAGAGCAAACGUGACUUAUUU 3033
              ||||||||||:|||::|:::
Db          1 AAGAGCAAACGTGACTTATTT 21
```

RESULT 672
ADJ97631
ID ADJ97631 standard; DNA; 21 BP.
XX
AC ADJ97631;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 404.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX

```
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 404; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3140 AAAGCUUUGCGAGCUCCGGCU 3160
              |||||:::|||||:|||||:
Db          1 AAAGCTTTGCGAGCTCCGGCT 21


RESULT 673
ADJ97655
ID   ADJ97655 standard; DNA; 21 BP.
XX
AC   ADJ97655;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 428.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 428; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3455 AAUCUAUCUUUGACAAAAUCU 3475
              ||:|:|:|:::|||||||:|:
Db          1 AATCTATCTTTGACAAAATCT 21


RESULT 674
ADJ97657
ID   ADJ97657 standard; DNA; 21 BP.
XX
AC   ADJ97657;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 430.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
```

PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 430; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3470 AAAUCUACAGCACCAAGAGCG 3490
||||:|:||||||||||||||||
Db 1 AAATCTACAGCACCAAGAGCG 21

RESULT 675
ADJ97658
ID ADJ97658 standard; DNA; 21 BP.
XX
AC ADJ97658;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 431.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 431; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3471 AAUCUACAGCACCAAGAGCGA 3491
||:|:||||||||||||||||
Db 1 AATCTACAGCACCAAGAGCGA 21

RESULT 676
ADJ97662
ID ADJ97662 standard; DNA; 21 BP.
XX
AC ADJ97662;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 435.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.

```
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 435; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3560 AAAUGGAUGAGGACUUUUGCA 3580
              |||:|||:||||||::::|||
Db          1 AAATGGATGAGGACTTTTGCA 21


RESULT 677
ADJ97675
ID   ADJ97675 standard; DNA; 21 BP.
XX
AC   ADJ97675;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 448.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 448; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3705 AAAACUAGGUGAUUUGCUUCA 3725
              |||||:|||:||:::||::||
Db          1 AAAACTAGGTGATTTGCTTCA 21


RESULT 678
ADJ97682
ID   ADJ97682 standard; DNA; 21 BP.
XX
AC   ADJ97682;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 455.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
```

```
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 455; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3748 AAAGACUACAUCCCAAUCAAU 3768
              ||||||:|||:||||||:|||:
Db          1 AAAGACTACATCCCAATCAAT 21


RESULT 679
ADJ97699
ID   ADJ97699 standard; DNA; 21 BP.
XX
AC   ADJ97699;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 472.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 472; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3918 AAGAAUCAAAACCUUUGAAGA 3938
              |||||:|||||||:::|||||
Db          1 AAGAATCAAAACCTTTGAAGA 21


RESULT 680
ADJ97373
ID   ADJ97373 standard; DNA; 21 BP.
XX
AC   ADJ97373;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 146.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
```

```
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 146; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 12 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        835 AAUGCAACGUACAAAGAAAUA 855
              ||:||||||:|||||||||:|
Db          1 AATGCAACGTACAAAGAAATA 21


RESULT 681
ADJ97383
ID   ADJ97383 standard; DNA; 21 BP.
XX
AC   ADJ97383;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 156.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 156; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        903 AAACUAUCUCACACAUCGACA 923
              ||||:|:|:|||||:|||||
Db          1 AAACTATCTCACACATCGACA 21


RESULT 682
ADJ97393
ID   ADJ97393 standard; DNA; 21 BP.
XX
AC   ADJ97393;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 166.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
```

```
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 166; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        971 AAUUACUUAGAGGCCAUACUC 991
              ||::||::||||||||:||:|
Db          1 AATTACTTAGAGGCCATACTC 21


RESULT 683
ADJ97412
ID   ADJ97412 standard; DNA; 21 BP.
XX
AC   ADJ97412;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 185.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 185; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 12 A; 3 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1149 AAUGCAGAACAAAGACAAAGG 1169
              ||:||||||||||||||||||
Db          1 AATGCAGAACAAAGACAAAGG 21


RESULT 684
ADJ97419
ID   ADJ97419 standard; DNA; 21 BP.
XX
AC   ADJ97419;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 192.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
```

PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 192; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1207 AAAUCUGUUAACACCUCAGUG 1227
              |||:|:|::||||||:|||:|
Db          1 AAATCTGTTAACACCTCAGTG 21
```

RESULT 685
ADJ97422
ID ADJ97422 standard; DNA; 21 BP.
XX
AC ADJ97422;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 195.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 195; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1240 AAAGCAUUCAUCACUGUGAAA 1260
              ||||||::||:|||:|:||||
Db          1 AAAGCATTCATCACTGTGAAA 21
```

RESULT 686
ADJ97425
ID ADJ97425 standard; DNA; 21 BP.
XX
AC ADJ97425;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 198.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic

PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 198; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1259 AACAUCGAAAACAGCAGGUGC 1279
||||:||||||||||||:||
Db 1 AACATCGAAAACAGCAGGTGC 21

RESULT 687
ADJ97441
ID ADJ97441 standard; DNA; 21 BP.
XX
AC ADJ97441;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 214.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 214; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1419 AAUUAUCAAGGACGUAACUGA 1439
||::|:||||||||:|||:||
Db 1 AATTATCAAGGACGTAACTGA 21

RESULT 688
ADJ97494
ID ADJ97494 standard; DNA; 21 BP.
XX
AC ADJ97494;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 267.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX

```
PS   Disclosure; SEQ ID NO 267; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1893 AAGCUUUUAUAUCACAGAUGU 1913
              ||||::::|:|:||||||:|:
Db          1 AAGCTTTTATATCACAGATGT 21


RESULT 689
ADJ97495
ID   ADJ97495 standard; DNA; 21 BP.
XX
AC   ADJ97495;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 268.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 268; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 2 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 2.3e+03;
  Matches   12;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1917 AAAUGGGUUUCAUGUUAACUU 1937
              |||:|||:::||:|::|||::
Db          1 AAATGGGTTTCATGTTAACTT 21


RESULT 690
ADJ97499
ID   ADJ97499 standard; DNA; 21 BP.
XX
AC   ADJ97499;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 272.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 272; 218pp; English.
XX
```

```
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1941 AAAAAUGCCGACGGAAGGAGA 1961
              |||||:|||||||||||||||
Db          1 AAAAATGCCGACGGAAGGAGA 21


RESULT 691
ADJ97505
ID   ADJ97505 standard; DNA; 21 BP.
XX
AC   ADJ97505;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 278.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 278; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1970 AACUGUCUUGCACAGUUAACA 1990
              |||:|:|::||||||::||||
Db          1 AACTGTCTTGCACAGTTAACA 21


RESULT 692
ADJ97506
ID   ADJ97506 standard; DNA; 21 BP.
XX
AC   ADJ97506;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 279.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 279; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
```

```
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1987 AACAAGUUCUUAUACAGAGAC 2007
              ||||||::|::|:||||||||
Db          1 AACAAGTTCTTATACAGAGAC 21


RESULT 693
ADJ97508
ID   ADJ97508 standard; DNA; 21 BP.
XX
AC   ADJ97508;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 281.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 281; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2035 AAUAACAGAACAAUGCACUAC 2055
              ||:|||||||||:||||:||
Db          1 AATAACAGAACAATGCACTAC 21


RESULT 694
ADJ97515
ID   ADJ97515 standard; DNA; 21 BP.
XX
AC   ADJ97515;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 288.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 288; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
```

CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2071 AAAAUGGCCAUCACUAAGGAG 2091
||||:|||||:|||:||||||
Db 1 AAAATGGCCATCACTAAGGAG 21

RESULT 695
ADJ97538
ID ADJ97538 standard; DNA; 21 BP.
XX
AC ADJ97538;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 311.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 311; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 14 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2337 AAACAACCACAAAAUACAACA 2357
||||||||||||||:||||||
Db 1 AAACAACCACAAAATACAACA 21

RESULT 696
ADJ97548
ID ADJ97548 standard; DNA; 21 BP.
XX
AC ADJ97548;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 321.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 321; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention

```
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2405 AAAGAGUCACAGAAGAGGAUG 2425
              ||||||:|||||||||||||:|
Db          1 AAAGAGTCACAGAAGAGGATG 21


RESULT 697
ADJ97573
ID   ADJ97573 standard; DNA; 21 BP.
XX
AC   ADJ97573;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 346.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 346; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2619 AAAGACUGACUACCUAUCAAU 2639
              ||||||:|||:|||:|:|||:
Db          1 AAAGACTGACTACCTATCAAT 21


RESULT 698
ADJ97580
ID   ADJ97580 standard; DNA; 21 BP.
XX
AC   ADJ97580;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 353.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 353; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
```

CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2732 AACUGGGCAAAUCACUUGGAA 2752
||||:|||||||:|||::||||
Db 1 AACTGGGCAAATCACTTGGAA 21

RESULT 699
ADJ97585
ID ADJ97585 standard; DNA; 21 BP.
XX
AC ADJ97585;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 358.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 358; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2767 AAAGUGGUUCAAGCAUCAGCA 2787
||||:||::||||||:|||||
Db 1 AAAGTGGTTCAAGCATCAGCA 21

RESULT 700
ADJ97608
ID ADJ97608 standard; DNA; 21 BP.
XX
AC ADJ97608;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 381.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 381; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and

```
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2987 AAUAUGGAAAUCUCUCCAACU 3007
              ||:|:|||||:|:|:|||||:
Db          1 AATATGGAAATCTCTCCAACT 21


RESULT 701
ADJ97665
ID   ADJ97665 standard; DNA; 21 BP.
XX
AC   ADJ97665;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 438.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 438; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3632 AAAUCUAUCAGAUCAUGCUGG 3652
              |||:|:|:||||:||:||:||
Db          1 AAATCTATCAGATCATGCTGG 21


RESULT 702
ADJ97667
ID   ADJ97667 standard; DNA; 21 BP.
XX
AC   ADJ97667;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 440.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 440; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
```

```
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3672 AAAAGAAAGGCCAAGAUUUGC 3692
              ||||||||||||||||:::||
Db          1 AAAAGAAAGGCCAAGATTTGC 21


RESULT 703
ADJ97670
ID   ADJ97670 standard; DNA; 21 BP.
XX
AC   ADJ97670;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 443.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 443; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3677 AAAGGCCAAGAUUUGCAGAAC 3697
              ||||||||||:::|||||||
Db          1 AAAGGCCAAGATTTGCAGAAC 21


RESULT 704
ADJ97681
ID   ADJ97681 standard; DNA; 21 BP.
XX
AC   ADJ97681;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 454.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 454; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
```

```
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3737 AACAGGAUGGUAAAGACUACA 3757
              |||||||:||:||||||:|||
Db          1 AACAGGATGGTAAAGACTACA 21


RESULT 705
ADJ97695
ID   ADJ97695 standard; DNA; 21 BP.
XX
AC   ADJ97695;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 468.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 468; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3891 AAAUGCUUUCAAGUUCAUGAG 3911
              |||:||:::||||::||:|||
Db          1 AAATGCTTTCAAGTTCATGAG 21


RESULT 706
ADJ97327
ID   ADJ97327 standard; DNA; 21 BP.
XX
AC   ADJ97327;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 100.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 100; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
```

```
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        459 AAGCGAAAGGCUGAGCAUAAC 479
              ||||||||||:|||||:|||
Db          1 AAGCGAAAGGCTGAGCATAAC 21


RESULT 707
ADJ97333
ID   ADJ97333 standard; DNA; 21 BP.
XX
AC   ADJ97333;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 106.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 106; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        495 AAGAAAUGGCAAACAAUUCUG 515
              ||||||:||||||||::|:|
Db          1 AAGAAATGGCAAACAATTCTG 21


RESULT 708
ADJ97370
ID   ADJ97370 standard; DNA; 21 BP.
XX
AC   ADJ97370;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 143.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 143; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
```

```
XX
SQ   Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        816 AAAGGGCUUCAUCAUAUCAAA 836
              |||||||::||:||:|:||||
Db          1 AAAGGGCTTCATCATATCAAA 21


RESULT 709
ADJ97380
ID   ADJ97380 standard; DNA; 21 BP.
XX
AC   ADJ97380;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 153.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 153; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        876 AACAGUCAAUGGGCAUUUGUA 896
              |||||:|||:|||||:::|:|
Db          1 AACAGTCAATGGGCATTTGTA 21


RESULT 710
ADJ97385
ID   ADJ97385 standard; DNA; 21 BP.
XX
AC   ADJ97385;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 158.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 158; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 2 G; 4 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        923 AAACCAAUACAAUCAUAGAUG 943
              |||||||:||||:||:|||:|
Db          1 AAACCAATACAATCATAGATG 21


RESULT 711
ADJ97399
ID   ADJ97399 standard; DNA; 21 BP.
XX
AC   ADJ97399;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 172.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 172; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1062 AAAAAAUAAGAGAGCUUCCGU 1082
              ||||||:||||||||::|||:
Db          1 AAAAAATAAGAGAGCTTCCGT 21


RESULT 712
ADJ97408
ID   ADJ97408 standard; DNA; 21 BP.
XX
AC   ADJ97408;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 181.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 181; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1101 AAGCAAUUCCCAUGCCAACAU 1121
              ||||||::||||:|||||||:
Db          1 AAGCAATTCCCATGCCAACAT 21


RESULT 713
ADJ97437
ID   ADJ97437 standard; DNA; 21 BP.
XX
AC   ADJ97437;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 210.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 210; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1360 AAAGAUGGGUUACCUGCGACU 1380
              |||||:|||::|||:|||||:
Db          1 AAAGATGGGTTACCTGCGACT 21


RESULT 714
ADJ97469
ID   ADJ97469 standard; DNA; 21 BP.
XX
AC   ADJ97469;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 242.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 242; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1669 AAUCAUUCCGAAGCAAGGUGU 1689
              ||:||::||||||||||:|:
Db          1 AATCATTCCGAAGCAAGGTGT 21
```

RESULT 715
ADJ97490
ID ADJ97490 standard; DNA; 21 BP.
XX
AC ADJ97490;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 263.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 263; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 1 C; 9 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1868 AAGUUGGGACUGUGGGAAGAA 1888
              |||::|||||:|:||||||||
Db          1 AAGTTGGGACTGTGGGAAGAA 21
```

RESULT 716
ADJ97533
ID ADJ97533 standard; DNA; 21 BP.
XX
AC ADJ97533;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 306.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 306; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2244 AAACCUCAGUGAUCACACAGU 2264
```

```
                    |||||:|||:||:|||||||:
Db          1 AAACCTCAGTGATCACACAGT 21
```

RESULT 717
ADJ97552
ID ADJ97552 standard; DNA; 21 BP.
XX
AC ADJ97552;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 325.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 325; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 7 C; 5 G; 0 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 AAAGCCACCAACCAGAAGGGC 2463
              |||||||||||||||||||||
Db          1 AAAGCCACCAACCAGAAGGGC 21
```

RESULT 718
ADJ97556
ID ADJ97556 standard; DNA; 21 BP.
XX
AC ADJ97556;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 329.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 329; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2471 AAAGUUCAGCAUACCUCACUG 2491
              ||||::|||||:|||:|||:|
Db          1 AAAGTTCAGCATACCTCACTG 21
```

```
RESULT 719
ADJ97564
ID   ADJ97564 standard; DNA; 21 BP.
XX
AC   ADJ97564;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 337.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 337; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2592 AAAAAUGAAAAGGUCUUCUUC 2612
              |||||:|||||||:|::|::|
Db          1 AAAAATGAAAAGGTCTTCTTC 21
```

```
RESULT 720
ADJ97565
ID   ADJ97565 standard; DNA; 21 BP.
XX
AC   ADJ97565;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 338.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 338; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2593 AAAAUGAAAAGGUCUUCUUCU 2613
              ||||:|||||||:|::|::|:
Db          1 AAAATGAAAAGGTCTTCTTCT 21
```

```
RESULT 721
ADJ97581
ID   ADJ97581 standard; DNA; 21 BP.
XX
AC   ADJ97581;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 354.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 354; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2740 AAAUCACUUGGAAGAGGGGCU 2760
              |||:|||::||||||||||:
Db          1 AAATCACTTGGAAGAGGGGCT 21


RESULT 722
```

```
ADJ97623
ID   ADJ97623 standard; DNA; 21 BP.
XX
AC   ADJ97623;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 396.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 396; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3080 AAAUGGAGCCAGGCCUGGAAC 3100
              |||:||||||||||:|||||
Db          1 AAATGGAGCCAGGCCTGGAAC 21


RESULT 723
ADJ97626
```

```
ID   ADJ97626 standard; DNA; 21 BP.
XX
AC   ADJ97626;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 399.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 399; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3101 AAGGCAAGAAACCAAGACUAG 3121
              ||||||||||||||||||:||
Db          1 AAGGCAAGAAACCAAGACTAG 21


RESULT 724
ADJ97635
ID   ADJ97635 standard; DNA; 21 BP.
XX
AC   ADJ97635;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 408.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 408; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3173 AAAGUCUGAGUGAUGUUGAGG 3193
              ||||:|:|||:||:|::||||
Db          1 AAAGTCTGAGTGATGTTGAGG 21


RESULT 725
ADJ97661
ID   ADJ97661 standard; DNA; 21 BP.
XX
```

```
AC   ADJ97661;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 434.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 434; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3522 AAUCUUCUCCUUAGGUGGGUC 3542
              ||:|::|:||::|||:|||:|
Db          1 AATCTTCTCCTTAGGTGGGTC 21


RESULT 726
ADJ97663
ID   ADJ97663 standard; DNA; 21 BP.
XX
AC   ADJ97663;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 436.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 436; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3561 AAUGGAUGAGGACUUUUGCAG 3581
              ||:|||:||||||::::||||
Db          1 AATGGATGAGGACTTTTGCAG 21


RESULT 727
ADJ97678
ID   ADJ97678 standard; DNA; 21 BP.
XX
AC   ADJ97678;
XX
```

```
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 451.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 451; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3725 AAGCAAAUGUACAACAGGAUG 3745
              |||||||:|:||||||||:|
Db          1 AAGCAAATGTACAACAGGATG 21


RESULT 728
ADJ97679
ID   ADJ97679 standard; DNA; 21 BP.
XX
AC   ADJ97679;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 452.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 452; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3729 AAAUGUACAACAGGAUGGUAA 3749
              |||:|:|||||||||:||:||
Db          1 AAATGTACAACAGGATGGTAA 21


RESULT 729
ADJ97683
ID   ADJ97683 standard; DNA; 21 BP.
XX
AC   ADJ97683;
XX
DT   06-MAY-2004  (first entry)
XX
```

```
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 456.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 456; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3749 AAGACUACAUCCCAAUCAAUG 3769
              |||||:|||:|||||:|||:|
Db          1 AAGACTACATCCCAATCAATG 21


RESULT 730
ADJ97689
ID   ADJ97689 standard; DNA; 21 BP.
XX
AC   ADJ97689;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 462.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 462; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3832 AAGGAAAGUAUUUCAGCUCCG 3852
              ||||||||:|:::||||:|||
Db          1 AAGGAAAGTATTTCAGCTCCG 21


RESULT 731
ADJ97701
ID   ADJ97701 standard; DNA; 21 BP.
XX
AC   ADJ97701;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 474.
XX
```

```
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 474; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3925 AAAACCUUUGAAGAACUUUUA 3945
              ||||||:::|||||||::::|
Db          1 AAAACCTTTGAAGAACTTTTA 21


RESULT 732
ADJ97704
ID   ADJ97704 standard; DNA; 21 BP.
XX
AC   ADJ97704;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 477.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 477; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3935 AAGAACUUUUACCGAAUGCCA 3955
              ||||||::::||||||:||||
Db          1 AAGAACTTTTACCGAATGCCA 21


RESULT 733
ADJ97716
ID   ADJ97716 standard; DNA; 21 BP.
XX
AC   ADJ97716;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 489.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
```

KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 489; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 4087 AAGGAGUCGGGGCUGUCUGAU 4107
||||||:||||||:|:|:||:
Db 1 AAGGAGTCGGGGCTGTCTGAT 21

RESULT 734
ADJ97731
ID ADJ97731 standard; DNA; 21 BP.
XX
AC ADJ97731;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 504.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 504; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 4048 GCCUCGCUCAAGAUUGACUUG 4068
|||:|||:|||||::|||::|
Db 1 GCCTCGCTCAAGATTGACTTG 21

RESULT 735
ADJ97325
ID ADJ97325 standard; DNA; 21 BP.
XX
AC ADJ97325;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 98.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;

```
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 98; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        454 AAGGAAAGCGAAAGGCUGAGC 474
              ||||||||||||||||:||||
Db          1 AAGGAAAGCGAAAGGCTGAGC 21


RESULT 736
ADJ97331
ID   ADJ97331 standard; DNA; 21 BP.
XX
AC   ADJ97331;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 104.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 104; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AAAUCUGCCUGUGGAAGAAAU 501
              |||:|:|||:|:||||||||:
Db          1 AAATCTGCCTGTGGAAGAAAT 21


RESULT 737
ADJ97359
ID   ADJ97359 standard; DNA; 21 BP.
XX
AC   ADJ97359;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 132.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
```

```
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 132; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        702 AAGGGAGCUCGUCAUUCCCUG 722
              ||||||||:||:||::|||:|
Db          1 AAGGGAGCTCGTCATTCCCTG 21


RESULT 738
ADJ97363
ID   ADJ97363 standard; DNA; 21 BP.
XX
AC   ADJ97363;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 136.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 136; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 AAAAGUUUCCACUUGACACUU 778
              |||||:::||||::|||||::
Db          1 AAAAGTTTCCACTTGACACTT 21


RESULT 739
ADJ97377
ID   ADJ97377 standard; DNA; 21 BP.
XX
AC   ADJ97377;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 150.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
```

```
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 150; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        851 AAAUAGGGCUUCUGACCUGUG 871
              |||:|||||::|:||||:|:|
Db          1 AAATAGGGCTTCTGACCTGTG 21


RESULT 740
ADJ97378
ID   ADJ97378 standard; DNA; 21 BP.
XX
AC   ADJ97378;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 151.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 151; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        852 AAUAGGGCUUCUGACCUGUGA 872
              ||:|||||::|:||||:|:||
Db          1 AATAGGGCTTCTGACCTGTGA 21


RESULT 741
ADJ97402
ID   ADJ97402 standard; DNA; 21 BP.
XX
AC   ADJ97402;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 175.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
```

```
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 175; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1065 AAAUAAGAGAGCUUCCGUAAG 1085
              |||:||||||||::|||:|||
Db          1 AAATAAGAGAGCTTCCGTAAG 21


RESULT 742
ADJ97418
ID   ADJ97418 standard; DNA; 21 BP.
XX
AC   ADJ97418;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 191.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 191; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1188 AAGGAGUGGACCAUCAUUCAA 1208
              ||||||:||||||:||::|||
Db          1 AAGGAGTGGACCATCATTCAA 21


RESULT 743
ADJ97445
ID   ADJ97445 standard; DNA; 21 BP.
XX
AC   ADJ97445;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 218.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
```

```
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 218; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1453 AAUUAUACAAUCUUGCUGAGC 1473
              ||::|:||||:|::||:||||
Db          1 AATTATACAATCTTGCTGAGC 21


RESULT 744
ADJ97453
ID   ADJ97453 standard; DNA; 21 BP.
XX
AC   ADJ97453;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 226.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 226; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1496 AAAACCUCACUGCCACUCUAA 1516
              ||||||:|||:|||||:|:||
Db          1 AAAACCTCACTGCCACTCTAA 21


RESULT 745
ADJ97457
ID   ADJ97457 standard; DNA; 21 BP.
XX
AC   ADJ97457;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 230.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
```

```
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 230; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1522 AAUGUGAAACCCCAGAUUUAC 1542
              ||:|:||||||||||:::||
Db             1 AATGTGAAACCCCAGATTTAC 21


RESULT 746
ADJ97461
ID   ADJ97461 standard; DNA; 21 BP.
XX
AC   ADJ97461;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 234.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 234; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1545 AAAGGCCGUGUCAUCGUUUCC 1565
              |||||||:|:||:||:::||
Db             1 AAAGGCCGTGTCATCGTTTCC 21


RESULT 747
ADJ97476
ID   ADJ97476 standard; DNA; 21 BP.
XX
AC   ADJ97476;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 249.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
```

PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 249; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1746 AAACAGAAUUGAGAGCAUCAC 1766
||||||||::|||||||:|||
Db 1 AAACAGAATTGAGAGCATCAC 21

RESULT 748
ADJ97497
ID ADJ97497 standard; DNA; 21 BP.
XX
AC ADJ97497;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 270.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 270; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1933 AACUUGGAAAAAAUGCCGACG 1953
|||::|||||||:|||||||
Db 1 AACTTGGAAAAAATGCCGACG 21

RESULT 749
ADJ97519
ID ADJ97519 standard; DNA; 21 BP.
XX
AC ADJ97519;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 292.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.

```
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 292; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2107 AAUCUUACCAUCAUGAAUGUU 2127
              ||:|::||||:||:|||:|::
Db          1 AATCTTACCATCATGAATGTT 21


RESULT 750
ADJ97522
ID   ADJ97522 standard; DNA; 21 BP.
XX
AC   ADJ97522;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 295.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 295; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2167 AAUGUAUACACAGGGGAAGAA 2187
              ||:|:|:|||||||||||||||
Db          1 AATGTATACACAGGGGAAGAA 21


RESULT 751
ADJ97540
ID   ADJ97540 standard; DNA; 21 BP.
XX
AC   ADJ97540;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 313.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
```

```
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 313; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 13 A; 5 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2341 AACCACAAAAUACAACAAGAG 2361
              ||||||||||:||||||||||
Db          1 AACCACAAAATACAACAAGAG 21


RESULT 752
ADJ97543
ID   ADJ97543 standard; DNA; 21 BP.
XX
AC   ADJ97543;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 316.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 316; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2349 AAUACAACAAGAGCCUGGAAU 2369
              ||:|||||||||||:||||:
Db          1 AATACAACAAGAGCCTGGAAT 21


RESULT 753
ADJ97597
ID   ADJ97597 standard; DNA; 21 BP.
XX
AC   ADJ97597;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 370.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
```

```
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 370; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2867 AAGCUCUGAUGACUGAGCUAA 2887
              ||||:|:||:|||:||||:||
Db          1 AAGCTCTGATGACTGAGCTAA 21


RESULT 754
ADJ97642
ID   ADJ97642 standard; DNA; 21 BP.
XX
AC   ADJ97642;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 415.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 415; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3298 AAGUGCAUUCAUCGGGACCUG 3318
              |||:|||::||:||||||:|
Db          1 AAGTGCATTCATCGGGACCTG 21


RESULT 755
ADJ97647
ID   ADJ97647 standard; DNA; 21 BP.
XX
AC   ADJ97647;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 420.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
```

```
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 420; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 2 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3358 AAGAUUUGUGAUUUUGGCCUU 3378
              ||||:::|:||::::||||::
Db          1 AAGATTTGTGATTTTGGCCTT 21


RESULT 756
ADJ97650
ID   ADJ97650 standard; DNA; 21 BP.
XX
AC   ADJ97650;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 423.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 423; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3414 AAAAGGAGAUACUCGACUUCC 3434
              |||||||||:||:||||::||
Db          1 AAAAGGAGATACTCGACTTCC 21


RESULT 757
ADJ97698
ID   ADJ97698 standard; DNA; 21 BP.
XX
AC   ADJ97698;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 471.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
```

PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 471; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 11 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3917 AAAGAAUCAAAACCUUUGAAG 3937
||||||:|||||||:::||||
Db 1 AAAGAATCAAAACCTTTGAAG 21

RESULT 758
ADJ97703
ID ADJ97703 standard; DNA; 21 BP.
XX
AC ADJ97703;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 476.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 476; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3927 AACCUUUGAAGAACUUUUACC 3947
||||:::|||||||:::|||
Db 1 AACCTTTGAAGAACTTTTACC 21

RESULT 759
ADJ97721
ID ADJ97721 standard; DNA; 21 BP.
XX
AC ADJ97721;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 494.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic

PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 494; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 2 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 706 GAGCUCGUCAUUCCCUGCCGG 726
||||:||:||::|||:|||||
Db 1 GAGCTCGTCATTCCCTGCCGG 21

RESULT 760
ADJ97318
ID ADJ97318 standard; DNA; 21 BP.
XX
AC ADJ97318;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 91.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 91; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 380 AAGCAGGCCAGACACUGCAUC 400
||||||||||||||:|||:|
Db 1 AAGCAGGCCAGACACTGCATC 21

RESULT 761
ADJ97332
ID ADJ97332 standard; DNA; 21 BP.
XX
AC ADJ97332;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 105.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX

```
PS   Disclosure; SEQ ID NO 105; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        482 AAUCUGCCUGUGGAAGAAAUG 502
              ||:|:|||:|:|||||||:|
Db          1 AATCTGCCTGTGGAAGAAATG 21


RESULT 762
ADJ97335
ID   ADJ97335 standard; DNA; 21 BP.
XX
AC   ADJ97335;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 108.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 108; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 AAUGGCAAACAAUUCUGCAGU 519
              ||:|||||||||::|:||||:
Db          1 AATGGCAAACAATTCTGCAGT 21


RESULT 763
ADJ97348
ID   ADJ97348 standard; DNA; 21 BP.
XX
AC   ADJ97348;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 121.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 121; 218pp; English.
XX
```

```
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        598 AAGAAGGAAACAGAAUCUGCA 618
              ||||||||||||||||:|:|||
Db          1 AAGAAGGAAACAGAATCTGCA 21


RESULT 764
ADJ97362
ID   ADJ97362 standard; DNA; 21 BP.
XX
AC   ADJ97362;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 135.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 135; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        757 AAAAAGUUUCCACUUGACACU 777
              ||||||:::||||::|||||:
Db          1 AAAAAGTTTCCACTTGACACT 21


RESULT 765
ADJ97384
ID   ADJ97384 standard; DNA; 21 BP.
XX
AC   ADJ97384;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 157.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 157; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
```

```
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        904 AACUAUCUCACACAUCGACAA 924
              |||:|:|:||||||:||||||
Db          1 AACTATCTCACACATCGACAA 21


RESULT 766
ADJ97396
ID   ADJ97396 standard; DNA; 21 BP.
XX
AC   ADJ97396;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 169.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 169; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1037 AAAUGACCUGGAGUUACCCUG 1057
              |||:||||:||||::|||||:|
Db          1 AAATGACCTGGAGTTACCCTG 21


RESULT 767
ADJ97397
ID   ADJ97397 standard; DNA; 21 BP.
XX
AC   ADJ97397;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 170.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 170; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
```

CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 AAUGACCUGGAGUUACCCUGA 1058
||:||||:||||::||||:||
Db 1 AATGACCTGGAGTTACCCTGA 21

RESULT 768
ADJ97411
ID ADJ97411 standard; DNA; 21 BP.
XX
AC ADJ97411;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 184.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 184; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 14 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1147 AAAAUGCAGAACAAAGACAAA 1167
||||:|||||||||||||||
Db 1 AAAATGCAGAACAAAGACAAA 21

RESULT 769
ADJ97462
ID ADJ97462 standard; DNA; 21 BP.
XX
AC ADJ97462;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 235.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 235; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention

CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1546 AAGGCCGUGUCAUCGUUUCCA 1566
||||||:|:||:||:::|||
Db 1 AAGGCCGTGTCATCGTTTCCA 21

RESULT 770
ADJ97464
ID ADJ97464 standard; DNA; 21 BP.
XX
AC ADJ97464;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 237.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 237; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1599 AAUCCUGACUUGUACCGCAUA 1619
||:||:|||::|:|||||:|
Db 1 AATCCTGACTTGTACCGCATA 21

RESULT 771
ADJ97475
ID ADJ97475 standard; DNA; 21 BP.
XX
AC ADJ97475;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 248.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 248; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target

```
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 AACAUGGGAAACAGAAUUGAG 1758
              ||||:|||||||||||::|||
Db          1 AACATGGGAAACAGAATTGAG 21


RESULT 772
ADJ97489
ID   ADJ97489 standard; DNA; 21 BP.
XX
AC   ADJ97489;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 262.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 262; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 1 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1867 AAAGUUGGGACUGUGGGAAGA 1887
              ||||::|||||:|:|||||||
Db          1 AAAGTTGGGACTGTGGGAAGA 21


RESULT 773
ADJ97491
ID   ADJ97491 standard; DNA; 21 BP.
XX
AC   ADJ97491;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 264.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 264; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
```

```
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 AAGAAACAUAAGCUUUUAUAU 1904
              |||||||:||||::::|:|:
Db          1 AAGAAACATAAGCTTTTATAT 21


RESULT 774
ADJ97500
ID   ADJ97500 standard; DNA; 21 BP.
XX
AC   ADJ97500;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 273.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 273; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1942 AAAAUGCCGACGGAAGGAGAG 1962
              ||||:||||||||||||||||
Db          1 AAAATGCCGACGGAAGGAGAG 21


RESULT 775
ADJ97507
ID   ADJ97507 standard; DNA; 21 BP.
XX
AC   ADJ97507;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 280.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 280; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
```

```
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1990 AAGUUCUUAUACAGAGACGUU 2010
              |||::|::|:|||||||||::
Db          1 AAGTTCTTATACAGAGACGTT 21


RESULT 776
ADJ97509
ID   ADJ97509 standard; DNA; 21 BP.
XX
AC   ADJ97509;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 282.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 282; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 5 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 AACAGAACAAUGCACUACAGU 2058
              ||||||||||:||||:||||:
Db          1 AACAGAACAATGCACTACAGT 21


RESULT 777
ADJ97525
ID   ADJ97525 standard; DNA; 21 BP.
XX
AC   ADJ97525;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 298.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 298; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
```

```
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2187 AAUCCUCCAGAAGAAAGAAAU 2207
              ||:||:|||||||||||||||:
Db          1 AATCCTCCAGAAGAAAGAAAT 21


RESULT 778
ADJ97559
ID   ADJ97559 standard; DNA; 21 BP.
XX
AC   ADJ97559;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 332.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 332; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2499 AACCUCGGACAAGUCUAAUCU 2519
              ||||:|||||||:|:||:|:
Db          1 AACCTCGGACAAGTCTAATCT 21


RESULT 779
ADJ97574
ID   ADJ97574 standard; DNA; 21 BP.
XX
AC   ADJ97574;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 347.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 347; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
```

```
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2620 AAGACUGACUACCUAUCAAUU 2640
              |||||:|||:|||:|:|||::
Db          1 AAGACTGACTACCTATCAATT 21


RESULT 780
ADJ97576
ID   ADJ97576 standard; DNA; 21 BP.
XX
AC   ADJ97576;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 349.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 349; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2643 AAUGGACCCAGAUGAAGUUCC 2663
              ||:||||||||:||||::||
Db          1 AATGGACCCAGATGAAGTTCC 21


RESULT 781
ADJ97591
ID   ADJ97591 standard; DNA; 21 BP.
XX
AC   ADJ97591;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 364.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 364; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
```

```
XX
SQ   Sequence 21 BP; 8 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2830 AAAAUGCUGAAAGAGGGGGCC 2850
              ||||:||:|||||||||||||
Db          1 AAAATGCTGAAAGAGGGGGCC 21


RESULT 782
ADJ97601
ID   ADJ97601 standard; DNA; 21 BP.
XX
AC   ADJ97601;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 374.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 374; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2889 AAUCUUGACCCACAUUGGCCA 2909
              ||:|::|||||||::|||||
Db          1 AATCTTGACCCACATTGGCCA 21


RESULT 783
ADJ97605
ID   ADJ97605 standard; DNA; 21 BP.
XX
AC   ADJ97605;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 378.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 378; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2951 AAGGAGGGCCUCUGAUGGUGA 2971
              ||||||||||:|:||:||:||
Db          1 AAGGAGGGCCTCTGATGGTGA 21


RESULT 784
ADJ97656
ID   ADJ97656 standard; DNA; 21 BP.
XX
AC   ADJ97656;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 429.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 429; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3469 AAAAUCUACAGCACCAAGAGC 3489
              ||||:|:||||||||||||||
Db          1 AAAATCTACAGCACCAAGAGC 21


RESULT 785
ADJ97671
ID   ADJ97671 standard; DNA; 21 BP.
XX
AC   ADJ97671;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 444.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 444; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3678 AAGGCCAAGAUUUGCAGAACU 3698
              ||||||||||:::|||||||:
Db          1 AAGGCCAAGATTTGCAGAACT 21


RESULT 786
ADJ97676
ID   ADJ97676 standard; DNA; 21 BP.
XX
AC   ADJ97676;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 449.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 449; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3706 AAACUAGGUGAUUUGCUUCAA 3726
              ||||:|||:||:::||::|||
Db          1 AAACTAGGTGATTTGCTTCAA 21


RESULT 787
ADJ97677
ID   ADJ97677 standard; DNA; 21 BP.
XX
AC   ADJ97677;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 450.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 450; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3707 AACUAGGUGAUUUGCUUCAAG 3727
              |||:|||:||:::||::||||
Db          1 AACTAGGTGATTTGCTTCAAG 21
```

RESULT 788
ADJ97688
ID ADJ97688 standard; DNA; 21 BP.
XX
AC ADJ97688;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 461.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 461; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3804 AACUCCUGCCUUCUCUGAGGA 3824
              |||:||:|||::|:|:|||||
Db          1 AACTCCTGCCTTCTCTGAGGA 21
```

RESULT 789
ADJ97727
ID ADJ97727 standard; DNA; 21 BP.
XX
AC ADJ97727;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 500.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 500; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3056 UACACAUGGAGCCUAAGAAAG 3076
```

```
              :|||||:||||||:|||||||
Db          1 TACACATGGAGCCTAAGAAAG 21
```

RESULT 790
ADJ97343
ID ADJ97343 standard; DNA; 21 BP.
XX
AC ADJ97343;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 116.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 116; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        547 AACCACACUGGCUUCUACAGC 567
              ||||||||:|||::|:|||||
Db          1 AACCACACTGGCTTCTACAGC 21
```

RESULT 791
ADJ97344
ID ADJ97344 standard; DNA; 21 BP.
XX
AC ADJ97344;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 117.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 117; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AAAUAUCUAGCUGUACCUACU 591
              |||:|:|:|||:|:|||:||:
Db          1 AAATATCTAGCTGTACCTACT 21
```

```
RESULT 792
ADJ97346
ID   ADJ97346 standard; DNA; 21 BP.
XX
AC   ADJ97346;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 119.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 119; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 13 A; 2 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        594 AAAGAAGAAGGAAACAGAAUC 614
              |||||||||||||||||||:|
Db          1 AAAGAAGAAGGAAACAGAATC 21
```

```
RESULT 793
ADJ97382
ID   ADJ97382 standard; DNA; 21 BP.
XX
AC   ADJ97382;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 155.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 155; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 AAGACAAACUAUCUCACACAU 918
              |||||||||:|:|:||||||:
Db          1 AAGACAAACTATCTCACACAT 21
```

```
RESULT 794
ADJ97409
ID   ADJ97409 standard; DNA; 21 BP.
XX
AC   ADJ97409;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 182.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 182; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 7 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1105 AAUUCCCAUGCCAACAUAUUC 1125
              ||::||||:|||||||:|::|
Db          1 AATTCCCATGCCAACATATTC 21


RESULT 795
ADJ97413
ID   ADJ97413 standard; DNA; 21 BP.
XX
AC   ADJ97413;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 186.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 186; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1156 AACAAAGACAAAGGACUUUAU 1176
              |||||||||||||||:::|:
Db          1 AACAAAGACAAAGGACTTTAT 21


RESULT 796
ADJ97415
```

```
ID   ADJ97415 standard; DNA; 21 BP.
XX
AC   ADJ97415;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 188.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 188; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGACAAAGGACUUUAUACUU 1180
              ||||||||||||:::|:||::
Db          1 AAGACAAAGGACTTTATACTT 21


RESULT 797
ADJ97423
ID   ADJ97423 standard; DNA; 21 BP.
XX
AC   ADJ97423;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 196.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 196; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1241 AAGCAUUCAUCACUGUGAAAC 1261
              |||||::||:|||:|:|||||
Db          1 AAGCATTCATCACTGTGAAAC 21


RESULT 798
ADJ97452
ID   ADJ97452 standard; DNA; 21 BP.
XX
```

```
AC   ADJ97452;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 225.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 225; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1495 AAAAACCUCACUGCCACUCUA 1515
              |||||||:|||:|||||:|:|
Db          1 AAAAACCTCACTGCCACTCTA 21


RESULT 799
ADJ97488
ID   ADJ97488 standard; DNA; 21 BP.
XX
AC   ADJ97488;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 261.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 261; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 1 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1864 AAUAAAGUUGGGACUGUGGGA 1884
              ||:||||::|||||:|:||||
Db          1 AATAAAGTTGGGACTGTGGGA 21


RESULT 800
ADJ97492
ID   ADJ97492 standard; DNA; 21 BP.
XX
AC   ADJ97492;
XX
```

```
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 265.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 265; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1887 AAACAUAAGCUUUUAUAUCAC 1907
              |||||:||||::::|:|:|||
Db          1 AAACATAAGCTTTTATATCAC 21


RESULT 801
ADJ97513
ID   ADJ97513 standard; DNA; 21 BP.
XX
AC   ADJ97513;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 286.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 286; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2069 AAAAAAUGGCCAUCACUAAGG 2089
              ||||||:|||||:|||:||||
Db          1 AAAAAATGGCCATCACTAAGG 21


RESULT 802
ADJ97516
ID   ADJ97516 standard; DNA; 21 BP.
XX
AC   ADJ97516;
XX
DT   06-MAY-2004  (first entry)
XX
```

```
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 289.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 289; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2072 AAAUGGCCAUCACUAAGGAGC 2092
              |||:|||||:|||:|||||||
Db          1 AAATGGCCATCACTAAGGAGC 21


RESULT 803
ADJ97521
ID   ADJ97521 standard; DNA; 21 BP.
XX
AC   ADJ97521;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 294.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 294; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2135 AAGAUUCAGGCACCUAUGCCU 2155
              ||||::|||||||:|:|||:
Db          1 AAGATTCAGGCACCTATGCCT 21


RESULT 804
ADJ97590
ID   ADJ97590 standard; DNA; 21 BP.
XX
AC   ADJ97590;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 363.
XX
```

```
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 363; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2801 AAUCACCUACGUGCCGGACUG 2821
              ||:||||:|||:|||||||:|
Db          1 AATCACCTACGTGCCGGACTG 21


RESULT 805
ADJ97593
ID   ADJ97593 standard; DNA; 21 BP.
XX
AC   ADJ97593;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 366.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 366; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2832 AAUGCUGAAAGAGGGGGCCAC 2852
              ||:|||:|||||||||||||||
Db          1 AATGCTGAAAGAGGGGGCCAC 21


RESULT 806
ADJ97603
ID   ADJ97603 standard; DNA; 21 BP.
XX
AC   ADJ97603;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 376.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
```

KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 376; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2926 AACCUGCUGGGAGCCUGCACC 2946
||||:||:|||||||:|||||
Db 1 AACCTGCTGGGAGCCTGCACC 21

RESULT 807
ADJ97628
ID ADJ97628 standard; DNA; 21 BP.
XX
AC ADJ97628;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 401.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 401; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3109 AAACCAAGACUAGAUAGCGUC 3129
||||||||||:|||:||||:|
Db 1 AAACCAAGACTAGATAGCGTC 21

RESULT 808
ADJ97633
ID ADJ97633 standard; DNA; 21 BP.
XX
AC ADJ97633;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 406.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;

KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 406; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3167 AAGAUAAAAGUCUGAGUGAUG 3187
              ||||:|||||:|:|||:||:|
Db          1 AAGATAAAAGTCTGAGTGATG 21
```

RESULT 809
ADJ97638
ID ADJ97638 standard; DNA; 21 BP.
XX
AC ADJ97638;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 411.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 411; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3220 AAGGAGCCCAUCACUAUGGAA 3240
              ||||||||||:|||:|:||||
Db          1 AAGGAGCCCATCACTATGGAA 21
```

RESULT 810
ADJ97640
ID ADJ97640 standard; DNA; 21 BP.
XX
AC ADJ97640;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 413.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;

```
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 413; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3263 AAGUGGCCAGAGGCAUGGAGU 3283
              |||:|||||||||||:||||:
Db          1 AAGTGGCCAGAGGCATGGAGT 21


RESULT 811
ADJ97651
ID   ADJ97651 standard; DNA; 21 BP.
XX
AC   ADJ97651;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 424.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 424; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3415 AAAGGAGAUACUCGACUUCCU 3435
              ||||||||:||:||||::||:
Db          1 AAAGGAGATACTCGACTTCCT 21


RESULT 812
ADJ97680
ID   ADJ97680 standard; DNA; 21 BP.
XX
AC   ADJ97680;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 453.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
```

```
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 453; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3730 AAUGUACAACAGGAUGGUAAA 3750
              ||:|:||||||||||:||:|||
Db          1 AATGTACAACAGGATGGTAAA 21


RESULT 813
ADJ97685
ID   ADJ97685 standard; DNA; 21 BP.
XX
AC   ADJ97685;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 458.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 458; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3766 AAUGCCAUACUGACAGGAAAU 3786
              ||:||||:||:||||||||:
Db          1 AATGCCATACTGACAGGAAAT 21


RESULT 814
ADJ97692
ID   ADJ97692 standard; DNA; 21 BP.
XX
AC   ADJ97692;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 465.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
```

```
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 465; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3853 AAGUUUAAUUCAGGAAGCUCU 3873
              |||:::||::|||||||||:|:
Db          1 AAGTTTAATTCAGGAAGCTCT 21


RESULT 815
ADJ97694
ID   ADJ97694 standard; DNA; 21 BP.
XX
AC   ADJ97694;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 467.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 467; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3867 AAGCUCUGAUGAUGUCAGAUA 3887
              ||||:|:||:||:|:|||||:|
Db          1 AAGCTCTGATGATGTCAGATA 21


RESULT 816
ADJ97707
ID   ADJ97707 standard; DNA; 21 BP.
XX
AC   ADJ97707;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 480.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
```

PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 480; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 4039 AAACCCAAGGCCUCGCUCAAG 4059
||||||||||||:|||:||||
Db 1 AAACCCAAGGCCTCGCTCAAG 21

RESULT 817
ADJ97352
ID ADJ97352 standard; DNA; 21 BP.
XX
AC ADJ97352;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 125.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 125; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 2.3e+03;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 611 AAUCUGCAAUCUAUAUAUUUA 631
||:|:||||:|:|:|:|::|
Db 1 AATCTGCAATCTATATATTTA 21

RESULT 818
ADJ97354
ID ADJ97354 standard; DNA; 21 BP.
XX
AC ADJ97354;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 127.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX

```
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 127; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 AAAUCCCCGAAAUUAUACACA 691
              |||:|||||||::|:|||||
Db          1 AAATCCCCGAAATTATACACA 21


RESULT 819
ADJ97355
ID   ADJ97355 standard; DNA; 21 BP.
XX
AC   ADJ97355;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 128.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 128; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        672 AAUCCCCGAAAUUAUACACAU 692
              ||:|||||||::|:|||||:
Db          1 AATCCCCGAAATTATACACAT 21


RESULT 820
ADJ97416
ID   ADJ97416 standard; DNA; 21 BP.
XX
AC   ADJ97416;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 189.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
```

PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 189; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1165 AAAGGACUUUAUACUUGUCGU 1185
              |||||||:::|:||::|:||:
Db          1 AAAGGACTTTATACTTGTCGT 21
```

RESULT 821
ADJ97450
ID ADJ97450 standard; DNA; 21 BP.
XX
AC ADJ97450;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 223.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 223; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1485 AAAUGUGUUUAAAAACCUCAC 1505
              |||:|:|:::|||||||:|||
Db          1 AAATGTGTTTAAAAACCTCAC 21
```

RESULT 822
ADJ97465
ID ADJ97465 standard; DNA; 21 BP.
XX
AC ADJ97465;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 238.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.

```
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 238; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1631 AACCUACAAUCAAGUGGUUCU 1651
              ||||:||||:||||:||::|:
Db          1 AACCTACAATCAAGTGGTTCT 21


RESULT 823
ADJ97470
ID   ADJ97470 standard; DNA; 21 BP.
XX
AC   ADJ97470;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 243.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 243; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 2 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1679 AAGCAAGGUGUGACUUUUGUU 1699
              ||||||||:|:|||::::|::
Db          1 AAGCAAGGTGTGACTTTTGTT 21


RESULT 824
ADJ97484
ID   ADJ97484 standard; DNA; 21 BP.
XX
AC   ADJ97484;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 257.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
```

```
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 257; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1795 AAUAAGAUGGCUAGCACCUUG 1815
              ||:||||:|||:||||||::|
Db          1 AATAAGATGGCTAGCACCTTG 21


RESULT 825
ADJ97561
ID   ADJ97561 standard; DNA; 21 BP.
XX
AC   ADJ97561;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 334.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 334; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 AAUCUGGAGCUGAUCACUCUA 2535
              ||:|:|||||:||:|||:|:|
Db          1 AATCTGGAGCTGATCACTCTA 21


RESULT 826
ADJ97566
ID   ADJ97566 standard; DNA; 21 BP.
XX
AC   ADJ97566;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 339.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
```

```
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 339; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2594 AAAUGAAAAGGUCUUCUUCUG 2614
              |||:|||||||:|::|::|:|
Db          1 AAATGAAAAGGTCTTCTTCTG 21


RESULT 827
ADJ97572
ID   ADJ97572 standard; DNA; 21 BP.
XX
AC   ADJ97572;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 345.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 345; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2616 AAUAAAGACUGACUACCUAUC 2636
              ||:||||||:|||:|||:|:|
Db          1 AATAAAGACTGACTACCTATC 21


RESULT 828
ADJ97587
ID   ADJ97587 standard; DNA; 21 BP.
XX
AC   ADJ97587;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 360.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
```

```
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 360; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2777 AAGCAUCAGCAUUUGGCAUUA 2797
              |||||:|||||:::||||::|
Db          1 AAGCATCAGCATTTGGCATTA 21


RESULT 829
ADJ97595
ID   ADJ97595 standard; DNA; 21 BP.
XX
AC   ADJ97595;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 368.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 368; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2840 AAGAGGGGGCCACGGCCAGCG 2860
              |||||||||||||||||||||
Db          1 AAGAGGGGGCCACGGCCAGCG 21


RESULT 830
ADJ97602
ID   ADJ97602 standard; DNA; 21 BP.
XX
AC   ADJ97602;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 375.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
```

PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 375; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2917 AACGUGGUUAACCUGCUGGGA 2937
||||:||::||||:||:||||
Db 1 AACGTGGTTAACCTGCTGGGA 21

RESULT 831
ADJ97617
ID ADJ97617 standard; DNA; 21 BP.
XX
AC ADJ97617;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 390.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 390; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 13 A; 2 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3070 AAGAAAGAAAAAAUGGAGCCA 3090
||||||||||||:|||||||
Db 1 AAGAAAGAAAAAATGGAGCCA 21

RESULT 832
ADJ97659
ID ADJ97659 standard; DNA; 21 BP.
XX
AC ADJ97659;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 432.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic

```
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 432; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3484 AAGAGCGACGUGUGGUCUUAC 3504
              ||||||||||:|:||:|::||
Db          1 AAGAGCGACGTGTGGTCTTAC 21


RESULT 833
ADJ97664
ID   ADJ97664 standard; DNA; 21 BP.
XX
AC   ADJ97664;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 437.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 437; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3593 AAGGCAUGAGGAUGAGAGCUC 3613
              ||||||:|||||:||||||:|
Db          1 AAGGCATGAGGATGAGAGCTC 21


RESULT 834
ADJ97674
ID   ADJ97674 standard; DNA; 21 BP.
XX
AC   ADJ97674;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 447.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
```

```
PS   Disclosure; SEQ ID NO 447; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3704 AAAAACUAGGUGAUUUGCUUC 3724
              ||||||:|||:||:::||::|
Db          1 AAAAACTAGGTGATTTGCTTC 21


RESULT 835
ADJ97713
ID   ADJ97713 standard; DNA; 21 BP.
XX
AC   ADJ97713;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 486.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 486; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4081 AAAAGUAAGGAGUCGGGGCUG 4101
              |||||:||||||:||||||:|
Db          1 AAAAGTAAGGAGTCGGGGCTG 21


RESULT 836
ADJ97728
ID   ADJ97728 standard; DNA; 21 BP.
XX
AC   ADJ97728;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 501.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 501; 218pp; English.
XX
```

```
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3150 GAGCUCCGGCUUUCAGGAAGA 3170
                  ||||:|||||:::||||||||
Db          1 GAGCTCCGGCTTTCAGGAAGA 21


RESULT 837
ADJ97328
ID   ADJ97328 standard; DNA; 21 BP.
XX
AC   ADJ97328;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 101.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 101; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        464 AAAGGCUGAGCAUAACUAAAU 484
                  ||||||:|||||:|||:|||:
Db          1 AAAGGCTGAGCATAACTAAAT 21


RESULT 838
ADJ97341
ID   ADJ97341 standard; DNA; 21 BP.
XX
AC   ADJ97341;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 114.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 114; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
```

```
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        542 AAGCAAACCACACUGGCUUCU 562
              |||||||||||||:|||::|:
Db          1 AAGCAAACCACACTGGCTTCT 21


RESULT 839
ADJ97345
ID   ADJ97345 standard; DNA; 21 BP.
XX
AC   ADJ97345;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 118.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 118; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        572 AAUAUCUAGCUGUACCUACUU 592
              ||:|:|:|||:|:|||:||::
Db          1 AATATCTAGCTGTACCTACTT 21


RESULT 840
ADJ97386
ID   ADJ97386 standard; DNA; 21 BP.
XX
AC   ADJ97386;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 159.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 159; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
```

CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy        924 AACCAAUACAAUCAUAGAUGU 944
              ||||||:||||:||:|||:|:
Db          1 AACCAATACAATCATAGATGT 21
```

RESULT 841
ADJ97398
ID ADJ97398 standard; DNA; 21 BP.
XX
AC ADJ97398;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 171.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 171; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 11 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1061 AAAAAAAAUAAGAGAGCUUCCG 1081
              |||||||:|||||||::|||
Db          1 AAAAAAATAAGAGAGCTTCCG 21
```

RESULT 842
ADJ97426
ID ADJ97426 standard; DNA; 21 BP.
XX
AC ADJ97426;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 199.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 199; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention

```
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1266 AAAACAGCAGGUGCUUGAAAC 1286
              ||||||||||||:||::|||||
Db             1 AAAACAGCAGGTGCTTGAAAC 21


RESULT 843
ADJ97463
ID   ADJ97463 standard; DNA; 21 BP.
XX
AC   ADJ97463;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 236.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 236; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 AAAUCCUGACUUGUACCGCAU 1618
              |||:||:|||::|:||||||:
Db             1 AAATCCTGACTTGTACCGCAT 21


RESULT 844
ADJ97481
ID   ADJ97481 standard; DNA; 21 BP.
XX
AC   ADJ97481;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 254.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 254; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
```

CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 11 A; 1 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1787 AAGGAAAGAAUAAGAUGGCUA 1807
||||||||||:||||:|||:|
Db 1 AAGGAAAGAATAAGATGGCTA 21

RESULT 845
ADJ97487
ID ADJ97487 standard; DNA; 21 BP.
XX
AC ADJ97487;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 260.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 260; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 2.3e+03;
Matches 13; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1842 AAUCUACAUUUGCAUAGCUUC 1862
||:|:|||:::|||:|||::|
Db 1 AATCTACATTTGCATAGCTTC 21

RESULT 846
ADJ97496
ID ADJ97496 standard; DNA; 21 BP.
XX
AC ADJ97496;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 269.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 269; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and

```
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 2 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 2.3e+03;
  Matches   12;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1918 AAUGGGUUUCAUGUUAACUUG 1938
              ||:|||:::||:|::|||::|
Db          1 AATGGGTTTCATGTTAACTTG 21


RESULT 847
ADJ97531
ID   ADJ97531 standard; DNA; 21 BP.
XX
AC   ADJ97531;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 304.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 304; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2211 AAUCAGAGAUCAGGAAGCACC 2231
              ||:||||||:||||||||||
Db          1 AATCAGAGATCAGGAAGCACC 21


RESULT 848
ADJ97532
ID   ADJ97532 standard; DNA; 21 BP.
XX
AC   ADJ97532;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 305.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 305; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
```

```
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2225 AAGCACCAUACCUCCUGCGAA 2245
              ||||||||:|||:||:|||||
Db          1 AAGCACCATACCTCCTGCGAA 21


RESULT 849
ADJ97549
ID   ADJ97549 standard; DNA; 21 BP.
XX
AC   ADJ97549;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 322.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 322; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2406 AAGAGUCACAGAAGAGGAUGA 2426
              |||||:||||||||||||:||
Db          1 AAGAGTCACAGAAGAGGATGA 21


RESULT 850
ADJ97550
ID   ADJ97550 standard; DNA; 21 BP.
XX
AC   ADJ97550;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 323.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 323; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
```

```
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2417 AAGAGGAUGAAGGUGUCUAUC 2437
              |||||||:|||||:|:|:|:|
Db          1 AAGAGGATGAAGGTGTCTATC 21


RESULT 851
ADJ97557
ID   ADJ97557 standard; DNA; 21 BP.
XX
AC   ADJ97557;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 330.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 330; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2472 AAGUUCAGCAUACCUCACUGU 2492
              |||::|||||:|||:|||:|:
Db          1 AAGTTCAGCATACCTCACTGT 21


RESULT 852
ADJ97594
ID   ADJ97594 standard; DNA; 21 BP.
XX
AC   ADJ97594;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 367.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 367; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
```

```
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2839 AAAGAGGGGGCCACGGCCAGC 2859
              |||||||||||||||||||||
Db          1 AAAGAGGGGGCCACGGCCAGC 21


RESULT 853
ADJ97615
ID   ADJ97615 standard; DNA; 21 BP.
XX
AC   ADJ97615;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 388.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 388; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3040 AACAAGGAUGCAGCACUACAC 3060
              ||||||||:|||||||:|||||
Db          1 AACAAGGATGCAGCACTACAC 21


RESULT 854
ADJ97634
ID   ADJ97634 standard; DNA; 21 BP.
XX
AC   ADJ97634;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 407.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 407; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
```

```
XX
SQ   Sequence 21 BP; 7 A; 1 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3172 AAAAGUCUGAGUGAUGUUGAG 3192
              |||||:|:|||:||:|::|||
Db          1 AAAAGTCTGAGTGATGTTGAG 21


RESULT 855
ADJ97684
ID   ADJ97684 standard; DNA; 21 BP.
XX
AC   ADJ97684;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 457.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 457; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3762 AAUCAAUGCCAUACUGACAGG 3782
              ||:|||:||||:||:||||||
Db          1 AATCAATGCCATACTGACAGG 21


RESULT 856
ADJ97696
ID   ADJ97696 standard; DNA; 21 BP.
XX
AC   ADJ97696;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 469.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 469; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3892 AAUGCUUUCAAGUUCAUGAGC 3912
              ||:||:::||||::||:||||
Db          1 AATGCTTTCAAGTTCATGAGC 21


RESULT 857
ADJ97711
ID   ADJ97711 standard; DNA; 21 BP.
XX
AC   ADJ97711;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 484.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 484; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4057 AAGAUUGACUUGAGAGUAACC 4077
              ||||::|||::|||||:||||
Db          1 AAGATTGACTTGAGAGTAACC 21


RESULT 858
ADJ97715
ID   ADJ97715 standard; DNA; 21 BP.
XX
AC   ADJ97715;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 488.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 488; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4083 AAGUAAGGAGUCGGGGCUGUC 4103
              |||:||||||:||||||:|:|
Db          1 AAGTAAGGAGTCGGGGCTGTC 21


RESULT 859
ADJ97321
ID   ADJ97321 standard; DNA; 21 BP.
XX
AC   ADJ97321;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 94.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 94; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 AAAUGGUCUUUGCCUGAAAUG 447
              |||:||:|:::|||:||||:|
Db          1 AAATGGTCTTTGCCTGAAATG 21


RESULT 860
ADJ97336
ID   ADJ97336 standard; DNA; 21 BP.
XX
AC   ADJ97336;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 109.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 109; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        505 AAACAAUUCUGCAGUACUUUA 525
              |||||||:|:||||:||:::|
Db          1 AAACAATTCTGCAGTACTTTA 21
```

RESULT 861
ADJ97361
ID ADJ97361 standard; DNA; 21 BP.
XX
AC ADJ97361;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 134.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 134; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        756 AAAAAAGUUUCCACUUGACAC 776
              |||||||:::||||::|||||
Db          1 AAAAAAGTTTCCACTTGACAC 21
```

RESULT 862
ADJ97374
ID ADJ97374 standard; DNA; 21 BP.
XX
AC ADJ97374;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 147.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 147; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        840 AACGUACAAAGAAAUAGGGCU 860
```

```
                    ||||:||||||||:|||||:
Db          1 AACGTACAAAGAAATAGGGCT 21
```

RESULT 863
ADJ97392
ID ADJ97392 standard; DNA; 21 BP.
XX
AC ADJ97392;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 165.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 165; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        970 AAAUUACUUAGAGGCCAUACU 990
              |||::||::||||||||:||:
Db          1 AAATTACTTAGAGGCCATACT 21
```

RESULT 864
ADJ97421
ID ADJ97421 standard; DNA; 21 BP.
XX
AC ADJ97421;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 194.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 194; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1216 AACACCUCAGUGCAUAUAUAU 1236
              ||||||:|||:|||:|:|:|:
Db          1 AACACCTCAGTGCATATATAT 21
```

RESULT 865
ADJ97471
ID ADJ97471 standard; DNA; 21 BP.
XX
AC ADJ97471;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 244.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 244; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1683 AAGGUGUGACUUUUGUUCCAA 1703
              ||||:|:|||::::|::||||
Db          1 AAGGTGTGACTTTTGTTCCAA 21
```

RESULT 866
ADJ97498
ID ADJ97498 standard; DNA; 21 BP.
XX
AC ADJ97498;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 271.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 271; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1940 AAAAAAUGCCGACGGAAGGAG 1960
              |||||||:|||||||||||||||
Db          1 AAAAAATGCCGACGGAAGGAG 21
```

```
RESULT 867
ADJ97503
ID   ADJ97503 standard; DNA; 21 BP.
XX
AC   ADJ97503;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 276.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 276; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGU 1975
              ||||||||||||:|||||:|:
Db          1 AAGGAGAGGACCTGAAACTGT 21


RESULT 868
ADJ97511
ID   ADJ97511 standard; DNA; 21 BP.
XX
AC   ADJ97511;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 284.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 284; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2046 AAUGCACUACAGUAUUAGCAA 2066
              ||:||||:||||:|::|||||
Db          1 AATGCACTACAGTATTAGCAA 21


RESULT 869
ADJ97555
```

```
ID   ADJ97555 standard; DNA; 21 BP.
XX
AC   ADJ97555;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 328.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 328; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2458 AAGGGCUCUGUGGAAAGUUCA 2478
              ||||||:|:|:||||||::||
Db          1 AAGGGCTCTGTGGAAAGTTCA 21


RESULT 870
ADJ97571
ID   ADJ97571 standard; DNA; 21 BP.
XX
AC   ADJ97571;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 344.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 344; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2615 AAAUAAAGACUGACUACCUAU 2635
              |||:||||||:|||:|||:|:
Db          1 AAATAAAGACTGACTACCTAT 21


RESULT 871
ADJ97583
ID   ADJ97583 standard; DNA; 21 BP.
XX
```

```
AC   ADJ97583;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 356.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 356; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 1 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2751 AAGAGGGGCUUUUGGAAAAGU 2771
              |||||||||::::|||||||:
Db          1 AAGAGGGGCTTTTGGAAAAGT 21


RESULT 872
ADJ97609
ID   ADJ97609 standard; DNA; 21 BP.
XX
AC   ADJ97609;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 382.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 382; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2994 AAAUCUCUCCAACUACCUCAA 3014
              |||:|:|:|||||:|||:|||
Db          1 AAATCTCTCCAACTACCTCAA 21


RESULT 873
ADJ97619
ID   ADJ97619 standard; DNA; 21 BP.
XX
AC   ADJ97619;
XX
```

```
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 392.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 392; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3074 AAGAAAAAAUGGAGCCAGGCC 3094
              |||||||||:||||||||||
Db          1 AAGAAAAAATGGAGCCAGGCC 21


RESULT 874
ADJ97627
ID   ADJ97627 standard; DNA; 21 BP.
XX
AC   ADJ97627;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 400.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 400; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3106 AAGAAACCAAGACUAGAUAGC 3126
              |||||||||||||:|||:|||
Db          1 AAGAAACCAAGACTAGATAGC 21


RESULT 875
ADJ97643
ID   ADJ97643 standard; DNA; 21 BP.
XX
AC   ADJ97643;
XX
DT   06-MAY-2004  (first entry)
XX
```

```
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 416.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 416; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3327 AAACAUUCUUUUAUCUGAGAA 3347
              |||||::|::::|:|:|||||
Db          1 AAACATTCTTTTATCTGAGAA 21


RESULT 876
ADJ97648
ID   ADJ97648 standard; DNA; 21 BP.
XX
AC   ADJ97648;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 421.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 421; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 AAGAACCCCGAUUAUGUGAGA 3414
              ||||||||||::|:|:||||
Db          1 AAGAACCCCGATTATGTGAGA 21


RESULT 877
ADJ97668
ID   ADJ97668 standard; DNA; 21 BP.
XX
AC   ADJ97668;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 441.
XX
```

KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 441; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3673 AAAGAAAGGCCAAGAUUUGCA 3693
||||||||||||||:::|||
Db 1 AAAGAAAGGCCAAGATTTGCA 21

RESULT 878
ADJ97669
ID ADJ97669 standard; DNA; 21 BP.
XX
AC ADJ97669;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 442.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 442; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3674 AAGAAAGGCCAAGAUUUGCAG 3694
|||||||||||||:::||||
Db 1 AAGAAAGGCCAAGATTTGCAG 21

RESULT 879
ADJ97691
ID ADJ97691 standard; DNA; 21 BP.
XX
AC ADJ97691;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 464.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;

```
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 464; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3837 AAGUAUUUCAGCUCCGAAGUU 3857
              |||:|:::||||:||||||::
Db          1 AAGTATTTCAGCTCCGAAGTT 21


RESULT 880
ADJ97705
ID   ADJ97705 standard; DNA; 21 BP.
XX
AC   ADJ97705;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 478.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 478; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3938 AACUUUUACCGAAUGCCACCU 3958
              |||::::|||||||:||||||:
Db          1 AACTTTTACCGAATGCCACCT 21


RESULT 881
ADJ97729
ID   ADJ97729 standard; DNA; 21 BP.
XX
AC   ADJ97729;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 502.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
```

KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 502; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3473 UCUACAGCACCAAGAGCGACG 3493
:|:||||||||||||||||||
Db 1 TCTACAGCACCAAGAGCGACG 21

RESULT 882
ADJ97326
ID ADJ97326 standard; DNA; 21 BP.
XX
AC ADJ97326;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 99.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 99; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 458 AAAGCGAAAGGCUGAGCAUAA 478
||||||||||||:|||||:||
Db 1 AAAGCGAAAGGCTGAGCATAA 21

RESULT 883
ADJ97330
ID ADJ97330 standard; DNA; 21 BP.
XX
AC ADJ97330;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 103.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;

```
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 103; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        477 AACUAAAUCUGCCUGUGGAAG 497
              |||:|||:|:|||:|:|||||
Db          1 AACTAAATCTGCCTGTGGAAG 21


RESULT 884
ADJ97340
ID   ADJ97340 standard; DNA; 21 BP.
XX
AC   ADJ97340;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 113.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 113; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        532 AACACAGCUCAAGCAAACCAC 552
              ||||||||:|||||||||||||
Db          1 AACACAGCTCAAGCAAACCAC 21


RESULT 885
ADJ97353
ID   ADJ97353 standard; DNA; 21 BP.
XX
AC   ADJ97353;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 126.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
```

OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 126; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 1 C; 2 G; 10 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        618 AAUCUAUAUAUUUAUUAGUGA 638
              ||:|:|:|:|:::|::||:||
Db          1 AATCTATATATTTATTAGTGA 21
```

RESULT 886
ADJ97357
ID ADJ97357 standard; DNA; 21 BP.
XX
AC ADJ97357;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 130.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 130; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 AAUUAUACACAUGACUGAAGG 701
              ||::|:|||||:|||:|||||
Db          1 AATTATACACATGACTGAAGG 21
```

RESULT 887
ADJ97358
ID ADJ97358 standard; DNA; 21 BP.
XX
AC ADJ97358;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 131.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX

```
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 131; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AAGGAAGGGAGCUCGUCAUUC 718
              ||||||||||||:||:||::|
Db          1 AAGGAAGGGAGCTCGTCATTC 21


RESULT 888
ADJ97424
ID   ADJ97424 standard; DNA; 21 BP.
XX
AC   ADJ97424;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 197.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 197; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AAACAUCGAAAACAGCAGGUG 1278
              |||||:|||||||||||||:|
Db          1 AAACATCGAAAACAGCAGGTG 21


RESULT 889
ADJ97449
ID   ADJ97449 standard; DNA; 21 BP.
XX
AC   ADJ97449;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 222.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
```

```
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 222; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 AACAGUCAAAUGUGUUUAAAA 1498
              |||||:||||:|:|:::||||
Db          1 AACAGTCAAATGTGTTTAAAA 21


RESULT 890
ADJ97456
ID   ADJ97456 standard; DNA; 21 BP.
XX
AC   ADJ97456;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 229.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 229; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1515 AAUUGUCAAUGUGAAACCCCA 1535
              ||::|:|||:|:|||||||||
Db          1 AATTGTCAATGTGAAACCCCA 21


RESULT 891
ADJ97458
ID   ADJ97458 standard; DNA; 21 BP.
XX
AC   ADJ97458;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 231.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
```

PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 231; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 5 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1528 AAACCCCAGAUUUACGAAAAG 1548
||||||||||:::|||||||||
Db 1 AAACCCCAGATTTACGAAAAG 21

RESULT 892
ADJ97459
ID ADJ97459 standard; DNA; 21 BP.
XX
AC ADJ97459;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 232.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 232; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1529 AACCCCAGAUUUACGAAAAGG 1549
||||||||||:::|||||||||
Db 1 AACCCCAGATTTACGAAAAGG 21

RESULT 893
ADJ97512
ID ADJ97512 standard; DNA; 21 BP.
XX
AC ADJ97512;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 285.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX

PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 285; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 5 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2065 AAGCAAAAAAUGGCCAUCACU 2085
||||||||||:|||||:|||:
Db 1 AAGCAAAAAATGGCCATCACT 21

RESULT 894
ADJ97527
ID ADJ97527 standard; DNA; 21 BP.
XX
AC ADJ97527;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 300.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 300; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 12 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2200 AAAGAAAUUACAAUCAGAGAU 2220
|||||||::||||:||||||:
Db 1 AAAGAAATTACAATCAGAGAT 21

RESULT 895
ADJ97554
ID ADJ97554 standard; DNA; 21 BP.
XX
AC ADJ97554;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 327.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.

```
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 327; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2452 AACCAGAAGGGCUCUGUGGAA 2472
              ||||||||||||:|:|:||||
Db          1 AACCAGAAGGGCTCTGTGGAA 21


RESULT 896
ADJ97596
ID   ADJ97596 standard; DNA; 21 BP.
XX
AC   ADJ97596;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 369.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 369; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2866 AAAGCUCUGAUGACUGAGCUA 2886
              |||||:|:||:|||:||||:|
Db          1 AAAGCTCTGATGACTGAGCTA 21


RESULT 897
ADJ97600
ID   ADJ97600 standard; DNA; 21 BP.
XX
AC   ADJ97600;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 373.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
```

```
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 373; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2888 AAAUCUUGACCCACAUUGGCC 2908
              |||:|::|||||||::||||
Db          1 AAATCTTGACCCACATTGGCC 21


RESULT 898
ADJ97613
ID   ADJ97613 standard; DNA; 21 BP.
XX
AC   ADJ97613;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 386.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 386; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3019 AAACGUGACUUAUUUUUUCUC 3039
              |||||:|||::|::::::|:|
Db          1 AAACGTGACTTATTTTTTCTC 21


RESULT 899
ADJ97614
ID   ADJ97614 standard; DNA; 21 BP.
XX
AC   ADJ97614;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 387.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
```

```
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 387; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3020 AACGUGACUUAUUUUUUCUCA 3040
              ||||:|||::|::::::|:||
Db          1 AACGTGACTTATTTTTTCTCA 21


RESULT 900
ADJ97625
ID   ADJ97625 standard; DNA; 21 BP.
XX
AC   ADJ97625;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 398.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 398; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 12 A; 5 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3098 AACAAGGCAAGAAACCAAGAC 3118
              |||||||||||||||||||||
Db          1 AACAAGGCAAGAAACCAAGAC 21


RESULT 901
ADJ97636
ID   ADJ97636 standard; DNA; 21 BP.
XX
AC   ADJ97636;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 409.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
```

```
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 409; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3174 AAGUCUGAGUGAUGUUGAGGA 3194
              |||:|:|||:||:|::|||||
Db          1 AAGTCTGAGTGATGTTGAGGA 21


RESULT 902
ADJ97649
ID   ADJ97649 standard; DNA; 21 BP.
XX   .
AC   ADJ97649;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 422.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 422; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3397 AACCCCGAUUAUGUGAGAAAA 3417
              |||||||::|:|:|||||||
Db          1 AACCCCGATTATGTGAGAAAA 21


RESULT 903
ADJ97712
ID   ADJ97712 standard; DNA; 21 BP.
XX
AC   ADJ97712;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 485.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
```

PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 485; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 4074 AACCAGUAAAAGUAAGGAGUC 4094
||||||:|||||:|||||||:|
Db 1 AACCAGTAAAAGTAAGGAGTC 21

RESULT 904
ADJ97730
ID ADJ97730 standard; DNA; 21 BP.
XX
AC ADJ97730;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 503.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 503; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 2 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 2.3e+03;
Matches 13; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 3871 UCUGAUGAUGUCAGAUAUGUA 3891
:|:||:||:|:||||:|:|:|
Db 1 TCTGATGATGTCAGATATGTA 21

RESULT 905
ADJ97322
ID ADJ97322 standard; DNA; 21 BP.
XX
AC ADJ97322;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 95.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic

```
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 95; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        428 AAUGGUCUUUGCCUGAAAUGG 448
              ||:||:|:::|||:||||:||
Db          1 AATGGTCTTTGCCTGAAATGG 21


RESULT 906
ADJ97324
ID   ADJ97324 standard; DNA; 21 BP.
XX
AC   ADJ97324;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 97.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 97; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        444 AAUGGUGAGUAAGGAAAGCGA 464
              ||:||:|||:||||||||||||
Db          1 AATGGTGAGTAAGGAAAGCGA 21


RESULT 907
ADJ97334
ID   ADJ97334 standard; DNA; 21 BP.
XX
AC   ADJ97334;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 107.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
```

```
PS   Disclosure; SEQ ID NO 107; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        498 AAAUGGCAAACAAUUCUGCAG 518
              |||:|||||||||::|:||||
Db          1 AAATGGCAAACAATTCTGCAG 21


RESULT 908
ADJ97350
ID   ADJ97350 standard; DNA; 21 BP.
XX
AC   ADJ97350;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 123.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 123; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        605 AAACAGAAUCUGCAAUCUAUA 625
              ||||||||:|:||||:|:|:|
Db          1 AAACAGAATCTGCAATCTATA 21


RESULT 909
ADJ97369
ID   ADJ97369 standard; DNA; 21 BP.
XX
AC   ADJ97369;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 142.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 142; 218pp; English.
XX
```

```
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        801 AAUCUGGGACAGUAGAAAGGG 821
              ||:|:|||||||:|||||||||
Db          1 AATCTGGGACAGTAGAAAGGG 21


RESULT 910
ADJ97388
ID   ADJ97388 standard; DNA; 21 BP.
XX
AC   ADJ97388;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 161.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 161; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        933 AAUCAUAGAUGUCCAAAUAAG 953
              ||:||:|||:|:|||||:|||
Db          1 AATCATAGATGTCCAAATAAG 21


RESULT 911
ADJ97389
ID   ADJ97389 standard; DNA; 21 BP.
XX
AC   ADJ97389;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 162.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 162; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
```

```
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 8 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        947 AAAUAAGCACACCACGCCCAG 967
              |||:||||||||||||||||
Db          1 AAATAAGCACACCACGCCCAG 21


RESULT 912
ADJ97391
ID   ADJ97391 standard; DNA; 21 BP.
XX
AC   ADJ97391;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 164.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 164; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 9 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        951 AAGCACACCACGCCCAGUCAA 971
              ||||||||||||||||:|||
Db          1 AAGCACACCACGCCCAGTCAA 21


RESULT 913
ADJ97394
ID   ADJ97394 standard; DNA; 21 BP.
XX
AC   ADJ97394;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 167.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 167; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
```

CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1000 AAUUGUACUGCUACCACUCCC 1020
              ||::|:||:||:|||||:|||
Db          1 AATTGTACTGCTACCACTCCC 21
```

RESULT 914
ADJ97405
ID ADJ97405 standard; DNA; 21 BP.
XX
AC ADJ97405;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 178.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 178; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1083 AAGGCGACGAAUUGACCAAAG 1103
              ||||||||||::|||||||||
Db          1 AAGGCGACGAATTGACCAAAG 21
```

RESULT 915
ADJ97480
ID ADJ97480 standard; DNA; 21 BP.
XX
AC ADJ97480;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 253.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 253; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention

CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 13 A; 0 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1782 AAUAGAAGGAAAGAAUAAGAU 1802
||:||||||||||||:||||:
Db 1 AATAGAAGGAAAGAATAAGAT 21

RESULT 916
ADJ97520
ID ADJ97520 standard; DNA; 21 BP.
XX
AC ADJ97520;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 293.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 293; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 5 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2122 AAUGUUUCCCUGCAAGAUUCA 2142
||:|:::|||:||||||::||
Db 1 AATGTTTCCCTGCAAGATTCA 21

RESULT 917
ADJ97523
ID ADJ97523 standard; DNA; 21 BP.
XX
AC ADJ97523;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 296.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 296; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target

```
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2183 AAGAAAUCCUCCAGAAGAAAG 2203
              ||||||:||:||||||||||
Db          1 AAGAAATCCTCCAGAAGAAAG 21


RESULT 918
ADJ97535
ID   ADJ97535 standard; DNA; 21 BP.
XX
AC   ADJ97535;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 308.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 308; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2302 AAUGGUGUCCCCGAGCCUCAG 2322
              ||:||:|:||||||||||:|||
Db          1 AATGGTGTCCCCGAGCCTCAG 21


RESULT 919
ADJ97545
ID   ADJ97545 standard; DNA; 21 BP.
XX
AC   ADJ97545;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 318.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 318; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
```

```
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2357 AAGAGCCUGGAAUUAUUUUAG 2377
              |||||||:||||::|::::||
Db          1 AAGAGCCTGGAATTATTTTAG 21


RESULT 920
ADJ97551
ID   ADJ97551 standard; DNA; 21 BP.
XX
AC   ADJ97551;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 324.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 324; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2426 AAGGUGUCUAUCACUGCAAAG 2446
              ||||:|:|:|:|||:||||||
Db          1 AAGGTGTCTATCACTGCAAAG 21


RESULT 921
ADJ97568
ID   ADJ97568 standard; DNA; 21 BP.
XX
AC   ADJ97568;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 341.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 341; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
```

```
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2599 AAAAGGUCUUCUUCUGAAAUA 2619
              ||||||:|::|::|:||||:|
Db          1 AAAAGGTCTTCTTCTGAAATA 21


RESULT 922
ADJ97570
ID   ADJ97570 standard; DNA; 21 BP.
XX
AC   ADJ97570;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 343.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 343; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2601 AAGGUCUUCUUCUGAAAUAAA 2621
              ||||:|::|::|:||||:|||
Db          1 AAGGTCTTCTTCTGAAATAAA 21


RESULT 923
ADJ97577
ID   ADJ97577 standard; DNA; 21 BP.
XX
AC   ADJ97577;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 350.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 350; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
```

```
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2657 AAGUUCCUUUGGAUGAGCAGU 2677
              |||::||:::|||:||||||:
Db          1 AAGTTCCTTTGGATGAGCAGT 21


RESULT 924
ADJ97578
ID   ADJ97578 standard; DNA; 21 BP.
XX
AC   ADJ97578;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 351.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 351; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 4 A; 3 C; 10 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2704 AAGUGGGAGUUUGCCCGGGAG 2724
              |||:|||||:::|||||||||
Db          1 AAGTGGGAGTTTGCCCGGGAG 21


RESULT 925
ADJ97599
ID   ADJ97599 standard; DNA; 21 BP.
XX
AC   ADJ97599;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 372.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 372; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
```

```
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2887 AAAAUCUUGACCCACAUUGGC 2907
              ||||:|::||||||||::|||
Db          1 AAAATCTTGACCCACATTGGC 21


RESULT 926
ADJ97618
ID   ADJ97618 standard; DNA; 21 BP.
XX
AC   ADJ97618;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 391.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 391; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3073 AAAGAAAAAAAUGGAGCCAGGC 3093
              ||||||||||:||||||||||
Db          1 AAAGAAAAAAATGGAGCCAGGC 21


RESULT 927
ADJ97620
ID   ADJ97620 standard; DNA; 21 BP.
XX
AC   ADJ97620;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 393.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 393; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
```

```
XX
SQ   Sequence 21 BP; 8 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3077 AAAAAAUGGAGCCAGGCCUGG 3097
              ||||||:|||||||||||:||
Db          1 AAAAAATGGAGCCAGGCCTGG 21


RESULT 928
ADJ97624
ID   ADJ97624 standard; DNA; 21 BP.
XX
AC   ADJ97624;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 397.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 397; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3081 AAUGGAGCCAGGCCUGGAACA 3101
              ||:|||||||||||:||||||
Db          1 AATGGAGCCAGGCCTGGAACA 21


RESULT 929
ADJ97639
ID   ADJ97639 standard; DNA; 21 BP.
XX
AC   ADJ97639;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 412.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 412; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 3 G; 9 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 2.3e+03;
  Matches   12;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3239 AAGAUCUGAUUUCUUACAGUU 3259
              ||||:|:||:::|::||||::
Db          1 AAGATCTGATTTCTTACAGTT 21
```

RESULT 930
ADJ97641
ID ADJ97641 standard; DNA; 21 BP.
XX
AC ADJ97641;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 414.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 414; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3297 AAAGUGCAUUCAUCGGGACCU 3317
              ||||:|||::||:|||||||:
Db          1 AAAGTGCATTCATCGGGACCT 21
```

RESULT 931
ADJ97646
ID ADJ97646 standard; DNA; 21 BP.
XX
AC ADJ97646;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 419.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 419; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 1 C; 7 G; 7 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3349 AACGUGGUGAAGAUUUGUGAU 3369
              ||||:||:|||||:::|:||:
Db          1 AACGTGGTGAAGATTTGTGAT 21


RESULT 932
ADJ97672
ID   ADJ97672 standard; DNA; 21 BP.
XX
AC   ADJ97672;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 445.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 445; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3684 AAGAUUUGCAGAACUUGUGGA 3704
              |||:::|||||||::|:|||
Db          1 AAGATTTGCAGAACTTGTGGA 21


RESULT 933
ADJ97693
ID   ADJ97693 standard; DNA; 21 BP.
XX
AC   ADJ97693;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 466.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 466; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3859 AAUUCAGGAAGCUCUGAUGAU 3879
              ||::|||||||||:|:||:||:
Db          1 AATTCAGGAAGCTCTGATGAT 21
```

RESULT 934
ADJ97717
ID ADJ97717 standard; DNA; 21 BP.
XX
AC ADJ97717;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 490.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 490; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       4154 AAGGCAAGCGCAGGUUCACCU 4174
              ||||||||||||||::||||:
Db          1 AAGGCAAGCGCAGGTTCACCT 21
```

RESULT 935
ADJ97720
ID ADJ97720 standard; DNA; 21 BP.
XX
AC ADJ97720;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 493.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 493; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        557 GCUUCUACAGCUGCAAAUAUC 577
```

```
                ||::|:|||||:|||||:|:|
Db          1 GCTTCTACAGCTGCAAATATC 21
```

RESULT 936
ADJ97722
ID ADJ97722 standard; DNA; 21 BP.
XX
AC ADJ97722;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 495.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 495; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 8 C; 2 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 CCAAAGCAAUUCCCAUGCCAA 1118
              |||||||||::||||:|||||
```

```
Db          1 CCAAAGCAATTCCCATGCCAA 21
```

RESULT 937
ADJ97726
ID ADJ97726 standard; DNA; 21 BP.
XX
AC ADJ97726;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 499.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 499; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2653 GAUGAAGUUCCUUUGGAUGAG 2673
              ||:||||::||:::|||:|||
Db          1 GATGAAGTTCCTTTGGATGAG 21
```

```
RESULT 938
ADJ97320
ID   ADJ97320 standard; DNA; 21 BP.
XX
AC   ADJ97320;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 93.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 93; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        416 AAGCAGCCCATAAAATGGTCTT 436
              ||||||||||:|||:||:|::
Db          1 AAGCAGCCCATAAATGGTCTT 21
```

```
RESULT 939
ADJ97323
ID   ADJ97323 standard; DNA; 21 BP.
XX
AC   ADJ97323;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 96.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 96; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        443 AAAUGGUGAGUAAGGAAAGCG 463
              |||:||:|||:||||||||||
Db          1 AAATGGTGAGTAAGGAAAGCG 21
```

```
RESULT 940
ADJ97339
ID   ADJ97339 standard; DNA; 21 BP.
XX
AC   ADJ97339;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 112.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 112; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        525 AACCUUGAACACAGCUCAAGC 545
              ||||::||||||||||:|||||
Db          1 AACCTTGAACACAGCTCAAGC 21


RESULT 941
ADJ97351
ID   ADJ97351 standard; DNA; 21 BP.
XX
AC   ADJ97351;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 124.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 124; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        606 AACAGAAUCUGCAAUCUAUAU 626
              |||||||:|:||||:|:|:|:
Db          1 AACAGAATCTGCAATCTATAT 21


RESULT 942
ADJ97356
```

```
ID   ADJ97356 standard; DNA; 21 BP.
XX
AC   ADJ97356;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 129.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 129; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        680 AAAUUAUACACAUGACUGAAG 700
              |||::|:|||||:|||:||||
Db          1 AAATTATACACATGACTGAAG 21


RESULT 943
ADJ97372
ID   ADJ97372 standard; DNA; 21 BP.
XX
AC   ADJ97372;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 145.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 145; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 12 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        834 AAAUGCAACGUACAAAGAAAU 854
              |||:||||||:|||||||||:
Db          1 AAATGCAACGTACAAAGAAAT 21


RESULT 944
ADJ97375
ID   ADJ97375 standard; DNA; 21 BP.
XX
```

```
AC   ADJ97375;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 148.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 148; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAAGAAAUAGGGCUUCUGACC 867
              |||||||:|||||::|:||||
Db          1 AAAGAAATAGGGCTTCTGACC 21


RESULT 945
ADJ97379
ID   ADJ97379 standard; DNA; 21 BP.
XX
AC   ADJ97379;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 152.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 152; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        872 AAGCAACAGUCAAUGGGCAUU 892
              |||||||||:|||:|||||::
Db          1 AAGCAACAGTCAATGGGCATT 21


RESULT 946
ADJ97387
ID   ADJ97387 standard; DNA; 21 BP.
XX
AC   ADJ97387;
XX
```

```
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 160.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 160; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 AAUACAAUCAUAGAUGUCCAA 948
              ||:||||:||:|||:|:||||
Db          1 AATACAATCATAGATGTCCAA 21


RESULT 947
ADJ97414
ID   ADJ97414 standard; DNA; 21 BP.
XX
AC   ADJ97414;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 187.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 187; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1159 AAAGACAAAGGACUUUAUACU 1179
              |||||||||||||:::|:||:
Db          1 AAAGACAAAGGACTTTATACT 21


RESULT 948
ADJ97417
ID   ADJ97417 standard; DNA; 21 BP.
XX
AC   ADJ97417;
XX
DT   06-MAY-2004  (first entry)
XX
```

```
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 190.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 190; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1166 AAGGACUUUAUACUUGUCGUG 1186
              ||||||:::|:||::|:||:|
Db          1 AAGGACTTTATACTTGTCGTG 21


RESULT 949
ADJ97427
ID   ADJ97427 standard; DNA; 21 BP.
XX
AC   ADJ97427;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 200.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 200; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1267 AAACAGCAGGUGCUUGAAACC 1287
              ||||||||||:||::||||||
Db          1 AAACAGCAGGTGCTTGAAACC 21


RESULT 950
ADJ97430
ID   ADJ97430 standard; DNA; 21 BP.
XX
AC   ADJ97430;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 203.
XX
```

KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 203; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1284 AACCGUAGCUGGCAAGCGGUC 1304
              |||||:|||:||||||||:|
Db          1 AACCGTAGCTGGCAAGCGGTC 21
```

RESULT 951
ADJ97438
ID ADJ97438 standard; DNA; 21 BP.
XX
AC ADJ97438;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 211.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 211; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1361 AAGAUGGGUUACCUGCGACUG 1381
              ||||:|||::|||:|||||:|
Db          1 AAGATGGGTTACCTGCGACTG 21
```

RESULT 952
ADJ97440
ID ADJ97440 standard; DNA; 21 BP.
XX
AC ADJ97440;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 213.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;

KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 213; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 6 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 2.3e+03;
Matches 13; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1385 AAUCUGCUCGCUAUUUGACUC 1405
||:|:||:|||:|:::|||:|
Db 1 AATCTGCTCGCTATTTGACTC 21

RESULT 953
ADJ97442
ID ADJ97442 standard; DNA; 21 BP.
XX
AC ADJ97442;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 215.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 215; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 9 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1426 AAGGACGUAACUGAAGAGGAU 1446
|||||||:|||:|||||||:
Db 1 AAGGACGTAACTGAAGAGGAT 21

RESULT 954
ADJ97451
ID ADJ97451 standard; DNA; 21 BP.
XX
AC ADJ97451;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 224.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;

KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 224; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1486 AAUGUGUUUAAAAACCUCACU 1506
              ||:|:|:::|||||||:|||:
Db          1 AATGTGTTTAAAAACCTCACT 21
```

RESULT 955
ADJ97455
ID ADJ97455 standard; DNA; 21 BP.
XX
AC ADJ97455;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 228.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 228; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 8 C; 1 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1498 AACCUCACUGCCACUCUAAUU 1518
              ||||:|||:|||||:|:||::
Db          1 AACCTCACTGCCACTCTAATT 21
```

RESULT 956
ADJ97478
ID ADJ97478 standard; DNA; 21 BP.
XX
AC ADJ97478;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 251.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;

```
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 251; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1752 AAUUGAGAGCAUCACUCAGCG 1772
              ||::|||||||:|||:|||||
Db          1 AATTGAGAGCATCACTCAGCG 21


RESULT 957
ADJ97537
ID   ADJ97537 standard; DNA; 21 BP.
XX
AC   ADJ97537;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 310.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 310; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 14 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.3e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2336 AAAACAACCACAAAAUACAAC 2356
              ||||||||||||||:|||||
Db          1 AAAACAACCACAAAATACAAC 21


RESULT 958
ADJ97542
ID   ADJ97542 standard; DNA; 21 BP.
XX
AC   ADJ97542;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 315.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
```

```
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 315; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.3e+03;
  Matches   19;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2348 AAAUACAACAAGAGCCUGGAA 2368
              |||:||||||||||||:||||
Db          1 AAATACAACAAGAGCCTGGAA 21


RESULT 959
ADJ97546
ID   ADJ97546 standard; DNA; 21 BP.
XX
AC   ADJ97546;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 319.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 319; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2367 AAUUAUUUUAGGACCAGGAAG 2387
              ||::|::::|||||||||||||
Db          1 AATTATTTTAGGACCAGGAAG 21


RESULT 960
ADJ97584
ID   ADJ97584 standard; DNA; 21 BP.
XX
AC   ADJ97584;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 357.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
```

```
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 357; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2766 AAAAGUGGUUCAAGCAUCAGC 2786
              |||||:||::||||||:||||
Db          1 AAAAGTGGTTCAAGCATCAGC 21


RESULT 961
ADJ97588
ID   ADJ97588 standard; DNA; 21 BP.
XX
AC   ADJ97588;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 361.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 361; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2797 AAGAAAUCACCUACGUGCCGG 2817
              ||||||:||||:|||:|||||
Db          1 AAGAAATCACCTACGTGCCGG 21


RESULT 962
ADJ97598
ID   ADJ97598 standard; DNA; 21 BP.
XX
AC   ADJ97598;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 371.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
```

PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 371; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2886 AAAAAUCUUGACCCACAUUGG 2906
              |||||:|::||||||||::||
Db          1 AAAAATCTTGACCCACATTGG 21
```

RESULT 963
ADJ97606
ID ADJ97606 standard; DNA; 21 BP.
XX
AC ADJ97606;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 379.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 379; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 10 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2978 AAUACUGCAAAUAUGGAAAUC 2998
              ||:|||:|||||:|:|||||:|
Db          1 AATACTGCAAATATGGAAATC 21
```

RESULT 964
ADJ97645
ID ADJ97645 standard; DNA; 21 BP.
XX
AC ADJ97645;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 418.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX

PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 418; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 2.3e+03;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3346 AACAACGUGGUGAAGAUUUGU 3366
              |||||||:||:|||||:::|:
Db          1 AACAACGTGGTGAAGATTTGT 21
```

RESULT 965
ADJ97686
ID ADJ97686 standard; DNA; 21 BP.
XX
AC ADJ97686;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 459.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 459; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3783 AAAUAGUGGGUUUACAUACUC 3803
              |||:||:|||:::|||:||:|
Db          1 AAATAGTGGGTTTACATACTC 21
```

RESULT 966
ADJ97697
ID ADJ97697 standard; DNA; 21 BP.
XX
AC ADJ97697;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 470.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX

PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 470; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3901 AAGUUCAUGAGCCUGGAAAGA 3921
||||::||:|||||:|||||||
Db 1 AAGTTCATGAGCCTGGAAAGA 21

RESULT 967
ADJ97709
ID ADJ97709 standard; DNA; 21 BP.
XX
AC ADJ97709;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 482.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 482; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 4040 AACCCAAGGCCUCGCUCAAGA 4060
||||||||||:|||:|||||
Db 1 AACCCAAGGCCTCGCTCAAGA 21

RESULT 968
ADJ97723
ID ADJ97723 standard; DNA; 21 BP.
XX
AC ADJ97723;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 496.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.

```
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 496; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1466 UGCUGAGCAUAAAACAGUCAA 1486
              :||:|||||:|||||||:|||
Db          1 TGCTGAGCATAAAACAGTCAA 21


RESULT 969
ADJ97364
ID   ADJ97364 standard; DNA; 21 BP.
XX
AC   ADJ97364;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 137.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 137; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.3e+03;
  Matches   13;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        759 AAAGUUUCCACUUGACACUUU 779
              ||||:::||||::|||||:::
Db          1 AAAGTTTCCACTTGACACTTT 21


RESULT 970
ADJ97403
ID   ADJ97403 standard; DNA; 21 BP.
XX
AC   ADJ97403;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 176.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
```

```
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 176; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1066 AAUAAGAGAGCUUCCGUAAGG 1086
              ||:|||||||::|||:||||
Db          1 AATAAGAGAGCTTCCGTAAGG 21


RESULT 971
ADJ97410
ID   ADJ97410 standard; DNA; 21 BP.
XX
AC   ADJ97410;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 183.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 183; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 2.3e+03;
  Matches   12;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1117 AACAUAUUCUACAGUGUUCUU 1137
              ||||:|::|:||||:|::|::
Db          1 AACATATTCTACAGTGTTCTT 21


RESULT 972
ADJ97428
ID   ADJ97428 standard; DNA; 21 BP.
XX
AC   ADJ97428;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 201.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
```

```
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 201; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1268 AACAGCAGGUGCUUGAAACCG 1288
              |||||||||:||::|||||||
Db          1 AACAGCAGGTGCTTGAAACCG 21


RESULT 973
ADJ97436
ID   ADJ97436 standard; DNA; 21 BP.
XX
AC   ADJ97436;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 209.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 209; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1359 AAAAGAUGGGUUACCUGCGAC 1379
              ||||||:|||::|||:|||||
Db          1 AAAAGATGGGTTACCTGCGAC 21


RESULT 974
ADJ97472
ID   ADJ97472 standard; DNA; 21 BP.
XX
AC   ADJ97472;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 245.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
```

```
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 245; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 2.3e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1702 AAUAAUGAAGAGUCCUUUAUC 1722
              ||:||:||||||:||:::|:|
Db          1 AATAATGAAGAGTCCTTTATC 21


RESULT 975
ADJ97477
ID   ADJ97477 standard; DNA; 21 BP.
XX
AC   ADJ97477;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 250.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 250; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 AACAGAAUUGAGAGCAUCACU 1767
              |||||||::|||||||:|||:
Db          1 AACAGAATTGAGAGCATCACT 21


RESULT 976
ADJ97486
ID   ADJ97486 standard; DNA; 21 BP.
XX
AC   ADJ97486;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 259.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
```

PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 259; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 3 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 2.3e+03;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1833 AAUUUCUGGAAUCUACAUUUG 1853
              ||:::|:||||:|:|||:::|
Db          1 AATTTCTGGAATCTACATTTG 21
```

RESULT 977
ADJ97501
ID ADJ97501 standard; DNA; 21 BP.
XX
AC ADJ97501;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 274.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 274; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 8 A; 3 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+03;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1943 AAAUGCCGACGGAAGGAGAGG 1963
              |||:||||||||||||||||
Db          1 AAATGCCGACGGAAGGAGAGG 21
```

RESULT 978
ADJ97517
ID ADJ97517 standard; DNA; 21 BP.
XX
AC ADJ97517;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 290.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic

```
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 290; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2073 AAUGGCCAUCACUAAGGAGCA 2093
              ||:|||||:|||:||||||||
Db          1 AATGGCCATCACTAAGGAGCA 21


RESULT 979
ADJ97526
ID   ADJ97526 standard; DNA; 21 BP.
XX
AC   ADJ97526;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 299.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 299; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 13 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAGAAAGAAAUUACAAUCAGA 2217
              ||||||||||::||||:||||
Db          1 AAGAAAGAAATTACAATCAGA 21


RESULT 980
ADJ97558
ID   ADJ97558 standard; DNA; 21 BP.
XX
AC   ADJ97558;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 331.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
```

```
PS   Disclosure; SEQ ID NO 331; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2495 AAGGAACCUCGGACAAGUCUA 2515
              |||||||:||||||||:|:|
Db          1 AAGGAACCTCGGACAAGTCTA 21


RESULT 981
ADJ97560
ID   ADJ97560 standard; DNA; 21 BP.
XX
AC   ADJ97560;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 333.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 333; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2509 AAGUCUAAUCUGGAGCUGAUC 2529
              |||:|:||:|:|||||:||:|
Db          1 AAGTCTAATCTGGAGCTGATC 21


RESULT 982
ADJ97562
ID   ADJ97562 standard; DNA; 21 BP.
XX
AC   ADJ97562;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 335.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 335; 218pp; English.
XX
```

CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2535 AACAUGCACCUGUGUGGCUGC 2555
              ||||:|||||:|:|:|||:||
Db          1 AACATGCACCTGTGTGGCTGC 21
```

RESULT 983
ADJ97567
ID ADJ97567 standard; DNA; 21 BP.
XX
AC ADJ97567;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 340.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 340; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 2.3e+03;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2595 AAUGAAAAGGUCUUCUUCUGA 2615
              ||:|||||||:|::|::|:||
Db          1 AATGAAAAGGTCTTCTTCTGA 21
```

RESULT 984
ADJ97575
ID ADJ97575 standard; DNA; 21 BP.
XX
AC ADJ97575;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 348.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 348; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit

```
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2637 AAUUAUAAUGGACCCAGAUGA 2657
              ||::|:||:||||||||||:||
Db          1 AATTATAATGGACCCAGATGA 21


RESULT 985
ADJ97607
ID   ADJ97607 standard; DNA; 21 BP.
XX
AC   ADJ97607;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 380.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 380; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2986 AAAUAUGGAAAUCUCUCCAAC 3006
              |||:|:|||||:|:|:|||||
Db          1 AAATATGGAAATCTCTCCAAC 21


RESULT 986
ADJ97616
ID   ADJ97616 standard; DNA; 21 BP.
XX
AC   ADJ97616;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 389.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 389; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
```

```
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3043 AAGGAUGCAGCACUACACAUG 3063
              |||||:|||||||:|||||:|
Db          1 AAGGATGCAGCACTACACATG 21


RESULT 987
ADJ97710
ID   ADJ97710 standard; DNA; 21 BP.
XX
AC   ADJ97710;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 483.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 483; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4045 AAGGCCUCGCUCAAGAUUGAC 4065
              ||||||:|||:|||||::|||
Db          1 AAGGCCTCGCTCAAGATTGAC 21


RESULT 988
ADJ97714
ID   ADJ97714 standard; DNA; 21 BP.
XX
AC   ADJ97714;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 487.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 487; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
```

CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+03;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4082 AAAGUAAGGAGUCGGGGCUGU 4102
              ||||:||||||:||||||:|:
Db          1 AAAGTAAGGAGTCGGGGCTGT 21
```

RESULT 989
ADJ97719
ID ADJ97719 standard; DNA; 21 BP.
XX
AC ADJ97719;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 492.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 492; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 2.3e+03;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy        467 GGCUGAGCAUAACUAAAUCUG 487
              |||:|||||:|||:|||:|:|
Db          1 GGCTGAGCATAACTAAATCTG 21
```

RESULT 990
ADJ97338
ID ADJ97338 standard; DNA; 21 BP.
XX
AC ADJ97338;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 111.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 111; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target

CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 2.3e+03;
Matches 13; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 509 AAUUCUGCAGUACUUUAACCU 529
||::|:||||:||:::||||:
Db 1 AATTCTGCAGTACTTTAACCT 21

RESULT 991
ADJ97347
ID ADJ97347 standard; DNA; 21 BP.
XX
AC ADJ97347;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 120.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 120; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 12 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 21; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+03;
Matches 19; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 595 AAGAAGAAGGAAACAGAAUCU 615
|||||||||||||||||:|:
Db 1 AAGAAGAAGGAAACAGAATCT 21

RESULT 992
ADJ97406
ID ADJ97406 standard; DNA; 21 BP.
XX
AC ADJ97406;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 179.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 179; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and

```
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1092 AAUUGACCAAAGCAAUUCCCA 1112
              ||::||||||||||::||||
Db          1 AATTGACCAAAGCAATTCCCA 21


RESULT 993
ADJ97407
ID   ADJ97407 standard; DNA; 21 BP.
XX
AC   ADJ97407;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 180.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 180; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.3e+03;
  Matches   18;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1100 AAAGCAAUUCCCAUGCCAACA 1120
              |||||||::||||:|||||||
Db          1 AAAGCAATTCCCATGCCAACA 21


RESULT 994
ADJ97460
ID   ADJ97460 standard; DNA; 21 BP.
XX
AC   ADJ97460;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 233.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 233; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
```

```
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1544 AAAAGGCCGUGUCAUCGUUUC 1564
              |||||||||:|:||:||:::|
Db          1 AAAAGGCCGTGTCATCGTTTC 21


RESULT 995
ADJ97468
ID   ADJ97468 standard; DNA; 21 BP.
XX
AC   ADJ97468;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 241.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 241; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1663 AACCAUAAUCAUUCCGAAGCA 1683
              |||||:||:||::||||||||
Db          1 AACCATAATCATTCCGAAGCA 21


RESULT 996
ADJ97510
ID   ADJ97510 standard; DNA; 21 BP.
XX
AC   ADJ97510;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 283.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 283; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
```

```
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 2.3e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2043 AACAAUGCACUACAGUAUUAG 2063
              |||||:||||:||||:|::||
Db          1 AACAATGCACTACAGTATTAG 21


RESULT 997
ADJ97528
ID   ADJ97528 standard; DNA; 21 BP.
XX
AC   ADJ97528;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 301.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 301; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 11 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2201 AAGAAAUUACAAUCAGAGAUC 2221
              ||||||::||||:||||||:|
Db          1 AAGAAATTACAATCAGAGATC 21


RESULT 998
ADJ97529
ID   ADJ97529 standard; DNA; 21 BP.
XX
AC   ADJ97529;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 302.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 302; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
```

```
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 10 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2204 AAAUUACAAUCAGAGAUCAGG 2224
              |||::|||||:||||||:||||
Db          1 AAATTACAATCAGAGATCAGG 21


RESULT 999
ADJ97544
ID   ADJ97544 standard; DNA; 21 BP.
XX
AC   ADJ97544;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 317.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 317; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 8 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2354 AACAAGAGCCUGGAAUUAUUU 2374
              ||||||||||:||||::|:::
Db          1 AACAAGAGCCTGGAATTATTT 21


RESULT 1000
ADJ97547
ID   ADJ97547 standard; DNA; 21 BP.
XX
AC   ADJ97547;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 320.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 320; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
```

```
XX
SQ   Sequence 21 BP; 6 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 2.3e+03;
  Matches   15;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2385 AAGCAGCACGCUGUUUAUUGA 2405
              ||||||||||:|:::|::||
Db             1 AAGCAGCACGCTGTTTATTGA 21


Search completed: August 31, 2006, 15:06:27
Job time : 427 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 14:46:25 ; Search time 37 Seconds
(without alignments)
6.814 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 830 seqs, 16415 residues

Total number of hits satisfying chosen parameters: 1660

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Issued- ~~Appl~~ Patents_NA

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 809 summaries

Database : issdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	40	0.5	40	1	US-08-222-177A-119	Sequence 119, App
c	2	40	0.5	40	1	US-08-222-177A-400	Sequence 400, App
c	3	40	0.5	40	1	US-08-222-177A-403	Sequence 403, App
c	4	39	0.5	39	1	US-08-222-177A-137	Sequence 137, App
c	5	38.4	0.5	40	1	US-08-222-177A-152	Sequence 152, App
c	6	38.4	0.5	40	1	US-08-222-177A-175	Sequence 175, App
c	7	38	0.5	38	1	US-08-222-177A-198	Sequence 198, App
c	8	38	0.5	38	1	US-08-222-177A-397	Sequence 397, App
c	9	37.4	0.5	39	1	US-08-222-177A-86	Sequence 86, Appl
c	10	37	0.5	37	1	US-08-222-177A-140	Sequence 140, App
c	11	36.8	0.5	40	1	US-09-762-867A-11	Sequence 11, Appl
c	12	36.4	0.5	38	1	US-08-222-177A-68	Sequence 68, Appl
	13	36.4	0.5	38	1	US-08-643-839-18	Sequence 18, Appl
	14	36.4	0.5	38	1	US-08-874-678-18	Sequence 18, Appl
	15	36.4	0.5	38	1	US-09-348-886-18	Sequence 18, Appl
	16	36.4	0.5	38	1	US-10-105-901A-18	Sequence 18, Appl
c	17	36	0.5	36	1	US-08-222-177A-104	Sequence 104, App
c	18	36	0.5	36	1	US-08-222-177A-358	Sequence 358, App
c	19	35	0.5	35	1	US-08-222-177A-189	Sequence 189, App
c	20	35	0.5	35	1	US-08-222-177A-77	Sequence 77, Appl
c	21	34	0.4	34	1	US-08-222-177A-110	Sequence 110, App
c	22	34	0.4	34	1	US-08-222-177A-172	Sequence 172, App
c	23	34	0.4	34	1	US-08-222-177A-180	Sequence 180, App
c	24	34	0.4	34	1	US-08-222-177A-192	Sequence 192, App
c	25	34	0.4	34	1	US-08-222-177A-322	Sequence 322, App
	26	33.4	0.4	36	1	US-08-643-839-6	Sequence 6, Appli
	27	33.4	0.4	36	1	US-08-874-678-6	Sequence 6, Appli
	28	33.4	0.4	36	1	US-09-348-886-6	Sequence 6, Appli
	29	33.4	0.4	36	1	US-10-105-901A-6	Sequence 6, Appli
c	30	33	0.4	33	1	US-08-222-177A-218	Sequence 218, App
c	31	33	0.4	33	1	US-08-222-177A-59	Sequence 59, Appl
c	32	32	0.4	32	1	US-08-222-177A-210	Sequence 210, App
c	33	32	0.4	32	1	US-08-222-177A-376	Sequence 376, App
c	34	32	0.4	32	1	US-08-956-518A-10	Sequence 10, Appl
c	35	32	0.4	32	1	US-09-762-867A-5	Sequence 5, Appli
	36	31.4	0.4	33	1	US-08-643-839-22	Sequence 22, Appl
	37	31.4	0.4	33	1	US-08-643-839-30	Sequence 30, Appl
	38	31.4	0.4	33	1	US-08-874-678-22	Sequence 22, Appl
	39	31.4	0.4	33	1	US-08-874-678-30	Sequence 30, Appl
	40	31.4	0.4	33	1	US-09-348-886-22	Sequence 22, Appl
	41	31.4	0.4	33	1	US-09-348-886-30	Sequence 30, Appl
	42	31.4	0.4	33	1	US-10-105-901A-22	Sequence 22, Appl
	43	31.4	0.4	33	1	US-10-105-901A-30	Sequence 30, Appl
c	44	31	0.4	31	1	US-08-222-177A-215	Sequence 215, App
c	45	31	0.4	31	1	US-08-222-177A-235	Sequence 235, App
c	46	31	0.4	31	1	US-08-222-177A-271	Sequence 271, App
	47	30.6	0.4	37	1	US-08-643-839-14	Sequence 14, Appl
	48	30.6	0.4	37	1	US-08-874-678-14	Sequence 14, Appl
	49	30.6	0.4	37	1	US-09-348-886-14	Sequence 14, Appl
	50	30.6	0.4	37	1	US-10-105-901A-14	Sequence 14, Appl
c	51	30.4	0.4	32	1	US-08-222-177A-406	Sequence 406, App
c	52	30	0.4	30	1	US-08-222-177A-373	Sequence 373, App
c	53	29	0.4	29	1	US-08-222-177A-238	Sequence 238, App
c	54	29	0.4	29	1	US-08-222-177A-80	Sequence 80, Appl
c	55	29	0.4	29	1	US-08-455-627-25	Sequence 25, Appl
c	56	29	0.4	29	1	US-08-689-856-25	Sequence 25, Appl
c	57	29	0.4	29	1	US-08-859-998-410	Sequence 410, App
c	58	29	0.4	29	1	US-09-225-201B-410	Sequence 410, App
c	59	29	0.4	29	1	US-09-225-928-410	Sequence 410, App
c	60	28	0.4	28	1	US-08-222-177A-451	Sequence 451, App
	61	27.6	0.4	34	1	US-08-643-839-8	Sequence 8, Appli
	62	27.6	0.4	34	1	US-08-676-279-33	Sequence 33, Appl
	63	27.6	0.4	34	1	US-08-874-678-8	Sequence 8, Appli
	64	27.6	0.4	34	1	US-09-348-886-8	Sequence 8, Appli
	65	27.6	0.4	34	1	US-10-105-901A-8	Sequence 8, Appli
c	66	27.4	0.4	30	1	US-09-762-867A-20	Sequence 20, Appl
c	67	27	0.4	27	1	US-08-222-177A-143	Sequence 143, App
c	68	27	0.4	27	1	US-08-455-627-23	Sequence 23, Appl
c	69	27	0.4	27	1	US-08-689-856-23	Sequence 23, Appl
c	70	27	0.4	27	1	US-08-787-321-23	Sequence 23, Appl
	71	27	0.4	27	1	US-08-859-998-409	Sequence 409, App
	72	27	0.4	27	1	US-09-225-201B-409	Sequence 409, App
	73	27	0.4	27	1	US-09-225-928-409	Sequence 409, App
c	74	26.8	0.3	30	1	US-08-222-177A-415	Sequence 415, App
	75	26.8	0.3	30	1	US-08-643-839-26	Sequence 26, Appl
	76	26.8	0.3	30	1	US-08-874-678-26	Sequence 26, Appl
	77	26.8	0.3	30	1	US-09-348-886-26	Sequence 26, Appl
	78	26.8	0.3	30	1	US-10-105-901A-26	Sequence 26, Appl
	79	26.2	0.3	31	1	US-08-643-839-20	Sequence 20, Appl
	80	26.2	0.3	31	1	US-08-874-678-20	Sequence 20, Appl
	81	26.2	0.3	31	1	US-09-348-886-20	Sequence 20, Appl
	82	26.2	0.3	31	1	US-10-105-901A-20	Sequence 20, Appl
c	83	26.2	0.3	32	1	US-09-762-867A-27	Sequence 27, Appl
c	84	26	0.3	26	1	US-09-953-318-5	Sequence 5, Appli
c	85	25	0.3	25	1	US-08-222-177A-146	Sequence 146, App
c	86	25	0.3	25	1	US-08-643-839-36	Sequence 36, Appl
	87	25	0.3	25	1	US-08-643-839-37	Sequence 37, Appl
c	88	25	0.3	25	1	US-08-874-678-36	Sequence 36, Appl
	89	25	0.3	25	1	US-08-874-678-37	Sequence 37, Appl
c	90	25	0.3	25	1	US-09-348-886-36	Sequence 36, Appl
	91	25	0.3	25	1	US-09-348-886-37	Sequence 37, Appl
	92	25	0.3	25	1	US-09-396-196G-43420	Sequence 43420, A
	93	25	0.3	25	1	US-09-396-196G-43421	Sequence 43421, A
	94	25	0.3	25	1	US-09-396-196G-43422	Sequence 43422, A
	95	25	0.3	25	1	US-09-396-196G-43423	Sequence 43423, A
	96	25	0.3	25	1	US-09-396-196G-43424	Sequence 43424, A
	97	25	0.3	25	1	US-09-396-196G-43425	Sequence 43425, A
	98	25	0.3	25	1	US-09-396-196G-43426	Sequence 43426, A
	99	25	0.3	25	1	US-09-396-196G-43427	Sequence 43427, A
	100	25	0.3	25	1	US-09-396-196G-43428	Sequence 43428, A
	101	25	0.3	25	1	US-09-396-196G-43429	Sequence 43429, A
	102	25	0.3	25	1	US-09-396-196G-43430	Sequence 43430, A
	103	25	0.3	25	1	US-09-396-196G-43431	Sequence 43431, A
	104	25	0.3	25	1	US-09-396-196G-43432	Sequence 43432, A
	105	25	0.3	25	1	US-09-396-196G-43433	Sequence 43433, A
	106	25	0.3	25	1	US-09-396-196G-43434	Sequence 43434, A

	107	25	0.3	25	1	US-09-396-196G-43435	Sequence 43435, A
	108	25	0.3	25	1	US-09-396-196G-43436	Sequence 43436, A
	109	25	0.3	25	1	US-09-396-196G-43437	Sequence 43437, A
	110	25	0.3	25	1	US-09-396-196G-43438	Sequence 43438, A
	111	25	0.3	25	1	US-09-396-196G-43439	Sequence 43439, A
c	112	25	0.3	25	1	US-10-105-901A-36	Sequence 36, Appl
	113	25	0.3	25	1	US-10-105-901A-37	Sequence 37, Appl
c	114	24	0.3	24	1	US-08-222-177A-445	Sequence 445, App
c	115	23	0.3	23	1	US-08-222-177A-454	Sequence 454, App
	116	23	0.3	23	1	US-08-232-538-10	Sequence 10, Appl
	117	23	0.3	23	1	US-08-786-164-10	Sequence 10, Appl
c	118	23	0.3	23	1	US-08-787-321-22	Sequence 22, Appl
c	119	22.2	0.3	27	1	US-08-267-803B-36	Sequence 36, Appl
c	120	22.2	0.3	27	1	US-08-469-802B-18	Sequence 18, Appl
	121	22.2	0.3	27	1	US-08-643-839-16	Sequence 16, Appl
	122	22.2	0.3	27	1	US-08-874-678-16	Sequence 16, Appl
	123	22.2	0.3	27	1	US-09-348-886-16	Sequence 16, Appl
	124	22.2	0.3	27	1	US-10-105-901A-16	Sequence 16, Appl
c	125	22	0.3	22	1	US-08-222-177A-125	Sequence 125, App
	126	22	0.3	22	1	US-09-322-352A-3	Sequence 3, Appli
c	127	22	0.3	22	1	US-09-322-352A-4	Sequence 4, Appli
c	128	22	0.3	23	1	US-09-866-316B-1	Sequence 1, Appli
c	129	22	0.3	25	1	US-09-866-316B-3	Sequence 3, Appli
	130	21.8	0.3	25	1	US-08-643-839-4	Sequence 4, Appli
	131	21.8	0.3	25	1	US-08-874-678-4	Sequence 4, Appli
	132	21.8	0.3	25	1	US-09-348-886-4	Sequence 4, Appli
	133	21.8	0.3	25	1	US-10-105-901A-4	Sequence 4, Appli
c	134	21.8	0.3	26	1	PCT-US92-10792-45	Sequence 45, Appl
c	135	21.4	0.3	24	1	US-09-051-363-3	Sequence 3, Appli
	136	21.2	0.3	26	1	PCT-US92-10792-44	Sequence 44, Appl
c	137	21	0.3	21	1	US-08-222-177A-160	Sequence 160, App
	138	21	0.3	21	1	US-08-529-878B-9	Sequence 9, Appli
	139	21	0.3	21	1	US-09-051-363-2	Sequence 2, Appli
	140	21	0.3	21	1	US-09-453-718B-3	Sequence 3, Appli
	141	20	0.3	20	1	US-07-799-828C-44	Sequence 44, Appl
c	142	20	0.3	20	1	US-07-799-828C-45	Sequence 45, Appl
	143	20	0.3	20	1	US-07-922-723A-44	Sequence 44, Appl
c	144	20	0.3	20	1	US-07-922-723A-45	Sequence 45, Appl
	145	20	0.3	20	1	US-07-952-277A-44	Sequence 44, Appl
c	146	20	0.3	20	1	US-07-952-277A-45	Sequence 45, Appl
	147	20	0.3	20	1	US-08-232-538-1	Sequence 1, Appli
c	148	20	0.3	20	1	US-08-750-141A-11	Sequence 11, Appl
	149	20	0.3	20	1	US-08-750-141A-12	Sequence 12, Appl
c	150	20	0.3	20	1	US-08-750-141A-15	Sequence 15, Appl
	151	20	0.3	20	1	US-08-786-164-1	Sequence 1, Appli
c	152	20	0.3	20	1	US-08-863-639A-32	Sequence 32, Appl
	153	20	0.3	20	1	US-09-180-903-8	Sequence 8, Appli
c	154	20	0.3	20	1	US-09-407-675-5	Sequence 5, Appli
c	155	20	0.3	20	1	US-09-488-671-88	Sequence 88, Appl
c	156	20	0.3	21	1	US-09-374-454-13	Sequence 13, Appl
c	157	20	0.3	21	1	US-09-374-454-9	Sequence 9, Appli
c	158	19.4	0.3	21	1	US-08-136-118-10	Sequence 10, Appl
c	159	19	0.2	19	1	US-08-222-177A-442	Sequence 442, App
c	160	19	0.2	19	1	US-08-915-609-3	Sequence 3, Appli
	161	19	0.2	19	1	US-08-915-609-4	Sequence 4, Appli
c	162	19	0.2	19	1	US-09-557-423A-7	Sequence 7, Appli
	163	19	0.2	19	1	US-09-557-423A-8	Sequence 8, Appli
	164	19	0.2	21	1	US-09-314-246-1	Sequence 1, Appli
	165	19	0.2	21	1	US-09-314-246-2	Sequence 2, Appli
	166	18.8	0.2	23	1	US-08-018-129-15	Sequence 15, Appl
	167	18.8	0.2	23	1	US-08-448-250-15	Sequence 15, Appl
	168	18.8	0.2	23	1	US-08-621-914A-6	Sequence 6, Appli
	169	18.8	0.2	23	1	US-09-056-052-9	Sequence 9, Appli
	170	18.8	0.2	23	1	US-09-282-257-15	Sequence 15, Appl
c	171	18.4	0.2	20	1	US-09-762-867A-21	Sequence 21, Appl
	172	18	0.2	18	1	US-08-584-040-2983	Sequence 2983, Ap
c	173	18	0.2	18	1	US-08-700-530-1	Sequence 1, Appli
	174	18	0.2	18	1	US-08-700-530-2	Sequence 2, Appli
c	175	18	0.2	18	1	US-08-734-973-7	Sequence 7, Appli
c	176	18	0.2	18	1	US-08-734-973-8	Sequence 8, Appli
	177	18	0.2	18	1	US-08-976-427-28	Sequence 28, Appl
	178	18	0.2	18	1	US-09-371-772B-1411	Sequence 1411, Ap
	179	18	0.2	18	1	US-09-648-312-28	Sequence 28, Appl
	180	18	0.2	18	1	US-09-685-664B-1411	Sequence 1411, Ap
	181	18	0.2	18	1	US-09-896-650C-28	Sequence 28, Appl
	182	18	0.2	18	1	US-10-138-674B-1411	Sequence 1411, Ap
	183	17.4	0.2	19	1	US-09-909-544-5	Sequence 5, Appli
c	184	17.4	0.2	20	1	US-09-045-106-10	Sequence 10, Appl
	185	17.4	0.2	20	1	US-09-488-671-120	Sequence 120, App
	186	17.4	0.2	20	1	US-09-851-062-80	Sequence 80, Appl
	187	17.4	0.2	21	1	US-08-704-966-7	Sequence 7, Appli
	188	17.4	0.2	21	1	US-08-705-438-7	Sequence 7, Appli
c	189	17	0.2	17	1	US-08-222-177A-448	Sequence 448, App
	190	17	0.2	17	1	US-09-475-947A-118	Sequence 118, App
	191	17	0.2	17	1	US-09-958-221A-18	Sequence 18, Appl
c	192	17	0.2	17	1	US-09-958-221A-19	Sequence 19, Appl
c	193	17	0.2	18	1	US-08-734-973-2	Sequence 2, Appli
c	194	17	0.2	18	1	US-08-734-973-29	Sequence 29, Appl
c	195	17	0.2	18	1	US-08-734-973-30	Sequence 30, Appl
c	196	17	0.2	18	1	US-08-734-973-31	Sequence 31, Appl
c	197	17	0.2	18	1	US-08-734-973-32	Sequence 32, Appl
c	198	17	0.2	18	1	US-08-734-973-6	Sequence 6, Appli
	199	17	0.2	18	1	US-09-142-108C-28	Sequence 28, Appl
c	200	17	0.2	18	1	US-09-437-076-1	Sequence 1, Appli
	201	17	0.2	18	1	US-09-637-751A-7	Sequence 7, Appli
c	202	17	0.2	18	1	US-09-904-744-1	Sequence 1, Appli
	203	17	0.2	18	1	US-09-994-311-7	Sequence 7, Appli
	204	17	0.2	20	1	US-08-336-728A-34	Sequence 34, Appl
	205	17	0.2	20	1	US-08-482-918-34	Sequence 34, Appl
	206	17	0.2	20	1	US-09-224-681-34	Sequence 34, Appl
	207	17	0.2	20	1	US-09-224-683-34	Sequence 34, Appl
	208	17	0.2	20	1	US-09-604-325A-34	Sequence 34, Appl
	209	17	0.2	20	1	US-09-635-251-34	Sequence 34, Appl
	210	17	0.2	20	1	US-09-643-659B-34	Sequence 34, Appl
	211	16.8	0.2	19	1	US-08-973-857-6	Sequence 6, Appli
	212	16.8	0.2	20	1	PCT-US94-06799-7	Sequence 7, Appli
c	213	16.8	0.2	20	1	PCT-US94-06799-7	Sequence 7, Appli
	214	16.8	0.2	20	1	US-08-427-863-8	Sequence 8, Appli
c	215	16.8	0.2	20	1	US-08-427-863-8	Sequence 8, Appli
	216	16.8	0.2	20	1	US-08-763-417-7	Sequence 7, Appli
c	217	16.8	0.2	20	1	US-08-763-417-7	Sequence 7, Appli
c	218	16.8	0.2	21	1	US-09-724-126A-29	Sequence 29, Appl
	219	16.6	0.2	40	1	US-08-222-177A-175	Sequence 175, App
c	220	16.4	0.2	18	1	US-08-734-973-28	Sequence 28, Appl
c	221	16.4	0.2	18	1	US-08-734-973-33	Sequence 33, Appl
c	222	16.4	0.2	18	1	US-08-734-973-35	Sequence 35, Appl
c	223	16.4	0.2	18	1	US-08-734-973-37	Sequence 37, Appl
c	224	16.4	0.2	18	1	US-08-734-973-38	Sequence 38, Appl
c	225	16.4	0.2	18	1	US-08-734-973-4	Sequence 4, Appli
c	226	16.4	0.2	18	1	US-08-734-973-5	Sequence 5, Appli
	227	16.4	0.2	18	1	US-09-637-751A-5	Sequence 5, Appli
	228	16.4	0.2	18	1	US-09-994-311-5	Sequence 5, Appli
	229	16.4	0.2	20	1	US-09-198-452A-4759	Sequence 4759, Ap
c	230	16.4	0.2	20	1	US-09-475-947A-337	Sequence 337, App
c	231	16.4	0.2	20	1	US-09-593-711A-18	Sequence 18, Appl
	232	16.2	0.2	18	1	US-09-981-397A-1	Sequence 1, Appli
	233	16.2	0.2	19	1	US-08-881-784-18	Sequence 18, Appl
c	234	16.2	0.2	19	1	US-09-130-079-1	Sequence 1, Appli
	235	16.2	0.2	19	1	US-09-292-768-18	Sequence 18, Appl
	236	16.2	0.2	19	1	US-09-371-307-85	Sequence 85, Appl
c	237	16.2	0.2	19	1	US-10-103-614A-4	Sequence 4, Appli
	238	16.2	0.2	19	1	US-10-176-884-44	Sequence 44, Appl
	239	16.2	0.2	40	1	US-09-762-867A-11	Sequence 11, Appl
	240	16	0.2	16	1	US-07-971-978-36	Sequence 36, Appl
	241	16	0.2	16	1	US-07-971-978-42	Sequence 42, Appl
	242	16	0.2	16	1	US-07-971-978-60	Sequence 60, Appl
	243	16	0.2	16	1	US-08-087-387-6	Sequence 6, Appli
c	244	16	0.2	16	1	US-08-222-177A-439	Sequence 439, App
	245	16	0.2	16	1	US-08-415-370-2	Sequence 2, Appli
	246	16	0.2	16	1	US-08-455-627-6	Sequence 6, Appli
	247	16	0.2	16	1	US-08-461-271-6	Sequence 6, Appli
	248	16	0.2	16	1	US-08-687-551-15	Sequence 15, Appl
	249	16	0.2	16	1	US-08-689-856-6	Sequence 6, Appli
	250	16	0.2	16	1	US-08-713-685A-6	Sequence 6, Appli
c	251	16	0.2	16	1	US-08-851-843A-131	Sequence 131, App
c	252	16	0.2	16	1	US-08-854-050-131	Sequence 131, App

	253	16	0.2	16	1	US-09-070-477-6	Sequence 6, Appli
	254	16	0.2	16	1	US-09-141-764-2	Sequence 2, Appli
	255	16	0.2	16	1	US-09-152-059-70	Sequence 70, Appl
c	256	16	0.2	16	1	US-09-430-323-131	Sequence 131, App
c	257	16	0.2	16	1	US-09-438-486A-131	Sequence 131, App
	258	16	0.2	16	1	US-09-507-345A-2	Sequence 2, Appli
c	259	16	0.2	16	1	US-09-619-103-22	Sequence 22, Appl
	260	16	0.2	16	1	US-09-739-928-2	Sequence 2, Appli
c	261	16	0.2	16	1	US-09-762-867A-26	Sequence 26, Appl
c	262	16	0.2	16	1	US-09-766-253-131	Sequence 131, App
	263	16	0.2	16	1	US-09-895-585-9	Sequence 9, Appli
c	264	16	0.2	16	1	US-09-958-610A-1	Sequence 1, Appli
c	265	16	0.2	16	1	US-10-054-295-131	Sequence 131, App
c	266	16	0.2	16	1	US-10-054-611-131	Sequence 131, App
	267	16	0.2	16	1	US-10-072-975-9	Sequence 9, Appli
	268	16	0.2	16	1	US-10-203-780-9	Sequence 9, Appli
	269	16	0.2	16	1	US-10-208-650-70	Sequence 70, Appl
	270	16	0.2	16	1	US-10-227-001-21	Sequence 21, Appl
	271	16	0.2	17	1	US-08-821-827C-30	Sequence 30, Appl
	272	16	0.2	17	1	US-08-851-843A-132	Sequence 132, App
	273	16	0.2	17	1	US-08-854-050-132	Sequence 132, App
	274	16	0.2	17	1	US-08-885-126-9	Sequence 9, Appli
	275	16	0.2	17	1	US-08-960-111-11	Sequence 11, Appl
	276	16	0.2	17	1	US-09-090-672B-107	Sequence 107, App
	277	16	0.2	17	1	US-09-129-603-4	Sequence 4, Appli
	278	16	0.2	17	1	US-09-250-075-5	Sequence 5, Appli
	279	16	0.2	17	1	US-09-290-202B-30	Sequence 30, Appl
	280	16	0.2	17	1	US-09-430-323-132	Sequence 132, App
	281	16	0.2	17	1	US-09-438-486A-132	Sequence 132, App
	282	16	0.2	17	1	US-09-490-774-11	Sequence 11, Appl
c	283	16	0.2	17	1	US-09-619-103-23	Sequence 23, Appl
	284	16	0.2	17	1	US-09-726-096A-5	Sequence 5, Appli
	285	16	0.2	17	1	US-09-730-559B-109	Sequence 109, App
	286	16	0.2	17	1	US-09-766-253-132	Sequence 132, App
	287	16	0.2	17	1	US-09-958-221A-16	Sequence 16, Appl
	288	16	0.2	17	1	US-09-958-221A-17	Sequence 17, Appl
c	289	16	0.2	17	1	US-09-958-221A-20	Sequence 20, Appl
c	290	16	0.2	17	1	US-09-958-221A-21	Sequence 21, Appl
	291	16	0.2	17	1	US-10-019-832-3	Sequence 3, Appli
	292	16	0.2	17	1	US-10-054-295-132	Sequence 132, App
	293	16	0.2	17	1	US-10-054-611-132	Sequence 132, App
	294	16	0.2	18	1	PCT-US94-05407-4	Sequence 4, Appli
	295	16	0.2	18	1	US-08-295-509B-4	Sequence 4, Appli
c	296	16	0.2	18	1	US-08-346-429-3	Sequence 3, Appli
	297	16	0.2	18	1	US-08-358-556A-12	Sequence 12, Appl
c	298	16	0.2	18	1	US-08-358-556A-18	Sequence 18, Appl
	299	16	0.2	18	1	US-08-469-852A-4	Sequence 4, Appli
	300	16	0.2	18	1	US-08-621-914A-16	Sequence 16, Appl
c	301	16	0.2	18	1	US-08-734-973-1	Sequence 1, Appli
c	302	16	0.2	18	1	US-08-734-973-3	Sequence 3, Appli
c	303	16	0.2	18	1	US-08-734-973-34	Sequence 34, Appl
c	304	16	0.2	18	1	US-08-734-973-36	Sequence 36, Appl
	305	16	0.2	18	1	US-08-884-029-9	Sequence 9, Appli
c	306	16	0.2	18	1	US-08-941-445A-30	Sequence 30, Appl
	307	16	0.2	18	1	US-09-142-108C-27	Sequence 27, Appl
	308	16	0.2	18	1	US-09-142-108C-29	Sequence 29, Appl
	309	16	0.2	18	1	US-09-370-541-14	Sequence 14, Appl
	310	16	0.2	18	1	US-09-545-225-9	Sequence 9, Appli
c	311	16	0.2	18	1	US-09-619-103-24	Sequence 24, Appl
	312	16	0.2	18	1	US-09-637-751A-6	Sequence 6, Appli
	313	16	0.2	18	1	US-09-696-791-4272	Sequence 4272, Ap
c	314	16	0.2	18	1	US-09-803-263-6	Sequence 6, Appli
	315	16	0.2	18	1	US-09-803-263-7	Sequence 7, Appli
	316	16	0.2	18	1	US-09-809-545A-84	Sequence 84, Appl
	317	16	0.2	18	1	US-09-979-275A-7	Sequence 7, Appli
	318	16	0.2	18	1	US-09-994-311-6	Sequence 6, Appli
	319	16	0.2	18	1	US-10-125-295-9	Sequence 9, Appli
	320	16	0.2	18	1	US-10-352-704-12	Sequence 12, Appl
c	321	16	0.2	18	1	US-10-352-704-18	Sequence 18, Appl
c	322	16	0.2	19	1	PCT-US95-04712-38	Sequence 38, Appl
c	323	16	0.2	19	1	US-08-065-845-1	Sequence 1, Appli
c	324	16	0.2	19	1	US-08-233-608-38	Sequence 38, Appl
	325	16	0.2	19	1	US-08-271-882B-16	Sequence 16, Appl
	326	16	0.2	19	1	US-08-295-509B-2	Sequence 2, Appli
c	327	16	0.2	19	1	US-08-429-520-1	Sequence 1, Appli
c	328	16	0.2	19	1	US-08-429-522-1	Sequence 1, Appli
c	329	16	0.2	19	1	US-08-429-523-1	Sequence 1, Appli
c	330	16	0.2	19	1	US-08-429-532-1	Sequence 1, Appli
	331	16	0.2	19	1	US-08-469-852A-2	Sequence 2, Appli
c	332	16	0.2	19	1	US-08-722-187-38	Sequence 38, Appl
	333	16	0.2	19	1	US-08-726-278-16	Sequence 16, Appl
c	334	16	0.2	19	1	US-08-742-023-9	Sequence 9, Appli
	335	16	0.2	19	1	US-08-756-728A-1	Sequence 1, Appli
c	336	16	0.2	19	1	US-08-787-321-27	Sequence 27, Appl
c	337	16	0.2	19	1	US-08-887-480-38	Sequence 38, Appl
c	338	16	0.2	19	1	US-08-905-314A-1	Sequence 1, Appli
c	339	16	0.2	19	1	US-08-968-505-9	Sequence 9, Appli
	340	16	0.2	19	1	US-09-016-520-20	Sequence 20, Appl
	341	16	0.2	19	1	US-09-016-520-21	Sequence 21, Appl
	342	16	0.2	19	1	US-09-016-520-22	Sequence 22, Appl
	343	16	0.2	19	1	US-09-016-520-23	Sequence 23, Appl
	344	16	0.2	19	1	US-09-016-520-24	Sequence 24, Appl
	345	16	0.2	19	1	US-09-016-520-25	Sequence 25, Appl
	346	16	0.2	19	1	US-09-016-520-26	Sequence 26, Appl
	347	16	0.2	19	1	US-09-016-520-27	Sequence 27, Appl
	348	16	0.2	19	1	US-09-016-520-31	Sequence 31, Appl
	349	16	0.2	19	1	US-09-016-520-33	Sequence 33, Appl
	350	16	0.2	19	1	US-09-016-520-34	Sequence 34, Appl
	351	16	0.2	19	1	US-09-016-520-44	Sequence 44, Appl
c	352	16	0.2	19	1	US-09-026-601-1	Sequence 1, Appli
	353	16	0.2	19	1	US-09-123-108-6	Sequence 6, Appli
	354	16	0.2	19	1	US-09-130-973-20	Sequence 20, Appl
	355	16	0.2	19	1	US-09-130-973-21	Sequence 21, Appl
	356	16	0.2	19	1	US-09-130-973-22	Sequence 22, Appl
	357	16	0.2	19	1	US-09-130-973-23	Sequence 23, Appl
	358	16	0.2	19	1	US-09-130-973-24	Sequence 24, Appl
	359	16	0.2	19	1	US-09-130-973-25	Sequence 25, Appl
	360	16	0.2	19	1	US-09-130-973-26	Sequence 26, Appl
	361	16	0.2	19	1	US-09-130-973-27	Sequence 27, Appl
	362	16	0.2	19	1	US-09-130-973-31	Sequence 31, Appl
	363	16	0.2	19	1	US-09-130-973-33	Sequence 33, Appl
	364	16	0.2	19	1	US-09-130-973-34	Sequence 34, Appl
	365	16	0.2	19	1	US-09-130-973-44	Sequence 44, Appl
	366	16	0.2	19	1	US-09-142-212A-10	Sequence 10, Appl
	367	16	0.2	19	1	US-09-202-294-4	Sequence 4, Appli
	368	16	0.2	19	1	US-09-218-207-515	Sequence 515, App
	369	16	0.2	19	1	US-09-227-782-1	Sequence 1, Appli
	370	16	0.2	19	1	US-09-227-782-12	Sequence 12, Appl
	371	16	0.2	19	1	US-09-227-782-14	Sequence 14, Appl
	372	16	0.2	19	1	US-09-227-782-15	Sequence 15, Appl
	373	16	0.2	19	1	US-09-227-782-2	Sequence 2, Appli
	374	16	0.2	19	1	US-09-227-782-25	Sequence 25, Appl
	375	16	0.2	19	1	US-09-227-782-3	Sequence 3, Appli
	376	16	0.2	19	1	US-09-227-782-4	Sequence 4, Appli
	377	16	0.2	19	1	US-09-227-782-5	Sequence 5, Appli
	378	16	0.2	19	1	US-09-227-782-6	Sequence 6, Appli
	379	16	0.2	19	1	US-09-227-782-7	Sequence 7, Appli
	380	16	0.2	19	1	US-09-227-782-8	Sequence 8, Appli
	381	16	0.2	19	1	US-09-234-237-1	Sequence 1, Appli
c	382	16	0.2	19	1	US-09-258-967-1	Sequence 1, Appli
c	383	16	0.2	19	1	US-09-269-136B-1	Sequence 1, Appli
	384	16	0.2	19	1	US-09-288-679-1	Sequence 1, Appli
	385	16	0.2	19	1	US-09-303-586-15	Sequence 15, Appl
	386	16	0.2	19	1	US-09-303-586-16	Sequence 16, Appl
	387	16	0.2	19	1	US-09-303-586-17	Sequence 17, Appl
	388	16	0.2	19	1	US-09-303-586-18	Sequence 18, Appl
	389	16	0.2	19	1	US-09-303-586-26	Sequence 26, Appl
c	390	16	0.2	19	1	US-09-311-260-111	Sequence 111, App
	391	16	0.2	19	1	US-09-329-416-3	Sequence 3, Appli
	392	16	0.2	19	1	US-09-338-907-515	Sequence 515, App
	393	16	0.2	19	1	US-09-349-033A-1	Sequence 1, Appli
	394	16	0.2	19	1	US-09-349-040A-3	Sequence 3, Appli
	395	16	0.2	19	1	US-09-349-040A-4	Sequence 4, Appli
	396	16	0.2	19	1	US-09-349-040A-5	Sequence 5, Appli
	397	16	0.2	19	1	US-09-378-568-4	Sequence 4, Appli
	398	16	0.2	19	1	US-09-378-665A-5	Sequence 5, Appli

	399	16	0.2	19	1	US-09-409-926-17	Sequence 17, Appl
	400	16	0.2	19	1	US-09-409-926-18	Sequence 18, Appl
	401	16	0.2	19	1	US-09-435-806-6	Sequence 6, Appli
	402	16	0.2	19	1	US-09-435-806-7	Sequence 7, Appli
	403	16	0.2	19	1	US-09-477-902-20	Sequence 20, Appl
	404	16	0.2	19	1	US-09-477-902-21	Sequence 21, Appl
	405	16	0.2	19	1	US-09-477-902-22	Sequence 22, Appl
	406	16	0.2	19	1	US-09-477-902-23	Sequence 23, Appl
	407	16	0.2	19	1	US-09-477-902-24	Sequence 24, Appl
	408	16	0.2	19	1	US-09-477-902-25	Sequence 25, Appl
	409	16	0.2	19	1	US-09-477-902-26	Sequence 26, Appl
	410	16	0.2	19	1	US-09-477-902-27	Sequence 27, Appl
	411	16	0.2	19	1	US-09-477-902-31	Sequence 31, Appl
	412	16	0.2	19	1	US-09-477-902-33	Sequence 33, Appl
	413	16	0.2	19	1	US-09-477-902-34	Sequence 34, Appl
	414	16	0.2	19	1	US-09-477-902-44	Sequence 44, Appl
c	415	16	0.2	19	1	US-09-481-293-1	Sequence 1, Appli
	416	16	0.2	19	1	US-09-612-531-13	Sequence 13, Appl
	417	16	0.2	19	1	US-09-612-531-3	Sequence 3, Appli
	418	16	0.2	19	1	US-09-612-531-7	Sequence 7, Appli
c	419	16	0.2	19	1	US-09-619-103-25	Sequence 25, Appl
c	420	16	0.2	19	1	US-09-635-747-1	Sequence 1, Appli
c	421	16	0.2	19	1	US-09-673-298-1	Sequence 1, Appli
c	422	16	0.2	19	1	US-09-939-379B-1	Sequence 1, Appli
c	423	16	0.2	19	1	US-09-961-663-1	Sequence 1, Appli
c	424	16	0.2	19	1	US-09-961-755A-9	Sequence 9, Appli
	425	16	0.2	19	1	US-10-058-740-3	Sequence 3, Appli
	426	16	0.2	19	1	US-10-098-816-15	Sequence 15, Appl
	427	16	0.2	19	1	US-10-098-816-16	Sequence 16, Appl
	428	16	0.2	19	1	US-10-098-816-17	Sequence 17, Appl
	429	16	0.2	19	1	US-10-098-816-18	Sequence 18, Appl
	430	16	0.2	19	1	US-10-098-816-26	Sequence 26, Appl
c	431	16	0.2	19	1	US-10-100-321A-22	Sequence 22, Appl
c	432	16	0.2	19	1	US-10-100-321A-24	Sequence 24, Appl
	433	16	0.2	19	1	US-10-121-135-26	Sequence 26, Appl
	434	16	0.2	19	1	US-10-121-135-5	Sequence 5, Appli
	435	16	0.2	19	1	US-10-121-135-5	Sequence 5, Appli
	436	16	0.2	19	1	US-10-123-597-1	Sequence 1, Appli
	437	16	0.2	19	1	US-10-123-597-12	Sequence 12, Appl
	438	16	0.2	19	1	US-10-123-597-14	Sequence 14, Appl
	439	16	0.2	19	1	US-10-123-597-15	Sequence 15, Appl
	440	16	0.2	19	1	US-10-123-597-2	Sequence 2, Appli
	441	16	0.2	19	1	US-10-123-597-25	Sequence 25, Appl
	442	16	0.2	19	1	US-10-123-597-3	Sequence 3, Appli
	443	16	0.2	19	1	US-10-123-597-4	Sequence 4, Appli
	444	16	0.2	19	1	US-10-123-597-5	Sequence 5, Appli
	445	16	0.2	19	1	US-10-123-597-6	Sequence 6, Appli
	446	16	0.2	19	1	US-10-123-597-7	Sequence 7, Appli
	447	16	0.2	19	1	US-10-123-597-8	Sequence 8, Appli
	448	16	0.2	19	1	US-10-232-881-1	Sequence 1, Appli
	449	16	0.2	19	1	US-10-247-893-13	Sequence 13, Appl
	450	16	0.2	19	1	US-10-247-893-3	Sequence 3, Appli
	451	16	0.2	19	1	US-10-247-893-7	Sequence 7, Appli
	452	16	0.2	19	1	US-10-322-242-1	Sequence 1, Appli
c	453	16	0.2	20	1	PCT-US93-07603-6	Sequence 6, Appli
	454	16	0.2	20	1	US-07-912-900-20	Sequence 20, Appl
	455	16	0.2	20	1	US-08-093-144-20	Sequence 20, Appl
	456	16	0.2	20	1	US-08-146-504-16	Sequence 16, Appl
	457	16	0.2	20	1	US-08-285-309-20	Sequence 20, Appl
	458	16	0.2	20	1	US-08-313-075A-11	Sequence 11, Appl
	459	16	0.2	20	1	US-08-336-728A-32	Sequence 32, Appl
	460	16	0.2	20	1	US-08-336-728A-33	Sequence 33, Appl
	461	16	0.2	20	1	US-08-379-593-5	Sequence 5, Appli
	462	16	0.2	20	1	US-08-448-204-14	Sequence 14, Appl
	463	16	0.2	20	1	US-08-482-918-32	Sequence 32, Appl
	464	16	0.2	20	1	US-08-482-918-33	Sequence 33, Appl
	465	16	0.2	20	1	US-08-502-046-20	Sequence 20, Appl
	466	16	0.2	20	1	US-08-715-461-5	Sequence 5, Appli
	467	16	0.2	20	1	US-08-725-976-16	Sequence 16, Appl
	468	16	0.2	20	1	US-08-765-340-96	Sequence 96, Appl
c	469	16	0.2	20	1	US-08-873-970-83	Sequence 83, Appl
	470	16	0.2	20	1	US-08-965-780-1	Sequence 1, Appli
c	471	16	0.2	20	1	US-08-997-080-83	Sequence 83, Appl
c	472	16	0.2	20	1	US-08-997-362-83	Sequence 83, Appl
c	473	16	0.2	20	1	US-09-095-855-83	Sequence 83, Appl
	474	16	0.2	20	1	US-09-173-936B-14	Sequence 14, Appl
c	475	16	0.2	20	1	US-09-205-426-83	Sequence 83, Appl
	476	16	0.2	20	1	US-09-224-681-32	Sequence 32, Appl
	477	16	0.2	20	1	US-09-224-681-33	Sequence 33, Appl
	478	16	0.2	20	1	US-09-224-683-32	Sequence 32, Appl
	479	16	0.2	20	1	US-09-224-683-33	Sequence 33, Appl
	480	16	0.2	20	1	US-09-250-075-1	Sequence 1, Appli
c	481	16	0.2	20	1	US-09-324-542-83	Sequence 83, Appl
	482	16	0.2	20	1	US-09-344-260A-10	Sequence 10, Appl
c	483	16	0.2	20	1	US-09-407-675-1	Sequence 1, Appli
	484	16	0.2	20	1	US-09-450-656-29	Sequence 29, Appl
c	485	16	0.2	20	1	US-09-454-704A-13	Sequence 13, Appl
c	486	16	0.2	20	1	US-09-603-830-55	Sequence 55, Appl
	487	16	0.2	20	1	US-09-604-325A-32	Sequence 32, Appl
	488	16	0.2	20	1	US-09-604-325A-33	Sequence 33, Appl
c	489	16	0.2	20	1	US-09-619-103-26	Sequence 26, Appl
	490	16	0.2	20	1	US-09-635-251-32	Sequence 32, Appl
	491	16	0.2	20	1	US-09-635-251-33	Sequence 33, Appl
	492	16	0.2	20	1	US-09-643-659B-32	Sequence 32, Appl
	493	16	0.2	20	1	US-09-643-659B-33	Sequence 33, Appl
	494	16	0.2	20	1	US-09-724-857-36	Sequence 36, Appl
	495	16	0.2	20	1	US-09-726-096A-1	Sequence 1, Appli
c	496	16	0.2	20	1	US-09-760-500A-55	Sequence 55, Appl
c	497	16	0.2	20	1	US-09-820-279D-55	Sequence 55, Appl
c	498	16	0.2	20	1	US-09-820-279D-70	Sequence 70, Appl
	499	16	0.2	20	1	US-09-859-736-3	Sequence 3, Appli
	500	16	0.2	20	1	US-09-859-736-4	Sequence 4, Appli
c	501	16	0.2	20	1	US-09-957-313A-55	Sequence 55, Appl
c	502	16	0.2	20	1	US-09-957-318A-55	Sequence 55, Appl
c	503	16	0.2	20	1	US-09-961-949A-55	Sequence 55, Appl
	504	16	0.2	20	1	US-09-965-599-4	Sequence 4, Appli
c	505	16	0.2	20	1	US-09-966-312-55	Sequence 55, Appl
c	506	16	0.2	20	1	US-09-966-491A-55	Sequence 55, Appl
c	507	16	0.2	20	1	US-09-967-409A-55	Sequence 55, Appl
c	508	16	0.2	20	1	US-09-973-638A-55	Sequence 55, Appl
c	509	16	0.2	20	1	US-09-973-788A-55	Sequence 55, Appl
c	510	16	0.2	20	1	US-09-974-500A-55	Sequence 55, Appl
c	511	16	0.2	20	1	US-09-975-059A-55	Sequence 55, Appl
c	512	16	0.2	20	1	US-09-975-062A-55	Sequence 55, Appl
c	513	16	0.2	20	1	US-09-975-498-55	Sequence 55, Appl
c	514	16	0.2	20	1	US-09-976-378A-55	Sequence 55, Appl
c	515	16	0.2	20	1	US-09-976-577-55	Sequence 55, Appl
c	516	16	0.2	20	1	US-09-976-601A-55	Sequence 55, Appl
c	517	16	0.2	20	1	US-09-976-617A-55	Sequence 55, Appl
c	518	16	0.2	20	1	US-09-976-618A-55	Sequence 55, Appl
c	519	16	0.2	20	1	US-09-976-863A-55	Sequence 55, Appl
c	520	16	0.2	20	1	US-09-976-900A-55	Sequence 55, Appl
c	521	16	0.2	20	1	US-09-976-968A-55	Sequence 55, Appl
c	522	16	0.2	20	1	US-09-976-971A-55	Sequence 55, Appl
c	523	16	0.2	20	1	US-09-976-978A-55	Sequence 55, Appl
c	524	16	0.2	20	1	US-09-981-344-55	Sequence 55, Appl
c	525	16	0.2	20	1	US-10-008-978-55	Sequence 55, Appl
c	526	16	0.2	20	1	US-10-008-978-70	Sequence 70, Appl
	527	16	0.2	20	1	US-10-234-764-10	Sequence 10, Appl
	528	16	0.2	20	1	US-10-278-047-1	Sequence 1, Appli
c	529	16	0.2	20	1	US-10-410-324-55	Sequence 55, Appl
c	530	15.8	0.2	19	1	US-08-424-550B-667	Sequence 667, App
c	531	15.8	0.2	19	1	US-08-467-344A-667	Sequence 667, App
c	532	15.8	0.2	19	1	US-08-469-260A-667	Sequence 667, App
c	533	15.8	0.2	19	1	US-08-488-446-667	Sequence 667, App
	534	15.8	0.2	19	1	US-08-849-021-74	Sequence 74, Appl
	535	15.8	0.2	19	1	US-08-899-029-1	Sequence 1, Appli
c	536	15.8	0.2	19	1	US-09-434-382-54	Sequence 54, Appl
c	537	15.8	0.2	19	1	US-09-564-805-54	Sequence 54, Appl
	538	15.8	0.2	38	1	US-08-222-177A-68	Sequence 68, Appl
	539	15.8	0.2	39	1	US-08-222-177A-86	Sequence 86, Appl
	540	15.6	0.2	17	1	US-08-937-067-17	Sequence 17, Appl
c	541	15.4	0.2	17	1	US-08-050-073-205	Sequence 205, App
c	542	15.4	0.2	17	1	US-08-050-073-305	Sequence 305, App
	543	15.4	0.2	17	1	US-08-050-073-71	Sequence 71, Appl
c	544	15.4	0.2	17	1	US-09-866-108A-9685	Sequence 9685, Ap

545	15.4	0.2	17	1	US-10-156-306B-521	Sequence 521, App
546	15.4	0.2	18	1	US-08-050-073-100	Sequence 100, App
547	15.4	0.2	18	1	US-08-283-917-28	Sequence 28, Appl
c 548	15.4	0.2	18	1	US-08-363-585-86	Sequence 86, Appl
549	15.4	0.2	18	1	US-08-961-716-28	Sequence 28, Appl
c 550	15.4	0.2	18	1	US-09-328-174A-8	Sequence 8, Appli
c 551	15.4	0.2	19	1	PCT-US93-00977-292	Sequence 292, App
c 552	15.4	0.2	19	1	US-07-974-409C-292	Sequence 292, App
553	15.4	0.2	19	1	US-08-050-073-113	Sequence 113, App
c 554	15.4	0.2	19	1	US-08-379-078-708	Sequence 708, App
555	15.4	0.2	19	1	US-09-696-791-4087	Sequence 4087, Ap
556	15.4	0.2	19	1	US-09-696-791-4088	Sequence 4088, Ap
557	15.4	0.2	19	1	US-09-696-791-4089	Sequence 4089, Ap
558	15.4	0.2	19	1	US-09-818-943-6	Sequence 6, Appli
559	15.2	0.2	17	1	US-09-390-324B-2	Sequence 2, Appli
560	15.2	0.2	17	1	US-10-015-593-2	Sequence 2, Appli
561	15	0.2	15	1	US-07-971-978-1	Sequence 1, Appli
562	15	0.2	15	1	US-08-108-591B-17	Sequence 17, Appl
c 563	15	0.2	15	1	US-08-108-591B-18	Sequence 18, Appl
564	15	0.2	15	1	US-08-150-156A-19	Sequence 19, Appl
c 565	15	0.2	15	1	US-08-150-156A-20	Sequence 20, Appl
566	15	0.2	15	1	US-08-292-620A-361	Sequence 361, App
567	15	0.2	15	1	US-08-292-620A-362	Sequence 362, App
568	15	0.2	15	1	US-08-292-620A-363	Sequence 363, App
569	15	0.2	15	1	US-08-358-556A-10	Sequence 10, Appl
c 570	15	0.2	15	1	US-08-358-556A-16	Sequence 16, Appl
c 571	15	0.2	15	1	US-08-452-196A-6	Sequence 6, Appli
572	15	0.2	15	1	US-08-462-977B-17	Sequence 17, Appl
c 573	15	0.2	15	1	US-08-462-977B-18	Sequence 18, Appl
574	15	0.2	15	1	US-08-468-719A-17	Sequence 17, Appl
c 575	15	0.2	15	1	US-08-468-719A-18	Sequence 18, Appl
576	15	0.2	15	1	US-08-663-918-3	Sequence 3, Appli
c 577	15	0.2	15	1	US-08-663-918-4	Sequence 4, Appli
578	15	0.2	15	1	US-08-693-831-1	Sequence 1, Appli
c 579	15	0.2	15	1	US-08-756-728A-2	Sequence 2, Appli
580	15	0.2	15	1	US-08-771-789-3	Sequence 3, Appli
c 581	15	0.2	15	1	US-08-771-789-4	Sequence 4, Appli
c 582	15	0.2	15	1	US-08-787-321-24	Sequence 24, Appl
583	15	0.2	15	1	US-08-832-021-33	Sequence 33, Appl
584	15	0.2	15	1	US-08-849-021-10	Sequence 10, Appl
c 585	15	0.2	15	1	US-08-849-021-7	Sequence 7, Appli
c 586	15	0.2	15	1	US-08-849-021-8	Sequence 8, Appli
587	15	0.2	15	1	US-08-849-021-9	Sequence 9, Appli
c 588	15	0.2	15	1	US-08-863-639A-5	Sequence 5, Appli
589	15	0.2	15	1	US-08-863-639A-9	Sequence 9, Appli
590	15	0.2	15	1	US-08-922-170B-5	Sequence 5, Appli
591	15	0.2	15	1	US-08-988-024C-9	Sequence 9, Appli
592	15	0.2	15	1	US-09-071-845-361	Sequence 361, App
593	15	0.2	15	1	US-09-071-845-362	Sequence 362, App
594	15	0.2	15	1	US-09-071-845-363	Sequence 363, App
c 595	15	0.2	15	1	US-09-167-375-1	Sequence 1, Appli
596	15	0.2	15	1	US-09-183-619-4	Sequence 4, Appli
597	15	0.2	15	1	US-09-300-958A-68	Sequence 68, Appl
598	15	0.2	15	1	US-09-435-739-5	Sequence 5, Appli
c 599	15	0.2	15	1	US-09-619-103-21	Sequence 21, Appl
600	15	0.2	15	1	US-09-793-146-54	Sequence 54, Appl
601	15	0.2	15	1	US-09-793-146-55	Sequence 55, Appl
602	15	0.2	15	1	US-09-850-982B-4	Sequence 4, Appli
603	15	0.2	15	1	US-09-930-218-5	Sequence 5, Appli
604	15	0.2	15	1	US-09-988-113-5	Sequence 5, Appli
605	15	0.2	15	1	US-10-072-975-10	Sequence 10, Appl
606	15	0.2	15	1	US-10-091-231-2	Sequence 2, Appli
607	15	0.2	15	1	US-10-227-001-23	Sequence 23, Appl
608	15	0.2	15	1	US-10-352-704-10	Sequence 10, Appl
c 609	15	0.2	15	1	US-10-352-704-16	Sequence 16, Appl
610	15	0.2	15	1	US-10-384-450A-5	Sequence 5, Appli
c 611	15	0.2	16	1	US-09-479-005A-295	Sequence 295, App
612	15	0.2	16	1	US-09-507-345A-3	Sequence 3, Appli
613	15	0.2	16	1	US-09-507-345A-4	Sequence 4, Appli
614	15	0.2	16	1	US-09-507-345A-5	Sequence 5, Appli
615	15	0.2	16	1	US-09-507-345A-6	Sequence 6, Appli
616	15	0.2	16	1	US-09-507-345A-7	Sequence 7, Appli
617	15	0.2	16	1	US-09-507-345A-8	Sequence 8, Appli
618	15	0.2	16	1	US-09-739-928-3	Sequence 3, Appli
619	15	0.2	16	1	US-09-739-928-4	Sequence 4, Appli
620	15	0.2	16	1	US-09-739-928-5	Sequence 5, Appli
621	15	0.2	16	1	US-09-739-928-6	Sequence 6, Appli
622	15	0.2	16	1	US-09-739-928-7	Sequence 7, Appli
623	15	0.2	16	1	US-09-739-928-8	Sequence 8, Appli
624	15	0.2	16	1	US-10-227-001-20	Sequence 20, Appl
625	15	0.2	17	1	US-08-679-645-114	Sequence 114, App
626	15	0.2	17	1	US-09-090-672B-105	Sequence 105, App
627	15	0.2	17	1	US-09-090-672B-106	Sequence 106, App
628	15	0.2	17	1	US-09-300-958A-63	Sequence 63, Appl
629	15	0.2	17	1	US-09-300-958A-64	Sequence 64, Appl
630	15	0.2	17	1	US-09-730-559B-107	Sequence 107, App
631	15	0.2	17	1	US-09-730-559B-108	Sequence 108, App
632	15	0.2	17	1	US-09-788-338-3	Sequence 3, Appli
633	15	0.2	17	1	US-10-019-832-2	Sequence 2, Appli
634	15	0.2	17	1	US-10-019-832-4	Sequence 4, Appli
635	15	0.2	17	1	US-10-156-306B-522	Sequence 522, App
636	15	0.2	17	1	US-10-156-306B-523	Sequence 523, App
637	15	0.2	18	1	US-09-437-076-2	Sequence 2, Appli
c 638	15	0.2	18	1	US-09-556-127-44	Sequence 44, Appl
639	15	0.2	18	1	US-09-630-706-59	Sequence 59, Appl
640	15	0.2	18	1	US-09-696-791-4271	Sequence 4271, Ap
c 641	15	0.2	18	1	US-09-725-265-44	Sequence 44, Appl
642	15	0.2	18	1	US-09-904-744-2	Sequence 2, Appli
643	15	0.2	39	1	US-08-222-177A-137	Sequence 137, App
644	15	0.2	40	1	US-08-222-177A-119	Sequence 119, App
645	15	0.2	40	1	US-08-222-177A-152	Sequence 152, App
646	15	0.2	40	1	US-08-222-177A-400	Sequence 400, App
647	15	0.2	40	1	US-08-222-177A-403	Sequence 403, App
c 648	14.8	0.2	18	1	US-08-275-951-32	Sequence 32, Appl
c 649	14.8	0.2	18	1	US-08-275-951-33	Sequence 33, Appl
c 650	14.8	0.2	18	1	US-08-440-646A-20	Sequence 20, Appl
c 651	14.8	0.2	18	1	US-08-440-689-20	Sequence 20, Appl
c 652	14.8	0.2	18	1	US-08-447-985-25	Sequence 25, Appl
c 653	14.8	0.2	18	1	US-08-622-740-20	Sequence 20, Appl
c 654	14.8	0.2	18	1	US-08-852-340-25	Sequence 25, Appl
c 655	14.8	0.2	18	1	US-09-122-399-20	Sequence 20, Appl
656	14.8	0.2	18	1	US-09-341-700A-12	Sequence 12, Appl
c 657	14.8	0.2	18	1	US-09-344-520-40	Sequence 40, Appl
658	14.8	0.2	18	1	US-09-475-316A-122	Sequence 122, App
659	14.8	0.2	18	1	US-09-500-700-68	Sequence 68, Appl
660	14.8	0.2	18	1	US-09-704-640-122	Sequence 122, App
661	14.6	0.2	37	1	US-08-222-177A-140	Sequence 140, App
662	14.6	0.2	38	1	US-08-222-177A-198	Sequence 198, App
663	14.6	0.2	38	1	US-08-222-177A-397	Sequence 397, App
664	14.4	0.2	16	1	US-08-060-952C-57	Sequence 57, Appl
665	14.4	0.2	16	1	US-08-151-477A-58	Sequence 58, Appl
666	14.4	0.2	16	1	US-08-153-051B-58	Sequence 58, Appl
667	14.4	0.2	16	1	US-08-464-011B-57	Sequence 57, Appl
668	14.4	0.2	16	1	US-08-819-867-80	Sequence 80, Appl
669	14.4	0.2	16	1	US-09-378-535-80	Sequence 80, Appl
670	14.4	0.2	16	1	US-09-479-005A-256	Sequence 256, App
c 671	14.4	0.2	16	1	US-09-479-005A-294	Sequence 294, App
672	14.4	0.2	17	1	US-08-998-099-68	Sequence 68, Appl
673	14.4	0.2	17	1	US-09-341-700A-818	Sequence 818, App
c 674	14.4	0.2	17	1	US-09-866-108A-9684	Sequence 9684, Ap
c 675	14.4	0.2	17	1	US-09-866-108A-9686	Sequence 9686, Ap
676	14.4	0.2	17	1	US-10-156-306B-520	Sequence 520, App
677	14.4	0.2	18	1	PCT-US91-03680-73	Sequence 73, Appl
678	14.4	0.2	18	1	PCT-US91-03680-74	Sequence 74, Appl
c 679	14.4	0.2	18	1	PCT-US94-12947A-16	Sequence 16, Appl
c 680	14.4	0.2	18	1	US-08-152-313-16	Sequence 16, Appl
c 681	14.4	0.2	18	1	US-08-297-395-52	Sequence 52, Appl
c 682	14.4	0.2	18	1	US-08-297-395-55	Sequence 55, Appl
c 683	14.4	0.2	18	1	US-08-297-395-61	Sequence 61, Appl
c 684	14.4	0.2	18	1	US-08-297-395-64	Sequence 64, Appl
c 685	14.4	0.2	18	1	US-08-579-223-16	Sequence 16, Appl
686	14.4	0.2	18	1	US-08-857-946-14	Sequence 14, Appl
687	14.4	0.2	18	1	US-08-970-740-14	Sequence 14, Appl
688	14.4	0.2	18	1	US-09-205-995-25	Sequence 25, Appl
689	14.4	0.2	18	1	US-09-422-978-4233	Sequence 4233, Ap
c 690	14.4	0.2	18	1	US-09-422-978-7435	Sequence 7435, Ap

c 691	14.4	0.2	18	1	US-09-828-034-15	Sequence 15, Appl
692	14.4	0.2	18	1	US-10-006-069A-117	Sequence 117, App
693	14.2	0.2	16	1	US-08-882-649A-8	Sequence 8, Appli
694	14.2	0.2	16	1	US-09-880-727-8	Sequence 8, Appli
695	14.2	0.2	35	1	US-08-222-177A-189	Sequence 189, App
696	14.2	0.2	36	1	US-08-222-177A-104	Sequence 104, App
697	14.2	0.2	36	1	US-08-222-177A-358	Sequence 358, App
c 698	14	0.2	15	1	US-08-182-968A-170	Sequence 170, App
699	14	0.2	15	1	US-08-292-620A-360	Sequence 360, App
700	14	0.2	15	1	US-08-292-620A-364	Sequence 364, App
c 701	14	0.2	15	1	US-08-452-196A-3	Sequence 3, Appli
c 702	14	0.2	15	1	US-08-452-196A-4	Sequence 4, Appli
c 703	14	0.2	15	1	US-08-774-306A-170	Sequence 170, App
704	14	0.2	15	1	US-08-832-021-26	Sequence 26, Appl
705	14	0.2	15	1	US-08-832-021-34	Sequence 34, Appl
706	14	0.2	15	1	US-08-832-021-35	Sequence 35, Appl
707	14	0.2	15	1	US-08-832-021-36	Sequence 36, Appl
708	14	0.2	15	1	US-08-893-204C-2	Sequence 2, Appli
c 709	14	0.2	15	1	US-09-064-156A-170	Sequence 170, App
710	14	0.2	15	1	US-09-071-845-360	Sequence 360, App
711	14	0.2	15	1	US-09-071-845-364	Sequence 364, App
712	14	0.2	15	1	US-09-475-947A-158	Sequence 158, App
713	14	0.2	15	1	US-09-680-889-1	Sequence 1, Appli
714	14	0.2	15	1	US-10-227-001-24	Sequence 24, Appl
c 715	14	0.2	16	1	US-08-378-617A-30	Sequence 30, Appl
c 716	14	0.2	16	1	US-08-431-080-3	Sequence 3, Appli
717	14	0.2	16	1	US-08-894-251A-5	Sequence 5, Appli
c 718	14	0.2	16	1	US-08-938-534-3	Sequence 3, Appli
c 719	14	0.2	16	1	US-08-984-900-30	Sequence 30, Appl
720	14	0.2	16	1	US-09-124-238A-4	Sequence 4, Appli
721	14	0.2	16	1	US-09-300-958A-56	Sequence 56, Appl
722	14	0.2	16	1	US-09-300-958A-83	Sequence 83, Appl
723	14	0.2	16	1	US-09-331-930A-4	Sequence 4, Appli
c 724	14	0.2	16	1	US-09-345-294-3	Sequence 3, Appli
725	14	0.2	16	1	US-09-527-972-15	Sequence 15, Appl
726	14	0.2	16	1	US-09-531-000-24	Sequence 24, Appl
727	14	0.2	16	1	US-09-569-956-11	Sequence 11, Appl
728	14	0.2	16	1	US-09-721-975-4	Sequence 4, Appli
729	14	0.2	16	1	US-09-724-857-26	Sequence 26, Appl
730	14	0.2	16	1	US-09-854-326-11	Sequence 11, Appl
731	14	0.2	16	1	US-09-949-270A-5	Sequence 5, Appli
732	14	0.2	16	1	US-09-949-271A-5	Sequence 5, Appli
733	14	0.2	16	1	US-09-949-272A-5	Sequence 5, Appli
734	14	0.2	16	1	US-09-949-476A-5	Sequence 5, Appli
735	14	0.2	16	1	US-09-986-621-4	Sequence 4, Appli
736	14	0.2	16	1	US-09-986-625-4	Sequence 4, Appli
737	14	0.2	16	1	US-10-136-082-11	Sequence 11, Appl
738	14	0.2	16	1	US-10-257-819A-3	Sequence 3, Appli
739	14	0.2	16	1	US-10-261-821-11	Sequence 11, Appl
740	14	0.2	16	1	US-10-262-252-11	Sequence 11, Appl
c 741	14	0.2	16	1	US-10-780-464-1	Sequence 1, Appli
c 742	14	0.2	17	1	US-08-325-955-2	Sequence 2, Appli
c 743	14	0.2	17	1	US-08-849-021-16	Sequence 16, Appl
c 744	14	0.2	17	1	US-09-343-698-2	Sequence 2, Appli
745	14	0.2	17	1	US-09-818-875-4290	Sequence 4290, Ap
c 746	14	0.2	17	1	US-09-818-875-4291	Sequence 4291, Ap
747	14	0.2	17	1	US-09-866-108A-804	Sequence 804, App
748	14	0.2	17	1	US-09-866-108A-805	Sequence 805, App
749	14	0.2	17	1	US-09-866-108A-806	Sequence 806, App
750	14	0.2	17	1	US-09-866-108A-807	Sequence 807, App
751	14	0.2	17	1	US-10-156-306B-524	Sequence 524, App
752	14	0.2	30	1	US-08-222-177A-415	Sequence 415, App
753	14	0.2	32	1	US-08-222-177A-406	Sequence 406, App
754	13.8	0.2	17	1	PCT-US94-12947A-93	Sequence 93, Appl
c 755	13.8	0.2	17	1	US-08-050-073-82	Sequence 82, Appl
756	13.8	0.2	17	1	US-08-152-313-93	Sequence 93, Appl
757	13.8	0.2	17	1	US-08-373-124A-2147	Sequence 2147, Ap
c 758	13.8	0.2	17	1	US-08-373-124A-2321	Sequence 2321, Ap
c 759	13.8	0.2	17	1	US-08-373-124A-274	Sequence 274, App
760	13.8	0.2	17	1	US-08-373-124A-590	Sequence 590, App
761	13.8	0.2	17	1	US-08-373-124A-872	Sequence 872, App
762	13.8	0.2	17	1	US-08-435-628-2147	Sequence 2147, Ap
c 763	13.8	0.2	17	1	US-08-435-628-2321	Sequence 2321, Ap
c 764	13.8	0.2	17	1	US-08-435-628-274	Sequence 274, App
765	13.8	0.2	17	1	US-08-435-628-590	Sequence 590, App
766	13.8	0.2	17	1	US-08-435-628-872	Sequence 872, App
767	13.8	0.2	17	1	US-08-485-602-25	Sequence 25, Appl
768	13.8	0.2	17	1	US-08-579-223-93	Sequence 93, Appl
769	13.8	0.2	17	1	US-08-585-595-23	Sequence 23, Appl
770	13.8	0.2	17	1	US-08-745-638-25	Sequence 25, Appl
771	13.8	0.2	17	1	US-08-757-180-24	Sequence 24, Appl
c 772	13.8	0.2	17	1	US-08-758-306-171	Sequence 171, App
c 773	13.8	0.2	17	1	US-08-758-306-93	Sequence 93, Appl
c 774	13.8	0.2	17	1	US-08-758-306-95	Sequence 95, Appl
c 775	13.8	0.2	17	1	US-08-985-162-677	Sequence 677, App
776	13.8	0.2	17	1	US-09-050-159-64	Sequence 64, Appl
c 777	13.8	0.2	17	1	US-09-401-063-677	Sequence 677, App
778	13.8	0.2	17	1	US-09-404-912-262	Sequence 262, App
779	13.8	0.2	17	1	US-09-404-912-564	Sequence 564, App
780	13.8	0.2	17	1	US-09-404-912-608	Sequence 608, App
781	13.8	0.2	17	1	US-09-474-432B-558	Sequence 558, App
782	13.8	0.2	17	1	US-09-474-432B-740	Sequence 740, App
c 783	13.8	0.2	17	1	US-09-474-432B-893	Sequence 893, App
784	13.8	0.2	17	1	US-09-476-387-557	Sequence 557, App
785	13.8	0.2	17	1	US-09-476-387-739	Sequence 739, App
c 786	13.8	0.2	17	1	US-09-476-387-892	Sequence 892, App
c 787	13.8	0.2	17	1	US-09-479-645A-23	Sequence 23, Appl
788	13.8	0.2	17	1	US-09-818-875-811	Sequence 811, App
c 789	13.8	0.2	17	1	US-09-818-875-812	Sequence 812, App
790	13.8	0.2	17	1	US-09-827-998-384	Sequence 384, App
791	13.8	0.2	17	1	US-09-827-998-385	Sequence 385, App
792	13.8	0.2	17	1	US-09-827-998-386	Sequence 386, App
793	13.8	0.2	17	1	US-09-827-998-387	Sequence 387, App
c 794	13.8	0.2	17	1	US-09-827-998-482	Sequence 482, App
c 795	13.8	0.2	17	1	US-09-827-998-483	Sequence 483, App
c 796	13.8	0.2	17	1	US-09-866-108A-10743	Sequence 10743, A
c 797	13.8	0.2	17	1	US-09-866-108A-10744	Sequence 10744, A
798	13.8	0.2	17	1	US-09-866-108A-1344	Sequence 1344, Ap
c 799	13.8	0.2	17	1	US-09-866-108A-433	Sequence 433, App
c 800	13.8	0.2	17	1	US-09-866-108A-434	Sequence 434, App
801	13.8	0.2	17	1	US-09-866-108A-6286	Sequence 6286, Ap
c 802	13.8	0.2	17	1	US-09-866-108A-639	Sequence 639, App
803	13.8	0.2	17	1	US-09-866-108A-7298	Sequence 7298, Ap
804	13.8	0.2	17	1	US-09-866-108A-7545	Sequence 7545, Ap
c 805	13.8	0.2	17	1	US-09-866-108A-8809	Sequence 8809, Ap
c 806	13.8	0.2	17	1	US-10-106-831-36	Sequence 36, Appl
807	13.8	0.2	17	1	US-10-156-306B-1646	Sequence 1646, Ap
c 808	13.8	0.2	17	1	US-10-156-306B-4373	Sequence 4373, Ap
809	13.8	0.2	17	1	US-10-156-306B-519	Sequence 519, App

ALIGNMENTS

```
RESULT 1
US-08-222-177A-119/c
; Sequence 119, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  119:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd23rs
US-08-222-177A-119

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.3;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 2
US-08-222-177A-400/c
; Sequence 400, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  400:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-400

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.3;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 3
US-08-222-177A-403/c
; Sequence 403, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  403:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-403

  Query Match             0.5%;  Score 40;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 2.3;
  Matches   20;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 4
US-08-222-177A-137/c
; Sequence 137, Application US/08222177A
; Patent No. 5582979
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  137:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  39 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd29rs
US-08-222-177A-137

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   48.7%;  Pred. No. 2.9;
  Matches   19;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         39 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 5
US-08-222-177A-152/c
; Sequence 152, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  152:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd34rs
US-08-222-177A-152

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 3.8;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGT 1


RESULT 6
US-08-222-177A-175/c
; Sequence 175, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  175:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd42rs
US-08-222-177A-175

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 3.8;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 TGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 7
US-08-222-177A-198/c
; Sequence 198, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  198:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd50rs
US-08-222-177A-198

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 3.7;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 8
US-08-222-177A-397/c
; Sequence 397, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  397:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-397

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 3.7;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         38 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 9
US-08-222-177A-86/c
; Sequence 86, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/222,177A
;       FILING DATE:
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/341,562
;       FILING DATE:  21-APR-1989
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Sara, Charles S.
;       REGISTRATION NUMBER:  30,492
;       REFERENCE/DOCKET NUMBER:  09865.601
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (608) 831-2100
;       TELEFAX:  (608) 831-2106
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  86:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  39 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     IMMEDIATE SOURCE:
;       CLONE:  mfd12rs
US-08-222-177A-86

  Query Match             0.5%;  Score 37.4;  DB 1;  Length 39;
  Best Local Similarity   46.2%;  Pred. No. 4.8;
  Matches   18;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|: :|:|:|:|:|:|:|:|:|:|:
Db         39 TGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGT 1


RESULT 10
US-08-222-177A-140/c
; Sequence 140, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  140:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  37 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd30rs
US-08-222-177A-140

  Query Match             0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 4.7;
  Matches   18;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         37 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 11
US-09-762-867A-11/c
; Sequence 11, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-11

  Query Match             0.5%;  Score 36.8;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 6.2;
  Matches   19;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:| |:|
Db         40 TGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGTG 1


RESULT 12
US-08-222-177A-68/c
; Sequence 68, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  68:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd6rs
US-08-222-177A-68

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   47.4%;  Pred. No. 6.1;
  Matches   18;  Conservative   19;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTTTGTGTGTGTG 1


RESULT 13
US-08-643-839-18
; Sequence 18, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-643-839-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 6.1;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:|||||||||||: :|||||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 14
US-08-874-678-18
; Sequence 18, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-874-678-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
```

```
  Best Local Similarity   78.9%;  Pred. No. 6.1;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 15
US-09-348-886-18
; Sequence 18, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-09-348-886-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 6.1;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 16
US-10-105-901A-18
; Sequence 18, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;    APPLICANT: Davis-Smyth, Terri L.
;               Chen, Helen H.
;               Presta, Leonard
;               Ferrara, Napoleone
;    TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                        GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                        PRODUCTION
;    NUMBER OF SEQUENCES: 52
;    CORRESPONDENCE ADDRESS:
;         ADDRESSEE: Dorsey & Whitney LLP
;         STREET: Four Embarcadero Center, Suite 3400
;         CITY: San Francisco
;         STATE: California
;         COUNTRY: United States
;         ZIP: 94111-4187
;    COMPUTER READABLE FORM:
;         MEDIUM TYPE: Floppy disk
;         COMPUTER: IBM PC compatible
;         OPERATING SYSTEM: PC-DOS/MS-DOS
;         SOFTWARE: PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;         APPLICATION NUMBER: US/10/105,901A
;         FILING DATE: 20-Mar-2002
;         CLASSIFICATION: <Unknown>
;    PRIOR APPLICATION DATA:
;         APPLICATION NUMBER: 09/348,886
;         FILING DATE: 01-JUL-1999
;         APPLICATION NUMBER: US 08/643,839
;         FILING DATE: 07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;         NAME: Richard F. Trecartin
;         REGISTRATION NUMBER: 31,801
;         REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;    TELECOMMUNICATION INFORMATION:
;         TELEPHONE: (415) 781-1989
;         TELEFAX: (415) 398-3249
;         TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 18:
;    SEQUENCE CHARACTERISTICS:
;         LENGTH: 38 base pairs
;         TYPE: nucleic acid
;         STRANDEDNESS: unknown
;         TOPOLOGY: unknown
;    MOLECULE TYPE: DNA
;    FEATURE:
;         NAME/KEY:  CDS
;         LOCATION:  1..36
;    SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-105-901A-18

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 6.1;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 17
US-08-222-177A-104/c
; Sequence 104, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
```

```
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  104:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd18rs
US-08-222-177A-104

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 6;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 18
US-08-222-177A-358/c
; Sequence 358, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  358:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd113rs
US-08-222-177A-358

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 6;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 19
US-08-222-177A-189/c
; Sequence 189, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  189:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  35 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd47rs
US-08-222-177A-189
```

```
  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 7.5;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         35 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 20
US-08-222-177A-77/c
; Sequence 77, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  77:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  35 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd9rs
US-08-222-177A-77

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 7.5;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         35 CTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 21
US-08-222-177A-110/c
; Sequence 110, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  110:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd20rs
US-08-222-177A-110

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 9.4;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 22
US-08-222-177A-172/c
; Sequence 172, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  172:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd41rs
US-08-222-177A-172

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 9.4;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 23
US-08-222-177A-180/c
; Sequence 180, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  180:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd44rs
US-08-222-177A-180

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 9.4;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 24
US-08-222-177A-192/c
; Sequence 192, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  192:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd48rs
US-08-222-177A-192

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 9.4;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 25
US-08-222-177A-322/c
; Sequence 322, Application US/08222177A
```

```
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  322:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd101rs
US-08-222-177A-322

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 9.4;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 26
US-08-643-839-6
; Sequence 6, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-643-839-6

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 13;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 27
US-08-874-678-6
; Sequence 6, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-874-678-6

  Query Match              0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 13;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 28
US-09-348-886-6
; Sequence 6, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-09-348-886-6

  Query Match              0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 13;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 29
US-10-105-901A-6
; Sequence 6, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 6:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 36 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..36
;       SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-105-901A-6

  Query Match              0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 13;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
```

```
                  |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 30
US-08-222-177A-218/c
; Sequence 218, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  218:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd58rs
US-08-222-177A-218

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 12;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 31
US-08-222-177A-59/c
; Sequence 59, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  59:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd3rs
US-08-222-177A-59

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 12;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 32
US-08-222-177A-210/c
; Sequence 210, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
```

```
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  210:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  32 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd55rs
US-08-222-177A-210

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 15;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 33
US-08-222-177A-376/c
; Sequence 376, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  376:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  32 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd119rs
US-08-222-177A-376

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 15;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 34
US-08-956-518A-10/c
; Sequence 10, Application US/08956518A
; Patent No. 6875606
;  GENERAL INFORMATION:
;    APPLICANT:  Leonard, Sherry
;    APPLICANT:  Freedman, Robert
;    TITLE OF INVENTION:  ALPHA-7 NICOTINIC RECEPTOR
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/956,518A
;      FILING DATE:  23-OCT-1997
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MacKnight, Kamrin T.
;      REGISTRATION NUMBER:  38,230
;      REFERENCE/DOCKET NUMBER:  UTC-03042
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-705-8410
;      TELEFAX:  415-397-8338
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  32 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-956-518A-10

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 15;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 35
US-09-762-867A-5/c
; Sequence 5, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
```

```
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 32
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-5

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 15;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 36
US-08-643-839-22
; Sequence 22, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-08-643-839-22

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 19;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
                :::::|:|:||||||: :|||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 37
US-08-643-839-30
; Sequence 30, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-08-643-839-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 19;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 38
US-08-874-678-22
; Sequence 22, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
```

```
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-08-874-678-22

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 19;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 39
US-08-874-678-30
; Sequence 30, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-08-874-678-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 19;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 40
US-09-348-886-22
; Sequence 22, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  22:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  33 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..33
US-09-348-886-22

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 19;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 41
US-09-348-886-30
; Sequence 30, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  33 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..33
US-09-348-886-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 19;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 42
US-10-105-901A-22
; Sequence 22, Application US/10105901A
; Patent No. 6897294
;   GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 22:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 33 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..33
;       SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-105-901A-22

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 19;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :||||||:|||:::||:
```

```
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 43
US-10-105-901A-30
; Sequence 30, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 30:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 33 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..33
;       SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-10-105-901A-30

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 19;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 44
US-08-222-177A-215/c
; Sequence 215, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  215:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd57rs
US-08-222-177A-215

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 18;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 45
US-08-222-177A-235/c
; Sequence 235, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
```

```
;       FILING DATE:
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/341,562
;       FILING DATE:  21-APR-1989
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Sara, Charles S.
;       REGISTRATION NUMBER:  30,492
;       REFERENCE/DOCKET NUMBER:  09865.601
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (608) 831-2100
;       TELEFAX:  (608) 831-2106
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  235:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  31 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     IMMEDIATE SOURCE:
;       CLONE:  mfd64rs
US-08-222-177A-235

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 18;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 46
US-08-222-177A-271/c
; Sequence 271, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  271:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd79rs
US-08-222-177A-271

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 18;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 47
US-08-643-839-14
; Sequence 14, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  37 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-643-839-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 33;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::|||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37
```

```
RESULT 48
US-08-874-678-14
; Sequence 14, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  37 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-08-874-678-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 33;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|   |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 49
US-09-348-886-14
; Sequence 14, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  37 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..36
US-09-348-886-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 33;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|   |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 50
US-10-105-901A-14
; Sequence 14, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;          CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;          PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;          ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;          TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;     INFORMATION FOR SEQ ID NO: 14:
;          SEQUENCE CHARACTERISTICS:
;            LENGTH: 37 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;          MOLECULE TYPE: DNA
;          FEATURE:
;            NAME/KEY: CDS
;            LOCATION: 1..36
;          SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-10-105-901A-14

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 33;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 51
US-08-222-177A-406/c
; Sequence 406, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  406:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  32 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-406

  Query Match             0.4%;  Score 30.4;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 24;
  Matches   16;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:| |:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGAGTGTGTGTGTGTGTGTGTGTG 1


RESULT 52
US-08-222-177A-373/c
; Sequence 373, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  373:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd118rs
US-08-222-177A-373

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 23;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
```

```
                  |:|:|:|
```

```
;       TELEPHONE:  415-843-5000
;       TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  29 nucleotides
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-627-25

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 28;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 56
US-08-689-856-25/c
; Sequence 25, Application US/08689856
; Patent No. 5830658
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,856
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-689-856-25

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 28;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 57
US-08-859-998-410/c
; Sequence 410, Application US/08859998
; Patent No. 5994076
;  GENERAL INFORMATION:
;    APPLICANT:  Chenchik, Alex
;    APPLICANT:  Jokhadze, George
;    APPLICANT:  Bibilashvilli, Robert
;    TITLE OF INVENTION:  METHOD OF ASSAYING DIFFERENTIAL
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  1375
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson, P.C.
;      STREET:  2200 Sand Hill Road, Suite 100
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/859,998
;      FILING DATE:  21-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Field, Bret E.
;      REGISTRATION NUMBER:  37,620
;      REFERENCE/DOCKET NUMBER:  09096/002001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-322-5070
;      TELEFAX:  415-854-0875
;  INFORMATION FOR SEQ ID NO:  410:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      OTHER INFORMATION:  oligonucleotide primer
US-08-859-998-410

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 28;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 58
US-09-225-201B-410/c
; Sequence 410, Application US/09225201B
; Patent No. 6489455
;   GENERAL INFORMATION:
;        APPLICANT: Chenchik, Alex
;                   Jokhadze, George
;                   Bibilashvilli, Robert
;        TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                            EXPRESSION
;        NUMBER OF SEQUENCES: 1375
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fish & Richardson, P.C.
;             STREET: 2200 Sand Hill Road, Suite 100
;             CITY: Menlo Park
;             STATE: CA
```

```
;             COUNTRY: US
;             ZIP: 94025
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: Windows95
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/225,201B
;             FILING DATE: 05-Jan-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/859,998
;             FILING DATE: 21-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Field, Bret E.
;             REGISTRATION NUMBER: 37,620
;             REFERENCE/DOCKET NUMBER: 09096/002001
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-322-5070
;             TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 410:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 29 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             OTHER INFORMATION:  oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 410:
US-09-225-201B-410

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 28;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 59
US-09-225-928-410/c
; Sequence 410, Application US/09225928
; Patent No. 6352829
;  GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,928
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 410:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 29 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 410:
US-09-225-928-410

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 28;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 60
US-08-222-177A-451/c
; Sequence 451, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  451:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  28 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-451

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
```

```
  Best Local Similarity   50.0%;  Pred. No. 35;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         28 GTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 61
US-08-643-839-8
; Sequence 8, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..34
US-08-643-839-8

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 64;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||   || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 62
US-08-676-279-33
; Sequence 33, Application US/08676279
; Patent No. 5869247
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  MACROPHAGE NUCLEOTIDE SEQUENCE
;    NUMBER OF SEQUENCES:  63
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/676,279
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/GB95/00095
;      APPLICATION NUMBER:  GB 9400929.7
;      FILING DATE:  19-JAN-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  GB 9422021.7
;      FILING DATE:  31-OCT-1994
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-676-279-33

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   44.1%;  Pred. No. 64;
  Matches   15;  Conservative   15;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:  |:|:|:|:|:  |:|:|:|:|
Db          1 TGTGTGTGTGTACGTGTGTGTACGTGTGTGTG 34


RESULT 63
US-08-874-678-8
; Sequence 8, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  8:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..34
US-08-874-678-8

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 64;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||    || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 64
US-09-348-886-8
; Sequence 8, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..34
US-09-348-886-8

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 64;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||    || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 65
US-10-105-901A-8
; Sequence 8, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 8:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 34 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  2..34
;       SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-105-901A-8

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 64;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||    || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 66
```

```
US-09-762-867A-20/c
; Sequence 20, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 30
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-20

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 30;
  Best Local Similarity   44.8%;  Pred. No. 50;
  Matches   13;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|: :|:
Db         30 TGTGTGTGTGTGTGTGTGTGTGTATGT 2


RESULT 67
US-08-222-177A-143/c
; Sequence 143, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  143:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd31rs
US-08-222-177A-143

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 43;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         27 TGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 68
US-08-455-627-23/c
; Sequence 23, Application US/08455627
; Patent No. 5571677
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-627-23

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 43;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 69
US-08-689-856-23/c
; Sequence 23, Application US/08689856
; Patent No. 5830658
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,856
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-689-856-23

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 43;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
             |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 70
US-08-787-321-23/c
; Sequence 23, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-23

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 43;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
             |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 71
US-08-859-998-409
; Sequence 409, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
;    APPLICANT:  Chenchik, Alex
;    APPLICANT:  Jokhadze, George
;    APPLICANT:  Bibilashvilli, Robert
;    TITLE OF INVENTION:  METHOD OF ASSAYING DIFFERENTIAL
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  1375
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson, P.C.
;      STREET:  2200 Sand Hill Road, Suite 100
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/859,998
;      FILING DATE:  21-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Field, Bret E.
;      REGISTRATION NUMBER:  37,620
;      REFERENCE/DOCKET NUMBER:  09096/002001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-322-5070
;      TELEFAX:  415-854-0875
;  INFORMATION FOR SEQ ID NO:  409:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      OTHER INFORMATION:  oligonucleotide primer
US-08-859-998-409

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 43;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
             |:|||:|||||||||:|::|||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 72
US-09-225-201B-409
; Sequence 409, Application US/09225201B
; Patent No. 6489455
;   GENERAL INFORMATION:
;        APPLICANT: Chenchik, Alex
;                   Jokhadze, George
;                   Bibilashvilli, Robert
;        TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                            EXPRESSION
;        NUMBER OF SEQUENCES: 1375
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fish & Richardson, P.C.
```

```
;             STREET: 2200 Sand Hill Road, Suite 100
;             CITY: Menlo Park
;             STATE: CA
;             COUNTRY: US
;             ZIP: 94025
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: Windows95
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/225,201B
;             FILING DATE: 05-Jan-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/859,998
;             FILING DATE: 21-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Field, Bret E.
;             REGISTRATION NUMBER: 37,620
;             REFERENCE/DOCKET NUMBER: 09096/002001
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-322-5070
;             TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 409:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 27 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             OTHER INFORMATION: oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 409:
US-09-225-201B-409

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 43;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
             |:|||:|||||||||:|::||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 73
US-09-225-928-409
; Sequence 409, Application US/09225928
; Patent No. 6352829
;  GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,928
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 409:
;        SEQUENCE CHARACTERISTICS:
;            LENGTH: 27 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;            OTHER INFORMATION: oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 409:
US-09-225-928-409

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 43;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
             |:|||:|||||||||:|::||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 74
US-08-222-177A-415/c
; Sequence 415, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  415:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
```

```
US-08-222-177A-415

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   43.3%;  Pred. No. 59;
  Matches   13;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|:|: :|: :|:|:|:|:|
Db         30 TGTGTGTGTGTGTGTCTGTCTGTGTGTGTG 1


RESULT 75
US-08-643-839-26
; Sequence 26, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..30
US-08-643-839-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 59;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 76
US-08-874-678-26
; Sequence 26, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..30
US-08-874-678-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 59;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 77
US-09-348-886-26
; Sequence 26, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
```

```
;       STATE:  California
;       COUNTRY:  United States
;       ZIP:  94111-4187
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/348,886
;       FILING DATE:  01-JUL-1999
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/643,839
;       FILING DATE:  07-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Dolly A. Vance
;       REGISTRATION NUMBER:  39,054
;       REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  26:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  30 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..30
US-09-348-886-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 59;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :|||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 78
US-10-105-901A-26
; Sequence 26, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;  INFORMATION FOR SEQ ID NO: 26:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 30 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..30
;       SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-10-105-901A-26

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 59;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :|||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 79
US-08-643-839-20
; Sequence 20, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  20:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..31
US-08-643-839-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 77;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 80
US-08-874-678-20
; Sequence 20, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..31
US-08-874-678-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 77;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 81
US-09-348-886-20
; Sequence 20, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  31 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..31
US-09-348-886-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 77;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 82
US-10-105-901A-20
; Sequence 20, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
```

```
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 20:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 31 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  2..31
;       SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-105-901A-20

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 77;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:||||| |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 83
US-09-762-867A-27/c
; Sequence 27, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 32
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-27

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 32;
  Best Local Similarity   58.1%;  Pred. No. 84;
  Matches   18;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6994 GUGUGUGUGUGUGUGUGUGGGGUGUGGGUG 7024
              | |:|:|:|:|:|:|:|:|:|:|||  | |||:|
Db         31 GGGTGTGTGTGTGTGTGTGGGGGGGGGTG 1


RESULT 84
US-09-953-318-5/c
; Sequence 5, Application US/09953318
; Patent No. 6710174
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTC
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0232
;  CURRENT APPLICATION NUMBER: US/09/953,318
;  CURRENT FILING DATE:  2001-09-13
;  NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 5
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-09-953-318-5

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   57.7%;  Pred. No. 52;
  Matches   15;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1399 UUGACUCGUGGCUACUCGUUAAUUAU 1424
              ::|||:||:|||:||:||::||::|:
Db         26 TTGACTCGTGGCTACTCGTTAATTAT 1


RESULT 85
US-08-222-177A-146/c
; Sequence 146, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  146:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd32rs
US-08-222-177A-146

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 64;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         25 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 86
US-08-643-839-36/c
; Sequence 36, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-643-839-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 87
US-08-643-839-37
; Sequence 37, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-643-839-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 64;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::|||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 88
US-08-874-678-36/c
; Sequence 36, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-874-678-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
             |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 89
US-08-874-678-37
; Sequence 37, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-874-678-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 64;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 90
US-09-348-886-36/c
; Sequence 36, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
```

```
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  36:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  25 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
US-09-348-886-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              ||||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 91
US-09-348-886-37
; Sequence 37, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;     APPLICANT:  Davis-Smyth, Terri L.
;     APPLICANT:  Chen, Helen H.
;     APPLICANT:  Presta, Leonard
;     APPLICANT:  Ferrara, Napoleone
;     TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;     TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;     TITLE OF INVENTION:  PRODUCTION
;     NUMBER OF SEQUENCES:  48
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;       STREET:  Four Embarcadero Center, Suite 3400
;       CITY:  San Francisco
;       STATE:  California
;       COUNTRY:  United States
;       ZIP:  94111-4187
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/348,886
;       FILING DATE:  01-JUL-1999
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/643,839
;       FILING DATE:  07-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Dolly A. Vance
;       REGISTRATION NUMBER:  39,054
;       REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  37:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  25 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA
US-09-348-886-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 64;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 92
US-09-396-196G-43420
; Sequence 43420, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43420
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43420

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4020 CUUCACCUGGACUGACAGCAAACCC 4044
              |::||||:||||:||||||||||||
Db          1 CTTCACCTGGACTGACAGCAAACCC 25


RESULT 93
US-09-396-196G-43421
; Sequence 43421, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43421
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43421

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 64;
  Matches   23;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4029 GACUGACAGCAAACCCAAGGCCUCG 4053
              |||:||||||||||||||||||:||
Db          1 GACTGACAGCAAACCCAAGGCCTCG 25


RESULT 94
US-09-396-196G-43422
; Sequence 43422, Application US/09396196G
```

; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43422
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43422

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 64;
Matches 17; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 4119 CAGUUUCUGCCAUUCCAGCUGUGGG 4143
||||:::|:||||::|||||:|:|||
Db 1 CAGTTTCTGCCATTCCAGCTGTGGG 25

RESULT 95
US-09-396-196G-43423
; Sequence 43423, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43423
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43423

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 64;
Matches 17; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 4122 UUUCUGCCAUUCCAGCUGUGGGCAC 4146
:::|:||||::|||||:|:||||||
Db 1 TTTCTGCCATTCCAGCTGTGGGCAC 25

RESULT 96
US-09-396-196G-43424
; Sequence 43424, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43424
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43424

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 64;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 4125 CUGCCAUUCCAGCUGUGGGCACGUC 4149
|:||||::|||||:|:|||||||:|
Db 1 CTGCCATTCCAGCTGTGGGCACGTC 25

RESULT 97
US-09-396-196G-43425
; Sequence 43425, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43425
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43425

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 64;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 4128 CCAUUCCAGCUGUGGGCACGUCAGC 4152
|||::|||||:|:|||||||:||||
Db 1 CCATTCCAGCTGTGGGCACGTCAGC 25

RESULT 98
US-09-396-196G-43426
; Sequence 43426, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43426
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus

US-09-396-196G-43426

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 64;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4137 CUGUGGGCACGUCAGCGAAGGCAAG 4161
              |:|:|||||||:|||||||||||||
Db          1 CTGTGGGCACGTCAGCGAAGGCAAG 25
```

RESULT 99
US-09-396-196G-43427
; Sequence 43427, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43427
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43427

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 64;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4158 CAAGCGCAGGUUCACCUACGACCAC 4182
              ||||||||||::||||:||||||||
Db          1 CAAGCGCAGGTTCACCTACGACCAC 25
```

RESULT 100
US-09-396-196G-43428
; Sequence 43428, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43428
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43428

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 64;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4164 CAGGUUCACCUACGACCACGCUGAG 4188
              ||||::||||:||||||||||:|||
Db          1 CAGGTTCACCTACGACCACGCTGAG 25
```

RESULT 101
US-09-396-196G-43429
; Sequence 43429, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43429
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43429

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 64;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4167 GUUCACCUACGACCACGCUGAGCUG 4191
              |::||||:||||||||||:||||:|
Db          1 GTTCACCTACGACCACGCTGAGCTG 25
```

RESULT 102
US-09-396-196G-43430
; Sequence 43430, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43430
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-43430

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 64;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4170 CACCUACGACCACGCUGAGCUGGAA 4194
              ||||:||||||||||:||||:||||
Db          1 CACCTACGACCACGCTGAGCTGGAA 25
```

RESULT 103
US-09-396-196G-43431
; Sequence 43431, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack

```
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43431
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43431

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 64;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4179 CCACGCUGAGCUGGAAAGGAAAAUC 4203
              |||||:||||:||||||||||||:|
Db          1 CCACGCTGAGCTGGAAAGGAAAATC 25


RESULT 104
US-09-396-196G-43432
; Sequence 43432, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43432
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43432

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 64;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4032 UGACAGCAAACCCAAGGCCUCGCUC 4056
              :||||||||||||||||||:|||:|
Db          1 TGACAGCAAACCCAAGGCCTCGCTC 25


RESULT 105
US-09-396-196G-43433
; Sequence 43433, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43433
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43433

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4038 CAAACCCAAGGCCUCGCUCAAGAUU 4062
              |||||||||||||:|||:|||||::
Db          1 CAAACCCAAGGCCTCGCTCAAGATT 25


RESULT 106
US-09-396-196G-43434
; Sequence 43434, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43434
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43434

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4041 ACCCAAGGCCUCGCUCAAGAUUGAC 4065
              ||||||||||:|||:|||||::|||
Db          1 ACCCAAGGCCTCGCTCAAGATTGAC 25


RESULT 107
US-09-396-196G-43435
; Sequence 43435, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43435
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43435

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 64;
```

```
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4047 GGCCUCGCUCAAGAUUGACUUGAGA 4071
              ||||:|||:|||||::|||::||||
Db          1 GGCCTCGCTCAAGATTGACTTGAGA 25


RESULT 108
US-09-396-196G-43436
; Sequence 43436, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43436
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43436

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 64;
  Matches   18;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4086 UAAGGAGUCGGGGCUGUCUGAUGUC 4110
              :||||||:||||||:|:|:||:|:|
Db          1 TAAGGAGTCGGGGCTGTCTGATGTC 25


RESULT 109
US-09-396-196G-43437
; Sequence 43437, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43437
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43437

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 64;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4110 CAGCAGGCCCAGUUUCUGCCAUUCC 4134
              |||||||||||||:::|:||||::||
Db          1 CAGCAGGCCCAGTTTCTGCCATTCC 25


RESULT 110
US-09-396-196G-43438
; Sequence 43438, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43438
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43438

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 64;
  Matches   19;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4113 CAGGCCCAGUUUCUGCCAUUCCAGC 4137
              |||||||||:::|:||||::|||||
Db          1 CAGGCCCAGTTTCTGCCATTCCAGC 25


RESULT 111
US-09-396-196G-43439
; Sequence 43439, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/09/396,196G
;  CURRENT FILING DATE:  1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43439
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-09-396-196G-43439

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   68.0%;  Pred. No. 64;
  Matches   17;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4116 GCCCAGUUUCUGCCAUUCCAGCUGU 4140
              ||||||:::|:||||::|||||:|:
Db          1 GCCCAGTTTCTGCCATTCCAGCTGT 25


RESULT 112
US-10-105-901A-36/c
; Sequence 36, Application US/10105901A
; Patent No. 6897294
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
```

```
;                          PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 36:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 25 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-10-105-901A-36

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 64;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 113
US-10-105-901A-37
; Sequence 37, Application US/10105901A
; Patent No. 6897294
;   GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 781-1989
;            TELEFAX: (415) 398-3249
;            TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 37:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 25 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: unknown
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-10-105-901A-37

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 64;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 114
US-08-222-177A-445/c
; Sequence 445, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
```

```
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  445:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-445

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 77;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTG 1


RESULT 115
US-08-222-177A-454/c
; Sequence 454, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  454:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-454

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 93;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 116
US-08-232-538-10
; Sequence 10, Application US/08232538
; Patent No. 5712380
;  GENERAL INFORMATION:
;    APPLICANT:  Thomas, Kenneth A.
;    APPLICANT:  Kendall, Richard L.
;    TITLE OF INVENTION:  INHIBITOR OF VASCULAR ENDOTHELIAL CELL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O. Box 2000 126 E Lincoln Avenue
;      CITY:  Rahway
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/232,538
;      FILING DATE:
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wallen, John W.III
;      REGISTRATION NUMBER:  35,403
;      REFERENCE/DOCKET NUMBER:  18888IA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908) 594-3905
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-232-538-10

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 93;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              |||||:::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 117
US-08-786-164-10
; Sequence 10, Application US/08786164
; Patent No. 5861484
;  GENERAL INFORMATION:
;    APPLICANT:  THOMAS, KENNETH A.
;    APPLICANT:  KENDALL, RICHARD L
;    TITLE OF INVENTION:  INHIBITOR OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  CELL GROWTH FACTOR
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O. Box 2000, 126 E. Lincoln Ave.
;      CITY:  Rahway
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07065-0900
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  Microsoft Word 6.0
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/786,164
;      FILING DATE:  21-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mark Hand, J
;      REGISTRATION NUMBER:  36,545
;      REFERENCE/DOCKET NUMBER:  18888DA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-594-3905
;      TELEFAX:  908-594-4720
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Genomic DNA
US-08-786-164-10

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 93;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 118
US-08-787-321-22/c
; Sequence 22, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-22

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 93;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|
Db         23 GTGTGTGTGTGTGTGTGTGTG 1


RESULT 119
US-08-267-803B-36/c
; Sequence 36, Application US/08267803B
; Patent No. 5834183
;  GENERAL INFORMATION:
;    APPLICANT:  Orr, Harry T.
;    APPLICANT:  Ranum, Laura P.W.
;    APPLICANT:  Chung, Ming-yi
;    APPLICANT:  Zoghbi, Huda Y.
;    TITLE OF INVENTION:  Gene Sequence for Spinocerebellar Ataxia
; Patent No. 5834183
;    TITLE OF INVENTION:  Type 1 and Method for Diagnosis
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Mueting, Raasch, Gebhardt & Schwappach, P.A.
;      STREET:  P.O. Box 581415
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55458-1415
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/267,803B
;      FILING DATE:  28-JUN-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McCormack, Myra H.
;      REGISTRATION NUMBER:  36,602
;      REFERENCE/DOCKET NUMBER:  110.00030120
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-305-1217
;      TELEFAX:  612-305-1228
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-267-803B-36

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 1.7e+02;
  Matches   14;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6996 GUGUGUGUGUGUGUGUGUGGGUGUGGG 7022
              |:|:|:|:|:|:|:|:|:|| :  |||
Db         27 GTGTGTGTGTGTGTGTGTGGATCCGGG 1


RESULT 120
US-08-469-802B-18/c
; Sequence 18, Application US/08469802B
; Patent No. 5741645
;  GENERAL INFORMATION:
;    APPLICANT:  Orr, Harry T.
;    APPLICANT:  Ranum, Laura P.W.
;    APPLICANT:  Chung, Ming-yi
;    APPLICANT:  Zoghbi, Huda Y.
;    TITLE OF INVENTION:  Gene Sequence for Spinocerebellar Ataxia
; Patent No. 5741645
;    TITLE OF INVENTION:  Type 1 and Method for Diagnosis
;    NUMBER OF SEQUENCES:  47
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Mueting, Raasch, Gebhardt & Schwappach, P.A.
;      STREET:  119 No. 5741645th Fourth Street, Suite 203
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55401
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/469,802B
```

```
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mueting, Ann M.
;      REGISTRATION NUMBER:  33,977
;      REFERENCE/DOCKET NUMBER:  110.00030101
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-305-1217
;      TELEFAX:  612-305-1225
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-469-802B-18

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 1.7e+02;
  Matches   14;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6996 GUGUGUGUGUGUGUGUGUGGGUGUGGG 7022
              |:|:|:|:|:|:|:|:|:|| :  |||
Db         27 GTGTGTGTGTGTGTGTGTGGATCCGGG 1


RESULT 121
US-08-643-839-16
; Sequence 16, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..27
US-08-643-839-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::|||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 122
US-08-874-678-16
; Sequence 16, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,678
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..27
US-08-874-678-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::|||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 123
```

```
US-09-348-886-16
; Sequence 16, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..27
US-09-348-886-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 124
US-10-105-901A-16
; Sequence 16, Application US/10105901A
; Patent No. 6897294
;   GENERAL INFORMATION:
;        APPLICANT: Davis-Smyth, Terri L.
;                   Chen, Helen H.
;                   Presta, Leonard
;                   Ferrara, Napoleone
;        TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                            GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                            PRODUCTION
;        NUMBER OF SEQUENCES: 52
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Dorsey & Whitney LLP
;             STREET: Four Embarcadero Center, Suite 3400
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States
;             ZIP: 94111-4187
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/105,901A
;             FILING DATE: 20-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/348,886
;             FILING DATE: 01-JUL-1999
;             APPLICATION NUMBER: US 08/643,839
;             FILING DATE: 07-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Richard F. Trecartin
;             REGISTRATION NUMBER: 31,801
;             REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 16:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 27 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..27
;        SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-105-901A-16

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 125
US-08-222-177A-125/c
; Sequence 125, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  125:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd25rs
US-08-222-177A-125

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 1.1e+02;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6995
              |:|:|:|:|:|:|:|:|:|:
Db         22 GTGTGTGTGTGTGTGTGTGT 1


RESULT 126
US-09-322-352A-3
; Sequence 3, Application US/09322352A
; Patent No. 6586192
; GENERAL INFORMATION:
;  APPLICANT: PESCHLE, Cesare
;  APPLICANT:  ZIEGLER, Benedikt L
;  TITLE OF INVENTION: Compositions and Methods for Use in Affecting Hematopoietic Stem
;  TITLE OF INVENTION:  Populations in Mammals
;  FILE REFERENCE: 9855-26U1
;  CURRENT APPLICATION NUMBER: US/09/322,352A
;  CURRENT FILING DATE:  1999-05-28
;  PRIOR APPLICATION NUMBER: US 60/087,153
;  PRIOR FILING DATE: 1998-05-28
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFRI/Flt1 Primer
US-09-322-352A-3

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   86.4%;  Pred. No. 1.1e+02;
  Matches   19;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3109 AAACCAAGACUAGAUAGCGUCA 3130
              |||||||||:|||:||||:||
Db          1 AAACCAAGACTAGATAGCGTCA 22


RESULT 127
US-09-322-352A-4/c
; Sequence 4, Application US/09322352A
; Patent No. 6586192
; GENERAL INFORMATION:
;  APPLICANT: PESCHLE, Cesare
;  APPLICANT:  ZIEGLER, Benedikt L
;  TITLE OF INVENTION: Compositions and Methods for Use in Affecting Hematopoietic Stem
;  TITLE OF INVENTION:  Populations in Mammals
;  FILE REFERENCE: 9855-26U1
;  CURRENT APPLICATION NUMBER: US/09/322,352A
;  CURRENT FILING DATE:  1999-05-28
;  PRIOR APPLICATION NUMBER: US 60/087,153
;  PRIOR FILING DATE: 1998-05-28
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFRI/Flt1 Primer
US-09-322-352A-4

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 1.1e+02;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 AAGAACCCCGAUUAUGUGAGAA 3415
              ||||||||||::|:|:|||||
Db         22 AAGAACCCCGATTATGTGAGAA 1


RESULT 128
US-09-866-316B-1/c
; Sequence 1, Application US/09866316B
; Patent No. 6673611
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with No. 6673611el Chemical Compositions C
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/09/866,316B
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(7)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(22)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(3)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;   NAME/KEY: misc_feature
;   LOCATION: (8)..(16)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (20)..(22)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-09-866-316B-1

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   77.3%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         22 TTCATGAGCCTGGAAAGAATCA 1


RESULT 129
US-09-866-316B-3/c
; Sequence 3, Application US/09866316B
; Patent No. 6673611
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Haeberli, Pete
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Bellon, Lauren
;  APPLICANT:  Reynolds, Mark
;  APPLICANT:  Zwick, Michael
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Woolf, Todd
;  APPLICANT:  Matulic-Adamic, Jasenka
;  TITLE OF INVENTION: Nucleic Acid Molecules with No. 6673611el Chemical Compositions C
;  TITLE OF INVENTION:  Modulating Gene Expression
;  FILE REFERENCE: MBHB00,873-H 500/004
;  CURRENT APPLICATION NUMBER: US/09/866,316B
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: US 09/103,656
;  PRIOR FILING DATE: 1998-06-23
;  PRIOR APPLICATION NUMBER: US 60/082,404
;  PRIOR FILING DATE: 1998-04-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Active GeneBloc Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
;   NAME/KEY: misc_feature
;   LOCATION: (25)..(25)
;   OTHER INFORMATION: 3'-3' inverted abasic moiety
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(8)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(24)
;   OTHER INFORMATION: 2'-O-Methyl
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(17)
;   OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-09-866-316B-3

  Query Match             0.3%;  Score 22;  DB 1;  Length 25;
  Best Local Similarity   77.3%;  Pred. No. 1.5e+02;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         23 TTCATGAGCCTGGAAAGAATCA 2


RESULT 130
US-08-643-839-4
; Sequence 4, Application US/08643839
; Patent No. 6100071
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/643,839
;      FILING DATE:  07-MAY-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Walter H.
;      REGISTRATION NUMBER:  24,190
;      REFERENCE/DOCKET NUMBER:  A-63291/WHD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..25
US-08-643-839-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 131
US-08-874-678-4
; Sequence 4, Application US/08874678
; Patent No. 5952199
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
;    TITLE OF INVENTION:  ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton & Herbert
```

```
;       STREET:  Four Embarcadero Center, Suite 3400
;       CITY:  San Francisco
;       STATE:  California
;       COUNTRY:  United States
;       ZIP:  94111-4187
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/874,678
;       FILING DATE:  HEREWITH
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/643,839
;       FILING DATE:  07-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Dreger, Walter H.
;       REGISTRATION NUMBER:  24,190
;       REFERENCE/DOCKET NUMBER:  A-63291-1/WHD
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  25 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA (genomic)
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  2..25
US-08-874-678-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 132
US-09-348-886-4
; Sequence 4, Application US/09348886
; Patent No. 6383486
;  GENERAL INFORMATION:
;    APPLICANT:  Davis-Smyth, Terri L.
;    APPLICANT:  Chen, Helen H.
;    APPLICANT:  Presta, Leonard
;    APPLICANT:  Ferrara, Napoleone
;    TITLE OF INVENTION:  NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;    TITLE OF INVENTION:  PRODUCTION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/348,886
;      FILING DATE:  01-JUL-1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/643,839
;      FILING DATE:  07-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dolly A. Vance
;      REGISTRATION NUMBER:  39,054
;      REFERENCE/DOCKET NUMBER:  A-63291-2/RMS/DAV
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  2..25
US-09-348-886-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 133
US-10-105-901A-4
; Sequence 4, Application US/10105901A
; Patent No. 6897294
;  GENERAL INFORMATION:
;       APPLICANT: Davis-Smyth, Terri L.
;                  Chen, Helen H.
;                  Presta, Leonard
;                  Ferrara, Napoleone
;       TITLE OF INVENTION: NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL
;                           GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR
;                           PRODUCTION
;       NUMBER OF SEQUENCES: 52
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Dorsey & Whitney LLP
;            STREET: Four Embarcadero Center, Suite 3400
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States
;            ZIP: 94111-4187
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/105,901A
;            FILING DATE: 20-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/348,886
;            FILING DATE: 01-JUL-1999
;            APPLICATION NUMBER: US 08/643,839
;            FILING DATE: 07-MAY-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Richard F. Trecartin
;            REGISTRATION NUMBER: 31,801
;            REFERENCE/DOCKET NUMBER: A-63291-3/RFT/NBC
;       TELECOMMUNICATION INFORMATION:
```

```
;             TELEPHONE: (415) 781-1989
;             TELEFAX: (415) 398-3249
;             TELEX: 910 277299
;   INFORMATION FOR SEQ ID NO: 4:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 25 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: unknown
;             TOPOLOGY: unknown
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  2..25
;        SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-105-901A-4

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 134
PCT-US92-10792-45/c
; Sequence 45, Application PC/TUS9210792
;  GENERAL INFORMATION:
;    APPLICANT:  Jayasena, Sumedha D.
;    APPLICANT:  Johnston, Brian H.
;    TITLE OF INVENTION:  Triple Helix Formation at
;    TITLE OF INVENTION:  (PuNPyN)-(PuNPyN) Tracts
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SRI International
;      STREET:  333 Ravenswood Avenue
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10792
;      FILING DATE:  19921211
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/826,934
;      FILING DATE:  21-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/808,452
;      FILING DATE:  13-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fabian, Gary R.
;      REGISTRATION NUMBER:  33,875
;      REFERENCE/DOCKET NUMBER:  P-3141
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 859-4550
;      TELEFAX:  (415) 859-3880
;  INFORMATION FOR SEQ ID NO:  45:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ORIGINAL SOURCE:
;      INDIVIDUAL ISOLATE:  FIGURE 14A, TARGET SEQUENCE #8
PCT-US92-10792-45

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 26;
  Best Local Similarity   48.0%;  Pred. No. 1.8e+02;
  Matches   12;  Conservative   11;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUG 6996
              |:  |:|:|:|:|:|:|:|:|:|
Db         26 CTAGGTGTGTGTGTGTGTGTGTG 2


RESULT 135
US-09-051-363-3/c
; Sequence 3, Application US/09051363
; Patent No. 6270993
;  GENERAL INFORMATION:
;    APPLICANT:  Shibuya, Masabumi
;    APPLICANT:  Okamoto, Masaji
;    APPLICANT:  Niwa, Mikio
;    APPLICANT:  Matsumoto, Tomoe
;    APPLICANT:  Asano, Makoto
;    APPLICANT:  Segawa, Toshiaki
;    TITLE OF INVENTION:  VEGF-BINDING POLYPEPTIDES
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/051,363
;      FILING DATE:  07-APR-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP96/02906
;      FILING DATE:  07-OCT-1996
;      APPLICATION NUMBER:  8/211892 JP
;      FILING DATE:  23-JUL-1996
;      APPLICATION NUMBER:  7/296476 JP
;      FILING DATE:  07-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fraser, Ph.D., J.D., Janis K.
;      REGISTRATION NUMBER:  34,819
;      REFERENCE/DOCKET NUMBER:  06501/012001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617/542-5070
;      TELEFAX:  617/542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  synthetic DNA
US-09-051-363-3

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 1.7e+02;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:|||||||||||:::||||| |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 136
```

```
PCT-US92-10792-44
; Sequence 44, Application PC/TUS9210792
;  GENERAL INFORMATION:
;    APPLICANT:  Jayasena, Sumedha D.
;    APPLICANT:  Johnston, Brian H.
;    TITLE OF INVENTION:  Triple Helix Formation at
;    TITLE OF INVENTION:  (PuNPyN)-(PuNPyN) Tracts
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SRI International
;      STREET:  333 Ravenswood Avenue
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10792
;      FILING DATE:  19921211
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/826,934
;      FILING DATE:  21-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/808,452
;      FILING DATE:  13-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fabian, Gary R.
;      REGISTRATION NUMBER:  33,875
;      REFERENCE/DOCKET NUMBER:  P-3141
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 859-4550
;      TELEFAX:  (415) 859-3880
;  INFORMATION FOR SEQ ID NO:  44:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ORIGINAL SOURCE:
;      INDIVIDUAL ISOLATE:  FIGURE 14A, TARGET SEQUENCE #8
PCT-US92-10792-44

  Query Match             0.3%;  Score 21.2;  DB 1;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative   11;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUG 6996
                |  :  |:|:|:|:|:|:|:|:|:|
Db          1 AATTCGTGTGTGTGTGTGTGTGTG 26


RESULT 137
US-08-222-177A-160/c
; Sequence 160, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  160:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd37rs
US-08-222-177A-160

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 1.3e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
                :|:|:|:|:|:|:|:|:|:|:
Db         21 TGTGTGTGTGTGTGTGTGTGT 1


RESULT 138
US-08-529-878B-9
; Sequence 9, Application US/08529878B
; Patent No. 5932556
;  GENERAL INFORMATION:
;    APPLICANT:  Tam, Robert C.
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  REGULATION OF CD28 EXPRESSION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Crockett & Fish
;      STREET:  3000 S. Augusta Court
;      CITY:  La Habra
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  90631
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/529,878B
;      FILING DATE:  13-SEP-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fish, Robert D.
;      REGISTRATION NUMBER:  33,880
;      REFERENCE/DOCKET NUMBER:  213/003
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-525-3433
;      TELEFAX:  714-525-3303
```

```
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  9:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  21 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  unknown
;       TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-529-878B-9

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 1.3e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21


RESULT 139
US-09-051-363-2
; Sequence 2, Application US/09051363
; Patent No. 6270993
;  GENERAL INFORMATION:
;    APPLICANT:  Shibuya, Masabumi
;    APPLICANT:  Okamoto, Masaji
;    APPLICANT:  Niwa, Mikio
;    APPLICANT:  Matsumoto, Tomoe
;    APPLICANT:  Asano, Makoto
;    APPLICANT:  Segawa, Toshiaki
;    TITLE OF INVENTION:  VEGF-BINDING POLYPEPTIDES
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/051,363
;      FILING DATE:  07-APR-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP96/02906
;      FILING DATE:  07-OCT-1996
;      APPLICATION NUMBER:  8/211892 JP
;      FILING DATE:  23-JUL-1996
;      APPLICATION NUMBER:  7/296476 JP
;      FILING DATE:  07-OCT-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fraser, Ph.D., J.D., Janis K.
;      REGISTRATION NUMBER:  34,819
;      REFERENCE/DOCKET NUMBER:  06501/012001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617/542-5070
;      TELEFAX:  617/542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  synthetic DNA
US-09-051-363-2

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 CGUCGCGCUCACCAUGGUCAG 257
              ||:|||||:|||||:||:|||
Db          1 CGTCGCGCTCACCATGGTCAG 21


RESULT 140
US-09-453-718B-3
; Sequence 3, Application US/09453718B
; Patent No. 6986890
; GENERAL INFORMATION:
;  APPLICANT: SHITARA, KENYA
;  APPLICANT:  ITO, MIKITO
;  APPLICANT:  HANAI, NOBUO
;  APPLICANT:  KAWADA, YOKO
;  APPLICANT:  NAKAMURA, KAZUYASU
;  APPLICANT:  SHIBUYA, MASABUMI
;  TITLE OF INVENTION: ANTI-HUMAN VEGF RECEPTOR FLT-1 MONOCLONAL ANTIBODY
;  FILE REFERENCE: 249-107
;  CURRENT APPLICATION NUMBER: US/09/453,718B
;  CURRENT FILING DATE:  1999-12-03
;  PRIOR APPLICATION NUMBER: 09/315,051
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/119,014
;  PRIOR FILING DATE: 1998-07-20
;  PRIOR APPLICATION NUMBER: PCT/JP97/04259
;  PRIOR FILING DATE: 1997-11-21
;  NUMBER OF SEQ ID NOS: 111
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-453-718B-3

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 GGAAUCUACAUUUGCAUAGCU 1860
              ||||:|:|||:::|||:|||:
Db          1 GGAATCTACATTTGCATAGCT 21


RESULT 141
US-07-799-828C-44
; Sequence 44, Application US/07799828C
; Patent No. 5378602
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Carl R. Merril and
;    APPLICANT:  Mihael H. Polymeropoulos
;    TITLE OF INVENTION:  TWENTY SEVEN HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  MICROSATELLITE REPEAT
;    TITLE OF INVENTION:  POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  63
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/799,828C
;      FILING DATE:  19911127
```

```
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34,506
;      REFERENCE/DOCKET NUMBER:  717081A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  44:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-799-828C-44

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6952 UUUGGCCGACAGUGGUGUAA 6971
              :::|||||||||:||:|:||
Db          1 TTTGGCCGACAGTGGTGTAA 20


RESULT 142
US-07-799-828C-45/c
; Sequence 45, Application US/07799828C
; Patent No. 5378602
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Carl R. Merril and
;    APPLICANT:  Mihael H. Polymeropoulos
;    TITLE OF INVENTION:  TWENTY SEVEN HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  MICROSATELLITE REPEAT
;    TITLE OF INVENTION:  POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  63
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/799,828C
;      FILING DATE:  19911127
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34,506
;      REFERENCE/DOCKET NUMBER:  717081A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  45:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-799-828C-45

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7112 GACAGACAUGGUUUGGUCCU 7131
              ||||||||:||:::||:||:
Db          20 GACAGACATGGTTTGGTCCT 1


RESULT 143
US-07-922-723A-44
; Sequence 44, Application US/07922723A
; Patent No. 5369004
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Mihael H. Polymeropoulos
;    APPLICANT:  and Carl R. Merril
;    TITLE OF INVENTION:  FIVE HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  REPEAT POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  73
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/922,723A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34506
;      REFERENCE/DOCKET NUMBER:  717081B
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  44:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-922-723A-44

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6952 UUUGGCCGACAGUGGUGUAA 6971
              :::|||||||||:||:|:||
Db          1 TTTGGCCGACAGTGGTGTAA 20


RESULT 144
US-07-922-723A-45/c
; Sequence 45, Application US/07922723A
; Patent No. 5369004
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Mihael H. Polymeropoulos
;    APPLICANT:  and Carl R. Merril
;    TITLE OF INVENTION:  FIVE HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  REPEAT POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  73
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
```

```
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/922,723A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34506
;      REFERENCE/DOCKET NUMBER:  717081B
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  45:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-922-723A-45

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7112 GACAGACAUGGUUUGGUCCU 7131
             ||||||||:||:::||:||:
Db         20 GACAGACATGGTTTGGTCCT 1


RESULT 145
US-07-952-277A-44
; Sequence 44, Application US/07952277A
; Patent No. 5861504
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Mihael H. Polymeropoulos
;    APPLICANT:  and Carl R. Merril
;    TITLE OF INVENTION:  ELEVEN HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  REPEAT POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/952,277A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34506
;      REFERENCE/DOCKET NUMBER:  717081C
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  44:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-952-277A-44

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6952 UUUGGCCGACAGUGGUGUAA 6971
              :::|||||||||:||:|:||
Db          1 TTTGGCCGACAGTGGTGTAA 20


RESULT 146
US-07-952-277A-45/c
; Sequence 45, Application US/07952277A
; Patent No. 5861504
;  GENERAL INFORMATION:
;    APPLICANT:  Drs. Mihael H. Polymeropoulos
;    APPLICANT:  and Carl R. Merril
;    TITLE OF INVENTION:  ELEVEN HIGHLY INFORMATIVE
;    TITLE OF INVENTION:  REPEAT POLYMORPHIC DNA MARKERS
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lowe, Price, LeBlanc & Becker
;      STREET:  Suite 300, 99 Canal Center Plaza
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  DOS Text File
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/952,277A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  D.J. Mills
;      REGISTRATION NUMBER:  34506
;      REFERENCE/DOCKET NUMBER:  717081C
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703 684 1111
;  INFORMATION FOR SEQ ID NO:  45:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-952-277A-45

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7112 GACAGACAUGGUUUGGUCCU 7131
             ||||||||:||:::||:||:
Db         20 GACAGACATGGTTTGGTCCT 1


RESULT 147
US-08-232-538-1
; Sequence 1, Application US/08232538
; Patent No. 5712380
;  GENERAL INFORMATION:
;    APPLICANT:  Thomas, Kenneth A.
;    APPLICANT:  Kendall, Richard L.
;    TITLE OF INVENTION:  INHIBITOR OF VASCULAR ENDOTHELIAL CELL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O. Box 2000 126 E Lincoln Avenue
;      CITY:  Rahway
;      STATE:  NJ
;      COUNTRY:  USA
```

```
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/232,538
;      FILING DATE:
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wallen, John W.III
;      REGISTRATION NUMBER:  35,403
;      REFERENCE/DOCKET NUMBER:  18888IA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908) 594-3905
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-232-538-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1808 GCACCUUGGUUGUGGCUGAC 1827
              |||||::||::|:|||:|||
Db          1 GCACCTTGGTTGTGGCTGAC 20


RESULT 148
US-08-750-141A-11/c
; Sequence 11, Application US/08750141A
; Patent No. 6011003
;  GENERAL INFORMATION:
;    APPLICANT:  Charnock-Jones, David S.
;    APPLICANT:  Boocock, Christine A.
;    APPLICANT:  Sharkey, Andrew M.
;    APPLICANT:  Smith, Stephen K.
;    TITLE OF INVENTION:  FLT-4-(FMS-LIKE TYROSINE-KINASE),
;    TITLE OF INVENTION:  FLT-15, VARIANTS THEREOF USED AS GROWTH FACTOR INHIBITORS
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Klauber & Jackson
;      STREET:  411 Hackensack Avenue, 4th Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/750,141A
;      FILING DATE:  12-MAY-1997
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1396-1-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;      TELEX:  133521
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
;    HYPOTHETICAL:  NO
US-08-750-141A-11

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 UACACAGGGGAAGAAAUCCU 2192
              :|||||||||||||||:||:
Db         20 TACACAGGGGAAGAAATCCT 1


RESULT 149
US-08-750-141A-12
; Sequence 12, Application US/08750141A
; Patent No. 6011003
;  GENERAL INFORMATION:
;    APPLICANT:  Charnock-Jones, David S.
;    APPLICANT:  Boocock, Christine A.
;    APPLICANT:  Sharkey, Andrew M.
;    APPLICANT:  Smith, Stephen K.
;    TITLE OF INVENTION:  FLT-4-(FMS-LIKE TYROSINE-KINASE),
;    TITLE OF INVENTION:  FLT-15, VARIANTS THEREOF USED AS GROWTH FACTOR INHIBITORS
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Klauber & Jackson
;      STREET:  411 Hackensack Avenue, 4th Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/750,141A
;      FILING DATE:  12-MAY-1997
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1396-1-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;      TELEX:  133521
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
;    HYPOTHETICAL:  NO
US-08-750-141A-12

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   60.0%;  Pred. No. 1.6e+02;
  Matches   12;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1681 GCAAGGUGUGACUUUUGUUC 1700
              ||||||:|:|||::::|::|
Db          1 GCAAGGTGTGACTTTTGTTC 20
```

```
RESULT 150
US-08-750-141A-15/c
; Sequence 15, Application US/08750141A
; Patent No. 6011003
;  GENERAL INFORMATION:
;    APPLICANT:  Charnock-Jones, David S.
;    APPLICANT:  Boocock, Christine A.
;    APPLICANT:  Sharkey, Andrew M.
;    APPLICANT:  Smith, Stephen K.
;    TITLE OF INVENTION:  FLT-4-(FMS-LIKE TYROSINE-KINASE),
;    TITLE OF INVENTION:  FLT-15, VARIANTS THEREOF USED AS GROWTH FACTOR INHIBITORS
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Klauber & Jackson
;      STREET:  411 Hackensack Avenue, 4th Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/750,141A
;      FILING DATE:  12-MAY-1997
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1396-1-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;      TELEX:  133521
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
;    HYPOTHETICAL:  NO
US-08-750-141A-15

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 UACACAGGGGAAGAAAUCCU 2192
                :||||||||||||||:||:
Db         20 TACACAGGGGAAGAAATCCT 1


RESULT 151
US-08-786-164-1
; Sequence 1, Application US/08786164
; Patent No. 5861484
;  GENERAL INFORMATION:
;    APPLICANT:  THOMAS, KENNETH A.
;    APPLICANT:  KENDALL, RICHARD L
;    TITLE OF INVENTION:  INHIBITOR OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  CELL GROWTH FACTOR
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O. Box 2000, 126 E. Lincoln Ave.
;      CITY:  Rahway
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07065-0900
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  Microsoft Word 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/786,164
;      FILING DATE:  21-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mark Hand, J
;      REGISTRATION NUMBER:  36,545
;      REFERENCE/DOCKET NUMBER:  18888DA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-594-3905
;      TELEFAX:  908-594-4720
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-786-164-1

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1808 GCACCUUGGUUGUGGCUGAC 1827
                ||||::||::|:|||:|||
Db          1 GCACCTTGGTTGTGGCTGAC 20


RESULT 152
US-08-863-639A-32/c
; Sequence 32, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
```

```
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-32

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 1.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 153
US-09-180-903-8
; Sequence 8, Application US/09180903
; Patent No. 6316190
;   GENERAL INFORMATION:
;        APPLICANT: Rein, Alan
;                   Casas-Finet, Jose
;                   Fisher, Robert
;                   Fivash, Matthew
;                   Henderson, Louis E.
;        TITLE OF INVENTION: Oligonucleotides Which Specifically Bind
;                            Retroviral Nucleocapsid Proteins
;        NUMBER OF SEQUENCES: 15
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/180,903
;             FILING DATE: 12-Jul-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 60/017,128
;             FILING DATE: 20-MAY-1996
;             APPLICATION NUMBER: WO PCT/US97/08936
;             FILING DATE: 19-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Choi, Kathleen L.
;             REGISTRATION NUMBER: 43,433
;             REFERENCE/DOCKET NUMBER: 015280-279100US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 8:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-180-903-8

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 1.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 154
US-09-407-675-5/c
; Sequence 5, Application US/09407675
; Patent No. 6169176
; GENERAL INFORMATION:
;  APPLICANT:  Bruice, Thomas C.
;  APPLICANT:  Arya, Dev P.
;  TITLE OF INVENTION:  DEOXYNUCLEIC ALKYL THIOUREA COMPOUNDS AND USES THEREOF
;  FILE REFERENCE:  30448.65US02
;  CURRENT APPLICATION NUMBER: US/09/407,675
;  CURRENT FILING DATE:  1999-09-28
;  PRIOR APPLICATION NUMBER:  09/347,443
;  PRIOR FILING DATE:  1999-07-02
;  PRIOR APPLICATION NUMBER:  60/091,481
;  PRIOR FILING DATE:  1998-07-02
;  PRIOR APPLICATION NUMBER:  60/111,800
;  PRIOR FILING DATE:  1998-12-11
;  NUMBER OF SEQ ID NOS:  5
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Oligo 5
US-09-407-675-5

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 1.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 155
US-09-488-671-88/c
; Sequence 88, Application US/09488671A
; Patent No. 6187545
; GENERAL INFORMATION:
;  APPLICANT: Robert McKay
;  APPLICANT: Madeline M. Butler
;  APPLICANT: Jacqueline Wyatt
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION
;  FILE REFERENCE: RTS-0123
;  CURRENT APPLICATION NUMBER: US/09/488,671A
;  CURRENT FILING DATE: 2000-01-21
;  NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 88
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-88

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 1.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 156
```

```
US-09-374-454-13/c
; Sequence 13, Application US/09374454
; Patent No. 6395548
; GENERAL INFORMATION:
;  APPLICANT: Lee, Mu-En
;  APPLICANT: Maemura, Koji
;  APPLICANT: Hsieh, Chung-Ming
;  TITLE OF INVENTION: METHODS OF MODULATING OF ANGIOGENESIS
;  FILE REFERENCE: 05433/037001
;  CURRENT APPLICATION NUMBER: US/09/374,454
;  CURRENT FILING DATE: 1999-08-13
;  EARLIER APPLICATION NUMBER: US 60/096,515
;  EARLIER FILING DATE: 1998-08-14
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 13
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-09-374-454-13

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 157
US-09-374-454-9/c
; Sequence 9, Application US/09374454
; Patent No. 6395548
; GENERAL INFORMATION:
;  APPLICANT: Lee, Mu-En
;  APPLICANT: Maemura, Koji
;  APPLICANT: Hsieh, Chung-Ming
;  TITLE OF INVENTION: METHODS OF MODULATING OF ANGIOGENESIS
;  FILE REFERENCE: 05433/037001
;  CURRENT APPLICATION NUMBER: US/09/374,454
;  CURRENT FILING DATE: 1999-08-13
;  EARLIER APPLICATION NUMBER: US 60/096,515
;  EARLIER FILING DATE: 1998-08-14
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-09-374-454-9

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 158
US-08-136-118-10/c
; Sequence 10, Application US/08136118
; Patent No. 5580969
;  GENERAL INFORMATION:
;    APPLICANT:  HOKE, Glenn D
;    APPLICANT:  BRADLEY, Matthews O
;    APPLICANT:  WILLIAMS, Taffy J
;    APPLICANT:  LEE, Che-Hung
;    TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDES DIRECTED
;    TITLE OF INVENTION:  AGAINST HUMAN ICAM-1
;    NUMBER OF SEQUENCES:  15
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Naval Medical Res. & Dev. Cmd.
;      STREET:  8901 Wisconsin Ave.
;      CITY:  Bethesda
;      STATE:  Maryland
;      COUNTRY:  USA
;      ZIP:  20889-5606
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/136,118
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/918,259
;      FILING DATE:  24-JUL-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spevack, A. David
;      REGISTRATION NUMBER:  24,743
;      REFERENCE/DOCKET NUMBER:  N.C. 75,776
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 295-6759
;      TELEFAX:  (202) 295-1022
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-136-118-10

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 2.1e+02;
  Matches    9;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|: :|:|:
Db         21 TGTGTGTGTGTGTGTATGTGT 1


RESULT 159
US-08-222-177A-442/c
; Sequence 442, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
```

```
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  442:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-442

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 1.9e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 160
US-08-915-609-3/c
; Sequence 3, Application US/08915609
; Patent No. 6054300
; GENERAL INFORMATION:
;  APPLICANT: McKendree Jr., William L.
;  TITLE OF INVENTION: Single-SIte Amplification (SSA) Method for Accelerated
;  TITLE OF INVENTION: Development of Nucleic Acid Marker
;  FILE REFERENCE: 0115.97
;  CURRENT APPLICATION NUMBER: US/08/915,609
;  CURRENT FILING DATE: 1997-08-21
;  EARLIER APPLICATION NUMBER: 60/028,775
;  EARLIER FILING DATE: 1996-08-23
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0 - beta
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: (1)..(19)
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: (1)..(19)
US-08-915-609-3

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 1.9e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db         19 GTGTGTGTGTGTGTGTGTG 1


RESULT 161
US-08-915-609-4
; Sequence 4, Application US/08915609
; Patent No. 6054300
; GENERAL INFORMATION:
;  APPLICANT: McKendree Jr., William L.
;  TITLE OF INVENTION: Single-SIte Amplification (SSA) Method for Accelerated
;  TITLE OF INVENTION: Development of Nucleic Acid Marker
;  FILE REFERENCE: 0115.97
;  CURRENT APPLICATION NUMBER: US/08/915,609
;  CURRENT FILING DATE: 1997-08-21
;  EARLIER APPLICATION NUMBER: 60/028,775
;  EARLIER FILING DATE: 1996-08-23
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0 - beta
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: (1)..(19)
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: (1)..(19)
US-08-915-609-4

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 1.9e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTG 19


RESULT 162
US-09-557-423A-7/c
; Sequence 7, Application US/09557423A
; Patent No. 6977295
; GENERAL INFORMATION:
;  APPLICANT: BELOTSERKOVSKII, BORIS
;  APPLICANT:  REDDY, GURUCHARAN
;  APPLICANT:  ZARLING, DAVID A.
;  TITLE OF INVENTION: LOCKED NUCLEIC ACID HYBRIDS AND METHODS OF USE
;  FILE REFERENCE: 41428-0312
;  CURRENT APPLICATION NUMBER: US/09/557,423A
;  CURRENT FILING DATE:  2000-04-21
;  PRIOR APPLICATION NUMBER: 60/130,345
;  PRIOR FILING DATE: 1999-04-21
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-557-423A-7

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 1.9e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db         19 TGTGTGTGTGTGTGTGTGT 1


RESULT 163
US-09-557-423A-8
; Sequence 8, Application US/09557423A
; Patent No. 6977295
; GENERAL INFORMATION:
;  APPLICANT: BELOTSERKOVSKII, BORIS
```

```
;  APPLICANT:  REDDY, GURUCHARAN
;  APPLICANT:  ZARLING, DAVID A.
;  TITLE OF INVENTION: LOCKED NUCLEIC ACID HYBRIDS AND METHODS OF USE
;  FILE REFERENCE: 41428-0312
;  CURRENT APPLICATION NUMBER: US/09/557,423A
;  CURRENT FILING DATE:  2000-04-21
;  PRIOR APPLICATION NUMBER: 60/130,345
;  PRIOR FILING DATE: 1999-04-21
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-557-423A-8

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 1.9e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 19


RESULT 164
US-09-314-246-1
; Sequence 1, Application US/09314246
; Patent No. 6180349
; GENERAL INFORMATION:
;  APPLICANT:  Ginzinger, David G.
;  APPLICANT:  Godfrey, Tony E.
;  APPLICANT:  Jensen, Ronald H.
;  APPLICANT:  Gray, Joe W.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION:  A Quantitative PCR Method to Enumerate DNA Copy Number
;  FILE REFERENCE:  2307AA-096200US
;  CURRENT APPLICATION NUMBER: US/09/314,246
;  CURRENT FILING DATE:  1999-05-18
;  NUMBER OF SEQ ID NOS:  2
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:TM-TaqMan
;   OTHER INFORMATION: dual-labeled fluorogenic oligonucleotide probe
;   OTHER INFORMATION: complementary to amplification products of
;   OTHER INFORMATION: CA-repeat
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: 5'-t attached to 6-carboxy fluorescein (FAM)
;   NAME/KEY: modified_base
;   LOCATION: (21)
;   OTHER INFORMATION: 3'-t attached to 6-carboxy tetramethyl rhodamine
;   OTHER INFORMATION: (TAMRA)
US-09-314-246-1

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTG 20


RESULT 165
US-09-314-246-2
; Sequence 2, Application US/09314246
; Patent No. 6180349
; GENERAL INFORMATION:
;  APPLICANT:  Ginzinger, David G.
;  APPLICANT:  Godfrey, Tony E.
;  APPLICANT:  Jensen, Ronald H.
;  APPLICANT:  Gray, Joe W.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION:  A Quantitative PCR Method to Enumerate DNA Copy Number
;  FILE REFERENCE:  2307AA-096200US
;  CURRENT APPLICATION NUMBER: US/09/314,246
;  CURRENT FILING DATE:  1999-05-18
;  NUMBER OF SEQ ID NOS:  2
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:TM-TaqMan
;   OTHER INFORMATION: dual-labeled fluorogenic oligonucleotide probe
;   OTHER INFORMATION: complementary to amplification products of
;   OTHER INFORMATION: CA-repeat
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: 5'-t attached to reporter dye
;   NAME/KEY: modified_base
;   LOCATION: (21)
;   OTHER INFORMATION: 3'-t attached to quenching dye
US-09-314-246-2

  Query Match             0.2%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTG 20


RESULT 166
US-08-018-129-15
; Sequence 15, Application US/08018129
; Patent No. 5589375
;  GENERAL INFORMATION:
;    APPLICANT:  Ullrich, Axel
;    APPLICANT:  Vogel, Wolfgang
;    TITLE OF INVENTION:  PTP 1D: A NOVEL PROTEIN TYROSINE
;    TITLE OF INVENTION:  PHOSPHATASE
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/018,129
;      FILING DATE:  19930216
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  7683-017
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864/9741
```

```
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-018-129-15

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 3.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUUU 6361
              |:| | ::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 167
US-08-448-250-15
; Sequence 15, Application US/08448250
; Patent No. 5981251
;  GENERAL INFORMATION:
;    APPLICANT:  Ullrich, Axel
;    APPLICANT:  Vogel, Wolfgang
;    TITLE OF INVENTION:  PTP 1D: A NOVEL PROTEIN TYROSINE
;    TITLE OF INVENTION:  PHOSPHATASE
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/448,250
;      FILING DATE:  23-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/018,129
;      FILING DATE:  16-FEB-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  7683-017
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-448-250-15

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 3.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUUU 6361
              |:| | ::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 168
US-08-621-914A-6
; Sequence 6, Application US/08621914A
; Patent No. 5707807
;  GENERAL INFORMATION:
;    APPLICANT:  KATO, KIKUYA
;    TITLE OF INVENTION:  MOLECULAR INDEXING FOR EXPRESSED GENE
;    TITLE OF INVENTION:  ANALYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 AVENUE OF THE AMERICAS
;      CITY:  NEW YORK
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/621,914A
;      FILING DATE:  26-MAR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LAWRENCE III, STANTON T.
;      REGISTRATION NUMBER:  25,736
;      REFERENCE/DOCKET NUMBER:  7005-107-999
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  other nucleic acid
US-08-621-914A-6

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 3.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUUU 6361
              |:| | ::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 169
US-09-056-052-9
; Sequence 9, Application US/09056052
; Patent No. 6090556
; GENERAL INFORMATION:
;  APPLICANT: Kato, Kikuya
;  TITLE OF INVENTION: Adaptor-Tagged Competitive PCR
;  FILE REFERENCE: 07898/026001
;  CURRENT APPLICATION NUMBER: US/09/056,052
;  CURRENT FILING DATE: 1998-04-06
;  EARLIER APPLICATION NUMBER: JP88495/1997
;  EARLIER FILING DATE: 1997-04-07
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-056-052-9
```

```
  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 3.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUU 6361
              |:| | :::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 170
US-09-282-257-15
; Sequence 15, Application US/09282257
; Patent No. 6548641
;  GENERAL INFORMATION:
;    APPLICANT:  Ullrich, Axel
;    APPLICANT:  Vogel, Wolfgang
;    TITLE OF INVENTION:  PTP 1D: A NOVEL PROTEIN TYROSINE
;    TITLE OF INVENTION:  PHOSPHATASE
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/282,257
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/018,129
;      FILING DATE:  16-FEB-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  7683-017
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-09-282-257-15

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   13.6%;  Pred. No. 3.1e+02;
  Matches    3;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUUUU 6361
              |:| | :::::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTTTT 22


RESULT 171
US-09-762-867A-21/c
; Sequence 21, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-21

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 2.5e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|: :|:|:|
Db         20 TGTGTGTGTGTGTTTGTGTG 1


RESULT 172
US-08-584-040-2983
; Sequence 2983, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2983:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
US-08-584-040-2983

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 173
US-08-700-530-1/c
; Sequence 1, Application US/08700530
; Patent No. 6316186
; GENERAL INFORMATION:
;  APPLICANT: EKINS, Roger P
;  TITLE OF INVENTION: Binding assay using binding agents with tail groups
;  FILE REFERENCE: 0380-P01180US0
;  CURRENT APPLICATION NUMBER: US/08/700,530
;  CURRENT FILING DATE:  1996-10-23
;  PRIOR APPLICATION NUMBER: PCT/GB95/00521
;  PRIOR FILING DATE: 1995-03-10
;  PRIOR APPLICATION NUMBER: GB 9404709.9
;  PRIOR FILING DATE: 1994-03-11
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-08-700-530-1

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGG 6990
              :|:|:|:|:|:|:|:|:|
Db         18 TGTGTGTGTGTGTGTGTG 1


RESULT 174
US-08-700-530-2
; Sequence 2, Application US/08700530
; Patent No. 6316186
; GENERAL INFORMATION:
;  APPLICANT: EKINS, Roger P
;  TITLE OF INVENTION: Binding assay using binding agents with tail groups
;  FILE REFERENCE: 0380-P01180US0
;  CURRENT APPLICATION NUMBER: US/08/700,530
;  CURRENT FILING DATE:  1996-10-23
;  PRIOR APPLICATION NUMBER: PCT/GB95/00521
;  PRIOR FILING DATE: 1995-03-10
;  PRIOR APPLICATION NUMBER: GB 9404709.9
;  PRIOR FILING DATE: 1994-03-11
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-08-700-530-2

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6991
              |:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGT 18


RESULT 175
US-08-734-973-7/c
; Sequence 7, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  7 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-7

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 2.2e+02;
  Matches   10;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGG 6988
              ||:|:|:|:|:|:|:|:|
Db         18 ACTGTGTGTGTGTGTGTG 1


RESULT 176
US-08-734-973-8/c
; Sequence 8, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
```

```
;       CITY:  Buffalo
;       STATE:  New York
;       COUNTRY:  United States
;       ZIP:  14203-2391
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.5 inch
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;       SOFTWARE:  Wordperfect for Windows
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/734,973
;       FILING DATE:  October 1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Nelson, M. Bud
;       REGISTRATION NUMBER:  35,300
;       REFERENCE/DOCKET NUMBER:  03551.0021
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (716) 856-4000
;       TELEFAX:  (716) 849-0349
;   INFORMATION FOR SEQ ID NO:  8 :
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 nucleotides
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single-stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
;     HYPOTHETICAL:  No
US-08-734-973-8

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 2.2e+02;
  Matches   10;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              ||:|:|:|:|:|:|:|:|
Db         18 ACTGTGTGTGTGTGTGTG 1


RESULT 177
US-08-976-427-28
; Sequence 28, Application US/08976427A
; Patent No. 6322968
; GENERAL INFORMATION:
;  APPLICANT: Head, Steven R.
;  APPLICANT: Geolet, Philip
;  APPLICANT: Karn, Jonathan
;  APPLICANT: Boyce-Jacino, Michael
;  TITLE OF INVENTION: De No. 6322968o or "Universal" Sequencing Array
;  FILE REFERENCE: 04990.0049
;  CURRENT APPLICATION NUMBER: US/08/976,427A
;  CURRENT FILING DATE: 1997-11-21
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-08-976-427-28

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTG 18


RESULT 178
US-09-371-772B-1411
; Sequence 1411, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 179
US-09-648-312-28
; Sequence 28, Application US/09648312
; Patent No. 6337188
; GENERAL INFORMATION:
;  APPLICANT:  Head, Steven R.
;  APPLICANT:  Goelet, Philip
;  APPLICANT:  Karn, Jonathan
;  APPLICANT:  Boyce-Jacino, Michael
;  TITLE OF INVENTION:  De No. 6337188o or "Universal" Sequencing Array
;  FILE REFERENCE:  04990.0049
;  CURRENT APPLICATION NUMBER: US/09/648,312
;  CURRENT FILING DATE:  2000-08-25
;  NUMBER OF SEQ ID NOS:  31
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
US-09-648-312-28

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTG 18


RESULT 180
US-09-685-664B-1411
; Sequence 1411, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
```

```
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 181
US-09-896-650C-28
; Sequence 28, Application US/09896650C
; Patent No. 6946249
; GENERAL INFORMATION:
;  APPLICANT: HEAD, Steven R.
;  APPLICANT:  GOELET, Philip
;  APPLICANT:  KARN, Jonathan
;  APPLICANT:  BOYCE-JACINO, Michael
;  TITLE OF INVENTION: De No. 6946249o or Universal Sequencing Array
;  FILE REFERENCE: 13019-2
;  CURRENT APPLICATION NUMBER: US/09/896,650C
;  CURRENT FILING DATE:  2001-06-29
;  PRIOR APPLICATION NUMBER: 08/976,427
;  PRIOR FILING DATE: 1997-11-21
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-896-650C-28

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+02;
  Matches    9;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              :|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTG 18


RESULT 182
US-10-138-674B-1411
; Sequence 1411, Application US/10138674B
; Patent No. 7034009
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674B
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20829
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674B-1411

  Query Match             0.2%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         10 CCUCUCGGCUCCUCCCCG 27
              ||||||||||||||||||
Db          1 CCUCUCGGCUCCUCCCCG 18


RESULT 183
US-09-909-544-5
; Sequence 5, Application US/09909544
; Patent No. 6852323
; GENERAL INFORMATION:
;  APPLICANT: Lue, Tom F.
;  APPLICANT:  Lin, Ching-Shwun
;  APPLICANT:  Kan, Yuet W.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PREVENTING
;  TITLE OF INVENTION:  AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE SEXUAL
;  TITLE OF INVENTION:  AROUSAL DISORDER
;  FILE REFERENCE: 220022001600
;  CURRENT APPLICATION NUMBER: US/09/909,544
;  CURRENT FILING DATE:  2001-07-19
;  PRIOR APPLICATION NUMBER: 60/220,031
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: VEGFR-1s Primer
US-09-909-544-5

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||| :||:||||||
Db          1 ATGCTGGATTGCTGGCACA 19


RESULT 184
US-09-045-106-10/c
; Sequence 10, Application US/09045106
; Patent No. 6001651
;  GENERAL INFORMATION:
;    APPLICANT:  C. Frank Bennett, Thomas Condon,
;    APPLICANT:  Shin Flournoy, Jordan S. Pober, Weillie Ma
;    TITLE OF INVENTION:  ANTISENSE MODULATION OF LFA-3
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 EAST MAIN STREET
;      CITY:  MARLTON
;      STATE:  NJ
;      COUNTRY:  USA
```

```
;       ZIP:  08053
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 MB
;       MEDIUM TYPE:  STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/045,106
;       FILING DATE:  Herewith
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Jane Massey Licata
;       REGISTRATION NUMBER:  32,257
;       REFERENCE/DOCKET NUMBER:  ISPH-0301
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (609) 779-2400
;       TELEFAX:  (609) 810-1454
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  Nucleic Acid
;       STRANDEDNESS:  Single
;       TOPOLOGY:  Linear
;     ANTI-SENSE:  Yes
US-09-045-106-10

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 3.3e+02;
  Matches   17;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6722 CACUAACAAAGAACGAGCA 6740
                ||||:|||||||||| ||||
Db         19 CACTAACAAAGAACAAGCA 1


RESULT 185
US-09-488-671-120
; Sequence 120, Application US/09488671A
; Patent No. 6187545
; GENERAL INFORMATION:
;  APPLICANT: Robert McKay
;  APPLICANT: Madeline M. Butler
;  APPLICANT: Jacqueline Wyatt
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION
;  FILE REFERENCE: RTS-0123
;  CURRENT APPLICATION NUMBER: US/09/488,671A
;  CURRENT FILING DATE: 2000-01-21
;  NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 120
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-120

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   52.6%;  Pred. No. 3.3e+02;
  Matches   10;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
                |:|:|:|:| |:|:|:|:|
Db          1 GTGTGTGTGAGTGTGTGTG 19


RESULT 186
US-09-851-062-80
; Sequence 80, Application US/09851062
; Patent No. 6448081
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
;  FILE REFERENCE: RTS-0247
;  CURRENT APPLICATION NUMBER: US/09/851,062
;  CURRENT FILING DATE:  2001-05-07
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-851-062-80

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   63.2%;  Pred. No. 3.3e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        294 CAGCUGUCUGCUUCUCACA 312
                || |:|:|:||::|:||||
Db          2 CATCTGTCTGCTTCTCACA 20


RESULT 187
US-08-704-966-7
; Sequence 7, Application US/08704966
; Patent No. 6013523
;  GENERAL INFORMATION:
;    APPLICANT:  Adang, Michael J.
;    APPLICANT:  Rocheleau, Thomas A.
;    APPLICANT:  Merlo, Donald
;    APPLICANT:  Murray, Elizabeth E.
;    TITLE OF INVENTION:  Synthetic Insecticidal Crystal Protein
;    TITLE OF INVENTION:  Gene
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Saliwanchik, Lloyd & Saliwanchik
;      STREET:  1000 Legion Place, Suite 1750
;      CITY:  Orlando
;      STATE:  Florida
;      COUNTRY:  USA
;      ZIP:  32801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,966
;      FILING DATE:  29-AUG-1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/369,839
;      FILING DATE:  06-JAN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/057,191
;      FILING DATE:  03-MAY-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,844
;      FILING DATE:  28-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/242,482
;      FILING DATE:  09-SEP-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lloyd, Jeff
;      REGISTRATION NUMBER:  35,589
;      REFERENCE/DOCKET NUMBER:  MPS 8-88AFD3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  407-426-7500
;      TELEFAX:  407-839-8589
```

```
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-704-966-7

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   36.8%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::|:::|:|:|:|: ||
Db          1 TTTTUTTTUTUTUTUTGCA 19


RESULT 188
US-08-705-438-7
; Sequence 7, Application US/08705438
; Patent No. 6015891
;  GENERAL INFORMATION:
;    APPLICANT:  Adang, Michael J.
;    APPLICANT:  Rocheleau, Thomas A.
;    APPLICANT:  Merlo, Donald
;    APPLICANT:  Murray, Elizabeth E.
;    TITLE OF INVENTION:  Synthetic Insecticidal Crystal Protein
;    TITLE OF INVENTION:  Gene
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Saliwanchik, Lloyd & Saliwanchik
;      STREET:  1000 Legion Place, Suite 1750
;      CITY:  Orlando
;      STATE:  Florida
;      COUNTRY:  USA
;      ZIP:  32801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/705,438
;      FILING DATE:  29-AUG-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/369,839
;      FILING DATE:  06-JAN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/057,191
;      FILING DATE:  03-MAY-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,844
;      FILING DATE:  28-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/242,482
;      FILING DATE:  09-SEP-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lloyd, Jeff
;      REGISTRATION NUMBER:  35,589
;      REFERENCE/DOCKET NUMBER:  MPS 8-88AFD4
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  407-426-7500
;      TELEFAX:  407-839-8589
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-705-438-7

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   36.8%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::|:::|:|:|:|: ||
Db          1 TTTTUTTTUTUTUTUTGCA 19


RESULT 189
US-08-222-177A-448/c
; Sequence 448, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  448:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-448

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 2.5e+02;
  Matches    8;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|:|:|:|:|:|:
Db         17 TGTGTGTGTGTGTGTGT 1


RESULT 190
US-09-475-947A-118
; Sequence 118, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
```

```
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 118
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: human
US-09-475-947A-118

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   11.8%;  Pred. No. 2.5e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db          1 TTTTTTTTTTTTTTTCC 17


RESULT 191
US-09-958-221A-18
; Sequence 18, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-18

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 2.5e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTG 17


RESULT 192
US-09-958-221A-19/c
"; Sequence 19, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-19

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 2.5e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6999 UGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTGG 1


RESULT 193
US-08-734-973-2/c
; Sequence 2, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  2 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-2

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db         17 CTGTGTGTGTGTGTGTG 1


RESULT 194
US-08-734-973-29/c
; Sequence 29, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
```

```
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  29 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-29

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db         17 CTGTGTGTGTGTGTGTG 1


RESULT 195
US-08-734-973-30/c
; Sequence 30, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  30 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-30

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |:|:|:|:|:|:|:|:|
Db         17 GTGTGTGTGTGTGTGTG 1


RESULT 196
US-08-734-973-31/c
; Sequence 31, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  31 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-31

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
```

```
              |:|:|:|:|:|:|:|:|
Db         17 GTGTGTGTGTGTGTGTG 1


RESULT 197
US-08-734-973-32/c
; Sequence 32, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  32 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-32

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |:|:|:|:|:|:|:|:|
Db         17 GTGTGTGTGTGTGTGTG 1


RESULT 198
US-08-734-973-6/c
; Sequence 6, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  6 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-6

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   52.9%;  Pred. No. 2.9e+02;
  Matches    9;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|:|
Db         17 CTGTGTGTGTGTGTGTG 1


RESULT 199
US-09-142-108C-28
; Sequence 28, Application US/09142108C
; Patent No. 6774285
; GENERAL INFORMATION:
;  APPLICANT: Brugliera, Filippa
;  APPLICANT:  Holton, Timothy A.
;  APPLICANT:  Michael, Michael Z.
;  TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 11658
;  CURRENT APPLICATION NUMBER: US/09/142,108C
;  CURRENT FILING DATE:  1998-09-01
;  PRIOR APPLICATION NUMBER: PN8386
;  PRIOR FILING DATE: 1996-03-01
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-142-108C-28

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 2.9e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTTC 18


RESULT 200
US-09-437-076-1/c
; Sequence 1, Application US/09437076
; Patent No. 6261779
```

```
; GENERAL INFORMATION:
;  APPLICANT: Barber-Guillem, Emilio
;  APPLICANT: Nelson, M. Bud
;  APPLICANT: Castro, Stephanie
;  TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
;  CURRENT APPLICATION NUMBER: US/09/437,076
;  CURRENT FILING DATE: 1999-11-09
;  EARLIER APPLICATION NUMBER:
;  EARLIER FILING DATE:
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: Word for Windows
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY:
;   LOCATION:
;   OTHER INFORMATION: synthesized
US-09-437-076-1

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   11.8%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db         18 TTTTTTTTTTTTTTCC 2


RESULT 201
US-09-637-751A-7
; Sequence 7, Application US/09637751A
; Patent No. 6383754
; GENERAL INFORMATION:
;  APPLICANT:  Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION:  Binary Encoded Sequence Tags
; Patent No. 6383754
;  FILE REFERENCE:  AGL 100
;  CURRENT APPLICATION NUMBER: US/09/637,751A
;  CURRENT FILING DATE:  2000-08-11
;  NUMBER OF SEQ ID NOS:  10
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-637-751A-7

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 2.9e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17


RESULT 202
US-09-904-744-1/c
; Sequence 1, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
;  APPLICANT: Barbera-Guillem, Emilio
;  APPLICANT:  Nelson, M. Bud
;  APPLICANT:  Castro, Stephanie
;  TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
;  TITLE OF INVENTION:  dendrimers in a signal amplification system
;  FILE REFERENCE: B-73
;  CURRENT APPLICATION NUMBER: US/09/904,744
;  CURRENT FILING DATE:  2001-07-13
;  PRIOR APPLICATION NUMBER: 09/437076
;  PRIOR FILING DATE: 1999-11-09
;  PRIOR APPLICATION NUMBER: 60/107828
;  PRIOR FILING DATE: 1998-11-10
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthesized
US-09-904-744-1

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   11.8%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db         18 TTTTTTTTTTTTTTCC 2


RESULT 203
US-09-994-311-7
; Sequence 7, Application US/09994311
; Patent No. 6773886
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
; Patent No. 6773886
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/09/994,311
;  CURRENT FILING DATE:  2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-7

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 2.9e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTTC 17


RESULT 204
US-08-336-728A-34
; Sequence 34, Application US/08336728A
; Patent No. 6207802
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
```

```
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/336,728A
;      FILING DATE:  09-NOV-1994
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/32956
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-336-728A-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 205
US-08-482-918-34
; Sequence 34, Application US/08482918
; Patent No. 6207417
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,918
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/33005
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-482-918-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 206
US-09-224-681-34
; Sequence 34, Application US/09224681
; Patent No. 6207454
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Method for Enhancing the Efficiency of Gene
;    TITLE OF INVENTION:  Transfer with Stem Cell Factor (SCF) Polypeptide
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,681
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
```

```
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/982,255
;       FILING DATE:  25-NOV-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/589,701
;       FILING DATE:  01-OCT-1990
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/573,616
;       FILING DATE:  24-AUG-1990
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/537,198
;       FILING DATE:  11-JUN-1990
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/422,383
;       FILING DATE:  16-OCT-1989
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Clough, David W.
;       REGISTRATION NUMBER:  36,107
;       REFERENCE/DOCKET NUMBER:  01017/35199
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  312/474-6300
;       TELEFAX:  312/474-0448
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  34:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-09-224-681-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 207
US-09-224-683-34
; Sequence 34, Application US/09224683
; Patent No. 6841147
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 208
US-09-604-325A-34
; Sequence 34, Application US/09604325A
; Patent No. 6852313
;  GENERAL INFORMATION:
;       APPLICANT: Zsebo, Krisztina M.
;                  Bosselman, Robert A.
;                  Suggs, Sidney V.
;                  Martin, Francis H.
;       TITLE OF INVENTION: Stem Cell Factor
;       NUMBER OF SEQUENCES: 104
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;            STREET: 6300 Sears Tower, 233 South Wacker Drive
;            CITY: Chicago
;            STATE: Illinois
;            COUNTRY: United States of America
;            ZIP: 60606-6402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/604,325A
;            FILING DATE: 17-Jun-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
```

```
;              APPLICATION NUMBER: 07/982,255
;              FILING DATE: 25-NOV-1992
;              APPLICATION NUMBER: 07/589,701
;              FILING DATE: 01-OCT-1990
;              APPLICATION NUMBER: 07/573,616
;              FILING DATE: 24-AUG-1990
;              APPLICATION NUMBER: 07/537,198
;              FILING DATE: 11-JUN-1990
;              APPLICATION NUMBER: 07/422,383
;              FILING DATE: 16-OCT-1989
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Clough, David W.
;              REGISTRATION NUMBER: 36,107
;              REFERENCE/DOCKET NUMBER: 01017/32953
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: 312/474-6300
;              TELEFAX: 312/474-0448
;              TELEX: 25-3856
;    INFORMATION FOR SEQ ID NO: 34:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 20 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: DNA
;         SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-09-604-325A-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 209
US-09-635-251-34
; Sequence 34, Application US/09635251
; Patent No. 6759215
;   GENERAL INFORMATION:
;         APPLICANT: Zsebo, Krisztina M.
;                    Bosselman, Robert A.
;                    Suggs, Sidney V.
;                    Martin, Francis H.
;         TITLE OF INVENTION: Stem Cell Factor
;         NUMBER OF SEQUENCES: 104
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;              STREET: 6300 Sears Tower, 233 South Wacker Drive
;              CITY: Chicago
;              STATE: Illinois
;              COUNTRY: United States of America
;              ZIP: 60606-6402
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/635,251
;              FILING DATE: 07-Aug-2000
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/449,182
;              FILING DATE: 24-MAY-1995
;              APPLICATION NUMBER: 08/172,329
;              FILING DATE: 21-DEC-1993
;              APPLICATION NUMBER: 07/982,255
;              FILING DATE: 25-NOV-1992
;              APPLICATION NUMBER: 07/684,535
;              FILING DATE: 04-OCT-1991
;              APPLICATION NUMBER: 07/589,701
;              FILING DATE: 01-OCT-1990
;              APPLICATION NUMBER: 07/573,616
;              FILING DATE: 24-AUG-1990
;              APPLICATION NUMBER: 07/537,198
;              FILING DATE: 11-JUN-1990
;              APPLICATION NUMBER: 07/422,383
;              FILING DATE: 16-OCT-1989
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Clough, David W.
;              REGISTRATION NUMBER: 36,107
;              REFERENCE/DOCKET NUMBER: 01017/32957A
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: 312/474-6300
;              TELEFAX: 312/474-0448
;              TELEX: <Unknown>
;    INFORMATION FOR SEQ ID NO: 34:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 20 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: DNA
;         SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-09-635-251-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 210
US-09-643-659B-34
; Sequence 34, Application US/09643659B
; Patent No. 6967029
;   GENERAL INFORMATION:
;         APPLICANT: Zsebo, Krisztina M.
;                    Bosselman, Robert A.
;                    Suggs, Sidney V.
;                    Martin, Francis H.
;         TITLE OF INVENTION: Stem Cell Factor
;         NUMBER OF SEQUENCES: 104
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;              STREET: 6300 Sears Tower, 233 South Wacker Drive
;              CITY: Chicago
;              STATE: Illinois
;              COUNTRY: United States of America
;              ZIP: 60606-6402
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/643,659B
;              FILING DATE: 21-Aug-2000
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/448,729
;              FILING DATE: 24-MAY-1995
;              APPLICATION NUMBER: 08/172,329
;              FILING DATE: 21-DEC-1993
;              APPLICATION NUMBER: 07/982,255
;              FILING DATE: 25-NOV-1992
;              APPLICATION NUMBER: 07/684,535
;              FILING DATE: 10-APR-1991
;              APPLICATION NUMBER: 07/589,701
;              FILING DATE: 01-OCT-1990
```

```
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;       ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;       TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 34:
;       SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-09-643-659B-34

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTC 19


RESULT 211
US-08-973-857-6
; Sequence 6, Application US/08973857
; Patent No. 6221584
;  GENERAL INFORMATION:
;    APPLICANT:  EMRICH, Thomas
;    APPLICANT:  LEYING, Hermann
;    APPLICANT:  HINZPETER, Matthias
;    APPLICANT:  KARL, Gerlinde
;    TITLE OF INVENTION:  METHOD FOR THE DETECTION OF
;    TITLE OF INVENTION:  POLYMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nikaido, Marmelstein, Murray & Oram LLP
;      STREET:  655 Fifteenth St., NW
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20005-5701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/973,857
;      FILING DATE:  29-DEC-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/EP96/05245
;      FILING DATE:  11-AUG-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DE 19544317.9
;      FILING DATE:  28-NOV-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DE 19644302.4
;      FILING DATE:  24-OCT-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Berman, Richard J.
;      REGISTRATION NUMBER:  39,107
;      REFERENCE/DOCKET NUMBER:  P564-7031
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 638-5000
;      TELEFAX:  (202) 638-4810
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-973-857-6

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 3.5e+02;
  Matches    0;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::::
Db          2 TTTTTTTTTTTTTTTTMH 19


RESULT 212
PCT-US94-06799-7
; Sequence 7, Application PC/TUS9406799
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06799
;      FILING DATE:  17-JUN-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
PCT-US94-06799-7

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| ::::::::
Db          1 AAAAAAAAAGCTTTTTTTT 20


RESULT 213
PCT-US94-06799-7/c
```

```
; Sequence 7, Application PC/TUS9406799
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/06799
;      FILING DATE:  17-JUN-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
PCT-US94-06799-7

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| ::::::: 
Db         20 AAAAAAAAAGCTTTTTTTT 1


RESULT 214
US-08-427-863-8
; Sequence 8, Application US/08427863
; Patent No. 5593834
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  METHOD OF PREPARING DNA SEQUENCES WITH KNOWN
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/427,863
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17 JUNE 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TNI-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-427-863-8

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| ::::::: 
Db          1 AAAAAAAAAGCTTTTTTTT 20


RESULT 215
US-08-427-863-8/c
; Sequence 8, Application US/08427863
; Patent No. 5593834
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  METHOD OF PREPARING DNA SEQUENCES WITH KNOWN
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/427,863
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17 JUNE 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TNI-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-427-863-8

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
```

```
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| : :::::::
Db         20 AAAAAAAAAGCTTTTTTTT 1


RESULT 216
US-08-763-417-7
; Sequence 7, Application US/08763417
; Patent No. 6027884
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/763,417
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/260,200
;      FILING DATE:  17-JUN-1994
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-763-417-7

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| : :::::::
Db          1 AAAAAAAAAGCTTTTTTTT 20


RESULT 217
US-08-763-417-7/c
; Sequence 7, Application US/08763417
; Patent No. 6027884
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/763,417
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/260,200
;      FILING DATE:  17-JUN-1994
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-763-417-7

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7296 AAAGAAAAAGCUCUUUUUUU 7315
              ||| ||||||| : :::::::
Db         20 AAAAAAAAAGCTTTTTTTT 1


RESULT 218
US-09-724-126A-29/c
; Sequence 29, Application US/09724126A
; Patent No. 6706505
; GENERAL INFORMATION:
;  APPLICANT: Han, Hui-Quan
;  APPLICANT:  Kwak, Keith
;  TITLE OF INVENTION: Human E3 Alpha Ubiquitin Ligase Family
;  FILE REFERENCE: 01017/35966A
;  CURRENT APPLICATION NUMBER: US/09/724,126A
;  CURRENT FILING DATE:  2000-11-28
;  PRIOR APPLICATION NUMBER: US 60/187,211
;  PRIOR FILING DATE: 1999-03-01
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
```

```
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-09-724-126A-29

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1436 CUGAAGAGGAUGCAGGGAAU 1455
              |:|||| | |:||||||||:
Db         21 CTGAAGTGCATGCAGGGAAT 2


RESULT 219
US-08-222-177A-175
; Sequence 175, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  175:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd42rs
US-08-222-177A-175

  Query Match             0.2%;  Score 16.6;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 8e+02;
  Matches   24;  Conservative    1;  Mismatches   14;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  |:|||  ||
Db          2 ACACACACACACACACACACACACACACACATACACACA 40


RESULT 220
```

```
US-08-734-973-28/c
; Sequence 28, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  28 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-28

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   44.4%;  Pred. No. 3.4e+02;
  Matches    8;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6990
              : :|:|:|:|:|:|:|:|
Db         18 TTTGTGTGTGTGTGTGTG 1


RESULT 221
US-08-734-973-33/c
; Sequence 33, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
```

```
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  33 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-33

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 AATGTGTGTGTGTGTGTG 1


RESULT 222
US-08-734-973-35/c
; Sequence 35, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  35 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-35

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 AATGTGTGTGTGTGTGTG 1


RESULT 223
US-08-734-973-37/c
; Sequence 37, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  37 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-37

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 AATGTGTGTGTGTGTGTG 1


RESULT 224
US-08-734-973-38/c
; Sequence 38, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  38 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-38

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 AATGTGTGTGTGTGTGTG 1


RESULT 225
US-08-734-973-4/c
; Sequence 4, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  4 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-4

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 ATTGTGTGTGTGTGTGTG 1


RESULT 226
US-08-734-973-5/c
; Sequence 5, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  5 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-5

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUG 6988
              | :|:|:|:|:|:|:|:|
Db         18 ATTGTGTGTGTGTGTGTG 1


RESULT 227
US-09-637-751A-5
```

```
; Sequence 5, Application US/09637751A
; Patent No. 6383754
; GENERAL INFORMATION:
;  APPLICANT:  Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION:  Binary Encoded Sequence Tags
; Patent No. 6383754
;  FILE REFERENCE:  AGL 100
;  CURRENT APPLICATION NUMBER: US/09/637,751A
;  CURRENT FILING DATE:  2000-08-11
;  NUMBER OF SEQ ID NOS:  10
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-637-751A-5

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   5.6%;  Pred. No. 3.4e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              :::::::::::::::: |
Db          1 TTTTTTTTTTTTTTTGC 18


RESULT 228
US-09-994-311-5
; Sequence 5, Application US/09994311
; Patent No. 6773886
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
; Patent No. 6773886
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/09/994,311
;  CURRENT FILING DATE:  2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-5

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   5.6%;  Pred. No. 3.4e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              :::::::::::::::: |
Db          1 TTTTTTTTTTTTTTTGC 18


RESULT 229
US-09-198-452A-4759
; Sequence 4759, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4759
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4759

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   77.8%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3156 CGGCUUUCAGGAAGAUAA 3173
              |||| : |||||||||:||
Db          1 CGGCTATCAGGAAGATAA 18


RESULT 230
US-09-475-947A-337/c
; Sequence 337, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 337
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: human
US-09-475-947A-337

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 4.3e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
              | |:|:|:|:|:|:|:|:
Db         18 GGGTGTGTGTGTGTGTGT 1


RESULT 231
US-09-593-711A-18/c
; Sequence 18, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
;  APPLICANT:    Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION:    ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
;  FILE REFERENCE:    RTS-0118
;  CURRENT APPLICATION NUMBER: US/09/593,711A
;  CURRENT FILING DATE:  2000-06-14
;  NUMBER OF SEQ ID NOS:    244
; SEQ ID NO 18
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-18
```

```
  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 4.3e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         24 CCCGGCAGCGGCGGCGGC 41
              ||||||||||||||| ||
Db         20 CCCGGCAGCGGCGGCAGC 3


RESULT 232
US-09-981-397A-1
; Sequence 1, Application US/09981397A
; Patent No. 6849409
; GENERAL INFORMATION:
;  APPLICANT: Axxima Pharmaceuticals AG
;  APPLICANT:  Schubart, Daniel
;  APPLICANT:  Habenberger, Peter
;  APPLICANT:  Stein-Gerlach, Matthias
;  APPLICANT:  Bevec, Dorian
;  TITLE OF INVENTION: Cellular Kinases Involved in Cytomegalovirus Infection and their
;  TITLE OF INVENTION:  Inhibition
;  FILE REFERENCE: AXM-004.1 US
;  CURRENT APPLICATION NUMBER: US/09/981,397A
;  CURRENT FILING DATE:  2002-06-28
;  PRIOR APPLICATION NUMBER: 60/240,750
;  PRIOR FILING DATE: 2000-10-16
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic polyT primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: n = a,c,g or t
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: v = a,g or c
US-09-981-397A-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.6e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          1 TTTTTTTTTTTTTTTTV 17


RESULT 233
US-08-881-784-18
; Sequence 18, Application US/08881784
; Patent No. 6083731
;  GENERAL INFORMATION:
;    APPLICANT:  Croteau, Rodney B.
;    APPLICANT:  Lupien, Shari L.
;    APPLICANT:  Karp, Frank
;    TITLE OF INVENTION:  RECOMBINANT MATERIALS AND METHODS FOR
;    TITLE OF INVENTION:  THE PRODUCTION OF LIMONENE HYDROXYLASES
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen, O'Connor, Johnson and Kindness
;      ADDRESSEE:  PLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/881,784
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Shelton, Dennis K.
;      REGISTRATION NUMBER:  26,997
;      REFERENCE/DOCKET NUMBER:  WSUR19777
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 224-0718
;      TELEFAX:  (206) 224-0779
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..19
;      OTHER INFORMATION:  /product= "Primer 3.B (Table 1)"
US-08-881-784-18

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTH 19


RESULT 234
US-09-130-079-1/c
; Sequence 1, Application US/09130079
; Patent No. 6270966
;  GENERAL INFORMATION:
;    APPLICANT:  The United States of America, as represented by the
;    APPLICANT:  Secretary, Department of Health and Human Services
;    TITLE OF INVENTION:  RESTRICTION DISPLAY (RD-PCR) OF DIFFERENTIALLY EXPRESS
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson & Bear
;      STREET:  620 Newport Center Drive, 16th Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/130,079
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/011/379
;      FILING DATE:  09-FEB-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kirkpatrick, Anita M
;      REGISTRATION NUMBER:  32,617
;      REFERENCE/DOCKET NUMBER:  NIH108.001VPC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-235-8550
;      TELEFAX:  619-235-0176
;      TELEX:
```

```
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  mRNA
US-09-130-079-1

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db         18 TTTTTTTTTTTTTTTV 2


RESULT 235
US-09-292-768-18
; Sequence 18, Application US/09292768
; Patent No. 6194185
; GENERAL INFORMATION:
;  APPLICANT: Croteau, Rodney B
;  APPLICANT: Lupien, Shari L
;  APPLICANT: Karp, Frank
;  TITLE OF INVENTION: RECOMBINANT MATERIALS AND METHODS FOR THE PRODUCTION OF
;  TITLE OF INVENTION: LIMONENE HYDROXYLASES
;  FILE REFERENCE: wsur13463
;  CURRENT APPLICATION NUMBER: US/09/292,768
;  CURRENT FILING DATE: 1999-04-14
;  EARLIER APPLICATION NUMBER: 08/881,784
;  EARLIER FILING DATE: 1997-06-24
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer 3.B
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Oligonucleotide primer that primes the polyA tail
;   OTHER INFORMATION: on cDNA molecules
US-09-292-768-18

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTH 19


RESULT 236
US-09-371-307-85
; Sequence 85, Application US/09371307A
; Patent No. 6723897
; GENERAL INFORMATION:
;  APPLICANT: Brown, Sherri M.
;  APPLICANT: Heck, Gregory R.
;  APPLICANT: Piller, Kenneth J.
;  APPLICANT: Kishore, Ganesh M.
;  APPLICANT: Elich, Tedd D.
;  APPLICANT: Logusch, Eugene W.
;  APPLICANT: Rao, Sudabathula
;  APPLICANT: Ream, Joel E.
;  APPLICANT: Logusch, Sherry J.
;  TITLE OF INVENTION: Methods for controlling gibberellin levels
;  FILE REFERENCE: MOBT:216
;  CURRENT APPLICATION NUMBER: US/09/371,307A
;  CURRENT FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 89
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 85
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Primer
US-09-371-307-85

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTV 19


RESULT 237
US-10-103-614A-4/c
; Sequence 4, Application US/10103614A
; Patent No. 6716585
; GENERAL INFORMATION:
;  APPLICANT: SALMAN AL-MAHMOOD
;  TITLE OF INVENTION: METHOD FOR IDENTIFYING NOVEL GENES INVOLVED IN THE
;  TITLE OF INVENTION:  REGULATION OF ANGIOGENESIS, STUDY OF SAID GENES AND USE
;  TITLE OF INVENTION:  THEREOF FOR THERAPEUTIC PURPOSES
;  FILE REFERENCE: 1071-02
;  CURRENT APPLICATION NUMBER: US/10/103,614A
;  CURRENT FILING DATE:  2002-08-22
;  PRIOR APPLICATION NUMBER: PCT/FR00/02607
;  PRIOR FILING DATE: 2000-09-20
;  PRIOR APPLICATION NUMBER: FR 99/11790
;  PRIOR FILING DATE: 1999-09-21
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: a, t, c or g
;   NAME/KEY: modified_base
;   LOCATION: (19)
;   OTHER INFORMATION: a, t, c or g
US-10-103-614A-4

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db         18 TTTTTTTTTTTTTTTB 2


RESULT 238
US-10-176-884-44
; Sequence 44, Application US/10176884
; Patent No. 6906244
; GENERAL INFORMATION:
;  APPLICANT: Fischer, Robert
;  APPLICANT:  Kinoshita, Tetsu
;  APPLICANT:  Yadegari, Ramin
;  APPLICANT:  Gehring, Mary
;  APPLICANT:  Okamuro, Jack
;  APPLICANT:  Dang, Van-Dinh
```

```
;  APPLICANT:  The Regents of the University of California
;  APPLICANT:  Ceres, Inc.
;  TITLE OF INVENTION: Compositions and Methods for Modulating Plant
;  TITLE OF INVENTION:  Development
;  FILE REFERENCE: 02307O-116710US
;  CURRENT APPLICATION NUMBER: US/10/176,884
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: US 60/300,506
;  PRIOR FILING DATE: 2001-06-22
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo(dT)-18
;   OTHER INFORMATION: primer, oligo dTV
US-10-176-884-44

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::
Db          3 TTTTTTTTTTTTTTTTV 19


RESULT 239
US-09-762-867A-11
; Sequence 11, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 40
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-11

  Query Match             0.2%;  Score 16.2;  DB 1;  Length 40;
  Best Local Similarity   59.5%;  Pred. No. 8.1e+02;
  Matches   22;  Conservative    2;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        897 UAAGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              : | ||| ||   | ||||||   ||| ||  |:|||
Db          4 TCACACACACACACACACACACACACACACATACA 40


RESULT 240
US-07-971-978-36
; Sequence 36, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  1
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  2
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  3
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  5
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  6
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  7
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  8
;      OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
```

```
;       NAME/KEY:  Modified-site
;       LOCATION:  9
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  10
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  11
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  12
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  13
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  14
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
;     FEATURE:
;       NAME/KEY:  Modified-site
;       LOCATION:  15
;       OTHER INFORMATION:  5-fluoro-2'-deoxyuridine
;       OTHER INFORMATION:  substitution
US-07-971-978-36

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 241
US-07-971-978-42
; Sequence 42, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  42:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  1
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  2
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  3
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  5
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  6
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  7
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  8
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  9
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  10
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  11
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
```

```
;      LOCATION:  12
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
;      OTHER INFORMATION:  5-bromo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
US-07-971-978-42

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 242
US-07-971-978-60
; Sequence 60, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  60:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  1
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  2
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  3
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  5
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  6
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  7
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  8
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  9
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  10
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  11
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  12
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
```

```
;      OTHER INFORMATION:  5-iodo-2'-deoxyuridine
;      OTHER INFORMATION:  substitution
US-07-971-978-60

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 243
US-08-087-387-6
; Sequence 6, Application US/08087387
; Patent No. 5473060
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic andtherapeutic applic
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/087,387
;      FILING DATE:  19930702
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-087-387-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16


RESULT 244
US-08-222-177A-439/c
; Sequence 439, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  439:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-439

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 2.9e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTGTG 1


RESULT 245
US-08-415-370-2
; Sequence 2, Application US/08415370
; Patent No. 5801155
;  GENERAL INFORMATION:
;    APPLICANT:  Kutyavin, Igor V.
;    APPLICANT:  Lukhtanov, Eugeny A.
;    APPLICANT:  Gamper, Howard B.
;    APPLICANT:  Meyer, Jr., Rich B.
;    TITLE OF INVENTION:  COVALENTLY LINKED OLIGONUCLEOTIDE MINOR
;    TITLE OF INVENTION:  GROOVE BINDER CONJUGATES
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  KLEIN & SZEKERES
;      STREET:  4199 Campus Drive, Suite 700
;      CITY:  Irvine
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92715
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/415,370
;      FILING DATE:  03-APR-1995
;      CLASSIFICATION:  536
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Szekeres, Gabor L.
;      REGISTRATION NUMBER:  28,675
;      REFERENCE/DOCKET NUMBER:  491-09-PA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-854-5502
;      TELEFAX:  714-854-4897
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-415-370-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 246
US-08-455-627-6
; Sequence 6, Application US/08455627
; Patent No. 5571677
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-627-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16


RESULT 247
US-08-461-271-6
; Sequence 6, Application US/08461271
; Patent No. 5741643
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/461,271
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-461-271-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16


RESULT 248
US-08-687-551-15
; Sequence 15, Application US/08687551
; Patent No. 5856435
;  GENERAL INFORMATION:
;    APPLICANT:  BAZILE, Didier
;    APPLICANT:  EMILE, Carole
;    APPLICANT:  HELENE, Claude
;    APPLICANT:  SPENLEHAUER, Gilles
;    TITLE OF INVENTION:  NUCLEIC ACID-CONTAINING COMPOSITION, ITS
;    TITLE OF INVENTION:  PREPARATION AND USE
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rhone-Poulenc Rorer Inc.
;      STREET:  500 Arcola Rd. 3C43
;      CITY:  Collegeville
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19426
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/687,551
;       FILING DATE:
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  FR 94/01381
;       FILING DATE:  08-FEB-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  WO PCT/FR95/00098
;       FILING DATE:  27-JAN-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Smith Ph.D., Julie K.
;       REGISTRATION NUMBER:  38,619
;       REFERENCE/DOCKET NUMBER:  ST94007-US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (610)454-3839
;       TELEFAX:  (610)454-3808
;   INFORMATION FOR SEQ ID NO:  15:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "oligonucleotide"
US-08-687-551-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 249
US-08-689-856-6
; Sequence 6, Application US/08689856
; Patent No. 5830658
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,856
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-843-5000
;       TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 nucleotides
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-689-856-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16


RESULT 250
US-08-713-685A-6
; Sequence 6, Application US/08713685A
; Patent No. 5817795
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:.
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/713,685A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/461,271
;      FILING DATE:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-713-685A-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16
```

```
RESULT 251
US-08-851-843A-131/c
; Sequence 131, Application US/08851843A
; Patent No. 6093809
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. 6093809el Telomerase
;    NUMBER OF SEQUENCES:  225
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/851,843A
;      FILING DATE:  06-MAY-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/846,017
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/844,419
;      FILING DATE:  18-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/724,643
;      FILING DATE:  01-OCT-1996
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Apple,  Randolph T.
;      REGISTRATION NUMBER:  36,429
;      REFERENCE/DOCKET NUMBER:  015389-002930US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  131:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-851-843A-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 252
US-08-854-050-131/c
; Sequence 131, Application US/08854050
; Patent No. 6261836
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. 6261836el Telomerase
;    NUMBER OF SEQUENCES:  225
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/854,050
;      FILING DATE:  09-MAY-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/851,843
;      FILING DATE:  06-MAY-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/846,017
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/844,419
;      FILING DATE:  18-APR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/724,643
;      FILING DATE:  01-OCT-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Apple,  Randolph T.
;      REGISTRATION NUMBER:  36,429
;      REFERENCE/DOCKET NUMBER:  015389-002930US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  131:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-854-050-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 253
US-09-070-477-6
; Sequence 6, Application US/09070477
; Patent No. 6048974
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/070,477
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/713,685
;      FILING DATE:
;      APPLICATION NUMBER:  08/461,271
;      FILING DATE:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-070-477-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   12.5%;  Pred. No. 2.9e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||:::::::::::::::
Db          1 ACTTTTTTTTTTTTTT 16


RESULT 254
US-09-141-764-2
; Sequence 2, Application US/09141764
; Patent No. 6084102
;  GENERAL INFORMATION:
;    APPLICANT:  Kutyavin, Igor V.
;    APPLICANT:  Lukhtanov, Eugeny A.
;    APPLICANT:  Gamper, Howard B.
;    APPLICANT:  Meyer, Jr., Rich B.
;    TITLE OF INVENTION:  COVALENTLY LINKED OLIGONUCLEOTIDE
;    TITLE OF INVENTION:  MINOR
;    TITLE OF INVENTION:  GROOVE BINDER CONJUGATES
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  KLEIN & SZEKERES
;      STREET:  4199 Campus Drive, Suite 700
;      CITY:  Irvine
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92715
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/141,764
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/415,370
;      FILING DATE:  03-APR-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Szekeres, Gabor L.
;      REGISTRATION NUMBER:  28,675
;      REFERENCE/DOCKET NUMBER:  491-09-PA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-854-5502
;      TELEFAX:  714-854-4897
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-141-764-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 255
US-09-152-059-70
; Sequence 70, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165 (71994)
;  CURRENT APPLICATION NUMBER: US/09/152,059
;  CURRENT FILING DATE:  1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn'Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-152-059-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 256
US-09-430-323-131/c
; Sequence 131, Application US/09430323
; Patent No. 6309867
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. 6309867el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/430,323
;             FILING DATE: 29-Oct-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/854,050
;             FILING DATE: 09-MAY-1997
;             APPLICATION NUMBER: US 08/851,843
;             FILING DATE: 06-MAY-1997
;             APPLICATION NUMBER: US 08/846,017
;             FILING DATE: 25-APR-1997
;             APPLICATION NUMBER: US 08/844,419
;             FILING DATE: 18-APR-1997
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002930US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 131:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-09-430-323-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 257
US-09-438-486A-131/c
; Sequence 131, Application US/09438486A
; Patent No. 6927285
; GENERAL INFORMATION:
; APPLICANT: CECH, THOMAS R.
; APPLICANT:  LINGNER, JOACHIM
; APPLICANT:  NAKAMURA, TORU
; APPLICANT:  CHAPMAN, KAREN B.
; APPLICANT:  MORIN, GREGG B.
; APPLICANT:  HARLEY, CALVIN
; APPLICANT:  ANDREWS, WILLIAM H.
; TITLE OF INVENTION: GENE FOR HUMAN TELOMERASE REVERSE TRANSCRIPTASE AND
; TITLE OF INVENTION:  TELOMERASE VARIANTS
; FILE REFERENCE: 018/062
; CURRENT APPLICATION NUMBER: US/09/438,486A
; CURRENT FILING DATE:  1999-11-12
; PRIOR APPLICATION NUMBER: 08/851,843
; PRIOR FILING DATE: 1997-05-06
; PRIOR APPLICATION NUMBER: 08/846,017
; PRIOR FILING DATE: 1997-04-25
; PRIOR APPLICATION NUMBER: 08/844,419
; PRIOR FILING DATE: 1997-04-18
; PRIOR APPLICATION NUMBER: 08/724,643
; PRIOR FILING DATE: 1996-10-01
; NUMBER OF SEQ ID NOS: 223
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 131
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-09-438-486A-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 258
US-09-507-345A-2
; Sequence 2, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/507,345A
;             FILING DATE: 18-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;        ATTORNEY/AGENT INFORMATION:
```

```
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003500US
;       TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 2:
;       SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-507-345A-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 259
US-09-619-103-22/c
; Sequence 22, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 260
US-09-739-928-2
; Sequence 2, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/739,928
;            FILING DATE: 11-May-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;            APPLICATION NUMBER: US 09/507,345
;            FILING DATE: 18-FEB-2000
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003510US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 2:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-739-928-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 261
US-09-762-867A-26/c
; Sequence 26, Application US/09762867A
; Patent No. 6919443
; GENERAL INFORMATION:
;  APPLICANT: Takahashi, Hideaki
;  APPLICANT:  Sekino, Masashi
;  TITLE OF INVENTION: METHOD FOR ISOLATING SATELLITE SEQUENCES
;  FILE REFERENCE: 201487/1060
;  CURRENT APPLICATION NUMBER: US/09/762,867A
;  CURRENT FILING DATE:  2001-02-14
;  PRIOR APPLICATION NUMBER: JP 10/232153
;  PRIOR FILING DATE: 1998-08-18
;  PRIOR APPLICATION NUMBER: PCT/JP99/03551
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Haliotis discus discus
US-09-762-867A-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 2.9e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTGTG 1


RESULT 262
US-09-766-253-131/c
; Sequence 131, Application US/09766253
; Patent No. 6808880
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. 6808880el Telomerase
;        NUMBER OF SEQUENCES: 171
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/766,253
;             FILING DATE: 19-Jan-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/846,017
;             FILING DATE: 1997-04-25
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002920US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 131:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-09-766-253-131

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 263
US-09-895-585-9
; Sequence 9, Application US/09895585
; Patent No. 6759039
; GENERAL INFORMATION:
;  APPLICANT: Tsang, Wen-Ghih
;  APPLICANT:  Zheng, Tianli
;  APPLICANT:  Huang, Chang Jiang
;  APPLICANT:  AmCyte, Inc.
;  TITLE OF INVENTION: Culturing Pancreatic Stem Cells Having a Specified,
;  TITLE OF INVENTION:  Intermediate Stage of Development
;  FILE REFERENCE: 021164-000100US
;  CURRENT APPLICATION NUMBER: US/09/895,585
;  CURRENT FILING DATE:  2002-12-10
;  PRIOR APPLICATION NUMBER: US 60/215,634
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 60/246,306
;  PRIOR FILING DATE: 2000-11-06
;  PRIOR APPLICATION NUMBER: US 60/291,787
;  PRIOR FILING DATE: 2001-05-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo-(dT)-16
US-09-895-585-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 264
US-09-958-610A-1/c
; Sequence 1, Application US/09958610A
; Patent No. 6756492
; GENERAL INFORMATION:
;  APPLICANT: Beier, Markus
;  APPLICANT:  Hoheisel, Jorg
;  TITLE OF INVENTION: Nucleoside Derivatives with Photolabile Protective Groups
;  FILE REFERENCE: 03528.0135.PCUS00
;  CURRENT APPLICATION NUMBER: US/09/958,610A
;  CURRENT FILING DATE:  2002-02-21
;  PRIOR APPLICATION NUMBER: PCT/DE00/011448
;  PRIOR FILING DATE: 2000-04-07
;  PRIOR APPLICATION NUMBER: DE 100 03 631.7
;  PRIOR FILING DATE: 2000-01-28
;  PRIOR APPLICATION NUMBER: DE 199 15. 867.3
;  PRIOR FILING DATE: 1999-04-08
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-09-958-610A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 265
US-10-054-295-131/c
; Sequence 131, Application US/10054295
; Patent No. 6921664
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
```

```
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;         TITLE OF INVENTION: No. 6921664el Telomerase
;         NUMBER OF SEQUENCES: 225
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Townsend and Townsend and Crew LLP
;              STREET: Two Embarcadero Center, 8th Floor
;              CITY: San Francisco
;              STATE: California
;              COUNTRY: United States of America
;              ZIP: 94111
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,295
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 131:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 16 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-10-054-295-131

  Query Match           0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 266
US-10-054-611-131/c
; Sequence 131, Application US/10054611
; Patent No. 7005262
;   GENERAL INFORMATION:
;         APPLICANT: Cech, Thomas R.
;                    Lingner, Joachim
;                    Nakamura, Toru
;                    Chapman, Karen B.
;                    Morin, Gregg B.
;                    Harley, Calvin
;                    Andrews, William H.
;         TITLE OF INVENTION: No. 7005262el Telomerase
;         NUMBER OF SEQUENCES: 225
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Townsend and Townsend and Crew LLP
;              STREET: Two Embarcadero Center, 8th Floor
;              CITY: San Francisco
;              STATE: California
;              COUNTRY: United States of America
;              ZIP: 94111
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/054,611
;              FILING DATE: 18-Jan-2002
;              CLASSIFICATION: 536
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/854,050
;              FILING DATE: <Unknown>
;              APPLICATION NUMBER: US 08/846,017
;              FILING DATE: 25-APR-1997
;              APPLICATION NUMBER: US 08/844,419
;              FILING DATE: 18-APR-1997
;              APPLICATION NUMBER: US 08/724,643
;              FILING DATE: 01-OCT-1996
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Apple,  Randolph T.
;              REGISTRATION NUMBER: 36,429
;              REFERENCE/DOCKET NUMBER: 015389-002930US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 131:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 16 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 131:
US-10-054-611-131

  Query Match           0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 267
US-10-072-975-9
; Sequence 9, Application US/10072975
; Patent No. 6962906
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1.1US
;  CURRENT APPLICATION NUMBER: US/10/072,975
;  CURRENT FILING DATE:  2002-02-09
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  PRIOR APPLICATION NUMBER: 09/805,296
;  PRIOR FILING DATE: 2001-03-13
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/0811
;  PRIOR FILING DATE: 2001-03-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Construct
US-10-072-975-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 268
US-10-203-780-9
; Sequence 9, Application US/10203780
; Patent No. 6861515
; GENERAL INFORMATION:
;  APPLICANT: CUZIN, MARC
;  APPLICANT:  PELTIE, PHILIPPE
;  APPLICANT:  FONTECAVE, MARC
;  APPLICANT:  DECOUT, JEAN-LUC
;  APPLICANT:  DUEYMES, CECILE
;  TITLE OF INVENTION: ANALYSIS OF BIOLOGICAL TARGETS USING A BIOCHIP COMPRISING A FLUOR
;  TITLE OF INVENTION:  MARKER
;  FILE REFERENCE: 226286US0XPCT
;  CURRENT APPLICATION NUMBER: US/10/203,780
;  CURRENT FILING DATE:  2002-11-25
;  PRIOR APPLICATION NUMBER: PCT/FR01/00516
;  PRIOR FILING DATE: 2001-02-22
;  PRIOR APPLICATION NUMBER: FR 00 02236
;  PRIOR FILING DATE: 2000-02-23
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: t is modified with a covalent linkage to flavin
US-10-203-780-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 269
US-10-208-650-70
; Sequence 70, Application US/10208650
; Patent No. 7034133
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165-C2(71994)
;  CURRENT APPLICATION NUMBER: US/10/208,650
;  CURRENT FILING DATE:  2002-07-29
;  PRIOR APPLICATION NUMBER: US/10/008,029
;  PRIOR FILING DATE: 2001-11-05
;  PRIOR APPLICATION NUMBER: 09/152,059
;  PRIOR FILING DATE: 1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-208-650-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 270
US-10-227-001-21
; Sequence 21, Application US/10227001
; Patent No. 6951930
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Afonina, Irina Aleksandrovna
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: Hybridization-Triggered Fluorescent
;  TITLE OF INVENTION:  Detection of Nucleic Acids
;  FILE REFERENCE: 17682A-004210US
;  CURRENT APPLICATION NUMBER: US/10/227,001
;  CURRENT FILING DATE:  2002-08-21
;  PRIOR APPLICATION NUMBER: US 09/428,236
;  PRIOR FILING DATE: 1999-10-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 21
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: R2 (ODN) of fluorophore-MGB-ODN
;   OTHER INFORMATION: conjugate
US-10-227-001-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 2.9e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
```

```
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 271
US-08-821-827C-30
; Sequence 30, Application US/08821827C
; Patent No. 6297425
; GENERAL INFORMATION:
;  APPLICANT: Scelonge, Christopher J.
;  APPLICANT:  Bidney, Dennis L.
;  TITLE OF INVENTION: GENE ENCODING OXALATE DECARBOXYLASE FROM
;  TITLE OF INVENTION:  ASPERGILLUS PHOENICES
;  FILE REFERENCE: 0561A
;  CURRENT APPLICATION NUMBER: US/08/821,827C
;  CURRENT FILING DATE:  1997-03-21
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(17)
;   OTHER INFORMATION: n = A,T,C or G
US-08-821-827C-30

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17


RESULT 272
US-08-851-843A-132
; Sequence 132, Application US/08851843A
; Patent No. 6093809
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. 6093809el Telomerase
;    NUMBER OF SEQUENCES:  225
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/851,843A
;      FILING DATE:  06-MAY-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/846,017
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/844,419
;      FILING DATE:  18-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/724,643
;      FILING DATE:  01-OCT-1996
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Apple,  Randolph T.
;      REGISTRATION NUMBER:  36,429
;      REFERENCE/DOCKET NUMBER:  015389-002930US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  132:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-851-843A-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 273
US-08-854-050-132
; Sequence 132, Application US/08854050
; Patent No. 6261836
;  GENERAL INFORMATION:
;    APPLICANT:  Cech, Thomas R.
;    APPLICANT:  Lingner, Joachim
;    APPLICANT:  Nakamura, Toru
;    APPLICANT:  Chapman, Karen B.
;    APPLICANT:  Morin, Gregg B.
;    APPLICANT:  Harley, Calvin
;    APPLICANT:  Andrews, William H.
;    TITLE OF INVENTION:  No. 6261836el Telomerase
;    NUMBER OF SEQUENCES:  225
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/854,050
;      FILING DATE:  09-MAY-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/851,843
;      FILING DATE:  06-MAY-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/846,017
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/844,419
;      FILING DATE:  18-APR-1997
;      CLASSIFICATION:  536
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/724,643
;      FILING DATE:  01-OCT-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Apple,  Randolph T.
;      REGISTRATION NUMBER:  36,429
;      REFERENCE/DOCKET NUMBER:  015389-002930US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  132:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-854-050-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 274
US-08-885-126-9
; Sequence 9, Application US/08885126A
; Patent No. 5955597
; GENERAL INFORMATION:
;  APPLICANT: Arnold, Lyle J.
;  APPLICANT: Riley, Timothy A.
;  APPLICANT: Reynolds, Mark A.
;  APPLICANT: Schwartz, David A.
;  TITLE OF INVENTION: CHIRALLY ENRICHED SYNTHETIC PHOSPHATE
;  TITLE OF INVENTION: OLIGOMERS
;  FILE REFERENCE: GENTA.020FW2
;  CURRENT APPLICATION NUMBER: US/08/885,126A
;  CURRENT FILING DATE: 1997-06-30
;  EARLIER APPLICATION NUMBER: 08/343,018
;  EARLIER FILING DATE: 1994-11-21
;  EARLIER APPLICATION NUMBER: 08/154,013
;  EARLIER FILING DATE: 1993-11-16
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Chemically synthesized oligomer
US-08-885-126-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGU 6989
              |:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGT 16


RESULT 275
US-08-960-111-11
; Sequence 11, Application US/08960111
; Patent No. 6060456
;  GENERAL INFORMATION:
;    APPLICANT:  Arnold Jr., Lyle J
;    APPLICANT:  Reynolds, Mark A
;    APPLICANT:  Giachetti, Christina
;    TITLE OF INVENTION:  Chimeric Oligonucleoside Compounds
;    NUMBER OF SEQUENCES:  27
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth St.
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/960,111
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/238,177
;      FILING DATE:  04-MAY-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meier, Paul H.
;      REGISTRATION NUMBER:  32,274
;      REFERENCE/DOCKET NUMBER:  207/174
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  213/489-1600
;      TELEFAX:  213/955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  GT oligomers 2517-1, 2516-1
;      IDENTIFICATION METHOD:  synthesis experiments
;      OTHER INFORMATION:  complementary to synthetic RNA
;      OTHER INFORMATION:  target
US-08-960-111-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGU 6989
              |:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGT 16


RESULT 276
US-09-090-672B-107
; Sequence 107, Application US/09090672B
; Patent No. 6828428
;  GENERAL INFORMATION:
;    APPLICANT:  Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
;    APPLICANT:  Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
;    APPLICANT:  Shigemasa; Takei, Masami
;    TITLE OF INVENTION:  IgA Nephropathy-Related Genes
;    NUMBER OF SEQUENCES:  111
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fitzpatrick, Cella, Harper & Scinto
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      ZIP:  10112-3801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  Compaq PC
```

```
;       OPERATING SYSTEM:  Windows 95
;       SOFTWARE:  WordPerfect 8.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/090,672B
;       FILING DATE:  04-JUNE-1998
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/JP97/04468
;       FILING DATE:  05-DEC-1997
;       APPLICATION NUMBER:  JP-8-325763
;       FILING DATE:  05-DEC-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Perry, Lawrence S.
;       REGISTRATION NUMBER:  31865
;       REFERENCE/DOCKET NUMBER:  766.21
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (212) 218-2100
;       TELEFAX:  (212) 218-2200
;   INFORMATION FOR SEQ ID NO:  107:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid, synthetic DNA
US-09-090-672B-107

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 3.3e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 277
US-09-129-603-4
; Sequence 4, Application US/09129603A
; Patent No. 6790944
; GENERAL INFORMATION:
;  APPLICANT: Ishiwata, Tetsuyoshi
;  APPLICANT: Sakurada, Mikiko
;  APPLICANT: Nishimura, Ayako
;  APPLICANT: Nakagawa, Satoshi
;  APPLICANT: Kuga, Tetsuro
;  APPLICANT: Nishi, Tatsunari
;  APPLICANT: No. 6790944ura, No. 6790944uo
;  APPLICANT: Sawada, Shigemasa
;  APPLICANT: Nagase, Takahiro
;  APPLICANT: Takei, Masami
;  TITLE OF INVENTION: No. 6790944el Protein
;  FILE REFERENCE: 766.25
;  CURRENT APPLICATION NUMBER: US/09/129,603A
;  CURRENT FILING DATE: 1998-08-05
;  EARLIER APPLICATION NUMBER: PCT/JP97/04469
;  EARLIER FILING DATE: 1997-12-05
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: other nucleic acid from homo sapiens, synthesized
;   OTHER INFORMATION: DNA
US-09-129-603-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 3.3e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 278
US-09-250-075-5
; Sequence 5, Application US/09250075
; Patent No. 6207819
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A
;  TITLE OF INVENTION:  Compounds Processes And Intermediates For Synthesis Of
;  TITLE OF INVENTION:  Mixed Backbone Oligomeric Compounds
;  FILE REFERENCE:  ISIS3299
;  CURRENT APPLICATION NUMBER: US/09/250,075
;  CURRENT FILING DATE:  1999-02-12
;  NUMBER OF SEQ ID NOS:  12
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE); modified linkage
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6207819el
;   OTHER INFORMATION: Sequence
US-09-250-075-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 279
US-09-290-202B-30
; Sequence 30, Application US/09290202B
; Patent No. 6303846
; GENERAL INFORMATION:
;  APPLICANT: Scelonge, Christopher J.
;  APPLICANT:  Bidney, Dennis L.
;  TITLE OF INVENTION: GENE ENCODING OXALATE DECARBOXYLASE FROM
;  TITLE OF INVENTION:  ASPERGILLUS PHOENICES
;  FILE REFERENCE: 0561D
;  CURRENT APPLICATION NUMBER: US/09/290,202B
;  CURRENT FILING DATE:  1999-04-12
;  PRIOR APPLICATION NUMBER: 08/821,827
;  PRIOR FILING DATE: 1997-03-21
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 30
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(17)
;   OTHER INFORMATION: n = A,T,C or G
US-09-290-202B-30

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17
```

```
RESULT 280
US-09-430-323-132
; Sequence 132, Application US/09430323
; Patent No. 6309867
;  GENERAL INFORMATION:
;       APPLICANT: Cech, Thomas R.
;                  Lingner, Joachim
;                  Nakamura, Toru
;                  Chapman, Karen B.
;                  Morin, Gregg B.
;                  Harley, Calvin
;                  Andrews, William H.
;       TITLE OF INVENTION: No. 6309867el Telomerase
;       NUMBER OF SEQUENCES: 225
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, 8th Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States of America
;            ZIP: 94111
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/430,323
;            FILING DATE: 29-Oct-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/854,050
;            FILING DATE: 09-MAY-1997
;            APPLICATION NUMBER: US 08/851,843
;            FILING DATE: 06-MAY-1997
;            APPLICATION NUMBER: US 08/846,017
;            FILING DATE: 25-APR-1997
;            APPLICATION NUMBER: US 08/844,419
;            FILING DATE: 18-APR-1997
;            APPLICATION NUMBER: US 08/724,643
;            FILING DATE: 01-OCT-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Apple,  Randolph T.
;            REGISTRATION NUMBER: 36,429
;            REFERENCE/DOCKET NUMBER: 015389-002930US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 17 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-430-323-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 281
US-09-438-486A-132
; Sequence 132, Application US/09438486A
; Patent No. 6927285
; GENERAL INFORMATION:
;  APPLICANT: CECH, THOMAS R.
;  APPLICANT:  LINGNER, JOACHIM
;  APPLICANT:  NAKAMURA, TORU
;  APPLICANT:  CHAPMAN, KAREN B.
;  APPLICANT:  MORIN, GREGG B.
;  APPLICANT:  HARLEY, CALVIN
;  APPLICANT:  ANDREWS, WILLIAM H.
;  TITLE OF INVENTION: GENE FOR HUMAN TELOMERASE REVERSE TRANSCRIPTASE AND
;  TITLE OF INVENTION:  TELOMERASE VARIANTS
;  FILE REFERENCE: 018/062
;  CURRENT APPLICATION NUMBER: US/09/438,486A
;  CURRENT FILING DATE:  1999-11-12
;  PRIOR APPLICATION NUMBER: 08/851,843
;  PRIOR FILING DATE: 1997-05-06
;  PRIOR APPLICATION NUMBER: 08/846,017
;  PRIOR FILING DATE: 1997-04-25
;  PRIOR APPLICATION NUMBER: 08/844,419
;  PRIOR FILING DATE: 1997-04-18
;  PRIOR APPLICATION NUMBER: 08/724,643
;  PRIOR FILING DATE: 1996-10-01
;  NUMBER OF SEQ ID NOS: 223
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 132
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-09-438-486A-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 282
US-09-490-774-11
; Sequence 11, Application US/09490774
; Patent No. 6262036
;  GENERAL INFORMATION:
;    APPLICANT:  Arnold Jr., Lyle J
;    APPLICANT:  Reynolds, Mark A
;    APPLICANT:  Giachetti, Christina
;    TITLE OF INVENTION:  Chimeric Oligonucleoside Compounds
;    NUMBER OF SEQUENCES:  27
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth St.
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/490,774
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/960,111
;      FILING DATE:
;      APPLICATION NUMBER:  US/08/238,177
;      FILING DATE:  04-MAY-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meier, Paul H.
;      REGISTRATION NUMBER:  32,274
```

```
;      REFERENCE/DOCKET NUMBER:  207/174
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  213/489-1600
;      TELEFAX:  213/955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  GT oligomers 2517-1, 2516-1
;      IDENTIFICATION METHOD:  synthesis experiments
;      OTHER INFORMATION:  complementary to synthetic RNA
;      OTHER INFORMATION:  target
US-09-490-774-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGU 6989
              |:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGT 16


RESULT 283
US-09-619-103-23/c
; Sequence 23, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 284
US-09-726-096A-5
; Sequence 5, Application US/09726096A
; Patent No. 6462184
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Back
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS4528
;  CURRENT APPLICATION NUMBER: US/09/726,096A
;  CURRENT FILING DATE:  2000-11-29
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE); phosphorothioate
;   OTHER INFORMATION: internucleoside linkage
US-09-726-096A-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 285
US-09-730-559B-109
; Sequence 109, Application US/09730559B
; Patent No. 6962984
; GENERAL INFORMATION:
;  APPLICANT: ISHIWATA, TETSUYOSHI
;  APPLICANT:  SAKURADA, MIKIKO
;  APPLICANT:  KAWABATA, AYAKO
;  APPLICANT:  NAKAGAWA, SATOSHI
;  APPLICANT:  NISHI, TATSUNARI
;  APPLICANT:  KUGA, TETSURO
;  APPLICANT:  SAWADA, SHIGEMASA
;  APPLICANT:  TAKEI, MASAMI
;  APPLICANT:  SHIBATA, KENJI
;  APPLICANT:  FURUYA, AKIKO
;  TITLE OF INVENTION: IgA NEPHROPATHY-ASSOCIATED GENE
;  FILE REFERENCE: 766.21 CIP
;  CURRENT APPLICATION NUMBER: US/09/730,559B
;  CURRENT FILING DATE:  2000-12-07
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 109
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-730-559B-109

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 3.3e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 17


RESULT 286
US-09-766-253-132
; Sequence 132, Application US/09766253
; Patent No. 6808880
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
```

```
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. 6808880el Telomerase
;        NUMBER OF SEQUENCES: 171
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/766,253
;             FILING DATE: 19-Jan-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/846,017
;             FILING DATE: 1997-04-25
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002920US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-766-253-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 287
US-09-958-221A-16
; Sequence 16, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 288
US-09-958-221A-17
; Sequence 17, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTG 17


RESULT 289
US-09-958-221A-20/c
; Sequence 20, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
```

```
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 290
US-09-958-221A-21/c
; Sequence 21, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTGTG 2


RESULT 291
US-10-019-832-3
; Sequence 3, Application US/10019832
; Patent No. 6986990
; GENERAL INFORMATION:
;  APPLICANT: Genox Research, Inc.
;  TITLE OF INVENTION: POLLEN ALLERGY-RELATED GENE 513
;  FILE REFERENCE: G1-103PCT
;  CURRENT APPLICATION NUMBER: US/10/019,832
;  CURRENT FILING DATE:  2001-10-26
;  PRIOR APPLICATION NUMBER: JP   1999-120491
;  PRIOR FILING DATE: 1999-04-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Artificially
;   OTHER INFORMATION: Synthesized Primer Sequence
US-10-019-832-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 3.3e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::|
Db          2 TTTTTTTTTTTTTTC 17


RESULT 292
US-10-054-295-132
; Sequence 132, Application US/10054295
; Patent No. 6921664
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
;                   Morin, Gregg B.
;                   Harley, Calvin
;                   Andrews, William H.
;        TITLE OF INVENTION: No. 6921664el Telomerase
;        NUMBER OF SEQUENCES: 225
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: United States of America
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/054,295
;             FILING DATE: 18-Jan-2002
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/854,050
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/846,017
;             FILING DATE: 25-APR-1997
;             APPLICATION NUMBER: US 08/844,419
;             FILING DATE: 18-APR-1997
;             APPLICATION NUMBER: US 08/724,643
;             FILING DATE: 01-OCT-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Apple,  Randolph T.
;             REGISTRATION NUMBER: 36,429
;             REFERENCE/DOCKET NUMBER: 015389-002930US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-10-054-295-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 293
US-10-054-611-132
; Sequence 132, Application US/10054611
; Patent No. 7005262
;   GENERAL INFORMATION:
;        APPLICANT: Cech, Thomas R.
;                   Lingner, Joachim
;                   Nakamura, Toru
;                   Chapman, Karen B.
```

```
;                 Morin, Gregg B.
;                 Harley, Calvin
;                 Andrews, William H.
;       TITLE OF INVENTION: No. 7005262el Telomerase
;       NUMBER OF SEQUENCES: 225
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, 8th Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: United States of America
;            ZIP: 94111
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/054,611
;            FILING DATE: 18-Jan-2002
;            CLASSIFICATION: 536
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/854,050
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 08/846,017
;            FILING DATE: 25-APR-1997
;            APPLICATION NUMBER: US 08/844,419
;            FILING DATE: 18-APR-1997
;            APPLICATION NUMBER: US 08/724,643
;            FILING DATE: 01-OCT-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Apple,  Randolph T.
;            REGISTRATION NUMBER: 36,429
;            REFERENCE/DOCKET NUMBER: 015389-002930US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 132:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 17 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-10-054-611-132

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 294
PCT-US94-05407-4
; Sequence 4, Application PC/TUS9405407
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  "NUCLEIC ACID TAGGED IMMUNOASSAY"
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/05407
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/061,694
;      FILING DATE:  13-MAY-1993
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  oligonucleotide
PCT-US94-05407-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 295
US-08-295-509B-4
; Sequence 4, Application US/08295509B
; Patent No. 6045995
;  GENERAL INFORMATION:
;    APPLICANT:  Cummins, Lendell L.
;    APPLICANT:  Freier, Susan M.
;    APPLICANT:  Griffey, Richard
;    APPLICANT:  Srivatsa, Susan G.
;    TITLE OF INVENTION:  Capillary Electrophoretic Detection of
;    TITLE OF INVENTION:  Nucleic Acids
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6045995ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/295,509B
;      FILING DATE:  24-AUG-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Michael P. Straher
;      REGISTRATION NUMBER:  38,325
;      REFERENCE/DOCKET NUMBER:  ISIS-1395
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-295-509B-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db          1 TTTTTTTTTTTTTTT 16


RESULT 296
US-08-346-429-3/c
; Sequence 3, Application US/08346429
; Patent No. 5837820
;  GENERAL INFORMATION:
;    APPLICANT:  DeRose, Richard
;    APPLICANT:  Douce, Roland
;    APPLICANT:  Duval, Manuel
;    APPLICANT:  Job, Claudette
;    APPLICANT:  Job, Dominique
;    TITLE OF INVENTION:  PROTEIN CAPABLE OF BEING BIOTINYLATED WHICH CAN
;    TITLE OF INVENTION:  BE USED FOR DETERMINING THE GERMINATION STAGE OF
;    TITLE OF INVENTION:  A SEED
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY SCOTT MURPHY & PRESSER
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/346,429
;      FILING DATE:  29-NOV-1994
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9507
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  516-742-4343
;      TELEFAX:  516-742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-346-429-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 297
US-08-358-556A-12
; Sequence 12, Application US/08358556A
; Patent No. 5869643
;  GENERAL INFORMATION:
;    APPLICANT:  Chatelain, Francois
;    APPLICANT:  Kumarev, Viktor
;    TITLE OF INVENTION:  Process for Preparing Polynucleotides on
;    TITLE OF INVENTION:  a Solid Support and Apparatus Permitting its
;    TITLE OF INVENTION:  Implementation
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/358,556A
;      FILING DATE:  14-DEC-1994
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9315164
;      FILING DATE:  16-DEC-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  N-terminal
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..18
US-08-358-556A-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 298
US-08-358-556A-18/c
; Sequence 18, Application US/08358556A
; Patent No. 5869643
;  GENERAL INFORMATION:
;    APPLICANT:  Chatelain, Francois
;    APPLICANT:  Kumarev, Viktor
;    TITLE OF INVENTION:  Process for Preparing Polynucleotides on
;    TITLE OF INVENTION:  a Solid Support and Apparatus Permitting its
;    TITLE OF INVENTION:  Implementation
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/358,556A
;      FILING DATE:  14-DEC-1994
;      CLASSIFICATION:  536
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9315164
;      FILING DATE:  16-DEC-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  N-terminal
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..18
US-08-358-556A-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 299
US-08-469-852A-4
; Sequence 4, Application US/08469852A
; Patent No. 5874213
;  GENERAL INFORMATION:
;    APPLICANT:  Cummins, Lendell L.
;    APPLICANT:  Freier, Susan M.
;    APPLICANT:  Griffey, Richard
;    APPLICANT:  Srivatsa, Susan G.
;    TITLE OF INVENTION:  Capillary Electrophoretic Detection of
;    TITLE OF INVENTION:  Nucleic Acids
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5874213ris LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/469,852A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/295,509
;      FILING DATE:  24-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Michael P. Straher
;      REGISTRATION NUMBER:  38,325
;      REFERENCE/DOCKET NUMBER:  ISIS-2015
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-469-852A-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 300
US-08-621-914A-16
; Sequence 16, Application US/08621914A
; Patent No. 5707807
;  GENERAL INFORMATION:
;    APPLICANT:  KATO, KIKUYA
;    TITLE OF INVENTION:  MOLECULAR INDEXING FOR EXPRESSED GENE
;    TITLE OF INVENTION:  ANALYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 AVENUE OF THE AMERICAS
;      CITY:  NEW YORK
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/621,914A
;      FILING DATE:  26-MAR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LAWRENCE III, STANTON T.
;      REGISTRATION NUMBER:  25,736
;      REFERENCE/DOCKET NUMBER:  7005-107-999
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  other nucleic acid
US-08-621-914A-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 301
US-08-734-973-1/c
; Sequence 1, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  1 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.8e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTGTG 1


RESULT 302
US-08-734-973-3/c
; Sequence 3, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  3 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.8e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTGTG 1


RESULT 303
US-08-734-973-34/c
; Sequence 34, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  34 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-34

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.8e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6973 UGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTG 1


RESULT 304
US-08-734-973-36/c
; Sequence 36, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  36 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-36

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 3.8e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUG 6988
              :|:|:|:|:|:|:|
Db         16 TGTGTGTGTGTGTG 1


RESULT 305
US-08-884-029-9
; Sequence 9, Application US/08884029
; Patent No. 6071745
;  GENERAL INFORMATION:
;    APPLICANT:  Lin, Ching-I Patsy
;    APPLICANT:  Wallace, Robert Bruce
;    APPLICANT:  Cossman, Jeffrey
;    APPLICANT:  French, Cynthia
;    TITLE OF INVENTION:  Lyophilization of Cultured Human Cells
;    TITLE OF INVENTION:  to Preserve RNA and DNA
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/884,029
;      FILING DATE:  27-JUN-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parent, Annette S.
;      REGISTRATION NUMBER:  42,058
;      REFERENCE/DOCKET NUMBER:  02558B-059100US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  modified_base
;      LOCATION:  13..18
;      OTHER INFORMATION:  /mod_base= OTHER
;      OTHER INFORMATION:  /note= "t at positions 13-18 may be
;      OTHER INFORMATION:  present or absent"
US-08-884-029-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 306
US-08-941-445A-30/c
; Sequence 30, Application US/08941445A
; Patent No. 6107060
;  GENERAL INFORMATION:
;    APPLICANT:  Keeling, Peter
;    APPLICANT:  Guan, Hanping
;    TITLE OF INVENTION:  Starch Encapsulation
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Greenlee, Winner and Sullivan, P.C.
;      STREET:  5370 Manhattan Circle
;      CITY:  Boulder
;      STATE:  CO
;      COUNTRY:  US
;      ZIP:  80303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/941,445A
;      FILING DATE:  30-SEP-1997
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/026,855
;      FILING DATE:  30-SEP-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Winner, Ellen P
```

```
;       REGISTRATION NUMBER:  28,547
;       REFERENCE/DOCKET NUMBER:  89-97
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (303) 499-8080
;       TELEFAX:  (303) 499-8089
;   INFORMATION FOR SEQ ID NO:  30:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  not relevant
;     MOLECULE TYPE:  cDNA to mRNA
;     HYPOTHETICAL:  NO
US-08-941-445A-30

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 307
US-09-142-108C-27
; Sequence 27, Application US/09142108C
; Patent No. 6774285
; GENERAL INFORMATION:
;  APPLICANT: Brugliera, Filippa
;  APPLICANT:  Holton, Timothy A.
;  APPLICANT:  Michael, Michael Z.
;  TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 11658
;  CURRENT APPLICATION NUMBER: US/09/142,108C
;  CURRENT FILING DATE:  1998-09-01
;  PRIOR APPLICATION NUMBER: PN8386
;  PRIOR FILING DATE: 1996-03-01
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-142-108C-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 308
US-09-142-108C-29
; Sequence 29, Application US/09142108C
; Patent No. 6774285
; GENERAL INFORMATION:
;  APPLICANT: Brugliera, Filippa
;  APPLICANT:  Holton, Timothy A.
;  APPLICANT:  Michael, Michael Z.
;  TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 11658
;  CURRENT APPLICATION NUMBER: US/09/142,108C
;  CURRENT FILING DATE:  1998-09-01
;  PRIOR APPLICATION NUMBER: PN8386
;  PRIOR FILING DATE: 1996-03-01
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-142-108C-29

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 309
US-09-370-541-14
; Sequence 14, Application US/09370541
; Patent No. 6639062
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT: Prakash, Thazha P
;  APPLICANT: Kawasaki, Andrew M
;  TITLE OF INVENTION: Aminoxxy-Modified Nucleosidic Compounds And Oligomeric
;  TITLE OF INVENTION: Compounds Prepared Therefrom
;  FILE REFERENCE: ISIS3993
;  CURRENT APPLICATION NUMBER: US/09/370,541
;  CURRENT FILING DATE: 1999-08-09
;  EARLIER APPLICATION NUMBER: 09/130,973
;  EARLIER FILING DATE: 1998-08-07
;  EARLIER APPLICATION NUMBER: 09/016,520
;  EARLIER FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  EARLIER APPLICATION NUMBER: 09/344,260
;  EARLIER FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: sequence
US-09-370-541-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 310
US-09-545-225-9
; Sequence 9, Application US/09545225
; Patent No. 6410321
;   GENERAL INFORMATION:
;       APPLICANT: Lin, Ching-I Patsy
;                  Wallace, Robert Bruce
;                  Cossman, Jeffrey
;                  French, Cynthia
;       TITLE OF INVENTION: Lyophilization of Cultured Human Cells
;                           to Preserve RNA and DNA
;       NUMBER OF SEQUENCES: 9
```

```
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/545,225
;            FILING DATE: 07-Apr-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/884,029
;            FILING DATE: 27-JUN-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Parent, Annette S.
;            REGISTRATION NUMBER: 42,058
;            REFERENCE/DOCKET NUMBER: 02558B-059100US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 9:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  13..18
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "t at positions 13-18 may be
;            present or absent"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-545-225-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 311
US-09-619-103-24/c
; Sequence 24, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 312
US-09-637-751A-6
; Sequence 6, Application US/09637751A
; Patent No. 6383754
; GENERAL INFORMATION:
;  APPLICANT:  Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION:  Binary Encoded Sequence Tags
; Patent No. 6383754
;  FILE REFERENCE:  AGL 100
;  CURRENT APPLICATION NUMBER: US/09/637,751A
;  CURRENT FILING DATE:  2000-08-11
;  NUMBER OF SEQ ID NOS:  10
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-637-751A-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 313
US-09-696-791-4272
; Sequence 4272, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4272
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4272

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   56.2%;  Pred. No. 3.8e+02;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGCC 3381
              :||::::||||::|||
```

```
Db          3 TGATTTTGGCCTTGCC 18


RESULT 314
US-09-803-263-6/c
; Sequence 6, Application US/09803263
; Patent No. 6706476
; GENERAL INFORMATION:
;  APPLICANT: Thirstrup, Kenneth
;  TITLE OF INVENTION: A Process for Amplifying and Labeling Single Stranded cDNA by 5'
;  TITLE OF INVENTION:  Adapter Mediated Amplification
;  FILE REFERENCE: 674513-2003.1
;  CURRENT APPLICATION NUMBER: US/09/803,263
;  CURRENT FILING DATE:  2001-03-09
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Poly-a tail
US-09-803-263-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 315
US-09-803-263-7
; Sequence 7, Application US/09803263
; Patent No. 6706476
; GENERAL INFORMATION:
;  APPLICANT: Thirstrup, Kenneth
;  TITLE OF INVENTION: A Process for Amplifying and Labeling Single Stranded cDNA by 5'
;  TITLE OF INVENTION:  Adapter Mediated Amplification
;  FILE REFERENCE: 674513-2003.1
;  CURRENT APPLICATION NUMBER: US/09/803,263
;  CURRENT FILING DATE:  2001-03-09
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Complement of poly-a tail
US-09-803-263-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 316
US-09-809-545A-84
; Sequence 84, Application US/09809545A
; Patent No. 6800455
; GENERAL INFORMATION:
;  APPLICANT: Stanton, Lawrence W.
;  APPLICANT:  White, R. Tyler
;  TITLE OF INVENTION: SECRETED FACTORS
;  FILE REFERENCE: SCIOS.017A
;  CURRENT APPLICATION NUMBER: US/09/809,545A
;  CURRENT FILING DATE:  2001-03-14
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 317
US-09-979-275A-7
; Sequence 7, Application US/09979275A
; Patent No. 6855803
; GENERAL INFORMATION:
;  APPLICANT: NAGAI, HIROSHI
;  APPLICANT:  KURODA, KYOKO
;  APPLICANT:  NAKAJIMA, TERUMI
;  TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
;  TITLE OF INVENTION:  ENCODING THE PROTEIN
;  FILE REFERENCE: 037181.50611US
;  CURRENT APPLICATION NUMBER: US/09/979,275A
;  CURRENT FILING DATE:  2003-05-27
;  PRIOR APPLICATION NUMBER: PCT/JP01/02209
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: JP 2000-78967
;  PRIOR FILING DATE: 2000-03-21
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-09-979-275A-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 318
US-09-994-311-6
; Sequence 6, Application US/09994311
; Patent No. 6773886
; GENERAL INFORMATION:
;  APPLICANT: Kaufman, Joseph C.
;  APPLICANT:  Roth, Matthew E.
;  APPLICANT:  Lizardi, Paul M.
;  APPLICANT:  Feng, Li
;  APPLICANT:  Latimer, Darin R.
;  TITLE OF INVENTION: Binary Encoded Sequence Tags
; Patent No. 6773886
;  FILE REFERENCE: AGL 100
;  CURRENT APPLICATION NUMBER: US/09/994,311
```

```
;  CURRENT FILING DATE:  2001-11-26
;  PRIOR APPLICATION NUMBER: US/09/637,751
;  PRIOR FILING DATE: 2000-08-11
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-994-311-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 319
US-10-125-295-9
; Sequence 9, Application US/10125295
; Patent No. 6686460
;   GENERAL INFORMATION:
;        APPLICANT: Lin, Ching-I Patsy
;                   Wallace, Robert Bruce
;                   Cossman, Jeffrey
;                   French, Cynthia
;        TITLE OF INVENTION: Lyophilization of Cultured Human Cells
;                            to Preserve RNA and DNA
;        NUMBER OF SEQUENCES: 9
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/125,295
;             FILING DATE: 17-Apr-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/545,225
;             FILING DATE: 07-Apr-2000
;             APPLICATION NUMBER: US 08/884,029
;             FILING DATE: 27-JUN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Parent, Annette S.
;             REGISTRATION NUMBER: 42,058
;             REFERENCE/DOCKET NUMBER: 02558B-059100US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 9:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  13..18
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "t at positions 13-18 may be
;             present or absent"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-125-295-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 320
US-10-352-704-12
; Sequence 12, Application US/10352704
; Patent No. 6825339
;   GENERAL INFORMATION:
;        APPLICANT: Chatelain, Francois
;                   Kumarev, Viktor
;        TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                            a Solid Support and Apparatus Permitting its
;                            Implementation
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Jacobson, Price, Holman & Stern
;             STREET: 400 Seventh St. N.W.
;             CITY: Washington D.C
;             STATE: D.C
;             COUNTRY: U.S.A.
;             ZIP: 20004
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/352,704
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/358,556A
;             FILING DATE: 14-DEC-1994
;             APPLICATION NUMBER: FR 9315164
;             FILING DATE: 16-DEC-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Player, William E.
;             REGISTRATION NUMBER: 31,409
;             REFERENCE/DOCKET NUMBER: 10577/P58418
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (202)638-6666
;             TELEFAX: (202) 393-5350
;             TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 12:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: N-terminal
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..18
;        SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 321
US-10-352-704-18/c
; Sequence 18, Application US/10352704
; Patent No. 6825339
;   GENERAL INFORMATION:
;        APPLICANT: Chatelain, Francois
;                   Kumarev, Viktor
;        TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                            a Solid Support and Apparatus Permitting its
;                            Implementation
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Jacobson, Price, Holman & Stern
;             STREET: 400 Seventh St. N.W.
;             CITY: Washington D.C
;             STATE: D.C
;             COUNTRY: U.S.A.
;             ZIP: 20004
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/352,704
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/358,556A
;             FILING DATE: 14-DEC-1994
;             APPLICATION NUMBER: FR 9315164
;             FILING DATE: 16-DEC-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Player, William E.
;             REGISTRATION NUMBER: 31,409
;             REFERENCE/DOCKET NUMBER: 10577/P58418
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (202)638-6666
;             TELEFAX: (202) 393-5350
;             TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 18:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: N-terminal
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..18
;        SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 322
PCT-US95-04712-38/c
; Sequence 38, Application PC/TUS9504712
;  GENERAL INFORMATION:
;    APPLICANT:  Ligon, James M
;    APPLICANT:  Beck, James J
;    TITLE OF INVENTION:  Detection of Fungal Pathogens Using the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  86
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ciba-Geigy Corporation
;      STREET:  7 Skyline Drive
;      CITY:  Hawthorne
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10532
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/04712
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/233,608
;      FILING DATE:  04-APR-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Walsh, Andrea C.
;      REGISTRATION NUMBER:  34,988
;      REFERENCE/DOCKET NUMBER:  CGC 1739
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-541-8666
;      TELEFAX:  919-541-8689
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  Oligonucleotide primer ITS1
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
PCT-US95-04712-38

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 323
US-08-065-845-1/c
; Sequence 1, Application US/08065845
; Patent No. 5426027
;  GENERAL INFORMATION:
;    APPLICANT:  LOTT, TIMOTHY J.
;    APPLICANT:  MORRISON, CHRISTINE J.
;    APPLICANT:  REISS, ERROLL
;    APPLICANT:  LASKER, BRENT
;    APPLICANT:  ZAKROFF, SANDRA
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES AND METHODS FOR
;    TITLE OF INVENTION:  DETECTING DNA FROM CANDIDA CELLS IN BLOOD
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
```

```
;       ZIP:  30303
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/065,845
;       FILING DATE:  19930520
;       CLASSIFICATION:  436
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  SPRATT, GWENDOLYN D.
;       REGISTRATION NUMBER:  36,016
;       REFERENCE/DOCKET NUMBER:  1414.066
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  404/688-0770
;       TELEFAX:  404/688-9880
;   INFORMATION FOR SEQ ID NO:  1:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  19 base pairs
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-065-845-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 324
US-08-233-608-38/c
; Sequence 38, Application US/08233608
; Patent No. 5585238
;  GENERAL INFORMATION:
;    APPLICANT:  Ligon, James M
;    APPLICANT:  Beck, James J
;    TITLE OF INVENTION:  Detection of Fungal Pathogens Using the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ciba-Geigy Corporation
;      STREET:  7 Skyline Drive
;      CITY:  Hawthorne
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10532
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/233,608
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spruill, W. Murray
;      REGISTRATION NUMBER:  32,943
;      REFERENCE/DOCKET NUMBER:  CGC 1739
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-541-8615
;      TELEFAX:  919-541-8689
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  Oligonucleotide primer ITS1
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-233-608-38

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 325
US-08-271-882B-16
; Sequence 16, Application US/08271882B
; Patent No. 6017696
;  GENERAL INFORMATION:
;    APPLICANT:  Michael J. Heller
;    APPLICANT:  Eugene Tu
;    APPLICANT:  Glen A. Evans
;    APPLICANT:  Ronald G. Sosnowski
;    TITLE OF INVENTION:  SELF-ADDRESSABLE
;    TITLE OF INVENTION:  SELF-ASSEMBLING
;    TITLE OF INVENTION:  MICROELECTRONIC SYSTEMS AND
;    TITLE OF INVENTION:  DEVICES FOR
;    TITLE OF INVENTION:  MOLECULAR BIOLOGICAL ANALYSIS
;    TITLE OF INVENTION:  AND DIAGNOSTICS
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/271,882B
;      FILING DATE:  July 7, 1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/146,504
;      FILING DATE:  No. 6017696ember 1, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy, David B.
;      REGISTRATION NUMBER:  31,125
;      REFERENCE/DOCKET NUMBER:  207/263
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  nucleic
;      TYPE:  acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-271-882B-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 326
US-08-295-509B-2
; Sequence 2, Application US/08295509B
; Patent No. 6045995
;  GENERAL INFORMATION:
;    APPLICANT:  Cummins, Lendell L.
;    APPLICANT:  Freier, Susan M.
;    APPLICANT:  Griffey, Richard
;    APPLICANT:  Srivatsa, Susan G.
;    TITLE OF INVENTION:  Capillary Electrophoretic Detection of
;    TITLE OF INVENTION:  Nucleic Acids
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 6045995ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/295,509B
;      FILING DATE:  24-AUG-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Michael P. Straher
;      REGISTRATION NUMBER:  38,325
;      REFERENCE/DOCKET NUMBER:  ISIS-1395
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-295-509B-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 327
US-08-429-520-1/c
; Sequence 1, Application US/08429520
; Patent No. 5688644
;  GENERAL INFORMATION:
;    APPLICANT:  LOTT, TIMOTHY J.
;    APPLICANT:  MORRISON, CHRISTINE J.
;    APPLICANT:  REISS, ERROLL
;    APPLICANT:  LASKER, BRENT
;    APPLICANT:  ZAKROFF, SANDRA
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES AND METHODS FOR
;    TITLE OF INVENTION:  DETECTING DNA FROM CANDIDA CELLS IN BLOOD
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/429,520
;      FILING DATE:  26-APR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/065,845
;      FILING DATE:  20-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SPRATT, GWENDOLYN D.
;      REGISTRATION NUMBER:  36,016
;      REFERENCE/DOCKET NUMBER:  1414.066
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  404/688-0770
;      TELEFAX:  404/688-9880
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-429-520-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 328
US-08-429-522-1/c
; Sequence 1, Application US/08429522
; Patent No. 5645992
;  GENERAL INFORMATION:
;    APPLICANT:  LOTT, TIMOTHY J.
;    APPLICANT:  MORRISON, CHRISTINE J.
;    APPLICANT:  REISS, ERROLL
;    APPLICANT:  LASKER, BRENT
;    APPLICANT:  ZAKROFF, SANDRA
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES AND METHODS FOR
;    TITLE OF INVENTION:  DETECTING DNA FROM CANDIDA CELLS IN BLOOD
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/429,522
;      FILING DATE:  26-APR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/065,845
;      FILING DATE:  20-MAY-1993
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SPRATT, GWENDOLYN D.
;      REGISTRATION NUMBER:  36,016
;      REFERENCE/DOCKET NUMBER:  1414.066
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  404/688-0770
;      TELEFAX:  404/688-9880
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-429-522-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 329
US-08-429-523-1/c
; Sequence 1, Application US/08429523
; Patent No. 5631132
;  GENERAL INFORMATION:
;    APPLICANT:  LOTT, TIMOTHY J.
;    APPLICANT:  MORRISON, CHRISTINE J.
;    APPLICANT:  REISS, ERROLL
;    APPLICANT:  LASKER, BRENT
;    APPLICANT:  ZAKROFF, SANDRA
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES AND METHODS FOR
;    TITLE OF INVENTION:  DETECTING DNA FROM CANDIDA CELLS IN BLOOD
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/429,523
;      FILING DATE:  26-APR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/065,845
;      FILING DATE:  20-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SPRATT, GWENDOLYN D.
;      REGISTRATION NUMBER:  36,016
;      REFERENCE/DOCKET NUMBER:  1414.066
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  404/688-0770
;      TELEFAX:  404/688-9880
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-429-523-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 330
US-08-429-532-1/c
; Sequence 1, Application US/08429532
; Patent No. 5635353
;  GENERAL INFORMATION:
;    APPLICANT:  LOTT, TIMOTHY J.
;    APPLICANT:  MORRISON, CHRISTINE J.
;    APPLICANT:  REISS, ERROLL
;    APPLICANT:  LASKER, BRENT
;    APPLICANT:  ZAKROFF, SANDRA
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES AND METHODS FOR
;    TITLE OF INVENTION:  DETECTING DNA FROM CANDIDA CELLS IN BLOOD
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NEEDLE & ROSENBERG, P.C.
;      STREET:  Suite 1200, 127 Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/429,532
;      FILING DATE:  26-APR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/065,845
;      FILING DATE:  20-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SPRATT, GWENDOLYN D.
;      REGISTRATION NUMBER:  36,016
;      REFERENCE/DOCKET NUMBER:  1414.066
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  404/688-0770
;      TELEFAX:  404/688-9880
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-429-532-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
                ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 331
US-08-469-852A-2
; Sequence 2, Application US/08469852A
; Patent No. 5874213
;  GENERAL INFORMATION:
;    APPLICANT:  Cummins, Lendell L.
;    APPLICANT:  Freier, Susan M.
```

```
;    APPLICANT:  Griffey, Richard
;    APPLICANT:  Srivatsa, Susan G.
;    TITLE OF INVENTION:  Capillary Electrophoretic Detection of
;    TITLE OF INVENTION:  Nucleic Acids
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5874213ris LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/469,852A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/295,509
;      FILING DATE:  24-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Michael P. Straher
;      REGISTRATION NUMBER:  38,325
;      REFERENCE/DOCKET NUMBER:  ISIS-2015
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-469-852A-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 332
US-08-722-187-38/c
; Sequence 38, Application US/08722187
; Patent No. 5955274
;  GENERAL INFORMATION:
;    APPLICANT:  Ligon, James M
;    APPLICANT:  Beck, James J
;    TITLE OF INVENTION:  Detection of Fungal Pathogens Using the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  86
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ciba-Geigy Corporation
;      STREET:  7 Skyline Drive
;      CITY:  Hawthorne
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10532
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/722,187
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/233,608
;      FILING DATE:  04-APR-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Walsh, Andrea C.
;      REGISTRATION NUMBER:  34,988
;      REFERENCE/DOCKET NUMBER:  CGC 1739
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-541-8666
;      TELEFAX:  919-541-8689
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  Oligonucleotide primer ITS1
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-722-187-38

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 333
US-08-726-278-16
; Sequence 16, Application US/08726278
; Patent No. 6238624
; GENERAL INFORMATION:
;  APPLICANT:  Heller, Michael J.
;  APPLICANT:  Tu, Eugene
;  APPLICANT:  Evans, Glen A.
;  APPLICANT:  Sosnowski, Ronald G.
;  TITLE OF INVENTION:  METHODS FOR ELECTRONIC TRANSPORT IN MOLECULAR
;  TITLE OF INVENTION:  BIOLOGICAL ANALYSIS AND DIAGNOSTICS
;  FILE REFERENCE:  DAVID B. MURPHY/NANOGEN:  222-210
;  CURRENT APPLICATION NUMBER: US/08/726,278
;  CURRENT FILING DATE:  1996-10-04
;  PRIOR APPLICATION NUMBER:  08/271,882
;  PRIOR FILING DATE:  1994-07-07
;  NUMBER OF SEQ ID NOS:  44
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Sequences for
;   OTHER INFORMATION: Labeling
US-08-726-278-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 334
US-08-742-023-9/c
; Sequence 9, Application US/08742023
; Patent No. 5800997
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Beck, James J.
;    TITLE OF INVENTION:  Detection of Maize Fungal Pathogens
;    TITLE OF INVENTION:  Using the Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CIBA-GEIGY Corporation
;      STREET:  520 White Plains Road, P.O. Box 2005
;      CITY:  Tarrytown
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10591
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/742,023
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meigs, J. Timothy
;      REGISTRATION NUMBER:  38,241
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919) 541-8587
;      TELEFAX:  (919) 541-8689
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "primer ITS1"
US-08-742-023-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 335
US-08-756-728A-1
; Sequence 1, Application US/08756728A
; Patent No. 5821354
;  GENERAL INFORMATION:
;    APPLICANT:  Leclerc, Guy
;    APPLICANT:  Martel, Remi
;    TITLE OF INVENTION:  RADIOLABELED DNA OLIGONUCLEOTIDE, METHOD
;    TITLE OF INVENTION:  OF PREPARATION AND THERAPEUTIC USES THEREOF
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Klauber & Jackson
;      STREET:  411 Hackensack Avenue, 4th Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/756,728A
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1398-1-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;      TELEX:  133521
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
;    HYPOTHETICAL:  NO
US-08-756-728A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 336
US-08-787-321-27/c
; Sequence 27, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   56.2%;  Pred. No. 4.3e+02;
  Matches    9;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7000 GUGUGUGUGUGUGUGG 7015
              |:|:|:|:|:|:|:||
Db         19 GTGTGTGTGTGTGTGG 4


RESULT 337
US-08-887-480-38/c
; Sequence 38, Application US/08887480
; Patent No. 5814453
;  GENERAL INFORMATION:
;    APPLICANT:  Beck, James J
;    TITLE OF INVENTION:  Detection of Fungal Pathogens Using the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  96
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  No. 5814453artis Corporation
;      STREET:  520 White Plains Road
;      CITY:  Tarrytown
;      STATE:  NY
;      COUNTRY:  USA
```

```
;      ZIP:  10591
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/887,480
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/722,187
;      FILING DATE:  15-OCT-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meigs, J. Timothy
;      REGISTRATION NUMBER:  38,241
;      REFERENCE/DOCKET NUMBER:  CGC 1739/PCT/CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-541-8587
;      TELEFAX:  919-541-8689
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  Oligonucleotide primer ITS1
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-887-480-38

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 338
US-08-905-314A-1/c
; Sequence 1, Application US/08905314A
; Patent No. 5827695
;  GENERAL INFORMATION:
;    APPLICANT:  Beck, James J.
;    TITLE OF INVENTION:  DETECTION OF WHEAT FUNGAL PATHOGENS
;    TITLE OF INVENTION:  USING THE POLYMERASE CHAIN REACTION
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  No. 5827695artis Corporation Patent Department
;      STREET:  3054 Cornwallis Road
;      CITY:  Research Triangle Park
;      STATE:  NC
;      COUNTRY:  USA
;      ZIP:  20779-2257
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/905,314A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meigs, J. Timothy
;      REGISTRATION NUMBER:  38,241
;      REFERENCE/DOCKET NUMBER:  CGC 1944
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919) 541-8587
;      TELEFAX:  (919) 541-8689
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "primer ITS1"
US-08-905-314A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 339
US-08-968-505-9/c
; Sequence 9, Application US/08968505
; Patent No. 6071698
;  GENERAL INFORMATION:
;    APPLICANT:  Beck, James J.
;    TITLE OF INVENTION:  Detection of Maize Fungal Pathogens
;    TITLE OF INVENTION:  Using the Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CIBA-GEIGY Corporation
;      STREET:  520 White Plains Road, P.O. Box 2005
;      CITY:  Tarrytown
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10591
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/968,505
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/742,023
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meigs, J. Timothy
;      REGISTRATION NUMBER:  38,241
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919) 541-8587
;      TELEFAX:  (919) 541-8689
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "primer ITS1"
US-08-968-505-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 340
```

US-09-016-520-20
; Sequence 20, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5-methyl-2'-aminooxyethoxy
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
US-09-016-520-20

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 341
US-09-016-520-21
; Sequence 21, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
US-09-016-520-21

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 342
US-09-016-520-22
; Sequence 22, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 2'-methoxyethoxy
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
US-09-016-520-22

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 343
US-09-016-520-23
; Sequence 23, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
US-09-016-520-23

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 344
US-09-016-520-24
; Sequence 24, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Kawasaki, Andrew
;  TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE: ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/016,520A
;  CURRENT FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-016-520-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 345
US-09-016-520-25
; Sequence 25, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Kawasaki, Andrew
;  TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE: ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/016,520A
;  CURRENT FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-O-propyl
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-016-520-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 346
US-09-016-520-26
; Sequence 26, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Kawasaki, Andrew
;  TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE: ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/016,520A
;  CURRENT FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-016-520-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 347
US-09-016-520-27
; Sequence 27, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Kawasaki, Andrew
;  TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE: ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/016,520A
;  CURRENT FILING DATE: 1998-01-30
;  EARLIER APPLICATION NUMBER: 60/037,143
;  EARLIER FILING DATE: 1997-02-14
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
```

US-09-016-520-27

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 348
US-09-016-520-31
; Sequence 31, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-016-520-31

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 349
US-09-016-520-33
; Sequence 33, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-016-520-33

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 350
US-09-016-520-34
; Sequence 34, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-016-520-34

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 351
US-09-016-520-44
; Sequence 44, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminooxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methyleneiminooxyethoxy
US-09-016-520-44

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 352
US-09-026-601-1/c
; Sequence 1, Application US/09026601
; Patent No. 6358680
;  GENERAL INFORMATION:
;    APPLICANT:  Beck, James J.
;    TITLE OF INVENTION:  Detection of Wheat and Barley Fungal
;    TITLE OF INVENTION:  Pathogens Using the Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  No. 6358680artis Corporation
;      STREET:  3054 Cornwallis Road
;      CITY:  Research Triangle Park
;      STATE:  No. 6358680th Carolina
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/026,601
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meigs, J. Timothy
;      REGISTRATION NUMBER:  38,241
;      REFERENCE/DOCKET NUMBER:  CGC 1984
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-541-8587
;      TELEFAX:  919-541-8689
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Primer ITS1"
US-09-026-601-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 353
US-09-123-108-6
; Sequence 6, Application US/09123108
; Patent No. 6271358
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Mohan, Venkatraman
;  APPLICANT: Boswell, Herb
;  TITLE OF INVENTION: RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE
;  TITLE OF INVENTION: CONFORMATIONALLY PREORGANIZED
;  FILE REFERENCE: ISIS-3147 sequence listing
;  CURRENT APPLICATION NUMBER: US/09/123,108
;  CURRENT FILING DATE: 1998-07-27
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6271358el sequence
US-09-123-108-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 354
US-09-130-973-20
; Sequence 20, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5 methyl, 2'-aminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 355
US-09-130-973-21
; Sequence 21, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
```

```
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5 methyl, 2'-dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 356
US-09-130-973-22
; Sequence 22, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-O-methoxyethyl (MOE)
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 357
US-09-130-973-23
; Sequence 23, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-dimethylaminooxyethyl
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 358
US-09-130-973-24
; Sequence 24, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-methoxyethyl
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 359
US-09-130-973-25
; Sequence 25, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
```

```
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-propyl
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 360
US-09-130-973-26
; Sequence 26, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5 methyl, 2'-dimethylaminooxyethyl
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 361
US-09-130-973-27
; Sequence 27, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5 methyl, 2'-O-methoxyethyl
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 362
US-09-130-973-31
; Sequence 31, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 31
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-dimethylaminooxyethyl thymidine (T-2'-DMAOE)
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 363
US-09-130-973-33
; Sequence 33, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
```

```
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-dimethylaminooxyethyl thymidine (T-2'-DMAOE)
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 364
US-09-130-973-34
; Sequence 34, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 34
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-dimethylaminooxyethyl thymidine (T-2'-DMAOE)
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
US-09-130-973-34

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 365
US-09-130-973-44
; Sequence 44, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Kawasaki, Andrew M
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides And Methods For
;  TITLE OF INVENTION:  Making Same
;  FILE REFERENCE:  ISIS2955
;  CURRENT APPLICATION NUMBER: US/09/130,973
;  CURRENT FILING DATE:  1998-08-07
;  NUMBER OF SEQ ID NOS:  58
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 44
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6172209el
;   OTHER INFORMATION: Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-O-methyleneiminooxyethyl thymidine
US-09-130-973-44

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 366
US-09-142-212A-10
; Sequence 10, Application US/09142212A
; Patent No. 6562960
; GENERAL INFORMATION:
;  APPLICANT:  Baxter, Anthony David
;  APPLICANT:  Collingwood, Stephen Paul
;  APPLICANT:  Douglas, Mark Edward
;  APPLICANT:  Taylor, Roger John
;  TITLE OF INVENTION:  Oligonucleotide Analogues
;  FILE REFERENCE:  ISIS4385
;  CURRENT APPLICATION NUMBER: US/09/142,212A
;  CURRENT FILING DATE:  1998-10-09
;  PRIOR APPLICATION NUMBER:  97/00499
;  PRIOR FILING DATE:  1997-02-24
;  NUMBER OF SEQ ID NOS:  13
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(18)
;   OTHER INFORMATION: Modified internucleoside linkage
US-09-142-212A-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 367
US-09-202-294-4
```

; Sequence 4, Application US/09202294
; Patent No. 6329519
; GENERAL INFORMATION:
; APPLICANT: Collingwood, Stephen P.
; APPLICANT: Moser, Heinz E.
; APPLICANT: Altmann, Karl-Heinz
; APPLICANT: Douglas, Mark E.
; TITLE OF INVENTION: Intermediates for oligonucleotides
; FILE REFERENCE: 4-20900/A/MA2134/PCT
; CURRENT APPLICATION NUMBER: US/09/202,294
; CURRENT FILING DATE: 1999-03-15
; EARLIER APPLICATION NUMBER: PCT/GB97/01490
; EARLIER FILING DATE: 1997-06-03
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-09-202-294-4

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 368
US-09-218-207-515
; Sequence 515, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 515
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..19
; OTHER INFORMATION: potential microsequencing oligo for 4-4-187.mis2
US-09-218-207-515

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 369
US-09-227-782-1
; Sequence 1, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5-methyl- 2'- aminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-1

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 370
US-09-227-782-12
; Sequence 12, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-12

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 371
US-09-227-782-14
; Sequence 14, Application US/09227782
; Patent No. 6403779

; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-14

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 372
US-09-227-782-15
; Sequence 15, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-15

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 373
US-09-227-782-2
; Sequence 2, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 5- methyl- 2'- dimethylaminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-2

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 374
US-09-227-782-25
; Sequence 25, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M
; APPLICANT: Fraser, Allister S
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D
; APPLICANT: Prakash, Thazha P
; TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
; FILE REFERENCE: ISIS3315
; CURRENT APPLICATION NUMBER: US/09/227,782
; CURRENT FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(18)
; OTHER INFORMATION: 2'-methyleneiminooxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-25

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 4.3e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 375
US-09-227-782-3
; Sequence 3, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
; APPLICANT: Kawasaki, Andrew M

```
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 376
US-09-227-782-4
; Sequence 4, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5- methyl- 2'- dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 377
US-09-227-782-5
; Sequence 5, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5- methyl- 2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 378
US-09-227-782-6
; Sequence 6, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5- methyl- 2'-O-propyl
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 379
US-09-227-782-7
; Sequence 7, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
```

```
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5- methyl- 2'- dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 380
US-09-227-782-8
; Sequence 8, Application US/09227782
; Patent No. 6403779
; GENERAL INFORMATION:
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT:  Fraser, Allister S
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Prakash, Thazha P
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS3315
;  CURRENT APPLICATION NUMBER: US/09/227,782
;  CURRENT FILING DATE:  1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5- methyl- 2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6403779el Sequence
US-09-227-782-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 381
US-09-234-237-1
; Sequence 1, Application US/09234237
; Patent No. 6127124
; GENERAL INFORMATION:
;  APPLICANT: Leeds, Janet M
;  APPLICANT: Cummins, Lendell L
;  TITLE OF INVENTION: Fluorescence Based Nuclease Assay
;  FILE REFERENCE: ISIS3308
;  CURRENT APPLICATION NUMBER: US/09/234,237
;  CURRENT FILING DATE: 1999-01-20
;  NUMBER OF SEQ ID NOS: 1
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6127124el
;   OTHER INFORMATION: Sequence
US-09-234-237-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 382
US-09-258-967-1/c
; Sequence 1, Application US/09258967
; Patent No. 6221595
; GENERAL INFORMATION:
;  APPLICANT: No. 6221595artis
;  TITLE OF INVENTION: Detection of Monilinia Spp using the polymerase chain
;  TITLE OF INVENTION: reaction
;  FILE REFERENCE: Monilinia
;  CURRENT APPLICATION NUMBER: US/09/258,967
;  CURRENT FILING DATE: 1999-03-01
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-09-258-967-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              |||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 383
US-09-269-136B-1/c
; Sequence 1, Application US/09269136B
; Patent No. 6235890
; GENERAL INFORMATION:
;  APPLICANT:  Morrison, Christine J.
;  APPLICANT:  Reiss, Errol
;  APPLICANT:  Holloway, Brian
;  APPLICANT:  Shin, Jong Hee
;  TITLE OF INVENTION:  Methods and Compositions for the Detection of Candida
;  TITLE OF INVENTION:  Spp.
;  FILE REFERENCE:  03063-0261
;  CURRENT APPLICATION NUMBER: US/09/269,136B
;  CURRENT FILING DATE:  1999-07-12
;  NUMBER OF SEQ ID NOS:  16
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: ITS1 Primer
US-09-269-136B-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 384
US-09-288-679-1
; Sequence 1, Application US/09288679
; Patent No. 6465628
; GENERAL INFORMATION:
;  APPLICANT:  Ravikumar, Vasulinga
;  APPLICANT:  Manoharan, Muthia
;  APPLICANT:  Capaldi, Daniel
;  APPLICANT:  Krotz, Achim
;  APPLICANT:  Cole, Douglas
;  APPLICANT:  Guzaev, Andrei
;  TITLE OF INVENTION:  Improved Process for the Synthesis of Oligomeric Compounds
;  FILE REFERENCE:  ISIS3380
;  CURRENT APPLICATION NUMBER: US/09/288,679
;  CURRENT FILING DATE:  1999-04-09
;  PRIOR APPLICATION NUMBER:  60/118,564
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  7
;  SOFTWARE:  PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: No. 6465628el Sequence
US-09-288-679-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 385
US-09-303-586-15
; Sequence 15, Application US/09303586
; Patent No. 6369209
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form Confirmational
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/09/303,586
;  CURRENT FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-09-303-586-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 386
US-09-303-586-16
; Sequence 16, Application US/09303586
; Patent No. 6369209
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form Confirmational
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/09/303,586
;  CURRENT FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE linkage
US-09-303-586-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 387
US-09-303-586-17
; Sequence 17, Application US/09303586
; Patent No. 6369209
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form Confirmational
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/09/303,586
;  CURRENT FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-09-303-586-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 388
US-09-303-586-18
; Sequence 18, Application US/09303586
; Patent No. 6369209
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form Confirmational
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/09/303,586
;  CURRENT FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2' - O-MOE
US-09-303-586-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 389
US-09-303-586-26
; Sequence 26, Application US/09303586
; Patent No. 6369209
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form Confirmational
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/09/303,586
;  CURRENT FILING DATE:  1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2'-modified T linkage
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-modified T linkage
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
US-09-303-586-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 390
US-09-311-260-111/c
; Sequence 111, Application US/09311260
; Patent No. 6214555
;  GENERAL INFORMATION:
;    APPLICANT:  Leushner, James
;    APPLICANT:  Hui, May
;    APPLICANT:  Dunn, James M.
;    APPLICANT:  LaCroix, Jean-Michel
;    TITLE OF INVENTION:  METHOD, COMPOSITIONS AND KIT FOR DETECTION OF
;    TITLE OF INVENTION:  MICROORGANISMS AND BI-DIRECTIONAL SEQUENCING OF NUCLEIC ACID
;    TITLE OF INVENTION:  POLYMERS
;    NUMBER OF SEQUENCES:  189
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oppedahl & Larson LLP
;      STREET:  P.O. Box 5270
;      CITY:  Frisco
;      STATE:  CO
;      COUNTRY:  US
;      ZIP:  80443-5270
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette - 3.5 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  MS DOS
;      SOFTWARE:  Word Perfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/311,260
;      FILING DATE:
```

```
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Marina T.
;      REGISTRATION NUMBER:  32,038
;      REFERENCE/DOCKET NUMBER:  VGEN.P-058-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (970) 668-2050
;      TELEFAX:  (970) 668-2082
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  111:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  yes
;    FRAGMENT TYPE:  internal
US-09-311-260-111

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 391
US-09-329-416-3
; Sequence 3, Application US/09329416
; Patent No. 6919437
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Guzaev, Andrei
;  TITLE OF INVENTION: Synthetic Methods and Intermediates for Triester
;  TITLE OF INVENTION: Oligonucleotides
;  FILE REFERENCE: ISIS3683
;  CURRENT APPLICATION NUMBER: US/09/329,416
;  CURRENT FILING DATE: 1999-06-10
;  EARLIER APPLICATION NUMBER: 09/095,822
;  EARLIER FILING DATE: 1998-06-11
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: sequence
US-09-329-416-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 392
US-09-338-907-515
; Sequence 515, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/338,907
;  CURRENT FILING DATE: 1999-06-23
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  EARLIER APPLICATION NUMBER: 09/218,207
;  EARLIER FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 515
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: potential microsequencing oligo for 4-4-187.mis2
US-09-338-907-515

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 393
US-09-349-033A-1
; Sequence 1, Application US/09349033A
; Patent No. 6639061
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Maier, Martin
;  APPLICANT:  An, Haoyun
;  TITLE OF INVENTION: C3'-Methylene Hydrogen Phosphonate Oligomers and Related Compound
;  FILE REFERENCE: ISIS-3312
;  CURRENT APPLICATION NUMBER: US/09/349,033A
;  CURRENT FILING DATE:  1999-07-07
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-09-349-033A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 394
US-09-349-040A-3
; Sequence 3, Application US/09349040A
; Patent No. 6593466
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
```

```
;  APPLICANT:  Prakash, Thazha
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Functionalized Oligomers
;  FILE REFERENCE: ISIS-3811
;  CURRENT APPLICATION NUMBER: US/09/349,040A
;  CURRENT FILING DATE:  1999-07-07
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6593466el Sequence
US-09-349-040A-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 395
US-09-349-040A-4
; Sequence 4, Application US/09349040A
; Patent No. 6593466
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Functionalized Oligomers
;  FILE REFERENCE: ISIS-3811
;  CURRENT APPLICATION NUMBER: US/09/349,040A
;  CURRENT FILING DATE:  1999-07-07
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6593466el Sequence
US-09-349-040A-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 396
US-09-349-040A-5
; Sequence 5, Application US/09349040A
; Patent No. 6593466
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Prakash, Thazha
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Functionalized Oligomers
;  FILE REFERENCE: ISIS-3811
;  CURRENT APPLICATION NUMBER: US/09/349,040A
;  CURRENT FILING DATE:  1999-07-07
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6593466el Sequence
US-09-349-040A-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 397
US-09-378-568-4
; Sequence 4, Application US/09378568
; Patent No. 6147200
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT: Kawasaki, Andrew M
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT: Fraser, Allister S
;  APPLICANT: Prakash, Thazha P
;  TITLE OF INVENTION: 2'-O-acetamido Modified Monomers and Oligomers
;  FILE REFERENCE: ISIS4071
;  CURRENT APPLICATION NUMBER: US/09/378,568
;  CURRENT FILING DATE: 1999-08-19
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: sequence
US-09-378-568-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 398
US-09-378-665A-5
; Sequence 5, Application US/09378665A
; Patent No. 6277982
; GENERAL INFORMATION:
;  APPLICANT:  Fraser, Allister S.
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Jung, Michael E.
;  APPLICANT:  Kawasaki, Andrew M.
;  TITLE OF INVENTION:  Alkylation of Alcohols, Amines, Thiols and Their
;  TITLE OF INVENTION:  Derivatives by Cyclic Sulfate Intermediates
;  FILE REFERENCE:  ISIS4072
;  CURRENT APPLICATION NUMBER: US/09/378,665A
;  CURRENT FILING DATE:  1999-08-20
;  NUMBER OF SEQ ID NOS:  27
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6277982el Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-modified T
US-09-378-665A-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 399
US-09-409-926-17
; Sequence 17, Application US/09409926
; Patent No. 6617442
; GENERAL INFORMATION:
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Lima, Walter F.
;  APPLICANT:  Wu, Hongjiang
;  TITLE OF INVENTION:  Human Rnase H1 and Oligonucleotide Compositions Thereof
;  FILE REFERENCE:  ISIS4186
;  CURRENT APPLICATION NUMBER: US/09/409,926
;  CURRENT FILING DATE:  1999-09-30
;  NUMBER OF SEQ ID NOS:  33
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6617442el Sequence
US-09-409-926-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 400
US-09-409-926-18
; Sequence 18, Application US/09409926
; Patent No. 6617442
; GENERAL INFORMATION:
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Lima, Walter F.
;  APPLICANT:  Wu, Hongjiang
;  TITLE OF INVENTION:  Human Rnase H1 and Oligonucleotide Compositions Thereof
;  FILE REFERENCE:  ISIS4186
;  CURRENT APPLICATION NUMBER: US/09/409,926
;  CURRENT FILING DATE:  1999-09-30
;  NUMBER OF SEQ ID NOS:  33
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;   OTHER INFORMATION: Oligonucleotide
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6617442el Sequence
US-09-409-926-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 401
US-09-435-806-6
; Sequence 6, Application US/09435806
; Patent No. 6653458
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Guinoso, Charles J.
;  TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4289
;  CURRENT APPLICATION NUMBER: US/09/435,806
;  CURRENT FILING DATE:  1999-11-08
;  PRIOR APPLICATION NUMBER: US 09/115,043
;  PRIOR FILING DATE: 1998-07-14
;  PRIOR APPLICATION NUMBER: US 08/602,862
;  PRIOR FILING DATE: 1996-02-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
US-09-435-806-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 402
US-09-435-806-7
; Sequence 7, Application US/09435806
; Patent No. 6653458
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Guinoso, Charles J.
;  TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES
;  FILE REFERENCE: ISIS-4289
;  CURRENT APPLICATION NUMBER: US/09/435,806
;  CURRENT FILING DATE:  1999-11-08
;  PRIOR APPLICATION NUMBER: US 09/115,043
;  PRIOR FILING DATE: 1998-07-14
;  PRIOR APPLICATION NUMBER: US 08/602,862
;  PRIOR FILING DATE: 1996-02-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: n = uracil
US-09-435-806-7
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 403
US-09-477-902-20
; Sequence 20, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-aminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 404
US-09-477-902-21
; Sequence 21, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-21

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 405
US-09-477-902-22
; Sequence 22, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 406
US-09-477-902-23
; Sequence 23, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 19
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-23

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 407
US-09-477-902-24
; Sequence 24, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 408
US-09-477-902-25
; Sequence 25, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-O-propyl
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 409
US-09-477-902-26
; Sequence 26, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 410
US-09-477-902-27
; Sequence 27, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
```

```
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 27
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
US-09-477-902-27

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 411
US-09-477-902-31
; Sequence 31, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 31
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-477-902-31

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 412
US-09-477-902-33
; Sequence 33, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-477-902-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 413
US-09-477-902-34
; Sequence 34, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 34
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-09-477-902-34

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 414
US-09-477-902-44
; Sequence 44, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Kawasaki, Andrew
;  TITLE OF INVENTION:  Aminooxy-Modified Oligonucleotides
;  FILE REFERENCE:  ISIS2824
;  CURRENT APPLICATION NUMBER: US/09/477,902
;  CURRENT FILING DATE:  2000-01-05
;  PRIOR APPLICATION NUMBER:  09/016,520
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  60/037,143
;  PRIOR FILING DATE:  1997-02-14
;  NUMBER OF SEQ ID NOS:  47
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 44
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methyleneiminooxyethoxy
US-09-477-902-44

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 415
US-09-481-293-1/c
; Sequence 1, Application US/09481293
; Patent No. 6485907
; GENERAL INFORMATION:
;  APPLICANT:  Beck, James
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION:  PCR-Based Detection of Rhizoctonia cerealis
;  FILE REFERENCE:  PB/5-31135P1
;  CURRENT APPLICATION NUMBER: US/09/481,293
;  CURRENT FILING DATE:  2000-01-11
;  NUMBER OF SEQ ID NOS:  33
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: ITS1
US-09-481-293-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 416
US-09-612-531-13
; Sequence 13, Application US/09612531
; Patent No. 6534639
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/09/612,531
;  CURRENT FILING DATE:  2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-09-612-531-13

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 417
US-09-612-531-3
; Sequence 3, Application US/09612531
; Patent No. 6534639
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/09/612,531
;  CURRENT FILING DATE:  2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-09-612-531-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 418
US-09-612-531-7
; Sequence 7, Application US/09612531
; Patent No. 6534639
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/09/612,531
;  CURRENT FILING DATE:  2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-09-612-531-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 419
US-09-619-103-25/c
; Sequence 25, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 420
US-09-635-747-1/c
; Sequence 1, Application US/09635747
; Patent No. 6319673
; GENERAL INFORMATION:
;  APPLICANT:  Beck, James J
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION:  PCR-BASED DETECTION AND QUANTIFICATION OF TAPESIA
;  TITLE OF INVENTION:  YALLUNDAE AND TAPESIA ACUFORMIS
;  FILE REFERENCE:  PB/5-31084A
;  CURRENT APPLICATION NUMBER: US/09/635,747
;  CURRENT FILING DATE:  2000-08-10
;  NUMBER OF SEQ ID NOS:  44
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:ITS1
US-09-635-747-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 421
US-09-673-298-1/c
; Sequence 1, Application US/09673298
; Patent No. 6469156
; GENERAL INFORMATION:
;  APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
;  APPLICANT:  REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF
;  APPLICANT:  HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE
;  APPLICANT:  CONTROL AND PREVENTION
;  APPLICANT:  SCHAFER, MILLIE P.
;  APPLICANT:  REID, THOMAS M.
;  TITLE OF INVENTION: RAPID AND SENSITIVE METHOD FOR DETECTING
;  TITLE OF INVENTION:  HISTOPLASMA CAPSULATUM
;  FILE REFERENCE: 62951 / PCT
;  CURRENT APPLICATION NUMBER: US/09/673,298
;  CURRENT FILING DATE:  2000-10-12
;  PRIOR APPLICATION NUMBER: U.S. 60/082,477
;  PRIOR FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: PRIMER
US-09-673-298-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 422
US-09-939-379B-1/c
; Sequence 1, Application US/09939379B
; Patent No. 6645720
; GENERAL INFORMATION:
;  APPLICANT: Syngenta Biotechnology Inc.
;  APPLICANT:  Barnett, Charles Jason
;  APPLICANT:  Beck, Jim
```

```
;  TITLE OF INVENTION: Detection of Almond Pathogens Using the Polymerase Chain Reaction
;  FILE REFERENCE: 60063P1
;  CURRENT APPLICATION NUMBER: US/09/939,379B
;  CURRENT FILING DATE:  2002-04-08
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1) . .(19)
;   OTHER INFORMATION: Primer ITS1
US-09-939-379B-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 423
US-09-961-663-1/c
; Sequence 1, Application US/09961663
; Patent No. 6733972
; GENERAL INFORMATION:
;  APPLICANT: Barnett, Jason
;  APPLICANT:  Beck, James
;  TITLE OF INVENTION: Detection of Mycosphaerella Using the Polymerase Chain
;  TITLE OF INVENTION:  Reaction
;  FILE REFERENCE: PB/5-31382A
;  CURRENT APPLICATION NUMBER: US/09/961,663
;  CURRENT FILING DATE:  2001-09-24
;  PRIOR APPLICATION NUMBER: US 60/211902
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer ITS1
US-09-961-663-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 424
US-09-961-755A-9/c
; Sequence 9, Application US/09961755A
; Patent No. 6846631
; GENERAL INFORMATION:
;  APPLICANT: Beck, Jim
;  APPLICANT:  Barnett, Jason
;  TITLE OF INVENTION: Detection of Fusarium Species infecting Corn Using the
;  TITLE OF INVENTION:  Polymerase Chain Reaction
;  FILE REFERENCE: 60055
;  CURRENT APPLICATION NUMBER: US/09/961,755A
;  CURRENT FILING DATE:  2001-09-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Primer ITS1
US-09-961-755A-9

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   81.2%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db         18 CGCAGGTTCACCTACG 3


RESULT 425
US-10-058-740-3
; Sequence 3, Application US/10058740
; Patent No. 6921812
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P.
;  TITLE OF INVENTION: Methods Of Modulating Pharmacokinetics Of Oligonucleotides
;  FILE REFERENCE: ISIS-4853
;  CURRENT APPLICATION NUMBER: US/10/058,740
;  CURRENT FILING DATE:  2002-08-12
;  PRIOR APPLICATION NUMBER: 09/932,898
;  PRIOR FILING DATE: 2001-08-20
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-[2-(methylthio)ethyl]-5-methyluridine
US-10-058-740-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 426
US-10-098-816-15
; Sequence 15, Application US/10098816
; Patent No. 6737520
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-10-098-816-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 427
US-10-098-816-16
; Sequence 16, Application US/10098816
; Patent No. 6737520
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE linkage
US-10-098-816-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 428
US-10-098-816-17
; Sequence 17, Application US/10098816
; Patent No. 6737520
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 3' - O-MOE linkage
US-10-098-816-17

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 429
US-10-098-816-18
; Sequence 18, Application US/10098816
; Patent No. 6737520
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(16)
;   OTHER INFORMATION: sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2' - O-MOE; sub O linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2' - O-MOE
US-10-098-816-18

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 430
US-10-098-816-26
; Sequence 26, Application US/10098816
; Patent No. 6737520
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Oligonucleotides Having A DNA Form And B-DNA Form
;  TITLE OF INVENTION:  Confirmational Geometry
;  FILE REFERENCE: ISIS3310
;  CURRENT APPLICATION NUMBER: US/10/098,816
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/303,586
;  PRIOR FILING DATE: 1999-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(17)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: 2'-modified T linkage
US-10-098-816-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 431
US-10-100-321A-22/c
; Sequence 22, Application US/10100321A
; Patent No. 6946251
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/100,321A
;  CURRENT FILING DATE:  2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1
;   OTHER INFORMATION: n = A,T,C or G
US-10-100-321A-22

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 432
US-10-100-321A-24/c
; Sequence 24, Application US/10100321A
; Patent No. 6946251
; GENERAL INFORMATION:
;  APPLICANT: Kurn, Nurith
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;  TITLE OF INVENTION:  AMPLIFICATION OF RNA SEQUENCES
;  FILE REFERENCE: 492692000500
;  CURRENT APPLICATION NUMBER: US/10/100,321A
;  CURRENT FILING DATE:  2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/274,550
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-100-321A-24

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
```

```
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 433
US-10-121-135-26
; Sequence 26, Application US/10121135
; Patent No. 6552178
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
;  FILE REFERENCE: ISIS-5036
;  CURRENT APPLICATION NUMBER: US/10/121,135
;  CURRENT FILING DATE:  2002-04-11
;  PRIOR APPLICATION NUMBER: 09/370,625
;  PRIOR FILING DATE: 1999-08-06
;  PRIOR APPLICATION NUMBER: 09/130,566
;  PRIOR FILING DATE: 1998-08-07
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-O-[2-(2-N,N-dimethylaminoethyl) oxyethyl]-5-methyl uridine (2'
;   OTHER INFORMATION: -sub-T)
US-10-121-135-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 434
US-10-121-135-5
; Sequence 5, Application US/10121135
; Patent No. 6673912
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
;  FILE REFERENCE: ISIS-5036
;  CURRENT APPLICATION NUMBER: US/10/121,135
;  CURRENT FILING DATE:  2002-04-11
;  PRIOR APPLICATION NUMBER: 09/370,625
;  PRIOR FILING DATE: 1999-08-06
;  PRIOR APPLICATION NUMBER: 09/130,566
;  PRIOR FILING DATE: 1998-08-07
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-modified T
US-10-121-135-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 435
US-10-121-135-5
; Sequence 5, Application US/10121135
; Patent No. 6552178
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Phillip Dan
;  TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
;  FILE REFERENCE: ISIS-5036
;  CURRENT APPLICATION NUMBER: US/10/121,135
;  CURRENT FILING DATE:  2002-04-11
;  PRIOR APPLICATION NUMBER: 09/370,625
;  PRIOR FILING DATE: 1999-08-06
;  PRIOR APPLICATION NUMBER: 09/130,566
;  PRIOR FILING DATE: 1998-08-07
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 2'-modified T
US-10-121-135-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 436
US-10-123-597-1
; Sequence 1, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-aminooxyethoxy
US-10-123-597-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 437
US-10-123-597-12
; Sequence 12, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-12

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 438
US-10-123-597-14
; Sequence 14, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 439
US-10-123-597-15
; Sequence 15, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-15

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 440
US-10-123-597-2
; Sequence 2, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 5-methyl-2'dimethylaminooxyethoxy
US-10-123-597-2

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 441
US-10-123-597-25
; Sequence 25, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methyleneiminooxyethoxy
US-10-123-597-25

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 442
US-10-123-597-3
; Sequence 3, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-methoxyethoxy
US-10-123-597-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 443
US-10-123-597-4
; Sequence 4, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-dimethylaminooxyethoxy
US-10-123-597-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 444
US-10-123-597-5
; Sequence 5, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
```

```
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
US-10-123-597-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 445
US-10-123-597-6
; Sequence 6, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: 5-methyl-2'-O-propyl
US-10-123-597-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 446
US-10-123-597-7
; Sequence 7, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 5-methyl-2'dimethylaminooxyethoxy
US-10-123-597-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 447
US-10-123-597-8
; Sequence 8, Application US/10123597
; Patent No. 6624294
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip D
;  APPLICANT:  Kawasaki, Andrew M
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Prakash, Thazha P
;  APPLICANT:  Fraser, Allister S
;  TITLE OF INVENTION: Regioselective Synthesis of 2'-O-Modified Nucleosides
;  FILE REFERENCE: ISIS5040
;  CURRENT APPLICATION NUMBER: US/10/123,597
;  CURRENT FILING DATE:  2002-07-10
;  PRIOR APPLICATION NUMBER: 09/227,782
;  PRIOR FILING DATE: 1999-01-08
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic construct
;   NAME/KEY: misc_feature
;   LOCATION: (18)..(18)
;   OTHER INFORMATION: 5-methyl-2'-methoxyethoxy
US-10-123-597-8

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 448
US-10-232-881-1
; Sequence 1, Application US/10232881
; Patent No. 6858715
; GENERAL INFORMATION:
;  APPLICANT: Ravikumar, Vasulinga
```

```
;  APPLICANT:  Manoharan, Muthia
;  APPLICANT:  Capaldi, Daniel
;  APPLICANT:  Krotz, Achim
;  APPLICANT:  Cole, Douglas
;  APPLICANT:  Guzaev, Andrei
;  TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric
;  TITLE OF INVENTION:  Compounds
;  FILE REFERENCE: ISIS3380
;  CURRENT APPLICATION NUMBER: US/10/232,881
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: US/09/288,679
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/118,564
;  PRIOR FILING DATE: 1999-02-04
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: No. 6858715el Sequence
US-10-232-881-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 449
US-10-247-893-13
; Sequence 13, Application US/10247893
; Patent No. 6914148
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-10-247-893-13

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 450
US-10-247-893-3
; Sequence 3, Application US/10247893
; Patent No. 6914148
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
US-10-247-893-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 451
US-10-247-893-7
; Sequence 7, Application US/10247893
; Patent No. 6914148
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Cook, Philip Dan
;  APPLICANT:  Prakash, Thazha P.
;  APPLICANT:  Mohan, Venkatraman
;  TITLE OF INVENTION: Guanidinium Functionalized Oligomers And Methods
;  FILE REFERENCE: Isis-4406
;  CURRENT APPLICATION NUMBER: US/10/247,893
;  CURRENT FILING DATE:  2002-09-20
;  PRIOR APPLICATION NUMBER: US/09/612,531
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: 09/349,040
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: T*=2'-O-[2-(guanidinium)ethyl]
```

```
US-10-247-893-7

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 452
US-10-322-242-1
; Sequence 1, Application US/10322242
; Patent No. 6974865
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Maier, Martin
;  APPLICANT:  An, Haoyun
;  TITLE OF INVENTION: C3'-Methylene Hydrogen Phosphonate Oligomers and Related Compound
;  FILE REFERENCE: ISIS-3312
;  CURRENT APPLICATION NUMBER: US/10/322,242
;  CURRENT FILING DATE:  2002-12-18
;  PRIOR APPLICATION NUMBER: US/09/349,033
;  PRIOR FILING DATE: 1999-07-07
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-10-322-242-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 4.3e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 453
PCT-US93-07603-6/c
; Sequence 6, Application PC/TUS9307603
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  NUCLEIC ACID RECOGNITION AND TRANSPORT
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Wolf, Greenfield & Sacks, P.C.
;      STREET:  600 Atlantic Avenue
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  United States of America
;      ZIP:  02210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/07603
;      FILING DATE:  19930813
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/930,087
;      FILING DATE:  14-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Gates, Edward R.
;      REGISTRATION NUMBER:  31,616
;      REFERENCE/DOCKET NUMBER:  M0636/7007WO
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-720-3500
;      TELEFAX:  617-720-2441
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  Synthetic RNA oligonucleotide.
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
PCT-US93-07603-6

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 454
US-07-912-900-20
; Sequence 20, Application US/07912900
; Patent No. 5349125
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING FLAVONOID
;    TITLE OF INVENTION:  PATHWAY ENZYMES AND USES THEREFOR
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/912,900
;      FILING DATE:  19920713
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-912-900-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
```

```
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 455
US-08-093-144-20
; Sequence 20, Application US/08093144
; Patent No. 5434048
;  GENERAL INFORMATION:
;    APPLICANT:  SIMON, LUC
;    APPLICANT:  LALONDE, MAURICE
;    TITLE OF INVENTION:  DNA PROBES FOR THE DETECTION OF
;    TITLE OF INVENTION:  ARBUSCULAR ENDOMYCORRHIZAL FUNGI
;    NUMBER OF SEQUENCES:  21
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CUSHMAN, DARBY & CUSHMAN
;      STREET:  Eleventh Floor, 1615 L. Street, N.W.
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20036-5601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Tape
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/093,144
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/745,192
;      FILING DATE:  15-AUG-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hymo, Lawrence A.
;      REGISTRATION NUMBER:  19,057
;      REFERENCE/DOCKET NUMBER:  LAH/3122/92223/MJW
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 861-3000
;      TELEFAX:  (202) 822-0944
;      TELEX:  6714627 CUSH
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-093-144-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   81.2%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db          3 CGCAGGTTCACCTACG 18


RESULT 456
US-08-146-504-16
; Sequence 16, Application US/08146504
; Patent No. 5605662
;  GENERAL INFORMATION:
;    APPLICANT:  Heller, Michael J.; and Tu, Eugene
;    TITLE OF INVENTION:  SELF-ADDRESSABLE SELF-ASSEMBLING
;    TITLE OF INVENTION:  MICROELECTRONIC SYSTEMS AND DEVICES FOR
;    TITLE OF INVENTION:  MOLECULAR BIOLOGICAL ANALYSIS AND
;    TITLE OF INVENTION:  DIAGNOSTICS
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/146,504
;      FILING DATE:  No. 5605662ember 1, 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    none
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  203/218
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-146-504-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 457
US-08-285-309-20
; Sequence 20, Application US/08285309
; Patent No. 5569832
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING A 3,5'-
;    TITLE OF INVENTION:  HYDROXYLASE AND USES
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/285,309
```

```
;      FILING DATE:  03-AUG-1994
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-285-309-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 458
US-08-313-075A-11
; Sequence 11, Application US/08313075A
; Patent No. 5639870
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Tanaka, Yoshikazu
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING FLAVONOID
;    TITLE OF INVENTION:  PATHWAY ENZYMES AND USES THEREFOR
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/313,075A
;      FILING DATE:  30-NOV-1994
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  AU PL 1538/92
;      FILING DATE:  27-MAR-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  AU PL 6698/93
;      FILING DATE:  07-JAN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  AU PCT/AU93/00127
;      FILING DATE:  25-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9433
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-313-075A-11

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 459
US-08-336-728A-32
; Sequence 32, Application US/08336728A
; Patent No. 6207802
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/336,728A
;      FILING DATE:  09-NOV-1994
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/32956
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

```
;    MOLECULE TYPE:  DNA
US-08-336-728A-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 460
US-08-336-728A-33
; Sequence 33, Application US/08336728A
; Patent No. 6207802
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/336,728A
;      FILING DATE:  09-NOV-1994
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/32956
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-336-728A-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 461
US-08-379-593-5
; Sequence 5, Application US/08379593
; Patent No. 5849480
;  GENERAL INFORMATION:
;    APPLICANT:  Cros, Philippe
;    APPLICANT:  Kurfurst, Robin
;    APPLICANT:  Battail, Nicole
;    APPLICANT:  Piga, Nadia
;    TITLE OF INVENTION:  HAPTEN ASSAY DEVICE AND USE THEREOF
;    NUMBER OF SEQUENCES:  5
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OLIFF & BERRIDGE
;      STREET:  700 South Washington Street, Suite 300
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Floppy disk, 1.44M storage
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,593
;      FILING DATE:  02-FEB-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Berridge, William P.
;      REGISTRATION NUMBER:  30,024
;      REFERENCE/DOCKET NUMBER:  WPB 36056
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-836-6400
;      TELEFAX:  703-836-2787
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "SYNTHETIC DNA"
;    FEATURE:
;      OTHER INFORMATION:  consists of nucleosides with an alpha anomer and carries
US-08-379-593-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 462
US-08-448-204-14
; Sequence 14, Application US/08448204
; Patent No. 5593836
;  GENERAL INFORMATION:
;    APPLICANT:  Niemiec, John
;    APPLICANT:  Young, Karen K.Y.
;    TITLE OF INVENTION:  Primers and Probes for Detecting
;    TITLE OF INVENTION:  Pneumocystis carinii
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07110-1199
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/448,204
;      FILING DATE:  23-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/062,089
;      FILING DATE:  14-MAY-1993
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-448-204-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   81.2%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db          3 CGCAGGTTCACCTACG 18


RESULT 463
US-08-482-918-32
; Sequence 32, Application US/08482918
; Patent No. 6207417
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,918
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/33005
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-482-918-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 464
US-08-482-918-33
; Sequence 33, Application US/08482918
; Patent No. 6207417
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,918
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/33005
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-482-918-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 465
US-08-502-046-20
; Sequence 20, Application US/08502046
; Patent No. 5861487
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Holton, Timothy A.
;    APPLICANT:  Cornish, Edwina C.
;    APPLICANT:  Kovacic, Filippa
;    APPLICANT:  Tanaka, Yoshikazu
;    APPLICANT:  Lester, Diane R.
;    TITLE OF INVENTION:  GENETIC SEQUENCES ENCODING A 3,5'-
;    TITLE OF INVENTION:  HYDROXYLASE AND USES
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/502,046
;      FILING DATE:  14-JUL-1995
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/285,309
;      FILING DATE:  03-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  8633Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-502-046-20

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 466
US-08-715-461-5
; Sequence 5, Application US/08715461
; Patent No. 5985556
;  GENERAL INFORMATION:
;    APPLICANT:  KAMBARA, Hideki
;    APPLICANT:  OKANO, Kazunori
;    TITLE OF INVENTION:  DNA SEQUENCING METHOD AND DNA SAMPLE
;    TITLE OF INVENTION:  PREPARATION METHOD
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ANTONELLI, TERRY STOUT & KRAUS
;      STREET:  1300 No. 5985556th Seventeenth Street, Suite 1800
;      CITY:  Arlington
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22209
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/715,461
;      FILING DATE:  18-SEP-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  TERRY, David T.
;      REGISTRATION NUMBER:  20,178
;      REFERENCE/DOCKET NUMBER:  500.34872X00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-312-6600
;      TELEFAX:  703-312-6666
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-715-461-5

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   6.2%;  Pred. No. 4.8e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 467
US-08-725-976-16
; Sequence 16, Application US/08725976
; Patent No. 5929208
;  GENERAL INFORMATION:
;    APPLICANT:  Heller, Michael J.; and Tu, Eugene
;    TITLE OF INVENTION:  METHODS FOR ELECTRONIC SYNTHESIS OF POLYMERS
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  WINDOWS (VERSION 3.0)
;      SOFTWARE:  WordPerfect (Version 6.0)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/725,976
;      FILING DATE:  October 4, 1996
;      CLASSIFICATION:  422
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:
;      APPLICATION NUMBER:  08/146,504
;      FILING DATE:  No. 5929208ember 1, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy, David B.
;      REGISTRATION NUMBER:  31,125
;      REFERENCE/DOCKET NUMBER:  222/211
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEFAX:  67-3510
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-725-976-16

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 468
US-08-765-340-96
; Sequence 96, Application US/08765340
; Patent No. 6150092
;  GENERAL INFORMATION:
;    APPLICANT:  UCHIDA, K.,
;    APPLICANT:  UCHIDA, T.,
;    APPLICANT:  TANAKA, Y.,
;    APPLICANT:  MATSUDA, Y.,
;    APPLICANT:  KONDO, S.
;    TITLE OF INVENTION:  AN ANTISENSE NUCLEIC ACID
;    TITLE OF INVENTION:  COMPOUND
;    NUMBER OF SEQUENCES;  185
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORGAN & FINNEGAN, L.L.P.
;      STREET:  345 PARK AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version
;      SOFTWARE:  #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/765,340
;      FILING DATE:  23-DEC-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 145146/94
;      FILING DATE:  27-JUN-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 311130/94
;      FILING DATE:  21-NOV-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SERUNIAN, LESLIE
;      REGISTRATION NUMBER:  35,353
;      REFERENCE/DOCKET NUMBER:  1452-4005
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 758-4800
;      TELEFAX:  (212) 751-6849
;  INFORMATION FOR SEQ ID NO:  96:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "synthetic DNA"
US-08-765-340-96

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 469
US-08-873-970-83/c
; Sequence 83, Application US/08873970
; Patent No. 6001361
;  GENERAL INFORMATION:
;    APPLICANT:  Tan, Paul
;    APPLICANT:  Hiyama, Jun
;    APPLICANT:  Visser, Elizabeth
;    APPLICANT:  Skinner, Margot
;    APPLICANT:  Scott, Linda
;    APPLICANT:  Prestidge, Ross
;    TITLE OF INVENTION:  COMPOUNDS AND METHODS FOR
;    TITLE OF INVENTION:  TREATMENT AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Ann W. Speckman
;      STREET:  2601 Elliott Avenue, Suite 4185
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98121
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/873,970
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/705,347
;      FILING DATE:  29-AUG-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sleath, Janet
;      REGISTRATION NUMBER:  37,007
;      REFERENCE/DOCKET NUMBER:  11000.1002C1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-269-0565
;      TELEFAX:  206-269-0563
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other
US-08-873-970-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 470
US-08-965-780-1
; Sequence 1, Application US/08965780
; Patent No. 5986084
;  GENERAL INFORMATION:
;    APPLICANT:  Pitsch, Stefan
;    APPLICANT:  Weiss, Patrick A.
;    APPLICANT:  Jenny, Luzi
;    TITLE OF INVENTION:  RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR
;    TITLE OF INVENTION:  PREPARING THE SAME
;    NUMBER OF SEQUENCES:  2
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  KUBOVCIK & KUBOVCIK
;      STREET:  900 17th Street, N.W., Suite 990
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20006
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/965,780
;      FILING DATE:  07-NOV-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  CH 01931/97
;      FILING DATE:  18-AUG-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kubovcik, Ronald J.
;      REGISTRATION NUMBER:  25,401
;      REFERENCE/DOCKET NUMBER:  FREI-002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-887-9023
;      TELEFAX:  202-887-9093
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "oligoribonucleotide"
US-08-965-780-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ||||||||||||||||
Db          1 UUUUUUUUUUUUUUUU 16


RESULT 471
US-08-997-080-83/c
; Sequence 83, Application US/08997080
; Patent No. 5968524
;  GENERAL INFORMATION:
;    APPLICANT:  WATSON, JAMES D.
;    APPLICANT:  TAN, PAUL L.J.
;    TITLE OF INVENTION:  METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-
;    NUMBER OF SEQUENCES:  194
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Ann W. Speckman
;      STREET:  2601 Elliott Avenue, Suite 4185
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98121
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/997,080
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sleath, Janet
;      REGISTRATION NUMBER:  37,007
;      REFERENCE/DOCKET NUMBER:  11000.1007
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-269-0565
;      TELEFAX:  206-269-0563
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other
US-08-997-080-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 472
US-08-997-362-83/c
; Sequence 83, Application US/08997362
; Patent No. 5985287
;  GENERAL INFORMATION:
;    APPLICANT:  Tan, Paul
;    APPLICANT:  Hiyama, Jun
;    APPLICANT:  Visser, Elizabeth
;    APPLICANT:  Skinner, Margot
;    APPLICANT:  Scott, Linda
;    APPLICANT:  Prestidge, Ross
;    TITLE OF INVENTION:  COMPOUNDS AND METHODS FOR
;    TITLE OF INVENTION:  TREATMENT AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS
;    NUMBER OF SEQUENCES:  194
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Ann W. Speckman
;      STREET:  2601 Elliott Avenue, Suite 4185
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98121
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/997,362
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  U.S. Patent Application No. 5985287 08/873,970
;      FILING DATE:  June 12, 1997
;      APPLICATION NUMBER:  U.S. Patent Application No. 5985287 08/705,347
;      FILING DATE:  August 29, 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sleath, Janet
;      REGISTRATION NUMBER:  37,007
;      REFERENCE/DOCKET NUMBER:  11000.1002c2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-269-0565
;      TELEFAX:  206-269-0563
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other
US-08-997-362-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 473
US-09-095-855-83/c
; Sequence 83, Application US/09095855
; Patent No. 6160093
;  GENERAL INFORMATION:
;    APPLICANT:  Tan, Paul
;    APPLICANT:  Visser, Elizabeth
;    APPLICANT:  Skinner, Margot
;    APPLICANT:  Prestidge, Ross
;    TITLE OF INVENTION:  Compounds and Methods for
;    TITLE OF INVENTION:  Treatment and Diagnosis of Mycobacterial Infections
;    NUMBER OF SEQUENCES:  208
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Ann W. Speckman
;      STREET:  2601 Elliott Avenue, Suite 4185
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98121
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/095,855
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/705,347
;      FILING DATE:  29-AUG-1996
;      APPLICATION NUMBER:  08/873,970
;      FILING DATE:  12-JUN-1997
;      APPLICATION NUMBER:  08/997,362
;      FILING DATE:  23-DEC-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sleath, Janet
;      REGISTRATION NUMBER:  37,007
;      REFERENCE/DOCKET NUMBER:  11000.1002c3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-269-0565
;      TELEFAX:  206-269-0563
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other
US-09-095-855-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 474
US-09-173-936B-14
; Sequence 14, Application US/09173936B
; Patent No. 6238865
;  GENERAL INFORMATION:
;       APPLICANT: Zhen, Huang; Szostak, Jack W.
;       TITLE OF INVENTION: A Simple and Efficient Method to Label and Modify 3'-
;                           Terminal
;                           of RNA Using DNA Polymerase and a Synthetic Template with D
;                           Nucleotides
;       NUMBER OF SEQUENCES: 21
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Cohen,Pontani,Lieberman & Pavane
;            STREET: 551 Fifth Avenue
;            CITY: New York
;            STATE: New York
;            COUNTRY: USA
;            ZIP: 10176
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.50 inch Diskette
;            COMPUTER: IBM-MS
;            OPERATING SYSTEM: Window 95
;            SOFTWARE: Microsoft Word
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/173,936B
;            FILING DATE: 16-Oct-1998
;            CLASSIFICATION: 435
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 60/063,757
;            FILING DATE: 17-OCT-1997
;  INFORMATION FOR SEQ ID NO: 14:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 bases
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-173-936B-14

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 475
US-09-205-426-83/c
; Sequence 83, Application US/09205426
; Patent No. 6406704
; GENERAL INFORMATION:
;  APPLICANT: Watson, James D.
;  APPLICANT: Tan, Paul L. J.
;  TITLE OF INVENTION: Compounds and Methods for Treatment and
;  TITLE OF INVENTION: Diagnosis of Mycobacterial Infections
;  FILE REFERENCE: 11000.1002c4
;  CURRENT APPLICATION NUMBER: US/09/205,426
;  CURRENT FILING DATE: 1998-12-04
;  EARLIER APPLICATION NUMBER: 09/095,855
;  EARLIER FILING DATE: 1998-06-11
;  EARLIER APPLICATION NUMBER: 08/997,362
;  EARLIER FILING DATE: 1997-12-23
;  EARLIER APPLICATION NUMBER: 08/873,970
;  EARLIER FILING DATE: 1997-06-12
;  EARLIER APPLICATION NUMBER: 08/705,347
;  EARLIER FILING DATE: 1996-08-29
;  NUMBER OF SEQ ID NOS: 208
;  SOFTWARE: FastSEQ for Windows Version 3.0
```

```
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Made in a lab
US-09-205-426-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 476
US-09-224-681-32
; Sequence 32, Application US/09224681
; Patent No. 6207454
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Method for Enhancing the Efficiency of Gene
;    TITLE OF INVENTION:  Transfer with Stem Cell Factor (SCF) Polypeptide
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,681
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35199
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-681-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 477
US-09-224-681-33
; Sequence 33, Application US/09224681
; Patent No. 6207454
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Method for Enhancing the Efficiency of Gene
;    TITLE OF INVENTION:  Transfer with Stem Cell Factor (SCF) Polypeptide
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,681
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
```

```
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35199
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-681-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 478
US-09-224-683-32
; Sequence 32, Application US/09224683
; Patent No. 6841147
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 479
US-09-224-683-33
; Sequence 33, Application US/09224683
; Patent No. 6841147
;  GENERAL INFORMATION:
;    APPLICANT:  Zsebo, Krisztina M.
;    APPLICANT:  Bosselman, Robert A.
;    APPLICANT:  Suggs, Sidney V.
;    APPLICANT:  Martin, Francis H.
;    TITLE OF INVENTION:  Stem Cell Factor: Composition Claims
;    NUMBER OF SEQUENCES:  104
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower, 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/224,683
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/005,893
;      FILING DATE:  12-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/449,653
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/982,255
;      FILING DATE:  25-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/589,701
;      FILING DATE:  01-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/573,616
;      FILING DATE:  24-AUG-1990
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  07/537,198
;      FILING DATE:  11-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/422,383
;      FILING DATE:  16-OCT-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clough, David W.
;      REGISTRATION NUMBER:  36,107
;      REFERENCE/DOCKET NUMBER:  01017/35136
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-224-683-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 480
US-09-250-075-1
; Sequence 1, Application US/09250075
; Patent No. 6207819
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A
;  TITLE OF INVENTION:  Compounds Processes And Intermediates For Synthesis Of
;  TITLE OF INVENTION:  Mixed Backbone Oligomeric Compounds
;  FILE REFERENCE:  ISIS3299
;  CURRENT APPLICATION NUMBER: US/09/250,075
;  CURRENT FILING DATE:  1999-02-12
;  NUMBER OF SEQ ID NOS:  12
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE)
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6207819el
;   OTHER INFORMATION: Sequence
US-09-250-075-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 481
US-09-324-542-83/c
; Sequence 83, Application US/09324542
; Patent No. 6328978
; GENERAL INFORMATION:
;  APPLICANT: Watson, James D.
;  APPLICANT: Tan, Paul L.J.
;  APPLICANT: Prestidge, Ross
;  TITLE OF INVENTION: Methods and Compounds for the Treatment
;  TITLE OF INVENTION: of Immunologically-Mediated Skin Disorders
;  FILE REFERENCE: 11000.1007c1
;  CURRENT APPLICATION NUMBER: US/09/324,542
;  CURRENT FILING DATE: 1999-06-02
;  EARLIER APPLICATION NUMBER: US 08/997,080
;  EARLIER FILING DATE: 1997-12-23
;  NUMBER OF SEQ ID NOS: 194
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Made in a lab
US-09-324-542-83

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 482
US-09-344-260A-10
; Sequence 10, Application US/09344260A
; Patent No. 6576752
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Lonnberg, Harri
;  APPLICANT:  Salo, Harri
;  APPLICANT:  Virta, Pasi
;  TITLE OF INVENTION: Aminooxy Functionalized Oligomers
;  FILE REFERENCE: ISIS-3508
;  CURRENT APPLICATION NUMBER: US/09/344,260A
;  CURRENT FILING DATE:  1999-06-25
;  PRIOR APPLICATION NUMBER: 09/016,520
;  PRIOR FILING DATE: 1998-01-30
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6576752el Sequence
US-09-344-260A-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 483
US-09-407-675-1/c
; Sequence 1, Application US/09407675
; Patent No. 6169176
; GENERAL INFORMATION:
;  APPLICANT:  Bruice, Thomas C.
;  APPLICANT:  Arya, Dev P.
;  TITLE OF INVENTION:  DEOXYNUCLEIC ALKYL THIOUREA COMPOUNDS AND USES THEREOF
;  FILE REFERENCE:  30448.65US02
;  CURRENT APPLICATION NUMBER: US/09/407,675
;  CURRENT FILING DATE:  1999-09-28
```

```
;  PRIOR APPLICATION NUMBER:  09/347,443
;  PRIOR FILING DATE:  1999-07-02
;  PRIOR APPLICATION NUMBER:  60/091,481
;  PRIOR FILING DATE:  1998-07-02
;  PRIOR APPLICATION NUMBER:  60/111,800
;  PRIOR FILING DATE:  1998-12-11
;  NUMBER OF SEQ ID NOS:  5
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Oligo 1
US-09-407-675-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 484
US-09-450-656-29
; Sequence 29, Application US/09450656
; Patent No. 6251606
; GENERAL INFORMATION:
;  APPLICANT:  HSEU, Ruey-Shyang
;  APPLICANT:  CHEN, Chih-Shang
;  TITLE OF INVENTION:  Gene Sequence and Method for Distinguishing Cordyceps Sinensis
; Patent No. 6251606
;  FILE REFERENCE:  2410-166P
;  CURRENT APPLICATION NUMBER: US/09/450,656
;  CURRENT FILING DATE:  1999-11-30
;  NUMBER OF SEQ ID NOS:  29
;  SOFTWARE:  PatentIn version 3.0
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: primer NS8
US-09-450-656-29

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   81.2%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4162 CGCAGGUUCACCUACG 4177
              ||||||::||||:|||
Db          3 CGCAGGTTCACCTACG 18


RESULT 485
US-09-454-704A-13/c
; Sequence 13, Application US/09454704A
; Patent No. 6274321
; GENERAL INFORMATION:
;  APPLICANT:  Blumberg, Bruce
;  TITLE OF INVENTION:  High Throughput Functional Screening of
;  TITLE OF INVENTION:  cDNAs
;  FILE REFERENCE:  P-UC 3662
;  CURRENT APPLICATION NUMBER: US/09/454,704A
;  CURRENT FILING DATE:  1999-12-03
;  NUMBER OF SEQ ID NOS:  14
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: cDNA
US-09-454-704A-13

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 486
US-09-603-830-55/c
; Sequence 55, Application US/09603830
; Patent No. 6506564
; GENERAL INFORMATION:
;  APPLICANT:  Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION:  NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE:  4149-1-1-1-1
;  CURRENT APPLICATION NUMBER: US/09/603,830
;  CURRENT FILING DATE:  2000-06-26
;  PRIOR APPLICATION NUMBER:  60/031,809
;  PRIOR FILING DATE:  1996-07-29
;  PRIOR APPLICATION NUMBER:  PCT/US97/12783
;  PRIOR FILING DATE:  1997-07-21
;  PRIOR APPLICATION NUMBER:  09/240,755
;  PRIOR FILING DATE:  1999-01-29
;  PRIOR APPLICATION NUMBER:  09/344,667
;  PRIOR FILING DATE:  1999-06-25
;  PRIOR APPLICATION NUMBER:  60/200,161
;  PRIOR FILING DATE:  2000-04-26
;  NUMBER OF SEQ ID NOS:  64
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO.55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-603-830-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 487
US-09-604-325A-32
; Sequence 32, Application US/09604325A
; Patent No. 6852313
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
```

```
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/604,325A
;             FILING DATE: 17-Jun-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32953
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-09-604-325A-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 488
US-09-604-325A-33
; Sequence 33, Application US/09604325A
; Patent No. 6852313
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/604,325A
;             FILING DATE: 17-Jun-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32953
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-604-325A-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 489
US-09-619-103-26/c
; Sequence 26, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-26

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5
```

```
RESULT 490
US-09-635-251-32
; Sequence 32, Application US/09635251
; Patent No. 6759215
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/635,251
;             FILING DATE: 07-Aug-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/449,182
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 04-OCT-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32957A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-09-635-251-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 491
US-09-635-251-33
; Sequence 33, Application US/09635251
; Patent No. 6759215
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/635,251
;             FILING DATE: 07-Aug-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/449,182
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 04-OCT-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32957A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-635-251-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 492
US-09-643-659B-32
; Sequence 32, Application US/09643659B
```

```
; Patent No. 6967029
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/643,659B
;             FILING DATE: 21-Aug-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/448,729
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-09-643-659B-32

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 493
US-09-643-659B-33
; Sequence 33, Application US/09643659B
; Patent No. 6967029
;   GENERAL INFORMATION:
;        APPLICANT: Zsebo, Krisztina M.
;                   Bosselman, Robert A.
;                   Suggs, Sidney V.
;                   Martin, Francis H.
;        TITLE OF INVENTION: Stem Cell Factor
;        NUMBER OF SEQUENCES: 104
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 6300 Sears Tower, 233 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/643,659B
;             FILING DATE: 21-Aug-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/448,729
;             FILING DATE: 24-MAY-1995
;             APPLICATION NUMBER: 08/172,329
;             FILING DATE: 21-DEC-1993
;             APPLICATION NUMBER: 07/982,255
;             FILING DATE: 25-NOV-1992
;             APPLICATION NUMBER: 07/684,535
;             FILING DATE: 10-APR-1991
;             APPLICATION NUMBER: 07/589,701
;             FILING DATE: 01-OCT-1990
;             APPLICATION NUMBER: 07/573,616
;             FILING DATE: 24-AUG-1990
;             APPLICATION NUMBER: 07/537,198
;             FILING DATE: 11-JUN-1990
;             APPLICATION NUMBER: 07/422,383
;             FILING DATE: 16-OCT-1989
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Clough, David W.
;             REGISTRATION NUMBER: 36,107
;             REFERENCE/DOCKET NUMBER: 01017/32958A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312/474-6300
;             TELEFAX: 312/474-0448
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-643-659B-33

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 494
US-09-724-857-36
; Sequence 36, Application US/09724857
; Patent No. 6855866
; GENERAL INFORMATION:
;  APPLICANT: Weterings, Koen
;  APPLICANT:  Apuya, Nestor R.
```

```
;  APPLICANT:  Tatarinova, Tatiana
;  APPLICANT:  Goldberg, Robert B.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Polynucleotides Useful for Modulating Transcription
;  FILE REFERENCE: 02307O-114700US
;  CURRENT APPLICATION NUMBER: US/09/724,857
;  CURRENT FILING DATE:  2002-05-06
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligo(dT-20)
;   OTHER INFORMATION: primer
US-09-724-857-36

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 495
US-09-726-096A-1
; Sequence 1, Application US/09726096A
; Patent No. 6462184
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Maier, Martin A.
;  TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Back
;  TITLE OF INVENTION:  Oligomeric Compounds
;  FILE REFERENCE: ISIS4528
;  CURRENT APPLICATION NUMBER: US/09/726,096A
;  CURRENT FILING DATE:  2000-11-29
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
;   OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-09-726-096A-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 496
US-09-760-500A-55/c
; Sequence 55, Application US/09760500A
; Patent No. 6767702
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-715-A
;  CURRENT APPLICATION NUMBER: US/09/760,500A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-760-500A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 497
US-09-820-279D-55/c
; Sequence 55, Application US/09820279D
; Patent No. 6750016
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1085-A
;  CURRENT APPLICATION NUMBER: US/09/820,279D
;  CURRENT FILING DATE:  2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
```

```
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:random
;    OTHER INFORMATION: synthetic sequence
US-09-820-279D-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 498
US-09-820-279D-70/c
; Sequence 70, Application US/09820279D
; Patent No. 6750016
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1085-A
;  CURRENT APPLICATION NUMBER: US/09/820,279D
;  CURRENT FILING DATE:  2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:random
;    OTHER INFORMATION: synthetic sequence
US-09-820-279D-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 499
US-09-859-736-3
; Sequence 3, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
;  APPLICANT: LI, WAN-LIANG ROBERT
;  APPLICANT:  ZHOU, JIAN S.
;  TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 16517.248
;  CURRENT APPLICATION NUMBER: US/09/859,736
;  CURRENT FILING DATE:  2001-05-18
;  PRIOR APPLICATION NUMBER: 60/205,452
;  PRIOR FILING DATE: 2000-05-19
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: CAT1 oligonucleotide
US-09-859-736-3

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 500
US-09-859-736-4
; Sequence 4, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
;  APPLICANT: LI, WAN-LIANG ROBERT
;  APPLICANT:  ZHOU, JIAN S.
;  TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 16517.248
;  CURRENT APPLICATION NUMBER: US/09/859,736
;  CURRENT FILING DATE:  2001-05-18
;  PRIOR APPLICATION NUMBER: 60/205,452
;  PRIOR FILING DATE: 2000-05-19
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: CAT2 oligonucleotide
US-09-859-736-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
```

```
                :::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 501
US-09-957-313A-55/c
; Sequence 55, Application US/09957313A
; Patent No. 6645721
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i3
;  CURRENT APPLICATION NUMBER: US/09/957,313A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-957-313A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                :::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 502
US-09-957-318A-55/c
; Sequence 55, Application US/09957318A
; Patent No. 6759199
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i2
;  CURRENT APPLICATION NUMBER: US/09/957,318A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-957-318A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                :::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 503
US-09-961-949A-55/c
; Sequence 55, Application US/09961949A
; Patent No. 6582921
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i1
;  CURRENT APPLICATION NUMBER: US/09/961,949A
;  CURRENT FILING DATE:  2001-09-20
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-961-949A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                :::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5
```

```
RESULT 504
US-09-965-599-4
; Sequence 4, Application US/09965599
; Patent No. 6555670
; GENERAL INFORMATION:
;  APPLICANT: Aizawa, Akira
;  APPLICANT:  Kawakami, Akiko
;  APPLICANT:  Kondo, Toshihiko
;  TITLE OF INVENTION: Testis-Specific Gene
;  FILE REFERENCE: 6920/0J871
;  CURRENT APPLICATION NUMBER: US/09/965,599
;  CURRENT FILING DATE:  2001-09-26
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer HT15-C
US-09-965-599-4

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   6.2%;  Pred. No. 4.8e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6360
              |:::::::::::::::
Db          4 CTTTTTTTTTTTTTT 19


RESULT 505
US-09-966-312-55/c
; Sequence 55, Application US/09966312
; Patent No. 6673548
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i5
;  CURRENT APPLICATION NUMBER: US/09/966,312
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-966-312-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 506
US-09-966-491A-55/c
; Sequence 55, Application US/09966491A
; Patent No. 6610491
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i4
;  CURRENT APPLICATION NUMBER: US/09/966,491A
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-966-491A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 507
US-09-967-409A-55/c
; Sequence 55, Application US/09967409A
; Patent No. 6740491
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i6
;  CURRENT APPLICATION NUMBER: US/09/967,409A
;  CURRENT FILING DATE:  2001-09-28
;  PRIOR APPLICATION NUMBER: 09/603,830
```

```
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-967-409A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 508
US-09-973-638A-55/c
; Sequence 55, Application US/09973638A
; Patent No. 6878814
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i9
;  CURRENT APPLICATION NUMBER: US/09/973,638A
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-973-638A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 509
US-09-973-788A-55/c
; Sequence 55, Application US/09973788A
; Patent No. 6720411
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i10
;  CURRENT APPLICATION NUMBER: US/09/973,788A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-973-788A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 510
US-09-974-500A-55/c
; Sequence 55, Application US/09974500A
; Patent No. 6709825
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i7
;  CURRENT APPLICATION NUMBER: US/09/974,500A
;  CURRENT FILING DATE:  2002-04-01
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
```

```
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-974-500A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 511
US-09-975-059A-55/c
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i15
;  CURRENT APPLICATION NUMBER: US/09/975,059A
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 512
US-09-975-062A-55/c
; Sequence 55, Application US/09975062A
; Patent No. 6677122
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i11
;  CURRENT APPLICATION NUMBER: US/09/975,062A
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-062A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 513
US-09-975-498-55/c
; Sequence 55, Application US/09975498
; Patent No. 6861221
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i14
;  CURRENT APPLICATION NUMBER: US/09/975,498
;  CURRENT FILING DATE:  2001-10-11
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
```

```
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-975-498-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 514
US-09-976-378A-55/c
; Sequence 55, Application US/09976378A
; Patent No. 6969761
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i25
;  CURRENT APPLICATION NUMBER: US/09/976,378A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-378A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 515
US-09-976-577-55/c
; Sequence 55, Application US/09976577
; Patent No. 6720147
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i20
;  CURRENT APPLICATION NUMBER: US/09/976,577
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-577-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 516
US-09-976-601A-55/c
; Sequence 55, Application US/09976601A
; Patent No. 6903207
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i16
;  CURRENT APPLICATION NUMBER: US/09/976,601A
;  CURRENT FILING DATE:  2001-10-15
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
```

```
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-601A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 517
US-09-976-617A-55/c
; Sequence 55, Application US/09976617A
; Patent No. 6730269
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i24
;  CURRENT APPLICATION NUMBER: US/09/976,617A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-617A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 518
US-09-976-618A-55/c
; Sequence 55, Application US/09976618A
; Patent No. 6812334
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i21
;  CURRENT APPLICATION NUMBER: US/09/976,618A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-618A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 519
US-09-976-863A-55/c
; Sequence 55, Application US/09976863A
; Patent No. 6986989
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i19
;  CURRENT APPLICATION NUMBER: US/09/976,863A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
```

```
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-863A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 520
US-09-976-900A-55/c
; Sequence 55, Application US/09976900A
; Patent No. 6902895
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i23
;  CURRENT APPLICATION NUMBER: US/09/976,900A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-900A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 521
US-09-976-968A-55/c
; Sequence 55, Application US/09976968A
; Patent No. 6818753
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i17
;  CURRENT APPLICATION NUMBER: US/09/976,968A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-968A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 522
US-09-976-971A-55/c
; Sequence 55, Application US/09976971A
; Patent No. 6682895
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i18
;  CURRENT APPLICATION NUMBER: US/09/976,971A
;  CURRENT FILING DATE:  2001-10-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
```

```
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-971A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 523
US-09-976-978A-55/c
; Sequence 55, Application US/09976978A
; Patent No. 6532097
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i17
;  CURRENT APPLICATION NUMBER: US/09/976,978A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-976-978A-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 524
US-09-981-344-55/c
; Sequence 55, Application US/09981344
; Patent No. 6777186
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-i22
;  CURRENT APPLICATION NUMBER: US/09/981,344
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-09-981-344-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 525
US-10-008-978-55/c
; Sequence 55, Application US/10008978
; Patent No. 6984491
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  APPLICANT:  Lu, Gang
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1272-C
;  CURRENT APPLICATION NUMBER: US/10/008,978
;  CURRENT FILING DATE:  2002-05-20
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
```

```
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 60/224,631
;  PRIOR FILING DATE: 2000-08-11
;  PRIOR APPLICATION NUMBER: 60/254,392
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/254,418
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/255,235
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 60/255,236
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 60/282,640
;  PRIOR FILING DATE: 2000-04-01
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-008-978-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 526
US-10-008-978-70/c
; Sequence 70, Application US/10008978
; Patent No. 6984491
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  APPLICANT:  Garimella, Viswanadham
;  APPLICANT:  Li, Zhi
;  APPLICANT:  Park, So-Jung
;  APPLICANT:  Lu, Gang
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-1272-C
;  CURRENT APPLICATION NUMBER: US/10/008,978
;  CURRENT FILING DATE:  2002-05-20
;  PRIOR APPLICATION NUMBER: 09/927,777
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 09/820,279
;  PRIOR FILING DATE: 2001-03-28
;  PRIOR APPLICATION NUMBER: 09/760,500
;  PRIOR FILING DATE: 2001-01-12
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/176,409
;  PRIOR FILING DATE: 2000-01-13
;  PRIOR APPLICATION NUMBER: 60/192,699
;  PRIOR FILING DATE: 2000-03-28
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  PRIOR APPLICATION NUMBER: 60/213,906
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 60/224,631
;  PRIOR FILING DATE: 2000-08-11
;  PRIOR APPLICATION NUMBER: 60/254,392
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/254,418
;  PRIOR FILING DATE: 2000-12-08
;  PRIOR APPLICATION NUMBER: 60/255,235
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 60/255,236
;  PRIOR FILING DATE: 2000-12-11
;  PRIOR APPLICATION NUMBER: 60/282,640
;  PRIOR FILING DATE: 2000-04-01
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-008-978-70

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 527
US-10-234-764-10
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Lonnberg, Harri
;  APPLICANT:  Salo, Harri
;  APPLICANT:  Virta, Pasi
;  TITLE OF INVENTION: Aminooxy Functionalized Oligomers
;  FILE REFERENCE: ISIS5089
;  CURRENT APPLICATION NUMBER: US/10/234,764
;  CURRENT FILING DATE:  2002-09-03
;  PRIOR APPLICATION NUMBER: 09/016,520
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 09/344,260
;  PRIOR FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Synthetic construct
US-10-234-764-10

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 528
US-10-278-047-1
; Sequence 1, Application US/10278047
; Patent No. 6902900
; GENERAL INFORMATION:
;  APPLICANT: Davies, Martin
;  APPLICANT:  Bruce, Ian
;  APPLICANT:  Wolter, Andreas
;  TITLE OF INVENTION: NUCLEIC ACID PROBES AND METHODS TO DETECT AND/OR QUANTIFY NUCLEIC
;  TITLE OF INVENTION:  ACID ANALYTES
;  FILE REFERENCE: PRO.07
;  CURRENT APPLICATION NUMBER: US/10/278,047
;  CURRENT FILING DATE:  2002-10-21
;  PRIOR APPLICATION NUMBER: 60/336,432
;  PRIOR FILING DATE: 2001-10-19
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic Nucleic Acid Probe
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(20)
US-10-278-047-1

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 529
US-10-410-324-55/c
; Sequence 55, Application US/10410324
; Patent No. 6962786
; GENERAL INFORMATION:
;  APPLICANT: Mirkin, Chad A.
;  APPLICANT:  Letsinger, Robert L.
;  APPLICANT:  Mucic, Robert C.
;  APPLICANT:  Storhoff, James J.
;  APPLICANT:  Elghanian, Robert
;  APPLICANT:  Taton, Thomas A.
;  TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE: 00-713-I26
;  CURRENT APPLICATION NUMBER: US/10/410,324
;  CURRENT FILING DATE:  2003-04-09
;  PRIOR APPLICATION NUMBER: 09/961,949
;  PRIOR FILING DATE: 2001-09-20
;  PRIOR APPLICATION NUMBER: 09/603,830
;  PRIOR FILING DATE: 2000-06-26
;  PRIOR APPLICATION NUMBER: 09/344,667
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: 09/240,755
;  PRIOR FILING DATE: 1999-01-29
;  PRIOR APPLICATION NUMBER: PCT/US97/12783
;  PRIOR FILING DATE: 1997-07-21
;  PRIOR APPLICATION NUMBER: 60/031,809
;  PRIOR FILING DATE: 1996-07-29
;  PRIOR APPLICATION NUMBER: 60/200,161
;  PRIOR FILING DATE: 2000-04-26
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:random
;   OTHER INFORMATION: synthetic sequence
US-10-410-324-55

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 530
US-08-424-550B-667/c
; Sequence 667, Application US/08424550B
; Patent No. 6720166
;  GENERAL INFORMATION:
;    APPLICANT:  JOHN N. SIMONS
;    APPLICANT:  TAMI J. PILOT-MATIAS
;    APPLICANT:  GEORGE J. DAWSON
;    APPLICANT:  GEORGE G. SCHLAUDER
;    APPLICANT:  SURESH M. DESAI
;    APPLICANT:  THOMAS P. LEARY
;    APPLICANT:  ANTHONY SCOTT MUERHOFF
;    APPLICANT:  JAMES C. ERKER
;    APPLICANT:  SHERI L. BUIJK
;    APPLICANT:  ISA K. MUSHAHWAR
;    TITLE OF INVENTION:  NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
;    TITLE OF INVENTION:  REAGENTS AND METHODS FOR THEIR USE
;    NUMBER OF SEQUENCES:  716
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ABBOTT LABORATORIES  D377/AP6D
;      STREET:  100 ABBOTT PARK ROAD
;      CITY:  ABBOTT PARK
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60064-3500
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/424,550B
;      FILING DATE:
;      CLASSIFICATION:  435435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  POREMBSKI, PRISCILLA E.
;      REGISTRATION NUMBER:  33,207
;      REFERENCE/DOCKET NUMBER:  5527.PC.01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  708-937-6365
;      TELEFAX:  708-938-2623
;  INFORMATION FOR SEQ ID NO:  667:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-424-550B-667

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 GGCCGGGGGAGCGCGGGCA 220
              |||:|:||||: ||:||||
Db         19 GGCMGKGGGARAGCKGGCA 1


RESULT 531
US-08-467-344A-667/c
; Sequence 667, Application US/08467344A
; Patent No. 6586568
;  GENERAL INFORMATION:
;       APPLICANT: JOHN N. SIMONS
;                  TAMI J. PILOT-MATIAS
;                  GEORGE J. DAWSON
;                  GEORGE G. SCHLAUDER
;                  SURESH M. DESAI
;                  THOMAS P. LEARY
;                  ANTHONY SCOTT MUERHOFF
;                  JAMES C. ERKER
;                  SHERI L. BUIJK
;                  ISA K. MUSHAHWAR
;       TITLE OF INVENTION: NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
;                           REAGENTS AND METHODS FOR THEIR USE
;       NUMBER OF SEQUENCES: 716
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: ABBOTT LABORATORIES  D377/AP6D
;            STREET: 100 ABBOTT PARK ROAD
;            CITY: ABBOTT PARK
;            STATE: IL
;            COUNTRY: USA
;            ZIP: 60064-3500
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/467,344A
;            FILING DATE: 07-Jun-1995
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/424,550
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: POREMBSKI, PRISCILLA E.
;            REGISTRATION NUMBER: 33,207
;            REFERENCE/DOCKET NUMBER: 5527.PC.01
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 708-937-6365
;            TELEFAX: 708-938-2623
;  INFORMATION FOR SEQ ID NO: 667:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 19 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: double
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 667:
US-08-467-344A-667

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 GGCCGGGGGAGCGCGGGCA 220
              |||:|:||||: ||:||||
Db         19 GGCMGKGGGARAGCKGGCA 1


RESULT 532
US-08-469-260A-667/c
; Sequence 667, Application US/08469260A
; Patent No. 6451578
;  GENERAL INFORMATION:
;    APPLICANT:  JOHN N. SIMONS
;    APPLICANT:  TAMI J. PILOT-MATIAS
;    APPLICANT:  GEORGE J. DAWSON
;    APPLICANT:  GEORGE G. SCHLAUDER
;    APPLICANT:  SURESH M. DESAI
;    APPLICANT:  THOMAS P. LEARY
;    APPLICANT:  ANTHONY SCOTT MUERHOFF
;    APPLICANT:  JAMES C. ERKER
;    APPLICANT:  SHERI L. BUIJK
;    APPLICANT:  ISA K. MUSHAHWAR
;    TITLE OF INVENTION:  NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
;    TITLE OF INVENTION:  REAGENTS AND METHODS FOR THEIR USE
;    NUMBER OF SEQUENCES:  716
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ABBOTT LABORATORIES  D377/AP6D
;      STREET:  100 ABBOTT PARK ROAD
;      CITY:  ABBOTT PARK
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60064-3500
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/469,260A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/424,550
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  POREMBSKI, PRISCILLA E.
;      REGISTRATION NUMBER:  33,207
;      REFERENCE/DOCKET NUMBER:  5527.PC.01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  708-937-6365
;      TELEFAX:  708-938-2623
;  INFORMATION FOR SEQ ID NO:  667:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-469-260A-667

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 GGCCGGGGGAGCGCGGGCA 220
              |||:|:||||: ||:||||
Db         19 GGCMGKGGGARAGCKGGCA 1


RESULT 533
US-08-488-446-667/c
; Sequence 667, Application US/08488446
; Patent No. 6558898
;  GENERAL INFORMATION:
;    APPLICANT:  JOHN N. SIMONS
;    APPLICANT:  TAMI J. PILOT-MATIAS
;    APPLICANT:  GEORGE J. DAWSON
```

```
;    APPLICANT:  GEORGE G. SCHLAUDER
;    APPLICANT:  SURESH M. DESAI
;    APPLICANT:  THOMAS P. LEARY
;    APPLICANT:  ANTHONY SCOTT MUERHOFF
;    APPLICANT:  JAMES C. ERKER
;    APPLICANT:  SHERI L. BUIJK
;    APPLICANT:  ISA K. MUSHAHWAR
;    TITLE OF INVENTION:  NON-A, NON-B. NON-C, NON-D, NON-E HEPATITIS
;    TITLE OF INVENTION:  REAGENTS AND METHODS FOR THEIR USE
;    NUMBER OF SEQUENCES:  716
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ABBOTT LABORATORIES  D377/AP6D
;      STREET:  100 ABBOTT PARK ROAD
;      CITY:  ABBOTT PARK
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60064-3500
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,446
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/424,550
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  POREMBSKI, PRISCILLA E.
;      REGISTRATION NUMBER:  33,207
;      REFERENCE/DOCKET NUMBER:  5527.PC.01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  708-937-6365
;      TELEFAX:  708-938-2623
;  INFORMATION FOR SEQ ID NO:  667:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-488-446-667

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 GGCCGGGGGAGCGCGGGCA 220
              |||:|:||||: ||:||||
Db         19 GGCMGKGGGARAGCKGGCA 1


RESULT 534
US-08-849-021-74
; Sequence 74, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  74:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-74

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   36.8%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|: : :
Db          1 TGTGTGTGTGTGTGTATAT 19


RESULT 535
US-08-899-029-1
; Sequence 1, Application US/08899029
; Patent No. 6143531
;  GENERAL INFORMATION:
;    APPLICANT:  HUSE, WILLIAM D.
;    TITLE OF INVENTION:  IMPROVED METHOD OF DOUBLE
;    TITLE OF INVENTION:  STRANDED DNA SYNTHESIS
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds, LLP
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York,
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/899,029
;      FILING DATE:  22-JUL-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/116,049
;      FILING DATE:  02-SEP-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Abrams, Samuel B
;      REGISTRATION NUMBER:  30,605
;      REFERENCE/DOCKET NUMBER:  8142-125-999
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-790-9090
;      TELEFAX:  212-869-9741
```

```
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
US-08-899-029-1

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   15.8%;  Pred. No. 4.5e+02;
  Matches    3;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUUU 6358
              |:| | ::::::::::::::
Db          1 CTCGAGTTTTTTTTTTTTT 19


RESULT 536
US-09-434-382-54/c
; Sequence 54, Application US/09434382
; Patent No. 6844189
; GENERAL INFORMATION:
;  APPLICANT: Tavtigian, Sean V.
;  APPLICANT: Teng, David H.F.
;  APPLICANT: Simard, Jacques
;  APPLICANT: Rommens, Johanna M.
;  APPLICANT: Myriad Genetics, Inc.
;  TITLE OF INVENTION: Chromosome 17q-Linked Prostate Cancer Susceptibility
;  TITLE OF INVENTION: Gene
;  FILE REFERENCE: HPC2 Gene
;  CURRENT APPLICATION NUMBER: US/09/434,382
;  CURRENT FILING DATE: 1999-11-05
;  EARLIER APPLICATION NUMBER: US 60/107,468
;  EARLIER FILING DATE: 1999-11-06
;  NUMBER OF SEQ ID NOS: 213
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 54
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-434-382-54

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5549 CAAGGUAUUUCUCCAGUUG 5567
              | |||:|::: :||||::|
Db         19 CGAGGTATTTTTCCAGTTG 1


RESULT 537
US-09-564-805-54/c
; Sequence 54, Application US/09564805
; Patent No. 6333403
; GENERAL INFORMATION:
;  APPLICANT:  Tavtigian, Sean V.
;  APPLICANT:  Teng, David H.F.
;  APPLICANT:  Simard, Jacques
;  APPLICANT:  Rommens, Johanna M.
;  APPLICANT:  Myriad Genetics, Inc.
;  TITLE OF INVENTION:  Chromosome 17p-Linked Prostate Cancer Susceptibility
;  TITLE OF INVENTION:  Gene and a Paralog and Orthologous Genes
;  FILE REFERENCE:  2318-258
;  CURRENT APPLICATION NUMBER: US/09/564,805
;  CURRENT FILING DATE:  2000-05-05
;  PRIOR APPLICATION NUMBER:  US 60/107,468
;  PRIOR FILING DATE:  1998-11-06
;  PRIOR APPLICATION NUMBER:  09/434,382
;  PRIOR FILING DATE:  1999-11-05
;  NUMBER OF SEQ ID NOS:  240
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 54
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-564-805-54

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5549 CAAGGUAUUUCUCCAGUUG 5567
              | |||:|::: :||||::|
Db         19 CGAGGTATTTTTCCAGTTG 1


RESULT 538
US-08-222-177A-68
; Sequence 68, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  68:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd6rs
US-08-222-177A-68

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 38;
  Best Local Similarity   65.7%;  Pred. No. 8.5e+02;
  Matches   23;  Conservative    0;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| || | | ||||||   ||| ||  | |||
Db          2 ACACACACAAACACACACACACACACACACACACA 36


RESULT 539
US-08-222-177A-86
```

```
; Sequence 86, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  86:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  39 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd12rs
US-08-222-177A-86

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 39;
  Best Local Similarity   62.9%;  Pred. No. 8.3e+02;
  Matches   22;  Conservative    1;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||   | ||||||:  ||| ||  | |||
Db          3 ACACACACACACACACACATACACACACACACACA 37


RESULT 540
US-08-937-067-17
; Sequence 17, Application US/08937067
; Patent No. 6433155
;  GENERAL INFORMATION:
;    APPLICANT:  Umansky, Samuil
;    APPLICANT:  Melkonyan, Hovsep
;    TITLE OF INVENTION:  A FAMILY OF GENES ENCODING
;    TITLE OF INVENTION:  APOPTOSIS-RELATED PEPTIDES; PEPTIDES ENCODED THEREBY AND
;    TITLE OF INVENTION:  METHODS OF USE THEREOF
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 Page Mill Road
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/937,067
;      FILING DATE:
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lehnhardt, Susan K.
;      REGISTRATION NUMBER:  33,943
;      REFERENCE/DOCKET NUMBER:  23647-20018.00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (650) 813-5600
;      TELEFAX:  (650) 494-0792
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-937-067-17

  Query Match             0.2%;  Score 15.6;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::: :
Db          1 TTTTTTTTTTTTTTTNS 17


RESULT 541
US-08-050-073-205/c
; Sequence 205, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  205:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-205

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.9e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| |||:
Db         17 CCTGTCTTCCAGGAAGT 1


RESULT 542
US-08-050-073-305/c
; Sequence 305, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  305:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-305

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.9e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| |||:
Db         17 CCTGTCTTCCAGGAAGT 1


RESULT 543
US-08-050-073-71
; Sequence 71, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  71:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-71

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.9e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| |||:
Db          1 CCTGTCTTCCAGGAAGT 17


RESULT 544
US-09-866-108A-9685/c
; Sequence 9685, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9685
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9685

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6154 GAGUGGGACAGUCCUCU 6170
                ||||:||| |||:||:|:
Db         17 GAGTGGGCCAGTCCTCT 1


RESULT 545
US-10-156-306B-521
; Sequence 521, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 521
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-521

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 3.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUUU 6359
                | ||||||||||||||||
Db          1 UUCUUUUUUUUUUUUUU 17


RESULT 546
US-08-050-073-100
; Sequence 100, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  100:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-100

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   64.7%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
                ||:|:|::|||| |||:
Db          2 CCTGTCTTCCAGGAAGT 18


RESULT 547
US-08-283-917-28
; Sequence 28, Application US/08283917
; Patent No. 5849557
;  GENERAL INFORMATION:
;    APPLICANT:  ADACHI, HIDEKI
;    APPLICANT:  TSUJIMOTO, MASAFUMI
;    APPLICANT:  INOUE, KEIZO
;    APPLICANT:  ARAI, HIROYUKI
;    TITLE OF INVENTION:  OXIDIZED PHOPHOLIPID DEGRADING ENZYME
;    TITLE OF INVENTION:  AND GENE THEREOF
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER &
;      ADDRESSEE:  NEUSTADT,P.C.
;      STREET:  1755 S. Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/283,917
;      FILING DATE:  03-AUG-1994
;      CLASSIFICATION:  435
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 209943/1993
;      FILING DATE:  03-AUG-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Oblon, No. 5849557man F.
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  2292-030-0
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 413-3000
;      TELEFAX:  (703) 413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  Other nucleic acid
US-08-283-917-28

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3664 AGAGACCCAAAAGAAAG 3680
              ||||||||||||||| |
Db          2 AGAGACCCAAAAGAATG 18


RESULT 548
US-08-363-585-86/c
; Sequence 86, Application US/08363585
; Patent No. 5683872
;  GENERAL INFORMATION:
;    APPLICANT:  Rudert, William A.
;    APPLICANT:  Trucco, Massimo
;    TITLE OF INVENTION:  Polymers of Oligonucleotide Probes
;    TITLE OF INVENTION:  As The Bound Ligands For Use In Reverse
;    TITLE OF INVENTION:  Dot Blots
;    NUMBER OF SEQUENCES:  112
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  University of Pittsburgh
;      STREET:  Office of Intellectual Property
;      STREET:  911 William Pitt Union
;      CITY:  Pittsburgh
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  15260
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5-1/4" low density diskette
;      COMPUTER:  IBM PC or compatibles
;      OPERATING SYSTEM:  MS-DOS
;      SOFTWARE:  ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,585
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/786,228
;      FILING DATE:  31-OCT-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Frederick H. Colen; Mary-Elizabeth Buckles
;      REGISTRATION NUMBER:  28,061; 31,907
;      REFERENCE/DOCKET NUMBER:  92-232
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  412/288-4164
;      TELEFAX:  412/288-3063
;      TELEX:  277871
;  INFORMATION FOR SEQ ID NO:  86:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;    PUBLICATION INFORMATION:
;      AUTHORS:  Kimura, A.
;      AUTHORS:  Sasazuki, T.
;      TITLE:  Eleventh International Histocompatibility
;      TITLE:  Workshop Reference Protocol for the HLA-DNA-Typing
;      TITLE:  Technique
;      JOURNAL:  HLA 1991
;      VOLUME:  1
;      PAGES:  397-419
;      DATE:  1992
;      RELEVANT RESIDUES IN SEQ ID NO:  86: 1 to 18
US-08-363-585-86

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   64.7%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| |||:
Db         18 CCTGTCTTCCAGGAAGT 2


RESULT 549
US-08-961-716-28
; Sequence 28, Application US/08961716
; Patent No. 5880272
;  GENERAL INFORMATION:
;    APPLICANT:  ADACHI, HIDEKI
;    APPLICANT:  TSUJIMOTO, MASAFUMI
;    APPLICANT:  INOUE, KEIZO
;    APPLICANT:  ARAI, HIROYUKI
;    TITLE OF INVENTION:  OXIDIZED PHOPHOLIPID DEGRADING ENZYME
;    TITLE OF INVENTION:  AND GENE THEREOF
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER &
;      ADDRESSEE:  NEUSTADT,P.C.
;      STREET:  1755 S. Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/961,716
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/283,917
;      FILING DATE:  03-AUG-1994
;      APPLICATION NUMBER:  JP 209943/1993
;      FILING DATE:  03-AUG-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Oblon, No. 5880272man F.
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  2292-030-0
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 413-3000
;      TELEFAX:  (703) 413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  Other nucleic acid
```

```
US-08-961-716-28

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3664 AGAGACCCAAAAGAAAG 3680
              |||||||||||||||| |
Db          2 AGAGACCCAAAAGAATG 18


RESULT 550
US-09-328-174A-8/c
; Sequence 8, Application US/09328174A
; Patent No. 6448003
; GENERAL INFORMATION:
;  APPLICANT:  Guida, Marco
;  APPLICANT:  Kurth, Janice
;  TITLE OF INVENTION:  Genotyping Human Phenol Sulfotransferase
;  TITLE OF INVENTION:  (STP2)
;  FILE REFERENCE:  4389-6 (formerly SEQ-16P)
;  CURRENT APPLICATION NUMBER: US/09/328,174A
;  CURRENT FILING DATE:  1999-06-08
;  PRIOR APPLICATION NUMBER:  09/328,174
;  PRIOR FILING DATE:  1999-06-08
;  NUMBER OF SEQ ID NOS:  110
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: H. sapiens
US-09-328-174A-8

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       5349 GGAAGACCCCGUCUCUA 5365
              |||||||||| :|:|:|
Db         18 GGAAGACCCCATCTCTA 2


RESULT 551
PCT-US93-00977-292/c
; Sequence 292, Application PC/TUS9300977
;  GENERAL INFORMATION:
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR MEASURING MESSENGER RNA
;    NUMBER OF SEQUENCES:  711
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson, and Bear
;      STREET:  620 Newport Center Dr.  Sixteenth Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/00977
;      FILING DATE:  19930129
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E.
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  HITACHI.006H
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-760-0404
;      TELEFAX:  714-760-9502
;  INFORMATION FOR SEQ ID NO:  292:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
PCT-US93-00977-292

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3188 UUGAGGAAGAGGAGGAU 3204
              ::|||||||||||| ||:
Db         19 TTGAGGAAGAGGATGAT 3


RESULT 552
US-07-974-409C-292/c
; Sequence 292, Application US/07974409C
; Patent No. 6300058
;  GENERAL INFORMATION:
;    APPLICANT:  Akitaya, Tatsuo
;    APPLICANT:  Mitsuhashi, Masato
;    APPLICANT:  Cooper, Allan
;    TITLE OF INVENTION:  METHOD AND REAGENT
;    TITLE OF INVENTION:  FOR MEASURING MESSENGER RNA
;    NUMBER OF SEQUENCES:  457
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson, and Bear
;      STREET:  620 Newport Center Dr.  Sixteenth Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/974,409C
;      FILING DATE:  12-NOV-1992
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E.
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  HITACHI.006CP2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-760-0404
;      TELEFAX:  714-760-9502
;  INFORMATION FOR SEQ ID NO:  292:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-07-974-409C-292

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3188 UUGAGGAAGAGGAGGAU 3204
              ::|||||||||||| ||:
Db         19 TTGAGGAAGAGGATGAT 3


RESULT 553
```

```
US-08-050-073-113
; Sequence 113, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  113:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-113

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 5e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| |||:
Db          3 CCTGTCTTCCAGGAAGT 19


RESULT 554
US-08-379-078-708/c
; Sequence 708, Application US/08379078
; Patent No. 5639612
;  GENERAL INFORMATION:
;    APPLICANT:  Mitsuhashi, Masato
;    APPLICANT:  Cooper, Allan
;    TITLE OF INVENTION:  Gene Detection System
;    NUMBER OF SEQUENCES:  726
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  KNOBBE, MARTENS, OLSON AND BEAR
;      STREET:  620 Newport Center Drive  16th Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,078
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/974,406
;      FILING DATE:  12-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E.
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  HITACHI.011CP2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-760-0404
;      TELEFAX:  714-760-9502
;  INFORMATION FOR SEQ ID NO:  708:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-379-078-708

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3188 UUGAGGAAGAGGAGGAU 3204
              ::|||||||||||| ||:
Db         19 TTGAGGAAGAGGATGAT 3


RESULT 555
US-09-696-791-4087
; Sequence 4087, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4087
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-09-696-791-4087

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 5e+02;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          3 TTGTGATTTTTATAATA 19


RESULT 556
US-09-696-791-4088
; Sequence 4088, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
```

```
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4088
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-09-696-791-4088

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 5e+02;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          2 TTGTGATTTTTATAATA 18


RESULT 557
US-09-696-791-4089
; Sequence 4089, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4089
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: PCNA HH ribozyme binding site
US-09-696-791-4089

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   35.3%;  Pred. No. 5e+02;
  Matches    6;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4391 UUGUGAUUUUUUUAAUA 4407
              ::|:||::::: :||:|
Db          1 TTGTGATTTTTATAATA 17


RESULT 558
US-09-818-943-6
; Sequence 6, Application US/09818943
; Patent No. 7034200
; GENERAL INFORMATION:
;  APPLICANT: ERIKSSON, Ulf
;  APPLICANT:  LI, Xuri
;  APPLICANT:  PONTEN, Annica
;  APPLICANT:  AASE, Karin
;  APPLICANT:  LI, Hong
;  TITLE OF INVENTION: NON-HUMAN TRANSGENIC ANIMALS EXPRESSING PLATELET-DERIVED GROWTH F
;  TITLE OF INVENTION:  (PDGF-C) AND USES THEREOF
;  FILE REFERENCE: 1064/48487
;  CURRENT APPLICATION NUMBER: US/09/818,943
;  CURRENT FILING DATE:  2001-03-28
;  PRIOR APPLICATION NUMBER: US 60/192,507
;  PRIOR FILING DATE: 2000-03-28
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Murinae gen. sp.
US-09-818-943-6

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 5e+02;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2604 GUCUUCUUCUGAAAUAA 2620
              |:|::|::| ||||:||
Db          1 GTCTTCTTCAGAAATAA 17


RESULT 559
US-09-390-324B-2
; Sequence 2, Application US/09390324B
; Patent No. 6342376
; GENERAL INFORMATION:
;  APPLICANT: Kozian, Detlef
;  APPLICANT:  Reuner, Birgit
;  TITLE OF INVENTION: Two-color differential display as a method for
;  TITLE OF INVENTION:  detecting regulated genes
;  FILE REFERENCE: 2481-1635
;  CURRENT APPLICATION NUMBER: US/09/390,324B
;  CURRENT FILING DATE:  1999-09-07
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: exon
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: Description of Artificial Sequence: synthetic
;   OTHER INFORMATION: "V=A,C,G; N=A,C,G,T"
US-09-390-324B-2

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTV 16


RESULT 560
US-10-015-593-2
; Sequence 2, Application US/10015593
; Patent No. 6645741
; GENERAL INFORMATION:
;  APPLICANT: Kozian, Detlef
;  APPLICANT:  Reuner, Birgit
;  TITLE OF INVENTION: Two-color differential display as a method for
;  TITLE OF INVENTION:  detecting regulated genes
;  FILE REFERENCE: 2481-1635
;  CURRENT APPLICATION NUMBER: US/10/015,593
;  CURRENT FILING DATE:  2001-12-17
;  PRIOR APPLICATION NUMBER: 09/390,324
;  PRIOR FILING DATE: 2001-05-21
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: exon
```

```
;   LOCATION: (1)..(17)
;   OTHER INFORMATION: Description of Artificial Sequence: synthetic
;   OTHER INFORMATION: "V=A,C,G; N=A,C,G,T"
US-10-015-593-2

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTV 16


RESULT 561
US-07-971-978-1
; Sequence 1, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  1
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  2
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  3
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  5
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  6
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  7
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  8
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  9
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  10
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  11
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  12
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  6-aza-thymidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  6-aza-thymidine substitution
US-07-971-978-1

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 562
US-08-108-591B-17
; Sequence 17, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/08/108,591B
;  CURRENT FILING DATE:  2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6395474el Sequence
```

```
US-08-108-591B-17

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 563
US-08-108-591B-18/c
; Sequence 18, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/08/108,591B
;  CURRENT FILING DATE:  2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-18

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 564
US-08-150-156A-19
; Sequence 19, Application US/08150156A
; Patent No. 6357163
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/150,156A
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-08-150-156A-19

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 565
US-08-150-156A-20/c
; Sequence 20, Application US/08150156A
; Patent No. 6357163
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/150,156A
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-08-150-156A-20

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 566
US-08-292-620A-361
; Sequence 361, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  361:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-361

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             |||||||||||||||
Db          1 UUUUUUUUUUUUUUU 15


RESULT 567
US-08-292-620A-362
; Sequence 362, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  362:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-362

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             |||||||||||||||
Db          1 UUUUUUUUUUUUUUU 15


RESULT 568
US-08-292-620A-363
; Sequence 363, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
```

```
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  363:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-363

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUC 6362
              |||||||||||||||
Db          1 UUUUUUUUUUUUUUC 15


RESULT 569
US-08-358-556A-10
; Sequence 10, Application US/08358556A
; Patent No. 5869643
;  GENERAL INFORMATION:
;    APPLICANT:  Chatelain, Francois
;    APPLICANT:  Kumarev, Viktor
;    TITLE OF INVENTION:  Process for Preparing Polynucleotides on
;    TITLE OF INVENTION:  a Solid Support and Apparatus Permitting its
;    TITLE OF INVENTION:  Implementation
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/358,556A
;      FILING DATE:  14-DEC-1994
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9315164
;      FILING DATE:  16-DEC-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  N-terminal
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..15
US-08-358-556A-10

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 570
US-08-358-556A-16/c
; Sequence 16, Application US/08358556A
; Patent No. 5869643
;  GENERAL INFORMATION:
;    APPLICANT:  Chatelain, Francois
;    APPLICANT:  Kumarev, Viktor
;    TITLE OF INVENTION:  Process for Preparing Polynucleotides on
;    TITLE OF INVENTION:  a Solid Support and Apparatus Permitting its
;    TITLE OF INVENTION:  Implementation
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/358,556A
;      FILING DATE:  14-DEC-1994
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9315164
;      FILING DATE:  16-DEC-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  16:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  N-terminal
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..15
US-08-358-556A-16

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 571
US-08-452-196A-6/c
; Sequence 6, Application US/08452196A
; Patent No. 5576427
;  GENERAL INFORMATION:
;    APPLICANT:  Cook, Philip D.
;    APPLICANT:  Delecki, Daniel J.
;    APPLICANT:  Guinosso, Charles
;    TITLE OF INVENTION:  ACYCLIC NUCLEOSIDE
;    TITLE OF INVENTION:  ANALOGS AND
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE
;    TITLE OF INVENTION:  SEQUENCES
;    TITLE OF INVENTION:  CONTAINING THEM
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patent Department
;      STREET:  9 Great Valley Parkway
;      CITY:  Malvern
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19355
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch,
;      MEDIUM TYPE:  1.4 MB storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 7.1
;      SOFTWARE:  Microsoft Word 5.0B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/452,196A
;      FILING DATE:  26-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/040,326
;      FILING DATE:  30 March 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul E. Dupont
;      REGISTRATION NUMBER:  27,438
;      REFERENCE/DOCKET NUMBER:  2525
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215)889-6338
;      TELEFAX:  (215)889-8800
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Nucleic Acid
;      DESCRIPTION:
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:  synthesized
US-08-452-196A-6

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 572
US-08-462-977B-17
; Sequence 17, Application US/08462977B
; Patent No. 6713602
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS-1993
;  CURRENT APPLICATION NUMBER: US/08/462,977B
;  CURRENT FILING DATE:  1995-06-05
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6713602el Sequence
US-08-462-977B-17

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 573
US-08-462-977B-18/c
; Sequence 18, Application US/08462977B
; Patent No. 6713602
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS-1993
;  CURRENT APPLICATION NUMBER: US/08/462,977B
;  CURRENT FILING DATE:  1995-06-05
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6713602el Sequence
US-08-462-977B-18
```

```
  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 574
US-08-468-719A-17
; Sequence 17, Application US/08468719A
; Patent No. 6710163
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf H.
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS SYNTHONS
;  FILE REFERENCE: ISPS-1999
;  CURRENT APPLICATION NUMBER: US/08/468,719A
;  CURRENT FILING DATE:  1995-06-06
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
US-08-468-719A-17

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 575
US-08-468-719A-18/c
; Sequence 18, Application US/08468719A
; Patent No. 6710163
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf H.
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS SYNTHONS
;  FILE REFERENCE: ISPS-1999
;  CURRENT APPLICATION NUMBER: US/08/468,719A
;  CURRENT FILING DATE:  1995-06-06
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
US-08-468-719A-18

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 576
US-08-663-918-3
; Sequence 3, Application US/08663918
; Patent No. 5824793
;  GENERAL INFORMATION:
;    APPLICANT:  Bernard Hirschbein, Karen Fearon, Sergei Gryaznov, Sarah McCurdy, Jeffe
;    TITLE OF INVENTION:  Solid Phase Synthesis of Oligonucleotide N3 {symbol 174 \f "Sym
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics, Inc.
;      STREET:  3832 Bay Center Place
;      CITY:  Hayward
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94545
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch diskette
;      COMPUTER:  IBM compatable
;      OPERATING SYSTEM:  Windows 3.1
;      SOFTWARE:  Microsoft Word for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/663,918
;      FILING DATE:
;      CLASSIFICATION:  436
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/603,566
;      FILING DATE:  21-FEB-96
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  LYNX-035/01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 670-9365
;      TELEFAX:  (510) 670-9302
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-663-918-3

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 577
US-08-663-918-4/c
; Sequence 4, Application US/08663918
; Patent No. 5824793
;  GENERAL INFORMATION:
;    APPLICANT:  Bernard Hirschbein, Karen Fearon, Sergei Gryaznov, Sarah McCurdy, Jeffe
;    TITLE OF INVENTION:  Solid Phase Synthesis of Oligonucleotide N3 {symbol 174 \f "Sy
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics, Inc.
;      STREET:  3832 Bay Center Place
;      CITY:  Hayward
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94545
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch diskette
;      COMPUTER:  IBM compatable
```

```
;       OPERATING SYSTEM:  Windows 3.1
;       SOFTWARE:  Microsoft Word for Windows 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/663,918
;       FILING DATE:
;       CLASSIFICATION:  436
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/603,566
;       FILING DATE:  21-FEB-96
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Stephen C. Macevicz
;       REGISTRATION NUMBER:  30,285
;       REFERENCE/DOCKET NUMBER:  LYNX-035/01
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (510) 670-9365
;       TELEFAX:  (510) 670-9302
;   INFORMATION FOR SEQ ID NO:  4:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 nucleotides
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-663-918-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 578
US-08-693-831-1
; Sequence 1, Application US/08693831
; Patent No. 6017700
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  APPLICANT: Letsinger, Robert L.
;  APPLICANT: Balasubramanian, Tanjore N.
;  TITLE OF INVENTION: CATIONIC OLIGONUCLEOTIDES, AND RELATED METHODS OF
;  TITLE OF INVENTION: SYNTHESIS AND USE
;  FILE REFERENCE: 1117.002
;  CURRENT APPLICATION NUMBER: US/08/693,831
;  CURRENT FILING DATE: 1996-07-31
;  EARLIER APPLICATION NUMBER: US 08/693,831
;  EARLIER FILING DATE: 1996-07-31
;  NUMBER OF SEQ ID NOS: 1
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: Description of Artificial Sequence: poly-T
US-08-693-831-1

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 579
US-08-756-728A-2/c
; Sequence 2, Application US/08756728A
; Patent No. 5821354
;  GENERAL INFORMATION:
;    APPLICANT:  Leclerc, Guy
;    APPLICANT:  Martel, Remi
;    TITLE OF INVENTION:  RADIOLABELED DNA OLIGONUCLEOTIDE, METHOD
;    TITLE OF INVENTION:  OF PREPARATION AND THERAPEUTIC USES THEREOF
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Klauber & Jackson
;      STREET:  411 Hackensack Avenue, 4th Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/756,728A
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1398-1-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;      TELEX:  133521
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
;    HYPOTHETICAL:  NO
US-08-756-728A-2

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 580
US-08-771-789-3
; Sequence 3, Application US/08771789
; Patent No. 5859233
;  GENERAL INFORMATION:
;    APPLICANT:  Bernard Hirschbein
;    APPLICANT:  Karen Fearon
;    APPLICANT:  Sergei Gryaznov
;    APPLICANT:  Sarah McCurdy
;    APPLICANT:  Jeffery Nelson
;    APPLICANT:  Ronald G. Schultz
;    TITLE OF INVENTION:  Solid Phase Synthesis of Oligonucleotide
;    TITLE OF INVENTION:  N3 {symbol 174 \f "Symbol" \s 12|}P5  Phosphoramidates
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics, Inc.
;      STREET:  3832 Bay Center Place
;      CITY:  Hayward
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94545
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch diskette
;      COMPUTER:  IBM compatable
;      OPERATING SYSTEM:  Windows 3.1
```

```
;      SOFTWARE:  Microsoft Word for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/771,789
;      FILING DATE:  20-DEC-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/663,918
;      FILING DATE:  14-JUN-1996
;      APPLICATION NUMBER:  08/603,566
;      FILING DATE:  21-FEB-96
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  LYNX-035/01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 670-9365
;      TELEFAX:  (510) 670-9302
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-771-789-3

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 581
US-08-771-789-4/c
; Sequence 4, Application US/08771789
; Patent No. 5859233
;  GENERAL INFORMATION:
;    APPLICANT:  Bernard Hirschbein
;    APPLICANT:  Karen Fearon
;    APPLICANT:  Sergei Gryaznov
;    APPLICANT:  Sarah McCurdy
;    APPLICANT:  Jeffery Nelson
;    APPLICANT:  Ronald G. Schultz
;    TITLE OF INVENTION:  Solid Phase Synthesis of Oligonucleotide
;    TITLE OF INVENTION:  N3 {symbol 174 \f "Symbol" \s 12|}P5  Phosphoramidates
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics, Inc.
;      STREET:  3832 Bay Center Place
;      CITY:  Hayward
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94545
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch diskette
;      COMPUTER:  IBM compatable
;      OPERATING SYSTEM:  Windows 3.1
;      SOFTWARE:  Microsoft Word for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/771,789
;      FILING DATE:  20-DEC-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/663,918
;      FILING DATE:  14-JUN-1996
;      APPLICATION NUMBER:  08/603,566
;      FILING DATE:  21-FEB-96
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  LYNX-035/01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 670-9365
;      TELEFAX:  (510) 670-9302
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-771-789-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          15 TTTTTTTTTTTTTTT 1


RESULT 582
US-08-787-321-24/c
; Sequence 24, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-24

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|
Db         15 GTGTGTGTGTGTGTG 1


RESULT 583
US-08-832-021-33
; Sequence 33, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;  OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-33

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   20.0%;  Pred. No. 3.3e+02;
  Matches    3;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6350 UUUUUUUUUUUUCCA 6364
              :::::::::::|||
Db          1 TTTTTTTTTTTTCCA 15


RESULT 584
US-08-849-021-10
; Sequence 10, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-10

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTG 15


RESULT 585
US-08-849-021-7/c
; Sequence 7, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-7

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   46.7%;  Pred. No. 3.3e+02;
  Matches    7;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGU 6987
              :|:|:|:|:|:|:|:
Db         15 TGTGTGTGTGTGTGT 1


RESULT 586
US-08-849-021-8/c
; Sequence 8, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
```

```
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-8

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 3.3e+02;
  Matches    8;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUG 6988
              |:|:|:|:|:|:|:|
Db         15 GTGTGTGTGTGTGTG 1


RESULT 587
US-08-849-021-9
; Sequence 9, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-9

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   46.7%;  Pred. No. 3.3e+02;
  Matches    7;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGU 6987
              :|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGT 15


RESULT 588
US-08-863-639A-5/c
; Sequence 5, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1
```

```
RESULT 589
US-08-863-639A-9
; Sequence 9, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-9

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 590
US-08-922-170B-5
; Sequence 5, Application US/08922170B
; Patent No. 5968822
;  GENERAL INFORMATION:
;    APPLICANT:  Iris Pecker, Israel Vlodavsky and Elena
;    APPLICANT:  Feinstein
;    TITLE OF INVENTION:  POLYNUCLEOTIDE ENCODING A POLYPEPTIDE
;    TITLE OF INVENTION:  HAVING HEPARANASE ACTIVITY AND EXPRESSION OF
;    TITLE OF INVENTION:  SAME IN TRANSDUCED CELLS
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Mark M. Friedman c/o Robert Sheinbein
;      STREET:  2940 Birchtree lane
;      CITY:  Silver Spring
;      STATE:  Maryland
;      COUNTRY:  United States of America
;      ZIP:  20906
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  1.44 megabyte, 3.5" microdisk
;      COMPUTER:  Twinhead* Slimnote-890TX
;      OPERATING SYSTEM:  MS DOS version 6.2,
;      OPERATING SYSTEM:  Windows version 3.11
;      SOFTWARE:  Word for Windows version 2.0 converted to
;      SOFTWARE:  an ASCI file
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/922,170B
;      FILING DATE:  2 SEP 1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Friedmam, Mark M.
;      REGISTRATION NUMBER:  33,883
;      REFERENCE/DOCKET NUMBER:  910/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  972-3-5625553
;      TELEFAX:  972-3-5625554
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-922-170B-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 591
US-08-988-024C-9
; Sequence 9, Application US/08988024C
; Patent No. 6635452
; GENERAL INFORMATION:
;  APPLICANT: Monforte, Joseph A.
;  APPLICANT:  Becker, Christopher H.
;  APPLICANT:  Pollart, Daniel J.
;  APPLICANT:  Shaler, Thomas A.
;  TITLE OF INVENTION: Releasable No. 6635452volatile Mass-Label Molecules
;  FILE REFERENCE: 24736-2057
;  CURRENT APPLICATION NUMBER: US/08/988,024C
;  CURRENT FILING DATE:  1997-12-10
;  PRIOR APPLICATION NUMBER: US 60/033,037
;  PRIOR FILING DATE: 1996-12-10
;  PRIOR APPLICATION NUMBER: US 60/046,719
;  PRIOR FILING DATE: 1997-05-16
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-08-988-024C-9

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 592
```

```
US-09-071-845-361
; Sequence 361, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  361:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-361

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              |||||||||||||||
Db          1 UUUUUUUUUUUUUUU 15


RESULT 593
US-09-071-845-362
; Sequence 362, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  362:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-362

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              |||||||||||||||
Db          1 UUUUUUUUUUUUUUU 15


RESULT 594
US-09-071-845-363
; Sequence 363, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
```

```
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  363:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-363

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUC 6362
              |||||||||||||||
Db          1 UUUUUUUUUUUUUUC 15


RESULT 595
US-09-167-375-1/c
; Sequence 1, Application US/09167375B
; Patent No. 6291438
; GENERAL INFORMATION:
;  APPLICANT: Jui H. Wang
;  TITLE OF INVENTION: Antiviral anticancer poly-substituted phenyl derivatized oligorib
;  TITLE OF INVENTION: methods for their use.
;  FILE REFERENCE: WNGJ 2002 (CIP-1)
;  CURRENT APPLICATION NUMBER: US/09/167,375B
;  CURRENT FILING DATE: 1998-10-06
;  NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 1
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Retroviral reverse transcriptase inhibitor
US-09-167-375-1

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 596
US-09-183-619-4
; Sequence 4, Application US/09183619
; Patent No. 6103474
; GENERAL INFORMATION:
;  APPLICANT: DELLINGER, DOUGLAS J.
;  APPLICANT: DAHM, SUEANN C.
;  APPLICANT: ILSLEY, DIANE D.
;  APPLICANT: ACH, ROBERT A.
;  APPLICANT: TROLL, MARK A.
;  TITLE OF INVENTION: HYBRIDIZATION ASSAY SIGNAL ENHANCEMENT
;  FILE REFERENCE: 10981619-1
;  CURRENT APPLICATION NUMBER: US/09/183,619
;  CURRENT FILING DATE: 1998-10-30
;  EARLIER APPLICATION NUMBER: 08/735,381
;  EARLIER FILING DATE: 1996-10-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Reporter probe
US-09-183-619-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              |||||||||||||||
Db          1 UUUUUUUUUUUUUUU 15


RESULT 597
US-09-300-958A-68
; Sequence 68, Application US/09300958A
; Patent No. 6495319
; GENERAL INFORMATION:
;  APPLICANT:  McClelland, Michael
;  APPLICANT:  Welsh, John
;  APPLICANT:  Trenkle, Thomas
;  TITLE OF INVENTION:  Reduced Complexity Nucleic Acid Targets and Methods of
;  TITLE OF INVENTION:  Using Same
;  FILE REFERENCE:  P-PH 3457
;  CURRENT APPLICATION NUMBER: US/09/300,958A
;  CURRENT FILING DATE:  1999-04-27
;  PRIOR APPLICATION NUMBER:  60/083,331
;  PRIOR FILING DATE:  1998-04-27
;  PRIOR APPLICATION NUMBER:  60/098,070
;  PRIOR FILING DATE:  1998-08-27
;  PRIOR APPLICATION NUMBER:  60/118,624
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 68
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-300-958A-68

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
```

```
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 598
US-09-435-739-5
; Sequence 5, Application US/09435739
; Patent No. 6664105
; GENERAL INFORMATION:
;  APPLICANT: Pecker, Iris
;  APPLICANT:  Vlodavsky, Israel
;  APPLICANT:  Feinstein, Elena
;  TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING HEPARANASE ACTIVITY
;  TITLE OF INVENTION:  EXPRESSION OF SAME IN GENETICALLY MODIFIED CELLS
;  FILE REFERENCE: 00/20454
;  CURRENT APPLICATION NUMBER: US/09/435,739
;  CURRENT FILING DATE:  2001-06-05
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-435-739-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 599
US-09-619-103-21/c
; Sequence 21, Application US/09619103
; Patent No. 6429300
; GENERAL INFORMATION:
;  APPLICANT:  Kurz, Markus
;  APPLICANT:  Lohse, Peter
;  APPLICANT:  Wagner, Richard
;  TITLE OF INVENTION:  Peptide Acceptor Ligation Methods
;  FILE REFERENCE:  50036/031002
;  CURRENT APPLICATION NUMBER: US/09/619,103
;  CURRENT FILING DATE:  2000-07-19
;  PRIOR APPLICATION NUMBER:  60/145,834
;  PRIOR FILING DATE:  1999-07-27
;  NUMBER OF SEQ ID NOS:  26
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 21
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: designed sequence for nucleic acid purification
US-09-619-103-21

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 600
US-09-793-146-54
; Sequence 54, Application US/09793146
; Patent No. 6919441
; GENERAL INFORMATION:
;  APPLICANT: UHLMANN, EUGEN
;  APPLICANT:  BREIPOHL, GERHARD
;  TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
;  TITLE OF INVENTION:  PREPARATION AND USE
;  FILE REFERENCE: 02481.1437-02
;  CURRENT APPLICATION NUMBER: US/09/793,146
;  CURRENT FILING DATE:  2001-02-27
;  PRIOR APPLICATION NUMBER: P 44 08 528.1
;  PRIOR FILING DATE: 1994-03-14
;  PRIOR APPLICATION NUMBER: 08/402,838
;  PRIOR FILING DATE: 1995-03-13
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-54

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 601
US-09-793-146-55
; Sequence 55, Application US/09793146
; Patent No. 6919441
; GENERAL INFORMATION:
;  APPLICANT: UHLMANN, EUGEN
;  APPLICANT:  BREIPOHL, GERHARD
;  TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
;  TITLE OF INVENTION:  PREPARATION AND USE
;  FILE REFERENCE: 02481.1437-02
;  CURRENT APPLICATION NUMBER: US/09/793,146
;  CURRENT FILING DATE:  2001-02-27
;  PRIOR APPLICATION NUMBER: P 44 08 528.1
;  PRIOR FILING DATE: 1994-03-14
;  PRIOR APPLICATION NUMBER: 08/402,838
;  PRIOR FILING DATE: 1995-03-13
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 55
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-55

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 602
US-09-850-982B-4
; Sequence 4, Application US/09850982B
; Patent No. 6841662
```

```
; GENERAL INFORMATION:
;  APPLICANT: Nestec S.A.
;  TITLE OF INVENTION: COFFEE MANNANASE
;  FILE REFERENCE: 88265-4025
;  CURRENT APPLICATION NUMBER: US/09/850,982B
;  CURRENT FILING DATE:  2001-05-08
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotides provided by Eurogentec (Parc Scientifi
;   OTHER INFORMATION: que due Sart Tilman [Sart Tilman Scientific Park]-4102 Seraing-Be
;   OTHER INFORMATION: lguim).
US-09-850-982B-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 603
US-09-930-218-5
; Sequence 5, Application US/09930218
; Patent No. 6677137
; GENERAL INFORMATION:
;  APPLICANT: goldshmidt, orit
;  APPLICANT:  pecker, iris
;  APPLICANT:  vlodavsky, israel
;  APPLICANT:  israel, michal
;  TITLE OF INVENTION: AVIAN AND REPTILE DERIVED POLYNUCLEOTIDE ENCODING A POLYPEPTIDE H
;  TITLE OF INVENTION:  HEPARANASE ACTIVITY
;  FILE REFERENCE: 01/22335
;  CURRENT APPLICATION NUMBER: US/09/930,218
;  CURRENT FILING DATE:  2001-08-16
;  PRIOR APPLICATION NUMBER: 09/666,390
;  PRIOR FILING DATE: 2000-09-20
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic polynucleotide
US-09-930-218-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 604
US-09-988-113-5
; Sequence 5, Application US/09988113
; Patent No. 6790658
; GENERAL INFORMATION:
;  APPLICANT: Pecker, Iris
;  APPLICANT:  Vlodavsky , Israel
;  APPLICANT:  Feinstein, Elena
;  TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING HEPARANASE ACTIVITY
;  TITLE OF INVENTION:  EXPRESSION OF SAME IN GENETICALLY MODIFIED CELLS
;  FILE REFERENCE: 01/22781
;  CURRENT APPLICATION NUMBER: US/09/988,113
;  CURRENT FILING DATE:  2001-11-19
;  PRIOR APPLICATION NUMBER: US 09/776,874
;  PRIOR FILING DATE: 2001-02-06
;  PRIOR APPLICATION NUMBER: US09/258,892
;  PRIOR FILING DATE: 1999-03-01
;  PRIOR APPLICATION NUMBER: PCT/US98/17954
;  PRIOR FILING DATE: 1998-08-31
;  PRIOR APPLICATION NUMBER: US 09/109,386
;  PRIOR FILING DATE: 1998-07-02
;  PRIOR APPLICATION NUMBER: US 08/922,170
;  PRIOR FILING DATE: 1997-09-02
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-09-988-113-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 605
US-10-072-975-10
; Sequence 10, Application US/10072975
; Patent No. 6962906
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1.1US
;  CURRENT APPLICATION NUMBER: US/10/072,975
;  CURRENT FILING DATE:  2002-02-09
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  PRIOR APPLICATION NUMBER: 09/805,296
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/0811
;  PRIOR FILING DATE: 2001-03-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthtic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: SynthetiConstruct
US-10-072-975-10

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 606
US-10-091-231-2
; Sequence 2, Application US/10091231
; Patent No. 6664388
; GENERAL INFORMATION:
;  APPLICANT: NELSON, Jeffrey S.
;  TITLE OF INVENTION: REAGENTS FOR OLIGONUCLEOTIDE CLEAVAGE AND DEPROTECTION
;  FILE REFERENCE: 4688US
;  CURRENT APPLICATION NUMBER: US/10/091,231
;  CURRENT FILING DATE:  2002-03-04
;  PRIOR APPLICATION NUMBER: US 60/274,309
;  PRIOR FILING DATE: 2001-03-08
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Synthetic DNA
US-10-091-231-2

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 607
US-10-227-001-23
; Sequence 23, Application US/10227001
; Patent No. 6951930
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Afonina, Irina Aleksandrovna
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: Hybridization-Triggered Fluorescent
;  TITLE OF INVENTION:  Detection of Nucleic Acids
;  FILE REFERENCE: 17682A-004210US
;  CURRENT APPLICATION NUMBER: US/10/227,001
;  CURRENT FILING DATE:  2002-08-21
;  PRIOR APPLICATION NUMBER: US 09/428,236
;  PRIOR FILING DATE: 1999-10-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 23
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: R2 (ODN) of fluorophore-MGB-ODN
;   OTHER INFORMATION: conjugate
US-10-227-001-23

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 608
US-10-352-704-10
; Sequence 10, Application US/10352704
; Patent No. 6825339
;   GENERAL INFORMATION:
;        APPLICANT: Chatelain, Francois
;                   Kumarev, Viktor
;        TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                            a Solid Support and Apparatus Permitting its
;                            Implementation
;        NUMBER OF SEQUENCES: 31
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Jacobson, Price, Holman & Stern
;             STREET: 400 Seventh St. N.W.
;             CITY: Washington D.C
;             STATE: D.C
;             COUNTRY: U.S.A.
;             ZIP: 20004
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/352,704
;             FILING DATE: 28-Jan-2003
;             CLASSIFICATION: 536
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/358,556A
;             FILING DATE: 14-DEC-1994
;             APPLICATION NUMBER: FR 9315164
;             FILING DATE: 16-DEC-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Player, William E.
;             REGISTRATION NUMBER: 31,409
;             REFERENCE/DOCKET NUMBER: 10577/P58418
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (202)638-6666
;             TELEFAX: (202) 393-5350
;             TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 10:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: N-terminal
;        FEATURE:
;             NAME/KEY:  CDS
;             LOCATION:  1..15
;        SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-352-704-10

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 609
US-10-352-704-16/c
; Sequence 16, Application US/10352704
; Patent No. 6825339
;   GENERAL INFORMATION:
;        APPLICANT: Chatelain, Francois
;                   Kumarev, Viktor
;        TITLE OF INVENTION: Process for Preparing Polynucleotides on
;                            a Solid Support and Apparatus Permitting its
```

```
;                          Implementation
;       NUMBER OF SEQUENCES: 31
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Jacobson, Price, Holman & Stern
;            STREET: 400 Seventh St. N.W.
;            CITY: Washington D.C
;            STATE: D.C
;            COUNTRY: U.S.A.
;            ZIP: 20004
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/352,704
;            FILING DATE: 28-Jan-2003
;            CLASSIFICATION: 536
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/358,556A
;            FILING DATE: 14-DEC-1994
;            APPLICATION NUMBER: FR 9315164
;            FILING DATE: 16-DEC-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Player, William E.
;            REGISTRATION NUMBER: 31,409
;            REFERENCE/DOCKET NUMBER: 10577/P58418
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (202)638-6666
;            TELEFAX: (202) 393-5350
;            TELEX: RCA 248593 IDEA UR
;   INFORMATION FOR SEQ ID NO: 16:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 15 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       FRAGMENT TYPE: N-terminal
;       FEATURE:
;            NAME/KEY:  CDS
;            LOCATION:  1..15
;       SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-352-704-16

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 610
US-10-384-450A-5
; Sequence 5, Application US/10384450A
; Patent No. 6960471
; GENERAL INFORMATION:
;  APPLICANT: Pecker, Iris
;  APPLICANT:  Vlodavsky , Israel
;  APPLICANT:  Feinstein, Elena
;  TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING HEPARANASE ACTIVITY
;  TITLE OF INVENTION:  EXPRESSION OF SAME IN GENETICALLY MODIFIED CELLS
;  FILE REFERENCE: 25717
;  CURRENT APPLICATION NUMBER: US/10/384,450A
;  CURRENT FILING DATE:  2003-03-10
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-384-450A-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 3.3e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 611
US-09-479-005A-295/c
; Sequence 295, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 295
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-295

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3656 GCUGGCACAGAGACC 3670
              ||:|||||||||||||
Db         16 GCTGGCACAGAGACC 2


RESULT 612
US-09-507-345A-3
; Sequence 3, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
```

```
;            APPLICATION NUMBER: US/09/507,345A
;            FILING DATE: 18-Feb-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003500US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 3:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by 6-aminohexanoic acid
;            (-NH(CH-2)-6COOH)"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-507-345A-3

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 613
US-09-507-345A-4
; Sequence 4, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/507,345A
;            FILING DATE: 18-Feb-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003500US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 4:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by minor groove binder moiety
;            represented by X, where m = one
;            4-amino-N-methylpyrrol-2-carboxylic acid residue"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-507-345A-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 614
US-09-507-345A-5
; Sequence 5, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/507,345A
;            FILING DATE: 18-Feb-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003500US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
```

```
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  16
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "N = thymidine modified by minor groove binder moiety
;             represented by X, where m = two
;             4-amino-N-methylpyrrol-2-carboxylic acid residues"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-507-345A-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 615
US-09-507-345A-6
; Sequence 6, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/507,345A
;             FILING DATE: 18-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003500US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 6:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  16
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "N = thymidine modified by minor groove binder moiety
;             represented by X, where m = three
;             4-amino-N-methylpyrrol-2-carboxylic acid residues"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-507-345A-6

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 616
US-09-507-345A-7
; Sequence 7, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/507,345A
;             FILING DATE: 18-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003500US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 7:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  16
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "N = thymidine modified by minor groove binder moiety
;             represented by X, where m = four
;             4-amino-N-methylpyrrol-2-carboxylic acid residues"
```

```
;       SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-507-345A-7

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 617
US-09-507-345A-8
; Sequence 8, Application US/09507345A
; Patent No. 6426408
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/507,345A
;            FILING DATE: 18-Feb-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003500US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 8:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by minor groove binder moiety
;            represented by X, where m = five
;            4-amino-N-methylpyrrol-2-carboxylic acid residues"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-507-345A-8

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 618
US-09-739-928-3
; Sequence 3, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/739,928
;            FILING DATE: 11-May-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;            APPLICATION NUMBER: US 09/507,345
;            FILING DATE: 18-FEB-2000
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003510US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 3:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by 6-aminohexanoic acid
;            (-NH(CH-2)-6COOH)"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-739-928-3

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 619
```

```
US-09-739-928-4
; Sequence 4, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/739,928
;             FILING DATE: 11-May-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;             APPLICATION NUMBER: US 09/507,345
;             FILING DATE: 18-FEB-2000
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003510US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 4:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  16
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "N = thymidine modified by minor groove binder moiety
;             represented by X, where m = one
;             4-amino-N-methylpyrrol-2-carboxylic acid residue"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-739-928-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 620
US-09-739-928-5
; Sequence 5, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
;        NUMBER OF SEQUENCES: 12
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/739,928
;             FILING DATE: 11-May-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/415,370
;             FILING DATE: 03-APR-1995
;             APPLICATION NUMBER: US 09/141,764
;             FILING DATE: 27-AUG-1998
;             APPLICATION NUMBER: US 09/507,345
;             FILING DATE: 18-FEB-2000
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Kezer, William B.
;             REGISTRATION NUMBER: 37,369
;             REFERENCE/DOCKET NUMBER: 17682A-003510US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             NAME/KEY:  modified_base
;             LOCATION:  16
;             OTHER INFORMATION:  /mod_base= OTHER
;             /note= "N = thymidine modified by minor groove binder moiety
;             represented by X, where m = two
;             4-amino-N-methylpyrrol-2-carboxylic acid residues"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-739-928-5

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 621
US-09-739-928-6
; Sequence 6, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;        APPLICANT: Kutyavin, Igor V.
;                   Lukhtanov, Eugeny A.
;                   Gamper, Howard B.
;                   Meyer Jr., Rich B.
;        TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                            Groove Binder Conjugates
```

```
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/739,928
;            FILING DATE: 11-May-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;            APPLICATION NUMBER: US 09/507,345
;            FILING DATE: 18-FEB-2000
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003510US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 6:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by minor groove binder moiety
;            represented by X, where m = three
;            4-amino-N-methylpyrrol-2-carboxylic acid residues"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-739-928-6

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 622
US-09-739-928-7
; Sequence 7, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/739,928
;            FILING DATE: 11-May-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/415,370
;            FILING DATE: 03-APR-1995
;            APPLICATION NUMBER: US 09/141,764
;            FILING DATE: 27-AUG-1998
;            APPLICATION NUMBER: US 09/507,345
;            FILING DATE: 18-FEB-2000
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Kezer, William B.
;            REGISTRATION NUMBER: 37,369
;            REFERENCE/DOCKET NUMBER: 17682A-003510US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 7:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            NAME/KEY:  modified_base
;            LOCATION:  16
;            OTHER INFORMATION:  /mod_base= OTHER
;            /note= "N = thymidine modified by minor groove binder moiety
;            represented by X, where m = four
;            4-amino-N-methylpyrrol-2-carboxylic acid residues"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-739-928-7

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 623
US-09-739-928-8
; Sequence 8, Application US/09739928
; Patent No. 6486308
;   GENERAL INFORMATION:
;       APPLICANT: Kutyavin, Igor V.
;                  Lukhtanov, Eugeny A.
;                  Gamper, Howard B.
;                  Meyer Jr., Rich B.
;       TITLE OF INVENTION: Covalently Linked Oligonucleotide Minor
;                           Groove Binder Conjugates
;       NUMBER OF SEQUENCES: 12
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Townsend and Townsend and Crew LLP
;            STREET: Two Embarcadero Center, Eighth Floor
;            CITY: San Francisco
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94111-3834
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
```

```
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/739,928
;              FILING DATE: 11-May-2001
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: US 08/415,370
;              FILING DATE: 03-APR-1995
;              APPLICATION NUMBER: US 09/141,764
;              FILING DATE: 27-AUG-1998
;              APPLICATION NUMBER: US 09/507,345
;              FILING DATE: 18-FEB-2000
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Kezer, William B.
;              REGISTRATION NUMBER: 37,369
;              REFERENCE/DOCKET NUMBER: 17682A-003510US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (415) 576-0200
;              TELEFAX: (415) 576-0300
;    INFORMATION FOR SEQ ID NO: 8:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 16 base pairs
;              TYPE: nucleic acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: DNA
;         FEATURE:
;              NAME/KEY:  modified_base
;              LOCATION:  16
;              OTHER INFORMATION:  /mod_base= OTHER
;              /note= "N = thymidine modified by minor groove binder moiety
;              represented by X, where m = five
;              4-amino-N-methylpyrrol-2-carboxylic acid residues"
;         SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-739-928-8

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 624
US-10-227-001-20
; Sequence 20, Application US/10227001
; Patent No. 6951930
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Afonina, Irina Aleksandrovna
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: Hybridization-Triggered Fluorescent
;  TITLE OF INVENTION:  Detection of Nucleic Acids
;  FILE REFERENCE: 17682A-004210US
;  CURRENT APPLICATION NUMBER: US/10/227,001
;  CURRENT FILING DATE:  2002-08-21
;  PRIOR APPLICATION NUMBER: US 09/428,236
;  PRIOR FILING DATE: 1999-10-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 20
;    LENGTH: 16
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: polydT-MGB-
;    OTHER INFORMATION: (2-dimethylaminonaphthalene-6-sulfonamide)
;    OTHER INFORMATION: conjugate
;    FEATURE:
;    NAME/KEY: modified_base
;    LOCATION: (1)
;    OTHER INFORMATION: n = thymine modified by MGB-
;    OTHER INFORMATION: (2-dimethylaminonaphthalene-6-sulfonamide)
US-10-227-001-20

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 625
US-08-679-645-114
; Sequence 114, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  114:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-114
```

```
  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3006 CUACCUCAAGAGCAA 3020
              ||||||||||||||
Db          3 CUACCUCAAGAGCAA 17


RESULT 626
US-09-090-672B-105
; Sequence 105, Application US/09090672B
; Patent No. 6828428
;  GENERAL INFORMATION:
;    APPLICANT:  Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
;    APPLICANT:  Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
;    APPLICANT:  Shigemasa; Takei, Masami
;    TITLE OF INVENTION:  IgA Nephropathy-Related Genes
;    NUMBER OF SEQUENCES:  111
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fitzpatrick, Cella, Harper & Scinto
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      ZIP:  10112-3801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  Compaq PC
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WordPerfect 8.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/090,672B
;      FILING DATE:  04-JUNE-1998
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP97/04468
;      FILING DATE:  05-DEC-1997
;      APPLICATION NUMBER:  JP-8-325763
;      FILING DATE:  05-DEC-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Perry, Lawrence S.
;      REGISTRATION NUMBER:  31865
;      REFERENCE/DOCKET NUMBER:  766.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 218-2100
;      TELEFAX:  (212) 218-2200
;  INFORMATION FOR SEQ ID NO:  105:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid, synthetic DNA
US-09-090-672B-105

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 627
US-09-090-672B-106
; Sequence 106, Application US/09090672B
; Patent No. 6828428
;  GENERAL INFORMATION:
;    APPLICANT:  Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
;    APPLICANT:  Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
;    APPLICANT:  Shigemasa; Takei, Masami
;    TITLE OF INVENTION:  IgA Nephropathy-Related Genes
;    NUMBER OF SEQUENCES:  111
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fitzpatrick, Cella, Harper & Scinto
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      ZIP:  10112-3801
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  Compaq PC
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WordPerfect 8.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/090,672B
;      FILING DATE:  04-JUNE-1998
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP97/04468
;      FILING DATE:  05-DEC-1997
;      APPLICATION NUMBER:  JP-8-325763
;      FILING DATE:  05-DEC-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Perry, Lawrence S.
;      REGISTRATION NUMBER:  31865
;      REFERENCE/DOCKET NUMBER:  766.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 218-2100
;      TELEFAX:  (212) 218-2200
;  INFORMATION FOR SEQ ID NO:  106:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid, synthetic DNA
US-09-090-672B-106

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 628
US-09-300-958A-63
; Sequence 63, Application US/09300958A
; Patent No. 6495319
; GENERAL INFORMATION:
;  APPLICANT:  McClelland, Michael
;  APPLICANT:  Welsh, John
;  APPLICANT:  Trenkle, Thomas
;  TITLE OF INVENTION:  Reduced Complexity Nucleic Acid Targets and Methods of
;  TITLE OF INVENTION:  Using Same
;  FILE REFERENCE:  P-PH 3457
;  CURRENT APPLICATION NUMBER: US/09/300,958A
;  CURRENT FILING DATE:  1999-04-27
;  PRIOR APPLICATION NUMBER:  60/083,331
;  PRIOR FILING DATE:  1998-04-27
;  PRIOR APPLICATION NUMBER:  60/098,070
;  PRIOR FILING DATE:  1998-08-27
;  PRIOR APPLICATION NUMBER:  60/118,624
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 63
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
```

```
US-09-300-958A-63

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 629
US-09-300-958A-64
; Sequence 64, Application US/09300958A
; Patent No. 6495319
; GENERAL INFORMATION:
;  APPLICANT:  McClelland, Michael
;  APPLICANT:  Welsh, John
;  APPLICANT:  Trenkle, Thomas
;  TITLE OF INVENTION:  Reduced Complexity Nucleic Acid Targets and Methods of
;  TITLE OF INVENTION:  Using Same
;  FILE REFERENCE:  P-PH 3457
;  CURRENT APPLICATION NUMBER: US/09/300,958A
;  CURRENT FILING DATE:  1999-04-27
;  PRIOR APPLICATION NUMBER:  60/083,331
;  PRIOR FILING DATE:  1998-04-27
;  PRIOR APPLICATION NUMBER:  60/098,070
;  PRIOR FILING DATE:  1998-08-27
;  PRIOR APPLICATION NUMBER:  60/118,624
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 64
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-300-958A-64

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 630
US-09-730-559B-107
; Sequence 107, Application US/09730559B
; Patent No. 6962984
; GENERAL INFORMATION:
;  APPLICANT: ISHIWATA, TETSUYOSHI
;  APPLICANT:  SAKURADA, MIKIKO
;  APPLICANT:  KAWABATA, AYAKO
;  APPLICANT:  NAKAGAWA, SATOSHI
;  APPLICANT:  NISHI, TATSUNARI
;  APPLICANT:  KUGA, TETSURO
;  APPLICANT:  SAWADA, SHIGEMASA
;  APPLICANT:  TAKEI, MASAMI
;  APPLICANT:  SHIBATA, KENJI
;  APPLICANT:  FURUYA, AKIKO
;  TITLE OF INVENTION: IgA NEPHROPATHY-ASSOCIATED GENE
;  FILE REFERENCE: 766.21 CIP
;  CURRENT APPLICATION NUMBER: US/09/730,559B
;  CURRENT FILING DATE:  2000-12-07
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 107
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-730-559B-107

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 631
US-09-730-559B-108
; Sequence 108, Application US/09730559B
; Patent No. 6962984
; GENERAL INFORMATION:
;  APPLICANT: ISHIWATA, TETSUYOSHI
;  APPLICANT:  SAKURADA, MIKIKO
;  APPLICANT:  KAWABATA, AYAKO
;  APPLICANT:  NAKAGAWA, SATOSHI
;  APPLICANT:  NISHI, TATSUNARI
;  APPLICANT:  KUGA, TETSURO
;  APPLICANT:  SAWADA, SHIGEMASA
;  APPLICANT:  TAKEI, MASAMI
;  APPLICANT:  SHIBATA, KENJI
;  APPLICANT:  FURUYA, AKIKO
;  TITLE OF INVENTION: IgA NEPHROPATHY-ASSOCIATED GENE
;  FILE REFERENCE: 766.21 CIP
;  CURRENT APPLICATION NUMBER: US/09/730,559B
;  CURRENT FILING DATE:  2000-12-07
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 108
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-730-559B-108

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 632
US-09-788-338-3
; Sequence 3, Application US/09788338
; Patent No. 6485916
; GENERAL INFORMATION:
;  APPLICANT: MURAMATSU, TAKAMICHI
;  APPLICANT:  FUJITA, TAKESHI
;  APPLICANT:  KIYAMA, MASAHARU
;  APPLICANT:  IRIE, TAKASHI
;  TITLE OF INVENTION: PREPARATION METHOD OF NUCLEIC ACID SAMPLE FOR RARE
;  TITLE OF INVENTION:  EXPRESSED GENES AND ANALYZING METHOD USING THE PREPARED
;  TITLE OF INVENTION:  NUCLEIC ACID SAMPLES THEREBY
;  FILE REFERENCE: NIT-129-02
;  CURRENT APPLICATION NUMBER: US/09/788,338
;  CURRENT FILING DATE:  2001-02-21
;  PRIOR APPLICATION NUMBER: 09/313,637
;  PRIOR FILING DATE: 1999-05-18
;  PRIOR APPLICATION NUMBER: JP 10-153651
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
```

```
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-788-338-3

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 633
US-10-019-832-2
; Sequence 2, Application US/10019832
; Patent No. 6986990
; GENERAL INFORMATION:
;  APPLICANT: Genox Research, Inc.
;  TITLE OF INVENTION: POLLEN ALLERGY-RELATED GENE 513
;  FILE REFERENCE: G1-103PCT
;  CURRENT APPLICATION NUMBER: US/10/019,832
;  CURRENT FILING DATE:  2001-10-26
;  PRIOR APPLICATION NUMBER: JP   1999-120491
;  PRIOR FILING DATE: 1999-04-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Artificially
;   OTHER INFORMATION: Synthesized Primer Sequence
US-10-019-832-2

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 634
US-10-019-832-4
; Sequence 4, Application US/10019832
; Patent No. 6986990
; GENERAL INFORMATION:
;  APPLICANT: Genox Research, Inc.
;  TITLE OF INVENTION: POLLEN ALLERGY-RELATED GENE 513
;  FILE REFERENCE: G1-103PCT
;  CURRENT APPLICATION NUMBER: US/10/019,832
;  CURRENT FILING DATE:  2001-10-26
;  PRIOR APPLICATION NUMBER: JP   1999-120491
;  PRIOR FILING DATE: 1999-04-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Artificially
;   OTHER INFORMATION: Synthesized Primer Sequence
US-10-019-832-4

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          2 TTTTTTTTTTTTTTT 16


RESULT 635
US-10-156-306B-522
; Sequence 522, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 522
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-522

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
              |||||||||||||||
Db          2 CUUUUUUUUUUUUUU 16


RESULT 636
US-10-156-306B-523
; Sequence 523, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-523

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
              |||||||||||||||
Db          1 CUUUUUUUUUUUUUU 15


RESULT 637
US-09-437-076-2
; Sequence 2, Application US/09437076
; Patent No. 6261779
; GENERAL INFORMATION:
;  APPLICANT: Barber-Guillem, Emilio
;  APPLICANT: Nelson, M. Bud
```

```
;  APPLICANT: Castro, Stephanie
;  TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
;  CURRENT APPLICATION NUMBER: US/09/437,076
;  CURRENT FILING DATE: 1999-11-09
;  EARLIER APPLICATION NUMBER:
;  EARLIER FILING DATE:
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: Word for Windows
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   NAME/KEY:
;   LOCATION:
;   OTHER INFORMATION: synthesized
US-09-437-076-2

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          4 TTTTTTTTTTTTTTT 18


RESULT 638
US-09-556-127-44/c
; Sequence 44, Application US/09556127
; Patent No. 6699661
; GENERAL INFORMATION:
;  APPLICANT: KURANE, RYUICHIRO
;  APPLICANT:  KANAGAWA, TAKAHIRO
;  APPLICANT:  KAMAGATA, YOICHI
;  APPLICANT:  YAMADA, KAZUTAKA
;  APPLICANT:  YOKOMAKU, TOYOKAZU
;  APPLICANT:  KOYAMA, OSAMU
;  APPLICANT:  FURUSHO, KENTA
;  TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
;  TITLE OF INVENTION:  NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
;  TITLE OF INVENTION:  THE METHOD
;  FILE REFERENCE: 0163-0758-0X
;  CURRENT APPLICATION NUMBER: US/09/556,127
;  CURRENT FILING DATE:  2002-06-17
;  PRIOR APPLICATION NUMBER: JP 1999-111601
;  PRIOR FILING DATE: 1999-04-20
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
US-09-556-127-44

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   13.3%;  Pred. No. 5e+02;
  Matches    2;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCC 6363
              :::::::::::::||
Db         18 TTTTTTTTTTTTTCC 4


RESULT 639
US-09-630-706-59
; Sequence 59, Application US/09630706
; Patent No. 6277640
; GENERAL INFORMATION:
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:  ANTISENSE MODULATION OF HER-3 EXPRESSION
;  FILE REFERENCE:  RTS-0053
;  CURRENT APPLICATION NUMBER: US/09/630,706
;  CURRENT FILING DATE:  2000-08-01
;  NUMBER OF SEQ ID NOS:  94
; SEQ ID NO 59
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-630-706-59

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   60.0%;  Pred. No. 5e+02;
  Matches    9;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        988 ACUCUUGUCCUCAAU 1002
              ||:|::|:||:|||:
Db          3 ACTCTTGTCCTCAAT 17


RESULT 640
US-09-696-791-4271
; Sequence 4271, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4271
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4271

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   53.3%;  Pred. No. 5e+02;
  Matches    8;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3366 UGAUUUUGGCCUUGC 3380
              :||::::||||::||
Db          4 TGATTTTGGCCTTGC 18


RESULT 641
US-09-725-265-44/c
; Sequence 44, Application US/09725265
; Patent No. 6492121
; GENERAL INFORMATION:
;  APPLICANT: KURANE, RYUICHIRO
;  APPLICANT:  KANAGAWA, TAKAHIRO
;  APPLICANT:  KAMAGATA, YOICHI
;  APPLICANT:  YAMADA, KAZUTAKA
;  APPLICANT:  YOKOMAKU, TOYOKAZU
;  APPLICANT:  KOYAMA, OSAMU
;  APPLICANT:  FURUSHO, KENTA
;  TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
;  TITLE OF INVENTION:  NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
;  TITLE OF INVENTION:  THE METHOD
;  FILE REFERENCE: 199953US0XDIV
;  CURRENT APPLICATION NUMBER: US/09/725,265
;  CURRENT FILING DATE:  2000-11-29
;  PRIOR APPLICATION NUMBER: US 09/556,127
;  PRIOR FILING DATE: 2000-04-20
```

```
;  PRIOR APPLICATION NUMBER: JP 1999-111601
;  PRIOR FILING DATE: 1999-04-20
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
US-09-725-265-44

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   13.3%;  Pred. No. 5e+02;
  Matches    2;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUCC 6363
              :::::::::::::||
Db         18 TTTTTTTTTTTTCC 4


RESULT 642
US-09-904-744-2
; Sequence 2, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
;  APPLICANT: Barbera-Guillem, Emilio
;  APPLICANT:  Nelson, M. Bud
;  APPLICANT:  Castro, Stephanie
;  TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
;  TITLE OF INVENTION:  dendrimers in a signal amplification system
;  FILE REFERENCE: B-73
;  CURRENT APPLICATION NUMBER: US/09/904,744
;  CURRENT FILING DATE:  2001-07-13
;  PRIOR APPLICATION NUMBER: 09/437076
;  PRIOR FILING DATE: 1999-11-09
;  PRIOR APPLICATION NUMBER: 60/107828
;  PRIOR FILING DATE: 1998-11-10
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthesized
US-09-904-744-2

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          4 TTTTTTTTTTTTTTT 18


RESULT 643
US-08-222-177A-137
; Sequence 137, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  137:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  39 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd29rs
US-08-222-177A-137

  Query Match             0.2%;  Score 15;  DB 1;  Length 39;
  Best Local Similarity   61.5%;  Pred. No. 8.4e+02;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  | |||  ||
Db          1 ACACACACACACACACACACACACACACACACACACACA 39


RESULT 644
US-08-222-177A-119
; Sequence 119, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (608) 831-2100
;       TELEFAX:  (608) 831-2106
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  119:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  40 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     IMMEDIATE SOURCE:
;       CLONE:  mfd23rs
US-08-222-177A-119

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 8.2e+02;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  | |||  ||
Db          1 ACACACACACACACACACACACACACACACACACACACA 39


RESULT 645
US-08-222-177A-152
; Sequence 152, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  152:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd34rs
US-08-222-177A-152

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 8.2e+02;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  | |||  ||
Db          1 ACACACACATACACACACACACACACACACACACACACA 39


RESULT 646
US-08-222-177A-400
; Sequence 400, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  400:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  40 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-400

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 8.2e+02;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  | |||  ||
Db          1 ACACACACACACACACACACACACACACACACACACACA 39


RESULT 647
US-08-222-177A-403
; Sequence 403, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
```

```
;       STATE:  Wisconsin
;       COUNTRY:  USA
;       ZIP:  53717-1914
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/222,177A
;       FILING DATE:
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/341,562
;       FILING DATE:  21-APR-1989
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Sara, Charles S.
;       REGISTRATION NUMBER:  30,492
;       REFERENCE/DOCKET NUMBER:  09865.601
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (608) 831-2100
;       TELEFAX:  (608) 831-2106
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  403:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  40 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-403

  Query Match             0.2%;  Score 15;  DB 1;  Length 40;
  Best Local Similarity   61.5%;  Pred. No. 8.2e+02;
  Matches   24;  Conservative    0;  Mismatches   15;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              | ||| ||   | ||||||   ||| ||  | |||  ||
Db          2 ACACACACACACACACACACACACACACACACACACACA 40


RESULT 648
US-08-275-951-32/c
; Sequence 32, Application US/08275951
; Patent No. 6451968
; GENERAL INFORMATION:
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Kiely, John
;  APPLICANT:  Griffin, Michael
;  APPLICANT:  Coull, James M.
;  APPLICANT:  Neilsen, Peter
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Dueholm, Kim L.
;  APPLICANT:  Christensen, Leif
;  TITLE OF INVENTION:  Linked Peptide Nucleic Acids
;  FILE REFERENCE:  ISIS1577
;  CURRENT APPLICATION NUMBER: US/08/275,951
;  CURRENT FILING DATE:  1994-07-15
;  PRIOR APPLICATION NUMBER:  08/108,591
;  PRIOR FILING DATE:  1993-11-22
;  PRIOR APPLICATION NUMBER:  08/088,658
;  PRIOR FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  08/088,661
;  PRIOR FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  PCT/EP92/01219
;  PRIOR FILING DATE:  1992-05-22
;  PRIOR APPLICATION NUMBER:  986/91
;  PRIOR FILING DATE:  1991-05-22
;  PRIOR APPLICATION NUMBER:  987/91
;  PRIOR FILING DATE:  1991-05-24
;  PRIOR APPLICATION NUMBER:  510/92
;  PRIOR FILING DATE:  1991-04-15
;  NUMBER OF SEQ ID NOS:  65
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(10)
;   OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino
;   OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-32

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4740 AAAGGAAAAAAAGCAAAA 4757
              ||| |||||||| |||||
Db         18 AAAAGAAAAAAAACAAAA 1


RESULT 649
US-08-275-951-33/c
; Sequence 33, Application US/08275951
; Patent No. 6451968
; GENERAL INFORMATION:
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Kiely, John
;  APPLICANT:  Griffin, Michael
;  APPLICANT:  Coull, James M.
;  APPLICANT:  Neilsen, Peter
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Dueholm, Kim L.
;  APPLICANT:  Christensen, Leif
;  TITLE OF INVENTION:  Linked Peptide Nucleic Acids
;  FILE REFERENCE:  ISIS1577
;  CURRENT APPLICATION NUMBER: US/08/275,951
;  CURRENT FILING DATE:  1994-07-15
;  PRIOR APPLICATION NUMBER:  08/108,591
;  PRIOR FILING DATE:  1993-11-22
;  PRIOR APPLICATION NUMBER:  08/088,658
;  PRIOR FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  08/088,661
;  PRIOR FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  PCT/EP92/01219
;  PRIOR FILING DATE:  1992-05-22
;  PRIOR APPLICATION NUMBER:  986/91
;  PRIOR FILING DATE:  1991-05-22
;  PRIOR APPLICATION NUMBER:  987/91
;  PRIOR FILING DATE:  1991-05-24
;  PRIOR APPLICATION NUMBER:  510/92
;  PRIOR FILING DATE:  1991-04-15
;  NUMBER OF SEQ ID NOS:  65
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(10)
;   OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino
;   OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-33

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4739 AAAAGGAAAAAAAGCAAA 4756
              ||||| |||||||| |||
```

```
Db         18 AAAAGAAAAAAAAGAAAA 1


RESULT 650
US-08-440-646A-20/c
; Sequence 20, Application US/08440646A
; Patent No. 6777589
;  GENERAL INFORMATION:
;       APPLICANT: Lundquist, Ronald C.
;                  Walters, David A.
;                  Kirihara, Julie A.
;       TITLE OF INVENTION: Methods and Compositions for the
;                           Production of Stably Transformed, Fertile Monocot Plants
;                           and Cells Thereof
;       NUMBER OF SEQUENCES: 22
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Schwegman, Lundberg & Woessner, P.A.
;            STREET: 3500 IDS Center
;            CITY: Minneapolis
;            STATE: MN
;            COUNTRY: USA
;            ZIP: 55402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/440,646A
;            FILING DATE: 15-May-1995
;            CLASSIFICATION: 800
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/112,245
;            FILING DATE: 25-AUG-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Woessner, Warren D.
;            REGISTRATION NUMBER: 30,440
;            REFERENCE/DOCKET NUMBER: 950.13US01
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 612-339-0331
;            TELEFAX: 612-339-3061
;   INFORMATION FOR SEQ ID NO: 20:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-08-440-646A-20

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 651
US-08-440-689-20/c
; Sequence 20, Application US/08440689
; Patent No. 6025545
;  GENERAL INFORMATION:
;    APPLICANT:  Lundquist, Ronald C.
;    APPLICANT:  Walters, David A.
;    APPLICANT:  Kirihara, Julie A.
;    TITLE OF INVENTION:  Methods and Compositions for the
;    TITLE OF INVENTION:  Production of Stably Transformed, Fertile Monocot Plants
;    TITLE OF INVENTION:  and Cells Thereof
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg, Woessner & Kluth, P.A.
;      STREET:  3500 IDS Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/440,689
;      FILING DATE:  15-MAY-1995
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  950.013US2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-339-0331
;      TELEFAX:  612-339-3061
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-440-689-20

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 652
US-08-447-985-25/c
; Sequence 25, Application US/08447985
; Patent No. 6399861
;  GENERAL INFORMATION:
;       APPLICANT: Adams, Thomas R. et al.
;       TITLE OF INVENTION: Methods and Compositions for the
;                           Production of Stably Transformed, Fertile Monocot Plants
;                           and Cells Thereof
;       NUMBER OF SEQUENCES: 26
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Arnold, White & Durkee
;            STREET: P.O. Box 4433
;            CITY: Houston
;            STATE: Texas
;            COUNTRY: USA
;            ZIP: 77210
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/447,985
;            FILING DATE: 23-May-1995
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/113,561
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Parker, David L.
;            REGISTRATION NUMBER: 32,165
;            REFERENCE/DOCKET NUMBER: DEKM:055/PAR
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 512/418-3000
```

```
;             TELEFAX: 713/789-2679
;             TELEX: 79-0924
;   INFORMATION FOR SEQ ID NO: 25:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-08-447-985-25

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 653
US-08-622-740-20/c
; Sequence 20, Application US/08622740
; Patent No. 5990390
;  GENERAL INFORMATION:
;    APPLICANT:  Lundquist, Ronald C.
;    APPLICANT:  Walters, David A.
;    APPLICANT:  Kirihara, Julie A.
;    TITLE OF INVENTION:  Methods and Compositions for the
;    TITLE OF INVENTION:  Production of Stably Transformed, Fertile Monocot Plants
;    TITLE OF INVENTION:  and Cells Thereof
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg, Woessner & Kluth, P.A.
;      STREET:  3500 IDS Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/622,740
;      FILING DATE:  27-MARCH-1996
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  950.013US4
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-339-0331
;      TELEFAX:  612-339-3061
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-622-740-20

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 654
US-08-852-340-25/c
; Sequence 25, Application US/08852340
; Patent No. 6803499
;  GENERAL INFORMATION:
;    APPLICANT:  Adams, Thomas R., et al.
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR THE
;    TITLE OF INVENTION:  PRODUCTION OF STABLY TRANSFORMED, FERTILE MONOCOT PLANTS
;    TITLE OF INVENTION:  AND CELLS THEREOF
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  U.S.
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/852,340
;      FILING DATE:  07-MAY-1997
;      CLASSIFICATION:  504
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/113,561
;      FILING DATE:  25-AUG-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wilson, Mark B.
;      REGISTRATION NUMBER:  37,259
;      REFERENCE/DOCKET NUMBER:  DEKM:146/WIM
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713)789-2679
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-852-340-25

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 655
US-09-122-399-20/c
; Sequence 20, Application US/09122399
; Patent No. 6329574
;  GENERAL INFORMATION:
;    APPLICANT:  Lundquist, Ronald C.
;    APPLICANT:  Walters, David A.
;    APPLICANT:  Kirihara, Julie A.
;    TITLE OF INVENTION:  Methods and Compositions for the
;    TITLE OF INVENTION:  Production of Stably Transformed, Fertile Monocot Plants
;    TITLE OF INVENTION:  and Cells Thereof
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg & Woessner, P.A.
;      STREET:  3500 IDS Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/122,399
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/112,245
;      FILING DATE:  25-AUG-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  950.13US01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-339-0331
;      TELEFAX:  612-339-3061
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-122-399-20

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 5.2e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6738 GCACUUCCUUUCAGAGUU 6755
              ||||::|| ::||| |::
Db         18 GCACTTCCATTCAGGGTT 1


RESULT 656
US-09-341-700A-12
; Sequence 12, Application US/09341700A
; Patent No. 6972171
; GENERAL INFORMATION:
;  APPLICANT:  Schlingensiepen, Karl-Hermann
;  APPLICANT:  Brysch, Wolfgang
;  TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
;  FILE REFERENCE:  10496/P63763USO
;  CURRENT APPLICATION NUMBER: US/09/341,700A
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER:  PCT/EP98/00497
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  EP 97 101 531.8
;  PRIOR FILING DATE:  1997-01-31
;  NUMBER OF SEQ ID NOS:  1764
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 12
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: antisense oligonucleotide
US-09-341-700A-12

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         72 GGCCAGCGGGCCUGGCGG 89
              || |||||||||| |||||
Db          1 GGGCAGCGGGCCGGGCGG 18


RESULT 657
US-09-344-520-40/c
; Sequence 40, Application US/09344520
; Patent No. 6037176
; GENERAL INFORMATION:
;  APPLICANT: Frank Bennett
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF integrin beta 3 EXPRESSION
;  FILE REFERENCE: RTS-0070
;  CURRENT APPLICATION NUMBER: US/09/344,520
;  CURRENT FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 40
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-520-40

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   38.9%;  Pred. No. 5.2e+02;
  Matches    7;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGU 6991
              |:|:|: : :|:|:|:|:
Db         18 GTGTGTTTATGTGTGTGT 1


RESULT 658
US-09-475-316A-122
; Sequence 122, Application US/09475316A
; Patent No. 6210942
; GENERAL INFORMATION:
;  APPLICANT:  Lewis, No. 6210942man G.
;  APPLICANT:  Davin, Laurence B.
;  APPLICANT:  Dinkova-Kostova, Albena T.
;  APPLICANT:  Fujita, Masayuki
;  APPLICANT:  Gang, David R.
;  APPLICANT:  Sarkanen, Simo
;  APPLICANT:  Ford, Joshua D
;  TITLE OF INVENTION:  RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASES,
;  TITLE OF INVENTION:  RECOMBINANT DIRIGENT PROTEINS AND METHODS OF USE
;  FILE REFERENCE:  WSUR-1-13793
;  CURRENT APPLICATION NUMBER: US/09/475,316A
;  CURRENT FILING DATE:  1999-12-30
;  PRIOR APPLICATION NUMBER:  09/307,653
;  PRIOR FILING DATE:  1999-05-07
;  PRIOR APPLICATION NUMBER:  PCT/US97/20391
;  PRIOR FILING DATE:  1997-11-07
;  PRIOR APPLICATION NUMBER:  60/054,380
;  PRIOR FILING DATE:  1997-07-31
;  PRIOR APPLICATION NUMBER:  60/030,522
;  PRIOR FILING DATE:  1996-11-08
;  NUMBER OF SEQ ID NOS:  122
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 122
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: Linker primer
US-09-475-316A-122

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   16.7%;  Pred. No. 5.2e+02;
  Matches    3;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUU 6357
              |:| | ::::::::::::
Db          1 CTCGAGTTTTTTTTTTT 18
```

```
RESULT 659
US-09-500-700-68
; Sequence 68, Application US/09500700
; Patent No. 6790941
; GENERAL INFORMATION:
;  APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
;  APPLICANT:  BARBAS III, Carlos F.
;  APPLICANT:  GOTTESFELD, Joel M.
;  APPLICANT:  WRIGHT, Peter E.
;  TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR
;  FILE REFERENCE: SCRIP1160-4
;  CURRENT APPLICATION NUMBER: US/09/500,700
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: US 08/863,813
;  PRIOR FILING DATE: 1997-05-27
;  PRIOR APPLICATION NUMBER: US 08/676,318
;  PRIOR FILING DATE: 1996-12-30
;  PRIOR APPLICATION NUMBER: PCT/US95/00829
;  PRIOR FILING DATE: 1995-01-18
;  PRIOR APPLICATION NUMBER: US 08/312,604
;  PRIOR FILING DATE: 1994-09-28
;  PRIOR APPLICATION NUMBER: US 08/183,119
;  PRIOR FILING DATE: 1994-01-18
;  NUMBER OF SEQ ID NOS: 127
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: (GCG)6 probe
US-09-500-700-68

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        151 GCGGGGCCGGCGGCGGCG 168
              |||| | ||||||||||
Db          1 GCGGCGGCGGCGGCGGCG 18


RESULT 660
US-09-704-640-122
; Sequence 122, Application US/09704640
; Patent No. 6635459
; GENERAL INFORMATION:
;  APPLICANT:  Lewis, No. 6635459man G.
;  APPLICANT:  Davin, Laurence B.
;  APPLICANT:  Dinkova-Kostova, Albena T.
;  APPLICANT:  Fujita, Masayuki
;  APPLICANT:  Gang, David R.
;  APPLICANT:  Sarkanen, Simo
;  APPLICANT:  Ford, Joshua D
;  TITLE OF INVENTION:  RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASE,
;  TITLE OF INVENTION:  RECOMBINANT DIRIGENT PROTEIN AND METHODS OF USE
;  FILE REFERENCE:  WSUR-1-16492
;  CURRENT APPLICATION NUMBER: US/09/704,640
;  CURRENT FILING DATE:  2000-11-02
;  PRIOR APPLICATION NUMBER:  09/475,316
;  PRIOR FILING DATE:  1999-12-30
;  PRIOR APPLICATION NUMBER:  09/307,653
;  PRIOR FILING DATE:  1999-05-07
;  PRIOR APPLICATION NUMBER:  PCT/US97/20391
;  PRIOR FILING DATE:  1997-11-07
;  PRIOR APPLICATION NUMBER:  60/054,380
;  PRIOR FILING DATE:  1997-07-31
;  PRIOR APPLICATION NUMBER:  60/030,522
;  PRIOR FILING DATE:  1996-11-08
;  NUMBER OF SEQ ID NOS:  122
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 122
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: Linker primer
US-09-704-640-122

  Query Match             0.2%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   16.7%;  Pred. No. 5.2e+02;
  Matches    3;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6340 CUCUACUUUUUUUUUUUU 6357
              |:| | ::::::::::::
Db          1 CTCGAGTTTTTTTTTTT 18


RESULT 661
US-08-222-177A-140
; Sequence 140, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  140:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  37 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd30rs
US-08-222-177A-140

  Query Match             0.2%;  Score 14.6;  DB 1;  Length 37;
  Best Local Similarity   62.2%;  Pred. No. 8.8e+02;
  Matches   23;  Conservative    0;  Mismatches   14;  Indels    0;  Gaps    0;

Qy        901 ACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              ||| ||   | ||||||   ||| ||  | |||  ||
```

```
Db          1 ACACACACACACACACACACACACACACACACACACA 37


RESULT 662
US-08-222-177A-198
; Sequence 198, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  198:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd50rs
US-08-222-177A-198

  Query Match             0.2%;  Score 14.6;  DB 1;  Length 38;
  Best Local Similarity   62.2%;  Pred. No. 8.6e+02;
  Matches   23;  Conservative    0;  Mismatches   14;  Indels    0;  Gaps    0;

Qy        901 ACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              ||| ||   | ||||||   ||| ||  | |||  ||
Db          2 ACACACACACACACACACACACACACACACACACACA 38


RESULT 663
US-08-222-177A-397
; Sequence 397, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  397:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-397

  Query Match             0.2%;  Score 14.6;  DB 1;  Length 38;
  Best Local Similarity   62.2%;  Pred. No. 8.6e+02;
  Matches   23;  Conservative    0;  Mismatches   14;  Indels    0;  Gaps    0;

Qy        901 ACAAACUAUCUCACACAUCGACAAACCAAUACAAUCA 937
              ||| ||   | ||||||   ||| ||  | |||  ||
Db          1 ACACACACACACACACACACACACACACACACACACA 37


RESULT 664
US-08-060-952C-57
; Sequence 57, Application US/08060952C
; Patent No. 5695932
;  GENERAL INFORMATION:
;    APPLICANT:  Michael D. West
;    APPLICANT:  Jerry W. Shay
;    APPLICANT:  Woodring E. Wright
;    APPLICANT:  Elizabeth Blackburn
;    TITLE OF INVENTION:  THERAPY AND DIAGNOSIS OF CONDITIONS
;    TITLE OF INVENTION:  RELATED TO TELOMERE LENGTH AND/OR
;    TITLE OF INVENTION:  TELOMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  57
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/060,952C
;      FILING DATE:  May 13, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,438
```

```
;      FILING DATE:  May 13, 1992
;      APPLICATION NUMBER:  08/038,766
;      FILING DATE:  March 24, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  202/045
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  57:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-060-952C-57

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 665
US-08-151-477A-58
; Sequence 58, Application US/08151477A
; Patent No. 5830644
;  GENERAL INFORMATION:
;    APPLICANT:  Michael D. West
;    APPLICANT:  Jerry W. Shay
;    APPLICANT:  Woodring E. Wright
;    APPLICANT:  Elizabeth Blackburn
;    APPLICANT:  Nam Woo Kim
;    APPLICANT:  Calvin B. Harley
;    APPLICANT:  Scott L. Weinrich
;    APPLICANT:  Catherine Strahl
;    APPLICANT:  Michael J. McEachern
;    APPLICANT:  Homayoun Vaziri
;    TITLE OF INVENTION:  THERAPY AND DIAGNOSIS OF
;    TITLE OF INVENTION:  CONDITIONS RELATED TO TELEOMERE
;    TITLE OF INVENTION:  LENGTH AND/OR TELOMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/151,477A
;      FILING DATE:  No. 5830644ember 12, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/038,766
;      FILING DATE:  March 24, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  202/189
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  58:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-151-477A-58

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 666
US-08-153-051B-58
; Sequence 58, Application US/08153051B
; Patent No. 5645986
;  GENERAL INFORMATION:
;    APPLICANT:  Michael D. West
;    APPLICANT:  Jerry W. Shay
;    APPLICANT:  Woodring E. Wright
;    APPLICANT:  Elizabeth Blackburn
;    APPLICANT:  Nam Woo Kim
;    APPLICANT:  Calvin B. Harley
;    APPLICANT:  Scott L. Weinrich
;    APPLICANT:  Catherine Strahl
;    APPLICANT:  Michael J. McEachern
;    APPLICANT:  Homayoun Vaziri
;    TITLE OF INVENTION:  THERAPY AND DIAGNOSIS OF
;    TITLE OF INVENTION:  CONDITIONS RELATED TO TELEOMERE
;    TITLE OF INVENTION:  LENGTH AND/OR TELOMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/153,051B
;      FILING DATE:  No. 5645986ember 12, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/038,766
;      FILING DATE:  March 24, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  204/195
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  58:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-153-051B-58
```

```
  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 667
US-08-464-011B-57
; Sequence 57, Application US/08464011B
; Patent No. 6368789
;   GENERAL INFORMATION:
;       APPLICANT: Michael D. West
;                  Jerry W. Shay
;                  Woodring E. Wright
;       TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
;                           RELATED TO TELOMERE LENGTH AND/OR
;                           TELOMERASE ACTIVITY
;       NUMBER OF SEQUENCES: 61
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Lyon & Lyon
;            STREET: 633 West Fifth Street
;                    Suite 4700
;            CITY: Los Angeles
;            STATE: California
;            COUNTRY: U.S.A.
;            ZIP: 90071-2066
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                         storage
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: IBM P.C. DOS 5.0
;            SOFTWARE: Word Perfect 5.1
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/464,011B
;            FILING DATE: 05-Jun-1995
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 07/882,438
;            FILING DATE: May 13, 1992
;            APPLICATION NUMBER: 08/038,766
;            FILING DATE: March 24, 1993
;            APPLICATION NUMBER: 08/060,952
;            FILING DATE: May 13, 1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Warburg, Richard J.
;            REGISTRATION NUMBER: 32,327
;            REFERENCE/DOCKET NUMBER: 202/045
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (213) 489-1600
;            TELEFAX: (213) 955-0440
;            TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 57:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-08-464-011B-57

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 668
US-08-819-867-80
; Sequence 80, Application US/08819867
; Patent No. 6007989
;  GENERAL INFORMATION:
;    APPLICANT:  Michael D. West
;    APPLICANT:  Calvin B. Harley
;    APPLICANT:  Scott L. Weinrich
;    APPLICANT:  Catherine M. Strahl
;    APPLICANT:  Michael J. Mceachern
;    APPLICANT:  Jerry Shay
;    APPLICANT:  Woodring E. Wright
;    APPLICANT:  Elizabeth H. Blackburn
;    APPLICANT:  Nam Woo Kim
;    APPLICANT:  Homayoun Vaziri
;    TITLE OF INVENTION:  THERAPY AND DIAGNOSIS OF
;    TITLE OF INVENTION:  CONDITIONS RELATED TO
;    TITLE OF INVENTION:  TEOLOMERE LENGTH AND/OR
;    TITLE OF INVENTION:  TELOMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  80
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/819,867
;      FILING DATE:  March 14, 1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/153,051
;      FILING DATE:  No. 6007989ember 12, 1993
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Chambers, Daniel M.
;      REGISTRATION NUMBER:  34,561
;      REFERENCE/DOCKET NUMBER:  224/232
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  80:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-819-867-80

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 669
US-09-378-535-80
; Sequence 80, Application US/09378535
; Patent No. 6551774
;   GENERAL INFORMATION:
```

```
;       APPLICANT: Michael D. West
;                  Calvin B. Harley
;                  Scott L. Weinrich
;                  Catherine M. Strahl
;                  Michael J. Mceachern
;                  Jerry Shay
;                  Woodring E. Wright
;                  Elizabeth H. Blackburn
;                  Nam Woo Kim
;                  Homayoun Vaziri
;       TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
;                           CONDITIONS RELATED TO
;                           TEOLOMERE LENGTH AND/OR
;                           TELOMERASE ACTIVITY
;       NUMBER OF SEQUENCES: 80
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Lyon & Lyon
;            STREET: 633 West Fifth Street
;                    Suite 4700
;            CITY: Los Angeles
;            STATE: California
;            COUNTRY: U.S.A.
;            ZIP: 90071-2066
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                         storage
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: IBM P.C. DOS 5.0
;            SOFTWARE: FastSEQ for Windows 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/378,535
;            FILING DATE: 20-Aug-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/819,867
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Chambers, Daniel M.
;            REGISTRATION NUMBER: 34,561
;            REFERENCE/DOCKET NUMBER: 224/232
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (213) 489-1600
;            TELEFAX: (213) 955-0440
;            TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 80:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-09-378-535-80

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUG 6988
              :| |:|:|:|:|:|:|
Db          1 TGGGTGTGTGTGTGTG 16


RESULT 670
US-09-479-005A-256
; Sequence 256, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 256
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-256

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3856 UUUAAUUCAGGAAGCU 3871
              ||||||||| ||||||
Db          1 UUUAAUUCAUGAAGCU 16


RESULT 671
US-09-479-005A-294/c
; Sequence 294, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 294
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-294

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3658 UGGCACAGAGACCCAA 3673
              :|||||||||||| ||
Db         16 TGGCACAGAGACCAAA 1


RESULT 672
US-08-998-099-68
; Sequence 68, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
;  APPLICANT: JARVIS, THALE
;  APPLICANT: MCSWIGGEN, JAMES A.
;  APPLICANT: STINCHCOMB, DAN T.
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
;  TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
;  FILE REFERENCE: 231/175
;  CURRENT APPLICATION NUMBER: US/08/998,099A
;  CURRENT FILING DATE: 1997-12-24
;  EARLIER APPLICATION NUMBER: 60/037,658
;  EARLIER FILING DATE: 1997-01-23
;  EARLIER APPLICATION NUMBER: 08/373,124
;  EARLIER FILING DATE: 1995-01-13
;  EARLIER APPLICATION NUMBER: 08/245,466
```

```
;  EARLIER FILING DATE: 1994-05-18
;  NUMBER OF SEQ ID NOS: 375
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 68
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-08-998-099-68

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 5.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 AAAGAAUAAGAUGGCU 1806
                || |||||||||||||
Db          2 AAGGAAUAAGAUGGCU 17


RESULT 673
US-09-341-700A-818
; Sequence 818, Application US/09341700A
; Patent No. 6972171
; GENERAL INFORMATION:
;  APPLICANT:  Schlingensiepen, Karl-Hermann
;  APPLICANT:  Brysch, Wolfgang
;  TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
;  FILE REFERENCE:  10496/P63763USO
;  CURRENT APPLICATION NUMBER: US/09/341,700A
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER:  PCT/EP98/00497
;  PRIOR FILING DATE:  1998-01-30
;  PRIOR APPLICATION NUMBER:  EP 97 101 531.8
;  PRIOR FILING DATE:  1997-01-31
;  NUMBER OF SEQ ID NOS:  1764
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 818
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:
;    OTHER INFORMATION: antisense oligonucleotide
US-09-341-700A-818

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 5.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        153 GGGGCCGGCGGCGGCG 168
              |||| ||||||||||||
Db          1 GGGGGCGGCGGCGGCG 16


RESULT 674
US-09-866-108A-9684/c
; Sequence 9684, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9684
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-9684

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6155 AGUGGGACAGUCCUCU 6170
              ||:||| |||:||:|:
Db         17 AGTGGGCCAGTCCTCT 2


RESULT 675
US-09-866-108A-9686/c
; Sequence 9686, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
```

```
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9686
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9686

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6154 GAGUGGGACAGUCCUC 6169
              |||:||| |||:||:|
Db         16 GAGTGGGCCAGTCCTC 1


RESULT 676
US-10-156-306B-520
; Sequence 520, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 520
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-520

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 5.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUU 6358
              | |||||||||||||||
Db          2 UUCUUUUUUUUUUUUU 17


RESULT 677
PCT-US91-03680-73
; Sequence 73, Application PC/TUS9103680
;  GENERAL INFORMATION:
;    APPLICANT:  Matteucci, Mark D.
;    APPLICANT:  Krawczyk, Steven
;    TITLE OF INVENTION:  SEQUENCE-SPECIFIC NONPHOTOACTIVATED
;    TITLE OF INVENTION:  CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
;    TITLE OF INVENTION:  DUPLEX DNA
;    NUMBER OF SEQUENCES:  158
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Morrison & Foerster
;      STREET:  545 Middlefield Road, Suite 200
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/03680
;      FILING DATE:  19910524
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murashige, Kate H.
;      REGISTRATION NUMBER:  29,959
;      REFERENCE/DOCKET NUMBER:  4610-0011.40
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-327-7250
;      TELEFAX:  415-327-2951
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  73:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  modified_base
;      LOCATION:  5
;      OTHER INFORMATION:  /mod_base= OTHER
;      OTHER INFORMATION:  /note= "5-methylcytosine"
;    FEATURE:
;      NAME/KEY:  modified_base
;      LOCATION:  18
;      OTHER INFORMATION:  /mod_base= OTHER
;      OTHER INFORMATION:  /note= "N4,N4-ethanocytosine"
PCT-US91-03680-73

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 5.8e+02;
  Matches    0;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              :::: ::::::::::::
Db          1 TTTTCTTTTTTTTTTT 16


RESULT 678
PCT-US91-03680-74
; Sequence 74, Application PC/TUS9103680
;  GENERAL INFORMATION:
;    APPLICANT:  Matteucci, Mark D.
;    APPLICANT:  Krawczyk, Steven
;    TITLE OF INVENTION:  SEQUENCE-SPECIFIC NONPHOTOACTIVATED
;    TITLE OF INVENTION:  CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
;    TITLE OF INVENTION:  DUPLEX DNA
;    NUMBER OF SEQUENCES:  158
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Morrison & Foerster
;      STREET:  545 Middlefield Road, Suite 200
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/03680
;      FILING DATE:  19910524
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murashige, Kate H.
;      REGISTRATION NUMBER:  29,959
;      REFERENCE/DOCKET NUMBER:  4610-0011.40
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-327-7250
;      TELEFAX:  415-327-2951
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  74:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  modified_base
;      LOCATION:  5
;      OTHER INFORMATION:  /mod_base= OTHER
;      OTHER INFORMATION:
;    FEATURE:
;      NAME/KEY:  modified_base
;      LOCATION:  18
;      OTHER INFORMATION:  /mod_base= OTHER
;      OTHER INFORMATION:  /note= "N4,N4-ethanocytosine"
PCT-US91-03680-74

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 5.8e+02;
  Matches    0;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              :::: ::::::::::::
Db          1 TTTTMTTTTTTTTTTT 16


RESULT 679
PCT-US94-12947A-16/c
; Sequence 16, Application PC/TUS9412947A
;  GENERAL INFORMATION:
;    APPLICANT:  The Johns Hopkins University School of Medicine
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12947A
;      FILING DATE:  10-NOV-1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Haile, Ph.D., Lisa A.
;      REGISTRATION NUMBER:  P-38,347
;      REFERENCE/DOCKET NUMBER:  FD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..18
PCT-US94-12947A-16

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 5.8e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 AUGCAAGCAGGCCAGA 391
              |:|||||||| |||||
Db         16 ATGCAAGCAGCCCAGA 1


RESULT 680
US-08-152-313-16/c
; Sequence 16, Application US/08152313
; Patent No. 5561041
;  GENERAL INFORMATION:
;    APPLICANT:  Sidransky, David
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/152,313
;      FILING DATE:  12-NOV-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wetherell, Jr., Ph.D., John R.,
;      REGISTRATION NUMBER:  31,678
;      REFERENCE/DOCKET NUMBER:  PD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..18
US-08-152-313-16

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 5.8e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 AUGCAAGCAGGCCAGA 391
              |:|||||||| |||||
Db         16 ATGCAAGCAGCCCAGA 1


RESULT 681
US-08-297-395-52/c
; Sequence 52, Application US/08297395A
; Patent No. 6039947
; GENERAL INFORMATION:
;  APPLICANT: Howard L. Weiner
;  APPLICANT: David A. Hafler
;  TITLE OF INVENTION: PEPTIDES DERIVED FROM IMMUNODOMINANT
;  TITLE OF INVENTION: EPITOPES OF MYELIN BASIC PROTEIN
;  FILE REFERENCE: 1010/05723US3
;  CURRENT APPLICATION NUMBER: US/08/297,395A
;  CURRENT FILING DATE: 1994-08-11
;  EARLIER APPLICATION NUMBER: 08/059,189
;  EARLIER FILING DATE: 1993-05-06
;  EARLIER APPLICATION NUMBER: 07/502,559
;  EARLIER FILING DATE: 1990-03-30
;  EARLIER APPLICATION NUMBER: PCT/US88/02139
;  EARLIER FILING DATE: 1988-06-24
;  EARLIER APPLICATION NUMBER: 07/065,734
```

```
;  EARLIER FILING DATE: 1987-06-24
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 52
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-297-395-52

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3653 ACUGCUGGCACAGAGA 3668
              ||: |:||||||||||
Db         18 ACTACTGGCACAGAGA 3


RESULT 682
US-08-297-395-55/c
; Sequence 55, Application US/08297395A
; Patent No. 6039947
; GENERAL INFORMATION:
;  APPLICANT: Howard L. Weiner
;  APPLICANT: David A. Hafler
;  TITLE OF INVENTION: PEPTIDES DERIVED FROM IMMUNODOMINANT
;  TITLE OF INVENTION: EPITOPES OF MYELIN BASIC PROTEIN
;  FILE REFERENCE: 1010/05723US3
;  CURRENT APPLICATION NUMBER: US/08/297,395A
;  CURRENT FILING DATE: 1994-08-11
;  EARLIER APPLICATION NUMBER: 08/059,189
;  EARLIER FILING DATE: 1993-05-06
;  EARLIER APPLICATION NUMBER: 07/502,559
;  EARLIER FILING DATE: 1990-03-30
;  EARLIER APPLICATION NUMBER: PCT/US88/02139
;  EARLIER FILING DATE: 1988-06-24
;  EARLIER APPLICATION NUMBER: 07/065,734
;  EARLIER FILING DATE: 1987-06-24
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 55
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-297-395-55

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3653 ACUGCUGGCACAGAGA 3668
              ||: |:||||||||||
Db         18 ACTACTGGCACAGAGA 3


RESULT 683
US-08-297-395-61/c
; Sequence 61, Application US/08297395A
; Patent No. 6039947
; GENERAL INFORMATION:
;  APPLICANT: Howard L. Weiner
;  APPLICANT: David A. Hafler
;  TITLE OF INVENTION: PEPTIDES DERIVED FROM IMMUNODOMINANT
;  TITLE OF INVENTION: EPITOPES OF MYELIN BASIC PROTEIN
;  FILE REFERENCE: 1010/05723US3
;  CURRENT APPLICATION NUMBER: US/08/297,395A
;  CURRENT FILING DATE: 1994-08-11
;  EARLIER APPLICATION NUMBER: 08/059,189
;  EARLIER FILING DATE: 1993-05-06
;  EARLIER APPLICATION NUMBER: 07/502,559
;  EARLIER FILING DATE: 1990-03-30
;  EARLIER APPLICATION NUMBER: PCT/US88/02139
;  EARLIER FILING DATE: 1988-06-24
;  EARLIER APPLICATION NUMBER: 07/065,734
;  EARLIER FILING DATE: 1987-06-24
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 61
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-297-395-61

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3653 ACUGCUGGCACAGAGA 3668
              ||: |:||||||||||
Db         18 ACTACTGGCACAGAGA 3


RESULT 684
US-08-297-395-64/c
; Sequence 64, Application US/08297395A
; Patent No. 6039947
; GENERAL INFORMATION:
;  APPLICANT: Howard L. Weiner
;  APPLICANT: David A. Hafler
;  TITLE OF INVENTION: PEPTIDES DERIVED FROM IMMUNODOMINANT
;  TITLE OF INVENTION: EPITOPES OF MYELIN BASIC PROTEIN
;  FILE REFERENCE: 1010/05723US3
;  CURRENT APPLICATION NUMBER: US/08/297,395A
;  CURRENT FILING DATE: 1994-08-11
;  EARLIER APPLICATION NUMBER: 08/059,189
;  EARLIER FILING DATE: 1993-05-06
;  EARLIER APPLICATION NUMBER: 07/502,559
;  EARLIER FILING DATE: 1990-03-30
;  EARLIER APPLICATION NUMBER: PCT/US88/02139
;  EARLIER FILING DATE: 1988-06-24
;  EARLIER APPLICATION NUMBER: 07/065,734
;  EARLIER FILING DATE: 1987-06-24
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 64
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-297-395-64

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3653 ACUGCUGGCACAGAGA 3668
              ||: |:||||||||||
Db         18 ACTACTGGCACAGAGA 3


RESULT 685
US-08-579-223-16/c
; Sequence 16, Application US/08579223
; Patent No. 5726019
;  GENERAL INFORMATION:
;    APPLICANT:  Sidransky, David
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/579,223
;       FILING DATE:  28-DEC-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/152,313
;       FILING DATE:  12-NOV-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Wetherell, Jr., Ph.D., John R.,
;       REGISTRATION NUMBER:  31,678
;       REFERENCE/DOCKET NUMBER:  PD-2912
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (619) 455-5100
;       TELEFAX:  (619) 455-5110
;   INFORMATION FOR SEQ ID NO:  16:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..18
US-08-579-223-16

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 5.8e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 AUGCAAGCAGGCCAGA 391
              |:||||||| |||||
Db         16 ATGCAAGCAGCCCAGA 1


RESULT 686
US-08-857-946-14
; Sequence 14, Application US/08857946
; Patent No. 5994075
;  GENERAL INFORMATION:
;    APPLICANT:  Goodfellow, P.N.
;    TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;    TITLE OF INVENTION:  GENE OF INTEREST
;    NUMBER OF SEQUENCES:  162
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  75 State Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109-1807
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/857,946
;      FILING DATE:  16-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/60/017,824
;      FILING DATE:  17-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kathleen M. Williams
;      REGISTRATION NUMBER:  34,380
;      REFERENCE/DOCKET NUMBER:  3529/05573
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-345-9100
;      TELEFAX:  617-345-9111
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-857-946-14

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 5.8e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              |||| ||||||||||
Db          2 CGGCGGCGGCGGCGGC 17


RESULT 687
US-08-970-740-14
; Sequence 14, Application US/08970740
; Patent No. 6015670
;  GENERAL INFORMATION:
;    APPLICANT:  Goodfellow, P.N.
;    TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;    TITLE OF INVENTION:  GENE OF INTEREST
;    NUMBER OF SEQUENCES:  162
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  28 State Street, 28th Floor
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/970,740
;      FILING DATE:  14-NOV-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/857,946
;      FILING DATE:  16-MAY-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/017,824
;      FILING DATE:  17-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kathleen M. Williams
;      REGISTRATION NUMBER:  34,380
;      REFERENCE/DOCKET NUMBER:  3529/59829
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-227-7111
;      TELEFAX:  617-227-4399
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-970-740-14

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 5.8e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              |||| ||||||||||
Db          2 CGGCGGCGGCGGCGGC 17
```

```
RESULT 688
US-09-205-995-25
; Sequence 25, Application US/09205995
; Patent No. 6368855
; GENERAL INFORMATION:
;  APPLICANT:  Xu, Minzhen
;  APPLICANT:  Qiu, Gang
;  APPLICANT:  Humphreys, Robert
;  TITLE OF INVENTION:  CANCER CELL VACCINE
;  FILE REFERENCE:  U.S. Application 09/205,995, (CIP)
;  CURRENT APPLICATION NUMBER: US/09/205,995
;  CURRENT FILING DATE:  1998-12-04
;  PRIOR APPLICATION NUMBER:  09/036,746
;  PRIOR FILING DATE:  1998-03-09
;  PRIOR APPLICATION NUMBER:  08/661,627
;  PRIOR FILING DATE:  1996-06-11
;  NUMBER OF SEQ ID NOS:  79
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 25
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: oligonucleotide corresponding to a specific region
;   OTHER INFORMATION: of the mouse Ii gene.
US-09-205-995-25

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 5.8e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4892 CCCAGCCAGGAGCAGA 4907
              |||||||| |||||||
Db          1 CCCAGCCAAGAGCAGA 16


RESULT 689
US-09-422-978-4233
; Sequence 4233, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4233
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-14090 for SEQ 299,
US-09-422-978-4233

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2416 GAAGAGGAUGAAGGUG 2431
              ||||||||:|||| :|
Db          2 GAAGAGGATGAAGCTG 17


RESULT 690
US-09-422-978-7435/c
; Sequence 7435, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7435
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-4649 for SEQ 3501,
US-09-422-978-7435

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 5.8e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1734 CAGCAACAUGGGAAAC 1749
              | |||||||:|||||||
Db         18 CTGCAACATGGGAAAC 3


RESULT 691
US-09-828-034-15/c
; Sequence 15, Application US/09828034
; Patent No. 6967075
; GENERAL INFORMATION:
;  APPLICANT: Zhong, Weidong
;  APPLICANT:  Hong, Zhi
;  APPLICANT:  Ferrari, Eric
;  TITLE OF INVENTION: HCV REPLICASE COMPLEXES
;  FILE REFERENCE: IN01165
;  CURRENT APPLICATION NUMBER: US/09/828,034
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: U.S. 60/195,852
;  PRIOR FILING DATE: 2000-04-06
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA
US-09-828-034-15

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   12.5%;  Pred. No. 5.8e+02;
  Matches    2;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUU 6359
              ||: ::::::::::::
Db         16 ACTGTTTTTTTTTTT 1
```

```
RESULT 692
US-10-006-069A-117
; Sequence 117, Application US/10006069A
; Patent No. 7026462
; GENERAL INFORMATION:
;  APPLICANT: Rebar, Edward
;  APPLICANT:  Jamieson, Andrew
;  APPLICANT:  Liu, Qiang
;  APPLICANT:  Liu, Pei-Qi
;  APPLICANT:  Wolffe, Alan
;  APPLICANT:  Eisenberg, Stephen P.
;  APPLICANT:  Jarvis, Eric
;  APPLICANT:  Sangamo BioSciences, Inc.
;  TITLE OF INVENTION: Regulation of Angiogenesis With Zinc
;  TITLE OF INVENTION:  Finger Proteins
;  FILE REFERENCE: 019496-005830US
;  CURRENT APPLICATION NUMBER: US/10/006,069A
;  CURRENT FILING DATE:  2001-12-17
;  PRIOR APPLICATION NUMBER: US 09/733,604
;  PRIOR FILING DATE: 2000-12-07
;  PRIOR APPLICATION NUMBER: US 09/736,083
;  PRIOR FILING DATE: 2000-12-12
;  PRIOR APPLICATION NUMBER: US 09/846,033
;  PRIOR FILING DATE: 2001-04-30
;  NUMBER OF SEQ ID NOS: 252
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 117
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: target
US-10-006-069A-117

  Query Match             0.2%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 5.8e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4824 GGAGGGGGACGGGGCU 4839
              |||||||| ||||||:
Db          3 GGAGGGGGTCGGGGCT 18


RESULT 693
US-08-882-649A-8
; Sequence 8, Application US/08882649A
; Patent No. 6344316
;   GENERAL INFORMATION:
;        APPLICANT: Lockhart, David J.
;                   Chee, Mark
;                   Gunderson, Kevin
;                   Chaoqiang, Lai
;                   Wodicka, Lisa
;                   Cronin, Maureen T.
;                   Lee, Danny
;                   Tran, Huu M.
;                   Matsuzaki, Hajime
;                   McGall, Glenn H.
;        TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES
;        NUMBER OF SEQUENCES: 32
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Joe Liebeschuetz
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/08/882,649A
;             FILING DATE: 25-Jun-1997
;             CLASSIFICATION: 435-006.000
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 60/010,471
;             FILING DATE: 23-JAN-1996
;             APPLICATION NUMBER: US 60/035,170
;             FILING DATE: 09-JAN-1997
;             APPLICATION NUMBER: PCT/US97/01603
;             FILING DATE: 22-JAN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-019410US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 8:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: YES
;                      (ix)  Features:
;        SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-08-882-649A-8

  Query Match             0.2%;  Score 14.2;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
              ::::::::::::::::
Db          2 VTTTTTTTTTTTTTT 16


RESULT 694
US-09-880-727-8
; Sequence 8, Application US/09880727
; Patent No. 6858711
;   GENERAL INFORMATION:
;        APPLICANT: Lockhart, David J.
;                   Chee, Mark
;                   Gunderson, Kevin
;                   Chaoqiang, Lai
;                   Wodicka, Lisa
;                   Cronin, Maureen T.
;                   Lee, Danny
;                   Tran, Huu M.
;                   Matsuzaki, Hajime
;                   McGall, Glenn H.
;        TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES
;        NUMBER OF SEQUENCES: 32
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Joe Liebeschuetz
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/880,727
;             FILING DATE: 13-Jun-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
```

```
;            APPLICATION NUMBER: 08/882,649
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 60/035,170
;            FILING DATE: 09-JAN-1997
;            APPLICATION NUMBER: PCT/US97/01603
;            FILING DATE: 22-JAN-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Liebeschuetz, Joe
;            REGISTRATION NUMBER: 37,505
;            REFERENCE/DOCKET NUMBER: 018547-019410US
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 576-0200
;            TELEFAX: (415) 576-0300
;  INFORMATION FOR SEQ ID NO: 8:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       HYPOTHETICAL: YES
;                    (ix)  Features:
;       SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-880-727-8

  Query Match             0.2%;  Score 14.2;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.8e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUU 6359
              ::::::::::::::
Db          2 VTTTTTTTTTTTTTT 16


RESULT 695
US-08-222-177A-189
; Sequence 189, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  189:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  35 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd47rs
US-08-222-177A-189

  Query Match             0.2%;  Score 14.2;  DB 1;  Length 35;
  Best Local Similarity   62.9%;  Pred. No. 9.3e+02;
  Matches   22;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||   | ||||||   ||| ||  | |||
Db          1 ACACACACACACACACACACACACACACACACACA 35


RESULT 696
US-08-222-177A-104
; Sequence 104, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  104:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd18rs
US-08-222-177A-104

  Query Match             0.2%;  Score 14.2;  DB 1;  Length 36;
  Best Local Similarity   62.9%;  Pred. No. 9.1e+02;
  Matches   22;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||   | ||||||   ||| ||  | |||
Db          1 ACACACACACACACACACACACACACACACACACA 35
```

```
RESULT 697
US-08-222-177A-358
; Sequence 358, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  358:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  36 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd113rs
US-08-222-177A-358

  Query Match             0.2%;  Score 14.2;  DB 1;  Length 36;
  Best Local Similarity   62.9%;  Pred. No. 9.1e+02;
  Matches   22;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||   | ||||||   ||| ||  | |||
Db          1 ACACACACACACACACACACACACACACACACACA 35


RESULT 698
US-08-182-968A-170/c
; Sequence 170, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  170:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-170

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4726 ACAUGUGAGGAGGA 4739
              |||:|:||||||||
Db         14 ACATGTGAGGAGGA 1


RESULT 699
US-08-292-620A-360
; Sequence 360, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
```

```
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                  two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  360:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-360

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6359
             ||||||||||||||
Db          2 UUUUUUUUUUUUUU 15


RESULT 700
US-08-292-620A-364
; Sequence 364, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                  two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  364:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-364

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUC 6362
             ||||||||||||||
Db          1 UUUUUUUUUUUUUC 14


RESULT 701
US-08-452-196A-3/c
; Sequence 3, Application US/08452196A
; Patent No. 5576427
;  GENERAL INFORMATION:
;    APPLICANT:  Cook, Philip D.
;    APPLICANT:  Delecki, Daniel J.
;    APPLICANT:  Guinosso, Charles
;    TITLE OF INVENTION:  ACYCLIC NUCLEOSIDE
;    TITLE OF INVENTION:  ANALOGS AND
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE
;    TITLE OF INVENTION:  SEQUENCES
;    TITLE OF INVENTION:  CONTAINING THEM
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patent Department
;      STREET:  9 Great Valley Parkway
;      CITY:  Malvern
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19355
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch,
;      MEDIUM TYPE:  1.4 MB storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 7.1
;      SOFTWARE:  Microsoft Word 5.0B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/452,196A
;      FILING DATE:  26-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/040,326
;      FILING DATE:  30 March 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul E. Dupont
;      REGISTRATION NUMBER:  27,438
;      REFERENCE/DOCKET NUMBER:  2525
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215)889-6338
;      TELEFAX:  (215)889-8800
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Nucleic Acid
;      DESCRIPTION:
```

```
;    ANTI-SENSE:  yes
;    ORIGINAL SOURCE:  synthesized
;    FEATURE:
;      LOCATION:  14
;      OTHER INFORMATION:  8-[2,2-bis
;      OTHER INFORMATION:  (methoxymethyl)
;      OTHER INFORMATION:  propoxy]-9-
;      OTHER INFORMATION:  methyladenosine
US-08-452-196A-3

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              : :::::::::::::
Db         15 TNTTTTTTTTTTTTT 1


RESULT 702
US-08-452-196A-4/c
; Sequence 4, Application US/08452196A
; Patent No. 5576427
;  GENERAL INFORMATION:
;    APPLICANT:  Cook, Philip D.
;    APPLICANT:  Delecki, Daniel J.
;    APPLICANT:  Guinosso, Charles
;    TITLE OF INVENTION:  ACYCLIC NUCLEOSIDE
;    TITLE OF INVENTION:  ANALOGS AND
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE
;    TITLE OF INVENTION:  SEQUENCES
;    TITLE OF INVENTION:  CONTAINING THEM
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patent Department
;      STREET:  9 Great Valley Parkway
;      CITY:  Malvern
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19355
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch,
;      MEDIUM TYPE:  1.4 MB storage
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 7.1
;      SOFTWARE:  Microsoft Word 5.0B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/452,196A
;      FILING DATE:  26-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/040,326
;      FILING DATE:  30 March 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul E. Dupont
;      REGISTRATION NUMBER:  27,438
;      REFERENCE/DOCKET NUMBER:  2525
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215)889-6338
;      TELEFAX:  (215)889-8800
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Nucleic Acid
;      DESCRIPTION:
;    ANTI-SENSE:  yes
;    ORIGINAL SOURCE:  synthesized
;    FEATURE:
;      LOCATION:  13
;      OTHER INFORMATION:  8-[2,2-bis
;      OTHER INFORMATION:  (methoxymethyl)
;      OTHER INFORMATION:  propoxy]-9-
;      OTHER INFORMATION:  methyladenosine
US-08-452-196A-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :: ::::::::::::
Db         15 TTNTTTTTTTTTTTT 1


RESULT 703
US-08-774-306A-170/c
; Sequence 170, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  170:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-170

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4726 ACAUGUGAGGAGGA 4739
              |||:|:||||||||
Db         14 ACATGTGAGGAGGA 1


RESULT 704
US-08-832-021-26
```

```
; Sequence 26, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 26
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-26

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   21.4%;  Pred. No. 4.4e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4412 UUUUUUUUUUUGAC 4425
              ::::::::::|||
Db          2 TTTTTTTTTTGAC 15


RESULT 705
US-08-832-021-34
; Sequence 34, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-34

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   14.3%;  Pred. No. 4.4e+02;
  Matches    2;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6350 UUUUUUUUUUUUCC 6363
              ::::::::::::||
Db          1 TTTTTTTTTTTCC 14


RESULT 706
US-08-832-021-35
; Sequence 35, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-35

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   14.3%;  Pred. No. 4.4e+02;
  Matches    2;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6350 UUUUUUUUUUUUCC 6363
              ::::::::::::||
Db          1 TTTTTTTTTTTCC 14


RESULT 707
US-08-832-021-36
; Sequence 36, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-36

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   14.3%;  Pred. No. 4.4e+02;
  Matches    2;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6350 UUUUUUUUUUUUCC 6363
              ::::::::::::||
Db          1 TTTTTTTTTTTCC 14


RESULT 708
US-08-893-204C-2
; Sequence 2, Application US/08893204C
; Patent No. 6043044
;  GENERAL INFORMATION:
;    APPLICANT:  Hudson, Perry B.
;    APPLICANT:  Hakky, Said I.
;    APPLICANT:  Meyer-Siegler, Katherine
;    APPLICANT:  Hakki, A-Hamid
;    TITLE OF INVENTION:  DIAGNOSTIC AND PROGNOSTIC MARKER
;    TITLE OF INVENTION:  FOR METASTATIC ADEMOCARCINOMA
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rosenberg, Klein & Bilker
;      STREET:  3444 Ellicott Center Drive, Suite 105
;      CITY:  Ellicott City
```

```
;       STATE:  Maryland
;       COUNTRY:  U.S.A.
;       ZIP:  21043
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inches,
;       MEDIUM TYPE:  1.44Mb storage
;       COMPUTER:  IBM
;       OPERATING SYSTEM:  Windows 95
;       SOFTWARE:  WordPerfect for Windows 7.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/893,204C
;       FILING DATE:  7/15/97
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Rosenberg, Morton
;       REGISTRATION NUMBER:  26,049
;       REFERENCE/DOCKET NUMBER:  MR2493-5
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (410) 465-6678
;       TELEFAX:  (410) 461-3067
;   INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
;     HYPOTHETICAL:  yes
;     ANTI-SENSE:  no
;     ORIGINAL SOURCE:  synthetic
;     PUBLICATION INFORMATION:
;       AUTHORS:  Katherine Meyer-Siegler
;       AUTHORS:  Perry Hudson
;       TITLE:  Enhanced Expression of Macrophage Migration
;       TITLE:  Inhibitory Factor in Prostatic Adenocarcinoma Metastases
;       JOURNAL:  Urology
;       VOLUME:  48
;       ISSUE:  3
;       PAGES:  448-452
;       DATE:  1996
;       RELEVANT RESIDUES IN SEQ ID NO:  2: FROM 1 TO 15
US-08-893-204C-2

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   7.1%;  Pred. No. 4.4e+02;
  Matches    1;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUC 6362
                :::::::::::::|
Db          1 TTTTTTTTTTTTTC 14


RESULT 709
US-09-064-156A-170/c
; Sequence 170, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/064,156A
;      FILING DATE:  April 21, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/774,306
;      FILING DATE:  December 26, 1996
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  234/083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  170:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-064-156A-170

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4726 ACAUGUGAGGAGGA 4739
                |||:|:||||||||
Db         14 ACATGTGAGGAGGA 1


RESULT 710
US-09-071-845-360
; Sequence 360, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
```

```
;       APPLICATION NUMBER:  US/08/292,620
;       FILING DATE:  August 17, 1994
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  208/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  360:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-360

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6359
             ||||||||||||||
Db          2 UUUUUUUUUUUUUU 15


RESULT 711
US-09-071-845-364
; Sequence 364, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  364:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-364

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6349 UUUUUUUUUUUUUC 6362
             ||||||||||||||
Db          1 UUUUUUUUUUUUUC 14


RESULT 712
US-09-475-947A-158
; Sequence 158, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 158
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: human
;   FEATURE:
;   OTHER INFORMATION: n signifies a, t, c or g.
US-09-475-947A-158

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6360
             :::::::::::: :::
Db          1 TTTTTTTTTTTNTTT 15


RESULT 713
US-09-680-889-1
; Sequence 1, Application US/09680889
; Patent No. 6818760
; GENERAL INFORMATION:
;  APPLICANT: Spicer, Douglas A.
;  APPLICANT:  Hughes, Karin A.
;  APPLICANT:  Kaiser, Robert J.
;  APPLICANT:  Mahoney, James E.
;  APPLICANT:  Springer, Amy L.
;  APPLICANT:  Stolowitz, Mark L.
;  APPLICANT:  Weissman, Carl H.D.
;  APPLICANT:  Prolinx, Inc.
;  TITLE OF INVENTION: Removal of Dye-Labeled Dideoxy Terminators From DNA
;  TITLE OF INVENTION:  Sequencing Reactions
;  FILE REFERENCE: 017635-001140US
;  CURRENT APPLICATION NUMBER: US/09/680,889
;  CURRENT FILING DATE:  2000-10-06
```

```
;  PRIOR APPLICATION NUMBER: US 60/158,188
;  PRIOR FILING DATE: 1999-10-06
;  PRIOR APPLICATION NUMBER: US 60/164,050
;  PRIOR FILING DATE: 1999-11-08
;  PRIOR APPLICATION NUMBER: US 09/564,117
;  PRIOR FILING DATE: 2000-05-03
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:software
;   OTHER INFORMATION: assigned sequence for region between 200 and 214
;   OTHER INFORMATION: bases
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (14)
;   OTHER INFORMATION: n = g, a, c or t
US-09-680-889-1

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   20.0%;  Pred. No. 4.4e+02;
  Matches    3;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUGA 4424
              ||:::::::::::: |
Db          1 GCTTTTTTTTTTTNA 15


RESULT 714
US-10-227-001-24
; Sequence 24, Application US/10227001
; Patent No. 6951930
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Afonina, Irina Aleksandrovna
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: Hybridization-Triggered Fluorescent
;  TITLE OF INVENTION:  Detection of Nucleic Acids
;  FILE REFERENCE: 17682A-004210US
;  CURRENT APPLICATION NUMBER: US/10/227,001
;  CURRENT FILING DATE:  2002-08-21
;  PRIOR APPLICATION NUMBER: US 09/428,236
;  PRIOR FILING DATE: 1999-10-26
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 24
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 15-mer poly dT-MGB-
;   OTHER INFORMATION: (2-dimethylaminonaphthalene-6-sulfonamide)
;   OTHER INFORMATION: conjugate, poly(dT)-15-MGB-dansyl conjugate
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (1)
;   OTHER INFORMATION: n = thymine modified by MGB-
;   OTHER INFORMATION: (2-dimethylaminonaphthalene-6-sulfonamide)
;   OTHER INFORMATION: (dansyl group)
US-10-227-001-24

  Query Match             0.2%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.4e+02;
  Matches    0;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6359
              ::::::::::::::
Db          2 TTTTTTTTTTTTTT 15


RESULT 715
US-08-378-617A-30/c
; Sequence 30, Application US/08378617A
; Patent No. 5849991
;  GENERAL INFORMATION:
;    APPLICANT:  d'Apice, Anthony J.F.
;    APPLICANT:  Pearse, Martin J.
;    APPLICANT:  Robins, Allan J.
;    APPLICANT:  Crawford, Robert J.
;    APPLICANT:  Rathjen, Peter D.
;    TITLE OF INVENTION:  MATERIALS AND METHODS FOR MANAGEMENT OF
;    TITLE OF INVENTION:  HYPERACUTE REJECTION IN HUMAN XENOTRANSPLANTATION
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  120 South Sixth Street, Suite 2500
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/378,617A
;      FILING DATE:  26-JAN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ellinger, Mark S.
;      REGISTRATION NUMBER:  34,812
;      REFERENCE/DOCKET NUMBER:  06868/005001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (612) 335-5070
;      TELEFAX:  (612) 288-9696
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-378-617A-30

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        455 AGGAAAGCGAAAGG 468
              ||||||||||||||
Db         16 AGGAAAGCGAAAGG 3


RESULT 716
US-08-431-080-3/c
; Sequence 3, Application US/08431080
; Patent No. 5698686
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/431,080
;      FILING DATE:  Concurrently Herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-431-080-3

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 5e+02;
  Matches    9;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7008 GUGUGUGGGUGUGG 7021
              |:|:|:|||:|:|| 
Db         16 GTGTGTGGGTGTGG 3


RESULT 717
US-08-894-251A-5
; Sequence 5, Application US/08894251A
; Patent No. 6455305
; GENERAL INFORMATION:
;  APPLICANT: Shlomo Melmed (Inventor)
;  APPLICANT:  Lin Pei (Inventor)
;  TITLE OF INVENTION: Pituitary-Tumor-Transforming Genes, and
;  TITLE OF INVENTION:  Related Products
;  FILE REFERENCE: P07 39556 (80392)
;  CURRENT APPLICATION NUMBER: US/08/894,251A
;  CURRENT FILING DATE:  1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-894-251A-5

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::| 
Db          3 GCTTTTTTTTTTTG 16


RESULT 718
US-08-938-534-3/c
; Sequence 3, Application US/08938534
; Patent No. 5916752
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/938,534
;      FILING DATE:  26-SEP-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/431,080
;      FILING DATE:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-938-534-3

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 5e+02;
  Matches    9;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7008 GUGUGUGGGUGUGG 7021
              |:|:|:|||:|:|| 
Db         16 GTGTGTGGGTGTGG 3


RESULT 719
US-08-984-900-30/c
; Sequence 30, Application US/08984900
; Patent No. 6849448
;  GENERAL INFORMATION:
;    APPLICANT:  d'Apice, Anthony J.F.
;    APPLICANT:  Pearse, Martin J.
;    APPLICANT:  Robins, Allan J.
;    APPLICANT:  Crawford, Robert J.
;    APPLICANT:  Rathjen, Peter D.
;    TITLE OF INVENTION:  MATERIALS AND METHODS FOR MANAGEMENT OF
;    TITLE OF INVENTION:  HYPERACUTE REJECTION IN HUMAN XENOTRANSPLANTATION
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  120 South Sixth Street, Suite 2500
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30B
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/984,900
;       FILING DATE:
;       CLASSIFICATION:  800
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/378,617
;       FILING DATE:  26-JAN-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Ellinger, Mark S.
;       REGISTRATION NUMBER:  34,812
;       REFERENCE/DOCKET NUMBER:  06868/005001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (612) 335-5070
;       TELEFAX:  (612) 288-9696
;   INFORMATION FOR SEQ ID NO:  30:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-984-900-30

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        455 AGGAAAGCGAAAGG 468
              ||||||||||||||
Db         16 AGGAAAGCGAAAGG 3


RESULT 720
US-09-124-238A-4
; Sequence 4, Application US/09124238A
; Patent No. 6300127
; GENERAL INFORMATION:
;  APPLICANT: Hair, Gregory A.
;  APPLICANT:  Boden, Scott D.
;  TITLE OF INVENTION: No. 6300127el Bone Mineralization Proteins, DNA, Vectors,
;  TITLE OF INVENTION:  Expression Systems
;  FILE REFERENCE: 06148.0115
;  CURRENT APPLICATION NUMBER: US/09/124,238A
;  CURRENT FILING DATE:  1998-07-29
;  PRIOR APPLICATION NUMBER: 60/054,219
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/080,407
;  PRIOR FILING DATE: 1998-04-02
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: MS Word
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Differential Display PCR Primer
US-09-124-238A-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTG 16


RESULT 721
US-09-300-958A-56
; Sequence 56, Application US/09300958A
; Patent No. 6495319
; GENERAL INFORMATION:
;  APPLICANT:  McClelland, Michael
;  APPLICANT:  Welsh, John
;  APPLICANT:  Trenkle, Thomas
;  TITLE OF INVENTION:  Reduced Complexity Nucleic Acid Targets and Methods of
;  TITLE OF INVENTION:  Using Same
;  FILE REFERENCE:  P-PH 3457
;  CURRENT APPLICATION NUMBER: US/09/300,958A
;  CURRENT FILING DATE:  1999-04-27
;  PRIOR APPLICATION NUMBER:  60/083,331
;  PRIOR FILING DATE:  1998-04-27
;  PRIOR APPLICATION NUMBER:  60/098,070
;  PRIOR FILING DATE:  1998-08-27
;  PRIOR APPLICATION NUMBER:  60/118,624
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 56
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-300-958A-56

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTG 16


RESULT 722
US-09-300-958A-83
; Sequence 83, Application US/09300958A
; Patent No. 6495319
; GENERAL INFORMATION:
;  APPLICANT:  McClelland, Michael
;  APPLICANT:  Welsh, John
;  APPLICANT:  Trenkle, Thomas
;  TITLE OF INVENTION:  Reduced Complexity Nucleic Acid Targets and Methods of
;  TITLE OF INVENTION:  Using Same
;  FILE REFERENCE:  P-PH 3457
;  CURRENT APPLICATION NUMBER: US/09/300,958A
;  CURRENT FILING DATE:  1999-04-27
;  PRIOR APPLICATION NUMBER:  60/083,331
;  PRIOR FILING DATE:  1998-04-27
;  PRIOR APPLICATION NUMBER:  60/098,070
;  PRIOR FILING DATE:  1998-08-27
;  PRIOR APPLICATION NUMBER:  60/118,624
;  PRIOR FILING DATE:  1999-02-04
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 83
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-300-958A-83

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTG 16
```

```
RESULT 723
US-09-331-930A-4
; Sequence 4, Application US/09331930A
; Patent No. 6436670
; GENERAL INFORMATION:
;  APPLICANT: ZIMMET, PAUL Z.
;  APPLICANT:  COLLIER, GREGORY
;  TITLE OF INVENTION: A NOVEL GENE AND USES THEREFOR
;  FILE REFERENCE: 22975-20007.00
;  CURRENT APPLICATION NUMBER: US/09/331,930A
;  CURRENT FILING DATE:  1999-06-30
;  PRIOR APPLICATION NUMBER: PCT/AU98/00902
;  PRIOR FILING DATE: 1998-10-30
;  PRIOR APPLICATION NUMBER: AU PP0117/97
;  PRIOR FILING DATE: 1997-10-31
;  PRIOR APPLICATION NUMBER: AU PP0323/97
;  PRIOR FILING DATE: 1997-11-11
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-331-930A-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 724
US-09-345-294-3/c
; Sequence 3, Application US/09345294
; Patent No. 6387619
;   GENERAL INFORMATION:
;        APPLICANT: Gottschling, Daniel E.
;                   Singer, Miriam S.
;        TITLE OF INVENTION: Telomerase Compositions and Methods
;        NUMBER OF SEQUENCES: 32
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Arnold, White & Durkee
;             STREET: P.O. Box 4433
;             CITY: Houston
;             STATE: TEXAS
;             COUNTRY: UNITED STATES OF AMERICA
;             ZIP: 77210
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/345,294
;             FILING DATE: 30-Jun-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/431,080
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Parker, David L.
;             REGISTRATION NUMBER: 32,165
;             REFERENCE/DOCKET NUMBER: ARCD:155/PAR
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (512) 418-3000
;             TELEFAX: (713) 789-2679
;             TELEX: 79-0924
;   INFORMATION FOR SEQ ID NO: 3:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-345-294-3

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 5e+02;
  Matches    9;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7008 GUGUGUGGGUGUGG 7021
              |:|:|:|||:|:||
Db         16 GTGTGTGGGTGTGG 3


RESULT 725
US-09-527-972-15
; Sequence 15, Application US/09527972
; Patent No. 6642438
; GENERAL INFORMATION:
;  APPLICANT: Clendennen, Stephanie K.
;  APPLICANT: Kellogg, Jill A.
;  APPLICANT: Phan, Chau B.
;  APPLICANT: Mathews, Helena V.
;  APPLICANT: Webb, Nancy M.
;  TITLE OF INVENTION: Banana and Melon Promoters for
;  TITLE OF INVENTION: Expression of Transgenes in Plants
;  FILE REFERENCE: 4257-0019.30
;  CURRENT APPLICATION NUMBER: US/09/527,972
;  CURRENT FILING DATE: 2000-03-17
;  EARLIER APPLICATION NUMBER: US 60/125,310
;  EARLIER FILING DATE: 1999-03-19
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide primer
US-09-527-972-15

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 726
US-09-531-000-24
; Sequence 24, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
;  APPLICANT:  JOHNSON, Marion D.
;  APPLICANT:  FRESCO, Jacques R.
;  TITLE OF INVENTION:  TRIPLEX IN-SITU HYBRIDIZATION
;  FILE REFERENCE:  2448-103
;  CURRENT APPLICATION NUMBER: US/09/531,000
;  CURRENT FILING DATE:  2000-09-08
;  PRIOR APPLICATION NUMBER:  PCT/US98/23765
;  PRIOR FILING DATE:  1998-11-10
;  PRIOR APPLICATION NUMBER:  60/064,997
;  PRIOR FILING DATE:  1997-11-10
;  NUMBER OF SEQ ID NOS:  77
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 16
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target
;   OTHER INFORMATION: sequences
US-09-531-000-24

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4734 GGAGGAAAAGGAAA 4747
              ||||||||||||||
Db          3 GGAGGAAAAGGAAA 16


RESULT 727
US-09-569-956-11
; Sequence 11, Application US/09569956
; Patent No. 6894031
; GENERAL INFORMATION:
;  APPLICANT:  Cedars-Sinai Medical Center (Assignee);
;  APPLICANT:  Gregory A. Horwitz (Inventor);
;  APPLICANT:  Xun Zhang (Inventor);
;  APPLICANT:  Shlomo Melmed (Inventor)
;  TITLE OF INVENTION:  Pituitary Tumor Transforming Gene (PTTG)
;  TITLE OF INVENTION:  Carboxy-Terminal Peptides and Methods of Use Thereof to
;  TITLE OF INVENTION:  Inhibit Neoplastic Cellular Proliferation and/or
;  TITLE OF INVENTION:  Transformation
;  FILE REFERENCE:  CEDAR-044527
;  CURRENT APPLICATION NUMBER: US/09/569,956
;  CURRENT FILING DATE:  2000-05-12
;  PRIOR APPLICATION NUMBER:  US 08/894,251
;  PRIOR FILING DATE:  1999-07-23
;  PRIOR APPLICATION NUMBER:  PCT/US97/21463
;  PRIOR FILING DATE:  1997-11-21
;  PRIOR APPLICATION NUMBER:  US 60/031,338
;  PRIOR FILING DATE:  1996-11-21
;  NUMBER OF SEQ ID NOS:  19
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Anchored primer sequence.
US-09-569-956-11

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 728
US-09-721-975-4
; Sequence 4, Application US/09721975
; Patent No. 6444803
; GENERAL INFORMATION:
;  APPLICANT: Hair, Gregory A.
;  APPLICANT:  Boden, Scott D.
;  TITLE OF INVENTION: No. 6444803el Bone Mineralization Proteins, DNA, Vectors,
;  TITLE OF INVENTION:  Expression Systems
;  FILE REFERENCE: 06148.0115
;  CURRENT APPLICATION NUMBER: US/09/721,975
;  CURRENT FILING DATE:  2000-11-27
;  PRIOR APPLICATION NUMBER: US 09/124,238
;  PRIOR FILING DATE: 1998-07-29
;  PRIOR APPLICATION NUMBER: 60/054,219
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/080,407
;  PRIOR FILING DATE: 1998-04-02
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: MS Word
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Differential Display PCR Primer
US-09-721-975-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 729
US-09-724-857-26
; Sequence 26, Application US/09724857
; Patent No. 6855866
; GENERAL INFORMATION:
;  APPLICANT: Weterings, Koen
;  APPLICANT:  Apuya, Nestor R.
;  APPLICANT:  Tatarinova, Tatiana
;  APPLICANT:  Goldberg, Robert B.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Polynucleotides Useful for Modulating Transcription
;  FILE REFERENCE: 02307O-114700US
;  CURRENT APPLICATION NUMBER: US/09/724,857
;  CURRENT FILING DATE:  2002-05-06
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:anchor/reverse
;   OTHER INFORMATION: primer G primer
US-09-724-857-26

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 730
US-09-854-326-11
; Sequence 11, Application US/09854326
; Patent No. 6913926
; GENERAL INFORMATION:
;  APPLICANT: Toni R. Prezant (Inventor)
;  APPLICANT:  Shlomo Melmed (Inventor)
;  APPLICANT:  Anthony P. Heaney (Inventor)
;  TITLE OF INVENTION: METHOD OF REGULATING BIOLOGICAL ACTIVITY
;  TITLE OF INVENTION:  OF PITUITARY TUMOR TRANSFORMING GENE (PTTG)1 USING PTTG2
;  FILE REFERENCE: 18810-81401
;  CURRENT APPLICATION NUMBER: US/09/854,326
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: US09/730,469
;  PRIOR FILING DATE: 2000-12-04
;  PRIOR APPLICATION NUMBER: US 09/687,911
;  PRIOR FILING DATE: 2000-10-13
;  PRIOR APPLICATION NUMBER: US 09/569,956
;  PRIOR FILING DATE: 2000-05-12
```

```
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US86/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 68
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Anchored primer sequence.
US-09-854-326-11

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 731
US-09-949-270A-5
; Sequence 5, Application US/09949270A
; Patent No. 6911320
; GENERAL INFORMATION:
;  APPLICANT: Shlomo Melmed (Inventor)
;  APPLICANT:  Lin Pei (Inventor)
;  TITLE OF INVENTION: Rat PRRG Polypeptide and Method for
;  TITLE OF INVENTION:  Producing It
;  FILE REFERENCE: 18810-81106
;  CURRENT APPLICATION NUMBER: US/09/949,270A
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-949-270A-5

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 732
US-09-949-271A-5
; Sequence 5, Application US/09949271A
; Patent No. 6723519
; GENERAL INFORMATION:
;  APPLICANT: Shlomo Melmed (Inventor)
;  APPLICANT:  Lin Pei (Inventor)
;  TITLE OF INVENTION: Compositions and Method for Determining
;  TITLE OF INVENTION:  The Presence of Rat PRRG Peptide In A Sample
;  FILE REFERENCE: 18810-81108
;  CURRENT APPLICATION NUMBER: US/09/949,271A
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-949-271A-5

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 733
US-09-949-272A-5
; Sequence 5, Application US/09949272A
; Patent No. 6900032
; GENERAL INFORMATION:
;  APPLICANT: Shlomo Melmed (Inventor)
;  APPLICANT:  Lin Pei (Inventor)
;  TITLE OF INVENTION: Human PTTG Polypeptide and Method for
;  TITLE OF INVENTION:  Producing It
;  FILE REFERENCE: 18810-81105
;  CURRENT APPLICATION NUMBER: US/09/949,272A
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-949-272A-5

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 734
US-09-949-476A-5
; Sequence 5, Application US/09949476A
; Patent No. 6750327
; GENERAL INFORMATION:
;  APPLICANT: Shlomo Melmed (Inventor)
;  APPLICANT:  Lin Pei (Inventor)
;  TITLE OF INVENTION: Compositions and Method for Determining
;  TITLE OF INVENTION:  The Presence of Human PRRG Peptide In A Sample
;  FILE REFERENCE: 18810-81107
;  CURRENT APPLICATION NUMBER: US/09/949,476A
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
```

```
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 7
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-949-476A-5

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 735
US-09-986-621-4
; Sequence 4, Application US/09986621
; Patent No. 6521750
; GENERAL INFORMATION:
;  APPLICANT: Hair, Gregory A.
;  APPLICANT:  Boden, Scott D.
;  TITLE OF INVENTION: No. 6521750el Bone Mineralization Proteins, DNA, Vectors,
;  TITLE OF INVENTION:  Expression Systems
;  FILE REFERENCE: 06148.0115
;  CURRENT APPLICATION NUMBER: US/09/986,621
;  CURRENT FILING DATE:  2001-11-09
;  PRIOR APPLICATION NUMBER: 09/124,238
;  PRIOR FILING DATE: 1998-07-29
;  PRIOR APPLICATION NUMBER: 60/080,407
;  PRIOR FILING DATE: 1998-04-02
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: MS Word
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Differential Display PCR Primer
US-09-986-621-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 736
US-09-986-625-4
; Sequence 4, Application US/09986625
; Patent No. 6858431
; GENERAL INFORMATION:
;  APPLICANT: Hair, Gregory A.
;  APPLICANT:  Boden, Scott D.
;  TITLE OF INVENTION: No. 6858431el Bone Mineralization Proteins, DNA, Vectors,
;  TITLE OF INVENTION:  Expression Systems
;  FILE REFERENCE: 06148.0115
;  CURRENT APPLICATION NUMBER: US/09/986,625
;  CURRENT FILING DATE:  2001-11-09
;  PRIOR APPLICATION NUMBER: US/09/124,238
;  PRIOR FILING DATE: 1998-07-29
;  PRIOR APPLICATION NUMBER: 60/054,219
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/080,407
;  PRIOR FILING DATE: 1998-04-02
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Differential Display PCR Primer
US-09-986-625-4

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 737
US-10-136-082-11
; Sequence 11, Application US/10136082
; Patent No. 6858586
; GENERAL INFORMATION:
;  APPLICANT: Cedars-Sinai Medical Center (Assignee);
;  APPLICANT:  Gregory A. Horwitz (Inventor);
;  APPLICANT:  Xun Zhang (Inventor);
;  APPLICANT:  Shlomo Melmed (Inventor)
;  TITLE OF INVENTION: Pituitary Tumor Transforming Gene (PTTG)
;  TITLE OF INVENTION:  Carboxy-Terminal Peptides and Methods of Use Thereof to
;  TITLE OF INVENTION:  Inhibit Neoplastic Cellular Proliferation and/or
;  TITLE OF INVENTION:  Transformation
;  FILE REFERENCE: CEDAR-044527
;  CURRENT APPLICATION NUMBER: US/10/136,082
;  CURRENT FILING DATE:  2002-04-29
;  PRIOR APPLICATION NUMBER: US/09/569,956
;  PRIOR FILING DATE: 2000-05-12
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Anchored primer sequence.
US-10-136-082-11

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 738
US-10-257-819A-3
; Sequence 3, Application US/10257819A
; Patent No. 6977296
; GENERAL INFORMATION:
;  APPLICANT: KIM, Jin Woo
;  TITLE OF INVENTION: HUMAN CERVICAL CANCER SUPPRESSOR PROTEIN, POLYNUCLEOTIDE ENCODIN
;  TITLE OF INVENTION:  PROTEIN, CELL TRANSFORMED WITH THE POLYNUCLEOTIDE AND METHOD FO
;  TITLE OF INVENTION:  PROLIFERATION OF CANCER CELL USING THE EXPRESSION VECTOR
;  FILE REFERENCE: PCA01147/KJW
;  CURRENT APPLICATION NUMBER: US/10/257,819A
;  CURRENT FILING DATE:  2003-06-01
```

```
;  PRIOR APPLICATION NUMBER: KR 2000-21897
;  PRIOR FILING DATE: 2000-04-25
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: KOPATIN 1.5
; SEQ ID NO 3
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: H-T11G anchored oligo-dT primer
US-10-257-819A-3

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 739
US-10-261-821-11
; Sequence 11, Application US/10261821
; Patent No. 6835380
; GENERAL INFORMATION:
;  APPLICANT: Cedars-Sinai Medical Center (Assignee);
;  APPLICANT:  Gregory A. Horwitz (Inventor);
;  APPLICANT:  Xun Zhang (Inventor);
;  APPLICANT:  Shlomo Melmed (Inventor)
;  TITLE OF INVENTION: Pituitary Tumor Transforming Gene (PTTG)
;  TITLE OF INVENTION:  Carboxy-Terminal Peptides and Methods of Use Thereof to
;  TITLE OF INVENTION:  Inhibit Neoplastic Cellular Proliferation and/or
;  TITLE OF INVENTION:  Transformation
;  FILE REFERENCE: CEDAR-044527
;  CURRENT APPLICATION NUMBER: US/10/261,821
;  CURRENT FILING DATE:  2002-09-30
;  PRIOR APPLICATION NUMBER: US/09/569,956
;  PRIOR FILING DATE: 2000-05-12
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Anchored primer sequence.
US-10-261-821-11

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 740
US-10-262-252-11
; Sequence 11, Application US/10262252
; Patent No. 6939544
; GENERAL INFORMATION:
;  APPLICANT: Cedars-Sinai Medical Center (Assignee);
;  APPLICANT:  Gregory A. Horwitz (Inventor);
;  APPLICANT:  Xun Zhang (Inventor);
;  APPLICANT:  Shlomo Melmed (Inventor)
;  TITLE OF INVENTION: Pituitary Tumor Transforming Gene (PTTG)
;  TITLE OF INVENTION:  Carboxy-Terminal Peptides and Methods of Use Thereof to
;  TITLE OF INVENTION:  Inhibit Neoplastic Cellular Proliferation and/or
;  TITLE OF INVENTION:  Transformation
;  FILE REFERENCE: CEDAR-044527
;  CURRENT APPLICATION NUMBER: US/10/262,252
;  CURRENT FILING DATE:  2002-09-30
;  PRIOR APPLICATION NUMBER: US/09/569,956
;  PRIOR FILING DATE: 2000-05-12
;  PRIOR APPLICATION NUMBER: US 08/894,251
;  PRIOR FILING DATE: 1999-07-23
;  PRIOR APPLICATION NUMBER: PCT/US97/21463
;  PRIOR FILING DATE: 1997-11-21
;  PRIOR APPLICATION NUMBER: US 60/031,338
;  PRIOR FILING DATE: 1996-11-21
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Anchored primer sequence.
US-10-262-252-11

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   21.4%;  Pred. No. 5e+02;
  Matches    3;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4410 GCUUUUUUUUUUUG 4423
              ||:::::::::::|
Db          3 GCTTTTTTTTTTTG 16


RESULT 741
US-10-780-464-1/c
; Sequence 1, Application US/10780464
; Patent No. 6905860
; GENERAL INFORMATION:
;  APPLICANT: Ishikawa, Fuyuki
;  APPLICANT:  Hasegawa, Mamoru
;  TITLE OF INVENTION: Artificial Chromosome
;  FILE REFERENCE: 50026/016002
;  CURRENT APPLICATION NUMBER: US/10/780,464
;  CURRENT FILING DATE:  2004-02-17
;  PRIOR APPLICATION NUMBER: 09/254,947
;  PRIOR FILING DATE: 2000-03-13
;  PRIOR APPLICATION NUMBER: PCT/JP97/03305
;  PRIOR FILING DATE: 1997-09-18
;  PRIOR APPLICATION NUMBER: JP 8/246749
;  PRIOR FILING DATE: 1996-09-18
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Saccharomyces cerevisiae
US-10-780-464-1

  Query Match             0.2%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 5e+02;
  Matches    9;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7008 GUGUGUGGGUGUGG 7021
              |:|:|:|||:|:||
Db         16 GTGTGTGGGTGTGG 3


RESULT 742
US-08-325-955-2/c
; Sequence 2, Application US/08325955
; Patent No. 6610299
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Seeman, Gerhard
;    APPLICANT:  Bosslet, Klaus
;    APPLICANT:  Czech, Joerg
;    APPLICANT:  Kolar, Cenek
;    APPLICANT:  Hoffman, Dieter
;    APPLICANT:  Sedlacek, Hans-Harald
;    TITLE OF INVENTION:  Glycosyl-Etoposide Prodrugs, A Process For
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner
;      STREET:  1300 I Street, N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/325,955
;      FILING DATE:  19-OCT-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ogden, Stasia L.
;      REGISTRATION NUMBER:  36,228
;      REFERENCE/DOCKET NUMBER:  05552.0981-04000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-408-4000
;      TELEFAX:  202-408-4400
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-325-955-2

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         28 GCAGCGGCGGCGGC 41
              ||||||||||||||
Db         16 GCAGCGGCGGCGGC 3


RESULT 743
US-08-849-021-16/c
; Sequence 16, Application US/08849021
; Patent No. 5955276
;  GENERAL INFORMATION:
;    APPLICANT:  MORGANTE, MICHELE
;    APPLICANT:  VOGEL, JULIE M.
;    TITLE OF INVENTION:  COMPOUND MICROSATELLITE
;    TITLE OF INVENTION:  PRIMERS FOR THE
;    TITLE OF INVENTION:  DETECTION OF GENETIC
;    TITLE OF INVENTION:  POLYMORPHISMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  E. I. DU PONT DE NEMOURS AND
;      ADDRESSEE:  COMPANY
;      STREET:  1007 MARKET STREET
;      CITY:  WILMINGTON
;      STATE:  DELAWARE
;      COUNTRY:  U.S.A.
;      ZIP:  19898
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PATENT IN RELEASE #1.0, VERSION 1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/849,021
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/346,456
;      FILING DATE:  28 NOVEMBER 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FLOYD, LINDA AXAMETHY
;      REGISTRATION NUMBER:  33,692
;      REFERENCE/DOCKET NUMBER:  BB-1064-A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  302-892-8112
;      TELEFAX:  302-992-7949
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-849-021-16

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUG 6986
              :|:|:|:|:|:|:|
Db         17 TGTGTGTGTGTGTG 4


RESULT 744
US-09-343-698-2/c
; Sequence 2, Application US/09343698
; Patent No. 6475486
;  GENERAL INFORMATION:
;       APPLICANT: Seeman, Gerhard
;                  Bosslet, Klaus
;                  Czech, Joerg
;                  Kolar, Cenek
;                  Hoffman, Dieter
;                  Sedlacek, Hans-Harald
;       TITLE OF INVENTION: Glycosyl-Etoposide Prodrugs, A Process For
;                           Preparation Thereof And The Use Thereof In Combination Wit
;                           Functionalized Tumor-Specific Enzyme Conjugates
;       NUMBER OF SEQUENCES: 8
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;                       Dunner
;            STREET: 1300 I Street, N.W., Suite 700
;            CITY: Washington
;            STATE: D.C.
;            COUNTRY: USA
;            ZIP: 20005
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/343,698
;            FILING DATE: 30-Jun-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/325,955
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Ogden, Stasia L.
;            REGISTRATION NUMBER: 36,228
;            REFERENCE/DOCKET NUMBER: 05552.0981-04000
```

```
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 202-408-4000
;             TELEFAX: 202-408-4400
;    INFORMATION FOR SEQ ID NO: 2:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-343-698-2

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         28 GCAGCGGCGGCGGC 41
              ||||||||||||||
Db         16 GCAGCGGCGGCGGC 3


RESULT 745
US-09-818-875-4290
; Sequence 4290, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4290
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4290

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1123 UUCUACAGUGUUCU 1136
              ::|:||||:|::|:
Db          2 TTCTACAGTGTTCT 15


RESULT 746
US-09-818-875-4291/c
; Sequence 4291, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4291
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4291

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1123 UUCUACAGUGUUCU 1136
              ::|:||||:|::|:
Db         16 TTCTACAGTGTTCT 3


RESULT 747
US-09-866-108A-804
; Sequence 804, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 804
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-804

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
```

```
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5257 GAAAGCUGAGAAGA 5270
              |||||||:|||||||
Db          4 GAAAGCTGAGAAGA 17


RESULT 748
US-09-866-108A-805
; Sequence 805, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 805
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-805

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5257 GAAAGCUGAGAAGA 5270
              |||||||:|||||||
Db          3 GAAAGCTGAGAAGA 16


RESULT 749
US-09-866-108A-806
; Sequence 806, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 806
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-806

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5257 GAAAGCUGAGAAGA 5270
              |||||||:|||||||
Db          2 GAAAGCTGAGAAGA 15


RESULT 750
US-09-866-108A-807
; Sequence 807, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 807
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-807

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5257 GAAAGCUGAGAAGA 5270
              ||||||:|||||||
Db          1 GAAAGCTGAGAAGA 14


RESULT 751
US-10-156-306B-524
; Sequence 524, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 524
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-524

  Query Match             0.2%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUU 6359
              ||||||||||||||
Db          1 UUUUUUUUUUUUUU 14


RESULT 752
US-08-222-177A-415
; Sequence 415, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  415:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  30 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-415

  Query Match             0.2%;  Score 14;  DB 1;  Length 30;
  Best Local Similarity   66.7%;  Pred. No. 1e+03;
  Matches   20;  Conservative    0;  Mismatches   10;  Indels    0;  Gaps    0;

Qy        910 CUCACACAUCGACAAACCAAUACAAUCAUA 939
              | ||||||  |||| ||  | |||  || |
Db          1 CACACACACAGACAGACACACACACACACA 30


RESULT 753
US-08-222-177A-406
; Sequence 406, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  406:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  32 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-222-177A-406

  Query Match             0.2%;  Score 14;  DB 1;  Length 32;
  Best Local Similarity   63.3%;  Pred. No. 1e+03;
  Matches   19;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy        912 CACACAUCGACAAACCAAUACAAUCAUAGA 941
              ||||||   ||| ||  | ||| :|| | |
Db          1 CACACACACACACACACACACTCACACA 30


RESULT 754
PCT-US94-12947A-93
; Sequence 93, Application PC/TUS9412947A
;  GENERAL INFORMATION:
;    APPLICANT:  The Johns Hopkins University School of Medicine
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12947A
;      FILING DATE:  10-NOV-1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Haile, Ph.D., Lisa A.
;      REGISTRATION NUMBER:  P-38,347
;      REFERENCE/DOCKET NUMBER:  FD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  93:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
PCT-US94-12947A-93

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        131 GCGAGACGGGCGCUCAG 147
              | ||||||||||| |||
Db          1 GAGAGACGGGCGCACAG 17


RESULT 755
US-08-050-073-82/c
; Sequence 82, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  82:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-82

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3285 CCUGUCUUCCAGAAAGU 3301
              ||:|:|::|||| | |:
Db         17 CCTGTCTTCCAGGATGT 1


RESULT 756
US-08-152-313-93
; Sequence 93, Application US/08152313
; Patent No. 5561041
;  GENERAL INFORMATION:
;    APPLICANT:  Sidransky, David
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/152,313
;      FILING DATE:  12-NOV-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wetherell, Jr., Ph.D., John R.,
;      REGISTRATION NUMBER:  31,678
;      REFERENCE/DOCKET NUMBER:  PD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  93:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
US-08-152-313-93

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        131 GCGAGACGGGCGCUCAG 147
              | ||||||||||| |||
Db          1 GAGAGACGGGCGCACAG 17


RESULT 757
US-08-373-124A-2147
; Sequence 2147, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2147:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2147

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUU 6360
              ||||||||| |||||| |
Db          1 ACUUUUUUAUUUUUUAU 17


RESULT 758
US-08-373-124A-2321/c
; Sequence 2321, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2321:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2321

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 CAAGUGGUUCUGGCACC 1657
              ||||:||:: :| ||||
Db         17 CAAGTGGTTATGCCACC 1


RESULT 759
US-08-373-124A-274/c
; Sequence 274, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  274:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-274

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 CAAGUGGUUCUGGCACC 1657
              ||||:||:: :| ||||
Db         17 CAAGTGGTTATGCCACC 1


RESULT 760
US-08-373-124A-590
; Sequence 590, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  590:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-590

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6281 UUAUAAAUCAGGUAACU 6297
              | ||||||||||| ||||
Db          1 UGAUAAAUCAGGAAACU 17


RESULT 761
US-08-373-124A-872
; Sequence 872, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  872:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-872

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7268 CAUAAAUUUUUCAAAAU 7284
                ||||  |||||| |||||
Db          1 CAUAUAUUUUUAAAAAU 17


RESULT 762
US-08-435-628-2147
; Sequence 2147, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2147:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2147

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUU 6360
                ||||||||  ||||||  |
Db          1 ACUUUUUUAUUUUUUAU 17


RESULT 763
US-08-435-628-2321/c
; Sequence 2321, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
```

```
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2321:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-2321

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 CAAGUGGUUCUGGCACC 1657
                ||||:||:: :| ||||
Db         17 CAAGTGGTTATGCCACC 1


RESULT 764
US-08-435-628-274/c
; Sequence 274, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  274:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-274

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 CAAGUGGUUCUGGCACC 1657
                ||||:||:: :| ||||
Db         17 CAAGTGGTTATGCCACC 1


RESULT 765
US-08-435-628-590
; Sequence 590, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  590:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-590

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6281 UUAUAAAUCAGGUAACU 6297
                | |||||||||| ||||
Db          1 UGAUAAAUCAGGAAACU 17


RESULT 766
US-08-435-628-872
; Sequence 872, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  872:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-872

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7268 CAUAAAUUUUUCAAAAU 7284
                |||| |||||| |||||
Db          1 CAUAUAUUUUUAAAAAU 17


RESULT 767
US-08-485-602-25
; Sequence 25, Application US/08485602
; Patent No. 5712095
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B.
;    APPLICANT:  Cangelosi, Gerard A.
;    TITLE OF INVENTION:  Rapid and Sensitive Detection of
;    TITLE OF INVENTION:  Antibiotic-Resistant Mycobacteria Using Oligonucleotide
;    TITLE OF INVENTION:  Probes Specific for Ribosomal RNA Precursors
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/485,602
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/261,068
;      FILING DATE:  16-JUN-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  11652-79-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  rRNA
```

```
;    ORIGINAL SOURCE:
;      ORGANISM:  Mycobacterium lufu
;    FEATURE:
;      NAME/KEY:  precursor_RNA
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "pre-rRNA open region"
US-08-485-602-25

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7009 UGUGUGGGUGUGGGUGU 7025
              ||||||||| ||| |||
Db          1 UGUGUGGGUAUGGUUGU 17


RESULT 768
US-08-579-223-93
; Sequence 93, Application US/08579223
; Patent No. 5726019
;  GENERAL INFORMATION:
;    APPLICANT:  Sidransky, David
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/579,223
;      FILING DATE:  28-DEC-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/152,313
;      FILING DATE:  12-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wetherell, Jr., Ph.D., John R.,
;      REGISTRATION NUMBER:  31,678
;      REFERENCE/DOCKET NUMBER:  PD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  93:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
US-08-579-223-93

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       131 GCGAGACGGGCGCUCAG 147
             | |||||||||| |||
Db         1 GAGAGACGGGCGCACAG 17


RESULT 769
US-08-585-595-23
; Sequence 23, Application US/08585595
; Patent No. 5795761
;  GENERAL INFORMATION:
;    APPLICANT:  POWERS, DAVID B.
;    APPLICANT:  ANDERSON, STEPHEN
;    TITLE OF INVENTION:  IMPROVED METHODS FOR PRODUCING VITAMIN C
;    NUMBER OF SEQUENCES:  35
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  HOWREY & SIMON
;      STREET:  1299 PENNSYLVANIA AVENUE, N.W.
;      CITY:  WASHINGTON
;      STATE:  DC
;      COUNTRY:  US
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,595
;      FILING DATE:  16-JAN-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/584,019
;      FILING DATE:  11-JAN-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  AUERBACH, JEFFREY I.
;      REGISTRATION NUMBER:  32680
;      REFERENCE/DOCKET NUMBER:  6137-0014 CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 383-7451
;      TELEFAX:  (202) 383-6610
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  CORYNEBACTERIUM SP
US-08-585-595-23

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       159 GGCGGCGGCGAACGAGA 175
             ||||| |||| ||||||
Db         1 GGCGGTGGCGTACGAGA 17


RESULT 770
US-08-745-638-25
; Sequence 25, Application US/08745638
; Patent No. 5770373
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B.
;    APPLICANT:  Cangelosi, Gerard A.
;    TITLE OF INVENTION:  Rapid and Sensitive Detection of
;    TITLE OF INVENTION:  Antibiotic-Resistant Mycobacteria Using Oligonucleotide
;    TITLE OF INVENTION:  Probes Specific for Ribosomal RNA Precursors
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  California
```

```
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/745,638
;      FILING DATE:  08-NOV-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/485,602
;      FILING DATE:  07-JUN-1995
;      APPLICATION NUMBER:  US 08/261,068
;      FILING DATE:  16-JUN-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  11652-79-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  rRNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Mycobacterium lufu
;    FEATURE:
;      NAME/KEY:  precursor_RNA
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "pre-rRNA open region"
US-08-745-638-25

  Query Match              0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7009 UGUGUGGGUGUGGGUGU 7025
              ||||||||| ||| |||
Db          1 UGUGUGGGUAUGGUUGU 17


RESULT 771
US-08-757-180-24
; Sequence 24, Application US/08757180
; Patent No. 5726021
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B
;    APPLICANT:  Cangelosi, Gerard A
;    TITLE OF INVENTION:  RAPID LYSIS METHODS FOR RELEASING INTACT
;    TITLE OF INVENTION:  RIBOSOMAL RNA PRECURSORS FROM MYCOBACTERIUM
;    NUMBER OF SEQUENCES:  98
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Neave
;      STREET:  1251 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  United States of America
;      ZIP:  10020
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,180
;      FILING DATE:  27-NOV-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/261,068
;      FILING DATE:  16-JUN-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hsi, Petrina S
;      REGISTRATION NUMBER:  38,496
;      REFERENCE/DOCKET NUMBER:  BD3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-596-9000
;      TELEFAX:  212-596-9090
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  rRNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Mycobacterium lufu
US-08-757-180-24

  Query Match              0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7009 UGUGUGGGUGUGGGUGU 7025
              ||||||||| ||| |||
Db          1 UGUGUGGGUAUGGUUGU 17


RESULT 772
US-08-758-306-171/c
; Sequence 171, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  171:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-171

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2769 AGUGGUUCAAGCAUCAG 2785
              ||:||::|||| |:| |
Db         17 AGTGGTTCAAGAATCTG 1


RESULT 773
US-08-758-306-93/c
; Sequence 93, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  93:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-93

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1697 GUUCCAAUAAUGAAGAG 1713
              |: ||||:||:| ||||
Db         17 GTACCAATAATGCAGAG 1


RESULT 774
US-08-758-306-95/c
; Sequence 95, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  95:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-95

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1696 UGUUCCAAUAAUGAAGA 1712
              :|: ||||:||:| |||
Db         17 TGTACCAATAATGCAGA 1


RESULT 775
US-08-985-162-677/c
; Sequence 677, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
```

```
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  677:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-677

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5517 UCCUUGAGUAAAAAGGU 5533
             :| ::|||:|||||| :
Db         17 TCTTTGAGTAAAAAGCT 1


RESULT 776
US-09-050-159-64
; Sequence 64, Application US/09050159A
; Patent No. 6197505
; GENERAL INFORMATION:
;  APPLICANT: No. 6197505berg, Leif T
;  APPLICANT: Andersson, Maria K
;  APPLICANT: Linstrom, Per H
;  TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
;  TITLE OF INVENTION: COMPOSITIONS FOR USE THEREOF
;  FILE REFERENCE: 1248/1D042
;  CURRENT APPLICATION NUMBER: US/09/050,159A
;  CURRENT FILING DATE: 1998-03-27
;  EARLIER APPLICATION NUMBER: 60/042,930
;  EARLIER FILING DATE: 1987-04-03
;  NUMBER OF SEQ ID NOS: 133
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 64
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-64

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6201 GCUAGAGCCAGAAGAGA 6217
             || |||||||| |||||
Db          1 GCCAGAGCCAGCAGAGA 17


RESULT 777
US-09-401-063-677/c
; Sequence 677, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  677:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-677

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5517 UCCUUGAGUAAAAAGGU 5533
             :| ::|||:|||||| :
Db         17 TCTTTGAGTAAAAAGCT 1


RESULT 778
US-09-404-912-262
; Sequence 262, Application US/09404912
; Patent No. 6703228
```

```
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 262
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-262

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7000 GUGUGUGUGUGUGGG 7016
              |:|:|:|:|:| | |||
Db          1 GTGTGTGTGTGGGGGG 17


RESULT 779
US-09-404-912-564
; Sequence 564, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 564
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-564

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 6e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|:|:|: :|: :
Db          1 TGTGTGTGTGTCTGTCT 17


RESULT 780
US-09-404-912-608
; Sequence 608, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 608
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-608

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3593 AAGGCAUGAGGAUGAGA 3609
              |||| |:|||||:| ||
Db          1 AAGGGATGAGGATGTGA 17


RESULT 781
US-09-474-432B-558
; Sequence 558, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleo
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 558
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-558

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              ||||||| |||| |||
Db          1 CUUUUUUUGUUUUGUUU 17


RESULT 782
US-09-474-432B-740
; Sequence 740, Application US/09474432B
```

```
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 740
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-740

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4893 CCAGCCAGGAGCAGAUG 4909
              ||| ||||| |||||||
Db          1 CCAACCAGGCGCAGAUG 17


RESULT 783
US-09-474-432B-893/c
; Sequence 893, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 893
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-893

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1722 CCUGGAUGCUGACAGCA 1738
              ||:|||: |:|||| ||
Db         17 CCTGGATACTGACACCA 1


RESULT 784
US-09-476-387-557
; Sequence 557, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 557
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-557

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              ||||||| |||| |||
Db          1 CUUUUUUUGUUUUGUUU 17


RESULT 785
US-09-476-387-739
; Sequence 739, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
```

```
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 739
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-739

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4893 CCAGCCAGGAGCAGAUG 4909
              ||| ||||| |||||||
Db          1 CCAACCAGGCGCAGAUG 17


RESULT 786
US-09-476-387-892/c
; Sequence 892, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 892
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-892

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1722 CCUGGAUGCUGACAGCA 1738
              ||:|||: |:|||| ||
Db         17 CCTGGATACTGACACCA 1


RESULT 787
US-09-479-645A-23/c
; Sequence 23, Application US/09479645A
; Patent No. 6489141
; GENERAL INFORMATION:
;  APPLICANT: FRAZER, Ian Hector
;  APPLICANT:  ZHOU, Jian
;  TITLE OF INVENTION: NUCLEIC ACID SEQUENCE AND METHOD FOR SELECTIVELY
;  TITLE OF INVENTION:  EXPRESSING A PROTEIN IN A TARGET CELL OR TISSUE
;  FILE REFERENCE: 210338.0001/1US
;  CURRENT APPLICATION NUMBER: US/09/479,645A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: PCT/AU98/00530
;  PRIOR FILING DATE: 1998-07-09
;  PRIOR APPLICATION NUMBER: AU PO7765
;  PRIOR FILING DATE: 1997-07-09
;  PRIOR APPLICATION NUMBER: AU PO9467
;  PRIOR FILING DATE: 1997-09-11
;  NUMBER OF SEQ ID NOS: 219
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 23
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide specific for Leu(CTA)
US-09-479-645A-23

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6e+02;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6183 AAAUCCAAACAAAAGCA 6199
              |||:||||| ||||| |
Db         17 AAATCCAAATAAAAGTA 1


RESULT 788
US-09-818-875-811
; Sequence 811, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 811
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-811

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4739 AAAAGGAAAAAAAGCAA 4755
              |||||||| |||| |||
Db          1 AAAAGGAAGAAAATCAA 17


RESULT 789
US-09-818-875-812/c
; Sequence 812, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
```

```
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 812
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-812

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4739 AAAAGGAAAAAAAGCAA 4755
              ||||||||  |||| |||
Db         17 AAAAGGAAGAAAATCAA 1


RESULT 790
US-09-827-998-384
; Sequence 384, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 384
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-384

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6e+02;
  Matches    8;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |:|:|:|: :|:| |:|
Db          1 GTGTGTGTTTGTGAGTG 17


RESULT 791
US-09-827-998-385
; Sequence 385, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 385
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-385

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 6e+02;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|:|: :|:| |:|:
Db          1 TGTGTGTTTGTGAGTGT 17


RESULT 792
US-09-827-998-386
; Sequence 386, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 386
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-386

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6e+02;
  Matches    8;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
              |:|:|: :|:| |:|:|
Db          1 GTGTGTTTGTGAGTGTG 17


RESULT 793
US-09-827-998-387
; Sequence 387, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
```

```
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 387
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-387

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 6e+02;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGU 6989
              :|:|: :|:| |:|:|:
Db          1 TGTGTTTGTGAGTGTGT 17


RESULT 794
US-09-827-998-482/c
; Sequence 482, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 482
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-482

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   11.8%;  Pred. No. 6e+02;
  Matches    2;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              : ::: :::::::::||
Db         17 TCTTTCTTTTTTTTCC 1


RESULT 795
US-09-827-998-483/c
; Sequence 483, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 483
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-483

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 6e+02;
  Matches    1;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :: ::: :::::::::|
Db         17 TTCTTTCTTTTTTTTC 1


RESULT 796
US-09-866-108A-10743/c
; Sequence 10743, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10743
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10743

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6e+02;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        541 CAAGCAAACCACACUGG 557
              || || ||||||||:||
Db         17 CAGGCCAACCACACTGG 1


RESULT 797
US-09-866-108A-10744/c
; Sequence 10744, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
```

```
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10744
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10744

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        540 UCAAGCAAACCACACUG 556
              :|| || ||||||||:|
Db         17 TCAGGCCAACCACACTG 1


RESULT 798
US-09-866-108A-1344
; Sequence 1344, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1344
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1344

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3069 UAAGAAAGAAAAAAUGG 3085
              :||||| ||||| |:||
Db          1 TAAGAAGGAAAAGATGG 17


RESULT 799
US-09-866-108A-433/c
; Sequence 433, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 433
;   LENGTH: 17
;   TYPE: DNA
```

```
;   ORGANISM: Homo sapiens
US-09-866-108A-433

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1380 UGAGAAAUCUGCUCGCU 1396
              :|||| |:|:||: ||:
Db         17 TGAGAGATCTGCTGGCT 1


RESULT 800
US-09-866-108A-434/c
; Sequence 434, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 434
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-434

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1379 CUGAGAAAUCUGCUCGC 1395
              |:|||| |:|:||: ||
Db         17 CTGAGAGATCTGCTGGC 1


RESULT 801
US-09-866-108A-6286
; Sequence 6286, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6286
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6286

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2811 GUGCCGGACUGUGGCUG 2827
              |:||||| |:|:||| |
Db          1 GTGCCGGGCTGTGGCAG 17


RESULT 802
US-09-866-108A-639/c
; Sequence 639, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 639
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-639

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2898 CCACAUUGGCCACCAUC 2914
              |||  ::||||||||:|
Db         17 CCAGCTTGGCCACCATC 1


RESULT 803
US-09-866-108A-7298
; Sequence 7298, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7298
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7298

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3010 CUCAAGAGCAAACGUGA 3026
              |:|||||||||  | :||
Db          1 CTCAAGAGCAAGCATGA 17


RESULT 804
US-09-866-108A-7545
; Sequence 7545, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7545
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7545

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 6e+02;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6623 AGUUACAAAGUGCUUGU 6639
              ||:: ||||| :||:: :
Db          1 AGTTGCAAAGTGCTTAT 17


RESULT 805
US-09-866-108A-8809/c
; Sequence 8809, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

```
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8809
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8809

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6e+02;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       5883 UCUGCACCUUCUGCAGC 5899
              :|:|||||::|:| | |
Db         17 TCTGCACCTTCTGGAAC 1


RESULT 806
US-10-106-831-36/c
; Sequence 36, Application US/10106831
; Patent No. 6943012
; GENERAL INFORMATION:
;  APPLICANT: Ehrhardt, Anja
;  APPLICANT:  Kay, Mark
;  TITLE OF INVENTION: Helper Dependent Adenoviral Vector
;  TITLE OF INVENTION:  System and Methods for Using the Same
;  FILE REFERENCE: STAN-215
;  CURRENT APPLICATION NUMBER: US/10/106,831
;  CURRENT FILING DATE:  2002-09-04
;  PRIOR APPLICATION NUMBER: 60/278,972
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: 60/284,335
;  PRIOR FILING DATE: 2001-04-16
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-106-831-36

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 6e+02;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6669 UGAAUUAACUGAUAAUA 6685
              :|||::|| :||:| :|
Db         17 TGAATTAATTGATATTA 1


RESULT 807
US-10-156-306B-1646
; Sequence 1646, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1646
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-1646

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |||| || |||||||||
Db          1 CUUUAUUCUUUUUUUUU 17


RESULT 808
US-10-156-306B-4373/c
; Sequence 4373, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306B
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8014
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4373
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306B-4373

  Query Match             0.2%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6e+02;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4009 AUGCUGAAGCGCUUCAC 4025
              |:||:| || ||::|||
Db         17 ATGCTGGAGAGCTTCAC 1


RESULT 809
US-10-156-306B-519
; Sequence 519, Application US/10156306B
```

; Patent No. 7022828
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306B
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8014
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306B-519

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 6341 UCUACUUUUUUUUUUUU 6357
| | ||||||||||||||
Db 1 UAUUCUUUUUUUUUUUU 17

Search completed: August 31, 2006, 14:47:04
Job time : 39 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 14:52:42 ; Search time 390 Seconds
(without alignments)
7.110 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 10263 seqs, 180519 residues

Total number of hits satisfying chosen parameters: 20526

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Genbank / EMBL

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : gedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	40	0.5	40	1	A69996	ACCESSION:A69996
c	2	40	0.5	40	1	I31207	ACCESSION:I31207
c	3	40	0.5	40	1	I31488	ACCESSION:I31488
c	4	40	0.5	40	1	I31491	ACCESSION:I31491
c	5	39	0.5	39	1	I31225	ACCESSION:I31225
c	6	38.4	0.5	40	1	I31240	ACCESSION:I31240
c	7	38.4	0.5	40	1	I31263	ACCESSION:I31263
c	8	38	0.5	38	1	A69994	ACCESSION:A69994
c	9	38	0.5	38	1	A69995	ACCESSION:A69995
c	10	38	0.5	38	1	BD251663	ACCESSION:BD251663
c	11	38	0.5	38	1	I31286	ACCESSION:I31286
c	12	38	0.5	38	1	I31485	ACCESSION:I31485
c	13	38	0.5	38	1	AX028364	ACCESSION:AX028364
c	14	37.4	0.5	39	1	I31174	ACCESSION:I31174
c	15	37	0.5	37	1	I31228	ACCESSION:I31228
c	16	36.8	0.5	40	1	AR699916	ACCESSION:AR699916
	17	36.4	0.5	38	1	AR073769	ACCESSION:AR073769
c	18	36.4	0.5	38	1	I31156	ACCESSION:I31156
	19	36.4	0.5	38	1	AR208265	ACCESSION:AR208265
	20	36.4	0.5	38	1	AR658762	ACCESSION:AR658762
c	21	36	0.5	36	1	I31192	ACCESSION:I31192
c	22	36	0.5	36	1	I31446	ACCESSION:I31446
c	23	35	0.5	35	1	I31165	ACCESSION:I31165
c	24	35	0.5	35	1	I31277	ACCESSION:I31277
c	25	34.8	0.5	38	1	E32209	ACCESSION:E32209
c	26	34	0.4	34	1	I31198	ACCESSION:I31198
c	27	34	0.4	34	1	I31260	ACCESSION:I31260
c	28	34	0.4	34	1	I31268	ACCESSION:I31268
c	29	34	0.4	34	1	I31280	ACCESSION:I31280
c	30	34	0.4	34	1	I31410	ACCESSION:I31410
	31	33.4	0.4	36	1	AR073763	ACCESSION:AR073763
	32	33.4	0.4	36	1	AR208259	ACCESSION:AR208259
	33	33.4	0.4	36	1	AR658756	ACCESSION:AR658756
c	34	33	0.4	33	1	I31147	ACCESSION:I31147
c	35	33	0.4	33	1	I31306	ACCESSION:I31306
c	36	32	0.4	32	1	E32203	ACCESSION:E32203
c	37	32	0.4	32	1	I31298	ACCESSION:I31298
c	38	32	0.4	32	1	I31464	ACCESSION:I31464
c	39	32	0.4	32	1	AR649365	ACCESSION:AR649365
c	40	32	0.4	32	1	AR699910	ACCESSION:AR699910
	41	32	0.4	40	1	MMVIMV26	ACCESSION:X89143
	42	31.4	0.4	33	1	AR073771	ACCESSION:AR073771
	43	31.4	0.4	33	1	AR073775	ACCESSION:AR073775
	44	31.4	0.4	33	1	AR208267	ACCESSION:AR208267
	45	31.4	0.4	33	1	AR208271	ACCESSION:AR208271
	46	31.4	0.4	33	1	AR658764	ACCESSION:AR658764
	47	31.4	0.4	33	1	AR658768	ACCESSION:AR658768
c	48	31	0.4	31	1	I31303	ACCESSION:I31303
c	49	31	0.4	31	1	I31323	ACCESSION:I31323
c	50	31	0.4	31	1	I31359	ACCESSION:I31359
	51	30.8	0.4	34	1	BD079200	ACCESSION:BD079200
	52	30.6	0.4	31	1	BD079191	ACCESSION:BD079191
	53	30.6	0.4	31	1	BD079192	ACCESSION:BD079192
	54	30.6	0.4	31	1	BD079193	ACCESSION:BD079193
	55	30.6	0.4	37	1	AR073767	ACCESSION:AR073767
	56	30.6	0.4	37	1	AR208263	ACCESSION:AR208263
	57	30.6	0.4	37	1	AR658760	ACCESSION:AR658760
c	58	30.4	0.4	32	1	I31494	ACCESSION:I31494
	59	30	0.4	30	1	BD107614	ACCESSION:BD107614
c	60	30	0.4	30	1	I31461	ACCESSION:I31461
c	61	29	0.4	29	1	AR051257	ACCESSION:AR051257
c	62	29	0.4	29	1	AR090290	ACCESSION:AR090290
c	63	29	0.4	29	1	I28386	ACCESSION:I28386
c	64	29	0.4	29	1	I31168	ACCESSION:I31168
c	65	29	0.4	29	1	I31326	ACCESSION:I31326
c	66	29	0.4	29	1	AR197325	ACCESSION:AR197325
c	67	29	0.4	29	1	AR259479	ACCESSION:AR259479
c	68	28	0.4	28	1	BD079201	ACCESSION:BD079201
c	69	28	0.4	28	1	I31539	ACCESSION:I31539
	70	28	0.4	31	1	BD079196	ACCESSION:BD079196
	71	27.6	0.4	34	1	A45639	ACCESSION:A45639
	72	27.6	0.4	34	1	AR033092	ACCESSION:AR033092
	73	27.6	0.4	34	1	AR073764	ACCESSION:AR073764
	74	27.6	0.4	34	1	AR208260	ACCESSION:AR208260
	75	27.6	0.4	34	1	AR658757	ACCESSION:AR658757
c	76	27.4	0.4	30	1	E32218	ACCESSION:E32218
c	77	27.4	0.4	30	1	AR699925	ACCESSION:AR699925
c	78	27.2	0.4	32	1	MME543971	ACCESSION:AJ543971
c	79	27	0.4	27	1	AR051255	ACCESSION:AR051255
	80	27	0.4	27	1	AR090289	ACCESSION:AR090289
c	81	27	0.4	27	1	AR127802	ACCESSION:AR127802
c	82	27	0.4	27	1	I28384	ACCESSION:I28384
c	83	27	0.4	27	1	I31231	ACCESSION:I31231
	84	27	0.4	27	1	AR197324	ACCESSION:AR197324
	85	27	0.4	27	1	AR259478	ACCESSION:AR259478
	86	27	0.4	27	1	AX175237	ACCESSION:AX175237
	87	27	0.4	27	1	AX175241	ACCESSION:AX175241
	88	27	0.4	27	1	AX175302	ACCESSION:AX175302
	89	27	0.4	27	1	AX189457	ACCESSION:AX189457
	90	26.8	0.3	30	1	AR073773	ACCESSION:AR073773
c	91	26.8	0.3	30	1	I31503	ACCESSION:I31503
	92	26.8	0.3	30	1	AR208269	ACCESSION:AR208269
	93	26.8	0.3	30	1	AR658766	ACCESSION:AR658766
	94	26.2	0.3	31	1	AR073770	ACCESSION:AR073770
	95	26.2	0.3	31	1	AR208266	ACCESSION:AR208266
	96	26.2	0.3	31	1	AR658763	ACCESSION:AR658763
c	97	26.2	0.3	32	1	E32225	ACCESSION:E32225
c	98	26.2	0.3	32	1	AR699932	ACCESSION:AR699932
c	99	26	0.3	26	1	AR489882	ACCESSION:AR489882
	100	26	0.3	26	1	AR489883	ACCESSION:AR489883
c	101	25	0.3	25	1	AR073777	ACCESSION:AR073777
	102	25	0.3	25	1	AR073778	ACCESSION:AR073778
c	103	25	0.3	25	1	I31234	ACCESSION:I31234
c	104	25	0.3	25	1	AR208273	ACCESSION:AR208273
	105	25	0.3	25	1	AR208274	ACCESSION:AR208274
c	106	25	0.3	25	1	AR658770	ACCESSION:AR658770

	107	25	0.3	25	1	AR658771	ACCESSION:AR658771
	108	25	0.3	25	1	AX115976	ACCESSION:AX115976
	109	25	0.3	25	1	AX739949	ACCESSION:AX739949
	110	25	0.3	25	1	AX739951	ACCESSION:AX739951
c	111	25	0.3	25	1	AX739952	ACCESSION:AX739952
	112	25	0.3	31	1	BD079197	ACCESSION:BD079197
	113	24.2	0.3	30	1	AX060548	ACCESSION:AX060548
	114	24	0.3	24	1	CQ979110	ACCESSION:CQ979110
c	115	24	0.3	24	1	CS082792	ACCESSION:CS082792
c	116	24	0.3	24	1	CS144192	ACCESSION:CS144192
c	117	24	0.3	24	1	I31533	ACCESSION:I31533
	118	24	0.3	24	1	AX104876	ACCESSION:AX104876
	119	24	0.3	24	1	AX175257	ACCESSION:AX175257
	120	24	0.3	24	1	AX175258	ACCESSION:AX175258
c	121	24	0.3	24	1	AX203709	ACCESSION:AX203709
	122	24	0.3	24	1	AX547929	ACCESSION:AX547929
c	123	24	0.3	25	1	AX117836	ACCESSION:AX117836
c	124	23.4	0.3	25	1	AX117828	ACCESSION:AX117828
c	125	23.4	0.3	25	1	AX117832	ACCESSION:AX117832
	126	23	0.3	23	1	AR030846	ACCESSION:AR030846
c	127	23	0.3	23	1	AR127801	ACCESSION:AR127801
	128	23	0.3	23	1	CS144190	ACCESSION:CS144190
	129	23	0.3	23	1	CS144191	ACCESSION:CS144191
	130	23	0.3	23	1	DD203516	ACCESSION:DD203516
	131	23	0.3	23	1	DD203517	ACCESSION:DD203517
	132	23	0.3	23	1	DD203518	ACCESSION:DD203518
	133	23	0.3	23	1	DD203519	ACCESSION:DD203519
	134	23	0.3	23	1	DD203528	ACCESSION:DD203528
	135	23	0.3	23	1	DD203529	ACCESSION:DD203529
	136	23	0.3	23	1	DD203530	ACCESSION:DD203530
	137	23	0.3	23	1	DD203531	ACCESSION:DD203531
	138	23	0.3	23	1	DD203532	ACCESSION:DD203532
	139	23	0.3	23	1	DD203533	ACCESSION:DD203533
	140	23	0.3	23	1	DD203534	ACCESSION:DD203534
	141	23	0.3	23	1	DD203535	ACCESSION:DD203535
	142	23	0.3	23	1	DD207267	ACCESSION:DD207267
	143	23	0.3	23	1	DD207268	ACCESSION:DD207268
	144	23	0.3	23	1	DD207269	ACCESSION:DD207269
	145	23	0.3	23	1	DD207270	ACCESSION:DD207270
	146	23	0.3	23	1	DD207271	ACCESSION:DD207271
	147	23	0.3	23	1	DD207272	ACCESSION:DD207272
	148	23	0.3	23	1	DD207273	ACCESSION:DD207273
	149	23	0.3	23	1	DD207274	ACCESSION:DD207274
c	150	23	0.3	23	1	I31542	ACCESSION:I31542
	151	23	0.3	23	1	I82805	ACCESSION:I82805
	152	23	0.3	23	1	AX203707	ACCESSION:AX203707
	153	23	0.3	23	1	AX203708	ACCESSION:AX203708
c	154	23	0.3	23	1	AX739950	ACCESSION:AX739950
c	155	22.2	0.3	27	1	AR002279	ACCESSION:AR002279
c	156	22.2	0.3	27	1	AR053130	ACCESSION:AR053130
	157	22.2	0.3	27	1	AR073768	ACCESSION:AR073768
	158	22.2	0.3	27	1	AR208264	ACCESSION:AR208264
	159	22.2	0.3	27	1	AR658761	ACCESSION:AR658761
	160	22	0.3	22	1	BD235062	ACCESSION:BD235062
	161	22	0.3	22	1	CS237350	ACCESSION:CS237350
c	162	22	0.3	22	1	CS237361	ACCESSION:CS237361
c	163	22	0.3	22	1	I31213	ACCESSION:I31213
	164	22	0.3	22	1	AR349812	ACCESSION:AR349812
c	165	22	0.3	22	1	AR349813	ACCESSION:AR349813
	166	22	0.3	22	1	AX009133	ACCESSION:AX009133
c	167	22	0.3	23	1	AR448724	ACCESSION:AR448724
c	168	22	0.3	25	1	AR448726	ACCESSION:AR448726
c	169	22	0.3	27	1	CS155980	ACCESSION:CS155980
	170	22	0.3	27	1	CS156035	ACCESSION:CS156035
	171	21.8	0.3	25	1	AR073762	ACCESSION:AR073762
	172	21.8	0.3	25	1	CS231251	ACCESSION:CS231251
	173	21.8	0.3	25	1	AR208258	ACCESSION:AR208258
	174	21.8	0.3	25	1	AR658755	ACCESSION:AR658755
c	175	21.4	0.3	23	1	CS144193	ACCESSION:CS144193
c	176	21.4	0.3	23	1	AX203710	ACCESSION:AX203710
c	177	21.4	0.3	24	1	AR163542	ACCESSION:AR163542
c	178	21.4	0.3	24	1	E13258	ACCESSION:E13258
c	179	21.4	0.3	24	1	E14002	ACCESSION:E14002
c	180	21.4	0.3	24	1	AX116747	ACCESSION:AX116747
	181	21	0.3	21	1	AR163541	ACCESSION:AR163541
	182	21	0.3	21	1	CS082791	ACCESSION:CS082791
c	183	21	0.3	21	1	CS237372	ACCESSION:CS237372
	184	21	0.3	21	1	DD203627	ACCESSION:DD203627
c	185	21	0.3	21	1	DD203628	ACCESSION:DD203628
	186	21	0.3	21	1	DD207617	ACCESSION:DD207617
c	187	21	0.3	21	1	DD207618	ACCESSION:DD207618
	188	21	0.3	21	1	E13257	ACCESSION:E13257
	189	21	0.3	21	1	E14001	ACCESSION:E14001
c	190	21	0.3	21	1	I31248	ACCESSION:I31248
	191	21	0.3	21	1	AX104715	ACCESSION:AX104715
	192	21	0.3	21	1	AX175255	ACCESSION:AX175255
	193	21	0.3	21	1	AX175256	ACCESSION:AX175256
	194	21	0.3	21	1	AX547768	ACCESSION:AX547768
c	195	21	0.3	26	1	CS155979	ACCESSION:CS155979
	196	21	0.3	26	1	CS156034	ACCESSION:CS156034
	197	20.8	0.3	24	1	AX117030	ACCESSION:AX117030
	198	20.4	0.3	22	1	BD016498	ACCESSION:BD016498
	199	20.4	0.3	23	1	AX926722	ACCESSION:AX926722
	200	20.4	0.3	23	1	AX116678	ACCESSION:AX116678
	201	20	0.3	20	1	A47340	ACCESSION:A47340
c	202	20	0.3	20	1	A47343	ACCESSION:A47343
	203	20	0.3	20	1	A63570	ACCESSION:A63570
	204	20	0.3	20	1	AR030838	ACCESSION:AR030838
	205	20	0.3	20	1	AR031056	ACCESSION:AR031056
c	206	20	0.3	20	1	AR031057	ACCESSION:AR031057
c	207	20	0.3	20	1	AR084543	ACCESSION:AR084543
c	208	20	0.3	20	1	AR123339	ACCESSION:AR123339
c	209	20	0.3	20	1	AR129684	ACCESSION:AR129684
	210	20	0.3	20	1	AX958323	ACCESSION:AX958323
	211	20	0.3	20	1	BD016468	ACCESSION:BD016468
	212	20	0.3	20	1	BD097545	ACCESSION:BD097545
c	213	20	0.3	20	1	BD105781	ACCESSION:BD105781
	214	20	0.3	20	1	CQ896116	ACCESSION:CQ896116
c	215	20	0.3	20	1	CQ896117	ACCESSION:CQ896117
	216	20	0.3	20	1	CQ979108	ACCESSION:CQ979108
c	217	20	0.3	20	1	CQ979109	ACCESSION:CQ979109
	218	20	0.3	20	1	CS037974	ACCESSION:CS037974
c	219	20	0.3	20	1	CS037975	ACCESSION:CS037975
	220	20	0.3	20	1	CS037976	ACCESSION:CS037976
	221	20	0.3	20	1	CS053040	ACCESSION:CS053040
c	222	20	0.3	20	1	CS053041	ACCESSION:CS053041
	223	20	0.3	20	1	CS053043	ACCESSION:CS053043
c	224	20	0.3	20	1	CS130466	ACCESSION:CS130466
	225	20	0.3	20	1	E14009	ACCESSION:E14009
	226	20	0.3	20	1	I82797	ACCESSION:I82797
c	227	20	0.3	20	1	AR489899	ACCESSION:AR489899
c	228	20	0.3	20	1	AR489900	ACCESSION:AR489900
c	229	20	0.3	20	1	AR489901	ACCESSION:AR489901
c	230	20	0.3	20	1	AR489902	ACCESSION:AR489902
c	231	20	0.3	20	1	AR489903	ACCESSION:AR489903
c	232	20	0.3	20	1	AR489904	ACCESSION:AR489904
c	233	20	0.3	20	1	AR489905	ACCESSION:AR489905
c	234	20	0.3	20	1	AR489906	ACCESSION:AR489906
c	235	20	0.3	20	1	AR489907	ACCESSION:AR489907
c	236	20	0.3	20	1	AR489908	ACCESSION:AR489908
c	237	20	0.3	20	1	AR489909	ACCESSION:AR489909
c	238	20	0.3	20	1	AR489910	ACCESSION:AR489910
c	239	20	0.3	20	1	AR489911	ACCESSION:AR489911
c	240	20	0.3	20	1	AR489912	ACCESSION:AR489912
c	241	20	0.3	20	1	AR489913	ACCESSION:AR489913
c	242	20	0.3	20	1	AR489914	ACCESSION:AR489914
c	243	20	0.3	20	1	AR489915	ACCESSION:AR489915
c	244	20	0.3	20	1	AR489916	ACCESSION:AR489916
c	245	20	0.3	20	1	AR489917	ACCESSION:AR489917
c	246	20	0.3	20	1	AR489918	ACCESSION:AR489918
c	247	20	0.3	20	1	AR489919	ACCESSION:AR489919
c	248	20	0.3	20	1	AR489920	ACCESSION:AR489920
c	249	20	0.3	20	1	AR489921	ACCESSION:AR489921
c	250	20	0.3	20	1	AR489922	ACCESSION:AR489922
c	251	20	0.3	20	1	AR489923	ACCESSION:AR489923
c	252	20	0.3	20	1	AR489924	ACCESSION:AR489924

c 253	20	0.3	20	1	AR489925	ACCESSION:AR489925
c 254	20	0.3	20	1	AR489926	ACCESSION:AR489926
c 255	20	0.3	20	1	AR489927	ACCESSION:AR489927
c 256	20	0.3	20	1	AR489928	ACCESSION:AR489928
c 257	20	0.3	20	1	AR489929	ACCESSION:AR489929
c 258	20	0.3	20	1	AR489930	ACCESSION:AR489930
c 259	20	0.3	20	1	AR489931	ACCESSION:AR489931
c 260	20	0.3	20	1	AR489932	ACCESSION:AR489932
c 261	20	0.3	20	1	AR489933	ACCESSION:AR489933
c 262	20	0.3	20	1	AR489934	ACCESSION:AR489934
c 263	20	0.3	20	1	AR489935	ACCESSION:AR489935
c 264	20	0.3	20	1	AR489936	ACCESSION:AR489936
c 265	20	0.3	20	1	AR489937	ACCESSION:AR489937
c 266	20	0.3	20	1	AR489938	ACCESSION:AR489938
c 267	20	0.3	20	1	AR489939	ACCESSION:AR489939
c 268	20	0.3	20	1	AR489940	ACCESSION:AR489940
c 269	20	0.3	20	1	AR489941	ACCESSION:AR489941
c 270	20	0.3	20	1	AR489942	ACCESSION:AR489942
c 271	20	0.3	20	1	AR489943	ACCESSION:AR489943
c 272	20	0.3	20	1	AR489944	ACCESSION:AR489944
c 273	20	0.3	20	1	AR489945	ACCESSION:AR489945
c 274	20	0.3	20	1	AR489946	ACCESSION:AR489946
c 275	20	0.3	20	1	AR489947	ACCESSION:AR489947
c 276	20	0.3	20	1	AR489948	ACCESSION:AR489948
c 277	20	0.3	20	1	AR489949	ACCESSION:AR489949
c 278	20	0.3	20	1	AR489950	ACCESSION:AR489950
c 279	20	0.3	20	1	AR489951	ACCESSION:AR489951
c 280	20	0.3	20	1	AR489952	ACCESSION:AR489952
c 281	20	0.3	20	1	AR489953	ACCESSION:AR489953
c 282	20	0.3	20	1	AR489954	ACCESSION:AR489954
c 283	20	0.3	20	1	AR489955	ACCESSION:AR489955
c 284	20	0.3	20	1	AR489956	ACCESSION:AR489956
c 285	20	0.3	20	1	AR489957	ACCESSION:AR489957
c 286	20	0.3	20	1	AR489958	ACCESSION:AR489958
c 287	20	0.3	20	1	AR489959	ACCESSION:AR489959
c 288	20	0.3	20	1	AR489960	ACCESSION:AR489960
c 289	20	0.3	20	1	AR489961	ACCESSION:AR489961
c 290	20	0.3	20	1	AR489962	ACCESSION:AR489962
c 291	20	0.3	20	1	AR489963	ACCESSION:AR489963
c 292	20	0.3	20	1	AR489964	ACCESSION:AR489964
c 293	20	0.3	20	1	AR489965	ACCESSION:AR489965
294	20	0.3	20	1	AX179298	ACCESSION:AX179298
c 295	20	0.3	20	1	AX179299	ACCESSION:AX179299
296	20	0.3	20	1	AX204798	ACCESSION:AX204798
c 297	20	0.3	20	1	AX204799	ACCESSION:AX204799
298	20	0.3	20	1	AX204800	ACCESSION:AX204800
c 299	20	0.3	20	1	AX204801	ACCESSION:AX204801
300	20	0.3	20	1	AX204806	ACCESSION:AX204806
301	20	0.3	21	1	CS069604	ACCESSION:CS069604
c 302	20	0.3	21	1	DD207636	ACCESSION:DD207636
c 303	20	0.3	21	1	DD207638	ACCESSION:DD207638
c 304	20	0.3	21	1	AR372055	ACCESSION:AR372055
c 305	20	0.3	21	1	AR372059	ACCESSION:AR372059
c 306	20	0.3	21	1	AX398276	ACCESSION:AX398276
307	20	0.3	21	1	AX398277	ACCESSION:AX398277
c 308	20	0.3	23	1	AX496104	ACCESSION:AX496104
c 309	20	0.3	25	1	CS155978	ACCESSION:CS155978
310	20	0.3	25	1	CS156033	ACCESSION:CS156033
c 311	19.4	0.3	21	1	AX958324	ACCESSION:AX958324
312	19.4	0.3	21	1	CS069602	ACCESSION:CS069602
c 313	19.4	0.3	21	1	I30547	ACCESSION:I30547
c 314	19.2	0.3	21	1	DD207639	ACCESSION:DD207639
315	19	0.2	19	1	CS049488	ACCESSION:CS049488
c 316	19	0.2	19	1	CS049498	ACCESSION:CS049498
317	19	0.2	19	1	CS049589	ACCESSION:CS049589
c 318	19	0.2	19	1	CS049590	ACCESSION:CS049590
319	19	0.2	19	1	CS049591	ACCESSION:CS049591
c 320	19	0.2	19	1	CS049592	ACCESSION:CS049592
c 321	19	0.2	19	1	CS050022	ACCESSION:CS050022
322	19	0.2	19	1	CS050023	ACCESSION:CS050023
c 323	19	0.2	19	1	CS155812	ACCESSION:CS155812
324	19	0.2	19	1	CS155813	ACCESSION:CS155813
325	19	0.2	19	1	CS155818	ACCESSION:CS155818
326	19	0.2	19	1	CS155819	ACCESSION:CS155819
327	19	0.2	19	1	CS155820	ACCESSION:CS155820
328	19	0.2	19	1	CS155821	ACCESSION:CS155821
329	19	0.2	19	1	CS155822	ACCESSION:CS155822
330	19	0.2	19	1	CS155823	ACCESSION:CS155823
331	19	0.2	19	1	CS155837	ACCESSION:CS155837
c 332	19	0.2	19	1	CS155875	ACCESSION:CS155875
c 333	19	0.2	19	1	CS155876	ACCESSION:CS155876
c 334	19	0.2	19	1	CS155877	ACCESSION:CS155877
c 335	19	0.2	19	1	CS155878	ACCESSION:CS155878
c 336	19	0.2	19	1	CS155879	ACCESSION:CS155879
c 337	19	0.2	19	1	CS155880	ACCESSION:CS155880
c 338	19	0.2	19	1	CS155881	ACCESSION:CS155881
c 339	19	0.2	19	1	CS155895	ACCESSION:CS155895
340	19	0.2	19	1	CS155943	ACCESSION:CS155943
341	19	0.2	19	1	CS155944	ACCESSION:CS155944
342	19	0.2	19	1	CS155945	ACCESSION:CS155945
343	19	0.2	19	1	CS155946	ACCESSION:CS155946
c 344	19	0.2	19	1	CS155964	ACCESSION:CS155964
c 345	19	0.2	19	1	CS155965	ACCESSION:CS155965
c 346	19	0.2	19	1	CS155966	ACCESSION:CS155966
c 347	19	0.2	19	1	CS155967	ACCESSION:CS155967
348	19	0.2	19	1	CS156079	ACCESSION:CS156079
349	19	0.2	19	1	DD201520	ACCESSION:DD201520
350	19	0.2	19	1	DD201521	ACCESSION:DD201521
351	19	0.2	19	1	DD201522	ACCESSION:DD201522
352	19	0.2	19	1	DD201523	ACCESSION:DD201523
353	19	0.2	19	1	DD201524	ACCESSION:DD201524
354	19	0.2	19	1	DD201525	ACCESSION:DD201525
355	19	0.2	19	1	DD201526	ACCESSION:DD201526
356	19	0.2	19	1	DD201527	ACCESSION:DD201527
357	19	0.2	19	1	DD201528	ACCESSION:DD201528
358	19	0.2	19	1	DD201529	ACCESSION:DD201529
359	19	0.2	19	1	DD201530	ACCESSION:DD201530
360	19	0.2	19	1	DD201531	ACCESSION:DD201531
361	19	0.2	19	1	DD201532	ACCESSION:DD201532
362	19	0.2	19	1	DD201533	ACCESSION:DD201533
363	19	0.2	19	1	DD201534	ACCESSION:DD201534
364	19	0.2	19	1	DD201535	ACCESSION:DD201535
365	19	0.2	19	1	DD201536	ACCESSION:DD201536
366	19	0.2	19	1	DD201537	ACCESSION:DD201537
367	19	0.2	19	1	DD201538	ACCESSION:DD201538
368	19	0.2	19	1	DD201539	ACCESSION:DD201539
369	19	0.2	19	1	DD201540	ACCESSION:DD201540
370	19	0.2	19	1	DD201541	ACCESSION:DD201541
371	19	0.2	19	1	DD201542	ACCESSION:DD201542
372	19	0.2	19	1	DD201543	ACCESSION:DD201543
373	19	0.2	19	1	DD201544	ACCESSION:DD201544
374	19	0.2	19	1	DD201545	ACCESSION:DD201545
375	19	0.2	19	1	DD201546	ACCESSION:DD201546
376	19	0.2	19	1	DD201547	ACCESSION:DD201547
377	19	0.2	19	1	DD201548	ACCESSION:DD201548
378	19	0.2	19	1	DD201549	ACCESSION:DD201549
379	19	0.2	19	1	DD201550	ACCESSION:DD201550
380	19	0.2	19	1	DD201551	ACCESSION:DD201551
381	19	0.2	19	1	DD201552	ACCESSION:DD201552
382	19	0.2	19	1	DD201553	ACCESSION:DD201553
383	19	0.2	19	1	DD201554	ACCESSION:DD201554
384	19	0.2	19	1	DD201555	ACCESSION:DD201555
385	19	0.2	19	1	DD201556	ACCESSION:DD201556
386	19	0.2	19	1	DD201557	ACCESSION:DD201557
387	19	0.2	19	1	DD201558	ACCESSION:DD201558
388	19	0.2	19	1	DD201559	ACCESSION:DD201559
389	19	0.2	19	1	DD201560	ACCESSION:DD201560
390	19	0.2	19	1	DD201561	ACCESSION:DD201561
391	19	0.2	19	1	DD201562	ACCESSION:DD201562
392	19	0.2	19	1	DD201563	ACCESSION:DD201563
393	19	0.2	19	1	DD201564	ACCESSION:DD201564
394	19	0.2	19	1	DD201565	ACCESSION:DD201565
395	19	0.2	19	1	DD201566	ACCESSION:DD201566
396	19	0.2	19	1	DD201567	ACCESSION:DD201567
397	19	0.2	19	1	DD201568	ACCESSION:DD201568
398	19	0.2	19	1	DD201569	ACCESSION:DD201569

399	19	0.2	19	1	DD201570	ACCESSION:DD201570
400	19	0.2	19	1	DD201571	ACCESSION:DD201571
401	19	0.2	19	1	DD201572	ACCESSION:DD201572
402	19	0.2	19	1	DD201573	ACCESSION:DD201573
403	19	0.2	19	1	DD201574	ACCESSION:DD201574
404	19	0.2	19	1	DD201575	ACCESSION:DD201575
405	19	0.2	19	1	DD201576	ACCESSION:DD201576
406	19	0.2	19	1	DD201577	ACCESSION:DD201577
407	19	0.2	19	1	DD201578	ACCESSION:DD201578
408	19	0.2	19	1	DD201579	ACCESSION:DD201579
409	19	0.2	19	1	DD201580	ACCESSION:DD201580
410	19	0.2	19	1	DD201581	ACCESSION:DD201581
411	19	0.2	19	1	DD201582	ACCESSION:DD201582
412	19	0.2	19	1	DD201583	ACCESSION:DD201583
413	19	0.2	19	1	DD201584	ACCESSION:DD201584
414	19	0.2	19	1	DD201585	ACCESSION:DD201585
415	19	0.2	19	1	DD201586	ACCESSION:DD201586
416	19	0.2	19	1	DD201587	ACCESSION:DD201587
417	19	0.2	19	1	DD201588	ACCESSION:DD201588
418	19	0.2	19	1	DD201589	ACCESSION:DD201589
419	19	0.2	19	1	DD201590	ACCESSION:DD201590
420	19	0.2	19	1	DD201591	ACCESSION:DD201591
421	19	0.2	19	1	DD201592	ACCESSION:DD201592
422	19	0.2	19	1	DD201593	ACCESSION:DD201593
423	19	0.2	19	1	DD201594	ACCESSION:DD201594
424	19	0.2	19	1	DD201595	ACCESSION:DD201595
425	19	0.2	19	1	DD201596	ACCESSION:DD201596
426	19	0.2	19	1	DD201597	ACCESSION:DD201597
427	19	0.2	19	1	DD201598	ACCESSION:DD201598
428	19	0.2	19	1	DD201599	ACCESSION:DD201599
429	19	0.2	19	1	DD201600	ACCESSION:DD201600
430	19	0.2	19	1	DD201601	ACCESSION:DD201601
431	19	0.2	19	1	DD201602	ACCESSION:DD201602
432	19	0.2	19	1	DD201603	ACCESSION:DD201603
433	19	0.2	19	1	DD201604	ACCESSION:DD201604
434	19	0.2	19	1	DD201605	ACCESSION:DD201605
435	19	0.2	19	1	DD201606	ACCESSION:DD201606
436	19	0.2	19	1	DD201607	ACCESSION:DD201607
437	19	0.2	19	1	DD201608	ACCESSION:DD201608
438	19	0.2	19	1	DD201609	ACCESSION:DD201609
439	19	0.2	19	1	DD201610	ACCESSION:DD201610
440	19	0.2	19	1	DD201611	ACCESSION:DD201611
441	19	0.2	19	1	DD201612	ACCESSION:DD201612
442	19	0.2	19	1	DD201613	ACCESSION:DD201613
443	19	0.2	19	1	DD201614	ACCESSION:DD201614
444	19	0.2	19	1	DD201615	ACCESSION:DD201615
445	19	0.2	19	1	DD201616	ACCESSION:DD201616
446	19	0.2	19	1	DD201617	ACCESSION:DD201617
447	19	0.2	19	1	DD201618	ACCESSION:DD201618
448	19	0.2	19	1	DD201619	ACCESSION:DD201619
449	19	0.2	19	1	DD201620	ACCESSION:DD201620
450	19	0.2	19	1	DD201621	ACCESSION:DD201621
451	19	0.2	19	1	DD201622	ACCESSION:DD201622
452	19	0.2	19	1	DD201623	ACCESSION:DD201623
453	19	0.2	19	1	DD201624	ACCESSION:DD201624
454	19	0.2	19	1	DD201625	ACCESSION:DD201625
455	19	0.2	19	1	DD201626	ACCESSION:DD201626
456	19	0.2	19	1	DD201627	ACCESSION:DD201627
457	19	0.2	19	1	DD201628	ACCESSION:DD201628
458	19	0.2	19	1	DD201629	ACCESSION:DD201629
459	19	0.2	19	1	DD201630	ACCESSION:DD201630
460	19	0.2	19	1	DD201631	ACCESSION:DD201631
461	19	0.2	19	1	DD201632	ACCESSION:DD201632
462	19	0.2	19	1	DD201633	ACCESSION:DD201633
463	19	0.2	19	1	DD201634	ACCESSION:DD201634
464	19	0.2	19	1	DD201635	ACCESSION:DD201635
465	19	0.2	19	1	DD201636	ACCESSION:DD201636
466	19	0.2	19	1	DD201637	ACCESSION:DD201637
467	19	0.2	19	1	DD201638	ACCESSION:DD201638
468	19	0.2	19	1	DD201639	ACCESSION:DD201639
469	19	0.2	19	1	DD201640	ACCESSION:DD201640
470	19	0.2	19	1	DD201641	ACCESSION:DD201641
471	19	0.2	19	1	DD201642	ACCESSION:DD201642
472	19	0.2	19	1	DD201643	ACCESSION:DD201643
473	19	0.2	19	1	DD201644	ACCESSION:DD201644
474	19	0.2	19	1	DD201645	ACCESSION:DD201645
475	19	0.2	19	1	DD201646	ACCESSION:DD201646
476	19	0.2	19	1	DD201647	ACCESSION:DD201647
477	19	0.2	19	1	DD201648	ACCESSION:DD201648
478	19	0.2	19	1	DD201649	ACCESSION:DD201649
479	19	0.2	19	1	DD201650	ACCESSION:DD201650
480	19	0.2	19	1	DD201651	ACCESSION:DD201651
481	19	0.2	19	1	DD201652	ACCESSION:DD201652
482	19	0.2	19	1	DD201653	ACCESSION:DD201653
483	19	0.2	19	1	DD201654	ACCESSION:DD201654
484	19	0.2	19	1	DD201655	ACCESSION:DD201655
485	19	0.2	19	1	DD201656	ACCESSION:DD201656
486	19	0.2	19	1	DD201657	ACCESSION:DD201657
487	19	0.2	19	1	DD201658	ACCESSION:DD201658
488	19	0.2	19	1	DD201659	ACCESSION:DD201659
489	19	0.2	19	1	DD201660	ACCESSION:DD201660
490	19	0.2	19	1	DD201661	ACCESSION:DD201661
491	19	0.2	19	1	DD201662	ACCESSION:DD201662
492	19	0.2	19	1	DD201663	ACCESSION:DD201663
493	19	0.2	19	1	DD201664	ACCESSION:DD201664
494	19	0.2	19	1	DD201665	ACCESSION:DD201665
495	19	0.2	19	1	DD201666	ACCESSION:DD201666
496	19	0.2	19	1	DD201667	ACCESSION:DD201667
497	19	0.2	19	1	DD201668	ACCESSION:DD201668
498	19	0.2	19	1	DD201669	ACCESSION:DD201669
499	19	0.2	19	1	DD201670	ACCESSION:DD201670
500	19	0.2	19	1	DD201671	ACCESSION:DD201671
501	19	0.2	19	1	DD201672	ACCESSION:DD201672
502	19	0.2	19	1	DD201673	ACCESSION:DD201673
503	19	0.2	19	1	DD201674	ACCESSION:DD201674
504	19	0.2	19	1	DD201675	ACCESSION:DD201675
505	19	0.2	19	1	DD201676	ACCESSION:DD201676
506	19	0.2	19	1	DD201677	ACCESSION:DD201677
507	19	0.2	19	1	DD201678	ACCESSION:DD201678
508	19	0.2	19	1	DD201679	ACCESSION:DD201679
509	19	0.2	19	1	DD201680	ACCESSION:DD201680
510	19	0.2	19	1	DD201681	ACCESSION:DD201681
511	19	0.2	19	1	DD201682	ACCESSION:DD201682
512	19	0.2	19	1	DD201683	ACCESSION:DD201683
513	19	0.2	19	1	DD201684	ACCESSION:DD201684
514	19	0.2	19	1	DD201685	ACCESSION:DD201685
515	19	0.2	19	1	DD201686	ACCESSION:DD201686
516	19	0.2	19	1	DD201687	ACCESSION:DD201687
517	19	0.2	19	1	DD201688	ACCESSION:DD201688
518	19	0.2	19	1	DD201689	ACCESSION:DD201689
519	19	0.2	19	1	DD201690	ACCESSION:DD201690
520	19	0.2	19	1	DD201691	ACCESSION:DD201691
521	19	0.2	19	1	DD201692	ACCESSION:DD201692
522	19	0.2	19	1	DD201693	ACCESSION:DD201693
523	19	0.2	19	1	DD201694	ACCESSION:DD201694
524	19	0.2	19	1	DD201695	ACCESSION:DD201695
525	19	0.2	19	1	DD201696	ACCESSION:DD201696
526	19	0.2	19	1	DD201697	ACCESSION:DD201697
527	19	0.2	19	1	DD201698	ACCESSION:DD201698
528	19	0.2	19	1	DD201699	ACCESSION:DD201699
529	19	0.2	19	1	DD201700	ACCESSION:DD201700
530	19	0.2	19	1	DD201701	ACCESSION:DD201701
531	19	0.2	19	1	DD201702	ACCESSION:DD201702
532	19	0.2	19	1	DD201703	ACCESSION:DD201703
533	19	0.2	19	1	DD201704	ACCESSION:DD201704
534	19	0.2	19	1	DD201705	ACCESSION:DD201705
535	19	0.2	19	1	DD201706	ACCESSION:DD201706
536	19	0.2	19	1	DD201707	ACCESSION:DD201707
537	19	0.2	19	1	DD201708	ACCESSION:DD201708
538	19	0.2	19	1	DD201709	ACCESSION:DD201709
539	19	0.2	19	1	DD201710	ACCESSION:DD201710
540	19	0.2	19	1	DD201711	ACCESSION:DD201711
541	19	0.2	19	1	DD201712	ACCESSION:DD201712
542	19	0.2	19	1	DD201713	ACCESSION:DD201713
543	19	0.2	19	1	DD201714	ACCESSION:DD201714
544	19	0.2	19	1	DD201715	ACCESSION:DD201715

545	19	0.2	19	1	DD201716	ACCESSION:DD201716
546	19	0.2	19	1	DD201717	ACCESSION:DD201717
547	19	0.2	19	1	DD201718	ACCESSION:DD201718
548	19	0.2	19	1	DD201719	ACCESSION:DD201719
549	19	0.2	19	1	DD201720	ACCESSION:DD201720
550	19	0.2	19	1	DD201721	ACCESSION:DD201721
551	19	0.2	19	1	DD201722	ACCESSION:DD201722
552	19	0.2	19	1	DD201723	ACCESSION:DD201723
553	19	0.2	19	1	DD201724	ACCESSION:DD201724
554	19	0.2	19	1	DD201725	ACCESSION:DD201725
555	19	0.2	19	1	DD201726	ACCESSION:DD201726
556	19	0.2	19	1	DD201727	ACCESSION:DD201727
557	19	0.2	19	1	DD201728	ACCESSION:DD201728
558	19	0.2	19	1	DD201729	ACCESSION:DD201729
559	19	0.2	19	1	DD201730	ACCESSION:DD201730
560	19	0.2	19	1	DD201731	ACCESSION:DD201731
561	19	0.2	19	1	DD201732	ACCESSION:DD201732
562	19	0.2	19	1	DD201733	ACCESSION:DD201733
563	19	0.2	19	1	DD201734	ACCESSION:DD201734
564	19	0.2	19	1	DD201735	ACCESSION:DD201735
565	19	0.2	19	1	DD201736	ACCESSION:DD201736
566	19	0.2	19	1	DD201737	ACCESSION:DD201737
567	19	0.2	19	1	DD201738	ACCESSION:DD201738
568	19	0.2	19	1	DD201739	ACCESSION:DD201739
569	19	0.2	19	1	DD201740	ACCESSION:DD201740
570	19	0.2	19	1	DD201741	ACCESSION:DD201741
571	19	0.2	19	1	DD201742	ACCESSION:DD201742
572	19	0.2	19	1	DD201743	ACCESSION:DD201743
573	19	0.2	19	1	DD201744	ACCESSION:DD201744
574	19	0.2	19	1	DD201745	ACCESSION:DD201745
575	19	0.2	19	1	DD201746	ACCESSION:DD201746
576	19	0.2	19	1	DD201747	ACCESSION:DD201747
577	19	0.2	19	1	DD201748	ACCESSION:DD201748
578	19	0.2	19	1	DD201749	ACCESSION:DD201749
579	19	0.2	19	1	DD201750	ACCESSION:DD201750
580	19	0.2	19	1	DD201751	ACCESSION:DD201751
581	19	0.2	19	1	DD201752	ACCESSION:DD201752
582	19	0.2	19	1	DD201753	ACCESSION:DD201753
583	19	0.2	19	1	DD201754	ACCESSION:DD201754
584	19	0.2	19	1	DD201755	ACCESSION:DD201755
585	19	0.2	19	1	DD201756	ACCESSION:DD201756
586	19	0.2	19	1	DD201757	ACCESSION:DD201757
587	19	0.2	19	1	DD201758	ACCESSION:DD201758
588	19	0.2	19	1	DD201759	ACCESSION:DD201759
589	19	0.2	19	1	DD201760	ACCESSION:DD201760
590	19	0.2	19	1	DD201761	ACCESSION:DD201761
591	19	0.2	19	1	DD201762	ACCESSION:DD201762
592	19	0.2	19	1	DD201763	ACCESSION:DD201763
593	19	0.2	19	1	DD201764	ACCESSION:DD201764
594	19	0.2	19	1	DD201765	ACCESSION:DD201765
595	19	0.2	19	1	DD201766	ACCESSION:DD201766
596	19	0.2	19	1	DD201767	ACCESSION:DD201767
597	19	0.2	19	1	DD201768	ACCESSION:DD201768
598	19	0.2	19	1	DD201769	ACCESSION:DD201769
599	19	0.2	19	1	DD201770	ACCESSION:DD201770
600	19	0.2	19	1	DD201771	ACCESSION:DD201771
601	19	0.2	19	1	DD201772	ACCESSION:DD201772
602	19	0.2	19	1	DD201773	ACCESSION:DD201773
603	19	0.2	19	1	DD201774	ACCESSION:DD201774
604	19	0.2	19	1	DD201775	ACCESSION:DD201775
605	19	0.2	19	1	DD201776	ACCESSION:DD201776
606	19	0.2	19	1	DD201777	ACCESSION:DD201777
607	19	0.2	19	1	DD201778	ACCESSION:DD201778
608	19	0.2	19	1	DD201779	ACCESSION:DD201779
609	19	0.2	19	1	DD201780	ACCESSION:DD201780
610	19	0.2	19	1	DD201781	ACCESSION:DD201781
611	19	0.2	19	1	DD201782	ACCESSION:DD201782
612	19	0.2	19	1	DD201783	ACCESSION:DD201783
613	19	0.2	19	1	DD201784	ACCESSION:DD201784
614	19	0.2	19	1	DD201785	ACCESSION:DD201785
615	19	0.2	19	1	DD201786	ACCESSION:DD201786
616	19	0.2	19	1	DD201787	ACCESSION:DD201787
617	19	0.2	19	1	DD201788	ACCESSION:DD201788
618	19	0.2	19	1	DD201789	ACCESSION:DD201789
619	19	0.2	19	1	DD201790	ACCESSION:DD201790
620	19	0.2	19	1	DD201791	ACCESSION:DD201791
621	19	0.2	19	1	DD201792	ACCESSION:DD201792
622	19	0.2	19	1	DD201793	ACCESSION:DD201793
623	19	0.2	19	1	DD201794	ACCESSION:DD201794
624	19	0.2	19	1	DD201795	ACCESSION:DD201795
625	19	0.2	19	1	DD201796	ACCESSION:DD201796
626	19	0.2	19	1	DD201797	ACCESSION:DD201797
627	19	0.2	19	1	DD201798	ACCESSION:DD201798
628	19	0.2	19	1	DD201799	ACCESSION:DD201799
629	19	0.2	19	1	DD201800	ACCESSION:DD201800
630	19	0.2	19	1	DD201801	ACCESSION:DD201801
631	19	0.2	19	1	DD201802	ACCESSION:DD201802
632	19	0.2	19	1	DD201803	ACCESSION:DD201803
633	19	0.2	19	1	DD201804	ACCESSION:DD201804
634	19	0.2	19	1	DD201805	ACCESSION:DD201805
635	19	0.2	19	1	DD201806	ACCESSION:DD201806
636	19	0.2	19	1	DD201807	ACCESSION:DD201807
637	19	0.2	19	1	DD201808	ACCESSION:DD201808
638	19	0.2	19	1	DD201809	ACCESSION:DD201809
639	19	0.2	19	1	DD201810	ACCESSION:DD201810
640	19	0.2	19	1	DD201811	ACCESSION:DD201811
641	19	0.2	19	1	DD201812	ACCESSION:DD201812
642	19	0.2	19	1	DD201813	ACCESSION:DD201813
643	19	0.2	19	1	DD201814	ACCESSION:DD201814
644	19	0.2	19	1	DD201815	ACCESSION:DD201815
645	19	0.2	19	1	DD201816	ACCESSION:DD201816
646	19	0.2	19	1	DD201817	ACCESSION:DD201817
647	19	0.2	19	1	DD201818	ACCESSION:DD201818
648	19	0.2	19	1	DD201819	ACCESSION:DD201819
649	19	0.2	19	1	DD201820	ACCESSION:DD201820
650	19	0.2	19	1	DD201821	ACCESSION:DD201821
651	19	0.2	19	1	DD201822	ACCESSION:DD201822
652	19	0.2	19	1	DD201823	ACCESSION:DD201823
653	19	0.2	19	1	DD201824	ACCESSION:DD201824
654	19	0.2	19	1	DD201825	ACCESSION:DD201825
655	19	0.2	19	1	DD201826	ACCESSION:DD201826
656	19	0.2	19	1	DD201827	ACCESSION:DD201827
657	19	0.2	19	1	DD201828	ACCESSION:DD201828
658	19	0.2	19	1	DD201829	ACCESSION:DD201829
659	19	0.2	19	1	DD201830	ACCESSION:DD201830
660	19	0.2	19	1	DD201831	ACCESSION:DD201831
661	19	0.2	19	1	DD201832	ACCESSION:DD201832
662	19	0.2	19	1	DD201833	ACCESSION:DD201833
663	19	0.2	19	1	DD201834	ACCESSION:DD201834
664	19	0.2	19	1	DD201835	ACCESSION:DD201835
665	19	0.2	19	1	DD201836	ACCESSION:DD201836
666	19	0.2	19	1	DD201837	ACCESSION:DD201837
667	19	0.2	19	1	DD201838	ACCESSION:DD201838
668	19	0.2	19	1	DD201839	ACCESSION:DD201839
669	19	0.2	19	1	DD201840	ACCESSION:DD201840
670	19	0.2	19	1	DD201841	ACCESSION:DD201841
671	19	0.2	19	1	DD201842	ACCESSION:DD201842
672	19	0.2	19	1	DD201843	ACCESSION:DD201843
673	19	0.2	19	1	DD201844	ACCESSION:DD201844
674	19	0.2	19	1	DD201845	ACCESSION:DD201845
675	19	0.2	19	1	DD201846	ACCESSION:DD201846
676	19	0.2	19	1	DD201847	ACCESSION:DD201847
677	19	0.2	19	1	DD201848	ACCESSION:DD201848
678	19	0.2	19	1	DD201849	ACCESSION:DD201849
679	19	0.2	19	1	DD201850	ACCESSION:DD201850
680	19	0.2	19	1	DD201851	ACCESSION:DD201851
681	19	0.2	19	1	DD201852	ACCESSION:DD201852
682	19	0.2	19	1	DD201853	ACCESSION:DD201853
683	19	0.2	19	1	DD201854	ACCESSION:DD201854
684	19	0.2	19	1	DD201855	ACCESSION:DD201855
685	19	0.2	19	1	DD201856	ACCESSION:DD201856
686	19	0.2	19	1	DD201857	ACCESSION:DD201857
687	19	0.2	19	1	DD201858	ACCESSION:DD201858
688	19	0.2	19	1	DD201859	ACCESSION:DD201859
689	19	0.2	19	1	DD201860	ACCESSION:DD201860
690	19	0.2	19	1	DD201861	ACCESSION:DD201861

691	19	0.2	19	1	DD201862	ACCESSION:DD201862
692	19	0.2	19	1	DD201863	ACCESSION:DD201863
693	19	0.2	19	1	DD201864	ACCESSION:DD201864
694	19	0.2	19	1	DD201865	ACCESSION:DD201865
695	19	0.2	19	1	DD201866	ACCESSION:DD201866
696	19	0.2	19	1	DD201867	ACCESSION:DD201867
697	19	0.2	19	1	DD201868	ACCESSION:DD201868
698	19	0.2	19	1	DD201869	ACCESSION:DD201869
699	19	0.2	19	1	DD201870	ACCESSION:DD201870
700	19	0.2	19	1	DD201871	ACCESSION:DD201871
701	19	0.2	19	1	DD201872	ACCESSION:DD201872
702	19	0.2	19	1	DD201873	ACCESSION:DD201873
703	19	0.2	19	1	DD201874	ACCESSION:DD201874
704	19	0.2	19	1	DD201875	ACCESSION:DD201875
705	19	0.2	19	1	DD201876	ACCESSION:DD201876
706	19	0.2	19	1	DD201877	ACCESSION:DD201877
707	19	0.2	19	1	DD201878	ACCESSION:DD201878
708	19	0.2	19	1	DD201879	ACCESSION:DD201879
709	19	0.2	19	1	DD201880	ACCESSION:DD201880
710	19	0.2	19	1	DD201881	ACCESSION:DD201881
711	19	0.2	19	1	DD201882	ACCESSION:DD201882
712	19	0.2	19	1	DD201883	ACCESSION:DD201883
713	19	0.2	19	1	DD201884	ACCESSION:DD201884
714	19	0.2	19	1	DD201885	ACCESSION:DD201885
715	19	0.2	19	1	DD201886	ACCESSION:DD201886
716	19	0.2	19	1	DD201887	ACCESSION:DD201887
717	19	0.2	19	1	DD201888	ACCESSION:DD201888
718	19	0.2	19	1	DD201889	ACCESSION:DD201889
719	19	0.2	19	1	DD201890	ACCESSION:DD201890
720	19	0.2	19	1	DD201891	ACCESSION:DD201891
721	19	0.2	19	1	DD201892	ACCESSION:DD201892
722	19	0.2	19	1	DD201893	ACCESSION:DD201893
723	19	0.2	19	1	DD201894	ACCESSION:DD201894
724	19	0.2	19	1	DD201895	ACCESSION:DD201895
725	19	0.2	19	1	DD201896	ACCESSION:DD201896
726	19	0.2	19	1	DD201897	ACCESSION:DD201897
727	19	0.2	19	1	DD201898	ACCESSION:DD201898
728	19	0.2	19	1	DD201899	ACCESSION:DD201899
729	19	0.2	19	1	DD201900	ACCESSION:DD201900
730	19	0.2	19	1	DD201901	ACCESSION:DD201901
731	19	0.2	19	1	DD201902	ACCESSION:DD201902
732	19	0.2	19	1	DD201903	ACCESSION:DD201903
733	19	0.2	19	1	DD201904	ACCESSION:DD201904
734	19	0.2	19	1	DD201905	ACCESSION:DD201905
735	19	0.2	19	1	DD201906	ACCESSION:DD201906
736	19	0.2	19	1	DD201907	ACCESSION:DD201907
737	19	0.2	19	1	DD201908	ACCESSION:DD201908
738	19	0.2	19	1	DD201909	ACCESSION:DD201909
739	19	0.2	19	1	DD201910	ACCESSION:DD201910
740	19	0.2	19	1	DD201911	ACCESSION:DD201911
741	19	0.2	19	1	DD201912	ACCESSION:DD201912
742	19	0.2	19	1	DD201913	ACCESSION:DD201913
743	19	0.2	19	1	DD201914	ACCESSION:DD201914
744	19	0.2	19	1	DD201915	ACCESSION:DD201915
745	19	0.2	19	1	DD201916	ACCESSION:DD201916
746	19	0.2	19	1	DD201917	ACCESSION:DD201917
747	19	0.2	19	1	DD201918	ACCESSION:DD201918
748	19	0.2	19	1	DD201919	ACCESSION:DD201919
749	19	0.2	19	1	DD201920	ACCESSION:DD201920
750	19	0.2	19	1	DD201921	ACCESSION:DD201921
751	19	0.2	19	1	DD201922	ACCESSION:DD201922
752	19	0.2	19	1	DD201923	ACCESSION:DD201923
753	19	0.2	19	1	DD201924	ACCESSION:DD201924
754	19	0.2	19	1	DD201925	ACCESSION:DD201925
755	19	0.2	19	1	DD201926	ACCESSION:DD201926
756	19	0.2	19	1	DD201927	ACCESSION:DD201927
757	19	0.2	19	1	DD201928	ACCESSION:DD201928
758	19	0.2	19	1	DD201929	ACCESSION:DD201929
759	19	0.2	19	1	DD201930	ACCESSION:DD201930
760	19	0.2	19	1	DD201931	ACCESSION:DD201931
761	19	0.2	19	1	DD201932	ACCESSION:DD201932
762	19	0.2	19	1	DD201933	ACCESSION:DD201933
763	19	0.2	19	1	DD201934	ACCESSION:DD201934
764	19	0.2	19	1	DD201935	ACCESSION:DD201935
765	19	0.2	19	1	DD201936	ACCESSION:DD201936
766	19	0.2	19	1	DD201937	ACCESSION:DD201937
767	19	0.2	19	1	DD201938	ACCESSION:DD201938
768	19	0.2	19	1	DD201939	ACCESSION:DD201939
769	19	0.2	19	1	DD201940	ACCESSION:DD201940
770	19	0.2	19	1	DD201941	ACCESSION:DD201941
771	19	0.2	19	1	DD201942	ACCESSION:DD201942
772	19	0.2	19	1	DD201943	ACCESSION:DD201943
773	19	0.2	19	1	DD201944	ACCESSION:DD201944
774	19	0.2	19	1	DD201945	ACCESSION:DD201945
775	19	0.2	19	1	DD201946	ACCESSION:DD201946
c 776	19	0.2	19	1	DD201947	ACCESSION:DD201947
c 777	19	0.2	19	1	DD201948	ACCESSION:DD201948
c 778	19	0.2	19	1	DD201949	ACCESSION:DD201949
c 779	19	0.2	19	1	DD201950	ACCESSION:DD201950
c 780	19	0.2	19	1	DD201951	ACCESSION:DD201951
c 781	19	0.2	19	1	DD201952	ACCESSION:DD201952
c 782	19	0.2	19	1	DD201953	ACCESSION:DD201953
c 783	19	0.2	19	1	DD201954	ACCESSION:DD201954
c 784	19	0.2	19	1	DD201955	ACCESSION:DD201955
c 785	19	0.2	19	1	DD201956	ACCESSION:DD201956
c 786	19	0.2	19	1	DD201957	ACCESSION:DD201957
c 787	19	0.2	19	1	DD201958	ACCESSION:DD201958
c 788	19	0.2	19	1	DD201959	ACCESSION:DD201959
c 789	19	0.2	19	1	DD201960	ACCESSION:DD201960
c 790	19	0.2	19	1	DD201961	ACCESSION:DD201961
c 791	19	0.2	19	1	DD201962	ACCESSION:DD201962
c 792	19	0.2	19	1	DD201963	ACCESSION:DD201963
c 793	19	0.2	19	1	DD201964	ACCESSION:DD201964
c 794	19	0.2	19	1	DD201965	ACCESSION:DD201965
c 795	19	0.2	19	1	DD201966	ACCESSION:DD201966
c 796	19	0.2	19	1	DD201967	ACCESSION:DD201967
c 797	19	0.2	19	1	DD201968	ACCESSION:DD201968
c 798	19	0.2	19	1	DD201969	ACCESSION:DD201969
c 799	19	0.2	19	1	DD201970	ACCESSION:DD201970
c 800	19	0.2	19	1	DD201971	ACCESSION:DD201971
c 801	19	0.2	19	1	DD201972	ACCESSION:DD201972
c 802	19	0.2	19	1	DD201973	ACCESSION:DD201973
c 803	19	0.2	19	1	DD201974	ACCESSION:DD201974
c 804	19	0.2	19	1	DD201975	ACCESSION:DD201975
c 805	19	0.2	19	1	DD201976	ACCESSION:DD201976
c 806	19	0.2	19	1	DD201977	ACCESSION:DD201977
c 807	19	0.2	19	1	DD201978	ACCESSION:DD201978
c 808	19	0.2	19	1	DD201979	ACCESSION:DD201979
c 809	19	0.2	19	1	DD201980	ACCESSION:DD201980
c 810	19	0.2	19	1	DD201981	ACCESSION:DD201981
c 811	19	0.2	19	1	DD201982	ACCESSION:DD201982
c 812	19	0.2	19	1	DD201983	ACCESSION:DD201983
c 813	19	0.2	19	1	DD201984	ACCESSION:DD201984
c 814	19	0.2	19	1	DD201985	ACCESSION:DD201985
c 815	19	0.2	19	1	DD201986	ACCESSION:DD201986
c 816	19	0.2	19	1	DD201987	ACCESSION:DD201987
c 817	19	0.2	19	1	DD201988	ACCESSION:DD201988
c 818	19	0.2	19	1	DD201989	ACCESSION:DD201989
c 819	19	0.2	19	1	DD201990	ACCESSION:DD201990
c 820	19	0.2	19	1	DD201991	ACCESSION:DD201991
c 821	19	0.2	19	1	DD201992	ACCESSION:DD201992
c 822	19	0.2	19	1	DD201993	ACCESSION:DD201993
c 823	19	0.2	19	1	DD201994	ACCESSION:DD201994
c 824	19	0.2	19	1	DD201995	ACCESSION:DD201995
c 825	19	0.2	19	1	DD201996	ACCESSION:DD201996
c 826	19	0.2	19	1	DD201997	ACCESSION:DD201997
c 827	19	0.2	19	1	DD201998	ACCESSION:DD201998
c 828	19	0.2	19	1	DD201999	ACCESSION:DD201999
c 829	19	0.2	19	1	DD202000	ACCESSION:DD202000
c 830	19	0.2	19	1	DD202001	ACCESSION:DD202001
c 831	19	0.2	19	1	DD202002	ACCESSION:DD202002
c 832	19	0.2	19	1	DD202003	ACCESSION:DD202003
c 833	19	0.2	19	1	DD202004	ACCESSION:DD202004
c 834	19	0.2	19	1	DD202005	ACCESSION:DD202005
c 835	19	0.2	19	1	DD202006	ACCESSION:DD202006
c 836	19	0.2	19	1	DD202007	ACCESSION:DD202007

c 837	19	0.2	19	1	DD202008	ACCESSION:DD202008
c 838	19	0.2	19	1	DD202009	ACCESSION:DD202009
c 839	19	0.2	19	1	DD202010	ACCESSION:DD202010
c 840	19	0.2	19	1	DD202011	ACCESSION:DD202011
c 841	19	0.2	19	1	DD202012	ACCESSION:DD202012
c 842	19	0.2	19	1	DD202013	ACCESSION:DD202013
c 843	19	0.2	19	1	DD202014	ACCESSION:DD202014
c 844	19	0.2	19	1	DD202015	ACCESSION:DD202015
c 845	19	0.2	19	1	DD202016	ACCESSION:DD202016
c 846	19	0.2	19	1	DD202017	ACCESSION:DD202017
c 847	19	0.2	19	1	DD202018	ACCESSION:DD202018
c 848	19	0.2	19	1	DD202019	ACCESSION:DD202019
c 849	19	0.2	19	1	DD202020	ACCESSION:DD202020
c 850	19	0.2	19	1	DD202021	ACCESSION:DD202021
c 851	19	0.2	19	1	DD202022	ACCESSION:DD202022
c 852	19	0.2	19	1	DD202023	ACCESSION:DD202023
c 853	19	0.2	19	1	DD202024	ACCESSION:DD202024
c 854	19	0.2	19	1	DD202025	ACCESSION:DD202025
c 855	19	0.2	19	1	DD202026	ACCESSION:DD202026
c 856	19	0.2	19	1	DD202027	ACCESSION:DD202027
c 857	19	0.2	19	1	DD202028	ACCESSION:DD202028
c 858	19	0.2	19	1	DD202029	ACCESSION:DD202029
c 859	19	0.2	19	1	DD202030	ACCESSION:DD202030
c 860	19	0.2	19	1	DD202031	ACCESSION:DD202031
c 861	19	0.2	19	1	DD202032	ACCESSION:DD202032
c 862	19	0.2	19	1	DD202033	ACCESSION:DD202033
c 863	19	0.2	19	1	DD202034	ACCESSION:DD202034
c 864	19	0.2	19	1	DD202035	ACCESSION:DD202035
c 865	19	0.2	19	1	DD202036	ACCESSION:DD202036
c 866	19	0.2	19	1	DD202037	ACCESSION:DD202037
c 867	19	0.2	19	1	DD202038	ACCESSION:DD202038
c 868	19	0.2	19	1	DD202039	ACCESSION:DD202039
c 869	19	0.2	19	1	DD202040	ACCESSION:DD202040
c 870	19	0.2	19	1	DD202041	ACCESSION:DD202041
c 871	19	0.2	19	1	DD202042	ACCESSION:DD202042
c 872	19	0.2	19	1	DD202043	ACCESSION:DD202043
c 873	19	0.2	19	1	DD202044	ACCESSION:DD202044
c 874	19	0.2	19	1	DD202045	ACCESSION:DD202045
c 875	19	0.2	19	1	DD202046	ACCESSION:DD202046
c 876	19	0.2	19	1	DD202047	ACCESSION:DD202047
c 877	19	0.2	19	1	DD202048	ACCESSION:DD202048
c 878	19	0.2	19	1	DD202049	ACCESSION:DD202049
c 879	19	0.2	19	1	DD202050	ACCESSION:DD202050
c 880	19	0.2	19	1	DD202051	ACCESSION:DD202051
c 881	19	0.2	19	1	DD202052	ACCESSION:DD202052
c 882	19	0.2	19	1	DD202053	ACCESSION:DD202053
c 883	19	0.2	19	1	DD202054	ACCESSION:DD202054
c 884	19	0.2	19	1	DD202055	ACCESSION:DD202055
c 885	19	0.2	19	1	DD202056	ACCESSION:DD202056
c 886	19	0.2	19	1	DD202057	ACCESSION:DD202057
c 887	19	0.2	19	1	DD202058	ACCESSION:DD202058
c 888	19	0.2	19	1	DD202059	ACCESSION:DD202059
c 889	19	0.2	19	1	DD202060	ACCESSION:DD202060
c 890	19	0.2	19	1	DD202061	ACCESSION:DD202061
c 891	19	0.2	19	1	DD202062	ACCESSION:DD202062
c 892	19	0.2	19	1	DD202063	ACCESSION:DD202063
c 893	19	0.2	19	1	DD202064	ACCESSION:DD202064
c 894	19	0.2	19	1	DD202065	ACCESSION:DD202065
c 895	19	0.2	19	1	DD202066	ACCESSION:DD202066
c 896	19	0.2	19	1	DD202067	ACCESSION:DD202067
c 897	19	0.2	19	1	DD202068	ACCESSION:DD202068
c 898	19	0.2	19	1	DD202069	ACCESSION:DD202069
c 899	19	0.2	19	1	DD202070	ACCESSION:DD202070
c 900	19	0.2	19	1	DD202071	ACCESSION:DD202071
c 901	19	0.2	19	1	DD202072	ACCESSION:DD202072
c 902	19	0.2	19	1	DD202073	ACCESSION:DD202073
c 903	19	0.2	19	1	DD202074	ACCESSION:DD202074
c 904	19	0.2	19	1	DD202075	ACCESSION:DD202075
c 905	19	0.2	19	1	DD202076	ACCESSION:DD202076
c 906	19	0.2	19	1	DD202077	ACCESSION:DD202077
c 907	19	0.2	19	1	DD202078	ACCESSION:DD202078
c 908	19	0.2	19	1	DD202079	ACCESSION:DD202079
c 909	19	0.2	19	1	DD202080	ACCESSION:DD202080
c 910	19	0.2	19	1	DD202081	ACCESSION:DD202081
c 911	19	0.2	19	1	DD202082	ACCESSION:DD202082
c 912	19	0.2	19	1	DD202083	ACCESSION:DD202083
c 913	19	0.2	19	1	DD202084	ACCESSION:DD202084
c 914	19	0.2	19	1	DD202085	ACCESSION:DD202085
c 915	19	0.2	19	1	DD202086	ACCESSION:DD202086
c 916	19	0.2	19	1	DD202087	ACCESSION:DD202087
c 917	19	0.2	19	1	DD202088	ACCESSION:DD202088
c 918	19	0.2	19	1	DD202089	ACCESSION:DD202089
c 919	19	0.2	19	1	DD202090	ACCESSION:DD202090
c 920	19	0.2	19	1	DD202091	ACCESSION:DD202091
c 921	19	0.2	19	1	DD202092	ACCESSION:DD202092
c 922	19	0.2	19	1	DD202093	ACCESSION:DD202093
c 923	19	0.2	19	1	DD202094	ACCESSION:DD202094
c 924	19	0.2	19	1	DD202095	ACCESSION:DD202095
c 925	19	0.2	19	1	DD202096	ACCESSION:DD202096
c 926	19	0.2	19	1	DD202097	ACCESSION:DD202097
c 927	19	0.2	19	1	DD202098	ACCESSION:DD202098
c 928	19	0.2	19	1	DD202099	ACCESSION:DD202099
c 929	19	0.2	19	1	DD202100	ACCESSION:DD202100
c 930	19	0.2	19	1	DD202101	ACCESSION:DD202101
c 931	19	0.2	19	1	DD202102	ACCESSION:DD202102
c 932	19	0.2	19	1	DD202103	ACCESSION:DD202103
c 933	19	0.2	19	1	DD202104	ACCESSION:DD202104
c 934	19	0.2	19	1	DD202105	ACCESSION:DD202105
c 935	19	0.2	19	1	DD202106	ACCESSION:DD202106
c 936	19	0.2	19	1	DD202107	ACCESSION:DD202107
c 937	19	0.2	19	1	DD202108	ACCESSION:DD202108
c 938	19	0.2	19	1	DD202109	ACCESSION:DD202109
c 939	19	0.2	19	1	DD202110	ACCESSION:DD202110
c 940	19	0.2	19	1	DD202111	ACCESSION:DD202111
c 941	19	0.2	19	1	DD202112	ACCESSION:DD202112
c 942	19	0.2	19	1	DD202113	ACCESSION:DD202113
c 943	19	0.2	19	1	DD202114	ACCESSION:DD202114
c 944	19	0.2	19	1	DD202115	ACCESSION:DD202115
c 945	19	0.2	19	1	DD202116	ACCESSION:DD202116
c 946	19	0.2	19	1	DD202117	ACCESSION:DD202117
c 947	19	0.2	19	1	DD202118	ACCESSION:DD202118
c 948	19	0.2	19	1	DD202119	ACCESSION:DD202119
c 949	19	0.2	19	1	DD202120	ACCESSION:DD202120
c 950	19	0.2	19	1	DD202121	ACCESSION:DD202121
c 951	19	0.2	19	1	DD202122	ACCESSION:DD202122
c 952	19	0.2	19	1	DD202123	ACCESSION:DD202123
c 953	19	0.2	19	1	DD202124	ACCESSION:DD202124
c 954	19	0.2	19	1	DD202125	ACCESSION:DD202125
c 955	19	0.2	19	1	DD202126	ACCESSION:DD202126
c 956	19	0.2	19	1	DD202127	ACCESSION:DD202127
c 957	19	0.2	19	1	DD202128	ACCESSION:DD202128
c 958	19	0.2	19	1	DD202129	ACCESSION:DD202129
c 959	19	0.2	19	1	DD202130	ACCESSION:DD202130
c 960	19	0.2	19	1	DD202131	ACCESSION:DD202131
c 961	19	0.2	19	1	DD202132	ACCESSION:DD202132
c 962	19	0.2	19	1	DD202133	ACCESSION:DD202133
c 963	19	0.2	19	1	DD202134	ACCESSION:DD202134
c 964	19	0.2	19	1	DD202135	ACCESSION:DD202135
c 965	19	0.2	19	1	DD202136	ACCESSION:DD202136
c 966	19	0.2	19	1	DD202137	ACCESSION:DD202137
c 967	19	0.2	19	1	DD202138	ACCESSION:DD202138
c 968	19	0.2	19	1	DD202139	ACCESSION:DD202139
c 969	19	0.2	19	1	DD202140	ACCESSION:DD202140
c 970	19	0.2	19	1	DD202141	ACCESSION:DD202141
c 971	19	0.2	19	1	DD202142	ACCESSION:DD202142
c 972	19	0.2	19	1	DD202143	ACCESSION:DD202143
c 973	19	0.2	19	1	DD202144	ACCESSION:DD202144
c 974	19	0.2	19	1	DD202145	ACCESSION:DD202145
c 975	19	0.2	19	1	DD202146	ACCESSION:DD202146
c 976	19	0.2	19	1	DD202147	ACCESSION:DD202147
c 977	19	0.2	19	1	DD202148	ACCESSION:DD202148
c 978	19	0.2	19	1	DD202149	ACCESSION:DD202149
c 979	19	0.2	19	1	DD202150	ACCESSION:DD202150
c 980	19	0.2	19	1	DD202151	ACCESSION:DD202151
c 981	19	0.2	19	1	DD202152	ACCESSION:DD202152
c 982	19	0.2	19	1	DD202153	ACCESSION:DD202153

c 983	19	0.2	19	1	DD202154	ACCESSION:DD202154
c 984	19	0.2	19	1	DD202155	ACCESSION:DD202155
c 985	19	0.2	19	1	DD202156	ACCESSION:DD202156
c 986	19	0.2	19	1	DD202157	ACCESSION:DD202157
c 987	19	0.2	19	1	DD202158	ACCESSION:DD202158
c 988	19	0.2	19	1	DD202159	ACCESSION:DD202159
c 989	19	0.2	19	1	DD202160	ACCESSION:DD202160
c 990	19	0.2	19	1	DD202161	ACCESSION:DD202161
c 991	19	0.2	19	1	DD202162	ACCESSION:DD202162
c 992	19	0.2	19	1	DD202163	ACCESSION:DD202163
c 993	19	0.2	19	1	DD202164	ACCESSION:DD202164
c 994	19	0.2	19	1	DD202165	ACCESSION:DD202165
c 995	19	0.2	19	1	DD202166	ACCESSION:DD202166
c 996	19	0.2	19	1	DD202167	ACCESSION:DD202167
c 997	19	0.2	19	1	DD202168	ACCESSION:DD202168
c 998	19	0.2	19	1	DD202169	ACCESSION:DD202169
c 999	19	0.2	19	1	DD202170	ACCESSION:DD202170
c1000	19	0.2	19	1	DD202171	ACCESSION:DD202171

ALIGNMENTS

RESULT 1
A69996/c
LOCUS A69996 40 bp DNA linear PAT 07-MAY-1999
DEFINITION Sequence 27 from Patent WO9807851.
ACCESSION A69996
VERSION A69996.1 GI:4774459
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE 1 (bases 1 to 40)
AUTHORS Preddie,E.R. and Bergmann,J.E.
TITLE AGENTS FOR THE PRE-SYMPTOMATIC DETECTION, PREVENTION AND TREATMENT
OF BREAST CANCER IN HUMANS
JOURNAL Patent: WO 9807851-A 27 26-FEB-1998;
PREDDIE ENRIQUE R (CA)
FEATURES Location/Qualifiers
source 1. .40
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/clone="BCFLT2"

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 62.5%; Pred. No. 29;
Matches 25; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

Qy 7218 ACCAACUUAAUUGAUAAACUUGGCAACUGCUUUUAUGUUC 7257
Db 40 ACCAACTTAATTGATAAACTTGGCAACTGCTTTTATGTTC 1

RESULT 2
I31207/c
LOCUS I31207 40 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 119 from patent US 5582979.
ACCESSION I31207
VERSION I31207.1 GI:1821998
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 40)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
method of using the same
JOURNAL Patent: US 5582979-A 119 10-DEC-1996;
FEATURES Location/Qualifiers
source 1. .40
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 50.0%; Pred. No. 29;
Matches 20; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
Db 40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 3
I31488/c
LOCUS I31488 40 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 400 from patent US 5582979.
ACCESSION I31488
VERSION I31488.1 GI:1822279
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 40)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
method of using the same
JOURNAL Patent: US 5582979-A 400 10-DEC-1996;
FEATURES Location/Qualifiers
source 1. .40
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 50.0%; Pred. No. 29;
Matches 20; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
Db 40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 4
I31491/c
LOCUS I31491 40 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 403 from patent US 5582979.
ACCESSION I31491
VERSION I31491.1 GI:1822282
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 40)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
method of using the same
JOURNAL Patent: US 5582979-A 403 10-DEC-1996;
FEATURES Location/Qualifiers
source 1. .40
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 50.0%; Pred. No. 29;
Matches 20; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

Qy 6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
Db 40 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 5
I31225/c

```
LOCUS       I31225                  39 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 137 from patent US 5582979.
ACCESSION   I31225
VERSION     I31225.1  GI:1822016
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 137 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 39;  DB 1;  Length 39;
  Best Local Similarity   48.7%;  Pred. No. 37;
  Matches   19;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         39 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 6
I31240/c
LOCUS       I31240                  40 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 152 from patent US 5582979.
ACCESSION   I31240
VERSION     I31240.1  GI:1822031
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 152 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 47;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGT 1


RESULT 7
I31263/c
LOCUS       I31263                  40 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 175 from patent US 5582979.
ACCESSION   I31263
VERSION     I31263.1  GI:1822054
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 175 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 38.4;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 47;
  Matches   19;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7012
              :|:|:|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 TGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 8
A69994/c
LOCUS       A69994                  38 bp    DNA     linear   PAT 07-MAY-1999
DEFINITION  Sequence 25 from Patent WO9807851.
ACCESSION   A69994
VERSION     A69994.1  GI:4774457
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Preddie,E.R. and Bergmann,J.E.
  TITLE     AGENTS FOR THE PRE-SYMPTOMATIC DETECTION, PREVENTION AND TREATMENT
            OF BREAST CANCER IN HUMANS
  JOURNAL   Patent: WO 9807851-A 25 26-FEB-1998;
            PREDDIE ENRIQUE R (CA)
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /clone="BCFLT2"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   68.4%;  Pred. No. 47;
  Matches   26;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7515 CCAUGAAAAUGCAAAUUAUCCAGUGUAGAUAUAUUUGA 7552
              |||:|||||:|||||::|:||||:|:|||:|:|:::||
Db         38 CCATGAAAATGCAAATTATCCAGTGTAGATATATTTGA 1


RESULT 9
A69995/c
LOCUS       A69995                  38 bp    DNA     linear   PAT 07-MAY-1999
DEFINITION  Sequence 26 from Patent WO9807851.
ACCESSION   A69995
VERSION     A69995.1  GI:4774458
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Preddie,E.R. and Bergmann,J.E.
  TITLE     AGENTS FOR THE PRE-SYMPTOMATIC DETECTION, PREVENTION AND TREATMENT
            OF BREAST CANCER IN HUMANS
  JOURNAL   Patent: WO 9807851-A 26 26-FEB-1998;
            PREDDIE ENRIQUE R (CA)
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /clone="BCFLT2"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   47.4%;  Pred. No. 47;
```

```
  Matches   18;  Conservative   20;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7309 UUUUUUUUCCUAAAAUAAACUCAAAUUUAUCCUUGUUU 7346
              :::::::::||:||||:||||:||||:::|:||::|:::
Db         38 TTTTTTTTCCTAAAATAAACTCAAATTTATCCTTGTTT 1


RESULT 10
BD251663/c
LOCUS       BD251663                38 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Selection of animal based on character imprinted by parent.
ACCESSION   BD251663
VERSION     BD251663.1  GI:33061433
KEYWORDS    JP 2002535963-A/183.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Andersson,L., Georges,M., Spincemaille,G. and Nezer,C.D.A.
  TITLE     Selection of animal based on character imprinted by parent
  JOURNAL   Patent: JP 2002535963-A 183 29-OCT-2002;
            UNIVERSITY OF LIEGE,MELICA HB,SEGHERS GENTEC NV
COMMENT     OS   Sus scrofa (pig)
            PN   JP 2002535963-A/183
            PD   29-OCT-2002
            PF   16-DEC-1999 JP 2000588390
            PR   16-DEC-1998 EP   98204291.3
            PI   LEIF ANDERSSON,MICHEL GEORGES,GEERT SPINCEMAILLE, PI   CARINE
            DANIELLE ANDREE NEZER
            PC   C12N15/09,A01K67/027,C12N5/06,C12Q1/68,C12N15/00,C12N5/00 CC
            /note='Microsatellite'
            FH   Key             Location/Qualifiers
            FT   source          1. .38
            FT                   /organism='Sus scrofa (pig)'.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Sus scrofa"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9823"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 47;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 11
I31286/c
LOCUS       I31286                  38 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 198 from patent US 5582979.
ACCESSION   I31286
VERSION     I31286.1  GI:1822077
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 198 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 47;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 12
I31485/c
LOCUS       I31485                  38 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 397 from patent US 5582979.
ACCESSION   I31485
VERSION     I31485.1  GI:1822276
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 397 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 47;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         38 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 13
AX028364/c
LOCUS       AX028364                38 bp    DNA     linear   PAT 16-SEP-2000
DEFINITION  Sequence 183 from Patent WO0036143.
ACCESSION   AX028364
VERSION     AX028364.1  GI:10189577
KEYWORDS    .
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1
  AUTHORS   Georges,M., Spincemaille,G. and Andersson,L.
  TITLE     Selecting animals for parentally imprinted traits
  JOURNAL   Patent: WO 0036143-A 183 22-JUN-2000;
            SEGHERSGENTEC N V (BE) ; GEORGES MICHEL (BE) ; UNIV LIEGE (BE) ;
            SPINCEMAILLE GEERT (BE) ; MELICA HB (SE) ; ANDERSSON LEIF (SE)
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Sus scrofa"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9823"
                     /note="Microsatellite"

  Query Match             0.5%;  Score 38;  DB 1;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 47;
  Matches   19;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 14
I31174/c
LOCUS       I31174                  39 bp    DNA     linear   PAT 06-FEB-1997
```

```
DEFINITION  Sequence 86 from patent US 5582979.
ACCESSION   I31174
VERSION     I31174.1  GI:1821965
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 86 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 37.4;  DB 1;  Length 39;
  Best Local Similarity   46.2%;  Pred. No. 59;
  Matches   18;  Conservative   20;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|: :|:|:|:|:|:|:|:|:|:|:
Db         39 TGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 15
I31228/c
LOCUS       I31228                    37 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 140 from patent US 5582979.
ACCESSION   I31228
VERSION     I31228.1  GI:1822019
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 140 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 37;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 59;
  Matches   18;  Conservative   19;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         37 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 16
AR699916/c
LOCUS       AR699916                  40 bp    DNA     linear   PAT 14-SEP-2005
DEFINITION  Sequence 11 from patent US 6919443.
ACCESSION   AR699916
VERSION     AR699916.1  GI:75205836
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Takahashi,H. and Sekino,M.
  TITLE     Method for isolating satellite sequences
  JOURNAL   Patent: US 6919443-A 11 19-JUL-2005;
            National Institute of Agrobiological Sciences; Ibaraki;
            JPX;
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.5%;  Score 36.8;  DB 1;  Length 40;
  Best Local Similarity   47.5%;  Pred. No. 73;
  Matches   19;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:| |:|
Db         40 TGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGTG 1


RESULT 17
AR073769
LOCUS       AR073769                  38 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 18 from patent US 5952199.
ACCESSION   AR073769
VERSION     AR073769.1  GI:10000529
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 18 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 74;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 18
I31156/c
LOCUS       I31156                    38 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 68 from patent US 5582979.
ACCESSION   I31156
VERSION     I31156.1  GI:1821947
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 68 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   47.4%;  Pred. No. 74;
  Matches   18;  Conservative   19;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTTTGTGTGTGTG 1


RESULT 19
AR208265
LOCUS       AR208265                  38 bp    DNA     linear   PAT 20-JUN-2002
```

```
DEFINITION  Sequence 18 from patent US 6383486.
ACCESSION   AR208265
VERSION     AR208265.1  GI:21509374
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 18 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 74;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 20
AR658762
LOCUS       AR658762                  38 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 18 from patent US 6897294.
ACCESSION   AR658762
VERSION     AR658762.1  GI:67593927
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 18 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.5%;  Score 36.4;  DB 1;  Length 38;
  Best Local Similarity   78.9%;  Pred. No. 74;
  Matches   30;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1519 GUCAAUGUGAAACCCCAGAUUUACGAAAAGGCCGUGUC 1556
              |:|||:|:||||||||||: :|||||||||||:|:|
Db          1 GTCAATGTGAAACCCCAGATCTACGAAAAGGCCGTGTC 38


RESULT 21
I31192/c
LOCUS       I31192                    36 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 104 from patent US 5582979.
ACCESSION   I31192
VERSION     I31192.1  GI:1821983
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 104 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 22
I31446/c
LOCUS       I31446                    36 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 358 from patent US 5582979.
ACCESSION   I31446
VERSION     I31446.1  GI:1822237
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 358 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 36;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         36 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 23
I31165/c
LOCUS       I31165                    35 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 77 from patent US 5582979.
ACCESSION   I31165
VERSION     I31165.1  GI:1821956
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 77 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 93;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         35 CTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 24
I31277/c
LOCUS       I31277                    35 bp    DNA     linear   PAT 06-FEB-1997
```

```
DEFINITION  Sequence 189 from patent US 5582979.
ACCESSION   I31277
VERSION     I31277.1  GI:1822068
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 189 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 93;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         35 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 25
E32209/c
LOCUS       E32209                    38 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for isolating satellite sequence.
ACCESSION   E32209
VERSION     E32209.1  GI:13021808
KEYWORDS    JP 2000060559-A/11.
SOURCE      Haliotis discus discus
  ORGANISM  Haliotis discus discus
            Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
            Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Hideaki,T. and Masashi,S.
  TITLE     Method for isolating satellite sequence
  JOURNAL   Patent: JP 2000060559-A 11 29-FEB-2000;
            NATL INST OF AGROBIOLOGICAL RESOUCES
COMMENT     OS   Haliotis discus discus
            PN   JP 2000060559-A/11
            PD   29-FEB-2000
            PF   18-AUG-1998 JP 1998232153
            PR
            PI   HIDEAKI TAKAHASHI,MASASHI SEKINO
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .38
            FT                   /organism='Haliotis discus discus'.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Haliotis discus discus"
                     /mol_type="genomic DNA"
                     /sub_species="discus"
                     /db_xref="taxon:91233"

  Query Match             0.5%;  Score 34.8;  DB 1;  Length 38;
  Best Local Similarity   47.4%;  Pred. No. 1.2e+02;
  Matches   18;  Conservative   18;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:| |:|
Db         38 TGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGAGTG 1


RESULT 26
I31198/c
LOCUS       I31198                    34 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 110 from patent US 5582979.
ACCESSION   I31198
VERSION     I31198.1  GI:1821989
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 110 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 27
I31260/c
LOCUS       I31260                    34 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 172 from patent US 5582979.
ACCESSION   I31260
VERSION     I31260.1  GI:1822051
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 172 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 28
I31268/c
LOCUS       I31268                    34 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 180 from patent US 5582979.
ACCESSION   I31268
VERSION     I31268.1  GI:1822059
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 180 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         34 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 29
I31280/c
LOCUS       I31280                   34 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 192 from patent US 5582979.
ACCESSION   I31280
VERSION     I31280.1  GI:1822071
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 192 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 30
I31410/c
LOCUS       I31410                   34 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 322 from patent US 5582979.
ACCESSION   I31410
VERSION     I31410.1  GI:1822201
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 322 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         34 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 31
AR073763
LOCUS       AR073763                 36 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 6 from patent US 5952199.
ACCESSION   AR073763
VERSION     AR073763.1  GI:10000523
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 6 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 32
AR208259
LOCUS       AR208259                 36 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 6 from patent US 6383486.
ACCESSION   AR208259
VERSION     AR208259.1  GI:21509367
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 6 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 33
AR658756
LOCUS       AR658756                 36 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 6 from patent US 6897294.
ACCESSION   AR658756
VERSION     AR658756.1  GI:67593921
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 6 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

```
  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   54.3%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        619 AUCUAUAUAUUUAUUAGUGAUACAGGUAGACCUUU 653
              |:|:|:|:|:::|::||:||:|| ||:|||||:::
Db          1 ATCTATATATTTATTAGTGATACCGGTAGACCTTT 35


RESULT 34
I31147/c
LOCUS       I31147                    33 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 59 from patent US 5582979.
ACCESSION   I31147
VERSION     I31147.1  GI:1821938
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 59 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 1.5e+02;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 35
I31306/c
LOCUS       I31306                    33 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 218 from patent US 5582979.
ACCESSION   I31306
VERSION     I31306.1  GI:1822097
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 218 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 1.5e+02;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         33 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 36
E32203/c
LOCUS       E32203                    32 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for isolating satellite sequence.
ACCESSION   E32203
VERSION     E32203.1  GI:13021740
KEYWORDS    JP 2000060559-A/5.
SOURCE      Haliotis discus discus
  ORGANISM  Haliotis discus discus
            Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
            Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Hideaki,T. and Masashi,S.
  TITLE     Method for isolating satellite sequence
  JOURNAL   Patent: JP 2000060559-A 5 29-FEB-2000;
            NATL INST OF AGROBIOLOGICAL RESOUCES
COMMENT     OS   Haliotis discus discus
            PN   JP 2000060559-A/5
            PD   29-FEB-2000
            PF   18-AUG-1998 JP 1998232153
            PR
            PI   HIDEAKI TAKAHASHI,MASASHI SEKINO
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .32
            FT                   /organism='Haliotis discus discus'.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Haliotis discus discus"
                     /mol_type="genomic DNA"
                     /sub_species="discus"
                     /db_xref="taxon:91233"

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 37
I31298/c
LOCUS       I31298                    32 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 210 from patent US 5582979.
ACCESSION   I31298
VERSION     I31298.1  GI:1822089
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 210 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 38
I31464/c
LOCUS       I31464                    32 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 376 from patent US 5582979.
ACCESSION   I31464
VERSION     I31464.1  GI:1822255
```

```
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 376 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 39
AR649365/c
LOCUS       AR649365                 32 bp    DNA     linear   PAT 20-APR-2005
DEFINITION  Sequence 10 from patent US 6875606.
ACCESSION   AR649365
VERSION     AR649365.1  GI:62790026
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Leonard,S. and Freedman,R.
  TITLE     Human .alpha.-7 nicotinic receptor promoter
  JOURNAL   Patent: US 6875606-A 10 05-APR-2005;
            The United States of America as represented by the Department of
            Veterans Affairs; Washington, DC
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 40
AR699910/c
LOCUS       AR699910                 32 bp    DNA     linear   PAT 14-SEP-2005
DEFINITION  Sequence 5 from patent US 6919443.
ACCESSION   AR699910
VERSION     AR699910.1  GI:75205829
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Takahashi,H. and Sekino,M.
  TITLE     Method for isolating satellite sequences
  JOURNAL   Patent: US 6919443-A 5 19-JUL-2005;
            National Institute of Agrobiological Sciences; Ibaraki;
            JPX;
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 41
MMVIMV26
LOCUS       MMVIMV26                 40 bp    DNA     linear   ROD 30-AUG-1996
DEFINITION  M.musculus DNA for vimentin-binding fragment V26.
ACCESSION   X89143
VERSION     X89143.1  GI:887548
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Wang,X., Tolstonog,G., Shoeman,R.L. and Traub,P.
  TITLE     Selective binding of specific mouse genomic DNA fragments by mouse
            vimentin filaments in vitro
  JOURNAL   DNA Cell Biol. 15 (3), 209-225 (1996)
   PUBMED   8634150
REFERENCE   2  (bases 1 to 40)
  AUTHORS   Shoeman,R.L.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-JUN-1995) Shoeman R. L., Max-Planck-Institute fuer
            Zellbiologie, Rosenhof, Ladenburg, Germany, D-68526
COMMENT     On Jul 6, 1995 this sequence version replaced gi:872151.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:10090"
                     /cell_line="Ehrlich ascites tumor cell"
     protein_bind    1. .40
                     /standard_name="fragment V26 in citation #1"
                     /experiment="experimental evidence, no additional details
                     recorded"
                     /citation=[1]
                     /bound_moiety="vimentin"
                     /function="sequence bound by vimentin filaments in vitro"
     repeat_region   1. .40
                     /citation=[1]
                     /function="recombination, potentially to form non-B DNA"
                     /rpt_family="d(CA/GT)n dinucleotide repeats, imperfect"
                     /rpt_type=DIRECT
                     /rpt_unit_range=1. .2

  Query Match             0.4%;  Score 32;  DB 1;  Length 40;
  Best Local Similarity   45.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative   17;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:| |:|  :|:|:| |:|: :|:
Db          1 GTGTGTGTGTGTGTGTGAGTGCCTGTGTGAGTGTATGT 40


RESULT 42
AR073771
LOCUS       AR073771                 33 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 22 from patent US 5952199.
ACCESSION   AR073771
VERSION     AR073771.1  GI:10000531
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
```

```
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 22 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 2.3e+02;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :|||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 43
AR073775
LOCUS       AR073775                  33 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 30 from patent US 5952199.
ACCESSION   AR073775
VERSION     AR073775.1  GI:10000535
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 30 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 2.3e+02;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 44
AR208267
LOCUS       AR208267                  33 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 22 from patent US 6383486.
ACCESSION   AR208267
VERSION     AR208267.1  GI:21509377
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 22 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 2.3e+02;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :|||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 45
AR208271
LOCUS       AR208271                  33 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 30 from patent US 6383486.
ACCESSION   AR208271
VERSION     AR208271.1  GI:21509382
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 30 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 2.3e+02;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::||||| |||:|||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 46
AR658764
LOCUS       AR658764                  33 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 22 from patent US 6897294.
ACCESSION   AR658764
VERSION     AR658764.1  GI:67593931
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 22 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   57.6%;  Pred. No. 2.3e+02;
  Matches   19;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 UUUUAUAUCACAGAUGUGCCAAAUGGGUUUCAU 1929
              ::::|:|:||||||: :|||||||:|||:::||:
Db          1 TTTTATATCACAGATCTGCCAAATGGGTTTCAT 33


RESULT 47
AR658768
LOCUS       AR658768                  33 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 30 from patent US 6897294.
ACCESSION   AR658768
VERSION     AR658768.1  GI:67593935
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
```

```
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 30 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   72.7%;  Pred. No. 2.3e+02;
  Matches   24;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCUCGGACAAGUCUAAU 2517
              |:|||:|::|||| |||:||||||||:|:||:
Db          1 CTCACTGTTCAAGGTACCTCGGACAAGTCTAAT 33


RESULT 48
I31303/c
LOCUS       I31303                    31 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 215 from patent US 5582979.
ACCESSION   I31303
VERSION     I31303.1  GI:1822094
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 215 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 2.3e+02;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 49
I31323/c
LOCUS       I31323                    31 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 235 from patent US 5582979.
ACCESSION   I31323
VERSION     I31323.1  GI:1822114
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 235 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 50
I31359/c
LOCUS       I31359                    31 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 271 from patent US 5582979.
ACCESSION   I31359
VERSION     I31359.1  GI:1822150
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 271 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 51
BD079200
LOCUS       BD079200                  34 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079200
VERSION     BD079200.1  GI:22624803
KEYWORDS    JP 2001299366-A/15.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 15 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/15
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .34
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 30.8;  DB 1;  Length 34;
```

```
  Best Local Similarity   64.7%;  Pred. No. 2.9e+02;
  Matches   22;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1919 AUGGGUUUCAUGUUAACUUGGAAAAAAUGCCGAC 1952
              |:|||:::||:|::|||::|||||||:||  ||
Db          1 ATGGGTTTCATGTTAACTTGGAAAAAATGCGTAC 34


RESULT 52
BD079191
LOCUS       BD079191                  31 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079191
VERSION     BD079191.1  GI:22624794
KEYWORDS    JP 2001299366-A/6.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 6 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/6
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .31
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   90.3%;  Pred. No. 2.5e+02;
  Matches   28;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 GGAAAAAAUGCCGACGGAAGGAGAGGACCUG 1968
              ||||||||:||||||:|||||||||||||:|
Db          1 GGAAAAAATGCCGACRGAAGGAGAGGACCTG 31


RESULT 53
BD079192
LOCUS       BD079192                  31 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079192
VERSION     BD079192.1  GI:22624795
KEYWORDS    JP 2001299366-A/7.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 7 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/7
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .31
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 2.5e+02;
  Matches   21;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3438 GAAAUGGAUGGCUCCCGAAUCUAUCUUUGAC 3468
              ||||:|||:|||:||:|||:|:|:|:::|||
Db          1 GAAATGGATGGCTCCYGAATCTATCTTTGAC 31


RESULT 54
BD079193
LOCUS       BD079193                  31 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079193
VERSION     BD079193.1  GI:22624796
KEYWORDS    JP 2001299366-A/8.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 8 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/8
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .31
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 31;
  Best Local Similarity   64.5%;  Pred. No. 2.5e+02;
  Matches   20;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3873 UGAUGAUGUCAGAUAUGUAAAUGCUUUCAAG 3903
              :||:||:|:||||:|:|:|||:||:::||||
```

```
Db          1 TGATGATGTCAGATAYGTAAATGCTTTCAAG 31


RESULT 55
AR073767
LOCUS       AR073767                  37 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 14 from patent US 5952199.
ACCESSION   AR073767
VERSION     AR073767.1  GI:10000527
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 14 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 3.6e+02;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 56
AR208263
LOCUS       AR208263                  37 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 14 from patent US 6383486.
ACCESSION   AR208263
VERSION     AR208263.1  GI:21509372
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 14 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 3.6e+02;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 57
AR658760
LOCUS       AR658760                  37 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 14 from patent US 6897294.
ACCESSION   AR658760
VERSION     AR658760.1  GI:67593925
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 14 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   59.5%;  Pred. No. 3.6e+02;
  Matches   22;  Conservative   11;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAGCAUUCAUCACUGUGAAAC 1261
              |:|||:|:|:|:||:|  |  ::||:|||:|:|||||
Db          1 GTGCATATATATGATACCGGTTTCATCACTGTGAAAC 37


RESULT 58
I31494/c
LOCUS       I31494                    32 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 406 from patent US 5582979.
ACCESSION   I31494
VERSION     I31494.1  GI:1822285
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 406 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 30.4;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:| |:|:|:|:|:|:|:|:|:|:|
Db         32 TGTGTGTGAGTGTGTGTGTGTGTGTGTGTG 1


RESULT 59
BD107614
LOCUS       BD107614                  30 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Novel microsatellite DNA derived from pear plants and method for
            discriminating pear plants using the same.
ACCESSION   BD107614
VERSION     BD107614.1  GI:23202432
KEYWORDS    JP 2002034597-A/23.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Yamamoto,T., Sawamura,Y., Imai,T., Matsuda,N., Saito,T., Shoda,M.,
            Kotobuki,K., Hayashi,K., Ba,Y., Kozono,M. and Kimura,T.
  TITLE     Novel microsatellite DNA derived from pear plants and method for
            discriminating pear plants using the same
  JOURNAL   Patent: JP 2002034597-A 23 05-FEB-2002;
            FRUIT TREE RES STATION
COMMENT     OS   Artificial Sequence
            PN   JP 2002034597-A/23
            PD   05-FEB-2002
            PF   21-JUL-2000 JP 2000220339
            PI   TOSHIYA YAMAMOTO,YUTAKA SAWAMURA,TSUYOSHI IMAI,NAGAO MATSUDA,
            PI   TOSHIHIRO SAITO,MORIYUKI SHODA,KAZUO KOTOBUKI,KENKI HAYASHI,
            PI   YOSHIYUKI BAN,
            PI   MASANORI KOZONO,TETSUYA KIMURA
```

```
            PC   C12Q1/68,A01H1/00,C12N15/09,C12N15/00
            CC   Description of Artificial Sequence:Probe
            FH   Key             Location/Qualifiers
            FT   source          1. .30
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 2.8e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 60
I31461/c
LOCUS       I31461                    30 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 373 from patent US 5582979.
ACCESSION   I31461
VERSION     I31461.1  GI:1822252
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 373 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 2.8e+02;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         30 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 61
AR051257/c
LOCUS       AR051257                  29 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 25 from patent US 5830658.
ACCESSION   AR051257
VERSION     AR051257.1  GI:5974621
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromolecular structures
  JOURNAL   Patent: US 5830658-A 25 03-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 3.5e+02;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 62
AR090290/c
LOCUS       AR090290                  29 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 410 from patent US 5994076.
ACCESSION   AR090290
VERSION     AR090290.1  GI:10017045
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 5994076-A 410 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 3.5e+02;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 63
I28386/c
LOCUS       I28386                    29 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 25 from patent US 5571677.
ACCESSION   I28386
VERSION     I28386.1  GI:1819162
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromomolecular structures
  JOURNAL   Patent: US 5571677-A 25 05-NOV-1996;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 3.5e+02;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 64
I31168/c
LOCUS       I31168                    29 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 80 from patent US 5582979.
ACCESSION   I31168
VERSION     I31168.1  GI:1821959
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
```

```
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 80 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         29 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 65
I31326/c
LOCUS       I31326                  29 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 238 from patent US 5582979.
ACCESSION   I31326
VERSION     I31326.1  GI:1822117
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 238 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   51.7%;  Pred. No. 3.5e+02;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 GTGTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 66
AR197325/c
LOCUS       AR197325                29 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 410 from patent US 6352829.
ACCESSION   AR197325
VERSION     AR197325.1  GI:20247174
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6352829-A 410 05-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 3.5e+02;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 67
AR259479/c
LOCUS       AR259479                29 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 410 from patent US 6489455.
ACCESSION   AR259479
VERSION     AR259479.1  GI:27309990
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 410 03-DEC-2002;
            Clontech Laboratories, Inc.; Palo Alto, CA
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   82.8%;  Pred. No. 3.5e+02;
  Matches   24;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1575 UCUCUACCCACUGGGCAGCAGACAAAUCC 1603
              :|:|:||||||:|||||||||||||:||
Db         29 TCTCTACCCACTGGGCAGCAGACAAATCC 1


RESULT 68
BD079201/c
LOCUS       BD079201                28 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079201
VERSION     BD079201.1  GI:22624804
KEYWORDS    JP 2001299366-A/16.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 16 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/16
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .28
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   64.3%;  Pred. No. 4.3e+02;
  Matches   18;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2098 AUCACUCUUAAUCUUACCAUCAUGAAUG 2125
              |:|||:|::||:|::||||:|||:|||:|
Db         28 ATCACTCTTAATCTTACCATCATGAATG 1


RESULT 69
I31539/c
LOCUS       I31539                    28 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 451 from patent US 5582979.
ACCESSION   I31539
VERSION     I31539.1  GI:1822330
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 451 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         28 GTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 70
BD079196
LOCUS       BD079196                  31 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079196
VERSION     BD079196.1  GI:22624799
KEYWORDS    JP 2001299366-A/11.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 11 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/11
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .31
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.4%;  Score 28;  DB 1;  Length 31;
  Best Local Similarity   76.7%;  Pred. No. 5.3e+02;
  Matches   23;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        177 GACGGACUCUGGCGGCCGGGUCGUUGGCCG 206
              |||||||:|:|||||:||||:| ::|||||
Db          1 GACGGACTCTGGCGGYCGGGTCTTTGGCCG 30


RESULT 71
A45639
LOCUS       A45639                    34 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 33 from Patent WO9520044.
ACCESSION   A45639
VERSION     A45639.1  GI:2300037
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Barton,C.H., White,J.K. and Blackwell,J.M.
  TITLE     NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN AND USES THEREOF
  JOURNAL   Patent: WO 9520044-A 33 27-JUL-1995;
            LYNXVALE LTD (GB)
COMMENT     Other publication CA 2181544 950727
            Other publication ZA 9500444 950927
            Other publication AU 1422595 950808.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   44.1%;  Pred. No. 7e+02;
  Matches   15;  Conservative   15;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:  |:|:|:|:|:  |:|:|:|:|
Db          1 TGTGTGTGTGTACGTGTGTGTGTACGTGTGTGTG 34


RESULT 72
AR033092
LOCUS       AR033092                  34 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 33 from patent US 5869247.
ACCESSION   AR033092
VERSION     AR033092.1  GI:5948697
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Barton,C.Howard., White,J.Katie. and Blackwell,J.Mary.
  TITLE     Natural resistance associated macrophage protein and uses thereof
  JOURNAL   Patent: US 5869247-A 33 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   44.1%;  Pred. No. 7e+02;
  Matches   15;  Conservative   15;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:  |:|:|:|:|:  |:|:|:|:|
Db          1 TGTGTGTGTGTACGTGTGTGTGTACGTGTGTGTG 34


RESULT 73
AR073764
LOCUS       AR073764                  34 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 8 from patent US 5952199.
```

```
ACCESSION   AR073764
VERSION     AR073764.1  GI:10000524
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 8 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 7e+02;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||   || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 74
AR208260
LOCUS       AR208260                34 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 8 from patent US 6383486.
ACCESSION   AR208260
VERSION     AR208260.1  GI:21509368
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 8 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 7e+02;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||   || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 75
AR658757
LOCUS       AR658757                34 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 8 from patent US 6897294.
ACCESSION   AR658757
VERSION     AR658757.1  GI:67593922
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 8 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   61.8%;  Pred. No. 7e+02;
  Matches   21;  Conservative    9;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        600 GAAGGAAACAGAAUCUGCAAUCUAUAUAUUUAUU 633
              ||||||||||||   || |:|:|:|:|:::|::
Db          1 GAAGGAAACAGAAGGCGCCATCTATATATTTATT 34


RESULT 76
E32218/c
LOCUS       E32218                    30 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for isolating satellite sequence.
ACCESSION   E32218
VERSION     E32218.1  GI:13021838
KEYWORDS    JP 2000060559-A/20.
SOURCE      Haliotis discus discus
  ORGANISM  Haliotis discus discus
            Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
            Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Hideaki,T. and Masashi,S.
  TITLE     Method for isolating satellite sequence
  JOURNAL   Patent: JP 2000060559-A 20 29-FEB-2000;
            NATL INST OF AGROBIOLOGICAL RESOUCES
COMMENT     OS   Haliotis discus discus
            PN   JP 2000060559-A/20
            PD   29-FEB-2000
            PF   18-AUG-1998 JP 1998232153
            PR
            PI   HIDEAKI TAKAHASHI,MASASHI SEKINO
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .30
            FT                   /organism='Haliotis discus discus'.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Haliotis discus discus"
                     /mol_type="genomic DNA"
                     /sub_species="discus"
                     /db_xref="taxon:91233"

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 30;
  Best Local Similarity   44.8%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|: :|:
Db         30 TGTGTGTGTGTGTGTGTGTGTGTATGT 2


RESULT 77
AR699925/c
LOCUS       AR699925                  30 bp    DNA     linear   PAT 14-SEP-2005
DEFINITION  Sequence 20 from patent US 6919443.
ACCESSION   AR699925
VERSION     AR699925.1  GI:75205846
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Takahashi,H. and Sekino,M.
  TITLE     Method for isolating satellite sequences
  JOURNAL   Patent: US 6919443-A 20 19-JUL-2005;
            National Institute of Agrobiological Sciences; Ibaraki;
            JPX;
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
```

```
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 30;
  Best Local Similarity   44.8%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|: :|:
Db         30 TGTGTGTGTGTGTGTGTGTGTGTATGT 2


RESULT 78
MME543971/c
LOCUS       MME543971                32 bp    DNA     linear   MAM 31-JAN-2005
DEFINITION  Meles meles microsatellite, locus Mel13, isolate t2.
ACCESSION   AJ543971
VERSION     AJ543971.1  GI:58371987
KEYWORDS    microsatellite; repetitive DNA.
SOURCE      Meles meles (Eurasian badger)
  ORGANISM  Meles meles
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia;
            Mustelidae; Melinae; Meles.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Lopez-Giraldez,J.F., Marmi,J. and Domingo-Roura,X.
  TITLE     High incidence of non-slippage mechanisms generating variability
            and complexity in Eurasian badger microsatellite
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 32)
  AUTHORS   Lopez-Giraldez,J.F., Marmi,J. and Domingo-Roura,X.
  TITLE     Direct Submission
  JOURNAL   Submitted (29-JAN-2003) Doctor Aiguader, 80, Barcelona 08003, Spain
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Meles meles"
                     /mol_type="genomic DNA"
                     /isolate="t2"
                     /db_xref="taxon:9662"
                     /country="Greece"
     satellite       5. .32
                     /note="microsatellite
                     locus Mel13"
                     /rpt_type=TANDEM
                     /rpt_unit_range=5. .6

  Query Match             0.4%;  Score 27.2;  DB 1;  Length 32;
  Best Local Similarity   46.9%;  Pred. No. 7e+02;
  Matches   15;  Conservative   14;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6985 UGUGUGUGUGUGUGUGUGUGUGUGUGUGGG 7016
              :|:|:|:|:|: :|:|:|:|:|:|:|:|  ||
Db         32 TGTGTGTGTGTCTGTGTGTGTGTGTGCAGG 1


RESULT 79
AR051255/c
LOCUS       AR051255                 27 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 23 from patent US 5830658.
ACCESSION   AR051255
VERSION     AR051255.1  GI:5974619
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromolecular structures
  JOURNAL   Patent: US 5830658-A 23 03-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 80
AR090289
LOCUS       AR090289                 27 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 409 from patent US 5994076.
ACCESSION   AR090289
VERSION     AR090289.1  GI:10017044
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 5994076-A 409 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 5.3e+02;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
              |:|||:||||||||:|::||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 81
AR127802/c
LOCUS       AR127802                 27 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 23 from patent US 6180777.
ACCESSION   AR127802
VERSION     AR127802.1  GI:14114397
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Horn,T.
  TITLE     Synthesis of branched nucleic acids
  JOURNAL   Patent: US 6180777-A 23 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 82
I28384/c
LOCUS       I28384                   27 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 23 from patent US 5571677.
ACCESSION   I28384
VERSION     I28384.1  GI:1819160
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromomolecular structures
  JOURNAL   Patent: US 5571677-A 23 05-NOV-1996;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 83
I31231/c
LOCUS       I31231                  27 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 143 from patent US 5582979.
ACCESSION   I31231
VERSION     I31231.1  GI:1822022
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 143 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         27 TGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 84
AR197324
LOCUS       AR197324                27 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 409 from patent US 6352829.
ACCESSION   AR197324
VERSION     AR197324.1  GI:20247173
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6352829-A 409 05-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 5.3e+02;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
              |:|||:|||||||||:|::|||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 85
AR259478
LOCUS       AR259478                27 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 409 from patent US 6489455.
ACCESSION   AR259478
VERSION     AR259478.1  GI:27309989
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 409 03-DEC-2002;
            Clontech Laboratories, Inc.; Palo Alto, CA
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   77.8%;  Pred. No. 5.3e+02;
  Matches   21;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1288 GUAGCUGGCAAGCGGUCUUACCGGCUC 1314
              |:|||:|||||||||:|::|||||||:|
Db          1 GTAGCTGGCAAGCGGTCTTACCGGCTC 27


RESULT 86
AX175237
LOCUS       AX175237                27 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 1 from Patent WO0144465.
ACCESSION   AX175237
VERSION     AX175237.1  GI:14598605
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 1 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 87
AX175241
LOCUS       AX175241                27 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 5 from Patent WO0144465.
ACCESSION   AX175241
VERSION     AX175241.1  GI:14598609
KEYWORDS    .
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 5 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
             :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 88
AX175302
LOCUS       AX175302                  27 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 66 from Patent WO0144465.
ACCESSION   AX175302
VERSION     AX175302.1  GI:14598670
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 66 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
             |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 89
AX189457
LOCUS       AX189457                  27 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 2 from Patent WO0147561.
ACCESSION   AX189457
VERSION     AX189457.1  GI:15142969
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Hyaluronic acid in the treatment of cancer
  JOURNAL   Patent: WO 0147561-A 2 05-JUL-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Oligonucleotide"

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
             |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 90
AR073773
LOCUS       AR073773                  30 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 26 from patent US 5952199.
ACCESSION   AR073773
VERSION     AR073773.1  GI:10000533
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 26 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 6.9e+02;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
             |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 91
I31503/c
LOCUS       I31503                    30 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 415 from patent US 5582979.
ACCESSION   I31503
VERSION     I31503.1  GI:1822294
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 415 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   43.3%;  Pred. No. 6.9e+02;
  Matches   13;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
             :|:|:|:|:|:|:|: :|: :|:|:|:|:|
Db         30 TGTGTGTGTGTGTCTGTCTGTGTGTGTG 1


RESULT 92
AR208269
LOCUS       AR208269                  30 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 26 from patent US 6383486.
ACCESSION   AR208269
```

```
VERSION     AR208269.1  GI:21509379
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 26 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 6.9e+02;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 93
AR658766
LOCUS       AR658766                  30 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 26 from patent US 6897294.
ACCESSION   AR658766
VERSION     AR658766.1  GI:67593933
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 26 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 26.8;  DB 1;  Length 30;
  Best Local Similarity   76.7%;  Pred. No. 6.9e+02;
  Matches   23;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 AUUACAAUCAGAGAUCAGGAAGCACCAUAC 2235
              |::||||:||||  :||||||||||||:||
Db          1 ATTACAATCAGATCTCAGGAAGCACCATAC 30


RESULT 94
AR073770
LOCUS       AR073770                  31 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 20 from patent US 5952199.
ACCESSION   AR073770
VERSION     AR073770.1  GI:10000530
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 20 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 8.6e+02;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:|||||  |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 95
AR208266
LOCUS       AR208266                  31 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 20 from patent US 6383486.
ACCESSION   AR208266
VERSION     AR208266.1  GI:21509376
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 20 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 8.6e+02;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:|||||  |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 96
AR658763
LOCUS       AR658763                  31 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 20 from patent US 6897294.
ACCESSION   AR658763
VERSION     AR658763.1  GI:67593928
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 20 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 31;
  Best Local Similarity   67.7%;  Pred. No. 8.6e+02;
  Matches   21;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1497 AAACCUCACUGCCACUCUAAUUGUCAAUGUG 1527
              |||||:|||:|||||  |:|  :|:|||:|:|
Db          1 AAACCTCACTGCCACGCTAGCTGTCAATGTG 31


RESULT 97
E32225/c
LOCUS       E32225                    32 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for isolating satellite sequence.
```

```
ACCESSION   E32225
VERSION     E32225.1  GI:13021859
KEYWORDS    JP 2000060559-A/27.
SOURCE      Haliotis discus discus
  ORGANISM  Haliotis discus discus
            Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
            Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Hideaki,T. and Masashi,S.
  TITLE     Method for isolating satellite sequence
  JOURNAL   Patent: JP 2000060559-A 27 29-FEB-2000;
            NATL INST OF AGROBIOLOGICAL RESOUCES
COMMENT     OS   Haliotis discus discus
            PN   JP 2000060559-A/27
            PD   29-FEB-2000
            PF   18-AUG-1998 JP 1998232153
            PR
            PI   HIDEAKI TAKAHASHI,MASASHI SEKINO
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .32
            FT                   /organism='Haliotis discus discus'.
FEATURES              Location/Qualifiers
     source           1. .32
                      /organism="Haliotis discus discus"
                      /mol_type="genomic DNA"
                      /sub_species="discus"
                      /db_xref="taxon:91233"

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 32;
  Best Local Similarity   58.1%;  Pred. No. 9.2e+02;
  Matches   18;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6994 GUGUGUGUGUGUGUGUGUGGGUGUGGGUG 7024
                | |:|:|:|:|:|:|:|:|:|:|:|| | |||:|
Db         31 GGGTGTGTGTGTGTGTGTGGGGGGGGGTG 1


RESULT 98
AR699932/c
LOCUS       AR699932                32 bp    DNA     linear   PAT 14-SEP-2005
DEFINITION  Sequence 27 from patent US 6919443.
ACCESSION   AR699932
VERSION     AR699932.1  GI:75205855
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Takahashi,H. and Sekino,M.
  TITLE     Method for isolating satellite sequences
  JOURNAL   Patent: US 6919443-A 27 19-JUL-2005;
            National Institute of Agrobiological Sciences; Ibaraki;
            JPX;
FEATURES              Location/Qualifiers
     source           1. .32
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             0.3%;  Score 26.2;  DB 1;  Length 32;
  Best Local Similarity   58.1%;  Pred. No. 9.2e+02;
  Matches   18;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6994 GUGUGUGUGUGUGUGUGUGGGUGUGGGUG 7024
                | |:|:|:|:|:|:|:|:|:|:|:|| | |||:|
Db         31 GGGTGTGTGTGTGTGTGTGGGGGGGGGTG 1


RESULT 99
AR489882/c
LOCUS       AR489882                26 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 5 from patent US 6710174.
ACCESSION   AR489882
VERSION     AR489882.1  GI:47256995
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 5 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES              Location/Qualifiers
     source           1. .26
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   57.7%;  Pred. No. 6.5e+02;
  Matches   15;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1399 UUGACUCGUGGCUACUCGUUAAUUAU 1424
                ::|||:||:|||:||:||::||::|:
Db         26 TTGACTCGTGGCTACTCGTTAATTAT 1


RESULT 100
AR489883
LOCUS       AR489883                26 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 6 from patent US 6710174.
ACCESSION   AR489883
VERSION     AR489883.1  GI:47256996
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 6 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES              Location/Qualifiers
     source           1. .26
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   76.9%;  Pred. No. 6.5e+02;
  Matches   20;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1371 ACCUGCGACUGAGAAAUCUGCUCGCU 1396
                |||:|||||:||||||:|:||:|||:
Db          1 ACCTGCGACTGAGAAATCTGCTCGCT 26


RESULT 101
AR073777/c
LOCUS       AR073777                25 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 36 from patent US 5952199.
ACCESSION   AR073777
VERSION     AR073777.1  GI:10000537
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 36 14-SEP-1999;
FEATURES              Location/Qualifiers
     source           1. .25
```

```
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 7.9e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 102
AR073778
LOCUS       AR073778                  25 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 37 from patent US 5952199.
ACCESSION   AR073778
VERSION     AR073778.1  GI:10000538
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 37 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 7.9e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 103
I31234/c
LOCUS       I31234                    25 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 146 from patent US 5582979.
ACCESSION   I31234
VERSION     I31234.1  GI:1822025
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 146 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 7.9e+02;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         25 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 104
AR208273/c
LOCUS       AR208273                  25 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 36 from patent US 6383486.
ACCESSION   AR208273
VERSION     AR208273.1  GI:21509384
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 36 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 7.9e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 105
AR208274
LOCUS       AR208274                  25 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 37 from patent US 6383486.
ACCESSION   AR208274
VERSION     AR208274.1  GI:21509386
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 37 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 7.9e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 106
AR658770/c
LOCUS       AR658770                  25 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 36 from patent US 6897294.
ACCESSION   AR658770
VERSION     AR658770.1  GI:67593939
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 36 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .25
```

```
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match              0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   84.0%;  Pred. No. 7.9e+02;
  Matches   21;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 GAACACGAGAGUUCAAAUGACCUGG 1047
              |||||||||||::||||:||||:||
Db         25 GAACACGAGAGTTCAAATGACCTGG 1


RESULT 107
AR658771
LOCUS       AR658771                 25 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 37 from patent US 6897294.
ACCESSION   AR658771
VERSION     AR658771.1  GI:67593940
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 37 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match              0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 7.9e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 UACUUAGAGGCCAUACUCUUGUCCU 998
              :||::||||||||:||:|::|:||:
Db          1 TACTTAGAGGCCATACTCTTGTCCT 25


RESULT 108
AX115976
LOCUS       AX115976                 25 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 1099 from Patent WO0129262.
ACCESSION   AX115976
VERSION     AX115976.1  GI:14032918
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 1099 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match              0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 7.9e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTG 25


RESULT 109
AX739949
LOCUS       AX739949                 25 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 21 from Patent WO03024478.
ACCESSION   AX739949
VERSION     AX739949.1  GI:30519225
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Delfani,K., Janson,A.M., Kuhn,G.H., Plate,K., Schanzer,A.,
            Wachs,F.P. and Zhao,M.
  TITLE     Treatment of central nervous system disorders by use of pdgf or
            vegf
  JOURNAL   Patent: WO 03024478-A 21 27-MAR-2003;
            Neuronova AB (SE)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match              0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 7.9e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        939 AGAUGUCCAAAUAAGCACACCACGC 963
              |||:|:|||||:||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 110
AX739951
LOCUS       AX739951                 25 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 23 from Patent WO03024478.
ACCESSION   AX739951
VERSION     AX739951.1  GI:30519227
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Delfani,K., Janson,A.M., Kuhn,G.H., Plate,K., Schanzer,A.,
            Wachs,F.P. and Zhao,M.
  TITLE     Treatment of central nervous system disorders by use of pdgf or
            vegf
  JOURNAL   Patent: WO 03024478-A 23 27-MAR-2003;
            Neuronova AB (SE)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match              0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 7.9e+02;
  Matches   22;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        939 AGAUGUCCAAAUAAGCACACCACGC 963
              |||:|:|||||:||||||||||||
Db          1 AGATGTCCAAATAAGCACACCACGC 25


RESULT 111
AX739952/c
LOCUS       AX739952                 25 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 24 from Patent WO03024478.
ACCESSION   AX739952
VERSION     AX739952.1  GI:30519228
KEYWORDS    .
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Delfani,K., Janson,A.M., Kuhn,G.H., Plate,K., Schanzer,A.,
            Wachs,F.P. and Zhao,M.
  TITLE     Treatment of central nervous system disorders by use of pdgf or
            vegf
  JOURNAL   Patent: WO 03024478-A 24 27-MAR-2003;
            Neuronova AB (SE)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 7.9e+02;
  Matches   16;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1385 AAUCUGCUCGCUAUUUGACUCGUGG 1409
              ||:|:||:|||:|:::|||:||:||
Db         25 AATCTGCTCGCTATTTGACTCGTGG 1

RESULT 112
BD079197
LOCUS       BD079197                  31 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnostic method.
ACCESSION   BD079197
VERSION     BD079197.1  GI:22624800
KEYWORDS    JP 2001299366-A/12.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Smith,J.C.
  TITLE     Diagnostic method
  JOURNAL   Patent: JP 2001299366-A 12 30-OCT-2001;
            ASTRAZENECA AB
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001299366-A/12
            PD   30-OCT-2001
            PF   22-FEB-2001 JP 2001046484
            PR   24-FEB-2000 GB      0004232
            PI   JOHN CRAIG SMITH
            PC   C12N15/09,A61K45/00,A61P15/00,A61P17/06,A61P27/06,A61P29/00,
            PC   A61P35/00,
            PC   C12M1/00,C12Q1/68,G01N33/15,G01N33/50,G01N33/50,G01N33/50, PC
             G01N33/566,
            PC   C12N15/00
            CC   Diagnostic method
            FH   Key             Location/Qualifiers
            FT   source          1. .31
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.3%;  Score 25;  DB 1;  Length 31;
  Best Local Similarity   74.1%;  Pred. No. 1.2e+03;
  Matches   20;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 UCUGGCGGCCGGGUCGUUGGCCGGGGG 210
              :|:||||||||||:|:::||||| |||
Db          1 TCTGGCGGCCGGGTCKTTGGCCGCGGG 27

RESULT 113
AX060548
LOCUS       AX060548                  30 bp    DNA     linear   PAT 22-JAN-2001
DEFINITION  Sequence 15 from Patent WO0100854.
ACCESSION   AX060548
VERSION     AX060548.1  GI:12406001
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Davis,P.D.
  TITLE     Chimeric proteins mediating targeted apoptosis
  JOURNAL   Patent: WO 0100854-A 15 04-JAN-2001;
            Angiogene Pharmaceuticals Ltd (GB)
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 24.2;  DB 1;  Length 30;
  Best Local Similarity   82.8%;  Pred. No. 1.4e+03;
  Matches   24;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         62 CGGGUGCAGCGGCCAGCGGGCCUGGCGGC 90
              ||||: | |||||||||||||:|||| |
Db          2 CGGGTACCGCGGCCAGCGGGCCTGGCGCC 30

RESULT 114
CQ979110
LOCUS       CQ979110                  24 bp    DNA     linear   PAT 19-JAN-2005
DEFINITION  Sequence 112 from Patent WO2004111273.
ACCESSION   CQ979110
VERSION     CQ979110.1  GI:57976363
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Agus,D., Baker,J.B., Natale,R. and Shak,S.
  TITLE     Gene expression markers for response to egfr inhibitor drugs
  JOURNAL   Patent: WO 2004111273-A 112 23-DEC-2004;
            Genomic Health, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="probe"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 9.6e+02;
  Matches   21;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3474 CUACAGCACCAAGAGCGACGUGUG 3497
              |:|||||||||||||||||:|:|
Db          1 CTACAGCACCAAGAGCGACGTGTG 24

RESULT 115
CS082792/c
LOCUS       CS082792                  24 bp    DNA     linear   PAT 18-MAY-2005
DEFINITION  Sequence 22 from Patent WO2005039616.
ACCESSION   CS082792
VERSION     CS082792.1  GI:66349409
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
```

```
  AUTHORS   Hardy,B., Battler,A., Raiter,A., Kornowski,R. and Weiss,C.
  TITLE     Angiogenic peptides and uses thereof
  JOURNAL   Patent: WO 2005039616-A 22 06-MAY-2005;
            Ramot at Tel Aviv University Ltd. (IL)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Single strand DNA oligonucleotide"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   75.0%;  Pred. No. 9.6e+02;
  Matches   18;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1794 GAAUAAGAUGGCUAGCACCUUGGU 1817
              |||:||||:|||:||||||::||:
Db         24 GAATAAGATGGCTAGCACCTTGGT 1


RESULT 116
CS144192/c
LOCUS       CS144192                  24 bp    DNA     linear   PAT 19-AUG-2005
DEFINITION  Sequence 44 from Patent EP1564292.
ACCESSION   CS144192
VERSION     CS144192.1  GI:73659139
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S.
  JOURNAL   Patent: EP 1564292-A 44 17-AUG-2005;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-2 gene specific primers for RT-PCT"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   83.3%;  Pred. No. 9.6e+02;
  Matches   20;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3736 CAACAGGAUGGUAAAGACUACAUC 3759
              ||||||||:||:||||||:|||:|
Db         24 CAACAGGATGGTAAAGACTACATC 1


RESULT 117
I31533/c
LOCUS       I31533                    24 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 445 from patent US 5582979.
ACCESSION   I31533
VERSION     I31533.1  GI:1822324
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 445 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 9.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 118
AX104876
LOCUS       AX104876                  24 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 1068 from Patent WO0122972.
ACCESSION   AX104876
VERSION     AX104876.1  GI:13921073
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 1068 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 9.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 119
AX175257
LOCUS       AX175257                  24 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 21 from Patent WO0144465.
ACCESSION   AX175257
VERSION     AX175257.1  GI:14598625
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 21 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 9.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 120
AX175258
LOCUS       AX175258                  24 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 22 from Patent WO0144465.
ACCESSION   AX175258
VERSION     AX175258.1  GI:14598626
```

```
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 22 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 9.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24


RESULT 121
AX203709/c
LOCUS       AX203709                 24 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 44 from Patent WO0152904.
ACCESSION   AX203709
VERSION     AX203709.1  GI:15393158
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S. and Masood,R.
  TITLE     Methods and compositions for antisense vegf oligonucleotides
  JOURNAL   Patent: WO 0152904-A 44 26-JUL-2001;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-2 gene specific primers for RT-PCT"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   83.3%;  Pred. No. 9.6e+02;
  Matches   20;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3736 CAACAGGAUGGUAAAGACUACAUC 3759
              ||||||||:||:||||||:|||:|
Db         24 CAACAGGATGGTAAAGACTACATC 1


RESULT 122
AX547929
LOCUS       AX547929                 24 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 1068 from Patent WO02053141.
ACCESSION   AX547929
VERSION     AX547929.1  GI:25813073
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 1068 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 9.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 24


RESULT 123
AX117836/c
LOCUS       AX117836                 25 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 2959 from Patent WO0129262.
ACCESSION   AX117836
VERSION     AX117836.1  GI:14034787
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 2959 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 24;  DB 1;  Length 25;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:
Db         24 GTGTGTGTGTGTGTGTGTGTGT 1


RESULT 124
AX117828/c
LOCUS       AX117828                 25 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 2951 from Patent WO0129262.
ACCESSION   AX117828
VERSION     AX117828.1  GI:14034779
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 2951 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGU 6995
              || |:|:|:|:|:|:|:|:|:|:|:
Db         25 ACCGTGTGTGTGTGTGTGTGTGT 1
```

```
RESULT 125
AX117832/c
LOCUS       AX117832                  25 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 2955 from Patent WO0129262.
ACCESSION   AX117832
VERSION     AX117832.1  GI:14034783
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 2955 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUG 6996
                | |:|:|:|:|:|:|:|:|:|:|
Db         25 CCGTGTGTGTGTGTGTGTGTGTG 1


RESULT 126
AR030846
LOCUS       AR030846                  23 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 10 from patent US 5861484.
ACCESSION   AR030846 .
VERSION     AR030846.1  GI:5944060
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Kendall,R.L. and Thomas,K.A. Jr.
  TITLE     Inhibitor of vascular endothelial cell growth factor
  JOURNAL   Patent: US 5861484-A 10 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 127
AR127801/c
LOCUS       AR127801                  23 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 22 from patent US 6180777.
ACCESSION   AR127801
VERSION     AR127801.1  GI:14114396
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Horn,T.
  TITLE     Synthesis of branched nucleic acids
  JOURNAL   Patent: US 6180777-A 22 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|
Db         23 GTGTGTGTGTGTGTGTGTGTG 1


RESULT 128
CS144190
LOCUS       CS144190                  23 bp    DNA     linear   PAT 19-AUG-2005
DEFINITION  Sequence 42 from Patent EP1564292.
ACCESSION   CS144190
VERSION     CS144190.1  GI:73659137
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S.
  JOURNAL   Patent: EP 1564292-A 42 17-AUG-2005;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-1 gene specific primers for RT-PCR"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 129
CS144191
LOCUS       CS144191                  23 bp    DNA     linear   PAT 19-AUG-2005
DEFINITION  Sequence 43 from Patent EP1564292.
ACCESSION   CS144191
VERSION     CS144191.1  GI:73659138
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S.
  JOURNAL   Patent: EP 1564292-A 43 17-AUG-2005;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-1 gene specific primers for RT-PCR"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:|||||||||||:||||::
```

```
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 130
DD203516
LOCUS       DD203516                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203516
VERSION     DD203516.1  GI:85660687
KEYWORDS    JP 2005517436-A/1997.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 1997 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/1997
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   65.2%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        296 GCUGUCUGCUUCUCACAGGAUCU 318
              ||:|:|:||::|:|||||||:|:
Db          1 GCTGTCTGCTTCTCACAGGATCT 23


RESULT 131
DD203517
LOCUS       DD203517                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203517
VERSION     DD203517.1  GI:85660688
KEYWORDS    JP 2005517436-A/1998.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 1998 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/1998
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 1.2e+03;
  Matches   20;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1954 GAAGGAGAGGACCUGAAACUGUC 1976
              |||||||||||||:|||||:|:|
Db          1 GAAGGAGAGGACCTGAAACTGTC 23


RESULT 132
DD203518
LOCUS       DD203518                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203518
VERSION     DD203518.1  GI:85660689
KEYWORDS    JP 2005517436-A/1999.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 1999 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/1999
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAGGAGAGGACCUGAAACUGUCU 1977
              |||||||||||:|||||:|:|:
Db          1 AAGGAGAGGACCTGAAACTGTCT 23
```

```
RESULT 133
DD203519
LOCUS       DD203519                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203519
VERSION     DD203519.1  GI:85660690
KEYWORDS    JP 2005517436-A/2000.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2000 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2000
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   73.9%;  Pred. No. 1.2e+03;
  Matches   17;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2785 GCAUUUGGCAUUAAGAAAUCACC 2807
              |||:::||||::||||||:||||
Db          1 GCATTTGGCATTAAGAAATCACC 23


RESULT 134
DD203528
LOCUS       DD203528                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203528
VERSION     DD203528.1  GI:85660699
KEYWORDS    JP 2005517436-A/2009.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2009 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2009
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCCAG 369
              |||:|||:::|||||||||||||
Db          1 AACTGAGTTTAAAAGGCACCCAG 23


RESULT 135
DD203529
LOCUS       DD203529                  23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203529
VERSION     DD203529.1  GI:85660700
KEYWORDS    JP 2005517436-A/2010.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2010 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2010
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 1.2e+03;
  Matches   22;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              |||||||||||||:|||||||||
Db          1 AACAACCACAAAATACAACAAGA 23


RESULT 136
```

```
DD203530
LOCUS       DD203530                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203530
VERSION     DD203530.1  GI:85660701
KEYWORDS    JP 2005517436-A/2011.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2011 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2011
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3910 AGCCUGGAAAGAAUCAAAACCUU 3932
              ||||:||||||||:|||||||::
Db          1 AGCCTGGAAAGAATCAAAACCTT 23


RESULT 137
DD203531
LOCUS       DD203531                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203531
VERSION     DD203531.1  GI:85660702
KEYWORDS    JP 2005517436-A/2012.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2012 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2012
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
              ||||||||||||||:|:||:||:
Db          1 AAGCAAGGAGGGCCTCTGATGGT 23


RESULT 138
DD203532
LOCUS       DD203532                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203532
VERSION     DD203532.1  GI:85660703
KEYWORDS    JP 2005517436-A/2013.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2013 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2013
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   73.9%;  Pred. No. 1.2e+03;
  Matches   17;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 UCGUGUAAGGAGUGGACCAUCAU 1204
              :||:|:||||||:||||||:||:
Db          1 TCGTGTAAGGAGTGGACCATCAT 23


RESULT 139
DD203533
LOCUS       DD203533                 23 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203533
VERSION     DD203533.1  GI:85660704
KEYWORDS    JP 2005517436-A/2014.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2014 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2014
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3501 UUACGGAGUAUUGCUGUGGGAAA 3523
              ::|||||||:|::||:|:|||||||
Db          1 TTACGGAGTATTGCTGTGGGAAA 23


RESULT 140
DD203534
LOCUS       DD203534                23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203534
VERSION     DD203534.1  GI:85660705
KEYWORDS    JP 2005517436-A/2015.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2015 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2015
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4713 UAGCAGGCCUAAGACAUGUGAGG 4735
              :||||||||:||||||:|:||||
Db          1 TAGCAGGCCTAAGACATGTGAGG 23


RESULT 141
DD203535
LOCUS       DD203535                23 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203535
VERSION     DD203535.1  GI:85660706
KEYWORDS    JP 2005517436-A/2016.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2016 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2016
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
              |||||||||||||||||||||||
Db          1 AGCAAAAAGCAAGGGAGAAAAGA 23


RESULT 142
DD207267
LOCUS       DD207267                23 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207267
VERSION     DD207267.1  GI:85644387
KEYWORDS    JP 2005518803-A/56.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 56 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/56
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        347 AACUGAGUUUAAAAGGCACCCAG 369
              |||:|||:::|||||||||||||
Db          1 AACTGAGTTTAAAAGGCACCCAG 23


RESULT 143
DD207268
LOCUS       DD207268                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207268
VERSION     DD207268.1  GI:85644388
KEYWORDS    JP 2005518803-A/57.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 57 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/57
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 1.2e+03;
  Matches   22;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAAGA 2360
              ||||||||||||:|||||||||
Db          1 AACAACCACAAAATACAACAAGA 23


RESULT 144
DD207269
LOCUS       DD207269                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207269
VERSION     DD207269.1  GI:85644389
KEYWORDS    JP 2005518803-A/58.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 58 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/58
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3910 AGCCUGGAAAGAAUCAAAACCUU 3932
              ||||:||||||||:|||||||::
Db          1 AGCCTGGAAAGAATCAAAACCTT 23


RESULT 145
DD207270
LOCUS       DD207270                 23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207270
VERSION     DD207270.1  GI:85644390
KEYWORDS    JP 2005518803-A/59.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 59 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/59
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAUGGU 2969
              |||||||||||||:|:||:||:
Db          1 AAGCAAGGAGGGCCTCTGATGGT 23


RESULT 146
DD207271
LOCUS       DD207271                23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207271
VERSION     DD207271.1  GI:85644391
KEYWORDS    JP 2005518803-A/60.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 60 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/60
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   73.9%;  Pred. No. 1.2e+03;
  Matches   17;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 UCGUGUAAGGAGUGGACCAUCAU 1204
              :||:|:||||||:||||||:||:
Db          1 TCGTGTAAGGAGTGGACCATCAT 23


RESULT 147
DD207272
LOCUS       DD207272                23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207272
VERSION     DD207272.1  GI:85644392
KEYWORDS    JP 2005518803-A/61.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 61 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/61
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .23
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3501 UUACGGAGUAUUGCUGUGGGAAA 3523
              ::||||||:|::||:|:||||||
Db          1 TTACGGAGTATTGCTGTGGGAAA 23


RESULT 148
DD207273
LOCUS       DD207273                23 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207273
VERSION     DD207273.1  GI:85644393
KEYWORDS    JP 2005518803-A/62.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
```

```
          Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE   RNA Interference Mediated Inhibition of Gene Expression Using Short
          Interfering Nucleic Acid (siNA)
  JOURNAL Patent: JP 2005518803-A 62 30-JUN-2005;
          Sirna Therapeutics Inc
COMMENT   OS   Artificial Sequence
          PN   JP 2005518803-A/62
          PD   30-JUN-2005
          PF   20-FEB-2003 JP 2003573107
          PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
          05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
          06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
          20-FEB-2002 US    60/358580
          PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
          chourira,
          PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
           Description of Artificial Sequence:  Target Sequence/siNA  CC
                sense region
          FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4713 UAGCAGGCCUAAGACAUGUGAGG 4735
              :||||||||:||||||:|:||||
Db          1 TAGCAGGCCTAAGACATGTGAGG 23


RESULT 149
DD207274
LOCUS       DD207274                23 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207274
VERSION     DD207274.1  GI:85644394
KEYWORDS    JP 2005518803-A/63.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 63 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/63
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  Target Sequence/siNA  CC
                  sense region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4751 AGCAAAAAGCAAGGGAGAAAAGA 4773
              |||||||||||||||||||||||
Db          1 AGCAAAAAGCAAGGGAGAAAAGA 23


RESULT 150
I31542/c
LOCUS       I31542                  23 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 454 from patent US 5582979.
ACCESSION   I31542
VERSION     I31542.1  GI:1822333
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 454 10-DEC-1996;
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.2e+03;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 151
I82805
LOCUS       I82805                  23 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 10 from patent US 5712380.
ACCESSION   I82805
VERSION     I82805.1  GI:3211102
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Kendall,R.L. and Thomas,K.A. Jr.
  TITLE     DNA encoding a soluble VEGF inhibitor
  JOURNAL   Patent: US 5712380-A 10 27-JAN-1998;
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.2e+03;
  Matches   16;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1807 AGCACCUUGGUUGUGGCUGACUC 1829
              ||||||::||::|:|||:|||:|
Db          1 AGCACCTTGGTTGTGGCTGACTC 23


RESULT 152
AX203707
LOCUS       AX203707                23 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 42 from Patent WO0152904.
ACCESSION   AX203707
VERSION     AX203707.1  GI:15393156
```

```
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S. and Masood,R.
  TITLE     Methods and compositions for antisense vegf oligonucleotides
  JOURNAL   Patent: WO 0152904-A 42 26-JUL-2001;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-1 gene specific primers for RT-PCR"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 153
AX203708
LOCUS       AX203708                  23 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 43 from Patent WO0152904.
ACCESSION   AX203708
VERSION     AX203708.1  GI:15393157
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S. and Masood,R.
  TITLE     Methods and compositions for antisense vegf oligonucleotides
  JOURNAL   Patent: WO 0152904-A 43 26-JUL-2001;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-1 gene specific primers for RT-PCR"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGAGUU 3284
              ||||:||||||||||:||||::
Db          1 CAAGTGGCCAGAGGCATGGAGTT 23


RESULT 154
AX739950/c
LOCUS       AX739950                  23 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 22 from Patent WO03024478.
ACCESSION   AX739950
VERSION     AX739950.1  GI:30519226
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Delfani,K., Janson,A.M., Kuhn,G.H., Plate,K., Schanzer,A.,
            Wachs,F.P. and Zhao,M.
  TITLE     Treatment of central nervous system disorders by use of pdgf or
            vegf
  JOURNAL   Patent: WO 03024478-A 22 27-MAR-2003;
            Neuronova AB (SE)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 1.2e+03;
  Matches   19;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1263 UCGAAAACAGCAGGUGCUUGAAA 1285
              :|||||||||||||:||::||||
Db         23 TCGAAAACAGCAGGTGCTTGAAA 1


RESULT 155
AR002279/c
LOCUS       AR002279                  27 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 18 from patent US 5741645.
ACCESSION   AR002279
VERSION     AR002279.1  GI:3963833
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Orr,H.T., Ranum,L.P.W., Chung,M.-Y. and Zoghbi,H.Y.
  TITLE     Gene sequence for spinocerebellar ataxia type 1 and method for
            diagnosis
  JOURNAL   Patent: US 5741645-A 18 21-APR-1998;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 2e+03;
  Matches   14;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6996 GUGUGUGUGUGUGUGUGGGUGUGGG 7022
             * |:|:|:|:|:|:|:|:|:|| :  |||
Db         27 GTGTGTGTGTGTGTGTGTGGATCCGGG 1


RESULT 156
AR053130/c
LOCUS       AR053130                  27 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 36 from patent US 5834183.
ACCESSION   AR053130
VERSION     AR053130.1  GI:5977992
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Orr,H.T., Ranum,L.P.W., Chung,M.-y. and Zoghbi,H.Y.
  TITLE     Gene sequence for spinocerebellar ataxia type 1 and method for
            diagnosis
  JOURNAL   Patent: US 5834183-A 36 10-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 2e+03;
  Matches   14;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6996 GUGUGUGUGUGUGUGUGGGUGUGGG 7022
              |:|:|:|:|:|:|:|:|:|| :  |||
Db         27 GTGTGTGTGTGTGTGTGTGGATCCGGG 1
```

```
RESULT 157
AR073768
LOCUS       AR073768                  27 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 16 from patent US 5952199.
ACCESSION   AR073768
VERSION     AR073768.1  GI:10000528
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 16 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 2e+03;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 158
AR208264
LOCUS       AR208264                  27 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 16 from patent US 6383486.
ACCESSION   AR208264
VERSION     AR208264.1  GI:21509373
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 16 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 2e+03;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 159
AR658761
LOCUS       AR658761                  27 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 16 from patent US 6897294.
ACCESSION   AR658761
VERSION     AR658761.1  GI:67593926
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 16 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 2e+03;
  Matches   16;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1213 GUUAACACCUCAGUGCAUAUAUAUGAU 1239
              |::||||||:|||:|||  : :|:||:
Db          1 GTTAACACCTCAGTGCACGTGTATGAT 27


RESULT 160
BD235062
LOCUS       BD235062                  22 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  A method for stimulating the immune system.
ACCESSION   BD235062
VERSION     BD235062.1  GI:33044832
KEYWORDS    JP 2002517434-A/166.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
          ° Hominidae; Homo.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Schlingensiepen,K.H., Schlingensiepen,R. and Brysch,W.
  TITLE     A method for stimulating the immune system
  JOURNAL   Patent: JP 2002517434-A 166 18-JUN-2002;
            BIOGNOSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002517434-A/166
            PD   18-JUN-2002
            PF   10-JUN-1999 JP 2000553044
            PR   10-JUN-1998 EP   98110709.7,25-JUL-1998 EP   98113974.4 PI
            KARL HERMANN SCHLINGENSIEPEN,REIMAR SCHLINGENSIEPEN,WOLFGANG  PI
            BRYSCH
            PC   A61K45/06,A61K31/7088,A61K38/00,A61K39/395,A61K39/395,A61P31/
            PC   00,A61P35/00,
            PC   A61P35/02,A61P37/02,C12N15/09,A61K37/02,C12N15/00 CC   A
            method for stimulating the immune system
            FH   Key             Location/Qualifiers
            FT   source          1. .22
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   72.7%;  Pred. No. 1.4e+03;
  Matches   16;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUG 2708
              :|||::|:||:||||||||:|
Db          1 TCCCTTATGATGCCAGCAAGTG 22


RESULT 161
CS237350
LOCUS       CS237350                  22 bp    DNA     linear   PAT 04-JAN-2006
DEFINITION  Sequence 65 from Patent WO2005113596.
ACCESSION   CS237350
VERSION     CS237350.1  GI:84364432
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
```

```
  AUTHORS   Jin,P.
  JOURNAL   Patent: WO 2005113596-A 65 01-DEC-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer VEGFR1_F1"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 1.4e+03;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        249 CAUGGUCAGCUACUGGGACACC 270
              ||:||:||||:||:||||||||
Db          1 CATGGTCAGCTACTGGGACACC 22


RESULT 162
CS237361/c
LOCUS       CS237361                  22 bp    DNA     linear   PAT 04-JAN-2006
DEFINITION  Sequence 76 from Patent WO2005113596.
ACCESSION   CS237361
VERSION     CS237361.1  GI:84364443
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jin,P.
  JOURNAL   Patent: WO 2005113596-A 76 01-DEC-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer VEGFR1_R1"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   77.3%;  Pred. No. 1.4e+03;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1763 UCACUCAGCGCAUGGCAAUAAU 1784
              :|||:|||||||:|||||:||:
Db         22 TCACTCAGCGCATGGCAATAAT 1


RESULT 163
I31213/c
LOCUS       I31213                    22 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 125 from patent US 5582979.
ACCESSION   I31213
VERSION     I31213.1  GI:1822004
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 125 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6995
              |:|:|:|:|:|:|:|:|:|:|:
Db         22 GTGTGTGTGTGTGTGTGTGTGT 1


RESULT 164
AR349812
LOCUS       AR349812                  22 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3 from patent US 6586192.
ACCESSION   AR349812
VERSION     AR349812.1  GI:33750700
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Peschle,C. and Ziegler,B.L.
  TITLE     Compositions and methods for use in affecting hematopoietic stem
            cell populations in mammals
  JOURNAL   Patent: US 6586192-A 3 01-JUL-2003;
            Thomas Jefferson University and Instituto Superiore di Sanita;
            Philadelphia, PA
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   86.4%;  Pred. No. 1.4e+03;
  Matches   19;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3109 AAACCAAGACUAGAUAGCGUCA 3130
              ||||||||||:|||:||||:||
Db          1 AAACCAAGACTAGATAGCGTCA 22


RESULT 165
AR349813/c
LOCUS       AR349813                  22 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 4 from patent US 6586192.
ACCESSION   AR349813
VERSION     AR349813.1  GI:33750701
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Peschle,C. and Ziegler,B.L.
  TITLE     Compositions and methods for use in affecting hematopoietic stem
            cell populations in mammals
  JOURNAL   Patent: US 6586192-A 4 01-JUL-2003;
            Thomas Jefferson University and Instituto Superiore di Sanita;
            Philadelphia, PA
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 1.4e+03;
  Matches   18;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 AAGAACCCCGAUUAUGUGAGAA 3415
              ||||||||||::|:|:|||||
Db         22 AAGAACCCCGATTATGTGAGAA 1


RESULT 166
AX009133
LOCUS       AX009133                  22 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 166 from Patent WO9963975.
ACCESSION   AX009133
VERSION     AX009133.1  GI:9996507
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1
  AUTHORS   Brysch,W., Schlingensiepen,K.H. and Schlingensiepen,R.
  TITLE     A method for stimulating the immune system
  JOURNAL   Patent: WO 9963975-A 166 16-DEC-1999;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE); SCHLINGENSIEPEN KARL
            HERMANN (DE); SCHLINGENSIEPEN REIMAR (DE)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   72.7%;  Pred. No. 1.4e+03;
  Matches   16;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2687 UCCCUUAUGAUGCCAGCAAGUG 2708
              :|||::|:||:||||||||:|
Db          1 TCCCTTATGATGCCAGCAAGTG 22


RESULT 167
AR448724/c
LOCUS       AR448724                  23 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1 from patent US 6673611.
ACCESSION   AR448724
VERSION     AR448724.1  GI:42677341
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Thompson,J., Beigelman,L., McSwiggen,J., Karpeisky,A., Bellon,L.,
            Reynolds,M., Zwick,M., Jarvis,T., Woolf,T., Haeberli,P. and
            Matulic-Adamic,J.
  TITLE     Nucleic acid molecules with novel chemical compositions capable of
            modulating gene expression
  JOURNAL   Patent: US 6673611-A 1 06-JAN-2004;
            Sirna Therapeutics, Inc.; Boulder, CO
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   77.3%;  Pred. No. 1.5e+03;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         22 TTCATGAGCCTGGAAAGAATCA 1


RESULT 168
AR448726/c
LOCUS       AR448726                  25 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 3 from patent US 6673611.
ACCESSION   AR448726
VERSION     AR448726.1  GI:42677343
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Thompson,J., Beigelman,L., McSwiggen,J., Karpeisky,A., Bellon,L.,
            Reynolds,M., Zwick,M., Jarvis,T., Woolf,T., Haeberli,P. and
            Matulic-Adamic,J.
  TITLE     Nucleic acid molecules with novel chemical compositions capable of
            modulating gene expression
  JOURNAL   Patent: US 6673611-A 3 06-JAN-2004;
            Sirna Therapeutics, Inc.; Boulder, CO
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 22;  DB 1;  Length 25;
  Best Local Similarity   77.3%;  Pred. No. 1.8e+03;
  Matches   17;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3904 UUCAUGAGCCUGGAAAGAAUCA 3925
              ::||:|||||:||||||||:||
Db         23 TTCATGAGCCTGGAAAGAATCA 2


RESULT 169
CS155980/c
LOCUS       CS155980                  27 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 171 from Patent WO2005078097.
ACCESSION   CS155980
VERSION     CS155980.1  GI:74271128
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 171 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 22;  DB 1;  Length 27;
  Best Local Similarity   68.2%;  Pred. No. 2.1e+03;
  Matches   15;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGUCA 1522
              |:|||:|||||:|:||::|:||
Db         22 CTCACTGCCACTCTAATTGTCA 1


RESULT 170
CS156035
LOCUS       CS156035                  27 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 226 from Patent WO2005078097.
ACCESSION   CS156035
VERSION     CS156035.1  GI:74271182
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 226 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 22;  DB 1;  Length 27;
  Best Local Similarity   68.2%;  Pred. No. 2.1e+03;
  Matches   15;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1501 CUCACUGCCACUCUAAUUGUCA 1522
              |:|||:|||||:|:||::|:||
Db          6 CTCACTGCCACTCTAATTGTCA 27


RESULT 171
AR073762
LOCUS       AR073762                  25 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 4 from patent US 5952199.
ACCESSION   AR073762
VERSION     AR073762.1  GI:10000522
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Chimeric receptors as inhibitors of vascular endothelial growth
            factor activity, and processes for their production
  JOURNAL   Patent: US 5952199-A 4 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.9e+03;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 172
CS231251
LOCUS       CS231251                  25 bp    DNA     linear   PAT 15-DEC-2005
DEFINITION  Sequence 89 from Patent WO2005108619.
ACCESSION   CS231251
VERSION     CS231251.1  GI:83698526
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1
  AUTHORS   Duff,G.W.
  TITLE     Diagnostics and therapeutics for diseases associated with an
            il-1inflammatory haplotype
  JOURNAL   Patent: WO 2005108619-A 89 17-NOV-2005;
            Interleukin Genetics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 1.9e+03;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|: :|:|: :|:|:|:|
Db          1 GTGTGTGTGTYTGTGTTTGTGTGTG 25


RESULT 173
AR208258
LOCUS       AR208258                  25 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 4 from patent US 6383486.
ACCESSION   AR208258
VERSION     AR208258.1  GI:21509366
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.Lynn., Chen,H.Hsifei., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6383486-A 4 07-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.9e+03;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 174
AR658755
LOCUS       AR658755                  25 bp    DNA     linear   PAT 13-JUN-2005
DEFINITION  Sequence 4 from patent US 6897294.
ACCESSION   AR658755
VERSION     AR658755.1  GI:67593920
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Davis-Smyth,T.L., Chen,H.H., Presta,L. and Ferrara,N.
  TITLE     Inhibitors of vascular endothelial growth factor activity, their
            uses and processes for their production
  JOURNAL   Patent: US 6897294-A 4 24-MAY-2005;
            Genentech, Inc.; South San Francisco, CA
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.9e+03;
  Matches   18;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        330 AAAAUUAAAAGAUCCUGAACUGAGU 354
              ||||::||||||:|| || |:|||:
Db          1 AAAATTAAAAGATCCAGATCTGAGT 25


RESULT 175
CS144193/c
LOCUS       CS144193                  23 bp    DNA     linear   PAT 19-AUG-2005
DEFINITION  Sequence 45 from Patent EP1564292.
ACCESSION   CS144193
VERSION     CS144193.1  GI:73659140
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S.
  JOURNAL   Patent: EP 1564292-A 45 17-AUG-2005;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-2 gene specific primers for RT-PCT"
```

```
  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.8e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||| ||:||:||||:||:||||
Db         23 CAGACCATGCTGGACTGCTGGCA 1


RESULT 176
AX203710/c
LOCUS       AX203710                  23 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 45 from Patent WO0152904.
ACCESSION   AX203710
VERSION     AX203710.1  GI:15393159
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Gill,P.S. and Masood,R.
  TITLE     Methods and compositions for antisense vegf oligonucleotides
  JOURNAL   Patent: WO 0152904-A 45 26-JUL-2001;
            Gill, Parkash, S. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGFR-2 gene specific primers for RT-PCT"

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.8e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3640 CAGAUCAUGCUGGACUGCUGGCA 3662
              |||| ||:||:||||:||:||||
Db         23 CAGACCATGCTGGACTGCTGGCA 1


RESULT 177
AR163542/c
LOCUS       AR163542                  24 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 3 from patent US 6270993.
ACCESSION   AR163542
VERSION     AR163542.1  GI:16234182
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Shibuya,M., Okamoto,M., Niwa,M., Matsumoto,T., Asano,M. and
            Segawa,T.
  TITLE     VEGF-binding polypeptide
  JOURNAL   Patent: US 6270993-A 3 07-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:||||||||||:::|||||  |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 178
E13258/c
LOCUS       E13258                    24 bp    DNA     linear   PAT 27-APR-1998
DEFINITION  PCR primer.
ACCESSION   E13258
VERSION     E13258.1  GI:3252063
KEYWORDS    JP 1997154588-A/3.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Shibuya,M., Okamoto,M., Niwa,M., Matsumoto,T., Asano,M. and
            Segawa,T.
  TITLE     VEGF-BINDING POLYPEPTIDE
  JOURNAL   Patent: JP 1997154588-A 3 17-JUN-1997;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1997154588-A/3
            PD   17-JUN-1997
            PF   23-JUL-1996 JP 1996211892
            PR   07-OCT-1995 JP 95P   286476
            PI   SHIBUYA MASASHI, OKAMOTO MASAJI, NIWA MIKIO, MATSUMOTO TOMOE,
            PI   ASANO MAKOTO, SEGAWA TOSHIAKI
            PC   C12N15/09,A61K38/00,A61K38/00,C07H21/04,C07K14/47,C12N5/10, PC
              C12P21/02,
            PC   G01N33/53,(C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .24
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:||||||||||:::|||||  |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 179
E14002/c
LOCUS       E14002                    24 bp    DNA     linear   PAT 27-APR-1998
DEFINITION  PCR primer.
ACCESSION   E14002
VERSION     E14002.1  GI:3252769
KEYWORDS    JP 1997255700-A/3.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Shibuya,M.
  TITLE     POLYPEPTIDE CAPABLE OF BINDING TO VEGF
  JOURNAL   Patent: JP 1997255700-A 3 30-SEP-1997;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1997255700-A/3
            PD   30-SEP-1997
            PF   22-MAR-1996 JP 1996066711
            PI   SHIBUYA MASASHI
            PC   C07K14/71,A61K38/00,A61K39/395,C07H21/04,C12N5/10,C12N15/09,
            PC   C12P21/02,
            PC   G01N33/53,G01N33/68,(C12P21/02,C12R1:91),(C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
```

```
           FT   source          1. .24
           FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2e+03;
  Matches   18;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 GUGAAACCCCAGAUUUACGAAAA 1547
              |:||||||||||||:::|||||| |
Db         24 GTGAAACCCCAGATTTACGAATA 2


RESULT 180
AX116747/c
LOCUS       AX116747                  24 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 1870 from Patent WO0129262.
ACCESSION   AX116747
VERSION     AX116747.1  GI:14033689
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 1870 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 21.4;  DB 1;  Length 24;
  Best Local Similarity   47.8%;  Pred. No. 2e+03;
  Matches   11;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGU 6993
              | :|:|:|:|:|:|:|:|:|:|:|:
Db         23 ATTGTGTGTGTGTGTGTGTGTGT 1


RESULT 181
AR163541
LOCUS       AR163541                  21 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 2 from patent US 6270993.
ACCESSION   AR163541
VERSION     AR163541.1  GI:16234180
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Shibuya,M., Okamoto,M., Niwa,M., Matsumoto,T., Asano,M. and
            Segawa,T.
  TITLE     VEGF-binding polypeptide
  JOURNAL   Patent: US 6270993-A 2 07-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        237 CGUCGCGCUCACCAUGGUCAG 257
              ||:|||||:|||||:||:|||
Db          1 CGTCGCGCTCACCATGGTCAG 21


RESULT 182
CS082791
LOCUS       CS082791                  21 bp    DNA     linear   PAT 18-MAY-2005
DEFINITION  Sequence 21 from Patent WO2005039616.
ACCESSION   CS082791
VERSION     CS082791.1  GI:66349408
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Hardy,B., Battler,A., Raiter,A., Kornowski,R. and Weiss,C.
  TITLE     Angiogenic peptides and uses thereof
  JOURNAL   Patent: WO 2005039616-A 21 06-MAY-2005;
            Ramot at Tel Aviv University Ltd. (IL)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Single strand DNA oligonucleotide"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1767 UCAGCGCAUGGCAAUAAUAGA 1787
              :|||||||:|||||:||:|||
Db          1 TCAGCGCATGGCAATAATAGA 21


RESULT 183
CS237372/c
LOCUS       CS237372                  21 bp    DNA     linear   PAT 04-JAN-2006
DEFINITION  Sequence 87 from Patent WO2005113596.
ACCESSION   CS237372
VERSION     CS237372.1  GI:84364454
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jin,P.
  JOURNAL   Patent: WO 2005113596-A 87 01-DEC-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer VEGFR1_R2"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 1.7e+03;
  Matches   16;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2694 UGAUGCCAGCAAGUGGGAGUU 2714
              :||:||||||||:|||||::
Db         21 TGATGCCAGCAAGTGGGAGTT 1


RESULT 184
DD203627
LOCUS       DD203627                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203627
VERSION     DD203627.1  GI:85660798
```

```
KEYWORDS    JP 2005517436-A/2108.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2108 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2108
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA sense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.7e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAAGA 2360
              ||||||||||||:|||||||||
Db          1 CAACCACAAAATACAACAAGA 21


RESULT 185
DD203628/c
LOCUS       DD203628                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD203628
VERSION     DD203628.1  GI:85660799
KEYWORDS    JP 2005517436-A/2109.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2109 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2109
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.7e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              |||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 186
DD207617
LOCUS       DD207617                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207617
VERSION     DD207617.1  GI:85645754
KEYWORDS    JP 2005518803-A/406.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 406 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/406
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  siNA sense region FH   Key
                    Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .21
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.7e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2340 CAACCACAAAAUACAACAAGA 2360
              ||||||||||||:|||||||||
Db          1 CAACCACAAAATACAACAAGA 21


RESULT 187
DD207618/c
LOCUS       DD207618                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207618
VERSION     DD207618.1  GI:85645755
KEYWORDS    JP 2005518803-A/407.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
```

```
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 407 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/407
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  siNA antisense region FH
            Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.7e+03;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              ||||||||||||||:|||||||
Db         21 AACAACCACAAAATACAACAA 1


RESULT 188
E13257
LOCUS       E13257                    21 bp    DNA     linear   PAT 27-APR-1998
DEFINITION  PCR primer.
ACCESSION   E13257
VERSION     E13257.1  GI:3252062
KEYWORDS    JP 1997154588-A/2.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Shibuya,M., Okamoto,M., Niwa,M., Matsumoto,T., Asano,M. and
            Segawa,T.
  TITLE     VEGF-BINDING POLYPEPTIDE
  JOURNAL   Patent: JP 1997154588-A 2 17-JUN-1997;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1997154588-A/2
            PD   17-JUN-1997
            PF   23-JUL-1996 JP 1996211892
            PR   07-OCT-1995 JP 95P   286476
            PI   SHIBUYA MASASHI, OKAMOTO MASAJI, NIWA MIKIO, MATSUMOTO TOMOE,
            PI   ASANO MAKOTO, SEGAWA TOSHIAKI
            PC   C12N15/09,A61K38/00,A61K38/00,C07H21/04,C07K14/47,C12N5/10, PC
              C12P21/02,
            PC   G01N33/53,(C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .21
            FT                   /organism='Artificial sequences'.
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       237 CGUCGCGCUCACCAUGGUCAG 257
             ||:|||||:|||||:||:|||
Db         1 CGTCGCGCTCACCATGGTCAG 21


RESULT 189
E14001
LOCUS       E14001                    21 bp    DNA     linear   PAT 27-APR-1998
DEFINITION  PCR primer.
ACCESSION   E14001
VERSION     E14001.1  GI:3252768
KEYWORDS    JP 1997255700-A/2.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Shibuya,M.
  TITLE     POLYPEPTIDE CAPABLE OF BINDING TO VEGF
  JOURNAL   Patent: JP 1997255700-A 2 30-SEP-1997;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1997255700-A/2
            PD   30-SEP-1997
            PF   22-MAR-1996 JP 1996066711
            PI   SHIBUYA MASASHI
            PC   C07K14/71,A61K38/00,A61K39/395,C07H21/04,C12N5/10,C12N15/09,
            PC   C12P21/02,
            PC   G01N33/53,G01N33/68,(C12P21/02,C12R1:91),(C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .21
            FT                   /organism='Artificial sequences'.
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+03;
  Matches   17;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       237 CGUCGCGCUCACCAUGGUCAG 257
             ||:|||||:|||||:||:|||
Db         1 CGTCGCGCTCACCATGGTCAG 21


RESULT 190
I31248/c
LOCUS       I31248                    21 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 160 from patent US 5582979.
ACCESSION   I31248
VERSION     I31248.1  GI:1822039
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 160 10-DEC-1996;
FEATURES              Location/Qualifiers
     source           1. .21
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   47.6%;  Pred. No. 1.7e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db         21 TGTGTGTGTGTGTGTGTGTG 1


RESULT 191
AX104715
LOCUS       AX104715                  21 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 907 from Patent WO0122972.
ACCESSION   AX104715
VERSION     AX104715.1  GI:13920912
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 907 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 1.7e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 192
AX175255
LOCUS       AX175255                  21 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 19 from Patent WO0144465.
ACCESSION   AX175255
VERSION     AX175255.1  GI:14598623
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 19 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 1.7e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 193
AX175256
LOCUS       AX175256                  21 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 20 from Patent WO0144465.
ACCESSION   AX175256
VERSION     AX175256.1  GI:14598624
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Phillips,N.C. and Filion,M.C.
  TITLE     Therapeutically useful synthetic oligonucleotides
  JOURNAL   Patent: WO 0144465-A 20 21-JUN-2001;
            Bioniche Life Sciences Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 1.7e+03;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21


RESULT 194
AX547768
LOCUS       AX547768                  21 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 907 from Patent WO02053141.
ACCESSION   AX547768
VERSION     AX547768.1  GI:25812912
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 907 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 1.7e+03;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6993
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 21


RESULT 195
CS155979/c
LOCUS       CS155979                  26 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 170 from Patent WO2005078097.
ACCESSION   CS155979
VERSION     CS155979.1  GI:74271127
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 170 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .26
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 21;  DB 1;  Length 26;
  Best Local Similarity   66.7%;  Pred. No. 2.5e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGUC 1521
              |:|||:|||||:|:||::|:|
Db         21 CTCACTGCCACTCTAATTGTC 1


RESULT 196
CS156034
LOCUS       CS156034                  26 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 225 from Patent WO2005078097.
ACCESSION   CS156034
VERSION     CS156034.1  GI:74271181
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 225 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 21;  DB 1;  Length 26;
  Best Local Similarity   66.7%;  Pred. No. 2.5e+03;
  Matches   14;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGUC 1521
              |:|||:|||||:|:||::|:|
Db          6 CTCACTGCCACTCTAATTGTC 26


RESULT 197
AX117030
LOCUS       AX117030                  24 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 2153 from Patent WO0129262.
ACCESSION   AX117030
VERSION     AX117030.1  GI:14033972
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 2153 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   45.8%;  Pred. No. 2.3e+03;
  Matches   11;  Conservative   11;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6993 UGUGUGUGUGUGUGUGUGUGGG 7016
              :|:|:|:|: :|:|:|:|:|: ||
Db          1 TGTGTGTGTATGTGTGTGTGTTGG 24


RESULT 198
BD016498
LOCUS       BD016498                  22 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Immortalized vascular endothelial cell strain.
ACCESSION   BD016498
VERSION     BD016498.1  GI:22557674
KEYWORDS    JP 2001231549-A/3.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Iizasa,H., Hattori,A., Nakajima,M., Terasaki,T. and Tatewaki,M.
  TITLE     Immortalized vascular endothelial cell strain
  JOURNAL   Patent: JP 2001231549-A 3 28-AUG-2001;
            JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT     OS   Artificial Sequence
            PN   JP 2001231549-A/3
            PD   28-AUG-2001
            PF   28-FEB-2000 JP 2000050691
            PI   HISASHI IIZASA,AKIYUKI HATTORI,MEGUMI NAKAJIMA,TETSUYA  PI
            TERASAKI,
            PI   MASUO TATEWAKI
            PC   C12N5/06,C12N5/10,C12N15/09,C12Q1/02,G01N33/15,G01N33/50 PC
            ,C12N5/00,C12N5/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Primer
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   77.3%;  Pred. No. 2.2e+03;
  Matches   17;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2414 CAGAAGAGGAUGAAGGUGUCUA 2435
              ||||||||||:|| ||:|:|:|
Db          1 CAGAAGAGGATGAGGGTGTCTA 22


RESULT 199
AX926722
LOCUS       AX926722                  23 bp    DNA     linear   PAT 19-DEC-2003
DEFINITION  Sequence 5 from Patent WO03085133.
ACCESSION   AX926722
VERSION     AX926722.1  GI:40247008
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Nagaraju,J.G.
  TITLE     Novel fissr-pcr primers and method of identifying genotyping
            diverse genomes of plant and animal systems including rice
            varieties, a kit thereof
  JOURNAL   Patent: WO 03085133-A 5 16-OCT-2003;
            Centre for DNA Fingerprinting and Diagnostics, Centre for; the
            Department of Biotechnology, Ministry of Science & Technology (IN)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="A novel FISSR-PCR primer for genotyping eukaryotes"

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 23;
  Best Local Similarity   45.5%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       6974 GUGUGUGUGUGUGUGUGUGU 6995
              |: :|:|:|:|:|:|:|:|:|:
Db          2 GTATGTGTGTGTGTGTGTGTGT 23


RESULT 200
AX116678
LOCUS       AX116678                  23 bp    DNA     linear   PAT 11-MAY-2001
DEFINITION  Sequence 1801 from Patent WO0129262.
ACCESSION   AX116678
VERSION     AX116678.1  GI:14033620
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Picoult-Newburg,L. and Pohl,M.
  TITLE     Genotyping reagents, kits and methods of use thereof
  JOURNAL   Patent: WO 0129262-A 1801 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 23;
  Best Local Similarity   45.5%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6994
              : :|:|:|:|:|:|:|:|:|:| :
Db          2 TTTGTGTGTGTGTGTGTGTG 23


RESULT 201
A47340
LOCUS       A47340                    20 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 1 from Patent WO9533050.
ACCESSION   A47340
VERSION     A47340.1  GI:2301348
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Charnock-Jones,D.S., Boocock,C.A., Sharkey,A.M. and Smith,S.K.
  TITLE     FLT-4 (FMS-LIKE TYROSINE-KINASE), FLT-15, VARIANTS THEREOF USES AS
            GROWTH FACTOR INHIBITORS
  JOURNAL   Patent: WO 9533050-A 1 07-DEC-1995;
            LYNXVALE LTD (GB)
COMMENT     Other publication AU 2535495 951221.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   60.0%;  Pred. No. 2e+03;
  Matches   12;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1681 GCAAGGUGUGACUUUUGUUC 1700
              ||||||:|:|||::::|::|
Db          1 GCAAGGTGTGACTTTTGTTC 20


RESULT 202
A47343/c
LOCUS       A47343                    20 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 4 from Patent WO9533050.
ACCESSION   A47343
VERSION     A47343.1  GI:2301351
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Charnock-Jones,D.S., Boocock,C.A., Sharkey,A.M. and Smith,S.K.
  TITLE     FLT-4 (FMS-LIKE TYROSINE-KINASE), FLT-15, VARIANTS THEREOF USES AS
            GROWTH FACTOR INHIBITORS
  JOURNAL   Patent: WO 9533050-A 4 07-DEC-1995;
            LYNXVALE LTD (GB)
COMMENT     Other publication AU 2535495 951221.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 UACACAGGGGAAGAAAUCCU 2192
              :|||||||||||||||:||:
Db         20 TACACAGGGGAAGAAATCCT 1


RESULT 203
A63570
LOCUS       A63570                    20 bp    DNA     linear   PAT 12-MAR-1998
DEFINITION  Sequence 11 from Patent WO9720924.
ACCESSION   A63570
VERSION     A63570.1  GI:3717225
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1
  AUTHORS   Scaggiante,B. and Quadrifoglio,F.
  TITLE     A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMOURAL
            AGENTS
  JOURNAL   Patent: WO 9720924-A 11 12-JUN-1997;
            SAICOM S R L (IT)
COMMENT     Other publication IT MI952539 19970604
            Other publication AU 1175497 19970627.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 204
AR030838
LOCUS       AR030838                  20 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1 from patent US 5861484.
ACCESSION   AR030838
VERSION     AR030838.1  GI:5944052
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kendall,R.L. and Thomas,K.A. Jr.
  TITLE     Inhibitor of vascular endothelial cell growth factor
```

```
  JOURNAL   Patent: US 5861484-A 1 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1808 GCACCUUGGUUGUGGCUGAC 1827
             |||||::||::|:|||:|||
Db         1 GCACCTTGGTTGTGGCTGAC 20


RESULT 205
AR031056
LOCUS       AR031056                 20 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 44 from patent US 5861504.
ACCESSION   AR031056
VERSION     AR031056.1  GI:5944270
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Polymeropoulos,M.H. and Merril,C.R.
  TITLE     Eleven highly informative microsatelite repeat polymorphic DNA
            markers
  JOURNAL   Patent: US 5861504-A 44 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      6952 UUUGGCCGACAGUGGUGUAA 6971
             :::||||||||:||:|:||
Db         1 TTTGGCCGACAGTGGTGTAA 20


RESULT 206
AR031057/c
LOCUS       AR031057                 20 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 45 from patent US 5861504.
ACCESSION   AR031057
VERSION     AR031057.1  GI:5944271
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Polymeropoulos,M.H. and Merril,C.R.
  TITLE     Eleven highly informative microsatelite repeat polymorphic DNA
            markers
  JOURNAL   Patent: US 5861504-A 45 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      7112 GACAGACAUGGUUUGGUCCU 7131
             ||||||||:||:::||:||:
Db        20 GACAGACATGGTTTGGTCCT 1


RESULT 207
AR084543/c
LOCUS       AR084543                 20 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 32 from patent US 5981185.
ACCESSION   AR084543
VERSION     AR084543.1  GI:10011314
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 32 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      6974 GUGUGUGUGUGUGUGUGUGU 6993
             |:|:|:|:|:|:|:|:|:|:
Db        20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 208
AR123339/c
LOCUS       AR123339                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 5 from patent US 6169176.
ACCESSION   AR123339
VERSION     AR123339.1  GI:14108305
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bruice,T.C. and Dev,A.P.
  TITLE     Deoxynucleic alkyl thiourea compounds and uses thereof
  JOURNAL   Patent: US 6169176-A 5 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      6973 UGUGUGUGUGUGUGUGUGUG 6992
             :|:|:|:|:|:|:|:|:|:|
Db        20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 209
AR129684/c
LOCUS       AR129684                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 88 from patent US 6187545.
ACCESSION   AR129684
VERSION     AR129684.1  GI:14117581
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   McKay,R., Butler,M.M., Wyatt,J. and Cowsert,L.M.
  TITLE     Antisense modulation of pepck-cytosolic expression
  JOURNAL   Patent: US 6187545-A 88 13-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
```

```
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 210
AX958323
LOCUS       AX958323                 20 bp    DNA     linear   PAT 08-JAN-2004
DEFINITION  Sequence 21 from Patent WO0174296.
ACCESSION   AX958323
VERSION     AX958323.1  GI:40785900
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Witte,L. and Rafii,S.
  TITLE     Treatment of non-solid mammalian tumors with vascular
            endothelialgrowth factor receptor antagonists
  JOURNAL   Patent: WO 0174296-A 21 11-OCT-2001;
            IMCLONE SYSTEMS, INC. (US) ; CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic primer"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3361 AUUUGUGAUUUUGGCCUUGC 3380
              |:::|:||::::||||::||
Db          1 ATTTGTGATTTTGGCCTTGC 20


RESULT 211
BD016468
LOCUS       BD016468                 20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for regulating telomeric length.
ACCESSION   BD016468
VERSION     BD016468.1  GI:22557644
KEYWORDS    JP 2001231567-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ota,K. and Shibata,T.
  TITLE     Method for regulating telomeric length
  JOURNAL   Patent: JP 2001231567-A 9 28-AUG-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, JAPAN SCIENCE AND
            TECHNOLOGY CORP
COMMENT     OS   Artificial Sequence
            PN   JP 2001231567-A/9
            PD   28-AUG-2001
            PF   18-FEB-2000 JP 2000041929
            PI   KUNIKAZU OTA,TAKEHIKO SHIBATA
            PC   C12N15/09,A61K35/76,A61K38/00,A61K48/00,A61P35/00,A61P43/00,
            PC   C07H21/00,
            PC   C07K14/395,C12N9/16,C12N15/00,A61K37/02
            CC   Description of Artificial Sequence:synthetic DNA FH   Key
                   Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 212
BD097545
LOCUS       BD097545                 20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for regulating telomeric length.
ACCESSION   BD097545
VERSION     BD097545.1  GI:22643119
KEYWORDS    WO 0160996-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ota,K. and Shibata,T.
  TITLE     Method for regulating telomeric length
  JOURNAL   Patent: WO 0160996-A 9 23-AUG-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, JAPAN SCIENCE AND
            TECHNOLOGY CORP,KUNIHIRO OTA,TAKEHIKO SHIBATA
COMMENT     OS   Artificial Sequence
            PN   WO 0160996-A/9
            PD   23-AUG-2001
            PF   14-FEB-2001 WO 2001JP001024
            PR   18-FEB-2000 JP 00P    41929
            PI   KUNIHIRO OTA,TAKEHIKO SHIBATA
            PC   C12N15/09,A61K35/76,A61K38/00,A61K48/00,A61P35/00,A61P43/00,
            PC   C07H21/00,
            PC   C07K14/395,C12N9/16
            CC   Description of Artificial Sequence:synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 213
BD105781/c
LOCUS       BD105781                 20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Conjugates of biologically stable polymers and polynucleotides for
            treating systemic lupus erythematosus.
ACCESSION   BD105781
VERSION     BD105781.1  GI:22651355
KEYWORDS    JP 2001354569-A/6.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Conrad,M.J. and Coutts,S.
  TITLE     Conjugates of biologically stable polymers and polynucleotides for
            treating systemic lupus erythematosus
  JOURNAL   Patent: JP 2001354569-A 6 25-DEC-2001;
            LA JOLLA PHARMACEUTICAL CO
COMMENT     OS   Artificial Sequence
```

```
            PN   JP 2001354569-A/6
            PD   25-DEC-2001
            PF   04-APR-2001 JP 2001106534
            PR   16-JAN-1990 US       466138,13-MAR-1990 US       494118 PI
            MICHAEL J CONRAD,STEPHEN COUTTS
            PC   A61K31/7088,A61K47/48,A61P37/02,C07K14/00,C12N15/00,C12N15/00
            CC   Synthetic Construct
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match              0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 214
CQ896116
LOCUS       CQ896116                  20 bp    DNA     linear   PAT 05-NOV-2004
DEFINITION  Sequence 1 from Patent WO2004089422.
ACCESSION   CQ896116
VERSION     CQ896116.1  GI:55467993
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linnik,M.D. and Joh,T.
  TITLE     Methods of treating and monitoring systemic lupus erythematosus in
            individuals
  JOURNAL   Patent: WO 2004089422-A 1 21-OCT-2004;
            LA JOLLA PHARMACEUTICAL COMPANY (CA)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Synthetic Construct"

  Query Match              0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 215
CQ896117/c
LOCUS       CQ896117                  20 bp    DNA     linear   PAT 05-NOV-2004
DEFINITION  Sequence 2 from Patent WO2004089422.
ACCESSION   CQ896117
VERSION     CQ896117.1  GI:55467994
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linnik,M.D. and Joh,T.
  TITLE     Methods of treating and monitoring systemic lupus erythematosus in
            individuals
  JOURNAL   Patent: WO 2004089422-A 2 21-OCT-2004;
            LA JOLLA PHARMACEUTICAL COMPANY (CA)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Synthetic Construct"

  Query Match              0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 216
CQ979108
LOCUS       CQ979108                  20 bp    DNA     linear   PAT 19-JAN-2005
DEFINITION  Sequence 110 from Patent WO2004111273.
ACCESSION   CQ979108
VERSION     CQ979108.1  GI:57976361
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Agus,D., Baker,J.B., Natale,R. and Shak,S.
  TITLE     Gene expression markers for response to egfr inhibitor drugs
  JOURNAL   Patent: WO 2004111273-A 110 23-DEC-2004;
            Genomic Health, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="forward primer"

  Query Match              0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3447 GGCUCCCGAAUCUAUCUUUG 3466
              |||:||||||:|:|:|:::|
Db          1 GGCTCCCGAATCTATCTTTG 20


RESULT 217
CQ979109/c
LOCUS       CQ979109                  20 bp    DNA     linear   PAT 19-JAN-2005
DEFINITION  Sequence 111 from Patent WO2004111273.
ACCESSION   CQ979109
VERSION     CQ979109.1  GI:57976362
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Agus,D., Baker,J.B., Natale,R. and Shak,S.
  TITLE     Gene expression markers for response to egfr inhibitor drugs
  JOURNAL   Patent: WO 2004111273-A 111 23-DEC-2004;
            Genomic Health, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="reverse primer"

  Query Match              0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3502 UACGGAGUAUUGCUGUGGGA 3521
              :||||||:|::||:|:||||
Db         20 TACGGAGTATTGCTGTGGGA 1


RESULT 218
CS037974
LOCUS       CS037974                  20 bp    DNA     linear   PAT 10-MAR-2005
DEFINITION  Sequence 43 from Patent WO2005016966.
ACCESSION   CS037974
VERSION     CS037974.1  GI:60734582
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Shepard,H.M., Clinton,G.M., Lackey,D.B. and Jin,P.
  TITLE     Intron fusion proteins, and methods of identifying and using same
  JOURNAL   Patent: WO 2005016966-A 43 24-FEB-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer -"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        102 GGGGAAGUGGUUGUCUCCUG 121
              |||||||:||::|:|:||:|
Db          1 GGGGAAGTGGTTGTCTCCTG 20


RESULT 219
CS037975/c
LOCUS       CS037975                  20 bp    DNA     linear   PAT 10-MAR-2005
DEFINITION  Sequence 44 from Patent WO2005016966.
ACCESSION   CS037975
VERSION     CS037975.1  GI:60734583
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Shepard,H.M., Clinton,G.M., Lackey,D.B. and Jin,P.
  TITLE     Intron fusion proteins, and methods of identifying and using same
  JOURNAL   Patent: WO 2005016966-A 44 24-FEB-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer -"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 AGAUGUGCCAAAUGGGUUUC 1927
              |||:|:||||||:|||:::|
Db         20 AGATGTGCCAAATGGGTTTC 1


RESULT 220
CS037976
LOCUS       CS037976                  20 bp    DNA     linear   PAT 10-MAR-2005
DEFINITION  Sequence 45 from Patent WO2005016966.
ACCESSION   CS037976
VERSION     CS037976.1  GI:60734584
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Shepard,H.M., Clinton,G.M., Lackey,D.B. and Jin,P.
  TITLE     Intron fusion proteins, and methods of identifying and using same
  JOURNAL   Patent: WO 2005016966-A 45 24-FEB-2005;
            Receptor Biologix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer -"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        858 GCUUCUGACCUGUGAAGCAA 877
              ||::|:||||:|:|||||||
Db          1 GCTTCTGACCTGTGAAGCAA 20


RESULT 221
CS053040
LOCUS       CS053040                  20 bp    DNA     linear   PAT 23-MAR-2005
DEFINITION  Sequence 13 from Patent EP1489422.
ACCESSION   CS053040
VERSION     CS053040.1  GI:61891702
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Rabbani,E., Donegan,J.J. and Stavrianopoulos,J.G.
  TITLE     Multisignal labeling reagents, processes and uses therefor
  JOURNAL   Patent: EP 1489422-A 13 22-DEC-2004;
            Enzo Life Sciences, Inc., c/o Enzo Biochem, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Combined DNA/RNA Molecule: Synthetic
                     oligonucleotide
                     Description of Artificial Sequence: Synthetic
                     oligonucleotide"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 222
CS053041/c
LOCUS       CS053041                  20 bp    DNA     linear   PAT 23-MAR-2005
DEFINITION  Sequence 14 from Patent EP1489422.
ACCESSION   CS053041
VERSION     CS053041.1  GI:61891703
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Rabbani,E., Donegan,J.J. and Stavrianopoulos,J.G.
  TITLE     Multisignal labeling reagents, processes and uses therefor
  JOURNAL   Patent: EP 1489422-A 14 22-DEC-2004;
```

```
           Enzo Life Sciences, Inc., c/o Enzo Biochem, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Combined DNA/RNA Molecule: Synthetic
                     oligonucleotide
                     Description of Artificial Sequence: Synthetic
                     oligonucleotide"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 223
CS053043
LOCUS       CS053043                  20 bp    DNA     linear   PAT 23-MAR-2005
DEFINITION  Sequence 16 from Patent EP1489422.
ACCESSION   CS053043
VERSION     CS053043.1  GI:61891705
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Rabbani,E., Donegan,J.J. and Stavrianopoulos,J.G.
  TITLE     Multisignal labeling reagents, processes and uses therefor
  JOURNAL   Patent: EP 1489422-A 16 22-DEC-2004;
            Enzo Life Sciences, Inc., c/o Enzo Biochem, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Combined DNA/RNA Molecule: Synthetic
                     oligonucleotide
                     Description of Artificial Sequence: Synthetic
                     oligonucleotide"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 224
CS130466/c
LOCUS       CS130466                  20 bp    DNA     linear   PAT 02-AUG-2005
DEFINITION  Sequence 21 from Patent WO2005063300.
ACCESSION   CS130466
VERSION     CS130466.1  GI:71792433
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Kippenberger,S.
  TITLE     Cosmetic or pharmaceutical preparations containing nucleic acid
            sequences forming a superstructure
  JOURNAL   Patent: WO 2005063300-A 21 14-JUL-2005;
            Phenion GmbH & Co KG (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="phosphorothioate"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 225
E14009
LOCUS       E14009                    20 bp    DNA     linear   PAT 27-APR-1998
DEFINITION  PCR primer.
ACCESSION   E14009
VERSION     E14009.1  GI:3252776
KEYWORDS    JP 1997255700-A/10.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shibuya,M.
  TITLE     POLYPEPTIDE CAPABLE OF BINDING TO VEGF
  JOURNAL   Patent: JP 1997255700-A 10 30-SEP-1997;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1997255700-A/10
            PD   30-SEP-1997
            PF   22-MAR-1996 JP 1996066711
            PI   SHIBUYA MASASHI
            PC   C07K14/71,A61K38/00,A61K39/395,C07H21/04,C12N5/10,C12N15/09,
            PC   C12P21/02,
            PC   G01N33/53,G01N33/68,(C12P21/02,C12R1:91),(C12P21/02,C12R1:91);
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .20
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1889 ACAUAAGCUUUUAUAUCACA 1908
              |||:||||::::|:|:||||
Db          1 ACATAAGCTTTTATATCACA 20


RESULT 226
I82797
LOCUS       I82797                    20 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 1 from patent US 5712380.
ACCESSION   I82797
VERSION     I82797.1  GI:3211094
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kendall,R.L. and Thomas,K.A. Jr.
  TITLE     DNA encoding a soluble VEGF inhibitor
  JOURNAL   Patent: US 5712380-A 1 27-JAN-1998;
FEATURES             Location/Qualifiers
```

```
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1808 GCACCUUGGUUGUGGCUGAC 1827
              |||||::||::|:|||:|||
Db          1 GCACCTTGGTTGTGGCTGAC 20


RESULT 227
AR489899/c
LOCUS       AR489899                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 22 from patent US 6710174.
ACCESSION   AR489899
VERSION     AR489899.1  GI:47257012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 22 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        239 UCGCGCUCACCAUGGUCAGC 258
              :|||||:|||||:||:||||
Db         20 TCGCGCTCACCATGGTCAGC 1


RESULT 228
AR489900/c
LOCUS       AR489900                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 23 from patent US 6710174.
ACCESSION   AR489900
VERSION     AR489900.1  GI:47257013
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 23 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        326 GUUCAAAAUUAAAAGAUCCU 345
              |::|||||::||||||:||:
Db         20 GTTCAAAATTAAAAGATCCT 1


RESULT 229
AR489901/c
LOCUS       AR489901                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 24 from patent US 6710174.
ACCESSION   AR489901
VERSION     AR489901.1  GI:47257014
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 24 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        346 GAACUGAGUUUAAAAGGCAC 365
              ||||:|||:::|||||||||
Db         20 GAACTGAGTTTAAAAGGCAC 1


RESULT 230
AR489902/c
LOCUS       AR489902                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 25 from patent US 6710174.
ACCESSION   AR489902
VERSION     AR489902.1  GI:47257015
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 25 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        352 AGUUUAAAAGGCACCCAGCA 371
              ||:::|||||||||||||||
Db         20 AGTTTAAAAGGCACCCAGCA 1


RESULT 231
AR489903/c
LOCUS       AR489903                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 26 from patent US 6710174.
ACCESSION   AR489903
VERSION     AR489903.1  GI:47257016
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
```

```
          receptor-1 expression
  JOURNAL   Patent: US 6710174-A 26 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        530 UGAACACAGCUCAAGCAAAC 549
              :||||||||||:||||||||||
Db         20 TGAACACAGCTCAAGCAAAC 1


RESULT 232
AR489904/c
LOCUS       AR489904                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 27 from patent US 6710174.
ACCESSION   AR489904
VERSION     AR489904.1  GI:47257017
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 27 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        585 ACCUACUUCAAAGAAGAAGG 604
              |||:||::||||||||||||
Db         20 ACCTACTTCAAAGAAGAAGG 1


RESULT 233
AR489905/c
LOCUS       AR489905                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 28 from patent US 6710174.
ACCESSION   AR489905
VERSION     AR489905.1  GI:47257018
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 28 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        636 UGAUACAGGUAGACCUUUCG 655
              :||:|||||:|||||:::||
Db         20 TGATACAGGTAGACCTTTCG 1


RESULT 234
AR489906/c
LOCUS       AR489906                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 29 from patent US 6710174.
ACCESSION   AR489906
VERSION     AR489906.1  GI:47257019
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 29 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        814 AGAAAGGGCUUCAUCAUAUC 833
              |||||||||::||:||:|:|
Db         20 AGAAAGGGCTTCATCATATC 1


RESULT 235
AR489907/c
LOCUS       AR489907                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 30 from patent US 6710174.
ACCESSION   AR489907
VERSION     AR489907.1  GI:47257020
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 30 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        862 CUGACCUGUGAAGCAACAGU 881
              |:||||:|:||||||||||:
Db         20 CTGACCTGTGAAGCAACAGT 1


RESULT 236
AR489908/c
LOCUS       AR489908                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 31 from patent US 6710174.
ACCESSION   AR489908
VERSION     AR489908.1  GI:47257021
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 31 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   60.0%;  Pred. No. 2e+03;
  Matches   12;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        991 CUUGUCCUCAAUUGUACUGC 1010
              |::|:||:|||::|:||:||
Db         20 CTTGTCCTCAATTGTACTGC 1


RESULT 237
AR489909/c
LOCUS       AR489909                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 32 from patent US 6710174.
ACCESSION   AR489909
VERSION     AR489909.1  GI:47257022
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 32 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1083 AAGGCGACGAAUUGACCAAA 1102
              ||||||||||||::|||||||
Db         20 AAGGCGACGAATTGACCAAA 1


RESULT 238
AR489910/c
LOCUS       AR489910                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 33 from patent US 6710174.
ACCESSION   AR489910
VERSION     AR489910.1  GI:47257023
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 33 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1165 AAAGGACUUUAUACUUGUCG 1184
              |||||||:::|:||::|:||
Db         20 AAAGGACTTTATACTTGTCG 1


RESULT 239
AR489911/c
LOCUS       AR489911                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 34 from patent US 6710174.
ACCESSION   AR489911
VERSION     AR489911.1  GI:47257024
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 34 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1195 GGACCAUCAUUCAAAUCUGU 1214
              ||||||:||::||||:|:|:
Db         20 GGACCATCATTCAAATCTGT 1


RESULT 240
AR489912/c
LOCUS       AR489912                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 35 from patent US 6710174.
ACCESSION   AR489912
VERSION     AR489912.1  GI:47257025
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 35 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1236 UGAUAAAGCAUUCAUCACUG 1255
              :||:||||||::||:|||:|
Db         20 TGATAAAGCATTCATCACTG 1


RESULT 241
AR489913/c
LOCUS       AR489913                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 36 from patent US 6710174.
ACCESSION   AR489913
```

```
VERSION     AR489913.1  GI:47257026
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 36 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1408 GGCUACUCGUUAAUUAUCAA 1427
              |||:||:||::||::|:|||
Db         20 GGCTACTCGTTAATTATCAA 1


RESULT 242
AR489914/c
LOCUS       AR489914                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 37 from patent US 6710174.
ACCESSION   AR489914
VERSION     AR489914.1  GI:47257027
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 37 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1464 CUUGCUGAGCAUAAAACAGU 1483
              |::||:|||||:|||||||:
Db         20 CTTGCTGAGCATAAAACAGT 1


RESULT 243
AR489915/c
LOCUS       AR489915                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 38 from patent US 6710174.
ACCESSION   AR489915
VERSION     AR489915.1  GI:47257028
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 38 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1486 AAUGUGUUUAAAAACCUCAC 1505
              ||:|:|:::|||||||:|||
Db         20 AATGTGTTTAAAAACCTCAC 1


RESULT 244
AR489916/c
LOCUS       AR489916                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 39 from patent US 6710174.
ACCESSION   AR489916
VERSION     AR489916.1  GI:47257029
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 39 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1494 UAAAAACCUCACUGCCACUC 1513
              :|||||||:|||:||||||:|
Db         20 TAAAAACCTCACTGCCACTC 1


RESULT 245
AR489917/c
LOCUS       AR489917                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 40 from patent US 6710174.
ACCESSION   AR489917
VERSION     AR489917.1  GI:47257030
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 40 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1502 UCACUGCCACUCUAAUUGUC 1521
              :|||:||||:|:||::|:|
Db         20 TCACTGCCACTCTAATTGTC 1


RESULT 246
```

```
AR489918/c
LOCUS       AR489918                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 41 from patent US 6710174.
ACCESSION   AR489918
VERSION     AR489918.1  GI:47257031
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 41 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1510 ACUCUAAUUGUCAAUGUGAA 1529
              ||:|:||::|:|||:|:|||
Db         20 ACTCTAATTGTCAATGTGAA 1


RESULT 247
AR489919/c
LOCUS       AR489919                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 42 from patent US 6710174.
ACCESSION   AR489919
VERSION     AR489919.1  GI:47257032
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 42 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1574 CUCUCUACCCACUGGGCAGC 1593
              |:|:|:||||||:|||||||
Db         20 CTCTCTACCCACTGGGCAGC 1


RESULT 248
AR489920/c
LOCUS       AR489920                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 43 from patent US 6710174.
ACCESSION   AR489920
VERSION     AR489920.1  GI:47257033
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 43 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   95.0%;  Pred. No. 2e+03;
  Matches   19;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1580 ACCCACUGGGCAGCAGACAA 1599
              ||||||:|||||||||||||
Db         20 ACCCACTGGGCAGCAGACAA 1


RESULT 249
AR489921/c
LOCUS       AR489921                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 44 from patent US 6710174.
ACCESSION   AR489921
VERSION     AR489921.1  GI:47257034
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 44 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1628 CUCAACCUACAAUCAAGUGG 1647
              |:|||||:||||:||||:||
Db         20 CTCAACCTACAATCAAGTGG 1


RESULT 250
AR489922/c
LOCUS       AR489922                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 45 from patent US 6710174.
ACCESSION   AR489922
VERSION     AR489922.1  GI:47257035
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 45 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1723 CUGGAUGCUGACAGCAACAU 1742
              |:|||:||:||||||||||:
```

```
Db         20 CTGGATGCTGACAGCAACAT 1


RESULT 251
AR489923/c
LOCUS       AR489923                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 46 from patent US 6710174.
ACCESSION   AR489923
VERSION     AR489923.1  GI:47257036
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 46 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 GAAACAGAAUUGAGAGCAUC 1764
              |||||||||::|||||||:|
Db         20 GAAACAGAATTGAGAGCATC 1


RESULT 252
AR489924/c
LOCUS       AR489924                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 47 from patent US 6710174.
ACCESSION   AR489924
VERSION     AR489924.1  GI:47257037
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 47 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1757 AGAGCAUCACUCAGCGCAUG 1776
              ||||||:|||:|||||||:|
Db         20 AGAGCATCACTCAGCGCATG 1


RESULT 253
AR489925/c
LOCUS       AR489925                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 48 from patent US 6710174.
ACCESSION   AR489925
VERSION     AR489925.1  GI:47257038
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 48 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1855 AUAGCUUCCAAUAAAGUUGG 1874
              |:|||::||||:||||::||
Db         20 ATAGCTTCCAATAAAGTTGG 1


RESULT 254
AR489926/c
LOCUS       AR489926                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 49 from patent US 6710174.
ACCESSION   AR489926
VERSION     AR489926.1  GI:47257039
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 49 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1956 AGGAGAGGACCUGAAACUGU 1975
              ||||||||||:|||||:|:
Db         20 AGGAGAGGACCTGAAACTGT 1


RESULT 255
AR489927/c
LOCUS       AR489927                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 50 from patent US 6710174.
ACCESSION   AR489927
VERSION     AR489927.1  GI:47257040
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 50 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   55.0%;  Pred. No. 2e+03;
```

```
  Matches   11;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2009 UUACUUGGAUUUUACUGCGG 2028
              ::||::|||::::||:||||
Db         20 TTACTTGGATTTTACTGCGG 1


RESULT 256
AR489928/c
LOCUS       AR489928                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 51 from patent US 6710174.
ACCESSION   AR489928
VERSION     AR489928.1  GI:47257041
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 51 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2051 ACUACAGUAUUAGCAAGCAA 2070
              ||:||||:|::|||||||||
Db         20 ACTACAGTATTAGCAAGCAA 1


RESULT 257
AR489929/c
LOCUS       AR489929                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 52 from patent US 6710174.
ACCESSION   AR489929
VERSION     AR489929.1  GI:47257042
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 52 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2143 GGCACCUAUGCCUGCAGAGC 2162
              ||||||:|:|||:|||||||
Db         20 GGCACCTATGCCTGCAGAGC 1


RESULT 258
AR489930/c
LOCUS       AR489930                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 53 from patent US 6710174.
ACCESSION   AR489930
VERSION     AR489930.1  GI:47257043
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 53 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2149 UAUGCCUGCAGAGCCAGGAA 2168
              :|:|||:|||||||||||||
Db         20 TATGCCTGCAGAGCCAGGAA 1


RESULT 259
AR489931/c
LOCUS       AR489931                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 54 from patent US 6710174.
ACCESSION   AR489931
VERSION     AR489931.1  GI:47257044
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 54 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2165 GGAAUGUAUACACAGGGGAA 2184
              ||||:|:|:||||||||||||
Db         20 GGAATGTATACACAGGGGAA 1


RESULT 260
AR489932/c
LOCUS       AR489932                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 55 from patent US 6710174.
ACCESSION   AR489932
VERSION     AR489932.1  GI:47257045
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 55 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
```

/mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2e+03;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2177 CAGGGGAAGAAAUCCUCCAG 2196
              ||||||||||||:||:||||
Db         20 CAGGGGAAGAAATCCTCCAG 1
```

RESULT 261
AR489933/c
LOCUS AR489933 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 56 from patent US 6710174.
ACCESSION AR489933
VERSION AR489933.1 GI:47257046
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 56 23-MAR-2004;
ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 2e+03;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2365 GGAAUUAUUUUAGGACCAGG 2384
              ||||::|::::|||||||||
Db         20 GGAATTATTTTAGGACCAGG 1
```

RESULT 262
AR489934/c
LOCUS AR489934 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 57 from patent US 6710174.
ACCESSION AR489934
VERSION AR489934.1 GI:47257047
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 57 23-MAR-2004;
ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 2e+03;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2389 AGCACGCUGUUUAUUGAAAG 2408
              |||||||:|:::|::|||||
Db         20 AGCACGCTGTTTATTGAAAG 1
```

RESULT 263
AR489935/c
LOCUS AR489935 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 58 from patent US 6710174.
ACCESSION AR489935
VERSION AR489935.1 GI:47257048
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 58 23-MAR-2004;
ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 65.0%; Pred. No. 2e+03;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2395 CUGUUUAUUGAAAGAGUCAC 2414
              |:|:::|::|||||||:|||
Db         20 CTGTTTATTGAAAGAGTCAC 1
```

RESULT 264
AR489936/c
LOCUS AR489936 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 59 from patent US 6710174.
ACCESSION AR489936
VERSION AR489936.1 GI:47257049
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 59 23-MAR-2004;
ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2e+03;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2403 UGAAAGAGUCACAGAAGAGG 2422
              :|||||||:||||||||||||
Db         20 TGAAAGAGTCACAGAAGAGG 1
```

RESULT 265
AR489937/c
LOCUS AR489937 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 60 from patent US 6710174.
ACCESSION AR489937
VERSION AR489937.1 GI:47257050
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 60 23-MAR-2004;

```
           ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2692 UAUGAUGCCAGCAAGUGGGA 2711
              :|:||:||||||||||:||||
Db         20 TATGATGCCAGCAAGTGGGA 1


RESULT 266
AR489938/c
LOCUS       AR489938                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 61 from patent US 6710174.
ACCESSION   AR489938
VERSION     AR489938.1  GI:47257051
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 61 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2698 GCCAGCAAGUGGGAGUUUGC 2717
              |||||||||:|||||:::||
Db         20 GCCAGCAAGTGGGAGTTTGC 1


RESULT 267
AR489939/c
LOCUS       AR489939                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 62 from patent US 6710174.
ACCESSION   AR489939
VERSION     AR489939.1  GI:47257052
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 62 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2787 AUUUGGCAUUAAGAAAUCAC 2806
              |:::||||::||||||:|||
Db         20 ATTTGGCATTAAGAAATCAC 1


RESULT 268
AR489940/c
LOCUS       AR489940                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 63 from patent US 6710174.
ACCESSION   AR489940
VERSION     AR489940.1  GI:47257053
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 63 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2812 UGCCGGACUGUGGCUGUGAA 2831
              :|||||||:|:|||:|:|||
Db         20 TGCCGGACTGTGGCTGTGAA 1


RESULT 269
AR489941/c
LOCUS       AR489941                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 64 from patent US 6710174.
ACCESSION   AR489941
VERSION     AR489941.1  GI:47257054
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 64 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2860 GAGUACAAAGCUCUGAUGAC 2879
              |||:|||||||:|:||:|||
Db         20 GAGTACAAAGCTCTGATGAC 1


RESULT 270
AR489942/c
LOCUS       AR489942                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 65 from patent US 6710174.
ACCESSION   AR489942
VERSION     AR489942.1  GI:47257055
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
```

```
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 65 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2933 UGGGAGCCUGCACCAAGCAA 2952
              :|||||||:||||||||||
Db         20 TGGGAGCCTGCACCAAGCAA 1


RESULT 271
AR489943/c
LOCUS       AR489943                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 66 from patent US 6710174.
ACCESSION   AR489943
VERSION     AR489943.1  GI:47257056
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 66 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   95.0%;  Pred. No. 2e+03;
  Matches   19;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2941 UGCACCAAGCAAGGAGGGCC 2960
              :||||||||||||||||||||
Db         20 TGCACCAAGCAAGGAGGGCC 1


RESULT 272
AR489944/c
LOCUS       AR489944                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 67 from patent US 6710174.
ACCESSION   AR489944
VERSION     AR489944.1  GI:47257057
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 67 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2947 AAGCAAGGAGGGCCUCUGAU 2966
              ||||||||||||||:|:||:
Db         20 AAGCAAGGAGGGCCTCTGAT 1


RESULT 273
AR489945/c
LOCUS       AR489945                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 68 from patent US 6710174.
ACCESSION   AR489945
VERSION     AR489945.1  GI:47257058
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 68 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2953 GGAGGGCCUCUGAUGGUGAU 2972
              ||||||||:|:||:||:|||:
Db         20 GGAGGGCCTCTGATGGTGAT 1


RESULT 274
AR489946/c
LOCUS       AR489946                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 69 from patent US 6710174.
ACCESSION   AR489946
VERSION     AR489946.1  GI:47257059
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 69 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3002 CCAACUACCUCAAGAGCAAA 3021
              |||||:|||:||||||||||
Db         20 CCAACTACCTCAAGAGCAAA 1


RESULT 275
AR489947/c
LOCUS       AR489947                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 70 from patent US 6710174.
ACCESSION   AR489947
VERSION     AR489947.1  GI:47257060
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 70 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3008 ACCUCAAGAGCAAACGUGAC 3027
              |||:||||||||||||:|||
Db         20 ACCTCAAGAGCAAACGTGAC 1


RESULT 276
AR489948/c
LOCUS       AR489948                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 71 from patent US 6710174.
ACCESSION   AR489948
VERSION     AR489948.1  GI:47257061
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 71 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3013 AAGAGCAAACGUGACUUAUU 3032
              ||||||||||:|||::|::
Db         20 AAGAGCAAACGTGACTTATT 1


RESULT 277
AR489949/c
LOCUS       AR489949                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 72 from patent US 6710174.
ACCESSION   AR489949
VERSION     AR489949.1  GI:47257062
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 72 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 CAAGUGGCCAGAGGCAUGGA 3281
              ||||:|||||||||||:|||
Db         20 CAAGTGGCCAGAGGCATGGA 1


RESULT 278
AR489950/c
LOCUS       AR489950                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 73 from patent US 6710174.
ACCESSION   AR489950
VERSION     AR489950.1  GI:47257063
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 73 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3292 UCCAGAAAGUGCAUUCAUCG 3311
              :||||||||:|||::||:||
Db         20 TCCAGAAAGTGCATTCATCG 1


RESULT 279
AR489951/c
LOCUS       AR489951                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 74 from patent US 6710174.
ACCESSION   AR489951
VERSION     AR489951.1  GI:47257064
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 74 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 AGUGCAUUCAUCGGGACCUG 3318
              ||:|||::||:|||||||:|
Db         20 AGTGCATTCATCGGGACCTG 1


RESULT 280
AR489952/c
LOCUS       AR489952                  20 bp    DNA     linear   PAT 15-MAY-2004
```

```
DEFINITION  Sequence 75 from patent US 6710174.
ACCESSION   AR489952
VERSION     AR489952.1  GI:47257065
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 75 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3306 UCAUCGGGACCUGGCAGCGA 3325
              :||:|||||||:||||||||
Db         20 TCATCGGGACCTGGCAGCGA 1


RESULT 281
AR489953/c
LOCUS       AR489953                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 76 from patent US 6710174.
ACCESSION   AR489953
VERSION     AR489953.1  GI:47257066
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 76 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3313 GACCUGGCAGCGAGAAACAU 3332
              ||||:||||||||||||||:
Db         20 GACCTGGCAGCGAGAAACAT 1


RESULT 282
AR489954/c
LOCUS       AR489954                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 77 from patent US 6710174.
ACCESSION   AR489954
VERSION     AR489954.1  GI:47257067
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 77 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3379 GCCCGGGAUAUUUAUAAGAA 3398
              ||||||||:|:::|:|||||
Db         20 GCCCGGGATATTTATAAGAA 1


RESULT 283
AR489955/c
LOCUS       AR489955                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 78 from patent US 6710174.
ACCESSION   AR489955
VERSION     AR489955.1  GI:47257068
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 78 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3439 AAAUGGAUGGCUCCCGAAUC 3458
              |||:|||:|||:|||||||:|
Db         20 AAATGGATGGCTCCCGAATC 1


RESULT 284
AR489956/c
LOCUS       AR489956                 20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 79 from patent US 6710174.
ACCESSION   AR489956
VERSION     AR489956.1  GI:47257069
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 79 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3737 AACAGGAUGGUAAAGACUAC 3756
              |||||||:||:|||||||:||
Db         20 AACAGGATGGTAAAGACTAC 1
```

```
RESULT 285
AR489957/c
LOCUS       AR489957                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 80 from patent US 6710174.
ACCESSION   AR489957
VERSION     AR489957.1  GI:47257070
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 80 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3742 GAUGGUAAAGACUACAUCCC 3761
              ||:||:||||||:|||:|||
Db         20 GATGGTAAAGACTACATCCC 1


RESULT 286
AR489958/c
LOCUS       AR489958                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 81 from patent US 6710174.
ACCESSION   AR489958
VERSION     AR489958.1  GI:47257071
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 81 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3905 UCAUGAGCCUGGAAAGAAUC 3924
              :||:|||||:||||||||:|
Db         20 TCATGAGCCTGGAAAGAATC 1


RESULT 287
AR489959/c
LOCUS       AR489959                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 82 from patent US 6710174.
ACCESSION   AR489959
VERSION     AR489959.1  GI:47257072
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 82 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3911 GCCUGGAAAGAAUCAAAACC 3930
              |||:||||||||:|||||||
Db         20 GCCTGGAAAGAATCAAAACC 1


RESULT 288
AR489960/c
LOCUS       AR489960                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 83 from patent US 6710174.
ACCESSION   AR489960
VERSION     AR489960.1  GI:47257073
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 83 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3949 AAUGCCACCUCCAUGUUUGA 3968
              ||:||||||:|||:|:::||
Db         20 AATGCCACCTCCATGTTTGA 1


RESULT 289
AR489961/c
LOCUS       AR489961                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 84 from patent US 6710174.
ACCESSION   AR489961
VERSION     AR489961.1  GI:47257074
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 84 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       4255 CCACCCAUCUAGAGUUUGAC 4274
              ||||||:|:||||:::|||
Db         20 CCACCCATCTAGAGTTTGAC 1


RESULT 290
AR489962/c
LOCUS       AR489962                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 85 from patent US 6710174.
ACCESSION   AR489962
VERSION     AR489962.1  GI:47257075
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 85 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4420 UUUGACUAACAAGAAUGUAA 4439
              :::|||:||||||||:|:||
Db         20 TTTGACTAACAAGAATGTAA 1


RESULT 291
AR489963/c
LOCUS       AR489963                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 86 from patent US 6710174.
ACCESSION   AR489963
VERSION     AR489963.1  GI:47257076
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 86 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   55.0%;  Pred. No. 2e+03;
  Matches   11;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5739 GUUUGAUGCUAUUUAUGCAA 5758
              |:::||:||:|:::|:||||
Db         20 GTTTGATGCTATTTATGCAA 1


RESULT 292
AR489964/c
LOCUS       AR489964                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 87 from patent US 6710174.
ACCESSION   AR489964
VERSION     AR489964.1  GI:47257077
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 87 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 2e+03;
  Matches   14;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6117 AGCGGCUUUUGUGGAAGACU 6136
              ||||||::::|:|||||||:
Db         20 AGCGGCTTTTGTGGAAGACT 1


RESULT 293
AR489965/c
LOCUS       AR489965                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 88 from patent US 6710174.
ACCESSION   AR489965
VERSION     AR489965.1  GI:47257078
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Watt,A.T.
  TITLE     Antisense inhibition of vascular endothelial growth factor
            receptor-1 expression
  JOURNAL   Patent: US 6710174-A 88 23-MAR-2004;
            ISIS Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6905 CAGAUACUCGCUAGCCUCAU 6924
              ||||:||:|||:||||:||:
Db         20 CAGATACTCGCTAGCCTCAT 1


RESULT 294
AX179298
LOCUS       AX179298                  20 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 1 from Patent WO0141813.
ACCESSION   AX179298
VERSION     AX179298.1  GI:14598969
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linnik,M.D. and Mcnealy,P.A.
  TITLE     Methods of treating lupus based on antibody affinity and screening
            methods and compositions for use thereof
  JOURNAL   Patent: WO 0141813-A 1 14-JUN-2001;
            LA JOLLA PHARMACEUTICAL COMPANY (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 295
AX179299/c
LOCUS       AX179299                  20 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 2 from Patent WO0141813.
ACCESSION   AX179299
VERSION     AX179299.1  GI:14598970
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linnik,M.D. and Mcnealy,P.A.
  TITLE     Methods of treating lupus based on antibody affinity and screening
            methods and compositions for use thereof
  JOURNAL   Patent: WO 0141813-A 2 14-JUN-2001;
            LA JOLLA PHARMACEUTICAL COMPANY (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 296
AX204798
LOCUS       AX204798                  20 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 17 from Patent WO0153345.
ACCESSION   AX204798
VERSION     AX204798.1  GI:15394135
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Harper,S.J.
  TITLE     Vegf148 isoform, a truncated splice variant of vegf. Vegf
            heterodimers and therapeutical uses thereof
  JOURNAL   Patent: WO 0153345-A 17 26-JUL-2001;
            North Bristol NHS Trust (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA probe"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2163 CAGGAAUGUAUACACAGGGG 2182
              ||||||:|:|:|||||||||
Db          1 CAGGAATGTATACACAGGGG 20


RESULT 297
AX204799/c
LOCUS       AX204799                  20 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 18 from Patent WO0153345.
ACCESSION   AX204799
VERSION     AX204799.1  GI:15394136
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Harper,S.J.
  TITLE     Vegf148 isoform, a truncated splice variant of vegf. Vegf
            heterodimers and therapeutical uses thereof
  JOURNAL   Patent: WO 0153345-A 18 26-JUL-2001;
            North Bristol NHS Trust (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA probe"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2797 AAGAAAUCACCUACGUGCCG 2816
              ||||||:||||:|||:||||
Db         20 AAGAAATCACCTACGTGCCG 1


RESULT 298
AX204800
LOCUS       AX204800                  20 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 19 from Patent WO0153345.
ACCESSION   AX204800
VERSION     AX204800.1  GI:15394137
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Harper,S.J.
  TITLE     Vegf148 isoform, a truncated splice variant of vegf. Vegf
            heterodimers and therapeutical uses thereof
  JOURNAL   Patent: WO 0153345-A 19 26-JUL-2001;
            North Bristol NHS Trust (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA probe"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2e+03;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2212 AUCAGAGAUCAGGAAGCACC 2231
              |:||||||:||||||||||
Db          1 ATCAGAGATCAGGAAGCACC 20


RESULT 299
AX204801/c
LOCUS       AX204801                  20 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 20 from Patent WO0153345.
ACCESSION   AX204801
VERSION     AX204801.1  GI:15394138
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Harper,S.J.
  TITLE     Vegf148 isoform, a truncated splice variant of vegf. Vegf
            heterodimers and therapeutical uses thereof
  JOURNAL   Patent: WO 0153345-A 20 26-JUL-2001;
            North Bristol NHS Trust (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA probe"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2e+03;
  Matches   16;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2644 AUGGACCCAGAUGAAGUUCC 2663
              |:||||||||:||||::||
Db         20 ATGGACCCAGATGAAGTTCC 1


RESULT 300
AX204806
LOCUS       AX204806                  20 bp    DNA     linear   PAT 30-AUG-2001
DEFINITION  Sequence 25 from Patent WO0153345.
ACCESSION   AX204806
VERSION     AX204806.1  GI:15394143
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Harper,S.J.
  TITLE     Vegf148 isoform, a truncated splice variant of vegf. Vegf
            heterodimers and therapeutical uses thereof
  JOURNAL   Patent: WO 0153345-A 25 26-JUL-2001;
            North Bristol NHS Trust (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA probe"

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2e+03;
  Matches   17;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2163 CAGGAAUGUAUACACAGGGG 2182
              ||||||:|:|:||||||||||
Db          1 CAGGAATGTATACACAGGGG 20


RESULT 301
CS069604
LOCUS       CS069604                  21 bp    DNA     linear   PAT 20-APR-2005
DEFINITION  Sequence 897 from Patent WO2005031002.
ACCESSION   CS069604
VERSION     CS069604.1  GI:62821272
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linsley,P.S., Mao,M., Kim,A.S., Friend,S.H., Bartz,S.R. and
            Cleary,M.A.
  TITLE     Synthetic lethal screen using rna interference
  JOURNAL   Patent: WO 2005031002-A 897 07-APR-2005;
            Rosetta Inpharmatics LLC. (US); Merck and Co., Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="siRNA with 19 paired ribonucleotides and two
                     unpaired nucleotides(#t#) on the 3' end of each strand
                     used in screens of DNA damaging agents: camptothecin
                     screen"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   65.0%;  Pred. No. 2.2e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3563 UGGAUGAGGACUUUUGCAGU 3582
              :|||:||||||::::||||:
Db          1 TGGATGAGGACTTTTGCAGT 20


RESULT 302
DD207636/c
LOCUS       DD207636                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207636
VERSION     DD207636.1  GI:85645773
KEYWORDS    JP 2005518803-A/425.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 425 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/425
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  siNA antisense region FH
            Key             Location/Qualifiers
            FT   misc_feature    (1). .(2)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (4). .(5)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (7). .(7)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (9). .(12)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (14). .(14)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (17). .(18)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (20). .(20)
            FT                   /note='n stands for thymidine' FT
            misc_feature    (21). .(21)
            FT                   /note='n stands for 3'-O-methyl uridine'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.2e+03;
  Matches   19;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2338 AACAACCACAAAAUACAACAA 2358
              | ||||||||||||:|||||||
Db         21 ANCAACCACAAAATACAACAA 1


RESULT 303
DD207638/c
LOCUS       DD207638                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207638
VERSION     DD207638.1  GI:85645775
KEYWORDS    JP 2005518803-A/427.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 427 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/427
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  siNA antisense region FH
            Key             Location/Qualifiers
            FT   misc_feature    (1). .(2)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (4). .(5)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (7). .(7)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (9). .(12)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (14). .(14)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (17). .(18)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (20). .(20)
            FT                   /note='n stands for thymidine' FT
            misc_feature    (21). .(21)
            FT                   /note='n stands for L-uridine'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.2e+03;
  Matches   19;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              | ||||||||||||:|||||||
Db         21 ANCAACCACAAAATACAACAA 1


RESULT 304
AR372055/c
LOCUS       AR372055                  21 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 9 from patent US 6395548.
ACCESSION   AR372055
VERSION     AR372055.1  GI:34609167
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lee,M.-E., Maemura,K. and Hsieh,C.-M.
  TITLE     Methods of modulating of angiogenesis
  JOURNAL   Patent: US 6395548-A 9 28-MAY-2002;
            President and Fellows of Harvard College; Cambridge, MA
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 2.2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 305
AR372059/c
LOCUS       AR372059                  21 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 13 from patent US 6395548.
ACCESSION   AR372059
VERSION     AR372059.1  GI:34609171
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lee,M.-E., Maemura,K. and Hsieh,C.-M.
  TITLE     Methods of modulating of angiogenesis
  JOURNAL   Patent: US 6395548-A 13 28-MAY-2002;
            President and Fellows of Harvard College; Cambridge, MA
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 2.2e+03;
  Matches   15;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2689 CCUUAUGAUGCCAGCAAGUG 2708
              ||::|:||:|||||||||:|
Db         20 CCTTATGATGCCAGCAAGTG 1


RESULT 306
AX398276/c
LOCUS       AX398276                  21 bp    DNA     linear   PAT 27-MAY-2002
DEFINITION  Sequence 1 from Patent WO0220543.
ACCESSION   AX398276
VERSION     AX398276.1  GI:21261077
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Sinha,N.
  TITLE     Synthons for oligonucleotide synthesis
  JOURNAL   Patent: WO 0220543-A 1 14-MAR-2002;
            Avecia Biotechnology, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
```

```
                     /note="Sequence prepared in Example 4"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:|:
Db         20 GTGTGTGTGTGTGTGTGTGT 1


RESULT 307
AX398277
LOCUS       AX398277                 21 bp    DNA     linear   PAT 27-MAY-2002
DEFINITION  Sequence 2 from Patent WO0220543.
ACCESSION   AX398277
VERSION     AX398277.1  GI:21261078
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Sinha,N.
  TITLE     Synthons for oligonucleotide synthesis
  JOURNAL   Patent: WO 0220543-A 2 14-MAR-2002;
            Avecia Biotechnology, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence prepared in Example 4"

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+03;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 308
AX496104/c
LOCUS       AX496104                 23 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 1869 from Patent WO02059256.
ACCESSION   AX496104
VERSION     AX496104.1  GI:23341714
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1
  AUTHORS   Tuijnder,M., Telerman,A., Amson,R. and Susini,L.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 02059256-A 1869 01-AUG-2002;
            MOLECULAR ENGINES LAB (FR)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.3%;  Score 20;  DB 1;  Length 23;
  Best Local Similarity   22.7%;  Pred. No. 2.6e+03;
  Matches    5;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUUCCAAA 6366
              |:::::::::::::::| ||||

Db         22 CTTTTTTTTTTTTTTNCNAAA 1


RESULT 309
CS155978/c
LOCUS       CS155978                 25 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 169 from Patent WO2005078097.
ACCESSION   CS155978
VERSION     CS155978.1  GI:74271126
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 169 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 20;  DB 1;  Length 25;
  Best Local Similarity   65.0%;  Pred. No. 3e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGU 1520
              |:|||:|||||:|:||::|:
Db         20 CTCACTGCCACTCTAATTGT 1


RESULT 310
CS156033
LOCUS       CS156033                 25 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 224 from Patent WO2005078097.
ACCESSION   CS156033
VERSION     CS156033.1  GI:74271180
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 224 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.3%;  Score 20;  DB 1;  Length 25;
  Best Local Similarity   65.0%;  Pred. No. 3e+03;
  Matches   13;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUGU 1520
              |:|||:|||||:|:||::|:
Db          6 CTCACTGCCACTCTAATTGT 25


RESULT 311
AX958324/c
LOCUS       AX958324                 21 bp    DNA     linear   PAT 08-JAN-2004
DEFINITION  Sequence 22 from Patent WO0174296.
ACCESSION   AX958324
VERSION     AX958324.1  GI:40785901
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Witte,L. and Rafii,S.
  TITLE     Treatment of non-solid mammalian tumors with vascular
            endothelialgrowth factor receptor antagonists
  JOURNAL   Patent: WO 0174296-A 22 11-OCT-2001;
            IMCLONE SYSTEMS, INC. (US) ; CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic primer"

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   61.9%;  Pred. No. 2.6e+03;
  Matches   13;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3895 GCUUUCAAGUUCAUGAGCCUG 3915
              | :::||||::||:|||||:|
Db         21 GATTTCAAGTTCATGAGCCTG 1


RESULT 312
CS069602
LOCUS       CS069602                  21 bp    DNA     linear   PAT 20-APR-2005
DEFINITION  Sequence 895 from Patent WO2005031002.
ACCESSION   CS069602
VERSION     CS069602.1  GI:62821270
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Linsley,P.S., Mao,M., Kim,A.S., Friend,S.H., Bartz,S.R. and
            Cleary,M.A.
  TITLE     Synthetic lethal screen using rna interference
  JOURNAL   Patent: WO 2005031002-A 895 07-APR-2005;
            Rosetta Inpharmatics LLC. (US); Merck and Co., Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="siRNA with 19 paired ribonucleotides and two
                     unpaired nucleotides(#t#) on the 3' end of each strand
                     used in screens of DNA damaging agents: camptothecin
                     screen"

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.6e+03;
  Matches   17;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1260 ACAUCGAAAACAGCAGGUGCU 1280
              |||:|||||||||||||:| :
Db          1 ACATCGAAAACAGCAGGTGTT 21


RESULT 313
I30547/c
LOCUS       I30547                    21 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 10 from patent US 5580969.
ACCESSION   I30547
VERSION     I30547.1  GI:1821338
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Hoke,G.D., Bradley,M.O., Williams,T.J. and Lee,C.-H.
  TITLE     Antisense oligonucleotides directed against human ICAM-I RNA
  JOURNAL   Patent: US 5580969-A 10 03-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 2.6e+03;
  Matches    9;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|: :|:|:
Db         21 TGTGTGTGTGTGTGTATGTGT 1


RESULT 314
DD207639/c
LOCUS       DD207639                  21 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA).
ACCESSION   DD207639
VERSION     DD207639.1  GI:85645776
KEYWORDS    JP 2005518803-A/428.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Jamison,S., Fosunafu,C., Beigelman,L., Chourira,B., Thompson,J.,
            Asuman,N., Pavco,P. and Mcswiggen,J.
  TITLE     RNA Interference Mediated Inhibition of Gene Expression Using Short
            Interfering Nucleic Acid (siNA)
  JOURNAL   Patent: JP 2005518803-A 428 30-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005518803-A/428
            PD   30-JUN-2005
            PF   20-FEB-2003 JP 2003573107
            PR   15-JAN-2003 US    60/440129,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            06-JUN-2002 US    60/386782,11-MAR-2002 US    60/363124, PR
            20-FEB-2002 US    60/358580
            PI   sharon jamison,cathy fosunafu,leonid beigelman,baratto  PI
            chourira,
            PI   james thompson,nashimu asuman,pamela pavco,james mcswiggen CC
             Description of Artificial Sequence:  siNA antisense region FH
            Key             Location/Qualifiers
            FT   misc_feature    (1). .(2)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (4). .(5)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (7). .(7)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (9). .(12)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (14). .(14)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (17). .(18)
            FT                   /note='2'-deoxy-2'-fluoro'
            FT   misc_feature    (20). .(20)
            FT                   /note='n stands for thymidine' FT
            misc_feature    (21). .(21)
            FT                   /note='n stands for 3',3'-inverted thymidine'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.3%;  Score 19.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 2.7e+03;
  Matches   18;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2338 AACAACCACAAAAUACAACAA 2358
              : |||||||||||:|||||||
Db         21 HNCAACCACAAAATACAACAA 1
```

```
RESULT 315
CS049488
LOCUS       CS049488                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 592 from Patent WO2005019453.
ACCESSION   CS049488
VERSION     CS049488.1  GI:61855102
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 592 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA sense
                     region"
     misc_feature    1
                     /note="5#-3 attached terminal deoxyabasic moeity"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||||
Db          1 CTGAGTTTAAAAGGCACCC 19


RESULT 316
CS049498/c
LOCUS       CS049498                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 602 from Patent WO2005019453.
ACCESSION   CS049498
VERSION     CS049498.1  GI:61855116
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 602 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1.. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA antisense
                     region"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 317
CS049589
LOCUS       CS049589                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 693 from Patent WO2005019453.
ACCESSION   CS049589
VERSION     CS049589.1  GI:61855241
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 693 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA sense
                     region"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||||
Db          1 CTGAGTTTAAAAGGCACCC 19


RESULT 318
CS049590/c
LOCUS       CS049590                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 694 from Patent WO2005019453.
ACCESSION   CS049590
VERSION     CS049590.1  GI:61855242
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 694 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA antisense
                     region"
     misc_feature    1
                     /note="5#-3 attached terminal deoxyabasic moeity"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 319
CS049591
LOCUS       CS049591                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 695 from Patent WO2005019453.
ACCESSION   CS049591
VERSION     CS049591.1  GI:61855243
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 695 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA sense
                     region"
     misc_feature    1. .2
                     /note="2#-deoxy-2#-Fluoro"
     misc_feature    6. .8
                     /note="2#-deoxy-2#-Fluoro"
     misc_feature    15
                     /note="2#-deoxy-2#-Fluoro"
     misc_feature    17. .19
                     /note="2#-deoxy-2#-Fluoro"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||
Db          1 CTGAGTTTAAAAGGCACCC 19


RESULT 320
CS049592/c
LOCUS       CS049592                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 696 from Patent WO2005019453.
ACCESSION   CS049592
VERSION     CS049592.1  GI:61855248
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 696 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: siNA antisense
                     region"
     misc_feature    4
                     /note="2#-deoxy-2#-Fluoro"
     misc_feature    6. .11
                     /note="2#-deoxy-2#-Fluoro"
     misc_feature    15. .17
                     /note="2#-deoxy-2#-Fluoro"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 321
CS050022/c
LOCUS       CS050022                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 1126 from Patent WO2005019453.
ACCESSION   CS050022
VERSION     CS050022.1  GI:61856032
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 1126 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: antisense siNA
                     targeting VEGFR1"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db         19 CTCACTGCCACTCTAATTG 1


RESULT 322
CS050023
LOCUS       CS050023                  19 bp    RNA     linear   PAT 22-MAR-2005
DEFINITION  Sequence 1127 from Patent WO2005019453.
ACCESSION   CS050023
VERSION     CS050023.1  GI:61856035
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   McSwiggen,J., Morrissey,D., Zinnen,S., Jadhav,V. and Vaish,N.
  TITLE     RNA interference mediated inhibition of gene expression using
            chemically modified short interfering Nucleic Acid (siNA)
  JOURNAL   Patent: WO 2005019453-A 1127 03-MAR-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: antisense siNA
                     targeting VEGFR1"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db          1 CTCACTGCCACTCTAATTG 19


RESULT 323
CS155812/c
LOCUS       CS155812                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 3 from Patent WO2005078097.
ACCESSION   CS155812
VERSION     CS155812.1  GI:74270960
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 3 25-AUG-2005;
          Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db         19 CTCACTGCCACTCTAATTG 1


RESULT 324
CS155813
LOCUS       CS155813                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 4 from Patent WO2005078097.
ACCESSION   CS155813
VERSION     CS155813.1  GI:74270961
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 4 25-AUG-2005;
          Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db          1 CTCACTGCCACTCTAATTG 19


RESULT 325
CS155818
LOCUS       CS155818                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 9 from Patent WO2005078097.
ACCESSION   CS155818
VERSION     CS155818.1  GI:74270966
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 9 25-AUG-2005;
          Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1175 AUACUUGUCGUGUAAGGAG 1193
              |:||::|:||:|:||||||
Db          1 ATACTTGTCGTGTAAGGAG 19


RESULT 326
CS155819
LOCUS       CS155819                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 10 from Patent WO2005078097.
ACCESSION   CS155819
VERSION     CS155819.1  GI:74270967
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 10 25-AUG-2005;
          Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db          1 CTCACTGCCACTCTAATTG 19


RESULT 327
CS155820
LOCUS       CS155820                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 11 from Patent WO2005078097.
ACCESSION   CS155820
VERSION     CS155820.1  GI:74270968
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
          other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 11 25-AUG-2005;
          Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1502 UCACUGCCACUCUAAUUGU 1520
              :|||:|||||:|:||::|:
Db          1 TCACTGCCACTCTAATTGT 19


RESULT 328
CS155821
LOCUS       CS155821                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 12 from Patent WO2005078097.
ACCESSION   CS155821
```

```
VERSION     CS155821.1  GI:74270969
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 12 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1503 CACUGCCACUCUAAUUGUC 1521
              |||:|||||:|:||::|:|
Db          1 CACTGCCACTCTAATTGTC 19


RESULT 329
CS155822
LOCUS       CS155822                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 13 from Patent WO2005078097.
ACCESSION   CS155822
VERSION     CS155822.1  GI:74270970
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 13 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1504 ACUGCCACUCUAAUUGUCA 1522
              ||:|||||:|:||::|:||
Db          1 ACTGCCACTCTAATTGTCA 19


RESULT 330
CS155823
LOCUS       CS155823                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 14 from Patent WO2005078097.
ACCESSION   CS155823
VERSION     CS155823.1  GI:74270971
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 14 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||||:||:||||||
Db          1 ATGCTGGACTGCTGGCACA 19


RESULT 331
CS155837
LOCUS       CS155837                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 28 from Patent WO2005078097.
ACCESSION   CS155837
VERSION     CS155837.1  GI:74270985
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 28 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3645 CAUGCUGGACUGCUGGCAC 3663
              ||:||:||||:||:|||||
Db          1 CATGCTGGACTGCTGGCAC 19


RESULT 332
CS155875/c
LOCUS       CS155875                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 66 from Patent WO2005078097.
ACCESSION   CS155875
VERSION     CS155875.1  GI:74271023
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 66 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||
Db         19 CTGAGTTTAAAAGGCACCC 1


RESULT 333
```

```
CS155876/c
LOCUS       CS155876                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 67 from Patent WO2005078097.
ACCESSION   CS155876
VERSION     CS155876.1  GI:74271024
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 67 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1175 AUACUUGUCGUGUAAGGAG 1193
              |:||::|:||:|:||||||
Db         19 ATACTTGTCGTGTAAGGAG 1


RESULT 334
CS155877/c
LOCUS       CS155877                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 68 from Patent WO2005078097.
ACCESSION   CS155877
VERSION     CS155877.1  GI:74271025
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 68 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1501 CUCACUGCCACUCUAAUUG 1519
              |:|||:|||||:|:||::|
Db         19 CTCACTGCCACTCTAATTG 1


RESULT 335
CS155878/c
LOCUS       CS155878                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 69 from Patent WO2005078097.
ACCESSION   CS155878
VERSION     CS155878.1  GI:74271026
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 69 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1502 UCACUGCCACUCUAAUUGU 1520
              :|||:|||||:|:||::|:
Db         19 TCACTGCCACTCTAATTGT 1


RESULT 336
CS155879/c
LOCUS       CS155879                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 70 from Patent WO2005078097.
ACCESSION   CS155879
VERSION     CS155879.1  GI:74271027
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 70 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1503 CACUGCCACUCUAAUUGUC 1521
              |||:|||||:|:||::|:|
Db         19 CACTGCCACTCTAATTGTC 1


RESULT 337
CS155880/c
LOCUS       CS155880                19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 71 from Patent WO2005078097.
ACCESSION   CS155880
VERSION     CS155880.1  GI:74271028
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 71 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1504 ACUGCCACUCUAAUUGUCA 1522
              ||:|||||:|:||::|:||
```

```
Db         19 ACTGCCACTCTAATTGTCA 1


RESULT 338
CS155881/c
LOCUS       CS155881                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 72 from Patent WO2005078097.
ACCESSION   CS155881
VERSION     CS155881.1  GI:74271029
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 72 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3646 AUGCUGGACUGCUGGCACA 3664
              |:||:||||:||:||||||
Db         19 ATGCTGGACTGCTGGCACA 1


RESULT 339
CS155895/c
LOCUS       CS155895                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 86 from Patent WO2005078097.
ACCESSION   CS155895
VERSION     CS155895.1  GI:74271043
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 86 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3645 CAUGCUGGACUGCUGGCAC 3663
              ||:||:||||:||:|||||
Db         19 CATGCTGGACTGCTGGCAC 1


RESULT 340
CS155943
LOCUS       CS155943                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 134 from Patent WO2005078097.
ACCESSION   CS155943
VERSION     CS155943.1  GI:74271091
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 134 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2063 GCAAGCAAAAAAUGGCCAU 2081
              ||||||||||||:|||||:
Db          1 GCAAGCAAAAAATGGCCAT 19


RESULT 341
CS155944
LOCUS       CS155944                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 135 from Patent WO2005078097.
ACCESSION   CS155944
VERSION     CS155944.1  GI:74271092
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 135 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5353 GACCCCGUCUCUAUACCAA 5371
              |||||||:|:|:|:|||||
Db          1 GACCCCGTCTCTATACCAA 19


RESULT 342
CS155945
LOCUS       CS155945                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 136 from Patent WO2005078097.
ACCESSION   CS155945
VERSION     CS155945.1  GI:74271093
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 136 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
```

```
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         47 GCGGGCUCCGGGGCUCGGG 65
              ||||||:|||||||:||||
Db          1 GCGGGCTCCGGGGCTCGGG 19


RESULT 343
CS155946
LOCUS       CS155946                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 137 from Patent WO2005078097.
ACCESSION   CS155946
VERSION     CS155946.1  GI:74271094
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 137 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 CGGCUCCUCCCCGGCAGCG 33
              ||||:||:||||||||||||
Db          1 CGGCTCCTCCCCGGCAGCG 19


RESULT 344
CS155964/c
LOCUS       CS155964                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 155 from Patent WO2005078097.
ACCESSION   CS155964
VERSION     CS155964.1  GI:74271112
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 155 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2063 GCAAGCAAAAAAUGGCCAU 2081
              ||||||||||||:|||||:
Db         19 GCAAGCAAAAAATGGCCAT 1


RESULT 345
CS155965/c
LOCUS       CS155965                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 156 from Patent WO2005078097.
ACCESSION   CS155965
VERSION     CS155965.1  GI:74271113
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 156 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5353 GACCCCGUCUCUAUACCAA 5371
              |||||||:|:|:|:|||||
Db         19 GACCCCGTCTCTATACCAA 1


RESULT 346
CS155966/c
LOCUS       CS155966                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 157 from Patent WO2005078097.
ACCESSION   CS155966
VERSION     CS155966.1  GI:74271114
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 157 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         47 GCGGGCUCCGGGGCUCGGG 65
              ||||||:|||||||:||||
Db         19 GCGGGCTCCGGGGCTCGGG 1


RESULT 347
CS155967/c
LOCUS       CS155967                 19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 158 from Patent WO2005078097.
ACCESSION   CS155967
VERSION     CS155967.1  GI:74271115
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 158 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
```

```
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 CGGCUCCUCCCCGGCAGCG 33
              ||||:||:||||||||||
Db         19 CGGCTCCTCCCCGGCAGCG 1


RESULT 348
CS156079
LOCUS       CS156079                  19 bp    RNA     linear   PAT 07-SEP-2005
DEFINITION  Sequence 270 from Patent WO2005078097.
ACCESSION   CS156079
VERSION     CS156079.1  GI:74271226
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Jadhav,V.
  JOURNAL   Patent: WO 2005078097-A 270 25-AUG-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        349 CUGAGUUUAAAAGGCACCC 367
              |:|||:::||||||||||
Db          1 CTGAGTTTAAAAGGCACCC 19


RESULT 349
DD201520
LOCUS       DD201520                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201520
VERSION     DD201520.1  GI:85654969
KEYWORDS    JP 2005517436-A/1.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 1 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/1
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GCGGACACUCCUCUCGGCU 19
              ||||||||:||:|:||||:
Db          1 GCGGACACTCCTCTCGGCT 19


RESULT 350
DD201521
LOCUS       DD201521                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201521
VERSION     DD201521.1  GI:85654970
KEYWORDS    JP 2005517436-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 2 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/2
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 UCCUCCCCGGCAGCGGCGG 37
              :||:||||||||||||||||
Db          1 TCCTCCCCGGCAGCGGCGG 19


RESULT 351
DD201522
LOCUS       DD201522                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201522
VERSION     DD201522.1  GI:85654971
KEYWORDS    JP 2005517436-A/3.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 3 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/3
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         37 GCGGCUCGGAGCGGGCUCC 55
              |||||:||||||||||:||
Db          1 GCGGCTCGGAGCGGGCTCC 19


RESULT 352
DD201523
LOCUS       DD201523                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201523
VERSION     DD201523.1  GI:85654972
KEYWORDS    JP 2005517436-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 4 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/4
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         55 CGGGGCUCGGGUGCAGCGG 73
              ||||||:||||:|||||||
Db          1 CGGGGCTCGGGTGCAGCGG 19


RESULT 353
DD201524
LOCUS       DD201524                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201524
VERSION     DD201524.1  GI:85654973
KEYWORDS    JP 2005517436-A/5.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 5 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/5
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         73 GCCAGCGGGCCUGGCGGCG 91
              ||||||||||:|||||||
Db          1 GCCAGCGGGCCTGGCGGCG 19


RESULT 354
DD201525
LOCUS       DD201525                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201525
VERSION     DD201525.1  GI:85654974
KEYWORDS    JP 2005517436-A/6.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 6 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/6
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         91 GAGGAUUACCCGGGGAAGU 109
              |||||::|||||||||||:
Db          1 GAGGATTACCCGGGGAAGT 19


RESULT 355
DD201526
LOCUS       DD201526                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201526
VERSION     DD201526.1  GI:85654975
KEYWORDS    JP 2005517436-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 7 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/7
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         109 UGGUUGUCUCCUGGCUGGA 127
               :||::|:|:||:|||:|||
Db          1 TGGTTGTCTCCTGGCTGGA 19


RESULT 356
DD201527
LOCUS       DD201527                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201527
VERSION     DD201527.1  GI:85654976
KEYWORDS    JP 2005517436-A/8.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 8 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/8
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         127 AGCCGCGAGACGGGCGCUC 145
               |||||||||||||||||:|
Db          1 AGCCGCGAGACGGGCGCTC 19


RESULT 357
DD201528
LOCUS       DD201528                19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201528
VERSION     DD201528.1  GI:85654977
KEYWORDS    JP 2005517436-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 9 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/9
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        145 CAGGGCGCGGGGCCGGCGG 163
              |||||||||||||||||||
Db          1 CAGGGCGCGGGGCCGGCGG 19


RESULT 358
DD201529
LOCUS       DD201529                 19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201529
VERSION     DD201529.1  GI:85654978
KEYWORDS    JP 2005517436-A/10.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 10 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/10
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630".

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        163 GCGGCGAACGAGAGGACGG 181
              |||||||||||||||||||
Db          1 GCGGCGAACGAGAGGACGG 19


RESULT 359
DD201530
LOCUS       DD201530                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201530
VERSION     DD201530.1  GI:85654979
KEYWORDS    JP 2005517436-A/11.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 11 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/11
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 GACUCUGGCGGCCGGGUCG 199
              |||:|:||||||||||:||
Db          1 GACTCTGGCGGCCGGGTCG 19


RESULT 360
DD201531
LOCUS       DD201531                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201531
VERSION     DD201531.1  GI:85654980
KEYWORDS    JP 2005517436-A/12.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 12 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/12
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        199 GUUGGCCGGGGGAGCGCGG 217
              |::||||||||||||||||
Db          1 GTTGGCCGGGGGAGCGCGG 19


RESULT 361
DD201532
LOCUS       DD201532                  19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201532
VERSION     DD201532.1  GI:85654981
KEYWORDS    JP 2005517436-A/13.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 13 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/13
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        217 GGCACCGGGCGAGCAGGCC 235
              |||||||||||||||||||
Db          1 GGCACCGGGCGAGCAGGCC 19


RESULT 362
DD201533
LOCUS       DD201533                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201533
VERSION     DD201533.1  GI:85654982
KEYWORDS    JP 2005517436-A/14.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 14 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/14
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        235 CGCGUCGCGCUCACCAUGG 253
              ||||:|||||:|||||:||
Db          1 CGCGTCGCGCTCACCATGG 19


RESULT 363
DD201534
LOCUS       DD201534                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201534
VERSION     DD201534.1  GI:85654983
KEYWORDS    JP 2005517436-A/15.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 15 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/15
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        253 GUCAGCUACUGGGACACCG 271
              |:||||:||:|||||||||
Db          1 GTCAGCTACTGGGACACCG 19


RESULT 364
DD201535
LOCUS       DD201535                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201535
VERSION     DD201535.1  GI:85654984
KEYWORDS    JP 2005517436-A/16.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 16 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/16
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 GGGGUCCUGCUGUGCGCGC 289
              ||||:||:||:|:||||||
Db          1 GGGGTCCTGCTGTGCGCGC 19


RESULT 365
DD201536
LOCUS       DD201536                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201536
VERSION     DD201536.1  GI:85654985
KEYWORDS    JP 2005517436-A/17.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 17 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/17
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        289 CUGCUCAGCUGUCUGCUUC 307
              |:||:||||:|:|:||::|
Db          1 CTGCTCAGCTGTCTGCTTC 19


RESULT 366
DD201537
LOCUS       DD201537                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201537
VERSION     DD201537.1  GI:85654986
KEYWORDS    JP 2005517436-A/18.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 18 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/18
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        307 CUCACAGGAUCUAGUUCAG 325
              |:|||||||:|:||::|||
Db          1 CTCACAGGATCTAGTTCAG 19


RESULT 367
DD201538
LOCUS       DD201538                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201538
VERSION     DD201538.1  GI:85654987
KEYWORDS    JP 2005517436-A/19.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 19 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/19
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        325 GGUUCAAAAUUAAAAGAUC 343
              ||::|||||::||||||:|
Db          1 GGTTCAAAATTAAAAGATC 19


RESULT 368
DD201539
LOCUS       DD201539                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201539
VERSION     DD201539.1  GI:85654988
KEYWORDS    JP 2005517436-A/20.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 20 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/20
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        343 CCUGAACUGAGUUUAAAAG 361
              ||:||||:|||:::|||||
Db          1 CCTGAACTGAGTTTAAAAG 19


RESULT 369
DD201540
LOCUS       DD201540                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201540
VERSION     DD201540.1  GI:85654989
KEYWORDS    JP 2005517436-A/21.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 21 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/21
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 361 GGCACCCAGCACAUCAUGC 379
||||||||||||||:||:||
Db 1 GGCACCCAGCACATCATGC 19

RESULT 370
DD201541
LOCUS DD201541 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201541
VERSION DD201541.1 GI:85654990
KEYWORDS JP 2005517436-A/22.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 22 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/22
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+03;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 379 CAAGCAGGCCAGACACUGC 397
||||||||||||||||:||
Db 1 CAAGCAGGCCAGACACTGC 19

RESULT 371
DD201542
LOCUS DD201542 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201542
VERSION DD201542.1 GI:85654991
KEYWORDS JP 2005517436-A/23.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 23 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/23
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 397 CAUCUCCAAUGCAGGGGGG 415
||:|:||||:||||||||||
Db 1 CATCTCCAATGCAGGGGGG 19

RESULT 372
DD201543
LOCUS DD201543 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201543
VERSION DD201543.1 GI:85654992
KEYWORDS JP 2005517436-A/24.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA

```
  JOURNAL   Patent: JP 2005517436-A 24 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/24
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        415 GAAGCAGCCCAUAAAUGGU 433
              ||||||||||:|||:||:
Db          1 GAAGCAGCCCATAAATGGT 19


RESULT 373
DD201544
LOCUS       DD201544                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201544
VERSION     DD201544.1  GI:85654993
KEYWORDS    JP 2005517436-A/25.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 25 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/25
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        433 UCUUUGCCUGAAAUGGUGA 451
              :|:::|||:||||:||:||
Db          1 TCTTTGCCTGAAATGGTGA 19


RESULT 374
DD201545
LOCUS       DD201545                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201545
VERSION     DD201545.1  GI:85654994
KEYWORDS    JP 2005517436-A/26.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 26 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/26
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 AGUAAGGAAAGCGAAAGGC 469
              ||:||||||||||||||||
Db          1 AGTAAGGAAAGCGAAAGGC 19


RESULT 375
DD201546
LOCUS       DD201546                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201546
VERSION     DD201546.1  GI:85654995
KEYWORDS    JP 2005517436-A/27.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 27 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/27
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        469 CUGAGCAUAACUAAAUCUG 487
              |:|||||:|||:|||:|:|
Db          1 CTGAGCATAACTAAATCTG 19


RESULT 376
DD201547
LOCUS       DD201547                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201547
VERSION     DD201547.1  GI:85654996
KEYWORDS    JP 2005517436-A/28.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 28 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/28
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        487 GCCUGUGGAAGAAAUGGCA 505
              |||:|:||||||||:||||
Db          1 GCCTGTGGAAGAAATGGCA 19


RESULT 377
DD201548
LOCUS       DD201548                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201548
VERSION     DD201548.1  GI:85654997
KEYWORDS    JP 2005517436-A/29.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 29 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/29
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        505 AAACAAUUCUGCAGUACUU 523
              ||||||::|:||||:||::
Db          1 AAACAATTCTGCAGTACTT 19


RESULT 378
DD201549
LOCUS       DD201549                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201549
VERSION     DD201549.1  GI:85654998
KEYWORDS    JP 2005517436-A/30.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 30 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/30
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        523 UUAACCUUGAACACAGCUC 541
              ::||||::|||||||||:|
Db          1 TTAACCTTGAACACAGCTC 19


RESULT 379
DD201550
LOCUS       DD201550                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201550
VERSION     DD201550.1  GI:85654999
KEYWORDS    JP 2005517436-A/31.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 31 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/31
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 CAAGCAAACCACACUGGCU 559
              |||||||||||||:|||:
Db          1 CAAGCAAACCACACTGGCT 19


RESULT 380
DD201551
LOCUS       DD201551                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201551
VERSION     DD201551.1  GI:85655000
KEYWORDS    JP 2005517436-A/32.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 32 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/32
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 UUCUACAGCUGCAAAUAUC 577
              ::|:|||||:|||||:|:|
Db          1 TTCTACAGCTGCAAATATC 19


RESULT 381
DD201552
LOCUS       DD201552                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201552
VERSION     DD201552.1  GI:85655001
KEYWORDS    JP 2005517436-A/33.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 33 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/33
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 577 CUAGCUGUACCUACUUCAA 595
|:|||:|:|||:||::|||
Db 1 CTAGCTGTACCTACTTCAA 19

RESULT 382
DD201553
LOCUS DD201553 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201553
VERSION DD201553.1 GI:85655002
KEYWORDS JP 2005517436-A/34.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 34 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/34
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+03;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 595 AAGAAGAAGGAAACAGAAU 613
||||||||||||||||||:
Db 1 AAGAAGAAGGAAACAGAAT 19

RESULT 383
DD201554
LOCUS DD201554 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201554
VERSION DD201554.1 GI:85655003
KEYWORDS JP 2005517436-A/35.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 35 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/35
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 2.4e+03;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 613 UCUGCAAUCUAUAUAUUUA 631
:|:||||:|:|:|:|:::|
Db 1 TCTGCAATCTATATATTTA 19

RESULT 384
DD201555
LOCUS DD201555 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201555
VERSION DD201555.1 GI:85655004
KEYWORDS JP 2005517436-A/36.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 36 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/36
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 AUUAGUGAUACAGGUAGAC 649
              |::||:||:|||||:||||
Db          1 ATTAGTGATACAGGTAGAC 19


RESULT 385
DD201556
LOCUS       DD201556                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201556
VERSION     DD201556.1  GI:85655005
KEYWORDS    JP 2005517436-A/37.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 37 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/37
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        649 CCUUUCGUAGAGAUGUACA 667
              ||:::||:|||||:|:|||
Db          1 CCTTTCGTAGAGATGTACA 19


RESULT 386
DD201557
LOCUS       DD201557                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201557
VERSION     DD201557.1  GI:85655006
KEYWORDS    JP 2005517436-A/38.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 38 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/38
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        667 AGUGAAAUCCCCGAAAUUA 685
              ||:||||:|||||||||::|
Db          1 AGTGAAATCCCCGAAATTA 19


RESULT 387
DD201558
LOCUS       DD201558                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201558
VERSION     DD201558.1  GI:85655007
KEYWORDS    JP 2005517436-A/39.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 39 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/39
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
          11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
          03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
          beigelman,james mcswiggen,pamela pavco CC   Description of
          Artificial Sequence:  Target Sequence/siNA  CC            sense
          region
          FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        685 AUACACAUGACUGAAGGAA 703
              |:|||||:|||:|||||||
Db          1 ATACACATGACTGAAGGAA 19


RESULT 388
DD201559
LOCUS       DD201559                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201559
VERSION     DD201559.1  GI:85655008
KEYWORDS    JP 2005517436-A/40.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 40 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/40
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        703 AGGGAGCUCGUCAUUCCCU 721
              |||||||:||:||::|||:
Db          1 AGGGAGCTCGTCATTCCCT 19


RESULT 389
DD201560
LOCUS       DD201560                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201560
VERSION     DD201560.1  GI:85655009
KEYWORDS    JP 2005517436-A/41.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 41 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/41
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 UGCCGGGUUACGUCACCUA 739
              :||||||::|||:|||||:|
Db          1 TGCCGGGTTACGTCACCTA 19


RESULT 390
DD201561
LOCUS       DD201561                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201561
VERSION     DD201561.1  GI:85655010
KEYWORDS    JP 2005517436-A/42.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 42 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/42
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 739 AACAUCACUGUUACUUUAA 757
||||:|||:|::|||:||
Db 1 AACATCACTGTTACTTTAA 19

RESULT 391
DD201562
LOCUS DD201562 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201562
VERSION DD201562.1 GI:85655011
KEYWORDS JP 2005517436-A/43.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 43 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/43
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 757 AAAAAGUUUCCACUUGACA 775
||||||:::||||::||||
Db 1 AAAAAGTTTCCACTTGACA 19

RESULT 392
DD201563
LOCUS DD201563 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201563
VERSION DD201563.1 GI:85655012
KEYWORDS JP 2005517436-A/44.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 44 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/44
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 775 ACUUUGAUCCCUGAUGGAA 793
||:::||:|||:||:||||
Db 1 ACTTTGATCCCTGATGGAA 19

RESULT 393
DD201564
LOCUS DD201564 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201564
VERSION DD201564.1 GI:85655013
KEYWORDS JP 2005517436-A/45.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 45 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/45
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense

```
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        793 AAACGCAUAAUCUGGGACA 811
              |||||||:||:|:||||||
Db          1 AAACGCATAATCTGGGACA 19


RESULT 394
DD201565
LOCUS       DD201565                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201565
VERSION     DD201565.1  GI:85655014
KEYWORDS    JP 2005517436-A/46.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 46 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/46
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        811 AGUAGAAAGGGCUUCAUCA 829
              ||:||||||||::||:||
Db          1 AGTAGAAAGGGCTTCATCA 19


RESULT 395
DD201566
LOCUS       DD201566                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201566
VERSION     DD201566.1  GI:85655015
KEYWORDS    JP 2005517436-A/47.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 47 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/47
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        829 AUAUCAAAUGCAACGUACA 847
              |:|:||||:||||||:|||
Db          1 ATATCAAATGCAACGTACA 19


RESULT 396
DD201567
LOCUS       DD201567                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201567
VERSION     DD201567.1  GI:85655016
KEYWORDS    JP 2005517436-A/48.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 48 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/48
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
```

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAAGAAAUAGGGCUUCUGA 865
              |||||||:|||||::|:||
Db          1 AAAGAAATAGGGCTTCTGA 19


RESULT 397
DD201568
LOCUS       DD201568                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201568
VERSION     DD201568.1  GI:85655017
KEYWORDS    JP 2005517436-A/49.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 49 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/49
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        865 ACCUGUGAAGCAACAGUCA 883
              |||:|:||||||||||:||
Db          1 ACCTGTGAAGCAACAGTCA 19


RESULT 398
DD201569
LOCUS       DD201569                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201569
VERSION     DD201569.1  GI:85655018
KEYWORDS    JP 2005517436-A/50.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 50 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/50
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        883 AAUGGGCAUUUGUAUAAGA 901
              ||:|||||:::|:|:||||
Db          1 AATGGGCATTTGTATAAGA 19


RESULT 399
DD201570
LOCUS       DD201570                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201570
VERSION     DD201570.1  GI:85655019
KEYWORDS    JP 2005517436-A/51.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 51 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/51
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
```

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        901 ACAAACUAUCUCACACAUC 919
              ||||||:|:|:||||||:|
Db          1 ACAAACTATCTCACACATC 19
```

RESULT 400
DD201571
LOCUS DD201571 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201571
VERSION DD201571.1 GI:85655020
KEYWORDS JP 2005517436-A/52.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 52 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/52
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy        919 CGACAAACCAAUACAAUCA 937
              ||||||||||:||||:||
Db          1 CGACAAACCAATACAATCA 19
```

RESULT 401
DD201572
LOCUS DD201572 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201572
VERSION DD201572.1 GI:85655021
KEYWORDS JP 2005517436-A/53.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 53 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/53
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        937 AUAGAUGUCCAAAUAAGCA 955
              |:|||:|:|||||:|||||
Db          1 ATAGATGTCCAAATAAGCA 19
```

RESULT 402
DD201573
LOCUS DD201573 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201573
VERSION DD201573.1 GI:85655022
KEYWORDS JP 2005517436-A/54.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 54 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/54
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"

/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy        955 ACACCACGCCCAGUCAAAU 973
              ||||||||||||:||||:
Db          1 ACACCACGCCCAGTCAAAT 19
```

RESULT 403
DD201574
LOCUS DD201574 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201574
VERSION DD201574.1 GI:85655023
KEYWORDS JP 2005517436-A/55.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 55 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/55
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy        973 UUACUUAGAGGCCAUACUC 991
              ::||::||||||||:||:|
Db          1 TTACTTAGAGGCCATACTC 19
```

RESULT 404
DD201575
LOCUS DD201575 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201575
VERSION DD201575.1 GI:85655024
KEYWORDS JP 2005517436-A/56.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 56 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/56
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2.4e+03;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

```
Qy        991 CUUGUCCUCAAUUGUACUG 1009
              |::|:||:|||::|:||:|
Db          1 CTTGTCCTCAATTGTACTG 19
```

RESULT 405
DD201576
LOCUS DD201576 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201576
VERSION DD201576.1 GI:85655025
KEYWORDS JP 2005517436-A/57.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 57 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/57
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1009 GCUACCACUCCCUUGAACA 1027
              ||:||||:|||::|||||
Db          1 GCTACCACTCCCTTGAACA 19


RESULT 406
DD201577
LOCUS       DD201577                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201577
VERSION     DD201577.1  GI:85655026
KEYWORDS    JP 2005517436-A/58.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 58 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/58
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1027 ACGAGAGUUCAAAUGACCU 1045
              |||||||::||||:||||:
Db          1 ACGAGAGTTCAAATGACCT 19


RESULT 407
DD201578
LOCUS       DD201578                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201578
VERSION     DD201578.1  GI:85655027
KEYWORDS    JP 2005517436-A/59.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 59 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/59
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1045 UGGAGUUACCCUGAUGAAA 1063
              :||||::||||:||:||||
Db          1 TGGAGTTACCCTGATGAAA 19


RESULT 408
DD201579
LOCUS       DD201579                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201579
VERSION     DD201579.1  GI:85655028
KEYWORDS    JP 2005517436-A/60.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 60 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/60
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
```

```
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1063 AAAAAUAAGAGAGCUUCCG 1081
              |||||:|||||||||::|||
Db          1 AAAAATAAGAGAGCTTCCG 19


RESULT 409
DD201580
LOCUS       DD201580                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201580
VERSION     DD201580.1  GI:85655029
KEYWORDS    JP 2005517436-A/61.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 61 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/61
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1081 GUAAGGCGACGAAUUGACC 1099
              |:||||||||||||::||||
Db          1 GTAAGGCGACGAATTGACC 19


RESULT 410
DD201581
LOCUS       DD201581                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201581
VERSION     DD201581.1  GI:85655030
KEYWORDS    JP 2005517436-A/62.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 62 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/62
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1099 CAAAGCAAUUCCCAUGCCA 1117
              ||||||||::||||:||||
Db          1 CAAAGCAATTCCCATGCCA 19


RESULT 411
DD201582
LOCUS       DD201582                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201582
VERSION     DD201582.1  GI:85655031
KEYWORDS    JP 2005517436-A/63.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 63 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/63
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1117 AACAUAUUCUACAGUGUUC 1135
              ||||:|::|:||||:|::|
Db          1 AACATATTCTACAGTGTTC 19


RESULT 412
DD201583
LOCUS       DD201583                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201583
VERSION     DD201583.1  GI:85655032
KEYWORDS    JP 2005517436-A/64.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 64 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/64
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1135 CUUACUAUUGACAAAAUGC 1153
              |::||:|::|||||||:||
Db          1 CTTACTATTGACAAAATGC 19


RESULT 413
DD201584
LOCUS       DD201584                19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201584
VERSION     DD201584.1  GI:85655033
KEYWORDS    JP 2005517436-A/65.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 65 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/65
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1153 CAGAACAAAGACAAAGGAC 1171
              |||||||||||||||||||
Db          1 CAGAACAAAGACAAAGGAC 19


RESULT 414
DD201585
LOCUS       DD201585                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201585
VERSION     DD201585.1  GI:85655034
KEYWORDS    JP 2005517436-A/66.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 66 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/66
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1171 CUUUAUACUUGUCGUGUAA 1189
              |:::|:||::|:||:|:||
Db          1 CTTTATACTTGTCGTGTAA 19


RESULT 415
DD201586
LOCUS       DD201586                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201586
VERSION     DD201586.1  GI:85655035
KEYWORDS    JP 2005517436-A/67.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 67 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/67
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1189 AGGAGUGGACCAUCAUUCA 1207
              |||||:||||||:||::||
Db          1 AGGAGTGGACCATCATTCA 19


RESULT 416
DD201587
LOCUS       DD201587                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201587
VERSION     DD201587.1  GI:85655036
KEYWORDS    JP 2005517436-A/68.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 68 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/68
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1207 AAAUCUGUUAACACCUCAG 1225
              |||:|:|::||||||:|||
Db          1 AAATCTGTTAACACCTCAG 19


RESULT 417
DD201588
LOCUS       DD201588                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201588
VERSION     DD201588.1  GI:85655037
KEYWORDS    JP 2005517436-A/69.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 69 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/69
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAG 1243
              |:|||:|:|:|:||:||||
```

```
Db          1 GTGCATATATATGATAAAG 19


RESULT 418
DD201589
LOCUS       DD201589                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201589
VERSION     DD201589.1  GI:85655038
KEYWORDS    JP 2005517436-A/70.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 70 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/70
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1243 GCAUUCAUCACUGUGAAAC 1261
              |||::||:|||:|:|||||
Db          1 GCATTCATCACTGTGAAAC 19


RESULT 419
DD201590
LOCUS       DD201590                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201590
VERSION     DD201590.1  GI:85655039
KEYWORDS    JP 2005517436-A/71.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 71 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/71
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1261 CAUCGAAAACAGCAGGUGC 1279
              ||:|||||||||||||:||
Db          1 CATCGAAAACAGCAGGTGC 19


RESULT 420
DD201591
LOCUS       DD201591                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201591
VERSION     DD201591.1  GI:85655040
KEYWORDS    JP 2005517436-A/72.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 72 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/72
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1279 CUUGAAACCGUAGCUGGCA 1297
              |::|||||||:|||:||||
Db          1 CTTGAAACCGTAGCTGGCA 19
```

```
RESULT 421
DD201592
LOCUS       DD201592                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201592
VERSION     DD201592.1  GI:85655041
KEYWORDS    JP 2005517436-A/73.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 73 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/73
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1297 AAGCGGUCUUACCGGCUCU 1315
              ||||||:|::||||||:|:
Db          1 AAGCGGTCTTACCGGCTCT 19


RESULT 422
DD201593
LOCUS       DD201593                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201593
VERSION     DD201593.1  GI:85655042
KEYWORDS    JP 2005517436-A/74.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 74 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/74
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1315 UCUAUGAAAGUGAAGGCAU 1333
              :|:|:|||||:|||||||:
Db          1 TCTATGAAAGTGAAGGCAT 19


RESULT 423
DD201594
LOCUS       DD201594                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201594
VERSION     DD201594.1  GI:85655043
KEYWORDS    JP 2005517436-A/75.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 75 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/75
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1333 UUUCCCUCGCCGGAAGUUG 1351
              :::|||:||||||||::|
Db          1 TTTCCCTCGCCGGAAGTTG 19


RESULT 424
```

```
DD201595
LOCUS       DD201595                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201595
VERSION     DD201595.1  GI:85655044
KEYWORDS    JP 2005517436-A/76.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 76 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/76
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1351 GUAUGGUUAAAAGAUGGGU 1369
              |:|:||::||||||:|||:
Db          1 GTATGGTTAAAAGATGGGT 19


RESULT 425
DD201596
LOCUS       DD201596                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201596
VERSION     DD201596.1  GI:85655045
KEYWORDS    JP 2005517436-A/77.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 77 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/77
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1369 UUACCUGCGACUGAGAAAU 1387
              ::|||:|||||:||||||:
Db          1 TTACCTGCGACTGAGAAAT 19


RESULT 426
DD201597
LOCUS       DD201597                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201597
VERSION     DD201597.1  GI:85655046
KEYWORDS    JP 2005517436-A/78.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 78 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/78
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1387 UCUGCUCGCUAUUUGACUC 1405
              :|:||:|||:|:::|||:|
Db          1 TCTGCTCGCTATTTGACTC 19


RESULT 427
DD201598
LOCUS       DD201598                 19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201598
VERSION     DD201598.1  GI:85655047
KEYWORDS    JP 2005517436-A/79.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 79 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/79
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1405 CGUGGCUACUCGUUAAUUA 1423
              ||:|||:|||:||::||::|
Db          1 CGTGGCTACTCGTTAATTA 19


RESULT 428
DD201599
LOCUS       DD201599                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201599
VERSION     DD201599.1  GI:85655048
KEYWORDS    JP 2005517436-A/80.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 80 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/80
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1423 AUCAAGGACGUAACUGAAG 1441
              |:||||||:|||:||||
Db          1 ATCAAGGACGTAACTGAAG 19


RESULT 429
DD201600
LOCUS       DD201600                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201600
VERSION     DD201600.1  GI:85655049
KEYWORDS    JP 2005517436-A/81.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 81 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/81
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1441 GAGGAUGCAGGGAAUUAUA 1459
              |||||:||||||||::|:|
Db          1 GAGGATGCAGGGAATTATA 19


RESULT 430
DD201601
LOCUS       DD201601                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD201601
VERSION     DD201601.1  GI:85655050
KEYWORDS    JP 2005517436-A/82.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 82 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/82
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1459 ACAAUCUUGCUGAGCAUAA 1477
              ||||:|::||:|||||:||
Db          1 ACAATCTTGCTGAGCATAA 19


RESULT 431
DD201602
LOCUS       DD201602                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201602
VERSION     DD201602.1  GI:85655051
KEYWORDS    JP 2005517436-A/83.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 83 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/83
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1477 AAACAGUCAAAUGUGUUUA 1495
              ||||||:||||:|:|:::|
Db          1 AAACAGTCAAATGTGTTTA 19


RESULT 432
DD201603
LOCUS       DD201603                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201603
VERSION     DD201603.1  GI:85655052
KEYWORDS    JP 2005517436-A/84.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 84 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/84
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1495 AAAAACCUCACUGCCACUC 1513
              |||||||:|||:|||||:|
Db          1 AAAAACCTCACTGCCACTC 19


RESULT 433
DD201604
LOCUS       DD201604                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201604
```

```
VERSION     DD201604.1  GI:85655053
KEYWORDS    JP 2005517436-A/85.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 85 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/85
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1513 CUAAUUGUCAAUGUGAAAC 1531
              |:||::|:|||:|:|||||
Db          1 CTAATTGTCAATGTGAAAC 19


RESULT 434
DD201605
LOCUS       DD201605                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201605
VERSION     DD201605.1  GI:85655054
KEYWORDS    JP 2005517436-A/86.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 86 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/86
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1531 CCCCAGAUUUACGAAAAGG 1549
              |||||||:::|||||||||
Db          1 CCCCAGATTTACGAAAAGG 19


RESULT 435
DD201606
LOCUS       DD201606                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201606
VERSION     DD201606.1  GI:85655055
KEYWORDS    JP 2005517436-A/87.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 87 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/87
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1549 GCCGUGUCAUCGUUUCCAG 1567
              ||||:|:||:||:::||||
Db          1 GCCGTGTCATCGTTTCCAG 19


RESULT 436
DD201607
LOCUS       DD201607                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201607
VERSION     DD201607.1  GI:85655056
KEYWORDS    JP 2005517436-A/88.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 88 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/88
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1567 GACCCGGCUCUCUACCCAC 1585
              ||||||||:|:|:||||||
Db          1 GACCCGGCTCTCTACCCAC 19


RESULT 437
DD201608
LOCUS       DD201608                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201608
VERSION     DD201608.1  GI:85655057
KEYWORDS    JP 2005517436-A/89.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 89 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/89
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 CUGGGCAGCAGACAAAUCC 1603
              |:|||||||||||||:||
Db          1 CTGGGCAGCAGACAAATCC 19


RESULT 438
DD201609
LOCUS       DD201609                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201609
VERSION     DD201609.1  GI:85655058
KEYWORDS    JP 2005517436-A/90.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 90 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/90
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1603 CUGACUUGUACCGCAUAUG 1621
              |:|||::|:||||||:|:|
Db          1 CTGACTTGTACCGCATATG 19


RESULT 439
DD201610
LOCUS       DD201610                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201610
VERSION     DD201610.1  GI:85655059
KEYWORDS    JP 2005517436-A/91.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 91 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/91
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1621 GGUAUCCCUCAACCUACAA 1639
              ||:|:|||:|||||:||||
Db          1 GGTATCCCTCAACCTACAA 19


RESULT 440
DD201611
LOCUS      DD201611                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION  DD201611
VERSION    DD201611.1  GI:85655060
KEYWORDS   JP 2005517436-A/92.
SOURCE     synthetic construct
  ORGANISM synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 92 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/92
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1639 AUCAAGUGGUUCUGGCACC 1657
              |:||||:||::|:||||||
Db          1 ATCAAGTGGTTCTGGCACC 19


RESULT 441
DD201612
LOCUS      DD201612                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION  DD201612
VERSION    DD201612.1  GI:85655061
KEYWORDS   JP 2005517436-A/93.
SOURCE     synthetic construct
  ORGANISM synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 93 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/93
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1657 CCCUGUAACCAUAAUCAUU 1675
              |||:|:|||||:||:||::
Db          1 CCCTGTAACCATAATCATT 19


RESULT 442
DD201613
LOCUS      DD201613                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION  DD201613
VERSION    DD201613.1  GI:85655062
KEYWORDS   JP 2005517436-A/94.
SOURCE     synthetic construct
  ORGANISM synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 94 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/94
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1675 UCCGAAGCAAGGUGUGACU 1693
              :|||||||||||:|:|||:
Db          1 TCCGAAGCAAGGTGTGACT 19


RESULT 443
DD201614
LOCUS       DD201614                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201614
VERSION     DD201614.1  GI:85655063
KEYWORDS    JP 2005517436-A/95.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 95 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/95
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1693 UUUUGUUCCAAUAAUGAAG 1711
              ::::|::||||:||:||||
Db          1 TTTTGTTCCAATAATGAAG 19


RESULT 444
DD201615
LOCUS       DD201615                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201615
VERSION     DD201615.1  GI:85655064
KEYWORDS    JP 2005517436-A/96.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 96 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/96
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1711 GAGUCCUUUAUCCUGGAUG 1729
              |||:||:::|:||:|||:|
Db          1 GAGTCCTTTATCCTGGATG 19


RESULT 445
DD201616
LOCUS       DD201616                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201616
VERSION     DD201616.1  GI:85655065
KEYWORDS    JP 2005517436-A/97.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 97 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/97
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1729 GCUGACAGCAACAUGGGAA 1747
              ||:||||||||||:|||||
Db          1 GCTGACAGCAACATGGGAA 19


RESULT 446
DD201617
LOCUS       DD201617                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201617
VERSION     DD201617.1  GI:85655066
KEYWORDS    JP 2005517436-A/98.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 98 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/98
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 AACAGAAUUGAGAGCAUCA 1765
              |||||||::|||||||:||
Db          1 AACAGAATTGAGAGCATCA 19


RESULT 447
DD201618
LOCUS       DD201618                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201618
VERSION     DD201618.1  GI:85655067
KEYWORDS    JP 2005517436-A/99.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 99 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/99
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1765 ACUCAGCGCAUGGCAAUAA 1783
              ||:|||||||:|||||:||
Db          1 ACTCAGCGCATGGCAATAA 19


RESULT 448
DD201619
LOCUS       DD201619                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201619
VERSION     DD201619.1  GI:85655068
KEYWORDS    JP 2005517436-A/100.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 100 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/100
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AUAGAAGGAAAGAAUAAGA 1801
              |:|||||||||||||:||||
Db          1 ATAGAAGGAAAGAATAAGA 19


RESULT 449
DD201620
LOCUS       DD201620                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201620
VERSION     DD201620.1  GI:85655069
KEYWORDS    JP 2005517436-A/101.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 101 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/101
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1801 AUGGCUAGCACCUUGGUUG 1819
              |:|||:||||||::||::|
Db          1 ATGGCTAGCACCTTGGTTG 19


RESULT 450
DD201621
LOCUS       DD201621                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201621
VERSION     DD201621.1  GI:85655070
KEYWORDS    JP 2005517436-A/102.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 102 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/102
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1819 GUGGCUGACUCUAGAAUUU 1837
              |:|||:|||:|:||||:::
Db          1 GTGGCTGACTCTAGAATTT 19


RESULT 451
DD201622
LOCUS       DD201622                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201622
VERSION     DD201622.1  GI:85655071
KEYWORDS    JP 2005517436-A/103.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 103 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/103
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1837 UCUGGAAUCUACAUUUGCA 1855
              :|:||||:|:|||:::|||
Db          1 TCTGGAATCTACATTTGCA 19


RESULT 452
DD201623
LOCUS       DD201623                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201623
VERSION     DD201623.1  GI:85655072
KEYWORDS    JP 2005517436-A/104.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 104 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/104
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1855 AUAGCUUCCAAUAAAGUUG 1873
              |:|||::||||:||||::|
Db          1 ATAGCTTCCAATAAAGTTG 19


RESULT 453
DD201624
LOCUS       DD201624                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201624
VERSION     DD201624.1  GI:85655073
KEYWORDS    JP 2005517436-A/105.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 105 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/105
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1873 GGGACUGUGGGAAGAAACA 1891
              |||||:|:||||||||||||
Db          1 GGGACTGTGGGAAGAAACA 19


RESULT 454
DD201625
LOCUS       DD201625                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201625
VERSION     DD201625.1  GI:85655074
KEYWORDS    JP 2005517436-A/106.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 106 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/106
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1891 AUAAGCUUUUAUAUCACAG 1909
              |:||||::::|:|:|||||
Db          1 ATAAGCTTTTATATCACAG 19


RESULT 455
DD201626
LOCUS       DD201626                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201626
VERSION     DD201626.1  GI:85655075
KEYWORDS    JP 2005517436-A/107.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 107 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/107
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches   0;  Indels    0;  Gaps    0;

Qy       1909 GAUGUGCCAAAUGGGUUUC 1927
              ||:|:||||||:|||:::|
Db          1 GATGTGCCAAATGGGTTTC 19


RESULT 456
DD201627
LOCUS       DD201627                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201627
VERSION     DD201627.1  GI:85655076
KEYWORDS    JP 2005517436-A/108.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 108 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/108
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1927 CAUGUUAACUUGGAAAAAA 1945
              ||:|::|||::||||||||
Db          1 CATGTTAACTTGGAAAAAA 19


RESULT 457
DD201628
LOCUS       DD201628                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201628
VERSION     DD201628.1  GI:85655077
KEYWORDS    JP 2005517436-A/109.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 109 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/109
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+03;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1945 AUGCCGACGGAAGGAGAGG 1963
|:||||||||||||||||||
Db 1 ATGCCGACGGAAGGAGAGG 19

RESULT 458
DD201629
LOCUS DD201629 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201629
VERSION DD201629.1 GI:85655078
KEYWORDS JP 2005517436-A/110.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 110 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/110
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1963 GACCUGAAACUGUCUUGCA 1981
||||:|||||:|:|::|||
Db 1 GACCTGAAACTGTCTTGCA 19

RESULT 459
DD201630
LOCUS DD201630 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201630
VERSION DD201630.1 GI:85655079
KEYWORDS JP 2005517436-A/111.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 111 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/111
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1981 ACAGUUAACAAGUUCUUAU 1999
||||::||||||::|::|:
Db 1 ACAGTTAACAAGTTCTTAT 19

RESULT 460
DD201631
LOCUS DD201631 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201631
VERSION DD201631.1 GI:85655080
KEYWORDS JP 2005517436-A/112.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 112 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/112
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1999 UACAGAGACGUUACUUGGA 2017
              :|||||||||::||::|||
Db          1 TACAGAGACGTTACTTGGA 19


RESULT 461
DD201632
LOCUS       DD201632                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201632
VERSION     DD201632.1  GI:85655081
KEYWORDS    JP 2005517436-A/113.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 113 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/113
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2017 AUUUUACUGCGGACAGUUA 2035
              |::::||:|||||||::|
Db          1 ATTTTACTGCGGACAGTTA 19


RESULT 462
DD201633
LOCUS       DD201633                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201633
VERSION     DD201633.1  GI:85655082
KEYWORDS    JP 2005517436-A/114.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 114 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/114
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2035 AAUAACAGAACAAUGCACU 2053
              ||:||||||||||:||||:
Db          1 AATAACAGAACAATGCACT 19


RESULT 463
DD201634
LOCUS       DD201634                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201634
VERSION     DD201634.1  GI:85655083
KEYWORDS    JP 2005517436-A/115.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 115 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/115
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2053 UACAGUAUUAGCAAGCAAA 2071
              :||||:|::||||||||||
Db          1 TACAGTATTAGCAAGCAAA 19


RESULT 464
DD201635
LOCUS       DD201635                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201635
VERSION     DD201635.1  GI:85655084
KEYWORDS    JP 2005517436-A/116.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 116 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/116
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2071 AAAAUGGCCAUCACUAAGG 2089
              ||||:|||||:|||:||||
Db          1 AAAATGGCCATCACTAAGG 19


RESULT 465
DD201636
LOCUS       DD201636                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201636
VERSION     DD201636.1  GI:85655085
KEYWORDS    JP 2005517436-A/117.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 117 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/117
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2089 GAGCACUCCAUCACUCUUA 2107
              ||||||:|||:|||:|::|
Db          1 GAGCACTCCATCACTCTTA 19


RESULT 466
DD201637
LOCUS       DD201637                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201637
VERSION     DD201637.1  GI:85655086
KEYWORDS    JP 2005517436-A/118.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 118 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/118
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2107 AAUCUUACCAUCAUGAAUG 2125
||:|::||||:||:|||:|
Db 1 AATCTTACCATCATGAATG 19

RESULT 467
DD201638
LOCUS DD201638 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201638
VERSION DD201638.1 GI:85655087
KEYWORDS JP 2005517436-A/119.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 119 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/119
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2125 GUUUCCCUGCAAGAUUCAG 2143
|:::|||:||||||::|||
Db 1 GTTTCCCTGCAAGATTCAG 19

RESULT 468
DD201639
LOCUS DD201639 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201639
VERSION DD201639.1 GI:85655088
KEYWORDS JP 2005517436-A/120.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 120 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/120
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2143 GGCACCUAUGCCUGCAGAG 2161
||||||:|:|||:||||||
Db 1 GGCACCTATGCCTGCAGAG 19

RESULT 469
DD201640
LOCUS DD201640 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201640
VERSION DD201640.1 GI:85655089
KEYWORDS JP 2005517436-A/121.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 121 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/121
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense

```
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2161 GCCAGGAAUGUAUACACAG 2179
              ||||||||:|:|:||||||
Db          1 GCCAGGAATGTATACACAG 19


RESULT 470
DD201641
LOCUS       DD201641                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201641
VERSION     DD201641.1  GI:85655090
KEYWORDS    JP 2005517436-A/122.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 122 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/122
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2179 GGGGAAGAAAUCCUCCAGA 2197
              ||||||||||:||:|||||
Db          1 GGGGAAGAAATCCTCCAGA 19


RESULT 471
DD201642
LOCUS       DD201642                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201642
VERSION     DD201642.1  GI:85655091
KEYWORDS    JP 2005517436-A/123.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 123 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/123
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAGAAAGAAAUUACAAUCA 2215
              ||||||||||::||||:||
Db          1 AAGAAAGAAATTACAATCA 19


RESULT 472
DD201643
LOCUS       DD201643                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201643
VERSION     DD201643.1  GI:85655092
KEYWORDS    JP 2005517436-A/124.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 124 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/124
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
```

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2215 AGAGAUCAGGAAGCACCAU 2233
              |||||:||||||||||||:
Db          1 AGAGATCAGGAAGCACCAT 19


RESULT 473
DD201644
LOCUS       DD201644                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201644
VERSION     DD201644.1  GI:85655093
KEYWORDS    JP 2005517436-A/125.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 125 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/125
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2233 UACCUCCUGCGAAACCUCA 2251
              :|||:||:||||||||:||
Db          1 TACCTCCTGCGAAACCTCA 19


RESULT 474
DD201645
LOCUS       DD201645                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201645
VERSION     DD201645.1  GI:85655094
KEYWORDS    JP 2005517436-A/126.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 126 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/126
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2251 AGUGAUCACACAGUGGCCA 2269
              ||:||:|||||||:|||||
Db          1 AGTGATCACACAGTGGCCA 19


RESULT 475
DD201646
LOCUS       DD201646                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201646
VERSION     DD201646.1  GI:85655095
KEYWORDS    JP 2005517436-A/127.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 127 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/127
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2269 AUCAGCAGUUCCACCACUU 2287
              |:||||||::|||||||::
Db          1 ATCAGCAGTTCCACCACTT 19


RESULT 476
DD201647
LOCUS       DD201647                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201647
VERSION     DD201647.1  GI:85655096
KEYWORDS    JP 2005517436-A/128.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 128 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/128
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2287 UUAGACUGUCAUGCUAAUG 2305
              ::||||:|:||:||:||:|
Db          1 TTAGACTGTCATGCTAATG 19


RESULT 477
DD201648
LOCUS       DD201648                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201648
VERSION     DD201648.1  GI:85655097
KEYWORDS    JP 2005517436-A/129.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 129 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/129
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GGUGUCCCCGAGCCUCAGA 2323
              ||:|:|||||||||:||||
Db          1 GGTGTCCCCGAGCCTCAGA 19


RESULT 478
DD201649
LOCUS       DD201649                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201649
VERSION     DD201649.1  GI:85655098
KEYWORDS    JP 2005517436-A/130.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 130 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/130
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
```

/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2323 AUCACUUGGUUUAAAAACA 2341
              |:|||::||:::|||||||
Db          1 ATCACTTGGTTTAAAAACA 19
```

RESULT 479
DD201650
LOCUS DD201650 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201650
VERSION DD201650.1 GI:85655099
KEYWORDS JP 2005517436-A/131.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 131 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/131
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+03;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2341 AACCACAAAAUACAACAAG 2359
              ||||||||||:||||||||
Db          1 AACCACAAAATACAACAAG 19
```

RESULT 480
DD201651
LOCUS DD201651 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201651
VERSION DD201651.1 GI:85655100
KEYWORDS JP 2005517436-A/132.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 132 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/132
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2359 GAGCCUGGAAUUAUUUUAG 2377
              |||||:||||::|::::||
Db          1 GAGCCTGGAATTATTTTAG 19
```

RESULT 481
DD201652
LOCUS DD201652 19 bp DNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201652
VERSION DD201652.1 GI:85655101
KEYWORDS JP 2005517436-A/133.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 133 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/133
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
CC The type of this sequence is wrong in the original data. It is
CC automatically modified by the JPO.
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"

```
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2377 GGACCAGGAAGCAGCACGC 2395
              ||||||||||||||||||||
Db          1 GGACCAGGAAGCAGCACGC 19


RESULT 482
DD201653
LOCUS       DD201653                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201653
VERSION     DD201653.1  GI:85655102
KEYWORDS    JP 2005517436-A/134.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 134 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/134
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2395 CUGUUUAUUGAAAGAGUCA 2413
              |:|:::|::|||||||:||
Db          1 CTGTTTATTGAAAGAGTCA 19


RESULT 483
DD201654
LOCUS       DD201654                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201654
VERSION     DD201654.1  GI:85655103
KEYWORDS    JP 2005517436-A/135.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 135 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/135
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2413 ACAGAAGAGGAUGAAGGUG 2431
              ||||||||||:|||||:|
Db          1 ACAGAAGAGGATGAAGGTG 19


RESULT 484
DD201655
LOCUS       DD201655                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201655
VERSION     DD201655.1  GI:85655105
KEYWORDS    JP 2005517436-A/136.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 136 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/136
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2431 GUCUAUCACUGCAAAGCCA 2449
              |:|:|:|||:||||||||||
Db          1 GTCTATCACTGCAAAGCCA 19


RESULT 485
DD201656
LOCUS       DD201656                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201656
VERSION     DD201656.1  GI:85655305
KEYWORDS    JP 2005517436-A/137.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 137 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/137
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2449 ACCAACCAGAAGGGCUCUG 2467
              ||||||||||||||||:|:|
Db          1 ACCAACCAGAAGGGCTCTG 19


RESULT 486
DD201657
LOCUS       DD201657                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201657
VERSION     DD201657.1  GI:85655306
KEYWORDS    JP 2005517436-A/138.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 138 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/138
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2467 GUGGAAAGUUCAGCAUACC 2485
              |:||||||::|||||:|||
Db          1 GTGGAAAGTTCAGCATACC 19


RESULT 487
DD201658
LOCUS       DD201658                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201658
VERSION     DD201658.1  GI:85655307
KEYWORDS    JP 2005517436-A/139.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 139 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/139
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
```

```
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCU 2503
              |:|||:|::|||||||||:
Db          1 CTCACTGTTCAAGGAACCT 19


RESULT 488
DD201659
LOCUS       DD201659                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201659
VERSION     DD201659.1  GI:85655308
KEYWORDS    JP 2005517436-A/140.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 140 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/140
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2503 UCGGACAAGUCUAAUCUGG 2521
              :|||||||||:|:||:|:||
Db          1 TCGGACAAGTCTAATCTGG 19


RESULT 489
DD201660
LOCUS       DD201660                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201660
VERSION     DD201660.1  GI:85655309
KEYWORDS    JP 2005517436-A/141.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 141 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/141
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2521 GAGCUGAUCACUCUAACAU 2539
              ||||:||:|||:|:||||:
Db          1 GAGCTGATCACTCTAACAT 19


RESULT 490
DD201661
LOCUS       DD201661                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201661
VERSION     DD201661.1  GI:85655310
KEYWORDS    JP 2005517436-A/142.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 142 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/142
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2539 UGCACCUGUGUGGCUGCGA 2557
              :|||||:|:|:|||:||||
Db          1 TGCACCTGTGTGGCTGCGA 19


RESULT 491
DD201662
LOCUS       DD201662                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201662
VERSION     DD201662.1  GI:85655311
KEYWORDS    JP 2005517436-A/143.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 143 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/143
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2557 ACUCUCUUCUGGCUCCUAU 2575
              ||:|:|::|:|||:||:|:
Db          1 ACTCTCTTCTGGCTCCTAT 19


RESULT 492
DD201663
LOCUS       DD201663                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201663
VERSION     DD201663.1  GI:85655312
KEYWORDS    JP 2005517436-A/144.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 144 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/144
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2575 UUAACCCUCCUUAUCCGAA 2593
              ::|||||:||::|:|||||
Db          1 TTAACCCTCCTTATCCGAA 19


RESULT 493
DD201664
LOCUS       DD201664                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201664
VERSION     DD201664.1  GI:85655313
KEYWORDS    JP 2005517436-A/145.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 145 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/145
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2593 AAAAUGAAAAGGUCUUCUU 2611
              ||||:|||||||:|::|::
```

```
Db          1 AAAATGAAAAGGTCTTCTT 19


RESULT 494
DD201665
LOCUS       DD201665                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201665
VERSION     DD201665.1  GI:85655314
KEYWORDS    JP 2005517436-A/146.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 146 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/146
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2611 UCUGAAAUAAAGACUGACU 2629
              :|:||||:||||||:|||:
Db          1 TCTGAAATAAAGACTGACT 19


RESULT 495
DD201666
LOCUS       DD201666                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201666
VERSION     DD201666.1  GI:85655315
KEYWORDS    JP 2005517436-A/147.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 147 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/147
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.   .
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2629 UACCUAUCAAUUAUAAUGG 2647
              :|||:|:|||::|:||:||
Db          1 TACCTATCAATTATAATGG 19


RESULT 496
DD201667
LOCUS       DD201667                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201667
VERSION     DD201667.1  GI:85655316
KEYWORDS    JP 2005517436-A/148.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 148 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/148
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2647 GACCCAGAUGAAGUUCCUU 2665
              ||||||||:||||::||::
Db          1 GACCCAGATGAAGTTCCTT 19
```

```
RESULT 497
DD201668
LOCUS       DD201668                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201668
VERSION     DD201668.1  GI:85655317
KEYWORDS    JP 2005517436-A/149.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 149 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/149
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2665 UUGGAUGAGCAGUGUGAGC 2683
              ::|||:||||||:|:||||
Db          1 TTGGATGAGCAGTGTGAGC 19


RESULT 498
DD201669
LOCUS       DD201669                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201669
VERSION     DD201669.1  GI:85655318
KEYWORDS    JP 2005517436-A/150.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 150 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/150
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2683 CGGCUCCCUUAUGAUGCCA 2701
              ||||:|||::|:||:||||
Db          1 CGGCTCCCTTATGATGCCA 19


RESULT 499
DD201670
LOCUS       DD201670                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201670
VERSION     DD201670.1  GI:85655319
KEYWORDS    JP 2005517436-A/151.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 151 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/151
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2701 AGCAAGUGGGAGUUUGCCC 2719
              ||||||:|||||:::||||
Db          1 AGCAAGTGGGAGTTTGCCC 19


RESULT 500
```

```
DD201671
LOCUS       DD201671                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201671
VERSION     DD201671.1  GI:85655320
KEYWORDS    JP 2005517436-A/152.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 152 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/152
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 CGGGAGAGACUUAAACUGG 2737
              ||||||||||::||||:||
Db          1 CGGGAGAGACTTAAACTGG 19


RESULT 501
DD201672
LOCUS       DD201672                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201672
VERSION     DD201672.1  GI:85655321
KEYWORDS    JP 2005517436-A/153.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 153 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/153
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2737 GGCAAAUCACUUGGAAGAG 2755
              ||||||:|||::|||||||
Db          1 GGCAAATCACTTGGAAGAG 19


RESULT 502
DD201673
LOCUS       DD201673                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201673
VERSION     DD201673.1  GI:85655322
KEYWORDS    JP 2005517436-A/154.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 154 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/154
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2755 GGGGCUUUUGGAAAAGUGG 2773
              |||||::::|||||||:||
Db          1 GGGGCTTTTGGAAAAGTGG 19


RESULT 503
DD201674
LOCUS       DD201674                  19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201674
VERSION     DD201674.1  GI:85655323
KEYWORDS    JP 2005517436-A/155.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 155 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/155
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2773 GUUCAAGCAUCAGCAUUUG 2791
              |::|||||:|||||:::|
Db          1 GTTCAAGCATCAGCATTTG 19


RESULT 504
DD201675
LOCUS       DD201675                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201675
VERSION     DD201675.1  GI:85655324
KEYWORDS    JP 2005517436-A/156.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 156 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/156
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2791 GGCAUUAAGAAAUCACCUA 2809
              ||||::||||||:||||:|
Db          1 GGCATTAAGAAATCACCTA 19


RESULT 505
DD201676
LOCUS       DD201676                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201676
VERSION     DD201676.1  GI:85655325
KEYWORDS    JP 2005517436-A/157.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 157 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/157
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2809 ACGUGCCGGACUGUGGCUG 2827
              |||:|||||||:|:|||:|
Db          1 ACGTGCCGGACTGTGGCTG 19


RESULT 506
DD201677
LOCUS       DD201677                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD201677
VERSION     DD201677.1  GI:85655326
KEYWORDS    JP 2005517436-A/158.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 158 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/158
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2827 GUGAAAAUGCUGAAAGAGG 2845
              |:||||:||:||||||||
Db          1 GTGAAAATGCTGAAAGAGG 19


RESULT 507
DD201678
LOCUS       DD201678                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201678
VERSION     DD201678.1  GI:85655327
KEYWORDS    JP 2005517436-A/159.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 159 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/159
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2845 GGGGCCACGGCCAGCGAGU 2863
              ||||||||||||||||||:
Db          1 GGGGCCACGGCCAGCGAGT 19


RESULT 508
DD201679
LOCUS       DD201679                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201679
VERSION     DD201679.1  GI:85655328
KEYWORDS    JP 2005517436-A/160.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 160 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/160
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2863 UACAAAGCUCUGAUGACUG 2881
              :|||||||:|:||:|||:|
Db          1 TACAAAGCTCTGATGACTG 19


RESULT 509
DD201680
LOCUS       DD201680                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201680
```

```
VERSION     DD201680.1  GI:85655329
KEYWORDS    JP 2005517436-A/161.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 161 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/161
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2881 GAGCUAAAAAUCUUGACCC 2899
              ||||:|||||:|::|||||
Db          1 GAGCTAAAAATCTTGACCC 19


RESULT 510
DD201681
LOCUS       DD201681                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201681
VERSION     DD201681.1  GI:85655330
KEYWORDS    JP 2005517436-A/162.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 162 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/162
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2899 CACAUUGGCCACCAUCUGA 2917
              ||||::|||||||||:|:||
Db          1 CACATTGGCCACCATCTGA 19


RESULT 511
DD201682
LOCUS       DD201682                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201682
VERSION     DD201682.1  GI:85655331
KEYWORDS    JP 2005517436-A/163.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 163 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/163
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2917 AACGUGGUUAACCUGCUGG 2935
              ||||:||::|||||:||:||
Db          1 AACGTGGTTAACCTGCTGG 19


RESULT 512
DD201683
LOCUS       DD201683                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201683
VERSION     DD201683.1  GI:85655332
KEYWORDS    JP 2005517436-A/164.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 164 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/164
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2935 GGAGCCUGCACCAAGCAAG 2953
              ||||||:||||||||||||
Db          1 GGAGCCTGCACCAAGCAAG 19


RESULT 513
DD201684
LOCUS       DD201684                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201684
VERSION     DD201684.1  GI:85655333
KEYWORDS    JP 2005517436-A/165.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 165 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/165
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2953 GGAGGGCCUCUGAUGGUGA 2971
              ||||||||:|:||:||:||
Db          1 GGAGGGCCTCTGATGGTGA 19


RESULT 514
DD201685
LOCUS       DD201685                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201685
VERSION     DD201685.1  GI:85655334
KEYWORDS    JP 2005517436-A/166.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 166 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/166
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2971 AUUGUUGAAUACUGCAAAU 2989
              |::|::|||:||:|||||:
Db          1 ATTGTTGAATACTGCAAAT 19


RESULT 515
DD201686
LOCUS       DD201686                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201686
VERSION     DD201686.1  GI:85655335
KEYWORDS    JP 2005517436-A/167.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 167 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/167
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC  Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2989 UAUGGAAAUCUCUCCAACU 3007
              :|:|||||:|:|:|||||:
Db          1 TATGGAAATCTCTCCAACT 19


RESULT 516
DD201687
LOCUS       DD201687                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201687
VERSION     DD201687.1  GI:85655336
KEYWORDS    JP 2005517436-A/168.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 168 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/168
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3007 UACCUCAAGAGCAAACGUG 3025
              :|||:||||||||||||:|
Db          1 TACCTCAAGAGCAAACGTG 19


RESULT 517
DD201688
LOCUS       DD201688                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201688
VERSION     DD201688.1  GI:85655337
KEYWORDS    JP 2005517436-A/169.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 169 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/169
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3025 GACUUAUUUUUUCUCAACA 3043
              |||::|::::::|:|||||
Db          1 GACTTATTTTTTCTCAACA 19


RESULT 518
DD201689
LOCUS       DD201689                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201689
VERSION     DD201689.1  GI:85655338
KEYWORDS    JP 2005517436-A/170.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 170 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/170
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3043 AAGGAUGCAGCACUACACA 3061
              |||||:|||||||:|||||
Db          1 AAGGATGCAGCACTACACA 19


RESULT 519
DD201690
LOCUS       DD201690                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201690
VERSION     DD201690.1  GI:85655339
KEYWORDS    JP 2005517436-A/171.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 171 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/171
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3061 AUGGAGCCUAAGAAAGAAA 3079
              |:|||||:||||||||||
Db          1 ATGGAGCCTAAGAAAGAAA 19


RESULT 520
DD201691
LOCUS       DD201691                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201691
VERSION     DD201691.1  GI:85655340
KEYWORDS    JP 2005517436-A/172.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 172 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/172
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 AAAAUGGAGCCAGGCCUGG 3097
              ||||:|||||||||||:||
Db          1 AAAATGGAGCCAGGCCTGG 19


RESULT 521
DD201692
LOCUS       DD201692                  19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201692
VERSION     DD201692.1  GI:85655341
KEYWORDS    JP 2005517436-A/173.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 173 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/173
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
CC The type of this sequence is wrong in the original data. It is
CC automatically modified by the JPO.
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3097 GAACAAGGCAAGAAACCAA 3115
||||||||||||||||||||
Db 1 GAACAAGGCAAGAAACCAA 19

RESULT 522
DD201693
LOCUS DD201693 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201693
VERSION DD201693.1 GI:85655342
KEYWORDS JP 2005517436-A/174.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 174 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/174
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3115 AGACUAGAUAGCGUCACCA 3133
|||| ||| |||| |||||
Db 1 AGACTAGATAGCGTCACCA 19

RESULT 523
DD201694
LOCUS DD201694 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201694
VERSION DD201694.1 GI:85655343
KEYWORDS JP 2005517436-A/175.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 175 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/175
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3133 AGCAGCGAAAGCUUUGCGA 3151
||||||||||||:::||||
Db 1 AGCAGCGAAAGCTTTGCGA 19

RESULT 524
DD201695
LOCUS DD201695 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201695
VERSION DD201695.1 GI:85655344
KEYWORDS JP 2005517436-A/176.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 176 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/176
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3151 AGCUCCGGCUUUCAGGAAG 3169
              |||:|||||:::|||||||
Db          1 AGCTCCGGCTTTCAGGAAG 19


RESULT 525
DD201696
LOCUS       DD201696                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201696
VERSION     DD201696.1  GI:85655345
KEYWORDS    JP 2005517436-A/177.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 177 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/177
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3169 GAUAAAAGUCUGAGUGAUG 3187
              ||:|||||:|:|||:||:|
Db          1 GATAAAAGTCTGAGTGATG 19


RESULT 526
DD201697
LOCUS       DD201697                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201697
VERSION     DD201697.1  GI:85655346
KEYWORDS    JP 2005517436-A/178.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 178 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/178
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3187 GUUGAGGAAGAGGAGGAUU 3205
              |::|||||||||||||::
Db          1 GTTGAGGAAGAGGAGGATT 19


RESULT 527
DD201698
LOCUS       DD201698                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201698
VERSION     DD201698.1  GI:85655347
KEYWORDS    JP 2005517436-A/179.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 179 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/179
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3205 UCUGACGGUUUCUACAAGG 3223
              :|:|||||:::|:||||||
Db          1 TCTGACGGTTTCTACAAGG 19


RESULT 528
DD201699
LOCUS       DD201699                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201699
VERSION     DD201699.1  GI:85655348
KEYWORDS    JP 2005517436-A/180.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 180 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/180
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3223 GAGCCCAUCACUAUGGAAG 3241
              |||||||:|||:|:|||||
Db          1 GAGCCCATCACTATGGAAG 19


RESULT 529
DD201700
LOCUS       DD201700                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201700
VERSION     DD201700.1  GI:85655349
KEYWORDS    JP 2005517436-A/181.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 181 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/181
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3241 GAUCUGAUUUCUUACAGUU 3259
              ||:|:||:::|::||||::
Db          1 GATCTGATTTCTTACAGTT 19


RESULT 530
DD201701
LOCUS       DD201701                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201701
VERSION     DD201701.1  GI:85655350
KEYWORDS    JP 2005517436-A/182.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 182 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/182
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 UUUCAAGUGGCCAGAGGCA 3277
              :::||||:||||||||||||
Db          1 TTTCAAGTGGCCAGAGGCA 19


RESULT 531
DD201702
LOCUS       DD201702                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201702
VERSION     DD201702.1  GI:85655351
KEYWORDS    JP 2005517436-A/183.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 183 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/183
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3277 AUGGAGUUCCUGUCUUCCA 3295
              |:||||::||:|:|::|||
Db          1 ATGGAGTTCCTGTCTTCCA 19


RESULT 532
DD201703
LOCUS       DD201703                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201703
VERSION     DD201703.1  GI:85655352
KEYWORDS    JP 2005517436-A/184.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 184 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/184
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3295 AGAAAGUGCAUUCAUCGGG 3313
              ||||||:|||::||:||||
Db          1 AGAAAGTGCATTCATCGGG 19


RESULT 533
DD201704
LOCUS       DD201704                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201704
VERSION     DD201704.1  GI:85655353
KEYWORDS    JP 2005517436-A/185.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 185 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/185
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3313 GACCUGGCAGCGAGAAACA 3331
              ||||:|||||||||||||||
Db          1 GACCTGGCAGCGAGAAACA 19


RESULT 534
DD201705
LOCUS       DD201705                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201705
VERSION     DD201705.1  GI:85655354
KEYWORDS    JP 2005517436-A/186.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 186 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/186
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3331 AUUCUUUUAUCUGAGAACA 3349
              |::|::::|:|:|||||||
Db          1 ATTCTTTTATCTGAGAACA 19


RESULT 535
DD201706
LOCUS       DD201706                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201706
VERSION     DD201706.1  GI:85655355
KEYWORDS    JP 2005517436-A/187.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 187 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/187
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3349 AACGUGGUGAAGAUUUGUG 3367
              ||||:||:|||||:::|:|
Db          1 AACGTGGTGAAGATTTGTG 19


RESULT 536
DD201707
LOCUS       DD201707                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201707
VERSION     DD201707.1  GI:85655356
KEYWORDS    JP 2005517436-A/188.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 188 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/188
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

```
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3367 GAUUUUGGCCUUGCCCGGG 3385
              ||::::||||::|||||||
Db          1 GATTTTGGCCTTGCCCGGG 19


RESULT 537
DD201708
LOCUS       DD201708                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201708
VERSION     DD201708.1  GI:85655357
KEYWORDS    JP 2005517436-A/189.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 189 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/189
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3385 GAUAUUUAUAAGAACCCCG 3403
              ||:|:::|:||||||||||
Db          1 GATATTTATAAGAACCCCG 19


RESULT 538
DD201709
LOCUS       DD201709                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201709
VERSION     DD201709.1  GI:85655358
KEYWORDS    JP 2005517436-A/190.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 190 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/190
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3403 GAUUAUGUGAGAAAAGGAG 3421
              ||::|:|:||||||||||
Db          1 GATTATGTGAGAAAAGGAG 19


RESULT 539
DD201710
LOCUS       DD201710                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201710
VERSION     DD201710.1  GI:85655359
KEYWORDS    JP 2005517436-A/191.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 191 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/191
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
```

```
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3421 GAUACUCGACUUCCUCUGA 3439
              ||:||:||||::||:|:||
Db             1 GATACTCGACTTCCTCTGA 19


RESULT 540
DD201711
LOCUS       DD201711                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201711
VERSION     DD201711.1  GI:85655360
KEYWORDS    JP 2005517436-A/192.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 192 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/192
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3439 AAAUGGAUGGCUCCCGAAU 3457
              |||:|||:|||:||||||:
Db             1 AAATGGATGGCTCCCGAAT 19


RESULT 541
DD201712
LOCUS       DD201712                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201712
VERSION     DD201712.1  GI:85655361
KEYWORDS    JP 2005517436-A/193.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 193 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/193
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3457 UCUAUCUUUGACAAAAUCU 3475
              :|:|:|:::|||||||:|:
Db             1 TCTATCTTTGACAAAATCT 19


RESULT 542
DD201713
LOCUS       DD201713                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201713
VERSION     DD201713.1  GI:85655362
KEYWORDS    JP 2005517436-A/194.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 194 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/194
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3475 UACAGCACCAAGAGCGACG 3493
              :||||||||||||||||||
Db          1 TACAGCACCAAGAGCGACG 19


RESULT 543
DD201714
LOCUS       DD201714                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201714
VERSION     DD201714.1  GI:85655363
KEYWORDS    JP 2005517436-A/195.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 195 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/195
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3493 GUGUGGUCUUACGGAGUAU 3511
              |:|:||:|::||||||:|:
Db          1 GTGTGGTCTTACGGAGTAT 19


RESULT 544
DD201715
LOCUS       DD201715                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201715
VERSION     DD201715.1  GI:85655364
KEYWORDS    JP 2005517436-A/196.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 196 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/196
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3511 UUGCUGUGGGAAAUCUUCU 3529
              ::||:|:||||||:|::|:
Db          1 TTGCTGTGGGAAATCTTCT 19


RESULT 545
DD201716
LOCUS       DD201716                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201716
VERSION     DD201716.1  GI:85655365
KEYWORDS    JP 2005517436-A/197.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 197 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/197
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3529 UCCUUAGGUGGGUCUCCAU 3547
:||::|||:|||:|:|||:
Db 1 TCCTTAGGTGGGTCTCCAT 19

RESULT 546
DD201717
LOCUS DD201717 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201717
VERSION DD201717.1 GI:85655366
KEYWORDS JP 2005517436-A/198.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 198 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/198
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3547 UACCCAGGAGUACAAAUGG 3565
:|||||||||:|||||:||
Db 1 TACCCAGGAGTACAAATGG 19

RESULT 547
DD201718
LOCUS DD201718 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201718
VERSION DD201718.1 GI:85655367
KEYWORDS JP 2005517436-A/199.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 199 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/199
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense
region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 3565 GAUGAGGACUUUUGCAGUC 3583
||:||||||::::||||:|
Db 1 GATGAGGACTTTTGCAGTC 19

RESULT 548
DD201719
LOCUS DD201719 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD201719
VERSION DD201719.1 GI:85655368
KEYWORDS JP 2005517436-A/200.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 200 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/200
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: Target Sequence/siNA CC sense

```
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3583 CGCCUGAGGGAAGGCAUGA 3601
              ||||:|||||||||||:||
Db          1 CGCCTGAGGGAAGGCATGA 19


RESULT 549
DD201720
LOCUS       DD201720                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201720
VERSION     DD201720.1  GI:85655369
KEYWORDS    JP 2005517436-A/201.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 201 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/201
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3601 AGGAUGAGAGCUCCUGAGU 3619
              ||||:||||||:||:|||:
Db          1 AGGATGAGAGCTCCTGAGT 19


RESULT 550
DD201721
LOCUS       DD201721                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201721
VERSION     DD201721.1  GI:85655370
KEYWORDS    JP 2005517436-A/202.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 202 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/202
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3619 UACUCUACUCCUGAAAUCU 3637
              :||:|:||:||:||||:|:
Db          1 TACTCTACTCCTGAAATCT 19


RESULT 551
DD201722
LOCUS       DD201722                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201722
VERSION     DD201722.1  GI:85655371
KEYWORDS    JP 2005517436-A/203.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 203 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/203
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
```

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3637 UAUCAGAUCAUGCUGGACU 3655
              :|:||||:||:||:||||:
Db          1 TATCAGATCATGCTGGACT 19


RESULT 552
DD201723
LOCUS       DD201723                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201723
VERSION     DD201723.1  GI:85655372
KEYWORDS    JP 2005517436-A/204.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 204 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/204
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3655 UGCUGGCACAGAGACCCAA 3673
              :||:||||||||||||||||
Db          1 TGCTGGCACAGAGACCCAA 19


RESULT 553
DD201724
LOCUS       DD201724                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201724
VERSION     DD201724.1  GI:85655373
KEYWORDS    JP 2005517436-A/205.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 205 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/205
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3673 AAAGAAAGGCCAAGAUUUG 3691
              |||||||||||||||:::|
Db          1 AAAGAAAGGCCAAGATTTG 19


RESULT 554
DD201725
LOCUS       DD201725                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201725
VERSION     DD201725.1  GI:85655374
KEYWORDS    JP 2005517436-A/206.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 206 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/206
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3691 GCAGAACUUGUGGAAAAAC 3709
              |||||||::|:||||||||
Db          1 GCAGAACTTGTGGAAAAAC 19


RESULT 555
DD201726
LOCUS       DD201726                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201726
VERSION     DD201726.1  GI:85655375
KEYWORDS    JP 2005517436-A/207.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 207 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/207
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3709 CUAGGUGAUUUGCUUCAAG 3727
              |:|||:||:::||::||||
Db          1 CTAGGTGATTTGCTTCAAG 19


RESULT 556
DD201727
LOCUS       DD201727                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201727
VERSION     DD201727.1  GI:85655376
KEYWORDS    JP 2005517436-A/208.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 208 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/208
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3727 GCAAAUGUACAACAGGAUG 3745
              |||||:|:||||||||:|
Db          1 GCAAATGTACAACAGGATG 19


RESULT 557
DD201728
LOCUS       DD201728                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201728
VERSION     DD201728.1  GI:85655377
KEYWORDS    JP 2005517436-A/209.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 209 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/209
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
```

/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3745 GGUAAAGACUACAUCCCAA 3763
              ||:||||||:|||:|||||
Db             1 GGTAAAGACTACATCCCAA 19
```

RESULT 558
DD201729
LOCUS DD201729 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201729
VERSION DD201729.1 GI:85655378
KEYWORDS JP 2005517436-A/210.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 210 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/210
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3763 AUCAAUGCCAUACUGACAG 3781
              |:|||:||||:||:|||||
Db             1 ATCAATGCCATACTGACAG 19
```

RESULT 559
DD201730
LOCUS DD201730 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201730
VERSION DD201730.1 GI:85655379
KEYWORDS JP 2005517436-A/211.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 211 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/211
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3781 GGAAAUAGUGGGUUUACAU 3799
              |||||:||:|||:::|||:
Db             1 GGAAATAGTGGGTTTACAT 19
```

RESULT 560
DD201731
LOCUS DD201731 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201731
VERSION DD201731.1 GI:85655380
KEYWORDS JP 2005517436-A/212.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 212 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/212
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3799 UACUCAACUCCUGCCUUCU 3817
              :||:||||:||:|||::|:
Db          1 TACTCAACTCCTGCCTTCT 19


RESULT 561
DD201732
LOCUS       DD201732                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201732
VERSION     DD201732.1  GI:85655381
KEYWORDS    JP 2005517436-A/213.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 213 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/213
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3817 UCUGAGGACUUCUUCAAGG 3835
              :|:||||||::|::|||||
Db          1 TCTGAGGACTTCTTCAAGG 19


RESULT 562
DD201733
LOCUS       DD201733                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201733
VERSION     DD201733.1  GI:85655382
KEYWORDS    JP 2005517436-A/214.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 214 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/214
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3835 GAAAGUAUUUCAGCUCCGA 3853
              |||||:|:::||||:||||
Db          1 GAAAGTATTTCAGCTCCGA 19


RESULT 563
DD201734
LOCUS       DD201734                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201734
VERSION     DD201734.1  GI:85655383
KEYWORDS    JP 2005517436-A/215.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 215 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/215
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
```

```
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3853 AAGUUUAAUUCAGGAAGCU 3871
              |||:::||::|||||||||:
Db          1 AAGTTTAATTCAGGAAGCT 19


RESULT 564
DD201735
LOCUS       DD201735                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201735
VERSION     DD201735.1  GI:85655384
KEYWORDS    JP 2005517436-A/216.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 216 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/216
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              :|:||:||:|:||||:|:|
Db          1 TCTGATGATGTCAGATATG 19


RESULT 565
DD201736
LOCUS       DD201736                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201736
VERSION     DD201736.1  GI:85655385
KEYWORDS    JP 2005517436-A/217.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 217 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/217
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3889 GUAAAUGCUUUCAAGUUCA 3907
              |:|||:||:::||||::||
Db          1 GTAAATGCTTTCAAGTTCA 19


RESULT 566
DD201737
LOCUS       DD201737                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201737
VERSION     DD201737.1  GI:85655386
KEYWORDS    JP 2005517436-A/218.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 218 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/218
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3907 AUGAGCCUGGAAAGAAUCA 3925
              |:|||||:||||||||:||
Db          1 ATGAGCCTGGAAAGAATCA 19


RESULT 567
DD201738
LOCUS       DD201738                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201738
VERSION     DD201738.1  GI:85655387
KEYWORDS    JP 2005517436-A/219.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 219 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/219
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3925 AAAACCUUUGAAGAACUUU 3943
              ||||||:::|||||||:::
Db          1 AAAACCTTTGAAGAACTTT 19


RESULT 568
DD201739
LOCUS       DD201739                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201739
VERSION     DD201739.1  GI:85655388
KEYWORDS    JP 2005517436-A/220.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 220 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/220
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3943 UUACCGAAUGCCACCUCCA 3961
              ::||||||:||||||:|||
Db          1 TTACCGAATGCCACCTCCA 19


RESULT 569
DD201740
LOCUS       DD201740                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201740
VERSION     DD201740.1  GI:85655389
KEYWORDS    JP 2005517436-A/221.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 221 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/221
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 AUGUUUGAUGACUACCAGG 3979
              |:|:::||:|||:||||||
```

```
Db          1 ATGTTTGATGACTACCAGG 19


RESULT 570
DD201741
LOCUS       DD201741                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201741
VERSION     DD201741.1  GI:85655390
KEYWORDS    JP 2005517436-A/222.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 222 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/222
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3979 GGCGACAGCAGCACUCUGU 3997
              ||||||||||||||:|:|:
Db          1 GGCGACAGCAGCACTCTGT 19


RESULT 571
DD201742
LOCUS       DD201742                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201742
VERSION     DD201742.1  GI:85655391
KEYWORDS    JP 2005517436-A/223.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 223 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/223
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3997 UUGGCCUCUCCCAUGCUGA 4015
              ::||||:|:||||:||:||
Db          1 TTGGCCTCTCCCATGCTGA 19


RESULT 572
DD201743
LOCUS       DD201743                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201743
VERSION     DD201743.1  GI:85655392
KEYWORDS    JP 2005517436-A/224.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 224 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/224
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4015 AAGCGCUUCACCUGGACUG 4033
              ||||||::||||:||||:|
Db          1 AAGCGCTTCACCTGGACTG 19
```

```
RESULT 573
DD201744
LOCUS       DD201744                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201744
VERSION     DD201744.1  GI:85655393
KEYWORDS    JP 2005517436-A/225.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 225 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/225
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4033 GACAGCAAACCCAAGGCCU 4051
              ||||||||||||||||||:
Db          1 GACAGCAAACCCAAGGCCT 19


RESULT 574
DD201745
LOCUS       DD201745                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201745
VERSION     DD201745.1  GI:85655394
KEYWORDS    JP 2005517436-A/226.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 226 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/226
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4051 UCGCUCAAGAUUGACUUGA 4069
              :|||:|||||::|||::||
Db          1 TCGCTCAAGATTGACTTGA 19


RESULT 575
DD201746
LOCUS       DD201746                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201746
VERSION     DD201746.1  GI:85655395
KEYWORDS    JP 2005517436-A/227.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 227 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/227
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4069 AGAGUAACCAGUAAAAGUA 4087
              ||||:||||||:|||||:|
Db          1 AGAGTAACCAGTAAAAGTA 19


RESULT 576
```

```
DD201747
LOCUS       DD201747                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201747
VERSION     DD201747.1  GI:85655396
KEYWORDS    JP 2005517436-A/228.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 228 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/228
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4087 AAGGAGUCGGGGCUGUCUG 4105
              ||||||:||||||:|:|:|
Db          1 AAGGAGTCGGGGCTGTCTG 19


RESULT 577
DD201748
LOCUS       DD201748                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201748
VERSION     DD201748.1  GI:85655397
KEYWORDS    JP 2005517436-A/229.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 229 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/229
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4105 GAUGUCAGCAGGCCCAGUU 4123
              ||:|:||||||||||||::
Db          1 GATGTCAGCAGGCCCAGTT 19


RESULT 578
DD201749
LOCUS       DD201749                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201749
VERSION     DD201749.1  GI:85655398
KEYWORDS    JP 2005517436-A/230.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 230 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/230
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4123 UUCUGCCAUUCCAGCUGUG 4141
              ::|:||||::|||||:|:|
Db          1 TTCTGCCATTCCAGCTGTG 19


RESULT 579
DD201750
LOCUS       DD201750                19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201750
VERSION     DD201750.1  GI:85655399
KEYWORDS    JP 2005517436-A/231.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 231 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/231
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4141 GGGCACGUCAGCGAAGGCA 4159
              |||||||:|||||||||||
Db          1 GGGCACGTCAGCGAAGGCA 19


RESULT 580
DD201751
LOCUS       DD201751                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201751
VERSION     DD201751.1  GI:85655400
KEYWORDS    JP 2005517436-A/232.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 232 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/232
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4159 AAGCGCAGGUUCACCUACG 4177
              |||||||||::||||:|||
Db          1 AAGCGCAGGTTCACCTACG 19


RESULT 581
DD201752
LOCUS       DD201752                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201752
VERSION     DD201752.1  GI:85655401
KEYWORDS    JP 2005517436-A/233.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 233 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/233
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4177 GACCACGCUGAGCUGGAAA 4195
              ||||||||:||||:|||||
Db          1 GACCACGCTGAGCTGGAAA 19


RESULT 582
DD201753
LOCUS       DD201753                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD201753
VERSION     DD201753.1  GI:85655402
KEYWORDS    JP 2005517436-A/234.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 234 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/234
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4195 AGGAAAAUCGCGUGCUGCU 4213
              |||||||:||||:||:||:
Db          1 AGGAAAATCGCGTGCTGCT 19


RESULT 583
DD201754
LOCUS       DD201754                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201754
VERSION     DD201754.1  GI:85655403
KEYWORDS    JP 2005517436-A/235.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 235 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/235
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4213 UCCCCGCCCCCAGACUACA 4231
              :|||||||||||||:|||
Db          1 TCCCCGCCCCCAGACTACA 19


RESULT 584
DD201755
LOCUS       DD201755                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201755
VERSION     DD201755.1  GI:85655404
KEYWORDS    JP 2005517436-A/236.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 236 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/236
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4231 AACUCGGUGGUCCUGUACU 4249
              |||:|||:||:||:|:||:
Db          1 AACTCGGTGGTCCTGTACT 19


RESULT 585
DD201756
LOCUS       DD201756                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201756
```

```
VERSION     DD201756.1  GI:85655405
KEYWORDS    JP 2005517436-A/237.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 237 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/237
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4249 UCCACCCCACCCAUCUAGA 4267
              :|||||||||||||:|:|||
Db          1 TCCACCCCACCCATCTAGA 19


RESULT 586
DD201757
LOCUS       DD201757                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201757
VERSION     DD201757.1  GI:85655406
KEYWORDS    JP 2005517436-A/238.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 238 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/238
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4267 AGUUUGACACGAAGCCUUA 4285
              ||:::|||||||||||::|
Db          1 AGTTTGACACGAAGCCTTA 19


RESULT 587
DD201758
LOCUS       DD201758                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201758
VERSION     DD201758.1  GI:85655407
KEYWORDS    JP 2005517436-A/239.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 239 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/239
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4285 AUUUCUAGAAGCACAUGUG 4303
              |:::|:|||||||||:|:|
Db          1 ATTTCTAGAAGCACATGTG 19


RESULT 588
DD201759
LOCUS       DD201759                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201759
VERSION     DD201759.1  GI:85655408
KEYWORDS    JP 2005517436-A/240.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 240 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/240
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4303 GUAUUUAUACCCCCAGGAA 4321
              |:|:::|:||||||||||||
Db          1 GTATTTATACCCCCAGGAA 19


RESULT 589
DD201760
LOCUS       DD201760                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201760
VERSION     DD201760.1  GI:85655409
KEYWORDS    JP 2005517436-A/241.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 241 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/241
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4321 AACUAGCUUUUGCCAGUAU 4339
              |||:|||::::|||||:|:
Db          1 AACTAGCTTTTGCCAGTAT 19


RESULT 590
DD201761
LOCUS       DD201761                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201761
VERSION     DD201761.1  GI:85655410
KEYWORDS    JP 2005517436-A/242.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 242 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/242
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4339 UUAUGCAUAUAUAAGUUUA 4357
              ::|:|||:|:|:|||:::|
Db          1 TTATGCATATATAAGTTTA 19


RESULT 591
DD201762
LOCUS       DD201762                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201762
VERSION     DD201762.1  GI:85655411
KEYWORDS    JP 2005517436-A/243.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 243 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/243
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4357 ACACCUUUAUCUUUCCAUG 4375
              |||||:::|:|:::|||:|
Db          1 ACACCTTTATCTTTCCATG 19


RESULT 592
DD201763
LOCUS       DD201763                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201763
VERSION     DD201763.1  GI:85655412
KEYWORDS    JP 2005517436-A/244.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 244 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/244
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4375 GGGAGCCAGCUGCUUUUUG 4393
              ||||||||||:||:::::|
Db          1 GGGAGCCAGCTGCTTTTTG 19


RESULT 593
DD201764
LOCUS       DD201764                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201764
VERSION     DD201764.1  GI:85655413
KEYWORDS    JP 2005517436-A/245.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 245 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/245
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4393 GUGAUUUUUUUAAUAGUGC 4411
              |:||:::::::||:||:||
Db          1 GTGATTTTTTTAATAGTGC 19


RESULT 594
DD201765
LOCUS       DD201765                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201765
VERSION     DD201765.1  GI:85655414
KEYWORDS    JP 2005517436-A/246.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 246 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/246
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC          sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   36.8%;  Pred. No. 2.4e+03;
  Matches    7;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4411 CUUUUUUUUUUUGACUAAC 4429
              |::::::::::::|||:|||
Db          1 CTTTTTTTTTTTGACTAAC 19


RESULT 595
DD201766
LOCUS       DD201766                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201766
VERSION     DD201766.1  GI:85655415
KEYWORDS    JP 2005517436-A/247.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 247 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/247
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC          sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4429 CAAGAAUGUAACUCCAGAU 4447
              ||||||:|:|||:|||||:
Db          1 CAAGAATGTAACTCCAGAT 19


RESULT 596
DD201767
LOCUS       DD201767                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201767
VERSION     DD201767.1  GI:85655416
KEYWORDS    JP 2005517436-A/248.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 248 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/248
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC          sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4447 UAGAGAAAUAGUGACAAGU 4465
              :|||||||:||:||||||:
Db          1 TAGAGAAATAGTGACAAGT 19


RESULT 597
DD201768
LOCUS       DD201768                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201768
VERSION     DD201768.1  GI:85655417
KEYWORDS    JP 2005517436-A/249.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 249 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/249
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4465 UGAAGAACACUACUGCUAA 4483
              :||||||||||:||:||:||
Db          1 TGAAGAACACTACTGCTAA 19


RESULT 598
DD201769
LOCUS       DD201769                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201769
VERSION     DD201769.1  GI:85655418
KEYWORDS    JP 2005517436-A/250.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 250 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/250
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4483 AAUCCUCAUGUUACUCAGU 4501
              ||:||:||:|::||:|||:
Db          1 AATCCTCATGTTACTCAGT 19


RESULT 599
DD201770
LOCUS       DD201770                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201770
VERSION     DD201770.1  GI:85655419
KEYWORDS    JP 2005517436-A/251.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 251 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/251
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4501 UGUUAGAGAAAUCCUUCCU 4519
              :|::||||||:||::||:
Db          1 TGTTAGAGAAATCCTTCCT 19


RESULT 600
DD201771
LOCUS       DD201771                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201771
VERSION     DD201771.1  GI:85655420
KEYWORDS    JP 2005517436-A/252.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 252 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/252
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4519 UAAACCCAAUGACUUCCCU 4537
              :||||||||:|||::|||:
Db          1 TAAACCCAATGACTTCCCT 19


RESULT 601
DD201772
LOCUS       DD201772                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201772
VERSION     DD201772.1  GI:85655421
KEYWORDS    JP 2005517436-A/253.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 253 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/253
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4537 UGCUCCAACCCCCGCCACC 4555
              :||:|||||||||||||||
Db          1 TGCTCCAACCCCCGCCACC 19


RESULT 602
DD201773
LOCUS       DD201773                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201773
VERSION     DD201773.1  GI:85655422
KEYWORDS    JP 2005517436-A/254.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 254 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/254
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4555 CUCAGGGCACGCAGGACCA 4573
              |:||||||||||||||||||
Db          1 CTCAGGGCACGCAGGACCA 19


RESULT 603
DD201774
LOCUS       DD201774                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201774
VERSION     DD201774.1  GI:85655423
KEYWORDS    JP 2005517436-A/255.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 255 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/255
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4573 AGUUUGAUUGAGGAGCUGC 4591
              ||:::||::|||||||:||
Db          1 AGTTTGATTGAGGAGCTGC 19


RESULT 604
DD201775
LOCUS       DD201775                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201775
VERSION     DD201775.1  GI:85655424
KEYWORDS    JP 2005517436-A/256.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 256 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/256
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4591 CACUGAUCACCCAAUGCAU 4609
              |||:||:|||||||:|||:
Db          1 CACTGATCACCCAATGCAT 19


RESULT 605
DD201776
LOCUS       DD201776                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201776
VERSION     DD201776.1  GI:85655425
KEYWORDS    JP 2005517436-A/257.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 257 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/257
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4609 UCACGUACCCCACUGGGCC 4627
              :||||:|||||||:|||||
Db          1 TCACGTACCCCACTGGGCC 19


RESULT 606
DD201777
LOCUS       DD201777                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201777
VERSION     DD201777.1  GI:85655426
KEYWORDS    JP 2005517436-A/258.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 258 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/258
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4627 CAGCCCUGCAGCCCAAAAC 4645
              ||||||:||||||||||||
Db          1 CAGCCCTGCAGCCCAAAAC 19


RESULT 607
DD201778
LOCUS       DD201778                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201778
VERSION     DD201778.1  GI:85655427
KEYWORDS    JP 2005517436-A/259.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 259 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/259
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4645 CCCAGGGCAACAAGCCCGU 4663
              ||||||||||||||||||:
Db          1 CCCAGGGCAACAAGCCCGT 19


RESULT 608
DD201779
LOCUS       DD201779                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201779
VERSION     DD201779.1  GI:85655428
KEYWORDS    JP 2005517436-A/260.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 260 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/260
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4663 UUAGCCCCAGGGGAUCACU 4681
              ::|||||||||||||:|||:
Db          1 TTAGCCCCAGGGGATCACT 19


RESULT 609
DD201780
LOCUS       DD201780                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201780
VERSION     DD201780.1  GI:85655429
KEYWORDS    JP 2005517436-A/261.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 261 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/261
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

```
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4681 UGGCUGGCCUGAGCAACAU 4699
              :|||:||||:||||||||:
Db          1 TGGCTGGCCTGAGCAACAT 19


RESULT 610
DD201781
LOCUS       DD201781                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201781
VERSION     DD201781.1  GI:85655430
KEYWORDS    JP 2005517436-A/262.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 262 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/262
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4699 UCUCGGGAGUCCUCUAGCA 4717
              :|:||||||:||:|:||||
Db          1 TCTCGGGAGTCCTCTAGCA 19


RESULT 611
DD201782
LOCUS       DD201782                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201782
VERSION     DD201782.1  GI:85655431
KEYWORDS    JP 2005517436-A/263.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 263 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/263
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4717 AGGCCUAAGACAUGUGAGG 4735
              |||||:||||||:|:||||
Db          1 AGGCCTAAGACATGTGAGG 19


RESULT 612
DD201783
LOCUS       DD201783                  19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201783
VERSION     DD201783.1  GI:85655432
KEYWORDS    JP 2005517436-A/264.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 264 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/264
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
```

```
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4735 GAGGAAAAGGAAAAAAAGC 4753
              ||||||||||||||||||||
Db          1 GAGGAAAAGGAAAAAAAGC 19


RESULT 613
DD201784
LOCUS       DD201784                  19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201784
VERSION     DD201784.1  GI:85655433
KEYWORDS    JP 2005517436-A/265.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 265 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/265
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4753 CAAAAAGCAAGGGAGAAAA 4771
              ||||||||||||||||||||
Db          1 CAAAAAGCAAGGGAGAAAA 19


RESULT 614
DD201785
LOCUS       DD201785                  19 bp    DNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201785
VERSION     DD201785.1  GI:85655434
KEYWORDS    JP 2005517436-A/266.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 266 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/266
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            CC   The type of this sequence is wrong in the original data. It is
            CC   automatically modified by the JPO.
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4771 AGAGAAACCGGGAGAAGGC 4789
              ||||||||||||||||||||
Db          1 AGAGAAACCGGGAGAAGGC 19


RESULT 615
DD201786
LOCUS       DD201786                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201786
VERSION     DD201786.1  GI:85655435
KEYWORDS    JP 2005517436-A/267.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 267 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/267
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4789 CAUGAGAAAGAAUUUGAGA 4807
              ||:||||||||:::|||| 
Db          1 CATGAGAAAGAATTTGAGA 19


RESULT 616
DD201787
LOCUS       DD201787                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201787
VERSION     DD201787.1  GI:85655436
KEYWORDS    JP 2005517436-A/268.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 268 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/268
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4807 ACGCACCAUGUGGGCACGG 4825
              ||||||||:|:|||||||| 
Db          1 ACGCACCATGTGGGCACGG 19


RESULT 617
DD201788
LOCUS       DD201788                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201788
VERSION     DD201788.1  GI:85655437
KEYWORDS    JP 2005517436-A/269.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 269 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/269
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4825 GAGGGGGACGGGGCUCAGC 4843
              |||||||||||||||:|||| 
Db          1 GAGGGGGACGGGGCTCAGC 19


RESULT 618
DD201789
LOCUS       DD201789                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201789
VERSION     DD201789.1  GI:85655438
KEYWORDS    JP 2005517436-A/270.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 270 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/270
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 4843 CAAUGCCAUUUCAGUGGCU 4861
||:||||:::|||:|||:
Db 1 CAATGCCATTTCAGTGGCT 19

RESULT 619
DD201790
LOCUS DD201790 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201790
VERSION DD201790.1 GI:85655439
KEYWORDS JP 2005517436-A/271.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 271 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/271
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 4861 UUCCCAGCUCUGACCCUUC 4879
::||||||:|:|||||::|
Db 1 TTCCCAGCTCTGACCCTTC 19

RESULT 620
DD201791
LOCUS DD201791 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201791
VERSION DD201791.1 GI:85655440
KEYWORDS JP 2005517436-A/272.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 272 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/272
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 4879 CUACAUUUGAGGGCCCAGC 4897
|:|||:::|||||||||||
Db 1 CTACATTTGAGGGCCCAGC 19

RESULT 621
DD201792
LOCUS DD201792 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201792
VERSION DD201792.1 GI:85655441
KEYWORDS JP 2005517436-A/273.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 273 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/273
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4897 CCAGGAGCAGAUGGACAGC 4915
              ||||||||||:|||||||
Db          1 CCAGGAGCAGATGGACAGC 19


RESULT 622
DD201793
LOCUS       DD201793                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201793
VERSION     DD201793.1  GI:85655442
KEYWORDS    JP 2005517436-A/274.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 274 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/274
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4915 CGAUGAGGGGACAUUUUCU 4933
              |||:|||||||||::::|:
Db          1 CGATGAGGGGACATTTTCT 19


RESULT 623
DD201794
LOCUS       DD201794                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201794
VERSION     DD201794.1  GI:85655443
KEYWORDS    JP 2005517436-A/275.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 275 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/275
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4933 UGGAUUCUGGGAGGCAAGA 4951
              :|||::|:||||||||||||
Db          1 TGGATTCTGGGAGGCAAGA 19


RESULT 624
DD201795
LOCUS       DD201795                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201795
VERSION     DD201795.1  GI:85655444
KEYWORDS    JP 2005517436-A/276.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 276 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/276
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
          11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
          03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
          beigelman,james mcswiggen,pamela pavco CC   Description of
          Artificial Sequence:  Target Sequence/siNA  CC            sense
          region
          FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4951 AAAAGGACAAAUAUCUUUU 4969
              ||||||||||:|:|::::
Db          1 AAAAGGACAAATATCTTTT 19


RESULT 625
DD201796
LOCUS       DD201796                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201796
VERSION     DD201796.1  GI:85655445
KEYWORDS    JP 2005517436-A/277.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 277 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/277
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4969 UUUGGAACUAAAGCAAAUU 4987
              :::|||||:|||||||::
Db          1 TTTGGAACTAAAGCAAATT 19


RESULT 626
DD201797
LOCUS       DD201797                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201797
VERSION     DD201797.1  GI:85655446
KEYWORDS    JP 2005517436-A/278.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 278 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/278
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4987 UUUAGACCUUUACCUAUGG 5005
              :::|||||:::|||:|:||
Db          1 TTTAGACCTTTACCTATGG 19


RESULT 627
DD201798
LOCUS       DD201798                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201798
VERSION     DD201798.1  GI:85655447
KEYWORDS    JP 2005517436-A/279.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 279 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/279
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 5005 GAAGUGGUUCUAUGUCCAU 5023
||||:||::|:|:|:|||:
Db 1 GAAGTGGTTCTATGTCCAT 19

RESULT 628
DD201799
LOCUS DD201799 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201799
VERSION DD201799.1 GI:85655448
KEYWORDS JP 2005517436-A/280.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 280 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/280
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 2.4e+03;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 5023 UUCUCAUUCGUGGCAUGUU 5041
::|:||::||:||||:|::
Db 1 TTCTCATTCGTGGCATGTT 19

RESULT 629
DD201800
LOCUS DD201800 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201800
VERSION DD201800.1 GI:85655449
KEYWORDS JP 2005517436-A/281.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 281 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/281
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2.4e+03;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 5041 UUUGAUUUGUAGCACUGAG 5059
:::||:::|:|||||:|||
Db 1 TTTGATTTGTAGCACTGAG 19

RESULT 630
DD201801
LOCUS DD201801 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201801
VERSION DD201801.1 GI:85655450
KEYWORDS JP 2005517436-A/282.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 282 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/282
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense

```
          region
          FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5059 GGGUGGCACUCAACUCUGA 5077
              |||:|||||:||||:|:||
Db          1 GGGTGGCACTCAACTCTGA 19


RESULT 631
DD201802
LOCUS       DD201802                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201802
VERSION     DD201802.1  GI:85655451
KEYWORDS    JP 2005517436-A/283.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 283 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/283
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5077 AGCCCAUACUUUUGGCUCC 5095
              ||||||:||::::|||:||
Db          1 AGCCCATACTTTTGGCTCC 19


RESULT 632
DD201803
LOCUS       DD201803                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201803
VERSION     DD201803.1  GI:85655452
KEYWORDS    JP 2005517436-A/284.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 284 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/284
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5095 CUCUAGUAAGAUGCACUGA 5113
              |:|:||:||||:||||:||
Db          1 CTCTAGTAAGATGCACTGA 19


RESULT 633
DD201804
LOCUS       DD201804                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201804
VERSION     DD201804.1  GI:85655453
KEYWORDS    JP 2005517436-A/285.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 285 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/285
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
```

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5113 AAAACUUAGCCAGAGUUAG 5131
              |||||::|||||||::||
Db          1 AAAACTTAGCCAGAGTTAG 19


RESULT 634
DD201805
LOCUS       DD201805                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201805
VERSION     DD201805.1  GI:85655454
KEYWORDS    JP 2005517436-A/286.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 286 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/286
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5131 GGUUGUCUCCAGGCCAUGA 5149
              ||::|:|:|||||||||:||
Db          1 GGTTGTCTCCAGGCCATGA 19


RESULT 635
DD201806
LOCUS       DD201806                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201806
VERSION     DD201806.1  GI:85655455
KEYWORDS    JP 2005517436-A/287.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 287 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/287
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5149 AUGGCCUUACACUGAAAAU 5167
              |:||||::||||:|||||:
Db          1 ATGGCCTTACACTGAAAAT 19


RESULT 636
DD201807
LOCUS       DD201807                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201807
VERSION     DD201807.1  GI:85655456
KEYWORDS    JP 2005517436-A/288.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 288 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/288
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
```

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 2.4e+03;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 5167 UGUCACAUUCUAUUUUGGG 5185
:|:||||::|:|::::|||
Db 1 TGTCACATTCTATTTTGGG 19

RESULT 637
DD201808
LOCUS DD201808 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201808
VERSION DD201808.1 GI:85655457
KEYWORDS JP 2005517436-A/289.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 289 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/289
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 5185 GUAUUAAUAUAUAGUCCAG 5203
|:|::||:|:|:||:||||
Db 1 GTATTAATATATAGTCCAG 19

RESULT 638
DD201809
LOCUS DD201809 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201809
VERSION DD201809.1 GI:85655458
KEYWORDS JP 2005517436-A/290.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 290 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/290
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 5203 GACACUUAACUCAAUUUCU 5221
|||||::|||:|||:::|:
Db 1 GACACTTAACTCAATTTCT 19

RESULT 639
DD201810
LOCUS DD201810 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201810
VERSION DD201810.1 GI:85655459
KEYWORDS JP 2005517436-A/291.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 291 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/291
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"

/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 36.8%; Pred. No. 2.4e+03;
Matches 7; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```
Qy       5221 UUGGUAUUAUUCUGUUUUG 5239
              ::||:|::|::|:|::::|
Db          1 TTGGTATTATTCTGTTTTG 19
```

RESULT 640
DD201811
LOCUS DD201811 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201811
VERSION DD201811.1 GI:85655460
KEYWORDS JP 2005517436-A/292.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 292 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/292
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       5239 GCACAGUUAGUUGUGAAAG 5257
              ||||||::||::|:|||||
Db          1 GCACAGTTAGTTGTGAAAG 19
```

RESULT 641
DD201812
LOCUS DD201812 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201812
VERSION DD201812.1 GI:85655461
KEYWORDS JP 2005517436-A/293.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 293 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/293
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       5257 GAAAGCUGAGAAGAAUGAA 5275
              ||||||:||||||||:|||
Db          1 GAAAGCTGAGAAGAATGAA 19
```

RESULT 642
DD201813
LOCUS DD201813 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201813
VERSION DD201813.1 GI:85655462
KEYWORDS JP 2005517436-A/294.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 294 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/294
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5275 AAAUGCAGUCCUGAGGAGA 5293
              |||:||||:||:|||||||
Db          1 AAATGCAGTCCTGAGGAGA 19


RESULT 643
DD201814
LOCUS       DD201814                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201814
VERSION     DD201814.1  GI:85655463
KEYWORDS    JP 2005517436-A/295.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 295 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/295
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5293 AGUUUUCUCCAUAUCAAAA 5311
              ||::::|:|||:|:|||||
Db          1 AGTTTTCTCCATATCAAAA 19


RESULT 644
DD201815
LOCUS       DD201815                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201815
VERSION     DD201815.1  GI:85655464
KEYWORDS    JP 2005517436-A/296.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 296 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/296
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5311 ACGAGGGCUGAUGGAGGAA 5329
              |||||||||:||:|||||||
Db          1 ACGAGGGCTGATGGAGGAA 19


RESULT 645
DD201816
LOCUS       DD201816                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201816
VERSION     DD201816.1  GI:85655465
KEYWORDS    JP 2005517436-A/297.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 297 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/297
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
```

```
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5329 AAAAGGUCAAUAAGGUCAA 5347
              ||||||:|||:||||:|||
Db          1 AAAAGGTCAATAAGGTCAA 19


RESULT 646
DD201817
LOCUS       DD201817                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201817
VERSION     DD201817.1  GI:85655466
KEYWORDS    JP 2005517436-A/298.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 298 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/298
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5347 AGGGAAGACCCCGUCUCUA 5365
              ||||||||||||:|:|:|
Db          1 AGGGAAGACCCCGTCTCTA 19


RESULT 647
DD201818
LOCUS       DD201818                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201818
VERSION     DD201818.1  GI:85655467
KEYWORDS    JP 2005517436-A/299.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 299 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/299
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5365 AUACCAACCAAACCAAUUC 5383
              |:|||||||||||||::|
Db          1 ATACCAACCAAACCAATTC 19


RESULT 648
DD201819
LOCUS       DD201819                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201819
VERSION     DD201819.1  GI:85655468
KEYWORDS    JP 2005517436-A/300.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 300 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/300
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       5383 CACCAACACAGUUGGGACC 5401
              ||||||||||::||||||
Db          1 CACCAACACAGTTGGGACC 19


RESULT 649
DD201820
LOCUS       DD201820                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201820
VERSION     DD201820.1  GI:85655469
KEYWORDS    JP 2005517436-A/301.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 301 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/301
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5401 CCAAAACACAGGAAGUCAG 5419
              ||||||||||||||:|||
Db          1 CCAAAACACAGGAAGTCAG 19


RESULT 650
DD201821
LOCUS       DD201821                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201821
VERSION     DD201821.1  GI:85655470
KEYWORDS    JP 2005517436-A/302.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 302 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/302
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5419 GUCACGUUUCCUUUUCAUU 5437
              |:||||:::||::::||::
Db          1 GTCACGTTTCCTTTTCATT 19


RESULT 651
DD201822
LOCUS       DD201822                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201822
VERSION     DD201822.1  GI:85655471
KEYWORDS    JP 2005517436-A/303.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 303 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/303
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5437 UUAAUGGGGAUUCCACUAU 5455
              ::||:|||||::||||:|:
```

```
Db          1 TTAATGGGGATTCCACTAT 19


RESULT 652
DD201823
LOCUS       DD201823                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201823
VERSION     DD201823.1  GI:85655472
KEYWORDS    JP 2005517436-A/304.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 304 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/304
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5455 UCUCACACUAAUCUGAAAG 5473
              :|:|||||:||:|:|||||
Db          1 TCTCACACTAATCTGAAAG 19


RESULT 653
DD201824
LOCUS       DD201824                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201824
VERSION     DD201824.1  GI:85655473
KEYWORDS    JP 2005517436-A/305.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 305 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/305
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5473 GGAUGUGGAAGAGCAUUAG 5491
              |||:|:||||||||::||
Db          1 GGATGTGGAAGAGCATTAG 19


RESULT 654
DD201825
LOCUS       DD201825                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201825
VERSION     DD201825.1  GI:85655474
KEYWORDS    JP 2005517436-A/306.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 306 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/306
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5491 GCUGGCGCAUAUUAAGCAC 5509
              ||:|||||:|::||||||
Db          1 GCTGGCGCATATTAAGCAC 19
```

```
RESULT 655
DD201826
LOCUS       DD201826                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201826
VERSION     DD201826.1  GI:85655475
KEYWORDS    JP 2005517436-A/307.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 307 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/307
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5509 CUUUAAGCUCCUUGAGUAA 5527
              |:::||||:||::|||:||
Db          1 CTTTAAGCTCCTTGAGTAA 19


RESULT 656
DD201827
LOCUS       DD201827                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201827
VERSION     DD201827.1  GI:85655476
KEYWORDS    JP 2005517436-A/308.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 308 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/308
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5527 AAAAGGUGGUAUGUAAUUU 5545
              ||||||:||:|:|:||:::
Db          1 AAAAGGTGGTATGTAATTT 19


RESULT 657
DD201828
LOCUS       DD201828                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201828
VERSION     DD201828.1  GI:85655477
KEYWORDS    JP 2005517436-A/309.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 309 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/309
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5545 UAUGCAAGGUAUUUCUCCA 5563
              :|:||||||:|:::|:|||
Db          1 TATGCAAGGTATTTCTCCA 19


RESULT 658
```

```
DD201829
LOCUS       DD201829                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201829
VERSION     DD201829.1  GI:85655478
KEYWORDS    JP 2005517436-A/310.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 310 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/310
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5563 AGUUGGGACUCAGGAUAUU 5581
              ||::|||||:|||||:|::
Db          1 AGTTGGGACTCAGGATATT 19


RESULT 659
DD201830
LOCUS       DD201830                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201830
VERSION     DD201830.1  GI:85655479
KEYWORDS    JP 2005517436-A/311.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 311 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/311
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5581 UAGUUAAUGAGCCAUCACU 5599
              :||::||:||||||:|||:
Db          1 TAGTTAATGAGCCATCACT 19


RESULT 660
DD201831
LOCUS       DD201831                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201831
VERSION     DD201831.1  GI:85655480
KEYWORDS    JP 2005517436-A/312.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 312 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/312
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5599 UAGAAGAAAAGCCCAUUUU 5617
              :|||||||||||||::::
Db          1 TAGAAGAAAAGCCCATTTT 19


RESULT 661
DD201832
LOCUS       DD201832                 19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201832
VERSION     DD201832.1  GI:85655481
KEYWORDS    JP 2005517436-A/313.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 313 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/313
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5617 UCAACUGCUUUGAAACUUG 5635
              :||||:||:::|||||::|
Db          1 TCAACTGCTTTGAAACTTG 19


RESULT 662
DD201833
LOCUS       DD201833                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201833
VERSION     DD201833.1  GI:85655482
KEYWORDS    JP 2005517436-A/314.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 314 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/314
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5635 GCCUGGGGUCUGAGCAUGA 5653
              |||:||||:|:|||||:||
Db          1 GCCTGGGGTCTGAGCATGA 19


RESULT 663
DD201834
LOCUS       DD201834                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201834
VERSION     DD201834.1  GI:85655483
KEYWORDS    JP 2005517436-A/315.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 315 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/315
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5653 AUGGGAAUAGGGAGACAGG 5671
              |:|||||:||||||||||||
Db          1 ATGGGAATAGGGAGACAGG 19


RESULT 664
DD201835
LOCUS       DD201835                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD201835
VERSION     DD201835.1  GI:85655484
KEYWORDS    JP 2005517436-A/316.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 316 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/316
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5671 GGUAGGAAAGGGCGCCUAC 5689
              ||:|||||||||||||:||
Db          1 GGTAGGAAAGGGCGCCTAC 19


RESULT 665
DD201836
LOCUS       DD201836                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201836
VERSION     DD201836.1  GI:85655485
KEYWORDS    JP 2005517436-A/317.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 317 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/317
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5689 CUCUUCAGGGUCUAAAGAU 5707
              |:|::|||||:|:|||||:
Db          1 CTCTTCAGGGTCTAAAGAT 19


RESULT 666
DD201837
LOCUS       DD201837                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201837
VERSION     DD201837.1  GI:85655486
KEYWORDS    JP 2005517436-A/318.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 318 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/318
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC           sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5707 UCAAGUGGGCCUUGGAUCG 5725
              :||||:|||||::|||:||
Db          1 TCAAGTGGGCCTTGGATCG 19


RESULT 667
DD201838
LOCUS       DD201838                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201838
```

```
VERSION     DD201838.1  GI:85655487
KEYWORDS    JP 2005517436-A/319.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 319 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS  Artificial Sequence
            PN  JP 2005517436-A/319
            PD  16-JUN-2005
            PF  20-FEB-2003 JP 2003569803
            PR  15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5725 GCUAAGCUGGCUCUGUUUG 5743
              ||:||||:|||:|:|:::|
Db          1 GCTAAGCTGGCTCTGTTTG 19


RESULT 668
DD201839
LOCUS       DD201839                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201839
VERSION     DD201839.1  GI:85655488
KEYWORDS    JP 2005517436-A/320.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 320 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS  Artificial Sequence
            PN  JP 2005517436-A/320
            PD  16-JUN-2005
            PF  20-FEB-2003 JP 2003569803
            PR  15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5743 GAUGCUAUUUAUGCAAGUU 5761
              ||:||:|:::|:|||||::
Db          1 GATGCTATTTATGCAAGTT 19


RESULT 669
DD201840
LOCUS       DD201840                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201840
VERSION     DD201840.1  GI:85655489
KEYWORDS    JP 2005517436-A/321.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 321 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS  Artificial Sequence
            PN  JP 2005517436-A/321
            PD  16-JUN-2005
            PF  20-FEB-2003 JP 2003569803
            PR  15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5761 UAGGGUCUAUGUAUUUAGG 5779
              :||||:|:|:|:|:::|||
Db          1 TAGGGTCTATGTATTTAGG 19


RESULT 670
DD201841
LOCUS       DD201841                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201841
VERSION     DD201841.1  GI:85655490
KEYWORDS    JP 2005517436-A/322.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 322 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/322
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5779 GAUGCGCCUACUCUUCAGG 5797
              ||:|||||:||:|::||||
Db          1 GATGCGCCTACTCTTCAGG 19


RESULT 671
DD201842
LOCUS       DD201842                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201842
VERSION     DD201842.1  GI:85655491
KEYWORDS    JP 2005517436-A/323.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 323 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/323
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5697 GGUCUAAAGAUCAAGUGGG 5715
              ||:|:|||||:||||:|||
Db          1 GGTCTAAAGATCAAGTGGG 19


RESULT 672
DD201843
LOCUS       DD201843                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201843
VERSION     DD201843.1  GI:85655492
KEYWORDS    JP 2005517436-A/324.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 324 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/324
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5715 GCCUUGGAUCGCUAAGCUG 5733
              |||::|||:|||:||||:|
Db          1 GCCTTGGATCGCTAAGCTG 19


RESULT 673
DD201844
LOCUS       DD201844                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201844
VERSION     DD201844.1  GI:85655493
KEYWORDS    JP 2005517436-A/325.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 325 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/325
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5733 GGCUCUGUUUGAUGCUAUU 5751
              |||:|:|:::||:||:|::
Db          1 GGCTCTGTTTGATGCTATT 19


RESULT 674
DD201845
LOCUS       DD201845                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201845
VERSION     DD201845.1  GI:85655494
KEYWORDS    JP 2005517436-A/326.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 326 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/326
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5751 UUAUGCAAGUUAGGGUCUA 5769
              ::|:|||||::||||:|:|
Db          1 TTATGCAAGTTAGGGTCTA 19


RESULT 675
DD201846
LOCUS       DD201846                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201846
VERSION     DD201846.1  GI:85655495
KEYWORDS    JP 2005517436-A/327.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
  AUTHORS  Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE    RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL  Patent: JP 2005517436-A 327 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT    OS   Artificial Sequence
           PN   JP 2005517436-A/327
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5869 AUGUAUUUAGGAUGUCUGC 5887
              |:|:|:::||||:|:|:||
Db          1 ATGTATTTAGGATGTCTGC 19


RESULT 676
DD201847
LOCUS       DD201847                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201847
VERSION     DD201847.1  GI:85655496
KEYWORDS    JP 2005517436-A/328.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE  1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 328 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/328
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5887 CACCUUCUGCAGCCAGUCA 5905
              ||||::|:||||||||:||
Db          1 CACCTTCTGCAGCCAGTCA 19


RESULT 677
DD201848
LOCUS       DD201848                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201848
VERSION     DD201848.1  GI:85655497
KEYWORDS    JP 2005517436-A/329.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 329 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/329
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5905 AGAAGCUGGAGAGGCAACA 5923
              ||||||:|||||||||||||
Db          1 AGAAGCTGGAGAGGCAACA 19


RESULT 678
DD201849
LOCUS       DD201849                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201849
VERSION     DD201849.1  GI:85655498
KEYWORDS    JP 2005517436-A/330.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 330 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/330
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5923 AGUGGAUUGCUGCUUCUUG 5941
              ||:|||::||:||::|::|
Db          1 AGTGGATTGCTGCTTCTTG 19


RESULT 679
DD201850
LOCUS       DD201850                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201850
VERSION     DD201850.1  GI:85655499
KEYWORDS    JP 2005517436-A/331.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 331 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/331
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5941 GGGGAGAAGAGUAUGCUUC 5959
              ||||||||||:|:||::|
Db          1 GGGGAGAAGAGTATGCTTC 19


RESULT 680
DD201851
LOCUS       DD201851                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201851
VERSION     DD201851.1  GI:85655500
KEYWORDS    JP 2005517436-A/332.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 332 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/332
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5959 CCUUUUAUCCAUGUAAUUU 5977
              ||::::|:|||:|:||:::
Db          1 CCTTTTATCCATGTAATTT 19


RESULT 681
DD201852
LOCUS       DD201852                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201852
VERSION     DD201852.1  GI:85655501
KEYWORDS    JP 2005517436-A/333.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 333 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/333
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5977 UAACUGUAGAACCUGAGCU 5995
              :|||:|:||||||:|||||:
Db          1 TAACTGTAGAACCTGAGCT 19


RESULT 682
DD201853
LOCUS       DD201853                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201853
VERSION     DD201853.1  GI:85655502
KEYWORDS    JP 2005517436-A/334.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 334 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/334
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5995 UCUAAGUAACCGAAGAAUG 6013
              :|:|||:||||||||||:|
Db          1 TCTAAGTAACCGAAGAATG 19


RESULT 683
DD201854
LOCUS       DD201854                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201854
VERSION     DD201854.1  GI:85655901
KEYWORDS    JP 2005517436-A/335.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 335 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/335
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6013 GUAUGCCUCUGUUCUUAUG 6031
              |:|:|||:|:|::|::|:|
Db          1 GTATGCCTCTGTTCTTATG 19


RESULT 684
DD201855
LOCUS       DD201855                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201855
VERSION     DD201855.1  GI:85655902
KEYWORDS    JP 2005517436-A/336.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 336 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/336
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6031 GUGCCACAUCCUUGUUUAA 6049
              |:||||||:||::|:::||
Db          1 GTGCCACATCCTTGTTTAA 19


RESULT 685
DD201856
LOCUS       DD201856                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201856
VERSION     DD201856.1  GI:85655903
KEYWORDS    JP 2005517436-A/337.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 337 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/337
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6049 AAGGCUCUCUGUAUGAAGA 6067
              |||||:|:|:|:|:|||||
Db          1 AAGGCTCTCTGTATGAAGA 19


RESULT 686
DD201857
LOCUS       DD201857                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201857
VERSION     DD201857.1  GI:85655904
KEYWORDS    JP 2005517436-A/338.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 338 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/338
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6067 AGAUGGGACCGUCAUCAGC 6085
              |||:|||||||:||:||||
Db          1 AGATGGGACCGTCATCAGC 19


RESULT 687
DD201858
LOCUS       DD201858                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201858
VERSION     DD201858.1  GI:85655905
KEYWORDS    JP 2005517436-A/339.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 339 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/339
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6085 CACAUUCCCUAGUGAGCCU 6103
              ||||::|||:||:|||||:
Db          1 CACATTCCCTAGTGAGCCT 19


RESULT 688
DD201859
LOCUS       DD201859                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201859
VERSION     DD201859.1  GI:85655906
KEYWORDS    JP 2005517436-A/340.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 340 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/340
```

```
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6103 UACUGGCUCCUGGCAGCGG 6121
              :||:|||:||:||||||||
Db          1 TACTGGCTCCTGGCAGCGG 19


RESULT 689
DD201860
LOCUS       DD201860                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201860
VERSION     DD201860.1  GI:85655907
KEYWORDS    JP 2005517436-A/341.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 341 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/341
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6121 GCUUUUGUGGAAGACUCAC 6139
              ||::::|:|||||||:|||
Db          1 GCTTTTGTGGAAGACTCAC 19


RESULT 690
DD201861
LOCUS       DD201861                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201861
VERSION     DD201861.1  GI:85655908
KEYWORDS    JP 2005517436-A/342.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 342 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/342
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6139 CUAGCCAGAAGAGAGGAGU 6157
              |:||||||||||||||||:
Db          1 CTAGCCAGAAGAGAGGAGT 19


RESULT 691
DD201862
LOCUS       DD201862                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201862
VERSION     DD201862.1  GI:85655909
KEYWORDS    JP 2005517436-A/343.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 343 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/343
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 6157 UGGGACAGUCCUCUCCACC 6175
:|||||||:||:|:|||||
Db 1 TGGGACAGTCCTCTCCACC 19

RESULT 692
DD201863
LOCUS DD201863 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201863
VERSION DD201863.1 GI:85655910
KEYWORDS JP 2005517436-A/344.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 344 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/344
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 6175 CAAGAUCUAAAUCCAAACA 6193
|||||:|:|||:|||||||
Db 1 CAAGATCTAAATCCAAACA 19

RESULT 693
DD201864
LOCUS DD201864 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201864
VERSION DD201864.1 GI:85655911
KEYWORDS JP 2005517436-A/345.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 345 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/345
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2.4e+03;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 6193 AAAAGCAGGCUAGAGCCAG 6211
||||||||||:||||||||
Db 1 AAAAGCAGGCTAGAGCCAG 19

RESULT 694
DD201865
LOCUS DD201865 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201865
VERSION DD201865.1 GI:85655912
KEYWORDS JP 2005517436-A/346.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 346 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/346
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  Target Sequence/siNA  CC            sense
           region
           FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6211 GAAGAGAGGACAAAUCUUU 6229
              ||||||||||||||:|:::
Db          1 GAAGAGAGGACAAATCTTT 19


RESULT 695
DD201866
LOCUS       DD201866                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201866
VERSION     DD201866.1  GI:85655913
KEYWORDS    JP 2005517436-A/347.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 347 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/347
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   42.1%;  Pred. No. 2.4e+03;
  Matches    8;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6229 UGUUGUUCCUCUUCUUUAC 6247
              :|::|::||:|::|:::||
Db          1 TGTTGTTCCTCTTCTTTAC 19


RESULT 696
DD201867
LOCUS       DD201867                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201867
VERSION     DD201867.1  GI:85655914
KEYWORDS    JP 2005517436-A/348.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 348 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/348
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6247 CACAUACGCAAACCACCUG 6265
              ||||:|||||||||||||:|
Db          1 CACATACGCAAACCACCTG 19


RESULT 697
DD201868
LOCUS       DD201868                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201868
VERSION     DD201868.1  GI:85655915
KEYWORDS    JP 2005517436-A/349.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 349 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/349
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6265 GUGACAGCUGGCAAUUUUA 6283
              |:||||||:|||||::::|
Db          1 GTGACAGCTGGCAATTTTA 19


RESULT 698
DD201869
LOCUS       DD201869                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201869
VERSION     DD201869.1  GI:85655916
KEYWORDS    JP 2005517436-A/350.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 350 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/350
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6283 AUAAAUCAGGUAACUGGAA 6301
              |:|||:||||:|||:||||
Db          1 ATAAATCAGGTAACTGGAA 19


RESULT 699
DD201870
LOCUS       DD201870                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201870
VERSION     DD201870.1  GI:85655917
KEYWORDS    JP 2005517436-A/351.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 351 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/351
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6301 AGGAGGUUAAACUCAGAAA 6319
              ||||||::||||:||||||
Db          1 AGGAGGTTAAACTCAGAAA 19


RESULT 700
DD201871
LOCUS       DD201871                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201871
VERSION     DD201871.1  GI:85655918
KEYWORDS    JP 2005517436-A/352.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 352 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/352
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

```
          beigelman,james mcswiggen,pamela pavco CC   Description of
          Artificial Sequence:  Target Sequence/siNA  CC            sense
          region
          FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6319 AAAAGAAGACCUCAGUCAA 6337
              ||||||||||:|||:|||
Db          1 AAAAGAAGACCTCAGTCAA 19


RESULT 701
DD201872
LOCUS       DD201872                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201872
VERSION     DD201872.1  GI:85655919
KEYWORDS    JP 2005517436-A/353.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 353 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/353
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   26.3%;  Pred. No. 2.4e+03;
  Matches    5;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6337 AUUCUCUACUUUUUUUUUU 6355
              |::|:|:||::::::::::
Db          1 ATTCTCTACTTTTTTTTT 19


RESULT 702
DD201873
LOCUS       DD201873                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201873
VERSION     DD201873.1  GI:85655920
KEYWORDS    JP 2005517436-A/354.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 354 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/354
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6355 UUUUUUUCCAAAUCAGAUA 6373
              ::::::::|||||:||||:|
Db          1 TTTTTTTCCAAATCAGATA 19


RESULT 703
DD201874
LOCUS       DD201874                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201874
VERSION     DD201874.1  GI:85655921
KEYWORDS    JP 2005517436-A/355.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 355 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/355
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
```

region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 6373 AAUAGCCCAGCAAAUAGUG 6391
||:|||||||||||:||:|
Db 1 AATAGCCCAGCAAATAGTG 19

RESULT 704
DD201875
LOCUS DD201875 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201875
VERSION DD201875.1 GI:85655922
KEYWORDS JP 2005517436-A/356.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 356 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/356
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 6391 GAUAACAAAUAAAACCUUA 6409
||:||||||:||||||::|
Db 1 GATAACAAATAAAACCTTA 19

RESULT 705
DD201876
LOCUS DD201876 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201876
VERSION DD201876.1 GI:85655923
KEYWORDS JP 2005517436-A/357.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 357 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/357
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 2.4e+03;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 6409 AGCUGUUCAUGUCUUGAUU 6427
|||:|::||:|:|::||::
Db 1 AGCTGTTCATGTCTTGATT 19

RESULT 706
DD201877
LOCUS DD201877 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201877
VERSION DD201877.1 GI:85655924
KEYWORDS JP 2005517436-A/358.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 358 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/358
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6427 UUCAAUAAUUAAUUCUUAA 6445
              ::|||:||::||::|::||
Db          1 TTCAATAATTAATTCTTAA 19


RESULT 707
DD201878
LOCUS       DD201878                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201878
VERSION     DD201878.1  GI:85655925
KEYWORDS    JP 2005517436-A/359.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 359 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/359
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6445 AUCAUUAAGAGACCAUAAU 6463
              |:||::||||||||:||:
Db          1 ATCATTAAGAGACCATAAT 19


RESULT 708
DD201879
LOCUS       DD201879                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201879
VERSION     DD201879.1  GI:85655926
KEYWORDS    JP 2005517436-A/360.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 360 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/360
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6463 UAAAUACUCCUUUUCAAGA 6481
              :|||:||:||::::|||||
Db          1 TAAATACTCCTTTTCAAGA 19


RESULT 709
DD201880
LOCUS       DD201880                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201880
VERSION     DD201880.1  GI:85655927
KEYWORDS    JP 2005517436-A/361.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 361 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/361
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
```

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6481 AGAAAAGCAAAACCAUUAG 6499
              ||||||||||||||::||
Db          1 AGAAAAGCAAAACCATTAG 19
```

RESULT 710
DD201881
LOCUS DD201881 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201881
VERSION DD201881.1 GI:85655928
KEYWORDS JP 2005517436-A/362.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 362 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/362
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6499 GAAUUGUUACUCAGCUCCU 6517
              |||::|::||:||||:||:
Db          1 GAATTGTTACTCAGCTCCT 19
```

RESULT 711
DD201882
LOCUS DD201882 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201882
VERSION DD201882.1 GI:85655929
KEYWORDS JP 2005517436-A/363.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 363 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/363
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6517 UUCAAACUCAGGUUUGUAG 6535
              ::|||||:||||:::|:||
Db          1 TTCAAACTCAGGTTTGTAG 19
```

RESULT 712
DD201883
LOCUS DD201883 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201883
VERSION DD201883.1 GI:85655930
KEYWORDS JP 2005517436-A/364.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 364 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/364
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"

```
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6535 GCAUACAUGAGUCCAUCCA 6553
              |||:|||:|||:|||:|||
Db          1 GCATACATGAGTCCATCCA 19


RESULT 713
DD201884
LOCUS       DD201884                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201884
VERSION     DD201884.1  GI:85655931
KEYWORDS    JP 2005517436-A/365.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 365 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/365
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6553 AUCAGUCAAAGAAUGGUUC 6571
              |:|||:|||||||:||::|
Db          1 ATCAGTCAAAGAATGGTTC 19


RESULT 714
DD201885
LOCUS       DD201885                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201885
VERSION     DD201885.1  GI:85655932
KEYWORDS    JP 2005517436-A/366.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 366 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/366
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6571 CCAUCUGGAGUCUUAAUGU 6589
              |||:|:||||:|::||:|:
Db          1 CCATCTGGAGTCTTAATGT 19


RESULT 715
DD201886
LOCUS       DD201886                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201886
VERSION     DD201886.1  GI:85655933
KEYWORDS    JP 2005517436-A/367.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 367 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/367
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6589 UAGAAAGAAAAAUGGAGAC 6607
              :||||||||||:||||||
Db          1 TAGAAAGAAAAATGGAGAC 19


RESULT 716
DD201887
LOCUS       DD201887                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201887
VERSION     DD201887.1  GI:85655934
KEYWORDS    JP 2005517436-A/368.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 368 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/368
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6607 CUUGUAAUAAUGAGCUAGU 6625
              |::|:||:||:||||:||:
Db          1 CTTGTAATAATGAGCTAGT 19


RESULT 717
DD201888
LOCUS       DD201888                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201888
VERSION     DD201888.1  GI:85655935
KEYWORDS    JP 2005517436-A/369.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 369 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/369
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6625 UUACAAAGUGCUUGUUCAU 6643
              ::||||||:||::|::||:
Db          1 TTACAAAGTGCTTGTTCAT 19


RESULT 718
DD201889
LOCUS       DD201889                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201889
VERSION     DD201889.1  GI:85655936
KEYWORDS    JP 2005517436-A/370.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 370 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/370
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
```

```
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6643 UUAAAAUAGCACUGAAAAU 6661
              ::||||:|||||:|||||:
Db          1 TTAAAATAGCACTGAAAAT 19


RESULT 719
DD201890
LOCUS       DD201890                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201890
VERSION     DD201890.1  GI:85655937
KEYWORDS    JP 2005517436-A/371.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 371 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/371
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6661 UUGAAACAUGAAUUAACUG 6679
              ::||||||:|||::|||:|
Db          1 TTGAAACATGAATTAACTG 19


RESULT 720
DD201891
LOCUS       DD201891                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201891
VERSION     DD201891.1  GI:85655938
KEYWORDS    JP 2005517436-A/372.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 372 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/372
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6679 GAUAAUAUUCCAAUCAUUU 6697
              ||:||:|::||||:||:::
Db          1 GATAATATTCCAATCATTT 19


RESULT 721
DD201892
LOCUS       DD201892                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201892
VERSION     DD201892.1  GI:85655939
KEYWORDS    JP 2005517436-A/373.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 373 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/373
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6697 UGCCAUUUAUGACAAAAAU 6715
              :||||:::|:|||||||:
Db          1 TGCCATTTATGACAAAAAT 19


RESULT 722
DD201893
LOCUS       DD201893                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201893
VERSION     DD201893.1  GI:85655940
KEYWORDS    JP 2005517436-A/374.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 374 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/374
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6715 UGGUUGGCACUAACAAAGA 6733
              :||::|||||:||||||||
Db          1 TGGTTGGCACTAACAAAGA 19


RESULT 723
DD201894
LOCUS       DD201894                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201894
VERSION     DD201894.1  GI:85655941
KEYWORDS    JP 2005517436-A/375.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 375 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/375
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6733 AACGAGCACUUCCUUUCAG 6751
              |||||||||::||:::|||
Db          1 AACGAGCACTTCCTTTCAG 19


RESULT 724
DD201895
LOCUS       DD201895                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201895
VERSION     DD201895.1  GI:85655942
KEYWORDS    JP 2005517436-A/376.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 376 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/376
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6751 GAGUUUCUGAGAUAAUGUA 6769
              |||:::|:||||:||:|:|
```

```
Db          1 GAGTTTCTGAGATAATGTA 19


RESULT 725
DD201896
LOCUS       DD201896                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201896
VERSION     DD201896.1  GI:85655943
KEYWORDS    JP 2005517436-A/377.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 377 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/377
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6769 ACGUGGAACAGUCUGGGUG 6787
              |||:|||||||:|:|||:|
Db          1 ACGTGGAACAGTCTGGGTG 19


RESULT 726
DD201897
LOCUS       DD201897                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201897
VERSION     DD201897.1  GI:85655944
KEYWORDS    JP 2005517436-A/378.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 378 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/378
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6787 GGAAUGGGGCUGAAACCAU 6805
              ||||:|||||:|||||||:
Db          1 GGAATGGGGCTGAAACCAT 19


RESULT 727
DD201898
LOCUS       DD201898                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201898
VERSION     DD201898.1  GI:85655945
KEYWORDS    JP 2005517436-A/379.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 379 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/379
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6805 UGUGCAAGUCUGUGUCUUG 6823
              :|:|||||:|:|:|:|::|
Db          1 TGTGCAAGTCTGTGTCTTG 19
```

```
RESULT 728
DD201899
LOCUS       DD201899                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201899
VERSION     DD201899.1  GI:85655946
KEYWORDS    JP 2005517436-A/380.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 380 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/380
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6823 GUCAGUCCAAGAAGUGACA 6841
              |:|||:||||||||:||||
Db          1 GTCAGTCCAAGAAGTGACA 19


RESULT 729
DD201900
LOCUS       DD201900                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201900
VERSION     DD201900.1  GI:85655947
KEYWORDS    JP 2005517436-A/381.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 381 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/381
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6841 ACCGAGAUGUUAAUUUUAG 6859
              |||||||:|::||::::||
Db          1 ACCGAGATGTTAATTTTAG 19


RESULT 730
DD201901
LOCUS       DD201901                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201901
VERSION     DD201901.1  GI:85655948
KEYWORDS    JP 2005517436-A/382.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 382 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/382
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6859 GGGACCCGUGCCUUGUUUC 6877
              ||||||||:|||::|:::|
Db          1 GGGACCCGTGCCTTGTTTC 19


RESULT 731
```

```
DD201902
LOCUS       DD201902                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201902
VERSION     DD201902.1  GI:85655949
KEYWORDS    JP 2005517436-A/383.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 383 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/383
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6877 CCUAGCCCACAAGAAUGCA 6895
              ||:||||||||||||:|||
Db          1 CCTAGCCCACAAGAATGCA 19


RESULT 732
DD201903
LOCUS       DD201903                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201903
VERSION     DD201903.1  GI:85655950
KEYWORDS    JP 2005517436-A/384.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 384 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/384
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6895 AAACAUCAAACAGAUACUC 6913
              |||||:|||||||:||:|
Db          1 AAACATCAAACAGATACTC 19


RESULT 733
DD201904
LOCUS       DD201904                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201904
VERSION     DD201904.1  GI:85655951
KEYWORDS    JP 2005517436-A/385.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 385 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/385
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6913 CGCUAGCCUCAUUUAAAUU 6931
              |||:||||:||:::|||::
Db          1 CGCTAGCCTCATTTAAATT 19


RESULT 734
DD201905
LOCUS       DD201905                  19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201905
VERSION     DD201905.1  GI:85655952
KEYWORDS    JP 2005517436-A/386.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 386 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/386
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6931 UGAUUAAAGGAGGAGUGCA 6949
                :||::||||||||||:|||
Db          1 TGATTAAAGGAGGAGTGCA 19


RESULT 735
DD201906
LOCUS       DD201906                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201906
VERSION     DD201906.1  GI:85655953
KEYWORDS    JP 2005517436-A/387.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 387 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/387
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6949 AUCUUUGGCCGACAGUGGU 6967
                |:|:::||||||||:||:
Db          1 ATCTTTGGCCGACAGTGGT 19


RESULT 736
DD201907
LOCUS       DD201907                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201907
VERSION     DD201907.1  GI:85655954
KEYWORDS    JP 2005517436-A/388.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 388 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/388
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6967 UGUAACUGUGUGUGUGUGU 6985
                :|:|||:|:|:|:|:|:|:
Db          1 TGTAACTGTGTGTGTGTGT 19


RESULT 737
DD201908
LOCUS       DD201908                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD201908
VERSION     DD201908.1  GI:85655955
KEYWORDS    JP 2005517436-A/389.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 389 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/389
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 19


RESULT 738
DD201909
LOCUS       DD201909                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201909
VERSION     DD201909.1  GI:85655956
KEYWORDS    JP 2005517436-A/390.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 390 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/390
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7003 UGUGUGUGUGUGGGUGUGG 7021
              :|:|:|:|:|:|||:|:||
Db          1 TGTGTGTGTGTGGGTGTGG 19


RESULT 739
DD201910
LOCUS       DD201910                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201910
VERSION     DD201910.1  GI:85655957
KEYWORDS    JP 2005517436-A/391.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 391 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/391
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7021 GGUGUAUGUGUGUUUUGUG 7039
              ||:|:|:|:|:|::::|:|
Db          1 GGTGTATGTGTGTTTTGTG 19


RESULT 740
DD201911
LOCUS       DD201911                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201911
```

```
VERSION     DD201911.1  GI:85655958
KEYWORDS    JP 2005517436-A/392.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 392 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/392
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7039 GCAUAACUAUUUAAGGAAA 7057
              |||:|||:|:::|||||||
Db          1 GCATAACTATTTAAGGAAA 19


RESULT 741
DD201912
LOCUS       DD201912                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201912
VERSION     DD201912.1  GI:85655959
KEYWORDS    JP 2005517436-A/393.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 393 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/393
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7057 ACUGGAAUUUUAAAGUUAC 7075
              ||:||||::::||||::||
Db          1 ACTGGAATTTTAAAGTTAC 19


RESULT 742
DD201913
LOCUS       DD201913                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201913
VERSION     DD201913.1  GI:85655960
KEYWORDS    JP 2005517436-A/394.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 394 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/394
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7075 CUUUUAUACAAACCAAGAA 7093
              |::::|:|||||||||||||
Db          1 CTTTTATACAAACCAAGAA 19


RESULT 743
DD201914
LOCUS       DD201914                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201914
VERSION     DD201914.1  GI:85655961
KEYWORDS    JP 2005517436-A/395.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 395 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/395
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7093 AUAUAUGCUACAGAUAUAA 7111
              |:|:|:||:|||||:|:||
Db          1 ATATATGCTACAGATATAA 19


RESULT 744
DD201915
LOCUS       DD201915                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201915
VERSION     DD201915.1  GI:85655962
KEYWORDS    JP 2005517436-A/396.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 396 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/396
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7111 AGACAGACAUGGUUUGGUC 7129
              |||||||||:||:::||:|
Db          1 AGACAGACATGGTTTGGTC 19


RESULT 745
DD201916
LOCUS       DD201916                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201916
VERSION     DD201916.1  GI:85655963
KEYWORDS    JP 2005517436-A/397.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 397 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/397
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7129 CCUAUAUUUCUAGUCAUGA 7147
              ||:|:|:::|:||:||:||
Db          1 CCTATATTTCTAGTCATGA 19


RESULT 746
DD201917
LOCUS       DD201917                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201917
VERSION     DD201917.1  GI:85655964
KEYWORDS    JP 2005517436-A/398.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 398 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/398
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7147 AUGAAUGUAUUUUGUAUAC 7165
              |:|||:|:|::::|:|:||
Db          1 ATGAATGTATTTTGTATAC 19


RESULT 747
DD201918
LOCUS       DD201918                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201918
VERSION     DD201918.1  GI:85655965
KEYWORDS    JP 2005517436-A/399.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 399 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/399
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7165 CCAUCUUCAUAUAAUAUAC 7183
              |||:|::||:|:||:|:||
Db          1 CCATCTTCATATAATATAC 19


RESULT 748
DD201919
LOCUS       DD201919                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201919
VERSION     DD201919.1  GI:85655966
KEYWORDS    JP 2005517436-A/400.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 400 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/400
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7183 CUUAAAAAUAUUUCUUAAU 7201
              |::|||||:|:::|::||:
Db          1 CTTAAAAATATTTCTTAAT 19


RESULT 749
DD201920
LOCUS       DD201920                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201920
VERSION     DD201920.1  GI:85655967
KEYWORDS    JP 2005517436-A/401.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 401 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/401
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7201 UUGGGAUUUGUAAUCGUAC 7219
              ::||||:::|:||:||:||
Db          1 TTGGGATTTGTAATCGTAC 19


RESULT 750
DD201921
LOCUS       DD201921                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201921
VERSION     DD201921.1  GI:85655968
KEYWORDS    JP 2005517436-A/402.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 402 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/402
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7219 CCAACUUAAUUGAUAAACU 7237
              |||||::||::||:||||:
Db          1 CCAACTTAATTGATAAACT 19


RESULT 751
DD201922
LOCUS       DD201922                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201922
VERSION     DD201922.1  GI:85655969
KEYWORDS    JP 2005517436-A/403.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 403 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/403
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7237 UUGGCAACUGCUUUUAUGU 7255
              ::||||||:||::::|:|:
Db          1 TTGGCAACTGCTTTTATGT 19


RESULT 752
DD201923
LOCUS       DD201923                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201923
VERSION     DD201923.1  GI:85655970
KEYWORDS    JP 2005517436-A/404.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 404 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/404
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7255 UUCUGUCUCCUUCCAUAAA 7273
              ::|:|:|:||::|||:|||
Db          1 TTCTGTCTCCTTCCATAAA 19


RESULT 753
DD201924
LOCUS       DD201924                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201924
VERSION     DD201924.1  GI:85655971
KEYWORDS    JP 2005517436-A/405.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 405 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/405
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7273 AUUUUUCAAAAUACUAAUU 7291
              |:::::|||||:||:||::
Db          1 ATTTTTCAAAATACTAATT 19


RESULT 754
DD201925
LOCUS       DD201925                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201925
VERSION     DD201925.1  GI:85655972
KEYWORDS    JP 2005517436-A/406.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 406 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/406
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7291 UCAACAAAGAAAAAGCUCU 7309
              :|||||||||||||||:|:
Db          1 TCAACAAAGAAAAAGCTCT 19


RESULT 755
DD201926
LOCUS       DD201926                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201926
VERSION     DD201926.1  GI:85655973
KEYWORDS    JP 2005517436-A/407.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 407 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/407
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.4e+03;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7309 UUUUUUUUCCUAAAAUAAA 7327
              ::::::::||:||||:|||
Db          1 TTTTTTTTCCTAAAATAAA 19


RESULT 756
DD201927
LOCUS       DD201927                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201927
VERSION     DD201927.1  GI:85655974
KEYWORDS    JP 2005517436-A/408.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 408 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/408
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7327 ACUCAAAUUUAUCCUUGUU 7345
              ||:||||:::|:||::|::
Db          1 ACTCAAATTTATCCTTGTT 19


RESULT 757
DD201928
LOCUS       DD201928                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201928
VERSION     DD201928.1  GI:85655975
KEYWORDS    JP 2005517436-A/409.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 409 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/409
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7345 UUAGAGCAGAGAAAAAUUA 7363
              ::|||||||||||||::|
Db          1 TTAGAGCAGAGAAAAATTA 19


RESULT 758
DD201929
LOCUS       DD201929                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201929
VERSION     DD201929.1  GI:85655976
KEYWORDS    JP 2005517436-A/410.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 410 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/410
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7363 AAGAAAAACUUUGAAAUGG 7381
              |||||||||:::||||:||
Db          1 AAGAAAAACTTTGAAATGG 19


RESULT 759
DD201930
LOCUS       DD201930                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201930
VERSION     DD201930.1  GI:85655977
KEYWORDS    JP 2005517436-A/411.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 411 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/411
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7381 GUCUCAAAAAAUUGCUAAA 7399
              |:|:|||||||::||:|||
Db          1 GTCTCAAAAAATTGCTAAA 19


RESULT 760
DD201931
LOCUS       DD201931                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201931
VERSION     DD201931.1  GI:85655978
KEYWORDS    JP 2005517436-A/412.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 412 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/412
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7399 AUAUUUUCAAUGGAAAACU 7417
              |:|::::|||:|||||||:
Db          1 ATATTTTCAATGGAAAACT 19


RESULT 761
DD201932
LOCUS       DD201932                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201932
VERSION     DD201932.1  GI:85655979
KEYWORDS    JP 2005517436-A/413.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 413 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/413
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7417 UAAAUGUUAGUUUAGCUGA 7435
              :|||:|::||:::|||:||
Db             1 TAAATGTTAGTTTAGCTGA 19


RESULT 762
DD201933
LOCUS       DD201933                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201933
VERSION     DD201933.1  GI:85655980
KEYWORDS    JP 2005517436-A/414.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 414 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/414
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7435 AUUGUAUGGGGUUUUCGAA 7453
              |::|:|:||||::::||||
Db             1 ATTGTATGGGGTTTTCGAA 19


RESULT 763
DD201934
LOCUS       DD201934                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201934
VERSION     DD201934.1  GI:85655981
KEYWORDS    JP 2005517436-A/415.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 415 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/415
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   42.1%;  Pred. No. 2.4e+03;
  Matches    8;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7453 ACCUUUCACUUUUUGUUUG 7471
              |||:::|||:::::|:::|
Db             1 ACCTTTCACTTTTTGTTTG 19


RESULT 764
DD201935
LOCUS       DD201935                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201935
VERSION     DD201935.1  GI:85655982
KEYWORDS    JP 2005517436-A/416.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 416 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/416
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2.4e+03;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 7471 GUUUUACCUAUUUCACAAC 7489
|::::|||:|:::||||||
Db 1 GTTTTACCTATTTCACAAC 19

RESULT 765
DD201936
LOCUS DD201936 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201936
VERSION DD201936.1 GI:85655983
KEYWORDS JP 2005517436-A/417.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 417 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/417
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 7489 CUGUGUAAAUUGCCAAUAA 7507
|:|:|:|||::|||||:||
Db 1 CTGTGTAAATTGCCAATAA 19

RESULT 766
DD201937
LOCUS DD201937 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201937
VERSION DD201937.1 GI:85655984
KEYWORDS JP 2005517436-A/418.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 418 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/418
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: Target Sequence/siNA CC sense region
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 7507 AUUCCUGUCCAUGAAAAUG 7525
|::||:|:|||:|||||:|
Db 1 ATTCCTGTCCATGAAAATG 19

RESULT 767
DD201938
LOCUS DD201938 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201938
VERSION DD201938.1 GI:85655985
KEYWORDS JP 2005517436-A/419.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 419 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/419
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
          05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
          20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
          11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
          03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
          beigelman,james mcswiggen,pamela pavco CC   Description of
          Artificial Sequence:  Target Sequence/siNA  CC            sense
          region
          FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7525 GCAAAUUAUCCAGUGUAGA 7543
              |||||::|:||||:|:|||
Db          1 GCAAATTATCCAGTGTAGA 19


RESULT 768
DD201939
LOCUS       DD201939                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201939
VERSION     DD201939.1  GI:85655986
KEYWORDS    JP 2005517436-A/420.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 420 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/420
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7543 AUAUAUUUGACCAUCACCC 7561
              |:|:|:::|||||:|||||
Db          1 ATATATTTGACCATCACCC 19


RESULT 769
DD201940
LOCUS       DD201940                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201940
VERSION     DD201940.1  GI:85655987
KEYWORDS    JP 2005517436-A/421.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 421 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/421
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7561 CUAUGGAUAUUGGCUAGUU 7579
              |:|:|||:|::|||:||::
Db          1 CTATGGATATTGGCTAGTT 19


RESULT 770
DD201941
LOCUS       DD201941                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201941
VERSION     DD201941.1  GI:85655988
KEYWORDS    JP 2005517436-A/422.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 422 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/422
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7579 UUUGCCUUUAUUAAGCAAA 7597
              :::|||:::|::|||||||
Db          1 TTTGCCTTTATTAAGCAAA 19


RESULT 771
DD201942
LOCUS       DD201942                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201942
VERSION     DD201942.1  GI:85655989
KEYWORDS    JP 2005517436-A/423.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 423 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/423
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7597 AUUCAUUUCAGCCUGAAUG 7615
              |::||:::|||||:|||:|
Db          1 ATTCATTTCAGCCTGAATG 19


RESULT 772
DD201943
LOCUS       DD201943                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201943
VERSION     DD201943.1  GI:85655990
KEYWORDS    JP 2005517436-A/424.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 424 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/424
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7615 GUCUGCCUAUAUAUUCUCU 7633
              |:|:|||:|:|:|::|:|:
Db          1 GTCTGCCTATATATTCTCT 19


RESULT 773
DD201944
LOCUS       DD201944                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201944
VERSION     DD201944.1  GI:85655991
KEYWORDS    JP 2005517436-A/425.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 425 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/425
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
```

```
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   42.1%;  Pred. No. 2.4e+03;
  Matches    8;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7633 UGCUCUUUGUAUUCUCCUU 7651
              :||:|:::|:|::|:||::
Db          1 TGCTCTTTGTATTCTCCTT 19


RESULT 774
DD201945
LOCUS       DD201945                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201945
VERSION     DD201945.1  GI:85655992
KEYWORDS    JP 2005517436-A/426.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 426 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/426
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7651 UUGAACCCGUUAAAACAUC 7669
              ::|||||||::||||||:|
Db          1 TTGAACCCGTTAAAACATC 19


RESULT 775
DD201946
LOCUS       DD201946                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201946
VERSION     DD201946.1  GI:85655993
KEYWORDS    JP 2005517436-A/427.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 427 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/427
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  Target Sequence/siNA  CC            sense
            region
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7662 AAAACAUCCUGUGGCACUC 7680
              ||||||:||:|:|||||:|
Db          1 AAAACATCCTGTGGCACTC 19


RESULT 776
DD201947/c
LOCUS       DD201947                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201947
VERSION     DD201947.1  GI:85655994
KEYWORDS    JP 2005517436-A/428.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 428 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/428
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
```

```
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GCGGACACUCCUCUCGGCU 19
              ||||||||:||:|:||||:
Db         19 GCGGACACTCCTCTCGGCT 1


RESULT 777
DD201948/c
LOCUS       DD201948                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201948
VERSION     DD201948.1  GI:85655995
KEYWORDS    JP 2005517436-A/429.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 429 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/429
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 UCCUCCCCGGCAGCGGCGG 37
              :||:|||||||||||||||
Db         19 TCCTCCCCGGCAGCGGCGG 1


RESULT 778
DD201949/c
LOCUS       DD201949                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201949
VERSION     DD201949.1  GI:85655996
KEYWORDS    JP 2005517436-A/430.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 430 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/430
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         37 GCGGCUCGGAGCGGGCUCC 55
              |||||:||||||||||:||
Db         19 GCGGCTCGGAGCGGGCTCC 1


RESULT 779
DD201950/c
LOCUS       DD201950                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201950
VERSION     DD201950.1  GI:85655997
KEYWORDS    JP 2005517436-A/431.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 431 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/431
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
```

```
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         55 CGGGGCUCGGGUGCAGCGG 73
              ||||||:||||:|||||||
Db         19 CGGGGCTCGGGTGCAGCGG 1


RESULT 780
DD201951/c
LOCUS       DD201951                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201951
VERSION     DD201951.1  GI:85655998
KEYWORDS    JP 2005517436-A/432.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 432 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/432
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         73 GCCAGCGGGCCUGGCGGCG 91
              ||||||||||:|||||||
Db         19 GCCAGCGGGCCTGGCGGCG 1


RESULT 781
DD201952/c
LOCUS       DD201952                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201952
VERSION     DD201952.1  GI:85655999
KEYWORDS    JP 2005517436-A/433.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 433 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/433
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         91 GAGGAUUACCCGGGGAAGU 109
              |||||::|||||||||||:
Db         19 GAGGATTACCCGGGGAAGT 1


RESULT 782
DD201953/c
LOCUS       DD201953                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201953
VERSION     DD201953.1  GI:85656000
KEYWORDS    JP 2005517436-A/434.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 434 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/434
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        109 UGGUUGUCUCCUGGCUGGA 127
              :||::|:|:||:|||:|||
Db         19 TGGTTGTCTCCTGGCTGGA 1


RESULT 783
DD201954/c
LOCUS       DD201954                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201954
VERSION     DD201954.1  GI:85656001
KEYWORDS    JP 2005517436-A/435.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 435 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/435
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        127 AGCCGCGAGACGGGCGCUC 145
              ||||||||||||||||:|
Db         19 AGCCGCGAGACGGGCGCTC 1


RESULT 784
DD201955/c
LOCUS       DD201955                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201955
VERSION     DD201955.1  GI:85656002
KEYWORDS    JP 2005517436-A/436.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 436 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/436
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        145 CAGGGCGCGGGGCCGGCGG 163
              |||||||||||||||||||
Db         19 CAGGGCGCGGGGCCGGCGG 1


RESULT 785
DD201956/c
LOCUS       DD201956                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201956
VERSION     DD201956.1  GI:85656003
KEYWORDS    JP 2005517436-A/437.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 437 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/437
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        163 GCGGCGAACGAGAGGACGG 181
              |||||||||||||||||||
Db         19 GCGGCGAACGAGAGGACGG 1
```

```
RESULT 786
DD201957/c
LOCUS       DD201957                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201957
VERSION     DD201957.1  GI:85656004
KEYWORDS    JP 2005517436-A/438.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 438 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/438
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 GACUCUGGCGGCCGGGUCG 199
              |||:|:||||||||||:||
Db         19 GACTCTGGCGGCCGGGTCG 1


RESULT 787
DD201958/c
LOCUS       DD201958                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201958
VERSION     DD201958.1  GI:85656005
KEYWORDS    JP 2005517436-A/439.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 439 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/439
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        199 GUUGGCCGGGGGAGCGCGG 217
              |::|||||||||||||||||
Db         19 GTTGGCCGGGGGAGCGCGG 1


RESULT 788
DD201959/c
LOCUS       DD201959                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201959
VERSION     DD201959.1  GI:85656006
KEYWORDS    JP 2005517436-A/440.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 440 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/440
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        217 GGCACCGGGCGAGCAGGCC 235
              |||||||||||||||||||
Db         19 GGCACCGGGCGAGCAGGCC 1


RESULT 789
DD201960/c
LOCUS       DD201960                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201960
VERSION DD201960.1 GI:85656007
KEYWORDS JP 2005517436-A/441.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 441 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/441
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 235 CGCGUCGCGCUCACCAUGG 253
||||:|||||:||||||
Db 19 CGCGTCGCGCTCACCATGG 1

RESULT 790
DD201961/c
LOCUS DD201961 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201961
VERSION DD201961.1 GI:85656008
KEYWORDS JP 2005517436-A/442.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 442 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/442
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 253 GUCAGCUACUGGGACACCG 271
|:||||:||:|||||||||
Db 19 GTCAGCTACTGGGACACCG 1

RESULT 791
DD201962/c
LOCUS DD201962 19 bp DNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201962
VERSION DD201962.1 GI:85656009
KEYWORDS JP 2005517436-A/443.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 443 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/443
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region CC The type of this sequence is wrong in the original data. It is CC automatically modified by the JPO.
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 271 GGGGUCCUGCUGUGCGCGC 289
||||:||:||:|:||||||
Db 19 GGGGTCCTGCTGTGCGCGC 1

RESULT 792
DD201963/c
LOCUS DD201963 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD201963

```
VERSION     DD201963.1  GI:85656010
KEYWORDS    JP 2005517436-A/444.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 444 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/444
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        289 CUGCUCAGCUGUCUGCUUC 307
              |:||:||||:|:|:||::|
Db         19 CTGCTCAGCTGTCTGCTTC 1


RESULT 793
DD201964/c
LOCUS       DD201964                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201964
VERSION     DD201964.1  GI:85656011
KEYWORDS    JP 2005517436-A/445.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 445 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/445
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        307 CUCACAGGAUCUAGUUCAG 325
              |:|||||||:|:|||::|||
Db         19 CTCACAGGATCTAGTTCAG 1


RESULT 794
DD201965/c
LOCUS       DD201965                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201965
VERSION     DD201965.1  GI:85656012
KEYWORDS    JP 2005517436-A/446.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 446 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/446
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        325 GGUUCAAAAUUAAAAGAUC 343
              ||::|||||::||||||:|
Db         19 GGTTCAAAATTAAAAGATC 1


RESULT 795
DD201966/c
LOCUS       DD201966                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201966
VERSION     DD201966.1  GI:85656013
KEYWORDS    JP 2005517436-A/447.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
```

```
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 447 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/447
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        343 CCUGAACUGAGUUUAAAAG 361
              ||:||||:|||:::|||||
Db         19 CCTGAACTGAGTTTAAAAG 1


RESULT 796
DD201967/c
LOCUS       DD201967                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201967
VERSION     DD201967.1  GI:85656014
KEYWORDS    JP 2005517436-A/448.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 448 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/448
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GGCACCCAGCACAUCAUGC 379
              ||||||||||||:||:||
Db         19 GGCACCCAGCACATCATGC 1


RESULT 797
DD201968/c
LOCUS       DD201968                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201968
VERSION     DD201968.1  GI:85656015
KEYWORDS    JP 2005517436-A/449.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 449 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/449
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        379 CAAGCAGGCCAGACACUGC 397
              ||||||||||||||||:||
Db         19 CAAGCAGGCCAGACACTGC 1


RESULT 798
DD201969/c
LOCUS       DD201969                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201969
VERSION     DD201969.1  GI:85656016
KEYWORDS    JP 2005517436-A/450.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 450 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/450
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        397 CAUCUCCAAUGCAGGGGGG 415
              ||:|:||||:|||||||||
Db         19 CATCTCCAATGCAGGGGGG 1


RESULT 799
DD201970/c
LOCUS       DD201970                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201970
VERSION     DD201970.1  GI:85656017
KEYWORDS    JP 2005517436-A/451.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 451 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/451
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        415 GAAGCAGCCCAUAAAUGGU 433
              ||||||||||:|||:||:
Db         19 GAAGCAGCCCATAAATGGT 1


RESULT 800
DD201971/c
LOCUS       DD201971                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201971
VERSION     DD201971.1  GI:85656018
KEYWORDS    JP 2005517436-A/452.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 452 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/452
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        433 UCUUUGCCUGAAAUGGUGA 451
              :|:::|||:||||:||:||
Db         19 TCTTTGCCTGAAATGGTGA 1


RESULT 801
DD201972/c
LOCUS       DD201972                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201972
VERSION     DD201972.1  GI:85656019
KEYWORDS    JP 2005517436-A/453.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 453 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/453
            PD   16-JUN-2005
```

```
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 AGUAAGGAAAGCGAAAGGC 469
              ||:||||||||||||||||
Db         19 AGTAAGGAAAGCGAAAGGC 1


RESULT 802
DD201973/c
LOCUS       DD201973                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201973
VERSION     DD201973.1  GI:85656020
KEYWORDS    JP 2005517436-A/454.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 454 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/454
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        469 CUGAGCAUAACUAAAUCUG 487
              |:|||||:|||:|||:|:|
Db         19 CTGAGCATAACTAAATCTG 1


RESULT 803
DD201974/c
LOCUS       DD201974                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201974
VERSION     DD201974.1  GI:85656021
KEYWORDS    JP 2005517436-A/455.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 455 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/455
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        487 GCCUGUGGAAGAAAUGGCA 505
              |||:|:|||||||:||||
Db         19 GCCTGTGGAAGAAATGGCA 1


RESULT 804
DD201975/c
LOCUS       DD201975                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201975
VERSION     DD201975.1  GI:85656022
KEYWORDS    JP 2005517436-A/456.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 456 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/456
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

```
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        505 AAACAAUUCUGCAGUACUU 523
              ||||||::|:||||:||::
Db         19 AAACAATTCTGCAGTACTT 1


RESULT 805
DD201976/c
LOCUS       DD201976                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201976
VERSION     DD201976.1  GI:85656023
KEYWORDS    JP 2005517436-A/457.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 457 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/457
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        523 UUAACCUUGAACACAGCUC 541
              ::||||::||||||||||:|
Db         19 TTAACGTTGAACACAGCTC 1


RESULT 806
DD201977/c
LOCUS       DD201977                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201977
VERSION     DD201977.1  GI:85656024
KEYWORDS    JP 2005517436-A/458.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 458 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/458
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 CAAGCAAACCACACUGGCU 559
              |||||||||||||:|||:
Db         19 CAAGCAAACCACACTGGCT 1


RESULT 807
DD201978/c
LOCUS       DD201978                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD201978
VERSION     DD201978.1  GI:85656025
KEYWORDS    JP 2005517436-A/459.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 459 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/459
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
```

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 UUCUACAGCUGCAAAUAUC 577
              ::|:|||||:|||||:|:|
Db         19 TTCTACAGCTGCAAATATC 1


RESULT 808
DD201979/c
LOCUS       DD201979                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201979
VERSION     DD201979.1  GI:85656026
KEYWORDS    JP 2005517436-A/460.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 460 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/460
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        577 CUAGCUGUACCUACUUCAA 595
              |:|||:|:|||:||::|||
Db         19 CTAGCTGTACCTACTTCAA 1


RESULT 809
DD201980/c
LOCUS       DD201980                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201980
VERSION     DD201980.1  GI:85656027
KEYWORDS    JP 2005517436-A/461.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 461 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/461
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        595 AAGAAGAAGGAAACAGAAU 613
              ||||||||||||||||||:
Db         19 AAGAAGAAGGAAACAGAAT 1


RESULT 810
DD201981/c
LOCUS       DD201981                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201981
VERSION     DD201981.1  GI:85656028
KEYWORDS    JP 2005517436-A/462.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 462 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/462
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        613 UCUGCAAUCUAUAUAUUUA 631
              :|:||||:|:|:|:|:::|
Db         19 TCTGCAATCTATATATTTA 1


RESULT 811
DD201982/c
LOCUS       DD201982                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201982
VERSION     DD201982.1  GI:85656029
KEYWORDS    JP 2005517436-A/463.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 463 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/463
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 AUUAGUGAUACAGGUAGAC 649
              |::||:||:|||||:||||
Db         19 ATTAGTGATACAGGTAGAC 1


RESULT 812
DD201983/c
LOCUS       DD201983                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201983
VERSION     DD201983.1  GI:85656030
KEYWORDS    JP 2005517436-A/464.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 464 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/464
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        649 CCUUUCGUAGAGAUGUACA 667
              ||:::||:|||||:|:|||
Db         19 CCTTTCGTAGAGATGTACA 1


RESULT 813
DD201984/c
LOCUS       DD201984                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201984
VERSION     DD201984.1  GI:85656031
KEYWORDS    JP 2005517436-A/465.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 465 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/465
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        667 AGUGAAAUCCCCGAAAUUA 685
              ||:||||:||||||||::|
Db         19 AGTGAAATCCCCGAAATTA 1
```

```
RESULT 814
DD201985/c
LOCUS       DD201985                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201985
VERSION     DD201985.1  GI:85656032
KEYWORDS    JP 2005517436-A/466.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 466 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/466
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        685 AUACACAUGACUGAAGGAA 703
              |:|||||:|||:|||||||
Db         19 ATACACATGACTGAAGGAA 1
```

```
RESULT 815
DD201986/c
LOCUS       DD201986                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201986
VERSION     DD201986.1  GI:85656033
KEYWORDS    JP 2005517436-A/467.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 467 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/467
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        703 AGGGAGCUCGUCAUUCCCU 721
              |||||||:||:||::|||:
Db         19 AGGGAGCTCGTCATTCCCT 1
```

```
RESULT 816
DD201987/c
LOCUS       DD201987                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201987
VERSION     DD201987.1  GI:85656034
KEYWORDS    JP 2005517436-A/468.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 468 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/468
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 UGCCGGGUUACGUCACCUA 739
              :||||||::|||:||||:|
Db         19 TGCCGGGTTACGTCACCTA 1
```

```
RESULT 817
DD201988/c
LOCUS       DD201988                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201988
VERSION     DD201988.1  GI:85656035
KEYWORDS    JP 2005517436-A/469.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 469 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/469
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        739 AACAUCACUGUUACUUUAA 757
              ||||:|||:|::||:::||
Db         19 AACATCACTGTTACTTTAA 1


RESULT 818
DD201989/c
LOCUS       DD201989                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201989
VERSION     DD201989.1  GI:85656036
KEYWORDS    JP 2005517436-A/470.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 470 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/470
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        757 AAAAAGUUUCCACUUGACA 775
              ||||||:::||||::||||
Db         19 AAAAAGTTTCCACTTGACA 1


RESULT 819
DD201990/c
LOCUS       DD201990                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201990
VERSION     DD201990.1  GI:85656037
KEYWORDS    JP 2005517436-A/471.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 471 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/471
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        775 ACUUUGAUCCCUGAUGGAA 793
              ||:::||:|||:||:||||
Db         19 ACTTTGATCCCTGATGGAA 1


RESULT 820
DD201991/c
LOCUS       DD201991                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
          Expression Using Short Interfering RNA.
ACCESSION   DD201991
VERSION     DD201991.1  GI:85656038
KEYWORDS    JP 2005517436-A/472.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 472 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/472
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        793 AAACGCAUAAUCUGGGACA 811
              |||||||:||:|:||||||
Db         19 AAACGCATAATCTGGGACA 1


RESULT 821
DD201992/c
LOCUS       DD201992                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201992
VERSION     DD201992.1  GI:85656039
KEYWORDS    JP 2005517436-A/473.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 473 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/473
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        811 AGUAGAAAGGGCUUCAUCA 829
              ||:||||||||::||:||
Db         19 AGTAGAAAGGGCTTCATCA 1


RESULT 822
DD201993/c
LOCUS       DD201993                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201993
VERSION     DD201993.1  GI:85656040
KEYWORDS    JP 2005517436-A/474.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 474 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/474
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        829 AUAUCAAAUGCAACGUACA 847
              |:|:||||:||||||:|||
Db         19 ATATCAAATGCAACGTACA 1


RESULT 823
DD201994/c
LOCUS       DD201994                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201994
VERSION     DD201994.1  GI:85656041
KEYWORDS    JP 2005517436-A/475.
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 475 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/475
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAAGAAAUAGGGCUUCUGA 865
              |||||||:|||||::|:||
Db         19 AAAGAAATAGGGCTTCTGA 1


RESULT 824
DD201995/c
LOCUS       DD201995                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201995
VERSION     DD201995.1  GI:85656042
KEYWORDS    JP 2005517436-A/476.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 476 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/476
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        865 ACCUGUGAAGCAACAGUCA 883
              |||:|:||||||||||:||
Db         19 ACCTGTGAAGCAACAGTCA 1


RESULT 825
DD201996/c
LOCUS       DD201996                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201996
VERSION     DD201996.1  GI:85656043
KEYWORDS    JP 2005517436-A/477.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 477 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/477
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        883 AAUGGGCAUUUGUAUAAGA 901
              ||:|||||:::|:|:||||
Db         19 AATGGGCATTTGTATAAGA 1


RESULT 826
DD201997/c
LOCUS       DD201997                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201997
VERSION     DD201997.1  GI:85656044
KEYWORDS    JP 2005517436-A/478.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 478 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/478
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        901 ACAAACUAUCUCACACAUC 919
              ||||||:|:|:||||||:|
Db         19 ACAAACTATCTCACACATC 1


RESULT 827
DD201998/c
LOCUS       DD201998                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201998
VERSION     DD201998.1  GI:85656045
KEYWORDS    JP 2005517436-A/479.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 479 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/479
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        919 CGACAAACCAAUACAAUCA 937
              ||||||||||:||||:||
Db         19 CGACAAACCAATACAATCA 1


RESULT 828
DD201999/c
LOCUS       DD201999                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD201999
VERSION     DD201999.1  GI:85656046
KEYWORDS    JP 2005517436-A/480.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 480 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/480
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        937 AUAGAUGUCCAAAUAAGCA 955
              |:|||:|:|||||:|||||
Db         19 ATAGATGTCCAAATAAGCA 1


RESULT 829
DD202000/c
LOCUS       DD202000                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202000
VERSION     DD202000.1  GI:85656047
KEYWORDS    JP 2005517436-A/481.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 481 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
```

```
            PN   JP 2005517436-A/481
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        955 ACACCACGCCCAGUCAAAU 973
              ||||||||||||:||||:
Db         19 ACACCACGCCCAGTCAAAT 1


RESULT 830
DD202001/c
LOCUS       DD202001                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202001
VERSION     DD202001.1  GI:85656048
KEYWORDS    JP 2005517436-A/482.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 482 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/482
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        973 UUACUUAGAGGCCAUACUC 991
              ::||::||||||||:||:|
Db         19 TTACTTAGAGGCCATACTC 1


RESULT 831
DD202002/c
LOCUS       DD202002                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202002
VERSION     DD202002.1  GI:85656049
KEYWORDS    JP 2005517436-A/483.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 483 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/483
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        991 CUUGUCCUCAAUUGUACUG 1009
              |::|:||:|||::|:||:|
Db         19 CTTGTCCTCAATTGTACTG 1


RESULT 832
DD202003/c
LOCUS       DD202003                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202003
VERSION     DD202003.1  GI:85656050
KEYWORDS    JP 2005517436-A/484.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 484 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/484
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
```

05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1009 GCUACCACUCCCUUGAACA 1027
||:|||||:|||::|||||
Db 19 GCTACCACTCCCTTGAACA 1

RESULT 833
DD202004/c
LOCUS DD202004 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202004
VERSION DD202004.1 GI:85656051
KEYWORDS JP 2005517436-A/485.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 485 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/485
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1027 ACGAGAGUUCAAAUGACCU 1045
|||||||::||||:|||||:
Db 19 ACGAGAGTTCAAATGACCT 1

RESULT 834
DD202005/c
LOCUS DD202005 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202005
VERSION DD202005.1 GI:85656052
KEYWORDS JP 2005517436-A/486.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 486 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/486
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1045 UGGAGUUACCCUGAUGAAA 1063
:||||::||||:||:||||
Db 19 TGGAGTTACCCTGATGAAA 1

RESULT 835
DD202006/c
LOCUS DD202006 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202006
VERSION DD202006.1 GI:85656053
KEYWORDS JP 2005517436-A/487.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 487 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/487
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of

```
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1063 AAAAAUAAGAGAGCUUCCG 1081
              |||||:||||||||::|||
Db         19 AAAAATAAGAGAGCTTCCG 1


RESULT 836
DD202007/c
LOCUS       DD202007                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202007
VERSION     DD202007.1  GI:85656054
KEYWORDS    JP 2005517436-A/488.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 488 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/488
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1081 GUAAGGCGACGAAUUGACC 1099
              |:|||||||||||::||||
Db         19 GTAAGGCGACGAATTGACC 1


RESULT 837
DD202008/c
LOCUS       DD202008                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202008
VERSION     DD202008.1  GI:85656055
KEYWORDS    JP 2005517436-A/489.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 489 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/489
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1099 CAAAGCAAUUCCCAUGCCA 1117
              ||||||||::||||:||||
Db         19 CAAAGCAATTCCCATGCCA 1


RESULT 838
DD202009/c
LOCUS       DD202009                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202009
VERSION     DD202009.1  GI:85656056
KEYWORDS    JP 2005517436-A/490.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 490 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/490
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
```

```
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1117 AACAUAUUCUACAGUGUUC 1135
              ||||:|::|:||||:|::|
Db         19 AACATATTCTACAGTGTTC 1


RESULT 839
DD202010/c
LOCUS       DD202010                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202010
VERSION     DD202010.1  GI:85656057
KEYWORDS    JP 2005517436-A/491.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 491 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/491
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR.
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1135 CUUACUAUUGACAAAAUGC 1153
              |::||:|::|||||||:||
Db         19 CTTACTATTGACAAAATGC 1


RESULT 840
DD202011/c
LOCUS       DD202011                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202011
VERSION     DD202011.1  GI:85656058
KEYWORDS    JP 2005517436-A/492.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 492 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/492
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1153 CAGAACAAAGACAAAGGAC 1171
              |||||||||||||||||||
Db         19 CAGAACAAAGACAAAGGAC 1


RESULT 841
DD202012/c
LOCUS       DD202012                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202012
VERSION     DD202012.1  GI:85656059
KEYWORDS    JP 2005517436-A/493.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 493 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/493
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
```

```
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1171 CUUUAUACUUGUCGUGUAA 1189
              |:::|:||::|:||:|:||
Db         19 CTTTATACTTGTCGTGTAA 1


RESULT 842
DD202013/c
LOCUS       DD202013                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202013
VERSION     DD202013.1  GI:85656060
KEYWORDS    JP 2005517436-A/494.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 494 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/494
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1189 AGGAGUGGACCAUCAUUCA 1207
              |||||:||||||:||::||
Db         19 AGGAGTGGACCATCATTCA 1


RESULT 843
DD202014/c
LOCUS       DD202014                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202014
VERSION     DD202014.1  GI:85656061
KEYWORDS    JP 2005517436-A/495.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 495 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/495
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1207 AAAUCUGUUAACACCUCAG 1225
              |||:|:|::||||||:|||
Db         19 AAATCTGTTAACACCTCAG 1


RESULT 844
DD202015/c
LOCUS       DD202015                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202015
VERSION     DD202015.1  GI:85656062
KEYWORDS    JP 2005517436-A/496.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 496 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/496
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1225 GUGCAUAUAUAUGAUAAAG 1243
              |:|||:|:|:|:||:||||
Db         19 GTGCATATATATGATAAAG 1
```

```
RESULT 845
DD202016/c
LOCUS       DD202016                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202016
VERSION     DD202016.1  GI:85656063
KEYWORDS    JP 2005517436-A/497.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 497 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/497
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1243 GCAUUCAUCACUGUGAAAC 1261
              |||::||:|||:|:|||||
Db         19 GCATTCATCACTGTGAAAC 1


RESULT 846
DD202017/c
LOCUS       DD202017                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202017
VERSION     DD202017.1  GI:85656064
KEYWORDS    JP 2005517436-A/498.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 498 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/498
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1261 CAUCGAAAACAGCAGGUGC 1279
              ||:|||||||||||||:||
Db         19 CATCGAAAACAGCAGGTGC 1


RESULT 847
DD202018/c
LOCUS       DD202018                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202018
VERSION     DD202018.1  GI:85656065
KEYWORDS    JP 2005517436-A/499.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 499 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/499
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1279 CUUGAAACCGUAGCUGGCA 1297
              |::|||||||:|||:||||
Db         19 CTTGAAACCGTAGCTGGCA 1


RESULT 848
DD202019/c
LOCUS       DD202019                19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202019
VERSION     DD202019.1  GI:85656066
KEYWORDS    JP 2005517436-A/500.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 500 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/500
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1297 AAGCGGUCUUACCGGCUCU 1315
              ||||||:|::||||||:|:
Db         19 AAGCGGTCTTACCGGCTCT 1


RESULT 849
DD202020/c
LOCUS       DD202020                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202020
VERSION     DD202020.1  GI:85656067
KEYWORDS    JP 2005517436-A/501.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 501 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/501
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1315 UCUAUGAAAGUGAAGGCAU 1333
              :|:|:|||||:|||||||:
Db         19 TCTATGAAAGTGAAGGCAT 1


RESULT 850
DD202021/c
LOCUS       DD202021                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202021
VERSION     DD202021.1  GI:85656068
KEYWORDS    JP 2005517436-A/502.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 502 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/502
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1333 UUUCCCUCGCCGGAAGUUG 1351
              :::|||:||||||||::|
Db         19 TTTCCCTCGCCGGAAGTTG 1


RESULT 851
DD202022/c
LOCUS       DD202022                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202022
VERSION     DD202022.1  GI:85656069
```

```
KEYWORDS    JP 2005517436-A/503.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 503 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/503
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1351 GUAUGGUUAAAAGAUGGGU 1369
              |:|:||::||||||:|||:
Db         19 GTATGGTTAAAAGATGGGT 1


RESULT 852
DD202023/c
LOCUS       DD202023                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202023
VERSION     DD202023.1  GI:85656070
KEYWORDS    JP 2005517436-A/504.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 504 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/504
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1369 UUACCUGCGACUGAGAAAU 1387
              ::|||:|||||:||||||:
Db         19 TTACCTGCGACTGAGAAAT 1


RESULT 853
DD202024/c
LOCUS       DD202024                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202024
VERSION     DD202024.1  GI:85656071
KEYWORDS    JP 2005517436-A/505.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 505 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/505
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1387 UCUGCUCGCUAUUUGACUC 1405
              :|:||:|||:|:::|||:|
Db         19 TCTGCTCGCTATTTGACTC 1


RESULT 854
DD202025/c
LOCUS       DD202025                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202025
VERSION     DD202025.1  GI:85656072
KEYWORDS    JP 2005517436-A/506.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 506 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/506
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1405 CGUGGCUACUCGUUAAUUA 1423
              ||:|||:||:||::||::|
Db         19 CGTGGCTACTCGTTAATTA 1


RESULT 855
DD202026/c
LOCUS       DD202026                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202026
VERSION     DD202026.1  GI:85656073
KEYWORDS    JP 2005517436-A/507.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 507 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/507
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1423 AUCAAGGACGUAACUGAAG 1441
              |:||||||||:|||:||||
Db         19 ATCAAGGACGTAACTGAAG 1


RESULT 856
DD202027/c
LOCUS       DD202027                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202027
VERSION     DD202027.1  GI:85656074
KEYWORDS    JP 2005517436-A/508.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 508 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/508
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1441 GAGGAUGCAGGGAAUUAUA 1459
              |||||:||||||||::|:|
Db         19 GAGGATGCAGGGAATTATA 1


RESULT 857
DD202028/c
LOCUS       DD202028                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202028
VERSION     DD202028.1  GI:85656075
KEYWORDS    JP 2005517436-A/509.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 509 16-JUN-2005;
```

```
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/509
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1459 ACAAUCUUGCUGAGCAUAA 1477
              ||||:|::||:|||||:||
Db         19 ACAATCTTGCTGAGCATAA 1


RESULT 858
DD202029/c
LOCUS       DD202029                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202029
VERSION     DD202029.1  GI:85656076
KEYWORDS    JP 2005517436-A/510.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 510 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/510
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1477 AAACAGUCAAAUGUGUUUA 1495
              ||||||:||||:|:|:::|
Db         19 AAACAGTCAAATGTGTTTA 1


RESULT 859
DD202030/c
LOCUS       DD202030                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202030
VERSION     DD202030.1  GI:85656077
KEYWORDS    JP 2005517436-A/511.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 511 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/511
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1495 AAAAACCUCACUGCCACUC 1513
              |||||||:|||:|||||:|
Db         19 AAAAACCTCACTGCCACTC 1


RESULT 860
DD202031/c
LOCUS       DD202031                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202031
VERSION     DD202031.1  GI:85656078
KEYWORDS    JP 2005517436-A/512.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 512 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/512
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
```

```
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1513 CUAAUUGUCAAUGUGAAAC 1531
              |:||::|:|||:|:|||||                  o
Db         19 CTAATTGTCAATGTGAAAC 1


RESULT 861
DD202032/c
LOCUS       DD202032                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202032
VERSION     DD202032.1  GI:85656079
KEYWORDS    JP 2005517436-A/513.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 513 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/513
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1531 CCCCAGAUUUACGAAAAGG 1549
              |||||||:::|||||||||
Db         19 CCCCAGATTTACGAAAAGG 1


RESULT 862
DD202033/c
LOCUS       DD202033                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202033
VERSION     DD202033.1  GI:85656080
KEYWORDS    JP 2005517436-A/514.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 514 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/514
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1549 GCCGUGUCAUCGUUUCCAG 1567
              ||||:|:||:||:::||||
Db         19 GCCGTGTCATCGTTTCCAG 1


RESULT 863
DD202034/c
LOCUS       DD202034                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202034
VERSION     DD202034.1  GI:85656081
KEYWORDS    JP 2005517436-A/515.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 515 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/515
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
```

```
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19; .
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1567 GACCCGGCUCUCUACCCAC 1585
              ||||||||:|:|:||||||
Db         19 GACCCGGCTCTCTACCCAC 1


RESULT 864
DD202035/c
LOCUS       DD202035                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202035
VERSION     DD202035.1  GI:85656082
KEYWORDS    JP 2005517436-A/516.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 516 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/516
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 CUGGGCAGCAGACAAAUCC 1603
              |:|||||||||||||||:||
Db         19 CTGGGCAGCAGACAAATCC 1


RESULT 865
DD202036/c
LOCUS       DD202036                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202036
VERSION     DD202036.1  GI:85656083
KEYWORDS    JP 2005517436-A/517.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 517 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/517
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers..
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1603 CUGACUUGUACCGCAUAUG 1621
              |:|||::|:||||||:|:|
Db         19 CTGACTTGTACCGCATATG 1


RESULT 866
DD202037/c
LOCUS       DD202037                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202037
VERSION     DD202037.1  GI:85656084
KEYWORDS    JP 2005517436-A/518.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 518 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/518
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
```

```
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1621 GGUAUCCCUCAACCUACAA 1639
              ||:|:|||:|||||:||||
Db         19 GGTATCCCTCAACCTACAA 1


RESULT 867
DD202038/c
LOCUS       DD202038                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202038
VERSION     DD202038.1  GI:85656085
KEYWORDS    JP 2005517436-A/519.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 519 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/519
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1639 AUCAAGUGGUUCUGGCACC 1657
              |:||||:||::|:||||||
Db         19 ATCAAGTGGTTCTGGCACC 1


RESULT 868
DD202039/c
LOCUS       DD202039                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202039
VERSION     DD202039.1  GI:85656086
KEYWORDS    JP 2005517436-A/520.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 520 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/520
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1657 CCCUGUAACCAUAAUCAUU 1675
              |||:|:|||||:||:||::
Db         19 CCCTGTAACCATAATCATT 1


RESULT 869
DD202040/c
LOCUS       DD202040                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202040
VERSION     DD202040.1  GI:85656087
KEYWORDS    JP 2005517436-A/521.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 521 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/521
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1675 UCCGAAGCAAGGUGUGACU 1693
              :||||||||||:|:|||:
Db         19 TCCGAAGCAAGGTGTGACT 1


RESULT 870
DD202041/c
LOCUS       DD202041                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202041
VERSION     DD202041.1  GI:85656088
KEYWORDS    JP 2005517436-A/522.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 522 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/522
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1693 UUUUGUUCCAAUAAUGAAG 1711
              ::::|::||||:||:||||
Db         19 TTTTGTTCCAATAATGAAG 1


RESULT 871
DD202042/c
LOCUS       DD202042                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202042
VERSION     DD202042.1  GI:85656089
KEYWORDS    JP 2005517436-A/523.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 523 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/523
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1711 GAGUCCUUUAUCCUGGAUG 1729
              |||:||:::|:||:|||:|
Db         19 GAGTCCTTTATCCTGGATG 1


RESULT 872
DD202043/c
LOCUS       DD202043                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202043
VERSION     DD202043.1  GI:85656090
KEYWORDS    JP 2005517436-A/524.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 524 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/524
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1729 GCUGACAGCAACAUGGGAA 1747
```

```
                ||:||||||||||:|||||
Db         19 GCTGACAGCAACATGGGAA 1


RESULT 873
DD202044/c
LOCUS       DD202044                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202044
VERSION     DD202044.1  GI:85656091
KEYWORDS    JP 2005517436-A/525.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 525 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/525
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 AACAGAAUUGAGAGCAUCA 1765
              |||||||::|||||||:||
Db         19 AACAGAATTGAGAGCATCA 1


RESULT 874
DD202045/c
LOCUS       DD202045                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202045
VERSION     DD202045.1  GI:85656092
KEYWORDS    JP 2005517436-A/526.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 526 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/526
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1765 ACUCAGCGCAUGGCAAUAA 1783
              ||:|||||||:|||||:||
Db         19 ACTCAGCGCATGGCAATAA 1


RESULT 875
DD202046/c
LOCUS       DD202046                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202046
VERSION     DD202046.1  GI:85656093
KEYWORDS    JP 2005517436-A/527.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 527 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/527
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AUAGAAGGAAAGAAUAAGA 1801
              |:|||||||||||||:||||
Db         19 ATAGAAGGAAAGAATAAGA 1


RESULT 876
```

```
DD202047/c
LOCUS       DD202047                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202047
VERSION     DD202047.1  GI:85656094
KEYWORDS    JP 2005517436-A/528.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 528 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/528
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1801 AUGGCUAGCACCUUGGUUG 1819
              |:|||:||||||::||::|
Db         19 ATGGCTAGCACCTTGGTTG 1


RESULT 877
DD202048/c
LOCUS       DD202048                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202048
VERSION     DD202048.1  GI:85656095
KEYWORDS    JP 2005517436-A/529.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 529 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/529
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1819 GUGGCUGACUCUAGAAUUU 1837
              |:|||:|||:|:||||:::
Db         19 GTGGCTGACTCTAGAATTT 1


RESULT 878
DD202049/c
LOCUS       DD202049                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202049
VERSION     DD202049.1  GI:85656096
KEYWORDS    JP 2005517436-A/530.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 530 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/530
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1837 UCUGGAAUCUACAUUUGCA 1855
              :|:||||:|:|||:::|||
Db         19 TCTGGAATCTACATTTGCA 1


RESULT 879
DD202050/c
LOCUS       DD202050                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
```

```
ACCESSION   DD202050
VERSION     DD202050.1  GI:85656097
KEYWORDS    JP 2005517436-A/531.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 531 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/531
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1855 AUAGCUUCCAAUAAAGUUG 1873
              |:|||::||||:||||::|
Db         19 ATAGCTTCCAATAAAGTTG 1


RESULT 880
DD202051/c
LOCUS       DD202051                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202051
VERSION     DD202051.1  GI:85656098
KEYWORDS    JP 2005517436-A/532.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 532 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/532
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1873 GGGACUGUGGGAAGAAACA 1891
              |||||:|:||||||||||||
Db         19 GGGACTGTGGGAAGAAACA 1


RESULT 881
DD202052/c
LOCUS       DD202052                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202052
VERSION     DD202052.1  GI:85656300
KEYWORDS    JP 2005517436-A/533.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 533 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/533
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,jamès mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1891 AUAAGCUUUUAUAUCACAG 1909
              |:||||::::|:|:|||||
Db         19 ATAAGCTTTTATATCACAG 1


RESULT 882
DD202053/c
LOCUS       DD202053                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202053
VERSION     DD202053.1  GI:85656500
KEYWORDS    JP 2005517436-A/534.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 534 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/534
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1909 GAUGUGCCAAAUGGGUUUC 1927
              ||:|:||||||:|||:::|
Db         19 GATGTGCCAAATGGGTTTC 1


RESULT 883
DD202054/c
LOCUS       DD202054                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202054
VERSION     DD202054.1  GI:85656501
KEYWORDS    JP 2005517436-A/535.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 535 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/535
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1927 CAUGUUAACUUGGAAAAAA 1945
              ||:|::|||::|||||||
Db         19 CATGTTAACTTGGAAAAAA 1


RESULT 884
DD202055/c
LOCUS       DD202055                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202055
VERSION     DD202055.1  GI:85656502
KEYWORDS    JP 2005517436-A/536.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 536 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/536
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1945 AUGCCGACGGAAGGAGAGG 1963
              |:||||||||||||||||||
Db         19 ATGCCGACGGAAGGAGAGG 1


RESULT 885
DD202056/c
LOCUS       DD202056                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202056
VERSION     DD202056.1  GI:85656503
KEYWORDS    JP 2005517436-A/537.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
          Expression Using Short Interfering RNA
  JOURNAL Patent: JP 2005517436-A 537 16-JUN-2005;
          Sirna Therapeutics Inc
COMMENT   OS   Artificial Sequence
          PN   JP 2005517436-A/537
          PD   16-JUN-2005
          PF   20-FEB-2003 JP 2003569803
          PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
          04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
          05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
          20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
          11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
          03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
          beigelman,james mcswiggen,pamela pavco CC   Description of
          Artificial Sequence:  siNA antisense region FH   Key
          Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1963 GACCUGAAACUGUCUUGCA 1981
              ||||:|||||:|:|::|||
Db         19 GACCTGAAACTGTCTTGCA 1


RESULT 886
DD202057/c
LOCUS       DD202057                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202057
VERSION     DD202057.1  GI:85656504
KEYWORDS    JP 2005517436-A/538.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 538 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/538
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 ACAGUUAACAAGUUCUUAU 1999
              ||||::||||||::|::|:
Db         19 ACAGTTAACAAGTTCTTAT 1


RESULT 887
DD202058/c
LOCUS       DD202058                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202058
VERSION     DD202058.1  GI:85656505
KEYWORDS    JP 2005517436-A/539.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 539 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/539
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1999 UACAGAGACGUUACUUGGA 2017
              :|||||||||::||::|||
Db         19 TACAGAGACGTTACTTGGA 1


RESULT 888
DD202059/c
LOCUS       DD202059                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202059
VERSION     DD202059.1  GI:85656506
KEYWORDS    JP 2005517436-A/540.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 540 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/540
```

```
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2017 AUUUUACUGCGGACAGUUA 2035
              |::::||:||||||||::|
Db         19 ATTTTACTGCGGACAGTTA 1


RESULT 889
DD202060/c
LOCUS       DD202060                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202060
VERSION     DD202060.1  GI:85656507
KEYWORDS    JP 2005517436-A/541.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 541 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/541
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2035 AAUAACAGAACAAUGCACU 2053
              ||:||||||||||:||||:
Db         19 AATAACAGAACAATGCACT 1


RESULT 890
DD202061/c
LOCUS       DD202061                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202061
VERSION     DD202061.1  GI:85656508
KEYWORDS    JP 2005517436-A/542.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 542 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/542
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2053 UACAGUAUUAGCAAGCAAA 2071
              :||||:|::||||||||||
Db         19 TACAGTATTAGCAAGCAAA 1


RESULT 891
DD202062/c
LOCUS       DD202062                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202062
VERSION     DD202062.1  GI:85656509
KEYWORDS    JP 2005517436-A/543.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 543 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/543
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
```

```
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2071 AAAAUGGCCAUCACUAAGG 2089
              ||||:|||||:|||:||||
Db         19 AAAATGGCCATCACTAAGG 1


RESULT 892
DD202063/c
LOCUS       DD202063                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202063
VERSION     DD202063.1  GI:85656510
KEYWORDS    JP 2005517436-A/544.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 544 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/544
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2089 GAGCACUCCAUCACUCUUA 2107
              ||||||:|||:|||:|::|
Db         19 GAGCACTCCATCACTCTTA 1


RESULT 893
DD202064/c
LOCUS       DD202064                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202064
VERSION     DD202064.1  GI:85656511
KEYWORDS    JP 2005517436-A/545.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 545 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/545
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2107 AAUCUUACCAUCAUGAAUG 2125
              ||:|::||||:||:|||:|
Db         19 AATCTTACCATCATGAATG 1


RESULT 894
DD202065/c
LOCUS       DD202065                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202065
VERSION     DD202065.1  GI:85656512
KEYWORDS    JP 2005517436-A/546.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 546 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/546
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
```

```
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2125 GUUUCCCUGCAAGAUUCAG 2143
              |:::|||:||||||::|||
Db         19 GTTTCCCTGCAAGATTCAG 1


RESULT 895
DD202066/c
LOCUS       DD202066                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202066
VERSION     DD202066.1  GI:85656513
KEYWORDS    JP 2005517436-A/547.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 547 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/547
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2143 GGCACCUAUGCCUGCAGAG 2161
              ||||||:|:|||:||||||
Db         19 GGCACCTATGCCTGCAGAG 1


RESULT 896
DD202067/c
LOCUS       DD202067                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202067
VERSION     DD202067.1  GI:85656514
KEYWORDS    JP 2005517436-A/548.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 548 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/548
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match              0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2161 GCCAGGAAUGUAUACACAG 2179
              ||||||||:|:|:||||||
Db         19 GCCAGGAATGTATACACAG 1


RESULT 897
DD202068/c
LOCUS       DD202068                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202068
VERSION     DD202068.1  GI:85656515
KEYWORDS    JP 2005517436-A/549.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 549 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/549
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
```

/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2179 GGGGAAGAAAUCCUCCAGA 2197
              ||||||||||:||:|||||
Db         19 GGGGAAGAAATCCTCCAGA 1
```

RESULT 898
DD202069/c
LOCUS DD202069 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202069
VERSION DD202069.1 GI:85656516
KEYWORDS JP 2005517436-A/550.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 550 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/550
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2197 AAGAAAGAAAUUACAAUCA 2215
              ||||||||||::||||:||
Db         19 AAGAAAGAAATTACAATCA 1
```

RESULT 899
DD202070/c
LOCUS DD202070 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202070
VERSION DD202070.1 GI:85656517
KEYWORDS JP 2005517436-A/551.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 551 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/551
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2215 AGAGAUCAGGAAGCACCAU 2233
              |||||:||||||||||||:
Db         19 AGAGATCAGGAAGCACCAT 1
```

RESULT 900
DD202071/c
LOCUS DD202071 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202071
VERSION DD202071.1 GI:85656518
KEYWORDS JP 2005517436-A/552.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 552 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/552
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2233 UACCUCCUGCGAAACCUCA 2251
              :|||:||:|||||||||:||
Db         19 TACCTCCTGCGAAACCTCA 1


RESULT 901
DD202072/c
LOCUS       DD202072                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202072
VERSION     DD202072.1  GI:85656519
KEYWORDS    JP 2005517436-A/553.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 553 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/553
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2251 AGUGAUCACACAGUGGCCA 2269
              ||:||:|||||||:|||||
Db         19 AGTGATCACACAGTGGCCA 1


RESULT 902
DD202073/c
LOCUS       DD202073                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202073
VERSION     DD202073.1  GI:85656520
KEYWORDS    JP 2005517436-A/554.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 554 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/554
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2269 AUCAGCAGUUCCACCACUU 2287
              |:||||||::||||||::
Db         19 ATCAGCAGTTCCACCACTT 1


RESULT 903
DD202074/c
LOCUS       DD202074                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202074
VERSION     DD202074.1  GI:85656521
KEYWORDS    JP 2005517436-A/555.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 555 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/555
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2287 UUAGACUGUCAUGCUAAUG 2305
              ::||||:|:||:||:||:|
Db         19 TTAGACTGTCATGCTAATG 1
```

```
RESULT 904
DD202075/c
LOCUS       DD202075                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202075
VERSION     DD202075.1  GI:85656522
KEYWORDS    JP 2005517436-A/556.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 556 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/556
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GGUGUCCCCGAGCCUCAGA 2323
              ||:|:||||||||||:||||
Db         19 GGTGTCCCCGAGCCTCAGA 1


RESULT 905
DD202076/c
LOCUS       DD202076                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202076
VERSION     DD202076.1  GI:85656523
KEYWORDS    JP 2005517436-A/557.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 557 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/557
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2323 AUCACUUGGUUUAAAAACA 2341
              |:|||::||:::|||||||
Db         19 ATCACTTGGTTTAAAAACA 1


RESULT 906
DD202077/c
LOCUS       DD202077                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202077
VERSION     DD202077.1  GI:85656524
KEYWORDS    JP 2005517436-A/558.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 558 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/558
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2341 AACCACAAAAUACAACAAG 2359
              ||||||||||:||||||||
Db         19 AACCACAAAATACAACAAG 1


RESULT 907
DD202078/c
LOCUS       DD202078                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202078
VERSION DD202078.1 GI:85656525
KEYWORDS JP 2005517436-A/559.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 559 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/559
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR 04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR 05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR 20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR 11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR 03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2359 GAGCCUGGAAUUAUUUUAG 2377
||||:||||::|::::||
Db 19 GAGCCTGGAATTATTTTAG 1

RESULT 908
DD202079/c
LOCUS DD202079 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202079
VERSION DD202079.1 GI:85656526
KEYWORDS JP 2005517436-A/560.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 560 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/560
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR 04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR 05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR 20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR 11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR 03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2377 GGACCAGGAAGCAGCACGC 2395
||||||||||||||||||
Db 19 GGACCAGGAAGCAGCACGC 1

RESULT 909
DD202080/c
LOCUS DD202080 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202080
VERSION DD202080.1 GI:85656527
KEYWORDS JP 2005517436-A/561.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 561 16-JUN-2005; Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/561
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR 04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR 05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR 20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR 11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR 03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2395 CUGUUUAUUGAAAGAGUCA 2413
|:|:::|::|||||||:||
Db 19 CTGTTTATTGAAAGAGTCA 1

RESULT 910
DD202081/c
LOCUS DD202081 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202081
VERSION DD202081.1 GI:85656528
KEYWORDS JP 2005517436-A/562.

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 562 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/562
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2413 ACAGAAGAGGAUGAAGGUG 2431
              ||||||||||:|||||:|
Db         19 ACAGAAGAGGATGAAGGTG 1


RESULT 911
DD202082/c
LOCUS       DD202082                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202082
VERSION     DD202082.1  GI:85656529
KEYWORDS    JP 2005517436-A/563.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 563 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/563
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2431 GUCUAUCACUGCAAAGCCA 2449
              |:|:|:|||:|||||||||
Db         19 GTCTATCACTGCAAAGCCA 1


RESULT 912
DD202083/c
LOCUS       DD202083                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202083
VERSION     DD202083.1  GI:85656530
KEYWORDS    JP 2005517436-A/564.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 564 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/564
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2449 ACCAACCAGAAGGGCUCUG 2467
              |||||||||||||||:|:|
Db         19 ACCAACCAGAAGGGCTCTG 1


RESULT 913
DD202084/c
LOCUS       DD202084                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202084
VERSION     DD202084.1  GI:85656531
KEYWORDS    JP 2005517436-A/565.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
```

```
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 565 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/565
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2467 GUGGAAAGUUCAGCAUACC 2485
              |:||||||::|||||:|||
Db         19 GTGGAAAGTTCAGCATACC 1


RESULT 914
DD202085/c
LOCUS       DD202085                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202085
VERSION     DD202085.1  GI:85656532
KEYWORDS    JP 2005517436-A/566.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 566 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/566
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2485 CUCACUGUUCAAGGAACCU 2503
              |:|||:|::|||||||||:
Db         19 CTCACTGTTCAAGGAACCT 1


RESULT 915
DD202086/c
LOCUS       DD202086                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202086
VERSION     DD202086.1  GI:85656533
KEYWORDS    JP 2005517436-A/567.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 567 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/567
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2503 UCGGACAAGUCUAAUCUGG 2521
              :|||||||:|:||:|:||
Db         19 TCGGACAAGTCTAATCTGG 1


RESULT 916
DD202087/c
LOCUS       DD202087                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202087
VERSION     DD202087.1  GI:85656534
KEYWORDS    JP 2005517436-A/568.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 568 16-JUN-2005;
            Sirna Therapeutics Inc
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/568
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2521 GAGCUGAUCACUCUAACAU 2539
              ||||:||:|||:|:||||:
Db         19 GAGCTGATCACTCTAACAT 1


RESULT 917
DD202088/c
LOCUS       DD202088                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202088
VERSION     DD202088.1  GI:85656535
KEYWORDS    JP 2005517436-A/569.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 569 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/569
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2539 UGCACCUGUGUGGCUGCGA 2557
              :|||||:|:|:|||:||||
Db         19 TGCACCTGTGTGGCTGCGA 1


RESULT 918
DD202089/c
LOCUS       DD202089                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202089
VERSION     DD202089.1  GI:85656536
KEYWORDS    JP 2005517436-A/570.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 570 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/570
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2557 ACUCUCUUCUGGCUCCUAU 2575
              ||:|:|::|:|||:||:|:
Db         19 ACTCTCTTCTGGCTCCTAT 1


RESULT 919
DD202090/c
LOCUS       DD202090                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202090
VERSION     DD202090.1  GI:85656537
KEYWORDS    JP 2005517436-A/571.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 571 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/571
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
```

04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2575 UUAACCCUCCUUAUCCGAA 2593
::|||||:||::|:|||||
Db 19 TTAACCCTCCTTATCCGAA 1

RESULT 920
DD202091/c
LOCUS DD202091 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202091
VERSION DD202091.1 GI:85656538
KEYWORDS JP 2005517436-A/572.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 572 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/572
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 2.4e+03;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2593 AAAAUGAAAAGGUCUUCUU 2611
||||:|||||||:|::|::
Db 19 AAAATGAAAAGGTCTTCTT 1

RESULT 921
DD202092/c
LOCUS DD202092 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202092
VERSION DD202092.1 GI:85656539
KEYWORDS JP 2005517436-A/573.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 573 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/573
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2611 UCUGAAAUAAAGACUGACU 2629
:|:||||:||||||:|||:
Db 19 TCTGAAATAAAGACTGACT 1

RESULT 922
DD202093/c
LOCUS DD202093 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202093
VERSION DD202093.1 GI:85656540
KEYWORDS JP 2005517436-A/574.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 574 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/574
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid

beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 2629 UACCUAUCAAUUAUAAUGG 2647
:|||:|:|||::|:||:||
Db 19 TACCTATCAATTATAATGG 1

RESULT 923
DD202094/c
LOCUS DD202094 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202094
VERSION DD202094.1 GI:85656541
KEYWORDS JP 2005517436-A/575.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 575 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/575
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2647 GACCCAGAUGAAGUUCCUU 2665
|||||||:||||::||::
Db 19 GACCCAGATGAAGTTCCTT 1

RESULT 924
DD202095/c
LOCUS DD202095 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202095
VERSION DD202095.1 GI:85656542
KEYWORDS JP 2005517436-A/576.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 576 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/576
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2665 UUGGAUGAGCAGUGUGAGC 2683
::|||:||||||:|:||||
Db 19 TTGGATGAGCAGTGTGAGC 1

RESULT 925
DD202096/c
LOCUS DD202096 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202096
VERSION DD202096.1 GI:85656543
KEYWORDS JP 2005517436-A/577.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 577 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/577
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2683 CGGCUCCCUUAUGAUGCCA 2701
              ||||:|||::|:||:||||
Db         19 CGGCTCCCTTATGATGCCA 1
```

RESULT 926
DD202097/c
LOCUS DD202097 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202097
VERSION DD202097.1 GI:85656544
KEYWORDS JP 2005517436-A/578.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 578 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/578
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2701 AGCAAGUGGGAGUUUGCCC 2719
              ||||||:|||||:::||||
Db         19 AGCAAGTGGGAGTTTGCCC 1
```

RESULT 927
DD202098/c
LOCUS DD202098 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202098
VERSION DD202098.1 GI:85656545
KEYWORDS JP 2005517436-A/579.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 579 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/579
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2719 CGGGAGAGACUUAAACUGG 2737
              ||||||||||::||||:||
Db         19 CGGGAGAGACTTAAACTGG 1
```

RESULT 928
DD202099/c
LOCUS DD202099 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202099
VERSION DD202099.1 GI:85656546
KEYWORDS JP 2005517436-A/580.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 580 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/580
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;

```
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2737 GGCAAAUCACUUGGAAGAG 2755
              ||||||:|||::|||||||
Db         19 GGCAAATCACTTGGAAGAG 1


RESULT 929
DD202100/c
LOCUS       DD202100                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202100
VERSION     DD202100.1  GI:85656547
KEYWORDS    JP 2005517436-A/581.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 581 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/581
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2755 GGGGCUUUUGGAAAAGUGG 2773
              |||||::::|||||||:||
Db         19 GGGGCTTTTGGAAAAGTGG 1


RESULT 930
DD202101/c
LOCUS       DD202101                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202101
VERSION     DD202101.1  GI:85656548
KEYWORDS    JP 2005517436-A/582.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 582 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/582
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2773 GUUCAAGCAUCAGCAUUUG 2791
              |::||||||:|||||:::|
Db         19 GTTCAAGCATCAGCATTTG 1


RESULT 931
DD202102/c
LOCUS       DD202102                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202102
VERSION     DD202102.1  GI:85656549
KEYWORDS    JP 2005517436-A/583.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 583 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/583
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2791 GGCAUUAAGAAAUCACCUA 2809
              ||||::||||||:||||:|
```

```
Db         19 GGCATTAAGAAATCACCTA 1


RESULT 932
DD202103/c
LOCUS       DD202103                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202103
VERSION     DD202103.1  GI:85656550
KEYWORDS    JP 2005517436-A/584.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 584 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/584
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2809 ACGUGCCGGACUGUGGCUG 2827
              |||:|||||||:|:|||:|
Db         19 ACGTGCCGGACTGTGGCTG 1


RESULT 933
DD202104/c
LOCUS       DD202104                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202104
VERSION     DD202104.1  GI:85656551
KEYWORDS    JP 2005517436-A/585.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 585 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/585
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2827 GUGAAAAUGCUGAAAGAGG 2845
              |:|||||:||:||||||||
Db         19 GTGAAAATGCTGAAAGAGG 1


RESULT 934
DD202105/c
LOCUS       DD202105                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202105
VERSION     DD202105.1  GI:85656552
KEYWORDS    JP 2005517436-A/586.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 586 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/586
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2845 GGGGCCACGGCCAGCGAGU 2863
              ||||||||||||||||||:
Db         19 GGGGCCACGGCCAGCGAGT 1


RESULT 935
DD202106/c
```

```
LOCUS       DD202106                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202106
VERSION     DD202106.1  GI:85656553
KEYWORDS    JP 2005517436-A/587.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 587 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/587
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2863 UACAAAGCUCUGAUGACUG 2881
              :|||||||:|:||:|||:|
Db         19 TACAAAGCTCTGATGACTG 1


RESULT 936
DD202107/c
LOCUS       DD202107                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202107
VERSION     DD202107.1  GI:85656554
KEYWORDS    JP 2005517436-A/588.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 588 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/588
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2881 GAGCUAAAAAUCUUGACCC 2899
              ||||:|||||:|::|||||
Db         19 GAGCTAAAAATCTTGACCC 1


RESULT 937
DD202108/c
LOCUS       DD202108                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202108
VERSION     DD202108.1  GI:85656555
KEYWORDS    JP 2005517436-A/589.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 589 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/589
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2899 CACAUUGGCCACCAUCUGA 2917
              ||||::||||||||:|:||
Db         19 CACATTGGCCACCATCTGA 1


RESULT 938
DD202109/c
LOCUS       DD202109                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202109
```

```
VERSION     DD202109.1  GI:85656556
KEYWORDS    JP 2005517436-A/590.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 590 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/590
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2917 AACGUGGUUAACCUGCUGG 2935
              ||||:||::||||:||:||
Db         19 AACGTGGTTAACCTGCTGG 1


RESULT 939
DD202110/c
LOCUS       DD202110                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202110
VERSION     DD202110.1  GI:85656557
KEYWORDS    JP 2005517436-A/591.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 591 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/591
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2935 GGAGCCUGCACCAAGCAAG 2953
              ||||||:|||||||||||||
Db         19 GGAGCCTGCACCAAGCAAG 1


RESULT 940
DD202111/c
LOCUS       DD202111                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202111
VERSION     DD202111.1  GI:85656558
KEYWORDS    JP 2005517436-A/592.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 592 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/592
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2953 GGAGGGCCUCUGAUGGUGA 2971
              ||||||||:|:||:||:||
Db         19 GGAGGGCCTCTGATGGTGA 1


RESULT 941
DD202112/c
LOCUS       DD202112                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202112
VERSION     DD202112.1  GI:85656559
KEYWORDS    JP 2005517436-A/593.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
```

```
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 593 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/593
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2971 AUUGUUGAAUACUGCAAAU 2989
              |::|::|||:||:|||||:
Db         19 ATTGTTGAATACTGCAAAT 1


RESULT 942
DD202113/c
LOCUS       DD202113                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202113
VERSION     DD202113.1  GI:85656560
KEYWORDS    JP 2005517436-A/594.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 594 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/594
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2989 UAUGGAAAUCUCUCCAACU 3007
              :|:|||||:|:|:|||||:
Db         19 TATGGAAATCTCTCCAACT 1


RESULT 943
DD202114/c
LOCUS       DD202114                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202114
VERSION     DD202114.1  GI:85656561
KEYWORDS    JP 2005517436-A/595.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 595 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/595
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3007 UACCUCAAGAGCAAACGUG 3025
              :|||:||||||||||||:|
Db         19 TACCTCAAGAGCAAACGTG 1


RESULT 944
DD202115/c
LOCUS       DD202115                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202115
VERSION     DD202115.1  GI:85656562
KEYWORDS    JP 2005517436-A/596.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
```

```
  JOURNAL   Patent: JP 2005517436-A 596 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/596
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3025 GACUUAUUUUUUCUCAACA 3043
              |||::|:::::::|:|||||
Db         19 GACTTATTTTTTCTCAACA 1


RESULT 945
DD202116/c
LOCUS       DD202116                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202116
VERSION     DD202116.1  GI:85656563
KEYWORDS    JP 2005517436-A/597.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 597 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/597
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3043 AAGGAUGCAGCACUACACA 3061
              |||||:|||||||:|||||
Db         19 AAGGATGCAGCACTACACA 1


RESULT 946
DD202117/c
LOCUS       DD202117                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202117
VERSION     DD202117.1  GI:85656564
KEYWORDS    JP 2005517436-A/598.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 598 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/598
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3061 AUGGAGCCUAAGAAAGAAA 3079
              |:||||||:||||||||||
Db         19 ATGGAGCCTAAGAAAGAAA 1


RESULT 947
DD202118/c
LOCUS       DD202118                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202118
VERSION     DD202118.1  GI:85656565
KEYWORDS    JP 2005517436-A/599.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 599 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/599
            PD   16-JUN-2005
```

```
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 AAAAUGGAGCCAGGCCUGG 3097
              ||||:|||||||||||:||
Db         19 AAAATGGAGCCAGGCCTGG 1


RESULT 948
DD202119/c
LOCUS       DD202119                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202119
VERSION     DD202119.1  GI:85656566
KEYWORDS    JP 2005517436-A/600.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 600 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/600
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3097 GAACAAGGCAAGAAACCAA 3115
              ||||||||||||||||||||
Db         19 GAACAAGGCAAGAAACCAA 1


RESULT 949
DD202120/c
LOCUS       DD202120                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202120
VERSION     DD202120.1  GI:85656567
KEYWORDS    JP 2005517436-A/601.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 601 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/601
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3115 AGACUAGAUAGCGUCACCA 3133
              ||||:|||:||||:|||||
Db         19 AGACTAGATAGCGTCACCA 1


RESULT 950
DD202121/c
LOCUS       DD202121                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202121
VERSION     DD202121.1  GI:85656568
KEYWORDS    JP 2005517436-A/602.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 602 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/602
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
```

11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.4e+03;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3133 AGCAGCGAAAGCUUUGCGA 3151
||||||||||||:::||||
Db 19 AGCAGCGAAAGCTTTGCGA 1

RESULT 951
DD202122/c
LOCUS DD202122 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202122
VERSION DD202122.1 GI:85656569
KEYWORDS JP 2005517436-A/603.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 603 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/603
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3151 AGCUCCGGCUUUCAGGAAG 3169
|||:|||||:::|||||||
Db 19 AGCTCCGGCTTTCAGGAAG 1

RESULT 952
DD202123/c
LOCUS DD202123 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202123
VERSION DD202123.1 GI:85656570
KEYWORDS JP 2005517436-A/604.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 604 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/604
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 2.4e+03;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 3169 GAUAAAAGUCUGAGUGAUG 3187
||:|||||:|:|||:||:|
Db 19 GATAAAAGTCTGAGTGATG 1

RESULT 953
DD202124/c
LOCUS DD202124 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA.
ACCESSION DD202124
VERSION DD202124.1 GI:85656571
KEYWORDS JP 2005517436-A/605.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth
Factor and Vascular Endothelial Growth Factor Receptor Gene
Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 605 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/605
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid
beigelman,james mcswiggen,pamela pavco CC Description of
Artificial Sequence: siNA antisense region FH Key
Location/Qualifiers.

```
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3187 GUUGAGGAAGAGGAGGAUU 3205
              |::|||||||||||||::
Db         19 GTTGAGGAAGAGGAGGATT 1


RESULT 954
DD202125/c
LOCUS       DD202125                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202125
VERSION     DD202125.1  GI:85656572
KEYWORDS    JP 2005517436-A/606.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 606 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/606
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3205 UCUGACGGUUUCUACAAGG 3223
              :|:|||||:::|:||||||
Db         19 TCTGACGGTTTCTACAAGG 1


RESULT 955
DD202126/c
LOCUS       DD202126                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202126
VERSION     DD202126.1  GI:85656573
KEYWORDS    JP 2005517436-A/607.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 607 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/607
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3223 GAGCCCAUCACUAUGGAAG 3241
              |||||||:|||:|:|||||
Db         19 GAGCCCATCACTATGGAAG 1


RESULT 956
DD202127/c
LOCUS       DD202127                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202127
VERSION     DD202127.1  GI:85656574
KEYWORDS    JP 2005517436-A/608.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 608 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/608
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.4e+03;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3241 GAUCUGAUUUCUUACAGUU 3259
              ||:|:||:::|::||||::
Db         19 GATCTGATTTCTTACAGTT 1


RESULT 957
DD202128/c
LOCUS       DD202128                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202128
VERSION     DD202128.1  GI:85656575
KEYWORDS    JP 2005517436-A/609.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 609 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/609
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 UUUCAAGUGGCCAGAGGCA 3277
              :::||||:||||||||||||
Db         19 TTTCAAGTGGCCAGAGGCA 1


RESULT 958
DD202129/c
LOCUS       DD202129                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202129
VERSION     DD202129.1  GI:85656576
KEYWORDS    JP 2005517436-A/610.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 610 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/610
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3277 AUGGAGUUCCUGUCUUCCA 3295
              |:||||::||:|:|::|||
Db         19 ATGGAGTTCCTGTCTTCCA 1


RESULT 959
DD202130/c
LOCUS       DD202130                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202130
VERSION     DD202130.1  GI:85656577
KEYWORDS    JP 2005517436-A/611.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 611 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/611
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3295 AGAAAGUGCAUUCAUCGGG 3313
              ||||||:|||::||:||||
Db         19 AGAAAGTGCATTCATCGGG 1


RESULT 960
DD202131/c
LOCUS       DD202131                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202131
VERSION     DD202131.1  GI:85656578
KEYWORDS    JP 2005517436-A/612.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 612 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/612
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3313 GACCUGGCAGCGAGAAACA 3331
              ||||:|||||||||||||||
Db         19 GACCTGGCAGCGAGAAACA 1


RESULT 961
DD202132/c
LOCUS       DD202132                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202132
VERSION     DD202132.1  GI:85656579
KEYWORDS    JP 2005517436-A/613.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 613 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/613
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3331 AUUCUUUUAUCUGAGAACA 3349
              |::|::::|:|:|||||||
Db         19 ATTCTTTTATCTGAGAACA 1


RESULT 962
DD202133/c
LOCUS       DD202133                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202133
VERSION     DD202133.1  GI:85656580
KEYWORDS    JP 2005517436-A/614.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 614 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/614
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3349 AACGUGGUGAAGAUUUGUG 3367
              ||||:||:|||||:::|:|
Db         19 AACGTGGTGAAGATTTGTG 1
```

```
RESULT 963
DD202134/c
LOCUS       DD202134                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202134
VERSION     DD202134.1  GI:85656581
KEYWORDS    JP 2005517436-A/615.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 615 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/615
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3367 GAUUUUGGCCUUGCCCGGG 3385
              ||::::||||::|||||||
Db         19 GATTTTGGCCTTGCCCGGG 1


RESULT 964
DD202135/c
LOCUS       DD202135                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202135
VERSION     DD202135.1  GI:85656582
KEYWORDS    JP 2005517436-A/616.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 616 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/616
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3385 GAUAUUUAUAAGAACCCCG 3403
              ||:|:::|:||||||||||
Db         19 GATATTTATAAGAACCCCG 1


RESULT 965
DD202136/c
LOCUS       DD202136                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202136
VERSION     DD202136.1  GI:85656583
KEYWORDS    JP 2005517436-A/617.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 617 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/617
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3403 GAUUAUGUGAGAAAAGGAG 3421
              ||::|:|:|||||||||||
Db         19 GATTATGTGAGAAAAGGAG 1


RESULT 966
DD202137/c
LOCUS       DD202137                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
```

```
            Expression Using Short Interfering RNA.
ACCESSION   DD202137
VERSION     DD202137.1  GI:85656584
KEYWORDS    JP 2005517436-A/618.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 618 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/618
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3421 GAUACUCGACUUCCUCUGA 3439
              ||:||:||||::||:|:||
Db         19 GATACTCGACTTCCTCTGA 1


RESULT 967
DD202138/c
LOCUS       DD202138                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202138
VERSION     DD202138.1  GI:85656585
KEYWORDS    JP 2005517436-A/619.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 619 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/619
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3439 AAAUGGAUGGCUCCCGAAU 3457
              |||:|||:|||:||||||:
Db         19 AAATGGATGGCTCCCGAAT 1


RESULT 968
DD202139/c
LOCUS       DD202139                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202139
VERSION     DD202139.1  GI:85656586
KEYWORDS    JP 2005517436-A/620.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 620 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/620
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3457 UCUAUCUUUGACAAAAUCU 3475
              :|:|:|:::|||||||:|:
Db         19 TCTATCTTTGACAAAATCT 1


RESULT 969
DD202140/c
LOCUS       DD202140                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202140
VERSION     DD202140.1  GI:85656587
KEYWORDS    JP 2005517436-A/621.
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 621 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/621
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3475 UACAGCACCAAGAGCGACG 3493
              :||||||||||||||||||
Db         19 TACAGCACCAAGAGCGACG 1


RESULT 970
DD202141/c
LOCUS       DD202141                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202141
VERSION     DD202141.1  GI:85656588
KEYWORDS    JP 2005517436-A/622.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 622 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/622
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3493 GUGUGGUCUUACGGAGUAU 3511
              |:|:||:|::||||||:|:
Db         19 GTGTGGTCTTACGGAGTAT 1


RESULT 971
DD202142/c
LOCUS       DD202142                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202142
VERSION     DD202142.1  GI:85656589
KEYWORDS    JP 2005517436-A/623.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 623 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/623
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.4e+03;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3511 UUGCUGUGGGAAAUCUUCU 3529
              ::||:|:||||||:|::|:
Db         19 TTGCTGTGGGAAATCTTCT 1


RESULT 972
DD202143/c
LOCUS       DD202143                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202143
VERSION     DD202143.1  GI:85656590
KEYWORDS    JP 2005517436-A/624.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
```

```
            Factor ahd Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 624 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/624
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3529 UCCUUAGGUGGGUCUCCAU 3547
              :||::|||:|||:|:|||:
Db         19 TCCTTAGGTGGGTCTCCAT 1


RESULT 973
DD202144/c
LOCUS       DD202144                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202144
VERSION     DD202144.1  GI:85656591
KEYWORDS    JP 2005517436-A/625.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 625 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/625
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3547 UACCCAGGAGUACAAAUGG 3565
              :|||||||||:|||||:||
Db         19 TACCCAGGAGTACAAATGG 1


RESULT 974
DD202145/c
LOCUS       DD202145                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202145
VERSION     DD202145.1  GI:85656592
KEYWORDS    JP 2005517436-A/626.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 626 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/626
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3565 GAUGAGGACUUUUGCAGUC 3583
              ||:||||||::::|||||:|
Db         19 GATGAGGACTTTTGCAGTC 1


RESULT 975
DD202146/c
LOCUS       DD202146                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202146
VERSION     DD202146.1  GI:85656593
KEYWORDS    JP 2005517436-A/627.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 627 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
```

PN JP 2005517436-A/627
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.4e+03;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3583 CGCCUGAGGGAAGGCAUGA 3601
||||:||||||||||:||
Db 19 CGCCTGAGGGAAGGCATGA 1

RESULT 976
DD202147/c
LOCUS DD202147 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202147
VERSION DD202147.1 GI:85656594
KEYWORDS JP 2005517436-A/628.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 628 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/628
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.4e+03;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3601 AGGAUGAGAGCUCCUGAGU 3619
||||:||||||:||:|||:
Db 19 AGGATGAGAGCTCCTGAGT 1

RESULT 977
DD202148/c
LOCUS DD202148 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202148
VERSION DD202148.1 GI:85656595
KEYWORDS JP 2005517436-A/629.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 629 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/629
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR
05-SEP-2002 US 60/408378,29-AUG-2002 US 60/406784, PR
20-FEB-2002 US 60/358580,29-MAY-2002 US T/US02/17674, PR
11-MAR-2002 US 60/363124,06-JUN-2002 US 60/386782, PR
03-JUL-2002 US 60/393796,29-JUL-2002 US 60/399348 PI leonid beigelman,james mcswiggen,pamela pavco CC Description of Artificial Sequence: siNA antisense region FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.4e+03;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3619 UACUCUACUCCUGAAAUCU 3637
:||:|:||:||:||||:|:
Db 19 TACTCTACTCCTGAAATCT 1

RESULT 978
DD202149/c
LOCUS DD202149 19 bp RNA linear PAT 19-JAN-2006
DEFINITION RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA.
ACCESSION DD202149
VERSION DD202149.1 GI:85656596
KEYWORDS JP 2005517436-A/630.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Beigelman,L., Mcswiggen,J. and Pavco,P.
TITLE RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering RNA
JOURNAL Patent: JP 2005517436-A 630 16-JUN-2005;
Sirna Therapeutics Inc
COMMENT OS Artificial Sequence
PN JP 2005517436-A/630
PD 16-JUN-2005
PF 20-FEB-2003 JP 2003569803
PR 15-JAN-2003 US 60/440129,27-NOV-2002 US 10/306747, PR
04-NOV-2002 US 10/287949,09-SEP-2002 US 60/409293, PR

```
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3637 UAUCAGAUCAUGCUGGACU 3655
              :|:||||:||:||:||||:
Db         19 TATCAGATCATGCTGGACT 1


RESULT 979
DD202150/c
LOCUS       DD202150                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202150
VERSION     DD202150.1  GI:85656597
KEYWORDS    JP 2005517436-A/631.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 631 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/631
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 2.4e+03;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3655 UGCUGGCACAGAGACCCAA 3673
              :||:||||||||||||||||
Db         19 TGCTGGCACAGAGACCCAA 1


RESULT 980
DD202151/c
LOCUS       DD202151                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202151
VERSION     DD202151.1  GI:85656598
KEYWORDS    JP 2005517436-A/632.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 632 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/632
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3673 AAAGAAAGGCCAAGAUUUG 3691
              ||||||||||||||:::|
Db         19 AAAGAAAGGCCAAGATTTG 1


RESULT 981
DD202152/c
LOCUS       DD202152                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA.
ACCESSION   DD202152
VERSION     DD202152.1  GI:85656599
KEYWORDS    JP 2005517436-A/633.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
           other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
           Factor and Vascular Endothelial Growth Factor Receptor Gene
           Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 633 16-JUN-2005;
           Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
           PN   JP 2005517436-A/633
           PD   16-JUN-2005
           PF   20-FEB-2003 JP 2003569803
           PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
           04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
           05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
           20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
           11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
           03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
           beigelman,james mcswiggen,pamela pavco CC   Description of
```

```
           Artificial Sequence:  siNA antisense region FH   Key
           Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3691 GCAGAACUUGUGGAAAAAC 3709
              |||||||::|:||||||||
Db         19 GCAGAACTTGTGGAAAAAC 1


RESULT 982
DD202153/c
LOCUS       DD202153                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202153
VERSION     DD202153.1  GI:85656600
KEYWORDS    JP 2005517436-A/634.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 634 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/634
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3709 CUAGGUGAUUUGCUUCAAG 3727
              |:|||:||:::||::||||
Db         19 CTAGGTGATTTGCTTCAAG 1


RESULT 983
DD202154/c
LOCUS       DD202154                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202154
VERSION     DD202154.1  GI:85656601
KEYWORDS    JP 2005517436-A/635.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 635 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/635
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3727 GCAAAUGUACAACAGGAUG 3745
              |||||:|:||||||||:|
Db         19 GCAAATGTACAACAGGATG 1


RESULT 984
DD202155/c
LOCUS       DD202155                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202155
VERSION     DD202155.1  GI:85656602
KEYWORDS    JP 2005517436-A/636.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 636 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/636
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
```

```
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3745 GGUAAAGACUACAUCCCAA 3763
              ||:||||||:|||:|||||
Db         19 GGTAAAGACTACATCCCAA 1


RESULT 985
DD202156/c
LOCUS       DD202156                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202156
VERSION     DD202156.1  GI:85656603
KEYWORDS    JP 2005517436-A/637.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 637 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/637
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3763 AUCAAUGCCAUACUGACAG 3781
              |:|||:||||:||:|||||
Db         19 ATCAATGCCATACTGACAG 1


RESULT 986
DD202157/c
LOCUS       DD202157                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202157
VERSION     DD202157.1  GI:85656604
KEYWORDS    JP 2005517436-A/638.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 638 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/638
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3781 GGAAAUAGUGGGUUUACAU 3799
              |||||:||:|||:::|||:
Db         19 GGAAATAGTGGGTTTACAT 1


RESULT 987
DD202158/c
LOCUS       DD202158                 19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202158
VERSION     DD202158.1  GI:85656605
KEYWORDS    JP 2005517436-A/639.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 639 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/639
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
```

```
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3799 UACUCAACUCCUGCCUUCU 3817
              :||:||||:||:|||::|:
Db         19 TACTCAACTCCTGCCTTCT 1


RESULT 988
DD202159/c
LOCUS       DD202159                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202159
VERSION     DD202159.1  GI:85656606
KEYWORDS    JP 2005517436-A/640.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 640 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/640
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3817 UCUGAGGACUUCUUCAAGG 3835
              :|:||||||::|::|||||
Db         19 TCTGAGGACTTCTTCAAGG 1


RESULT 989
DD202160/c
LOCUS       DD202160                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202160
VERSION     DD202160.1  GI:85656607
KEYWORDS    JP 2005517436-A/641.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 641 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/641
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 2.4e+03;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3835 GAAAGUAUUUCAGCUCCGA 3853
              |||||:|:::||||:||||
Db         19 GAAAGTATTTCAGCTCCGA 1


RESULT 990
DD202161/c
LOCUS       DD202161                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202161
VERSION     DD202161.1  GI:85656608
KEYWORDS    JP 2005517436-A/642.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 642 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/642
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3853 AAGUUUAAUUCAGGAAGCU 3871
              |||:::||::|||||||:
Db         19 AAGTTTAATTCAGGAAGCT 1
```

```
RESULT 991
DD202162/c
LOCUS       DD202162                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202162
VERSION     DD202162.1  GI:85656609
KEYWORDS    JP 2005517436-A/643.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 643 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/643
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3871 UCUGAUGAUGUCAGAUAUG 3889
              :|:||:||:|:||||:|:|
Db         19 TCTGATGATGTCAGATATG 1


RESULT 992
DD202163/c
LOCUS       DD202163                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202163
VERSION     DD202163.1  GI:85656610
KEYWORDS    JP 2005517436-A/644.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 644 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/644
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.4e+03;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3889 GUAAAUGCUUUCAAGUUCA 3907
              |:|||:||:::||||::||
Db         19 GTAAATGCTTTCAAGTTCA 1


RESULT 993
DD202164/c
LOCUS       DD202164                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202164
VERSION     DD202164.1  GI:85656611
KEYWORDS    JP 2005517436-A/645.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 645 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/645
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3907 AUGAGCCUGGAAAGAAUCA 3925
              |:|||||:||||||||:||
Db         19 ATGAGCCTGGAAAGAATCA 1


RESULT 994
DD202165/c
LOCUS       DD202165                  19 bp    RNA     linear   PAT 19-JAN-2006
```

```
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202165
VERSION     DD202165.1  GI:85656612
KEYWORDS    JP 2005517436-A/646.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 646 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/646
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3925 AAAACCUUUGAAGAACUUU 3943
              ||||||:::|||||||:::
Db         19 AAAACCTTTGAAGAACTTT 1


RESULT 995
DD202166/c
LOCUS       DD202166                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202166
VERSION     DD202166.1  GI:85656613
KEYWORDS    JP 2005517436-A/647.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 647 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/647
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3943 UUACCGAAUGCCACCUCCA 3961
              ::||||||:||||||:|||
Db         19 TTACCGAATGCCACCTCCA 1


RESULT 996
DD202167/c
LOCUS       DD202167                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202167
VERSION     DD202167.1  GI:85656614
KEYWORDS    JP 2005517436-A/648.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 648 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/648
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 AUGUUUGAUGACUACCAGG 3979
              |:|:::||:|||:||||||
Db         19 ATGTTTGATGACTACCAGG 1


RESULT 997
DD202168/c
LOCUS       DD202168                19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202168
VERSION     DD202168.1  GI:85656615
```

```
KEYWORDS    JP 2005517436-A/649.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 649 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/649
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.4e+03;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3979 GGCGACAGCAGCACUCUGU 3997
              ||||||||||||||:|:|:
Db         19 GGCGACAGCAGCACTCTGT 1


RESULT 998
DD202169/c
LOCUS       DD202169                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202169
VERSION     DD202169.1  GI:85656616
KEYWORDS    JP 2005517436-A/650.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 650 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/650
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+03;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3997 UUGGCCUCUCCCAUGCUGA 4015
              ::||||:|:||||:||:||
Db         19 TTGGCCTCTCCCATGCTGA 1


RESULT 999
DD202170/c
LOCUS       DD202170                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202170
VERSION     DD202170.1  GI:85656617
KEYWORDS    JP 2005517436-A/651.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 651 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/651
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="synthetic construct"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 2.4e+03;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4015 AAGCGCUUCACCUGGACUG 4033
              ||||||::||||:||||:|
Db         19 AAGCGCTTCACCTGGACTG 1


RESULT 1000
DD202171/c
LOCUS       DD202171                  19 bp    RNA     linear   PAT 19-JAN-2006
DEFINITION  RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA.
ACCESSION   DD202171
VERSION     DD202171.1  GI:85656618
KEYWORDS    JP 2005517436-A/652.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Beigelman,L., Mcswiggen,J. and Pavco,P.
  TITLE     RNA Interference Mediated Inhibition of Vascular Endothelial Growth
            Factor and Vascular Endothelial Growth Factor Receptor Gene
            Expression Using Short Interfering RNA
  JOURNAL   Patent: JP 2005517436-A 652 16-JUN-2005;
            Sirna Therapeutics Inc
COMMENT     OS   Artificial Sequence
            PN   JP 2005517436-A/652
            PD   16-JUN-2005
            PF   20-FEB-2003 JP 2003569803
            PR   15-JAN-2003 US    60/440129,27-NOV-2002 US    10/306747, PR
            04-NOV-2002 US    10/287949,09-SEP-2002 US    60/409293, PR
            05-SEP-2002 US    60/408378,29-AUG-2002 US    60/406784, PR
            20-FEB-2002 US    60/358580,29-MAY-2002 US T/US02/17674, PR
            11-MAR-2002 US    60/363124,06-JUN-2002 US    60/386782, PR
            03-JUL-2002 US    60/393796,29-JUL-2002 US    60/399348 PI   leonid
            beigelman,james mcswiggen,pamela pavco CC   Description of
            Artificial Sequence:  siNA antisense region FH   Key
            Location/Qualifiers.
FEATURES            Location/Qualifiers
     source         1. .19
                    /organism="synthetic construct"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32630"

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2.4e+03;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4033 GACAGCAAACCCAAGGCCU 4051
              ||||||||||||||||||:  .
Db         19 GACAGCAAACCCAAGGCCT 1


Search completed: August 31, 2006, 14:59:14
Job time : 392 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 31, 2006, 14:42:07 ; Search time 41 Seconds
(without alignments)
6.145 Million cell updates/sec

Title: US-10-665-951A-2460
Perfect score: 7680
Sequence: 1 gcggacacuccucucggcuc.....uaaaacauccuguggcacuc 7680

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 722 seqs, 16402 residues

Total number of hits satisfying chosen parameters: 1444

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

EST

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 701 summaries

Database : estdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	40	0.5	40	1	AZ387867	ACCESSION:AZ387867
c	2	40	0.5	40	1	AZ587825	ACCESSION:AZ587825
	3	39	0.5	39	1	AZ418950	ACCESSION:AZ418950
	4	39	0.5	39	1	AZ470417	ACCESSION:AZ470417
	5	39	0.5	39	1	AZ837376	ACCESSION:AZ837376
	6	39	0.5	40	1	AZ305049	ACCESSION:AZ305049
	7	39	0.5	40	1	AZ338857	ACCESSION:AZ338857
	8	39	0.5	40	1	AZ513473	ACCESSION:AZ513473
c	9	38.4	0.5	40	1	AZ603138	ACCESSION:AZ603138
	10	38.4	0.5	40	1	AZ808181	ACCESSION:AZ808181
	11	38	0.5	38	1	AZ326400	ACCESSION:AZ326400
	12	38	0.5	38	1	AZ367342	ACCESSION:AZ367342
	13	38	0.5	38	1	AZ586159	ACCESSION:AZ586159
c	14	38	0.5	38	1	AZ816720	ACCESSION:AZ816720
	15	38	0.5	38	1	AZ968714	ACCESSION:AZ968714
	16	38	0.5	39	1	AZ345520	ACCESSION:AZ345520
	17	38	0.5	39	1	AZ765740	ACCESSION:AZ765740
	18	38	0.5	39	1	AZ947712	ACCESSION:AZ947712
	19	37.4	0.5	39	1	AZ781129	ACCESSION:AZ781129
	20	37	0.5	37	1	AZ308741	ACCESSION:AZ308741
	21	37	0.5	37	1	AZ441623	ACCESSION:AZ441623
	22	37	0.5	37	1	AZ653918	ACCESSION:AZ653918
	23	37	0.5	37	1	AZ995480	ACCESSION:AZ995480
	24	37	0.5	38	1	AZ433034	ACCESSION:AZ433034
c	25	36.8	0.5	40	1	AZ837355	ACCESSION:AZ837355
	26	36.4	0.5	38	1	AZ504337	ACCESSION:AZ504337
	27	36	0.5	36	1	AZ514497	ACCESSION:AZ514497
	28	36	0.5	36	1	AZ766984	ACCESSION:AZ766984
c	29	36	0.5	36	1	AZ939576	ACCESSION:AZ939576
	30	36	0.5	36	1	DR12B17S	ACCESSION:AL747133
	31	36	0.5	37	1	AZ426831	ACCESSION:AZ426831
	32	36	0.5	37	1	AZ826021	ACCESSION:AZ826021
	33	35.8	0.5	39	1	AZ346424	ACCESSION:AZ346424
	34	35.8	0.5	39	1	AZ480184	ACCESSION:AZ480184
	35	35.8	0.5	39	1	AZ974885	ACCESSION:AZ974885
	36	35.8	0.5	40	1	AZ513013	ACCESSION:AZ513013
	37	35.4	0.5	37	1	AZ857946	ACCESSION:AZ857946
c	38	35.4	0.5	37	1	AZ875282	ACCESSION:AZ875282
	39	35.4	0.5	39	1	AZ824420	ACCESSION:AZ824420
	40	35.4	0.5	39	1	AZ826855	ACCESSION:AZ826855
	41	35	0.5	35	1	AZ343541	ACCESSION:AZ343541
	42	35	0.5	35	1	AZ623738	ACCESSION:AZ623738
	43	35	0.5	35	1	AZ643234	ACCESSION:AZ643234
	44	35	0.5	36	1	AZ373001	ACCESSION:AZ373001
	45	35	0.5	36	1	AZ422282	ACCESSION:AZ422282
	46	35	0.5	36	1	AZ579564	ACCESSION:AZ579564
	47	35	0.5	36	1	AZ848143	ACCESSION:AZ848143
	48	35	0.5	39	1	AZ389462	ACCESSION:AZ389462
	49	34.8	0.5	40	1	AZ397262	ACCESSION:AZ397262
	50	34.4	0.4	36	1	AZ411170	ACCESSION:AZ411170
	51	34.4	0.4	36	1	AZ648468	ACCESSION:AZ648468
c	52	34.4	0.4	37	1	AZ346800	ACCESSION:AZ346800
	53	34.4	0.4	37	1	AZ430974	ACCESSION:AZ430974
	54	34.4	0.4	40	1	AZ319970	ACCESSION:AZ319970
	55	34	0.4	34	1	AZ484963	ACCESSION:AZ484963
	56	34	0.4	35	1	AZ612777	ACCESSION:AZ612777
	57	34	0.4	35	1	AZ819087	ACCESSION:AZ819087
	58	33.8	0.4	37	1	AZ456482	ACCESSION:AZ456482
	59	33.8	0.4	37	1	AZ647581	ACCESSION:AZ647581
	60	33.8	0.4	38	1	AZ447539	ACCESSION:AZ447539
	61	33.8	0.4	38	1	AZ803581	ACCESSION:AZ803581
	62	33.6	0.4	40	1	AZ819018	ACCESSION:AZ819018
	63	33.4	0.4	35	1	AZ370273	ACCESSION:AZ370273
c	64	33.4	0.4	35	1	AZ626427	ACCESSION:AZ626427
	65	33.4	0.4	36	1	AZ489673	ACCESSION:AZ489673
	66	33	0.4	33	1	AZ464370	ACCESSION:AZ464370
	67	33	0.4	33	1	AZ594701	ACCESSION:AZ594701
	68	33	0.4	33	1	AZ623603	ACCESSION:AZ623603
	69	33	0.4	33	1	AZ623817	ACCESSION:AZ623817
	70	33	0.4	33	1	AZ817793	ACCESSION:AZ817793
	71	33	0.4	33	1	AZ853249	ACCESSION:AZ853249
	72	33	0.4	34	1	AZ365445	ACCESSION:AZ365445
	73	32.6	0.4	39	1	AZ511942	ACCESSION:AZ511942
	74	32.4	0.4	34	1	AZ509672	ACCESSION:AZ509672
	75	32.4	0.4	38	1	AZ484773	ACCESSION:AZ484773
	76	32	0.4	32	1	AZ307970	ACCESSION:AZ307970
	77	32	0.4	32	1	AZ311840	ACCESSION:AZ311840
	78	32	0.4	32	1	AZ495235	ACCESSION:AZ495235
	79	31.8	0.4	35	1	AZ483942	ACCESSION:AZ483942
	80	31.4	0.4	33	1	BX559884	ACCESSION:BX559884
	81	31.4	0.4	33	1	AZ638769	ACCESSION:AZ638769
	82	31.4	0.4	35	1	AZ613057	ACCESSION:AZ613057
	83	31.2	0.4	36	1	AZ968276	ACCESSION:AZ968276
	84	31	0.4	31	1	BX559875	ACCESSION:BX559875
	85	31	0.4	31	1	AZ459099	ACCESSION:AZ459099
	86	31	0.4	31	1	AZ470636	ACCESSION:AZ470636
	87	31	0.4	31	1	AZ479719	ACCESSION:AZ479719
c	88	31	0.4	31	1	AZ494924	ACCESSION:AZ494924
	89	31	0.4	31	1	AZ666438	ACCESSION:AZ666438
	90	31	0.4	31	1	AZ769716	ACCESSION:AZ769716
c	91	31	0.4	31	1	AZ874102	ACCESSION:AZ874102
c	92	31	0.4	31	1	AZ987243	ACCESSION:AZ987243
c	93	31	0.4	32	1	AZ377767	ACCESSION:AZ377767
	94	31	0.4	33	1	AZ834388	ACCESSION:AZ834388
c	95	30.6	0.4	37	1	AZ991583	ACCESSION:AZ991583
	96	30.4	0.4	32	1	AZ448483	ACCESSION:AZ448483
	97	30.4	0.4	34	1	CD744339	ACCESSION:CD744339
c	98	30.2	0.4	35	1	AZ832583	ACCESSION:AZ832583
	99	30	0.4	30	1	AZ475919	ACCESSION:AZ475919
	100	30	0.4	30	1	AZ809101	ACCESSION:AZ809101
	101	30	0.4	30	1	AZ989744	ACCESSION:AZ989744
	102	30	0.4	32	1	AZ606329	ACCESSION:AZ606329
c	103	29.8	0.4	33	1	AZ514079	ACCESSION:AZ514079
	104	29.8	0.4	35	1	AZ512195	ACCESSION:AZ512195
	105	29.4	0.4	34	1	AZ438581	ACCESSION:AZ438581
c	106	29.2	0.4	35	1	AZ960947	ACCESSION:AZ960947

	107	29	0.4	29	1	AZ315179	ACCESSION:AZ315179
	108	29	0.4	29	1	AZ414401	ACCESSION:AZ414401
	109	29	0.4	29	1	AG189223	ACCESSION:AG189223
	110	29	0.4	30	1	AZ497897	ACCESSION:AZ497897
	111	29	0.4	30	1	AZ635862	ACCESSION:AZ635862
c	112	29	0.4	31	1	AZ628068	ACCESSION:AZ628068
c	113	28.8	0.4	32	1	AZ335085	ACCESSION:AZ335085
	114	28.8	0.4	32	1	AZ661921	ACCESSION:AZ661921
	115	28.4	0.4	30	1	AZ412174	ACCESSION:AZ412174
c	116	28.4	0.4	30	1	AZ458713	ACCESSION:AZ458713
c	117	28.4	0.4	30	1	TA7A12P	ACCESSION:AL452578
	118	28.4	0.4	31	1	AZ399554	ACCESSION:AZ399554
	119	28.4	0.4	31	1	AZ440652	ACCESSION:AZ440652
	120	28.4	0.4	31	1	AZ659684	ACCESSION:AZ659684
	121	28.4	0.4	31	1	AZ841151	ACCESSION:AZ841151
	122	28.4	0.4	33	1	AZ626646	ACCESSION:AZ626646
	123	28.2	0.4	34	1	AZ875700	ACCESSION:AZ875700
	124	28	0.4	28	1	BX553058	ACCESSION:BX553058
	125	28	0.4	28	1	BX559897	ACCESSION:BX559897
	126	28	0.4	28	1	AZ330730	ACCESSION:AZ330730
	127	28	0.4	28	1	AZ366137	ACCESSION:AZ366137
	128	28	0.4	28	1	AZ467078	ACCESSION:AZ467078
	129	28	0.4	28	1	AZ514383	ACCESSION:AZ514383
	130	28	0.4	28	1	AZ644345	ACCESSION:AZ644345
	131	28	0.4	28	1	AZ648665	ACCESSION:AZ648665
c	132	28	0.4	28	1	AZ649197	ACCESSION:AZ649197
	133	28	0.4	28	1	AZ777903	ACCESSION:AZ777903
	134	28	0.4	30	1	AZ815799	ACCESSION:AZ815799
	135	28	0.4	30	1	AZ961995	ACCESSION:AZ961995
	136	28	0.4	32	1	AZ829236	ACCESSION:AZ829236
	137	28	0.4	34	1	AZ304764	ACCESSION:AZ304764
c	138	27.8	0.4	31	1	AZ432709	ACCESSION:AZ432709
	139	27.8	0.4	31	1	AZ494653	ACCESSION:AZ494653
	140	27.8	0.4	32	1	AZ496969	ACCESSION:AZ496969
	141	27.8	0.4	33	1	AZ473611	ACCESSION:AZ473611
	142	27.6	0.4	34	1	AZ483866	ACCESSION:AZ483866
c	143	27.4	0.4	29	1	AZ663681	ACCESSION:AZ663681
	144	27.4	0.4	30	1	AZ425112	ACCESSION:AZ425112
	145	27.4	0.4	32	1	AZ304813	ACCESSION:AZ304813
	146	27	0.4	27	1	AZ342492	ACCESSION:AZ342492
	147	27	0.4	27	1	AZ435344	ACCESSION:AZ435344
	148	27	0.4	27	1	AZ583081	ACCESSION:AZ583081
	149	27	0.4	27	1	AZ638238	ACCESSION:AZ638238
	150	27	0.4	27	1	AZ758321	ACCESSION:AZ758321
c	151	27	0.4	27	1	AZ981811	ACCESSION:AZ981811
	152	27	0.4	28	1	AZ405219	ACCESSION:AZ405219
	153	27	0.4	28	1	AZ443611	ACCESSION:AZ443611
	154	27	0.4	28	1	AZ782113	ACCESSION:AZ782113
c	155	27	0.4	28	1	AZ812746	ACCESSION:AZ812746
	156	27	0.4	29	1	AZ774254	ACCESSION:AZ774254
	157	26.6	0.3	33	1	AZ642584	ACCESSION:AZ642584
c	158	26.6	0.3	33	1	TA245A09Q	ACCESSION:AL482142
	159	26.4	0.3	29	1	AZ786559	ACCESSION:AZ786559
	160	26.4	0.3	31	1	AZ803691	ACCESSION:AZ803691
	161	26	0.3	26	1	BX569116	ACCESSION:BX569116
	162	26	0.3	26	1	AZ307889	ACCESSION:AZ307889
c	163	26	0.3	26	1	AZ345505	ACCESSION:AZ345505
	164	26	0.3	26	1	AZ494537	ACCESSION:AZ494537
	165	26	0.3	26	1	AZ503652	ACCESSION:AZ503652
	166	26	0.3	26	1	AZ795803	ACCESSION:AZ795803
	167	26	0.3	26	1	AZ806004	ACCESSION:AZ806004
c	168	26	0.3	26	1	AZ975568	ACCESSION:AZ975568
	169	26	0.3	27	1	AZ329433	ACCESSION:AZ329433
	170	26	0.3	27	1	AZ788874	ACCESSION:AZ788874
	171	26	0.3	27	1	AZ801217	ACCESSION:AZ801217
	172	25.8	0.3	29	1	AZ807584	ACCESSION:AZ807584
	173	25.8	0.3	29	1	AZ860659	ACCESSION:AZ860659
	174	25.8	0.3	29	1	AZ866837	ACCESSION:AZ866837
c	175	25.4	0.3	27	1	AZ442363	ACCESSION:AZ442363
	176	25.4	0.3	28	1	AZ625192	ACCESSION:AZ625192
	177	25.2	0.3	31	1	AZ346705	ACCESSION:AZ346705
	178	25	0.3	25	1	BX563211	ACCESSION:BX563211
	179	25	0.3	25	1	AZ339866	ACCESSION:AZ339866
c	180	25	0.3	25	1	AZ404057	ACCESSION:AZ404057
	181	25	0.3	25	1	AZ769673	ACCESSION:AZ769673
	182	25	0.3	25	1	AZ771881	ACCESSION:AZ771881
	183	25	0.3	26	1	AZ646850	ACCESSION:AZ646850
	184	25	0.3	26	1	AZ830551	ACCESSION:AZ830551
	185	25	0.3	30	1	AZ371116	ACCESSION:AZ371116
	186	24.8	0.3	31	1	R14943	ACCESSION:R14943
c	187	24.4	0.3	26	1	AZ419877	ACCESSION:AZ419877
	188	24.4	0.3	26	1	AZ766495	ACCESSION:AZ766495
	189	24.4	0.3	26	1	AZ781130	ACCESSION:AZ781130
	190	24.4	0.3	27	1	AZ946507	ACCESSION:AZ946507
	191	24	0.3	24	1	BX559963	ACCESSION:BX559963
	192	24	0.3	24	1	AZ419602	ACCESSION:AZ419602
	193	24	0.3	24	1	AZ621455	ACCESSION:AZ621455
	194	24	0.3	24	1	AZ807762	ACCESSION:AZ807762
c	195	24	0.3	24	1	AZ813106	ACCESSION:AZ813106
	196	24	0.3	24	1	AZ846178	ACCESSION:AZ846178
c	197	24	0.3	24	1	TA163H11P	ACCESSION:AL472248
	198	24	0.3	25	1	AZ345553	ACCESSION:AZ345553
	199	24	0.3	25	1	AZ467470	ACCESSION:AZ467470
	200	24	0.3	25	1	AZ762101	ACCESSION:AZ762101
	201	24	0.3	26	1	AZ467063	ACCESSION:AZ467063
	202	23.8	0.3	28	1	AZ466703	ACCESSION:AZ466703
c	203	23.4	0.3	25	1	AZ451588	ACCESSION:AZ451588
	204	23.4	0.3	25	1	AZ459694	ACCESSION:AZ459694
	205	23.4	0.3	25	1	AZ465273	ACCESSION:AZ465273
c	206	23.4	0.3	28	1	AZ345426	ACCESSION:AZ345426
	207	23.4	0.3	29	1	N53413	ACCESSION:N53413
	208	23.2	0.3	29	1	AZ826631	ACCESSION:AZ826631
	209	23	0.3	23	1	BX557786	ACCESSION:BX557786
	210	23	0.3	23	1	AZ328763	ACCESSION:AZ328763
	211	23	0.3	23	1	AZ483624	ACCESSION:AZ483624
c	212	23	0.3	23	1	AZ637290	ACCESSION:AZ637290
c	213	23	0.3	23	1	AZ789907	ACCESSION:AZ789907
	214	23	0.3	23	1	AZ824638	ACCESSION:AZ824638
c	215	23	0.3	23	1	AZ828969	ACCESSION:AZ828969
c	216	23	0.3	23	1	AZ829195	ACCESSION:AZ829195
	217	23	0.3	24	1	AZ446429	ACCESSION:AZ446429
	218	23	0.3	24	1	AZ647335	ACCESSION:AZ647335
	219	23	0.3	25	1	AZ506209	ACCESSION:AZ506209
	220	23	0.3	26	1	AZ494629	ACCESSION:AZ494629
c	221	22.8	0.3	26	1	AZ774981	ACCESSION:AZ774981
	222	22.8	0.3	27	1	AZ404479	ACCESSION:AZ404479
	223	22.8	0.3	27	1	AZ823699	ACCESSION:AZ823699
c	224	22.4	0.3	25	1	AZ780500	ACCESSION:AZ780500
	225	22.2	0.3	27	1	AZ646963	ACCESSION:AZ646963
	226	22	0.3	22	1	AZ484090	ACCESSION:AZ484090
	227	22	0.3	22	1	AZ985497	ACCESSION:AZ985497
	228	22	0.3	23	1	AZ371475	ACCESSION:AZ371475
	229	21.8	0.3	25	1	AZ766498	ACCESSION:AZ766498
c	230	21.4	0.3	23	1	AZ309945	ACCESSION:AZ309945
c	231	21.4	0.3	23	1	AZ356191	ACCESSION:AZ356191
	232	21.4	0.3	23	1	AZ602037	ACCESSION:AZ602037
	233	21	0.3	21	1	AZ310642	ACCESSION:AZ310642
	234	21	0.3	21	1	AZ333309	ACCESSION:AZ333309
	235	21	0.3	21	1	AZ635627	ACCESSION:AZ635627
	236	21	0.3	21	1	AZ641805	ACCESSION:AZ641805
	237	21	0.3	21	1	AZ762904	ACCESSION:AZ762904
	238	21	0.3	21	1	AZ854856	ACCESSION:AZ854856
c	239	21	0.3	22	1	AZ780002	ACCESSION:AZ780002
	240	21	0.3	22	1	AZ780118	ACCESSION:AZ780118
	241	20.4	0.3	22	1	AZ784203	ACCESSION:AZ784203
	242	20.4	0.3	22	1	AZ793094	ACCESSION:AZ793094
	243	20.4	0.3	22	1	AZ801266	ACCESSION:AZ801266
	244	20.4	0.3	23	1	AW335179	ACCESSION:AW335179
	245	20.4	0.3	24	1	AZ822069	ACCESSION:AZ822069
	246	20	0.3	20	1	AZ368875	ACCESSION:AZ368875
	247	20	0.3	20	1	AZ465453	ACCESSION:AZ465453
	248	20	0.3	20	1	AZ470768	ACCESSION:AZ470768
	249	20	0.3	20	1	AZ580200	ACCESSION:AZ580200
	250	20	0.3	20	1	AZ634201	ACCESSION:AZ634201
c	251	20	0.3	20	1	AZ946508	ACCESSION:AZ946508
c	252	20	0.3	20	1	AZ959039	ACCESSION:AZ959039

	253	20	0.3	21	1	AZ818214	ACCESSION:AZ818214
c	254	20	0.3	21	1	AZ991225	ACCESSION:AZ991225
	255	20	0.3	23	1	AZ452951	ACCESSION:AZ452951
	256	20	0.3	24	1	AZ645446	ACCESSION:AZ645446
	257	20	0.3	25	1	AZ760251	ACCESSION:AZ760251
	258	19.4	0.3	21	1	AZ415089	ACCESSION:AZ415089
c	259	19.4	0.3	21	1	AZ513902	ACCESSION:AZ513902
	260	19.2	0.3	24	1	AZ811237	ACCESSION:AZ811237
	261	19	0.2	19	1	AZ431700	ACCESSION:AZ431700
c	262	19	0.2	19	1	AZ461642	ACCESSION:AZ461642
	263	19	0.2	19	1	AZ649147	ACCESSION:AZ649147
c	264	19	0.2	19	1	AZ774954	ACCESSION:AZ774954
	265	19	0.2	19	1	AZ795767	ACCESSION:AZ795767
	266	19	0.2	19	1	AZ822936	ACCESSION:AZ822936
	267	19	0.2	19	1	AZ827177	ACCESSION:AZ827177
c	268	19	0.2	20	1	AZ818055	ACCESSION:AZ818055
c	269	19	0.2	22	1	AZ514387	ACCESSION:AZ514387
	270	19	0.2	23	1	CF334146	ACCESSION:CF334146
	271	18.8	0.2	22	1	AZ464442	ACCESSION:AZ464442
	272	18.8	0.2	23	1	AL587602	ACCESSION:AL587602
	273	18.4	0.2	20	1	CF282165	ACCESSION:CF282165
	274	18.4	0.2	20	1	AZ482421	ACCESSION:AZ482421
	275	18.4	0.2	20	1	AZ654458	ACCESSION:AZ654458
	276	18.4	0.2	20	1	AZ785549	ACCESSION:AZ785549
c	277	18.4	0.2	23	1	AG192026	ACCESSION:AG192026
c	278	18	0.2	19	1	AZ853220	ACCESSION:AZ853220
	279	18	0.2	20	1	AZ345856	ACCESSION:AZ345856
	280	18	0.2	20	1	AZ370699	ACCESSION:AZ370699
c	281	18	0.2	22	1	AL038464	ACCESSION:AL038464
c	282	18	0.2	22	1	CR786821	ACCESSION:CR786821
	283	18	0.2	22	1	AZ309907	ACCESSION:AZ309907
	284	18	0.2	22	1	TA386H07Q	ACCESSION:AL498291
	285	17.8	0.2	21	1	CF293087	ACCESSION:CF293087
	286	17.8	0.2	21	1	AZ610868	ACCESSION:AZ610868
c	287	17.8	0.2	21	1	AZ621072	ACCESSION:AZ621072
c	288	17.8	0.2	21	1	AZ764492	ACCESSION:AZ764492
	289	17.8	0.2	22	1	CF297521	ACCESSION:CF297521
c	290	17.8	0.2	22	1	CF310486	ACCESSION:CF310486
	291	17.8	0.2	22	1	AZ762424	ACCESSION:AZ762424
c	292	17.8	0.2	22	1	BH000233	ACCESSION:BH000233
c	293	17.8	0.2	40	1	AZ513013	ACCESSION:AZ513013
c	294	17.4	0.2	19	1	AA995094	ACCESSION:AA995094
	295	17.4	0.2	20	1	AZ632650	ACCESSION:AZ632650
c	296	17.4	0.2	20	1	AZ793887	ACCESSION:AZ793887
c	297	17.4	0.2	20	1	DX071075	ACCESSION:DX071075
c	298	17.4	0.2	21	1	AL038627	ACCESSION:AL038627
c	299	17.4	0.2	40	1	AZ397262	ACCESSION:AZ397262
	300	17	0.2	17	1	CF302447	ACCESSION:CF302447
	301	17	0.2	17	1	CF313013	ACCESSION:CF313013
	302	17	0.2	18	1	CF300456	ACCESSION:CF300456
	303	17	0.2	18	1	CF301057	ACCESSION:CF301057
	304	17	0.2	18	1	CF301359	ACCESSION:CF301359
	305	17	0.2	18	1	CF320418	ACCESSION:CF320418
c	306	17	0.2	19	1	CF298134	ACCESSION:CF298134
c	307	17	0.2	20	1	CF298207	ACCESSION:CF298207
	308	17	0.2	20	1	CF300961	ACCESSION:CF300961
	309	17	0.2	20	1	CF319428	ACCESSION:CF319428
c	310	17	0.2	20	1	AZ638704	ACCESSION:AZ638704
	311	17	0.2	20	1	AZ645312	ACCESSION:AZ645312
	312	17	0.2	21	1	CF276638	ACCESSION:CF276638
	313	17	0.2	21	1	CF318152	ACCESSION:CF318152
c	314	17	0.2	21	1	DT496709	ACCESSION:DT496709
	315	17	0.2	21	1	AZ943299	ACCESSION:AZ943299
	316	17	0.2	21	1	DX056270	ACCESSION:DX056270
c	317	16.8	0.2	20	1	AL038507	ACCESSION:AL038507
c	318	16.8	0.2	20	1	AL038576	ACCESSION:AL038576
c	319	16.8	0.2	20	1	AL038754	ACCESSION:AL038754
c	320	16.8	0.2	20	1	AL038845	ACCESSION:AL038845
	321	16.8	0.2	20	1	CF299570	ACCESSION:CF299570
c	322	16.8	0.2	20	1	AZ368518	ACCESSION:AZ368518
c	323	16.8	0.2	20	1	AZ849506	ACCESSION:AZ849506
	324	16.8	0.2	21	1	BX548564	ACCESSION:BX548564
	325	16.8	0.2	21	1	BX564412	ACCESSION:BX564412
	326	16.8	0.2	21	1	CX000923	ACCESSION:CX000923
	327	16.8	0.2	21	1	DN955796	ACCESSION:DN955796
	328	16.8	0.2	21	1	AZ629111	ACCESSION:AZ629111
c	329	16.8	0.2	21	1	AZ665302	ACCESSION:AZ665302
	330	16.4	0.2	18	1	CF329285	ACCESSION:CF329285
c	331	16.4	0.2	18	1	CR786637	ACCESSION:CR786637
	332	16.4	0.2	19	1	CF308042	ACCESSION:CF308042
c	333	16.4	0.2	19	1	CF326845	ACCESSION:CF326845
c	334	16.4	0.2	19	1	AZ509929	ACCESSION:AZ509929
c	335	16.4	0.2	19	1	AZ764517	ACCESSION:AZ764517
	336	16.4	0.2	20	1	AL587727	ACCESSION:AL587727
	337	16.4	0.2	20	1	AL587759	ACCESSION:AL587759
c	338	16.4	0.2	20	1	AZ341237	ACCESSION:AZ341237
	339	16.4	0.2	20	1	AZ772074	ACCESSION:AZ772074
	340	16	0.2	16	1	BQ590166	ACCESSION:BQ590166
c	341	16	0.2	16	1	BQ592600	ACCESSION:BQ592600
	342	16	0.2	16	1	BQ592965	ACCESSION:BQ592965
c	343	16	0.2	16	1	BQ595717	ACCESSION:BQ595717
	344	16	0.2	16	1	CF279325	ACCESSION:CF279325
	345	16	0.2	16	1	CF311057	ACCESSION:CF311057
	346	16	0.2	16	1	CF314377	ACCESSION:CF314377
	347	16	0.2	16	1	CF315789	ACCESSION:CF315789
	348	16	0.2	16	1	CF316056	ACCESSION:CF316056
	349	16	0.2	16	1	CF317718	ACCESSION:CF317718
	350	16	0.2	16	1	CF320356	ACCESSION:CF320356
	351	16	0.2	16	1	CF327722	ACCESSION:CF327722
c	352	16	0.2	16	1	CF333386	ACCESSION:CF333386
c	353	16	0.2	16	1	CR786853	ACCESSION:CR786853
c	354	16	0.2	16	1	DT498583	ACCESSION:DT498583
	355	16	0.2	17	1	BQ590128	ACCESSION:BQ590128
c	356	16	0.2	17	1	BQ590687	ACCESSION:BQ590687
	357	16	0.2	17	1	BQ591177	ACCESSION:BQ591177
	358	16	0.2	17	1	CF290854	ACCESSION:CF290854
	359	16	0.2	17	1	CF294668	ACCESSION:CF294668
	360	16	0.2	17	1	CF295807	ACCESSION:CF295807
	361	16	0.2	17	1	CF295988	ACCESSION:CF295988
	362	16	0.2	17	1	CF298589	ACCESSION:CF298589
	363	16	0.2	17	1	CF299639	ACCESSION:CF299639
	364	16	0.2	17	1	CF299997	ACCESSION:CF299997
	365	16	0.2	17	1	CF310219	ACCESSION:CF310219
	366	16	0.2	17	1	CF334566	ACCESSION:CF334566
	367	16	0.2	17	1	CF336950	ACCESSION:CF336950
	368	16	0.2	17	1	CX309551	ACCESSION:CX309551
c	369	16	0.2	18	1	AJ725584	ACCESSION:AJ725584
c	370	16	0.2	18	1	AL038692	ACCESSION:AL038692
c	371	16	0.2	18	1	AL048754	ACCESSION:AL048754
	372	16	0.2	18	1	BQ582676	ACCESSION:BQ582676
	373	16	0.2	18	1	BQ590027	ACCESSION:BQ590027
	374	16	0.2	18	1	CF277873	ACCESSION:CF277873
	375	16	0.2	18	1	CF297446	ACCESSION:CF297446
	376	16	0.2	18	1	CF299027	ACCESSION:CF299027
	377	16	0.2	18	1	CF299674	ACCESSION:CF299674
	378	16	0.2	18	1	CF301151	ACCESSION:CF301151
	379	16	0.2	18	1	CF301325	ACCESSION:CF301325
	380	16	0.2	18	1	CF301760	ACCESSION:CF301760
	381	16	0.2	18	1	CF302409	ACCESSION:CF302409
	382	16	0.2	18	1	CF320046	ACCESSION:CF320046
	383	16	0.2	18	1	DR073142	ACCESSION:DR073142
	384	16	0.2	18	1	DR074121	ACCESSION:DR074121
	385	16	0.2	19	1	AJ668179	ACCESSION:AJ668179
	386	16	0.2	19	1	AJ669138	ACCESSION:AJ669138
c	387	16	0.2	19	1	BQ588729	ACCESSION:BQ588729
	388	16	0.2	19	1	CB174047	ACCESSION:CB174047
	389	16	0.2	19	1	CF279008	ACCESSION:CF279008
	390	16	0.2	19	1	CF291089	ACCESSION:CF291089
c	391	16	0.2	19	1	CF291090	ACCESSION:CF291090
	392	16	0.2	19	1	CF291665	ACCESSION:CF291665
	393	16	0.2	19	1	CF291899	ACCESSION:CF291899
	394	16	0.2	19	1	CF292072	ACCESSION:CF292072
	395	16	0.2	19	1	CF292144	ACCESSION:CF292144
	396	16	0.2	19	1	CF293167	ACCESSION:CF293167
	397	16	0.2	19	1	CF298396	ACCESSION:CF298396
	398	16	0.2	19	1	CF299598	ACCESSION:CF299598

	399	16	0.2	19	1	CF302327	ACCESSION:CF302327
	400	16	0.2	19	1	CF302456	ACCESSION:CF302456
	401	16	0.2	19	1	CF304589	ACCESSION:CF304589
	402	16	0.2	19	1	CF309801	ACCESSION:CF309801
	403	16	0.2	19	1	CF309821	ACCESSION:CF309821
c	404	16	0.2	19	1	CF309943	ACCESSION:CF309943
c	405	16	0.2	19	1	CF310688	ACCESSION:CF310688
	406	16	0.2	19	1	CF311496	ACCESSION:CF311496
	407	16	0.2	19	1	CF311513	ACCESSION:CF311513
c	408	16	0.2	19	1	CF311668	ACCESSION:CF311668
	409	16	0.2	19	1	CF311778	ACCESSION:CF311778
c	410	16	0.2	19	1	CF312403	ACCESSION:CF312403
	411	16	0.2	19	1	CF315299	ACCESSION:CF315299
	412	16	0.2	19	1	CF316480	ACCESSION:CF316480
c	413	16	0.2	19	1	CF318788	ACCESSION:CF318788
	414	16	0.2	19	1	CF327587	ACCESSION:CF327587
	415	16	0.2	19	1	CF329136	ACCESSION:CF329136
c	416	16	0.2	19	1	CF329986	ACCESSION:CF329986
	417	16	0.2	19	1	CF331361	ACCESSION:CF331361
	418	16	0.2	19	1	CF332063	ACCESSION:CF332063
c	419	16	0.2	19	1	CF333507	ACCESSION:CF333507
c	420	16	0.2	19	1	CF333753	ACCESSION:CF333753
	421	16	0.2	19	1	CF334014	ACCESSION:CF334014
	422	16	0.2	19	1	CF335293	ACCESSION:CF335293
	423	16	0.2	19	1	CN545602	ACCESSION:CN545602
	424	16	0.2	19	1	CN545922	ACCESSION:CN545922
	425	16	0.2	19	1	CN545923	ACCESSION:CN545923
	426	16	0.2	19	1	CN545964	ACCESSION:CN545964
	427	16	0.2	19	1	CN546303	ACCESSION:CN546303
	428	16	0.2	19	1	CX002732	ACCESSION:CX002732
c	429	16	0.2	19	1	CX003880	ACCESSION:CX003880
	430	16	0.2	19	1	CX007355	ACCESSION:CX007355
	431	16	0.2	19	1	DN954273	ACCESSION:DN954273
	432	16	0.2	19	1	DN955154	ACCESSION:DN955154
c	433	16	0.2	19	1	DN955630	ACCESSION:DN955630
c	434	16	0.2	19	1	DR062165	ACCESSION:DR062165
c	435	16	0.2	19	1	DR063041	ACCESSION:DR063041
	436	16	0.2	19	1	DR063459	ACCESSION:DR063459
	437	16	0.2	19	1	DR065256	ACCESSION:DR065256
	438	16	0.2	19	1	DR073123	ACCESSION:DR073123
c	439	16	0.2	19	1	DR074208	ACCESSION:DR074208
c	440	16	0.2	19	1	DT497638	ACCESSION:DT497638
c	441	16	0.2	19	1	AZ307313	ACCESSION:AZ307313
	442	16	0.2	19	1	AZ310079	ACCESSION:AZ310079
	443	16	0.2	19	1	AZ310105	ACCESSION:AZ310105
c	444	16	0.2	19	1	AZ317743	ACCESSION:AZ317743
	445	16	0.2	19	1	AZ340311	ACCESSION:AZ340311
c	446	16	0.2	19	1	AZ345795	ACCESSION:AZ345795
	447	16	0.2	19	1	AZ350519	ACCESSION:AZ350519
c	448	16	0.2	19	1	AZ364226	ACCESSION:AZ364226
c	449	16	0.2	19	1	AZ365696	ACCESSION:AZ365696
c	450	16	0.2	19	1	AZ374409	ACCESSION:AZ374409
c	451	16	0.2	19	1	AZ374619	ACCESSION:AZ374619
c	452	16	0.2	19	1	AZ385952	ACCESSION:AZ385952
c	453	16	0.2	19	1	AZ391509	ACCESSION:AZ391509
c	454	16	0.2	19	1	AZ410050	ACCESSION:AZ410050
c	455	16	0.2	19	1	AZ414413	ACCESSION:AZ414413
c	456	16	0.2	19	1	AZ422604	ACCESSION:AZ422604
	457	16	0.2	19	1	AZ424716	ACCESSION:AZ424716
	458	16	0.2	19	1	AZ441329	ACCESSION:AZ441329
	459	16	0.2	19	1	AZ442365	ACCESSION:AZ442365
c	460	16	0.2	19	1	AZ450180	ACCESSION:AZ450180
	461	16	0.2	19	1	AZ453930	ACCESSION:AZ453930
c	462	16	0.2	19	1	AZ460906	ACCESSION:AZ460906
	463	16	0.2	19	1	AZ471494	ACCESSION:AZ471494
	464	16	0.2	19	1	AZ476576	ACCESSION:AZ476576
	465	16	0.2	19	1	AZ486786	ACCESSION:AZ486786
	466	16	0.2	19	1	AZ490652	ACCESSION:AZ490652
c	467	16	0.2	19	1	AZ508040	ACCESSION:AZ508040
c	468	16	0.2	19	1	AZ579119	ACCESSION:AZ579119
c	469	16	0.2	19	1	AZ583970	ACCESSION:AZ583970
c	470	16	0.2	19	1	AZ585865	ACCESSION:AZ585865
c	471	16	0.2	19	1	AZ593210	ACCESSION:AZ593210
	472	16	0.2	19	1	AZ616154	ACCESSION:AZ616154
	473	16	0.2	19	1	AZ627844	ACCESSION:AZ627844
c	474	16	0.2	19	1	AZ631701	ACCESSION:AZ631701
c	475	16	0.2	19	1	AZ633821	ACCESSION:AZ633821
c	476	16	0.2	19	1	AZ643659	ACCESSION:AZ643659
	477	16	0.2	19	1	AZ644698	ACCESSION:AZ644698
c	478	16	0.2	19	1	AZ648335	ACCESSION:AZ648335
	479	16	0.2	19	1	AZ649888	ACCESSION:AZ649888
c	480	16	0.2	19	1	AZ650575	ACCESSION:AZ650575
c	481	16	0.2	19	1	AZ764497	ACCESSION:AZ764497
c	482	16	0.2	19	1	AZ764522	ACCESSION:AZ764522
c	483	16	0.2	19	1	AZ764534	ACCESSION:AZ764534
c	484	16	0.2	19	1	AZ770387	ACCESSION:AZ770387
c	485	16	0.2	19	1	AZ778858	ACCESSION:AZ778858
c	486	16	0.2	19	1	AZ779901	ACCESSION:AZ779901
c	487	16	0.2	19	1	AZ781876	ACCESSION:AZ781876
	488	16	0.2	19	1	AZ786779	ACCESSION:AZ786779
	489	16	0.2	19	1	AZ787634	ACCESSION:AZ787634
	490	16	0.2	19	1	AZ788058	ACCESSION:AZ788058
	491	16	0.2	19	1	AZ789590	ACCESSION:AZ789590
	492	16	0.2	19	1	AZ792713	ACCESSION:AZ792713
c	493	16	0.2	19	1	AZ795403	ACCESSION:AZ795403
	494	16	0.2	19	1	AZ801970	ACCESSION:AZ801970
c	495	16	0.2	19	1	AZ810717	ACCESSION:AZ810717
	496	16	0.2	19	1	AZ822225	ACCESSION:AZ822225
c	497	16	0.2	19	1	AZ841581	ACCESSION:AZ841581
c	498	16	0.2	19	1	AZ841622	ACCESSION:AZ841622
	499	16	0.2	19	1	AZ856873	ACCESSION:AZ856873
c	500	16	0.2	19	1	AZ861896	ACCESSION:AZ861896
c	501	16	0.2	19	1	AZ936798	ACCESSION:AZ936798
c	502	16	0.2	19	1	AZ950028	ACCESSION:AZ950028
c	503	16	0.2	19	1	AZ985501	ACCESSION:AZ985501
c	504	16	0.2	19	1	BH000498	ACCESSION:BH000498
c	505	16	0.2	19	1	CL680736	ACCESSION:CL680736
c	506	16	0.2	19	1	CL685439	ACCESSION:CL685439
c	507	16	0.2	19	1	CL693186	ACCESSION:CL693186
c	508	16	0.2	19	1	CL693191	ACCESSION:CL693191
	509	16	0.2	20	1	AJ666275	ACCESSION:AJ666275
	510	16	0.2	20	1	AJ666402	ACCESSION:AJ666402
c	511	16	0.2	20	1	AL038427	ACCESSION:AL038427
c	512	16	0.2	20	1	AL038429	ACCESSION:AL038429
c	513	16	0.2	20	1	AL038460	ACCESSION:AL038460
c	514	16	0.2	20	1	AL038570	ACCESSION:AL038570
c	515	16	0.2	20	1	AL038750	ACCESSION:AL038750
	516	16	0.2	20	1	AL587572	ACCESSION:AL587572
	517	16	0.2	20	1	CA853586	ACCESSION:CA853586
c	518	16	0.2	20	1	CF280913	ACCESSION:CF280913
	519	16	0.2	20	1	CF282002	ACCESSION:CF282002
c	520	16	0.2	20	1	CF282035	ACCESSION:CF282035
c	521	16	0.2	20	1	CF282414	ACCESSION:CF282414
	522	16	0.2	20	1	CF298018	ACCESSION:CF298018
	523	16	0.2	20	1	CF299822	ACCESSION:CF299822
	524	16	0.2	20	1	CF301101	ACCESSION:CF301101
	525	16	0.2	20	1	CF301720	ACCESSION:CF301720
	526	16	0.2	20	1	CF302027	ACCESSION:CF302027
c	527	16	0.2	20	1	CF310604	ACCESSION:CF310604
c	528	16	0.2	20	1	CF313067	ACCESSION:CF313067
	529	16	0.2	20	1	CF313569	ACCESSION:CF313569
	530	16	0.2	20	1	CF316662	ACCESSION:CF316662
	531	16	0.2	20	1	CF318278	ACCESSION:CF318278
	532	16	0.2	20	1	CF319133	ACCESSION:CF319133
	533	16	0.2	20	1	CF320843	ACCESSION:CF320843
	534	16	0.2	20	1	CF321721	ACCESSION:CF321721
c	535	16	0.2	20	1	CF328565	ACCESSION:CF328565
	536	16	0.2	20	1	CF333052	ACCESSION:CF333052
	537	16	0.2	20	1	CF333173	ACCESSION:CF333173
	538	16	0.2	20	1	CF334170	ACCESSION:CF334170
	539	16	0.2	20	1	CF336525	ACCESSION:CF336525
	540	16	0.2	20	1	CF337494	ACCESSION:CF337494
	541	16	0.2	20	1	CF339443	ACCESSION:CF339443
	542	16	0.2	20	1	AW334823	ACCESSION:AW334823
	543	16	0.2	20	1	CN545446	ACCESSION:CN545446
	544	16	0.2	20	1	CN545501	ACCESSION:CN545501

c 545	16	0.2	20	1	CN754148	ACCESSION:CN754148
c 546	16	0.2	20	1	DN953918	ACCESSION:DN953918
547	16	0.2	20	1	DN954281	ACCESSION:DN954281
c 548	16	0.2	20	1	DN954289	ACCESSION:DN954289
c 549	16	0.2	20	1	DN955202	ACCESSION:DN955202
c 550	16	0.2	20	1	DR065440	ACCESSION:DR065440
551	16	0.2	20	1	DR073089	ACCESSION:DR073089
552	16	0.2	20	1	DR073130	ACCESSION:DR073130
c 553	16	0.2	20	1	DT493556	ACCESSION:DT493556
554	16	0.2	20	1	T50579	ACCESSION:T50579
555	16	0.2	20	1	AZ307671	ACCESSION:AZ307671
556	16	0.2	20	1	AZ333980	ACCESSION:AZ333980
c 557	16	0.2	20	1	AZ341530	ACCESSION:AZ341530
c 558	16	0.2	20	1	AZ343031	ACCESSION:AZ343031
c 559	16	0.2	20	1	AZ351273	ACCESSION:AZ351273
c 560	16	0.2	20	1	AZ357623	ACCESSION:AZ357623
c 561	16	0.2	20	1	AZ369734	ACCESSION:AZ369734
c 562	16	0.2	20	1	AZ386573	ACCESSION:AZ386573
c 563	16	0.2	20	1	AZ396481	ACCESSION:AZ396481
c 564	16	0.2	20	1	AZ442328	ACCESSION:AZ442328
565	16	0.2	20	1	AZ463331	ACCESSION:AZ463331
566	16	0.2	20	1	AZ477734	ACCESSION:AZ477734
567	16	0.2	20	1	AZ479464	ACCESSION:AZ479464
568	16	0.2	20	1	AZ486784	ACCESSION:AZ486784
569	16	0.2	20	1	AZ486787	ACCESSION:AZ486787
570	16	0.2	20	1	AZ498625	ACCESSION:AZ498625
c 571	16	0.2	20	1	AZ514729	ACCESSION:AZ514729
c 572	16	0.2	20	1	AZ579178	ACCESSION:AZ579178
c 573	16	0.2	20	1	AZ581208	ACCESSION:AZ581208
c 574	16	0.2	20	1	AZ588011	ACCESSION:AZ588011
c 575	16	0.2	20	1	AZ607328	ACCESSION:AZ607328
576	16	0.2	20	1	AZ623155	ACCESSION:AZ623155
577	16	0.2	20	1	AZ623214	ACCESSION:AZ623214
c 578	16	0.2	20	1	AZ643992	ACCESSION:AZ643992
579	16	0.2	20	1	AZ645829	ACCESSION:AZ645829
c 580	16	0.2	20	1	AZ650271	ACCESSION:AZ650271
c 581	16	0.2	20	1	AZ760838	ACCESSION:AZ760838
c 582	16	0.2	20	1	AZ764504	ACCESSION:AZ764504
583	16	0.2	20	1	AZ765211	ACCESSION:AZ765211
c 584	16	0.2	20	1	AZ772091	ACCESSION:AZ772091
585	16	0.2	20	1	AZ779425	ACCESSION:AZ779425
c 586	16	0.2	20	1	AZ784041	ACCESSION:AZ784041
587	16	0.2	20	1	AZ793467	ACCESSION:AZ793467
588	16	0.2	20	1	AZ798529	ACCESSION:AZ798529
c 589	16	0.2	20	1	AZ805163	ACCESSION:AZ805163
c 590	16	0.2	20	1	AZ806521	ACCESSION:AZ806521
c 591	16	0.2	20	1	AZ806585	ACCESSION:AZ806585
c 592	16	0.2	20	1	AZ809306	ACCESSION:AZ809306
c 593	16	0.2	20	1	AZ810986	ACCESSION:AZ810986
c 594	16	0.2	20	1	AZ813908	ACCESSION:AZ813908
c 595	16	0.2	20	1	AZ817323	ACCESSION:AZ817323
c 596	16	0.2	20	1	AZ817414	ACCESSION:AZ817414
c 597	16	0.2	20	1	AZ817467	ACCESSION:AZ817467
598	16	0.2	20	1	AZ817608	ACCESSION:AZ817608
599	16	0.2	20	1	AZ818489	ACCESSION:AZ818489
600	16	0.2	20	1	AZ818816	ACCESSION:AZ818816
c 601	16	0.2	20	1	AZ821905	ACCESSION:AZ821905
c 602	16	0.2	20	1	AZ837491	ACCESSION:AZ837491
c 603	16	0.2	20	1	AZ841342	ACCESSION:AZ841342
604	16	0.2	20	1	AZ841558	ACCESSION:AZ841558
c 605	16	0.2	20	1	AZ858052	ACCESSION:AZ858052
c 606	16	0.2	20	1	AZ858419	ACCESSION:AZ858419
c 607	16	0.2	20	1	AZ936914	ACCESSION:AZ936914
608	16	0.2	20	1	AZ949180	ACCESSION:AZ949180
609	16	0.2	20	1	AZ963973	ACCESSION:AZ963973
c 610	16	0.2	20	1	CW979138	ACCESSION:CW979138
611	16	0.2	20	1	DU834188	ACCESSION:DU834188
c 612	16	0.2	20	1	DU835125	ACCESSION:DU835125
c 613	16	0.2	20	1	DX045751	ACCESSION:DX045751
c 614	16	0.2	20	1	DX055580	ACCESSION:DX055580
615	16	0.2	20	1	DX070282	ACCESSION:DX070282
616	16	0.2	20	1	DX071064	ACCESSION:DX071064
c 617	16	0.2	37	1	AZ456482	ACCESSION:AZ456482
c 618	16	0.2	40	1	AZ305049	ACCESSION:AZ305049
619	15.8	0.2	19	1	CF278272	ACCESSION:CF278272
620	15.8	0.2	19	1	CF319596	ACCESSION:CF319596
621	15.8	0.2	19	1	AZ447251	ACCESSION:AZ447251
c 622	15.8	0.2	20	1	CF300961	ACCESSION:CF300961
623	15.8	0.2	37	1	AZ875282	ACCESSION:AZ875282
c 624	15.8	0.2	38	1	AZ504337	ACCESSION:AZ504337
625	15.6	0.2	22	1	AL038464	ACCESSION:AL038464
626	15.4	0.2	17	1	CF298341	ACCESSION:CF298341
627	15.4	0.2	17	1	CF311499	ACCESSION:CF311499
628	15.4	0.2	18	1	CF309376	ACCESSION:CF309376
629	15.4	0.2	18	1	CF329484	ACCESSION:CF329484
c 630	15.4	0.2	18	1	CF329485	ACCESSION:CF329485
631	15.4	0.2	19	1	AJ666205	ACCESSION:AJ666205
c 632	15.4	0.2	19	1	AZ360314	ACCESSION:AZ360314
633	15.4	0.2	19	1	AZ491644	ACCESSION:AZ491644
c 634	15.4	0.2	36	1	AZ489673	ACCESSION:AZ489673
c 635	15.4	0.2	37	1	AZ647581	ACCESSION:AZ647581
c 636	15.2	0.2	36	1	AZ848143	ACCESSION:AZ848143
c 637	15.2	0.2	37	1	AZ826021	ACCESSION:AZ826021
c 638	15.2	0.2	39	1	AZ765740	ACCESSION:AZ765740
c 639	15.2	0.2	40	1	AZ513473	ACCESSION:AZ513473
640	15	0.2	15	1	AJ690565	ACCESSION:AJ690565
641	15	0.2	15	1	BQ582543	ACCESSION:BQ582543
642	15	0.2	15	1	BQ585820	ACCESSION:BQ585820
643	15	0.2	15	1	BQ590410	ACCESSION:BQ590410
644	15	0.2	15	1	BQ590656	ACCESSION:BQ590656
645	15	0.2	15	1	BQ591170	ACCESSION:BQ591170
646	15	0.2	15	1	BQ591178	ACCESSION:BQ591178
647	15	0.2	15	1	BQ591223	ACCESSION:BQ591223
648	15	0.2	15	1	BQ594689	ACCESSION:BQ594689
649	15	0.2	15	1	CF277319	ACCESSION:CF277319
650	15	0.2	15	1	CF281923	ACCESSION:CF281923
651	15	0.2	15	1	CF290920	ACCESSION:CF290920
652	15	0.2	15	1	CF291029	ACCESSION:CF291029
653	15	0.2	15	1	CF291103	ACCESSION:CF291103
654	15	0.2	15	1	CF291717	ACCESSION:CF291717
655	15	0.2	15	1	CF291798	ACCESSION:CF291798
656	15	0.2	15	1	CF292458	ACCESSION:CF292458
657	15	0.2	15	1	CF292461	ACCESSION:CF292461
658	15	0.2	15	1	CF298148	ACCESSION:CF298148
659	15	0.2	15	1	CF298630	ACCESSION:CF298630
660	15	0.2	15	1	CF298733	ACCESSION:CF298733
661	15	0.2	15	1	CF298805	ACCESSION:CF298805
662	15	0.2	15	1	CF298889	ACCESSION:CF298889
663	15	0.2	15	1	CF299602	ACCESSION:CF299602
664	15	0.2	15	1	CF299608	ACCESSION:CF299608
665	15	0.2	15	1	CF300121	ACCESSION:CF300121
666	15	0.2	15	1	CF300361	ACCESSION:CF300361
667	15	0.2	15	1	CF300992	ACCESSION:CF300992
668	15	0.2	15	1	CF302034	ACCESSION:CF302034
669	15	0.2	15	1	CF302124	ACCESSION:CF302124
670	15	0.2	15	1	CF302182	ACCESSION:CF302182
671	15	0.2	15	1	CF307923	ACCESSION:CF307923
672	15	0.2	15	1	CF311159	ACCESSION:CF311159
673	15	0.2	15	1	CF311907	ACCESSION:CF311907
674	15	0.2	15	1	CF313319	ACCESSION:CF313319
c 675	15	0.2	15	1	CF313320	ACCESSION:CF313320
c 676	15	0.2	15	1	CF316251	ACCESSION:CF316251
677	15	0.2	15	1	CF318035	ACCESSION:CF318035
678	15	0.2	15	1	CF327434	ACCESSION:CF327434
679	15	0.2	15	1	CF330195	ACCESSION:CF330195
680	15	0.2	15	1	CF330668	ACCESSION:CF330668
681	15	0.2	15	1	CF332178	ACCESSION:CF332178
682	15	0.2	15	1	CF336202	ACCESSION:CF336202
c 683	15	0.2	15	1	BE230585	ACCESSION:BE230585
c 684	15	0.2	15	1	CR547282	ACCESSION:CR547282
c 685	15	0.2	15	1	CV933720	ACCESSION:CV933720
686	15	0.2	16	1	BQ590207	ACCESSION:BQ590207
687	15	0.2	16	1	BQ590507	ACCESSION:BQ590507
688	15	0.2	16	1	BQ595369	ACCESSION:BQ595369
c 689	15	0.2	16	1	CF291803	ACCESSION:CF291803
690	15	0.2	16	1	CF296130	ACCESSION:CF296130

691	15	0.2	16	1	CF314013	ACCESSION:CF314013
692	15	0.2	16	1	CF318894	ACCESSION:CF318894
693	15	0.2	16	1	CF327923	ACCESSION:CF327923
694	15	0.2	16	1	CF328223	ACCESSION:CF328223
695	15	0.2	16	1	CF329320	ACCESSION:CF329320
c 696	15	0.2	16	1	CR786609	ACCESSION:CR786609
697	15	0.2	17	1	BQ591181	ACCESSION:BQ591181
698	15	0.2	17	1	CF291802	ACCESSION:CF291802
699	15	0.2	17	1	CF297251	ACCESSION:CF297251
700	15	0.2	17	1	CF319075	ACCESSION:CF319075
701	15	0.2	18	1	CF298591	ACCESSION:CF298591

ALIGNMENTS

RESULT 1
AZ387867
LOCUS AZ387867 40 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0147N21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0147N21 R, genomic survey sequence.
ACCESSION AZ387867
VERSION AZ387867.1 GI:10501575
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0147 row: N column: 21
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0147N21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 50.0%; Pred. No. 9;
Matches 20; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 40
```

RESULT 2
AZ587825/c
LOCUS AZ587825 40 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0395F16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0395F16 R, genomic survey sequence.
ACCESSION AZ587825
VERSION AZ587825.1 GI:11710015
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0395 row: F column: 16
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0395F16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 40; DB 1; Length 40;
Best Local Similarity 50.0%; Pred. No. 9;
Matches 20; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
```

RESULT 3
AZ418950
LOCUS AZ418950 39 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0195D17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0195D17 F, genomic survey sequence.
ACCESSION AZ418950
VERSION AZ418950.1 GI:10542963
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 39)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0195 row: D column: 17
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 39.
FEATURES Location/Qualifiers
source 1. .39
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0195D17"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 39;
Best Local Similarity 51.3%; Pred. No. 11;
Matches 20; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39
```

RESULT 4
AZ470417
LOCUS AZ470417 39 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0284B04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0284B04 R, genomic survey sequence.
ACCESSION AZ470417
VERSION AZ470417.1 GI:10628542
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 39)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0284 row: B column: 04
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 39.
FEATURES Location/Qualifiers
source 1. .39
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0284B04"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 39;
Best Local Similarity 48.7%; Pred. No. 11;
Matches 19; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39
```

RESULT 5
AZ837376
LOCUS AZ837376 39 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0132C10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0132C10 R, genomic survey sequence.
ACCESSION AZ837376
VERSION AZ837376.1 GI:13007284
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 39)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0132 row: C column: 10
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 39.
FEATURES Location/Qualifiers
source 1. .39
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0132C10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 39;
Best Local Similarity 51.3%; Pred. No. 11;
Matches 20; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39
```

RESULT 6
AZ305049
LOCUS AZ305049 40 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0005B05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0005B05 R, genomic survey sequence.
ACCESSION AZ305049
VERSION AZ305049.1 GI:10341678
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0005 row: B column: 05
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0005B05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/).. The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 40;
Best Local Similarity 48.7%; Pred. No. 11;
Matches 19; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 40
```

RESULT 7
AZ338857
LOCUS AZ338857 40 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0070A08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0070A08 F, genomic survey sequence.
ACCESSION AZ338857
VERSION AZ338857.1 GI:10412546
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0070 row: A column: 08
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0070A08"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 40;
Best Local Similarity 48.7%; Pred. No. 11;
Matches 19; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39
```

RESULT 8
AZ513473
LOCUS AZ513473 40 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0359O21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0359O21 R, genomic survey sequence.
ACCESSION AZ513473
VERSION AZ513473.1 GI:10694789
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0359 row: O column: 21
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0359O21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 39; DB 1; Length 40;
Best Local Similarity 48.7%; Pred. No. 11;
Matches 19; Conservative 20; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 40
```

RESULT 9
AZ603138/c
LOCUS AZ603138 40 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0422G15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0422G15 F, genomic survey sequence.
ACCESSION AZ603138
VERSION AZ603138.1 GI:11725328
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0422 row: G column: 15
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0422G15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38.4; DB 1; Length 40;
Best Local Similarity 47.5%; Pred. No. 13;
Matches 19; Conservative 20; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         40 GTGTGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
```

RESULT 10
AZ808181
LOCUS AZ808181 40 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0071A18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0071A18 R, genomic survey sequence.
ACCESSION AZ808181
VERSION AZ808181.1 GI:12973460
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0071 row: A column: 18
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0071A18"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38.4; DB 1; Length 40;
Best Local Similarity 47.5%; Pred. No. 13;
Matches 19; Conservative 20; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTGT 40
```

RESULT 11
AZ326400
LOCUS AZ326400 38 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0049H14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0049H14 F, genomic survey sequence.
ACCESSION AZ326400
VERSION AZ326400.1 GI:10384116
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0049 row: H column: 14
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 38.
FEATURES Location/Qualifiers
source 1. .38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0049H14"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 38;
Best Local Similarity 50.0%; Pred. No. 13;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 38
```

RESULT 12
AZ367342
LOCUS AZ367342 38 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0116O22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0116O22 R, genomic survey sequence.
ACCESSION AZ367342
VERSION AZ367342.1 GI:10481042
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0116 row: O column: 22
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 38.
FEATURES Location/Qualifiers
source 1. .38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0116O22"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 38;
Best Local Similarity 50.0%; Pred. No. 13;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|
```

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 38;
Best Local Similarity 50.0%; Pred. No. 13;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         38 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 15
AZ968714
LOCUS AZ968714 38 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0241L08F Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0241L08 F, genomic survey sequence.
ACCESSION AZ968714
VERSION AZ968714.1 GI:13839941
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0241 row: L column: 08
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 38.
FEATURES Location/Qualifiers
source 1. .38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0241L08"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 38;
Best Local Similarity 50.0%; Pred. No. 13;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 38
```

RESULT 16
AZ345520
LOCUS AZ345520 39 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0080L01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0080L01 F, genomic survey sequence.
ACCESSION AZ345520
VERSION AZ345520.1 GI:10424757
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 39)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0080 row: L column: 01
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 39.
FEATURES Location/Qualifiers
source 1. .39
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080L01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 39;
Best Local Similarity 50.0%; Pred. No. 14;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|
```

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 38; DB 1; Length 39;
Best Local Similarity 50.0%; Pred. No. 14;
Matches 19; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 39
```

RESULT 19
AZ781129
LOCUS AZ781129 39 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0019P06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0019P06 F, genomic survey sequence.
ACCESSION AZ781129
VERSION AZ781129.1 GI:12913511
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 39)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0019 row: P column: 06
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 39.
FEATURES Location/Qualifiers
source 1. .39
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0019P06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37.4; DB 1; Length 39;
Best Local Similarity 48.7%; Pred. No. 16;
Matches 19; Conservative 19; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 CTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39
```

RESULT 20
AZ308741
LOCUS AZ308741 37 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0012J23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0012J23 F, genomic survey sequence.
ACCESSION AZ308741
VERSION AZ308741.1 GI:10349038
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0012 row: J column: 23
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 37.
FEATURES Location/Qualifiers
source 1. .37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0012J23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37; DB 1; Length 37;
Best Local Similarity 48.6%; Pred. No. 16;
Matches 18; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37
```

RESULT 21
AZ441623
LOCUS AZ441623 37 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0233N01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0233N01 R, genomic survey sequence.
ACCESSION AZ441623
VERSION AZ441623.1 GI:10565636
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0233 row: N column: 01
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 37.
FEATURES Location/Qualifiers
source 1. .37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0233N01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37; DB 1; Length 37;
Best Local Similarity 51.4%; Pred. No. 16;
Matches 19; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 37
```

RESULT 22
AZ653918
LOCUS AZ653918 37 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0527M15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0527M15 R, genomic survey sequence.
ACCESSION AZ653918
VERSION AZ653918.1 GI:11791064
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0527 row: M column: 15
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 37.
FEATURES Location/Qualifiers
source 1. .37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0527M15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37; DB 1; Length 37;
Best Local Similarity 51.4%; Pred. No. 16;
Matches 19; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 37
```

RESULT 23
AZ995480
LOCUS AZ995480 37 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0281N16F Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0281N16 F, genomic survey sequence.
ACCESSION AZ995480
VERSION AZ995480.1 GI:13866707
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0281 row: N column: 16
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 37.
FEATURES Location/Qualifiers
source 1. .37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0281N16"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37; DB 1; Length 37;
Best Local Similarity 48.6%; Pred. No. 16;
Matches 18; Conservative 19; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37
```

RESULT 24
AZ433034
LOCUS AZ433034 38 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0218N08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0218N08 R, genomic survey sequence.
ACCESSION AZ433034
VERSION AZ433034.1 GI:10557047
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0218 row: N column: 08
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 38.
FEATURES Location/Qualifiers
source 1. .38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0218N08"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 37; DB 1; Length 38;
Best Local Similarity 51.4%; Pred. No. 17;
Matches 19; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 38
```

RESULT 25
AZ837355/c
LOCUS AZ837355 40 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0132O04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0132O04 R, genomic survey sequence.
ACCESSION AZ837355
VERSION AZ837355.1 GI:13007263
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0132 row: O column: 04
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.
FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0132O04"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 36.8; DB 1; Length 40;
Best Local Similarity 45.0%; Pred. No. 19;
Matches 18; Conservative 20; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7013
              |:|:|:|:|:|:|:|:|:|:|:|:|:|: :|:|:|: :
Db         40 GTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTAT 1
```

RESULT 26
AZ504337
LOCUS AZ504337 38 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0344C08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0344C08 R, genomic survey sequence.
ACCESSION AZ504337
VERSION AZ504337.1 GI:10685653
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0344 row: C column: 08
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 38.
FEATURES Location/Qualifiers
source 1. .38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0344C08"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 36.4; DB 1; Length 38;
Best Local Similarity 47.4%; Pred. No. 19;
Matches 18; Conservative 19; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 38
```

RESULT 27
AZ514497
LOCUS AZ514497 36 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0361I19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0361I19 F, genomic survey sequence.
ACCESSION AZ514497
VERSION AZ514497.1 GI:10695909
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 36)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0361 row: I column: 19
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 36.
FEATURES Location/Qualifiers
source 1. .36
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0361I19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 36; DB 1; Length 36;
Best Local Similarity 50.0%; Pred. No. 19;
Matches 18; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36
```

RESULT 28
AZ766984
LOCUS AZ766984 36 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0564F24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0564F24 R, genomic survey sequence.
ACCESSION AZ766984
VERSION AZ766984.1 GI:12884612
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 36)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0564 row: F column: 24
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 36.
FEATURES Location/Qualifiers
source 1. .36
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0564F24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 36; DB 1; Length 36;
Best Local Similarity 50.0%; Pred. No. 19;
Matches 18; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36
```

RESULT 29
AZ939576/c
LOCUS AZ939576 36 bp DNA linear GSS 26-APR-2001
DEFINITION 2M0198C11R Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0198C11 R, genomic survey sequence.
ACCESSION AZ939576
VERSION AZ939576.1 GI:13800333
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 36)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0198 row: C column: 11
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 36.
FEATURES Location/Qualifiers
source 1. .36
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0198C11"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 36; DB 1; Length 36;
Best Local Similarity 50.0%; Pred. No. 19;
Matches 18; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         36 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 30
DR12B17S
LOCUS DR12B17S 36 bp DNA linear GSS 26-NOV-2002
DEFINITION Danio rerio genomic clone DKEY-12B17, genomic survey sequence.
ACCESSION AL747133
VERSION AL747133.1 GI:21340969
KEYWORDS GSS.
SOURCE Danio rerio (zebrafish)
ORGANISM Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.
REFERENCE 1 (bases 1 to 36)
AUTHORS Humphray,S.J., Huckle,E. and Hunt,S.E.
TITLE Direct Submission
JOURNAL Submitted (06-JUN-2002) The Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail contact: humquery@sanger.ac.uk Unpublished
COMMENT This sequence was generated from the SP6 end of BAC 12B17. 12B17 is part of the Daniokey BAC Library created by R. Plasterk and N.V. Keygene.
Further details: http://www.sanger.ac.uk/Projects/D_rerio/.
FEATURES Location/Qualifiers
source 1. .36
/organism="Danio rerio"
/mol_type="genomic DNA"
/db_xref="taxon:7955"
/clone="DKEY-12B17"
/tissue_type="Testis"
/note="vector pIndigoBAC-536"

Query Match 0.5%; Score 36; DB 1; Length 36;
Best Local Similarity 50.0%; Pred. No. 19;
Matches 18; Conservative 18; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36
```

RESULT 31
AZ426831
LOCUS AZ426831 37 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0208E01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0208E01 R, genomic survey sequence.
ACCESSION AZ426831
VERSION AZ426831.1 GI:10550844
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0208  row: E  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES              Location/Qualifiers
     source           1. .37
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0208E01"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.5%;  Score 36;  DB 1;  Length 37;
  Best Local Similarity   50.0%;  Pred. No. 20;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37


RESULT 32
AZ826021
LOCUS       AZ826021                 37 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0101F02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0101F02 R, genomic survey sequence.
ACCESSION   AZ826021
VERSION     AZ826021.1  GI:12995929
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil;C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0101  row: F  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES              Location/Qualifiers
     source           1. .37
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0101F02"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.5%;  Score 36;  DB 1;  Length 37;
  Best Local Similarity   50.0%;  Pred. No. 20;
  Matches   18;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 37


RESULT 33
AZ346424
LOCUS       AZ346424                 39 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0081N12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0081N12 R, genomic survey sequence.
ACCESSION   AZ346424
VERSION     AZ346424.1  GI:10425661
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0081  row: N  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0081N12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.8;  DB 1;  Length 39;
  Best Local Similarity   46.2%;  Pred. No. 23;
  Matches   18;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|: : :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTTTCTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 34
AZ480184
LOCUS       AZ480184                 39 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0301E04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0301E04 R, genomic survey sequence.
ACCESSION   AZ480184
VERSION     AZ480184.1  GI:10641249
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0301  row: E  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0301E04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.8;  DB 1;  Length 39;
  Best Local Similarity   51.3%;  Pred. No. 23;
  Matches   20;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7012
              |:|:|:|:|:|:|:| |:|:|:|:|:|:|:| |:|:|:|
Db          1 GTGTGTGTGTGTGTGAGTGTGTGTGTGTGTGAGTGTGTG 39


RESULT 35
AZ974885
LOCUS       AZ974885                 39 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0249P09R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0249P09 R, genomic survey sequence.
ACCESSION   AZ974885
VERSION     AZ974885.1  GI:13846112
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0249  row: P  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0249P09"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.8;  DB 1;  Length 39;
  Best Local Similarity   43.6%;  Pred. No. 23;
  Matches   17;  Conservative   20;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              :|:|:|:|: :|:|:|:|:|:|: :|:|:|:|:|:|:|:
Db          1 TGTGTGTGTATGTGTGTGTGTGTATGTGTGTGTGTGTGT 39


RESULT 36
AZ513013
LOCUS       AZ513013                 40 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0358M21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0358M21 R, genomic survey sequence.
ACCESSION   AZ513013
VERSION     AZ513013.1  GI:10694329
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0358  row: M  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0358M21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.8;  DB 1;  Length 40;
  Best Local Similarity   46.2%;  Pred. No. 25;
  Matches   18;  Conservative   19;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              | :|:|:|:|:|:|: :|:|:|:|:|:|:|:|:|:|:
Db          2 ATTGTGTGTGTGTCTGTGTGTGTGTGTGTGTGTGTGT 40


RESULT 37
AZ857946
LOCUS       AZ857946                 37 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0162M19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0162M19 R, genomic survey sequence.
ACCESSION   AZ857946
VERSION     AZ857946.1  GI:13050609
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0162  row: M  column: 19
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0162M19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.4;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 23;
  Matches   18;  Conservative   18;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|: :|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTG 37


RESULT 38
AZ875282/c
LOCUS       AZ875282                37 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0189A20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0189A20 R, genomic survey sequence.
ACCESSION   AZ875282
VERSION     AZ875282.1  GI:13085139
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0189  row: A  column: 20
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0189A20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.4;  DB 1;  Length 37;
  Best Local Similarity   51.4%;  Pred. No. 23;
  Matches   19;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         37 GTGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTG 1


RESULT 39
AZ824420
LOCUS       AZ824420                39 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0099C06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0099C06 F, genomic survey sequence.
ACCESSION   AZ824420
VERSION     AZ824420.1  GI:12994328
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0099  row: C  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0099C06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.4;  DB 1;  Length 39;
  Best Local Similarity   48.6%;  Pred. No. 26;
  Matches   18;  Conservative   18;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 CTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 40
AZ826855
LOCUS       AZ826855                 39 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0102F23R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0102F23 R, genomic survey sequence.
ACCESSION   AZ826855
VERSION     AZ826855.1  GI:12996763
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0102  row: F  column: 23
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0102F23"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35.4;  DB 1;  Length 39;
  Best Local Similarity   48.6%;  Pred. No. 26;
  Matches   18;  Conservative   18;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 CTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 41
AZ343541
LOCUS       AZ343541                 35 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0077P01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0077P01 F, genomic survey sequence.
ACCESSION   AZ343541
VERSION     AZ343541.1  GI:10421882
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0077  row: P  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0077P01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 22;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 42
AZ623738
LOCUS       AZ623738                 35 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0461E18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0461E18 R, genomic survey sequence.
ACCESSION   AZ623738
VERSION     AZ623738.1  GI:11745928
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0461  row: E  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0461E18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 22;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 35


RESULT 43
AZ643234
LOCUS       AZ643234                 35 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0506C05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0506C05 R, genomic survey sequence.
ACCESSION   AZ643234
VERSION     AZ643234.1  GI:11770446
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0506  row: C  column: 05
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0506C05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 22;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 44
AZ373001
LOCUS       AZ373001                 36 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0125A12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0125A12 F, genomic survey sequence.
ACCESSION   AZ373001
VERSION     AZ373001.1  GI:10486701
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0125  row: A  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0125A12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 36;
  Best Local Similarity   51.4%;  Pred. No. 24;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 CTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 45
AZ422282
LOCUS       AZ422282                 36 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0200H10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0200H10 R, genomic survey sequence.
ACCESSION   AZ422282
VERSION     AZ422282.1  GI:10546295
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0200  row: H  column: 10
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 36.
FEATURES            Location/Qualifiers
     source         1. .36
                    /organism="Mus musculus"
                    /mol_type="genomic DNA"
                    /strain="C57BL/6J"
                    /db_xref="taxon:10090"
                    /clone="UUGC1M0200H10"
                    /sex="Male"
                    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                    /clone_lib="Mouse 10kb plasmid UUGC1M library"
                    /note="Vector: PWD42nv; Purified genomic DNA from M.
                    musculus C57BL/6J (male) was obtained  from the Jackson
                    Laboratory Mouse DNA Resource
                    (http://www.jax.org/resources/documents/dnares/). The DNA
                    was hydrodynamically sheared by repeated passage through a
                    0.005 inch orifice at constant velocity. The sheared DNA
                    was blunt end-repaired with T4 DNA polymerase and T4
                    polynucleotide kinase. Adaptor oligonucleotides were
                    ligated to the blunt ends in high  molar excess. The
                    adaptored DNA was purified and size-selected for a 9.5 to
                    10.5 kb range using preparative agarose gel
                    electrophoresis. Vector DNA was prepared from a derivative
                    of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                    inducible derivative of plasmid R1. The vector was ligated
                    with adaptors complementary to the insert adaptors and
                    purified. The sheared, adaptored mouse DNA was annealed to
                    adaptored vector DNA, and transformed into
                    chemically-competent E. coli XL10-Gold (Stratagene) cells
                    and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 36;
  Best Local Similarity   51.4%;  Pred. No. 24;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 36


RESULT 46
AZ579564
LOCUS       AZ579564                 36 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0367L06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0367L06 F, genomic survey sequence.
ACCESSION   AZ579564
VERSION     AZ579564.1  GI:11693993
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0367  row: L  column: 06
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 36.
FEATURES            Location/Qualifiers
     source         1. .36
                    /organism="Mus musculus"
                    /mol_type="genomic DNA"
                    /strain="C57BL/6J"
                    /db_xref="taxon:10090"
                    /clone="UUGC1M0367L06"
                    /sex="Male"
                    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                    /clone_lib="Mouse 10kb plasmid UUGC1M library"
                    /note="Vector: PWD42nv; Purified genomic DNA from M.
                    musculus C57BL/6J (male) was obtained  from the Jackson
                    Laboratory Mouse DNA Resource
                    (http://www.jax.org/resources/documents/dnares/). The DNA
                    was hydrodynamically sheared by repeated passage through a
                    0.005 inch orifice at constant velocity. The sheared DNA
                    was blunt end-repaired with T4 DNA polymerase and T4
                    polynucleotide kinase. Adaptor oligonucleotides were
                    ligated to the blunt ends in high  molar excess. The
                    adaptored DNA was purified and size-selected for a 9.5 to
                    10.5 kb range using preparative agarose gel
                    electrophoresis. Vector DNA was prepared from a derivative
                    of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                    inducible derivative of plasmid R1. The vector was ligated
                    with adaptors complementary to the insert adaptors and
                    purified. The sheared, adaptored mouse DNA was annealed to
                    adaptored vector DNA, and transformed into
                    chemically-competent E. coli XL10-Gold (Stratagene) cells
                    and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 36;
  Best Local Similarity   48.6%;  Pred. No. 24;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 47
AZ848143
LOCUS       AZ848143                 36 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0149A17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0149A17 F, genomic survey sequence.
ACCESSION   AZ848143
VERSION     AZ848143.1  GI:13029405
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0149  row: A  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0149A17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 36;
  Best Local Similarity   48.6%;  Pred. No. 24;
  Matches   17;  Conservative   18;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 35


RESULT 48
AZ389462
LOCUS       AZ389462                 39 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0150D06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0150D06 F, genomic survey sequence.
ACCESSION   AZ389462
VERSION     AZ389462.1  GI:10503170
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0150  row: D  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0150D06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.5%;  Score 35;  DB 1;  Length 39;
  Best Local Similarity   51.4%;  Pred. No. 28;
  Matches   18;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          5 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 39


RESULT 49
AZ397262
LOCUS       AZ397262                 40 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0162I12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0162I12 F, genomic survey sequence.
ACCESSION   AZ397262
VERSION     AZ397262.1  GI:10512334
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0162  row: I  column: 12
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 40.
FEATURES            Location/Qualifiers
     source         1. .40
                    /organism="Mus musculus"
                    /mol_type="genomic DNA"
                    /strain="C57BL/6J"
                    /db_xref="taxon:10090"
                    /clone="UUGC1M0162I12"
                    /sex="Male"
                    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                    /clone_lib="Mouse 10kb plasmid UUGC1M library"
                    /note="Vector: PWD42nv; Purified genomic DNA from M.
                    musculus C57BL/6J (male) was obtained  from the Jackson
                    Laboratory Mouse DNA Resource
                    (http://www.jax.org/resources/documents/dnares/). The DNA
                    was hydrodynamically sheared by repeated passage through a
                    0.005 inch orifice at constant velocity. The sheared DNA
                    was blunt end-repaired with T4 DNA polymerase and T4
                    polynucleotide kinase. Adaptor oligonucleotides were
                    ligated to the blunt ends in high  molar excess. The
                    adaptored DNA was purified and size-selected for a 9.5 to
                    10.5 kb range using preparative agarose gel
                    electrophoresis. Vector DNA was prepared from a derivative
                    of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                    inducible derivative of plasmid R1. The vector was ligated
                    with adaptors complementary to the insert adaptors and
                    purified. The sheared, adaptored mouse DNA was annealed to
                    adaptored vector DNA, and transformed into
                    chemically-competent E. coli XL10-Gold (Stratagene) cells
                    and selected for ampicillin resistance."

  Query Match             0.5%;  Score 34.8;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 31;
  Matches   19;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
              |:|:|:|:|:|:|:|:|:|:|:|:| |:| |:|:|:|:
Db          2 GTGTGTGTGTGTGTGTGTGTGTGAGTGAGTGTGTGT 39


RESULT 50
AZ411170
LOCUS       AZ411170                 36 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0184D09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0184D09 F, genomic survey sequence.
ACCESSION   AZ411170
VERSION     AZ411170.1  GI:10535183
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0184  row: D  column: 09
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 36.
FEATURES            Location/Qualifiers
     source         1. .36
                    /organism="Mus musculus"
                    /mol_type="genomic DNA"
                    /strain="C57BL/6J"
                    /db_xref="taxon:10090"
                    /clone="UUGC1M0184D09"
                    /sex="Male"
                    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                    /clone_lib="Mouse 10kb plasmid UUGC1M library"
                    /note="Vector: PWD42nv; Purified genomic DNA from M.
                    musculus C57BL/6J (male) was obtained  from the Jackson
                    Laboratory Mouse DNA Resource
                    (http://www.jax.org/resources/documents/dnares/). The DNA
                    was hydrodynamically sheared by repeated passage through a
                    0.005 inch orifice at constant velocity. The sheared DNA
                    was blunt end-repaired with T4 DNA polymerase and T4
                    polynucleotide kinase. Adaptor oligonucleotides were
                    ligated to the blunt ends in high  molar excess. The
                    adaptored DNA was purified and size-selected for a 9.5 to
                    10.5 kb range using preparative agarose gel
                    electrophoresis. Vector DNA was prepared from a derivative
                    of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                    inducible derivative of plasmid R1. The vector was ligated
                    with adaptors complementary to the insert adaptors and
                    purified. The sheared, adaptored mouse DNA was annealed to
                    adaptored vector DNA, and transformed into
                    chemically-competent E. coli XL10-Gold (Stratagene) cells
                    and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34.4;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 27;
  Matches   18;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:| |
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAG 36


RESULT 51
AZ648468
LOCUS       AZ648468                 36 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0517E02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0517E02 R, genomic survey sequence.
ACCESSION   AZ648468
VERSION     AZ648468.1  GI:11780965
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0517  row: E  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES              Location/Qualifiers
     source           1. .36
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0517E02"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34.4;  DB 1;  Length 36;
  Best Local Similarity   50.0%;  Pred. No. 27;
  Matches   18;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
                | |:|:|:|
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0215  row: L  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0215L08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34.4;  DB 1;  Length 37;
  Best Local Similarity   50.0%;  Pred. No. 29;
  Matches   18;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6969 UAACUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|| :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 37


RESULT 54
AZ319970
LOCUS       AZ319970                 40 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0039K17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0039K17 R, genomic survey sequence.
ACCESSION   AZ319970
VERSION     AZ319970.1  GI:10371276
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0039  row: K  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0039K17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34.4;  DB 1;  Length 40;
  Best Local Similarity   50.0%;  Pred. No. 34;
  Matches   18;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCG 36


RESULT 55
AZ484963
LOCUS       AZ484963                 34 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0311M17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0311M17 R, genomic survey sequence.
ACCESSION   AZ484963
VERSION     AZ484963.1  GI:10650316
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0311  row: M  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 34.
FEATURES              Location/Qualifiers
     source           1. .34
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0311M17"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 27;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 34


RESULT 56
AZ612777
LOCUS       AZ612777                 35 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0439P13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0439P13 R, genomic survey sequence.
ACCESSION   AZ612777
VERSION     AZ612777.1  GI:11734967
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0439  row: P  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES              Location/Qualifiers
     source           1. .35
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0439P13"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34;  DB 1;  Length 35;
  Best Local Similarity   50.0%;  Pred. No. 28;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 57
AZ819087
LOCUS       AZ819087                 35 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0089G02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0089G02 R, genomic survey sequence.
ACCESSION   AZ819087
VERSION     AZ819087.1  GI:12988995
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0089  row: G  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0089G02"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 34;  DB 1;  Length 35;
  Best Local Similarity   50.0%;  Pred. No. 28;
  Matches   17;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 58
AZ456482
LOCUS       AZ456482                 37 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0259P11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0259P11 F, genomic survey sequence.
ACCESSION   AZ456482
VERSION     AZ456482.1  GI:10614523
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0259  row: P  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0259P11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.8;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 33;
  Matches   18;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |: :|:| |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 CTCTGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTG 37


RESULT 59
AZ647581
LOCUS       AZ647581                 37 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0514J14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0514J14 F, genomic survey sequence.
ACCESSION   AZ647581
VERSION     AZ647581.1  GI:11779189
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0514  row: J  column: 14
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0514J14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.8;  DB 1;  Length 37;
  Best Local Similarity   45.9%;  Pred. No. 33;
  Matches   17;  Conservative   18;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7009
              :|:  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTTGGTGTGTGTGTGTGTGTGTGTGTGTGTGT 37


RESULT 60
AZ447539
LOCUS       AZ447539                38 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0244E14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0244E14 R, genomic survey sequence.
ACCESSION   AZ447539
VERSION     AZ447539.1  GI:10599435
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0244  row: E  column: 14
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 38.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0244E14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.8;  DB 1;  Length 38;
  Best Local Similarity   48.6%;  Pred. No. 35;
  Matches   18;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              |  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GCGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTG 38


RESULT 61
AZ803581
LOCUS       AZ803581                38 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0064L05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0064L05 F, genomic survey sequence.
ACCESSION   AZ803581
VERSION     AZ803581.1  GI:12955904
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0064  row: L  column: 05
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 38.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0064L05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.8;  DB 1;  Length 38;
  Best Local Similarity   48.6%;  Pred. No. 35;
  Matches   18;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7010
              | |: :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GAGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 38


RESULT 62
AZ819018
LOCUS       AZ819018                 40 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0089I19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0089I19 F, genomic survey sequence.
ACCESSION   AZ819018
VERSION     AZ819018.1  GI:12988926
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0089  row: I  column: 19
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0089I19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.6;  DB 1;  Length 40;
  Best Local Similarity   45.0%;  Pred. No. 41;
  Matches   18;  Conservative   18;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6964 UGGUGUAACUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :||  :|  :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGGATTACGTGTGTGTGTGTGTGTGTGTGTGTGTGT 40


RESULT 63
AZ370273
LOCUS       AZ370273                 35 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0121B13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0121B13 F, genomic survey sequence.
ACCESSION   AZ370273
VERSION     AZ370273.1  GI:10483973
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0121  row: B  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0121B13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 35;
  Best Local Similarity   51.4%;  Pred. No. 33;
  Matches   18;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6970 AACUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
                || :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 AAGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 64
AZ626427/c
LOCUS       AZ626427                 35 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0466K09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0466K09 R, genomic survey sequence.
ACCESSION   AZ626427
VERSION     AZ626427.1  GI:11748617
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0466  row: K  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0466K09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 35;
  Best Local Similarity   45.7%;  Pred. No. 33;
  Matches   16;  Conservative   18;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
                : :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         35 TTTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 65
AZ489673
LOCUS       AZ489673                 36 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0322E18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0322E18 F, genomic survey sequence.
ACCESSION   AZ489673
VERSION     AZ489673.1  GI:10659652
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0322  row: E  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES             Location/Qualifiers
     source          1. .36
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0322E18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33.4;  DB 1;  Length 36;
  Best Local Similarity   48.6%;  Pred. No. 35;
  Matches   17;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:| |:|:|:|:|:|:|:|:|:|:|:|:
Db          2 TGTGTGTGGGTGTGTGTGTGTGTGTGTGTGTGT 36


RESULT 66
AZ464370
LOCUS       AZ464370                 33 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0273P11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0273P11 R, genomic survey sequence.
ACCESSION   AZ464370
VERSION     AZ464370.1  GI:10622495
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0273  row: P  column: 11
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0273P11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 32;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 33


RESULT 67
AZ594701
LOCUS       AZ594701                 33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0406C21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0406C21 R, genomic survey sequence.
ACCESSION   AZ594701
VERSION     AZ594701.1  GI:11716891
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0406  row: C  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0406C21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 32;
  Matches   16;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 68
AZ623603
LOCUS       AZ623603                 33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0461G04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0461G04 R, genomic survey sequence.
ACCESSION   AZ623603
VERSION     AZ623603.1  GI:11745793
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0461  row: G  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0461G04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 32;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 33


RESULT 69
AZ623817
LOCUS       AZ623817                 33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0461G24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0461G24 R, genomic survey sequence.
ACCESSION   AZ623817
VERSION     AZ623817.1  GI:11746007
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0461  row: G  column: 24
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0461G24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 32;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 33


RESULT 70
AZ817793
LOCUS       AZ817793                 33 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0087P19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0087P19 F, genomic survey sequence.
ACCESSION   AZ817793
VERSION     AZ817793.1  GI:12987701
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0087  row: P  column: 19
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0087P19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   51.5%;  Pred. No. 32;
  Matches   17;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 33


RESULT 71
AZ853249
LOCUS       AZ853249                 33 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0156O15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0156O15 F, genomic survey sequence.
ACCESSION   AZ853249
VERSION     AZ853249.1  GI:13041174
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0156  row: O  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0156O15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 32;
  Matches   16;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 72
AZ365445
LOCUS       AZ365445                 34 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0112B09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0112B09 F, genomic survey sequence.
ACCESSION   AZ365445
VERSION     AZ365445.1  GI:10479145
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0112  row: B  column: 09
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 34.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0112B09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 33;  DB 1;  Length 34;
  Best Local Similarity   48.5%;  Pred. No. 34;
  Matches   16;  Conservative   17;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 34


RESULT 73
AZ511942
LOCUS       AZ511942                 39 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0357O08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0357O08 F, genomic survey sequence.
ACCESSION   AZ511942
VERSION     AZ511942.1  GI:10693258
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0357  row: O  column: 08
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0357O08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32.6;  DB 1;  Length 39;
  Best Local Similarity   41.0%;  Pred. No. 50;
  Matches   16;  Conservative   19;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7011
                :|:|:|:|: :|:|:|:|:|:|:|: :|:  |:|:|:|:
Db          1 TGTGTGTGTATGTGTGTGTGTGTGTATGTAGGTGTGTGT 39


RESULT 74
AZ509672
LOCUS       AZ509672                 34 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0352A18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0352A18 R, genomic survey sequence.
ACCESSION   AZ509672
VERSION     AZ509672.1  GI:10690988
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0352  row: A  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 34.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0352A18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32.4;  DB 1;  Length 34;
  Best Local Similarity   50.0%;  Pred. No. 39;
  Matches   17;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
                :|:|:|:|:|:| |:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGCGTGTGTGTGTGTGTGTGTGTG 34


RESULT 75
AZ484773
LOCUS       AZ484773                 38 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0311B02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0311B02 R, genomic survey sequence.
ACCESSION   AZ484773
VERSION     AZ484773.1  GI:10649940
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0311  row: B  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 38.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0311B02"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32.4;  DB 1;  Length 38;
  Best Local Similarity   47.1%;  Pred. No. 49;
  Matches   16;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:| :
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTAT 35


RESULT 76
AZ307970
LOCUS       AZ307970                 32 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0010A03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0010A03 R, genomic survey sequence.
ACCESSION   AZ307970
VERSION     AZ307970.1  GI:10347495
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0010  row: A  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0010A03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 38;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 77
AZ311840
LOCUS       AZ311840                 32 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0027M21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0027M21 F, genomic survey sequence.
ACCESSION   AZ311840
VERSION     AZ311840.1  GI:10355201
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0027  row: M  column: 21
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0027M21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 38;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
             :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 78
AZ495235
LOCUS       AZ495235                 32 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0331E05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0331E05 F, genomic survey sequence.
ACCESSION   AZ495235
VERSION     AZ495235.1  GI:10670567
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
          Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE   Mouse whole genome scaffolding with paired end reads from 10kb
          plasmid inserts
  JOURNAL Unpublished (2000)
COMMENT   Contact: Robert B. Weiss
          University of Utah Genome Center
          University of Utah
          Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
          84112, USA
          Tel: 801 585 5606
          Fax: 801 585 7177
          Email: ddunn@genetics.utah.edu
          Insert Length: 10000   Std Error: 0.00
          Plate: 0331  row: E  column: 05
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0331E05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 32;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 38;
  Matches   16;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
             :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 79
AZ483942
LOCUS       AZ483942                 35 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0309H20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0309H20 R, genomic survey sequence.
ACCESSION   AZ483942
VERSION     AZ483942.1  GI:10648262
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
```

```
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0309  row: H  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0309H20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 31.8;  DB 1;  Length 35;
  Best Local Similarity   48.6%;  Pred. No. 48;
  Matches   17;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:| |: :|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGCGTCTG 35


RESULT 80
BX559884
LOCUS       BX559884                 33 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX559884 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse46c02_p1c, mRNA sequence.
ACCESSION   BX559884
VERSION     BX559884.1  GI:33367775
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
  PUBMED    14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse46c02_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 46;
  Matches   16;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|:|:|:|:|:|: :|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTATGTGTGTGTGTGTG 33


RESULT 81
AZ638769
LOCUS       AZ638769                 33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0498B20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0498B20 R, genomic survey sequence.
ACCESSION   AZ638769
VERSION     AZ638769.1  GI:11760959
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0498  row: B  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
```

```
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0498B20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 33;
  Best Local Similarity   45.5%;  Pred. No. 46;
  Matches   15;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              : :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TTTGTGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 82
AZ613057
LOCUS       AZ613057                35 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0441C17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0441C17 F, genomic survey sequence.
ACCESSION   AZ613057
VERSION     AZ613057.1  GI:11735247
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0441  row: C  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
```

```
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0441C17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 31.4;  DB 1;  Length 35;
  Best Local Similarity   48.5%;  Pred. No. 52;
  Matches   16;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
              |:|:|: :|:|:|:|:|:|:|:|:|:|:|:|
Db          3 GTGTGTCTGTGTGTGTGTGTGTGTGTGTG 35


RESULT 83
AZ968276
LOCUS       AZ968276                36 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0240K02R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0240K02 R, genomic survey sequence.
ACCESSION   AZ968276
VERSION     AZ968276.1  GI:13839503
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0240  row: K  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES             Location/Qualifiers
```

```
    source          1. .36
                    /organism="Mus musculus"
                    /mol_type="genomic DNA"
                    /strain="C57BL/6J"
                    /db_xref="taxon:10090"
                    /clone="UUGC2M0240K02"
                    /sex="Female"
                    /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                    /clone_lib="Mouse 10kb plasmid UUGC2M library"
                    /note="Vector: PWD42nv; Purified genomic DNA from M.
                    musculus C57BL/6J (female) was obtained  from the Jackson
                    Laboratory Mouse DNA Resource
                    (http://www.jax.org/resources/documents/dnares/). The DNA
                    was hydrodynamically sheared by repeated passage through a
                    0.005 inch orifice at constant velocity. The sheared DNA
                    was blunt end-repaired with T4 DNA polymerase and T4
                    polynucleotide kinase. Adaptor oligonucleotides were
                    ligated to the blunt ends in high  molar excess. The
                    adaptored DNA was purified and size-selected for a 9.5 to
                    10.5 kb range using preparative agarose gel
                    electrophoresis. Vector DNA was prepared from a derivative
                    of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                    inducible derivative of plasmid R1. The vector was ligated
                    with adaptors complementary to the insert adaptors and
                    purified. The sheared, adaptored mouse DNA was annealed to
                    adaptored vector DNA, and transformed into
                    chemically-competent E. coli XL10-Gold (Stratagene) cells
                    and selected for ampicillin resistance."

  Query Match             0.4%;  Score 31.2;  DB 1;  Length 36;
  Best Local Similarity   47.2%;  Pred. No. 58;
  Matches   17;  Conservative   16;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7008
              :|:|:|:|:|:|:|:|:|:|:|:|:|  |   :|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGCGCATGTG 36


RESULT 84
BX559875
LOCUS       BX559875                 31 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX559875 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse46b07_p1c, mRNA sequence.
ACCESSION   BX559875
VERSION     BX559875.1  GI:33367759
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse46b07_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTG 31


RESULT 85
AZ459099
LOCUS       AZ459099                 31 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0263O12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0263O12 R, genomic survey sequence.
ACCESSION   AZ459099
VERSION     AZ459099.1  GI:10617224
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0263  row: O  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0263O12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 31
```

```
RESULT 86
AZ470636
LOCUS       AZ470636                 31 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0284N13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0284N13 R, genomic survey sequence.
ACCESSION   AZ470636
VERSION     AZ470636.1  GI:10628761
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0284  row: N  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0284N13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 45;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31
```

```
RESULT 87
AZ479719
LOCUS       AZ479719                 31 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0300N01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0300N01 R, genomic survey sequence.
ACCESSION   AZ479719
VERSION     AZ479719.1  GI:10639888
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0300  row: N  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0300N01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 45;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 31
```

```
RESULT 88
AZ494924/c
LOCUS       AZ494924                 31 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0330D03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0330D03 R, genomic survey sequence.
ACCESSION   AZ494924
VERSION     AZ494924.1  GI:10669930
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0330  row: D  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0330D03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

```
RESULT 89
AZ666438
LOCUS       AZ666438                 31 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0548N21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0548N21 F, genomic survey sequence.
ACCESSION   AZ666438
VERSION     AZ666438.1  GI:11803584
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0548  row: N  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0548N21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 31
```

```
RESULT 90
AZ769716
LOCUS       AZ769716                31 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0570M12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0570M12 R, genomic survey sequence.
ACCESSION   AZ769716
VERSION     AZ769716.1  GI:12890142
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0570  row: M  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0570M12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 31
```

```
RESULT 91
AZ874102/c
LOCUS       AZ874102                31 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0188C07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0188C07 F, genomic survey sequence.
ACCESSION   AZ874102
VERSION     AZ874102.1  GI:13082806
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0188  row: C  column: 07
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0188C07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   51.6%;  Pred. No. 45;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 92
AZ987243/c

```
LOCUS       AZ987243                  31 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0269D16R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0269D16 R, genomic survey sequence.
ACCESSION   AZ987243
VERSION     AZ987243.1  GI:13858470
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0269  row: D  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0269D16"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 45;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
```

RESULT 93
AZ377767/c

```
LOCUS       AZ377767                  32 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0132F15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0132F15 F, genomic survey sequence.
ACCESSION   AZ377767
VERSION     AZ377767.1  GI:10491467
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0132  row: F  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0132F15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 32;
  Best Local Similarity   48.4%;  Pred. No. 48;
  Matches   15;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db         32 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2
```

RESULT 94
AZ834388
LOCUS AZ834388 33 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0117N01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0117N01 F, genomic survey sequence.
ACCESSION AZ834388
VERSION AZ834388.1 GI:13004296
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 33)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0117 row: N column: 01
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 33.
FEATURES Location/Qualifiers
source 1. .33
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0117N01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 31;  DB 1;  Length 33;
  Best Local Similarity   51.6%;  Pred. No. 51;
  Matches   16;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 GTGTGTGTGTGTGTGTGTGTGTGTGTGTG 33
```

RESULT 95
AZ991583/c
LOCUS AZ991583 37 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0275G21R Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0275G21 R, genomic survey sequence.
ACCESSION AZ991583
VERSION AZ991583.1 GI:13862810
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 37)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0275 row: G column: 21
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 37.
FEATURES Location/Qualifiers
source 1. .37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0275G21"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 30.6;  DB 1;  Length 37;
  Best Local Similarity   48.6%;  Pred. No. 71;
  Matches   18;  Conservative   15;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6979 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGUGG 7015
              :|:|:| |:|:|:|:|:|:| |:|:| |:|:|:|: |
Db         37 TGTGTGCGTGTGTGTGTGTGCGTGTGCGTGTGTGTAG 1
```

RESULT 96
AZ448483
LOCUS AZ448483 32 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0246M11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0246M11 F, genomic survey sequence.
ACCESSION AZ448483
VERSION AZ448483.1 GI:10601321
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 32)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0246 row: M column: 11
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 32.
FEATURES Location/Qualifiers
source 1. .32
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0246M11"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.4%;  Score 30.4;  DB 1;  Length 32;
  Best Local Similarity   46.9%;  Pred. No. 55;
  Matches   15;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              |: :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTTTGTGTGTGTGTGTGTGTGTGTGTGT 32
```

RESULT 97
CD744339
LOCUS CD744339 34 bp mRNA linear EST 25-JUN-2004
DEFINITION IRB4_F06_4_048 Infected Rat Blood-fed (IRB) An.gam. 30 hr Abdomen Library Anopheles gambiae cDNA 5', mRNA sequence.
ACCESSION CD744339
VERSION CD744339.1 GI:49248276
KEYWORDS EST.
SOURCE Anopheles gambiae (African malaria mosquito)
ORGANISM Anopheles gambiae
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Culicidae; Anophelinae; Anopheles.
REFERENCE 1 (bases 1 to 34)
AUTHORS Dana,A.N., Lobo,N.F., Hillenmeyer,M.E. and Collins,F.H.
TITLE Hematophagy-associated gene expression patterns in adult female Anopheles gambiae mosquitoes
JOURNAL Unpublished (2003)
COMMENT Contact: Dana A.N.
Frank H. Collins Laboratory
University of Notre Dame
Center for Tropical Disease Research and Training, Dept. of Biol. Sci., Notre Dame, IN 46556, USA
Tel: 574 - 631 - 3241
Fax: 574 - 631 - 3996
Email: adana@nd.edu
PCR PRimers
FORWARD: ctcgggaagcgcgccattgtgttgg
BACKWARD: atacgactcactatagggcgaattggc
Seq primer: ctcgggaagcgcgccattgtgttgg.
FEATURES Location/Qualifiers
source 1. .34
/organism="Anopheles gambiae"
/mol_type="mRNA"
/strain="4Arr"
/db_xref="taxon:7165"
/sex="female"
/tissue_type="Abdomens"
/dev_stage="Female adult 5-7 days post eclosion"
/lab_host="E. coli XLI-Blue"
/clone_lib="Infected Rat Blood-fed (IRB) An.gam. 30 hr Abdomen Library"
/note="Vector: lamdaTriplEx2 (Clontech); Site_1: Sfi IA; Site_2: Sfi IB; Plasmodium berghei-infected rat blood-fed adult female An. gambiae mosquitoes were flash frozen after a 30 hour incubation of adult mosquitoes at 19 degrees Celsius. Total RNA extracted from abdomens separated from remaining carcass. CDNA inserts >500 bp cloned directionally into lTriplEx2; Sfi IA site is 5'. Non-normalized and Non-amplified phagemid library. Single pass sequencing reactions from 5' end."

```
  Query Match             0.4%;  Score 30.4;  DB 1;  Length 34;
```

```
  Best Local Similarity   50.0%;  Pred. No. 62;
  Matches   17;  Conservative   14;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              | |:| |:|:| |:|:|:|:|:|:|:|:|:|:
Db          1 GGGTGNGTGTGNGTGTGTGTGTGTGTGTGT 34


RESULT 98
AZ832583/c
LOCUS       AZ832583                35 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0113N06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0113N06 F, genomic survey sequence.
ACCESSION   AZ832583
VERSION     AZ832583.1  GI:13002491
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0113  row: N  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0113N06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 30.2;  DB 1;  Length 35;
```

```
  Best Local Similarity   42.9%;  Pred. No. 69;
  Matches   15;  Conservative   17;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7007
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|  : :
Db         35 TGTGTGTGTGTGTGTGTGTGTGTGTGTGAATTT 1


RESULT 99
AZ475919
LOCUS       AZ475919                30 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0294P15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0294P15 F, genomic survey sequence.
ACCESSION   AZ475919
VERSION     AZ475919.1  GI:10634044
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0294  row: P  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0294P15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
```

```
  Best Local Similarity   50.0%;  Pred. No. 53;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 100
AZ809101
LOCUS       AZ809101                 30 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0072N22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0072N22 R, genomic survey sequence.
ACCESSION   AZ809101
VERSION     AZ809101.1  GI:12975120
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0072  row: N  column: 22
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0072N22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
```

```
  Best Local Similarity   50.0%;  Pred. No. 53;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 101
AZ989744
LOCUS       AZ989744                 30 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0273N10F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0273N10 F, genomic survey sequence.
ACCESSION   AZ989744
VERSION     AZ989744.1  GI:13860971
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0273  row: N  column: 10
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0273N10"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 30;  DB 1;  Length 30;
```

```
  Best Local Similarity   50.0%;  Pred. No. 53;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 102
AZ606329
LOCUS       AZ606329                 32 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0428K07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0428K07 F, genomic survey sequence.
ACCESSION   AZ606329
VERSION     AZ606329.1  GI:11728519
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0428  row: K  column: 07
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0428K07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 30;  DB 1;  Length 32;
```

```
  Best Local Similarity   50.0%;  Pred. No. 61;
  Matches   15;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 32


RESULT 103
AZ514079/c
LOCUS       AZ514079                 33 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0360F07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0360F07 R, genomic survey sequence.
ACCESSION   AZ514079
VERSION     AZ514079.1  GI:10695395
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0360  row: F  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0360F07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29.8;  DB 1;  Length 33;
```

```
  Best Local Similarity   48.5%;  Pred. No. 68;
  Matches   16;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
              :|:|:|:|:| |:|:|:|:| |:|:|:|:|:|:
Db         33 TGTGTGTGTGAGTGTGTGTGAGTGTGTGTGT 1


RESULT 104
AZ512195
LOCUS       AZ512195                 35 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0357O04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0357O04 R, genomic survey sequence.
ACCESSION   AZ512195
VERSION     AZ512195.1  GI:10693511
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0357  row: O  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0357O04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29.8;  DB 1;  Length 35;

  Best Local Similarity   45.5%;  Pred. No. 76;
  Matches   15;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6983 UGUGUGUGUGUGUGUGUGUGUGUGUGUGUGG 7015
              :|:|:|:|:| :|:|:|:|:|:|: :|:|:||
Db          1 TGTGTGTGTGTATGTGTGTGTGTATGTGTGG 33


RESULT 105
AZ438581
LOCUS       AZ438581                 34 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0228D16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0228D16 R, genomic survey sequence.
ACCESSION   AZ438581
VERSION     AZ438581.1  GI:10562594
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0228  row: D  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 34.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0228D16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29.4;  DB 1;  Length 34;
```

```
  Best Local Similarity   51.6%;  Pred. No. 79;
  Matches   16;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              | |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          4 CAGTGTGTGTGTGTGTGTGTGTGTGTGTG 34


RESULT 106
AZ960947/c
LOCUS       AZ960947                 35 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0229M11F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0229M11 F, genomic survey sequence.
ACCESSION   AZ960947
VERSION     AZ960947.1  GI:13832174
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 35)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0229  row: M  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 35.
FEATURES             Location/Qualifiers
     source          1. .35
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0229M11"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29.2;  DB 1;  Length 35;
```

```
  Best Local Similarity   47.1%;  Pred. No. 87;
  Matches   16;  Conservative   15;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6983 UGUGUGUGUGUGUGUGUGUGUGUGUGUGGG 7016
              :|:|:|:|:|:|:|:|:|:|:|: : :| |||
Db         35 TGTGTGTGTGTGTGTGTGTGTGTTTTTGGGGG 2


RESULT 107
AZ315179
LOCUS       AZ315179                 29 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0032K18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0032K18 F, genomic survey sequence.
ACCESSION   AZ315179
VERSION     AZ315179.1  GI:10361776
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0032  row: K  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0032K18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
```

```
  Best Local Similarity   51.7%;  Pred. No. 63;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTG 29


RESULT 108
AZ414401
LOCUS       AZ414401                 29 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0188M13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0188M13 R, genomic survey sequence.
ACCESSION   AZ414401
VERSION     AZ414401.1  GI:10538414
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0188  row: M  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0188M13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 63;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 109
AG189223
LOCUS       AG189223                 29 bp    DNA     linear   GSS 06-MAR-2004
DEFINITION  Pan troglodytes DNA, clone: RP43-063J22.T7, genomic survey
            sequence.
ACCESSION   AG189223
VERSION     AG189223.1  GI:45221399
KEYWORDS    GSS.
SOURCE      Pan troglodytes (chimpanzee)
  ORGANISM  Pan troglodytes
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pan.
REFERENCE   1
  AUTHORS   Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
            Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
  TITLE     BAC end sequences of Library RP-43
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 29)
  AUTHORS   Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
            Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
            Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);
            52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
            (E-mail:redstone@mail.kribb.re.kr, URL:http://phs.grc.kribb.re.kr/,
            Tel:82-42-866-7181, Fax:82-42-860-4409)
COMMENT     Clones are derived from the chimpanzee BAC library RP-43 This BAC
            end was generated during the R&D process and may have higher chance
            of clone tracking errors.
             PRIMERS
                Sequencing: T7
             LIBRARY
                Vector    : pBACe3.6
                R.Site 1  : EcoRI
                R.Site 2  : EcoRI.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Pan troglodytes"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9598"
                     /clone="RP43-063J22.T7"
                     /sex="male"
                     /cell_type="lymphocytes"
                     /clone_lib="RP-43 Chimpanzee Male BAC Library"

  Query Match             0.4%;  Score 29;  DB 1;  Length 29;
  Best Local Similarity   48.3%;  Pred. No. 63;
  Matches   14;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 29


RESULT 110
AZ497897
LOCUS       AZ497897                 30 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0334K20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0334K20 R, genomic survey sequence.
ACCESSION   AZ497897
VERSION     AZ497897.1  GI:10675242
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0334  row: K  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0334K20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29;  DB 1;  Length 30;
  Best Local Similarity   51.7%;  Pred. No. 67;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 111
AZ635862
LOCUS       AZ635862                  30 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0493O04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0493O04 F, genomic survey sequence.
ACCESSION   AZ635862
VERSION     AZ635862.1  GI:11758052
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0493  row: O  column: 04
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0493O04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29;  DB 1;  Length 30;
  Best Local Similarity   51.7%;  Pred. No. 67;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUG 7000
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 CTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 112
AZ628068/c
LOCUS       AZ628068                  31 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0476P22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0476P22 F, genomic survey sequence.
ACCESSION   AZ628068
VERSION     AZ628068.1  GI:11750258
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0476  row: P  column: 22
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0476P22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 29;  DB 1;  Length 31;
  Best Local Similarity   51.7%;  Pred. No. 72;
  Matches   15;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
             |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         31 GTGTGTGTGTGTGTGTGTGTGTGTGTG 3


RESULT 113
AZ335085/c
LOCUS       AZ335085                32 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0064F17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0064F17 R, genomic survey sequence.
ACCESSION   AZ335085
VERSION     AZ335085.1  GI:10403046
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0064  row: F  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0064F17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.8;  DB 1;  Length 32;
  Best Local Similarity   46.9%;  Pred. No. 80;
  Matches   15;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
             |:|:|:|:|:|:|:|:|:|:|:|:|:|  :|:
Db         32 GTGTGTGTGTGTGTGTGTGTGTGTGCATGT 1


RESULT 114
AZ661921
LOCUS       AZ661921                32 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0540B17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0540B17 R, genomic survey sequence.
ACCESSION   AZ661921
VERSION     AZ661921.1  GI:11799067
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0540  row: B  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0540B17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.8;  DB 1;  Length 32;
  Best Local Similarity   46.9%;  Pred. No. 80;
  Matches   15;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6967 UGUAACUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:  |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTTGCTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 115
AZ412174
LOCUS       AZ412174                 30 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0185H01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0185H01 R, genomic survey sequence.
ACCESSION   AZ412174
VERSION     AZ412174.1  GI:10536187
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0185  row: H  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0185H01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.4;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 77;
  Matches   15;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              | |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GGGTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 116
AZ458713/c
LOCUS       AZ458713                 30 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0263L02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0263L02 F, genomic survey sequence.
ACCESSION   AZ458713
VERSION     AZ458713.1  GI:10616838
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 30)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0263 row: L column: 02
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 30.
FEATURES Location/Qualifiers
source 1. .30
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0263L02"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28.4; DB 1; Length 30;
Best Local Similarity 46.7%; Pred. No. 77;
Matches 14; Conservative 15; Mismatches 1; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7003
|:|:|:|:|:|:|: :|:|:|:|:|:|:|:
Db 30 GTGTGTGTGTGTGTATGTGTGTGTGTGT 1

RESULT 117
TA7A12P/c
LOCUS TA7A12P 30 bp DNA linear GSS 13-DEC-2000
DEFINITION T. brucei sheared genomic DNA clone 7a12, forward sequence, genomic survey sequence.
ACCESSION AL452578
VERSION AL452578.1 GI:11859429
KEYWORDS GSS.
SOURCE Trypanosoma brucei
ORGANISM Trypanosoma brucei
Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
REFERENCE 1 (bases 1 to 30)
AUTHORS Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R., Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L., Melville,S.E., Rajandream,M.A. and Barrell,B.G.
TITLE Direct Submission
JOURNAL Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and nh1@sanger.ac.uk
COMMENT Constructed at the Institute for Genomic Research (TIGR), Rockville, MD. Genomic DNA isolated from a cloned population of Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared to give a tight size distribution (
4 kb). The v + i method used for the library construction is described in detail in Smith, H. and Venter, J.C. (Making small insert libraries for whole genome shotgun sequencing projects. In Genome Sequencing: A Practical Approach, eds. M. Vaudin and B. Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES Location/Qualifiers
source 1. .30
/organism="Trypanosoma brucei"
/mol_type="genomic DNA"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="7a12"

Query Match 0.4%; Score 28.4; DB 1; Length 30;
Best Local Similarity 50.0%; Pred. No. 77;
Matches 15; Conservative 14; Mismatches 1; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
|:|:|:|:| |:|:|:|:|:|:|:|:|:|:
Db 30 GTGTGTGTGGGTGTGTGTGTGTGTGTGTGT 1

RESULT 118
AZ399554
LOCUS AZ399554 31 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0165O19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0165O19 F, genomic survey sequence.
ACCESSION AZ399554
VERSION AZ399554.1 GI:10514628
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 31)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0165 row: O column: 19
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends

High quality sequence stop: 31.

FEATURES Location/Qualifiers
source 1. .31
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0165O19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28.4; DB 1; Length 31;
Best Local Similarity 53.3%; Pred. No. 82;
Matches 16; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6989 UGUGUGUGUGUGUGUGUGUGUGUGGGUG 7018
              :|:|:|:|:|:|:|:|:|:|:| |:|||:|
Db          1 TGTGTGTGTGTGTGTGTGTGGGTGGGTG 30
```

RESULT 119
AZ440652
LOCUS AZ440652 31 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0231N14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0231N14 R, genomic survey sequence.
ACCESSION AZ440652
VERSION AZ440652.1 GI:10564665
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 31)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0231 row: N column: 14
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends

High quality sequence stop: 31.

FEATURES Location/Qualifiers
source 1. .31
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0231N14"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28.4; DB 1; Length 31;
Best Local Similarity 50.0%; Pred. No. 82;
Matches 15; Conservative 14; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:| |:|:|:|:|:|:|:|:
Db          2 GTGTGTGTGTGAGTGTGTGTGTGTGTGT 31
```

RESULT 120
AZ659684
LOCUS AZ659684 31 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0537C17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0537C17 F, genomic survey sequence.
ACCESSION AZ659684
VERSION AZ659684.1 GI:11796830
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 31)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0537 row: C column: 17
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends

```
          High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0537C17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.4;  DB 1;  Length 31;
  Best Local Similarity   46.7%;  Pred. No. 82;
  Matches   14;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
              : :|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TATGTGTGTGTGTGTGTGTGTGTGTGTG 31


RESULT 121
AZ841151
LOCUS       AZ841151                 31 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0139D04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0139D04 F, genomic survey sequence.
ACCESSION   AZ841151
VERSION     AZ841151.1  GI:13011059
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0139  row: D  column: 04
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
```

```
          High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0139D04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.4;  DB 1;  Length 31;
  Best Local Similarity   46.7%;  Pred. No. 82;
  Matches   14;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              |: :|:|:|:|:|:|:|:|:|:|:|:|:
Db          2 CTCTGTGTGTGTGTGTGTGTGTGTGTGT 31


RESULT 122
AZ626646
LOCUS       AZ626646                 33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0467E06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0467E06 F, genomic survey sequence.
ACCESSION   AZ626646
VERSION     AZ626646.1  GI:11748836
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0467  row: E  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
```

```
          High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0467E06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.4;  DB 1;  Length 33;
  Best Local Similarity   46.7%;  Pred. No. 93;
  Matches   14;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              |:|:|:|:|:|:|:|:|:|: :|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTTTGTGTGTGT 30


RESULT 123
AZ875700
LOCUS       AZ875700                 34 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0190D19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0190D19 F, genomic survey sequence.
ACCESSION   AZ875700
VERSION     AZ875700.1  GI:13085970
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0190  row: D  column: 19
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
```

```
          High quality sequence stop: 34.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0190D19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28.2;  DB 1;  Length 34;
  Best Local Similarity   48.5%;  Pred. No. 1e+02;
  Matches   16;  Conservative   14;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6984 GUGUGUGUGUGUGUGUGUGUGUGUGUGGG 7016
              |:|:|:|:|: :|:|:|:|:|:|:|:|:  |||
Db          1 GTGTGTGTGTCTGTGTGTGTGTGTGTTGGGG 33


RESULT 124
BX553058
LOCUS       BX553058                 28 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX553058 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse127a09_p1c, mRNA sequence.
ACCESSION   BX553058
VERSION     BX553058.1  GI:33377257
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
```

```
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse127a09_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match              0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 125
BX559897
LOCUS       BX559897                 28 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX559897 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse46d02_p1c, mRNA sequence.
ACCESSION   BX559897
VERSION     BX559897.1  GI:33367800
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse46d02_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match              0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 126
AZ330730
LOCUS       AZ330730                 28 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0056C11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0056C11 F, genomic survey sequence.
ACCESSION   AZ330730
VERSION     AZ330730.1  GI:10392723
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0056  row: C  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0056C11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match              0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
             |:|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 28
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 127
AZ366137
LOCUS       AZ366137                 28 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0115B21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0115B21 F, genomic survey sequence.
ACCESSION   AZ366137
VERSION     AZ366137.1  GI:10479837
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0115  row: B  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0115B21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 128
AZ467078
LOCUS       AZ467078                 28 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0278C15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0278C15 F, genomic survey sequence.
ACCESSION   AZ467078
VERSION     AZ467078.1  GI:10625203
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0278  row: C  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0278C15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                    :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28
```

RESULT 129
AZ514383
LOCUS AZ514383 28 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0361G05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0361G05 F, genomic survey sequence.
ACCESSION AZ514383
VERSION AZ514383.1 GI:10695699
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0361 row: G column: 05
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 28.
FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0361G05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent.E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28; DB 1; Length 28;
Best Local Similarity 50.0%; Pred. No. 74;
Matches 14; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                    :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28
```

RESULT 130
AZ644345
LOCUS AZ644345 28 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0508E16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0508E16 F, genomic survey sequence.
ACCESSION AZ644345
VERSION AZ644345.1 GI:11772782
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0508 row: E column: 16
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 28.
FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0508E16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28; DB 1; Length 28;
Best Local Similarity 50.0%; Pred. No. 74;
Matches 14; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGT 28


RESULT 131
AZ648665
LOCUS       AZ648665                 28 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0517J18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0517J18 R, genomic survey sequence.
ACCESSION   AZ648665
VERSION     AZ648665.1  GI:11781356
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0517  row: J  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0517J18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                   :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28


RESULT 132
AZ649197/c
LOCUS       AZ649197                 28 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0518E11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0518E11 R, genomic survey sequence.
ACCESSION   AZ649197
VERSION     AZ649197.1  GI:11782434
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0518  row: E  column: 11
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0518E11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 28;
  Best Local Similarity   50.0%;  Pred. No. 74;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          28 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
```

RESULT 133
AZ777903
LOCUS AZ777903 28 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0012D16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0012D16 R, genomic survey sequence.
ACCESSION AZ777903
VERSION AZ777903.1 GI:12906986
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0012 row: D column: 16
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 28.
FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0012D16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28; DB 1; Length 28;
Best Local Similarity 50.0%; Pred. No. 74;
Matches 14; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                  :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db           1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28
```

RESULT 134
AZ815799
LOCUS AZ815799 30 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0084F24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0084F24 F, genomic survey sequence.
ACCESSION AZ815799
VERSION AZ815799.1 GI:12985707
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 30)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0084 row: F column: 24
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 30.
FEATURES Location/Qualifiers
source 1. .30
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0084F24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28; DB 1; Length 30;
Best Local Similarity 50.0%; Pred. No. 85;
Matches 14; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 CTGTGTGTGTGTGTGTGTGTGTGTGT 30


RESULT 135
AZ961995
LOCUS       AZ961995                30 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0230G12R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0230G12 R, genomic survey sequence.
ACCESSION   AZ961995
VERSION     AZ961995.1  GI:13833222
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0230  row: G  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0230G12"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 85;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGTG 28


RESULT 136
AZ829236
LOCUS       AZ829236                32 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0106H16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0106H16 R, genomic survey sequence.
ACCESSION   AZ829236
VERSION     AZ829236.1  GI:12999144
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0106  row: H  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0106H16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 28;  DB 1;  Length 32;
  Best Local Similarity   50.0%;  Pred. No. 96;
  Matches   14;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          5 GTGTGTGTGTGTGTGTGTGTGTGTGT 32
```

RESULT 137
AZ304764
LOCUS AZ304764 34 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0005A14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0005A14 F, genomic survey sequence.
ACCESSION AZ304764
VERSION AZ304764.1 GI:10341104
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 34)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0005 row: A column: 14
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 34.

FEATURES Location/Qualifiers
source 1. .34
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0005A14"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 28; DB 1; Length 34;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 7001
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          7 GTGTGTGTGTGTGTGTGTGTGTGTGT 34
```

RESULT 138
AZ432709/c
LOCUS AZ432709 31 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0218C16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0218C16 F, genomic survey sequence.
ACCESSION AZ432709
VERSION AZ432709.1 GI:10556722
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 31)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0218 row: C column: 16
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 31.

FEATURES Location/Qualifiers
source 1. .31
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0218C16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 27.8; DB 1; Length 31;
Best Local Similarity 48.4%; Pred. No. 95;
Matches 15; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
```

```
                :|:|:|:|:| | |:|:|:|:|:|:|:|:|:|:
Db         31 TGTGTGTGTGAGCGTGTGTGTGTGTGTGTGT 1


RESULT 139
AZ494653
LOCUS       AZ494653                 31 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0330K03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0330K03 F, genomic survey sequence.
ACCESSION   AZ494653
VERSION     AZ494653.1  GI:10669443
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0330  row: K  column: 03
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0330K03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.8;  DB 1;  Length 31;
  Best Local Similarity   48.4%;  Pred. No. 95;
  Matches   15;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7004
```

```
                  |: :| |:|:|:|:|:|:|:|:|:|:|:|:|
Db         1 GTTTGGGTGTGTGTGTGTGTGTGTGTGTG 31


RESULT 140
AZ496969
LOCUS       AZ496969                 32 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0333E07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0333E07 R, genomic survey sequence.
ACCESSION   AZ496969
VERSION     AZ496969.1  GI:10673522
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0333  row: E  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0333E07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.8;  DB 1;  Length 32;
  Best Local Similarity   48.4%;  Pred. No. 1e+02;
  Matches   15;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
```

```
                |:  |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 CTTGGTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 141
AZ473611
LOCUS       AZ473611                33 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0289O01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0289O01 R, genomic survey sequence.
ACCESSION   AZ473611
VERSION     AZ473611.1  GI:10631736
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0289  row: O  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0289O01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.8;  DB 1;  Length 33;
  Best Local Similarity   45.2%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6969 UAACUGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                : | :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          3 TCAATGTGTGTGTGTGTGTGTGTGTGTGT 33


RESULT 142
AZ483866
LOCUS       AZ483866                34 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0310N01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0310N01 F, genomic survey sequence.
ACCESSION   AZ483866
VERSION     AZ483866.1  GI:10648465
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 34)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0310  row: N  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 34.
FEATURES             Location/Qualifiers
     source          1. .34
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0310N01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.6;  DB 1;  Length 34;
  Best Local Similarity   38.2%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative   17;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUGUGUGU 7005
```

```
                  |: : : : :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 CTCTTTCTCTGTGTGTGTGTGTGTGTGTGTGT 34


RESULT 143
AZ663681/c
LOCUS       AZ663681                 29 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0543M21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0543M21 F, genomic survey sequence.
ACCESSION   AZ663681
VERSION     AZ663681.1  GI:11800827
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0543  row: M  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0543M21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 29;
  Best Local Similarity   44.8%;  Pred. No. 91;
  Matches   13;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
```

```
                  : :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         29 TATGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 144
AZ425112
LOCUS       AZ425112                 30 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0205I01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0205I01 F, genomic survey sequence.
ACCESSION   AZ425112
VERSION     AZ425112.1  GI:10549125
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 30)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0205  row: I  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES             Location/Qualifiers
     source          1. .30
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0205I01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 30;
  Best Local Similarity   51.7%;  Pred. No. 97;
  Matches   15;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
```

```
                    | |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GCGTGTGTGTGTGTGTGTGTGTGTGTGTG 30


RESULT 145
AZ304813
LOCUS       AZ304813                32 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0005L18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0005L18 F, genomic survey sequence.
ACCESSION   AZ304813
VERSION     AZ304813.1  GI:10341207
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 32)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0005  row: L  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 32.
FEATURES             Location/Qualifiers
     source          1. .32
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0005L18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27.4;  DB 1;  Length 32;
  Best Local Similarity   51.7%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
```

```
                    | |:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          4 GCGTGTGTGTGTGTGTGTGTGTGTGTGTG 32


RESULT 146
AZ342492
LOCUS       AZ342492                27 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0075O04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0075O04 R, genomic survey sequence.
ACCESSION   AZ342492
VERSION     AZ342492.1  GI:10419783
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0075  row: O  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 27.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0075O04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 86;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 147
AZ435344
LOCUS       AZ435344                27 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0222K17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0222K17 F, genomic survey sequence.
ACCESSION   AZ435344
VERSION     AZ435344.1  GI:10559357
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0222  row: K  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 27.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0222K17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 86;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                  :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27


RESULT 148
AZ583081
LOCUS       AZ583081                27 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0376L16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0376L16 R, genomic survey sequence.
ACCESSION   AZ583081
VERSION     AZ583081.1  GI:11702607
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0376  row: L  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 27.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0376L16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   51.9%;  Pred. No. 86;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 27
```

RESULT 149
AZ638238
LOCUS AZ638238 27 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0498H05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0498H05 F, genomic survey sequence.
ACCESSION AZ638238
VERSION AZ638238.1 GI:11760428
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0498 row: H column: 05
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0498H05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 27; DB 1; Length 27;
Best Local Similarity 48.1%; Pred. No. 86;
Matches 13; Conservative 14; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                  :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27
```

RESULT 150
AZ758321
LOCUS AZ758321 27 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0550G18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0550G18 F, genomic survey sequence.
ACCESSION AZ758321
VERSION AZ758321.1 GI:12863998
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0550 row: G column: 18
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0550G18"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 27; DB 1; Length 27;
Best Local Similarity 51.9%; Pred. No. 86;
Matches 14; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGTG 27


RESULT 151
AZ981811/c
LOCUS       AZ981811                27 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0262D23F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0262D23 F, genomic survey sequence.
ACCESSION   AZ981811
VERSION     AZ981811.1  GI:13853038
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0262  row: D  column: 23
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 27.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0262D23"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   48.1%;  Pred. No. 86;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         27 TGTGTGTGTGTGTGTGTGTGTGTGT 1


RESULT 152
AZ405219
LOCUS       AZ405219                28 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0173N21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0173N21 R, genomic survey sequence.
ACCESSION   AZ405219
VERSION     AZ405219.1  GI:10529232
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0173  row: N  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0173N21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 28;
  Best Local Similarity   48.1%;  Pred. No. 93;
  Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 27
```

RESULT 153
AZ443611
LOCUS AZ443611 28 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0238N03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0238N03 R, genomic survey sequence.
ACCESSION AZ443611
VERSION AZ443611.1 GI:10591759
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0238 row: N column: 03
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 28.

FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0238N03"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
Query Match              0.4%;  Score 27;  DB 1;  Length 28;
Best Local Similarity   48.1%;  Pred. No. 93;
Matches   13;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6999
```

```
                :|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTGTGTGTGT 28
```

RESULT 154
AZ782113
LOCUS AZ782113 28 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0022N03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0022N03 F, genomic survey sequence.
ACCESSION AZ782113
VERSION AZ782113.1 GI:12915480
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0022 row: N column: 03
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 28.

FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0022N03"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
Query Match              0.4%;  Score 27;  DB 1;  Length 28;
Best Local Similarity   51.9%;  Pred. No. 93;
Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGTGTG 28


RESULT 155
AZ812746/c
LOCUS       AZ812746                28 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0079H07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0079H07 R, genomic survey sequence.
ACCESSION   AZ812746
VERSION     AZ812746.1  GI:12982297
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0079  row: H  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0079H07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 28;
  Best Local Similarity   51.9%;  Pred. No. 93;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         28 GTGTGTGTGTGTGTGTGTGTGTGTG 2


RESULT 156
AZ774254
LOCUS       AZ774254                29 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0003L23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0003L23 F, genomic survey sequence.
ACCESSION   AZ774254
VERSION     AZ774254.1  GI:12899490
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0003  row: L  column: 23
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0003L23"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.4%;  Score 27;  DB 1;  Length 29;
  Best Local Similarity   51.9%;  Pred. No. 99;
  Matches   14;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
```

```
                  |:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 GTGTGTGTGTGTGTGTGTGTGTGTG 29


RESULT 157
AZ642584
LOCUS       AZ642584                 33 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0505K12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0505K12 R, genomic survey sequence.
ACCESSION   AZ642584
VERSION     AZ642584.1  GI:11769336
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0505  row: K  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 33.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0505K12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 26.6;  DB 1;  Length 33;
  Best Local Similarity   45.5%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative   14;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGUG 7006
```

```
                  |:|:|:|:|:|:|  :|:|:|  :|:|:|:|:|:|
Db          1 GTGTGTGTGTGCATGTGTGCATGTGTGTGTGTG 33


RESULT 158
TA245A09Q/c
LOCUS       TA245A09Q                33 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  T. brucei sheared genomic DNA clone 245a09, reverse sequence,
            genomic survey sequence.
ACCESSION   AL482142
VERSION     AL482142.1  GI:11848147
KEYWORDS    GSS.
SOURCE      Trypanosoma brucei
  ORGANISM  Trypanosoma brucei
            Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
            Trypanosoma.
REFERENCE   1  (bases 1 to 33)
  AUTHORS   Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
            Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
            Melville,S.E., Rajandream,M.A. and Barrell,B.G.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
            project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
            Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
            nh1@sanger.ac.uk
COMMENT     Constructed at the Institute for Genomic Research (TIGR),
            Rockville, MD. Genomic DNA isolated from a cloned population of
            Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
            to give a tight size distribution (
            4 kb).  The v + i method used for the library construction is
            described in detail in Smith, H. and Venter, J.C. (Making small
            insert libraries for whole genome shotgun sequencing projects.  In
            Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
            Barrell, Oxford University Press, 1999).
            Email: nelsayed@tigr.org
            Details of T. brucei sequencing at the Sanger Centre are available
            at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES             Location/Qualifiers
     source          1. .33
                     /organism="Trypanosoma brucei"
                     /mol_type="genomic DNA"
                     /strain="TREU927"
                     /db_xref="taxon:5691"
                     /clone="245a09"

  Query Match             0.3%;  Score 26.6;  DB 1;  Length 33;
  Best Local Similarity   48.5%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative   13;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       6970 AACUGUGUGUGUGUGUGUGUGUGUGUGUG 7002
                |||:|    :|:|:|:|:|:|:|:|:|:|:|
Db         33 AACTGCCCCTGTGTGTGTGTGTGTGTGTGTG 1


RESULT 159
AZ786559
LOCUS       AZ786559                 29 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0032D12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0032D12 F, genomic survey sequence.
ACCESSION   AZ786559
VERSION     AZ786559.1  GI:12924441
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
```

```
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0032  row: D  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0032D12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 26.4;  DB 1;  Length 29;
  Best Local Similarity   46.4%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative   14;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
              :|:|:|:|:|:|:|:|:|: :|:|:|:|
Db          2 TGTGTGTGTGTGTGTGTTTGTGTGTG 29


RESULT 160
AZ803691
LOCUS       AZ803691                 31 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0064A17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0064A17 F, genomic survey sequence.
ACCESSION   AZ803691
VERSION     AZ803691.1  GI:12956014
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
```

```
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0064  row: A  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 31.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0064A17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 26.4;  DB 1;  Length 31;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 7000
              :|:|:|:|:|:|:|:|:|:|:| |:|:|
Db          4 TGTGTGTGTGTGTGTGTGTGAGTGTG 31


RESULT 161
BX569116
LOCUS       BX569116                 26 bp    mRNA    linear   EST 14-OCT-2003
DEFINITION  BX569116 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse97f02_p1c, mRNA sequence.
ACCESSION   BX569116
VERSION     BX569116.1  GI:33437055
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
```

```
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse97f02_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26


RESULT 162
AZ307889
LOCUS       AZ307889                 26 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0010L18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0010L18 F, genomic survey sequence.
ACCESSION   AZ307889
VERSION     AZ307889.1  GI:10347331
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0010  row: L  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0010L18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1e+02;
  Matches   13;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26


RESULT 163
AZ345505/c
LOCUS       AZ345505                 26 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0080H01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0080H01 F, genomic survey sequence.
ACCESSION   AZ345505
VERSION     AZ345505.1  GI:10424742
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0080  row: H  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
```

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080H01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|:|
Db         26 TGTGTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 164
AZ494537
LOCUS AZ494537 26 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0329D24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0329D24 R, genomic survey sequence.
ACCESSION AZ494537
VERSION AZ494537.1 GI:10669212
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0329 row: D column: 24
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0329D24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTGT 26
```

RESULT 165
AZ503652
LOCUS AZ503652 26 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0343F01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0343F01 R, genomic survey sequence.
ACCESSION AZ503652
VERSION AZ503652.1 GI:10684968
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0343 row: F column: 01
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0343F01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26
```

RESULT 166
AZ795803
LOCUS AZ795803 26 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0051P11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0051P11 F, genomic survey sequence.
ACCESSION AZ795803
VERSION AZ795803.1 GI:12943205
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0051 row: P column: 11
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0051P11"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 26
```

RESULT 167
AZ806004
LOCUS AZ806004 26 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0067H16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0067H16 R, genomic survey sequence.
ACCESSION AZ806004
VERSION AZ806004.1 GI:12966815
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0067 row: H column: 16
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0067H16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 26
```

RESULT 168
AZ975568/c
LOCUS AZ975568 26 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0250L12R Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0250L12 R, genomic survey sequence.
ACCESSION AZ975568
VERSION AZ975568.1 GI:13846795
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0250 row: L column: 12
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0250L12"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|:
Db         26 GTGTGTGTGTGTGTGTGTGTGTGT 1
```

RESULT 169
AZ329433
LOCUS AZ329433 27 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0053K11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0053K11 R, genomic survey sequence.
ACCESSION AZ329433
VERSION AZ329433.1 GI:10390140
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0053 row: K column: 11
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0053K11"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 27;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGT 27
```

RESULT 170
AZ788874
LOCUS AZ788874 27 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0036H16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0036H16 F, genomic survey sequence.
ACCESSION AZ788874
VERSION AZ788874.1 GI:12929113
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0036 row: H column: 16
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0036H16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 27;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGT 27
```

RESULT 171
AZ801217
LOCUS AZ801217 27 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0059P03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0059P03 R, genomic survey sequence.
ACCESSION AZ801217
VERSION AZ801217.1 GI:12953540
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0059 row: P column: 03
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0059P03"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 26; DB 1; Length 27;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTGTGT 27
```

RESULT 172
AZ807584
LOCUS AZ807584 29 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0070H04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0070H04 R, genomic survey sequence.
ACCESSION AZ807584
VERSION AZ807584.1 GI:12972078
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 29)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0070 row: H column: 04
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 29.
FEATURES Location/Qualifiers
source 1. .29
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0070H04"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.8; DB 1; Length 29;
Best Local Similarity 48.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6968 GUAACUGUGUGUGUGUGUGUGUGUGUG 6996
              |:|  :|:|:|:|:|:|:|:|:|:|:|
Db          1 GTATTTGTGTGTGTGTGTGTGTGTGTG 29
```

RESULT 173
AZ860659
LOCUS AZ860659 29 bp DNA linear GSS 21-FEB-2001
DEFINITION 2M0166F14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0166F14 R, genomic survey sequence.
ACCESSION AZ860659
VERSION AZ860659.1 GI:13056201
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 29)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0166 row: F column: 14
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 29.
FEATURES Location/Qualifiers
source 1. .29
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0166F14"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.8; DB 1; Length 29;
Best Local Similarity 41.4%; Pred. No. 1.3e+02;
Matches 12; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUGU 7001
              :|:|:|: : :|:|:|:|:|:|:|:|:
Db          1 TGTGTGTATATGTGTGTGTGTGTGTGT 29
```

RESULT 174
AZ866837
LOCUS AZ866837 29 bp DNA linear GSS 21-FEB-2001
DEFINITION 2M0177O21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0177O21 F, genomic survey sequence.
ACCESSION AZ866837
VERSION AZ866837.1 GI:13068543
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 29)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0177 row: O column: 21
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 29.
FEATURES Location/Qualifiers
source 1. .29
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0177O21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.8; DB 1; Length 29;
Best Local Similarity 44.8%; Pred. No. 1.3e+02;
Matches 13; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              | :|:|:|:|:|: :|:|:|:|:|:|:|:
Db          1 AATGTGTGTGTGTATGTGTGTGTGTGT 29
```

RESULT 175
AZ442363/c
LOCUS AZ442363 27 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0236B17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0236B17 F, genomic survey sequence.
ACCESSION AZ442363
VERSION AZ442363.1 GI:10566376
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0236 row: B column: 17
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0236B17"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.4; DB 1; Length 27;
Best Local Similarity 51.9%; Pred. No. 1.2e+02;
Matches 14; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:| |:|:|:|:|:|:|:|:|:|
Db         27 GTGTGTGCGTGTGTGTGTGTGTGTG 1
```

RESULT 176
AZ625192
LOCUS AZ625192 28 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0464J22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0464J22 F, genomic survey sequence.
ACCESSION AZ625192
VERSION AZ625192.1 GI:11747382
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 28)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0464 row: J column: 22
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 28.
FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0464J22"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.4; DB 1; Length 28;
Best Local Similarity 48.1%; Pred. No. 1.3e+02;
Matches 13; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6993 UGUGUGUGUGUGUGUGUGUGUGGGUGU 7019
              :|:|:|:|:|:|:|:|:|: :|||:|:
Db          1 TGTGTGTGTGTGTGTGTGTATGGGTGT 27
```

RESULT 177
AZ346705
LOCUS AZ346705 31 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0082M02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0082M02 F, genomic survey sequence.
ACCESSION AZ346705
VERSION AZ346705.1 GI:10425942
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 31)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0082 row: M column: 02
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 31.
FEATURES Location/Qualifiers
source 1. .31
/organism="Mus musculus"

/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0082M02"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson. Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25.2; DB 1; Length 31;
Best Local Similarity 50.0%; Pred. No. 1.7e+02;
Matches 15; Conservative 12; Mismatches 3; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGUGU 7003
              | |:| |:| |:|:|:|:|:|:|:|:|:
Db          2 GCGTGCGTGCGTGTGTGTGTGTGTGTGT 31
```

RESULT 178
BX563211
LOCUS BX563211 25 bp mRNA linear EST 10-OCT-2003
DEFINITION BX563211 Glossina morsitans morsitans adult infected gut Glossina morsitans morsitans cDNA clone Tse65b06_p1c, mRNA sequence.
ACCESSION BX563211
VERSION BX563211.1 GI:33430473
KEYWORDS EST.
SOURCE Glossina morsitans morsitans
ORGANISM Glossina morsitans morsitans
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Hippoboscoidea; Glossinidae; Glossina.
REFERENCE 1 (bases 1 to 25)
AUTHORS Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M., Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
TITLE Adult midgut expressed sequence tags from the tsetse fly Glossina morsitans morsitans and expression analysis of putative immune response genes
JOURNAL Genome Biol. 4 (10), R63 (2003)
PUBMED 14519198
COMMENT Contact: Hall N
Pathogen Sequencing Unit
The Sanger Institute The Wellcome Trust Genome Campus
Hinxton, Cambridge, CB10 1SA, UK
Request for clones, please contact: Mike Lehane
Prof. M.J.Lehane
School of Biological Sciences,
University of Wales,
Bangor LL57 2UW
All clones with suffix q1c are reverse primer reads starting at 5' end of the cDNA all p1c reads are from the 3' end.
FEATURES Location/Qualifiers
source 1. .25
/organism="Glossina morsitans morsitans"
/mol_type="mRNA"
/sub_species="morsitans"
/db_xref="taxon:37546"
/clone="Tse65b06_p1c"
/tissue_type="adult infected gut"
/clone_lib="Glossina morsitans morsitans adult infected gut"
/note="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 48.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 13; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 25
```

RESULT 179
AZ339866
LOCUS AZ339866 25 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0071H01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0071H01 R, genomic survey sequence.
ACCESSION AZ339866
VERSION AZ339866.1 GI:10414560
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0071 row: H column: 01
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 25.
FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0071H01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   48.0%;  Pred. No. 1.2e+02;
  Matches   12;  Conservative   13;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGT 25
```

RESULT 180
AZ404057/c
LOCUS AZ404057 25 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0172D10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0172D10 F, genomic survey sequence.
ACCESSION AZ404057
VERSION AZ404057.1 GI:10528070
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0172 row: D column: 10
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 25.
FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0172D10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db         25 GTGTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 181
AZ769673
LOCUS AZ769673 25 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0570D12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0570D12 R, genomic survey sequence.
ACCESSION AZ769673
VERSION AZ769673.1 GI:12890050
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0570 row: D column: 12
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 25.
FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0570D12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGTG 25
```

RESULT 182
AZ771881
LOCUS AZ771881 25 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0574F23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0574F23 F, genomic survey sequence.
ACCESSION AZ771881
VERSION AZ771881.1 GI:12894610
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0574 row: F column: 23
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 25.
FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0574F23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTG 25

RESULT 183
AZ646850
LOCUS AZ646850 26 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0513L06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0513L06 F, genomic survey sequence.
ACCESSION AZ646850
VERSION AZ646850.1 GI:11777730
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0513 row: L column: 06
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0513L06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25; DB 1; Length 26;
Best Local Similarity 52.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 2 GTGTGTGTGTGTGTGTGTGTGTGTG 26

RESULT 184
AZ830551
LOCUS AZ830551 26 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0109C19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0109C19 R, genomic survey sequence.
ACCESSION AZ830551
VERSION AZ830551.1 GI:13000459
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0109 row: C column: 19
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0109C19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 25; DB 1; Length 26;
Best Local Similarity 52.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 2 GTGTGTGTGTGTGTGTGTGTGTGTG 26

RESULT 185
AZ371116
LOCUS AZ371116 30 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0122J05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0122J05 F, genomic survey sequence.
ACCESSION AZ371116
VERSION AZ371116.1 GI:10484816
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 30)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0122 row: J column: 05
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 30.
FEATURES Location/Qualifiers
source 1. .30
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0122J05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match              0.3%;  Score 25;  DB 1;  Length 30;
  Best Local Similarity   52.0%;  Pred. No. 1.7e+02;
  Matches   13;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          6 GTGTGTGTGTGTGTGTGTGTGTGTG 30
```

```
RESULT 186
R14943
LOCUS       R14943                    31 bp    mRNA    linear   EST 13-APR-1995
DEFINITION  yf94g04.r1 Soares infant brain 1NIB Homo sapiens cDNA clone
            IMAGE:30229 5' similar to gb:D14838 GLIA-ACTIVATING FACTOR
            PRECURSOR (HUMAN);, mRNA sequence.
ACCESSION   R14943
VERSION     R14943.1  GI:769216
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 31)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 1369
            High quality sequence starts: 1 High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL This clone is available royalty-free
            through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
            for further information. Trace considered overall poor quality
            Insert Length: 1369   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .31
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:402576"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:30229"
                     /sex="female"
                     /dev_stage="73 days post natal"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares infant brain 1NIB"
                     /note="Organ: whole brain; Vector: Lafmid BA; Site_1: Not
                     I; Site_2: Hind III; 1st strand cDNA was primed with a Not
                     I - oligo(dT) primer [5'
                     AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTT 3']
                     double-stranded cDNA was ligated to Hind III adaptors
                     (Pharmacia), digested with Not I and directionally cloned
                     into the Not I and Hind III sites of the Lafmid BA vector.
                     Library went through one round of normalization. Library
                     constructed by Bento Soares and M.Fatima Bonaldo."
```

```
  Query Match              0.3%;  Score 24.8;  DB 1;  Length 31;
  Best Local Similarity   44.8%;  Pred. No. 1.9e+02;
  Matches   13;  Conservative   13;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              | :| |:|: :|:|:|:|:|:|:|:|:|:
Db          3 ANTGAGTGTATGTGTGTGTGTGTGTGT 31
```

```
RESULT 187
AZ419877/c
LOCUS       AZ419877                  26 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0196N03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0196N03 R, genomic survey sequence.
ACCESSION   AZ419877
VERSION     AZ419877.1  GI:10543890
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0196  row: N  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0196N03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
```

and selected for ampicillin resistance."

Query Match 0.3%; Score 24.4; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:| |
Db         26 TGTGTGTGTGTGTGTGTGTGTGAG 1
```

RESULT 188
AZ766495
LOCUS AZ766495 26 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0564D08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0564D08 F, genomic survey sequence.
ACCESSION AZ766495
VERSION AZ766495.1 GI:12883629
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0564 row: D column: 08
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0564D08"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

Query Match 0.3%; Score 24.4; DB 1; Length 26;
Best Local Similarity 46.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|: :|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTTTGTGTGTGTGTGTGT 26
```

RESULT 189
AZ781130
LOCUS AZ781130 26 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0019A07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0019A07 F, genomic survey sequence.
ACCESSION AZ781130
VERSION AZ781130.1 GI:12913513
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 26)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0019 row: A column: 07
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 26.
FEATURES Location/Qualifiers
source 1. .26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0019A07"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

Query Match 0.3%; Score 24.4; DB 1; Length 26;
Best Local Similarity 46.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|: :|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTATG 26
```

RESULT 190
AZ946507
LOCUS AZ946507 27 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0208O18F Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0208O18 F, genomic survey sequence.
ACCESSION AZ946507
VERSION AZ946507.1 GI:13815567
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0208 row: O column: 18
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0208O18"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

Query Match 0.3%; Score 24.4; DB 1; Length 27;
Best Local Similarity 50.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGUG 6998
              :|:|:|:|:|:|:|:|:|:|:|:|: |
Db          1 TGTGTGTGTGTGTGTGTGTGTGTGCG 26
```

RESULT 191
BX559963
LOCUS BX559963 24 bp mRNA linear EST 10-OCT-2003
DEFINITION BX559963 Glossina morsitans morsitans adult infected gut Glossina morsitans morsitans cDNA clone Tse47a03_p1c, mRNA sequence.
ACCESSION BX559963
VERSION BX559963.1 GI:33367923
KEYWORDS EST.
SOURCE Glossina morsitans morsitans
ORGANISM Glossina morsitans morsitans
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Hippoboscoidea; Glossinidae; Glossina.
REFERENCE 1 (bases 1 to 24)
AUTHORS Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M., Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
TITLE Adult midgut expressed sequence tags from the tsetse fly Glossina morsitans morsitans and expression analysis of putative immune response genes
JOURNAL Genome Biol. 4 (10), R63 (2003)
PUBMED 14519198
COMMENT Contact: Hall N
Pathogen Sequencing Unit
The Sanger Institute The Wellcome Trust Genome Campus
Hinxton, Cambridge, CB10 1SA, UK
Request for clones, please contact: Mike Lehane
Prof. M.J.Lehane
School of Biological Sciences,
University of Wales,
Bangor LL57 2UW
All clones with suffix q1c are reverse primer reads starting at 5' end of the cDNA all p1c reads are from the 3' end.
FEATURES Location/Qualifiers
source 1. .24
/organism="Glossina morsitans morsitans"
/mol_type="mRNA"
/sub_species="morsitans"
/db_xref="taxon:37546"
/clone="Tse47a03_p1c"
/tissue_type="adult infected gut"
/clone_lib="Glossina morsitans morsitans adult infected gut"
/note="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match 0.3%; Score 24; DB 1; Length 24;
Best Local Similarity 50.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24
```

RESULT 192
AZ419602
LOCUS AZ419602 24 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0196L12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0196L12 F, genomic survey sequence.
ACCESSION AZ419602
VERSION AZ419602.1 GI:10543615

```
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0196  row: L  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0196L12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 193
AZ621455
LOCUS       AZ621455                 24 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0454K11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0454K11 R, genomic survey sequence.
ACCESSION   AZ621455
VERSION     AZ621455.1  GI:11743645
```

```
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0454  row: K  column: 11
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0454K11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGTG 24


RESULT 194
AZ807762
LOCUS       AZ807762                 24 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0070O14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0070O14 R, genomic survey sequence.
ACCESSION   AZ807762
VERSION     AZ807762.1  GI:12972432
```

```
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0070  row: O  column: 14
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0070O14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTGG 24


RESULT 195
AZ813106/c
LOCUS       AZ813106                 24 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0080A16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0080A16 F, genomic survey sequence.
ACCESSION   AZ813106
VERSION     AZ813106.1  GI:12983014
```

```
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0080  row: A  column: 16
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0080A16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGG 6996
              :|:|:|:|:|:|:|:|:|:|:|:|
Db         24 TGTGTGTGTGTGTGTGTGTGTGG 1


RESULT 196
AZ846178
LOCUS       AZ846178                 24 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0146F14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0146F14 F, genomic survey sequence.
ACCESSION   AZ846178
VERSION     AZ846178.1  GI:13016086
```

```
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0146  row: F  column: 14
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0146F14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
                |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGT 24


RESULT 197
TA163H11P/c
LOCUS       TA163H11P                 24 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  T. brucei sheared genomic DNA clone 163h11, forward sequence,
            genomic survey sequence.
ACCESSION   AL472248
VERSION     AL472248.1  GI:11837597
KEYWORDS    GSS.
SOURCE      Trypanosoma brucei
  ORGANISM  Trypanosoma brucei
            Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
            Trypanosoma.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
            Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
            Melville,S.E., Rajandream,M.A. and Barrell,B.G.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
            project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
            Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
            nh1@sanger.ac.uk
COMMENT     Constructed at the Institute for Genomic Research (TIGR),
            Rockville, MD. Genomic DNA isolated from a cloned population of
            Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
            to give a tight size distribution (
            4 kb).  The v + i method used for the library construction is
            described in detail in Smith, H. and Venter, J.C. (Making small
            insert libraries for whole genome shotgun sequencing projects.  In
            Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
            Barrell, Oxford University Press, 1999).
            Email: nelsayed@tigr.org
            Details of T. brucei sequencing at the Sanger Centre are available
            at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Trypanosoma brucei"
                     /mol_type="genomic DNA"
                     /strain="TREU927"
                     /db_xref="taxon:5691"
                     /clone="163h11"

  Query Match             0.3%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
                |:|:|:|:|:|:|:|:|:|:|:|:
Db         24 GTGTGTGTGTGTGTGTGTGTGT 1


RESULT 198
AZ345553
LOCUS       AZ345553                  25 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0080E16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0080E16 F, genomic survey sequence.
ACCESSION   AZ345553
VERSION     AZ345553.1  GI:10424790
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

Plate: 0080 row: E column: 16
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 25.

FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080E16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 24; DB 1; Length 25;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
             |:|:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24
```

RESULT 199
AZ467470
LOCUS AZ467470 25 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0278E21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0278E21 R, genomic survey sequence.
ACCESSION AZ467470
VERSION AZ467470.1 GI:10625595
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0278 row: E column: 21
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 25.

FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0278E21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 24; DB 1; Length 25;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6997
             |:|:|:|:|:|:|:|:|:|:|:|:
Db          2 GTGTGTGTGTGTGTGTGTGTGT 25
```

RESULT 200
AZ762101
LOCUS AZ762101 25 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0556K17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0556K17 R, genomic survey sequence.
ACCESSION AZ762101
VERSION AZ762101.1 GI:12871750
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

```
          Plate: 0556  row: K  column: 17
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0556K17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 25;
  Best Local Similarity   50.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6997
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTGTGT 24


RESULT 201
AZ467063
LOCUS       AZ467063                 26 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0278O07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0278O07 F, genomic survey sequence.
ACCESSION   AZ467063
VERSION     AZ467063.1  GI:10625188
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

```
          Plate: 0278  row: O  column: 07
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0278O07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 24;  DB 1;  Length 26;
  Best Local Similarity   50.0%;  Pred. No. 1.6e+02;
  Matches   12;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGU 6995
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          3 CTGTGTGTGTGTGTGTGTGTGTGT 26


RESULT 202
AZ466703
LOCUS       AZ466703                 28 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0277N06R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0277N06 R, genomic survey sequence.
ACCESSION   AZ466703
VERSION     AZ466703.1  GI:10624828
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

Plate: 0277 row: N column: 06
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 28.

FEATURES Location/Qualifiers
source 1. .28
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0277N06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 23.8; DB 1; Length 28;
Best Local Similarity 48.1%; Pred. No. 1.9e+02;
Matches 13; Conservative 12; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6972 CUGUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|: :|:| |:|:|:|:|:|:|:|:|
Db          1 CTGTTTGTGAGTGTGTGTGTGTGTG 27
```

RESULT 203
AZ451588/c
LOCUS AZ451588 25 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0251I05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0251I05 F, genomic survey sequence.
ACCESSION AZ451588
VERSION AZ451588.1 GI:10607541
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0251 row: I column: 05
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 25.

FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0251I05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6998
              |:|:|:|:|:|:|:|:|:|:| |:|
Db         25 GTGTGTGTGTGTGTGTGTGAGTG 1
```

RESULT 204
AZ459694
LOCUS AZ459694 25 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0264P10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0264P10 R, genomic survey sequence.
ACCESSION AZ459694
VERSION AZ459694.1 GI:10617819
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

```
          Plate: 0264  row: P  column: 10
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0264P10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   52.0%;  Pred. No. 1.7e+02;
  Matches   13;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6994 GUGUGUGUGUGUGUGUGUGGGUG 7018
              |:|:|:|:|:|:|:|:|:|: ||:|
Db          1 GTGTGTGTGTGTGTGTGTAGGTG 25


RESULT 205
AZ465273
LOCUS       AZ465273                 25 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0275P01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0275P01 F, genomic survey sequence.
ACCESSION   AZ465273
VERSION     AZ465273.1  GI:10623398
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

```
          Plate: 0275  row: P  column: 01
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0275P01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 1.7e+02;
  Matches   11;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|:|: :|:|:|:|:|:|:|:
Db          1 TGTGTGTGTTTGTGTGTGTGTGT 25


RESULT 206
AZ345426/c
LOCUS       AZ345426                 28 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0080A09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0080A09 F, genomic survey sequence.
ACCESSION   AZ345426
VERSION     AZ345426.1  GI:10424663
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

```
            Plate: 0080  row: A  column: 09
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 28.
FEATURES              Location/Qualifiers
     source           1. .28
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0080A09"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 28;
  Best Local Similarity   48.0%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6991 UGUGUGUGUGUGUGUGUGUGUGG 7015
             :|:|:|:|:|:|:|:|:|:|:|: |
Db         28 TGTGTGTGTGTGTGTGTGTGTAG 4


RESULT 207
N53413
LOCUS       N53413                   29 bp    mRNA    linear   EST 15-FEB-1996
DEFINITION  yz25d06.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA
            clone IMAGE:284075 3' similar to gb:M55047 SYNAPTOTAGMIN I
            (HUMAN);, mRNA sequence.
ACCESSION   N53413
VERSION     N53413.1  GI:1194579
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Seq primer: m13 -40 forward
            High quality sequence stop: 1.
FEATURES              Location/Qualifiers
     source           1. .29
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="GDB:3902603"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:284075"
                      /sex="male"
                      /tissue_type="multiple sclerosis lesions"
                      /dev_stage="Age 46"
                      /lab_host="DH10B (ampicillin resistant)"
                      /clone_lib="Soares_multiple_sclerosis_2NbHMSP"
                      /note="Vector: pT7T3D (Pharmacia) with a modified
                      polylinker V_TYPE: phagemid; Site_1: Not I; Site_2: Eco
                      RI; 1st strand cDNA was primed with a Not I - oligo(dT)
                      primer [5'
                      TGTTACCAATCTGAAGTGGGAGCGGCCGCATTTTTTTTTTTTTTTTTTT 3'],
                      double-stranded cDNA was size selected, ligated to Eco RI
                      adapters (Pharmacia), digested with Not I and cloned into
                      the Not I and Eco RI sites of a modified pT7T3 vector
                      (Pharmacia). Library went through one round of
                      normalization to a Cot = 5. Library constructed by Bento
                      Soares and M.Fatima Bonaldo. RNA from 4 multiple sclerosis
                      lesions from one patient was kindly provided by Dr. Kevin
                      G. Becker (NINDS/NIH). "

  Query Match             0.3%;  Score 23.4;  DB 1;  Length 29;
  Best Local Similarity   52.0%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGU 6995
             || |:|:|:|:|:|:|:|:|:|:|:
Db          5 ACCGTGTGTGTGTGTGTGTGTGT 29


RESULT 208
AZ826631
LOCUS       AZ826631                 29 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0102E22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0102E22 F, genomic survey sequence.
ACCESSION   AZ826631
VERSION     AZ826631.1  GI:12996455
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0102  row: E  column: 22
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 29.
FEATURES              Location/Qualifiers
```

```
     source          1. .29
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0102E22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 23.2;  DB 1;  Length 29;
  Best Local Similarity   42.9%;  Pred. No. 2.3e+02;
  Matches   12;  Conservative   13;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6967 UGUAACUGUGUGUGUGUGUGUGUGUG 6994
              : :|  :|:|:|:|:|:|:|:|:|:|
Db          2 TATATATGTGTGTGTGTGTGTGTGTG 29


RESULT 209
BX557786
LOCUS       BX557786                 23 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX557786 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse34f11_p1c, mRNA sequence.
ACCESSION   BX557786
VERSION     BX557786.1  GI:33428961
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse34f11_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.6e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGTGT 23


RESULT 210
AZ328763
LOCUS       AZ328763                 23 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0052L12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0052L12 R, genomic survey sequence.
ACCESSION   AZ328763
VERSION     AZ328763.1  GI:10388815
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0052  row: L  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0052L12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 1.6e+02;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 23
```

RESULT 211
AZ483624
LOCUS AZ483624 23 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0309C01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0309C01 R, genomic survey sequence.
ACCESSION AZ483624
VERSION AZ483624.1 GI:10647786
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0309 row: C column: 01
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0309C01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.6e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGT 23
```

RESULT 212
AZ637290/c
LOCUS AZ637290 23 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0496O05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0496O05 R, genomic survey sequence.
ACCESSION AZ637290
VERSION AZ637290.1 GI:11759480
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0496 row: O column: 05
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0496O05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.6e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1
```

```
RESULT 213
AZ789907/c
LOCUS       AZ789907                 23 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0038G13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0038G13 F, genomic survey sequence.
ACCESSION   AZ789907
VERSION     AZ789907.1  GI:12931412
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0038  row: G  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0038G13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.6e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1
```

```
RESULT 214
AZ824638
LOCUS       AZ824638                 23 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0099A22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0099A22 F, genomic survey sequence.
ACCESSION   AZ824638
VERSION     AZ824638.1  GI:12994546
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0099  row: A  column: 22
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0099A22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 1.6e+02;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGUG 6994
             |:|:|:|:|:|:|:|:|:|:|:|:|
Db          1 CTGTGTGTGTGTGTGTGTGTGTG 23
```

RESULT 215
AZ828969/c
LOCUS AZ828969 23 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0106O13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0106O13 F, genomic survey sequence.
ACCESSION AZ828969
VERSION AZ828969.1 GI:12998877
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0106 row: O column: 13
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0106O13"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 52.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6996
             |:|:|:|:|:|:|:|:|:|:|:|:|
Db         23 GTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 216
AZ829195/c
LOCUS AZ829195 23 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0106M12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0106M12 R, genomic survey sequence.
ACCESSION AZ829195
VERSION AZ829195.1 GI:12999103
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0106 row: M column: 12
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0106M12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   47.8%;  Pred. No. 1.6e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:
Db         23 TGTGTGTGTGTGTGTGTGTGTGT 1
```

```
RESULT 217
AZ446429
LOCUS       AZ446429                 24 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0242A24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0242A24 R, genomic survey sequence.
ACCESSION   AZ446429
VERSION     AZ446429.1  GI:10597224
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0242  row: A  column: 24
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0242A24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 24;
  Best Local Similarity   47.8%;  Pred. No. 1.7e+02;
  Matches   11;  Conservative   12;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGU 6995
              :|:|:|:|:|:|:|:|:|:|:|:
Db          2 TGTGTGTGTGTGTGTGTGTGTGT 24
```

```
RESULT 218
AZ647335
LOCUS       AZ647335                 24 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0513J15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0513J15 R, genomic survey sequence.
ACCESSION   AZ647335
VERSION     AZ647335.1  GI:11778698
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0513  row: J  column: 15
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0513J15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 24;
  Best Local Similarity   52.2%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|
Db          2 GTGTGTGTGTGTGTGTGTGTG 24
```

```
RESULT 219
AZ506209
LOCUS       AZ506209                 25 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0347F10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0347F10 F, genomic survey sequence.
ACCESSION   AZ506209
VERSION     AZ506209.1  GI:10687525
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0347  row: F  column: 10
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0347F10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 25;
  Best Local Similarity   52.2%;  Pred. No. 1.8e+02;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|:|
Db          3 CTGTGTGTGTGTGTGTGTGTG 25
```

```
RESULT 220
AZ494629
LOCUS       AZ494629                 26 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0330F01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0330F01 F, genomic survey sequence.
ACCESSION   AZ494629
VERSION     AZ494629.1  GI:10669392
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0330  row: F  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0330F01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 23;  DB 1;  Length 26;
  Best Local Similarity   52.2%;  Pred. No. 2e+02;
  Matches   12;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6996
              |:|:|:|:|:|:|:|:|:|:|:|:|
Db          4 GTGTGTGTGTGTGTGTGTGTGTG 26
```

```
RESULT 221
AZ774981/c
LOCUS       AZ774981                 26 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0004D22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0004D22 R, genomic survey sequence.
ACCESSION   AZ774981
VERSION     AZ774981.1  GI:12900999
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0004  row: D  column: 22
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 26.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0004D22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22.8;  DB 1;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:|:|:|:|:|:|:|  |:
Db         26 GTGTGTGTGTGTGTGTGTGTGTAAGT 1
```

```
RESULT 222
AZ404479
LOCUS       AZ404479                 27 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0172F18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0172F18 R, genomic survey sequence.
ACCESSION   AZ404479
VERSION     AZ404479.1  GI:10528408
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0172  row: F  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 27.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0172F18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22.8;  DB 1;  Length 27;
  Best Local Similarity   46.2%;  Pred. No. 2.2e+02;
  Matches   12;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUGU 6999
              |:|:|:|:| |:|:|:|:|:|:|: :
Db          2 GTGTGTGTGAGTGTGTGTGTGTGTAT 27
```

RESULT 223
AZ823699
LOCUS AZ823699 27 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0097G23R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0097G23 R, genomic survey sequence.
ACCESSION AZ823699
VERSION AZ823699.1 GI:12993607
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0097 row: G column: 23
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0097G23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22.8;  DB 1;  Length 27;
  Best Local Similarity   46.2%;  Pred. No. 2.2e+02;
  Matches   12;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUGUGUGUG 6996
              | :|:|:|:|: :|:|:|:|:|:|:|
Db          2 AATGTGTGTGTCTGTGTGTGTGTGTG 27
```

RESULT 224
AZ780500/c
LOCUS AZ780500 25 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0017J19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0017J19 R, genomic survey sequence.
ACCESSION AZ780500
VERSION AZ780500.1 GI:12912224
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0017 row: J column: 19
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 25.
FEATURES Location/Qualifiers
source 1. .25
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0017J19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   45.8%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUG 6996
              : :|:|:|:|:|:|:|:|:|:|:|
Db         24 TTTGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 225
AZ646963
LOCUS AZ646963 27 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0513C13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0513C13 F, genomic survey sequence.
ACCESSION AZ646963
VERSION AZ646963.1 GI:11777956
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0513 row: C column: 13
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0513C13"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22.2;  DB 1;  Length 27;
  Best Local Similarity   40.7%;  Pred. No. 2.5e+02;
  Matches   11;  Conservative   13;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUGUG 7000
              |:|:|:|:|:|:|:|: :|: :|: :|
Db          1 GTGTGTGTGTGTGTGTATGTATGTATG 27
```

RESULT 226
AZ484090
LOCUS AZ484090 22 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0310I15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0310I15 F, genomic survey sequence.
ACCESSION AZ484090
VERSION AZ484090.1 GI:10648679
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 22)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0310 row: I column: 15
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 22.
FEATURES Location/Qualifiers
source 1. .22
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0310I15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUG 6994
              :|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGTG 22
```

```
RESULT 227
AZ985497
LOCUS       AZ985497                 22 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0267D23F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0267D23 F, genomic survey sequence.
ACCESSION   AZ985497
VERSION     AZ985497.1  GI:13856724
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0267  row: D  column: 23
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0267D23"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 1.8e+02;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6995
              |:|:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGTGT 22
```

```
RESULT 228
AZ371475
LOCUS       AZ371475                 23 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0122K19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0122K19 R, genomic survey sequence.
ACCESSION   AZ371475
VERSION     AZ371475.1  GI:10485175
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0122  row: K  column: 19
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0122K19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 22;  DB 1;  Length 23;
  Best Local Similarity   50.0%;  Pred. No. 2e+02;
  Matches   11;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:|:
Db          2 CTGTGTGTGTGTGTGTGTGTGT 23
```

```
RESULT 229
AZ766498
LOCUS       AZ766498                 25 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0564E08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0564E08 F, genomic survey sequence.
ACCESSION   AZ766498
VERSION     AZ766498.1  GI:12883635
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0564  row: E  column: 08
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0564E08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   44.0%;  Pred. No. 2.4e+02;
  Matches   11;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGUGUGU 6997
              :|:|:|: :|:|:|:|:|:|:| |:
Db          1 TGTGTGTATGTGTGTGTGTGTGAGT 25
```

```
RESULT 230
AZ309945/c
LOCUS       AZ309945                 23 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0017K22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0017K22 F, genomic survey sequence.
ACCESSION   AZ309945
VERSION     AZ309945.1  GI:10351443
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0017  row: K  column: 22
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0017K22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 2.2e+02;
  Matches   12;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGUG 6996
             | |:|:|:|:|:|:|:|:|:|:|
Db         23 GGGTGTGTGTGTGTGTGTGTGTG 1
```

RESULT 231
AZ356191/c
LOCUS AZ356191 23 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0097L07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0097L07 F, genomic survey sequence.
ACCESSION AZ356191
VERSION AZ356191.1 GI:10469235
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0097 row: L column: 07
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0097L07"
/sex="Male"
/lab_host="E: Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 21.4; DB 1; Length 23;
Best Local Similarity 52.2%; Pred. No. 2.2e+02;
Matches 12; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

Qy 6974 GUGUGUGUGUGUGUGUGUGUGUG 6996
|:| |:|:|:|:|:|:|:|:|:|
Db 23 GTGGGTGTGTGTGTGTGTGTGTG 1

RESULT 232
AZ602037
LOCUS AZ602037 23 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0420A10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0420A10 R, genomic survey sequence.
ACCESSION AZ602037
VERSION AZ602037.1 GI:11724227
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0420 row: A column: 10
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0420A10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   52.2%;  Pred. No. 2.2e+02;
  Matches   12;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6970 AACUGUGUGUGUGUGUGUGUG 6992
              || :|:|:|:|:|:|:|:|:|:|
Db          1 AAGTGTGTGTGTGTGTGTGTG 23
```

```
RESULT 233
AZ310642
LOCUS       AZ310642                  21 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0025N09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0025N09 R, genomic survey sequence.
ACCESSION   AZ310642
VERSION     AZ310642.1  GI:10352832
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0025  row: N  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0025N09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.1e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTGT 21
```

```
RESULT 234
AZ333309
LOCUS       AZ333309                  21 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0062P13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0062P13 F, genomic survey sequence.
ACCESSION   AZ333309
VERSION     AZ333309.1  GI:10397798
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0062  row: P  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0062P13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.1e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21
```

```
RESULT 235
AZ635627
LOCUS       AZ635627                 21 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0493D06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0493D06 F, genomic survey sequence.
ACCESSION   AZ635627
VERSION     AZ635627.1  GI:11757817
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585.7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0493  row: D  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0493D06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21
```

```
RESULT 236
AZ641805
LOCUS       AZ641805                 21 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0504J04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0504J04 R, genomic survey sequence.
ACCESSION   AZ641805
VERSION     AZ641805.1  GI:11766140
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0504  row: J  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0504J04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   52.4%;  Pred. No. 2.1e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTGTG 21
```

```
RESULT 237
AZ762904
LOCUS       AZ762904                 21 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0558G12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0558G12 F, genomic survey sequence.
ACCESSION   AZ762904
VERSION     AZ762904.1  GI:12873391
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0558  row: G  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0558G12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.1e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21
```

```
RESULT 238
AZ854856
LOCUS       AZ854856                 21 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0158I09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0158I09 R, genomic survey sequence.
ACCESSION   AZ854856
VERSION     AZ854856.1  GI:13044389
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0158  row: I  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0158I09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.1e+02;
  Matches   10;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGTGT 21
```

```
RESULT 239
AZ780002/c
LOCUS       AZ780002                 22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0016J20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0016J20 R, genomic survey sequence.
ACCESSION   AZ780002
VERSION     AZ780002.1  GI:12911227
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0016  row: J  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0016J20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 22;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|:|:|:|:|
Db         22 GTGTGTGTGTGTGTGTGTGTG 2
```

```
RESULT 240
AZ780118
LOCUS       AZ780118                 22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0017G07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0017G07 F, genomic survey sequence.
ACCESSION   AZ780118
VERSION     AZ780118.1  GI:12911461
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0017  row: G  column: 07
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0017G07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 21;  DB 1;  Length 22;
  Best Local Similarity   52.4%;  Pred. No. 2.3e+02;
  Matches   11;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|:|
Db          2 CTGTGTGTGTGTGTGTGTGTG 22
```

```
RESULT 241
AZ784203
LOCUS       AZ784203                 22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0026G16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0026G16 R, genomic survey sequence.
ACCESSION   AZ784203
VERSION     AZ784203.1  GI:12919695
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0026  row: G  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0026G16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   45.5%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGG 6994
              :|:|: :|:|:|:|:|:|:|:|
Db          1 TGTGTTTGTGTGTGTGTGTGG 22
```

```
RESULT 242
AZ793094
LOCUS       AZ793094                 22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0045H20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0045H20 R, genomic survey sequence.
ACCESSION   AZ793094
VERSION     AZ793094.1  GI:12937525
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0045  row: H  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0045H20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   50.0%;  Pred. No. 2.6e+02;
  Matches   11;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUGU 6995
              |:|:|:|:|:|:| |:|:|:|:|:
Db          1 GTGTGTGTGTGAGTGTGTGTGT 22
```

RESULT 243
AZ801266

```
LOCUS       AZ801266                 22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0059I07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0059I07 R, genomic survey sequence.
ACCESSION   AZ801266
VERSION     AZ801266.1  GI:12953589
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0059  row: I  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0059I07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
```

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```
  Query Match             0.3%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   45.5%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGUGU 6993
              |: :|:|:|:|:|:|:|:|:|:
Db          1 CTCTGTGTGTGTGTGTGTGTGT 22
```

RESULT 244
AW335179

```
LOCUS       AW335179                 23 bp    mRNA    linear   EST 31-JAN-2000
DEFINITION  S44B4 AGS-1 Pneumocystis carinii cDNA 3', mRNA sequence.
ACCESSION   AW335179
VERSION     AW335179.1  GI:6831798
KEYWORDS    EST.
SOURCE      Pneumocystis carinii
  ORGANISM  Pneumocystis carinii
            Eukaryota; Fungi; Ascomycota; Pneumocystidomycetes;
            Pneumocystidaceae; Pneumocystis.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Smulian,A.G., Arnold,J., Weise,M., Wunderlich,J., Staben,C.,
            Edman,J.C., Kovacs,J. and Cushion,M.
  TITLE     Expressed sequence tags from Pneumocystis carinii
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Staben C
            School of Biological Sciences
            University of Kentucky
            101 Morgan Building, University of Kentucky, Lexington, KY
            40506-0225, USA
            Tel: 606 257 2161
            Fax: 606 257 1717
            Email: staben@pop.uky.edu.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Pneumocystis carinii"
                     /mol_type="mRNA"
                     /db_xref="taxon:4754"
                     /lab_host="E. coli"
                     /clone_lib="AGS-1"
                     /note="Vector: Lambda ZAP II; Site_1: EcoRI; Site_2: XhoI;
                     P. carinii organisms (3x10e9) from a single rat (99-1-6,
                     sacrificed on 3/17/99)  at Cincinnati VA facilities.
                     Trizol extracted RNA.  Oligo dT priming, standard
                     conditions described by  vendor, Stratagene. Further
                     details see www.uky.edu/Project/Pneumocystis/"
```

```
  Query Match             0.3%;  Score 20.4;  DB 1;  Length 23;
  Best Local Similarity   18.2%;  Pred. No. 2.8e+02;
  Matches    4;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAAAU 6367
              ::::::::::::::::| |||:
Db          1 TTTTTTTTTTTTTTTTCAAAAT 22
```

RESULT 245
AZ822069

```
LOCUS       AZ822069                 24 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0095D03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0095D03 F, genomic survey sequence.
ACCESSION   AZ822069
```

```
VERSION     AZ822069.1  GI:12991977
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0095  row: D  column: 03
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0095D03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20.4;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 3e+02;
  Matches   11;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:| |:|:|:|:|:|:
Db          3 CTGTGTGTGGGTGTGTGTGT 24


RESULT 246
AZ368875
LOCUS       AZ368875                 20 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0119I12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0119I12 F, genomic survey sequence.
ACCESSION   AZ368875
```

```
VERSION     AZ368875.1  GI:10482575
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0119  row: I  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0119I12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 247
AZ465453
LOCUS       AZ465453                 20 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0275F24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0275F24 F, genomic survey sequence.
ACCESSION   AZ465453
```

```
VERSION     AZ465453.1  GI:10623578
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0275  row: F  column: 24
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0275F24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 248
AZ470768
LOCUS       AZ470768                 20 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0285H09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0285H09 F, genomic survey sequence.
ACCESSION   AZ470768
```

```
VERSION     AZ470768.1  GI:10628893
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0285  row: H  column: 09
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0285H09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 249
AZ580200
LOCUS       AZ580200                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0368A20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0368A20 F, genomic survey sequence.
ACCESSION   AZ580200
```

```
VERSION     AZ580200.1  GI:11694629
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0368  row: A  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0368A20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 250
AZ634201
LOCUS       AZ634201                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0489C19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0489C19 R, genomic survey sequence.
ACCESSION   AZ634201
```

```
VERSION     AZ634201.1  GI:11756391
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0489  row: C  column: 19
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0489C19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          1 GTGTGTGTGTGTGTGTGTGT 20


RESULT 251
AZ946508/c
LOCUS       AZ946508                 20 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0208P13F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0208P13 F, genomic survey sequence.
ACCESSION   AZ946508
```

```
VERSION     AZ946508.1  GI:13815584
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0208  row: P  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0208P13"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 252
AZ959039/c
LOCUS       AZ959039                 20 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0226L05R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0226L05 R, genomic survey sequence.
ACCESSION   AZ959039
```

```
VERSION     AZ959039.1  GI:13830266
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0226  row: L  column: 05
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0226L05"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 2.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db         20 TGTGTGTGTGTGTGTGTGTG 1


RESULT 253
AZ818214
LOCUS       AZ818214                 21 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0088B08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0088B08 F, genomic survey sequence.
ACCESSION   AZ818214
```

```
VERSION     AZ818214.1  GI:12988122
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0088  row: B  column: 08
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0088B08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGUGU 6991
              |:|:|:|:|:|:|:|:|:|:
Db          2 CTGTGTGTGTGTGTGTGTGT 21


RESULT 254
AZ991225/c
LOCUS       AZ991225                 21 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0275K17F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0275K17 F, genomic survey sequence.
ACCESSION   AZ991225
```

```
VERSION     AZ991225.1  GI:13862452
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0275  row: K  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0275K17"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   50.0%;  Pred. No. 2.6e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db         21 GTGTGTGTGTGTGTGTGTGT 2


RESULT 255
AZ452951
LOCUS       AZ452951                 23 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0254M05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0254M05 F, genomic survey sequence.
ACCESSION   AZ452951
```

```
VERSION     AZ452951.1  GI:10610264
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0254  row: M  column: 05
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0254M05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 23;
  Best Local Similarity   50.0%;  Pred. No. 3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGU 6993
              |:|:|:|:|:|:|:|:|:|:
Db          4 GTGTGTGTGTGTGTGTGTGT 23


RESULT 256
AZ645446
LOCUS       AZ645446                 24 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0510H22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0510H22 R, genomic survey sequence.
ACCESSION   AZ645446
```

```
VERSION     AZ645446.1  GI:11774942
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0510  row: H  column: 22
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0510H22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 24;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches   10;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|:|:|:|
Db          1 TGTGTGTGTGTGTGTGTGTG 20


RESULT 257
AZ760251
LOCUS       AZ760251                 25 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0553E20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0553E20 R, genomic survey sequence.
ACCESSION   AZ760251
```

```
VERSION     AZ760251.1  GI:12867877
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0553  row: E  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0553E20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 20;  DB 1;  Length 25;
  Best Local Similarity   55.0%;  Pred. No. 3.5e+02;
  Matches   11;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6971 ACUGUGUGUGUGUGUGUGUG 6990
              ||:|:|:|:|:|:|:|:|:|
Db          6 ACTGTGTGTGTGTGTGTGTG 25


RESULT 258
AZ415089
LOCUS       AZ415089                 21 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0189G17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0189G17 R, genomic survey sequence.
ACCESSION   AZ415089
```

```
VERSION     AZ415089.1  GI:10539102
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0189  row: G  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0189G17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.9e+02;
  Matches   10;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:|:|:|: :|:|:|
Db          1 GTGTGTGTGTGTGTATGTGTG 21


RESULT 259
AZ513902/c
LOCUS       AZ513902                 21 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0360A13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0360A13 F, genomic survey sequence.
ACCESSION   AZ513902
```

```
VERSION     AZ513902.1  GI:10695218
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0360  row: A  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0360A13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   47.6%;  Pred. No. 2.9e+02;
  Matches   10;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGU 6993
              :|:|:|:|:|:|:|:|:|:| |:
Db         21 TGTGTGTGTGTGTGTGTGCGT 1


RESULT 260
AZ811237
LOCUS       AZ811237                 24 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0077K19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0077K19 F, genomic survey sequence.
ACCESSION   AZ811237
```

```
VERSION     AZ811237.1  GI:12979487
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0077  row: K  column: 19
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 24.
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0077K19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.3%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   45.8%;  Pred. No. 3.9e+02;
  Matches   11;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6993 UGUGUGUGUGUGUGUGUGUGGG 7016
              : : :| |:|:|:|:|:|:|:|||
Db          1 TATTTGGGTGTGTGTGTGTGGG 24


RESULT 261
AZ431700
LOCUS       AZ431700                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0216G18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0216G18 R, genomic survey sequence.
ACCESSION   AZ431700
```

```
VERSION     AZ431700.1  GI:10555713
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0216  row: G  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0216G18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTG 19


RESULT 262
AZ461642/c
LOCUS       AZ461642                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0267P06R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0267P06 R, genomic survey sequence.
ACCESSION   AZ461642
```

```
VERSION     AZ461642.1  GI:10619767
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0267  row: P  column: 06
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0267P06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db         19 GTGTGTGTGTGTGTGTGTG 1


RESULT 263
AZ649147
LOCUS       AZ649147                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0518B17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0518B17 R, genomic survey sequence.
ACCESSION   AZ649147
```

```
VERSION     AZ649147.1  GI:11782334
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0518  row: B  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0518B17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.7e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 19


RESULT 264
AZ774954/c
LOCUS       AZ774954                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0004N15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0004N15 R, genomic survey sequence.
ACCESSION   AZ774954
```

```
VERSION     AZ774954.1  GI:12900943
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0004  row: N  column: 15
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0004N15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db         19 GTGTGTGTGTGTGTGTGTG 1


RESULT 265
AZ795767
LOCUS       AZ795767                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0051I12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0051I12 F, genomic survey sequence.
ACCESSION   AZ795767
```

```
VERSION     AZ795767.1  GI:12943132
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0051  row: I  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0051I12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTG 19


RESULT 266
AZ822936
LOCUS       AZ822936                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0096E08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0096E08 R, genomic survey sequence.
ACCESSION   AZ822936
```

```
VERSION     AZ822936.1  GI:12992844
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0096  row: E  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0096E08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    9;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
              |:|:|:|:|:|:|:|:|:|
Db          1 GTGTGTGTGTGTGTGTGTG 19


RESULT 267
AZ827177
LOCUS       AZ827177                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0103A05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0103A05 R, genomic survey sequence.
ACCESSION   AZ827177
```

```
VERSION     AZ827177.1  GI:12997085
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0103  row: A  column: 05
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0103A05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.7e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:
Db          1 TGTGTGTGTGTGTGTGTGT 19


RESULT 268
AZ818055/c
LOCUS       AZ818055                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0087B23R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0087B23 R, genomic survey sequence.
ACCESSION   AZ818055
```

```
VERSION     AZ818055.1  GI:12987963
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0087  row: B  column: 23
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0087B23"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 20;
  Best Local Similarity   15.8%;  Pred. No. 2.9e+02;
  Matches    3;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::::|||
Db         19 TTTTTTTTTTTTTTTTCCA 1


RESULT 269
AZ514387/c
LOCUS       AZ514387                 22 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0361H03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0361H03 F, genomic survey sequence.
ACCESSION   AZ514387
```

```
VERSION     AZ514387.1  GI:10695703
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0361  row: H  column: 03
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0361H03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 19;  DB 1;  Length 22;
  Best Local Similarity   47.4%;  Pred. No. 3.5e+02;
  Matches    9;  Conservative   10;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|:|:|:|:|:|:|:|:|:
Db         22 TGTGTGTGTGTGTGTGTGT 4


RESULT 270
CF334146
LOCUS       CF334146                  23 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--03-F05.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--03-F05, mRNA sequence.
ACCESSION   CF334146
VERSION     CF334146.1  GI:33816628
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--03-F05"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 19;  DB 1;  Length 23;
  Best Local Similarity   15.8%;  Pred. No. 3.7e+02;
  Matches    3;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::::|||
Db          1 TTTTTTTTTTTTTTTTCCA 19


RESULT 271
AZ464442
LOCUS       AZ464442                  22 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0273N14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0273N14 R, genomic survey sequence.
ACCESSION   AZ464442
VERSION     AZ464442.1  GI:10622567
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
```

```
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0273  row: N  column: 14
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES              Location/Qualifiers
     source           1. .22
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0273N14"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   45.5%;  Pred. No. 3.6e+02;
  Matches   10;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUGG 6994
              :|:|:|:|:|:|:| |:|: :|:|
Db          1 TGTGTGTGTGTGAGTGTATGTG 22


RESULT 272
AL587602
LOCUS       AL587602                 23 bp    mRNA    linear   EST 02-MAR-2001
DEFINITION  AL587602 BP Chicken Brain Library Gallus gallus cDNA clone
            ROS059F08, mRNA sequence.
ACCESSION   AL587602
VERSION     AL587602.1  GI:13192636
KEYWORDS    EST.
SOURCE      Gallus gallus (chicken)
  ORGANISM  Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Murray,F.
  TITLE     BP Chicken Brain Library
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Frazer Murray
            Dept. Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UK
            Tel: +44 (0)131 527 4200
            Fax: +44 (0)131 440 0434
            Email: frazer.murray@bbsrc.ac.uk
            GCGGCCGCTTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from Clonetech
            (*6854-
            Seq primer: M13F.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="Gallus gallus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9031"
                      /clone="ROS059F08"
                      /tissue_type="Brain"
                      /dev_stage="Unknown"
                      /lab_host="DH10B"
                      /clone_lib="BP Chicken Brain Library"
                      /note="Vector: pSPORT1; Site_1: Not1; Site_2: Sal1; Cloned
                      unidirectionally. Primer: Oligo dT. 5' adaptor sequence:
                      5' TCGACCTCGAG 3' ; 3' adaptor sequence: 5'
                      GCGGCCGCTTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from
                      Clonetech (*6854-1)"

  Query Match             0.2%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   17.4%;  Pred. No. 3.9e+02;
  Matches    4;  Conservative   16;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       6336 AAUUCUCUACUUUUUUUUUUUUU 6358
              ||::|:|:  ::::: :::::::
Db          1 AATTCTCTTTTTTTTNTTTTTTT 23


RESULT 273
CF282165
LOCUS       CF282165                 20 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--09-I22.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--09-I22,
            mRNA sequence.
ACCESSION   CF282165
VERSION     CF282165.1  GI:33659552
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ETL--09-I22"
                      /tissue_type="leaf"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice etiolated leaf plasmid cDNA library
                      (14ETL)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   20.0%;  Pred. No. 3.3e+02;
  Matches    4;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCCAAAU 6367
              :::::::::::::: ||||:
```

```
Db          1 TTTTTTTTTTTTTTGCAAAT 20


RESULT 274
AZ482421
LOCUS       AZ482421                 20 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0307P01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0307P01 R, genomic survey sequence.
ACCESSION   AZ482421
VERSION     AZ482421.1  GI:10643486
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0307  row: P  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0307P01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 3.3e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|:|:|: :|:|
```

```
Db          1 TGTGTGTGTGTGTGTATGTG 20


RESULT 275
AZ654458
LOCUS       AZ654458                 20 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0528G10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0528G10 R, genomic survey sequence.
ACCESSION   AZ654458
VERSION     AZ654458.1  GI:11791604
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0528  row: G  column: 10
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0528G10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 3.3e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              :|:|:|:|:|: :|:|:|:|
```

```
Db          1 TGTGTGTGTGTTTGTGTGTG 20


RESULT 276
AZ785549
LOCUS       AZ785549                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0029F01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0029F01 R, genomic survey sequence.
ACCESSION   AZ785549
VERSION     AZ785549.1  GI:12922419
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0029  row: F  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0029F01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   45.0%;  Pred. No. 3.3e+02;
  Matches    9;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGUG 6992
              : :|:|:|:|:|:|:|:|:|

Db          1 TTTGTGTGTGTGTGTGTGTG 20


RESULT 277
AG192026/c
LOCUS       AG192026                 23 bp    DNA     linear   GSS 06-MAR-2004
DEFINITION  Pan troglodytes DNA, clone: RP43-068E14.TJ, genomic survey
            sequence.
ACCESSION   AG192026
VERSION     AG192026.1  GI:45224202
KEYWORDS    GSS.
SOURCE      Pan troglodytes (chimpanzee)
  ORGANISM  Pan troglodytes
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pan.
REFERENCE   1
  AUTHORS   Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
            Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
  TITLE     BAC end sequences of Library RP-43
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 23)
  AUTHORS   Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
            Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
            Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);
            52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
            (E-mail:redstone@mail.kribb.re.kr, URL:http://phs.grc.kribb.re.kr/,
            Tel:82-42-866-7181, Fax:82-42-860-4409)
COMMENT     Clones are derived from the chimpanzee BAC library RP-43 This BAC
            end was generated during the R&D process and may have higher chance
            of clone tracking errors.
             PRIMERS
                 Sequencing: TJ
             LIBRARY
                 Vector    : pBACe3.6
                 R.Site 1  : EcoRI
                 R.Site 2  : EcoRI.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Pan troglodytes"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9598"
                     /clone="RP43-068E14.TJ"
                     /sex="male"
                     /cell_type="lymphocytes"
                     /clone_lib="RP-43 Chimpanzee Male BAC Library"

  Query Match             0.2%;  Score 18.4;  DB 1;  Length 23;
  Best Local Similarity   10.0%;  Pred. No. 4.2e+02;
  Matches    2;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUUUUUC 6362
              :| ::::::::::::::::|
Db         20 TAATTTTTTTTTTTTTTTTC 1


RESULT 278
AZ853220/c
LOCUS       AZ853220                 19 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0156J15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0156J15 F, genomic survey sequence.
ACCESSION   AZ853220
VERSION     AZ853220.1  GI:13041116
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
```

```
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0156  row: J  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0156J15"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   11.1%;  Pred. No. 3.3e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
Db         18 TTTTTTTTTTTTTTTCC 1


RESULT 279
AZ345856
LOCUS       AZ345856                 20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0080G17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0080G17 R, genomic survey sequence.
ACCESSION   AZ345856
VERSION     AZ345856.1  GI:10425093
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0080  row: G  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0080G17"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18;  DB 1;  Length 20;
  Best Local Similarity   11.1%;  Pred. No. 3.6e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
              ||::::::::::::::::
Db          1 ACTTTTTTTTTTTTTTTT 18


RESULT 280
AZ370699
LOCUS       AZ370699                 20 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0121N17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0121N17 R, genomic survey sequence.
ACCESSION   AZ370699
VERSION     AZ370699.1  GI:10484399
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
```

```
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0121  row: N  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0121N17"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18;  DB 1;  Length 20;
  Best Local Similarity   11.1%;  Pred. No. 3.6e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
Db          3 TTTTTTTTTTTTTTTTCC 20


RESULT 281
AL038464/c
LOCUS       AL038464                 22 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566B0646_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566B0646, mRNA sequence.
ACCESSION   AL038464
VERSION     AL038464.1  GI:49682134
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES              Location/Qualifiers
     source           1. .22
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="taxon:9606"
                      /clone="DKFZp566B0646"
                      /tissue_type="kidney"
                      /dev_stage="fetal"
                      /lab_host="Xl-2blue"
                      /clone_lib="566 (synonym: hfkd2)"
                      /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   11.1%;  Pred. No. 4.3e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
Db         19 TTTTTTTTTTTTTTTTCC 2


RESULT 282
CR786821/c
LOCUS       CR786821                 22 bp    mRNA    linear   EST 01-OCT-2004
DEFINITION  DKFZp468F2431_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
            DKFZp468F2431 5', mRNA sequence.
ACCESSION   CR786821
VERSION     CR786821.1  GI:53705818
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
  ORGANISM  Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pongo.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
            Fobo,G., Han,M. and Wiemann,S.
  TITLE     Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
            This is the 5' sequence of the clone insert. Clone from S. Wiemann,
            Molecular Genome Analysis, German Cancer Research Center (DKFZ);
            Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
            Germany. Please contact RZPD for ordering:
            http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468F2431
            Further information about the clone and the sequencing project is
            available at http://mips.gsf.de/projects/cdna/.
FEATURES              Location/Qualifiers
     source           1. .22
                      /organism="Pongo pygmaeus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9600"
                      /clone="DKFZp468F2431"
                      /tissue_type="heart"
                      /dev_stage="adult"
                      /lab_host="DH10B"
                      /clone_lib="468 (synonym: phrt1)"
                      /note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

  Query Match             0.2%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   11.1%;  Pred. No. 4.3e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
```

```
Db         22 TTTTTTTTTTTTTTTCC 5


RESULT 283
AZ309907
LOCUS       AZ309907                 22 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0017N14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0017N14 F, genomic survey sequence.
ACCESSION   AZ309907
VERSION     AZ309907.1  GI:10351367
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0017  row: N  column: 14
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0017N14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   11.1%;  Pred. No. 4.3e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
```

```
Db         4 TTTTTTTTTTTTTTTCC 21


RESULT 284
TA386H07Q
LOCUS       TA386H07Q                22 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  T. brucei sheared genomic DNA clone 386h07, reverse sequence,
            genomic survey sequence.
ACCESSION   AL498291
VERSION     AL498291.1  GI:11874013
KEYWORDS    GSS.
SOURCE      Trypanosoma brucei
  ORGANISM  Trypanosoma brucei
            Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
            Trypanosoma.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
            Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
            Melville,S.E., Rajandream,M.A. and Barrell,B.G.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
            project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
            Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
            nh1@sanger.ac.uk
COMMENT     Constructed at the Institute for Genomic Research (TIGR),
            Rockville, MD. Genomic DNA isolated from a cloned population of
            Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
            to give a tight size distribution (
            4 kb).  The v + i method used for the library construction is
            described in detail in Smith, H. and Venter, J.C. (Making small
            insert libraries for whole genome shotgun sequencing projects.  In
            Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
            Barrell, Oxford University Press, 1999).
            Email: nelsayed@tigr.org
            Details of T. brucei sequencing at the Sanger Centre are available
            at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Trypanosoma brucei"
                     /mol_type="genomic DNA"
                     /strain="TREU927"
                     /db_xref="taxon:5691"
                     /clone="386h07"

  Query Match             0.2%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   11.1%;  Pred. No. 4.3e+02;
  Matches    2;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCC 6363
              ::::::::::::::::||
Db         3 TTTTTTTTTTTTTTTCC 20


RESULT 285
CF293087
LOCUS       CF293087                 21 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--02-C07.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--02-C07, mRNA
            sequence.
ACCESSION   CF293087
VERSION     CF293087.1  GI:33662120
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
```

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES Location/Qualifiers
source 1. .21
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="30DGS--02-C07"
/tissue_type="leaf"
/dev_stage="30 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 17.8; DB 1; Length 21;
Best Local Similarity 19.0%; Pred. No. 4.1e+02;
Matches 4; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUCCAAA 6366
              ::::::::::::::::  ||||
Db          1 TTTTTTTTTTTTTTGACAAA 21
```

RESULT 286
AZ610868
LOCUS AZ610868 21 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0436G12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0436G12 F, genomic survey sequence.
ACCESSION AZ610868
VERSION AZ610868.1 GI:11733058
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0436 row: G column: 12
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0436G12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 17.8; DB 1; Length 21;
Best Local Similarity 14.3%; Pred. No. 4.1e+02;
Matches 3; Conservative 16; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUCCAAA 6366
              ::::::::::::::::  |||
Db          1 TTTTTTTTTTTTTTTTAAAA 21
```

RESULT 287
AZ621072/c
LOCUS AZ621072 21 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0454M05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0454M05 F, genomic survey sequence.
ACCESSION AZ621072
VERSION AZ621072.1 GI:11743262
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0454 row: M column: 05
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0454M05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 17.8; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 4.1e+02;
Matches 10; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6974 GUGUGUGUGUGUGUGUGUGUG 6994
              |:|:|:|:| |:|:|:|: :|
Db         21 GTGTGTGTGCGTGTGTGTATG 1
```

RESULT 288
AZ764492/c
LOCUS AZ764492 21 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0560D04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0560D04 R, genomic survey sequence.
ACCESSION AZ764492
VERSION AZ764492.1 GI:12879511
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0560 row: D column: 04
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0560D04"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 17.8; DB 1; Length 21;
Best Local Similarity 14.3%; Pred. No. 4.1e+02;
Matches 3; Conservative 16; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUCCAAA 6366
              :::.:::::::::::::  |||
Db         21 TTTTTTTTTTTTTTTTAAAA 1
```

RESULT 289
CF297521
LOCUS CF297521 22 bp mRNA linear EST 14-AUG-2003
DEFINITION 30DGS--08-H01.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza sativa (japonica cultivar-group) cDNA clone 30DGS--08-H01, mRNA sequence.
ACCESSION CF297521
VERSION CF297521.1 GI:33666554
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 22)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .22
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="30DGS--08-H01"
/tissue_type="leaf"
/dev_stage="30 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 17.8; DB 1; Length 22;
Best Local Similarity 23.8%; Pred. No. 4.4e+02;

```
  Matches    5;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUUCCAAAUC 6368
              :::::::::::::::| ||| |
Db          1 TTTTTTTTTTTTTTCAAAACC 21


RESULT 290
CF310486/c
LOCUS       CF310486                  22 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--05-C16.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--05-C16, mRNA sequence.
ACCESSION   CF310486
VERSION     CF310486.1  GI:33682247
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--05-C16"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   14.3%;  Pred. No. 4.4e+02;
  Matches    3;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUUCCAAA 6366
              :::::::::::::::::  |||
Db         21 TTTTTTTTTTTTTTTTTTAAA 1


RESULT 291
AZ762424
LOCUS       AZ762424                  22 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0557K08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0557K08 F, genomic survey sequence.
ACCESSION   AZ762424
VERSION     AZ762424.1  GI:12872242
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0557  row: K  column: 08
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0557K08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   57.1%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       7002 GUGUGUGUGUGUGGGUGUGGG 7022
              |:|:|:|:|:|: || |:|||
Db          1 GTGTGTGTGTGTTGGGGTGGG 21


RESULT 292
BH000233/c
LOCUS       BH000233                  22 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0287L21R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0287L21 R, genomic survey sequence.
ACCESSION   BH000233
VERSION     BH000233.1  GI:13871459
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
```

```
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0287  row: L  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 22.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0287L21"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   4.8%;  Pred. No. 4.4e+02;
  Matches    1;  Conservative   18;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6341 UCUACUUUUUUUUUUUUUUUU 6361
                :|:  ::::::::::::::::
Db         22 TCTTTTTTTTTTTTTTTTTT 2


RESULT 293
AZ513013/c
LOCUS       AZ513013                 40 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0358M21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0358M21 R, genomic survey sequence.
ACCESSION   AZ513013
VERSION     AZ513013.1  GI:10694329
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
```

```
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0358  row: M  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0358M21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.8;  DB 1;  Length 40;
  Best Local Similarity   64.9%;  Pred. No. 7.4e+02;
  Matches   24;  Conservative    1;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAU 935
                | ||| ||   | ||||||  |||| ||  | ||||:
Db         38 ACACACACACACACACACAGACACACACACACAAT 2


RESULT 294
AA995094/c
LOCUS       AA995094                 19 bp    mRNA    linear   EST 27-AUG-1998
DEFINITION  ou89g09.s1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1635040 3'
            similar to TR:Q69566 Q69566 ;contains TAR1.t2 MER35 repetitive
            element ;, mRNA sequence.
ACCESSION   AA995094
VERSION     AA995094.1  GI:3181583
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
```

```
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Insert Length: 1087   Std Error: 0.00
            Seq primer: -40m13 fwd. ET from Amersham
            High quality sequence stop: 1.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:1635040"
                      /lab_host="DH10B"
                      /clone_lib="NCI_CGAP_Kid3"
                      /note="Organ: kidney; Vector: pT7T3D-PacI; Site_1: Not I;
                      Site_2: Eco RI; 1st strand cDNA was primed with a Not I -
                      oligo(dT) primer,  double-stranded cDNA was ligated to Eco
                      RI adaptors (Pharmacia),  digested with Not I and cloned
                      into the Not I and Eco RI sites  of the modified pT7T3
                      vector.  mRNA source: 2 pooled kidneys. Library went
                      through one round of normalization. Library constructed by
                      Bento Soares and M. Fatima Bonaldo.  "

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 3.8e+02;
  Matches   10;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUGUG 6992
                | |:|:|:|:|:|:|:|:|
Db         19 GCGTGTGTGTGTGTGTGTG 1


RESULT 295
AZ632650
LOCUS       AZ632650                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0487H23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0487H23 F, genomic survey sequence.
ACCESSION   AZ632650
VERSION     AZ632650.1  GI:11754840
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0487  row: H  column: 23
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0487H23"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   42.1%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUGU 6991
              :|:|: :|:|:|:|:|:|:
Db          2 TGTGTTTGTGTGTGTGTGT 20


RESULT 296
AZ793887/c
LOCUS       AZ793887                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0047G21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0047G21 F, genomic survey sequence.
ACCESSION   AZ793887
VERSION     AZ793887.1  GI:12939296
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
```

```
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0047  row: G  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0047G21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   42.1%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6973 UGUGUGUGUGUGUGUGUG 6991
              :|:|:|:|:|:|:|:|: :
Db         19 TGTGTGTGTGTGTGTTT 1


RESULT 297
DX071075/c
LOCUS       DX071075                 20 bp    DNA     linear   GSS 10-JAN-2006
DEFINITION  KBrB080L07F KBrB, Brassica rapa BamHI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrB080L07, genomic survey
            sequence.
ACCESSION   DX071075
VERSION     DX071075.1  GI:84765371
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J.H. and Park,B.S.
  TITLE     End sequence of Brassica rapa BamHI (KBrB) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone
            KBrB080L07
            Seq primer: T7
            Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Brassica rapa subsp. pekinensis"
                     /mol_type="genomic DNA"
                     /cultivar="Chiifu"
                     /sub_species="pekinensis"
                     /db_xref="taxon:51351"
                     /clone="KBrB080L07"
                     /lab_host="E.coli DH10B"
                     /clone_lib="KBrB, Brassica rapa BamHI BAC library"
                     /note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp
                     pekinensis var. Chiifu BAC library (KBrB BAC) is provided
                     by Yong-Pyo Lim (CNU)."

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   5.3%;  Pred. No. 4.1e+02;
  Matches    1;  Conservative   17;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUUUUU 6361
              : |:::::::::::::::::
Db         19 TTCTTTTTTTTTTTTTTTT 1


RESULT 298
AL038627/c
LOCUS       AL038627                 21 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566H2046_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566H2046, mRNA sequence.
ACCESSION   AL038627
VERSION     AL038627.1  GI:49682173
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566H2046"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="X1-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   10.5%;  Pred. No. 4.5e+02;
  Matches    2;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::::: ||
Db         19 TTTTTTTTTTTTTTTTCA 1


RESULT 299
AZ397262/c
LOCUS       AZ397262                 40 bp    DNA     linear   GSS 03-OCT-2000
```

```
DEFINITION  1M0162I12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0162I12 F, genomic survey sequence.
ACCESSION   AZ397262
VERSION     AZ397262.1  GI:10512334
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0162  row: I  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES             Location/Qualifiers
     source          1. .40
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0162I12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17.4;  DB 1;  Length 40;
  Best Local Similarity   62.9%;  Pred. No. 7.6e+02;
  Matches   22;  Conservative    2;  Mismatches   11;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||:  |:||||||   ||| ||  | |||
Db         39 ACACACACTCACTCACACACACACACACACACACA 5


RESULT 300
CF302447
LOCUS       CF302447                 17 bp    mRNA    linear   EST 15-AUG-2003
```

```
DEFINITION  7LEAF--07-P11.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-P11, mRNA
            sequence.
ACCESSION   CF302447
VERSION     CF302447.1  GI:33674208
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-P11"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 3.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 17


RESULT 301
CF313013
LOCUS       CF313013                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--08-P19.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--08-P19, mRNA sequence.
ACCESSION   CF313013
VERSION     CF313013.1  GI:33684774
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--08-P19"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 3.4e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 17


RESULT 302
CF300456
LOCUS       CF300456                  18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--04-N23.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--04-N23, mRNA
            sequence.
ACCESSION   CF300456
VERSION     CF300456.1  GI:33672217
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--04-N23"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 17


RESULT 303
CF301057
LOCUS       CF301057                  18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-M05.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-M05, mRNA
            sequence.
ACCESSION   CF301057
VERSION     CF301057.1  GI:33672818
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--05-M05"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          2 TTTTTTTTTTTTTTTC 18


RESULT 304
CF301359
LOCUS       CF301359                  18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--06-D05.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--06-D05, mRNA
            sequence.
ACCESSION   CF301359
VERSION     CF301359.1  GI:33673120
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
```

```
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--06-D05"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   11.8%;  Pred. No. 3.7e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db          1 TTTTTTTTTTTTTTCC 17


RESULT 305
CF320418
LOCUS       CF320418                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--11-E22.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--11-E22, mRNA sequence.
ACCESSION   CF320418
VERSION     CF320418.1  GI:33692179
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--11-E22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 3.7e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUU 6361
              |:::::::::::::::
Db          1 CTTTTTTTTTTTTTTT 17


RESULT 306
CF298134/c
LOCUS       CF298134                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-G09.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-G09, mRNA
            sequence.
ACCESSION   CF298134
VERSION     CF298134.1  GI:33669895
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--01-G09"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   11.8%;  Pred. No. 4.1e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db         19 TTTTTTTTTTTTTTCC 3


RESULT 307
CF298207/c
LOCUS       CF298207                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-H23.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-H23, mRNA
            sequence.
ACCESSION   CF298207
VERSION     CF298207.1  GI:33669968
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
```

```
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--01-H23"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 4.5e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db         18 CTTTTTTTTTTTTTTT 2


RESULT 308
CF300961
LOCUS       CF300961                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-K03.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-K03, mRNA
            sequence.
ACCESSION   CF300961
VERSION     CF300961.1  GI:33672722
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--05-K03"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   11.8%;  Pred. No. 4.5e+02;
  Matches    2;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCC 6363
              :::::::::::::::||
Db          1 TTTTTTTTTTTTTTCC 17


RESULT 309
CF319428
LOCUS       CF319428                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--09-O20.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--09-O20, mRNA sequence.
ACCESSION   CF319428
VERSION     CF319428.1  GI:33691189
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="HD--09-O20"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                      /lab_host="E.coli DH10B"
                      /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                      cDNA library (HD)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                      treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                      reverse transcribed and then used for PCR. mRNA was
                      derived from rice Histone Deacetylase overexpression
                      line."

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 4.5e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db          1 CTTTTTTTTTTTTTTT 17


RESULT 310
AZ638704/c
LOCUS       AZ638704                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0498E13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0498E13 R, genomic survey sequence.
```

```
ACCESSION   AZ638704
VERSION     AZ638704.1  GI:11760894
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0498  row: E  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0498E13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 4.5e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db         17 TTTTTTTTTTTTTTTTC 1


RESULT 311
AZ645312
LOCUS       AZ645312                 20 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0510K11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0510K11 R, genomic survey sequence.
```

```
ACCESSION   AZ645312
VERSION     AZ645312.1  GI:11774684
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0510  row: K  column: 11
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0510K11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   5.9%;  Pred. No. 4.5e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          3 TTTTTTTTTTTTTTTTC 19


RESULT 312
CF276638
LOCUS       CF276638                 21 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--01-N19.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--01-N19,
```

```
            mRNA sequence.
ACCESSION   CF276638
VERSION     CF276638.1  GI:33654024
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--01-N19"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   5.9%;  Pred. No. 4.8e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db          5 TTTTTTTTTTTTTTTTC 21


RESULT 313
CF318152
LOCUS       CF318152                21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--08-C11.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--08-C11, mRNA sequence.
ACCESSION   CF318152
VERSION     CF318152.1  GI:33689913
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--08-C11"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   5.9%;  Pred. No. 4.8e+02;
  Matches    1;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db          1 CTTTTTTTTTTTTTTT 17


RESULT 314
DT496709/c
LOCUS       DT496709                21 bp    mRNA    linear   EST 29-AUG-2005
DEFINITION  WS01124.BR_D19 PT-P-FL-A-2 Populus trichocarpa cDNA clone
            WS01124_D19 5', mRNA sequence.
ACCESSION   DT496709
VERSION     DT496709.1  GI:73893971
KEYWORDS    EST.
SOURCE      Populus trichocarpa (Populus balsamifera subsp. trichocarpa)
  ORGANISM  Populus trichocarpa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids I; Malpighiales; Salicaceae; Saliceae; Populus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Ralph,S., Cooper,D., Kolosova,N., Oddy,C., Butterfield,Y.,
            Kirkpatrick,R., Liu,J., Palmquist,D., Stott,J., Barber,S., Yang,G.,
            Babakaiff,R., Brown-John,M., Chand,S., Featherstone,R., Masson,A.,
            Mayo,M., Moran,J., Olson,T., Wong,D., Ritland,C.E., Siddiqui,A.,
            Holt,R., Jones,S., Marra,M., Ellis,B.E., Douglas,C., Ritland,K. and
            Bohlmann,J.
  TITLE     The poplar transcriptome: Analysis of expressed sequence tags from
            multiple cDNA libraries
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Joerg Bohlmann
            Genome BC forest genomics program
            University of British Columbia
            Michael Smith Laboratories, 6174 University Boulevard, Rm. 237,
            Vancouver, British Columbia, Canada, V6T 1Z3
            Tel: 1-604-822-0282
            Fax: 1-604-822-2114
            Email: bohlmann@msl.ubc.ca
            Plate: WS01124  row: D  column: 19
            High quality sequence stop: 116
            POLYA=Yes.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Populus trichocarpa"
                     /mol_type="mRNA"
                     /cultivar="383-2499 (Nisqually-1)"
                     /db_xref="taxon:3694"
                     /clone="WS01124_D19"
                     /sex="Female"
                     /lab_host="E. coli DH10B T1 phage resistant cells"
                     /clone_lib="PT-P-FL-A-2"
                     /note="Vector: pBluescript II SK (+) XR; Site_1: SstI (5'
                     end of cDNA); Site_2: XhoI (3' end of cDNA); Phloem and
                     cambium from 8 year old trees harvested within the Boise
```

Cascade region of Washington state on May 15th, 2001. cDNA was prepared from 20 micrograms of mRNA according to the full-length cDNA library construction method described by Carninci P. et al. (2000), Genome Research 10(10):1617-1630 and directionally ligated into the pBluescript II SK (+) XR vector digested with SstI (5' end) and XhoI (3'). Plasmid DNA was then transformed by electroporation into DH10B cells (Invitrogen) for propagation."

Query Match 0.2%; Score 17; DB 1; Length 21;
Best Local Similarity 5.9%; Pred. No. 4.8e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUUC 6362
              :::::::::::::::::|
Db         17 TTTTTTTTTTTTTTTC 1
```

RESULT 315
AZ943299
LOCUS AZ943299 21 bp DNA linear GSS 26-APR-2001
DEFINITION 2M0203K21R Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0203K21 R, genomic survey sequence.
ACCESSION AZ943299
VERSION AZ943299.1 GI:13807290
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0203 row: K column: 21
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0203K21"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 17; DB 1; Length 21;
Best Local Similarity 5.9%; Pred. No. 4.8e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db          4 CTTTTTTTTTTTTTTT 20
```

RESULT 316
DX056270
LOCUS DX056270 21 bp DNA linear GSS 10-JAN-2006
DEFINITION KBrB061B22F KBrB, Brassica rapa BamHI BAC library Brassica rapa subsp. pekinensis genomic clone KBrB061B22, genomic survey sequence.
ACCESSION DX056270
VERSION DX056270.1 GI:84750567
KEYWORDS GSS.
SOURCE Brassica rapa subsp. pekinensis
ORGANISM Brassica rapa subsp. pekinensis
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE 1 (bases 1 to 21)
AUTHORS Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M., Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S., Hahn,J.H. and Park,B.S.
TITLE End sequence of Brassica rapa BamHI (KBrB) BAC clone
JOURNAL Unpublished (2005)
COMMENT Contact: Beom-Seok Park
Brassica Genomics Team
National Institute of Agricultural Biotechnology
225 Seodun-Dong, Suwon, 441-707, Korea
Tel: +82-31-299-1670
Fax: +82-31-299-1672
Email: pbeom@rda.go.kr
BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone KBrB061B22
Seq primer: T7
Class: BAC ends.
FEATURES Location/Qualifiers
source 1. .21
/organism="Brassica rapa subsp. pekinensis"
/mol_type="genomic DNA"
/cultivar="Chiifu"
/sub_species="pekinensis"
/db_xref="taxon:51351"
/clone="KBrB061B22"
/lab_host="E.coli DH10B"
/clone_lib="KBrB, Brassica rapa BamHI BAC library"
/note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp pekinensis var. Chiifu BAC library (KBrB BAC) is provided by Yong-Pyo Lim (CNU)."

Query Match 0.2%; Score 17; DB 1; Length 21;
Best Local Similarity 5.9%; Pred. No. 4.8e+02;
Matches 1; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |:::::::::::::::::
Db          1 CTTTTTTTTTTTTTTT 17
```

```
RESULT 317
AL038507/c
LOCUS       AL038507                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566D1846_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566D1846, mRNA sequence.
ACCESSION   AL038507
VERSION     AL038507.1  GI:49682146
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566D1846"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 318
AL038576/c
LOCUS       AL038576                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566F0346_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566F0346, mRNA sequence.
ACCESSION   AL038576
VERSION     AL038576.1  GI:49682161
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566F0346"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 319
AL038754/c
LOCUS       AL038754                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566M1346_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566M1346, mRNA sequence.
ACCESSION   AL038754
VERSION     AL038754.1  GI:49682201
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566M1346"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 320
AL038845/c
LOCUS       AL038845                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566P1746_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566P1746, mRNA sequence.
ACCESSION   AL038845
VERSION     AL038845.1  GI:49682220
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
```

```
           Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566P1746"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="X1-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 321
CF299570
LOCUS       CF299570                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-K09.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-K09, mRNA
            sequence.
ACCESSION   CF299570
VERSION     CF299570.1  GI:33671331
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--03-K09"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              :::::::::::::::: | |
Db          1 TTTTTTTTTTTTTTTACTA 20


RESULT 322
```

```
AZ368518/c
LOCUS       AZ368518                 20 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0118G09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0118G09 R, genomic survey sequence.
ACCESSION   AZ368518
VERSION     AZ368518.1  GI:10482218
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0118  row: G  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0118G09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   20.0%;  Pred. No. 4.7e+02;
  Matches    4;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4388 UUUUUGUGAUUUUUUUAAUA 4407
              :::::|:  :::::::||:|
Db         20 TTTTTGTTTTTTTTTAATA 1


RESULT 323
```

```
AZ849506/c
LOCUS       AZ849506                20 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0150P21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0150P21 R, genomic survey sequence.
ACCESSION   AZ849506
VERSION     AZ849506.1  GI:13033596
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0150  row: P  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0150P21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   10.0%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db         20 TTTTTTTTTTTTTTTTTAA 1


RESULT 324
BX548564
LOCUS       BX548564                21 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX548564 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse101g03_p1c, mRNA sequence.
ACCESSION   BX548564
VERSION     BX548564.1  GI:33298798
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
  PUBMED    14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse101g03_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   5.0%;  Pred. No. 5e+02;
  Matches    1;  Conservative   17;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6341 UCUACUUUUUUUUUUUUUUU 6360
              : : |:::::::::::::::    .
Db          2 TTTTCTTTTTTTTTTTTTT 21


RESULT 325
BX564412
LOCUS       BX564412                21 bp    mRNA    linear   EST 10-OCT-2003
DEFINITION  BX564412 Glossina morsitans morsitans adult infected gut Glossina
            morsitans morsitans cDNA clone Tse71e10_p1c, mRNA sequence.
ACCESSION   BX564412
VERSION     BX564412.1  GI:33431592
KEYWORDS    EST.
SOURCE      Glossina morsitans morsitans
  ORGANISM  Glossina morsitans morsitans
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
            Hippoboscoidea; Glossinidae; Glossina.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M.,
            Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
  TITLE     Adult midgut expressed sequence tags from the tsetse fly Glossina
            morsitans morsitans and expression analysis of putative immune
            response genes
```

```
  JOURNAL   Genome Biol. 4 (10), R63 (2003)
   PUBMED   14519198
COMMENT     Contact: Hall N
            Pathogen Sequencing Unit
            The Sanger Institute The Wellcome Trust Genome Campus
            Hinxton, Cambridge, CB10 1SA, UK
            Request for clones, please contact: Mike Lehane
            Prof. M.J.Lehane
            School of Biological Sciences,
            University of Wales,
            Bangor LL57 2UW
            All clones with suffix q1c are reverse primer reads starting at 5'
            end of the cDNA all p1c reads are from
            the 3' end.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Glossina morsitans morsitans"
                     /mol_type="mRNA"
                     /sub_species="morsitans"
                     /db_xref="taxon:37546"
                     /clone="Tse71e10_p1c"
                     /tissue_type="adult infected gut"
                     /clone_lib="Glossina morsitans morsitans adult infected
                     gut"
                     /note="country: Zimbabwe; EST from adult gut infected with
                     T.brucei"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   10.0%;  Pred. No. 5e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db          1 TTTTTTTTTTTTTTTTGAA 20


RESULT 326
CX000923
LOCUS       CX000923                 21 bp    mRNA    linear   EST 03-DEC-2004
DEFINITION  tl24b01.g7 Left Cardiac Ventricle (DOGEST7) Canis familiaris cDNA,
            mRNA sequence.
ACCESSION   CX000923
VERSION     CX000923.1  GI:56272339
KEYWORDS    EST.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
            Canis.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Balija,V.S., Nascimento,L.U. and McCombie,W.R.
  TITLE     ESTs from Canis familiaris left cardiac ventricle (dog)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Canis familiaris"
                     /mol_type="mRNA"
                     /db_xref="taxon:9615"
                     /sex="Unknown"
                     /tissue_type="Cardiac muscle"
                     /dev_stage="3 month old normal canine"
                     /lab_host="XL10 Gold"
                     /clone_lib="Left Cardiac Ventricle (DOGEST7)"
                     /note="Organ: Heart; Vector: pBluescript II SK; Site_1:
                     EcoRI; Site_2: XhoI; Library constructed using pBluescript
                     XR kit from Stratagene. Cloned cDNA was size selected
                     between 1-3 kb. Tissue supplied by Mark Haskins VMD, PhD,
                     Pathology and Medical Genetics, School of Veterinary
                     Medicine, University of Pennsylvania, 3800 Spruce Street,
                     Philadelphia, PA 19104-6051"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   10.0%;  Pred. No. 5e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db          2 TTTTTTTTTTTTTTTTTAA 21


RESULT 327
DN955796
LOCUS       DN955796                 21 bp    mRNA    linear   EST 04-MAY-2005
DEFINITION  it94a03.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA
            sequence.
ACCESSION   DN955796
VERSION     DN955796.1  GI:63027934
KEYWORDS    EST.
SOURCE      Gnetum gnemon
  ORGANISM  Gnetum gnemon
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Gnetum female cone (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Gnetum gnemon"
                     /mol_type="mRNA"
                     /db_xref="taxon:3382"
                     /sex="female"
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   10.0%;  Pred. No. 5e+02;
  Matches    2;  Conservative   16;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       6342 CUACUUUUUUUUUUUUUUUU 6361
              | | ::::::::::::::::
Db          2 CGAGTTTTTTTTTTTTTTTT 21


RESULT 328
AZ629111
LOCUS       AZ629111                 21 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0481D22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0481D22 R, genomic survey sequence.
ACCESSION   AZ629111
VERSION     AZ629111.1  GI:11751301
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0481 row: D column: 22
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0481D22"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 5e+02;
Matches 10; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6997 UGUGUGUGUGUGUGUGGG 7016
              :|:|:|:|:|:|:|:  |||
Db          1 TGTGTGTGTGTGTAAGGG 20
```

RESULT 329
AZ665302/c
LOCUS AZ665302 21 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0546J09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0546J09 R, genomic survey sequence.
ACCESSION AZ665302
VERSION AZ665302.1 GI:11802448
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0546 row: J column: 09
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0546J09"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 40.0%; Pred. No. 5e+02;
Matches 8; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6973 UGUGUGUGUGUGUGUGUG 6992
              : :|: :|:|:|:|:|:|:|
Db         20 TTTGTTTGTGTGTGTGTG 1
```

RESULT 330
CF329285
LOCUS CF329285 18 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--04-I22.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--04-I22, mRNA sequence.
ACCESSION CF329285
VERSION CF329285.1 GI:33806806
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)

```
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--04-I22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   11.1%;  Pred. No. 4.2e+02;
  Matches    2;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::| |
Db          1 TTTTTTTTTTTTTTCTA 18


RESULT 331
CR786637/c
LOCUS       CR786637                 18 bp    mRNA    linear   EST 01-OCT-2004
DEFINITION  DKFZp468J2331_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
            DKFZp468J2331 5', mRNA sequence.
ACCESSION   CR786637
VERSION     CR786637.1  GI:53705634
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
  ORGANISM  Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pongo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
            Fobo,G., Han,M. and Wiemann,S.
  TITLE     Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
            This is the 5' sequence of the clone insert. Clone from S. Wiemann,
            Molecular Genome Analysis, German Cancer Research Center (DKFZ);
            Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
            Germany. Please contact RZPD for ordering:
            http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
            Further information about the clone and the sequencing project is
            available at http://mips.gsf.de/projects/cdna/.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Pongo pygmaeus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9600"
                     /clone="DKFZp468J2331"
                     /tissue_type="heart"
                     /dev_stage="adult"
                     /lab_host="DH10B"
                     /clone_lib="468 (synonym: phrt1)"
                     /note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   5.6%;  Pred. No. 4.2e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUUUU 6360
              :| ::::::::::::::::
Db         18 TATTTTTTTTTTTTTTT 1


RESULT 332
CF308042
LOCUS       CF308042                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--01-L07.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--01-L07, mRNA sequence.
ACCESSION   CF308042
VERSION     CF308042.1  GI:33679803
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--01-L07"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   11.1%;  Pred. No. 4.6e+02;
  Matches    2;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCCA 6364
              :::::::::::::::: ||
Db          1 TTTTTTTTTTTTTTACA 18


RESULT 333
CF326845/c
LOCUS       CF326845                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--01-B12.g1 Rice callus plasmid cDNA library (NACL) Oryza
```

```
            sativa (japonica cultivar-group) cDNA clone NACL--01-B12, mRNA
            sequence.
ACCESSION   CF326845
VERSION     CF326845.1  GI:33801944
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--01-B12"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   11.1%;  Pred. No. 4.6e+02;
  Matches    2;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUCCA 6364
              ::::::::::::::| |
Db         19 TTTTTTTTTTTTTTTCTA 2


RESULT 334
AZ509929/c
LOCUS       AZ509929                 19 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0354A07F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0354A07 F, genomic survey sequence.
ACCESSION   AZ509929
VERSION     AZ509929.1  GI:10691245
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0354  row: A  column: 07
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0354A07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   5.6%;  Pred. No. 4.6e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6343 UACUUUUUUUUUUUUUUU 6360
              :| ::::::::::::::::
Db         18 TAATTTTTTTTTTTTTTT 1


RESULT 335
AZ764517/c
LOCUS       AZ764517                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0560L07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0560L07 R, genomic survey sequence.
ACCESSION   AZ764517
VERSION     AZ764517.1  GI:12879561
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
```

```
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0560  row: L  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0560L07"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match              0.2%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   5.6%;  Pred. No. 4.6e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
              | ::::::::::::::::
Db         18 AATTTTTTTTTTTTTTT 1


RESULT 336
AL587727
LOCUS       AL587727                 20 bp    mRNA    linear   EST 02-MAR-2001
DEFINITION  AL587727 BP Chicken Brain Library Gallus gallus cDNA clone
            ROS061D01, mRNA sequence.
ACCESSION   AL587727
VERSION     AL587727.1  GI:13192761
KEYWORDS    EST.
SOURCE      Gallus gallus (chicken)
  ORGANISM  Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Murray,F.
  TITLE     BP Chicken Brain Library
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Frazer Murray
            Dept. Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UK
            Tel: +44 (0)131 527 4200
            Fax: +44 (0)131 440 0434
            Email: frazer.murray@bbsrc.ac.uk
            GCGGCCGCTTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from Clonetech
            (*6854-
            Seq primer: M13F.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Gallus gallus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9031"
                      /clone="ROS061D01"
                      /tissue_type="Brain"
                      /dev_stage="Unknown"
                      /lab_host="DH10B"
                      /clone_lib="BP Chicken Brain Library"
                      /note="Vector: pSPORT1; Site_1: Not1; Site_2: Sal1; Cloned
                      unidirectionally. Primer: Oligo dT. 5' adaptor sequence:
                      5' TCGACCTCGAG 3' ; 3' adaptor sequence: 5'
                      GCGGCCGCTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from
                      Clonetech (*6854-1)"

  Query Match              0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   5.6%;  Pred. No. 5e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
              | ::::::::::::::::
Db          1 ATTTTTTTTTTTTTTTT 18


RESULT 337
AL587759
LOCUS       AL587759                 20 bp    mRNA    linear   EST 02-MAR-2001
DEFINITION  AL587759 BP Chicken Brain Library Gallus gallus cDNA clone
            ROS061G06, mRNA sequence.
ACCESSION   AL587759
VERSION     AL587759.1  GI:13192793
KEYWORDS    EST.
SOURCE      Gallus gallus (chicken)
  ORGANISM  Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Murray,F.
  TITLE     BP Chicken Brain Library
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Frazer Murray
            Dept. Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UK
            Tel: +44 (0)131 527 4200
            Fax: +44 (0)131 440 0434
            Email: frazer.murray@bbsrc.ac.uk
            GCGGCCGCTTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from Clonetech
            (*6854-
            Seq primer: M13F.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Gallus gallus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9031"
                      /clone="ROS061G06"
                      /tissue_type="Brain"
                      /dev_stage="Unknown"
                      /lab_host="DH10B"
                      /clone_lib="BP Chicken Brain Library"
                      /note="Vector: pSPORT1; Site_1: Not1; Site_2: Sal1; Cloned
                      unidirectionally. Primer: Oligo dT. 5' adaptor sequence:
                      5' TCGACCTCGAG 3' ; 3' adaptor sequence: 5'
                      GCGGCCGCTTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from
                      Clonetech (*6854-1)"

  Query Match              0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   5.6%;  Pred. No. 5e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
```

```
                  | ::::::::::::::::
Db          1 ATTTTTTTTTTTTTTTT 18


RESULT 338
AZ341237/c
LOCUS       AZ341237                 20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0073G03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0073G03 R, genomic survey sequence.
ACCESSION   AZ341237
VERSION     AZ341237.1  GI:10417288
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0073  row: G  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0073G03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   5.6%;  Pred. No. 5e+02;
  Matches    1;  Conservative   16;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6344 ACUUUUUUUUUUUUUUUU 6361
```

```
                  | ::::::::::::::::
Db         20 ATTTTTTTTTTTTTTTT 3


RESULT 339
AZ772074
LOCUS       AZ772074                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0574M10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0574M10 R, genomic survey sequence.
ACCESSION   AZ772074
VERSION     AZ772074.1  GI:12895006
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0574  row: M  column: 10
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0574M10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity  50.0%;  Pred. No. 5e+02;
  Matches    9;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6972 CUGUGUGUGUGUGUGUGU 6989
```

```
                  | |:|:|:|:|:|:|:|:|:|:
Db          3 CAGTGTGTGTGTGTGTGT 20


RESULT 340
BQ590166
LOCUS       BQ590166                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012844-024-019-K18-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-019-K18 3-PRIME, mRNA sequence.
ACCESSION   BQ590166
VERSION     BQ590166.1  GI:26119749
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 19  row: K  column: 18
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:189955"
                     /db_xref="taxon:161934"
                     /clone="024-019-K18"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 341
BQ592600/c
LOCUS       BQ592600                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013686-024-028-F08-SP6R MPIZ-ADIS-024-developing root Beta
            vulgaris cDNA clone 024-028-F08 5-PRIME, mRNA sequence.
ACCESSION   BQ592600
VERSION     BQ592600.1  GI:26122183
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 28  row: F  column: 08
            Seq primer: SP6r; ATTTAGGTGACACTATAGAAGA.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:194262"
                     /db_xref="taxon:161934"
                     /clone="024-028-F08"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 342
BQ592965
LOCUS       BQ592965                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013324-024-028-A01-T7 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-028-A01 3-PRIME, mRNA sequence.
ACCESSION   BQ592965
VERSION     BQ592965.1  GI:26122548
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
```

```
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 28  row: A  column: 01
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:193895"
                     /db_xref="taxon:161934"
                     /clone="024-028-A01"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 343
BQ595717/c
LOCUS       BQ595717                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012692-024-022-H07-SP6 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-022-H07 5-PRIME, mRNA sequence.
ACCESSION   BQ595717
VERSION     BQ595717.1  GI:26125300
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 22  row: H  column: 07
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:191134"
                     /db_xref="taxon:161934"
                     /clone="024-022-H07"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
                ::::::::::::::::
Db          16 TTTTTTTTTTTTTTTT 1


RESULT 344
CF279325
LOCUS       CF279325                 16 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--05-J09.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--05-J09,
            mRNA sequence.
ACCESSION   CF279325
VERSION     CF279325.1  GI:33656711
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--05-J09"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
```

RT-PCR."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

RESULT 345
CF311057
LOCUS CF311057 16 bp mRNA linear EST 15-AUG-2003
DEFINITION ABF--06-C03.g1 ABF3-overexpressing transgenic rice plasmid cDNA library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone ABF--06-C03, mRNA sequence.
ACCESSION CF311057
VERSION CF311057.1 GI:33682818
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="ABF--06-C03"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="ABF3-overexpressing transgenic rice plasmid cDNA library (ABF)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried for 2hrs. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was prepared from ABA-responsive element binding transcription factor 3 overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

RESULT 346
CF314377
LOCUS CF314377 16 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--02-O01.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--02-O01, mRNA sequence.
ACCESSION CF314377
VERSION CF314377.1 GI:33686138
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--02-O01"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

RESULT 347
CF315789
LOCUS CF315789 16 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--04-N10.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--04-N10, mRNA sequence.
ACCESSION CF315789
VERSION CF315789.1 GI:33687550
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .16
/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--04-N10"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 348
CF316056
LOCUS CF316056 16 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--05-D07.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--05-D07, mRNA sequence.
ACCESSION CF316056
VERSION CF316056.1 GI:33687817
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--05-D07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 349
CF317718
LOCUS CF317718 16 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--07-I05.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--07-I05, mRNA sequence.
ACCESSION CF317718
VERSION CF317718.1 GI:33689479
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .16
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--07-I05"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 0.0%; Pred. No. 3.7e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 350
CF320356
LOCUS CF320356 16 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--11-D14.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--11-D14, mRNA sequence.
ACCESSION CF320356
VERSION CF320356.1 GI:33692117
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

```
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--11-D14"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 351
CF327722
LOCUS       CF327722                  16 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--02-F06.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--02-F06, mRNA
            sequence.
ACCESSION   CF327722
VERSION     CF327722.1  GI:33803695
KEYWORDS.   EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--02-F06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 352
CF333386/c
LOCUS       CF333386                  16 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--02-E05.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--02-E05, mRNA sequence.
ACCESSION   CF333386
VERSION     CF333386.1  GI:33815044
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--02-E05"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 353
CR786853/c
LOCUS       CR786853                  16 bp    mRNA    linear   EST 01-OCT-2004
DEFINITION  DKFZp468E2231_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
            DKFZp468E2231 5', mRNA sequence.
ACCESSION   CR786853
VERSION     CR786853.1  GI:53705850
```

```
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
  ORGANISM  Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pongo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
            Fobo,G., Han,M. and Wiemann,S.
  TITLE     Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
            This is the 5' sequence of the clone insert. Clone from S. Wiemann,
            Molecular Genome Analysis, German Cancer Research Center (DKFZ);
            Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
            Germany. Please contact RZPD for ordering:
            http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468E2231
            Further information about the clone and the sequencing project is
            available at http://mips.gsf.de/projects/cdna/.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Pongo pygmaeus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9600"
                     /clone="DKFZp468E2231"
                     /tissue_type="heart"
                     /dev_stage="adult"
                     /lab_host="DH10B"
                     /clone_lib="468 (synonym: phrt1)"
                     /note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 354
DT498583/c
LOCUS       DT498583                 16 bp    mRNA    linear   EST 29-AUG-2005
DEFINITION  WS0115.BR_M08 PT-P-FL-A-2 Populus trichocarpa cDNA clone WS0115_M08
            5', mRNA sequence.
ACCESSION   DT498583
VERSION     DT498583.1  GI:73895845
KEYWORDS    EST.
SOURCE      Populus trichocarpa (Populus balsamifera subsp. trichocarpa)
  ORGANISM  Populus trichocarpa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids I; Malpighiales; Salicaceae; Saliceae; Populus.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ralph,S., Cooper,D., Kolosova,N., Oddy,C., Butterfield,Y.,
            Kirkpatrick,R., Liu,J., Palmquist,D., Stott,J., Barber,S., Yang,G.,
            Babakaiff,R., Brown-John,M., Chand,S., Featherstone,R., Masson,A.,
            Mayo,M., Moran,J., Olson,T., Wong,D., Ritland,C.E., Siddiqui,A.,
            Holt,R., Jones,S., Marra,M., Ellis,B.E., Douglas,C., Ritland,K. and
            Bohlmann,J.
  TITLE     The poplar transcriptome: Analysis of expressed sequence tags from
            multiple cDNA libraries
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Joerg Bohlmann
            Genome BC forest genomics program
            University of British Columbia
            Michael Smith Laboratories, 6174 University Boulevard, Rm. 237,
            Vancouver, British Columbia, Canada, V6T 1Z3
            Tel: 1-604-822-0282
            Fax: 1-604-822-2114
            Email: bohlmann@msl.ubc.ca
            Plate: WS0115  row: M  column: 08
            High quality sequence stop: 122
            POLYA=Yes.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Populus trichocarpa"
                     /mol_type="mRNA"
                     /cultivar="383-2499 (Nisqually-1)"
                     /db_xref="taxon:3694"
                     /clone="WS0115_M08"
                     /sex="Female"
                     /lab_host="E. coli DH10B T1 phage resistant cells"
                     /clone_lib="PT-P-FL-A-2"
                     /note="Vector: pBluescript II SK (+) XR; Site_1: SstI (5'
                     end of cDNA); Site_2: XhoI (3' end of cDNA); Phloem and
                     cambium from 8 year old trees harvested within the Boise
                     Cascade region of Washington state on May 15th, 2001. cDNA
                     was prepared from 20 micrograms of mRNA according to the
                     full-length cDNA library construction method described by
                     Carninci P. et al. (2000), Genome Research
                     10(10):1617-1630 and directionally ligated into the
                     pBluescript II SK (+) XR vector digested with SstI (5'
                     end) and XhoI (3'). Plasmid DNA was then transformed by
                     electroporation into DH10B cells (Invitrogen) for
                     propagation."

  Query Match             0.2%;  Score 16;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 3.7e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 355
BQ590128
LOCUS       BQ590128                 17 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012843-024-019-E19-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-019-E19 3-PRIME, mRNA sequence.
ACCESSION   BQ590128
VERSION     BQ590128.1  GI:26119711
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  PUBMED    12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 17   Std Error: 0.00
            Plate: 19  row: E  column: 19
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:189986"
                     /db_xref="taxon:161934"
```

```
                     /clone="024-019-E19"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 356
BQ590687/c
LOCUS       BQ590687                 17 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013717-024-018-B24-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-018-B24 3-PRIME, mRNA sequence.
ACCESSION   BQ590687
VERSION     BQ590687.1  GI:26120270
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 17   Std Error: 0.00
            Plate: 18  row: B  column: 24
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:189432"
                     /db_xref="taxon:161934"
                     /clone="024-018-B24"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 357
BQ591177
LOCUS       BQ591177                 17 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012715-024-017-B22-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-B22 3-PRIME, mRNA sequence.
ACCESSION   BQ591177
VERSION     BQ591177.1  GI:26120760
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 17   Std Error: 0.00
            Plate: 17  row: B  column: 22
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:188948"
                     /db_xref="taxon:161934"
                     /clone="024-017-B22"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 358
CF290854
LOCUS       CF290854                 17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-A21.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-A21, mRNA
            sequence.
ACCESSION   CF290854
VERSION     CF290854.1  GI:33659887
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-A21"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 359
CF294668
LOCUS       CF294668                 17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--04-E17.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--04-E17, mRNA
            sequence.
ACCESSION   CF294668
VERSION     CF294668.1  GI:33663701
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--04-E17"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 360
CF295807
LOCUS       CF295807                 17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--05-O12.b1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--05-O12, mRNA
            sequence.
ACCESSION   CF295807
VERSION     CF295807.1  GI:33664840
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--05-O12"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 361
CF295988
LOCUS       CF295988                 17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--06-C17.b1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--06-C17, mRNA
            sequence.
ACCESSION   CF295988
VERSION     CF295988.1  GI:33665021
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--06-C17"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 362
CF298589
LOCUS       CF298589                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-A18.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-A18, mRNA
            sequence.
ACCESSION   CF298589
VERSION     CF298589.1  GI:33670350
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-A18"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 363
CF299639
LOCUS       CF299639                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-L20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L20, mRNA
            sequence.
ACCESSION   CF299639
VERSION     CF299639.1  GI:33671400
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--03-L20"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."
```

```
  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 364
CF299997
LOCUS       CF299997                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--04-D19.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--04-D19, mRNA
            sequence.
ACCESSION   CF299997
VERSION     CF299997.1  GI:33671758
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--04-D19"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   6.2%;  Pred. No. 4.2e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 365
CF310219
LOCUS       CF310219                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--04-M02.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--04-M02, mRNA sequence.
ACCESSION   CF310219
VERSION     CF310219.1  GI:33681980
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--04-M02"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 4.2e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 366
CF334566
LOCUS       CF334566                 17 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--03-O13.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--03-O13, mRNA sequence.
ACCESSION   CF334566
VERSION     CF334566.1  GI:33817460
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--03-O13"
```

/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was pepared from Arabidopsis Jasmoinate Carboxyl methyltransferase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 17;
Best Local Similarity 0.0%; Pred. No. 4.2e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 367
CF336950
LOCUS CF336950 17 bp mRNA linear EST 18-AUG-2003
DEFINITION JMT--07-D04.g1 AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone JMT--07-D04, mRNA sequence.
ACCESSION CF336950
VERSION CF336950.1 GI:33822280
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 17)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--07-D04"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was pepared from Arabidopsis Jasmoinate Carboxyl methyltransferase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 17;
Best Local Similarity 0.0%; Pred. No. 4.2e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 368
CX309551
LOCUS CX309551 17 bp mRNA linear EST 03-JAN-2005
DEFINITION AM02384.3prime AM Drosophila melanogaster Embryo Larva Pupa Adult Drosophila melanogaster cDNA clone AM02384 3, mRNA sequence.
ACCESSION CX309551
VERSION CX309551.1 GI:57011768
KEYWORDS EST.
SOURCE Drosophila melanogaster (fruit fly)
ORGANISM Drosophila melanogaster
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.
REFERENCE 1 (bases 1 to 17)
AUTHORS Yandell,M., Bailey,A.M., Misra,S., Shu,S., Wiel,C., Evans-Holm,M., Celniker,S.E. and Rubin,G.M.
TITLE A computational and experimental approach to validating annotations and gene predictions in the Drosophila melanogaster genome
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 102 (5), 1566-1571 (2005)
PUBMED 15668397
COMMENT Other_ESTs: AM02384.5prime
Contact: Stapleton, M.
BDGP
Lawrence Berkeley National Lab
One Cyclotron Rd, Berkeley, CA 94720, USA
Fax: 510 486 6798
Email: http://www.fruitfly.org/EST, est@fruitfly.berkeley.edu
Plate: AM.23 row: G column: 12
High quality sequence stop: 17.
FEATURES Location/Qualifiers
source 1. .17
/organism="Drosophila melanogaster"
/mol_type="mRNA"
/db_xref="taxon:7227"
/clone="AM02384"
/sex="male and female"
/dev_stage="0 to 24 hours mixed stage embryonic, late third instar larvae, mixed stage pupae, mixed age adults"
/clone_lib="AM Drosophila melanogaster Embryo Larva Pupa Adult"
/note="RT-PCR products were amplified with pairs of gene-specific primers from template RNA representing pooled Drosophila stages. Products were directly sequenced from both ends with the same oligos used to prime PCR."

Query Match 0.2%; Score 16; DB 1; Length 17;
Best Local Similarity 0.0%; Pred. No. 4.2e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 369
AJ725584/c
LOCUS AJ725584 18 bp mRNA linear EST 17-FEB-2005
DEFINITION AJ725584 riken1 Gallus gallus cDNA clone 2c16r4, mRNA sequence.
ACCESSION AJ725584
VERSION AJ725584.1 GI:53890998
KEYWORDS EST.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.
REFERENCE 1 (bases 1 to 18)
AUTHORS Caldwell,R.B., Kierzek,A.M., Arakawa,H., Bezzubov,Y., Zaim,J., Fiedler,P., Kutter,S., Blagodatski,A., Kostovska,D., Koter,M., Plachy,J., Carninci,P., Hayashizaki,Y. and Buerstedde,J.M.
TITLE Full-length cDNAs from chicken bursal lymphocytes to facilitate gene function analysis
JOURNAL Genome Biol. 6 (1), R6 (2005)
PUBMED 15642098

```
COMMENT     Contact: Caldwell RB
            GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
            Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Gallus gallus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9031"
                     /clone="2c16r4"
                     /cell_type="bursal lymphocyte"
                     /dev_stage="2-3 weeks old"
                     /clone_lib="riken1"
                     /note="CB inbred strain"

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 370
AL038692/c
LOCUS       AL038692                 18 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566J0846_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566J0846, mRNA sequence.
ACCESSION   AL038692
VERSION     AL038692.1  GI:49682190
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566J0846"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 371
AL048754/c
LOCUS       AL048754                 18 bp    mRNA    linear   EST 04-SEP-2003
DEFINITION  DKFZp566L173_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566L173, mRNA sequence.
ACCESSION   AL048754
VERSION     AL048754.1  GI:4727825
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Koehrer,K., Beyer,A., Mewes,H.W., Gassenhuber,J. and Wiemann,S.
  TITLE     EST (Koehrer, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566L173"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 372
BQ582676
LOCUS       BQ582676                 18 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012281-024-007-P18-SP6 MPIZ-ADIS-024-inflorescence Beta vulgaris
            cDNA clone 024-007-P18 5-PRIME, mRNA sequence.
ACCESSION   BQ582676
VERSION     BQ582676.1  GI:26112253
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 18   Std Error: 0.00
            Plate: 7  row: P  column: 18
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:184018"
                     /db_xref="taxon:161934"
                     /clone="024-007-P18"
                     /tissue_type="inflorescence"
```

/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-inflorescence"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.2%; Score 16; DB 1; Length 18;
Best Local Similarity 0.0%; Pred. No. 4.6e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 373
BQ590027
LOCUS BQ590027 18 bp mRNA linear EST 06-DEC-2002
DEFINITION E012844-024-019-E24-T7 MPIZ-ADIS-024-storage root Beta vulgaris cDNA clone 024-019-E24 3-PRIME, mRNA sequence.
ACCESSION BQ590027
VERSION BQ590027.1 GI:26119610
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 18)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 18 Std Error: 0.00
Plate: 19 row: E column: 24
Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES Location/Qualifiers
source 1. .18
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:190095"
/db_xref="taxon:161934"
/clone="024-019-E24"
/tissue_type="storage root"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-storage root"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.2%; Score 16; DB 1; Length 18;
Best Local Similarity 0.0%; Pred. No. 4.6e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 374
CF277873
LOCUS CF277873 18 bp mRNA linear EST 14-AUG-2003
DEFINITION 14ETL--03-J04.g1 Rice etiolated leaf plasmid cDNA library (14ETL) Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--03-J04, mRNA sequence.
ACCESSION CF277873
VERSION CF277873.1 GI:33655259
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 18)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .18
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="14ETL--03-J04"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 16; DB 1; Length 18;
Best Local Similarity 0.0%; Pred. No. 4.6e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 375
CF297446
LOCUS CF297446 18 bp mRNA linear EST 14-AUG-2003
DEFINITION 30DGS--08-F02.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza sativa (japonica cultivar-group) cDNA clone 30DGS--08-F02, mRNA sequence.
ACCESSION CF297446
VERSION CF297446.1 GI:33666479
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--08-F02"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 376
CF299027
LOCUS       CF299027                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-N14.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-N14, mRNA
            sequence.
ACCESSION   CF299027
VERSION     CF299027.1  GI:33670788
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-N14"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 377
CF299674
LOCUS       CF299674                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-M14.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-M14, mRNA
            sequence.
ACCESSION   CF299674
VERSION     CF299674.1  GI:33671435
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--03-M14"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 378
CF301151
LOCUS       CF301151                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-O05.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-O05, mRNA
            sequence.
ACCESSION   CF301151
```

```
VERSION     CF301151.1  GI:33672912
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--05-O05"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 379
CF301325
LOCUS       CF301325                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--06-C12.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--06-C12, mRNA
            sequence.
ACCESSION   CF301325
VERSION     CF301325.1  GI:33673086
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--06-C12"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 380
CF301760
LOCUS       CF301760                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--06-L22.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--06-L22, mRNA
            sequence.
ACCESSION   CF301760
VERSION     CF301760.1  GI:33673521
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--06-L22"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 381
CF302409
LOCUS       CF302409                 18 bp    mRNA    linear   EST 15-AUG-2003
```

```
DEFINITION  7LEAF--07-N19.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-N19, mRNA
            sequence.
ACCESSION   CF302409
VERSION     CF302409.1  GI:33674170
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-N19"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 382
CF320046
LOCUS       CF320046                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--10-M11.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--10-M11, mRNA sequence.
ACCESSION   CF320046
VERSION     CF320046.1  GI:33691807
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--10-M11"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 383
DR073142
LOCUS       DR073142                 18 bp    mRNA    linear   EST 08-JUN-2005
DEFINITION  qs66c01.g1 Ginkgo female leaf (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR073142
VERSION     DR073142.1  GI:67050994
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo female leaf (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="female"
                     /clone_lib="Ginkgo female leaf (NYBG)"
                     /note="Organ: leaf; Vector: :pBK-CMV; Site_1: XhoI;
                     Site_2: Eco RI; Stratagene ZAP Express cDNA Synthesis Kit.
                     The library was size-fractionated to enrich for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 384
DR074121
LOCUS       DR074121                 18 bp    mRNA    linear   EST 08-JUN-2005
DEFINITION  ik98c05.g1 Ginkgo male leaf (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR074121
VERSION     DR074121.1  GI:67052070
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo male leaf (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="male"
                     /clone_lib="Ginkgo male leaf (NYBG)"
                     /note="Organ: leaf; Vector: pBK-CMV; Site_1: XhoI; Site_2:
                     Eco RI; Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 385
AJ668179
LOCUS       AJ668179                 19 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ668179 CSEQRAN09 Sus scrofa cDNA clone C0000045_L19, mRNA
            sequence.
ACCESSION   AJ668179
VERSION     AJ668179.1  GI:49352630
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000045_L19"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 386
AJ669138
LOCUS       AJ669138                 19 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ669138 CSEQRAN09 Sus scrofa cDNA clone C0000048_O12, mRNA
            sequence.
ACCESSION   AJ669138
VERSION     AJ669138.1  GI:49353592
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000048_O12"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 387
BQ588729/c
LOCUS       BQ588729                 19 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013713-024-014-B24-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-014-B24 3-PRIME, mRNA sequence.
ACCESSION   BQ588729
VERSION     BQ588729.1  GI:26118312
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 19   Std Error: 0.00
            Plate: 14  row: B  column: 24
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:187281"
                     /db_xref="taxon:161934"
                     /clone="024-014-B24"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 388
CB174047
LOCUS       CB174047                 19 bp    mRNA    linear   EST 09-OCT-2003
DEFINITION  OR_2o32F05_010529.y1 Adult mouse olfactory epithelium library Mus
            musculus cDNA clone 2o32F05 5', mRNA sequence.
ACCESSION   CB174047
VERSION     CB174047.1  GI:37592676
KEYWORDS    EST.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Young,J.M., Shykind,B.M., Lane,R.P., Tonnes-Priddy,L., Ross,J.A.,
            Walker,M., Williams,E.M. and Trask,B.J.
  TITLE     Odorant receptor expressed sequence tags demonstrate olfactory
            expression of over 400 genes, extensive alternate splicing and
            unequal expression levels
  JOURNAL   Genome Biol. 4 (11), R71.1-R71.15 (2003)
COMMENT     Contact: Young JM
            Trask Lab, Division of Human Biology
            Fred Hutchinson Cancer Research Center
            1100 Fairview Avenue N., C3-168, P.O. Box 19024, Seattle, WA
            98109-1024, USA
            Tel: 206 667 1471
            Fax: 206 667 6524
            Email: jayoung@fhcrc.org
            Seq primer: M13 Reverse.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="mRNA"
                     /db_xref="taxon:10090"
                     /clone="2o32F05"
                     /tissue_type="Olfactory and respiratory epithelium"
                     /dev_stage="Adult"
                     /clone_lib="Adult mouse olfactory epithelium library"
                     /note="Organ: Olfactory turbinates; Vector:
                     LambdaZAPII-XR; Site_1: EcoRI; Site_2: XhoI; This library
                     was provided by Leslie Vosshall. mRNA was prepared from
                     the olfactory and respiratory epithelium of an adult
                     mouse. Oligo-dT primed cDNA was directionally cloned into
                     Stratagene's lambdaZAPII-XR vector."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 389
CF279008
LOCUS       CF279008                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--05-C13.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--05-C13,
            mRNA sequence.
ACCESSION   CF279008
VERSION     CF279008.1  GI:33656394
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--05-C13"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 390
CF291089
LOCUS       CF291089                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-G03.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-G03, mRNA
            sequence.
ACCESSION   CF291089
VERSION     CF291089.1  GI:33660122
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-G03"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 391
CF291090/c
LOCUS       CF291090                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-G03.g1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-G03, mRNA
            sequence.
ACCESSION   CF291090
VERSION     CF291090.1  GI:33660123
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-G03"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 392
CF291665
LOCUS       CF291665                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-D01.g1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-D01, mRNA
            sequence.
ACCESSION   CF291665
VERSION     CF291665.1  GI:33660698
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
```

```
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ROOT--02-D01"
                      /tissue_type="root"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 393
CF291899
LOCUS       CF291899                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-I08.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-I08, mRNA
            sequence.
ACCESSION   CF291899
VERSION     CF291899.1  GI:33660932
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ROOT--02-I08"
                      /tissue_type="root"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          3 TTTTTTTTTTTTTTTT 18


RESULT 394
CF292072
LOCUS       CF292072                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-M03.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-M03, mRNA
            sequence.
ACCESSION   CF292072
VERSION     CF292072.1  GI:33661105
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ROOT--02-M03"
                      /tissue_type="root"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          3 TTTTTTTTTTTTTTTT 18


RESULT 395
CF292144
LOCUS       CF292144                 19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-N17.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-N17, mRNA
            sequence.
ACCESSION   CF292144
VERSION     CF292144.1  GI:33661177
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
```

```
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--02-N17"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          3 TTTTTTTTTTTTTTTT 18


RESULT 396
CF293167
LOCUS       CF293167                19 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--02-E02.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--02-E02, mRNA
            sequence.
ACCESSION   CF293167
VERSION     CF293167.1  GI:33662200
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--02-E02"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17


RESULT 397
CF298396
LOCUS       CF298396                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-M05.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-M05, mRNA
            sequence.
ACCESSION   CF298396
VERSION     CF298396.1  GI:33670157
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--01-M05"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 398
CF299598
LOCUS       CF299598                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-K23.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-K23, mRNA
            sequence.
ACCESSION   CF299598
VERSION     CF299598.1  GI:33671359
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--03-K23"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 399
CF302327
LOCUS       CF302327                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-L24.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-L24, mRNA
            sequence.
ACCESSION   CF302327
VERSION     CF302327.1  GI:33674088
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-L24"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 400
CF302456
LOCUS       CF302456                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-P22.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-P22, mRNA
            sequence.
ACCESSION   CF302456
VERSION     CF302456.1  GI:33674217
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-P22"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 401
CF304589
LOCUS       CF304589                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF1--05-G10.g1 ABF3-overexpressing transgenic rice lambda phage
            cDNA library (ABF1) Oryza sativa (japonica cultivar-group) cDNA
            clone ABF1--05-G10, mRNA sequence.
ACCESSION   CF304589
VERSION     CF304589.1  GI:33676350
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF1--05-G10"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli SOLR"
                     /clone_lib="ABF3-overexpressing transgenic rice lambda
                     phage cDNA library (ABF1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Leaf was dried for 2hrs. cDNA was inserted into
                     lamda Uni-ZAP XR vector at 5' end with EcoRI and 3' end
                     with XhoI site. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 402
CF309801
LOCUS       CF309801                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--04-C04.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--04-C04, mRNA sequence.
ACCESSION   CF309801
VERSION     CF309801.1  GI:33681562
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--04-C04"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 403
CF309821
LOCUS       CF309821                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--04-C17.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--04-C17, mRNA sequence.
ACCESSION   CF309821
VERSION     CF309821.1  GI:33681582
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--04-C17"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db          2 TTTTTTTTTTTTTTT 17


RESULT 404
CF309943/c
LOCUS       CF309943                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--04-F15.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--04-F15, mRNA sequence.
ACCESSION   CF309943
VERSION     CF309943.1  GI:33681704
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--04-F15"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 405
CF310688/c
LOCUS       CF310688                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--05-H18.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--05-H18, mRNA sequence.
ACCESSION   CF310688
VERSION     CF310688.1  GI:33682449
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--05-H18"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         17 TTTTTTTTTTTTTTTT 2


RESULT 406
CF311496
LOCUS       CF311496                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--06-L18.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--06-L18, mRNA sequence.
ACCESSION   CF311496
VERSION     CF311496.1  GI:33683257
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--06-L18"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
```

```
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 407
CF311513
LOCUS       CF311513                  19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--06-M03.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--06-M03, mRNA sequence.
ACCESSION   CF311513
VERSION     CF311513.1  GI:33683274
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--06-M03"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 408
CF311668/c
LOCUS       CF311668                  19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--07-A05.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--07-A05, mRNA sequence.
ACCESSION   CF311668
VERSION     CF311668.1  GI:33683429
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--07-A05"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         16 TTTTTTTTTTTTTTTT 1


RESULT 409
CF311778
LOCUS       CF311778                  19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--07-D01.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--07-D01, mRNA sequence.
ACCESSION   CF311778
VERSION     CF311778.1  GI:33683539
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
```

```
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--07-D01"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17


RESULT 410
CF312403/c
LOCUS       CF312403                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--08-C07.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--08-C07, mRNA sequence.
ACCESSION   CF312403
VERSION     CF312403.1  GI:33684164
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--08-C07"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 411
CF315299
LOCUS       CF315299                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--04-C17.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--04-C17, mRNA sequence.
ACCESSION   CF315299
VERSION     CF315299.1  GI:33687060
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--04-C17"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 412
CF316480
LOCUS       CF316480                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--05-M14.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--05-M14, mRNA sequence.
ACCESSION   CF316480
VERSION     CF316480.1  GI:33688241
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--05-M14"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 413
CF318788/c
LOCUS       CF318788                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--09-A23.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--09-A23, mRNA sequence.
ACCESSION   CF318788
VERSION     CF318788.1  GI:33690549
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--09-A23"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 414
CF327587
LOCUS       CF327587                19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--02-C04.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--02-C04, mRNA
            sequence.
ACCESSION   CF327587
VERSION     CF327587.1  GI:33803426
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--02-C04"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 415
```

```
CF329136
LOCUS       CF329136                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--04-F15.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--04-F15, mRNA
            sequence.
ACCESSION   CF329136
VERSION     CF329136.1  GI:33806509
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--04-F15"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   6.2%;  Pred. No. 5e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 416
CF329986/c
LOCUS       CF329986                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--05-I09.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--05-I09, mRNA
            sequence.
ACCESSION   CF329986
VERSION     CF329986.1  GI:33808194
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--05-I09"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 417
CF331361
LOCUS       CF331361                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--07-H08.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--07-H08, mRNA
            sequence.
ACCESSION   CF331361
VERSION     CF331361.1  GI:33810941
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--07-H08"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db          2 TTTTTTTTTTTTTTT 17


RESULT 418
CF332063
LOCUS       CF332063                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--08-G19.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--08-G19, mRNA
            sequence.
ACCESSION   CF332063
VERSION     CF332063.1  GI:33812347
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--08-G19"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 419
CF333507/c
LOCUS       CF333507                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--02-G23.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--02-G23, mRNA sequence.
ACCESSION   CF333507
VERSION     CF333507.1  GI:33815309
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--02-G23"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 420
CF333753/c
LOCUS       CF333753                 19 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--02-M08.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--02-M08, mRNA sequence.
ACCESSION   CF333753
VERSION     CF333753.1  GI:33815809
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--02-M08"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
```

methyltransferase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4
```

RESULT 421
CF334014
LOCUS CF334014 19 bp mRNA linear EST 18-AUG-2003
DEFINITION JMT--03-C09.g1 AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone JMT--03-C09, mRNA sequence.
ACCESSION CF334014
VERSION CF334014.1 GI:33816333
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 19)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .19
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--03-C09"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was pepared from Arabidopsis Jasmoinate Carboxyl methyltransferase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

RESULT 422
CF335293
LOCUS CF335293 19 bp mRNA linear EST 18-AUG-2003
DEFINITION JMT--04-O17.g1 AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone JMT--04-O17, mRNA sequence.
ACCESSION CF335293
VERSION CF335293.1 GI:33818938
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 19)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .19
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="JMT--04-O17"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="AtJMT-overexpressing transgenic rice plasmid cDNA library (JMT)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was pepared from Arabidopsis Jasmoinate Carboxyl methyltransferase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 19;
Best Local Similarity 0.0%; Pred. No. 5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17
```

RESULT 423
CN545602
LOCUS CN545602 19 bp mRNA linear EST 30-APR-2004
DEFINITION EST 17546 Ripe Grape Skin Triplex2 Library Vitis vinifera cDNA clone B3CS00RL003H10 3', mRNA sequence.
ACCESSION CN545602
VERSION CN545602.1 GI:46910227
KEYWORDS EST.
SOURCE Vitis vinifera
ORGANISM Vitis vinifera
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; rosids; Vitaceae; Vitis.
REFERENCE 1 (bases 1 to 19)
AUTHORS Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F., Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J., Hamdi,S., Romieu,C. and Terrier,N.
TITLE Generation of Expressed Sequence Tag from Grape Berry (skin, pulp or seeds) at Various Developmental Stages
JOURNAL Unpublished (2002)
COMMENT Contact: Hamdi S.
UMR 619 - Equipe Biologie de la Vigne
Universite de Bordeaux I, Institut National de la Recherche Agronomique
71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex, France
Tel: 00-33-(0)5-57-12-25-50
Fax: 00-33-(0)5-57-12-25-48
Email: s.hamdi@bordeaux.inra.fr
Seq primer: T7.
FEATURES Location/Qualifiers

```
     source          1. .19
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00RL003H10"
                     /dev_stage="ripening stage"
                     /clone_lib="Ripe Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 424
CN545922
LOCUS       CN545922                19 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 17866 Ripe Grape Skin Triplex2 Library Vitis vinifera cDNA
            clone B3CS00RL006D07 3', mRNA sequence.
ACCESSION   CN545922
VERSION     CN545922.1  GI:46910547
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
            71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
            France
            Tel: 00-33-(0)5-57-12-25-50
            Fax: 00-33-(0)5-57-12-25-48
            Email: s.hamdi@bordeaux.inra.fr
            Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00RL006D07"
                     /dev_stage="ripening stage"
                     /clone_lib="Ripe Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 425
CN545923
LOCUS       CN545923                19 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 17867 Ripe Grape Skin Triplex2 Library Vitis vinifera cDNA
            clone B3CS00RL006D08 3', mRNA sequence.
ACCESSION   CN545923
VERSION     CN545923.1  GI:46910548
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
            71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
            France
            Tel: 00-33-(0)5-57-12-25-50
            Fax: 00-33-(0)5-57-12-25-48
            Email: s.hamdi@bordeaux.inra.fr
            Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00RL006D08"
                     /dev_stage="ripening stage"
                     /clone_lib="Ripe Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17


RESULT 426
CN545964
LOCUS       CN545964                19 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 17912 Ripe Grape Skin Triplex2 Library Vitis vinifera cDNA
            clone B3CS00RL006H10 3', mRNA sequence.
ACCESSION   CN545964
VERSION     CN545964.1  GI:46910589
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
```

```
           71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
           France
           Tel: 00-33-(0)5-57-12-25-50
           Fax: 00-33-(0)5-57-12-25-48
           Email: s.hamdi@bordeaux.inra.fr
           Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00RL006H10"
                     /dev_stage="ripening stage"
                     /clone_lib="Ripe Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 427
CN546303
LOCUS       CN546303                  19 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 18255 Green Grape Berry Lambda Triplex2 Library Vitis vinifera
            cDNA clone B3CS1XGB015E10 3', mRNA sequence.
ACCESSION   CN546303
VERSION     CN546303.1  GI:46910928
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
            71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
            France
            Tel: 00-33-(0)5-57-12-25-50
            Fax: 00-33-(0)5-57-12-25-48
            Email: s.hamdi@bordeaux.inra.fr
            Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS1XGB015E10"
                     /dev_stage="green stage"
                     /clone_lib="Green Grape Berry Lambda Triplex2 Library"
                     /note="Organ: Fruit without seeds; Vector: Lambda
                     TriplEx2; Site_1: SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 428
CX002732
LOCUS       CX002732                  19 bp    mRNA    linear   EST 03-DEC-2004
DEFINITION  iv33e03.b1 Left Cardiac Ventricle (DOGEST7) Canis familiaris cDNA,
            mRNA sequence.
ACCESSION   CX002732
VERSION     CX002732.1  GI:56274148
KEYWORDS    EST.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
            Canis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Balija,V.S., Nascimento,L.U. and McCombie,W.R.
  TITLE     ESTs from Canis familiaris left cardiac ventricle (dog)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Canis familiaris"
                     /mol_type="mRNA"
                     /db_xref="taxon:9615"
                     /sex="Unknown"
                     /tissue_type="Cardiac muscle"
                     /dev_stage="3 month old normal canine"
                     /lab_host="XL10 Gold"
                     /clone_lib="Left Cardiac Ventricle (DOGEST7)"
                     /note="Organ: Heart; Vector: pBluescript II SK; Site_1:
                     EcoRI; Site_2: XhoI; Library constructed using pBluescript
                     XR kit from Stratagene. Cloned cDNA was size selected
                     between 1-3 kb. Tissue supplied by Mark Haskins VMD, PhD,
                     Pathology and Medical Genetics, School of Veterinary
                     Medicine, University of Pennsylvania, 3800 Spruce Street,
                     Philadelphia, PA 19104-6051"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 429
CX003880/c
LOCUS       CX003880                  19 bp    mRNA    linear   EST 03-DEC-2004
DEFINITION  iv25a12.b1 Brain - Cerebellum Library (DOGEST8) Canis familiaris
            cDNA, mRNA sequence.
ACCESSION   CX003880
VERSION     CX003880.1  GI:56275296
KEYWORDS    EST.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
            Canis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Balija,V., Nascimento,L.U. and McCombie,W.R.
  TITLE     ESTs from Canis familiaris cerebellum (dog)
  JOURNAL   Unpublished (2004)
```

```
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Canis familiaris"
                     /mol_type="mRNA"
                     /db_xref="taxon:9615"
                     /sex="Unknown"
                     /tissue_type="Cerebellum"
                     /dev_stage="3 month old normal canine"
                     /lab_host="XL10 Gold"
                     /clone_lib="Brain - Cerebellum Library (DOGEST8)"
                     /note="Organ: Brain; Vector: pBluescript II SK; Site_1:
                     EcoRI; Site_2: XhoI; Library constructed using pBluescript
                     XR kit from Stratagene. Cloned cDNA was size selected
                     between 1-3 kb. Mark Haskins VMD, PhD, Pathology and
                     Medical Genetics, School of Veterinary Medicine,
                     University of Pennsylvania, 3800 Spruce Street,
                     Philadelphia, PA 19104-6051"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 430
CX007355
LOCUS       CX007355                 19 bp    mRNA    linear   EST 06-DEC-2004
DEFINITION  io27h10.g1 Whole Heart Library (DOGEST5) Canis familiaris cDNA,
            mRNA sequence.
ACCESSION   CX007355
VERSION     CX007355.1  GI:56389584
KEYWORDS    EST.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
            Canis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Balija,V.S., Nascimento,L.U. and McCombie,W.R.
  TITLE     ESTs from Canis familiaris whole heart (dog)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Canis familiaris"
                     /mol_type="mRNA"
                     /db_xref="taxon:9615"
                     /sex="Unknown"
                     /dev_stage="3 month old normal canine"
                     /lab_host="XL10 Gold"
                     /clone_lib="Whole Heart Library (DOGEST5)"
                     /note="Organ: Heart; Vector: pBluescript II SK; Site_1:
                     EcoRI; Site_2: XhoI; Library constructed using pBluescript
                     XR kit from Stratagene. Cloned cDNA was size selected
                     between 1-3 kb. Mark Haskins VMD, PhD, Pathology and
                     Medical Genetics, School of Veterinary Medicine,
                     University of Pennsylvania, 3800 Spruce Street,
                     Philadelphia, PA 19104-6051"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         1 TTTTTTTTTTTTTTTT 16


RESULT 431
DN954273
LOCUS       DN954273                 19 bp    mRNA    linear   EST 04-MAY-2005
DEFINITION  it71a04.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA
            sequence.
ACCESSION   DN954273
VERSION     DN954273.1  GI:63026411
KEYWORDS    EST.
SOURCE      Gnetum gnemon
  ORGANISM  Gnetum gnemon
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Gnetum female cone (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Gnetum gnemon"
                     /mol_type="mRNA"
                     /db_xref="taxon:3382"
                     /sex="female"
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         1 TTTTTTTTTTTTTTTT 16


RESULT 432
DN955154
LOCUS       DN955154                 19 bp    mRNA    linear   EST 04-MAY-2005
DEFINITION  it82g11.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA
            sequence.
ACCESSION   DN955154
VERSION     DN955154.1  GI:63027292
KEYWORDS    EST.
SOURCE      Gnetum gnemon
  ORGANISM  Gnetum gnemon
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Gnetum female cone (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Gnetum gnemon"
                     /mol_type="mRNA"
                     /db_xref="taxon:3382"
                     /sex="female"
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 433
DN955630/c
LOCUS       DN955630                 19 bp    mRNA    linear   EST 04-MAY-2005
DEFINITION  it91f11.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA
            sequence.
ACCESSION   DN955630
VERSION     DN955630.1  GI:63027768
KEYWORDS    EST.
SOURCE      Gnetum gnemon
  ORGANISM  Gnetum gnemon
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Gnetum female cone (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Gnetum gnemon"
                     /mol_type="mRNA"
                     /db_xref="taxon:3382"
                     /sex="female"
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 434
DR062165/c
LOCUS       DR062165                 19 bp    mRNA    linear   EST 06-JUN-2005
DEFINITION  iq09e02.g1 Cycas sporophyll (w/o ovule) (NYBG) Cycas rumphii cDNA
            3', mRNA sequence.
ACCESSION   DR062165
VERSION     DR062165.1  GI:66985731
KEYWORDS    EST.
SOURCE      Cycas rumphii
  ORGANISM  Cycas rumphii
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Cycadophyta; Cycadales; Cycadaceae; Cycas.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Cycas sporophyll (w/o ovule) (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Cycas rumphii"
                     /mol_type="mRNA"
                     /db_xref="taxon:58031"
                     /sex="Female"
                     /clone_lib="Cycas sporophyll (w/o ovule) (NYBG)"
                     /note="Organ: Sporophyll with ovules detached.; Vector:
                     PBK-CMV; Site_1: Xho I; Site_2: Eco RI; Date: Completed
                     08/09/2002. Submitted to CSHL 08/21/2002. Sample: Young
                     emergent sporopyhll with ovules detached (ovules used to
                     make a separate library). From New York Botanical Garden
                     Conservatory accssion number 808/59 A. (collected
                     06/04/2002). Library: Made using Stratagene's ZAP Express
                     Vector Kit. Library was size fractionated for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 435
DR063041/c
LOCUS       DR063041                 19 bp    mRNA    linear   EST 06-JUN-2005
DEFINITION  iq24h10.g1 Cycas ovule (NYBG) Cycas rumphii cDNA 3', mRNA sequence.
ACCESSION   DR063041
VERSION     DR063041.1  GI:66986609
KEYWORDS    EST.
SOURCE      Cycas rumphii
  ORGANISM  Cycas rumphii
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Cycadophyta; Cycadales; Cycadaceae; Cycas.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Cycas ovules (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Cycas rumphii"
                     /mol_type="mRNA"
                     /db_xref="taxon:58031"
                     /sex="Female"
                     /clone_lib="Cycas ovule (NYBG)"
                     /note="Organ: Ovules; Vector: pBK-CMV; Site_1: XhoI;
                     Site_2: Eco RI; Stratagene ZAP Express cDNA Synthesis Kit.
                     The library was size-fractionated to enrich for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 436
DR063459
LOCUS       DR063459                  19 bp    mRNA    linear   EST 06-JUN-2005
DEFINITION  ip65g04.g1 Ginkgo megasporophyll (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR063459
VERSION     DR063459.1  GI:66987027
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo megasporophyll (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="Female"
                     /clone_lib="Ginkgo megasporophyll (NYBG)"
                     /note="Organ: megasporophyll; Vector: pBK-CMV; Site_1:
                     XhoI; Site_2: Eco RI; Stratagene ZAP Express cDNA
                     Synthesis Kit. The library was size-fractionated to enrich
                     for large inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 437
DR065256
LOCUS       DR065256                  19 bp    mRNA    linear   EST 06-JUN-2005
DEFINITION  ip92c10.g1 Ginkgo microsporophyll (NYBG) Ginkgo biloba cDNA 3',
            mRNA sequence.
ACCESSION   DR065256
VERSION     DR065256.1  GI:66988824
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo microsporophyll (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="male"
                     /clone_lib="Ginkgo microsporophyll (NYBG)"
                     /note="Organ: microsporophyll; Vector: pBK-CMV; Site_1:
                     XhoI; Site_2: Eco RI; Stratagene ZAP Express cDNA
                     Synthesis Kit. The library was size-fractionated to enrich
                     for large inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 438
DR073123
LOCUS       DR073123                  19 bp    mRNA    linear   EST 08-JUN-2005
DEFINITION  ik86f08.g1 Ginkgo female leaf (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR073123
VERSION     DR073123.1  GI:67050974
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
```

```
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo female leaf (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="female"
                     /clone_lib="Ginkgo female leaf (NYBG)"
                     /note="Organ: leaf; Vector: :pBK-CMV; Site_1: XhoI;
                     Site_2: Eco RI; Stratagene ZAP Express cDNA Synthesis Kit.
                     The library was size-fractionated to enrich for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 439
DR074208/c
LOCUS       DR074208                  19 bp    mRNA    linear   EST 08-JUN-2005
DEFINITION  il53h03.g1 Ginkgo male leaf (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR074208
VERSION     DR074208.1  GI:67052176
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo male leaf (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="male"
                     /clone_lib="Ginkgo male leaf (NYBG)"
                     /note="Organ: leaf; Vector: pBK-CMV; Site_1: XhoI; Site_2:
                     Eco RI; Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large
                     inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 440
DT497638/c
LOCUS       DT497638                  19 bp    mRNA    linear   EST 29-AUG-2005
DEFINITION  WS0113.BR_A21 PT-P-FL-A-2 Populus trichocarpa cDNA clone WS0113_A21
            5', mRNA sequence.
ACCESSION   DT497638
VERSION     DT497638.1  GI:73894900
KEYWORDS    EST.
SOURCE      Populus trichocarpa (Populus balsamifera subsp. trichocarpa)
  ORGANISM  Populus trichocarpa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids I; Malpighiales; Salicaceae; Saliceae; Populus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Ralph,S., Cooper,D., Kolosova,N., Oddy,C., Butterfield,Y.,
            Kirkpatrick,R., Liu,J., Palmquist,D., Stott,J., Barber,S., Yang,G.,
            Babakaiff,R., Brown-John,M., Chand,S., Featherstone,R., Masson,A.,
            Mayo,M., Moran,J., Olson,T., Wong,D., Ritland,C.E., Siddiqui,A.,
            Holt,R., Jones,S., Marra,M., Ellis,B.E., Douglas,C., Ritland,K. and
            Bohlmann,J.
  TITLE     The poplar transcriptome: Analysis of expressed sequence tags from
            multiple cDNA libraries
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Joerg Bohlmann
            Genome BC forest genomics program
            University of British Columbia
            Michael Smith Laboratories, 6174 University Boulevard, Rm. 237,
            Vancouver, British Columbia, Canada, V6T 1Z3
            Tel: 1-604-822-0282
            Fax: 1-604-822-2114
            Email: bohlmann@msl.ubc.ca
            Plate: WS0113  row: A  column: 21
            High quality sequence stop: 129.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Populus trichocarpa"
                     /mol_type="mRNA"
                     /cultivar="383-2499 (Nisqually-1)"
                     /db_xref="taxon:3694"
                     /clone="WS0113_A21"
                     /sex="Female"
                     /lab_host="E. coli DH10B T1 phage resistant cells"
                     /clone_lib="PT-P-FL-A-2"
                     /note="Vector: pBluescript II SK (+) XR; Site_1: SstI (5'
                     end of cDNA); Site_2: XhoI (3' end of cDNA); Phloem and
                     cambium from 8 year old trees harvested within the Boise
                     Cascade region of Washington state on May 15th, 2001. cDNA
                     was prepared from 20 micrograms of mRNA according to the
                     full-length cDNA library construction method described by
                     Carninci P. et al. (2000), Genome Research
                     10(10):1617-1630 and directionally ligated into the
                     pBluescript II SK (+) XR vector digested with SstI (5'
                     end) and XhoI (3'). Plasmid DNA was then transformed by
                     electroporation into DH10B cells (Invitrogen) for
                     propagation."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTT 3


RESULT 441
AZ307313/c
```

```
LOCUS       AZ307313                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0008H20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0008H20 R, genomic survey sequence.
ACCESSION   AZ307313
VERSION     AZ307313.1  GI:10346192
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0008  row: H  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0008H20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 442
AZ310079
```

```
LOCUS       AZ310079                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0018K17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0018K17 R, genomic survey sequence.
ACCESSION   AZ310079
VERSION     AZ310079.1  GI:10351709
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0018  row: K  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0018K17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 443
AZ310105
```

```
LOCUS       AZ310105                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0018E21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0018E21 R, genomic survey sequence.
ACCESSION   AZ310105
VERSION     AZ310105.1  GI:10351761
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0018  row: E  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0018E21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 444
AZ317743/c
```

```
LOCUS       AZ317743                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0036B18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0036B18 R, genomic survey sequence.
ACCESSION   AZ317743
VERSION     AZ317743.1  GI:10366848
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0036  row: B  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0036B18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 445
AZ340311
```

```
LOCUS       AZ340311                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0072H15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0072H15 F, genomic survey sequence.
ACCESSION   AZ340311
VERSION     AZ340311.1  GI:10415441
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0072  row: H  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0072H15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 446
AZ345795/c
```

```
LOCUS       AZ345795                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0080H09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0080H09 R, genomic survey sequence.
ACCESSION   AZ345795
VERSION     AZ345795.1  GI:10425032
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0080  row: H  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0080H09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 447
AZ350519
```

```
LOCUS       AZ350519                19 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0088A10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0088A10 F, genomic survey sequence.
ACCESSION   AZ350519
VERSION     AZ350519.1  GI:10429756
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0088  row: A  column: 10
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0088A10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 448
AZ364226/c
```

```
LOCUS       AZ364226                19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0110B24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0110B24 F, genomic survey sequence.
ACCESSION   AZ364226
VERSION     AZ364226.1  GI:10477926
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0110  row: B  column: 24
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0110B24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 449
AZ365696/c
```

```
LOCUS       AZ365696                 19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0112A07R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0112A07 R, genomic survey sequence.
ACCESSION   AZ365696
VERSION     AZ365696.1  GI:10479396
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0112  row: A  column: 07
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0112A07"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 450
AZ374409/c
```

```
LOCUS       AZ374409                 19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0127D10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0127D10 F, genomic survey sequence.
ACCESSION   AZ374409
VERSION     AZ374409.1  GI:10488109
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0127  row: D  column: 10
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0127D10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 451
AZ374619/c
```

```
LOCUS       AZ374619                19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0127F04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0127F04 R, genomic survey sequence.
ACCESSION   AZ374619
VERSION     AZ374619.1  GI:10488319
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0127  row: F  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0127F04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 452
AZ385952/c
```

```
LOCUS       AZ385952                19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0144L10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0144L10 R, genomic survey sequence.
ACCESSION   AZ385952
VERSION     AZ385952.1  GI:10499652
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0144  row: L  column: 10
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0144L10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 453
AZ391509/c
```

```
LOCUS       AZ391509                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0153K08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0153K08 R, genomic survey sequence.
ACCESSION   AZ391509
VERSION     AZ391509.1  GI:10506552
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0153  row: K  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0153K08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 454
AZ410050/c
```

```
LOCUS       AZ410050                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0182P04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0182P04 F, genomic survey sequence.
ACCESSION   AZ410050
VERSION     AZ410050.1  GI:10534063
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0182  row: P  column: 04
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0182P04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 455
AZ414413/c
```

```
LOCUS       AZ414413                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0188O13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0188O13 R, genomic survey sequence.
ACCESSION   AZ414413
VERSION     AZ414413.1  GI:10538426
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0188  row: O  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0188O13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 456
AZ422604/c
```

```
LOCUS       AZ422604                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0201B21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0201B21 F, genomic survey sequence.
ACCESSION   AZ422604
VERSION     AZ422604.1  GI:10546617
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0201  row: B  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0201B21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 457
AZ424716
```

```
LOCUS       AZ424716                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0204O20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0204O20 F, genomic survey sequence.
ACCESSION   AZ424716
VERSION     AZ424716.1  GI:10548729
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0204  row: O  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0204O20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 458
AZ441329
```

```
LOCUS       AZ441329                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0233D01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0233D01 F, genomic survey sequence.
ACCESSION   AZ441329
VERSION     AZ441329.1  GI:10565342
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0233  row: D  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0233D01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 459
AZ442365
```

```
LOCUS       AZ442365                 19 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0236C13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0236C13 F, genomic survey sequence.
ACCESSION   AZ442365
VERSION     AZ442365.1  GI:10566378
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0236  row: C  column: 13
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0236C13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 460
AZ450180/c
```

```
LOCUS       AZ450180                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0248K13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0248K13 R, genomic survey sequence.
ACCESSION   AZ450180
VERSION     AZ450180.1  GI:10604710
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0248  row: K  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0248K13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 461
AZ453930
```

```
LOCUS       AZ453930                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0255G11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0255G11 R, genomic survey sequence.
ACCESSION   AZ453930
VERSION     AZ453930.1  GI:10612055
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0255  row: G  column: 11
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0255G11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 462
AZ460906/c
```

```
LOCUS       AZ460906                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0266E03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0266E03 R, genomic survey sequence.
ACCESSION   AZ460906
VERSION     AZ460906.1  GI:10619031
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0266  row: E  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0266E03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 463
AZ471494
```

```
LOCUS       AZ471494                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0286E11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0286E11 F, genomic survey sequence.
ACCESSION   AZ471494
VERSION     AZ471494.1  GI:10629619
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0286  row: E  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0286E11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 464
AZ476576
```

```
LOCUS       AZ476576                 19 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0295F04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0295F04 R, genomic survey sequence.
ACCESSION   AZ476576
VERSION     AZ476576.1  GI:10634701
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0295  row: F  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0295F04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 465
AZ486786
```

```
LOCUS       AZ486786                 19 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0315D21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0315D21 F, genomic survey sequence.
ACCESSION   AZ486786
VERSION     AZ486786.1  GI:10653902
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0315  row: D  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0315D21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 466
AZ490652
```

```
LOCUS       AZ490652                 19 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0323E17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0323E17 R, genomic survey sequence.
ACCESSION   AZ490652
VERSION     AZ490652.1  GI:10661595
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0323  row: E  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0323E17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 467
AZ508040/c
```

```
LOCUS       AZ508040                19 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0350B04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0350B04 F, genomic survey sequence.
ACCESSION   AZ508040
VERSION     AZ508040.1  GI:10689356
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0350  row: B  column: 04
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0350B04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 468
AZ579119/c
```

```
LOCUS       AZ579119                19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0363M16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0363M16 F, genomic survey sequence.
ACCESSION   AZ579119
VERSION     AZ579119.1  GI:11693580
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0363  row: M  column: 16
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0363M16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 469
AZ583970/c
```

```
LOCUS       AZ583970                19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0388M11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0388M11 F, genomic survey sequence.
ACCESSION   AZ583970
VERSION     AZ583970.1  GI:11704386
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0388  row: M  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0388M11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 470
AZ585865/c
```

```
LOCUS       AZ585865                19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0391D21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0391D21 F, genomic survey sequence.
ACCESSION   AZ585865
VERSION     AZ585865.1  GI:11708055
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0391  row: D  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0391D21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 471
AZ593210/c
```

```
LOCUS       AZ593210                19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0404C09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0404C09 R, genomic survey sequence.
ACCESSION   AZ593210
VERSION     AZ593210.1  GI:11715400
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0404  row: C  column: 09
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0404C09"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 472
AZ616154
```

```
LOCUS       AZ616154                19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0445P16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0445P16 R, genomic survey sequence.
ACCESSION   AZ616154
VERSION     AZ616154.1  GI:11738344
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0445  row: P  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0445P16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 473
AZ627844
```

```
LOCUS       AZ627844                 19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0474J05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0474J05 F, genomic survey sequence.
ACCESSION   AZ627844
VERSION     AZ627844.1  GI:11750130
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0474  row: J  column: 05
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0474J05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 474
AZ631701/c
```

```
LOCUS       AZ631701                 19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0486E01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0486E01 F, genomic survey sequence.
ACCESSION   AZ631701
VERSION     AZ631701.1  GI:11753891
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0486  row: E  column: 01
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0486E01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 475
AZ633821/c
```

```
LOCUS       AZ633821                 19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0489H15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0489H15 F, genomic survey sequence.
ACCESSION   AZ633821
VERSION     AZ633821.1  GI:11756011
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0489  row: H  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0489H15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 476
AZ643659/c
```

```
LOCUS       AZ643659                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0507D18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0507D18 F, genomic survey sequence.
ACCESSION   AZ643659
VERSION     AZ643659.1  GI:11771446
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0507  row: D  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0507D18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 477
AZ644698
```

```
LOCUS       AZ644698                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0508E17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0508E17 R, genomic survey sequence.
ACCESSION   AZ644698
VERSION     AZ644698.1  GI:11773485
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0508  row: E  column: 17
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0508E17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 478
AZ648335/c
```

```
LOCUS       AZ648335                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0517L16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0517L16 F, genomic survey sequence.
ACCESSION   AZ648335
VERSION     AZ648335.1  GI:11780699
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0517  row: L  column: 16
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0517L16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 479
AZ649888
```

```
LOCUS       AZ649888                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0519E15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0519E15 R, genomic survey sequence.
ACCESSION   AZ649888
VERSION     AZ649888.1  GI:11783820
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0519  row: E  column: 15
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0519E15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 480
AZ650575/c
```

```
LOCUS       AZ650575                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0520P13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0520P13 R, genomic survey sequence.
ACCESSION   AZ650575
VERSION     AZ650575.1  GI:11785200
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0520  row: P  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0520P13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 481
AZ764497/c
```

```
LOCUS       AZ764497                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0560H03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0560H03 R, genomic survey sequence.
ACCESSION   AZ764497
VERSION     AZ764497.1  GI:12879521
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0560  row: H  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0560H03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 482
AZ764522/c
```

```
LOCUS       AZ764522                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0560E16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0560E16 R, genomic survey sequence.
ACCESSION   AZ764522
VERSION     AZ764522.1  GI:12879571
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0560  row: E  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0560E16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 483
AZ764534/c
```

```
LOCUS       AZ764534                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0560P14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0560P14 R, genomic survey sequence.
ACCESSION   AZ764534
VERSION     AZ764534.1  GI:12879595
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0560  row: P  column: 14
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0560P14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 484
AZ770387/c
```

```
LOCUS       AZ770387                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0571L23R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0571L23 R, genomic survey sequence.
ACCESSION   AZ770387
VERSION     AZ770387.1  GI:12891520
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0571  row: L  column: 23
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0571L23"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 485
AZ778858/c
```

```
LOCUS       AZ778858                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0014O20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0014O20 F, genomic survey sequence.
ACCESSION   AZ778858
VERSION     AZ778858.1  GI:12908925
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0014  row: O  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0014O20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 486
AZ779901/c
```

```
LOCUS       AZ779901                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0016E16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0016E16 R, genomic survey sequence.
ACCESSION   AZ779901
VERSION     AZ779901.1  GI:12911024
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0016  row: E  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0016E16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 487
AZ781876/c
```

```
LOCUS       AZ781876                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0021O03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0021O03 R, genomic survey sequence.
ACCESSION   AZ781876
VERSION     AZ781876.1  GI:12915007
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0021  row: O  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0021O03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 488
AZ786779
```

```
LOCUS       AZ786779                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M00032C01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M00032C01 R, genomic survey sequence.
ACCESSION   AZ786779
VERSION     AZ786779.1  GI:12924882
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0032  row: C  column: 01
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M00032C01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 5e+02;
  Matches    8;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGU 6989
              |:|:|:|:|:|:|:|:
Db          3 GTGTGTGTGTGTGTGT 18


RESULT 489
AZ787634
```

```
LOCUS       AZ787634                19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0034M12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0034M12 F, genomic survey sequence.
ACCESSION   AZ787634
VERSION     AZ787634.1  GI:12926621
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0034  row: M  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0034M12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 490
AZ788058
```

```
LOCUS       AZ788058                19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0034I24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0034I24 R, genomic survey sequence.
ACCESSION   AZ788058
VERSION     AZ788058.1  GI:12927475
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0034  row: I  column: 24
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0034I24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 491
AZ789590
```

```
LOCUS       AZ789590                19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0037G06R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0037G06 R, genomic survey sequence.
ACCESSION   AZ789590
VERSION     AZ789590.1  GI:12930573
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0037  row: G  column: 06
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0037G06"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 492
AZ792713
```

```
LOCUS       AZ792713                19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0045C22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0045C22 F, genomic survey sequence.
ACCESSION   AZ792713
VERSION     AZ792713.1  GI:12936930
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0045  row: C  column: 22
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0045C22"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 493
AZ795403/c
```

```
LOCUS       AZ795403                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0049C12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0049C12 R, genomic survey sequence.
ACCESSION   AZ795403
VERSION     AZ795403.1  GI:12942392
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0049  row: C  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0049C12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 494
AZ801970
```

```
LOCUS       AZ801970                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0060I12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0060I12 R, genomic survey sequence.
ACCESSION   AZ801970
VERSION     AZ801970.1  GI:12954293
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0060  row: I  column: 12
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0060I12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 495
AZ810717/c
```

```
LOCUS       AZ810717                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0076N24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0076N24 F, genomic survey sequence.
ACCESSION   AZ810717
VERSION     AZ810717.1  GI:12978242
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0076  row: N  column: 24
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0076N24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   31.2%;  Pred. No. 5e+02;
  Matches    5;  Conservative   11;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6351 UUUUUUUUUUUCCAAA 6366
              ::::::::::|||||
Db         19 TTTTTTTTTTCCAAA 4


RESULT 496
AZ822225
```

```
LOCUS       AZ822225                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0095E17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0095E17 F, genomic survey sequence.
ACCESSION   AZ822225
VERSION     AZ822225.1  GI:12992133
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0095  row: E  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0095E17"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 497
AZ841581/c
```

```
LOCUS       AZ841581                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0139G08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0139G08 R, genomic survey sequence.
ACCESSION   AZ841581
VERSION     AZ841581.1  GI:13011489
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0139  row: G  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0139G08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 498
AZ841622/c
```

```
LOCUS       AZ841622                 19 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0139A16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0139A16 R, genomic survey sequence.
ACCESSION   AZ841622
VERSION     AZ841622.1  GI:13011530
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0139  row: A  column: 16
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0139A16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 499
AZ856873
```

```
LOCUS       AZ856873                 19 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0161O19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0161O19 F, genomic survey sequence.
ACCESSION   AZ856873
VERSION     AZ856873.1  GI:13048296
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0161  row: O  column: 19
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0161O19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   12.5%;  Pred. No. 5e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCC 6363
              ::::::::::::::||
Db          1 TTTTTTTTTTTTTTCC 16


RESULT 500
AZ861896/c
```

```
LOCUS       AZ861896                 19 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0168P10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0168P10 R, genomic survey sequence.
ACCESSION   AZ861896
VERSION     AZ861896.1  GI:13058674
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0168  row: P  column: 10
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0168P10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 501
AZ936798/c
```

```
LOCUS       AZ936798                 19 bp    DNA     linear   GSS 26-APR-2001
DEFINITION  2M0193L10R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0193L10 R, genomic survey sequence.
ACCESSION   AZ936798
VERSION     AZ936798.1  GI:13795379
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0193  row: L  column: 10
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0193L10"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 502
AZ950028/c
```

```
LOCUS       AZ950028                 19 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0213L19R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0213L19 R, genomic survey sequence.
ACCESSION   AZ950028
VERSION     AZ950028.1  GI:13821255
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0213  row: L  column: 19
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0213L19"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   12.5%;  Pred. No. 5e+02;
  Matches    2;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUCC 6363
              ::::::::::::::||
Db         19 TTTTTTTTTTTTTTCC 4


RESULT 503
AZ985501/c
```

```
LOCUS       AZ985501                19 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0267E21F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0267E21 F, genomic survey sequence.
ACCESSION   AZ985501
VERSION     AZ985501.1  GI:13856728
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0267  row: E  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0267E21"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 504
BH000498/c
```

```
LOCUS       BH000498                19 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0288I21F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0288I21 F, genomic survey sequence.
ACCESSION   BH000498
VERSION     BH000498.1  GI:13871724
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0288  row: I  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0288I21"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 505
CL680736/c
```

```
LOCUS       CL680736                  19 bp    DNA     linear   GSS 09-JUL-2004
DEFINITION  PRI012a_H07_2 - PRI012a.BR (19) Note: Recurring String Mixed stage
            fosmid library of P. pacificus var. California Pristionchus
            pacificus genomic, genomic survey sequence.
ACCESSION   CL680736
VERSION     CL680736.1  GI:50187696
KEYWORDS    GSS.
SOURCE      Pristionchus pacificus
  ORGANISM  Pristionchus pacificus
            Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida;
            Neodiplogasteridae; Pristionchus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
  TITLE     AppaDB: an AcedB database for the nematode satellite organism
            Pristionchus pacificus
  JOURNAL   Nucleic Acids Res. 32 (1), D421-D422 (2004)
   PUBMED   14681447
COMMENT     Contact: Sommer RJ
            Evolutionary Biology
            Max-Planck-Institute for Developmental Biology
            Spemannstr. 37-39, Tuebingen D-72076, Germany
            Tel: 00497071601371
            Fax: 00497071601498
            Email: ralf.sommer@tuebingen.mpg.de
            This library was generated at Caltech, Pasadena, USA and end
            sequenced at Vancouver, Canada.
            Seq primer: T7
            Class: fosmid ends.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Pristionchus pacificus"
                     /mol_type="genomic DNA"
                     /strain="California"
                     /db_xref="taxon:54126"
                     /clone_lib="Mixed stage fosmid library of P. pacificus
                     var. California"
                     /note="Vector: pEpifos-5 Fosmid vector"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 506
CL685439/c
LOCUS       CL685439                  19 bp    DNA     linear   GSS 09-JUL-2004
DEFINITION  PRI0141b_A04_2 - PRI0141b.BR (19) Mixed stage fosmid library of P.
            pacificus var. California Pristionchus pacificus genomic, genomic
            survey sequence.
ACCESSION   CL685439
VERSION     CL685439.1  GI:50193696
KEYWORDS    GSS.
SOURCE      Pristionchus pacificus
  ORGANISM  Pristionchus pacificus
            Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida;
            Neodiplogasteridae; Pristionchus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
  TITLE     AppaDB: an AcedB database for the nematode satellite organism
            Pristionchus pacificus
  JOURNAL   Nucleic Acids Res. 32 (1), D421-D422 (2004)
   PUBMED   14681447
COMMENT     Contact: Sommer RJ
            Evolutionary Biology
            Max-Planck-Institute for Developmental Biology
            Spemannstr. 37-39, Tuebingen D-72076, Germany
            Tel: 00497071601371
            Fax: 00497071601498
            Email: ralf.sommer@tuebingen.mpg.de
            This library was generated at Caltech, Pasadena, USA and end
            sequenced at Vancouver, Canada.
            Seq primer: T7
            Class: fosmid ends.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Pristionchus pacificus"
                     /mol_type="genomic DNA"
                     /strain="California"
                     /db_xref="taxon:54126"
                     /clone_lib="Mixed stage fosmid library of P. pacificus
                     var. California"
                     /note="Vector: pEpifos-5 Fosmid vector"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 507
CL693186/c
LOCUS       CL693186                  19 bp    DNA     linear   GSS 10-JUL-2004
DEFINITION  PRI0160c_B05_2 - PRI0160c.BR (19) Note: Recurring String Mixed
            stage fosmid library of P. pacificus var. California Pristionchus
            pacificus genomic, genomic survey sequence.
ACCESSION   CL693186
VERSION     CL693186.1  GI:50215094
KEYWORDS    GSS.
SOURCE      Pristionchus pacificus
  ORGANISM  Pristionchus pacificus
            Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida;
            Neodiplogasteridae; Pristionchus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
  TITLE     AppaDB: an AcedB database for the nematode satellite organism
            Pristionchus pacificus
  JOURNAL   Nucleic Acids Res. 32 (1), D421-D422 (2004)
   PUBMED   14681447
COMMENT     Contact: Sommer RJ
            Evolutionary Biology
            Max-Planck-Institute for Developmental Biology
            Spemannstr. 37-39, Tuebingen D-72076, Germany
            Tel: 00497071601371
            Fax: 00497071601498
            Email: ralf.sommer@tuebingen.mpg.de
            This library was generated at Caltech, Pasadena, USA and end
            sequenced at Vancouver, Canada.
            Seq primer: T7
            Class: fosmid ends.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Pristionchus pacificus"
                     /mol_type="genomic DNA"
                     /strain="California"
                     /db_xref="taxon:54126"
                     /clone_lib="Mixed stage fosmid library of P. pacificus
                     var. California"
                     /note="Vector: pEpifos-5 Fosmid vector"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 508
```

```
CL693191/c
LOCUS       CL693191                  19 bp    DNA     linear   GSS 10-JUL-2004
DEFINITION  PRI0160c_H08_2 - PRI0160c.BR (19) Note: Recurring String Mixed
            stage fosmid library of P. pacificus var. California Pristionchus
            pacificus genomic, genomic survey sequence.
ACCESSION   CL693191
VERSION     CL693191.1  GI:50215099
KEYWORDS    GSS.
SOURCE      Pristionchus pacificus
  ORGANISM  Pristionchus pacificus
            Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida;
            Neodiplogasteridae; Pristionchus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
  TITLE     AppaDB: an AcedB database for the nematode satellite organism
            Pristionchus pacificus
  JOURNAL   Nucleic Acids Res. 32 (1), D421-D422 (2004)
   PUBMED   14681447
COMMENT     Contact: Sommer RJ
            Evolutionary Biology
            Max-Planck-Institute for Developmental Biology
            Spemannstr. 37-39, Tuebingen D-72076, Germany
            Tel: 00497071601371
            Fax: 00497071601498
            Email: ralf.sommer@tuebingen.mpg.de
            This library was generated at Caltech, Pasadena, USA and end
            sequenced at Vancouver, Canada.
            Seq primer: T7
            Class: fosmid ends.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Pristionchus pacificus"
                     /mol_type="genomic DNA"
                     /strain="California"
                     /db_xref="taxon:54126"
                     /clone_lib="Mixed stage fosmid library of P. pacificus
                     var. California"
                     /note="Vector: pEpifos-5 Fosmid vector"

  Query Match             0.2%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   0.0%;  Pred. No. 5e+02;
  Matches    0;  Conservative    16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 509
AJ666275
LOCUS       AJ666275                  20 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ666275 CSEQRAN09 Sus scrofa cDNA clone C0000033_B07, mRNA
            sequence.
ACCESSION   AJ666275
VERSION     AJ666275.1  GI:49350726
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000033_B07"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative    16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          3 TTTTTTTTTTTTTTTT 18


RESULT 510
AJ666402
LOCUS       AJ666402                  20 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ666402 CSEQRAN09 Sus scrofa cDNA clone C0000033_C23, mRNA
            sequence.
ACCESSION   AJ666402
VERSION     AJ666402.1  GI:49350853
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000033_C23"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative    16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

```
RESULT 511
AL038427/c
LOCUS       AL038427                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566A1746_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566A1746, mRNA sequence.
ACCESSION   AL038427
VERSION     AL038427.1  GI:49682121
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566A1746"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 512
AL038429/c
LOCUS       AL038429                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566A1946_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566A1946, mRNA sequence.
ACCESSION   AL038429
VERSION     AL038429.1  GI:49682123
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566A1946"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 513
AL038460/c
LOCUS       AL038460                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566B2246_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566B2246, mRNA sequence.
ACCESSION   AL038460
VERSION     AL038460.1  GI:49682131
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566B2246"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 514
AL038570/c
LOCUS       AL038570                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566F1746_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566F1746, mRNA sequence.
ACCESSION   AL038570
VERSION     AL038570.1  GI:49682159
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
```

```
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566F1746"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 515
AL038750/c
LOCUS       AL038750                 20 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566M1146_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566M1146, mRNA sequence.
ACCESSION   AL038750
VERSION     AL038750.1  GI:49682199
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566M1146"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 516
AL587572
LOCUS       AL587572                 20 bp    mRNA    linear   EST 02-MAR-2001
DEFINITION  AL587572 BP Chicken Brain Library Gallus gallus cDNA clone
            ROS059B11, mRNA sequence.
ACCESSION   AL587572
VERSION     AL587572.1  GI:13192606
KEYWORDS    EST.
SOURCE      Gallus gallus (chicken)
  ORGANISM  Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Murray,F.
  TITLE     BP Chicken Brain Library
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Frazer Murray
            Dept. Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UK
            Tel: +44 (0)131 527 4200
            Fax: +44 (0)131 440 0434
            Email: frazer.murray@bbsrc.ac.uk
            GCGGCCGCTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from Clonetech
            (*6854-
            Seq primer: M13F.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Gallus gallus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9031"
                     /clone="ROS059B11"
                     /tissue_type="Brain"
                     /dev_stage="Unknown"
                     /lab_host="DH10B"
                     /clone_lib="BP Chicken Brain Library"
                     /note="Vector: pSPORT1; Site_1: Not1; Site_2: Sal1; Cloned
                     unidirectionally. Primer: Oligo dT. 5' adaptor sequence:
                     5' TCGACCTCGAG 3' ; 3' adaptor sequence: 5'
                     GCGGCCGCTTTTTTTTTTTTTTTT 3' Poly A RNA purchased from
                     Clonetech (*6854-1)"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 517
CA853586
LOCUS       CA853586                 20 bp    mRNA    linear   EST 01-AUG-2003
DEFINITION  B09H12.seq cDNA Peking library 12hr SCN3 Glycine max cDNA clone
            B09H12 5', mRNA sequence.
ACCESSION   CA853586
VERSION     CA853586.1  GI:33390391
KEYWORDS    EST.
SOURCE      Glycine max (soybean)
  ORGANISM  Glycine max
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
            Glycine.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Alkharouf,N., Khan,R. and Matthews,B.
  TITLE     Analysis of expressed sequence tags from roots of resistant soybean
            infected by the soybean cyst nematode
  JOURNAL   Genome 47 (2), 380-388 (2004)
  PUBMED    15060591
COMMENT     Contact: Alkharouf, N.W.
            Soybean Genomics and Improvement Laboratory (SGIL)
            US Department of Agriculture (USDA), ARS, PSI
            Bldg.006, Rm 118, 10300 Baltimore Ave., Beltsville, MD 20705-2350,
            USA
            Tel: 301 504 5750
            Fax: 301 504 5728
            Email: alkharon@ba.ars.usda.gov.
```

```
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Glycine max"
                     /mol_type="mRNA"
                     /cultivar="Peking"
                     /db_xref="taxon:3847"
                     /clone="B09H12"
                     /tissue_type="Roots"
                     /dev_stage="Seedlings"
                     /clone_lib="cDNA Peking library 12hr SCN3"
                     /note="Vector: pBluescript SK-; cDNA clones from mRNA
                     extracted from roots of soybean cv. Peking 12  hrs after
                     infection by SCN race 3. These are cloned in pBluescript
                     SK- phagemid. "

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          3 TTTTTTTTTTTTTTTT 18


RESULT 518
CF280913/c
LOCUS       CF280913                  20 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--07-M07.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--07-M07,
            mRNA sequence.
ACCESSION   CF280913
VERSION     CF280913.1  GI:33658299
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--07-M07"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 519
CF282002
LOCUS       CF282002                  20 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--09-F01.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--09-F01,
            mRNA sequence.
ACCESSION   CF282002
VERSION     CF282002.1  GI:33659389
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--09-F01"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17


RESULT 520
CF282035/c
LOCUS       CF282035                  20 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--09-F19.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--09-F19,
            mRNA sequence.
ACCESSION   CF282035
VERSION     CF282035.1  GI:33659422
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
```

```
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES                Location/Qualifiers
     source             1. .20
                        /organism="Oryza sativa (japonica cultivar-group)"
                        /mol_type="mRNA"
                        /cultivar="Nackdong"
                        /db_xref="taxon:39947"
                        /clone="14ETL--09-F19"
                        /tissue_type="leaf"
                        /dev_stage="14 days after germination"
                        /lab_host="E.coli DH10B"
                        /clone_lib="Rice etiolated leaf plasmid cDNA library
                        (14ETL)"
                        /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                        with oligoribonucleotides and then used as templates for
                        RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 521
CF282414/c
LOCUS       CF282414                 20 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--09-O19.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--09-O19,
            mRNA sequence.
ACCESSION   CF282414
VERSION     CF282414.1  GI:33659801
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES                Location/Qualifiers
     source             1. .20
                        /organism="Oryza sativa (japonica cultivar-group)"
                        /mol_type="mRNA"
                        /cultivar="Nackdong"
                        /db_xref="taxon:39947"
                        /clone="14ETL--09-O19"
                        /tissue_type="leaf"
                        /dev_stage="14 days after germination"
                        /lab_host="E.coli DH10B"
                        /clone_lib="Rice etiolated leaf plasmid cDNA library
                        (14ETL)"
                        /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                        with oligoribonucleotides and then used as templates for
                        RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 522
CF298018
LOCUS       CF298018                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-D19.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-D19, mRNA
            sequence.
ACCESSION   CF298018
VERSION     CF298018.1  GI:33669779
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES                Location/Qualifiers
     source             1. .20
                        /organism="Oryza sativa (japonica cultivar-group)"
                        /mol_type="mRNA"
                        /cultivar="Nackdong"
                        /db_xref="taxon:39947"
                        /clone="7LEAF--01-D19"
                        /tissue_type="leaf"
                        /dev_stage="7 days after germination"
                        /lab_host="E.coli DH10B"
                        /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                        /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                        with oligoribonucleotides and then used as templates for
                        RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 523
CF299822
LOCUS       CF299822                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-P22.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-P22, mRNA
            sequence.
ACCESSION   CF299822
VERSION     CF299822.1  GI:33671583
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
```

```
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--03-P22"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 524
CF301101
LOCUS       CF301101                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-N04.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-N04, mRNA
            sequence.
ACCESSION   CF301101
VERSION     CF301101.1  GI:33672862
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--05-N04"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   6.2%;  Pred. No. 5.5e+02;
  Matches    1;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6347 UUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTC 16


RESULT 525
CF301720
LOCUS       CF301720                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--06-L01.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--06-L01, mRNA
            sequence.
ACCESSION   CF301720
VERSION     CF301720.1  GI:33673481
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--06-L01"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 526
CF302027
LOCUS       CF302027                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-C16.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-C16, mRNA
            sequence.
ACCESSION   CF302027
VERSION     CF302027.1  GI:33673788
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
```

```
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-C16"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 527
CF310604/c
LOCUS       CF310604                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--05-F14.g1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--05-F14, mRNA sequence.
ACCESSION   CF310604
VERSION     CF310604.1  GI:33682365
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--05-F14"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 528
CF313067/c
LOCUS       CF313067                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--01-B02.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--01-B02, mRNA sequence.
ACCESSION   CF313067
VERSION     CF313067.1  GI:33684828
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--01-B02"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5
```

```
RESULT 529
CF313569
LOCUS       CF313569                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--01-L22.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--01-L22, mRNA sequence.
ACCESSION   CF313569
VERSION     CF313569.1  GI:33685330
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--01-L22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 530
CF316662
LOCUS       CF316662                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--06-A20.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--06-A20, mRNA sequence.
ACCESSION   CF316662
VERSION     CF316662.1  GI:33688423
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--06-A20"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 531
CF318278
LOCUS       CF318278                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--08-F13.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--08-F13, mRNA sequence.
ACCESSION   CF318278
VERSION     CF318278.1  GI:33690039
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--08-F13"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
```

reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17
```

RESULT 532
CF319133
LOCUS CF319133 20 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--09-I13.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--09-I13, mRNA sequence.
ACCESSION CF319133
VERSION CF319133.1 GI:33690894
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--09-I13"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16
```

RESULT 533
CF320843
LOCUS CF320843 20 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--11-O01.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--11-O01, mRNA sequence.
ACCESSION CF320843
VERSION CF320843.1 GI:33692604
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--11-O01"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          2 TTTTTTTTTTTTTTTT 17
```

RESULT 534
CF321721
LOCUS CF321721 20 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--13-B05.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--13-B05, mRNA sequence.
ACCESSION CF321721
VERSION CF321721.1 GI:33693482
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers

```
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--13-B05"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 535
CF328565/c
LOCUS       CF328565                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--03-I14.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--03-I14, mRNA
            sequence.
ACCESSION   CF328565
VERSION     CF328565.1  GI:33805376
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--03-I14"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          20 TTTTTTTTTTTTTTTT 5


RESULT 536
CF333052
LOCUS       CF333052                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--01-M17.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--01-M17, mRNA sequence.
ACCESSION   CF333052
VERSION     CF333052.1  GI:33814360
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--01-M17"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          4 TTTTTTTTTTTTTTTT 19


RESULT 537
CF333173
LOCUS       CF333173                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--01-P11.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--01-P11, mRNA sequence.
ACCESSION   CF333173
VERSION     CF333173.1  GI:33814617
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
```

```
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--01-P11"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 538
CF334170
LOCUS       CF334170                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--03-F17.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--03-F17, mRNA sequence.
ACCESSION   CF334170
VERSION     CF334170.1  GI:33816671
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--03-F17"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 539
CF336525
LOCUS       CF336525                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--06-J21.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--06-J21, mRNA sequence.
ACCESSION   CF336525
VERSION     CF336525.1  GI:33821425
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--06-J21"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 540
CF337494
LOCUS       CF337494                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--07-P04.g1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--07-P04, mRNA sequence.
ACCESSION   CF337494
VERSION     CF337494.1  GI:33823378
```

```
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--07-P04"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 541
CF339443
LOCUS       CF339443                 20 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  RCL1--04-O03.g1 Regenerated callus lambda phage cDNA library (RCL1)
            Oryza sativa (japonica cultivar-group) cDNA clone RCL1--04-O03,
            mRNA sequence.
ACCESSION   CF339443
VERSION     CF339443.1  GI:33827271
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="RCL1--04-O03"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli SOLR"
                     /clone_lib="Regenerated callus lambda phage cDNA library
                     (RCL1)"
                     /note="Vector: pBluescript SK(+); Site_1: SstI; Site_2:
                     XhoI; cDNA was inserted into lamda Uni-ZAP XR vector at 5'
                     end with SstI and 3' end with XhoI site. Callus was
                     induced on 2N6 media for 30 days and cultured for 36hrs on
                     regenerated media"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 CGGCAGCGGCGGCGGC 41
              ||||||||||||||||
Db          5 CGGCAGCGGCGGCGGC 20


RESULT 542
AW334823
LOCUS       AW334823                 20 bp    mRNA    linear   EST 31-JAN-2000
DEFINITION  S39F5 AGS-1 Pneumocystis carinii cDNA 3', mRNA sequence.
ACCESSION   AW334823
VERSION     AW334823.1  GI:6831180
KEYWORDS    EST.
SOURCE      Pneumocystis carinii
  ORGANISM  Pneumocystis carinii
            Eukaryota; Fungi; Ascomycota; Pneumocystidomycetes;
            Pneumocystidaceae; Pneumocystis.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Smulian,A.G., Arnold,J., Weise,M., Wunderlich,J., Staben,C.,
            Edman,J.C., Kovacs,J. and Cushion,M.
  TITLE     Expressed sequence tags from Pneumocystis carinii
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Staben C
            School of Biological Sciences
            University of Kentucky
            101 Morgan Building, University of Kentucky, Lexington, KY
            40506-0225, USA
            Tel: 606 257 2161
            Fax: 606 257 1717
            Email: staben@pop.uky.edu.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Pneumocystis carinii"
                     /mol_type="mRNA"
                     /db_xref="taxon:4754"
                     /lab_host="E. coli"
                     /clone_lib="AGS-1"
                     /note="Vector: Lambda ZAP II; Site_1: EcoRI; Site_2: XhoI;
                     P. carinii organisms (3x10e9) from a single rat (99-1-6,
                     sacrificed on 3/17/99)  at Cincinnati VA facilities.
                     Trizol extracted RNA.  Oligo dT priming, standard
                     conditions described by  vendor, Stratagene. Further
                     details see www.uky.edu/Project/Pneumocystis/"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 543
CN545446
```

```
LOCUS       CN545446                 20 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 17390 Green Grape Skin Triplex2 Library Vitis vinifera cDNA
            clone B3CS00GL005C02 3', mRNA sequence.
ACCESSION   CN545446
VERSION     CN545446.1  GI:46910071
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
            71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
            France
            Tel: 00-33-(0)5-57-12-25-50
            Fax: 00-33-(0)5-57-12-25-48
            Email: s.hamdi@bordeaux.inra.fr
            Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00GL005C02"
                     /dev_stage="green stage"
                     /clone_lib="Green Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 544
CN545501
LOCUS       CN545501                 20 bp    mRNA    linear   EST 30-APR-2004
DEFINITION  EST 17445 Green Grape Skin Triplex2 Library Vitis vinifera cDNA
            clone B3CS00GL005H02 3', mRNA sequence.
ACCESSION   CN545501
VERSION     CN545501.1  GI:46910126
KEYWORDS    EST.
SOURCE      Vitis vinifera
  ORGANISM  Vitis vinifera
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; Vitaceae; Vitis.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Abbal,P., Agasse,A., Ageorges,A., Atanassova,R., Barrieu,F.,
            Couture,C., Dedaldechamp,F., Delrot,S., Glissant,D., Grimplet,J.,
            Hamdi,S., Romieu,C. and Terrier,N.
  TITLE     Generation of Expressed Sequence Tag from Grape Berry (skin, pulp
            or seeds) at Various Developmental Stages
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hamdi S.
            UMR 619 - Equipe Biologie de la Vigne
            Universite de Bordeaux I, Institut National de la Recherche
            Agronomique
            71, Avenue Edouard Bourleaux, BP 81, 33883 Villenave D'Ornon Cedex,
            France
            Tel: 00-33-(0)5-57-12-25-50
            Fax: 00-33-(0)5-57-12-25-48
            Email: s.hamdi@bordeaux.inra.fr
            Seq primer: T7.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Vitis vinifera"
                     /mol_type="mRNA"
                     /cultivar="Cabernet Sauvignon"
                     /db_xref="taxon:29760"
                     /clone="B3CS00GL005H02"
                     /dev_stage="green stage"
                     /clone_lib="Green Grape Skin Triplex2 Library"
                     /note="Organ: Fruit skin; Vector: Lambda TriplEx2; Site_1:
                     SfiIA; Site_2: SfiIB; Oriented library"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 545
CN754148/c
LOCUS       CN754148                 20 bp    mRNA    linear   EST 19-MAY-2004
DEFINITION  ID0AAA12AG12RM1 ApMS Acyrthosiphon pisum cDNA clone ID0AAA12AG12
            5', mRNA sequence.
ACCESSION   CN754148
VERSION     CN754148.1  GI:47519145
KEYWORDS    EST.
SOURCE      Acyrthosiphon pisum (pea aphid)
  ORGANISM  Acyrthosiphon pisum
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;
            Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Hunter,W., Martinez-Torres,D., Rahbe,Y., Sabater-Munoz,B.,
            Stern,D., Tagu,D. and Wincker,P.
  TITLE     An expressed sequence tags database for the pea aphid Acyrthosiphon
            pisum
  JOURNAL   Unpublished (2004)
COMMENT     Contact: D. Tagu
            INRA Rennes
            UMR BiO3P, BP 35327, F-35653 Le Rheu Cedex France
            Tel: +33.2.23.48.51.65
            Fax: +33.2.23.48.51.50
            Risk of contamination by bacterial sequences from obligatory
            (Buchnera) or facultative endosymbionts. These sequences were
            obtained in the frame of the International Consortium of Aphid
            Genomics in collaboration with Genoscope
            PCR PRimers
            FORWARD: CAGGAAACAGCTATGACC
            Plate: 12  row: G  column: 12.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Acyrthosiphon pisum"
                     /mol_type="mRNA"
                     /cultivar="developmentstage"
                     /db_xref="taxon:7029"
                     /clone="ID0AAA12AG12"
                     /tissue_type="whole insect"
                     /dev_stage="nymphs and adults (parthenogenetic females)"
                     /lab_host="XL1-Blue"
                     /clone_lib="ApMS"
                     /note="Vector: pBS-SK minus; Site_1: EcoRI; Site_2: XhoI;
                     Sample name: ID0AAA ; Plant growth place: Department of
                     Ecology & Evolutionary Biology, Princeton University ;
                     Soil conditions: Soil ; Sowing date: 01/06/1999 ;
```

Harvesting date: 01/06/1999 ; Stress date: no stress ; Description: Aphids inoculated on one-week old Vicia faba under non-sterile conditions. All parthenogenetic stages and both winged and wingless adults were collected for library construction. ; experimental condition: long photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 546
DN953918/c
LOCUS DN953918 20 bp mRNA linear EST 04-MAY-2005
DEFINITION it66c07.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA sequence.
ACCESSION DN953918
VERSION DN953918.1 GI:63026056
KEYWORDS EST.
SOURCE Gnetum gnemon
ORGANISM Gnetum gnemon
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N., O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W., Benfey,P., Coruzzi,G. and Stevenson,D.
TITLE Expressed tag sequences from Gnetum female cone (NYBG)
JOURNAL Unpublished (2003)
COMMENT Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mccombie@cshl.org
Seq primer: -21M13UnivRev.
FEATURES Location/Qualifiers
source 1. .20
/organism="Gnetum gnemon"
/mol_type="mRNA"
/db_xref="taxon:3382"
/sex="female"
/clone_lib="Gnetum female cone (NYBG)"
/note="Organ: mature, unfertilized reproductive strobili; Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date: Completed 02/11/02, submitted for sequencing 02/12/02. Library: Stratagene ZAP Express cDNA Synthesis Kit. The library was size-fractionated to enrich for large inserts. Sample: NYBG accession number #436/84"

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 547
DN954281
LOCUS DN954281 20 bp mRNA linear EST 04-MAY-2005
DEFINITION it71b04.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA sequence.
ACCESSION DN954281
VERSION DN954281.1 GI:63026419
KEYWORDS EST.
SOURCE Gnetum gnemon
ORGANISM Gnetum gnemon
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N., O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W., Benfey,P., Coruzzi,G. and Stevenson,D.
TITLE Expressed tag sequences from Gnetum female cone (NYBG)
JOURNAL Unpublished (2003)
COMMENT Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mccombie@cshl.org
Seq primer: -21M13UnivRev.
FEATURES Location/Qualifiers
source 1. .20
/organism="Gnetum gnemon"
/mol_type="mRNA"
/db_xref="taxon:3382"
/sex="female"
/clone_lib="Gnetum female cone (NYBG)"
/note="Organ: mature, unfertilized reproductive strobili; Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date: Completed 02/11/02, submitted for sequencing 02/12/02. Library: Stratagene ZAP Express cDNA Synthesis Kit. The library was size-fractionated to enrich for large inserts. Sample: NYBG accession number #436/84"

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 548
DN954289/c
LOCUS DN954289 20 bp mRNA linear EST 04-MAY-2005
DEFINITION it71c01.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA sequence.
ACCESSION DN954289
VERSION DN954289.1 GI:63026427
KEYWORDS EST.
SOURCE Gnetum gnemon
ORGANISM Gnetum gnemon
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N., O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W., Benfey,P., Coruzzi,G. and Stevenson,D.
TITLE Expressed tag sequences from Gnetum female cone (NYBG)
JOURNAL Unpublished (2003)
COMMENT Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mccombie@cshl.org
Seq primer: -21M13UnivRev.
FEATURES Location/Qualifiers
source 1. .20
/organism="Gnetum gnemon"
/mol_type="mRNA"
/db_xref="taxon:3382"
/sex="female"

```
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 549
DN955202/c
LOCUS       DN955202                  20 bp    mRNA    linear   EST 04-MAY-2005
DEFINITION  it83f09.g1 Gnetum female cone (NYBG) Gnetum gnemon cDNA 3', mRNA
            sequence.
ACCESSION   DN955202
VERSION     DN955202.1  GI:63027340
KEYWORDS    EST.
SOURCE      Gnetum gnemon
  ORGANISM  Gnetum gnemon
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Gnetophyta; Gnetopsida; Gnetales; Gnetaceae; Gnetum.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Gnetum female cone (NYBG)
  JOURNAL   Unpublished (2003)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Gnetum gnemon"
                     /mol_type="mRNA"
                     /db_xref="taxon:3382"
                     /sex="female"
                     /clone_lib="Gnetum female cone (NYBG)"
                     /note="Organ: mature, unfertilized reproductive strobili;
                     Vector: pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Date:
                     Completed 02/11/02, submitted for sequencing 02/12/02.
                     Library: Stratagene ZAP Express cDNA Synthesis Kit. The
                     library was size-fractionated to enrich for large inserts.
                     Sample: NYBG accession number #436/84"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         19 TTTTTTTTTTTTTTTT 4


RESULT 550
DR065440/c
LOCUS       DR065440                  20 bp    mRNA    linear   EST 06-JUN-2005
DEFINITION  ip94g12.g1 Ginkgo microsporophyll (NYBG) Ginkgo biloba cDNA 3',
            mRNA sequence.
ACCESSION   DR065440
VERSION     DR065440.1  GI:66989008
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo microsporophyll (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="male"
                     /clone_lib="Ginkgo microsporophyll (NYBG)"
                     /note="Organ: microsporophyll; Vector: pBK-CMV; Site_1:
                     XhoI; Site_2: Eco RI; Stratagene ZAP Express cDNA
                     Synthesis Kit. The library was size-fractionated to enrich
                     for large inserts."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 551
DR073089
LOCUS       DR073089                  20 bp    mRNA    linear   EST 08-JUN-2005
DEFINITION  ik85h04.g1 Ginkgo female leaf (NYBG) Ginkgo biloba cDNA 3', mRNA
            sequence.
ACCESSION   DR073089
VERSION     DR073089.1  GI:67050939
KEYWORDS    EST.
SOURCE      Ginkgo biloba (maidenhair tree)
  ORGANISM  Ginkgo biloba
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N.,
            O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W.,
            Benfey,P., Coruzzi,G. and Stevenson,D.
  TITLE     Expressed tag sequences from Ginkgo female leaf (NYBG)
  JOURNAL   Unpublished (2005)
COMMENT     Contact: W. Richard McCombie
            Lita Annenberg Hazen Genome Sequencing Center
            Cold Spring Harbor Laboratory
            PO Box 100, Cold Spring Harbor, NY 11724, USA
            Tel: 516 367 8884
            Fax: 516 367 8874
            Email: mccombie@cshl.org
            Seq primer: -21M13UnivRev.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Ginkgo biloba"
                     /mol_type="mRNA"
                     /db_xref="taxon:3311"
                     /sex="female"
                     /clone_lib="Ginkgo female leaf (NYBG)"
```

/note="Organ: leaf; Vector: :pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Stratagene ZAP Express cDNA Synthesis Kit. The library was size-fractionated to enrich for large inserts."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 552
DR073130
LOCUS DR073130 20 bp mRNA linear EST 08-JUN-2005
DEFINITION ik86h03.g1 Ginkgo female leaf (NYBG) Ginkgo biloba cDNA 3', mRNA sequence.
ACCESSION DR073130
VERSION DR073130.1 GI:67050981
KEYWORDS EST.
SOURCE Ginkgo biloba (maidenhair tree)
ORGANISM Ginkgo biloba
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Ginkgophyta; Ginkgoales; Ginkgoaceae; Ginkgo.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brenner,E.D., Twigg,R.W., Runko,S.J., Katari,M.S., Dedhia,N.N., O'Shaughnessy,A.L., Balija,V., Martienssen,R.A., McCombie,R.W., Benfey,P., Coruzzi,G. and Stevenson,D.
TITLE Expressed tag sequences from Ginkgo female leaf (NYBG)
JOURNAL Unpublished (2005)
COMMENT Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mccombie@cshl.org
Seq primer: -21M13UnivRev.
FEATURES Location/Qualifiers
source 1. .20
/organism="Ginkgo biloba"
/mol_type="mRNA"
/db_xref="taxon:3311"
/sex="female"
/clone_lib="Ginkgo female leaf (NYBG)"
/note="Organ: leaf; Vector: :pBK-CMV; Site_1: XhoI; Site_2: Eco RI; Stratagene ZAP Express cDNA Synthesis Kit. The library was size-fractionated to enrich for large inserts."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 553
DT493556/c
LOCUS DT493556 20 bp mRNA linear EST 29-AUG-2005
DEFINITION WS0111.BR_L11 PT-P-FL-A-2 Populus trichocarpa cDNA clone WS0111_L11 5', mRNA sequence.
ACCESSION DT493556
VERSION DT493556.1 GI:73890818
KEYWORDS EST.
SOURCE Populus trichocarpa (Populus balsamifera subsp. trichocarpa)
ORGANISM Populus trichocarpa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; rosids; eurosids I; Malpighiales; Salicaceae; Saliceae; Populus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ralph,S., Cooper,D., Kolosova,N., Oddy,C., Butterfield,Y., Kirkpatrick,R., Liu,J., Palmquist,D., Stott,J., Barber,S., Yang,G., Babakaiff,R., Brown-John,M., Chand,S., Featherstone,R., Masson,A., Mayo,M., Moran,J., Olson,T., Wong,D., Ritland,C.E., Siddiqui,A., Holt,R., Jones,S., Marra,M., Ellis,B.E., Douglas,C., Ritland,K. and Bohlmann,J.
TITLE The poplar transcriptome: Analysis of expressed sequence tags from multiple cDNA libraries
JOURNAL Unpublished (2004)
COMMENT Contact: Joerg Bohlmann
Genome BC forest genomics program
University of British Columbia
Michael Smith Laboratories, 6174 University Boulevard, Rm. 237, Vancouver, British Columbia, Canada, V6T 1Z3
Tel: 1-604-822-0282
Fax: 1-604-822-2114
Email: bohlmann@msl.ubc.ca
Plate: WS0111 row: L column: 11
High quality sequence stop: 139
POLYA=Yes.
FEATURES Location/Qualifiers
source 1. .20
/organism="Populus trichocarpa"
/mol_type="mRNA"
/cultivar="383-2499 (Nisqually-1)"
/db_xref="taxon:3694"
/clone="WS0111_L11"
/sex="Female"
/lab_host="E. coli DH10B T1 phage resistant cells"
/clone_lib="PT-P-FL-A-2"
/note="Vector: pBluescript II SK (+) XR; Site_1: SstI (5' end of cDNA); Site_2: XhoI (3' end of cDNA); Phloem and cambium from 8 year old trees harvested within the Boise Cascade region of Washington state on May 15th, 2001. cDNA was prepared from 20 micrograms of mRNA according to the full-length cDNA library construction method described by Carninci P. et al. (2000), Genome Research 10(10):1617-1630 and directionally ligated into the pBluescript II SK (+) XR vector digested with SstI (5' end) and XhoI (3'). Plasmid DNA was then transformed by electroporation into DH10B cells (Invitrogen) for propagation."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 554
T50579
LOCUS T50579 20 bp mRNA linear EST 06-FEB-1995
DEFINITION yb76d04.r1 Stratagene ovary (#937217) Homo sapiens cDNA clone IMAGE:77095 5' similar to contains L1 repetitive element, mRNA sequence.
ACCESSION T50579
VERSION T50579.1 GI:652439
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 20)
AUTHORS Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B., Chissoe,S., Dietrich,N., DuBuque,T., Favello,A., Gish,W., Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N., Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,

```
            Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Meg,J.,
            Trevaskis,E., Underwood,K., Wohldmann,P., Waterston,R., Wilson,R.
            and Marra,M.
  TITLE     Generation and analysis of 280,000 human expressed sequence tags
  JOURNAL   Genome Res. 6 (9), 807-828 (1996)
   PUBMED   8889549
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Seq primer: M13RP1
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:506824"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:77095"
                     /sex="female"
                     /dev_stage="49 year old"
                     /lab_host="SOLR cells (kanamycin resistant)"
                     /clone_lib="Stratagene ovary (#937217)"
                     /note="Organ: ovary; Vector: Bluescript SK; Site_1: EcoRI;
                     Site_2: XhoI; Cloned unidirectionally.  Primer: Oligo dT.
                     Total ovary tissue, normal, caucasian. Average insert
                     size: 0.8 kb; Uni-ZAP XR Vector; ~5' adaptor sequence: 5'
                     GAATTCGGCACGAG 3' ~3' adaptor sequence: 5'
                     CTCGAGTTTTTTTTTTTTTTTTT 3'"

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 555
AZ307671
LOCUS       AZ307671                  20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0009M20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0009M20 R, genomic survey sequence.
ACCESSION   AZ307671
VERSION     AZ307671.1  GI:10346897
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0009  row: M  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0009M20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 556
AZ333980
LOCUS       AZ333980                  20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0063K10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0063K10 F, genomic survey sequence.
ACCESSION   AZ333980
VERSION     AZ333980.1  GI:10400856
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0063  row: K  column: 10
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0063K10"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 557
AZ341530/c
LOCUS       AZ341530                 20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0073N21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0073N21 R, genomic survey sequence.
ACCESSION   AZ341530
VERSION     AZ341530.1  GI:10417873
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0073  row: N  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0073N21"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 558
AZ343031/c
LOCUS       AZ343031                 20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0076F13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0076F13 F, genomic survey sequence.
ACCESSION   AZ343031
VERSION     AZ343031.1  GI:10420861
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0076  row: F  column: 13
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0076F13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 559
AZ351273/c
LOCUS       AZ351273                 20 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0089B18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0089B18 F, genomic survey sequence.
ACCESSION   AZ351273
VERSION     AZ351273.1  GI:10430510
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0089  row: B  column: 18
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0089B18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 560
AZ357623/c
LOCUS       AZ357623                 20 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0099A20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0099A20 F, genomic survey sequence.
ACCESSION   AZ357623
VERSION     AZ357623.1  GI:10471335
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

Insert Length: 10000 Std Error: 0.00
Plate: 0099 row: A column: 20
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0099A20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 561
AZ369734/c
LOCUS AZ369734 20 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0120O24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0120O24 F, genomic survey sequence.
ACCESSION AZ369734
VERSION AZ369734.1 GI:10483434
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0120 row: O column: 24
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0120O24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 562
AZ386573/c
LOCUS AZ386573 20 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0145C11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0145C11 R, genomic survey sequence.
ACCESSION AZ386573
VERSION AZ386573.1 GI:10500273
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0145  row: C  column: 11
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0145C11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 563
AZ396481/c
LOCUS       AZ396481                 20 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0161K02F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0161K02 F, genomic survey sequence.
ACCESSION   AZ396481
VERSION     AZ396481.1  GI:10511553
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0161  row: K  column: 02
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0161K02"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 564
AZ442328/c
LOCUS       AZ442328                 20 bp    DNA     linear   GSS 03-OCT-2000
DEFINITION  1M0236B11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0236B11 F, genomic survey sequence.
ACCESSION   AZ442328
VERSION     AZ442328.1  GI:10566341
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0236  row: B  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0236B11"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 565
AZ463331
LOCUS       AZ463331                 20 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0272O06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0272O06 F, genomic survey sequence.
ACCESSION   AZ463331
VERSION     AZ463331.1  GI:10621456
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0272  row: O  column: 06
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0272O06"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 566
AZ477734
LOCUS       AZ477734                 20 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0297E23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0297E23 F, genomic survey sequence.
ACCESSION   AZ477734
VERSION     AZ477734.1  GI:10635978
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

Insert Length: 10000 Std Error: 0.00
Plate: 0297 row: E column: 23
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0297E23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 567
AZ479464
LOCUS AZ479464 20 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0300P01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0300P01 F, genomic survey sequence.
ACCESSION AZ479464
VERSION AZ479464.1 GI:10638941
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0300 row: P column: 01
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0300P01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 568
AZ486784
LOCUS AZ486784 20 bp DNA linear GSS 05-OCT-2000
DEFINITION 1M0315C20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0315C20 F, genomic survey sequence.
ACCESSION AZ486784
VERSION AZ486784.1 GI:10653898
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0315  row: C  column: 20
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0315C20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 569
AZ486787
LOCUS       AZ486787                 20 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0315D23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0315D23 F, genomic survey sequence.
ACCESSION   AZ486787
VERSION     AZ486787.1  GI:10653904
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0315  row: D  column: 23
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0315D23"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          5 TTTTTTTTTTTTTTTT 20


RESULT 570
AZ498625
LOCUS       AZ498625                 20 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0336E05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0336E05 F, genomic survey sequence.
ACCESSION   AZ498625
VERSION     AZ498625.1  GI:10676657
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0336  row: E  column: 05
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0336E05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 571
AZ514729/c
LOCUS       AZ514729                20 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0361E11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0361E11 R, genomic survey sequence.
ACCESSION   AZ514729
VERSION     AZ514729.1  GI:10696045
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0361  row: E  column: 11
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0361E11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 572
AZ579178/c
LOCUS       AZ579178                20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0363F11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0363F11 F, genomic survey sequence.
ACCESSION   AZ579178
VERSION     AZ579178.1  GI:11693523
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0363  row: F  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0363F11"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 573
AZ581208/c
LOCUS       AZ581208                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0369P15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0369P15 R, genomic survey sequence.
ACCESSION   AZ581208
VERSION     AZ581208.1  GI:11695991
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0369  row: P  column: 15
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0369P15"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 574
AZ588011/c
LOCUS       AZ588011                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0396A13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0396A13 F, genomic survey sequence.
ACCESSION   AZ588011
VERSION     AZ588011.1  GI:11710297
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0396  row: A  column: 13
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0396A13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 575
AZ607328/c
LOCUS       AZ607328                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0429A14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0429A14 R, genomic survey sequence.
ACCESSION   AZ607328
VERSION     AZ607328.1  GI:11729518
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0429  row: A  column: 14
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0429A14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 576
AZ623155
LOCUS       AZ623155                 20 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0460K05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0460K05 R, genomic survey sequence.
ACCESSION   AZ623155
VERSION     AZ623155.1  GI:11745345
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

Insert Length: 10000 Std Error: 0.00
Plate: 0460 row: K column: 05
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0460K05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 577
AZ623214
LOCUS AZ623214 20 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0460L12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0460L12 R, genomic survey sequence.
ACCESSION AZ623214
VERSION AZ623214.1 GI:11745404
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0460 row: L column: 12
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0460L12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 578
AZ643992/c
LOCUS AZ643992 20 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0507D18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0507D18 R, genomic survey sequence.
ACCESSION AZ643992
VERSION AZ643992.1 GI:11772092
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0507  row: D  column: 18
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0507D18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 579
AZ645829
LOCUS       AZ645829                 20 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0511D03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0511D03 R, genomic survey sequence.
ACCESSION   AZ645829
VERSION     AZ645829.1  GI:11775703
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0511  row: D  column: 03
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0511D03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 580
AZ650271/c
LOCUS       AZ650271                 20 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0520C21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0520C21 F, genomic survey sequence.
ACCESSION   AZ650271
VERSION     AZ650271.1  GI:11784588
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0520  row: C  column: 21
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0520C21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 581
AZ760838/c
LOCUS       AZ760838                20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0554A24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0554A24 R, genomic survey sequence.
ACCESSION   AZ760838
VERSION     AZ760838.1  GI:12869112
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0554  row: A  column: 24
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0554A24"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 582
AZ764504/c
LOCUS       AZ764504                20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0560M02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0560M02 R, genomic survey sequence.
ACCESSION   AZ764504
VERSION     AZ764504.1  GI:12879535
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

Insert Length: 10000 Std Error: 0.00
Plate: 0560 row: M column: 02
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0560M02"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 20 TTTTTTTTTTTTTTTT 5

RESULT 583
AZ765211
LOCUS AZ765211 20 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0562H04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0562H04 F, genomic survey sequence.
ACCESSION AZ765211
VERSION AZ765211.1 GI:12880970
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0562 row: H column: 04
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0562H04"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 584
AZ772091/c
LOCUS AZ772091 20 bp DNA linear GSS 16-FEB-2001
DEFINITION 1M0574A13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0574A13 R, genomic survey sequence.
ACCESSION AZ772091
VERSION AZ772091.1 GI:12895040
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0574  row: A  column: 13
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0574A13"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 585
AZ779425
LOCUS       AZ779425                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0015M18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0015M18 R, genomic survey sequence.
ACCESSION   AZ779425
VERSION     AZ779425.1  GI:12910066
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
            Insert Length: 10000   Std Error: 0.00
            Plate: 0015  row: M  column: 18
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0015M18"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 586
AZ784041/c
LOCUS       AZ784041                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0026B21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0026B21 F, genomic survey sequence.
ACCESSION   AZ784041
VERSION     AZ784041.1  GI:12919375
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0026  row: B  column: 21
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0026B21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 587
AZ793467
LOCUS       AZ793467                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0046C16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0046C16 R, genomic survey sequence.
ACCESSION   AZ793467
VERSION     AZ793467.1  GI:12938450
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0046  row: C  column: 16
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0046C16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 588
AZ798529
LOCUS       AZ798529                 20 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0055G19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0055G19 F, genomic survey sequence.
ACCESSION   AZ798529
VERSION     AZ798529.1  GI:12948718
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
           Insert Length: 10000   Std Error: 0.00
           Plate: 0055  row: G  column: 19
           Seq primer: CGTTGTAAAACGACGGCCAGT
           Class: plasmid ends
           High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0055G19"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 589
AZ805163/c
LOCUS       AZ805163                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0066L14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0066L14 F, genomic survey sequence.
ACCESSION   AZ805163
VERSION     AZ805163.1  GI:12965890
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
           Insert Length: 10000   Std Error: 0.00
           Plate: 0066  row: L  column: 14
           Seq primer: CGTTGTAAAACGACGGCCAGT
           Class: plasmid ends
           High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0066L14"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 590
AZ806521/c
LOCUS       AZ806521                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0068C08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0068C08 R, genomic survey sequence.
ACCESSION   AZ806521
VERSION     AZ806521.1  GI:12969953
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0068  row: C  column: 08
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0068C08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 591
AZ806585/c
LOCUS       AZ806585                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0068C15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0068C15 R, genomic survey sequence.
ACCESSION   AZ806585
VERSION     AZ806585.1  GI:12970081
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0068  row: C  column: 15
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0068C15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 592
AZ809306/c
LOCUS       AZ809306                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0073D15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0073D15 F, genomic survey sequence.
ACCESSION   AZ809306
VERSION     AZ809306.1  GI:12975468
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
           Insert Length: 10000   Std Error: 0.00
           Plate: 0073  row: D  column: 15
           Seq primer: CGTTGTAAAACGACGGCCAGT
           Class: plasmid ends
           High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0073D15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 593
AZ810986/c
LOCUS       AZ810986                20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0076I20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0076I20 R, genomic survey sequence.
ACCESSION   AZ810986
VERSION     AZ810986.1  GI:12978793
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
           Insert Length: 10000   Std Error: 0.00
           Plate: 0076  row: I  column: 20
           Seq primer: CACACAGGAAACAGCTATGACC
           Class: plasmid ends
           High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0076I20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 594
AZ813908/c
LOCUS       AZ813908                20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0081F21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0081F21 F, genomic survey sequence.
ACCESSION   AZ813908
VERSION     AZ813908.1  GI:12983804
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0081  row: F  column: 21
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0081F21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 595
AZ817323/c
LOCUS       AZ817323                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0086C20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0086C20 R, genomic survey sequence.
ACCESSION   AZ817323
VERSION     AZ817323.1  GI:12987327
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0086  row: C  column: 20
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0086C20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 596
AZ817414/c
LOCUS       AZ817414                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0086K08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0086K08 R, genomic survey sequence.
ACCESSION   AZ817414
VERSION     AZ817414.1  GI:12987238
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0086  row: K  column: 08
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0086K08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 597
AZ817467/c
LOCUS       AZ817467                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0086J15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0086J15 R, genomic survey sequence.
ACCESSION   AZ817467
VERSION     AZ817467.1  GI:12987291
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0086  row: J  column: 15
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0086J15"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 598
AZ817608
LOCUS       AZ817608                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0087K08F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0087K08 F, genomic survey sequence.
ACCESSION   AZ817608
VERSION     AZ817608.1  GI:12987516
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0087  row: K  column: 08
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0087K08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 599
AZ818489
LOCUS       AZ818489                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0088K01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0088K01 R, genomic survey sequence.
ACCESSION   AZ818489
VERSION     AZ818489.1  GI:12988397
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0088  row: K  column: 01
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0088K01"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 600
AZ818816
LOCUS       AZ818816                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0089M05F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0089M05 F, genomic survey sequence.
ACCESSION   AZ818816
VERSION     AZ818816.1  GI:12988724
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0089  row: M  column: 05
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0089M05"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 601
AZ821905/c
LOCUS       AZ821905                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0094D20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0094D20 R, genomic survey sequence.
ACCESSION   AZ821905
VERSION     AZ821905.1  GI:12991813
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0094  row: D  column: 20
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0094D20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 602
AZ837491/c
LOCUS       AZ837491                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0132K13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0132K13 R, genomic survey sequence.
ACCESSION   AZ837491
VERSION     AZ837491.1  GI:13007399
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0132  row: K  column: 13
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0132K13"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 603
AZ841342/c
LOCUS       AZ841342                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0139H16F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0139H16 F, genomic survey sequence.
ACCESSION   AZ841342
VERSION     AZ841342.1  GI:13011250
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0139  row: H  column: 16
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0139H16"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 604
AZ841558
LOCUS       AZ841558                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0139A10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0139A10 R, genomic survey sequence.
ACCESSION   AZ841558
VERSION     AZ841558.1  GI:13011466
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0139  row: A  column: 10
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0139A10"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 605
AZ858052/c
LOCUS       AZ858052                 20 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0163O03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0163O03 F, genomic survey sequence.
ACCESSION   AZ858052
VERSION     AZ858052.1  GI:13050813
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0163  row: O  column: 03
          Seq primer: CGTTGTAAAACGACGGCCAGT
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0163O03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 606
AZ858419/c
LOCUS       AZ858419                 20 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0163O03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0163O03 R, genomic survey sequence.
ACCESSION   AZ858419
VERSION     AZ858419.1  GI:13051545
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0163  row: O  column: 03
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0163O03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 607
AZ936914/c
LOCUS       AZ936914                 20 bp    DNA     linear   GSS 26-APR-2001
DEFINITION  2M0193G23R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0193G23 R, genomic survey sequence.
ACCESSION   AZ936914
VERSION     AZ936914.1  GI:13795495
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

```
          Insert Length: 10000   Std Error: 0.00
          Plate: 0193  row: G  column: 23
          Seq primer: CACACAGGAAACAGCTATGACC
          Class: plasmid ends
          High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0193G23"
                     /sex="Female"
                     /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC2M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (female) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 608
AZ949180
LOCUS       AZ949180                 20 bp    DNA     linear   GSS 27-APR-2001
DEFINITION  2M0212I02R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
            clone UUGC2M0212I02 R, genomic survey sequence.
ACCESSION   AZ949180
VERSION     AZ949180.1  GI:13820407
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
```

Insert Length: 10000 Std Error: 0.00
Plate: 0212 row: I column: 02
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0212I02"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 609
AZ963973
LOCUS AZ963973 20 bp DNA linear GSS 27-APR-2001
DEFINITION 2M0233J01F Mouse 10kb plasmid UUGC2M library Mus musculus genomic clone UUGC2M0233J01 F, genomic survey sequence.
ACCESSION AZ963973
VERSION AZ963973.1 GI:13835200
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 20)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0233 row: J column: 01
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES Location/Qualifiers
source 1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0233J01"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 20;
Best Local Similarity 0.0%; Pred. No. 5.5e+02;
Matches 0; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUUU 6361
:::::::::::::::::
Db 1 TTTTTTTTTTTTTTTT 16

RESULT 610
CW979138/c
LOCUS CW979138 20 bp DNA linear GSS 28-DEC-2004
DEFINITION KBrH001K19R KBrH, Brassica rapa HindIII BAC library Brassica rapa subsp. pekinensis genomic clone KBrH001K19, genomic survey sequence.
ACCESSION CW979138
VERSION CW979138.1 GI:56810425
KEYWORDS GSS.
SOURCE Brassica rapa subsp. pekinensis
ORGANISM Brassica rapa subsp. pekinensis
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE 1 (bases 1 to 20)
AUTHORS Yang,T.J., Kwon,S.J., Kim,J.A., Kim,J.S., Lim,K.B., Jin,M., Park,J.Y., Lim,M.H., Kim,H.I., Lim,Y.P. and Park,B.S.
TITLE End sequence of Brassica rapa HindIII BAC library (KBrH)
JOURNAL Unpublished (2004)
COMMENT Contact: Beom-Seok Park
Brassica Genomics Team
National Institute of Agricultural Biotechnology
225 Seodun-Dong, Suwon, 441-707, Korea
Tel: +82-31-299-1670
Fax: +82-31-299-1672
Email: pbeom@rda.go.kr
BAC end sequence of Brassica rapa ssp. pekinensis HindIII BAC clone KBrH001K19
Seq primer: M13 Reverse

```
          Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Brassica rapa subsp. pekinensis"
                     /mol_type="genomic DNA".
                     /cultivar="Chiifu"
                     /sub_species="pekinensis"
                     /db_xref="taxon:51351"
                     /clone="KBrH001K19"
                     /tissue_type="young leaves"
                     /lab_host="E.coli DH10B"
                     /clone_lib="KBrH, Brassica rapa HindIII BAC library"
                     /note="Vector: pCUGIBac1; Site_1: HindIII; Brassica rapa
                     spp. pekinensis inbred line Chiifu BAC library (KBrH BAC)
                     is provided by Yong-Pyo Lim."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 611
DU834188
LOCUS       DU834188                  20 bp    DNA     linear   GSS 22-DEC-2005
DEFINITION  KBrS013J15F KBrS, Brassica rapa Sau3AI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrS013J15, genomic survey
            sequence.
ACCESSION   DU834188
VERSION     DU834188.1  GI:83870784
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A., Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J. H. and Park,B.S.
  TITLE     End sequence of Brassica rapa Sau3AI (KBrS) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis Sau3AI BAC clone
            KBrS013J15
            Seq primer: T7
            Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Brassica rapa subsp. pekinensis"
                     /mol_type="genomic DNA"
                     /cultivar="Chiifu"
                     /sub_species="pekinensis"
                     /db_xref="taxon:51351"
                     /clone="KBrS013J15"
                     /lab_host="E. coli DH10B"
                     /clone_lib="KBrS, Brassica rapa Sau3AI BAC library"
                     /note="Vector: pCUGIBAC1; Site_1: Sau3AI; Brassica rapa
                     ssp pekinensis var. Chiifu BAC library (KBrS BAC) is
                     available at NIAB."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTT 16


RESULT 612
DU835125/c
LOCUS       DU835125                  20 bp    DNA     linear   GSS 22-DEC-2005
DEFINITION  KBrS016A17F KBrS, Brassica rapa Sau3AI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrS016A17, genomic survey
            sequence.
ACCESSION   DU835125
VERSION     DU835125.1  GI:83871721
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A., Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J. H. and Park,B.S.
  TITLE     End sequence of Brassica rapa Sau3AI (KBrS) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis Sau3AI BAC clone
            KBrS016A17
            Seq primer: T7
            Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Brassica rapa subsp. pekinensis"
                     /mol_type="genomic DNA"
                     /cultivar="Chiifu"
                     /sub_species="pekinensis"
                     /db_xref="taxon:51351"
                     /clone="KBrS016A17"
                     /lab_host="E. coli DH10B"
                     /clone_lib="KBrS, Brassica rapa Sau3AI BAC library"
                     /note="Vector: pCUGIBAC1; Site_1: Sau3AI; Brassica rapa
                     ssp pekinensis var. Chiifu BAC library (KBrS BAC) is
                     available at NIAB."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 613
DX045751/c
LOCUS       DX045751                  20 bp    DNA     linear   GSS 10-JAN-2006
DEFINITION  KBrB047C15F KBrB, Brassica rapa BamHI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrB047C15, genomic survey
            sequence.
ACCESSION   DX045751
VERSION     DX045751.1  GI:84740048
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
```

```
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J.H. and Park,B.S.
  TITLE     End sequence of Brassica rapa BamHI (KBrB) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone
            KBrB047C15
            Seq primer: T7
            Class: BAC ends.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Brassica rapa subsp. pekinensis"
                      /mol_type="genomic DNA"
                      /cultivar="Chiifu"
                      /sub_species="pekinensis"
                      /db_xref="taxon:51351"
                      /clone="KBrB047C15"
                      /lab_host="E.coli DH10B"
                      /clone_lib="KBrB, Brassica rapa BamHI BAC library"
                      /note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp
                      pekinensis var. Chiifu BAC library (KBrB BAC) is provided
                      by Yong-Pyo Lim (CNU)."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 614
DX055580/c
LOCUS       DX055580                 20 bp    DNA     linear   GSS 10-JAN-2006
DEFINITION  KBrB060D05R KBrB, Brassica rapa BamHI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrB060D05, genomic survey
            sequence.
ACCESSION   DX055580
VERSION     DX055580.1  GI:84749877
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J.H. and Park,B.S.
  TITLE     End sequence of Brassica rapa BamHI (KBrB) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone
            KBrB060D05
            Seq primer: M13 Reverse
            Class: BAC ends.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Brassica rapa subsp. pekinensis"
                      /mol_type="genomic DNA"
                      /cultivar="Chiifu"
                      /sub_species="pekinensis"
                      /db_xref="taxon:51351"
                      /clone="KBrB060D05"
                      /lab_host="E.coli DH10B"
                      /clone_lib="KBrB, Brassica rapa BamHI BAC library"
                      /note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp
                      pekinensis var. Chiifu BAC library (KBrB BAC) is provided
                      by Yong-Pyo Lim (CNU)."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db         20 TTTTTTTTTTTTTTTT 5


RESULT 615
DX070282
LOCUS       DX070282                 20 bp    DNA     linear   GSS 10-JAN-2006
DEFINITION  KBrB079J23F KBrB, Brassica rapa BamHI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrB079J23, genomic survey
            sequence.
ACCESSION   DX070282
VERSION     DX070282.1  GI:84764578
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J.H. and Park,B.S.
  TITLE     End sequence of Brassica rapa BamHI (KBrB) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone
            KBrB079J23
            Seq primer: T7
            Class: BAC ends.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Brassica rapa subsp. pekinensis"
                      /mol_type="genomic DNA"
                      /cultivar="Chiifu"
                      /sub_species="pekinensis"
                      /db_xref="taxon:51351"
                      /clone="KBrB079J23"
                      /lab_host="E.coli DH10B"
                      /clone_lib="KBrB, Brassica rapa BamHI BAC library"
                      /note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp
                      pekinensis var. Chiifu BAC library (KBrB BAC) is provided
                      by Yong-Pyo Lim (CNU)."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
```

```
Db          1 TTTTTTTTTTTTTTT 16


RESULT 616
DX071064
LOCUS       DX071064                  20 bp    DNA     linear   GSS 10-JAN-2006
DEFINITION  KBrB080L01F KBrB, Brassica rapa BamHI BAC library Brassica rapa
            subsp. pekinensis genomic clone KBrB080L01, genomic survey
            sequence.
ACCESSION   DX071064
VERSION     DX071064.1  GI:84765360
KEYWORDS    GSS.
SOURCE      Brassica rapa subsp. pekinensis
  ORGANISM  Brassica rapa subsp. pekinensis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            rosids; eurosids II; Brassicales; Brassicaceae; Brassica.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,T.J., Kwon,S.J., Kim,J.A, Kim,J.S., Lim,K.B., Jin,M.,
            Park,J.Y., Lim,M.H., Kim,H.I., Choi,B.S., Seol,Y.J., Park,D.S.,
            Hahn,J.H. and Park,B.S.
  TITLE     End sequence of Brassica rapa BamHI (KBrB) BAC clone
  JOURNAL   Unpublished (2005)
COMMENT     Contact: Beom-Seok Park
            Brassica Genomics Team
            National Institute of Agricultural Biotechnology
            225 Seodun-Dong, Suwon, 441-707, Korea
            Tel: +82-31-299-1670
            Fax: +82-31-299-1672
            Email: pbeom@rda.go.kr
            BAC end sequence of Brassica rapa ssp. pekinensis BamHI BAC clone
            KBrB080L01
            Seq primer: T7
            Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Brassica rapa subsp. pekinensis"
                     /mol_type="genomic DNA"
                     /cultivar="Chiifu"
                     /sub_species="pekinensis"
                     /db_xref="taxon:51351"
                     /clone="KBrB080L01"
                     /lab_host="E.coli DH10B"
                     /clone_lib="KBrB, Brassica rapa BamHI BAC library"
                     /note="Vector: pCUGIBAC1; Site_1: BamHI; Brassica rapa spp
                     pekinensis var. Chiifu BAC library (KBrB BAC) is provided
                     by Yong-Pyo Lim (CNU)."

  Query Match             0.2%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   0.0%;  Pred. No. 5.5e+02;
  Matches    0;  Conservative   16;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUU 6361
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 16


RESULT 617
AZ456482/c
LOCUS       AZ456482                  37 bp    DNA     linear   GSS 04-OCT-2000
DEFINITION  1M0259P11F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0259P11 F, genomic survey sequence.
ACCESSION   AZ456482
VERSION     AZ456482.1  GI:10614523
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0259  row: P  column: 11
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0259P11"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 16;  DB 1;  Length 37;
  Best Local Similarity   65.6%;  Pred. No. 8.3e+02;
  Matches   21;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy        910 CUCACACAUCGACAAACCAAUACAAUCAUAGA 941
              | ||||||   ||| ||  | ||| :|| |||
Db         33 CACACACACACACACACACACACTCACAGA 2


RESULT 618
AZ305049/c
LOCUS       AZ305049                  40 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0005B05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0005B05 R, genomic survey sequence.
ACCESSION   AZ305049
VERSION     AZ305049.1  GI:10341678
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
```

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0005 row: B column: 05
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 40.

FEATURES Location/Qualifiers
source 1. .40
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0005B05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 16; DB 1; Length 40;
Best Local Similarity 60.0%; Pred. No. 8e+02;
Matches 24; Conservative 1; Mismatches 15; Indels 0; Gaps 0;

```
Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAAUCAU 938
              | ||| ||   | ||||||   ||| ||  | |||  ||:
Db         40 ACACACACACACACACACACACACACACACACACACACAT 1
```

RESULT 619
CF278272
LOCUS CF278272 19 bp mRNA linear EST 14-AUG-2003
DEFINITION 14ETL--04-C01.b1 Rice etiolated leaf plasmid cDNA library (14ETL) Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--04-C01, mRNA sequence.
ACCESSION CF278272
VERSION CF278272.1 GI:33655658
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 19)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES Location/Qualifiers
source 1. .19
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="14ETL--04-C01"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 15.8; DB 1; Length 19;
Best Local Similarity 10.5%; Pred. No. 5.2e+02;
Matches 2; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6347 UUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db          1 TTTTTTTTTTTTTTTAAAA 19
```

RESULT 620
CF319596
LOCUS CF319596 19 bp mRNA linear EST 15-AUG-2003
DEFINITION HD--10-C14.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa (japonica cultivar-group) cDNA clone HD--10-C14, mRNA sequence.
ACCESSION CF319596
VERSION CF319596.1 GI:33691357
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 19)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES Location/Qualifiers
source 1. .19
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HD--10-C14"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"

/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 15.8; DB 1; Length 19;
Best Local Similarity 10.5%; Pred. No. 5.2e+02;
Matches 2; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6347 UUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db          1 TTTTTTTTTTTTTTTGAAA 19
```

RESULT 621
AZ447251
LOCUS AZ447251 19 bp DNA linear GSS 04-OCT-2000
DEFINITION 1M0244J19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0244J19 F, genomic survey sequence.
ACCESSION AZ447251
VERSION AZ447251.1 GI:10599050
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 19)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0244 row: J column: 19
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 19.
FEATURES Location/Qualifiers
source 1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0244J19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.2%; Score 15.8; DB 1; Length 19;
Best Local Similarity 10.5%; Pred. No. 5.2e+02;
Matches 2; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

```
Qy       6347 UUUUUUUUUUUUUUUCCAA 6365
              ::::::::::::::::  ||
Db          1 TTTTTTTTTTTTTTTATAA 19
```

RESULT 622
CF300961/c
LOCUS CF300961 20 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--05-K03.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza sativa (japonica cultivar-group) cDNA clone 7LEAF--05-K03, mRNA sequence.
ACCESSION CF300961
VERSION CF300961.1 GI:33672722
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-K03"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       4740 AAAGGAAAAAAAGCAAAAA 4758
              ||||||||||| |||||
Db         20 AAAGGAAAAAAAAAAAAAA 2
```

RESULT 623
AZ875282
LOCUS AZ875282 37 bp DNA linear GSS 21-FEB-2001
DEFINITION 2M0189A20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0189A20 R, genomic survey sequence.
ACCESSION AZ875282
VERSION AZ875282.1 GI:13085139
KEYWORDS GSS.

```
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0189  row: A  column: 20
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES             Location/Qualifiers
     source          1. .37
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0189A20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 37;
  Best Local Similarity   62.9%;  Pred. No. 8.4e+02;
  Matches   22;  Conservative    1;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||:  | ||||||   ||| ||  | |||
Db          2 ACACACACTCACACACACACACACACACACACA 36


RESULT 624
AZ504337/c
LOCUS       AZ504337                 38 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0344C08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0344C08 R, genomic survey sequence.
ACCESSION   AZ504337
VERSION     AZ504337.1  GI:10685653
KEYWORDS    GSS.
```

```
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0344  row: C  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 38.
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0344C08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.8;  DB 1;  Length 38;
  Best Local Similarity   62.9%;  Pred. No. 8.3e+02;
  Matches   22;  Conservative    1;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              | ||| ||   | ||||||   ||| ||  |:|||
Db         36 ACACACACACACACACACACACACACACACATACA 2


RESULT 625
AL038464
LOCUS       AL038464                 22 bp    mRNA    linear   EST 06-JUL-2004
DEFINITION  DKFZp566B0646_r1 566 (synonym: hfkd2) Homo sapiens cDNA clone
            DKFZp566B0646, mRNA sequence.
ACCESSION   AL038464
VERSION     AL038464.1  GI:49682134
KEYWORDS    EST.
```

```
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Ottenwaelder,B., Obermaier,B., Mewes,H.W., Gassenhuber,J. and
            Wiemann,S.
  TITLE     EST (Ottenwaelder, et al.)
  JOURNAL   Unpublished (1999)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DKFZp566B0646"
                     /tissue_type="kidney"
                     /dev_stage="fetal"
                     /lab_host="Xl-2blue"
                     /clone_lib="566 (synonym: hfkd2)"
                     /note="Vector: pAMP1; Site_1: NotI; Site_2: SalI"

  Query Match             0.2%;  Score 15.6;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 6.7e+02;
  Matches   18;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       4736 AGGAAAAGGAAAAAAAGCAAAA 4757
              ||||||| ||||||| ||||
Db          1 AGGAAAAAAAAAAAAAAAAAAA 22


RESULT 626
CF298341
LOCUS       CF298341                  17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-K24.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-K24, mRNA
            sequence.
ACCESSION   CF298341
VERSION     CF298341.1  GI:33670102
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--01-K24"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 4.7e+02;
  Matches    1;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTGC 17


RESULT 627
CF311499
LOCUS       CF311499                  17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--06-L20.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--06-L20, mRNA sequence.
ACCESSION   CF311499
VERSION     CF311499.1  GI:33683260
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--06-L20"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   5.9%;  Pred. No. 4.7e+02;
  Matches    1;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::|
Db          1 TTTTTTTTTTTTTTTAC 17


RESULT 628
CF309376
LOCUS       CF309376                  18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--03-I19.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--03-I19, mRNA sequence.
ACCESSION   CF309376
VERSION     CF309376.1  GI:33681137
KEYWORDS    EST.
```

```
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--03-I19"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 5.2e+02;
  Matches    1;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTAC 17


RESULT 629
CF329484
LOCUS       CF329484                 18 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--04-N06.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--04-N06, mRNA
            sequence.
ACCESSION   CF329484
VERSION     CF329484.1  GI:33807207
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--04-N06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 5.2e+02;
  Matches    1;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTTAC 17


RESULT 630
CF329485/c
LOCUS       CF329485                 18 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--04-N06.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--04-N06, mRNA
            sequence.
ACCESSION   CF329485
VERSION     CF329485.1  GI:33807209
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--04-N06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   5.9%;  Pred. No. 5.2e+02;
  Matches    1;  Conservative   15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::::::::::::
Db         18 TTTTTTTTTTTTTTTAC 2


RESULT 631
AJ666205
```

```
LOCUS       AJ666205                19 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ666205 CSEQRAN09 Sus scrofa cDNA clone C0000033_E15, mRNA
            sequence.
ACCESSION   AJ666205
VERSION     AJ666205.1  GI:49350656
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
            Sus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000033_E15"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 5.7e+02;
  Matches    1;  Conservative    15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6345 CUUUUUUUUUUUUUUUU 6361
              |::::::: :::::::::
Db          1 CTTTTTTTCTTTTTTT 17


RESULT 632
AZ360314/c
LOCUS       AZ360314                19 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0103G03R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0103G03 R, genomic survey sequence.
ACCESSION   AZ360314
VERSION     AZ360314.1  GI:10474014
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0103  row: G  column: 03
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0103G03"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   5.9%;  Pred. No. 5.7e+02;
  Matches    1;  Conservative    15;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUUUC 6362
              ::::::: :::::::|
Db         17 TTTTTTTCTTTTTTTC 1


RESULT 633
AZ491644
LOCUS       AZ491644                19 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0325A20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0325A20 F, genomic survey sequence.
ACCESSION   AZ491644
VERSION     AZ491644.1  GI:10663543
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
```

```
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0325  row: A  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0325A20"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   52.9%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       6974 GUGUGUGUGUGUGUGUG 6990
                | |:|:|:|:|:|:|:|
Db          3 GCGTGTGTGTGTGTGTG 19


RESULT 634
AZ489673/c
LOCUS       AZ489673                36 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0322E18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0322E18 F, genomic survey sequence.
ACCESSION   AZ489673
VERSION     AZ489673.1  GI:10659652
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0322  row: E  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES              Location/Qualifiers
     source           1. .36
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0322E18"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 36;
  Best Local Similarity   66.7%;  Pred. No. 8.6e+02;
  Matches   22;  Conservative    0;  Mismatches   11;  Indels    0;  Gaps    0;

Qy        901 ACAAACUAUCUCACACAUCGACAAACCAAUACA 933
                ||| ||   | ||||||   ||| ||| | |||
Db         36 ACACACACACACACACACACACACACCCACACA 4


RESULT 635
AZ647581/c
LOCUS       AZ647581                37 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0514J14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0514J14 F, genomic survey sequence.
ACCESSION   AZ647581
VERSION     AZ647581.1  GI:11779189
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
```

```
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0514  row: J  column: 14
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES              Location/Qualifiers
     source           1. .37
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0514J14"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.4;  DB 1;  Length 37;
  Best Local Similarity   66.7%;  Pred. No. 8.5e+02;
  Matches   22;  Conservative    0;  Mismatches   11;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUA 931
              | ||| ||   | ||||||   ||| ||||| |
Db         33 ACACACACACACACACACACACACACCAACA 1


RESULT 636
AZ848143/c
LOCUS       AZ848143                 36 bp    DNA     linear   GSS 21-FEB-2001
DEFINITION  2M0149A17F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0149A17 F, genomic survey sequence.
ACCESSION   AZ848143
VERSION     AZ848143.1  GI:13029405
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 36)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0149  row: A  column: 17
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 36.
FEATURES              Location/Qualifiers
     source           1. .36
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0149A17"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 36;
  Best Local Similarity   63.9%;  Pred. No. 8.7e+02;
  Matches   23;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        898 AAGACAAACUAUCUCACACAUCGACAAACCAAUACA 933
              || ||| ||   | ||||||   ||| ||  | |||
Db         36 AACACACACACACACACACACACACACACACACACA 1


RESULT 637
AZ826021/c
LOCUS       AZ826021                 37 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0101F02R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0101F02 R, genomic survey sequence.
ACCESSION   AZ826021
VERSION     AZ826021.1  GI:12995929
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 37)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
```

```
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0101  row: F  column: 02
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 37.
FEATURES              Location/Qualifiers
     source           1. .37
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0101F02"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 37;
  Best Local Similarity   63.9%;  Pred. No. 8.6e+02;
  Matches   23;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAA 934
              | ||| ||   | ||||||   ||| ||  | ||||
Db         36 ACACACACACACACACACACACACACACACACACAA 1


RESULT 638
AZ765740/c
LOCUS       AZ765740                 39 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  1M0562C19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0562C19 R, genomic survey sequence.
ACCESSION   AZ765740
VERSION     AZ765740.1  GI:12882075
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0562  row: C  column: 19
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 39.
FEATURES              Location/Qualifiers
     source           1. .39
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0562C19"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 39;
  Best Local Similarity   63.9%;  Pred. No. 8.3e+02;
  Matches   23;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAA 934
              | ||| ||   | ||||||   ||| ||  | ||||
Db         36 ACACACACACACACACACACACACACACACACACAA 1


RESULT 639
AZ513473/c
LOCUS       AZ513473                 40 bp    DNA     linear   GSS 05-OCT-2000
DEFINITION  1M0359O21R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0359O21 R, genomic survey sequence.
ACCESSION   AZ513473
VERSION     AZ513473.1  GI:10694789
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
            Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 40)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
```

```
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0359  row: O  column: 21
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 40.
FEATURES              Location/Qualifiers
     source           1. .40
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0359O21"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.2%;  Score 15.2;  DB 1;  Length 40;
  Best Local Similarity   63.9%;  Pred. No. 8.1e+02;
  Matches   23;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy        899 AGACAAACUAUCUCACACAUCGACAAACCAAUACAA 934
              | ||| ||   | ||||||   ||| ||  | ||||
Db         36 ACACACACACACACACACACACACACACACACAA 1


RESULT 640
AJ690565
LOCUS       AJ690565                 15 bp    mRNA    linear   EST 29-JUN-2004
DEFINITION  AJ690565 KN261 Bos taurus cDNA clone KN261-054_B13, mRNA sequence.
ACCESSION   AJ690565
VERSION     AJ690565.1  GI:49423173
KEYWORDS    EST.
SOURCE      Bos taurus (cattle)
  ORGANISM  Bos taurus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
            Pecora; Bovidae; Bovinae; Bos.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(SK+) R. Site1: EcoRI
            R. Site2: SmaI 3' Seq Primer M13F Normalised library constructed
            from bovine ovary. Clones available from UK Centre for Functional
            Genomics in Farm Animals, Roslin Institite, Roslin, Midlothian, UK,
            EH25 9PS, www.arkgenomics.org.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Bos taurus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9913"
                      /clone="KN261-054_B13"
                      /tissue_type="ovary"
                      /clone_lib="KN261"
                      /note="Vector: pBlueScriptII(SK+); Site_1: EcoRI; Site_2:
                      SmaI; Single pass sequencing. Normalised library
                      constructed from bovine ovary."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 641
BQ582543
LOCUS       BQ582543                 15 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013300-024-007-B02-T7 MPIZ-ADIS-024-inflorescence Beta vulgaris
            cDNA clone 024-007-B02 3-PRIME, mRNA sequence.
ACCESSION   BQ582543
VERSION     BQ582543.1  GI:26112120
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 7  row: B  column: 02
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:184162"
                      /db_xref="taxon:161934"
                      /clone="024-007-B02"
                      /tissue_type="inflorescence"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-inflorescence"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
```

project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15
```

RESULT 642
BQ585820
LOCUS BQ585820 15 bp mRNA linear EST 06-DEC-2002
DEFINITION E012533-024-014-H17-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone 024-014-H17 5-PRIME, mRNA sequence.
ACCESSION BQ585820
VERSION BQ585820.1 GI:26115402
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 15)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 15 Std Error: 0.00
Plate: 14 row: H column: 17
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .15
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:187164"
/db_xref="taxon:161934"
/clone="024-014-H17"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-leaf"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database:http://gabi.rzpd.de"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15
```

RESULT 643
BQ590410
LOCUS BQ590410 15 bp mRNA linear EST 06-DEC-2002
DEFINITION E012844-024-019-M08-T7 MPIZ-ADIS-024-storage root Beta vulgaris cDNA clone 024-019-M08 3-PRIME, mRNA sequence.
ACCESSION BQ590410
VERSION BQ590410.1 GI:26119993
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 15)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 15 Std Error: 0.00
Plate: 19 row: M column: 08
Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES Location/Qualifiers
source 1. .15
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:189710"
/db_xref="taxon:161934"
/clone="024-019-M08"
/tissue_type="storage root"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-storage root"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

```
Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15
```

RESULT 644
BQ590656
LOCUS BQ590656 15 bp mRNA linear EST 06-DEC-2002
DEFINITION S015086-024-018-L13-SP6 MPIZ-ADIS-024-storage root Beta vulgaris cDNA clone 024-018-L13 5-PRIME, mRNA sequence.
ACCESSION BQ590656
VERSION BQ590656.1 GI:26120239
KEYWORDS EST.
SOURCE Beta vulgaris

```
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 18  row: L  column: 13
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:189464"
                      /db_xref="taxon:161934"
                      /clone="024-018-L13"
                      /tissue_type="storage root"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-storage root"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
                      project, local PI: Dr. Katharina Schneider, coordinator:
                      Prof. Christian Jung;  Sequence submission managed by
                      RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 645
BQ591170
LOCUS       BQ591170                 15 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012715-024-017-N18-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-N18 3-PRIME, mRNA sequence.
ACCESSION   BQ591170
VERSION     BQ591170.1  GI:26120753
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 17  row: N  column: 18
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:188941"
                      /db_xref="taxon:161934"
                      /clone="024-017-N18"
                      /tissue_type="storage root"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-storage root"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
                      project, local PI: Dr. Katharina Schneider, coordinator:
                      Prof. Christian Jung;  Sequence submission managed by
                      RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 646
BQ591178
LOCUS       BQ591178                 15 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012715-024-017-F22-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-F22 3-PRIME, mRNA sequence.
ACCESSION   BQ591178
VERSION     BQ591178.1  GI:26120761
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 17  row: F  column: 22
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES              Location/Qualifiers
```

```
     source          1. .15
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:188949"
                     /db_xref="taxon:161934"
                     /clone="024-017-F22"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 647
BQ591223
LOCUS       BQ591223                 15 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012715-024-017-H02-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-H02 3-PRIME, mRNA sequence.
ACCESSION   BQ591223
VERSION     BQ591223.1  GI:26120806
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 17  row: H  column: 02
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:188901"
                     /db_xref="taxon:161934"
                     /clone="024-017-H02"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 648
BQ594689
LOCUS       BQ594689                 15 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012404-024-024-M05-T7 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-024-M05 3-PRIME, mRNA sequence.
ACCESSION   BQ594689
VERSION     BQ594689.1  GI:26124272
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 15   Std Error: 0.00
            Plate: 24  row: M  column: 05
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:192163"
                     /db_xref="taxon:161934"
                     /clone="024-024-M05"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"
```

```
  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 649
CF277319
LOCUS       CF277319                  15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--02-M23.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--02-M23,
            mRNA sequence.
ACCESSION   CF277319
VERSION     CF277319.1  GI:33654705
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--02-M23"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 650
CF281923
LOCUS       CF281923                  15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--09-D04.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--09-D04,
            mRNA sequence.
ACCESSION   CF281923
VERSION     CF281923.1  GI:33659310
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ETL--09-D04"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 651
CF290920
LOCUS       CF290920                  15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-C09.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-C09, mRNA
            sequence.
ACCESSION   CF290920
VERSION     CF290920.1  GI:33659953
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-C09"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
```

```
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
                :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 652
CF291029
LOCUS       CF291029                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-E19.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA
            sequence.
ACCESSION   CF291029
VERSION     CF291029.1  GI:33660062
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-E19"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
                :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 653
CF291103
LOCUS       CF291103                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-G10.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-G10, mRNA
            sequence.
ACCESSION   CF291103
VERSION     CF291103.1  GI:33660136
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--01-G10"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
                :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 654
CF291717
LOCUS       CF291717                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-E04.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-E04, mRNA
            sequence.
ACCESSION   CF291717
VERSION     CF291717.1  GI:33660750
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
```

```
                     /db_xref="taxon:39947"
                     /clone="14ROOT--02-E04"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 655
CF291798
LOCUS       CF291798                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-G02.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-G02, mRNA
            sequence.
ACCESSION   CF291798
VERSION     CF291798.1  GI:33660831
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--02-G02"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 656
CF292458
LOCUS       CF292458                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--01-E17.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--01-E17, mRNA
            sequence.
ACCESSION   CF292458
VERSION     CF292458.1  GI:33661491
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--01-E17"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 657
CF292461
LOCUS       CF292461                 15 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--01-E19.b1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--01-E19, mRNA
            sequence.
ACCESSION   CF292461
VERSION     CF292461.1  GI:33661494
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
```

```
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--01-E19"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 658
CF298148
LOCUS       CF298148                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--01-G17.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--01-G17, mRNA
            sequence.
ACCESSION   CF298148
VERSION     CF298148.1  GI:33669909
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--01-G17"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 659
CF298630
LOCUS       CF298630                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-B23.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-B23, mRNA
            sequence.
ACCESSION   CF298630
VERSION     CF298630.1  GI:33670391
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-B23"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 660
CF298733
LOCUS       CF298733                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-E20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-E20, mRNA
            sequence.
ACCESSION   CF298733
VERSION     CF298733.1  GI:33670494
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
```

```
           Tel: 82 31 330 6193
           Fax: 82 31 321 6355
           Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-E20"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 661
CF298805
LOCUS       CF298805                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-G20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-G20, mRNA
            sequence.
ACCESSION   CF298805
VERSION     CF298805.1  GI:33670566
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-G20"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 662
CF298889
LOCUS       CF298889                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-J09.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-J09, mRNA
            sequence.
ACCESSION   CF298889
VERSION     CF298889.1  GI:33670650
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-J09"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 663
CF299602
LOCUS       CF299602                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-L01.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L01, mRNA
            sequence.
ACCESSION   CF299602
VERSION     CF299602.1  GI:33671363
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
```

```
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--03-L01"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 664
CF299608
LOCUS       CF299608                  15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-L04.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L04, mRNA
            sequence.
ACCESSION   CF299608
VERSION     CF299608.1  GI:33671369
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--03-L04"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 665
CF300121
LOCUS       CF300121                  15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--04-G12.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--04-G12, mRNA
            sequence.
ACCESSION   CF300121
VERSION     CF300121.1  GI:33671882
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--04-G12"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 666
CF300361
LOCUS       CF300361                  15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--04-L16.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--04-L16, mRNA
            sequence.
ACCESSION   CF300361
VERSION     CF300361.1  GI:33672122
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
```

```
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--04-L16"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 667
CF300992
LOCUS       CF300992                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-K19.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-K19, mRNA
            sequence.
ACCESSION   CF300992
VERSION     CF300992.1  GI:33672753
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--05-K19"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 668
CF302034
LOCUS       CF302034                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-C24.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-C24, mRNA
            sequence.
ACCESSION   CF302034
VERSION     CF302034.1  GI:33673795
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-C24"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 669
CF302124
LOCUS       CF302124                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-F16.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-F16, mRNA
            sequence.
ACCESSION   CF302124
VERSION     CF302124.1  GI:33673885
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-F16"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 670
CF302182
LOCUS       CF302182                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-H20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-H20, mRNA
            sequence.
ACCESSION   CF302182
VERSION     CF302182.1  GI:33673943
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-H20"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 671
CF307923
LOCUS       CF307923                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--01-I15.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--01-I15, mRNA sequence.
ACCESSION   CF307923
VERSION     CF307923.1  GI:33679684
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--01-I15"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 672
CF311159
LOCUS       CF311159                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--06-E11.b1 ABF3-overexpressing transgenic rice plasmid cDNA
```

```
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--06-E11, mRNA sequence.
ACCESSION   CF311159
VERSION     CF311159.1  GI:33682920
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--06-E11"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 673
CF311907
LOCUS       CF311907                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  ABF--07-G04.b1 ABF3-overexpressing transgenic rice plasmid cDNA
            library (ABF) Oryza sativa (japonica cultivar-group) cDNA clone
            ABF--07-G04, mRNA sequence.
ACCESSION   CF311907
VERSION     CF311907.1  GI:33683668
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="ABF--07-G04"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="ABF3-overexpressing transgenic rice plasmid
                     cDNA library (ABF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Leaf was dried
                     for 2hrs. Oligo-capped mRNA was reverse transcribed and
                     then used for PCR. mRNA was prepared from ABA-responsive
                     element binding transcription factor 3 overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 674
CF313319
LOCUS       CF313319                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--01-G13.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--01-G13, mRNA sequence.
ACCESSION   CF313319
VERSION     CF313319.1  GI:33685080
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--01-G13"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."
```

```
  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 675
CF313320/c
LOCUS       CF313320                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--01-G13.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--01-G13, mRNA sequence.
ACCESSION   CF313320
VERSION     CF313320.1  GI:33685081
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--01-G13"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 676
CF316251/c
LOCUS       CF316251                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--05-H15.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--05-H15, mRNA sequence.
ACCESSION   CF316251
VERSION     CF316251.1  GI:33688012
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--05-H15"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 677
CF318035
LOCUS       CF318035                 15 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--07-P06.b1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--07-P06, mRNA sequence.
ACCESSION   CF318035
VERSION     CF318035.1  GI:33689796
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
```

/db_xref="taxon:39947"
/clone="HD--07-P06"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli DH10B"
/clone_lib="OsHDAC1-overexpressing transgenic rice plasmid cDNA library (HD)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was treated with ABA(20um) for 1hr. Oligo-capped mRNA was reverse transcribed and then used for PCR. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUU 6360
:::::::::::::::
Db 1 TTTTTTTTTTTTTTT 15

RESULT 678
CF327434
LOCUS CF327434 15 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--01-O18.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--01-O18, mRNA sequence.
ACCESSION CF327434
VERSION CF327434.1 GI:33803127
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .15
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--01-O18"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUU 6360
:::::::::::::::
Db 1 TTTTTTTTTTTTTTT 15

RESULT 679
CF330195
LOCUS CF330195 15 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--05-N03.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--05-N03, mRNA sequence.
ACCESSION CF330195
VERSION CF330195.1 GI:33808618
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .15
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--05-N03"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 0.0%; Pred. No. 4.1e+02;
Matches 0; Conservative 15; Mismatches 0; Indels 0; Gaps 0;

Qy 6346 UUUUUUUUUUUUUUU 6360
:::::::::::::::
Db 1 TTTTTTTTTTTTTTT 15

RESULT 680
CF330668
LOCUS CF330668 15 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--06-H16.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--06-H16, mRNA sequence.
ACCESSION CF330668
VERSION CF330668.1 GI:33809572
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193

```
           Fax: 82 31 321 6355
           Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--06-H16"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 681
CF332178
LOCUS       CF332178                 15 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--08-J10.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--08-J10, mRNA
            sequence.
ACCESSION   CF332178
VERSION     CF332178.1  GI:33812580
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--08-J10"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 682
CF336202
LOCUS       CF336202                 15 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  JMT--06-C20.b1 AtJMT-overexpressing transgenic rice plasmid cDNA
            library (JMT) Oryza sativa (japonica cultivar-group) cDNA clone
            JMT--06-C20, mRNA sequence.
ACCESSION   CF336202
VERSION     CF336202.1  GI:33820794
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="JMT--06-C20"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="AtJMT-overexpressing transgenic rice plasmid
                     cDNA library (JMT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Oligo-capped mRNA
                     was reverse transcribed and then used for PCR. mRNA was
                     pepared from Arabidopsis Jasmoinate Carboxyl
                     methyltransferase overexpression line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 683
BE230585/c
LOCUS       BE230585                 15 bp    mRNA    linear   EST 07-JUL-2000
DEFINITION  99AS799 Rice Seedling Lambda ZAPII cDNA Library Oryza sativa
            (indica cultivar-group) cDNA clone 99AS799, mRNA sequence.
ACCESSION   BE230585
VERSION     BE230585.1  GI:8956782
KEYWORDS    EST.
SOURCE      Oryza sativa (indica cultivar-group)
  ORGANISM  Oryza sativa (indica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Lee,M.C., Shin,Y.C., Lee,T.H., Jeong,S.H., Kim,J.K., Eun,M.Y. and
            Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of ESTs from Rice Seedling
  JOURNAL   Unpublished (1999)
```

```
COMMENT     Contact: Eun M.Y.
            Department of Cytogenetics
            National Inst. of Agri. Sci. and Tech, RDA
            Suwon, Kyunggido, Korea
            Tel: 82 331 290 0301
            Fax: 82 331 290 0307
            Email: myeun@sun20.asti.re.kr.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Oryza sativa (indica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Milyang 23"
                      /db_xref="taxon:39946"
                      /clone="99AS799"
                      /dev_stage="5 days after pollination"
                      /lab_host="E. coli SOLR"
                      /clone_lib="Rice Seedling Lambda ZAPII cDNA Library"
                      /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                      XhoI; Directional cDNA library inserted into lambda ZAPII
                      vector at 5'end with EcoRI and 3' end with Xho I site"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 684
CR547282/c
LOCUS       CR547282                 15 bp    mRNA    linear   EST 12-JUL-2004
DEFINITION  DKFZp468I112_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
            DKFZp468I112 5', mRNA sequence.
ACCESSION   CR547282
VERSION     CR547282.1  GI:50240938
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
  ORGANISM  Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pongo.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Bloecker,H., Boecher,M., Brandt,P., Mewes,H.W., Weil,B., Amid,C.,
            Osanger,A., Fobo,G., Han,M. and Wiemann,S.
  TITLE     Pongo pygmaeus mRNA (Bloecker,H., Boecher,M., Brandt,P., et al.)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
            This is the 5' sequence of the clone insert Clone from S. Wiemann,
            Molecular Genome Analysis, German Cancer Research Center (DKFZ);
            Email s.wiemann@dkfz-heidelberg.de; sequenced by GBF (National
            Research Centre for Biotechnology Ltd., Braunschweig/Germany)
            within the cDNA sequencing consortium of the German Genome Project.
            This clone (DKFZp468I112) is available at the RZPD in Berlin.
            Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059
            Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de Further
            information about the clone and the sequencing project is available
            at http://mips.gsf.de/projects/cdna/.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Pongo pygmaeus"
                      /mol_type="mRNA"
                      /db_xref="taxon:9600"
                      /clone="DKFZp468I112"
                      /tissue_type="heart"
                      /dev_stage="adult"
                      /lab_host="DH10B"
                      /clone_lib="468 (synonym: phrt1)"
                      /note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 685
CV933720/c
LOCUS       CV933720                 15 bp    mRNA    linear   EST 25-JAN-2005
DEFINITION  PMrpcm_3846 mating of 88069 (A1) and 618 (A2) Phytophthora
            infestans cDNA, mRNA sequence.
ACCESSION   CV933720
VERSION     CV933720.1  GI:58123335
KEYWORDS    EST.
SOURCE      Phytophthora infestans (potato late blight agent)
  ORGANISM  Phytophthora infestans
            Eukaryota; stramenopiles; Oomycetes; Peronosporales; Phytophthora.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Randall,T., Dwyer,R.A., Huitema,E., Beyer,K., Cvitanich,C.,
            Kelkar,H., Fong,A.M., Gates,K., Roberts,S., Yatzkan,E., Gaffney,T.,
            Law,M., Testa,A., Torto-Alalibo,A., Zhang,M., Zheng,L., Mueller,E.,
            Windass,J., Binder,A., Birch,P.R.J., Gisi,U., Govers,F., Gow,N.A.,
            Mauch,F., van West,P., Waugh,M.E., Yu,J., Boller,T., Kamoun,S.,
            Lam,S.T. and Judelson, H.S.
  TITLE     Large-scale gene discovery in the oomycete Phytophthora infestans
            reveals likely components of phytopathogenicity shared with true
            fungi
  JOURNAL   Mol. Plant-Microbe Interact. 18 (3), 229-243 (2005)
   PUBMED   15782637
COMMENT     Contact: Judelson HS
            Department of Plant Pathology
            University of California
            Webber Hall, Riverside, CA 92521, USA
            Tel: 909 787 4199
            Fax: 909 787 4294
            Email: howard.judelson@ucr.edu.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Phytophthora infestans"
                      /mol_type="mRNA"
                      /strain="88069 and 618"
                      /db_xref="taxon:4787"
                      /sex="A1 and A2"
                      /clone_lib="mating of 88069 (A1) and 618 (A2)"
                      /note="Vector: pSPORT1"

  Query Match             0.2%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   0.0%;  Pred. No. 4.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db         15 TTTTTTTTTTTTTTT 1


RESULT 686
BQ590207
LOCUS       BQ590207                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012843-024-019-O15-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-019-O15 3-PRIME, mRNA sequence.
ACCESSION   BQ590207
VERSION     BQ590207.1  GI:26119790
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
```

```
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 19  row: O  column: 15
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES            Location/Qualifiers
     source         1. .16
                    /organism="Beta vulgaris"
                    /mol_type="mRNA"
                    /cultivar="KWS2320 (double haploid, monogerm breeding
                    line)"
                    /db_xref="GABI:189913"
                    /db_xref="taxon:161934"
                    /clone="024-019-O15"
                    /tissue_type="storage root"
                    /lab_host="EMDH10B"
                    /clone_lib="MPIZ-ADIS-024-storage root"
                    /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                    cDNA library from sugar beet, library provided by KWS
                    Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                    b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                    orientation:
                    SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                    Sequencing granted in the context of the GABI-Beet
                    project, local PI: Dr. Katharina Schneider, coordinator:
                    Prof. Christian Jung;  Sequence submission managed by
                    RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 687
BQ590507
LOCUS       BQ590507                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012844-024-019-M04-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-019-M04 3-PRIME, mRNA sequence.
ACCESSION   BQ590507
VERSION     BQ590507.1  GI:26120090
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 19  row: M  column: 04
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES            Location/Qualifiers
     source         1. .16
                    /organism="Beta vulgaris"
                    /mol_type="mRNA"
                    /cultivar="KWS2320 (double haploid, monogerm breeding
                    line)"
                    /db_xref="GABI:189608"
                    /db_xref="taxon:161934"
                    /clone="024-019-M04"
                    /tissue_type="storage root"
                    /lab_host="EMDH10B"
                    /clone_lib="MPIZ-ADIS-024-storage root"
                    /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                    cDNA library from sugar beet, library provided by KWS
                    Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                    b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                    orientation:
                    SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                    Sequencing granted in the context of the GABI-Beet
                    project, local PI: Dr. Katharina Schneider, coordinator:
                    Prof. Christian Jung;  Sequence submission managed by
                    RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 688
BQ595369
LOCUS       BQ595369                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  S013317-024-022-P02-T7 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-022-P02 3-PRIME, mRNA sequence.
ACCESSION   BQ595369
VERSION     BQ595369.1  GI:26124952
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 22  row: P  column: 02
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES            Location/Qualifiers
     source         1. .16
                    /organism="Beta vulgaris"
                    /mol_type="mRNA"
                    /cultivar="KWS2320 (double haploid, monogerm breeding
                    line)"
                    /db_xref="GABI:191489"
```

```
                     /db_xref="taxon:161934"
                     /clone="024-022-P02"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 689
CF291803/c
LOCUS       CF291803                  16 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-G05.g1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-G05, mRNA
            sequence.
ACCESSION   CF291803
VERSION     CF291803.1  GI:33660836
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="14ROOT--02-G05"
                     /tissue_type="root"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   6.7%;  Pred. No. 4.6e+02;
  Matches    1;  Conservative   14;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6348 UUUUUUUUUUUUUUC 6362
              ::::::::::::::|
Db         16 TTTTTTTTTTTTTTC 2


RESULT 690
CF296130
LOCUS       CF296130                  16 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--06-F22.b1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--06-F22, mRNA
            sequence.
ACCESSION   CF296130
VERSION     CF296130.1  GI:33665163
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="30DGS--06-F22"
                     /tissue_type="leaf"
                     /dev_stage="30 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              ::::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 691
CF314013
LOCUS       CF314013                  16 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--02-G01.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--02-G01, mRNA sequence.
ACCESSION   CF314013
VERSION     CF314013.1  GI:33685774
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
```

```
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="HD--02-G01"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                      /lab_host="E.coli DH10B"
                      /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                      cDNA library (HD)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                      treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                      reverse transcribed and then used for PCR. mRNA was
                      derived from rice Histone Deacetylase overexpression
                      line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 692
CF318894
LOCUS       CF318894                 16 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--09-D06.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--09-D06, mRNA sequence.
ACCESSION   CF318894
VERSION     CF318894.1  GI:33690655
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="HD--09-D06"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                      /lab_host="E.coli DH10B"
                      /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                      cDNA library (HD)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                      treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                      reverse transcribed and then used for PCR. mRNA was
                      derived from rice Histone Deacetylase overexpression
                      line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 693
CF327923
LOCUS       CF327923                 16 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--02-J18.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--02-J18, mRNA
            sequence.
ACCESSION   CF327923
VERSION     CF327923.1  GI:33804096
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="NACL--02-J18"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 30 days"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice callus plasmid cDNA library (NACL)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 694
CF328223
LOCUS       CF328223                 16 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--03-A10.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--03-A10, mRNA
            sequence.
ACCESSION   CF328223
VERSION     CF328223.1  GI:33804692
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--03-A10"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 695
CF329320
LOCUS       CF329320                 16 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--04-J17.b1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--04-J17, mRNA
            sequence.
ACCESSION   CF329320
VERSION     CF329320.1  GI:33806877
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--04-J17"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 696
CR786609/c
LOCUS       CR786609                 16 bp    mRNA    linear   EST 01-OCT-2004
DEFINITION  DKFZp468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
            DKFZp468C2031 5', mRNA sequence.
ACCESSION   CR786609
VERSION     CR786609.1  GI:53705606
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
  ORGANISM  Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Pongo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
            Fobo,G., Han,M. and Wiemann,S.
  TITLE     Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
  JOURNAL   Unpublished (2004)
COMMENT     Contact: MIPS
            MIPS
            Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
            This is the 5' sequence of the clone insert. Clone from S. Wiemann,
            Molecular Genome Analysis, German Cancer Research Center (DKFZ);
            Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
            Germany. Please contact RZPD for ordering:
            http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468C2031
            Further information about the clone and the sequencing project is
            available at http://mips.gsf.de/projects/cdna/.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Pongo pygmaeus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9600"
                     /clone="DKFZp468C2031"
                     /tissue_type="heart"
                     /dev_stage="adult"
                     /lab_host="DH10B"
                     /clone_lib="468 (synonym: phrt1)"
                     /note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

  Query Match             0.2%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   0.0%;  Pred. No. 4.6e+02;
  Matches    0;  Conservative    15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db         16 TTTTTTTTTTTTTTT 2


RESULT 697
BQ591181
LOCUS       BQ591181                 17 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012715-024-017-H16-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-H16 3-PRIME, mRNA sequence.
ACCESSION   BQ591181
VERSION     BQ591181.1  GI:26120764
KEYWORDS    EST.
```

```
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 17   Std Error: 0.00
            Plate: 17  row: H  column: 16
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:188932"
                      /db_xref="taxon:161934"
                      /clone="024-017-H16"
                      /tissue_type="storage root"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-storage root"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
                      project, local PI: Dr. Katharina Schneider, coordinator:
                      Prof. Christian Jung;  Sequence submission managed by
                      RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 5.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 698
CF291802
LOCUS       CF291802                  17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--02-G05.b1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--02-G05, mRNA
            sequence.
ACCESSION   CF291802
VERSION     CF291802.1  GI:33660835
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ROOT--02-G05"
                      /tissue_type="root"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 5.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
              :::::::::::::::
Db          3 TTTTTTTTTTTTTTT 17


RESULT 699
CF297251
LOCUS       CF297251                  17 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  30DGS--07-P12.g1 Rice leaf plasmid cDNA library I (30DGS) Oryza
            sativa (japonica cultivar-group) cDNA clone 30DGS--07-P12, mRNA
            sequence.
ACCESSION   CF297251
VERSION     CF297251.1  GI:33666284
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="30DGS--07-P12"
                      /tissue_type="leaf"
                      /dev_stage="30 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library I (30DGS)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
```

```
  Best Local Similarity   0.0%;  Pred. No. 5.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 700
CF319075
LOCUS       CF319075                 17 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HD--09-H06.g1 OsHDAC1-overexpressing transgenic rice plasmid cDNA
            library (HD) Oryza sativa (japonica cultivar-group) cDNA clone
            HD--09-H06, mRNA sequence.
ACCESSION   CF319075
VERSION     CF319075.1  GI:33690836
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HD--09-H06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli DH10B"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice plasmid
                     cDNA library (HD)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; Callus was
                     treated with ABA(20um) for 1hr. Oligo-capped mRNA was
                     reverse transcribed and then used for PCR. mRNA was
                     derived from rice Histone Deacetylase overexpression
                     line."

  Query Match             0.2%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   0.0%;  Pred. No. 5.1e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


RESULT 701
CF298591
LOCUS       CF298591                 18 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--02-A20.b1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--02-A20, mRNA
            sequence.
ACCESSION   CF298591
VERSION     CF298591.1  GI:33670352
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP
            clade; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--02-A20"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.2%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   0.0%;  Pred. No. 5.6e+02;
  Matches    0;  Conservative   15;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       6346 UUUUUUUUUUUUUUU 6360
             ::::::::::::::
Db          1 TTTTTTTTTTTTTTT 15


Search completed: August 31, 2006, 14:42:51
Job time : 44 secs
```

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)